<SEC-DOCUMENT>0001179929-23-000025.txt : 20230213
<SEC-HEADER>0001179929-23-000025.hdr.sgml : 20230213
<ACCEPTANCE-DATETIME>20230213162224
ACCESSION NUMBER:		0001179929-23-000025
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		122
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230213
DATE AS OF CHANGE:		20230213

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MOLINA HEALTHCARE, INC.
		CENTRAL INDEX KEY:			0001179929
		STANDARD INDUSTRIAL CLASSIFICATION:	HOSPITAL & MEDICAL SERVICE PLANS [6324]
		IRS NUMBER:				134204626
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31719
		FILM NUMBER:		23618828

	BUSINESS ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802
		BUSINESS PHONE:		5624353666

	MAIL ADDRESS:	
		STREET 1:		200 OCEANGATE, SUITE 100
		CITY:			LONG BEACH
		STATE:			CA
		ZIP:			90802

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MOLINA HEALTHCARE INC
		DATE OF NAME CHANGE:	20020812
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>moh-20221231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:a6be6ee9-88ed-425c-ba06-deafc74c4611,g:0568f791-801e-41fa-b039-5982169b2ced,d:a6131cdf4d354d56b8257b8e26eb9181--><html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:moh="http://www.molinahealthcare.com/20221231" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>moh-20221231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV80L2ZyYWc6YzY1YWE0NjM1OTkwNGQzNWI2NTc1ZWI5NWZlMmUzZmUvdGFibGU6MmQ0MzU4MDAyMDM1NDMyZTk4NmY4NjcyYmUwNTE0MWUvdGFibGVyYW5nZToyZDQzNTgwMDIwMzU0MzJlOTg2Zjg2NzJiZTA1MTQxZV8xLTEtMS0xLTY4NzY2_5c6acd97-1f47-4bb6-adf0-b6366a53d8f2">0001179929</ix:nonNumeric><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV80L2ZyYWc6YzY1YWE0NjM1OTkwNGQzNWI2NTc1ZWI5NWZlMmUzZmUvdGFibGU6MmQ0MzU4MDAyMDM1NDMyZTk4NmY4NjcyYmUwNTE0MWUvdGFibGVyYW5nZToyZDQzNTgwMDIwMzU0MzJlOTg2Zjg2NzJiZTA1MTQxZV8yLTEtMS0xLTY4NzY2_6b8d2278-8a74-40a9-bd62-ae12e9af7081">false</ix:nonNumeric><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV80L2ZyYWc6YzY1YWE0NjM1OTkwNGQzNWI2NTc1ZWI5NWZlMmUzZmUvdGFibGU6MmQ0MzU4MDAyMDM1NDMyZTk4NmY4NjcyYmUwNTE0MWUvdGFibGVyYW5nZToyZDQzNTgwMDIwMzU0MzJlOTg2Zjg2NzJiZTA1MTQxZV8zLTEtMS0xLTY4NzY2_aab69003-a8ea-4bd2-9f67-96607ba371a3">2022</ix:nonNumeric><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV80L2ZyYWc6YzY1YWE0NjM1OTkwNGQzNWI2NTc1ZWI5NWZlMmUzZmUvdGFibGU6MmQ0MzU4MDAyMDM1NDMyZTk4NmY4NjcyYmUwNTE0MWUvdGFibGVyYW5nZToyZDQzNTgwMDIwMzU0MzJlOTg2Zjg2NzJiZTA1MTQxZV80LTEtMS0xLTY4NzY2_a24e127f-0ae8-4d1d-9f74-53fbb20d2bc4">FY</ix:nonNumeric><ix:nonNumeric contextRef="i406902950217439984d39e91eadf0f62_D20220101-20221231" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzY3OA_6f2a845c-6f22-4bcc-9cb4-a0ec1e4ca0c4">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="ia8b74ae9eb6d45a8ba7fcf53e5356106_D20220101-20221231" name="moh:HealthPlanContractTerm" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzEwOTk1MTE2NDU4MTc_95927849-eb03-4285-a11c-36386eebadfb">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ieb8a1f0e16d84ec0a669cac6d07c2042_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3Nzg_99b8badb-97fb-4a1c-8779-f7186aae231d">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i8df844efd93545ae81dc29ce059d9765_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM1OA_a83fded9-5651-4fc9-bbd0-f88b865ee371">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="i55b78cda26784d3785265b3a4fef2f5a_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzUzNQ_5c091379-9c3b-4ddb-b0f8-72f24ac68c1e">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="moh-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0aedc9af750a409fa2db8df9d13e5fae_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i1d4e025ccdc84d63b8840e2ad276c200_I20230210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i863e60c11f294d5382a62b168dc11650_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i999be11240344aa48da9e906b939d685_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199fd9ed80d34939adcf4df9bd792f0d_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8771041280f54d5e8602cbc70ecac436_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff8f933345f844fa938f287ea4acbefa_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8df5a01609344460bb17a1e2311459c7_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cdb516bfdef4a8f9b6c6c031e73cef1_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ec77d8e31ee46229cf16bffe3977e23_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e5861f8a1be489fbadca2791aa90afe_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifc10bd10790d4245a58fd5f3eb995125_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c5174cdc8a543aab6a82650213fae42_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if519cf6d7ba746faa633b1d247f21140_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if419e645396c4411a00a65c9c61e8f4b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa1000dd422a4091b6562e182ae3a5e6_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad023f53ea0d4a398b072037f4fa5a28_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a1b426cbcba4d009021f4ffbe5138b1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie888b7a86e1749beb1747431a08efb69_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20ffea858f7a413e84d7c60bd51a39ad_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i579cf48f5d864bddb56457fa28bb2587_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c46a6c267b9418ea1b14da3214406ec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i587b2eb5aff244fbb08b0618fb285d59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7a7caae068640048ce1c869c4207d7f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa9ec9408e524d0c9ce56cae77d8fddc_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac9f15a52524444587078e926f065feb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i790f6598096b4e42affcce597dc39434_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i014d76748d9c435e8c2252256e738466_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8454949eb924409fbf2446822fa8d947_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1db3a5ad94a4885a560d39ee09283e7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1426d89bce2644bcb46ee222394ca3ab_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95d5fbc5f32e4d71bf63e8a5e693b170_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>moh:segment</xbrli:measure></xbrli:unit><xbrli:context id="i85e7dfbb25714e6fa1e9c665d5b451ed_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="member"><xbrli:measure>moh:member</xbrli:measure></xbrli:unit><xbrli:unit id="state"><xbrli:measure>moh:state</xbrli:measure></xbrli:unit><xbrli:context id="i406902950217439984d39e91eadf0f62_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0401c2aac1bd43f18925d12817958d7a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8b74ae9eb6d45a8ba7fcf53e5356106_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99e5c5b493404f65b708b3004c6d9e12_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthAndHumanServicesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i880dcbd954c94606b002149fe2d46983_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d1626275dac4e1fb93d80b9a4189fb4_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f69658aa2554010bae3200d5bca4c4d_D20220801-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MS</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i307d98a799304ec9b2ea5e24af4f8721_D20220713-20220713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MyChoiceWisconsinMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-13</xbrli:startDate><xbrli:endDate>2022-07-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3076577c633490db40aa71614578a1e_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5986c52b45c34430a4e46e84fd09578e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e1b19ab0d1440b7bfda152e607a2ac4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ac7e7cce7c7488f856cfee3ee520a77_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95f4006db8de462884c07a9ec0cebfd1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i283a40999d534f9f8762d3200d2894ff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72c7bccfd8ca4bf18d2185d8ddf074de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i386078af04c247fa901c709fe93c58dd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb8a1f0e16d84ec0a669cac6d07c2042_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a3656d06a5b43eaa3ec5dfdecceaac7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01aae92c76f5467c8edb776a572ee453_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f1d77f589974a46b23eddba5474dc63_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i04d52aa82e834517bbc667b377f4ad2c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2133a1cf36b14bcf8da5c42ae85115a7_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d0d8ea348c241a4b9f809ef2b12dfa2_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i7eaace7d309845f986541d1f02db8612_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePremiumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i889ea50e28bb4eed8c94a76a4a8d2cfb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic15c81fc6ee74eb7b1b3e900ac2e9c64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida4424c349994a84985daff56e365e13_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="combination"><xbrli:measure>moh:combination</xbrli:measure></xbrli:unit><xbrli:context id="id9fa89e4cd2b4b9e91fa9ccde542996c_D20221001-20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AgeWellNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i634b4c45a645473796839899d286be1f_D20221001-20221001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:MemberListsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AgeWellNewYorkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61710d4352384e94a9ce3f422ff24847_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1c23ba3104a41408eac767b2e726ada_D20220101-20220101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:MemberListsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibebb703fd4a9457dbfd3f97701ae04f3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0385a25993b0446c89a46930f0f91bde_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c65081a30c46cf8460d6a803e1f17a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f9337e55d484c09b5a1513d389ccf3b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide3af300aa304f619ca228fba2ff8fa4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29148aa5c5964b8f8d10939beb34fe33_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d53aea5bdb946b5b111b4810dc4fa29_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c870ec0a4794f988790a6078f3f01f9_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idda4ab8b08044fecb8346dffcc274008_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c7feed041254360ad5d3019f6a744aa_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18ece6617d5c496d9258ce72e661253f_D20211025-20211025"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-25</xbrli:startDate><xbrli:endDate>2021-10-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ac9097825cf45b8aee7acbbe22e2785_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8d5c0a352f4015825c1a2b0847caff_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5816b9d063fd4d4f9679ec48c22e7f0a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a831368a2374281bb348964ee80005f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7194e3bc65f34309acccfe5e8eebc910_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2225551d260b4fff8b1fcd8b2225a4d5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f5ae5c597454f189bef195ea3021a0e_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02199c67baf944d3a3c45249783e8405_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349d4816275045dfaa89200a39cfc5ef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if032025c0fb244a08e3b1ef2e3941040_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86889d94e8904988ac5e365d286d4a7b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i962ee0b812d44a069fd6c87304d4bc42_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ca41013f9c540f28757acf9f49962e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd8a5c0011b40b3bcaa8d6d87dd0520_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed1689dee4a41eda03bdc9c92c02453_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic9e4ac3e01c944c0b4c5b9718ba2c91c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i777ac9767d8c4e58a9ba5410baae7037_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5fcc352ead24246b3f108ce7dd02772_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib53a75ae39b14988836f4967971ce19b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie00e6ad84a254b709450ec9c3505658d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i335b83f184544942bc8b176a2ac44633_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2d1b7f1d31c442bfa81f382822fcd6b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba848d4237f8438e92d576eea416786f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic804f30bbe1941a5bd3069bece3d95c1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e5e68ad6d9c4c8ea513343c44695691_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d9f57cf49eb4b3d93701dd1a0ade3fd_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7e3a24c60394b48a399eb0153944cd5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1c35ad3ddab44e749e3b1e84bd0af3d1_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i960d1aa66067454ba42f52aed1e487bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0945f141b7f04212b9df4d20cbd510cc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30c11d9f4dee4390998e42cc33eb779e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8d46c859e204a6a80f2c36c08a46f8e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie4a239b8e14f435d944f2c1891cd59f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59f46e8b96ab457584d0f833330e5f53_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i576bade46abf49a3a06593cc4f8c1b09_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63aa4f07c83c4604ab411ba61e492802_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67dd714df638487ea61a28b66c207c9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3697cd3591404f5ab704c339859f4118_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib12a73884b8842b28e11041aea7f7b00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaaa9d3cee0f4342b73d5a8600dde796_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4319bd7e084d4fe6bbe30097e8b6ea2a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9e1553afa264028b0cd457a33f5a149_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ab0ae951a4e4b62b8083cf3e819c96a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9677ef65e67d487cabd070ff51ef3d1c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ada07a36a9546358030aaca313e8c59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bb2d39305ab437ebcfcb31c936ff8e7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cba98a86a954f7e8b177f14d18360bd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e93ce10aaba4d8b9c22ff0c09bacdc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14f045e80bf74bfdb5641b6aed955093_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibbd8a7e880f542339bc89afd0861bdf2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7757357193c94ad298e824f0d0518470_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16c45403f97a4dfb89f109633839fb86_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">moh:MinimumMemberEnrollmentTargetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016cfea50f2e421f88790001362b8498_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">moh:OperatingIncomeGuaranteeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73f9280e97a540afba84f71174ad29c4_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cdbd3860d6c488798e272302d58dcf7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib074c81f11e84dd0a6eb9b5acffd5118_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9641bb00844a4cbb9f0155ed3c8b8bed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieada9e735cbd4500babf6903ca597d7e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i562391d3973d4bd18a2b1c897b6c4610_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4446a6c953714ca891cd94c12831bb57_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia5acbc39836d44c0877b4659cfa91af9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7548748313094c9dbe3ac25160bfe723_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i396dfc81f74a4ecfa6a338862899d231_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32599e3034534c39973f424bf0a0d5a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a98f51b9a6349488555f9c9a14a3df0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i597b3ae4dd8e4818b13a24f5c890394d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbc3bf6d7b6442e59a8c61f5a4fcd73f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2790faed091468abda4356c61276b5a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i88055e4dad2440acb86c85055d57ae20_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48bac014b28a4af083ee0516405e8d5a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3dde019b6c3e473c978eda9b0c5c1d4a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34ceb7d8e4e84d52bcad92498c815f6e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9b5c6207fdc407187736e67b43692ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="position"><xbrli:measure>moh:position</xbrli:measure></xbrli:unit><xbrli:context id="i78c795544d9047bab9b654c5a011d8fe_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib20d5076d1754f178426259e52222452_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8df844efd93545ae81dc29ce059d9765_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dfbd2fd237c43bc9219d4395d0474dd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59d9a78c5ed049d0817ec4ff2cc838cd_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55b78cda26784d3785265b3a4fef2f5a_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a82111ac8a5487a824e9ddb07e72a1e_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd312c63a968473280db7fe49cdb0016_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6864266f9a2488da514854481f1778b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54050094325c4beba6d8861066ebb7a0_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b87a358731a498a8531fb81dfa9704f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15dba481187544f8ba4896f21c4e17cd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a482fdc9d8b4a328f48fa2052fe7c15_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifd2a2696dfc6483caf233c53d8331a83_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf0ed51712cb44a1a1fc04300c9d5c82_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibdcfd494f0b044d6a63a13ddfb1e9737_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib470bce1e1e7439682a2b7cf6079bc24_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f8881d1acd421683ecb16c150ac455_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13f72b45b4644a468fe3bf237a344ae5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie051c5fdd0164b7692de987d735b5614_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ica8010c73a874479be005b5c0efe2f9b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic83f163bbbec4901a4db9c0cd3b6beae_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35d2514974d648b4a321860ce0da423a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8d5443c6c445b7b1df9e882c954e13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i471861f0bd924c028fddde43043e03e5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba0e6e336cc2457895f26a4b547de184_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i277bd722f8d244c98c6cb91f7a6d9c98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ded5b162e2f49728c0e31ad73edfaeb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie099f36d881c40a3badd49fcbe24a158_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc025417eb148d5848c4dc550d72cf1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ContractRightsandLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a10f9e2abb34524aa6d8bc510e1aa4e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ContractRightsandLicensingAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4767b4d9b3f84070acc01bf02ca7feef_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4f6a981430a48419a3e8f282bae5cee_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8398f04c5a124683b46e82729ddf8f33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i390ee1c0be844452a70fa034460742a3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iea3d5b8372df4c6abfbb27c274bc673a_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0023c6ef83664597b60b89a484a483bc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i791cb3b2e1414dc995d8c3832e970a59_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CompleteCareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e256b4d3f8045d6a0d60842042e5330_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i628668ecbc2f46759154eeb9586c550c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f8bd3d713d84b16b5d4c1c2e0b0602f_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5b1cb8aec941ee8481b1247d22f717_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i048dd0bf323147f88d1ce251936a8002_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c45749706a94b278c9d69ee05c26153_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90f37a0e7ed48588693d942d7439522_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa1f11b3a0464f1c8a8e9399866f72eb_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e82750ee1ba4f92ba421980442e025f_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d21f0289d0f4503a608e0c544fa3528_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>moh:claim</xbrli:measure></xbrli:unit><xbrli:context id="ibc6e982b4b304fa2849be3b24940489a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d09c2e933d841399382aeaf45b11f51_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib60f70f36c784daabd311b0746a76015_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ce51eb40d964399bcbf595c78a3712c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ca478154d99467c8fbc5952a0a6af98_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iacb62ab94ca7487b9f7d98e6acaec0bd_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i820c538fe10a42b88e632ca56ab2d10e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id22d0b329d7a4bb5a67d6402f8b59ed8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71d56b2727844c739f8fc7c6c248b44d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia02c779ff61241edbb85961d0ca9c5eb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd32afbbde514f44b74fc5c5bac8e578_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a8a1bfa4d2646619b114fd4ca9f2f3c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i894911675af3435aaff732b2e986f5cb_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia92d461677b3467aad6b5cb1343d01b8_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7209f6abd53942d2b14fad2f133eb977_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0857a373c3b4a04a563c80433da37a7_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i231fe0f403304e04821105e21c970d54_D20221001-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic666c8c846a6470fa80b6fd8546e1fb8_D20230101-20230213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-02-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d872067ad8c4dfdb6ad4e01a7b702fc_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf47a0c9203348a4a82289677971cd52_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71b7d1ac171e4a1480d0d094dfc1146d_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748536bf845448ec8b3a8851a8779612_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i730ca96dd7ca4ca290d11ea041a783c7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:RestrictedandPerformanceStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d9217daf844c889c548acff4d0a65a_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:RestrictedandPerformanceStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic983aeae5acc408cb7dab92ea09a8f01_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:RestrictedandPerformanceStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31147c355a2444291af45d631a17138_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:EmployeeStockPurchasePlanandStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b98d941fd8447b4b70e3c1c0b270359_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:EmployeeStockPurchasePlanandStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49563c89a0044495a4024b953890bdec_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:EmployeeStockPurchasePlanandStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i808268ffa68b43739052deba1dced859_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">moh:EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e073e88099741bfbc940e573293e498_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i290c59f46b35464aaccca35307808b88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia92853bb15c348949754087573c60ee1_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i781d050a46354e80ade11c0f5bf7feda_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbd67479e4964d2fa6a1a3d75f41f688_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e2d29204efe4a1ca22aeb31da2ce2ac_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1ee1afc55d64732912318aa5e962ea8_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if47f80d012ad40879d50cdef41999002_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d6e9c94477f48d3bda9237fd401466b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0cb083a718842129d8611165782b40b_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba3d39cbcb0e429cbc30596a5203c015_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0d5667fa1324091ae2ef23e403af7b3_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63c5437de6ea46768cb132375cf8d34c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e239d54c717494dbfa7e61bb51ad771_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i077768d476524c85ac1e4304def5f128_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fdd93fd019b4782acece4fa6c2d7a43_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41fcaf49be0f49c4851f37e732bfb025_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8578fffd2f7a460688cbe76bc35b7b1a_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2480da1aa27740debeb057251b13ddd3_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e83845445404707a8b2523b0d438117_I20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001179929</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.257%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.722%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc2_3c6dd4f5-23c8-4628-9b80-d72ce34b157b">10-K</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Mark One)</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:4.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.459%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6NDU4ZmFhNGVhZmI4NDMzYzg3NjFiOTI2M2VkY2U0NmMvdGFibGVyYW5nZTo0NThmYWE0ZWFmYjg0MzNjODc2MWI5MjYzZWRjZTQ2Y18wLTAtMS0xLTY4NzY2_5e79791b-f30e-47cd-99c2-bda8348c488c">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center;text-indent:31.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FOR THE FISCAL YEAR ENDED <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8xMjg_1404695d-2199-4ddf-83f4-24630aa83948"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8xMjg_c3b089e9-e1b7-4acc-8646-02ded351ea54">DECEMBER 31</ix:nonNumeric>, 2022</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">or</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6YWExYzBmZTEwMWVkNGIwZjlkYjQ2ZjUwODEyMjYwMGEvdGFibGVyYW5nZTphYTFjMGZlMTAxZWQ0YjBmOWRiNDZmNTA4MTIyNjAwYV8wLTAtMS0xLTY4NzY2_6177eacf-ae42-43aa-829d-a18579130ece">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjgz_73ab9dc4-567a-4bfe-a66a-056cc7d89fc6">1-31719</ix:nonNumeric></span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.088%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><img src="moh-20221231_g1.jpg" alt="moh-20221231_g1.jpg" style="height:106px;margin-bottom:5pt;vertical-align:text-bottom;width:250px"/></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjg0_41d89fc0-b30d-44a0-82b2-a21c86944037">MOLINA HEALTHCARE, INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:32.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.428%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.137%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:512.25pt"><tr><td style="width:1.0pt"></td><td style="width:252.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:1.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:252.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6YWJhY2I5ZWEyMGE1NDVjYjljNTIyODA5NjRjMzk0YWQvdGFibGVyYW5nZTphYmFjYjllYTIwYTU0NWNiOWM1MjI4MDk2NGMzOTRhZF8wLTAtMS0xLTY4NzY2_135cabc2-5f0e-44af-9239-1168b74d05dc">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6YWJhY2I5ZWEyMGE1NDVjYjljNTIyODA5NjRjMzk0YWQvdGFibGVyYW5nZTphYmFjYjllYTIwYTU0NWNiOWM1MjI4MDk2NGMzOTRhZF8wLTItMS0xLTY4NzY2_75182737-5dc2-4779-aaba-3cb28fe45f93">13-4204626</ix:nonNumeric></span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(State or other jurisdiction of</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">incorporation or organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Identification No.)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc3_d72dec33-bdf9-4fd5-a641-a3bdbc76d946">200 Oceangate</ix:nonNumeric>, <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityAddressAddressLine2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc4_8d5b8481-4edd-4ac6-9277-e2164efb0310">Suite 100</ix:nonNumeric>, <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjcy_cfaf8de2-cd0c-43ad-82c0-27d4b85965eb">Long Beach</ix:nonNumeric>, <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjcz_0932a667-9ec6-450e-80bf-e6859394b21f">California</ix:nonNumeric> <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc5_fe243628-8a10-4445-9909-43637188612c">90802</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjcw_7aaf0425-465e-45e5-ae7f-4daac8ae01ef">562</ix:nonNumeric>) <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc0_03dabde5-91a3-4eaf-b5d5-cecb75dff260">435-3666</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="margin-bottom:6pt;margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:513.00pt"><tr><td style="width:1.0pt"></td><td style="width:183.25pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:140.50pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:183.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Title of Each Class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Each Exchange on Which Registered</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6NDk5MDFmNjhkYWYxNDA0ODliYjc4NmQyZGI0ZDkzMzUvdGFibGVyYW5nZTo0OTkwMWY2OGRhZjE0MDQ4OWJiNzg2ZDJkYjRkOTMzNV8xLTAtMS0xLTY4NzY2_426c1939-7806-404d-8122-b48611daead5">Common Stock, $0.001 Par Value</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6NDk5MDFmNjhkYWYxNDA0ODliYjc4NmQyZGI0ZDkzMzUvdGFibGVyYW5nZTo0OTkwMWY2OGRhZjE0MDQ4OWJiNzg2ZDJkYjRkOTMzNV8xLTEtMS0xLTY4NzY2_4e97d985-90fa-491c-91b3-9471b2e6afdf">MOH</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6NDk5MDFmNjhkYWYxNDA0ODliYjc4NmQyZGI0ZDkzMzUvdGFibGVyYW5nZTo0OTkwMWY2OGRhZjE0MDQ4OWJiNzg2ZDJkYjRkOTMzNV8xLTItMS0xLTY4NzY2_88e36d65-5dd4-4a53-bc1a-20ddacdc8dd9">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">None</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.184%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjcx_ae592f38-923d-4f8a-b2c0-feafec73c338">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Yes&#160;&#160;&#160;&#160; </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjgx_3f76ce78-212d-4f7b-a6a9-54bd958f9cc5">No</ix:nonNumeric> </span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjgy_bdb6766f-74c3-4ff2-91ef-a2d4c9fa285e">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjY4_242ddb91-6af9-45e0-ac7e-b5b1baeb02fb">Yes</ix:nonNumeric>&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:1pt;margin-top:8pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.577%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.636%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.584%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6MzM2NGUwNTk0NDdkNGQ0MWE3ZGY5MmQ4ZWIxODU4ZDMvdGFibGVyYW5nZTozMzY0ZTA1OTQ0N2Q0ZDQxYTdkZjkyZDhlYjE4NThkM18wLTAtMS0xLTY4NzY2_7e69146f-0304-4d16-82a7-34e3f939ed19">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6MzM2NGUwNTk0NDdkNGQ0MWE3ZGY5MmQ4ZWIxODU4ZDMvdGFibGVyYW5nZTozMzY0ZTA1OTQ0N2Q0ZDQxYTdkZjkyZDhlYjE4NThkM18wLTctMS0xLTY4NzY2_0441609b-822a-4898-a944-0614f501dea6">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6MzM2NGUwNTk0NDdkNGQ0MWE3ZGY5MmQ4ZWIxODU4ZDMvdGFibGVyYW5nZTozMzY0ZTA1OTQ0N2Q0ZDQxYTdkZjkyZDhlYjE4NThkM18wLTktMS0xLTY4NzY2_fafeee24-7a3c-489a-99aa-e680409d9f48">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc1_ad6ae94a-7979-4508-8ee0-f11464549e59">&#9746;</ix:nonNumeric></span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the  Act).&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjY5_ed135c6c-9a2c-4da8-b916-b57d55c672ff">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Yes&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9746;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of Common Stock held by non-affiliates of the registrant as of June&#160;30, 2022, the last business day of our most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="usd" contextRef="i0aedc9af750a409fa2db8df9d13e5fae_I20220630" decimals="-8" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8yNzYy_c29c40be-d399-4745-862a-5d9b0027ff2a">16.1</ix:nonFraction> billion (based upon the closing price for shares of the registrant&#8217;s Common Stock as reported by the New York Stock Exchange, Inc. on June&#160;30, 2022).</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;10, 2023, approximately <ix:nonFraction unitRef="shares" contextRef="i1d4e025ccdc84d63b8840e2ad276c200_I20230210" decimals="-3" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8yOTI5_a37c6296-3592-416c-b746-f85dcfbe0a67">57,900,000</ix:nonFraction> shares of the registrant&#8217;s Common Stock, $0.001 par value per share, were outstanding.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.184%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:8pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><div style="margin-top:8pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjg1_e3aecd35-33a5-4a66-b6ae-224839dfc0dc" escape="true">Portions of the registrant&#8217;s Proxy Statement for the 2023 Annual Meeting of Stockholders to be held on May 3, 2023, are incorporated by reference into Part III of this Form 10-K, to the extent described therein.</ix:nonNumeric></span></div><div style="text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MOLINA HEALTHCARE, INC. 2022 FORM 10-K </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.371%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part I</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Item Number</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_13">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_13">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_46">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_46">19</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unresolved Staff Comments</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_49">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_49">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_52">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_52">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Mine Safety Disclosures</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part&#160;II</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_55">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_55">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">[Reserved]</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_61">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_61">34</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_100">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_100">46</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_103">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_103">48</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_193">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_193">85</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_202">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_202">89</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part&#160;III</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">89</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">89</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">89</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">89</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_205">89</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Part&#160;IV</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_208">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_208">90</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Form 10-K Summary </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Not Applicable.</span></td></tr></table></div><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_211">Signatures</a></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORWARD LOOKING STATEMENTS</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K (this &#8220;Form 10-K&#8221;) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Many of the forward-looking statements are located under the heading &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; Forward-looking statements provide current expectations of future events based on certain assumptions and include any statement that does not directly relate to any historical or current fact. Forward-looking statements can also be identified by words such as &#8220;guidance,&#8221; &#8220;future,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;growth,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should&#8221;, &#8220;can,&#8221; &#8220;may,&#8221; and similar terms, although not all forward-looking statements contain these identifying words. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company&#8217;s actual results may differ significantly due to numerous known and unknown risks and uncertainties. Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section of this Form 10-K titled &#8220;Risk Factors,&#8221; as well as risks related to the following:  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of Medicaid redeterminations across the country following the ending of the Public Health Emergency (&#8220;PHE&#8221;) for the COVID-19 pandemic, including the accuracy of our projections regarding the number of members we expect to retain, their health acuity levels, and the scale of the transition of members out of the Medicaid program and the actuarially sound adjustment of rates with regard to the remaining population;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">budget pressures on state governments following the ending of the PHE and reduced federal matching funds, and states&#8217; efforts to reduce rates or limit rate increases; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the constantly evolving market dynamics surrounding the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Affordable Care Act (</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ACA&#8221;) Marketplaces, including issues impacting enrollment, special enrollment periods, member choice, risk adjustment estimates and results, and the potential for disproportionate enrollment of higher acuity members;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our efforts to retain existing or awarded government contracts, the success of our bid submissions in response to requests for proposal, and our ability to identify merger and acquisition targets to support our continued growth over time; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of the scaling up of our operations in California, Iowa, and Nebraska in connection with recent request for proposal (&#8220;RFP&#8221;) wins;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to close, integrate, and realize benefits from acquisitions, including the acquisitions of AgeWell New York and My Choice Wisconsin;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">subsequent adjustments to reported premium revenue based upon subsequent developments or new information, including changes to estimated amounts payable or receivable related to Marketplace risk adjustment; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">effective management of our medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to predict with a reasonable degree of accuracy utilization rates, including utilization rates associated with COVID-19; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">cyber-attacks, ransomware attacks, or other privacy or data security incidents involving either ourselves or our contracted vendors that result in an inadvertent unauthorized disclosure of protected information, and the extent to which our working in a remote work environment heightens our exposure to these risks;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to manage our operations, including maintaining and creating adequate internal systems and controls relating to authorizations, approvals, provider payments, and the overall success of our care management initiatives; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of working on a regular basis in a remote work environment, including any associated impairment charges or contract termination costs;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our receipt of adequate premium rates to support increasing pharmacy costs, including costs associated with specialty drugs and costs resulting from formulary changes that allow the option of higher-priced non-generic drugs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to operate profitably in an environment where the trend in premium rate increases lags behind the trend in increasing medical costs; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation and implementation of federal or state medical cost expenditure floors, administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates of amounts owed for such minimum annual medical loss ratio (&#8220;Minimum MLR&#8221;), administrative cost and profit ceilings, premium stabilization programs, profit-sharing arrangements, and risk adjustment provisions and requirements; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the Medicaid expansion medical cost corridor, and any other retroactive adjustment to revenue where methodologies and procedures are subject to interpretation or dependent upon information about the health status of participants other than Molina members; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the interpretation and implementation of at-risk premium rules and state contract performance requirements regarding the achievement of certain quality measures, and our ability to recognize revenue amounts associated therewith; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success and continuance of programs in California, Illinois, Michigan, Ohio, South Carolina, and Texas serving those dually eligible for both Medicaid and Medicare; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the accurate estimation of incurred but not reported or paid medical costs across our health plans;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">efforts by states to recoup previously paid and recognized premium amounts; </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in our annual effective tax rate, due to federal and/or state legislation, or changes in our mix of earnings and other factors;</span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the efficient and effective operations of the vendors on whom our business relies; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">complications, member confusion, eligibility redeterminations, or enrollment backlogs related to the renewal of Medicaid coverage;   </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">fraud, waste and abuse matters, government audits or reviews, comment letters, or potential investigations, and any fine, sanction, enrollment freeze, corrective action plan, monitoring program, or premium recovery that may result therefrom;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our providers, including delegated providers, the adequacy of our provider networks, the successful maintenance of relations with our providers, and the potential loss of providers; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">approval by state regulators of dividends and distributions by our health plan subsidiaries;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes in funding under our contracts as a result of regulatory changes, programmatic adjustments, or other reforms;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">high dollar claims related to catastrophic illness; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the resolution of litigation, arbitration, or administrative proceedings;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the greater scale and revenues of our health plans in California, New York, Ohio, Texas, and Washington, and risks related to the concentration of our business in those states;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure to comply with the financial or other covenants in our credit agreement or the indentures governing our outstanding senior notes;  </span></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of adequate financing on acceptable terms to fund and capitalize our expansion and growth, repay our outstanding indebtedness at maturity, and meet our general liquidity needs;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of a state in which we operate to renew its federal Medicaid waiver;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">changes generally affecting the managed care industry, including any new federal or state legislation that impacts the business space in which we operate; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increases in government surcharges, taxes, and assessments;  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of inflation on our medical costs and the cost of refinancing our outstanding indebtedness; </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">the unexpected loss of the leadership of one or more of our senior executives; and</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">increasing competition and consolidation in the Medicaid industry.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of the terms &#8220;Molina Healthcare, Inc.&#8221; &#8220;Molina Healthcare,&#8221; &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us,&#8221; as used herein, refers collectively to Molina Healthcare, Inc. and its wholly owned subsidiaries, unless otherwise stated. The Company assumes no obligation to revise or update any forward-looking statements for any reason, except as required by law.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 2</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_16"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ABOUT MOLINA HEALTHCARE</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 125), provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). Molina was founded in 1980 as a provider organization serving low-income families in Southern California and reincorporated in Delaware in 2002. We served approximately 5.3 million members as of December&#160;31, 2022, located across 19 states. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business footprint, as of December&#160;31, 2022, is illustrated below.  </span></div><div style="margin-top:6pt;text-align:center"><img src="moh-20221231_g2.jpg" alt="moh-20221231_g2.jpg" style="height:331px;margin-bottom:5pt;vertical-align:text-bottom;width:540px"/></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL HIGHLIGHTS</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except per-share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium Revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,771&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Care Ratio (&#8220;MCR&#8221;) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net Income per Diluted Share</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">_______________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Medical care ratio represents medical care costs as a percentage of premium revenue.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OUR SEGMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes long-term services and supports consultative services in Wisconsin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Notes to Consolidated Financial Statements, Note 16, &#8220;Segments,&#8221; for further information, including segment revenue and profit information.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEGMENT MEMBERSHIP</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our membership by segment as of the dates indicated:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,754,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,329,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,258,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,199,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEGMENT PREMIUM REVENUE</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents our consolidated premium revenue by segment for the periods indicated:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,827&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_19"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MISSION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We improve the health and lives of our members by delivering high-quality healthcare. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VISION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will distinguish ourselves as the low-cost, most effective and reliable health plan delivering government-sponsored care. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STRATEGY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term growth strategy remains unchanged, as we continue to be a pure-play government-sponsored healthcare business, which provides us with opportunities to compete in high-growth, synergistic market segments with attractive and sustainable margins. Our strategic priorities include: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Organic growth of our core businesses by growing with new state procurement opportunities, retaining existing contracts, increasing market share in current service areas and pursuing carve-in and/or adjacent opportunities; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Strong MCR and G&amp;A management to drive attractive and sustainable margins; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inorganic growth through accretive acquisitions; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reinvesting excess capital in the business or returning it to shareholders through share repurchases. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following key capabilities enable our growth strategy: </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Low Cost</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We provide low-cost health plans to our state customers for Medicaid and to our customers for the Medicare-Medicaid Plan (&#8220;MMP&#8221;) and Marketplace programs. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">High Quality and Appropriate Access to Care</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We provide our members effective and appropriate access to care at the right time and in the right setting. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Reliable Service and Seamless Experience</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We offer our state customers, members, and providers reliable service and a seamless experience.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Committed to Building Future Capabilities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are building capabilities that help to ensure compliant core operations, retain our revenue base and margins, and grow the business, that include, but are not limited to, complex care management, scalable and agile technology infrastructure, and advanced data analytics.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Strong Capital Foundation: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a strong balance sheet that provides a foundation for stability and growth. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Right Management Team to Execute our Growth Strategy: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an accountable, performance driven culture and a proven industry-leading executive management team with decades of experience. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KEY DEVELOPMENTS</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are pleased with the continued success of our profitable growth strategy. Our performance on Medicaid state procurements in 2022 was exceptional, as we were successful on every request for proposal response that we submitted. The acquisitions component of our growth strategy has produced seven transactions since 2020, representing approximately $10 billion in annual premium revenue, including the acquisition of Cigna&#8217;s Texas Medicaid business that we closed at the beginning of 2022, the AgeWell acquisition that we closed at the beginning of the fourth quarter 2022, and the My Choice Wisconsin acquisition that we announced in July 2022. Presented below is more detail on the recent developments and accomplishments relating to our strategy: </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2023, the Texas Health and Human Services Commission posted a notice on its website indicating that it was issuing a Notice of Intent to Award to Molina Healthcare of Texas, Inc. a STAR+PLUS ABD contract in each of Bexar, Dallas, El Paso, Harris, Hidalgo, Jefferson, Northeast Texas, and Tarrant Service Areas. The notice follows a proposal that we submitted in June 2022 to continue serving STAR+PLUS members in the same service areas, in response to an RFP posted in March 2022. The start of operations for the new contract is expected to begin in February 2024. Further, in December 2022, the RFP was posted for the TANF and CHIP programs (known as the STAR &amp; CHIP programs, and both existing contracts for Molina), with awards expected in February 2024 and the start of operations in February 2025.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we announced that the California Department of Health Care Services (&#8220;DHCS&#8221;) had confirmed our California health plan&#8217;s footprint as originally announced in August 2022, including Medi-Cal contract awards in each of Riverside, San Bernardino, Sacramento, and San Diego Counties. In Los Angeles County, we will share membership equally with the current commercial incumbent. The Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand our footprint in Los Angeles County. DHCS has also agreed to grant Molina a contract to offer exclusively aligned enrollment special needs plan (&#8220;EAE-SNP&#8221;) products for dual eligible members in Los Angeles County. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York (&#8220;AgeWell&#8221;). </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nebraska Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we announced that our Nebraska health plan subsidiary was selected by the Nebraska Department of Health and Human Services (&#8220;DHHS&#8221;) to provide health care services to Nebraskans under the state&#8217;s Medicaid managed care program. The new five-year contract is expected to begin on January 1, 2024, and may be extended for an additional two-years. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iowa Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Iowa health plan had been notified by the Iowa Department of Health and Human Services (&#8220;Iowa HHS&#8221;) of its intent to award a Medicaid managed care contract pursuant to the RFP issued by Iowa HHS in February 2022. The new four-year contract is expected to begin on July 1, 2023, and may be extended for an additional four years. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Mississippi health plan had been notified by the Mississippi Division of Medicaid (&#8220;DOM&#8221;) of its intent to award a Medicaid Coordinated Care Contract for its Mississippi Coordinated Access Program and Mississippi Children&#8217;s Health Insurance Program pursuant to the Request for Qualifications issued by DOM in December 2021. The four-year contract is expected to begin on July 1, 2023, and may be extended for an additional two years. The award enables us to continue serving Medicaid members across the state. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wisconsin Acquisition&#8212;Medicaid and Medicare.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin, further adding to our market leading Long-Term Services and Supports business. The purchase price for the transaction is approximately $150 million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in mid-2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. This new contract has a term of four years with a potential two-year extension.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Medicaid and Medicare.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ohio Procurement&#8212;Medicaid</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On April 13, 2021, we announced that our Ohio health plan subsidiary was selected as an awardee in all three regions across the state pursuant to the Medicaid managed care request for award </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued on September 30, 2020, by the Ohio Department of Medicaid. This new contract was expected to begin on July 1, 2022, but was subsequently delayed until February 1, 2023. Pursuant to this contract, we will offer health care coverage to Medicaid beneficiaries through the state of Ohio&#8217;s Covered Family and Children, Expansion, and ABD programs. </span></div><div><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAPITAL MANAGEMENT</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued management of our cash, investments, and capital structure is enabling us to meet the short- and long-term objectives and obligations of our business while maintaining liquidity and financial flexibility. We have continued to execute a capital plan that has produced a strong and stable balance sheet, with a simplified capital structure, which resulted in the following accomplishments in 2022:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our regulated health plans paid $668 million in total dividends to the parent company, representing cash in excess of their capital needs. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In the second and fourth quarters of 2022, we completed purchases of our common stock pursuant to stock purchase programs authorized by our board of directors in September 2021 and November 2022, respectively. Under these programs, pursuant to a Rule 10b5-1 trading plans, we:</span></div><div style="padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Purchased approximately 590,000 shares for $200&#160;million in the fourth quarter of 2022 (average cost of $339.06 per share). </span></div><div style="margin-bottom:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Purchased approximately 658,000 shares for $200 million in the second quarter of 2022 (average cost of $304.13 per share). </span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_22"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OUR BUSINESS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDICAID</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid was established in 1965 under the U.S.&#160;Social Security Act to provide healthcare and long-term services and support to low-income Americans. Although jointly funded by federal and state governments, Medicaid is a state-operated and state-implemented program. Subject to federal laws and regulations, states have significant flexibility to structure their own programs in terms of eligibility, benefits, delivery of services, and provider payments. As a result, there are 56 separate Medicaid programs&#8212;one for each U.S. state, each U.S. territory, and the District of Columbia.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government guarantees matching funds to states for qualifying Medicaid expenditures based on each state&#8217;s federal medical assistance percentage (&#8220;FMAP&#8221;). A state&#8217;s FMAP is calculated annually and varies inversely with average personal income in the state. The approximate average FMAP across all jurisdictions is currently 66%, and currently ranges from a federally established FMAP floor of 56% to as high as 84%. See further discussion regarding the FMAP below in &#8220;COVID-19 Pandemic&#8212;Federal Economic Stabilization and Other Programs.&#8221; Most states have contracted with managed care plans to provide Medicaid services to beneficiaries, seeking to increase budget predictability, constrain spending, improve access to care and value, and meet other objectives. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the following Medicaid programs:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Temporary Assistance for Needy Families (&#8220;TANF&#8221;) - This is the most common Medicaid program. It primarily covers low-income families with children.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicaid Aged, Blind or Disabled (&#8220;ABD&#8221;) - ABD programs cover low-income persons with chronic physical disabilities or behavioral health impairments. ABD beneficiaries typically use more services than those served by other Medicaid programs because of their critical health issues.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Children&#8217;s Health Insurance Program (&#8220;CHIP&#8221;) - CHIP is a joint federal and state matching program that provides healthcare coverage to children whose families earn too much to qualify for Medicaid coverage. States have the option of administering CHIP through their Medicaid programs.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicaid Expansion -</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In states that have elected to participate, Medicaid Expansion provides eligibility to nearly all low-income individuals under age 65 with incomes at or below 138% of the federal poverty line.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Long-Term Services and Supports (&#8220;LTSS&#8221;) &#8211; LTSS programs cover a range of medical and personal care assistance that people may need &#8211; for several weeks, months, or years &#8211; when they experience difficulty completing self-care tasks as a result of aging, chronic illness, or disability. Such services include, but are not limited to, nursing facility care, adult daycare programs, home health aide services, personal care services, transportation, and supported employment as well as assistance provided by a family caregiver.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of three to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue RFP open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the ABD; and regions or service areas. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Status of Significant Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicaid premium revenue constituted 80% of our consolidated premium revenue in the year ended December 31, 2022. Our Medicaid contracts with each of the states of New York, Texas and Washington accounted for approximately 10% or more of our consolidated Medicaid premium revenues in the year ended December 31, 2022. Our Medicaid contract with the state of California accounted for slightly below 10% in 2022, but we expect that it will be above 10% in 2024, following the commencement of the new, recently announced Medi-Cal contracts. The current status of each of these contracts is described below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our Medi-Cal managed care contracts with DHCS cover six county regions in northern and southern California (including Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state). These contracts are effective through December 31, 2023. In December 2022, we were notified by DHCS of its confirmation to award a Medi-Cal contract in each of Los Angeles, Riverside, San Bernardino, Sacramento, and San Diego Counties. The five Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand our footprint in Los Angeles County. Our California Medicaid contracts represented premium revenue of approximately $1,902 million, or 8%, of our consolidated Medicaid premium revenue in 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our presence in New York has increased substantially after completion of the Magellan Complete Care acquisition in December 2020, the Affinity Health Plan acquisition in October 2021 and the AgeWell New York acquisition in 2022. Affinity Health Plan is a Medicaid managed care organization serving members in New York City, Westchester, Orange, Nassau, Suffolk, and Rockland counties in New York.  AgeWell is a specialty managed care organization that provides long-term care services at home or in the community for those who are chronically ill or disabled in The Bronx, New York (Manhattan), Queens, Kings (Brooklyn), Nassau, Westchester, and Suffolk counties. Our New York Medicaid contracts represented premium revenue of approximately $3,099 million, or 12%, of our consolidated Medicaid premium revenue in 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On January 27, 2023, the Texas Health and Human Services Commission posted a notice on its website indicating that it was issuing a notice of Intent to Award to Molina Healthcare of Texas, Inc. a STAR+PLUS ABD contract in each of Bexar, Dallas, El Paso, Harris, Hidalgo, Jefferson, Northeast Texas, and Tarrant Service Areas. The notice follows a proposal that we submitted in June 2022 to continue serving STAR+PLUS members in the same service areas, in response to an RFP posted in March 2022. The start of operations for the new contract is expected to begin in February 2024. Further, in December 2022, the RFP was posted for the TANF and CHIP programs (known as the STAR &amp; CHIP programs, and both existing contracts for Molina), with awards expected in February 2024 and the start of operations in February 2025. Our Texas Medicaid contracts represented approximately $3,718 million, or 15%, of consolidated Medicaid premium revenue in 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Washington. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our managed care contract with the Washington State Health Care Authority (&#8220;HCA&#8221;) covers all ten regions of the state&#8217;s Apple Health Integrated Managed Care program, and was effective through December&#160;31, 2022. HCA exercised its renewal option for at least one year, through December 31, 2023. HCA plans to reprocure for Medicaid with the release of an RFP in the fall of 2023, with the resulting contract effective January 1, 2025. Our Washington Medicaid contract represented approximately $4,191 million, or 17%, of consolidated Medicaid premium revenue in 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A loss of any of our significant Medicaid contracts could have a material adverse effect on our business, financial condition, cash flows, and results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Public Health Emergency and Maintenance of Eligibility </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2020, at the outbreak of the COVID-19 pandemic, the HHS Secretary declared a PHE which, among other things established a Maintenance of Eligibility (&#8220;MOE&#8221;) requirement in Medicaid. For the periods during which the PHE was in effect, the states were not allowed to recertify and disenroll members for most eligibility reasons. CMS reported that based on preliminary data for September 2022, Medicaid and CHIP enrollment had exceeded 90 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">million - an increase of over 20 million compared to early 2020. With the passage and signing of the Consolidated Appropriations Act of 2023, this situation is expected to change. This Act allows states to restore eligibility verification processes starting February 2023 and to terminate members deemed ineligible as early as April 1, 2023, irrespective of the status of the PHE. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upcoming redetermination backlog processing is a major risk for continuity of care of current Medicaid enrollees as well as an unprecedented operational challenge for state Medicaid agencies. The final outcome of the redetermination process is not known, and a range of estimated potential impacts are possible; however, we expect membership and premium revenues to decline once normal enrollment and renewal operations resume on April 1, 2023. We have been in close touch with the federal and state authorities in the states in which we operate to develop action plans designed to minimize potential disruptions in care for our members. Our local teams are ready to support our Medicaid-eligible members to recertify, and help to transition those who became eligible for Marketplace, in full compliance with federal and state regulations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Premium Rates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our Medicaid contracts, state government agencies pay our health plans fixed per-member per-month (&#8220;PMPM&#8221;) rates that vary by state, line of business, demographics and, in most instances, health risk factors. CMS requires these rates to be actuarially sound. In exchange for the payment received, Molina arranges, pays for, and manages healthcare services provided to Medicaid beneficiaries. Therefore, our health plans are at risk for the medical costs associated with their members&#8217; healthcare. Premium rates under our Medicaid contracts are subject to each state&#8217;s annual appropriation process. The premium rates paid to our health plans may vary substantially between states and among various government programs. For the year ended December 31, 2022, Medicaid program PMPM premium rates ranged from $170 to $1,130.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Member Enrollment and Marketing</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most states allow eligible Medicaid members to select the Medicaid plan of their choice. This opportunity to choose a plan is typically afforded to the member at the time of first enrollment and, at a minimum, annually thereafter.&#160;In some of the states in which we operate, a substantial majority of new Medicaid members voluntarily select a plan with the remainder subject to the auto-assignment process described below, while in other states less than half of new members voluntarily choose a plan.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicaid health plans may benefit from auto-assignment of individuals who do not choose a plan, but for whom participation in managed care programs is mandatory. Each state differs in its approach to auto-assignment, but one or more of the following criteria is typical in auto-assignment algorithms: a Medicaid beneficiary's previous enrollment with a health plan or experience with a particular provider contracted with a health plan, enrolling family members in the same plan, a plan's quality or performance status, a plan&#8217;s network and enrollment size, awarding all auto-assignments to a plan with the lowest bid in a county or region, and equal assignment of individuals who do not choose a plan in a specified county or region. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicaid marketing efforts are regulated by the states in which we operate, each of which imposes different requirements for, or restrictions on, Medicaid sales and marketing. These requirements and restrictions are revised from time to time. None of the jurisdictions in which we operate permit direct sales by Medicaid health plans.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDICARE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare is a federal program that provides eligible persons age&#160;65 and over, and some disabled persons, with a variety of hospital, medical insurance, and prescription drug benefits. Medicare is funded by Congress, and administered by the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;). Medicare beneficiaries may enroll in a Medicare Advantage plan, under which managed care plans contract with CMS to provide benefits that are comparable to original Medicare. Since 2006, Medicare beneficiaries have had the option of selecting a prescription drug benefit from an existing Medicare Advantage plan. The drug benefit, available to beneficiaries for a monthly premium, is subject to cost-sharing depending upon the specific benefit design of the selected plan. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over 12 million low-income elderly and disabled people qualify for both the Medicare and Medicaid programs (&#8220;dual eligible&#8221; individuals). These beneficiaries are more likely than other Medicare beneficiaries to be frail, live with multiple chronic conditions, and have functional and cognitive impairments. Medicare is their primary source of health insurance coverage. Medicaid supplements Medicare by paying for services not covered by Medicare, such as dental care and long-term care services and supports, and by helping to cover Medicare&#8217;s premiums and cost-sharing requirements. Together, these two programs help to shield very low-income Medicare beneficiaries from potentially unaffordable out-of-pocket medical and long-term care costs.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the following Medicare programs:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare Advantage-Part D, or MAPD &#8211; We contract with CMS under the Medicare Advantage program to provide benefits in excess of original Medicare, including cost-sharing and enhanced prescription drug benefits under Part D, that are targeted towards low-income beneficiaries;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Dual Eligible Special Needs Plan, or D-SNP &#8211; We contract with CMS to provide benefits in excess of original Medicare, including care coordination complex case management and care management;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fully-Integrated Dual Special Needs Plans, or FIDE &#8211; We contract with CMS and state Medicaid agencies to fully integrate care for dually eligible beneficiaries under a single managed care plan;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Medicare-Medicaid Plans, or MMPs &#8211; To coordinate care and deliver services in a more financially efficient manner, some states have undertaken demonstration programs to integrate Medicare and Medicaid services for dual-eligible individuals. We operate MMPs in six states, as described further below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into MAPD contracts with CMS annually, and for D-SNP, FIDE and MMP, we enter into contracts with CMS, in partnership with each state&#8217;s department of health and human services. Such contracts typically have terms of one to three years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Status of MMP Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, CMS published a Final Rule, that addressed the termination of the Financial Alignment Initiative Demonstration and provided a pathway for states to transition their MMP programs into an integrated dual eligible special needs plan. Under a provision within the Final Rule, states can maintain their existing MMP through a 2-year extension until December 31, 2025, so long as the applicable state provided CMS with a transition plan by October 1, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our California MMP contract, which expired on December&#160;31, 2022, represented aggregate premium revenue of approximately $134 million in 2022. Many of our California MMP members are being transitioned to Molina&#8217;s California EAE-SNP products in early 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Texas MMP contract is effective through December 31, 2023, which represented aggregate premium revenue of approximately $410 million in 2022. The Texas Medicaid agency submitted a plan to CMS for transitioning the current MMP contracts to integrated D-SNP contracts by January 1, 2026. In the interim, the agency is evaluating renewal options for the current MMP contracts which expire at the end of 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Illinois, Ohio, Michigan and South Carolina MMP contracts are effective through December 31, 2023, which represented aggregate premium revenue of approximately $1,519 million in 2022. Based on the transition plans submitted by those states to CMS, we expect to transition these members to our integrated D-SNP plans by January 1, 2026. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Premium Rates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Medicare Advantage, managed care plans contract with CMS to provide benefits in exchange for a fixed PMPM premium payment that varies based on health plan star rating and member demographics, including county residence and health risk factors. CMS also considers inflation, changes in utilization patterns and average per capita fee-for-service Medicare costs in the calculation of the fixed PMPM premium payment. Amounts payable to us under the Medicare Advantage contracts are subject to annual revision by CMS, including any federal budget cuts or tax changes applicable to Medicare. We elect to participate in each Medicare service area or region on an annual basis. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CMS developed the Medicare Advantage Star ratings system to help beneficiaries choose among competing plans, awarding between 1.0 and 5.0 stars to Medicare Advantage plans based on performance in certain measures of quality. The Star ratings are used by CMS to award quality bonus payments to Medicare Advantage plans. Beginning with the 2014 Star ratings, Medicare Advantage plans were required to achieve a minimum of 4.0 Stars to qualify for a quality bonus payment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare Advantage premiums are subject to retroactive increase or decrease based on the health status of our Medicare members, as measured by member risk scores determined pursuant to the CMS risk adjustment model. The data we provide to CMS to determine risk scores is subject to audit by CMS at the contract level, by plan year on an on-going basis. Such risk adjustment data validation (&#8220;RADV&#8221;) audits can result in retroactive and prospective premium adjustments. We record the estimated impact of audit settlements as a reduction to premium revenues, based upon available information, in the year that CMS determines repayment is required. On January 30, 2023, CMS finalized its approach to RADV audits, including its decision to extrapolate the results of audit samples when calculating payment errors, but without comparison of the audit results to a similar audit of the government&#8217;s original </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare program. CMS will begin extrapolation with audits for the 2018 plan year and, as a result, will settle payment errors identified in RADV audits for plan years 2011 through 2017 on a non-extrapolated basis. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compared with our Medicaid plans, Medicare Advantage and MMP contracts generate higher average PMPM revenues and healthcare costs. For the year ended December 31, 2022, Medicare program PMPM premium rates ranged from $840 to $3,900.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Member Enrollment and Marketing</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare members may be enrolled through auto-assignment, as described above in &#8220;Medicaid&#8212;Member Enrollment and Marketing,&#8221; or by enrolling in our plans with the assistance of insurance agents employed by Molina, outside brokers, or via the Internet. Generally, the enrollment period occurs between mid-October and early December for coverage that begins on the following January 1.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Medicare marketing and sales activities are regulated by CMS and the states in which we operate. CMS has oversight over all marketing materials used by Medicare Advantage plans, and in some cases has imposed advance approval requirements. CMS generally limits sales activities to those conveying information regarding benefits, describing the operations of our managed care plans, and providing information about eligibility requirements. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ our own insurance agents and contract with independent, licensed insurance agents to market our Medicare Advantage products. We have continued to expand our use of independent agents because the cost of these agents is largely variable and we believe the use of independent, licensed agents is more conducive to the shortened Medicare selling season and the open enrollment period. The activities of our independent, licensed insurance agents are also regulated by CMS. We also use direct mail, mass media and the Internet to market our Medicare Advantage products.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MARKETPLACE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ACA authorized the creation of Marketplace insurance exchanges, allowing individuals and small groups to purchase federally subsidized health insurance effective January 1, 2014. Marketplace plans must be ACA-compliant, meeting standards established by the federal government, including a requirement to cover certain essential health benefits. Certain beneficiaries qualify for premium tax credits and cost-sharing reductions based on annual household income. Plans are categorized by metal tiers (Platinum, Gold, Silver or Bronze), which determine how beneficiaries and the plan share costs (e.g., premiums, out-of-pocket costs and deductibles). We</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> offer Marketplace plans in many of the states where we offer Medicaid health plans. Our plans allow our Medicaid members to stay with their providers as they transition between Medicaid and the Marketplace. Additionally, our plans remove financial barriers to quality care and seek to minimize members' out-of-pocket expenses. In 2023, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are participating in the Marketplace in all our markets except Arizona, Massachusetts, Nevada, New York, and Virginia.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect Marketplace enrollment to decrease by approximately 30% in 2023, to a total of 230,000 members by the end of the year. This would represent an estimated Marketplace premium revenue decline of approximately 30% in 2023, and is in line with our product and pricing strategy to achieve our target margins in this business.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contracts</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We enter into contracts with CMS annually for the state Marketplace programs. These contracts have a one-year term ending on December 31, and must be renewed annually.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis for Premium Rates</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For Marketplace, we develop each state&#8217;s premium rates during the spring of each year for policies effective in the following calendar year. Premium rates are based on our estimates of utilization of services and unit costs, anticipated member risk acuity and related federal risk adjustment transfer amounts, and non-benefit expenses such as administrative costs, taxes, and fees. The premium rates are filed for approval with the various state and federal authorities in accordance with the rules and regulations applicable to the ACA individual market, including, but not limited to,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">minimum loss ratio thresholds and adjustments for permissible rate variations by age, geographic area, and variations in plan design. In the year ended December 31, 2022, Marketplace program PMPM premium rates ranged from $260 to $720. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Member Enrollment and Marketing</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Marketplace members enroll in our plans with the assistance of insurance agents employed by Molina, outside brokers, vendors, direct to consumer marketing and via the Internet.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our Marketplace sales activities are regulated by CMS (such as eligibility determinations), our marketing activities are regulated by the individual states in which we operate. Some states require us to obtain prior approval of our marketing materials, others simply require us to provide them with copies of our marketing materials, and some states do not request our marketing materials.&#160;We are able to freely contact our members and provide them with marketing materials as long as those materials are fair and do not discriminate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Marketplace sales and marketing strategy is to provide high quality, affordable, compliant and consumer-centric Marketplace products through a variety of distribution channels. Our Marketplace products are displayed on the Federally Facilitated Marketplace (&#8220;FFM&#8221;) and the State Based Marketplace (&#8220;SBM&#8221;) in the states in which we participate in the Marketplace. We also contract with independent, licensed insurance agents to market our Marketplace products. The activities of our independently licensed insurance agents are also regulated by both CMS and the departments of insurance in the states in which we participate. Our sales cycle typically peaks during the annual Open Enrollment Period (&#8220;OEP&#8221;) as defined and regulated by CMS and the applicable FFM and SBM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_25"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COVID-19 PANDEMIC</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the COVID-19 pandemic continues to evolve, its ultimate impact to our business, results of operations, financial condition and cash flows is uncertain and difficult to predict. Specific trends and uncertainties related to our health plans follow.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Federal Economic Stabilization and Other Programs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 30, 2023, the Biden Administration issued a Statement of Administration Policy declaring its intent to end the COVID-19 national emergency and PHE on May 11, 2023. While the Consolidated Appropriations Act of 2023 decoupled Medicaid eligibility redeterminations from the PHE, there are several other healthcare programs tied to the PHE which will be impacted by this change in policy. These include coverage of COVID-19 testing and vaccines, changes to the Medicare fee schedule for COVID-related treatments, and free coverage of at-home COVID-19 diagnostic tests. Upon the end of the PHE on May 11, 2023, per federal statutory and regulatory requirements, some of these policies will end immediately, some will continue for the rest of 2023 or through 2024, and some will remain in place permanently.  At this time, we are unable to reasonably estimate the cumulative impact of all these changes on our business, financial condition, and operating results.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enrollment and Premium Revenue</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding acquisitions and our exit from Puerto Rico, we added approximately 750,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for Medicaid eligibility. The recently passed Consolidated Appropriations Act of 2023 authorizes states to resume redeterminations and terminate coverage for ineligible enrollees starting on April 1, 2023, irrespective of the status of the PHE. Consequently, we expect Medicaid enrollment to continue to benefit from the current pause on membership redeterminations through March 31, 2023, and then decline thereafter as states resume normal enrollment and renewal operations on April 1, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which resulted in a reduction of our medical margin. The current rate environment is stable and rational. We continue to believe that the risk-sharing corridors previously introduced are related to the declared PHE and will likely be eliminated as the COVID pandemic subsides. However, the risk corridors continue to contribute an added level of variability to our results of operations. We recognized approximately $197&#160;million for the impact of risk corridors in the year ended December 21, 2022, compared to $323 million recognized in the year ended December 31, 2021. The decrease in 2022 is due to the elimination of most of the COVID-19 risk corridors. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medical Care Costs</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect continued uncertainty regarding utilization trends as the pandemic continues. The speed and extent to which utilization rebounds will be greatly impacted by the economy and consumer behavior, provider capacity, and the recent resurgence of COVID-19 infection rates. We believe that some portion of the utilization curtailment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experienced in the year ended December 31, 2022 is likely the result of service deferrals, which will likely be provided to members over the upcoming year.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Capital and Financial Resources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic and, as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future. Refer to &#8220;Liquidity and Financial Condition&#8221; below for a discussion of our capital and financial resources.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_28"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LEGISLATIVE AND POLITICAL ENVIRONMENT</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRESSURES ON FUNDING</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to states&#8217; budget challenges, including shortfalls resulting from the COVID-19 pandemic, and political agendas at both the state and federal levels, there are a number of different legislative proposals being considered, some of which would involve significantly reduced federal or state spending on the Medicaid and Medicare programs, constitute a fundamental change to the federal role in healthcare and, if enacted, could have a material adverse effect on our business, financial condition, cash flows, or results of operations. These proposals include elements such as the following, as well as numerous other potential changes and reforms:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in the entitlement nature of Medicaid (and perhaps Medicare as well) by capping future increases in federal health spending for these programs, and shifting much more of the risk for health costs in the future to states and consumers;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reversing the ACA&#8217;s expansion of Medicaid that enables states to cover low-income childless adults;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changing Medicaid to a state block grant program, including potentially capping spending on a per-enrollee basis;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Requiring Medicaid beneficiaries to work;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Limiting the amount of lifetime benefits for Medicaid beneficiaries; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising Medicare eligibility to age 67. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recently, House Republicans have started to weigh a series of legislative proposals targeting Medicaid, Medicare and other entitlement programs as part of a broader campaign to reduce federal spending and, to maximize their leverage, they have pursued these spending cuts in exchange for their support to raise the debt ceiling, the legal cap that allows the U.S. government to borrow money to pay its bills. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AFFORDABLE CARE ACT</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proposed changes and reforms to the ACA have included, or may include the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Prohibiting the federal government from operating Marketplaces;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Eliminating the advanced premium tax credits and cost sharing reductions for low income individuals who purchase their health insurance through the Marketplaces;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expanding and encouraging the use of private health savings accounts;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Providing for insurance plans that offer fewer and less extensive health insurance benefits than under the ACA&#8217;s essential health benefits package, including broader use of catastrophic coverage plans, or short-term health insurance;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establishing and funding high risk pools or reinsurance programs for individuals with chronic or high cost conditions; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Allowing insurers to sell insurance across state lines.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The passage of any of these changes or other reforms could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CORPORATE TAX REFORM</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent proposals related to corporate tax reform propose raising corporate taxes, among other things. Some proposed reforms could have a material impact on our future results of operations. We will continue to monitor developments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for the tax years beginning on or after January 1, 2023. We do not expect such tax provisions to have a material impact on our consolidated financial results. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 12</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OPERATIONS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUALITY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends, to a significant degree, on the quality of the services we provide. We are focused on providing our members effective and appropriate access to care at the right time and in the right setting, including preventive health and wellness and care management. We offer our government customers, members and providers reliable service and a seamless experience. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, 15 of our health plans were accredited by the National Committee for Quality Assurance (&#8220;NCQA&#8221;), of which 12 of those health plans also received the Multicultural Health Care Distinction, which is awarded to organizations that meet or exceed NCQA&#8217;s rigorous requirements for multicultural healthcare. Additionally, seven health plans earned NCQA&#8217;s Long Term Services and Supports Distinction. We believe that these objective measures of quality are important to state Medicaid agencies, as a growing number of states link reimbursement and patient assignment to quality scores. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, CMS published its updated Medicare Star Ratings for the plan year 2023. For the 2023 Star Ratings, five of our plans had a decrease of 0.5 Stars, two of our plans had a decrease of 1 Star, one plan had a decrease of 1.5 Stars, and two plans either maintained or increased Star ratings by 0.5. The decreases to the 2023 Star Ratings impact the 2024 bonus year payments. We have been actively working on improvement plans and remain committed to invest in these programs to improve our quality star scores with a focus on member experience and access measures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the states where our health plans are accredited by the NCQA and/or have Medicare Star Ratings, the table below presents such health plans&#8217; NCQA status, as well as their current scores as part of the Medicare Star Ratings, which measures the quality of Medicare plans across the country using a 5-star rating system. </span></div><div style="margin-top:6pt;text-align:center"><img src="moh-20221231_g3.jpg" alt="moh-20221231_g3.jpg" style="height:509px;margin-bottom:5pt;vertical-align:text-bottom;width:400px"/></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROVIDERS</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We arrange healthcare services for our members through contracts with a vast network of providers, including independent physicians and physician groups, hospitals, ancillary providers, and pharmacies. We strive to ensure that our providers have the appropriate expertise and cultural and linguistic experience. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The quality, depth and scope of our provider network are essential if we are to ensure quality, cost-effective care for our members. In partnering with quality, cost-effective providers, we utilize clinical and financial information derived by our medical informatics function, as well as the experience we have gained in serving Medicaid members, to gain insight into the needs of both our members and our providers. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Physicians</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with both primary care physicians and specialists, many of whom are organized into medical groups or independent practice associations. Primary care physicians provide office-based primary care services. Primary care physicians may be paid under capitation or fee-for-service contracts and may receive additional compensation by providing certain preventive care services. Under capitation payment arrangements, healthcare providers receive fixed, pre-arranged monthly payments per enrolled member, whereas under fee-for-service payment arrangements, healthcare providers are paid a fee for each particular service rendered. Our specialists care for patients for a specific episode or condition, usually upon referral from a primary care physician, and are usually compensated on a fee-for-service basis. When we contract with groups of physicians on a capitated basis, we monitor their solvency. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hospitals</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We generally contract with hospitals that have significant experience dealing with the medical needs of the Medicaid population. We reimburse hospitals under a variety of payment methods, including fee-for-service, per diems, diagnostic-related groups, capitation, and case rates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ancillary Providers</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ancillary agreements provide coverage of medically-necessary care, including laboratory services, home health, physical, speech and occupational therapy, durable medical equipment, radiology, ambulance and transportation services, and are reimbursed on a capitation and fee-for-service basis.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource pharmacy benefit management services, including claims processing, pharmacy network contracting, rebate processing and mail and specialty pharmacy fulfillment services. We have entered into an early renewal of our long-standing pharmacy benefit management (&#8220;PBM&#8221;) agreement with CVS Caremark (&#8220;Caremark&#8221;). Under the renewal, Caremark will continue to be the exclusive PBM provider to our health plan subsidiaries (except Medicaid plans in those states where the contacting agency designates a single PBM to provide services for members of all plans) through December 31, 2026. The renewal includes improvements to network rates and administrative costs as well as improved terms around performance standards. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDICAL MANAGEMENT</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to improve the health outcomes and lives of our members by delivering high-quality healthcare. We believe our singular focus on government-sponsored healthcare enables us to identify and implement efficiencies that distinguish us as the low-cost, high-quality health plan of choice. We emphasize primary care physicians as the central point of delivery for routine and preventive care, coordination of referrals to specialists, and appropriate assessment of the need for hospital care. This model has proved to be an effective method of coordinating medical care for our members.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Utilization Management </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our goal is to optimize access to low-cost, high-quality care. This is achieved by sound clinical policy based on current evidence-based practices. Additionally, we continuously monitor utilization patterns and strive to identify new opportunities to reduce cost and improve quality of care. Our utilization management process serves as a bridge to identify at-risk members for referral into internally developed case management programs such as &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Transitions of Care</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#8221; which facilitates post-discharge safety and appropriate outcomes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Population Management </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe high-quality, affordable care is achieved through a variety of programs tailored to our members&#8217; emerging needs. Individuals are identified for interventions, and programs are customized, based on predictive analytics and our member assessment process. These tools ensure that the appropriate level of services and support are provided to address physical health, behavioral health, and social determinants of health.&#160;This </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">comprehensive and customized approach is designed to help members achieve their goals and improve their overall quality of life.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmacy Management </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pharmacy programs are designed to make us a trusted partner in improving member health and healthcare affordability. We strategically partner with physicians and other healthcare providers who treat our members. This collaboration results in drug formularies and clinical initiatives that promote improved patient care. We employ full-time pharmacists and pharmacy technicians who work closely with providers to educate them about our formulary products, clinical programs, and the importance of cost-effective care.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Cost Management </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use various strategies to mitigate the negative effects of healthcare cost inflation. Specifically, our health plans try to control medical care costs through contracts with independent providers of healthcare services. Through these contracted providers, our health plans emphasize preventive healthcare and appropriate use of specialty and hospital services. There can be no assurance, however, that our strategies to mitigate medical care cost inflation will be successful. Competitive pressures, new healthcare and pharmaceutical product introductions, demands from healthcare providers and customers, applicable regulations, or other factors may affect our ability to control medical care costs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INFORMATION TECHNOLOGY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is dependent on effective and secure information systems that assist us in processing provider claims, monitoring utilization and other cost factors, supporting our medical management techniques, providing data to our regulators, and implementing our data security measures. Our members and providers also depend upon our information systems for enrollment, premium processing, primary care and specialist physician roster access, membership verifications, claims status, provider payments, and other information.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have partnered with third parties to support our information technology systems. This makes our operations vulnerable to adverse effects if such third parties fail to perform adequately. In 2019, we entered into an agreement with a third-party vendor who manages certain of our information technology services including, among other things, our infrastructure operations, end-user services, data centers, public cloud and application management. In 2022 we extended our agreement for an additional seven years.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the agreement, we were able to reduce our administrative expenses, while improving the reliability of our information technology functions, and maintain targeted levels of service and operating performance. A portion of these services are provided on our premises, while other portions of the services are performed at the vendor&#8217;s facilities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our information systems require an ongoing commitment of significant resources to maintain, protect, and enhance existing systems and develop new systems to keep pace with continuing changes in information processing technology, evolving systems and regulatory standards, changing customer preferences, acquisitions and increased security risks.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CENTRALIZED SERVICES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We provide certain centralized medical and administrative services to our subsidiaries pursuant to administrative services agreements that include, but are not limited to, information technology, product development and administration, underwriting, claims processing, customer service, certain care management services, human resources, marketing, purchasing, risk management, actuarial, finance, accounting, compliance, legal and public relations.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_34"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">COMPETITIVE CONDITIONS AND ENVIRONMENT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face varying levels of competition. Healthcare reform proposals may cause organizations to enter or exit the market for government-sponsored health programs. However, the licensing requirements and bidding and contracting procedures in some states may present partial barriers to entry into our industry.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compete for government contracts, renewals of those government contracts, members, and providers. State agencies consider many factors in awarding contracts to health plans. Among such factors are the health plan&#8217;s provider network, quality scores, medical management, degree of member satisfaction, timeliness of claims payment, and financial resources. Potential members typically choose a health plan based on a specific provider being a part of the network, the quality of care and services available, accessibility of services, and reputation or name recognition of the health plan. We believe factors that providers consider in deciding whether to contract with a health plan include potential member volume, payment methods, timeliness and accuracy of claims payment, and administrative service capabilities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid managed care industry is subject to ongoing changes as a result of healthcare reform, business consolidations and new strategic alliances. We compete with national, regional, and local Medicaid service providers, principally on the basis of size, location, quality of the provider network, quality of service, and reputation. Our primary competitors in the Medicaid managed care industry include Centene Corporation, CVS Health Corporation, Elevance Health, Inc., and UnitedHealth Group Incorporated and other large not-for-profit healthcare organizations. Competition can vary considerably from state to state. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare market is highly competitive across the country, with large competitors, such as CVS Health Corp., Humana Inc., and UnitedHealth Group Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketplace</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Low-income members who receive government subsidies comprise the vast majority of Marketplace membership, which is served by a limited number of health plans. Our primary competitor for low-income Marketplace membership is Centene Corporation.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_37"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REGULATION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health plans are highly regulated by both state and federal government agencies. Regulation of managed care products and healthcare services varies from jurisdiction to jurisdiction, and changes in applicable laws and rules occur frequently. Regulatory agencies generally have discretion to issue regulations and interpret and enforce laws and rules. Compliance with such laws and rules may lead to additional costs related to the implementation of additional systems, procedures and programs that we have not yet identified. Such agencies have become increasingly active in recent years in their review and scrutiny of health insurers and managed care organizations, including those operating in the Medicaid and Medicare programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HIPAA AND THE HITECH ACT </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1996, Congress enacted the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;). All health plans are subject to HIPAA, including ours. HIPAA generally requires health plans to:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Establish the capability to receive and transmit electronically certain administrative healthcare transactions, such as claims payments, in a standardized format;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Afford privacy to patient health information;&#160;and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Protect the privacy of patient health information through physical and electronic security measures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2009, the Health Information Technology for Economic and Clinical Health Act (&#8220;HITECH&#8221;) imposed requirements on uses and disclosures of health information; included requirements for HIPAA business associate agreements; extended parts of HIPAA privacy and security provisions to business associates; added data breach notification requirements for covered entities and business associates and reporting requirements to the U.S. Department of Health and Human Services (&#8220;HHS&#8221;) and, in some cases, to the media; strengthened enforcement; and imposed higher financial penalties for HIPAA violations. In the conduct of our business, depending on the circumstances, we may act as either a covered entity and/or a business associate.&#160;HIPAA privacy regulations do not preempt more stringent state laws and regulations that may apply to us.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a HIPAA compliance program, which we believe complies with HIPAA privacy and security regulations, and have dedicated resources to monitor compliance with this program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare reform created additional tools for fraud prevention, including increased oversight of providers and suppliers participating or enrolling in Medicaid, CHIP, and Medicare. Those enhancements included mandatory licensure for all providers, and site visits, fingerprinting, and criminal background checks for higher risk providers. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FRAUD AND ABUSE LAWS AND THE FALSE CLAIMS ACT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we receive payments from federal and state governmental agencies, we are subject to various laws commonly referred to as &#8220;fraud and abuse&#8221; laws, including federal and state anti-kickback statutes, prohibited referrals, and the federal False Claims Act, which permit agencies and enforcement authorities to institute a suit against us for violations and, in some cases, to seek treble damages, criminal and civil fines, penalties, and assessments. Violations of these laws can also result in exclusion, debarment, temporary or permanent suspension from participation in government healthcare programs, or the institution of corporate integrity agreements. Liability under such federal and state statutes and regulations may arise if we know, or it is determined that we should have known, that information we provide to form the basis for a claim for government payment is false or fraudulent, and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">some courts have permitted False Claims Act suits to proceed if the claimant was out of compliance with program requirements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fraud, waste and abuse prohibitions encompass a wide range of operating activities, including kickbacks or other inducements for referral of members or for the coverage of products (such as prescription drugs) by a plan, billing for unnecessary medical services by a provider, upcoding, payments made to excluded providers, improper marketing, and the violation of patient privacy rights. In particular, there has recently been increased scrutiny by the Department of Justice on health plans&#8217; risk adjustment practices, particularly in the Medicare program. Companies involved in public healthcare programs such as Medicaid and Medicare are required to maintain compliance programs to detect and deter fraud, waste and abuse, and are often the subject of fraud, waste and abuse investigations and audits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government has taken the position that claims presented in violation of the federal anti-kickback statute may be considered a violation of the federal False Claims Act. In addition, under the federal civil monetary penalty statute, the HHS Office of Inspector General has the authority to impose civil penalties against any person who, among other things, knowingly presents, or causes to be presented, certain false or otherwise improper claims. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">actions under federal and state law are brought by a private individual, known as a relator, on behalf of the government. A relator who brings a successful </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit can receive 15 to 30 percent of the damages the government recovers from the defendants, which damages are trebled under the False Claims Act. Because of these financial inducements offered to plaintiffs, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions have increased significantly in recent years, causing greater numbers of healthcare companies to incur the costs of having to defend false claims actions, many of which are spurious and without merit. In addition, meritorious false claims actions could result in fines, or debarment from the Medicare, Medicaid, or other state or federal healthcare programs.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LICENSING AND SOLVENCY</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health plans are generally licensed by the insurance departments in the states in which they operate, except the following: our California health plan is licensed by the California Department of Managed Health Care; one of our New York health plans is licensed as a prepaid health services plan by the New York State Department of Health; and our Massachusetts health plan is regulated as a risk-bearing entity by the Massachusetts Executive Office of Health and Human Services.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health plans are subject to stringent requirements to maintain a minimum amount of statutory capital determined by statute or regulation, and restrictions that limit their ability to pay dividends to us. For further information, refer to the Notes to Consolidated Financial Statements, Note 15, &#8220;Commitments and Contingencies&#8212;Regulatory Capital Requirements and Dividend Restrictions.&#8221;</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_40"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">HUMAN CAPITAL </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, we had nearly 15,000 employees. Our diverse employee population reflects the diversity of the members and communities we serve.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee experience and workplace modernization continue to be a top priority.  We are focused on providing opportunities for our employees that are intellectually stimulating, emotionally fulfilling, and financially rewarding. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consistent with those commitments, this year, we announced our transition to a permanent remote work environment for nearly all of our employees and enhanced benefit offerings for 2023 to include paid parental leave.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we continue to introduce improvements focused on employee development, diversity, equity and inclusion, total rewards offerings and human capital policies and practices. We believe these improvements help us to achieve our goal to become a destination employer in the government-sponsored healthcare industry.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Annually, we invite all employees to participate in our engagement survey. The purpose of our survey is to obtain honest, comprehensive feedback on what is going well and which strategic, operational or cultural concerns are top of mind for our employees. Our results demonstrate year-over-year improvement and exceed industry benchmark.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Succession planning and managing our talent pipelines are key to our human capital strategy. We regularly monitor high performer retention and development. Our performance management practices and pay and recognition programs are aligned with meeting and exceeding our corporate objectives. The board of directors has purview to our employee engagement results, key executive performance and succession planning.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer formal leadership development programs such as new leader orientation, executive onboarding, front-line leadership essentials, and experienced leader training. We have targeted development plans for critical roles with an emphasis on leadership and business acumen.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We invest in our workforce through market competitive total rewards including, pay, benefits and time-off. Our pay and recognition program is designed to engage, motivate and reward top performers and attract new employees. To foster ownership and align the interests of employees with shareholders, we offer an employee stock purchase plan and grant equity-based compensation under our long-term incentive plan to eligible employees.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also offer a comprehensive suite of benefits to all eligible employees, including, among others:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Comprehensive health insurance coverage for employees working 30 hours or more per week, with no increase in employee contributions for 2023;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">401(k) employer matching contributions of up to 100% on the first 4% contributed by the employee;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Personal time off that provides employees with paid time away from work, combining vacation and sick leave;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Volunteer time off that provides employees with paid time away from work to build strong community partnerships and connect with the people we serve;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employee wellness programs that provide tools and incentives to live a healthy life focusing on physical, emotional, financial and work well-being;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Up to ten dependent-care back-up visits per year for a low co-pay, and five hours of homework and tutoring support per child per month at no cost;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employee assistance program benefits that provide up to six confidential counseling sessions per rolling 12-month period and includes assistance with physical, emotional, and financial related matters; and</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Employee discount and other programs, including tuition reimbursement.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_43"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AVAILABLE INFORMATION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 200 Oceangate, Suite 100, Long Beach, California 90802, and our telephone number is (562) 435-3666. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You can access our website at </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.molinahealthcare.com</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to learn more about our Company. From that site, you can download and print copies of our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, along with amendments to those reports. You can also download our Corporate Governance Guidelines, board of director&#8217;s committee charters, Code of Business Conduct and Ethics and Environmental, Social and Governance Report. We make periodic reports and amendments available, free of charge, as soon as reasonably practicable after we file or furnish these reports to the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;). We will also provide a copy of any of our corporate governance policies published on our website free of charge, upon request. To request a copy of any of these documents, please submit your request to: Molina Healthcare, Inc., 200 Oceangate, Suite 100, Long Beach, California 90802, Attn: Investor Relations. Information on or linked to our website is neither part of nor incorporated by reference into this Form 10-K or any other SEC filings. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_46"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">You should carefully consider the risks described below and all of the other information set forth in this Form 10-K, including our consolidated financial statements and accompanying notes. These risks and other factors may affect our forward-looking statements, including those we make in this Form 10-K or elsewhere, such as in press releases, presentations to securities analysts or investors, or other communications made by or with the approval of one of our executive officers. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risks described in the following section are not the only risks facing our Company. Additional risks that we are unaware of, or that we currently believe are not material, may also become important factors that adversely affect our business. In addition to the risks relating to the COVID-19 pandemic that are specifically described in these risk factors, the effects of the COVID-19 pandemic may also have the effect of significantly heightening many of the other risks associated with our business, including those described below. If any of the following risks actually occurs, our business, financial condition, results of operations, and future prospects could be materially and adversely affected. In that event, among other effects, the trading price of our common stock could decline, and you could lose part or all of your investment.</span></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR INDUSTRY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Medicaid enrollees will be subject to redeterminations and potential disenrollments on a state by state basis starting in April 2023, and the number of Medicaid enrollees we retain may be lower than our current estimates.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 18, 2020, at the start of the COVID-19 pandemic, Congress enacted the Families First Coronavirus Response Act (&#8220;FFCRA&#8221;), which included a requirement that Medicaid programs keep people continuously enrolled through the end of the month in which the COVID-19 PHE ends, in exchange for enhanced federal funding. Primarily due to this continuous enrollment provision, during the pandemic Medicaid enrollment across the country, as well as our enrollment, has grown substantially compared to before the pandemic.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 29, 2022, the Consolidated Appropriations Act of 2023 was signed into law. This Act decouples the Medicaid continuous enrollment provision from the PHE and terminates this provision effective as of March 31, 2023, and it also phases down the enhanced federal Medicaid matching funds through December 2023. When the continuous enrollment provision ends on March 31, 2023, millions of people are likely to lose Medicaid coverage. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the number of Medicaid enrollees who may be disenrolled during the unwinding period is highly uncertain, it is estimated that millions will lose coverage. It is likely that the pace of disenrollments will vary significantly by state.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The groups that experienced the most growth due to the continuous enrollment provision&#8212;ACA expansion adults, other adults, and children&#8212;are likely to experience the largest enrollment declines. CMS requires states to develop operational plans for how they will approach the unwinding process. These plans must describe how the state will prioritize renewals, how long the state plans to take to complete the renewals as well as the processes and strategies the state is considering or has adopted to reduce inappropriate coverage loss during the unwinding period. Outcomes will differ across states as they make different choices and face challenges balancing workforce capacity, fiscal pressures, and the volume of work. We have estimated that we will retain approximately half of the new Medicaid enrollees who joined our health plans during the pendency of the PHE. But this expectation is subject to a number of uncertain variables and assumptions. We currently expect to lose approximately half of the new members we had gained organically during the COVID-19 pandemic. But this expectation is subject to a number of uncertain variables and assumptions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, with the significant and rapid change in the list of those eligible for Medicaid, actuarial assumptions related to the health acuity of the remaining members may become more difficult to predict or inaccurate, resulting in inaccurate rates to be paid to health plans. Finally, the COVID-19 pandemic may also continue to impact our business by causing potential spikes in hospitalizations related to the continued emergence of new variants of potentially greater transmissibility and virulence. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Errors in our estimates related to redeterminations and disenrollment, actuarial errors related to the acuity of Medicaid members, and ongoing spikes in the incident of the COVID-19 virus may material impact our business, financial condition, cash flows, and results of operations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The reduction of federal matching funds incidental to the termination of the PHE may result in state funding cuts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preponderance of our premium revenues come from the joint federal and state funding of the Medicaid program. The termination of enhanced federal matching funds may result in Medicaid rate cuts which could reduce our revenues and profit margins. Starting April 1, 2023, states can resume Medicaid redeterminations and disenrollments. States would be eligible for phase-down of the enhanced FMAP (6.2 percentage points through March 2023; 5 percentage points through June 2023; 2.5 percentage points through September 2023 and 1.5 percentage points through December 2023) if they comply with certain rules. Due to the uncertainties surrounding what states may do, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">CMS will end the current MMP program no later than December 2025, which could impact premium revenue. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To coordinate care for those who qualify to receive both Medicare and Medicaid services (the &#8220;dual eligibles&#8221;), under the direction of CMS some states implemented demonstration pilot programs to integrate Medicare and Medicaid services for the dual eligibles. The health plans participating in such demonstrations are referred to as MMPs. Pursuant to the 2023 CMS Medicare Final Rule, which will require MMP plans to end no later than December 2025, the five states that we operate MMPs in &#8211; Illinois, Michigan, Ohio, South Carolina, and Texas &#8211; were required to submit a transition plan to CMS by October 1, 2022, to convert their MMPs to integrated Dual Eligible Special Needs Plan (&#8220;D-SNP&#8221;). However, the five MMP plans will now be required to wind down or convert their product in line with the applicable state&#8217;s MMP transition planning. California concluded its MMP at the end of calendar year 2022 and began transitioning enrollees into integrated EAE-SNPs beginning on January 1, 2023. The economic impact of such wind down or conversion to D-SNP on our premium revenue is uncertain at this point.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our health plans operate with very low profit margins, and small changes in operating performance or slight changes to our accounting estimates could have a disproportionate impact on our reported net income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although most of our health plans over the last several years have generally operated with profit margins higher than those of our direct competitors, nevertheless the profit margins in our industry are low (in the single digits) compared to the profit margins in most other industries. Given these low profit margins, small changes in operating performance or slight changes to our accounting estimates could have a disproportionate impact on our reported net income and adversely affect our business.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If state regulators do not approve payments of dividends and distributions by our subsidiaries, it may negatively affect our ability to meet our debt service and other obligations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a corporate parent holding company and hold most of our assets in, and conduct most of our operations through, our direct subsidiaries. As a holding company, our results of operations depend on the results of operations of our subsidiaries. Moreover, we are dependent on dividends or other intercompany transfers of funds from our subsidiaries to meet our debt service and other obligations. The ability of our subsidiaries to pay dividends or make other payments or advances to us depends on their operating results and is subject to applicable laws and restrictions contained in agreements governing the debt of such subsidiaries. In addition, our health plan subsidiaries are subject to laws and regulations that limit the amount of ordinary dividends and distributions that they can pay to us without prior approval of, or notification to, state regulators. In general, our health plans must give thirty days&#8217; advance notice and the opportunity to disapprove &#8220;extraordinary&#8221; dividends to the respective state departments of insurance for amounts that exceed either (a)&#160;ten percent of surplus or net worth at the prior year end or (b)&#160;the net income for the prior year, depending on the respective state statute. The discretion of the state regulators, if any, in approving or disapproving a dividend is not clearly defined. Our health plans generally must provide notice to the applicable state regulator prior to paying a dividend or other distribution to us. Our parent company received $668 million and $564 million in dividends from our regulated health plan subsidiaries during 2022 and 2021, respectively. If the regulators were to deny or significantly restrict our subsidiaries&#8217; requests to pay dividends to us, the funds available to our Company as a whole would be limited, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our use and disclosure of personally identifiable information and other non-public information, including protected health information, is subject to federal and state privacy and security regulations, and our failure or the failure of our vendors to comply with those regulations or to adequately secure the information we hold could result in significant liability or reputational harm. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State and federal laws and regulations including, but not limited to, the Health Insurance Portability and Accountability Act, as amended by the Health Information Technology for Economic and Clinical Health Act, and all regulations promulgated thereunder (collectively, &#8220;HIPAA&#8221;), the California Consumer Privacy Act (the &#8220;CCPA&#8221;), the California Privacy Rights Act (the &#8220;CPRA&#8221;)  and the Gramm-Leach-Bliley Act, govern the collection, dissemination, use, privacy, confidentiality, security, availability, and integrity of personally identifiable information (&#8220;PII&#8221;), including protected health information (&#8220;PHI&#8221;). HIPAA establishes basic national privacy and security standards for protection of PHI by covered entities and business associates, including health plans such as ours. HIPAA requires covered entities like us to develop and maintain policies and procedures regarding PHI, and to adopt administrative, physical, and technical safeguards to protect PHI. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA violations may result in significant civil penalties. HIPAA authorizes state attorneys general to file suit under HIPAA on behalf of state residents. Courts can award damages, costs, and attorneys&#8217; fees related to violations of HIPAA in such cases. We have experienced HIPAA breaches in the past, including breaches affecting over 500 individuals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even when HIPAA does not apply, according to the Federal Trade Commission (the &#8220;FTC&#8221;), failing to take appropriate steps to keep consumers&#8217; personal information secure constitutes unfair acts or practices in or affecting commerce in violation of Section 5(a) of the Federal Trade Commission Act, 15 U.S.C &#167; 45(a). The FTC expects a company&#8217;s data security measures to be reasonable and appropriate in light of the sensitivity and volume of consumer information it holds, the size and complexity of its business, and the cost of available tools to improve security and reduce vulnerabilities. Individually identifiable health information is considered sensitive data that merits stronger safeguards. The FTC&#8217;s guidance for appropriately securing consumers&#8217; personal information is similar to what is required by the HIPAA security regulations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, thus complicating compliance efforts. For example, California enacted the CCPA, which became effective on January 1, 2020. The CCPA, among other things, creates new data privacy obligations for covered companies and provides new privacy rights to California residents, including the right to opt out of certain disclosures of their information. The CCPA also creates a private right of action with statutory damages for certain data breaches, thereby potentially increasing risks associated with a data breach. On January 1, 2023, the CPRA, which is the successor legislation to the CCPA, became effective. The CPRA amends and expands the CCPA, creating new privacy obligations, consumer privacy rights and enforcement mechanisms.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or one or more of our significant vendors do not comply with existing or new laws and regulations related to PHI, PII, or non-public information, we could be subject to criminal or civil sanctions. Any security breach involving the misappropriation, loss, or other unauthorized disclosure or use of confidential member information, whether by us or by our vendors, could subject us to civil and criminal penalties, divert management&#8217;s time and energy, and have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unforeseen changes in pharmaceutical regulations or market conditions may impact our revenues and adversely affect our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical products and services are a significant component of our healthcare costs. Evolving regulations and state and federal mandates regarding coverage may impact the ability of our health plans to continue to receive existing price discounts on pharmaceutical products for our members. Other factors affecting our pharmaceutical costs include, but are not limited to, the price of pharmaceuticals, geographic variation in utilization of new and existing pharmaceuticals, and changes in discounts. The unpredictable nature of these factors may have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Increases in our pharmaceutical costs could have a material adverse effect on the level of our medical costs and our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Introduction of new high cost specialty drugs and sudden cost spikes for existing drugs increase the risk that the pharmacy cost assumptions used to develop our capitation rates are not adequate to cover the actual pharmacy costs, which jeopardizes the overall actuarial soundness of our rates. Bearing the high costs of new specialty drugs or the high cost inflation of generic drugs without an appropriate rate adjustment or other reimbursement mechanism would have an adverse impact on our financial condition and results of operations. In addition, evolving regulations and state and federal mandates regarding coverage may impact the ability of our health plans to </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to receive existing price discounts on pharmaceutical products for our members. Other factors affecting our pharmaceutical costs include, but are not limited to, geographic variation in utilization of new and existing pharmaceuticals, changes in discounts, civil investigations, and litigation. Some of our competitors have been subject to substantial sanctions related to allegations of improper transfer pricing practices. Further, our principal pharmacy benefit manager, or PBM, CVS Caremark (&#8220;CVS&#8221;), is party to certain lawsuits and putative class actions regarding its drug pricing practices and its rebate arrangements with drug manufacturers. The ultimate outcome of these complaints may have an adverse impact on our pharmaceutical costs, or potentially could result in our becoming involved or impleaded into similar or related costly litigation. Although we will continue to work with state Medicaid agencies in an effort to ensure that we receive appropriate and actuarially sound reimbursement for all new drug therapies and pharmaceuticals trends, there can be no assurance that we will be successful in that regard.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Large-scale medical emergencies in one or more states in which we operate our health plans could significantly increase utilization rates and medical costs. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Large-scale medical emergencies can take many forms and be associated with widespread illness or medical conditions. For example, natural disasters, such as a major earthquake or wildfire in California, or a major hurricane affecting Florida, South Carolina or Texas, could have a significant impact on the health of a large number of our covered members. Other conditions that could impact our members include a virulent flu season or epidemic, or new viruses for which vaccines may not exist, are not effective, or have not been widely administered.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, federal and state law enforcement officials have issued warnings about potential terrorist activity involving biological or other weapons of mass destruction. All of these conditions, and others, could have a significant impact on the health of the population of wide-spread areas. If one of the states in which we operate were to experience a large-scale natural disaster, a significant terrorist attack, or some other large-scale event affecting the health of a large number of our members, our covered medical expenses in that state would rise, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face various risks inherent in the government contracting process that could materially and adversely affect our business and profitability, including periodic routine and non-routine reviews, audits, and investigations by government agencies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various risks inherent in the government contracting process. These risks include routine and non-routine governmental reviews, audits, and investigations, and compliance with government reporting requirements. Violation of the laws, regulations, or contract provisions governing our operations, or changes in interpretations of those laws and regulations, could result in the imposition of civil or criminal penalties, the cancellation of our government contracts, the suspension or revocation of our licenses, the exclusion from participation in government sponsored health programs, or the revision and recoupment of past payments made based on audit findings. If we are unable to correct any noted deficiencies, or become subject to material fines or other sanctions, we could suffer a substantial reduction in profitability, and could also lose one or more of our government contracts. In addition, government receivables are subject to government audit and negotiation, and government contracts are vulnerable to disagreements with the government. The final amounts we ultimately receive under government contracts may be different from the amounts we initially recognize in our financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Any changes to the laws and regulations governing our business, or the interpretation and enforcement of those laws or regulations, could require us to modify our operations and could negatively impact our operating results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is extensively regulated by the federal government and the states in which we operate. The laws and regulations governing our operations are generally intended to benefit and protect health plan members and providers rather than managed care organizations. The government agencies administering these laws and regulations have broad latitude in interpreting and applying them. Changes in the interpretation or application of our contracts could reduce our profitability if we have detrimentally relied on a prior interpretation or application. These laws and regulations, along with the terms of our government contracts, regulate how we do business, what services we offer, and how we interact with our members and the public. For instance, some states mandate minimum medical expense levels as a percentage of premium revenues. These laws and regulations, and their interpretations, are subject to frequent change. The interpretation of certain contract provisions by our governmental regulators may also change. Changes in existing laws or regulations, or their interpretations, or the enactment of new laws or regulations, could reduce our profitability by imposing additional capital requirements, increasing our liability, increasing our administrative and other costs, increasing mandated benefits, forcing us to restructure our relationships with providers, requiring us to implement additional or different programs and systems, or making it </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">more difficult to predict future results. Thus, any significant changes in existing health care laws or regulations could materially impact our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to extensive fraud and abuse laws that may give rise to lawsuits and claims against us, the outcome of which may have a material adverse effect on our business, financial condition, cash flows, or results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we receive payments from federal and state governmental agencies, we are subject to various laws commonly referred to as &#8220;fraud and abuse&#8221; laws, including federal and state anti-kickback statutes, prohibited referrals, and the federal False Claims Act, which permit agencies and enforcement authorities to institute a suit against us for violations and, in some cases, to seek treble damages, criminal and civil fines, penalties, and assessments. Violations of these laws can also result in exclusion, debarment, temporary or permanent suspension from participation in government healthcare programs, or the institution of corporate integrity agreements. Liability under such federal and state statutes and regulations may arise if we know, or it is determined that we should have known, that information we provide to form the basis for a claim for government payment is false or fraudulent, and some courts have permitted False Claims Act suits to proceed if the claimant was out of compliance with program requirements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fraud, waste and abuse prohibitions encompass a wide range of operating activities, including kickbacks or other inducements for referral of members or for the coverage of products (such as prescription drugs) by a plan, billing for unnecessary medical services by a provider, upcoding, payments made to excluded providers, improper marketing, and the violation of patient privacy rights. In particular, there has recently been increased scrutiny by the Department of Justice on health plans&#8217; risk adjustment practices, particularly in the Medicare program. Companies involved in public healthcare programs such as Medicaid and Medicare are required to maintain compliance programs to detect and deter fraud, waste and abuse, and are often the subject of fraud, waste and abuse investigations and audits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The federal government has taken the position that claims presented in violation of the federal anti-kickback statute may be considered a violation of the federal False Claims Act. In addition, under the federal civil monetary penalty statute, the U.S. Department of Health and Human Services&#8217; Office of Inspector General has the authority to impose civil penalties against any person who, among other things, knowingly presents, or causes to be presented, certain false or otherwise improper claims. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui tam </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">actions under federal and state law are brought by a private individual, known as a relator, on behalf of the government. A relator who brings a successful </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> lawsuit can receive 15 to 30 percent of the damages the government recovers from the defendants, which damages are trebled under the False Claims Act. Because of these financial inducements offered to plaintiffs, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions have increased significantly in recent years, causing greater numbers of healthcare companies to incur the costs of having to defend false claims actions, many of which are spurious and without merit. In addition, meritorious false claims actions could result in fines, or debarment from the Medicare, Medicaid, or other state or federal healthcare programs. If we are subject to liability under a </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or other actions, our business, financial condition, cash flows, or results of operations could be adversely affected. Even if we are successful in defending </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> actions against us, the fact that these actions were filed against us, even if ultimately determined to be without merit, could result in expensive defense costs, and also could have an adverse impact on our reputation and our ability to obtain regulatory approval for acquisitions that we may pursue. </span></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OUR BUSINESS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the responsive bids of our health plans for new or renewed Medicaid contracts are not successful, or if our government contracts are terminated or are not renewed on favorable terms, our premium revenues could be materially reduced and our operating results could be negatively impacted.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently derive our premium revenues from health plans that operate in 19 states. Our Medicaid premium revenue constituted 80% of our consolidated premium revenue in the year ended December 31, 2022. Measured by Medicaid premium revenue by health plan, our top four health plans were in New York, Ohio, Texas, and Washington, with aggregate Medicaid premium revenue of $13.3 billion, or approximately 54% of total Medicaid premium revenue, in the year ended December 31, 2022. If we are unable to continue to operate in any of our existing jurisdictions, or if our current operations in those jurisdictions or any portions of those jurisdictions are significantly curtailed or terminated entirely, our revenues could decrease materially.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our government contracts are effective only for a fixed period of time and will only be extended for an additional period of time if the contracting entity elects to do so. When our government contracts expire, they may be opened for bidding by competing health plans, and there is no guarantee that the contracts will be renewed or extended. Even if our contracts are renewed or extended, there can be no assurance that they will be renewed or extended on the same terms or without a reduction in the applicable service areas. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our responsive bids are successful, the bids may be based upon assumptions regarding enrollment, utilization, medical costs, or other factors which could result in the contract being less profitable than we had expected or could result in a net loss. Furthermore, our contracts contain certain provisions regarding, among other things, eligibility, enrollment and dis-enrollment processes for covered services, eligible providers, periodic financial and information reporting, quality assurance and timeliness of claims payment, and are subject to cancellation if we fail to perform in accordance with the standards set by regulatory agencies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to risks associated with outsourcing services and functions to third parties. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with third party vendors and service providers who provide services to us and our subsidiaries or to whom we delegate selected functions. Some of these third parties have direct access to our systems. Our arrangements with third party vendors and service providers may make our operations vulnerable if those third parties fail to satisfy their obligations to us, including their obligations to maintain and protect the security and confidentiality of our information and data or the information and data relating to our members or customers. We are also at risk of a data security incident involving a vendor or third party, which could result in a breakdown of such third party&#8217;s data protection processes or cyber-attackers gaining access to our infrastructure through the third party. To the extent that a vendor or third party suffers a data security incident that compromises its operations, we could incur significant costs and possible service interruption. Any contractual remedies and/or indemnification obligations we may have for vendor or service provider failures or incidents may not be adequate to fully compensate us for any losses suffered as a result of any vendor&#8217;s failure to satisfy its obligations to us or under applicable law. Violations of, or noncompliance with, laws and/or regulations governing our business or noncompliance with contract terms by third party vendors and service providers could increase our exposure to liability to our members, providers, or other third parties, or could result in sanctions and/or fines from the regulators that oversee our business. In turn, this could increase the costs associated with the operation of our business or have an adverse impact on our business and reputation. Moreover, if these vendor and service provider relationships were terminated for any reason, we may not be able to find alternative partners in a timely manner or on acceptable financial terms. We may incur significant costs and/or experience significant disruption to our operations in connection with any such vendor or service provider transition. As a result, we may not be able to meet the full demands of our members or customers and, in turn, our business, financial condition, and results of operations may be harmed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or one of our significant vendors sustain a cyber-attack or suffer data privacy or security breaches that disrupt our information systems or operations, or result in the dissemination of sensitive personal or confidential information, we could suffer increased costs, exposure to significant liability, reputational harm, loss of business, and other serious negative consequences.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our normal operations, we routinely collect, process, store, and transmit large amounts of data, including sensitive personal information as well as proprietary or confidential information relating to our business or third parties. To ensure information security, we have implemented controls designed to protect the confidentiality, integrity and availability of this data and the systems that store and transmit such data. However, our information technology systems and safety control systems are subject to a growing number of threats from computer programmers, hackers, and other adversaries that may be able to penetrate our network security and misappropriate our confidential information or that of third parties, create system disruptions, or cause damage, security issues, or shutdowns. They also may be able to develop and deploy viruses, worms, and other malicious software programs that attack our systems or otherwise exploit security vulnerabilities. All of these risks are also faced by our significant vendors who are also in possession of sensitive confidential information. As a result of the COVID-19 pandemic, we may face increased cybersecurity risks due to our reliance on internet technology and the number of our employees who are working remotely, which may create additional opportunities for cybercriminals to exploit vulnerabilities. Because the techniques used to circumvent, gain access to, or sabotage security systems can be highly sophisticated and change frequently, they often are not recognized until launched against a target, and may originate from less regulated and remote areas around the world. We may be unable to anticipate these techniques or implement adequate preventive measures, resulting in potential data loss and damage to our systems. Our systems are also subject to compromise from internal threats such as improper action by employees, including malicious insiders, or by vendors, counterparties, and other third parties with otherwise legitimate access to our systems. Our policies, employee training (including phishing prevention training), procedures and technical safeguards may not prevent all improper access to our network or proprietary or confidential information by employees, vendors, counterparties, or other third parties. Our facilities may also be vulnerable to security incidents or security attacks, acts of vandalism or theft, misplaced or lost data, human errors, or other similar events that could negatively affect our systems and our and our members&#8217; data.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we face the ongoing challenge of managing access controls in a complex environment. The process of enhancing our protective measures can itself create a risk of systems disruptions and security issues. Given the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">breadth of our operations and the increasing sophistication of cyberattacks, a particular incident could occur and persist for an extended period of time before being detected. The extent of a particular cyberattack and the steps that we may need to take to investigate the attack may take a significant amount of time before such an investigation could be completed and full and reliable information about the incident is known. During such time, the extent of any harm or how best to remediate it might not be known, which could further increase the risks, costs, and consequences of a data security incident. In addition, our systems must be routinely updated, patched, and upgraded to protect against known vulnerabilities. The volume of new software vulnerabilities has increased substantially, as has the importance of patches and other remedial measures. In addition to remediating newly identified vulnerabilities, previously identified vulnerabilities must also be updated. We are at risk that cyber attackers exploit these known vulnerabilities before they have been addressed. The complexity of our systems and platforms, the increased frequency at which vendors are issuing security patches to their products, our need to test patches and, in some instances, coordinate with third-parties before they can be deployed, all could further increase our risks.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where doing so is necessary in order to conduct our business, we also provide sensitive personal member information, as well as proprietary or confidential information relating to our business, to our third-party service providers. Although we obtain assurances from those third parties that they have systems and processes in place to protect such data, and that they will take steps to assure the protection of such data by other third parties, those third-party service providers may also be subject to data intrusion or data breach. Any compromise of the confidential data of our members, employees, or business, or the failure to prevent or mitigate the loss of or damage to this data through breach, could result in operational, reputational, competitive, or other business harm, as well as financial costs and regulatory action. The Company maintains cybersecurity insurance in the event of an information security or cyber incident. However, the coverage may not be sufficient to cover all financial losses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to successfully integrate our acquisitions or realize the anticipated benefits of such acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth strategy includes the pursuit of targeted inorganic growth opportunities that we believe will provide a strategic fit, leverage operational synergies, and lead to incremental earnings accretion. For example, in January 2022, we closed on our acquisition of the Medicaid assets of Cigna Corporation in Texas and in October 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York. In July 2022, we entered into a definitive agreement to acquire substantially all the assets of My Choice Wisconsin.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the receipt of applicable federal and state regulatory approvals and the satisfaction of customary closing conditions, the closing of this transaction is expected to occur in 2023.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The integration of acquired businesses with our existing business is a complex, costly and time-consuming process. The success of acquisitions we make will depend, in part, on our ability to successfully combine our existing business with such acquired businesses and realize the anticipated benefits, including synergies, cost savings, growth in earnings, innovation, and operational efficiencies, from the combinations. If we are unable to achieve these objectives within the anticipated time frame, or at all, the anticipated benefits may not be realized fully or at all, or may take longer to realize than expected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our acquisitions and the related integration activities involve a number of risks, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The transition services that a seller may have agreed to provide following the closing may not be provided in a timely or efficient manner, or certain necessary transition services may not be provided at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unforeseen expenses or delays associated with the acquisition and/or integration;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The assumptions underlying our expectations regarding the integration process or the expected benefits to be achieved from an acquisition may prove to be incorrect;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Maintaining employee morale and retaining key management and other employees;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Difficulties retaining the business and operational relationships of the acquired business, and attracting new business and operational relationships;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unanticipated attrition in the membership of the acquired business pending the completion of the proposed transaction or after the closing of the transaction;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unanticipated difficulties or costs in integrating information technology, communications and other systems, consolidating corporate and administrative infrastructures, and eliminating duplicative operations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Attention to integration activities may divert management&#8217;s attention from ongoing business concerns, which could result in performance shortfalls;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Successfully addressing the challenges inherent in managing a larger company and coordinating geographically separate organizations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Delays in obtaining, or inability to obtain, necessary state or federal regulatory approvals, or such approvals may impose conditions that were not anticipated.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these factors are outside of our control and any one of them could result in delays, increased costs, decreases in the amount of expected revenues, and diversion of management's time and energy, which could have a material adverse effect on our business, financial condition, cash flows or results of operations. There can be no assurances that we will be successful in managing our expanded operations as a result of acquisitions or that we will realize the expected growth in earnings, operating efficiencies, cost savings, or other benefits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to sustain our projected rate of growth due to a lack of merger and acquisition opportunities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the last five years we have entered into seven merger and acquisition transactions generating approximately $10 billion in premium revenue. Many of the targets of such transaction have been non-profit entities. If the number of health care entities willing and able to enter into consolidation transactions with us declines in the future, we may be unable to fully achieve our growth strategy, which could have an adverse effect on our business, financial condition, or results of operations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to attain profitability in any newly acquired health plans or new start-up operations could negatively affect our results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Start-up costs associated with a new business can be substantial. For example, to obtain a certificate of authority to operate as a health maintenance organization in most jurisdictions, we must first establish a provider network, develop and establish infrastructure and required systems, and demonstrate our ability to process claims. In 2023, we expect to incur substantial one-time contract implementation costs related to our expansions in Los Angeles County, Iowa, and Nebraska. Often, we are also required to contribute significant capital to fund mandated net worth requirements, performance bonds or escrows, or contingency guaranties. If we are unsuccessful in obtaining a certificate of authority, winning the bid to provide services, building out our provider network, or attracting and retaining members in sufficient numbers to cover our start-up costs, the new business could fail, or the losses we incur could impact our results of operations. The expenses associated with starting up a health plan in a new jurisdiction, expanding a health plan in an existing jurisdiction, or acquiring a new health plan, could have a material adverse effect on our business, financial condition, cash flows, or results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we lose contracts that constitute a significant amount of our premium revenue, we will lose the administrative cost efficiencies or cost leverage that is inherent in a larger revenue base. In such circumstances, we may not be able to reduce fixed costs proportionally with our lower revenue, and the financial impact of lost contracts may exceed the net income ascribed to those contracts.     </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently spread the cost of centralized services over a large revenue base. Many of our administrative costs are fixed in nature, and will be incurred at the same level regardless of the size of our revenue base. If we lose contracts that constitute a significant amount of our revenue, we may not be able to reduce the expense of centralized services in a manner that is proportional to that loss of revenue. In such circumstances, not only will our total dollar margins decline, but our percentage margins, measured as a percentage of revenue, will also decline. This loss of cost efficiency or cost leverage, and the resulting stranded administrative costs, could have a material and adverse impact on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our health plans are subject to risk associated with various contractual provisions and regulations establishing medical cost expenditure floors, profit ceilings, risk corridors, and quality withholds.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of our premium revenue is subject to contract provisions pertaining to medical cost expenditure floors and corridors, administrative cost and profit ceilings, premium stabilization programs, and cost-plus and performance-based reimbursement programs. Many of these contract provisions are complex, or are poorly or ambiguously drafted, and thus are subject to differing interpretations by us and the relevant government agency with whom we contract. If the applicable government agency disagrees with our interpretation or implementation of a particular contract provision, we could be required to adjust the amount of our obligation under that provision. Any such adjustment could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, many of our contracts contain provisions pertaining to at-risk premiums that require us to meet certain quality performance measures to earn all of our contract revenues. If we are unsuccessful in achieving the stated performance measure, we will be unable to recognize the revenue associated with that measure, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Medicaid premium revenues could be adversely impacted by retroactive adjustments or states&#8217; delays in processing rate changes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complexity of some of our Medicaid contract provisions, imprecise language in those contracts, the desire of state Medicaid agencies in some circumstances to retroactively adjust for the acuity of the medical needs of our members, and state delays in processing rate changes, can create uncertainty around the amount of revenue we should recognize. Any circumstance such as those described above could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If, in the interest of long-term profitability, we decide to exit certain state contractual arrangements, make changes to our provider networks, or make changes to our administrative infrastructure, we may incur disruptions to our business that could in the short term materially reduce our premium revenues and our net income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Decisions that we make with regard to retaining or exiting our portfolio of state or federal contracts, and changes to the manner in which we serve the members of those contracts, could generate substantial expenses associated with the run out of existing operations and the restructuring of those operations that remain. Such expenses could include, but would not be limited to, goodwill and intangible asset impairment charges, restructuring costs, additional medical costs incurred due to the inability to leverage long-term relationships with medical providers, and costs incurred to finish the run out of businesses that have ceased to generate revenue, all of which could materially reduce our premium revenues and net income. For example, following our exit from Puerto Rico in October 2020, significant accounts receivable under our Puerto Rico Medicaid contract remain uncollected, which we ultimately may never recover. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A failure to accurately estimate incurred but not paid medical care costs may negatively impact our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the lag in time between when medical services are actually rendered by our providers and when we receive, process, and pay a claim for those medical services, we must continually estimate our medical claims liability at particular points in time and establish claims reserves related to such estimates. Our estimated reserves for such incurred but not paid, or IBNP, medical care costs are based on numerous assumptions. We estimate our medical claims liabilities using actuarial methods based on historical data adjusted for claims receipt and payment experience (and variations in that experience), changes in membership, provider billing practices, healthcare service utilization trends, cost trends, product mix, seasonality, prior authorization of medical services, benefit changes, known incidence of disease, including COVID-19, or increased incidence of illness such as the flu, provider contract changes, changes to Medicaid fee schedules, and the incidence of high dollar or catastrophic claims. Our ability to accurately estimate claims for our newer lines of business or populations is negatively impacted by the more limited experience we have had with those newer lines of business or populations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IBNP estimation methods we use and the resulting reserves that we establish are reviewed and updated, and adjustments, if deemed necessary, are reflected in the current period. Given the numerous uncertainties inherent in such estimates, our actual claims liabilities for a particular quarter or other period could differ significantly from the amounts estimated and reserved for that quarter or period. Our actual claims liabilities have varied and will continue to vary from our estimates, particularly in times of significant changes in utilization, medical cost trends, and populations and markets served.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our actual liability for claims payments is higher than previously estimated, our earnings in any particular quarter or annual period could be negatively affected. Our estimates of IBNP may be inadequate in the future, which would negatively affect our results of operations for the relevant time period. Furthermore, if we are unable to accurately estimate IBNP, our ability to take timely corrective actions may be limited, further exacerbating the extent of the negative impact on our results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to accurately predict and effectively manage our medical care costs, our operating results could be materially and adversely affected.  </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability depends to a significant degree on our ability to accurately predict and effectively manage our medical care costs. Historically, our medical care ratio, meaning our medical care costs as a percentage of our premium revenue, has fluctuated substantially, and has varied across our health plans. Because the premium payments we receive are generally fixed in advance and we operate with a narrow profit margin, relatively small changes in our medical care ratio can create significant changes in our overall financial results. For example, if our overall medical care ratio of 88.0% for the year ended December&#160;31, 2022, had been one percentage point higher, or 89.0%, our net income per diluted share for the year ended December&#160;31, 2022 would have been approximately $9.51 rather than our actual net income per diluted share of $13.55, a difference of $4.04. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many factors may affect our medical care costs, including:</span></div><div style="margin-top:6pt;padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of utilization of healthcare services; </span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the COVID-19 pandemic;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the underlying risk acuity of our membership;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unexpected patterns in the annual flu season; </span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in hospital costs; </span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased incidences or acuity of high dollar claims related to catastrophic illnesses or medical conditions for which we do not have adequate reinsurance coverage;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased maternity costs;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in state eligibility certification methodologies;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">relatively low levels of hospital and specialty provider competition in certain geographic areas;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increases in the cost of pharmaceutical products and services;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in healthcare regulations and practices;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">epidemics;</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">new medical technologies; and</span></div><div style="padding-left:38.25pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">other various external factors. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of these factors are beyond our control. The inability to forecast and manage our medical care costs or to establish and maintain a satisfactory medical care ratio, either with respect to a particular health plan or across the consolidated entity, could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to deliver quality care, and maintain good relations with the physicians, hospitals, and other providers with whom we contract, or if we are unable to enter into cost-effective contracts with such providers, our profitability could be adversely affected. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We contract with physicians, hospitals, and other providers as a means to ensure access to healthcare services for our members, to manage medical care costs and utilization, and to better monitor the quality of care being delivered. We compete with other health plans to contract with these providers. We believe providers select plans in which they participate based on criteria including reimbursement rates, timeliness and accuracy of claims payment, potential to deliver new patient volume and/or retain existing patients, effectiveness of resolution of calls and complaints, and other factors. There can be no assurance that we will be able to successfully attract and retain providers to maintain a competitive network in the geographic areas we serve. In addition, in any particular market, providers could refuse to contract with us, demand higher payments, or take other actions which could result in higher medical care costs, disruption to provider access for current members, a decline in our growth rate, or difficulty in meeting regulatory or accreditation requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid program generally pays doctors and hospitals at levels well below those of Medicare and private insurance. Large numbers of doctors, therefore, do not accept Medicaid patients. In the face of fiscal pressures, some states may reduce rates paid to providers, which may further discourage participation in the Medicaid program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some markets, certain providers, particularly hospitals and some specialists, may have significant market positions or even monopolies. If these providers refuse to contract with us or utilize their market position to negotiate favorable contracts which are disadvantageous to us, our profitability in those areas could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some providers that render services to our members are not contracted with our health plans. In those cases, there is no pre-established understanding between the provider and our health plan about the amount of compensation that is due to the provider. In some states, the amount of compensation is defined by law or regulation, but in most instances it is either not defined or it is established by a standard that is not clearly translatable into dollars. In such instances, providers may claim they are underpaid for their services and may either litigate or arbitrate their dispute with our health plan. The uncertainty of the amount to pay to such providers and the possibility of subsequent adjustment of the payment or litigation with the provider that results in an adverse decision could adversely affect our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on the accuracy of eligibility lists provided by state governments. Inaccuracies in those lists would negatively affect our results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium payments to our health plans are based upon eligibility lists produced by state governments. From time to time, states require us to reimburse them for premiums paid to us based on an eligibility list that a state later discovers contains individuals who are not in fact eligible for a government sponsored program or are eligible for a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different premium category or a different program. Alternatively, a state could fail to pay us for members for whom we are entitled to payment. Our results of operations would be adversely affected as a result of such reimbursement to the state if we make or have made related payments to providers and are unable to recoup such payments from the providers.  Further, when a state implements new programs to determine eligibility, establishes new processes to assign or enroll eligible members into health plans, or chooses new subcontractors, there is an increased potential for an unanticipated impact on the overall number of members assigned to managed care health plans.&#160;Whenever a state effects an eligibility redetermination for any reason, there is generally an associated reduction in Medicaid membership, which could have an adverse effect on our premium revenues and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The insolvency of a delegated provider could obligate us to pay its referral claims, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our primary care physicians and a small portion of our specialists and hospitals are paid on a capitated basis. Under capitation arrangements, we pay a fixed amount per member per month to the provider without regard to the frequency, extent, or nature of the medical services actually furnished. Due to insolvency or other circumstances, such providers may be unable or unwilling to pay claims they have incurred with third parties in connection with referral services provided to our members. The inability or unwillingness of delegated providers to pay referral claims presents us with both immediate financial risk and potential disruption to member care, as well as potential loss of members. Depending on states&#8217; laws, we may be held liable for such unpaid referral claims even though the delegated provider has contractually assumed such risk. Additionally, competitive pressures or practical regulatory considerations may force us to pay such claims even when we have no legal obligation to do so; or we have already paid claims to a delegated provider and such payments cannot be recouped when the delegated provider becomes insolvent. Liabilities incurred or losses suffered as a result of provider insolvency or other circumstances could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receipt of inadequate or significantly delayed premiums could negatively affect our business, financial condition, cash flows, or results of operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our premium revenues consist of fixed monthly payments per member, and supplemental payments for other services such as maternity deliveries. These premiums are fixed by contract, and we are obligated during the contract periods to provide healthcare services as established by the state governments. We use a large portion of our revenues to pay the costs of healthcare services delivered to our members. If premiums do not increase when expenses related to healthcare services rise, our medical margins will be compressed, and our earnings will be negatively affected. A state could increase hospital or other provider rates without making a commensurate increase in the rates paid to us, could lower our rates without making a commensurate reduction in the rates paid to hospitals or other providers, or could delay the processing of rate changes. In addition, if the actuarial assumptions made by a state in implementing a rate or benefit change are incorrect or are at variance with the particular utilization patterns of the members of one or more of our health plans, our medical margins could be reduced. Any of these rate adjustments in one or more of the states in which we operate could have a material adverse effect on our business, financial condition, cash flows, or results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a state fails to renew its federal waiver application for mandated Medicaid enrollment into managed care or such application is denied, our membership in that state will likely decrease. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">States may only mandate Medicaid enrollment into managed care under federal waivers or demonstrations. Waivers and programs under demonstrations are approved for two- to five-year periods and can be renewed on an ongoing basis if the state applies and the waiver request is approved or renewed by CMS. We have no control over this renewal process. If a state in which we operate does not renew its mandated program or the federal government denies the state&#8217;s application for renewal, our business would suffer as a result of a likely decrease in membership.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends on our information and medical management systems, and our inability to effectively integrate, manage, update, and keep secure our information and medical management systems could disrupt our operations. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is dependent on effective and secure information systems that assist us in processing provider claims, monitoring utilization and other cost factors, supporting our medical management techniques, providing data to our regulators, and implementing our data security measures. Our members and providers also depend upon our information systems for enrollment, premium processing, primary care and specialist physician roster access, membership verifications, claims status, provider payments, and other information. If we experience a reduction in the performance, reliability, or availability of our information and medical management systems, our operations, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to pay claims, ability to produce timely and accurate reports, and ability to maintain proper security measures could be adversely affected. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have partnered with third parties to support our information technology systems. This makes our operations vulnerable to adverse effects if such third parties fail to perform adequately. For example, in February 2019, we entered into a master services agreement with a third party vendor who manages certain of our information technology infrastructure services including, among other things, our information technology operations, end-user services, and data centers. If any licensor or vendor of any technology which is integral to our operations were to become insolvent or otherwise fail to support the technology sufficiently, our operations could be negatively affected. Additionally, our operations are vulnerable to adverse effects if such third parties are unable to perform due to forces outside of their control, such as a natural disaster or serious weather event. For example, in 2021, our third party call center, located in the province of Cebu in the Philippines, suffered significant disruptions as a result of the destruction caused by Super Typhoon Rai. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our encounter data, or the encounter data of the health plans we acquire, may be inaccurate or incomplete, which could have a material adverse effect on our results of operations, financial condition, cash flows and ability to bid for, and continue to participate in, certain programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts require the submission of complete and correct encounter data. The accurate and timely reporting of encounter data is increasingly important to the success of our programs because more states are using encounter data to determine compliance with performance standards and to set premium rates. We have been, and continue to be, exposed to operating sanctions and financial fines and penalties for noncompliance. In some instances, our government clients have established retroactive requirements for the encounter data we must submit. There also may be periods of time in which we are unable to meet existing requirements. In either case, it may be prohibitively expensive or impossible for us to collect or reconstruct this historical data. Moreover, these same issues may also apply to the health plans we acquire, and we may be required to expend significant costs or pay fines to correct these deficiencies. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced challenges in obtaining complete and accurate encounter data, due to difficulties with providers and third-party vendors submitting claims in a timely fashion in the proper format, and with state agencies in coordinating such submissions. As states increase their reliance on encounter data, these difficulties could adversely affect the premium rates we receive and how membership is assigned to us and subject us to financial penalties, which could have a material adverse effect on our business, financial condition, cash flows, or results of operations, and on our ability to bid for, and continue to participate in, certain programs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An impairment charge with respect to our recorded goodwill, or our finite-lived intangible assets, could have a material impact on our financial results. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the carrying amount of goodwill was $1,115 million, and intangible assets, net, were $275 million. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase consideration over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Impairment indicators may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An event could occur that would cause us to revise our estimates and assumptions used in analyzing the value of our goodwill, and intangible assets, net. For example, if the responsive bid of one or more of our health plans is not successful, we will lose a contract in the applicable state or states and such loss may be an indicator of impairment. If an event or events occur that would cause us to revise our estimates and assumptions used in analyzing the value of our goodwill and other intangible assets, such revision could result in a non-cash impairment charge that could have a material impact on our results of operations in the period in which the impairment occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The May 2020 contract award to our Kentucky Medicaid plan is the subject of an ongoing legal challenge.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. This matter remains subject to additional appellate proceedings, and no assurances can be given regarding the ultimate outcome. In the event the contract award to our Kentucky health plan is overturned, the business and revenue of our Kentucky health plan may be materially and adversely affected.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are dependent on the leadership of our chief executive officer and other executive officers and key employees.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of our business and the ability to execute our strategy are highly dependent on the efforts of Mr. Zubretsky, our chief executive officer, and our other key executive officers and employees. The loss of their leadership, expertise, and experience could negatively impact our operations. Our ability to replace them or any other key employee may be difficult and may take an extended period of time because of the limited number of individuals in the healthcare industry who have the breadth and depth of skills and experience necessary to operate and lead a business such as ours. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain, or motivate these personnel. If we are unsuccessful in recruiting, retaining, managing, and motivating such personnel, our business, financial condition, cash flows, or results of operations could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face claims related to litigation which could result in substantial monetary damages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to a variety of legal actions, including provider claims, employment related disputes, healthcare regulatory law-based litigation and enforcement actions, breach of contract actions, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or False Claims Act actions, and securities class actions. If we incur liability materially in excess of the amount for which we have insurance coverage, our profitability would suffer. Even if any claims brought against us are unsuccessful or without merit, we may have to defend ourselves against such claims. The defense of any such actions may be time-consuming and costly, and may distract our management&#8217;s attention. Such legal actions could have a material adverse effect on our business, financial condition, results of operations, or cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to maintain effective internal controls over financial reporting could have a material adverse effect on our business, operating results, and stock price, and could subject us to sanctions by regulatory authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis. We have identified material weaknesses in our internal control over financial reporting in the past, which have subsequently been remediated. If additional material weaknesses in our internal control over financial reporting are discovered or occur in the future, our consolidated financial statements may contain material misstatements and we could be required to restate our financial results.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because our corporate headquarters are located in Southern California, our business operations may be disrupted as a result of a major earthquake or wildfire.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our corporate headquarters are located in Long Beach, California. In addition, some of our health plans&#8217; claims are processed in Long Beach, California. Southern California is exposed to a statistically greater risk of a major earthquake and wildfires than most other parts of the United States. If a major earthquake or wildfire were to strike Southern California, our corporate functions and claims processing could be impaired for an unforeseen period of time. If there is a major Southern California earthquake or wildfire, there can be no assurances that our disaster recovery plan will be successful or that the business operations of our health plans, including those that are remote from any such event, would not be impacted.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 31</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PROPERTIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own and lease certain real properties to support the business operations of our reportable segments. In the fourth quarter of 2022, we completed a plan to reduce the real estate footprint used in our business operations to accommodate our move to a permanent remote work environment, a model we have been working under successfully for over two years. Our remaining office space is being reconfigured and optimized for utilization and efficiency. While we believe our current and anticipated facilities are adequate to meet our operational needs in the near term, we continually evaluate the adequacy of our properties for our anticipated future needs.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_52"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. On September 9, 2022, the Kentucky Court of Appeals ruled that, with regard to the earlier Circuit Court ruling granting Anthem relief, the Circuit Court should not have invalidated the 2020 procurement and thus should not have awarded a contract to Anthem. Anthem has sought discretionary review by the Kentucky Supreme Court of the ruling by the Court of Appeals. Pending further Court order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#8220;MHPR&#8221;) filed a complaint asserting, among other claims, breach of contract against Puerto Rico Health Insurance Administration (&#8220;ASES&#8221;). On September 13, 2021, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. This matter remains subject to significant additional proceedings, and no prediction can be made as to the outcome.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the Notes to Consolidated Financial Statements, Note 15, &#8220;Commitments and Contingencies&#8212;Legal Proceedings,&#8221; for further information.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_55"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK REPURCHASE PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Purchases of common stock made by us or on our behalf during the quarter ended December&#160;31, 2022, including shares withheld by us to satisfy our employees&#8217; income tax obligations, are set forth below:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:33.596%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Purchased </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average Price Paid per<br/>Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares Purchased&#160;as</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Part of Publicly</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Announced Plans or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Programs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar&#160;Value of Shares That May Yet Be Purchased Under the Plans or Programs </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">October&#160;1 &#8212; October&#160;31</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331.74&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November&#160;1 &#8212; November&#160;30</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328.85&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">451,658,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December&#160;1 &#8212; December&#160;31</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">342.44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">443,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">300,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">592,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">339.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">590,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">During the three months ended December 31, 2022, there were approximately 590,000 shares repurchased as part of our publicly announced share repurchase program and we withheld approximately 2,000 shares of common stock to settle employee income tax obligations, for releases of awards granted under the Molina Healthcare, Inc. 2019 Equity Incentive Plan. For further information refer to Notes to Consolidated Financial Statements, Note 13, &#8220;Stockholders' Equity.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">For further information on our stock repurchase programs, refer to Notes to Consolidated Financial Statements, Note 13, &#8220;Stockholders' Equity.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK PERFORMANCE GRAPH</span></div><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following graph and related discussion are being furnished solely to accompany this Annual Report on Form 10-K pursuant to Item 201(e) of Regulation S-K and shall not be deemed to be &#8220;soliciting materials&#8221; or to be &#8220;filed&#8221; with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) (other than as provided in Item 201) nor shall this information be incorporated by reference into any future filing under the Securities Act or the Exchange Act, whether made before or after the date hereof and irrespective of any general incorporation language contained therein, except to the extent that we specifically incorporate it by reference into a filing.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following line graph compares the percentage change in the cumulative total return on our common stock against the cumulative total return of the Standard&#160;&amp; Poor&#8217;s Corporation Composite 500 Index (the &#8220;S&amp;P 500&#8221;) and a peer group index for the five-year period from December&#160;31, 2017 to December&#160;31, 2022. The comparison assumes $100 was invested on December 31, 2017, in our common stock and in each of the foregoing indices and assumes reinvestment of dividends. The stock performance shown on the graph below represents historical stock price performance and is not necessarily indicative of future stock price performance. </span></div><div style="margin-bottom:6pt;margin-top:8pt;text-align:center"><img src="moh-20221231_g4.jpg" alt="moh-20221231_g4.jpg" style="height:376px;margin-bottom:5pt;vertical-align:text-bottom;width:480px"/></div><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The peer group index consists of Acadia Healthcare Company, Inc. (ACHC), Elevance Health, Inc. (ELV), Centene Corporation (CNC), Cigna Corporation (CI), Community Health Systems, Inc. (CYH), HCA Healthcare, Inc. (HCA), Humana, Inc. (HUM), Laboratory Corporation of America Holdings (LH), Magellan Health, Inc. (MGLN), Quest Diagnostics Incorporated (DGX), Tenet Healthcare Corporation (THC) and Universal Health Services, Inc. (UHS). </span></div><div style="margin-bottom:6pt;margin-top:8pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">STOCK TRADING SYMBOL AND DIVIDENDS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is listed on the New York Stock Exchange under the trading symbol &#8220;MOH.&#8221; As of February&#160;10, 2023, there were 14 registered holders of record of our common stock, including Cede &amp; Co. To date we have not paid cash dividends on our common stock. We currently intend to retain any future earnings to fund our projected business operations. However, we intend to periodically evaluate our cash position to determine whether to pay a cash dividend in the future. Our ability to pay dividends is partially dependent on, among other things, our receipt of cash dividends from our regulated subsidiaries. The ability of our regulated subsidiaries to pay dividends to us is limited by the state departments of insurance in the states in which we operate or may operate, as well as requirements of the government-sponsored health programs in which we participate. Additionally, our credit agreement contains various covenants that limit our ability to pay dividends on our common stock. Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon, among other factors, our results of operations, financial condition, capital requirements and contractual and regulatory restrictions. For more information regarding restrictions on the ability of our regulated subsidiaries to pay dividends to us, please see the Notes to Consolidated Financial Statements, Note 15, &#8220;Commitments and Contingencies&#8212;Regulatory Capital Requirements and Dividend Restrictions.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 33</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (&#8220;MD&amp;A&#8221;)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of financial condition and results of operations as of and for the years ended December 31, 2022 and 2021, are presented in the sections that follow. Our MD&amp;A as of and for the year ended December 31, 2020, may be found in our 2021 Annual Report on Form 10-K, which prior disclosure is incorporated by reference herein.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_64"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc., a FORTUNE 500 company (currently ranked 125), provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). We served approximately 5.3 million members as of December&#160;31, 2022, located across 19 states. </span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_67"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2022 HIGHLIGHTS </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights of our 2022 results included the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net income of $792 million, or $13.55 per diluted share, compared to $659 million, or $11.25 per diluted share, in 2021;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total revenue of $32.0 billion, which increased 15% compared to 2021;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Premium revenue of $30.9 billion, which increased 15% compared to 2021;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Consolidated medical care ratio (&#8220;MCR&#8221;) of 88.0%, compared to 88.3% in 2021;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Membership increased 59,000 members year over year to 5.3 million at December&#160;31, 2022;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">General and administrative expense ratio (&#8220;G&amp;A ratio&#8221;) improved to 7.2%, compared to 7.4% in 2021; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">After-tax margin of 2.5%, compared to 2.4% in 2021.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Effect Of COVID</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net effect of COVID decreased 2022 net income per diluted share by $2.50 and decreased 2021 net income per diluted share by $3.50. The net effect of COVID impacted all three lines of business and increased the 2022 consolidated MCR by approximately 60 basis points, compared to an increase of approximately 90 basis points to the consolidated MCR in 2021. The net effect of COVID reflects COVID-related inpatient costs and COVID-related risk corridors enacted by a number of our state customers beginning in the second quarter of 2020, partially offset by a decrease in medical costs due to COVID-related utilization curtailment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Real Estate Impairment</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we recognized an impairment charge of $208 million, or $2.72 per diluted share, on right-of-use lease assets and related property and equipment in connection with the reduction in leased space used in our business operations, to accommodate the move to a permanent remote work environment.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Growth Initiatives</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our growth initiatives, including accretive acquisitions, state Medicaid procurement awards and other organic growth priorities, are driving increases in our current and expected future premium revenue base and operating income. The acquisitions of Affinity Health Plan, Inc.&#8217;s New York Medicaid business in October 2021, Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan contracts in January 2022, and AgeWell New York&#8217;s Medicaid Long Term Care business in October 2022 are all contributing to our 2022 results of operations. The commencement of Nevada Medicaid operations in January 2022 also contributed to our 2022 results of operations. Our recent Medicaid procurement wins in California, Iowa and Nebraska demonstrate our ability to win new state contracts and, along with the acquisition of My Choice Wisconsin&#8217;s LTSS business that we expect to close in mid-2023, will contribute to our expected growth in premium revenues and results of operations in 2023 and 2024. We expect our future results of operations will also be impacted by organic membership growth in Medicare, partially offset by the impact of known pharmacy carve-outs in Medicaid, the resumption of Medicaid redeterminations beginning in April 2023, the impact of lower Marketplace membership, and 2022 Medicaid premium revenue for directed payments in Texas that we don&#8217;t expect to recur in 2023. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 34</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL RESULTS SUMMARY</span></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">(In millions, except per-share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: medical care costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,704&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical margin </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,708&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">MCR </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenues: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,311&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,068&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">G&amp;A ratio </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per diluted share </span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted weighted average shares outstanding </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Key Statistics:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending Membership </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">After-tax margin </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">__________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">MCR represents medical care costs as a percentage of premium revenue.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">G&amp;A ratio represents general and administrative expenses as a percentage of total revenue. </span></div><div style="margin-bottom:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">After-tax margin represents net income as a percentage of total revenue. </span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_73"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED RESULTS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NET INCOME AND OPERATING INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income amounted to $792 million, or $13.55 per diluted share in 2022, compared with net income of $659 million, or $11.25 per diluted share, in 2021. We estimate that the net effect of COVID decreased net income by approximately $2.50 per diluted share in 2022 and by approximately $3.50 per diluted share in 2021. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating income was $1,173 million in 2022, compared with $1,020 million in 2021. The improvement in operating income was mainly due to membership growth and higher premium revenues, and a year-over-year decrease in the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MCR, partially offset by the impact of the $208 million impairment charge that we recognized in connection with the reduction in leased space.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share in 2022 was favorably impacted by the reduction in common shares outstanding as a result of our share repurchase programs in the second and fourth quarters of 2022. Net income per share in 2021 was favorably impacted by the reduction in common shares outstanding as a result of our share repurchase programs in 2020. See further discussion and information in &#8220;Liquidity and Financial Condition,&#8221; below.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PREMIUM REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue increased $4.0 billion, or 15%, in 2022, when compared with 2021. The higher premium revenue reflects the impact of acquisitions, and increased organic membership in the Medicaid and Medicare segments, partially offset by a decline in the Marketplace segment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDICAL CARE RATIO</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated MCR decreased to 88.0% in 2022, compared with 88.3% in 2021. The improvement relates to improved operating performance in our Medicaid segment, partially offset by an increase in the Medicare and Marketplace segments. The results also reflect a favorable year-over-year change in the net effect of COVID, which impacted all of our segments and increased the consolidated MCR by approximately 60 basis points in 2022, compared to approximately 90 basis points in 2021. The year-over-year change in the net effect of COVID mainly reflects lower COVID-related risk corridors and COVID inpatient costs, partially offset by lower COVID-related utilization curtailment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prior year reserve development in 2022 was favorable, but its impact on earnings was partially absorbed by the COVID-related risk corridors. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PREMIUM TAX REVENUE AND EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The premium tax ratio decreased to 2.7% in 2022, compared with 2.8% in 2021. The current year ratio decrease was mainly due to changes in business mix. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INVESTMENT INCOME</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment income increased to $143 million in 2022, compared with $52 million in 2021. The improvement was driven by recent increases in market interest rates and higher invested assets. Additionally, investment income was lower in the first half of 2021 due to a temporary allocation in shorter-term invested assets due to the COVID-19 pandemic, which was ended in the second quarter of 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER REVENUE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue decreased slightly to $75 million in 2022, compared with $77 million in 2021. Other revenue mainly includes service revenue associated with long-term services and supports consultative services we provide in Wisconsin.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL AND ADMINISTRATIVE (&#8220;G&amp;A&#8221;) EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The G&amp;A expense ratio decreased slightly to 7.2% in 2022 compared with 7.4% in 2021, which reflects the benefits of scale produced by our increase in revenue and disciplined cost management.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEPRECIATION AND AMORTIZATION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization increased to $176 million in 2022, compared with $131 million in 2021. The increase was due primarily to amortization associated with acquisitions completed in the fourth quarter of 2021 and the year ended December 31, 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">IMPAIRMENT</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we recognized an impairment of $208 million on right-of-use lease assets and related property and equipment in connection with the reduction in leased space to accommodate the move to a permanent remote work environment. Approximately $192 million of the impairment is directly associated with the reduction in leased space used in our business operations. We assessed ROU assets for impairment based on a valuation and recoverability analysis, which was determined with the assistance of a third-party real estate specialist. The remaining $16 million of the impairment relates to leasehold improvements and other property and equipment associated with the reduction in leased space. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER OPERATING EXPENSES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other operating expenses decreased slightly to $58 million in 2022, compared with $61 million in 2021. Other operating expenses mainly include service costs associated with long-term services and supports consultative services we provide in Wisconsin, as noted above.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTEREST EXPENSE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest expense decreased to $110 million in 2022, compared with $120 million in 2021. The decrease resulted from our early redemption of $700 million aggregate principal amount of our 5.375% senior notes due 2022 in the fourth quarter of 2021, partially offset by interest related to the private offering of $750 million aggregate principal amount of the 3.875% Notes due 2032 in the same period.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OTHER EXPENSES, NET</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021, we recognized a loss on debt repayment of $25 million in connection with early redemption of our 5.375% Notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INCOME TAXES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense amounted to $271 million in 2022, or 25.5% of pretax income, compared with income tax expense of $216 million in 2021, or 24.7% of the pretax income. The difference in the effective tax rate is primarily due to an increase in nondeductible expenses and state and local income taxes, and differences in discrete tax benefits recognized in the respective periods.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_76"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REPORTABLE SEGMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we served approximately 5.3 million members eligible for Medicaid, Medicare, and other government-sponsored healthcare programs for low-income families and individuals, including Marketplace members, most of whom receive government premium subsidies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes long-term services and supports consultative services in Wisconsin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Part I, Item 1. Business for further description of our segments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">HOW WE ASSESS PERFORMANCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive our revenues primarily from health insurance premiums. Our primary customers are state Medicaid agencies and the federal government.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is service margin. The service margin is equal to service revenue minus cost of service revenue. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of the change in medical margin is discussed below under &#8220;Segment Financial Performance.&#8221; For more information, see Notes to Consolidated Financial Statements, Note 16, &#8220;Segments.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TRENDS AND UNCERTAINTIES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of the trends, uncertainties and other developments that affected our reportable segments during the year, refer to &#8220;Item 1. Business&#8212;Our Business,&#8221; &#8220;&#8212;COVID-19 Pandemic,&#8221; &#8220;&#8212;Legislative and Political Environment,&#8221; &#8220;&#8212;Operations&#8212;Medical Management,&#8221; and &#8220;&#8212;Regulation.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 37</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SEGMENT FINANCIAL PERFORMANCE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our membership by segment as of the dates indicated:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.730%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.621%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,754,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,329,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">348,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,258,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,199,000&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below summarize premium revenue, medical margin, and MCR by segment for the periods indicated (dollars in millions):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Premium Revenue</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medical Margin</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">MCR</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,795&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,033&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,883&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,708&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,151&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicaid</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key factors affecting results for this segment include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Membership growth of 425,000 during the year, driven by our growth initiatives, including our acquisitions and expansion into new states;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The status of the PHE and the associated suspension of membership redeterminations;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Improved operating performance, including medical cost management; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The net effect of COVID, which increased the 2022 MCR by approximately 10 basis points, compared to an increase of 20 basis points in the 2021 MCR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid premium revenue increased $4.4 billion, or 21%&#160;in 2022, when compared with 2021. The increase was mainly due to the impact from the Affinity, Cigna and AgeWell acquisitions, and state directed payments in our Texas health plan, as well as organic membership growth, including our entry into Nevada. We also benefited from  organic membership growth across several other states, driven mainly by the extension of the PHE period and the associated suspension of membership redeterminations due to COVID-19.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described in &#8220;Item 1. Business&#8212;COVID-19 Pandemic,&#8221; we recognized approximately $197&#160;million in 2022 for the impact of COVID-related risk corridors, enacted by several states in 2020 in response to the lower utilization of medical services resulting from COVID-19. We recognized approximately $323&#160;million in 2021, for the impact of these risk corridors in 2021. The decrease was due to the elimination of most of the COVID-19 risk corridors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical margin of our Medicaid program increased $659 million in 2022, or 28%, when compared with 2021. The increase in margin was driven by the growth in membership and premium revenues discussed above and the MCR decrease discussed below.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid MCR decreased 70 basis points to 88.0% in 2022, from 88.7% in 2021. The improvement is mainly attributable to improved operating performance, including medical cost management, and the year-over-year change in the net effect of COVID, partially offset by the impact of state directed payments in our Texas health plan. The year-over-year change in the net effect of COVID for 2022 mainly reflects lower COVID-related risk corridors, partially offset by lower COVID-related utilization curtailment. The 2022 MCR of 88% is at the low end of our long-term target range of 88% to 89% and is consistent with pre-pandemic levels.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medicare</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key factors affecting results for this segment include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our expansion in MAPD and D-SNP membership;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achievement of member risk scores and associated risk-adjusted premium that are commensurate with the health status, or acuity, of our Medicare members; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The net effect of COVID, which increased the 2022 MCR by approximately 300 basis points, compared to an increase of 220 basis points in the 2021 MCR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicare premium revenue increased $434 million, or 13%, in 2022 compared to 2021. The increase was primarily due to the impact of MAPD and D-SNP membership expansion, including organic membership growth in existing states, partially offset by lower premium revenue PMPM from the change in business mix. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The medical margin for Medicare increased $7 million in 2022 compared to 2021. The year-over-year increase is mainly due to the increase in premium revenue, partially offset by the increase in the MCR discussed below.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicare MCR increased to 88.5% in 2022, from 87.2% in 2021, or 130 basis points. The MCR increase was primarily driven by the year-over-year change in the net effect of COVID. COVID-related utilization curtailment and corridor adjustments drove a lower MCR for 2021, and COVID inpatient costs increased in 2022. Additionally, the increase in MCR was driven by higher non-COVID utilization and the impact of lower risk-adjusted premiums associated with first year MAPD members, partially offset by higher risk scores on renewing members that more closely reflect the acuity of our membership, and strong medical cost management. The 2022 MCR of 88.5% was modestly above our long-term target range of 87% to 88% due to the net effect of COVID.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketplace</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key factors affecting results for this segment include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Our product and pricing strategy, which resulted in an overall reduction in membership and repositioning in the metallic tier membership mix;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achievement of member risk scores and associated risk-adjusted premium that are commensurate with the health status, or acuity, of our Marketplace members; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The net effect of COVID, which increased the 2022 MCR by approximately 120 basis points, compared to an increase of 430 basis points in the 2021 MCR.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketplace premium revenue decreased $772 million in 2022 compared to 2021. The decrease was mainly due to an expected decrease in membership in line with our product and pricing strategy, partially offset by an increase in premium revenue PMPM. Our Marketplace membership as of December 31, 2022, amounted to 348,000 members, representing a decrease of 380,000 members compared to December 31, 2021. The increase in premium revenue PMPM is consistent with the change in metallic tier mix, which reflects an increase of members in the sliver metal tier and a decrease of members in the bronze metal tier, partially offset by an increase in the 2021 risk adjustment payment that was finalized in June 2022. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Marketplace medical margin decreased $109 million in 2022, primarily due to the net decrease in membership and premiums, and the increase in the MCR described below. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Marketplace MCR increased to 87.2% in 2022, compared to 86.9% in 2021, or 30 basis points. The increase in 2022 reflects changes in membership mix that includes higher acuity members, the unfavorable change in the 2021 risk adjustment payable recognized in the second quarter of 2022, and the unfavorable impact of settling prior year provider balances, partially offset by the year-over-year change in the net effect of COVID. The 2022 MCR of 87.2% is higher than our long-term target range of 78% to 80% due to these factors. We expect MCR performance in 2023 to be within our target range, as we continue to execute on our product and pricing strategy. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Other segment includes service revenues and costs associated with the long-term services and supports consultative services we provide in Wisconsin, and also includes certain corporate amounts not allocated to the Medicaid, Medicare, or Marketplace segments. Such amounts were immaterial to our consolidated results of operations for 2022 and 2021.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_82"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">LIQUIDITY AND FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our cash, investments, and capital structure to meet the short- and long-term obligations of our business while maintaining liquidity and financial flexibility. We forecast, analyze, and monitor our cash flows to enable prudent investment management and financing within the confines of our financial strategy.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain liquidity at two levels: 1) the regulated health plan subsidiaries; and 2) the parent company. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulated health plan subsidiaries&#8217; primary liquidity requirements include payment of medical claims and other health care services; payment of certain settlements with our state and federal customers, such as minimum medical loss ratio and risk corridors and Marketplace risk transfers on behalf of CMS; general and administrative costs directly incurred or paid through an administrative services agreement to the parent company; and federal tax payments to the parent company under an intercompany tax sharing agreement. Our regulated health plan subsidiaries meet their liquidity needs by generating cash flows from operating activities, primarily from premium revenue; cash flows from investing activities, including investment income and sales of investments; and capital contributions received from our parent company.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulated health plan subsidiaries generally receive premiums in advance of payments of claims for medical and other health care services; however, cash and cash equivalents in regulated health plan subsidiaries can fluctuate significantly in a particular period depending on the timing of receipts for premiums from our government partners. Any decline or delay in receipt of premium revenue could have a negative impact on our liquidity. We did not experience noticeable delays to, or changes in, the timing or level of premium receipts in 2022 or 2021 as a result of the COVID-19 pandemic, but there can be no assurance that we will not experience such delays in the future. See further discussion below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Uses&#8212;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulated health plan subsidiaries are each subject to applicable state regulations that, among other things, require the maintenance of minimum levels of capital and surplus. We continue to maintain appropriate levels of aggregate excess statutory capital and surplus in our regulated health plan subsidiaries. See further discussion under &#8220;Regulatory Capital and Dividend Restrictions&#8221; below. When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plan subsidiaries is generally paid in the form of dividends to our parent company to be used for general corporate purposes. The regulated health plan subsidiaries paid dividends to the parent company amounting to $668 million in 2022 and $564 million in 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parent company liquidity requirements generally consist of payment of administrative costs not directly incurred by our regulated operations, including, but not limited to, staffing costs, lease payments, branding and certain information technology services; capital contributions paid to our regulated health plan subsidiaries, including funding for newer health plans; capital expenditures; debt service; funding for common stock purchases, acquisitions and other growth-related activities; and federal tax payments. The parent company contributed capital of $159 million and $440 million in 2022 and 2021, respectively, to our regulated health plan subsidiaries to satisfy statutory capital and surplus requirements. The higher contributions in 2021 were mainly attributed to fund growth in our New York and Kentucky health plans. Our parent company normally meets its liquidity requirements from administrative services fees earned under administrative services agreements; dividends received from our regulated subsidiaries; federal tax payments collected from the regulated subsidiaries; proceeds received from the issuance of debt and equity securities; and cash flows from investing activities, including investment income and sales of investments. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and investments at the parent company amounted to $375&#160;million and $348&#160;million as of December 31, 2022, and 2021, respectively. The increase in 2022 was primarily due to the dividends received from our regulated health plan subsidiaries, partially offset by the share repurchase program and the timing of corporate payments and capital contributions to regulated health plan subsidiaries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After considering expected cash flows from operating activities, we generally invest cash of regulated subsidiaries that exceeds our expected short-term obligations in longer term, investment-grade, and marketable debt securities to improve our overall investment return. These investments are made pursuant to board-approved investment policies which conform to applicable state laws and regulations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policies are designed to provide liquidity, preserve capital, and maximize total return on invested assets, all in a manner consistent with state requirements that prescribe the types of instruments in which our subsidiaries may invest. These investment policies require that our investments have final maturities of less than 15 years, or less than 15 years average life for structured securities. Professional portfolio managers operating under documented guidelines manage our investments and a portion of our cash equivalents. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the risks of the COVID-19 pandemic, as they relate to our investments, are minimal. The overall rating of our portfolio is A+. Our investment policy has directives in conjunction with state guidelines to minimize risks and exposures in volatile markets. Additionally, our portfolio managers assist us in navigating the current volatility in the capital markets. Our restricted investments are invested principally in cash, cash equivalents, U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury securities, and corporate debt securities; we have the ability to hold such restricted investments until maturity. All of our unrestricted investments are classified as current assets. </span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_85"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow Activities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows are summarized as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">773&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,346)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(790)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,653)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(258)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 21.25pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash, cash equivalents, and restricted cash and cash equivalents</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(458)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(741)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Operating Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically receive capitation payments monthly, in advance of payments for medical claims; however, government payors may adjust their payment schedules, positively or negatively impacting our reported cash flows from operating activities in any given period. For example, government payors may delay our premium payments, or they may prepay the following month&#8217;s premium payment. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by operations was $773 million in 2022, compared with $2,119 million in 2021. The $1,346 million&#160;decrease in 2022 cash flow was mainly due to the net impact of timing differences in government receivables and payables, including larger risk adjustment payments made in 2022 for the Marketplace 2021 plan year and payment for Medicaid minimum MLR and risk corridor settlements related to prior plan years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investing Activities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities was $790 million in 2022, compared with $1,653 million in 2021, an increase in year-over-year cash flow of $863 million. This change in cash flow was primarily due to the net impact of proceeds and purchases of investments. In 2022 and 2021, we funded acquisitions in the amounts of $134 million and $129 million, respectively.  </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Financing Activities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities was $441 million&#160;in 2022, compared with $183 million in 2021, a decrease in year-over-year cash flow of $258 million. In 2022, cash outflows included common stock purchases of $400 million and $54 million for common stock withheld to settle employee tax obligations. In 2021, cash inflows included $740 million from the issuance of the 3.875% Notes due 2032, and cash outflows included $723 million in repayment of the 5.375% Notes due 2022, common stock purchases of $128 million and $53 million for common stock withheld to settle employee tax obligations. Additionally, we paid $20 million in each of 2022 and 2021 to settle contingent consideration liabilities relating to our Kentucky Passport acquisition that closed in 2020.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_88"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL CONDITION</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our cash resources, borrowing capacity available under our Credit Agreement as discussed further below in &#8220;Future Sources and Uses of Liquidity&#8212;Future Sources,&#8221; and internally generated funds will be sufficient to support our operations, regulatory requirements, debt repayment obligations and capital expenditures for at least the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On a consolidated basis, as of December&#160;31, 2022, our working capital was $3.2 billion compared with $3.0 billion as of December&#160;31, 2021. At December&#160;31, 2022, our cash and investments amounted to $7.7 billion, compared with $7.9 billion of cash and investments at December&#160;31, 2021. A significant portion of our portfolio is held in cash and cash equivalents and we do not anticipate the fluctuations in the aggregate fair value of our financial assets to have a material impact on our liquidity or capital position since we intend to hold our securities to maturity. Net unrealized losses on our investments classified as current and available for sale increased to $210 million at December 31, 2022 compared to $6 million at December 31, 2021. We have determined that the unrealized losses primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the statutory restrictions that inhibit the ability of our health plan subsidiaries to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cash equivalents and investments held by our unregulated parent. For more information, see the &#8220;Liquidity&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">discussion presented above.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Capital and Dividend Restrictions </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our regulated, wholly owned subsidiaries must maintain a minimum amount of statutory capital determined by statute or regulations. Such statutes, regulations and capital requirements also restrict the timing, payment and amount of dividends and other distributions, loans or advances that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based upon current statutes and regulations, the minimum capital and surplus requirement for these subsidiaries was estimated to be approximately $2.3&#160;billion at December&#160;31, 2022, compared with $2.1&#160;billion at December&#160;31, 2021. The aggregate capital and surplus of our wholly owned subsidiaries was in excess of these minimum capital requirements as of both dates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under applicable regulatory requirements, the amount of dividends that may be paid by our wholly owned subsidiaries without prior approval by regulatory authorities as of December&#160;31, 2022, was approximately $210 million in the aggregate. The subsidiaries may pay dividends over this amount, but only after approval is granted by the regulatory authorities. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our cash and investments balances as of December&#160;31, 2022, management believes that our regulated wholly owned subsidiaries remain well capitalized and exceed their regulatory minimum requirements. We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with statutory capital and surplus requirements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Structure</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This new program supersedes the stock purchase program previously approved by our board of directors in September 2021. This new program will be funded with cash on hand and extends through December 31, 2023. During the fourth quarter of 2022, we used $200&#160;million to repurchase 590,000 shares under this program.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As debt held by the parent company comes due, we typically engage in a new private offering of debt to retire and replace the prior issuance. For several years we saw a continued decline in interest rates, which benefited our overall cost of capital during that time. However, interest rates have increased since we issued our 3.875% Notes due 2032 in 2021. Accordingly, future refinancing may occur at a higher rate than those we have achieved historically. This would increase our cost of capital in the future or may cause us to pursue alternative financing sources, should the need arise.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are not a party to any off-balance sheet financing arrangements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Ratings</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each of our senior notes is rated &#8220;BB-&#8221; by Standard &amp; Poor&#8217;s, and &#8220;Ba3&#8221; by Moody&#8217;s Investor Service, Inc. A downgrade in our ratings could adversely affect our borrowing capacity and increase our borrowing costs. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Covenants</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants, including a net leverage ratio and an interest coverage ratio. Such ratios are computed as defined by the terms of the Credit Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the indentures governing each of our outstanding senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. As of December&#160;31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_91"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FUTURE SOURCES AND USES OF LIQUIDITY</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Sources</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our regulated subsidiaries generate significant cash flows from premium revenue, which is generally received a short time before related healthcare services are paid. Premium revenue is our primary source of liquidity. Thus, any decline in the receipt of premium revenue, and our profitability, could have a negative impact on our liquidity.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Excluding acquisitions and our exit from Puerto Rico, we added approximately 750,000 new Medicaid members since March 31, 2020, when we first began to report on the impacts of the pandemic. We believe this membership increase was mainly due to the suspension of redeterminations for </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medicaid eligibility. The recently passed Consolidated Appropriations Act of 2023 authorizes states to resume redeterminations and terminate coverage for ineligible enrollees starting on April 1, 2023, irrespective of the status of the PHE. Consequently, we expect Medicaid enrollment to continue to benefit from the current pause on membership redeterminations through March 31, 2023, and then decline thereafter as states resume normal enrollment and renewal operations on April 1, 2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dividends from Subsidiaries. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available and as permitted by applicable regulations, cash in excess of the capital needs of our regulated health plans is generally paid in the form of dividends to our unregulated parent company to be used for general corporate purposes. As a result of the COVID-19 pandemic, state regulators could restrict the ability of our regulated health plan subsidiaries to pay dividends to the parent company, which could reduce the liquidity of the parent company. For more information on our regulatory capital requirements and dividend restrictions, refer to Notes to Consolidated Financial Statements, Note 15, &#8220;Commitments and Contingencies&#8212;Regulatory Capital Requirements and Dividend Restrictions,&#8221; and Note 17, &#8220;Condensed Financial Information of Registrant&#8212;Note&#160;C&#160;- Dividends and Capital Contributions.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Credit Agreement Borrowing Capacity.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December&#160;31, 2022, we had available borrowing capacity of $1&#160;billion under the revolving credit facility of our Credit Agreement. In addition, the Credit Agreement provides for a $15&#160;million swingline sub-facility and a $100&#160;million letter of credit sub-facility, as well as incremental term loans available to finance certain acquisitions up to $500&#160;million, plus an unlimited amount of such term loans as long as we maintain a minimum consolidated net leverage ratio. See further discussion in the Notes to Consolidated Financial Statements, Note 11, &#8220;Debt.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Future Uses</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Common Stock Purchases. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This new program supersedes the stock purchase program previously approved by our board of directors in September 2021. This new program will be funded with cash on hand and extends through December 31, 2023. The exact timing and amount of any repurchase is determined by management based on market conditions and share price, in addition to other factors, and subject to the restrictions relating to volume, price, and timing under applicable law. As of February&#160;13, 2023, $300 million remained available to purchase our common stock under this program through December 31, 2023. See further information in the Notes to Consolidated Financial Statements, Note 13, &#8220;Stockholders' Equity.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Acquisitions</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have a disciplined and steady approach to growth. Organic growth, which includes leveraging our existing health plan portfolio and winning new territories, is our highest priority. In addition to organic growth, we will consider targeted acquisitions that are a strategic fit that we believe will leverage operational synergies, and lead to incremental earnings accretion. For further information on our acquisitions, refer to the Notes to Consolidated Financial Statements, Note 4, &#8220;Business Combinations.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#8220;MCW&#8221;). The purchase price for the transaction is approximately $150 million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in mid-2023.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Impact of COVID-19 Pandemic</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As described in &#8220;Item 1. Business&#8212;COVID-19 Pandemic,&#8221; we have been subject to Medicaid risk corridors as a result of the pandemic. Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. We have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the year ended December 31, 2022, we recognized approximately $197&#160;million, in the aggregate, related to such risk corridors, in 2022, and approximately $323 million, in the aggregate, was recognized in 2021. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Regulatory Capital Requirements and Dividend Restrictions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability, and have committed to provide, additional capital to each of our health plans as necessary to ensure compliance with minimum statutory capital requirements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Molina Healthcare Charitable Foundation. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, we announced our commitment of $150 million to fund The Molina Healthcare Charitable Foundation (the &#8220;Foundation&#8221;), an independent not-for-profit charitable foundation. We have contributed $20 million to the Foundation on a cumulative basis as of December 31, 2022. </span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_94"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contractual Obligations. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to various contractual obligations that we will be required to satisfy over the short and long term. The majority are discussed in the Notes to Consolidated Financial Statements and primarily include the following: medical claims and benefits payable, amounts due to government agencies, principal and interest on our debt and leases. Some items are based on management&#8217;s estimates and assumptions about obligations, including duration, the possibility of renewal, anticipated actions by third parties, and other factors. Because these estimates and assumptions are necessarily subjective, the contractual obligations we will actually pay in future periods may vary. Additionally, we have a variety of other contractual agreements related to acquiring services used in our operations. However, we believe these other agreements do not contain material non-cancelable commitments. </span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_97"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures. Actual results could differ from these estimates, and some differences could be material. Our most significant accounting estimates, which include a higher degree of judgment and/or complexity, include the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Medical claims and benefits payable. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See discussion below, and refer to the Notes to Consolidated Financial Statements, Notes 2, &#8220;Significant Accounting Policies,&#8221; and 10, &#8220;Medical Claims and Benefits Payable&#8221; for more information.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Contractual provisions that may adjust or limit revenue or profit.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For a discussion of this topic, including amounts recorded in our consolidated financial statements, refer to the Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies.&#8221;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Quality incentives.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For a discussion of this topic, refer to the Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies.&#8221;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Business Combinations, and Goodwill and intangible assets, net.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> For a comprehensive discussion of this topic, including amounts recorded in our consolidated financial statements, refer to the Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies,&#8221; Note 4, &#8220;Business Combinations,&#8221; and Note 9, &#8220;Goodwill and Intangible Assets, Net.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MEDICAL CARE COSTS, MEDICAL CLAIMS AND BENEFITS PAYABLE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (&#8220;IBNP&#8221;). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table illustrates consolidated medical care costs by type for the periods indicated: </span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.812%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.643%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PMPM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PMPM</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except PMPM amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,703&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318.55&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26.47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,489&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.07&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,175&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">439.35&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,704&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">413.09&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk. IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors (measures the cumulative percentage of claims expense that will ultimately be paid for a given month of service based on historical payment patterns) and the assumed healthcare cost trend (the year-over-year change in per-member per-month medical care costs) to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For claims incurred more than three months before the financial statement date, we mainly use estimated completion factors to estimate the ultimate cost of those claims. Completion factors measure the cumulative percentage of claims expense that will ultimately be paid for a given month of service based on historical claims payment patterns. We analyze historical claims payment patterns by comparing claim incurred dates to claim payment dates to estimate completion factors. The estimated completion factors are then applied to claims paid through the financial statement date to estimate the ultimate claims cost for a given month&#8217;s incurred claim activity. The difference between the estimated ultimate claims cost and the claims paid through the financial statement date represents our estimate of claims remaining to be paid as of the financial statement date and is included in our IBNP liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For claims incurred within three months before the financial statement date, actual claims paid are a less reliable measure of our ultimate cost since a large portion of medical claims are not submitted to us until several months after services have been submitted. Accordingly, we estimate our IBNP liability for claims incurred during these months based on a blend of estimated completion factors and assumed medical care cost trend. The assumed medical care cost trend represents the year-over-year change in per-member per-month medical care costs, which can be affected by many factors including, but not limited to, our ability and practices to manage medical and pharmaceutical costs, changes in level and mix of services utilized, mix of benefits offered, including the impact of co-pays and deductibles, changes in medical practices, changes in member demographics, catastrophes and epidemics</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and other relevant factors.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Actuarial standards of practice generally require a level of confidence such that our overall best estimate of the IBNP liability has a greater probability of being adequate versus being insufficient, where the liability is sufficient to account for moderately adverse conditions. Adverse conditions are situations that may cause actual claims to be higher than the otherwise estimated value of such claims at the time of the estimate, such as changes in the magnitude or severity of claims, uncertainties related to our entry into new geographical markets or provision of services to new populations, changes in state-controlled fee schedules, and modifications or upgrades to our claims processing systems and practices. Therefore, in many situations, the claim amounts ultimately settled will be less than the estimate that satisfies the actuarial standards of practice. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When subsequent actual claims payments are less than we estimated, we recognize a benefit for favorable prior period development that is reported as part of &#8220;Components of medical care costs related to: Prior years&#8221; in the table presented in Note 10, &#8220;Medical Claims and Benefits Payable.&#8221; Our reserving practice is to consistently recognize the actuarial best estimate including a provision for moderately adverse conditions for each current period. This provision is reported as part of &#8220;Components of medical care costs related to: Current year&#8221; in the table presented in Note 10. Assuming stability in the size of our membership, the use of this consistent methodology, during any given period, usually results in the replenishment of reserves at a level that generally offsets the benefit of favorable prior period development in that period. In the case of material growth or decline of membership, replenishment can exceed or fall short of the favorable development, assuming all other factors remain unchanged.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. The following table reflects the hypothetical change in our estimate of claims liability as of December&#160;31, 2022 that would result if we change our completion factors for the fourth through the twelfth months preceding December&#160;31, 2022, by the percentages indicated. A reduction in the completion factor results in an increase in medical claims liabilities. Dollar amounts are in millions.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease) in Estimated Completion Factors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase&#160;<br/>(Decrease)&#160;<br/>in Medical Claims <br/>and<br/>Benefits Payable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">869&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(579)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(869)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reflects the hypothetical change in our estimate of claims liability as of December&#160;31, 2022 that would result if we alter our assumed medical care cost trend factors by the percentages indicated. An increase in the PMPM costs results in an increase in medical claims liabilities. Dollar amounts are in millions.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.620%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Decrease) Increase in Trended Per Member Per Month Cost Estimates</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Decrease)&#160;<br/>Increase&#160;<br/>in Medical Claims <br/>and<br/>Benefits Payable</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(307)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(102)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6%</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many related factors working in conjunction with one another that determine the accuracy of our estimates, some of which are qualitative in nature rather than quantitative. Therefore, we are seldom able to quantify the impact that any single factor has on a change in estimate. Given the variability inherent in the reserving process, we will only be able to identify specific factors if they represent a significant departure from expectations. As a result, we do not expect to be able to fully quantify the impact of individual factors on changes in estimates.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RECENTLY ISSUED ACCOUNTING STANDARDS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to the Notes to Consolidated Financial Statements, Note 2, &#8220;Significant Accounting Policies,&#8221; for a discussion of recent accounting pronouncements that affect us.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_100"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our earnings and financial position are exposed to financial market risk relating to changes in interest rates, and the resulting impact on investment income and interest expense.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Substantially all of our investments and restricted investments are subject to interest rate risk and will decrease in value if market interest rates increase. Assuming a hypothetical and immediate 1% increase in market interest rates at December&#160;31, 2022, the fair value of our fixed income investments would decrease by approximately $81 million.&#160;Declines in interest rates over time will reduce our investment income.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For further information on fair value measurements and our investment portfolio, please refer to the Notes to Consolidated Financial Statements, Note 5, &#8220;Fair Value Measurements,&#8221; and Note 6, &#8220;Investments.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus, in each case, the applicable margin. For further information, see Notes to Consolidated Financial Statements, Note 11, &#8220;Debt.&#8221;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 47</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_103"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">MOLINA HEALTHCARE, INC.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:84.405%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.395%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_106">Consolidated Statements of Income</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_106">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_109">Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_109">49</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_112">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_112">50</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_115">Consolidated Statements of Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_115">51</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_118">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_118">52</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_121">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ia6131cdf4d354d56b8257b8e26eb9181_121">54</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 48</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_106"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF INCOME</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share data)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzUtMS0xLTEtNjg3NjY_35ee02db-516d-4839-a6d0-cd297d5b0ab4">30,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzUtMy0xLTEtNjg3NjY_a6cfad03-36e0-4388-90ae-14fc880a36a1">26,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:PremiumsEarnedNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzUtNS0xLTEtNjg3NjY_0205a88c-2798-49bf-93fe-092c748600ae">18,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzYtMS0xLTEtNjg3NjY_33aff803-5d27-4b3e-abb3-b295becb62a7">873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzYtMy0xLTEtNjg3NjY_fe453aed-ee9f-4010-8b4c-d86fd2b99d12">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:HealthCareOrganizationPremiumTaxRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzYtNS0xLTEtNjg3NjY_12125efb-8f23-497d-b44a-c8449a95e63b">649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees reimbursed</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeRevenue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzctMS0xLTEtNjg3NjY_37ac83ea-a39f-413f-9394-8bd21bdba3ed">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeRevenue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzctMy0xLTEtNjg3NjY_bfe910a0-2d80-4c3b-86b8-2ec07e04d73d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzctNS0xLTEtNjg3NjY_5578af4e-ce3b-4b30-b55e-688e0f1e1a5e">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace risk corridor judgment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzgtMS0xLTEtNjg3NjY_0a46d7e5-7110-4e60-8e52-c490669b1063">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzgtMy0xLTEtNjg3NjY_769eb87a-9ab7-4176-9bac-6644ddae332c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzgtNS0xLTEtNjg3NjY_569fc31a-421a-4ceb-8131-3543a6d5ff68">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzktMS0xLTEtNjg3NjY_9c037b72-25d9-44ff-b884-2e805334effd">143</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzktMy0xLTEtNjg3NjY_ec6c5e1f-19fc-4f90-94e6-bb3ff631ad0e">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:NetInvestmentIncome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzktNS0xLTEtNjg3NjY_315517ae-e67e-46bb-92e2-f95468eddff2">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEwLTEtMS0xLTY4NzY2_d4dabae9-9457-4c2a-909a-fe26daff3454">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEwLTMtMS0xLTY4NzY2_1fc815d3-23d8-4d13-947b-acff3a0e0b20">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEwLTUtMS0xLTY4NzY2_4ebe8afe-f512-470b-8e8f-628193f8e717">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzExLTEtMS0xLTY4NzY2_cfe5217f-d603-4330-95fb-b7a1d8b3ac15">31,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzExLTMtMS0xLTY4NzY2_18e4dfa5-b0e2-47ba-982c-5951e117326e">27,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzExLTUtMS0xLTY4NzY2_f3e43a82-a0d7-4783-89c2-13dc2ee562e9">19,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical care costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEzLTEtMS0xLTY4NzY2_98b2fb43-6761-427e-8edb-a11580510221">27,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEzLTMtMS0xLTY4NzY2_08ffbefd-11c9-4065-a676-02b69a997c4b">23,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEzLTUtMS0xLTY4NzY2_7d58af61-326a-4d29-9d35-fc73616774a9">15,820</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE0LTEtMS0xLTY4NzY2_f602e943-23b9-42e5-8252-0b4d8d5a54d6">2,311</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE0LTMtMS0xLTY4NzY2_771e5272-14cb-4d5c-ba36-d386d2103f5c">2,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE0LTUtMS0xLTY4NzY2_4a6be338-dfa2-4d67-97a9-8f50c51d019f">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Premium tax expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE1LTEtMS0xLTY4NzY2_f137f477-5dd9-4dc5-8908-740eda754f9d">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE1LTMtMS0xLTY4NzY2_9555e604-9f6c-41e9-bb3a-6a68aa017c9d">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:PremiumTaxExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE1LTUtMS0xLTY4NzY2_54d0f20b-832b-450c-a194-d57481d511f1">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Health insurer fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE2LTEtMS0xLTY4NzY2_a940c22a-04f7-440c-b9ff-0c3cf556fcb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE2LTMtMS0xLTY4NzY2_5783d02c-eea9-49f8-8d27-b7fcf33444ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:HealthCareOrganizationInsurerFeeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE2LTUtMS0xLTY4NzY2_e44fdb10-49b3-45dd-8f01-5819ad290860">277</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE3LTEtMS0xLTY4NzY2_02cbde01-cdc6-4f16-a744-7af88dfa1c14">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE3LTMtMS0xLTY4NzY2_64cb518f-9615-4428-9e7a-6d15c7a77728">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE3LTUtMS0xLTY4NzY2_e450d9b8-d81a-4fc4-8252-1c21302804ea">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTEtMS0xLTcxNzUw_b1eba8d8-03bc-48dc-a58c-6480be8313f4">208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTMtMS0xLTcxNzUw_7460f495-57d8-4d7f-9b9c-f3652d289c89">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTUtMS0xLTcxNzUw_d83244d2-4dbd-4e8b-9bd8-e32218ec3a4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTEtMS0xLTY4NzY2_e4de5c3e-9965-4c51-9977-187fc9cd4892">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTMtMS0xLTY4NzY2_35eed9ff-80d9-4dab-b9f9-37f78c434e54">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OtherCostAndExpenseOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTUtMS0xLTY4NzY2_2dc677bf-6caa-477b-8217-9c97d5f4edba">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE5LTEtMS0xLTY4NzY2_fb97ea50-d5db-4e91-a7c5-72f8b378ab47">30,801</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE5LTMtMS0xLTY4NzY2_3e554f36-0333-4d4e-857f-db023f7c15d1">26,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE5LTUtMS0xLTY4NzY2_478d25c0-a438-40e5-a36b-fb6dc9c477a5">18,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIwLTEtMS0xLTY4NzY2_8c389bce-09e9-47cf-9080-835076fd12c1">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIwLTMtMS0xLTY4NzY2_c4dab664-bdba-426d-8cbc-f4c8cf91dae5">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIwLTUtMS0xLTY4NzY2_4a5ec5bd-5e3b-4e97-9a26-88274ba364bb">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIyLTEtMS0xLTY4NzY2_d448f41e-6f00-48fe-91e6-bc380d107968">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIyLTMtMS0xLTY4NzY2_f4bbd85f-881d-4125-991b-de5c3fe2b27d">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIyLTUtMS0xLTY4NzY2_6401e640-22c5-437c-8d4a-eaaa5c71c8a2">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIzLTEtMS0xLTY4NzY2_cf1c3889-9095-4c8e-b180-a7d9c4986b6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIzLTMtMS0xLTY4NzY2_900e6832-4656-4e23-a371-e95bae6c997d">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIzLTUtMS0xLTY4NzY2_31003c80-b964-41db-b03b-538630cafef3">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses, net </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI0LTEtMS0xLTY4NzY2_a761530a-c644-4bb7-9ecf-74040babfc38">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI0LTMtMS0xLTY4NzY2_5e9ce231-e6d3-40b2-a3e4-f6b478fcfa41">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI0LTUtMS0xLTY4NzY2_7fbe7ccb-55a8-432e-af8a-bc23c30284cf">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI1LTEtMS0xLTY4NzY2_bc993dda-96a9-4c4f-92e4-c339d5db1448">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI1LTMtMS0xLTY4NzY2_99c13d9b-a158-4f52-887b-d091b60c9deb">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI1LTUtMS0xLTY4NzY2_8b690aa5-e198-4db4-b159-1ae75028106d">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI2LTEtMS0xLTY4NzY2_47180281-12f3-4f2c-ae07-b6fa289a5e77">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI2LTMtMS0xLTY4NzY2_83414551-63e6-4b27-b4e6-84dc1864480c">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI2LTUtMS0xLTY4NzY2_b15cb40f-7845-4663-aba0-ef5157bf3c07">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI3LTEtMS0xLTY4NzY2_6b8c9fa1-024f-4195-86f2-8525f10b658d">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI3LTMtMS0xLTY4NzY2_cc2f757c-223d-42ce-b803-55903ae444a5">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI3LTUtMS0xLTY4NzY2_528163d5-1254-4c49-b590-9b4134987e06">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMwLTEtMS0xLTY4NzY2_15476e39-e4ad-4718-8039-ef0806aabf9e">13.72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMwLTMtMS0xLTY4NzY2_8f4f7f61-3ec9-4109-9227-80ba02fe7c4a">11.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMwLTUtMS0xLTY4NzY2_f51a01aa-1f7f-4385-800b-130f1b29f947">11.40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMxLTEtMS0xLTY4NzY2_691c704c-f4ef-4095-8b43-514de19e658c">13.55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMxLTMtMS0xLTY4NzY2_bee9ff1b-fea9-4ffe-9ec1-0244caa9d4dd">11.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMxLTUtMS0xLTY4NzY2_30cb36f4-7b93-4b13-8561-f1209a660a1a">11.23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMzLTEtMS0xLTY4NzY2_4bcd198d-31d5-42e7-9da0-e6d2507b9871">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMzLTMtMS0xLTY4NzY2_2c7c422c-7640-48be-b4ea-46fcd2629988">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMzLTUtMS0xLTY4NzY2_b6e873c7-0213-4034-91b2-832d82c1bd00">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzM0LTEtMS0xLTY4NzY2_462bf50e-7004-4f84-9034-f9f8ab27a739">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzM0LTMtMS0xLTY4NzY2_e5773359-eb55-465f-a696-b056553cd72e">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzM0LTUtMS0xLTY4NzY2_bf26eb9b-c9bc-4b0d-b503-8a269e5d2374">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_109"></div><div style="margin-top:11pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzQtMS0xLTEtNjg3NjY_73e8b16e-4082-41b0-9c63-8980b069a798">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzQtMy0xLTEtNjg3NjY_151e1d84-8d3b-4334-840c-0ddb6489f1e6">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzQtNS0xLTEtNjg3NjY_b78c6c7c-d4c2-438e-b2a7-9a578b1fc2b3">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized investment (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzYtMS0xLTEtNjg3NjY_90775e8a-a27e-4cc5-baf1-c0fd9144e6f0">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzYtMy0xLTEtNjg3NjY_6740c33a-ed08-4a5c-9f28-f3b323938663">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzYtNS0xLTEtNjg3NjY_42d918cc-d005-4e91-ad16-d807be81e9f2">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: effect of income taxes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzctMS0xLTEtNjg3NjY_3955267b-0bb5-4306-a856-e2015b098297">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzctMy0xLTEtNjg3NjY_d05be2aa-cad1-410a-94be-459da16c13e5">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzctNS0xLTEtNjg3NjY_210eae81-cb12-48a7-8717-bd8e474fedb1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzgtMS0xLTEtNjg3NjY_00684a3e-3290-4445-b1e0-e8ac2f38fc49">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzgtMy0xLTEtNjg3NjY_5c0af1d8-b0b3-4c33-9577-081426409862">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzgtNS0xLTEtNjg3NjY_c828d9f7-76fd-4ccc-9327-0cfe323cc568">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzktMS0xLTEtNjg3NjY_0f37ac0d-a68d-4d08-903c-65962c43570c">637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzktMy0xLTEtNjg3NjY_570a4cfa-c843-4f30-8b9c-9c0d2d49592c">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzktNS0xLTEtNjg3NjY_2149d352-6391-4f6a-aa28-cc5622823b58">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 49</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions,<br/>except per-share amounts)</span></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzYtMS0xLTEtNjg3NjY_fbb3446b-1a30-43fc-89c2-79f3a411ee7b">4,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzYtMy0xLTEtNjg3NjY_5eb865f0-b711-476b-b659-f957019a2c4f">4,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzctMS0xLTEtNjg3NjY_27b768a4-10ad-401c-b413-04b1a75335a7">3,499</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzctMy0xLTEtNjg3NjY_7378dcf4-b747-446e-b0a7-b1ea00b58048">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzgtMS0xLTEtNjg3NjY_8d0cb1d1-f501-499b-9cc1-bbee8e7be416">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzgtMy0xLTEtNjg3NjY_8e934f2f-9d45-4306-9e1f-377290f72af2">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzktMS0xLTEtNjg3NjY_524aab03-3373-4353-80a4-cdf7e3c0db5c">277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzktMy0xLTEtNjg3NjY_370fae1d-176b-4db9-a464-e6b752fdde6f">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEwLTEtMS0xLTY4NzY2_1805afd3-34bc-4cdf-bd9e-8ea1df6f8e14">10,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEwLTMtMS0xLTY4NzY2_2c2e8fa0-0c62-4504-a8ba-34e6cd22e628">10,064</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzExLTEtMS0xLTY4NzY2_ff8891d7-7026-4e0f-9dec-2c9a758cb83e">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzExLTMtMS0xLTY4NzY2_150fc824-450f-4bba-9875-d91387c9b638">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill and intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEyLTEtMS0xLTY4NzY2_f5da65e2-b5a4-486d-83d3-bfe02fd4bd15">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEyLTMtMS0xLTY4NzY2_ff40c2dc-cc39-4e7f-bb75-ff4a3995cdc1">1,252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEzLTEtMS0xLTY4NzY2_85e35d04-8991-4ce1-ad5b-a001a85af4f6">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEzLTMtMS0xLTY4NzY2_ea047b5a-d3dd-4e5b-8476-6d53d5ccb8a0">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE0LTEtMS0xLTY4NzY2_d2de0b68-9dd2-44c3-8327-09c9278bc92d">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE0LTMtMS0xLTY4NzY2_5a01756c-2f72-4988-b4fa-a2a41968d36e">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE1LTEtMS0xLTY4NzY2_07d079a8-c7f2-4ae4-96b0-3403e692064d">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE1LTMtMS0xLTY4NzY2_de0c3d08-6b53-4dfe-8264-fc4d34022ad0">179</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE2LTEtMS0xLTY4NzY2_15b29fe7-454f-4e3d-a715-636c1d653d2d">12,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE2LTMtMS0xLTY4NzY2_fc0447eb-2e50-4138-9829-d2d811bc8ed8">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIwLTEtMS0xLTY4NzY2_238a54d7-f8e6-4b2d-96bd-73130c2784cf">3,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIwLTMtMS0xLTY4NzY2_c4cd4ad7-1c16-49e0-b29f-5cd9dac4dadd">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIxLTEtMS0xLTY4NzY2_9ec139df-a5a1-4ea9-925f-f67e221c3018">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIxLTMtMS0xLTY4NzY2_403f36e3-56d5-48d8-8575-9d4d98ed9b65">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIyLTEtMS0xLTY4NzY2_f053531e-1a99-42ac-ade9-afd332bde3de">889</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIyLTMtMS0xLTY4NzY2_4bd5aa0d-11f4-4933-9bab-905f3408abfc">842</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIzLTEtMS0xLTY4NzY2_15730e6d-d26a-4622-9b13-1b15803ed57c">359</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIzLTMtMS0xLTY4NzY2_5a5954d8-fe50-4e66-8d39-b4ec8b26a130">370</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI0LTEtMS0xLTY4NzY2_4f316107-92d2-4cd7-8922-b86870b2c625">6,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI0LTMtMS0xLTY4NzY2_c0cc31f7-1114-41c8-a02e-9fcbf7118e1c">7,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI1LTEtMS0xLTY4NzY2_018f1f2a-0122-49f8-a3ee-854d11d25f70">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI1LTMtMS0xLTY4NzY2_d257789f-acf7-4ac6-bbd0-a0ff545d2fcd">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI2LTEtMS0xLTY4NzY2_4657eab9-b049-448e-9158-8425d708700a">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI2LTMtMS0xLTY4NzY2_4fd8d9dd-9a89-4186-9424-9280d76ce60b">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI3LTEtMS0xLTY4NzY2_e2c8bcc8-ea3c-475e-bf9d-de72c1c37533">104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI3LTMtMS0xLTY4NzY2_18bde2c6-add7-4468-bf0a-cd5564b5f70c">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI4LTEtMS0xLTY4NzY2_f3e2c8bf-b5de-46ef-a8a7-65565d556227">9,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI4LTMtMS0xLTY4NzY2_cf10cfda-8f60-4971-be9a-dfcd13210b00">9,579</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTIzNw_7e6c3393-c427-473a-b6b2-854e86014d5f"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTIzNw_e3410e44-b49c-4806-a3a4-3e851bdc76ef">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTI0MQ_0b4abc0e-4e9d-4a0d-84ef-5289b755bd04"><ix:nonFraction unitRef="shares" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTI0MQ_d98dd6b5-e438-4252-96a0-8f9f5913dcd2">150</ix:nonFraction></ix:nonFraction> million shares authorized; outstanding: <ix:nonFraction unitRef="shares" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTI0NQ_8243a8da-3c18-4a4b-860b-4ce7ca7e402f"><ix:nonFraction unitRef="shares" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTI0NQ_a4ee601f-8a75-47b4-b290-07c69abafc4c">58</ix:nonFraction></ix:nonFraction> million shares at each of December 31, 2022, and December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTEtMS0xLTY4NzY2_6977ae0f-db24-4fd7-a906-fbbadf6239b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTMtMS0xLTY4NzY2_c33f1e3f-1bcb-4bea-8c24-36d125179364">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIwNA_11c27540-eb43-4722-9cd7-4d58e997c982"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIwNA_29526d31-f90d-4b7b-a538-9d06a37c1693">0.001</ix:nonFraction></ix:nonFraction> par value per share; <ix:nonFraction unitRef="shares" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIwOA_c73dbffd-ff4f-4a0c-b0dc-4032cb60e177"><ix:nonFraction unitRef="shares" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIwOA_ceb831b4-7743-4adf-a097-9dbe1989a715">20</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="shares" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIxNA_1697c283-2b34-4151-9ec4-ca0969ba1c76"><ix:nonFraction unitRef="shares" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIxNA_65608097-4278-449f-837f-bb3e913bbc3c"><ix:nonFraction unitRef="shares" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIxNA_6fed0128-aae4-4975-82df-84bef82f9c62"><ix:nonFraction unitRef="shares" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIxNA_ef2a5b4e-25bb-4627-9e79-306761a077ab">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTEtMS0xLTY4NzY2_457c41fd-693d-40f9-ba89-6cd66fa7a23a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTMtMS0xLTY4NzY2_676274e7-17d0-4e7d-b1c3-ce53277a3ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMyLTEtMS0xLTY4NzY2_e43f860c-755c-4edb-a088-7fffb60b7d57">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMyLTMtMS0xLTY4NzY2_ff6cdda5-df02-44a4-9fc7-7a96c3e73060">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMzLTEtMS0xLTY4NzY2_23fa9ba4-9cb1-421a-a31b-44352052bab0">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMzLTMtMS0xLTY4NzY2_92d993d5-3a5c-4d9d-ae22-5cacf4d5fc96">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM0LTEtMS0xLTY4NzY2_ab39a348-d00b-4d5a-a063-02f25cd4c4b0">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM0LTMtMS0xLTY4NzY2_d635a271-4e97-4c57-92b7-32ecef76187e">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM1LTEtMS0xLTY4NzY2_eb15b30f-06a4-4f87-8a5a-944dc4c5eab1">2,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM1LTMtMS0xLTY4NzY2_f844babb-0002-4014-b60b-b43669ccc3ef">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM2LTEtMS0xLTY4NzY2_c86a0791-aa56-4015-b51e-a495800a40c3">12,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM2LTMtMS0xLTY4NzY2_238037de-46ff-485b-8b47-beb431719e6e">12,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 50</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_115"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:36.820%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.588%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.831%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.099%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.102%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive  (Loss) Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:18pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2019</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i999be11240344aa48da9e906b939d685_I20191231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtMS0xLTEtNjg3NjY_215116c4-c0ae-46d9-8a9b-c0174ad3a7bb">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i999be11240344aa48da9e906b939d685_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtMy0xLTEtNjg3NjY_f3c23ac9-a82d-4d59-b0bc-84b24d50e4cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199fd9ed80d34939adcf4df9bd792f0d_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtNS0xLTEtNjg3NjY_a1efa1c0-0076-466a-98c6-60efa53d2a72">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8771041280f54d5e8602cbc70ecac436_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtNy0xLTEtNjg3NjY_6162c387-3d41-479f-81c5-3bc377f81185">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8f933345f844fa938f287ea4acbefa_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtOS0xLTEtNjg3NjY_d95ea62c-17ee-4efa-a77c-fa01d06e1e76">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtMTEtMS0xLTY4NzY2_b41794f1-3f08-487e-9819-ec3e4c2bb2db">1,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cdb516bfdef4a8f9b6c6c031e73cef1_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzUtOS0xLTEtNjg3NjY_6d67ab64-0585-4934-a8ce-6daf4e131a26">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzUtMTEtMS0xLTY4NzY2_a9dfe792-3ce3-4714-86cc-04776e4a5a9f">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0ec77d8e31ee46229cf16bffe3977e23_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzYtMS0xLTEtNjg3NjY_4617b92c-17a4-4d2c-b1ab-3eca5340687a">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e5861f8a1be489fbadca2791aa90afe_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzYtNS0xLTEtNjg3NjY_778e353b-62a2-4741-9a85-63b3be524a59">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cdb516bfdef4a8f9b6c6c031e73cef1_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzYtOS0xLTEtNjg3NjY_c8a74504-5bc7-45df-8899-9438053c277b">594</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzYtMTEtMS0xLTY4NzY2_0d91678a-8963-43f4-8a96-6a30be524f34">605</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Termination of warrants</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e5861f8a1be489fbadca2791aa90afe_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzctNS0xLTEtNjg3NjY_000936c0-3f5d-40ef-919f-5c31053a2da8">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzctMTEtMS0xLTY4NzY2_036f0801-f002-4616-a8d3-df2803ab9171">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifc10bd10790d4245a58fd5f3eb995125_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE1LTctMS0xLTY4NzY2_94612f4a-f16f-4ada-b1d9-5da18d2fbe4c">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE1LTExLTEtMS02ODc2Ng_7706174b-0af0-46f4-a28c-5cb4dce46871">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0ec77d8e31ee46229cf16bffe3977e23_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE2LTEtMS0xLTY4NzY2_d3f2b254-df46-409f-8148-3a67d6ff8468">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e5861f8a1be489fbadca2791aa90afe_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE2LTUtMS0xLTY4NzY2_d912001b-7e73-4eac-bc28-15eea45ad1ce">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE2LTExLTEtMS02ODc2Ng_58278636-44d8-4735-af0d-51e84d20515e">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4c5174cdc8a543aab6a82650213fae42_I20201231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTEtMS0xLTY4NzY2_067b690d-0a52-4448-bbe1-7d5d2e7ba112">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c5174cdc8a543aab6a82650213fae42_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTMtMS0xLTY4NzY2_9fc845ed-42e3-4962-b7f9-5a2414eb1822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if519cf6d7ba746faa633b1d247f21140_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTUtMS0xLTY4NzY2_b477deb6-bc6e-4463-8697-4d754bacf870">199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if419e645396c4411a00a65c9c61e8f4b_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTctMS0xLTY4NzY2_e23c2efc-c5f6-4c8f-a420-da28e509d502">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1000dd422a4091b6562e182ae3a5e6_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTktMS0xLTY4NzY2_2bea48a6-a3a1-4ac9-aea2-559e9f357aa9">1,860</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTExLTEtMS02ODc2Ng_8aab55d7-b2f0-400f-ae71-9e37bf393402">2,096</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad023f53ea0d4a398b072037f4fa5a28_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE4LTktMS0xLTY4NzY2_2461052a-490b-40a0-8981-7e748494bb1d">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE4LTExLTEtMS02ODc2Ng_490b577c-f527-4929-a0c3-bf3883601a8d">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0a1b426cbcba4d009021f4ffbe5138b1_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE5LTEtMS0xLTY4NzY2_dd604ce0-f8a3-46e7-b9df-e88bf3495fa0">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie888b7a86e1749beb1747431a08efb69_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE5LTUtMS0xLTY4NzY2_5b347bdb-8b7f-4c9e-a952-69cf164a66b5">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iad023f53ea0d4a398b072037f4fa5a28_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE5LTktMS0xLTY4NzY2_dac7d361-a97d-4298-8cd5-2f4df8476da1">120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE5LTExLTEtMS02ODc2Ng_c01ad99e-0614-4823-b815-46b68da5cc14">122</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i20ffea858f7a413e84d7c60bd51a39ad_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzI4LTctMS0xLTY4NzY2_53f34220-6e13-48e5-8987-929ac01456f0">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzI4LTExLTEtMS02ODc2Ng_babdd6a4-3bac-4bf7-a901-30d510870311">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie888b7a86e1749beb1747431a08efb69_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzI5LTUtMS0xLTY4NzY2_bbe6bfa3-ad80-47a9-87c5-eda7ac00362f">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzI5LTExLTEtMS02ODc2Ng_5759a027-02f4-4ff0-b5f4-9d345e8e70cf">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i579cf48f5d864bddb56457fa28bb2587_I20211231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTEtMS0xLTY4NzY2_3dd080ab-4b7d-4929-9f4c-c2dd10a6c978">58</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i579cf48f5d864bddb56457fa28bb2587_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTMtMS0xLTY4NzY2_c0c8f0e9-4974-4264-88de-d831656b800f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c46a6c267b9418ea1b14da3214406ec_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTUtMS0xLTY4NzY2_2f15c31d-5177-41f5-b344-8ac53ce1ed7d">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i587b2eb5aff244fbb08b0618fb285d59_I20211231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTctMS0xLTY4NzY2_31dc3a13-6bd9-4292-9a40-4b0d0eacacc8">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a7caae068640048ce1c869c4207d7f_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTktMS0xLTY4NzY2_37abe088-25a0-4642-8efa-8ec0badfd6b6">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTExLTEtMS02ODc2Ng_485b65cd-bd8b-490e-8c34-3b34864ea7c9">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa9ec9408e524d0c9ce56cae77d8fddc_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMxLTktMS0xLTY4NzY2_8ef7758e-2858-4c7b-a775-96347217b90d">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMxLTExLTEtMS02ODc2Ng_eb0e063d-fa6c-46b3-b0c2-33d0d135e875">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="iac9f15a52524444587078e926f065feb_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMyLTEtMS0xLTY4NzY2_38399935-5f6a-4aeb-8761-5272230e44a6">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i790f6598096b4e42affcce597dc39434_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMyLTUtMS0xLTY4NzY2_c7512a57-d9f6-47a1-a999-96cf90c8c44d">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa9ec9408e524d0c9ce56cae77d8fddc_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMyLTktMS0xLTY4NzY2_3fa148b4-dbfe-43dd-b3aa-6657f4055d7d">395</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMyLTExLTEtMS02ODc2Ng_9e82aaab-4eda-4ffb-b80c-a0b6771cd4cc">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i014d76748d9c435e8c2252256e738466_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQxLTctMS0xLTY4NzY2_4e96afc0-bf7c-4da4-8b58-745bd82dd24a">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQxLTExLTEtMS02ODc2Ng_9136f628-6a23-4e66-ba75-cd299e9b3bb7">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iac9f15a52524444587078e926f065feb_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQyLTEtMS0xLTY4NzY2_ffffeece-884a-497b-9b3c-904d2e102dbb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i790f6598096b4e42affcce597dc39434_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQyLTUtMS0xLTY4NzY2_78483fa6-277b-448e-9927-b6513018a642">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQyLTExLTEtMS02ODc2Ng_081263a8-ccba-4972-86d2-0c8a66469e47">97</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8454949eb924409fbf2446822fa8d947_I20221231" decimals="-6" name="us-gaap:SharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTEtMS0xLTY4NzY2_b9af51f8-1791-4a1c-b1fc-aa855dd88d16">58</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8454949eb924409fbf2446822fa8d947_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTMtMS0xLTY4NzY2_f257421c-ff41-4394-9526-e09636d3f0ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1db3a5ad94a4885a560d39ee09283e7_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTUtMS0xLTY4NzY2_125a055c-8787-44e4-af2f-e1782a54d4c1">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1426d89bce2644bcb46ee222394ca3ab_I20221231" decimals="-6" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTctMS0xLTY4NzY2_edfe1472-3d42-4d57-bc12-17bdf5a89482">160</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95d5fbc5f32e4d71bf63e8a5e693b170_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTktMS0xLTY4NzY2_25321a94-9fc5-45cd-93dd-3423b22f3cd6">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTExLTEtMS02ODc2Ng_a4058fdb-cda2-4bc4-8f10-9888a1c7a846">2,964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 51</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_118"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In&#160;millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzUtMS0xLTEtNjg3NjY_75eed8b0-a9c0-4f6e-9d50-149afd804ce9">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzUtMy0xLTEtNjg3NjY_2d674381-752a-42a4-85cb-d1193d4709f5">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzUtNS0xLTEtNjg3NjY_297b3eb7-b09f-469c-940c-fabc1947257f">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzctMS0xLTEtNjg3NjY_436bd5f0-ed35-4ec0-876a-46334d1adf10">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzctMy0xLTEtNjg3NjY_8872ae9a-bf2d-43e6-b1f0-e46fbbea9fd3">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzctNS0xLTEtNjg3NjY_40b4c37a-0fe6-487c-be9d-44d6c5ad6f19">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzgtMS0xLTEtNjg3NjY_876ad958-1a27-4b1e-9097-9ce3dea59ea5">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzgtMy0xLTEtNjg3NjY_247db1e2-b596-4ed3-a410-4bef386cc81b">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzgtNS0xLTEtNjg3NjY_95ee6880-7790-4991-9ae2-39389fb5fcf2">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzktMS0xLTEtNjg3NjY_0e04b96a-e6a5-4808-957e-277e8e5ed608">103</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzktMy0xLTEtNjg3NjY_669eaee7-63fd-45ab-b2cd-d3fbdde336b2">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzktNS0xLTEtNjg3NjY_0440ea2e-e7ee-4129-ace0-7aa9f9da9018">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on debt repayment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:GainLossOnDebtRepayment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEwLTEtMS0xLTY4NzY2_501b3254-8d9e-4584-b001-58d098ea96ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="moh:GainLossOnDebtRepayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEwLTMtMS0xLTY4NzY2_24d75c5b-c017-40e1-98c6-01a5ce65ca7a">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="moh:GainLossOnDebtRepayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEwLTUtMS0xLTY4NzY2_ee9a3e05-eada-4808-91fc-4201f5ca1022">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTEtMS0xLTcxOTI1_901edcaf-f9fc-49d5-bdba-67065b39ceeb">208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTMtMS0xLTcxOTMz_a17fd5ae-bd69-435d-a033-83fd6ef417e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTUtMS0xLTcxOTMz_999b05c7-285f-4366-8cdb-2d049b6b7a9b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTEtMS0xLTY4NzY2_9e099e1d-cdc8-4817-ac47-2d01278d8ee9">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTMtMS0xLTY4NzY2_24947f9b-87ce-43a1-9775-f6770f4d8d56">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTUtMS0xLTY4NzY2_18758465-84cd-4e1a-b6ca-1be9246fc6bd">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of the effect of acquisitions:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEzLTEtMS0xLTY4NzY2_6f6bbd57-764c-4c57-a4b3-85370fb30d82">95</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEzLTMtMS0xLTY4NzY2_75b36088-fffd-49c2-93ea-4c07fa2157c5">415</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEzLTUtMS0xLTY4NzY2_83a2c355-d67f-42f6-881e-7679ae975aa2">100</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE0LTEtMS0xLTY4NzY2_93c5308c-3a56-45e6-bab0-5944752204d3">124</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE0LTMtMS0xLTY4NzY2_55520bd5-adaa-4be4-aae1-497389480ef8">19</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE0LTUtMS0xLTY4NzY2_10db9452-46c0-4309-9922-8e6b56878785">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE1LTEtMS0xLTY4NzY2_49490f55-aea6-4ce6-878b-496841ee01d6">153</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE1LTMtMS0xLTY4NzY2_4c4b2239-56f9-4f5d-9a95-be532061a627">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE1LTUtMS0xLTY4NzY2_722e7aa2-d605-4ccd-b8b9-949e7823019d">544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amounts due government agencies </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE2LTEtMS0xLTY4NzY2_9337e127-3c9b-4e20-b2c8-ce2187d0f343">428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE2LTMtMS0xLTY4NzY2_d0f857e5-74e6-45ea-90e1-a4e2ab16849d">1,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE2LTUtMS0xLTY4NzY2_02c750e2-8daa-431e-b7cb-506fb84a7f6f">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE3LTEtMS0xLTY4NzY2_a74e93b8-61c6-4f8c-9640-85c190411fd8">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE3LTMtMS0xLTY4NzY2_9207e240-68bc-45c7-b45b-dd237bda04c4">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE3LTUtMS0xLTY4NzY2_27cc3576-6528-46ef-a2c6-5127664991fb">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE4LTEtMS0xLTY4NzY2_8c7d6722-e764-402c-b330-9ebe8bc568de">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE4LTMtMS0xLTY4NzY2_3b1372f1-4be6-41b3-9ca4-2b48d9e7e686">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE4LTUtMS0xLTY4NzY2_052f567c-4a79-4995-85e6-d24cecd9bddf">126</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE5LTEtMS0xLTY4NzY2_03dc2421-48de-4964-a1b6-2b8cf5d29278">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE5LTMtMS0xLTY4NzY2_441fd06a-6f52-40ab-816a-950560abe73f">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE5LTUtMS0xLTY4NzY2_20a539c4-6c9f-48b3-83f3-3105a1c86a0f">14</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIwLTEtMS0xLTY4NzY2_118a4fcf-bcf2-430c-84d0-7fcf48080370">773</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIwLTMtMS0xLTY4NzY2_2249d4d1-8dda-483e-9c25-24626c248003">2,119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIwLTUtMS0xLTY4NzY2_55385322-24cb-4e5e-8612-35c6f2238017">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIyLTEtMS0xLTY4NzY2_fdfa09b5-d122-42c3-b8e3-5a6513acbf63">1,913</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIyLTMtMS0xLTY4NzY2_43be6761-544f-4deb-9f28-2152c330a514">2,713</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIyLTUtMS0xLTY4NzY2_3e03c95c-946b-46e2-b413-735e0c728f10">670</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIzLTEtMS0xLTY4NzY2_5f1624b2-a54b-4b99-abf2-e61ead477ccd">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIzLTMtMS0xLTY4NzY2_a72dbe7a-6b39-49e0-b2d1-a3161d7604ea">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIzLTUtMS0xLTY4NzY2_10b54943-6c7c-401f-8b93-6328c9faf61c">1,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid in business combinations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI0LTEtMS0xLTY4NzY2_3d662238-c300-4cef-8a5f-cf91d267f64a">134</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI0LTMtMS0xLTY4NzY2_9ab9efb2-6881-456d-a432-55a5cab72f5d">129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI0LTUtMS0xLTY4NzY2_a59a3c15-e16c-434a-934b-c072be4f7c14">755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, equipment and capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI1LTEtMS0xLTY4NzY2_a7905d86-39a8-430c-9fb5-7091065f543a">91</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI1LTMtMS0xLTY4NzY2_3cdb7546-66a6-4d8f-8baa-2fe0e97ffd0f">77</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI1LTUtMS0xLTY4NzY2_5d520445-3ae0-4c7e-b9e1-ef134365df80">74</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI2LTEtMS0xLTY4NzY2_7c41a4a5-734e-4335-a80a-ac27d319612f">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI2LTMtMS0xLTY4NzY2_8fe4aa5e-2712-44dc-bad6-81a8c69f3eb4">63</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI2LTUtMS0xLTY4NzY2_1f5494d4-1ca2-4d58-b226-995fff1ae4cc">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI3LTEtMS0xLTY4NzY2_3fa306c7-4df9-4777-a250-a8de21afc464">790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI3LTMtMS0xLTY4NzY2_0d540e2b-f548-45f8-aaa6-f6c3f6a041b2">1,653</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI3LTUtMS0xLTY4NzY2_1e4d3878-0c42-438b-b5c8-7a137a2d8724">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI5LTEtMS0xLTY4NzY2_e7526db5-5637-4fdb-848d-2747ebfa9fd7">400</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI5LTMtMS0xLTY4NzY2_00b1e35f-c728-4189-ad80-40164e7bf82a">128</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI5LTUtMS0xLTY4NzY2_2e9da017-1332-4538-8deb-cf2acfed54fa">606</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld to settle employee tax obligations</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMwLTEtMS0xLTY4NzY2_948d6ce1-657a-4406-b45a-85e05ac5dcdb">54</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMwLTMtMS0xLTY4NzY2_4d7b0519-c77c-4b53-be20-abdedf2ae0b5">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMwLTUtMS0xLTY4NzY2_9e3c9d7c-42bd-436f-9a12-bd841eaebe0c">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities settled</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMxLTEtMS0xLTY4NzY2_0d25a0e2-09e2-4999-beb2-28e7ac4344c1">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMxLTMtMS0xLTY4NzY2_d9b547c4-6000-4a94-80ec-b3915e517364">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMxLTUtMS0xLTY4NzY2_43068e4a-cc9f-4e63-a667-1db5e20747cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from senior notes offerings, net of issuance costs </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMyLTEtMS0xLTY4NzY2_9b7bafe8-7a00-42a6-b5f5-b5b353a02cce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMyLTMtMS0xLTY4NzY2_34e9d090-2448-4849-99ba-2a5b44d1c375">740</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMyLTUtMS0xLTY4NzY2_52e5688f-e93d-4c5f-8d8f-de4de768b1b2">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMzLTEtMS0xLTY4NzY2_ddb513da-342d-4af3-bb41-86d5f7a7047e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMzLTMtMS0xLTY4NzY2_837837f1-5a3b-4123-b4fd-6b7e6a581ffe">723</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMzLTUtMS0xLTY4NzY2_803b22fa-2560-4ed7-ba02-455bd8cc1fe3">338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of term loan facility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM0LTEtMS0xLTY4NzY2_20bf4d77-9395-4a52-8b5d-7df75c111913">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM0LTMtMS0xLTY4NzY2_122bc83b-b4d9-4a35-adcd-c8ccd7e486f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM0LTUtMS0xLTY4NzY2_547d4c56-0a65-4431-8ca2-31d2b9ce87ac">600</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan facility</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM1LTEtMS0xLTY4NzY2_5a6dae7c-a8cf-42fd-b2fe-0669f91288bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM1LTMtMS0xLTY4NzY2_14506bc2-7cde-48f8-90e0-e555f2779340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM1LTUtMS0xLTY4NzY2_8125fff4-81af-4483-82a4-5cf7d5e937ae">380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial termination of warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM2LTEtMS0xLTY4NzY2_d13ee961-3e61-4c9a-ab12-081a30b735de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM2LTMtMS0xLTY4NzY2_861be610-e585-4528-bb42-881d99fece6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM2LTUtMS0xLTY4NzY2_2c7339f0-67f3-41a3-98af-7982bfd48c1d">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial settlement of conversion option</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:CashPaidForSettlementOfConversionOption" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM3LTEtMS0xLTY4NzY2_460de9d9-7eee-4639-8e05-8cf98e719c2a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:CashPaidForSettlementOfConversionOption" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM3LTMtMS0xLTY4NzY2_75b8511c-0d78-43c2-9dbe-c0be34128c20">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:CashPaidForSettlementOfConversionOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM3LTUtMS0xLTY4NzY2_643a5951-0c6e-4166-bb60-0f019dcd0f12">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for partial settlement of call option</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM4LTEtMS0xLTY4NzY2_41e246e2-f198-4688-9c77-46fa6bddd52c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM4LTMtMS0xLTY4NzY2_9820b9af-9f61-4d8e-b0db-20b0772303bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM4LTUtMS0xLTY4NzY2_dababf54-5212-40f5-abcd-28718bddd2f6">27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of principal amount of convertible senior notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM5LTEtMS0xLTY4NzY2_3d2da302-6b20-41c9-9269-25d63c321cbd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM5LTMtMS0xLTY4NzY2_5dd911da-5f51-4b66-9f25-0a0e30d572b5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM5LTUtMS0xLTY4NzY2_a1c26a62-05d9-4fb8-8fcb-ecf82c2aee33">12</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQwLTEtMS0xLTY4NzY2_4fe0d0c4-565f-4082-9e51-819d910c9546">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQwLTMtMS0xLTY4NzY2_4158842d-3491-4e08-9a1a-4767b9231a1c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQwLTUtMS0xLTY4NzY2_a59486b8-8a5f-4956-8a8d-935a31f4381e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQxLTEtMS0xLTY4NzY2_6eb731d3-15f2-42ca-8e89-f1e8e5b3ef03">441</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQxLTMtMS0xLTY4NzY2_a33b267c-2aa0-4fba-af35-e76095fccd88">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQxLTUtMS0xLTY4NzY2_5f654541-441f-480c-a400-d10d5429c67b">217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQyLTEtMS0xLTY4NzY2_5fe38af6-62ac-42c7-be1c-b27be04cb173">458</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQyLTMtMS0xLTY4NzY2_aadd85b0-3e54-4c98-b2ab-4f43cab88ef3">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQyLTUtMS0xLTY4NzY2_61303348-88fb-4f23-9d99-56191197b17a">1,715</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQzLTEtMS0xLTY4NzY2_9e316368-65c9-4f5f-ad8d-edfcaae79be4">4,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQzLTMtMS0xLTY4NzY2_6f404e3f-2831-4e2a-a64b-0ca03940275f">4,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQzLTUtMS0xLTY4NzY2_d0628b18-1a4a-4a3e-b454-f40dfecd3b5b">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, and restricted cash and cash equivalents at end of period</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQ0LTEtMS0xLTY4NzY2_49673cd4-f3d6-4d3e-b6a3-5c88fe48987e">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQ0LTMtMS0xLTY4NzY2_5bae440f-b98e-4c97-b67f-8f0899431afd">4,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQ0LTUtMS0xLTY4NzY2_d7f9bef8-9ee9-4ccf-ac19-aecc42e7a8c6">4,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(continued)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the period for:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzYtMS0xLTEtNjg3NjY_3dbdfd61-f9e9-432f-abe4-1434357e7f9a">340</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzYtMy0xLTEtNjg3NjY_403d879c-9480-4c75-8f18-0c17ccbddf1c">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzYtNS0xLTEtNjg3NjY_145ace0b-c3f3-457b-8cb1-e319cf0112a1">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzctMS0xLTEtNjg3NjY_ac386aec-2bae-4a60-abe1-d3437afd081c">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzctMy0xLTEtNjg3NjY_ec6dbd44-c47e-4611-87eb-63c972d7de63">127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzctNS0xLTEtNjg3NjY_074c2dc9-fbc9-4e16-ae98-c9749c32167b">112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 53</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_124"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwNTg_c689c14f-bae2-40eb-acc7-54c7809c2154" continuedAt="i0db2903c190045f4a331c56ff6aa7e23" escape="true">Organization and Basis of Presentation </ix:nonNumeric></span></div><ix:continuation id="i0db2903c190045f4a331c56ff6aa7e23" continuedAt="i750a856659db4fe0b1d3ee838f7d5326"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). Molina was founded in 1980 as a provider organization serving low-income families in Southern California and reincorporated in Delaware in 2002. We currently have <ix:nonFraction unitRef="segment" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1ODY_a4362266-9afb-4b4c-9ff4-6ff84ec170a7">four</ix:nonFraction> reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we served approximately <ix:nonFraction unitRef="member" contextRef="i85e7dfbb25714e6fa1e9c665d5b451ed_I20221231" decimals="-5" name="moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzUzMg_ed0ce3bb-6533-406c-a7ca-1a4b8b3f4893">5.3</ix:nonFraction> million members eligible for government-sponsored healthcare programs, located across <ix:nonFraction unitRef="state" contextRef="i85e7dfbb25714e6fa1e9c665d5b451ed_I20221231" decimals="INF" name="moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzYxMw_8e9dc130-5f85-4b3e-9ce3-e71fe77967d3">19</ix:nonFraction> states. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzY3OA_6f2a845c-6f22-4bcc-9cb4-a0ec1e4ca0c4">three</span> to <ix:nonNumeric contextRef="i0401c2aac1bd43f18925d12817958d7a_D20220101-20221231" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzY4NA_300c2ee7-bf79-4f89-b7b3-3d57bdf4fac3">five years</ix:nonNumeric>, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFP&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#8220;ABD&#8221;); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Medicare, we enter into Medicare Advantage-Part D contracts with the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) annually, and for dual-eligible plans, we enter into contracts with CMS, in partnership with each state&#8217;s department of health and human services. Such contracts typically have terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzEwOTk1MTE2NDU4MTc_95927849-eb03-4285-a11c-36386eebadfb">one</span> to <ix:nonNumeric contextRef="i99e5c5b493404f65b708b3004c6d9e12_D20220101-20221231" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQzOTgwNDY1MjkxNTY_56f8afa9-78f8-4f36-9016-79faa63b3293">three years</ix:nonNumeric>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Marketplace, we enter into contracts with CMS, which end on December 31 of each year, and must be renewed annually. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2023, the Texas Health and Human Services Commission posted a notice on its website indicating that it was issuing a Notice of Intent to Award to Molina Healthcare of Texas, Inc. a STAR+PLUS ABD contract in each of Bexar, Dallas, El Paso, Harris, Hidalgo, Jefferson, Northeast Texas, and Tarrant Service Areas. The notice follows a proposal that we submitted in June 2022 to continue serving STAR+PLUS members in the same service areas, in response to an RFP posted in March 2022. The start of operations for the new contract is expected to begin in February 2024. Further, in December 2022, the RFP was posted for the TANF and CHIP programs (known as the STAR &amp; CHIP programs, and both existing contracts for Molina), with awards expected in February 2024 and the start of operations in February 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we announced that the California Department of Health Care Services (&#8220;DHCS&#8221;) had confirmed our California health plan&#8217;s footprint as originally announced in August 2022, including Medi-Cal contract awards in each of Riverside, San Bernardino, Sacramento, and San Diego Counties. In Los Angeles County, we will share membership equally with the current commercial incumbent. The Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand our footprint in Los Angeles County. DHCS has also agreed to grant Molina a contract to offer EAE-SNP products for dual eligible members in Los Angeles County.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York (&#8220;AgeWell&#8221;). See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nebraska Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we announced that our Nebraska health plan had been selected by the Nebraska Department of Health and Human Services to provide health care services to Nebraskans under the state&#8217;s Medicaid managed care program. The new <ix:nonNumeric contextRef="i880dcbd954c94606b002149fe2d46983_D20220901-20220930" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1Nzk_da260b0b-204d-4b63-9359-377c5b013e1c">five-year</ix:nonNumeric> contract is expected to begin on January 1, 2024, and may be extended for an additional <ix:nonNumeric contextRef="i880dcbd954c94606b002149fe2d46983_D20220901-20220930" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1NjU_2aea2302-3648-4a6a-aed2-1de3812bb7ec">two-years</ix:nonNumeric>.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iowa Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Iowa health plan had been notified by the Iowa Department of Health and Human Services (&#8220;Iowa HHS&#8221;) of its intent to award a Medicaid managed care contract pursuant to the RFP issued by Iowa HHS in February 2022. The new <ix:nonNumeric contextRef="i5d1626275dac4e1fb93d80b9a4189fb4_D20220801-20220831" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1NTI_cdec4946-ebdc-4aa1-9001-d365f2ffbd98">four-year</ix:nonNumeric> contract is expected to begin on July 1, 2023, and may be extended for an additional <ix:nonNumeric contextRef="i5d1626275dac4e1fb93d80b9a4189fb4_D20220801-20220831" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1MzQ_870fb43f-0412-4fbd-9008-4ca4829999d9">four years</ix:nonNumeric>.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i750a856659db4fe0b1d3ee838f7d5326" continuedAt="ic91268ed75744dc09e7a7867aaeb916a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Mississippi health plan had been notified by the Mississippi Division of Medicaid (&#8220;DOM&#8221;) of its intent to award a Medicaid Coordinated Care Contract for its Mississippi Coordinated Access Program and Mississippi Children&#8217;s Health Insurance Program pursuant to the Request for Qualifications issued by DOM in December 2021. The <ix:nonNumeric contextRef="i0f69658aa2554010bae3200d5bca4c4d_D20220801-20220831" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1MTA_907f4f42-be52-4262-a8aa-bb3c197a14fd">four-year</ix:nonNumeric> contract is expected to begin on July 1, 2023, and may be extended for an additional <ix:nonNumeric contextRef="i0f69658aa2554010bae3200d5bca4c4d_D20220801-20220831" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY0OTI_b9832065-bdb8-48e6-9944-db32c8692ea1">two years</ix:nonNumeric>. The award enables us to continue serving Medicaid members across the state.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wisconsin Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#8220;MCW&#8221;). The purchase price for the transaction is approximately $<ix:nonFraction unitRef="usd" contextRef="i307d98a799304ec9b2ea5e24af4f8721_D20220713-20220713" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY0NjY_f3623eb1-cf34-4156-ae1a-b66015bb1e28">150</ix:nonFraction>&#160;million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in mid-2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. This new contract is <ix:nonNumeric contextRef="ie3076577c633490db40aa71614578a1e_D20210901-20210930" name="moh:HealthPlanContractTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwODE_402ee0cf-6136-44c7-8261-0d3d96375487">four years</ix:nonNumeric> with a potential <ix:nonNumeric contextRef="ie3076577c633490db40aa71614578a1e_D20210901-20210930" name="moh:HealthPlanExtensionOptionPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwODY_b372c107-265b-44c3-9a3c-1387a478e4ab">two-year</ix:nonNumeric> extension.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. See Note 4, &#8220;Business Combinations,&#8221; for further information.</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwNTQ_6eaf0968-d22b-4166-97c2-872413da59d2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.</span></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwODQ_8f69c872-0086-4b63-a6f6-634f274d3de0" continuedAt="iaa117f220278409e902c389b7c3de990" escape="true">Use of Estimates</ix:nonNumeric></span></div></ix:continuation><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic91268ed75744dc09e7a7867aaeb916a"><ix:continuation id="iaa117f220278409e902c389b7c3de990">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</ix:continuation></ix:continuation> </span></div><div><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_127"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDI4_966c8a67-0ed9-4159-9fe0-0ce26659e4f1" continuedAt="idb59337e90f74a8faa20fb8bd11dc2f4" escape="true">Significant Accounting Policies</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="idb59337e90f74a8faa20fb8bd11dc2f4" continuedAt="ia4ac6bae5675428780f6ec87c6bfc821"> </ix:continuation></span></div><ix:continuation id="ia4ac6bae5675428780f6ec87c6bfc821" continuedAt="ib501fb9fc79c45788a01c6c0949b80ff"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTEw_fdf7275b-3493-4f7b-8b4e-8561db4dd038" continuedAt="ia39bd52c6faa454bbcd7fc72a187972b" escape="true">Cash and Cash Equivalents</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia39bd52c6faa454bbcd7fc72a187972b">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows.</ix:continuation> <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDAx_f0ea0e2e-e9eb-4580-b0bb-698bf8bd578a" continuedAt="ida2b2925cecf4b5a8d5d75a9148eddb7" escape="true"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDIx_b309cf23-af51-47ca-975b-44ed4180b825" continuedAt="i0b6e274608a344d5be5e3e2b5146d024" escape="true">The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. </ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="ida2b2925cecf4b5a8d5d75a9148eddb7"><ix:continuation id="i0b6e274608a344d5be5e3e2b5146d024"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.835%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.869%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzQtMS0xLTEtNjg3NjY_58fcda56-92df-43a9-b8e4-89412a1f774c">4,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzQtMy0xLTEtNjg3NjY_aed9434a-b8d6-4011-a045-211e790ef211">4,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzQtNS0xLTEtNjg3NjY_7b695711-5422-47f0-b3b4-ca7f214f8fbf">4,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzUtMS0xLTEtNjg3NjY_204b050f-ebc9-4be6-affc-0af9cbd926ad">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzUtMy0xLTEtNjg3NjY_67c12b9f-0f78-49a0-8bd7-d280ef71939d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:RestrictedCashAndCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzUtNS0xLTEtNjg3NjY_81393f82-46b2-4175-a21d-c6b965c64c94">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzYtMS0xLTEtNjg3NjY_197ec672-2920-41fe-8a14-77dd4cf8850c">4,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzYtMy0xLTEtNjg3NjY_270fc3e0-d3a0-4edd-b669-e3cbd4ffbd83">4,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzYtNS0xLTEtNjg3NjY_6b6a4b81-a4e1-42ae-bd86-fbe451931777">4,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTEx_6c094b85-65c4-4681-87a2-5c89a33dc1be" continuedAt="i301c7a5e1e884410bc71cb61e6a22830" escape="true"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#8220;AFS&#8221;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#8217; equity as other comprehensive income, net of applicable income taxes. Held-to-maturity (&#8220;HTM&#8221;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses arising from credit-related factors with respect to AFS </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib501fb9fc79c45788a01c6c0949b80ff" continuedAt="i1ba23c36f10a47948f8b97c55eff8b1b"><ix:continuation id="i301c7a5e1e884410bc71cb61e6a22830" continuedAt="i2911509c19e1472da5560a84b378a624"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy requires that all of our investments have final maturities of less than <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:InvestmentsMaturityPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzE2Mzc_88f3fda5-745d-48bb-a168-1c701578e830">15</ix:nonNumeric> years, or less than <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:InvestmentsAverageMaturityPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzE2NjA_68e11dab-7d0e-498f-a624-1d396c7a4cd2">15</ix:nonNumeric> years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2911509c19e1472da5560a84b378a624">In general, our AFS securities are classified as current assets without regard to the securities&#8217; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment.</ix:continuation> For comprehensive discussions of the fair value and classification of our investments, see Note&#160;5, &#8220;Fair Value Measurements,&#8221; and Note&#160;6, &#8220;Investments.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable relating to our AFS and HTM securities is presented within &#8220;Prepaid expenses and other current assets&#8221; in the accompanying consolidated balance sheets, and amounted to $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NDU_ae89e370-76bc-4219-81e0-ad3963881dac">35</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:InterestReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NTI_79992818-3e8e-48af-ad7c-a555b552a45e">11</ix:nonFraction> million at December 31, 2022, and 2021, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write offs as a reversal of investment income. No accrued interest was written off during the year ended December 31, 2022.</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ReceivablesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDI5_c00e4d2d-0068-4500-9ca6-b920b84e9d44" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div></ix:nonNumeric><div style="margin-bottom:1pt;margin-top:6pt"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTcw_2b7493bc-e1b4-43fe-9b06-b9f9d2a37aa9" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:72.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5986c52b45c34430a4e46e84fd09578e_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzQtMS0xLTEtNjg3NjY_b5ef705a-b68c-4f2b-8bb1-a58f4e268587">1,702</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e1b19ab0d1440b7bfda152e607a2ac4_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzQtMy0xLTEtNjg3NjY_0d893443-9500-4578-a891-2b1e596e25d0">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ac7e7cce7c7488f856cfee3ee520a77_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzUtMS0xLTEtNjg3NjY_94953fa1-6026-496f-950e-09a4b0931afd">291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95f4006db8de462884c07a9ec0cebfd1_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzUtMy0xLTEtNjg3NjY_3db4f214-c3cd-4339-abd7-426a8a957061">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i283a40999d534f9f8762d3200d2894ff_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzctMS0xLTEtNjg3NjY_5dfc46c7-2a46-4478-8b65-bcac11f1867b">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72c7bccfd8ca4bf18d2185d8ddf074de_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzctMy0xLTEtNjg3NjY_d7269126-f03e-469a-ac56-06c820f92e98">335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzgtMS0xLTEtNjg3NjY_a0797a69-169d-496e-8839-9e7bf2c054e1">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:ReceivablesNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzgtMy0xLTEtNjg3NjY_eb393800-f335-4504-bf7a-c63ae86fc536">2,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:BusinessCombinationsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTQ2_5a612965-703e-4436-bfb6-fd2e2c54fe46" continuedAt="i2afe236f3b5848dbb2852bf7634dec9f" escape="true">Business Combinations</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2afe236f3b5848dbb2852bf7634dec9f">We account for business combinations using the acquisition method of accounting, which requires us to recognize the assets acquired and the liabilities assumed at their acquisition date fair values. As discussed below, the excess of the purchase consideration transferred over the fair value of the net tangible and intangible assets acquired is recorded as goodwill. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated results of operations.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price for the acquisition of certain assets of Passport Health Plan, Inc. in 2020 included contingent consideration payable to seller relating to guarantees for minimum operating income in the post-acquisition period in 2020 and minimum membership targets in 2021. The liabilities are recorded at fair value on a recurring basis, which totaled $<ix:nonFraction unitRef="usd" contextRef="i386078af04c247fa901c709fe93c58dd_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzQ2ODI_beae4cf5-278c-4504-93c4-df5672ba22e1">8</ix:nonFraction> million as of December 31, 2022. For the amounts paid in the year ended December 31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzc2OTY1ODE0MzQ5Njk_d746f52e-66ba-4ba4-bbf2-e264b91b2706">20</ix:nonFraction>&#160;million has been presented in &#8220;Financing activities&#8221; in the accompanying consolidated statements of cash flows, with the balance reflected in &#8220;Operating activities.&#8221; We paid the remaining balance of the liabilities, reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets, in January 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, &#8220;Business Combinations,&#8221; and Note 9, &#8220;Goodwill and Intangible Assets, Net,&#8221; for further details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1ba23c36f10a47948f8b97c55eff8b1b" continuedAt="ib55c5d7fb33b4a8ebd198a8d452e75d8"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTY2_c4bd7a78-d133-4528-880c-bdae6ab30533" continuedAt="i59bc19fe198d45b0a01a28b855c8590a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets, including Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, &#8220;Property, Equipment, and Capitalized Software, Net&#8221;), and intangible assets resulting from acquisitions. Long-lived assets are subject to impairment tests when events or circumstances indicate that the asset&#8217;s (or asset group&#8217;s) carrying value may not be recoverable. Refer to the discussion in &#8220;Leases&#8221; below for impairment charges related to leasehold improvements and other property and equipment associated with the reduction in leased space used in our business operations. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3Nzg_99b8badb-97fb-4a1c-8779-f7186aae231d">five</span> and <ix:nonNumeric contextRef="i1a3656d06a5b43eaa3ec5dfdecceaac7_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3ODU_ad375fb2-1f0b-41e4-8ceb-01e5db429e74">16</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair value of separately identifiable intangible assets requires management to make estimates, which are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Determining the useful life of an intangible asset also requires judgment, as different types of intangible assets will have different useful lives. The most significant intangible asset we typically record in a business combination is contract rights associated with membership assumed. In determining the estimated fair value of the intangible assets, we typically apply the income approach, which discounts the projected future net cash flows using an appropriate discount rate that reflects the risk associated with such projected future cash flows. The most critical assumptions used in determining the fair value of contract rights include forecasted operating margins and the weighted average cost of capital.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDEx_afaf5599-3990-492d-bcd0-168506442a7d" escape="true">Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset&#8217;s (or asset group&#8217;s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.</ix:nonNumeric> Refer to Note 9, &#8220;Goodwill and Intangible Assets, Net,&#8221; for further details.</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTYw_2a8b6e95-ffec-4cc1-9a7e-e581b2ec6af5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase consideration over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Impairment indicators may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of our reporting units exceed their estimated fair values. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. We performed a qualitative goodwill assessment of our reporting units, and did not identify any factors indicating that the carrying value of our reporting units exceeded their estimated fair values. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows. The base year in the reporting units&#8217; discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly-traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units&#8217; fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib55c5d7fb33b4a8ebd198a8d452e75d8" continuedAt="id596729edd51437883e5bddbc0a8e32c"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTI0_8ebcdcd1-46c2-454d-85bd-75f84db4492e" continuedAt="ie121dd117c814b02a3840a8dcfafb4c0" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use (&#8220;ROU&#8221;) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie121dd117c814b02a3840a8dcfafb4c0">The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we recognized $<ix:nonFraction unitRef="usd" contextRef="i01aae92c76f5467c8edb776a572ee453_D20221001-20221231" decimals="-6" name="moh:OperatingAndFinanceLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk1OTA_8154da02-1e90-45a4-b7db-6fa576c67b1c">192</ix:nonFraction>&#160;million of ROU asset impairments in connection with the reduction in leased space to accommodate our move to a remote work environment, including vacating and abandonment of various leased properties. We assessed the ROU assets for impairment as a result of the reduction in leased space used in our business operations, and we engaged a third-party real estate specialist to determine the recoverability of the leased properties, based on estimated fair values. The valuation primarily considered comparable leased properties in each market and the assessment of actual and potential future rental income generated by the ROU assets. For further information, including the amount and location of the ROU assets and lease liabilities recognized in the accompanying consolidated balance sheets, see Note 8, &#8220;Leases.&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognized $<ix:nonFraction unitRef="usd" contextRef="i3f1d77f589974a46b23eddba5474dc63_D20220101-20221231" decimals="-6" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk1Nzc_1b2ba620-fda3-4f8f-9443-4ca38197dd6c">16</ix:nonFraction>&#160;million in impairment charges related to leasehold improvements and other property and equipment associated with the reduction in leased space used in our business operations. Please refer to Note 7, &#8220;Property, Equipment, and Capitalized Software, Net&#8221; for further discussion.</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTE0_c89ddfe2-c210-484e-b8e1-183ed8467d35" continuedAt="i265c9aed2fe14ccda323bd078409c4a6" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Claims and Benefits Payable</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (&#8220;IBNP&#8221;). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id596729edd51437883e5bddbc0a8e32c" continuedAt="i59cfeba7a96d49ff805bb16fd4c243de"><ix:continuation id="i265c9aed2fe14ccda323bd078409c4a6" continuedAt="ic88a0d0274bf4648bd17975bafc4f047"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period in which the adjustments are determined. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10, &#8220;Medical Claims and Benefits Payable,&#8221; for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates, including certain components of premium revenue that are subject to accounting estimates and are described below, under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic88a0d0274bf4648bd17975bafc4f047" continuedAt="ia08aa6ab3e124cf7ab29e2ec7942153f">Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.</ix:continuation> Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies&#8221; in the accompanying consolidated balance sheets. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ReservesReportedToOtherAgenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDMw_71b3dc3a-8d81-4519-aa04-f8eb1cf862a1" continuedAt="ic5035811d9854e59a37171ead6194fac" escape="true">Categorized by program, such amounts due government agencies included the following:</ix:nonNumeric></span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><ix:continuation id="ic5035811d9854e59a37171ead6194fac"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.204%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.206%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR, corridors, and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzUtMS0xLTEtNjg3NjY_ff0c02cc-4713-4bca-984c-b08591c40294">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzUtMy0xLTEtNjg3NjY_5c2e93b3-3895-41a5-b650-12f743be3bd9">1,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzYtMS0xLTEtNjg3NjY_6c536c22-8b39-40c9-882a-22b4bd4cda1f">482</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicaidOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzYtMy0xLTEtNjg3NjY_e8d66f43-0377-446b-8eef-de14ccea346c">263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzgtMS0xLTEtNjg3NjY_5b4c025f-5055-47f4-afe3-f4b80ac4a344">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzgtMy0xLTEtNjg3NjY_73886576-bcba-43bc-babd-d28b37d6c577">89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzktMS0xLTEtNjg3NjY_91a638a5-2e20-46f7-b7dd-247c7bece16a">84</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzktMy0xLTEtNjg3NjY_7daf7630-5409-476c-978c-e36ab83969b5">101</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEwLTEtMS0xLTY4NzY2_4d635a2c-31fc-4423-b004-3e0c171dedd1">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:OtherMedicareProgram" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEwLTMtMS0xLTY4NzY2_4ab650a8-dccc-479c-ae97-55c491e6c621">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEyLTEtMS0xLTY4NzY2_83a35e36-dccf-4447-a91f-a8ceeba483d9">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesRiskAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEyLTMtMS0xLTY4NzY2_4d8bba47-9814-43bb-ae87-ca22353cd6f7">902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEzLTEtMS0xLTY4NzY2_5c92308a-ca47-48b5-be82-e3e7cbc18cf1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEzLTMtMS0xLTY4NzY2_dfa91086-2811-4cde-8c67-7e9479b8a775">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzE0LTEtMS0xLTY4NzY2_7ac5a4fb-a1d7-4691-aded-55e13ad56c54">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AmountsDuetoGovernmentAgenciesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzE0LTMtMS0xLTY4NzY2_f8ed344b-dbee-40e8-89f9-9f65f88e4e60">48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzE2LTEtMS0xLTY4NzY2_f2866935-d855-41ef-a699-d2255739cf9a">2,079</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:MedicalPremiumLiabilityDueToAgency" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzE2LTMtMS0xLTY4NzY2_284fe3b9-78f7-4c23-a776-7d8593f3809a">2,472</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i59cfeba7a96d49ff805bb16fd4c243de" continuedAt="i5f65631bfa7142bb91c440755a3f0a24"><ix:continuation id="ia08aa6ab3e124cf7ab29e2ec7942153f" continuedAt="i2546301a3b4e4460944457b501a81bfc"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Medical Cost Corridors. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs as a percentage of premium revenue, or minimum medical loss ratio (&#8220;Minimum MLR&#8221;). Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2546301a3b4e4460944457b501a81bfc" continuedAt="i9ff0ed51ae244c238d967fef2222c731">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. We have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable.</ix:continuation> For the year ended December 31, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i04d52aa82e834517bbc667b377f4ad2c_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIwMzQ0_5077317d-a114-4202-8d0a-485e3582ec46">197</ix:nonFraction>&#160;million related to such risk corridors, primarily in the Medicaid segment, compared to $<ix:nonFraction unitRef="usd" contextRef="i2133a1cf36b14bcf8da5c42ae85115a7_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInPremiumsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzc2OTY1ODE0MzQ5ODI_4f8af1e3-f282-405b-8489-15f6d1946a42">323</ix:nonFraction>&#160;million recognized in the year ended December 31, 2021.The decrease in 2022 is due to the elimination of most of the COVID-19 risk corridors. </span></div><ix:continuation id="i9ff0ed51ae244c238d967fef2222c731" continuedAt="i0cebd9171c3f4108a0c34cfa68f9e5d0"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit Sharing. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium revenues on a retroactive basis for rate changes and changes in membership and eligibility data. In certain states, adjustments are made based on the health status of our members (as measured through a risk score). In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#8217; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#8217; health status, risk scores and CMS practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Affordable Care Act (&#8220;ACA&#8221;) established a Minimum MLR of 85% for Medicare. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i0cebd9171c3f4108a0c34cfa68f9e5d0" continuedAt="i1703c97c43554a6f9c150c4f224050c9">Risk Adjustment.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1703c97c43554a6f9c150c4f224050c9" continuedAt="ie94595725d664c34ad9043f02c00e8e3"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.</ix:continuation> As of December&#160;31, 2022, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyNzc1_2fdbee9e-7407-44eb-8fc5-756e69dae2a0">230</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyODE0_d2523038-4272-4314-a3a2-b14b1b455d11">135</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyODM5_78466b7b-5dcf-4393-8aed-8f2699ca9dd2">95</ix:nonFraction> million. As of December 31, 2021, Marketplace risk adjustment payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyOTE1_67c0e1ec-a192-4596-9678-e64e8b1da77c">902</ix:nonFraction> million and related receivables amounted to $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyOTU0_7222c048-a8b7-4368-945e-5d9269a2930c">7</ix:nonFraction> million, for a net payable of $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyOTc5_22db1ff6-2901-4a32-9047-d9d400205ba9">895</ix:nonFraction> million.</span></div><ix:continuation id="ie94595725d664c34ad9043f02c00e8e3" continuedAt="i8054a5070f1a442f960a0c88207052ae"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Incentives</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8054a5070f1a442f960a0c88207052ae">At many of our health plans, revenue ranging from approximately <ix:nonFraction unitRef="number" contextRef="i5d0d8ea348c241a4b9f809ef2b12dfa2_D20220101-20221231" decimals="2" name="moh:PercentageOfAdditionalIncrementalRevenueEarned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIzNDc0_6bf5c7ef-13dc-4543-8403-01cd89e262cd">1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i7eaace7d309845f986541d1f02db8612_D20220101-20221231" decimals="2" name="moh:PercentageOfAdditionalIncrementalRevenueEarned" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIzNDgw_a7a2b2f1-f0d0-4ed7-a0e6-1cc701fa5d12">4</ix:nonFraction>% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. Recognition of quality incentive premium revenue is subject to the use of estimates.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5f65631bfa7142bb91c440755a3f0a24" continuedAt="i011a0b32205444709d38168a42f10ea1"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ReinsuranceAccountingPolicy" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDUz_b37b063f-835c-45a7-a1ec-3331316be163" continuedAt="i0f07eeab97ab42028a8b7b6ddb889002" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bear underwriting and reserving risks associated with our health plan subsidiaries. In certain cases, we limit our risk of significant catastrophic losses by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#8220;third-party reinsurer&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we remain liable for losses in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#8217;s financial condition, including its ability to maintain high credit ratings. Intercompany transactions with our captive are eliminated in consolidation.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i0f07eeab97ab42028a8b7b6ddb889002">We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs.</ix:continuation> In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:PrepaidReinsurancePremiums" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NTUy_cc398590-61e7-4b4e-b891-ac1cefa359f9">2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:PrepaidReinsurancePremiums" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NTU2_da2ed8d6-bc9c-4638-a474-5fd537015437">2</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:PrepaidReinsurancePremiums" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NTY0_01fbff26-2bd7-4e09-b29b-9e48d8dbfea2">9</ix:nonFraction> million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. Reinsurance recoveries amounted to $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NjY1_330ddf5a-da45-4da7-9079-6219eac9317b">35</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NjY5_bf51a17f-e645-4862-a582-f16f15989573">33</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceRecoveries" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0Njc3_e8766a8e-de8f-472a-b51e-2b024c934a5e">23</ix:nonFraction> million for the years ended December 31, 2022, 2021, and 2020, respectively. Reinsurance recoverable of $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0Nzcw_79108872-82b1-4076-a651-a407d4b17a83">27</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0Nzc0_d09f9922-3c73-4724-82b2-771aaf1fc495">51</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0Nzgy_25129166-0cbc-48d1-9b03-36614a112e54">30</ix:nonFraction> million, as of December 31, 2022, 2021, and 2020, respectively, is included in &#8220;Receivables&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Deficiency Reserves on Loss Contracts</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the profitability of our contracts to determine if it is probable that a loss will be incurred in the future by reviewing current results and forecasts. For purposes of this assessment, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. A premium deficiency reserve (&#8220;PDR&#8221;) is recognized if anticipated future medical care and administrative costs exceed anticipated future premium revenue, investment income and reinsurance recoveries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDQ1_233450d7-af80-40d2-a5fe-da8dbcdbfab1" continuedAt="ie688e1407e724954900427a7e7bea27f" escape="true">Income Taxes</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie688e1407e724954900427a7e7bea27f">We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized.</ix:continuation> For further discussion and disclosure, see Note 12, &#8220;Income Taxes.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:TaxesBasedOnPremiumsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDE3_e58f4a13-7c3e-4e57-b368-3ceb5320bd75" continuedAt="if3351627ac6d4b638f1e677e6bc513a2" escape="true">Taxes Based on Premiums</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="if3351627ac6d4b638f1e677e6bc513a2" continuedAt="ib59b09e714b149dcab22ed6e91fe046e">Health Insurer Fee (&#8220;HIF&#8221;). </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ib59b09e714b149dcab22ed6e91fe046e">Under the Affordable Care Act, the federal government imposed an annual fee, or excise tax, on health insurers for each calendar year (the &#8220;HIF&#8221;).</ix:continuation> The Further Consolidated Appropriations Act, 2020 repealed the HIF effective for years after 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premium and Use Tax. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our health plans are assessed a tax based on premium revenue collected. The premium revenues we receive from these states include reimbursement for the premium tax assessment. We have reported these taxes on a gross basis, as premium tax revenue and as premium tax expenses in the consolidated statements of income. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ConcentrationRiskCreditRisk" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTU4_88785eb1-818d-4e5b-9efd-c133d7594798" continuedAt="if57d846bf2bf45f198da4047c5f25d09" escape="true">Concentrations of Credit Risk</ix:nonNumeric></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if57d846bf2bf45f198da4047c5f25d09">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:InvestmentsMaturityPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI3MzE1_88f3fda5-745d-48bb-a168-1c701578e830">15</ix:nonNumeric> years, or less than <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:InvestmentsAverageMaturityPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI3MzIw_68e11dab-7d0e-498f-a624-1d396c7a4cd2">15</ix:nonNumeric> years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</ix:continuation> </span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:RisksAndUncertaintiesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTE5_20b34364-d94b-4cb4-aceb-6c5a6127da27" continuedAt="id026a7363d53496c9208ad36d7baa5a5" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in healthcare practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i011a0b32205444709d38168a42f10ea1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id026a7363d53496c9208ad36d7baa5a5">We operate health plans primarily as a direct contractor with the states, and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a relatively small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.</ix:continuation></span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:SummarizedPremiumRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDAw_b8748863-7928-4ee0-8327-0f4e93a74d27" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive the majority of our revenues under contracts or subcontracts with state Medicaid managed care programs, which are considered individual external customers. Instances where these contracts were at least 10% of our total premium revenue for the year ended December 31, 2022 were New York with <ix:nonFraction unitRef="number" contextRef="i889ea50e28bb4eed8c94a76a4a8d2cfb_D20220101-20221231" decimals="2" name="moh:HealthCareOrganizationRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk2MDQ_06642c12-8bc9-4c90-b5a9-439b349c4727">10.0</ix:nonFraction>%, Texas with <ix:nonFraction unitRef="number" contextRef="ic15c81fc6ee74eb7b1b3e900ac2e9c64_D20220101-20221231" decimals="2" name="moh:HealthCareOrganizationRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk2MTg_a319fd4d-f003-40d3-a1ba-e9421cda968a">12.0</ix:nonFraction>% and Washington with <ix:nonFraction unitRef="number" contextRef="ida4424c349994a84985daff56e365e13_D20220101-20221231" decimals="3" name="moh:HealthCareOrganizationRevenuePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk2MTE_3965eb56-6704-4dbb-9fb2-b47097b82483">13.6</ix:nonFraction>%.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTY5_001e943c-f918-4f02-b8da-4c43b4033a15" escape="true"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_130"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90ZXh0cmVnaW9uOjFlMjQ2MmE0MjBlYTQ4MmI5NGYzZDlmZjMwNzRkZjFiXzQ4Mg_2fe16245-a852-4998-9e25-f71f43120fe0" continuedAt="ie640b27b18f4414aa8b46ecdb782b13d" escape="true">Net Income Per Share </ix:nonNumeric></span></div><ix:continuation id="ie640b27b18f4414aa8b46ecdb782b13d" continuedAt="ie5e835020f1345f580408d54997f72fb"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90ZXh0cmVnaW9uOjFlMjQ2MmE0MjBlYTQ4MmI5NGYzZDlmZjMwNzRkZjFiXzQ2Nw_291e1a8b-488d-4946-ac02-8d148db1493a" continuedAt="if62e5dace91b461c9fc8272e6ddcf11c" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:56.462%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzUtMS0xLTEtNjg3NjY_36fb960c-7e8e-4410-b6f7-bb700a3ed2b6">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzUtMy0xLTEtNjg3NjY_018ef386-2554-4c11-9662-fe3610f60208">659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzUtNS0xLTEtNjg3NjY_feeda5ae-7665-4b12-8353-45d14d7120a1">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzctMS0xLTEtNjg3NjY_e4ed94bf-9555-418a-b8ef-a2b3f142b210">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzctMy0xLTEtNjg3NjY_59a2d9f2-a52a-4af8-81b9-394ce3ecb5a2">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231" decimals="-5" name="moh:SharesOutstandingExcludingRestrictedStockAwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzctNS0xLTEtNjg3NjY_11536b63-ed2a-4fdf-b83f-5c276ff3fded">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzktMS0xLTEtNjg3NjY_042c0bae-188c-4b91-aa64-ac7de14b8b36">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzktMy0xLTEtNjg3NjY_d3f9fd77-b0a6-4c8c-85ce-203c99bef62e">0.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzktNS0xLTEtNjg3NjY_e068576b-adcb-420b-9241-12b9d84104c6">3.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEwLTEtMS0xLTY4NzY2_75e18257-9ae3-434c-b1cf-0a1ce203113e">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEwLTMtMS0xLTY4NzY2_be7316be-ad44-4a19-917e-f6e5b1e02ad6">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-5" name="moh:WeightedAverageNumberofSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEwLTUtMS0xLTY4NzY2_7a5878b3-ef03-4a2d-889b-67cd66f6bcb4">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzExLTEtMS0xLTY4NzY2_dc010192-2678-4622-9e9a-dc89a2cbe732">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzExLTMtMS0xLTY4NzY2_208178b9-e8af-492e-b8bf-920f28c92b16">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzExLTUtMS0xLTY4NzY2_6c934db8-ab9d-438f-9bf4-a9f298aa27c5">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEzLTEtMS0xLTY4NzY2_d8380370-578b-43b2-b0b0-32355e5d1373">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEzLTMtMS0xLTY4NzY2_4c635d47-49e9-42a8-9ea0-a3af65b24507">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEzLTUtMS0xLTY4NzY2_b0f9633d-7f4a-45b6-9d93-4b91862359d9">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE1LTEtMS0xLTY4NzY2_7fa0e84c-41c1-4cf0-8327-d8591396e1f5">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE1LTMtMS0xLTY4NzY2_1808d1eb-a3ba-4901-acdc-af9cd9108cf1">58.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE1LTUtMS0xLTY4NzY2_76965e98-d7ee-4a33-9af0-8c5de8479d3a">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE3LTEtMS0xLTY4NzY2_38f6a358-42b3-4b0c-b8fc-fb2df8aad76b">13.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE3LTMtMS0xLTY4NzY2_8d635d5c-616b-4ce4-8b53-2dcd0f8aa908">11.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE3LTUtMS0xLTY4NzY2_b447e99c-a55b-4374-8c69-97a3e8ce412e">11.40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE4LTEtMS0xLTY4NzY2_8b3dd3bc-63e2-4ebb-a2be-7965193140b1">13.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE4LTMtMS0xLTY4NzY2_6c3d75f5-751c-488f-a56a-b24de006f2e2">11.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE4LTUtMS0xLTY4NzY2_be245a35-eaba-47fa-b4ea-5b49aacd28f3">11.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income per share because to do so would have been anti-dilutive.</span></div></ix:nonNumeric></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ie5e835020f1345f580408d54997f72fb"><ix:continuation id="if62e5dace91b461c9fc8272e6ddcf11c">(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</ix:continuation></ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 62</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzI1MzI_977563dc-6f90-4b3f-a14d-8550b30f2bbc" continuedAt="i2062839684b1413c9f69e1bc1cd62955" escape="true">Business Combinations </ix:nonNumeric></span></div><ix:continuation id="i2062839684b1413c9f69e1bc1cd62955" continuedAt="i6f44dbffcb8140d4b97f5f291f7af364"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we closed on <ix:nonFraction unitRef="combination" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="INF" name="moh:BusinessCombinationNumberOfBusinessCombinations" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzMz_bc15aa2f-8e76-446d-938a-67e7e149de1a">two</ix:nonFraction> business combinations primarily in the Medicaid segment, consistent with our growth strategy. For these transactions, we applied the acquisition method of accounting, where the total purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed, based on their fair values as of the acquisition date. The proforma effects of these acquisitions for prior periods were not material to our consolidated results of operations. Costs to complete acquisitions amounted to $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:AcquisitionCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzg1Mg_4d133def-2cd0-40a8-816e-468735f58b96">2</ix:nonFraction> million in the aggregate for the year ended December 31, 2022, and were recorded as &#8220;General and administrative expenses&#8221; in the accompanying consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AgeWell. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York for purchase consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="id9fa89e4cd2b4b9e91fa9ccde542996c_D20221001-20221001" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzA2MTI_89159501-f0a9-4bc0-b1b3-acabc5b32bb0">134</ix:nonFraction>&#160;million. We acquired membership and a provider network with a fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="i634b4c45a645473796839899d286be1f_D20221001-20221001" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzc2OTY1ODEzOTc3MTY_1807f219-7dc4-491c-a700-f4dd44f4f61d">47</ix:nonFraction> million. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="id9fa89e4cd2b4b9e91fa9ccde542996c_D20221001-20221001" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzc2OTY1ODEzOTc3MTc_8db49608-8437-4c58-a5c3-36e2144d3322">87</ix:nonFraction> million of purchase consideration to goodwill, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership. The goodwill is deductible for income tax purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cigna.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i61710d4352384e94a9ce3f422ff24847_D20220101-20220101" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzNzI_8dd1e80f-bf70-4b2d-904a-75c7ba33b5b1">60</ix:nonFraction>&#160;million. Because the closing date fell on a holiday, the purchase price was paid on December 31, 2021 and was recorded to prepaid expenses and other assets. We acquired membership and a provider network with a fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="id1c23ba3104a41408eac767b2e726ada_D20220101-20220101" decimals="-6" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzODU_ad2f986f-33b9-4301-a22d-a00222076586">35</ix:nonFraction>&#160;million. We allocated the remaining $<ix:nonFraction unitRef="usd" contextRef="i61710d4352384e94a9ce3f422ff24847_D20220101-20220101" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzOTg_275ba32a-a47a-431a-a714-074861a2a2ee">25</ix:nonFraction>&#160;million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. </span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzI1MzM_d0e7906a-e185-4017-b56f-d89928e2898b" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents intangible assets acquired, by major class, for the AgeWell and Cigna acquisitions. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.572%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.623%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights - member list</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibebb703fd4a9457dbfd3f97701ae04f3_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzMtMS0xLTEtNjg3NjY_2332bd48-71e0-48bd-953f-39a331533b87">81</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0385a25993b0446c89a46930f0f91bde_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzMtMy0xLTEtNjg3NjY_0d3e7fe6-d921-4ec1-a18e-e148cde4781b">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="id5c65081a30c46cf8460d6a803e1f17a_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzMtNS0xLTEtNzMzODE_656d14bc-6fd8-4bdc-b6ee-a5eb1b1ab320">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f9337e55d484c09b5a1513d389ccf3b_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzMtNy0xLTEtNzMyNjk_bed72d57-b9df-48b8-bcf0-682a45d31ae7">3.7</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider network</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide3af300aa304f619ca228fba2ff8fa4_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzQtMS0xLTEtNjg3NjY_398f879f-87d2-4837-9acb-338e3f9464d7">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i29148aa5c5964b8f8d10939beb34fe33_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzQtMy0xLTEtNjg3NjY_10e35f05-429a-4c21-8b08-fce2032d4aa6">2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4d53aea5bdb946b5b111b4810dc4fa29_D20220101-20221231" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzQtNS0xLTEtNzMzODE_48ca7791-585a-45c9-aa90-4ae3fbf9eea8">5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1c870ec0a4794f988790a6078f3f01f9_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzQtNy0xLTEtNzMyOTQ_cdfe5fb9-0aab-427c-812b-5cf87e80b0cb">4.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idda4ab8b08044fecb8346dffcc274008_I20221231" decimals="-6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzYtMS0xLTEtNjg3NjY_9a37df09-8b90-4a9e-9b07-df28993a36f7">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3c7feed041254360ad5d3019f6a744aa_D20220101-20221231" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzUtNy0xLTEtNzMzMDI_e2b73595-8b1d-432e-9349-45f9e6833e4c">3.7</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i6f44dbffcb8140d4b97f5f291f7af364" continuedAt="ia2e928a180674c7dbd706d2d474142ab">Affinity. </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ia2e928a180674c7dbd706d2d474142ab">On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for purchase consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="i18ece6617d5c496d9258ce72e661253f_D20211025-20211025" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzMjI_c0a6cf50-20f9-4075-97f3-641ed43fef4e">176</ix:nonFraction>&#160;million. In the year ended December 31, 2022, we recorded various measurement period adjustments, including an increase of $<ix:nonFraction unitRef="usd" contextRef="i2ac9097825cf45b8aee7acbbe22e2785_D20220101-20221231" decimals="-6" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzNjA_56689a3b-571a-4b0c-bcaf-3bf70938edd5">12</ix:nonFraction>&#160;million to &#8220;Medical claims and benefits payable,&#8221; and an increase of $<ix:nonFraction unitRef="usd" contextRef="i2ac9097825cf45b8aee7acbbe22e2785_D20220101-20221231" decimals="-6" name="moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzMzY_deba9a25-534a-4e61-87a4-2a3e22e91311">4</ix:nonFraction>&#160;million to &#8220;Amounts due government agencies&#8221; net of &#8220;Receivables.&#8221; In the aggregate, we recorded a net increase of $<ix:nonFraction unitRef="usd" contextRef="i2ac9097825cf45b8aee7acbbe22e2785_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillPurchaseAccountingAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzNDg_cb5c99c8-7578-4d0a-b399-a4ae6574592f">21</ix:nonFraction>&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments, which have been finalized as of December 31, 2022.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_136"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzI5OTI_74e64f4d-71db-4196-993e-fc05d42c6e8d" continuedAt="iffa4363a2a4a40928d6cf787ae3c1799" escape="true"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzMwMTA_72fd5f70-3325-4a6b-a85b-e5a90f6da4f9" continuedAt="ic7160bff5eb54f078df6a1e463d470e9" escape="true">Fair Value Measurements </ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="iffa4363a2a4a40928d6cf787ae3c1799" continuedAt="i4bafc3508c9841a4ba66a4d51a0ae25d"><ix:continuation id="ic7160bff5eb54f078df6a1e463d470e9" continuedAt="i9c6c863956354a5898a9b2f420f887f8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to a three-tier fair value hierarchy as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 &#8212; Observable Inputs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 financial instruments are actively traded and therefore the fair value for these securities is based on quoted market prices for identical securities in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 &#8212; Directly or Indirectly Observable Inputs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value for these investments is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i9c6c863956354a5898a9b2f420f887f8" continuedAt="i4374851080c2412480f25b6195148f9b">Level 3 &#8212; Unobservable Inputs. </ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i4374851080c2412480f25b6195148f9b">Level 3 financial instruments are valued using unobservable inputs that represent management&#8217;s best estimate of what market participants would use in pricing the financial instrument at the measurement date. As of December 31, 2022 and 2021, our Level 3 financial instruments consisted of contingent consideration liabilities.</ix:continuation> </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4bafc3508c9841a4ba66a4d51a0ae25d" continuedAt="i29d7efc35b0c4dc2aa6224ef1dc578b5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in &#8220;Other&#8221; operating expenses in our consolidated statements of income. In the years ended December 31, 2022 and 2021, we recognized a loss of $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzE0Nzk_d71d74c6-a6b6-4365-8a32-45a52045dec5">4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzE0ODY_4fd6f735-1606-410e-88de-469ba13ae6f0">24</ix:nonFraction>&#160;million, respectively, primarily for the increase in the fair value of the contingent consideration liability described below. </span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzMwMDQ_c7fe00bd-c7b1-450b-aa3f-fea088757c1c" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzMtMS0xLTEtNjg3NjY_f472ce6f-5575-41b8-a95f-7cca8372aa00">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d8d5c0a352f4015825c1a2b0847caff_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzMtMy0xLTEtNjg3NjY_c6919f6a-d3c2-4d79-9127-6d33029e6144">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5816b9d063fd4d4f9679ec48c22e7f0a_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzMtNS0xLTEtNjg3NjY_d74b32d1-24bf-4bd6-aeef-183f9c4f43ef">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a831368a2374281bb348964ee80005f_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzMtNy0xLTEtNjg3NjY_53cc092a-7d09-42ef-87be-e16ff2b88c02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7194e3bc65f34309acccfe5e8eebc910_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzQtMS0xLTEtNjg3NjY_824149c6-1d04-4ef1-98b0-14849b3b9acc">731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2225551d260b4fff8b1fcd8b2225a4d5_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzQtMy0xLTEtNjg3NjY_e24444ec-752c-4c44-99ce-75b749ac8025">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f5ae5c597454f189bef195ea3021a0e_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzQtNS0xLTEtNjg3NjY_4d144aee-0fc5-4fb0-86fc-7027dd471535">731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02199c67baf944d3a3c45249783e8405_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzQtNy0xLTEtNjg3NjY_0de06d7b-7360-4df4-a3cd-710a7aa2ea6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzUtMS0xLTEtNjg3NjY_e9cecd7c-2246-4751-81fb-3349e43c47fb">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if032025c0fb244a08e3b1ef2e3941040_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzUtMy0xLTEtNjg3NjY_dce27a2c-cebe-42b5-baf5-98fb27589455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86889d94e8904988ac5e365d286d4a7b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzUtNS0xLTEtNjg3NjY_8433367e-ee6b-4b33-a1b2-2e2168c38557">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i962ee0b812d44a069fd6c87304d4bc42_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzUtNy0xLTEtNjg3NjY_568282a7-dce1-4ebc-b0c9-397a7c303a4a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzYtMS0xLTEtNjg3NjY_84407169-4859-47a9-bfcb-1e6996cf03dd">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd8a5c0011b40b3bcaa8d6d87dd0520_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzYtMy0xLTEtNjg3NjY_345ecb85-592a-4753-a8c1-d4e63425058d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ed1689dee4a41eda03bdc9c92c02453_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzYtNS0xLTEtNjg3NjY_1b59911d-0ef2-4269-aad8-fd66b23c2b8c">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9e4ac3e01c944c0b4c5b9718ba2c91c_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzYtNy0xLTEtNjg3NjY_1f0002a9-e578-4d1a-9a0f-0d88bf6013c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzctMS0xLTEtNjg3NjY_70941158-146f-4aad-98fe-777e31ff05e0">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fcc352ead24246b3f108ce7dd02772_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzctMy0xLTEtNjg3NjY_4fb5665d-546a-4236-b6f1-3b610767faf3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib53a75ae39b14988836f4967971ce19b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzctNS0xLTEtNjg3NjY_e1e7cabf-b963-4f70-a727-ea4dbe0f1938">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie00e6ad84a254b709450ec9c3505658d_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzctNy0xLTEtNjg3NjY_b24e21cc-ee64-4158-b1db-f2c880b07768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEwLTEtMS0xLTY4NzY2_ead8c210-b76d-46b4-ae81-352a3cbcde03">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d1b7f1d31c442bfa81f382822fcd6b8_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEwLTMtMS0xLTY4NzY2_bae6dfb3-a59f-48ce-a62f-9f3b5198d638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba848d4237f8438e92d576eea416786f_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEwLTUtMS0xLTY4NzY2_b7baadc9-a6cd-4d54-8f88-44022c4212e8">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic804f30bbe1941a5bd3069bece3d95c1_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEwLTctMS0xLTY4NzY2_fed85f49-4f42-49c9-a08c-dea7821960c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzExLTEtMS0xLTY4NzY2_4ce63c28-4317-41e8-b573-7a2e7b4dbec8">3,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5e68ad6d9c4c8ea513343c44695691_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzExLTMtMS0xLTY4NzY2_bd1628e3-03a3-420d-aed9-e5c460d1e983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9f57cf49eb4b3d93701dd1a0ade3fd_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzExLTUtMS0xLTY4NzY2_b0df9849-ac29-4925-ac08-f73f6eb1a76b">3,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386078af04c247fa901c709fe93c58dd_I20221231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzExLTctMS0xLTY4NzY2_a58709eb-e634-4f0e-8c5f-1b9a421e173f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEzLTEtMS0xLTY4NzY2_4b078208-eb53-4dc7-a4d7-f95f245f8afd">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5e68ad6d9c4c8ea513343c44695691_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEzLTMtMS0xLTY4NzY2_41c886dc-9018-4b30-960f-f17ae3154da2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9f57cf49eb4b3d93701dd1a0ade3fd_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEzLTUtMS0xLTY4NzY2_31c37662-25ae-42a2-b839-2c1ef83b3b86">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386078af04c247fa901c709fe93c58dd_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEzLTctMS0xLTY4NzY2_beae4cf5-278c-4504-93c4-df5672ba22e1">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzE0LTEtMS0xLTY4NzY2_76f1c96b-5af7-42c4-8bab-4d1c1bef8e35">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e5e68ad6d9c4c8ea513343c44695691_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzE0LTMtMS0xLTY4NzY2_0c8adb53-87a0-4e6f-ac71-9d1c7e358b4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d9f57cf49eb4b3d93701dd1a0ade3fd_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzE0LTUtMS0xLTY4NzY2_5f6c04e2-8b9f-41f9-b785-7e2106928975">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386078af04c247fa901c709fe93c58dd_I20221231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzE0LTctMS0xLTY4NzY2_1b969e9f-70e9-4890-985b-7304faeb4d41">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzMtMS0xLTEtNjg3NjY_4a126fbd-bb81-4bc8-85cb-26fc6cc75d5a">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c35ad3ddab44e749e3b1e84bd0af3d1_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzMtMy0xLTEtNjg3NjY_37ba2713-6802-4b22-bb20-c05559395738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i960d1aa66067454ba42f52aed1e487bc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzMtNS0xLTEtNjg3NjY_f31b9931-d24b-4d98-b185-eccb2fe9cef9">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0945f141b7f04212b9df4d20cbd510cc_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzMtNy0xLTEtNjg3NjY_e25289a2-5d10-4de3-8c2c-5a57e1e538ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30c11d9f4dee4390998e42cc33eb779e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzQtMS0xLTEtNjg3NjY_843bf2a9-79e7-4cb0-bcf0-4ce07cc8f436">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8d46c859e204a6a80f2c36c08a46f8e_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzQtMy0xLTEtNjg3NjY_cb2278b6-1594-4eb7-b232-5a94e7211716">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a239b8e14f435d944f2c1891cd59f4_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzQtNS0xLTEtNjg3NjY_861a7595-9d0e-4a9b-9fdc-5a0273cd37e7">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59f46e8b96ab457584d0f833330e5f53_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzQtNy0xLTEtNjg3NjY_d6bdf682-9561-4551-91c4-927b8dd54a98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzUtMS0xLTEtNjg3NjY_18b2e577-1a26-4ad6-9b9e-c202155bdba2">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i576bade46abf49a3a06593cc4f8c1b09_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzUtMy0xLTEtNjg3NjY_f4389e45-ca0b-4745-b276-c7ece2dc85b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63aa4f07c83c4604ab411ba61e492802_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzUtNS0xLTEtNjg3NjY_f2951d88-9722-47ce-9a50-dcfc382c545a">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67dd714df638487ea61a28b66c207c9d_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzUtNy0xLTEtNjg3NjY_cacc918a-dcc1-4a61-8504-d47a8ffd9650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzYtMS0xLTEtNjg3NjY_b14da10f-83b9-4c33-bb6d-3f4a70e9b5d2">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3697cd3591404f5ab704c339859f4118_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzYtMy0xLTEtNjg3NjY_c7939efd-0481-4005-be4b-f38ce58313c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12a73884b8842b28e11041aea7f7b00_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzYtNS0xLTEtNjg3NjY_94d75c98-b570-4b9c-971f-952fb683edc8">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaaa9d3cee0f4342b73d5a8600dde796_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzYtNy0xLTEtNjg3NjY_085cd1f4-8b6b-4c18-8a40-ff5a25e8bb1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzctMS0xLTEtNjg3NjY_b9b9599e-a8b0-40b6-b9fc-8f037be2a780">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4319bd7e084d4fe6bbe30097e8b6ea2a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzctMy0xLTEtNjg3NjY_a9497038-3511-42f9-9103-a6cf8aee8c7c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9e1553afa264028b0cd457a33f5a149_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzctNS0xLTEtNjg3NjY_d34ea15e-b3b9-4a95-b23c-993d01b80fcd">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab0ae951a4e4b62b8083cf3e819c96a_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzctNy0xLTEtNjg3NjY_7f733110-cc66-4645-aaee-01e63f839e7a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEwLTEtMS0xLTY4NzY2_5ffa7994-57a9-4844-a0e5-926ff94fc050">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ada07a36a9546358030aaca313e8c59_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEwLTMtMS0xLTY4NzY2_7600a122-ec46-42ee-a1d1-5ca2a26cc844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bb2d39305ab437ebcfcb31c936ff8e7_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEwLTUtMS0xLTY4NzY2_0732f089-54ed-486b-ab2f-9eaa89a889fa">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cba98a86a954f7e8b177f14d18360bd_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEwLTctMS0xLTY4NzY2_26a81257-676c-4c0c-8a36-3b93626a2a06">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzExLTEtMS0xLTY4NzY2_62cb66d7-9f5e-4223-9d36-00a9df67a3bd">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e93ce10aaba4d8b9c22ff0c09bacdc7_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzExLTMtMS0xLTY4NzY2_4e484b95-f293-4eba-a8f9-1d26915b4933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f045e80bf74bfdb5641b6aed955093_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzExLTUtMS0xLTY4NzY2_bd29cf44-e2dc-4ead-94a5-9435c2131d48">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd8a7e880f542339bc89afd0861bdf2_I20211231" decimals="-6" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzExLTctMS0xLTY4NzY2_5a1b0ff7-9730-4080-92db-99993d207d88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEzLTEtMS0xLTY4NzY2_c757aba1-064e-47fc-ba5f-4f80dc3b2758">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e93ce10aaba4d8b9c22ff0c09bacdc7_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEzLTMtMS0xLTY4NzY2_aefe8a7c-ff92-40f2-a40b-f3f3250f2fbe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f045e80bf74bfdb5641b6aed955093_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEzLTUtMS0xLTY4NzY2_8cb57571-b07c-4085-8f38-9755cfc1ba9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd8a7e880f542339bc89afd0861bdf2_I20211231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEzLTctMS0xLTY4NzY2_99faeea9-255a-4f76-a70f-44de8dd10c8b">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzE0LTEtMS0xLTY4NzY2_1e30a203-5104-4c53-9b3b-bbdc387261b0">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e93ce10aaba4d8b9c22ff0c09bacdc7_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzE0LTMtMS0xLTY4NzY2_26ad5ca4-b44c-4ed3-ba31-9240ffa377f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14f045e80bf74bfdb5641b6aed955093_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzE0LTUtMS0xLTY4NzY2_ec89bd1f-cef7-4f5a-9c77-869dceddd19d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibbd8a7e880f542339bc89afd0861bdf2_I20211231" decimals="-6" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzE0LTctMS0xLTY4NzY2_490f786f-3636-4a1f-9ffe-fce1155f2a17">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Level 3 Contingent Consideration Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 financial instruments at December 31, 2022 are comprised solely of contingent consideration liabilities of $<ix:nonFraction unitRef="usd" contextRef="i386078af04c247fa901c709fe93c58dd_I20221231" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzE5NjU_beae4cf5-278c-4504-93c4-df5672ba22e1">8</ix:nonFraction> million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Refer to Note 2, &#8220;Significant Accounting Policies&#8212;Business Combinations&#8221;, for further details. Such liabilities are recorded at fair value on a recurring basis. In 2022, the estimated fair value of contingent purchase consideration increased by approximately $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzIzMjQ_d71d74c6-a6b6-4365-8a32-45a52045dec5">4</ix:nonFraction>&#160;million, relating to an operating income guarantee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2022, we paid the seller $<ix:nonFraction unitRef="usd" contextRef="i7757357193c94ad298e824f0d0518470_D20220101-20221231" decimals="-6" name="moh:PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzc2OTY1ODEzOTg2NjI_db71f12d-b81b-49ac-813a-07105689eece">43</ix:nonFraction>&#160;million, of which $<ix:nonFraction unitRef="usd" contextRef="i16c45403f97a4dfb89f109633839fb86_D20220101-20221231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzI0MDg_f08dc642-dbb4-483b-a640-98ae7251fdff">23</ix:nonFraction>&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $<ix:nonFraction unitRef="usd" contextRef="i016cfea50f2e421f88790001362b8498_D20220101-20221231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzc2OTY1ODEzOTg2NzU_296ee8c0-9971-47a8-9567-708cf740eb3b">20</ix:nonFraction>&#160;million was for the first payment of the consideration due for the operating income guarantee. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i29d7efc35b0c4dc2aa6224ef1dc578b5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzMwMTY_0014d766-8ce3-4d01-b8ac-0c298901fcc9" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:49.779%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.632%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjo4ZTBkNjY3ODdlOTg0MjI2YjhlZTBlMzNiNGU1ZWZjMl80_a703ac38-9997-4647-a9bd-fc863bbebef9">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cdbd3860d6c488798e272302d58dcf7_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtMS0xLTEtNjg3NjY_9998311e-77b0-467f-ab71-54fd4d238f11">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib074c81f11e84dd0a6eb9b5acffd5118_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtMy0xLTEtNjg3NjY_4fb1c643-d7a4-460c-be4e-8be0926ee21f">729</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9641bb00844a4cbb9f0155ed3c8b8bed_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtNS0xLTEtNjg3NjY_0a7bba35-9ba3-4f1b-9013-c9726e15ef10">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieada9e735cbd4500babf6903ca597d7e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtNy0xLTEtNjg3NjY_a844f1c3-593a-4497-b359-f88bd60a5d05">829</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjo3ZDYyNDlhODA2MzQ0OTAxOGU5MGU5MzIyNzU4YzBlNF80_981093a5-53dc-4dd4-bee6-323c907b5574">3.875</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4446a6c953714ca891cd94c12831bb57_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtMS0xLTEtNjg3NjY_67c5def8-cb55-4b75-8d01-3bdd12d00f11">643</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5acbc39836d44c0877b4659cfa91af9_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtMy0xLTEtNjg3NjY_71b9e606-d649-4f7e-ab4e-52e44ac3b3bb">554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7548748313094c9dbe3ac25160bfe723_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtNS0xLTEtNjg3NjY_90406f69-eab3-460b-9b67-bc30647c613f">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i396dfc81f74a4ecfa6a338862899d231_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtNy0xLTEtNjg3NjY_591d9c4a-3395-42e1-84d1-e13917cce259">675</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjo4ZTA0ODQzNWZhYzQ0N2Y5YWNiYjJiNTA1MDI3OGVlN180_f0731975-5da3-49e5-a53d-eac52e0cb078">3.875</ix:nonFraction>% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a98f51b9a6349488555f9c9a14a3df0_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtMS0xLTEtNjg3NjY_508a2981-34e0-4414-ad37-f8165c0f6ee1">741</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i597b3ae4dd8e4818b13a24f5c890394d_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtMy0xLTEtNjg3NjY_8d801c77-9065-4b86-8a5b-8a34bb2368df">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbc3bf6d7b6442e59a8c61f5a4fcd73f_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtNS0xLTEtNjg3NjY_0f831fa6-8d56-4fa4-93ac-e6676ae135cd">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2790faed091468abda4356c61276b5a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtNy0xLTEtNjg3NjY_4c108b47-2e92-469e-ad42-0ad52453dd48">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88055e4dad2440acb86c85055d57ae20_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzctMS0xLTEtNjg3NjY_6a921429-5070-49c2-9cec-a010dd75dbd7">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48bac014b28a4af083ee0516405e8d5a_I20221231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzctMy0xLTEtNjg3NjY_f4f901ac-9923-4eda-b8af-a5cf9bbf5387">1,912</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dde019b6c3e473c978eda9b0c5c1d4a_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzctNS0xLTEtNjg3NjY_4ce2791b-6250-439b-abe5-50b15b126c6c">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34ceb7d8e4e84d52bcad92498c815f6e_I20211231" decimals="-6" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzctNy0xLTEtNjg3NjY_dfddbf3a-aa9e-42ba-bf05-5396f35177a3">2,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_139"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzExNjM_b87f3203-170d-48e6-a5ac-5a4300a64e86" continuedAt="ic9132097d5b94171a5809b3a64d8ca65" escape="true">Investments </ix:nonNumeric></span></div><ix:continuation id="ic9132097d5b94171a5809b3a64d8ca65" continuedAt="i5da24a0928e14a58ae27e1f806abb2bb"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all of our investments classified as current assets to be available-for-sale. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzExODY_7c5c72e0-2a62-48fa-b7dd-8acfdcb7dff7" continuedAt="ic162ebad66ed4db3b49a69b38415e912" escape="true">The following tables summarize our current investments as of the dates indicated:</ix:nonNumeric></span></div><ix:continuation id="ic162ebad66ed4db3b49a69b38415e912"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzUtMS0xLTEtNjg3NjY_4cb5f0a2-1c24-4c7c-9b2f-571cd347adfd">2,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzUtMy0xLTEtNjg3NjY_61485221-62c3-4e59-b3d8-78dbfdca14d6">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzUtNS0xLTEtNjg3NjY_f9cc3a87-4bbf-4e85-bc88-2c41f5e92902">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzUtNy0xLTEtNjg3NjY_8b4c2bdd-945a-4edd-8110-f9fdf840f6f0">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzYtMS0xLTEtNjg3NjY_5ea8f4c5-b7cd-4a8e-b2eb-6625e9fb3327">787</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzYtMy0xLTEtNjg3NjY_ccdaa0f3-9877-41d1-acbc-2999814a27dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzYtNS0xLTEtNjg3NjY_01ea9aa6-5291-4d2c-9359-809f7a4de324">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzYtNy0xLTEtNjg3NjY_e4c61a5b-79d3-4001-8e19-22a80872d94a">731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzctMS0xLTEtNjg3NjY_cf8cd2f5-8d3b-481a-8214-a947e3f2c79a">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzctMy0xLTEtNjg3NjY_b956c110-fafb-44b4-8bb9-99796a89e49d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzctNS0xLTEtNjg3NjY_f16e8c0d-9fb5-4039-ae0d-af58f1221cfb">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzctNy0xLTEtNjg3NjY_58f0a03d-2f6c-41ae-8b9d-e1029cc645b3">288</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzgtMS0xLTEtNjg3NjY_19772ea0-c986-4f9c-ae09-61150b9435a5">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzgtMy0xLTEtNjg3NjY_a6d9b8c7-36f8-4845-8364-126ed0078b88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzgtNS0xLTEtNjg3NjY_ad38094e-237c-4323-a253-1a8fd24efdd2">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzgtNy0xLTEtNjg3NjY_31ea4776-00a4-45d5-878c-aaf94c2339a6">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzktMS0xLTEtNjg3NjY_3a76dfd1-2163-4df0-9e46-21f3f8acdbca">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzktMy0xLTEtNjg3NjY_d0794f0d-e1d0-4d05-97f7-9285f63de541">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzktNS0xLTEtNjg3NjY_41c6290d-5d19-4bdf-af45-876c92cf8e72">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzktNy0xLTEtNjg3NjY_639cf7e2-d5ac-4814-9a85-08be89c22b62">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEyLTEtMS0xLTY4NzY2_643aa208-0ce2-4825-86af-7b5c2b3b62ca">45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEyLTMtMS0xLTY4NzY2_2499377c-fffe-4e32-af0b-a4113d7a9a98">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEyLTUtMS0xLTY4NzY2_f9e63ef7-f80d-4273-ae82-13b45a51cd44">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEyLTctMS0xLTY4NzY2_c3aa3732-e083-419d-bee3-8d0323fc6eae">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEzLTEtMS0xLTY4NzY2_ee85bec3-451f-4bfe-9734-ce9c9d623bb4">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEzLTMtMS0xLTY4NzY2_aacc22d4-f237-4539-9d8b-eb532e03cda2">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEzLTUtMS0xLTY4NzY2_54e05762-981c-4078-950e-8173814fe46f">212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEzLTctMS0xLTY4NzY2_37362c4b-3873-42eb-b678-8ec6b65d33b9">3,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzUtMS0xLTEtNjg3NjY_d817ca45-71d1-47ac-b8df-da0da7679adf">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzUtMy0xLTEtNjg3NjY_91e8a1db-1ad9-4422-94c3-993e1b76b9aa">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzUtNS0xLTEtNjg3NjY_a0b79f01-4827-46ae-a477-921c0e780e97">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzUtNy0xLTEtNjg3NjY_10900f18-65f3-4cff-ac6f-3b88a0fde5ce">1,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzYtMS0xLTEtNjg3NjY_eb2d0558-9a59-43a4-89b0-46c31b54e312">616</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzYtMy0xLTEtNjg3NjY_96886863-56c2-4c6e-9f06-a2473b431c97">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzYtNS0xLTEtNjg3NjY_e0e225d8-1d23-4d1f-b61d-c86ded36fae7">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzYtNy0xLTEtNjg3NjY_69de191b-749e-4b8f-9eee-20d9314117f5">614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzctMS0xLTEtNjg3NjY_976f558e-c82a-4793-bddf-4edd1356fdb9">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzctMy0xLTEtNjg3NjY_161cd061-0a5e-4979-89a8-674a3a118284">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzctNS0xLTEtNjg3NjY_991f8ea1-423f-4da1-9455-e3e6e0122ee9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzctNy0xLTEtNjg3NjY_8e6eaa39-a5c9-4af8-ad1d-5ba72496d247">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzgtMS0xLTEtNjg3NjY_6a92fde4-aacd-4cbb-a552-fc8d3552b0fc">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzgtMy0xLTEtNjg3NjY_d95b1781-00ac-4fdf-9d36-cc46818dc2ec">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzgtNS0xLTEtNjg3NjY_3a24ed0e-5459-4601-9e5a-c5a14f410bd1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzgtNy0xLTEtNjg3NjY_c71ac507-449d-4be2-8235-946d00be50c5">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzktMS0xLTEtNjg3NjY_8c2752dd-6c37-406d-a851-bb11024291c1">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzktMy0xLTEtNjg3NjY_e30c9ec3-cde8-4ca2-84c3-82098632cf8c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzktNS0xLTEtNjg3NjY_7eece9ba-344a-4186-aa99-2b10b8ae9939">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzktNy0xLTEtNjg3NjY_77e6b6b0-382e-417e-926c-9adc93c2c6d5">353</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEyLTEtMS0xLTY4NzY2_1ebf822e-037d-4464-aa0d-e783ea9e3be2">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEyLTMtMS0xLTY4NzY2_39519103-698f-4efc-96b8-3cc13f3137e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEyLTUtMS0xLTY4NzY2_ec4729a3-ab01-40c6-9ea8-8efc3f27451d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEyLTctMS0xLTY4NzY2_4f82bf6a-57fc-42e4-b724-9adcb42caa87">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEzLTEtMS0xLTY4NzY2_48135072-ea82-4872-9460-1d43e5c705be">3,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEzLTMtMS0xLTY4NzY2_d223a980-8bcd-4131-a5d5-0796ef7025b4">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEzLTUtMS0xLTY4NzY2_338e631b-20bf-4d75-a27f-814f4b889e32">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEzLTctMS0xLTY4NzY2_7aebb4b3-d305-434c-bf91-eb30ec51b5a2">3,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5da24a0928e14a58ae27e1f806abb2bb" continuedAt="ie71d3337914248479ef62a6e42d1e841"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzExNzg_4fc0d6a1-40dc-41f8-b500-7ec75744c248" escape="true"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of December&#160;31, 2022 are summarized below:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzMtMS0xLTEtNjg3NjY_d2ec794a-f17f-438e-b847-49166613c267">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzMtMy0xLTEtNjg3NjY_84e6a30c-d95c-4b88-9c55-0b8b7363079b">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzQtMS0xLTEtNjg3NjY_28c439d3-4e62-463e-868d-92897889f772">2,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzQtMy0xLTEtNjg3NjY_bfb84064-96d5-400f-8964-67ecb3cfd837">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzUtMS0xLTEtNjg3NjY_48ab26c3-8900-4fa8-858a-a566a8baf51b">364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzUtMy0xLTEtNjg3NjY_0aae4796-444d-4d78-bee9-0736d2030130">345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzYtMS0xLTEtNjg3NjY_848e957a-23f7-41f4-94b3-56993f351f2e">778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzYtMy0xLTEtNjg3NjY_7accd511-3ef8-4b69-9627-5a89ad014cc1">712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzctMS0xLTEtNjg3NjY_38066898-a958-455f-a683-6cb27d72415d">3,709</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzctMy0xLTEtNjg3NjY_8e8d8315-f9df-4c9a-bbe6-414c4a25f009">3,499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzUxMA_6da28897-cbc5-4560-a96c-350efe5555d5">1</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzUxNA_5e922cb4-7140-4abe-9d00-3592e98eea30">10</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzUyMQ_ffc33a47-7592-44b4-8e0b-c119e605aacc">6</ix:nonFraction>&#160;million in the years ended December&#160;31, 2022, 2021 and 2020, respectively, and were reclassified into earnings from other comprehensive income on a net-of-tax basis. Gross realized investment losses amounted to $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzcxNDY4MjU1ODE4Nzg_6d7fa201-2757-4dc5-a2ab-ffaec76a92a0">7</ix:nonFraction> million in the year ended December&#160;31, 2022, and were reclassified into earnings from other comprehensive income on a net-of-tax basis. Gross realized investment losses were insignificant in the years ended December 31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at December&#160;31, 2022 and 2021 primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience realized losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div></ix:continuation><div id="ia6131cdf4d354d56b8257b8e26eb9181_145"></div><ix:continuation id="ie71d3337914248479ef62a6e42d1e841" continuedAt="ib90f52601d2b44c88d64b8378682fa95"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90ZXh0cmVnaW9uOjgxMzBkMmZlZGRlNTRmZGI4NGViMDI3YTM5YmFkOWE2XzcxNDY4MjU1ODEwMDY_04e3b8e3-9ee7-40e4-baf5-0fe4d8cfc07d" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:24.559%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.633%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtMS0xLTEtNjg3NjY_5d19718f-496b-4e47-8ce8-e10076ab69fb">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtMy0xLTEtNjg3NjY_dbccdbe1-ffb7-4899-935f-e1d08b91137a">45</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtNS0xLTEtNjg3NjY_90314169-7f63-4354-91ae-cec6858d83a7">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtNy0xLTEtNjg3NjY_de3f94a3-073a-4b2e-8502-058e435c4224">887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtOS0xLTEtNjg3NjY_c4079f6e-9f0d-4a5d-bb7c-c998d5ded283">76</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtMTEtMS0xLTY4NzY2_43227f18-b1e7-4da1-8058-927d8cf8236a">371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtMS0xLTEtNjg3NjY_e7bef40b-94aa-4e82-be04-83450de8b3ac">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtMy0xLTEtNjg3NjY_bd67eb8b-6645-411a-ba7b-058f6b02a5ec">20</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtNS0xLTEtNjg3NjY_84c20ee8-0f21-4d10-9065-50fc1aa67175">220</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtNy0xLTEtNjg3NjY_dcd42163-9079-4544-8e67-d1201fd5e45b">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtOS0xLTEtNjg3NjY_e0263a51-77e5-414f-a010-bf92f5dd3665">36</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtMTEtMS0xLTY4NzY2_729a3060-03bb-4214-bc9a-4a174400e8e7">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtMS0xLTEtNjg3NjY_f1444d95-64ca-4da0-9f89-023b4848f20b">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtMy0xLTEtNjg3NjY_4c7badbe-bd2d-4c3f-9551-b1cd89955d3f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtNS0xLTEtNjg3NjY_9c5c7b2c-f280-427f-b0d9-e68867eac934">108</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtNy0xLTEtNjg3NjY_05801b7b-a136-4193-b78b-f862af7bd72a">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtOS0xLTEtNjg3NjY_c570ceb3-a42b-4efd-9be2-66204c94593b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtMTEtMS0xLTY4NzY2_009c10ff-b3cb-4bf6-b051-67d6921a48b9">59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtMS0xLTEtNjg3NjY_45297078-80e5-4383-bf1f-83d89ef503cd">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtMy0xLTEtNjg3NjY_da1f1edf-3d32-4300-978c-a94f9fd065a5">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtNS0xLTEtNjg3NjY_542452d4-cd40-4d70-aead-4ed4ed434413">83</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtNy0xLTEtNjg3NjY_b5270ccd-2fb4-478b-a2ba-634fb9d5fd6e">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtOS0xLTEtNjg3NjY_4463376b-0fcc-4345-be41-463276b7b53a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtMTEtMS0xLTY4NzY2_5b41c35c-4f76-4021-9a6d-a9025f46a8f5">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctMS0xLTEtNjg3NjY_be09b7d4-2321-4b33-b8b1-b49aa4e61c44">88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctMy0xLTEtNjg3NjY_f6957126-dc44-49dc-896f-e3131fa2d855">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctNS0xLTEtNjg3NjY_f1e9016d-5907-4936-bf26-b39acb51212e">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctNy0xLTEtNjg3NjY_9f72f958-30f9-4a32-8753-696e18a7bac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctOS0xLTEtNjg3NjY_c9de1035-453f-41eb-addd-8d9539213fb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctMTEtMS0xLTY4NzY2_482ab9c2-b8c2-427d-ba7f-e6c6d6804732">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktMS0xLTEtNjg3NjY_611aeb1c-73e8-478f-be51-552280ca2913">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktMy0xLTEtNjg3NjY_b14a0f65-f102-4daf-9385-dea72fc76965">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktNS0xLTEtNjg3NjY_6e5f264e-07db-4fd7-bf95-53fed127c8f0">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktNy0xLTEtNjg3NjY_14cb3f56-f9aa-47f7-83bc-21f2e88dd2eb">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktOS0xLTEtNjg3NjY_c3a4eae0-fbb3-4ad6-ae93-d8f141b30532">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i335b83f184544942bc8b176a2ac44633_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktMTEtMS0xLTY4NzY2_9f05dd59-b074-4939-8bf5-db1e8d3955e6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTEtMS0xLTY4NzY2_8961fbea-e0fd-49ca-bfd9-7feebde41314">1,858</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTMtMS0xLTY4NzY2_8327bf94-4d6a-42ed-911e-4c2b6141e408">77</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTUtMS0xLTY4NzY2_59bdb784-fc75-49ae-a5f5-81ce85b2867b">1,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTctMS0xLTY4NzY2_e418c64d-8ded-4604-8c10-65bcb56bfaf7">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTktMS0xLTY4NzY2_3b4e82d6-79ed-4a0a-8ea2-90251ff2ffbf">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTExLTEtMS02ODc2Ng_e66972cc-6389-4873-8821-ddf1622e2519">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:24.744%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.647%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.651%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtMS0xLTEtNjg3NjY_bc32e996-06f9-4d57-b600-40bba8459b52">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtMy0xLTEtNjg3NjY_5a5bd94d-316c-426f-aa7b-925c7b4e432a">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtNS0xLTEtNjg3NjY_7c6ed610-40a1-4c45-a62a-9be11f92f69c">395</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtNy0xLTEtNjg3NjY_d3fbf8ee-c0db-4200-bddf-5c8bafe0de53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtOS0xLTEtNjg3NjY_0dc1c806-8b85-4e09-abee-4902cc8b2272">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtMTEtMS0xLTY4NzY2_0a312766-c3d9-4c10-a947-8ae8ae9757f6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtMS0xLTEtNjg3NjY_c36791fe-14b0-4971-af54-893e845d4b82">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtMy0xLTEtNjg3NjY_8eb10cfc-df9c-4d76-a283-150379c08945">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtNS0xLTEtNjg3NjY_7bed27bc-29ed-48e3-a2f6-9e52433f52eb">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtNy0xLTEtNjg3NjY_c2eb8457-71dc-41b1-9937-0d3bb075dab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtOS0xLTEtNjg3NjY_c2954041-4897-4ee4-9d56-5271f0f2069f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtMTEtMS0xLTY4NzY2_c5a4d314-8152-4e73-b0b5-4177cef68dce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtMS0xLTEtNjg3NjY_2ab742e9-9ecd-459f-b359-a319bd8b3dca">166</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtMy0xLTEtNjg3NjY_55b05180-77b9-43c4-b38d-2a9a149fd007">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtNS0xLTEtNjg3NjY_b006919e-d7f2-407a-883b-0c5cb6f0792d">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtNy0xLTEtNjg3NjY_ab66ad60-4ce8-4e12-9012-1fd91b2c2511">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtOS0xLTEtNjg3NjY_48101fad-c3e9-4c7c-8199-d3e89469dd0d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtMTEtMS0xLTY4NzY2_3a4b1f41-f81e-47cc-aa93-1cc323f09957">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctMS0xLTEtNjg3NjY_166e7eb8-41d0-44cd-b212-b7b6acb57e73">69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctMy0xLTEtNjg3NjY_1e11acec-e793-4c5c-b035-0509db18c7a1">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctNS0xLTEtNjg3NjY_f0f0b83b-8c94-466b-b10b-f74add386f24">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctNy0xLTEtNjg3NjY_63307357-5296-4cce-97eb-61ff55d6eec6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctOS0xLTEtNjg3NjY_cf3b4c07-6f82-4ee4-85e9-5be326dbf260">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctMTEtMS0xLTY4NzY2_998a0eae-a7be-4c17-9a41-9ec763275d09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTEtMS0xLTY4NzY2_af4cbe4a-f09f-48be-98fd-6a5e51404990">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTMtMS0xLTY4NzY2_2067b95c-aac3-4800-8a47-322861af6a62">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTUtMS0xLTY4NzY2_461bca0e-4848-4a4e-ae65-b359ff8fd1db">677</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTctMS0xLTY4NzY2_dcd2edd5-b3ad-4bc6-bd1d-5a24fb03a70c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTktMS0xLTY4NzY2_9042fd2b-00e2-4908-ad7d-50668e37f705">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="position" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTExLTEtMS02ODc2Ng_28f05e7c-1ea6-4e83-8cbf-15f11ffb4ad5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 66</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib90f52601d2b44c88d64b8378682fa95"><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Investments Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value, of which $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90ZXh0cmVnaW9uOmMzYWZlZmZjZWU0NjQ3NWM4OGIxZDI2NjJmMTdjNjQwXzk5MQ_5ff2e7b5-8d6f-48e3-bc5f-0fedca1b78ef">193</ix:nonFraction> million will mature in one year or less, $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90ZXh0cmVnaW9uOmMzYWZlZmZjZWU0NjQ3NWM4OGIxZDI2NjJmMTdjNjQwXzEwMzE_96763720-06bd-493a-8827-151abddc46de">37</ix:nonFraction> million will mature in one through five years, and $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90ZXh0cmVnaW9uOmMzYWZlZmZjZWU0NjQ3NWM4OGIxZDI2NjJmMTdjNjQwXzEwOTk1MTE2MjkwMTg_e64e25c5-a2f6-4eab-b9e3-81c04a00dba3">8</ix:nonFraction> million will mature after five years. </span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:RestrictionsOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90ZXh0cmVnaW9uOmMzYWZlZmZjZWU0NjQ3NWM4OGIxZDI2NjJmMTdjNjQwXzExNDQ_60581fec-2ab0-4713-8d02-aeb793db26cf" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balances of restricted investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78c795544d9047bab9b654c5a011d8fe_I20221231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzQtMS0xLTEtNjg3NjY_2b2db4ca-e1f3-4fb0-81b0-47a4907b211d">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib20d5076d1754f178426259e52222452_I20211231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzQtMy0xLTEtNjg3NjY_c23372e7-ab88-494c-bf76-d9e8b8b4db9d">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzUtMS0xLTEtNjg3NjY_5b8d1883-0cf0-472f-b83c-194479838924">159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzUtMy0xLTEtNjg3NjY_1553f397-f501-4b39-bc7c-d9463eabcedf">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzYtMS0xLTEtNzAzNzk_c58515f5-138d-4804-ab22-71ba636a7180">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzYtMy0xLTEtNzAzNzk_d60960d1-fffb-4b49-a5b7-cf591b05446d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzctMS0xLTEtNjg3NjY_ec3bee80-a062-49c2-b85b-3c41acbe1e11">238</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:RestrictedInvestmentsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzctMy0xLTEtNjg3NjY_6f44406c-cbf0-49cf-a300-f2c2f7a3dcd4">212</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_151"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzg1Mg_b1bf7b66-4089-4577-95fe-664bd162dcb2" continuedAt="i096291bbc0554c8ca8c336fc40437060" escape="true">Property, Equipment, and Capitalized Software, Net </ix:nonNumeric></span></div><ix:continuation id="i096291bbc0554c8ca8c336fc40437060" continuedAt="i7a1e307b153443b78b2326bc33c6d45c"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i59bc19fe198d45b0a01a28b855c8590a">Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Software developed for internal use is capitalized. Property and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM1OA_a83fded9-5651-4fc9-bbd0-f88b865ee371">three</span> to <ix:nonNumeric contextRef="i3dfbd2fd237c43bc9219d4395d0474dd_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM2NA_445ee1e5-9e04-4cc3-a94c-ecc3495e09dc">seven years</ix:nonNumeric>. Software is generally amortized over its estimated useful life of <ix:nonNumeric contextRef="i59d9a78c5ed049d0817ec4ff2cc838cd_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzQzNA_e38466bf-90f1-4634-8fa0-25f9f50b4556">three years</ix:nonNumeric>. Leasehold improvements are amortized over the term of the lease, or over their useful lives from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzUzNQ_5c091379-9c3b-4ddb-b0f8-72f24ac68c1e">five</span> to <ix:nonNumeric contextRef="i6a82111ac8a5487a824e9ddb07e72a1e_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzU0MQ_e22affef-e01d-4469-a8a0-0d51214e77eb">10</ix:nonNumeric> years, whichever is shorter. Buildings are depreciated over their estimated useful lives of <ix:nonNumeric contextRef="icd312c63a968473280db7fe49cdb0016_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzYzNg_3980e66b-8788-4454-ad8f-d141faa5f593">31.5</ix:nonNumeric> to <ix:nonNumeric contextRef="if6864266f9a2488da514854481f1778b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzY0Mg_7166141c-1e51-44c8-b4d3-82e14cdfed5e">40</ix:nonNumeric>&#160;years.</ix:continuation></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2, &#8220;Significant Accounting Policies&#8221;, the Company recognized an impairment on property and equipment of $<ix:nonFraction unitRef="usd" contextRef="i54050094325c4beba6d8861066ebb7a0_D20221001-20221231" decimals="-6" name="us-gaap:TangibleAssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzc2OTY1ODEzOTgwNjM_9807b76b-a5b8-4403-91f8-f1b046c8b26c">16</ix:nonFraction> million associated with our reduction in leased space used in our business operations, in the quarter ended December 31, 2022.</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzg2MQ_f011aa6b-b69a-410e-9d16-43be1831c486" continuedAt="ibd2e521141344071a8c0e09237f0f035" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of property, equipment, and capitalized software is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b87a358731a498a8531fb81dfa9704f_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzQtMS0xLTEtNjg3NjY_c8000c5c-a1dc-42b6-bdd7-b15128f9b0c1">615</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15dba481187544f8ba4896f21c4e17cd_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzQtMy0xLTEtNjg3NjY_5bac0b6d-1e33-4ff4-bb56-86a38fc68452">547</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a482fdc9d8b4a328f48fa2052fe7c15_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzUtMS0xLTEtNjg3NjY_39cb7a29-2812-4188-b6be-ef7a7ca3a749">221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd2a2696dfc6483caf233c53d8331a83_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzUtMy0xLTEtNjg3NjY_06bc01f6-d2a4-449e-8323-6f0edbf616f9">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf0ed51712cb44a1a1fc04300c9d5c82_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzYtMS0xLTEtNjg3NjY_9a26c727-5a30-47b0-8b5f-5c09bba47891">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdcfd494f0b044d6a63a13ddfb1e9737_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzYtMy0xLTEtNjg3NjY_81dfb84e-6bfb-4fc1-9ee9-7ef98b748c3c">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib470bce1e1e7439682a2b7cf6079bc24_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzctMS0xLTEtNjg3NjY_5e792a3d-4576-47ae-bf2a-8d7444185d1d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54f8881d1acd421683ecb16c150ac455_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzctMy0xLTEtNjg3NjY_ec185fc4-ef64-41f3-abc5-54647f3fa76c">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzktMS0xLTEtNjg3NjY_8c89d4d0-f8dc-429a-bc02-252c5e21bc15">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzktMy0xLTEtNjg3NjY_208cea98-e1b7-4b9f-bd45-e6ec633562b0">822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated amortization - capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEwLTEtMS0xLTY4NzY2_83b147ad-b0f9-4205-9c2d-69c0b112e633">482</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEwLTMtMS0xLTY4NzY2_59362999-6ba8-4a08-8f5b-739b5c6c4b4a">427</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization - property, equipment, building, and improvements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzExLTEtMS0xLTY4NzY2_b97c0201-9dd6-49ee-a25c-c4b4daa64708">213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzExLTMtMS0xLTY4NzY2_c5b7e519-5a9a-4d3b-aa7e-df88c6c5abba">205</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEyLTEtMS0xLTY4NzY2_6ce22a34-44d7-4d94-a6e4-f7f7992783b8">695</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEyLTMtMS0xLTY4NzY2_20925c43-63de-45b6-8223-68c125a0d6ac">632</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets - finance leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEzLTEtMS0xLTY4NzY2_cffcc193-0045-4738-937d-6050f90bc27a">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEzLTMtMS0xLTY4NzY2_8a5f27c4-4c33-4639-b048-2443ed02d06d">206</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzE0LTEtMS0xLTY4NzY2_649dba46-b138-4333-b34a-b3430b6e341c">259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzE0LTMtMS0xLTY4NzY2_113acb1f-861b-4251-ac7b-b8a55afea7e2">396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7a1e307b153443b78b2326bc33c6d45c"><ix:continuation id="ibd2e521141344071a8c0e09237f0f035"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents all depreciation and amortization recognized in our consolidated statements of income:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recorded in depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzUtMS0xLTEtNjg3NjY_9e8d6297-bec4-416a-aebd-ed9972dd9cf3">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzUtMy0xLTEtNjg3NjY_75801e94-7eba-4f65-9db8-e793c4be4da0">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzUtNS0xLTEtNjg3NjY_ff3b0172-83cf-454e-84a3-8d6008ceb1e9">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:DepreciationAndAmortizationOfCapitalizedSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzYtMS0xLTEtNjg3NjY_db99fbec-843a-4444-8287-0301bdd39693">54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:DepreciationAndAmortizationOfCapitalizedSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzYtMy0xLTEtNjg3NjY_a014f20c-ac20-4129-96ac-21f13fea6a17">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:DepreciationAndAmortizationOfCapitalizedSoftware" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzYtNS0xLTEtNjg3NjY_d41f9304-37e4-4e82-9f92-285e2c162246">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzctMS0xLTEtNjg3NjY_d990a999-fe4f-4f8b-87a7-682dc74ce95f">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzctMy0xLTEtNjg3NjY_9b244c2b-2090-47cc-9e4f-868d19acb05b">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzctNS0xLTEtNjg3NjY_087ffb99-5aee-4a63-915d-eb6777b7891d">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of property, equipment, building, and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzgtMS0xLTEtNjg3NjY_7b5c8df4-1381-4c5b-84da-4f9140f5eb6e">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzgtMy0xLTEtNjg3NjY_e709f9d7-0184-42f8-abda-e112b24706f6">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzgtNS0xLTEtNjg3NjY_436f21b6-146b-41fd-803d-b1e150c1fa4a">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation and amortization recognized</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:DepreciationandAmortizationContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzktMS0xLTEtNjg3NjY_366c9157-0596-41b3-8995-f91ea958f984">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:DepreciationandAmortizationContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzktMy0xLTEtNjg3NjY_85a9d6d0-0c88-4596-b664-ecf90adc34a5">131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:DepreciationandAmortizationContinuingOperations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzktNS0xLTEtNjg3NjY_51b73e7d-d98c-4e8d-98a9-b1461bb47170">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_154"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:LesseeFinanceLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTI_13f2dab5-8230-4161-bf78-952df77885b8" continuedAt="i9bda87919140437088f823e5757b7117" escape="true"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTM_5505a3ea-d3a2-4a90-a52f-a690d95eb00f" continuedAt="i885146eada724b6b998d17fba50fbf18" escape="true">Leases</ix:nonNumeric></ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i9bda87919140437088f823e5757b7117" continuedAt="i1166ac92b7be4da6be6cdb1bfdf31ed9"><ix:continuation id="i885146eada724b6b998d17fba50fbf18" continuedAt="i56514da207c04202a9816ff007f3698f"> </ix:continuation></ix:continuation></span></div><ix:continuation id="i1166ac92b7be4da6be6cdb1bfdf31ed9" continuedAt="ida552fbd9c674c03b39d32fac39a0dde"><ix:continuation id="i56514da207c04202a9816ff007f3698f" continuedAt="i79cce75e331d4b3f924acaf1db8e12fc"><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to <ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzE2Nw_59b4080a-06dd-402d-9c84-8126d9324eb4">13</ix:nonNumeric> years, some of which include options to extend the leases for up to <ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzIzMg_bc396386-5f7b-45a8-8fff-352962d97bb8">10</ix:nonNumeric> years. As of December&#160;31, 2022, the weighted average remaining operating lease term is <ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzMwMQ_06e20dff-19b8-4376-9042-c39536af3c2a">8</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our finance leases have remaining lease terms up to <ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:LesseeFinanceLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzM1Nw_5cdc2451-9373-4e1d-8312-f97fa61ed284">16</ix:nonNumeric> years, some of which include options to extend the leases for up to <ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:LesseeFinanceLeaseRenewalTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzQyMg_e4fb484a-c31d-451a-bc0c-c87754b04731">25</ix:nonNumeric> years. As of December&#160;31, 2022, the weighted average remaining finance lease term is <ix:nonNumeric contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" name="us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzQ4OQ_1fd415af-d066-42da-9616-ad7cd47a1913">13</ix:nonNumeric> years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2, &#8220;Significant Accounting Policies&#8221;, the Company recognized $<ix:nonFraction unitRef="usd" contextRef="i01aae92c76f5467c8edb776a572ee453_D20221001-20221231" decimals="-6" name="moh:OperatingAndFinanceLeaseImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzE0MTgx_da26ea2c-0b55-4491-9a60-ec9109aab2d8">192</ix:nonFraction> million of ROU asset impairments associated with our reduction in leased space used in our business operations in the quarter ended December 31, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted-average discount rate used to compute the present value of lease payments was <ix:nonFraction unitRef="number" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzU5NA_18731d3d-5eae-4ba1-9e5b-0a3b26030097">4.4</ix:nonFraction>% for operating lease liabilities, and <ix:nonFraction unitRef="number" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="3" name="us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzYzNA_383e2286-88bc-452d-843e-7a00c7c156ef">6.3</ix:nonFraction>% for finance lease liabilities. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTQ_239776c7-1ac9-4d91-9a7b-6ffbd11a8be8" continuedAt="i04ba04f289e445f7a7951f5371f68da6" escape="true">The components of lease expense for the years ended December&#160;31, 2022, 2021, and 2020 are presented in the following table.</ix:nonNumeric></span></div><ix:continuation id="i04ba04f289e445f7a7951f5371f68da6"><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzQtMy0xLTEtNjg3NjY_98c5daf5-82ce-48cd-9881-5ca6d7250a8f">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzQtNS0xLTEtNjg3NjY_01f70c90-3c82-4f24-861f-17c1b2d67f96">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzQtNS0xLTEtNzIxMTk_ff4c8ef9-c65c-4101-b086-0b0eabd7a51e">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease expense: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzctMy0xLTEtNjg3NjY_cc52736b-1d4e-4b04-9f7d-6514400e9c08">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzctNS0xLTEtNjg3NjY_98d792f5-a20e-418b-bc59-c5b5ebbe0938">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAssetAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzctNS0xLTEtNzIxMjc_13b78104-e41c-4173-9478-0b8932e12490">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzgtMy0xLTEtNjg3NjY_bdd7da1e-8c30-483f-8560-fcfb98ff73b7">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzgtNS0xLTEtNjg3NjY_09bec621-3a03-42cf-80d3-fd3ae12dda92">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzgtNS0xLTEtNzIxMjc_ebc35e32-375b-4be4-9f7e-aa99aa3b00b6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzktMy0xLTEtNjg3NjY_2c23c997-76d7-4d89-a64c-884d37de09ab">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzktNS0xLTEtNjg3NjY_ddeff039-aa9f-4768-a586-1be85086556e">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:FinanceLeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzktNS0xLTEtNzIxMjc_32577b57-0f19-405d-8980-ff57f0b62987">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated cash flow information related to leases follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:56.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.516%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.385%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzUtMS0xLTEtNjg3NjY_1225e9df-cd35-472a-a660-5b7bce55112c">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzUtMy0xLTEtNjg3NjY_f5d52e25-a398-4178-82c0-6e6c227e73dd">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OperatingLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzUtNS0xLTEtNzIxNDg_30167b8f-5aad-4e57-8d78-ca40f37548b6">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzYtMS0xLTEtNjg3NjY_fcbcd697-ab93-4e86-b63a-16ea9b0117dd">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzYtMy0xLTEtNjg3NjY_72a071ea-fa1b-42bf-80d2-11fbb83ef317">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeaseInterestPaymentOnLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzYtNS0xLTEtNzIxNDg_7a9edbbc-df7c-4773-b26d-b763c463e8d6">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzgtMS0xLTEtNjg3NjY_d52fd281-f2f4-4aa9-8012-162eb3cd29ab">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzgtMy0xLTEtNjg3NjY_c71c96f1-ddb9-4a29-b942-2aed789fb098">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:FinanceLeasePrincipalPayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzgtNS0xLTEtNzIxNDg_8e35903c-e592-488a-809f-aef38b065f00">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets recognized in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzEwLTEtMS0xLTY4NzY2_df877f6f-d596-4576-9610-ce77ec96ee68">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzEwLTMtMS0xLTY4NzY2_8d038629-099f-46b1-9e71-d2f4d55a34c5">86</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzEwLTUtMS0xLTcyMTQ4_7cb92f2b-57a8-4f50-af92-6f21b0ab0ed7">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzExLTEtMS0xLTY4NzY2_01e10868-afb1-444d-a9f8-0135bb9b0c98">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzExLTMtMS0xLTY4NzY2_5a844c6c-9f85-4ced-8eca-c1920af6435e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzExLTUtMS0xLTcyMTQ4_1c02a45a-e8e8-439a-99a2-cfe1526e282a">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ida552fbd9c674c03b39d32fac39a0dde"><ix:continuation id="i79cce75e331d4b3f924acaf1db8e12fc"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTY_b42a2d90-ef61-4333-9e27-fc4ad9b2c89c" escape="true"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.498%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c">Other assets</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMS0xLTEtNjg3NjY_831824d5-40ff-40b4-aa1e-64c447245ad0">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMy0xLTEtNjg3NjY_483505ac-c1ae-4b9c-8f53-388387ff669d">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84">Accounts payable and accrued liabilities (current)</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTEtMS0xLTY4NzY2_c60010ea-0302-4b12-a0ae-c88f7bbd284e">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTMtMS0xLTY4NzY2_d7e70490-ad48-432a-84c1-a59bc7c5d918">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df">Other long-term liabilities (non-current)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTEtMS0xLTY4NzY2_e98b7914-bc48-42d2-b547-f9727f5a886b">77</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTMtMS0xLTY4NzY2_d0d6563c-97b1-4acd-b023-8a314d56cd15">99</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEzLTEtMS0xLTY4NzY2_97d71b7a-7ab7-4aa5-9272-041d2db30d89">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEzLTMtMS0xLTY4NzY2_b2be4c86-f90c-41fd-87b3-8653b00084ff">134</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ROU assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE2LTEtMS0xLTY4NzY2_cffcc193-0045-4738-937d-6050f90bc27a">72</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FinanceLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE2LTMtMS0xLTY4NzY2_b3d034f0-cb03-47ff-a777-83b5e395e2c3">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8">Accounts payable and accrued liabilities (current)</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTEtMS0xLTY4NzY2_178c16a9-e1b7-4b4d-bc5e-fd495f810147">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTMtMS0xLTY4NzY2_aabe057f-2c05-4802-93ea-a124d1a932f1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (non-current)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE5LTEtMS0xLTY4NzY2_1efa6866-d0ad-4b10-bd15-e286a5c68860">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE5LTMtMS0xLTY4NzY2_679b300d-bca8-45c6-888f-b1b404296af9">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:92.25pt;text-indent:-76.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzIwLTEtMS0xLTY4NzY2_295f3a87-7818-42af-979a-b67253ecbb8a">237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzIwLTMtMS0xLTY4NzY2_29951991-0ba7-4d2c-b9a9-737400810db3">234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTc_0fb4a9c7-e47f-473a-92d9-6a2647c8a7a5" escape="true"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTg_a112948b-7676-41d0-b29b-e4e27632e429" escape="true"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:70.894%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.536%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.537%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzQtMS0xLTEtNjg3NjY_657bf088-ba9c-4bad-a207-ce0cda45d46d">28</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzQtMy0xLTEtNjg3NjY_20e2f1c1-1592-4900-8144-a9bb72fad0cb">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzUtMS0xLTEtNjg3NjY_95637015-c62d-483c-9139-ddee69ee489a">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzUtMy0xLTEtNjg3NjY_9c24520e-5a60-42fc-805d-7ac15893b7fd">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzYtMS0xLTEtNjg3NjY_a0a15910-fedf-400b-8e99-3e308408635e">18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzYtMy0xLTEtNjg3NjY_0bcc9ee2-309f-47a2-b201-3b6a73fb6576">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzctMS0xLTEtNjg3NjY_50b7c7c6-e80b-42ea-942b-f3938c773c1b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzctMy0xLTEtNjg3NjY_b8277ead-9447-4a3e-b5f9-4f6dc5b4973f">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzgtMS0xLTEtNjg3NjY_d9897c03-b421-4d82-bb9d-3e946204b375">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzgtMy0xLTEtNjg3NjY_dbeced38-1dc6-4c99-bedd-574dfb74ef29">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzktMS0xLTEtNjg3NjY_6fa44eb4-7753-4e95-804f-70752a84def9">55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzktMy0xLTEtNjg3NjY_05a66849-2506-4d6d-bec1-52d1e05d2d3e">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal - undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzEwLTEtMS0xLTY4NzY2_775b713e-9c19-4f59-939b-ea8f76e0b21d">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityPaymentsDue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzEwLTMtMS0xLTY4NzY2_f6a671f6-d4dd-46e9-9b5c-6ae38cfcb9da">356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzExLTEtMS0xLTY4NzY2_ab9984b8-11ad-4f35-88b0-9674d886ec25">25</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzExLTMtMS0xLTY4NzY2_048a1c7c-b86c-4438-bada-2a461a9e60da">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzEyLTEtMS0xLTY4NzY2_d7ec32da-a960-44e7-9237-745a7da58455">118</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzEyLTMtMS0xLTY4NzY2_0ff1f772-2419-4093-bdd9-ab9b8ef38d8b">237</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_160"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzYwNA_6f14da1d-1f71-4fec-bd4e-6d8815838c70" continuedAt="i4561657c4e6f419ebec362679f5a9fea" escape="true">Goodwill and Intangible Assets, Net</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i4561657c4e6f419ebec362679f5a9fea" continuedAt="i12f42b27b5734892b472c8d59060fb00"> </ix:continuation></span></div><ix:continuation id="i12f42b27b5734892b472c8d59060fb00" continuedAt="i5cf0bc53dc334e2e917950dc25fbd211"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzYwOA_153b0033-78b3-4ad7-afb7-00f42a219407" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f72b45b4644a468fe3bf237a344ae5_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzMtMS0xLTEtNjg3NjY_71f00c45-598e-42b8-a4a7-dd286abfe1d5">489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie051c5fdd0164b7692de987d735b5614_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzMtMy0xLTEtNjg3NjY_ec52e083-cf50-4160-974a-0ef3dbcb006f">161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica8010c73a874479be005b5c0efe2f9b_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzMtNS0xLTEtNjg3NjY_b0fc05e1-0dbe-4ce6-b283-e7189e58125b">42</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzMtNy0xLTEtNjg3NjY_c21b99c5-0176-42e3-95ff-e87261d628c0">692</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and measurement period adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzQtMS0xLTEtNjg3NjY_b752dbba-c931-4117-b367-050e3c71a29d">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzQtMy0xLTEtNjg3NjY_1134ec01-d100-4f72-b8d1-e84cbeaadd4d">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83f163bbbec4901a4db9c0cd3b6beae_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzQtNS0xLTEtNjg3NjY_faeade68-4fbd-4d34-8080-1f2ce0647c8c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzQtNy0xLTEtNjg3NjY_3c9eb38f-fa22-4d0b-8f61-ada14379ea6f">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d2514974d648b4a321860ce0da423a_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzctMS0xLTEtNjg3NjY_40e3a006-b391-47c4-a4cb-1cd7cae392ec">769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8d5443c6c445b7b1df9e882c954e13_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzctMy0xLTEtNjg3NjY_726f1832-30e5-4f19-989a-dd5f4c302159">169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i471861f0bd924c028fddde43043e03e5_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzctNS0xLTEtNjg3NjY_46297c30-8d8d-4c5a-bb78-d0203aea6beb">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzctNy0xLTEtNjg3NjY_85072e81-f73d-4d3d-9d75-03decbf7fddb">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and measurement period adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzEyLTEtMS0xLTY4NzY2_e60cb4d8-8429-49f9-9be8-20da2cef095f">130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzEyLTMtMS0xLTY4NzY2_3c79806e-4ef3-4d6a-bfdc-76ce64df01c6">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0e6e336cc2457895f26a4b547de184_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzEyLTUtMS0xLTY4NzY2_32f31f56-f214-42cf-b775-dffd2c9344bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzEyLTctMS0xLTY4NzY2_daec0278-8aa0-49bb-a8b5-f25f31aba960">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277bd722f8d244c98c6cb91f7a6d9c98_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzE1LTEtMS0xLTY4NzY2_f4e8a89e-8365-4a81-91a9-b0af70def893">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ded5b162e2f49728c0e31ad73edfaeb_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzE1LTMtMS0xLTY4NzY2_1ff35f5f-fac5-4ae2-a5f9-af1e2b65d871">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie099f36d881c40a3badd49fcbe24a158_I20221231" decimals="-6" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzE1LTUtMS0xLTY4NzY2_7c802cf9-04da-4b36-99ec-65fc3db716ba">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzE1LTctMS0xLTY4NzY2_1305d4de-9738-43d9-a013-64d48c1f5af3">1,115</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of both goodwill and intangible assets, net, in 2022, were due to the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5cf0bc53dc334e2e917950dc25fbd211" continuedAt="i2a581a0d94ba4abeac2d1bbdacc0bdc6"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisitions and purchase price adjustments described in Note 4, &#8220;Business Combinations.&#8221; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzYwMA_a9b4105f-44e1-48ff-b03d-5dfa1a731188" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of identified intangible assets, by major class, for the periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:23.569%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.500%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.969%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights and licenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc025417eb148d5848c4dc550d72cf1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtMS0xLTEtNjg3NjY_d36c7f79-df6a-4046-8eb2-f3bdf2442d5c">507</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc025417eb148d5848c4dc550d72cf1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtMy0xLTEtNjg3NjY_ae98d261-edab-4b2b-aa84-b9eae480aea7">279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc025417eb148d5848c4dc550d72cf1_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtNS0xLTEtNjg3NjY_513df4cd-7748-4f27-88e4-5ddf0450031f">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a10f9e2abb34524aa6d8bc510e1aa4e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtNy0xLTEtNjg3NjY_57767190-472f-4777-8b40-c5bd80c45d1a">426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a10f9e2abb34524aa6d8bc510e1aa4e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtOS0xLTEtNjg3NjY_cc51ac04-9e24-4c18-be97-05e4f1b42366">210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a10f9e2abb34524aa6d8bc510e1aa4e_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtMTEtMS0xLTY4NzY2_19f4a5c1-e926-4be8-85c8-6301662f51d3">216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4767b4d9b3f84070acc01bf02ca7feef_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtMS0xLTEtNjg3NjY_1011f520-2444-481b-ac20-74752ae606bd">57</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4767b4d9b3f84070acc01bf02ca7feef_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtMy0xLTEtNjg3NjY_46034ccc-0a09-4f9f-abf2-d1bc2900611b">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4767b4d9b3f84070acc01bf02ca7feef_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtNS0xLTEtNjg3NjY_cd07a48b-1053-48b2-b6c1-2338dc028b30">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f6a981430a48419a3e8f282bae5cee_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtNy0xLTEtNjg3NjY_af779f19-67e4-412a-b115-ba658ebeeab9">56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f6a981430a48419a3e8f282bae5cee_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtOS0xLTEtNjg3NjY_ad2eb927-8fef-4cc0-a920-ffe8f6fabb2d">19</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4f6a981430a48419a3e8f282bae5cee_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtMTEtMS0xLTY4NzY2_2d9ffb65-618a-4bb1-8892-f13d24a8b788">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8398f04c5a124683b46e82729ddf8f33_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtMS0xLTEtNjg3NjY_d4570345-b025-4b51-a272-13ef04f63b25">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8398f04c5a124683b46e82729ddf8f33_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtMy0xLTEtNjg3NjY_969ee5ec-0f0d-4273-8243-90319d37e38b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8398f04c5a124683b46e82729ddf8f33_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtNS0xLTEtNjg3NjY_96aa5e96-6769-4937-909f-07b772b7e317">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390ee1c0be844452a70fa034460742a3_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtNy0xLTEtNjg3NjY_08a05569-c808-432e-837b-1f61c305293a">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390ee1c0be844452a70fa034460742a3_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtOS0xLTEtNjg3NjY_69752b9d-26d0-484d-852c-1f1b2ec3afe1">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i390ee1c0be844452a70fa034460742a3_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtMTEtMS0xLTY4NzY2_d39925b7-6628-4d3c-b38f-4896b2c36d7a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctMS0xLTEtNjg3NjY_37a25891-9ac0-4538-bd87-df046e06c8dc">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctMy0xLTEtNjg3NjY_4ea370cb-08b0-463c-8d6b-0d3f4fa3ad80">308</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctNS0xLTEtNjg3NjY_e63b2420-dbff-4af0-b925-25c0be9c0b5e">275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctNy0xLTEtNjg3NjY_7873b8a5-cc64-43e3-9501-be191cea6f23">501</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctOS0xLTEtNjg3NjY_20e5cb3e-2d9d-4e1b-94f8-49ab63fa59f0">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctMTEtMS0xLTY4NzY2_c7debf9c-4c1c-4a10-8927-3e470d466fa7">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2a581a0d94ba4abeac2d1bbdacc0bdc6">As of December&#160;31, 2022, we estimate that our intangible asset amortization will be approximately $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU0Mg_f55802a0-454b-40eb-a454-634673e1ab6a">84</ix:nonFraction> million in 2023, $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU1Mg_5f1abf52-7061-479f-8aee-ce450d3223e1">67</ix:nonFraction> million in 2024, $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU2Mg_ba51f733-32eb-45b5-8450-f4f6cf66e577">64</ix:nonFraction> million in 2025, $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU3Mg_7f6ef36e-d849-4f56-aa43-6dd06bd01e1f">25</ix:nonFraction> million in 2026, and $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU4Ng_f46a7349-7f19-4ed4-af94-603f10d46205">13</ix:nonFraction> million in 2027.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_163"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwOTg_e116ffc2-3467-4904-ae63-ce49078639a2" continuedAt="i442d227145884e0f8e762fd7949c3b1c" escape="true">Medical Claims and Benefits Payable </ix:nonNumeric></span></div><ix:continuation id="i442d227145884e0f8e762fd7949c3b1c" continuedAt="i9a4730904b924d57b6acf5a0e4aa805e"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwOTA_7e151859-cf77-4ab0-a268-b92060d5f70a" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzQtMS0xLTEtNjg3NjY_318af1b4-b4dc-4ca0-a35c-088621bdfead">2,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzQtMy0xLTEtNjg3NjY_5ac1fbd3-d843-4c84-baa2-055d1f495b68">2,486</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzQtNS0xLTEtNjg3NjY_0ae0cfe0-4066-4a82-8f2c-0c113e549400">1,647</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzUtMS0xLTEtNjg3NjY_d086b78e-e0a3-4648-8726-60446491939b">206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzUtMy0xLTEtNjg3NjY_e4c71d79-1ac5-48e8-b8d7-ca6901c2540c">219</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="moh:PharmacyClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzUtNS0xLTEtNjg3NjY_ca5b94ff-89b7-4d4a-92f7-4563b50e8f2b">157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzYtMS0xLTEtNjg3NjY_4b4c88c1-5a17-471c-80ab-f0fe4299fcce">94</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzYtMy0xLTEtNjg3NjY_cf47c005-d51b-40ad-b9b9-2957a34e01b3">82</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="moh:CapitationClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzYtNS0xLTEtNjg3NjY_0e4069a5-6d80-429b-8289-6da35df0303d">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzctMS0xLTEtNjg3NjY_eee98646-404a-4439-a6d6-6097eddbf97f">631</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzctMy0xLTEtNjg3NjY_485efcba-21bc-4d1c-bcc8-f986cd900357">576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="moh:OtherClaimsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzctNS0xLTEtNjg3NjY_b246dd14-a277-4f2e-b0c8-31a8bcb78840">528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3d5b8372df4c6abfbb27c274bc673a_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzgtMS0xLTEtNjg3NjY_13eccec0-39b1-4942-b66d-c51294f0cd81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0023c6ef83664597b60b89a484a483bc_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzgtMy0xLTEtNjg3NjY_67c3ee28-2cfc-4d7e-a2a0-c7d410cadb46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i791cb3b2e1414dc995d8c3832e970a59_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzgtNS0xLTEtNjg3NjY_0519cb9d-5d7b-49c4-aef1-1535934eb1c9">294</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzktMS0xLTEtNjg3NjY_b131e0c4-a2d9-4ee0-aedd-480b0fa1f324">3,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzktMy0xLTEtNjg3NjY_ec8b80a4-4800-4611-b6ef-02c0ab42de1f">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzktNS0xLTEtNjg3NjY_55ca9e9d-da2f-4f34-addc-f7971d5e1522">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzQ0NA_910d97c1-cf50-4907-8fc7-dedcfbca982d">228</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzQ0OA_538f50ed-ddba-4fb0-a1c5-7a1f5fd31fe5">226</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzQ1NQ_8103df8e-7121-48d9-a4bf-17450b3500e7">235</ix:nonFraction> million, as of December&#160;31, 2022, 2021, and 2020, respectively.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9a4730904b924d57b6acf5a0e4aa805e" continuedAt="ib864acfb54c94fd48b179bc9687670cd"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwODU_9e795a64-8603-451d-9754-1f8445e67956" continuedAt="i261b5e9b4beb46e9a67fc2f2e1adcba2" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d2514974d648b4a321860ce0da423a_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzQtMS0xLTEtNjg3NjY_a47268f9-3238-4d75-9e2f-67ef8a7d7552">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8d5443c6c445b7b1df9e882c954e13_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzQtMy0xLTEtNjg3NjY_af831916-d8dc-44e6-ade0-f58902906eb0">404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e256b4d3f8045d6a0d60842042e5330_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzQtNS0xLTEtNjg3NjY_1b8ccc17-c2bc-4d88-a29f-ffd4fdd3906a">379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzQtNy0xLTEtNjg3NjY_b6b14728-fe98-43bc-b123-2ee82d439208">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzYtMS0xLTEtNjg3NjY_9b97e904-5aae-4caa-9e27-fa22ac2673a0">22,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzYtMy0xLTEtNjg3NjY_9026c483-2c06-4d47-a492-315fd4a9deea">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzYtNS0xLTEtNjg3NjY_9cadd429-274f-408f-b23e-409f8c418d42">1,972</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzYtNy0xLTEtNjg3NjY_b89de130-a8c1-459d-9218-e7ba3a1ab460">27,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzctMS0xLTEtNjg3NjY_eed3cd02-2660-4c57-84d6-15f9bf52860b">251</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzctMy0xLTEtNjg3NjY_c0485e68-f113-4a60-ba15-9da8132dbf40">32</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzctNS0xLTEtNjg3NjY_5765ede2-2518-49cf-82a9-125cf1536b76">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzctNy0xLTEtNjg3NjY_29ae7d24-3016-40db-97e7-80a0267ce441">284</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzgtMS0xLTEtNjg3NjY_6248bd89-f92b-4dfe-9b1c-9a9eb624aa6b">21,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzgtMy0xLTEtNjg3NjY_b108ccdd-9c0e-45ab-82f4-205e3cc7c2a1">3,358</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzgtNS0xLTEtNjg3NjY_aa5fff0a-07b8-4952-9513-4e0942a7e98f">1,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzgtNy0xLTEtNjg3NjY_132e58bc-6646-4119-839a-ce3b9876cb0d">27,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEwLTEtMS0xLTY4NzY2_85491e71-8628-419b-ab7e-c66c1bd8b0b6">19,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEwLTMtMS0xLTY4NzY2_e47720ef-8153-4a96-a2dd-af54af7bb772">2,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEwLTUtMS0xLTY4NzY2_ad1d4ede-b335-438a-8b49-9623656ef01d">1,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEwLTctMS0xLTY4NzY2_19538566-2af2-4af1-a3cd-70170c88f71f">24,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzExLTEtMS0xLTY4NzY2_c817e34d-06d0-491c-b3dc-b56477a4a14f">1,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzExLTMtMS0xLTY4NzY2_12b74e64-74de-4379-a597-bf62e9ef5ebc">361</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzExLTUtMS0xLTY4NzY2_68ee3389-5441-4692-ba95-7e0839a7564a">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzExLTctMS0xLTY4NzY2_357b1264-b951-4059-a66d-c469fdfc31be">2,670</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEyLTEtMS0xLTY4NzY2_a03b3d2d-b88f-44ff-b090-2350266a7733">21,621</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEyLTMtMS0xLTY4NzY2_2094cbe6-833a-4575-901f-ed3b3f5afe3d">3,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEyLTUtMS0xLTY4NzY2_ee7d29d9-29c4-4862-a2e9-305f6920dcbd">2,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEyLTctMS0xLTY4NzY2_4435e11f-d463-48b9-b94e-38884dd69a32">27,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEzLTEtMS0xLTc1NjU3_e9332d00-b979-46e5-90ac-9b903eae1858">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEzLTMtMS0xLTc1NjU3_f0b46bf1-cdb5-4195-969c-b04faff31a4e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEzLTUtMS0xLTc1NjU3_814b5a09-18bf-4aa0-b901-321ea771e6cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEzLTctMS0xLTc1NjU3_855b43d5-db65-4ebb-929b-5657a883d7e0">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE0LTEtMS0xLTY4NzY2_6798cccf-d9a9-4ac8-a9e7-e7d6b3e90d13">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE0LTMtMS0xLTY4NzY2_ce0e3569-940e-4fc7-9cb5-991af18fda89">5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE0LTUtMS0xLTY4NzY2_ab565605-895f-4eae-8c7e-3294e3532c73">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE0LTctMS0xLTY4NzY2_65d94bd3-d9a6-4605-a7a7-35dc3338d1ea">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i277bd722f8d244c98c6cb91f7a6d9c98_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE1LTEtMS0xLTY4NzY2_262d4c77-cb93-44f6-8ba5-fbe021d631b4">2,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ded5b162e2f49728c0e31ad73edfaeb_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE1LTMtMS0xLTY4NzY2_75c7f16e-5a57-484b-8595-35c713372cec">452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628668ecbc2f46759154eeb9586c550c_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE1LTUtMS0xLTY4NzY2_55f602aa-1812-41c9-9b3e-93f1f6c6ba30">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE1LTctMS0xLTY4NzY2_d59ce5f2-f158-40d6-bf85-30024b585bf7">3,528</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f72b45b4644a468fe3bf237a344ae5_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzQtMS0xLTEtNjg3NjY_958e8fb5-3555-4516-a3f4-950d598eb8f9">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie051c5fdd0164b7692de987d735b5614_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzQtMy0xLTEtNjg3NjY_156504a1-5a10-48ba-866f-e5c2cff50834">392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8bd3d713d84b16b5d4c1c2e0b0602f_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzQtNS0xLTEtNjg3NjY_046e915a-74f9-4cbc-9dd6-074955a44d8c">175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzQtNy0xLTEtNjg3NjY_e7cfbc4d-9451-4f90-8a11-3cccc8103b4b">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzYtMS0xLTEtNjg3NjY_14bf18fa-9444-4057-acd9-32de0704a773">18,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzYtMy0xLTEtNjg3NjY_e49c44bc-aa6d-45b1-a4ac-7d25dcc7936d">2,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzYtNS0xLTEtNjg3NjY_ca6b030b-f579-4ba7-80a2-1807bb6a6cd5">2,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzYtNy0xLTEtNjg3NjY_395ce464-4626-44bc-8dc5-b3f39529aa54">23,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzctMS0xLTEtNjg3NjY_a68936a3-cccf-44cf-9c92-faebe6336a67">182</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzctMy0xLTEtNjg3NjY_a5dd5aee-814e-473b-83eb-3d6d4596fd68">39</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzctNS0xLTEtNjg3NjY_c3269f2e-c197-49de-bc8f-6ab4340299e7">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzctNy0xLTEtNjg3NjY_fe6e5bf0-6806-40bd-b44d-b0f3dddc65f6">239</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzgtMS0xLTEtNjg3NjY_2e835aaf-6fd3-4c23-8d46-65c1235ec373">18,139</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzgtMy0xLTEtNjg3NjY_285e2927-20a5-46fb-bd1c-615be4c79b11">2,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzgtNS0xLTEtNjg3NjY_e94cc89a-70fe-4610-9050-69e014ecb05f">2,634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzgtNy0xLTEtNjg3NjY_ba317561-6276-429d-b848-16bc74bf47c6">23,704</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEwLTEtMS0xLTY4NzY2_d97452d2-ce50-4f1f-ad7e-9cc5083135d1">16,284</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEwLTMtMS0xLTY4NzY2_f884e064-8667-4808-8adc-42bfa8551484">2,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEwLTUtMS0xLTY4NzY2_e6123831-4550-44ea-ad7f-ce7392d17819">2,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEwLTctMS0xLTY4NzY2_584107d8-f520-4046-bf03-0b491fd07f20">21,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzExLTEtMS0xLTY4NzY2_8c62e93f-7d11-4011-9189-5a067691c8d3">1,601</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzExLTMtMS0xLTY4NzY2_fd41dbf5-c93b-4144-8e91-5379daaa05ee">340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzExLTUtMS0xLTY4NzY2_3f60f795-28d5-4b0e-bc0b-7c796649fc6b">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzExLTctMS0xLTY4NzY2_c0936c69-347a-44c6-b3e2-80d783ec4dad">2,080</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEyLTEtMS0xLTY4NzY2_09929729-0af3-4139-af86-14e3ba256433">17,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEyLTMtMS0xLTY4NzY2_76ec88f1-4a5a-4bc2-b279-a47869f40ffa">2,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEyLTUtMS0xLTY4NzY2_e02697c7-cabe-4734-92b7-e2149b8031c7">2,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEyLTctMS0xLTY4NzY2_eeb90d66-4390-4a21-997b-ce3f71f8e518">23,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEzLTEtMS0xLTY4NzY2_f0ba9277-d007-4527-b895-99a452cf770f">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" sign="-" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEzLTMtMS0xLTY4NzY2_06a319a6-c96c-4f60-8354-e7bb09a6df22">8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEzLTUtMS0xLTY4NzY2_3d984dc7-be86-4c7c-a025-a1f6cd9b4e92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEzLTctMS0xLTY4NzY2_cb310b3d-7e6c-46cb-bcaf-9ed3f77780ff">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE0LTEtMS0xLTY4NzY2_cdc09b9b-0e5c-4024-80d8-bf5bc4f9a48c">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE0LTMtMS0xLTY4NzY2_fbc4e979-0a69-488a-a933-8070516eb26c">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE0LTUtMS0xLTY4NzY2_3315c8a2-7785-4b6e-ae62-edd8bacf7fb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE0LTctMS0xLTY4NzY2_2b087ee6-1e0c-41c2-8db2-de11fa7d8764">6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35d2514974d648b4a321860ce0da423a_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE1LTEtMS0xLTY4NzY2_a95dd40a-5d90-4473-9406-ceb066feb6ab">2,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a8d5443c6c445b7b1df9e882c954e13_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE1LTMtMS0xLTY4NzY2_f10aeb4f-1d61-4668-9f78-b59d9d1ade5f">404</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e256b4d3f8045d6a0d60842042e5330_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE1LTUtMS0xLTY4NzY2_aef556ad-1a48-4998-82ab-27635699a777">379</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE1LTctMS0xLTY4NzY2_072c39b6-4a7e-4518-aa25-1b0923c1395f">3,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib864acfb54c94fd48b179bc9687670cd" continuedAt="i832af00f49fc4ab7a597d212fe7f56b4"><div style="margin-top:6pt"><ix:continuation id="i261b5e9b4beb46e9a67fc2f2e1adcba2"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.829%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec5b1cb8aec941ee8481b1247d22f717_I20191231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzQtMS0xLTEtNjg3NjY_3cf38db6-7738-4c71-9e50-beb35a2382e4">1,465</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i048dd0bf323147f88d1ce251936a8002_I20191231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzQtMy0xLTEtNjg3NjY_32a3e0dc-fb27-4507-a111-686a8f65b272">267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c45749706a94b278c9d69ee05c26153_I20191231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzQtNS0xLTEtNjg3NjY_9f77c6c6-8daf-477c-99d9-664722d1c079">122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzQtNy0xLTEtNjg3NjY_49ddb950-9e1f-4f7d-921a-1da67272783e">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzYtMS0xLTEtNjg3NjY_5f188688-52a0-47e3-a6e6-81091c410837">12,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzYtMy0xLTEtNjg3NjY_83587ccb-d193-4475-9b1a-d0937401450f">2,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzYtNS0xLTEtNjg3NjY_1d0f7197-6bb3-42c6-93b2-cd1687aefd0b">1,205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzYtNy0xLTEtNjg3NjY_2f2a53a8-9a1c-4d2a-a921-c61e05de5b47">15,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzctMS0xLTEtNjg3NjY_a77711f7-3456-4221-aa45-96cee809814a">84</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzctMy0xLTEtNjg3NjY_0476c185-ec1c-4045-bb1e-217e3c9527af">28</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzctNS0xLTEtNjg3NjY_b3849d27-b936-4f10-bd33-e54329216694">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzctNy0xLTEtNjg3NjY_5cb04071-5dfe-402c-a14d-8b751992cdbe">119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzgtMS0xLTEtNjg3NjY_b8df035a-5a8c-4185-9a12-75d017f985fd">12,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzgtMy0xLTEtNjg3NjY_a9a15a16-b994-435d-98b4-6a245c632952">2,161</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzgtNS0xLTEtNjg3NjY_968012a6-fd53-4918-8535-880d133494f5">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzgtNy0xLTEtNjg3NjY_ef318bc4-2cd5-4b8b-9cd3-00343f5caacb">15,820</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEwLTEtMS0xLTY4NzY2_b44ebf01-e460-42eb-95a1-13f1021faf2b">10,940</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEwLTMtMS0xLTY4NzY2_fead3f4b-d6ff-4298-a167-21399739e762">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEwLTUtMS0xLTY4NzY2_dad0f114-b506-4505-91b4-1ab66afe9b3c">1,047</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEwLTctMS0xLTY4NzY2_2f6d08b1-e831-4216-a7e4-e54b7086d7c3">13,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzExLTEtMS0xLTY4NzY2_ba5de47a-27de-4730-b46d-cb6ebe8bd716">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzExLTMtMS0xLTY4NzY2_5dd9c910-990d-4590-9a5e-9174912f176b">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzExLTUtMS0xLTY4NzY2_e266549f-8e87-4d57-a069-586eebeb79d6">98</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzExLTctMS0xLTY4NzY2_3938b528-b38d-4087-8485-07a6f089a31b">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEyLTEtMS0xLTY4NzY2_bfcb8f4f-afe4-4ff6-8198-98d8252c5dc9">12,116</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEyLTMtMS0xLTY4NzY2_5142b210-32af-450d-b43d-45c91f263005">2,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEyLTUtMS0xLTY4NzY2_044a8af4-b55f-4202-8f0d-3d393b70a4ee">1,145</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForLossesAndLossAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEyLTctMS0xLTY4NzY2_db87acab-3986-46a4-80e6-5ab81ec11d68">15,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEzLTEtMS0xLTY4NzY2_1a9a4eae-fe40-4c8f-bf80-3f4550a1158b">215</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEzLTMtMS0xLTY4NzY2_3c225331-357f-46d0-8f9a-3805039a0d5a">79</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEzLTUtMS0xLTY4NzY2_0544509f-1daf-40ed-a43f-7369f67c7720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEzLTctMS0xLTY4NzY2_ddd592dc-c6b1-485d-a7a0-f32777f52f40">294</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE0LTEtMS0xLTY4NzY2_548b0569-fb8b-46e3-bedd-115d43e59c44">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE0LTMtMS0xLTY4NzY2_0c350fb3-5c6b-4dae-9b83-da75ab287e41">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE0LTUtMS0xLTY4NzY2_17a954ad-1155-400d-ad9b-98bf26457ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE0LTctMS0xLTY4NzY2_19d90c7e-1f23-4670-a33c-936ae838b975">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13f72b45b4644a468fe3bf237a344ae5_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE1LTEtMS0xLTY4NzY2_26156093-0ad6-4d89-a78b-38cffe52fc51">2,129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie051c5fdd0164b7692de987d735b5614_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE1LTMtMS0xLTY4NzY2_c0797871-dd35-4d6b-9b48-356e87ff4c4c">392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f8bd3d713d84b16b5d4c1c2e0b0602f_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE1LTUtMS0xLTY4NzY2_aa414216-cf19-4c78-86c7-2fceb509f988">175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE1LTctMS0xLTY4NzY2_a679bd23-4a0c-49fd-a9f0-d71f36189482">2,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2022, 2021 and 2020 developed favorably by approximately $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzExODQ_29ae7d24-3016-40db-97e7-80a0267ce441">284</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzExODg_fe6e5bf0-6806-40bd-b44d-b0f3dddc65f6">239</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzExOTU_5cb04071-5dfe-402c-a14d-8b751992cdbe">119</ix:nonFraction>&#160;million in 2022, 2021 and 2020, respectively. The favorable prior year development recognized in 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance, mainly in the Medicaid segment. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our estimates in 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior year development recognized in 2021 was primarily due to lower than expected utilization of medical services by our Medicaid members, and to a lesser extent our Medicare and Marketplace members, and improved operating performance. Consequently, the ultimate costs recognized in 2021 were lower than our original estimates in 2020, which was not discernible until additional information was provided, and as claims payments were processed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior year development recognized in 2020 was primarily due to lower than expected utilization of medical services by our Medicaid members, and improved operating performance. Consequently, the ultimate costs recognized in 2020 were lower than our original estimates in 2019, which was not discernible until additional information was provided, and as claims payments were processed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information about our consolidated incurred and paid claims development as of December&#160;31, 2022, as well as cumulative claims frequency and the total of incurred but not paid claims liabilities. The pattern of incurred and paid claims development is consistent across each of our segments. The cumulative claim frequency is measured by claim event, and includes claims covered under capitated arrangements.</span></div><div style="margin-top:6pt"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwNzc_3c96da77-28eb-4e89-9739-482617a2cc64" continuedAt="if1317b26da0f43b2b8f06fd6d2907e37" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.737%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.541%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.544%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Claims and Allocated Claims Adjustment Expenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total IBNP</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative number of reported claims</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90f37a0e7ed48588693d942d7439522_D20200101-20201231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtMi0xLTEtNjg3NjY_c8632ea8-bdf9-4f60-bba2-82dcabd23abc">16,233</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1f11b3a0464f1c8a8e9399866f72eb_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtNC0xLTEtNjg3NjY_75b049b4-ec66-4d57-bdc5-88398706b5d7">16,056</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e82750ee1ba4f92ba421980442e025f_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtNi0xLTEtNjg3NjY_66ef3640-3049-4522-9447-61802d84ca7b">16,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d21f0289d0f4503a608e0c544fa3528_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtOC0xLTEtNjg3NjY_e227932d-8f52-411c-bfb8-e09bbb172a37">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i0d21f0289d0f4503a608e0c544fa3528_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtMTAtMS0xLTY4NzY2_179c5fd3-9861-4999-97c6-696c43b154d9">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc6e982b4b304fa2849be3b24940489a_D20210101-20211231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzYtNC0xLTEtNjg3NjY_cf2d7011-e4dc-402d-bdce-76b04f8939fa">24,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d09c2e933d841399382aeaf45b11f51_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzYtNi0xLTEtNjg3NjY_8eb780fa-ba22-4641-999d-76164c79525c">23,979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60f70f36c784daabd311b0746a76015_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzYtOC0xLTEtNjg3NjY_eb83efdf-7a3b-4b22-b318-55863b6a4358">108</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="ib60f70f36c784daabd311b0746a76015_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzYtMTAtMS0xLTY4NzY2_1b1aebfb-bfbc-4880-a5d5-9fe746725f83">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ce51eb40d964399bcbf595c78a3712c_D20220101-20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzctNi0xLTEtNjg3NjY_d4fdc872-57d3-452e-8087-b9b219ad92df">27,459</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca478154d99467c8fbc5952a0a6af98_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzctOC0xLTEtNjg3NjY_29b15fdf-3d63-48e8-a552-839438654599">2,453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="claim" contextRef="i0ca478154d99467c8fbc5952a0a6af98_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzctMTAtMS0xLTY4NzY2_5994f84c-ea62-4f68-8da3-a2ddb3a015a3">264</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzgtNi0xLTEtNjg3NjY_f2565838-6e74-411e-8a57-9867870623c3">67,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzgtOC0xLTEtNjg3NjY_bd44a3da-7426-4432-a0da-123815bc7df1">2,588</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i832af00f49fc4ab7a597d212fe7f56b4"><div style="margin-top:6pt"><ix:continuation id="if1317b26da0f43b2b8f06fd6d2907e37"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.462%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claims Adjustment Expenses</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacb62ab94ca7487b9f7d98e6acaec0bd_I20201231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzUtMi0xLTEtNjg3NjY_3ae2ff0c-3c22-440b-9ec0-efe5b0f2fad9">13,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i820c538fe10a42b88e632ca56ab2d10e_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzUtNC0xLTEtNjg3NjY_b6db45e8-c2bd-478a-9946-29d259a2dc50">16,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d21f0289d0f4503a608e0c544fa3528_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzUtNi0xLTEtNjg3NjY_ab1635b6-9a7d-4dac-91a7-b6229b0a201f">15,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id22d0b329d7a4bb5a67d6402f8b59ed8_I20211231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzYtNC0xLTEtNjg3NjY_95074b69-6cec-4aa9-be62-2fb13da733e0">21,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib60f70f36c784daabd311b0746a76015_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzYtNi0xLTEtNjg3NjY_c7b99eac-7581-4f03-96ae-05b5dc6b78ce">23,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ca478154d99467c8fbc5952a0a6af98_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzctNi0xLTEtNjg3NjY_83d0f094-61b4-43f7-9369-8315f5f2b525">24,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzgtNi0xLTEtNjg3NjY_788556f1-afa5-445e-a523-f01acc254f96">64,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwODg_a19f90a2-c04a-4ad5-8521-e4a3499c0b4e" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.462%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incurred claims and allocated claims adjustment expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzMtNi0xLTEtNjg3NjY_4c71fd93-20de-4aca-a840-4da7c12335fa">67,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: cumulative paid claims and allocated claims adjustment expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzQtNi0xLTEtNjg3NjY_6c6aeab0-c073-4883-a9ef-d25a25507260">64,189</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All outstanding liabilities before 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzUtNi0xLTEtNjg3NjY_c42f0c9c-c27c-41c1-be6a-96e1a38a62cc">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-risk and other provider payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzctNi0xLTEtNjg3NjY_d8b1d617-add7-49a2-ab47-2fb1579f5524">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzgtNi0xLTEtNjg3NjY_d4fd3864-a717-4751-8f95-98dc84136799">3,528</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_169"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:LongTermDebtTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI3MzU_ee386cf7-6257-45c7-a5c1-359fb0dffce3" continuedAt="ia388607644324eac8e996ddea87af5bf" escape="true">Debt </ix:nonNumeric></span></div><ix:continuation id="ia388607644324eac8e996ddea87af5bf" continuedAt="i47f1d59f117d40109c915fda6ec30ef7"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI3Mjc_fa1dfad8-2f3b-4dd7-a870-dd181cf9d1b7" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt, as of December&#160;31, 2022, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.998%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjphNWM3NGMwODM3MWM0NmRkODUwNDY4NGNjM2ZhZTVjZF80_a703ac38-9997-4647-a9bd-fc863bbebef9">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMS0xLTEtNjg3NjY_5c085cac-2121-4cd3-b5fb-e988537e5370">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMy0xLTEtNjg3NjY_34714666-d32b-405a-a281-4ca504c7e2fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtNS0xLTEtNjg3NjY_852f95cb-d106-4839-a2e5-452deda54f99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtNy0xLTEtNjg3NjY_387fc85a-d630-4307-a63e-d7b4ebbe1c22">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtOS0xLTEtNjg3NjY_6b23d9e4-4a8e-4f73-a667-85fa01d60177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMTEtMS0xLTY4NzY2_d1307908-6936-4255-8a02-a3df123b6de8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMTMtMS0xLTY4NzY2_21a6d41e-033f-4e2e-8d8d-cc6410394c77">800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjphODM3YmM3Yzc0ZDg0NWE4YjU0NzFmMjExMDJiYmFlMF80_981093a5-53dc-4dd4-bee6-323c907b5574">3.875</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMS0xLTEtNjg3NjY_e43a32fa-e2ca-4b5e-9c37-bbae57c3967b">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMy0xLTEtNjg3NjY_afe84437-fc78-468e-bc7b-69a318bdfe4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtNS0xLTEtNjg3NjY_173b892e-f3b8-4118-97ae-34a83e08d0f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtNy0xLTEtNjg3NjY_ae1d1ab7-160e-4953-afab-79b69f69b617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtOS0xLTEtNjg3NjY_9cceb408-2055-419c-99ca-3744517c6782">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMTEtMS0xLTY4NzY2_6e7969b8-28a7-4d6d-acdc-b1d5d3b6c9d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMTMtMS0xLTY4NzY2_4b79ea21-2b9f-47a7-9014-f362495dae77">650</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjpjODU1Y2FmNTYwMzE0OTIxOWM4ODgwYjU4ODgwNjNiMl80_f0731975-5da3-49e5-a53d-eac52e0cb078">3.875</ix:nonFraction>% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMS0xLTEtNjg3NjY_01800a9b-b895-4fe9-a7a6-8b5f6afcfc67">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMy0xLTEtNjg3NjY_d957f2ae-7f62-436e-ad22-0fe63c8b59a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtNS0xLTEtNjg3NjY_207eaffb-6800-4a48-82ff-806230b08bc0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtNy0xLTEtNjg3NjY_0c96a1a1-bef3-4e93-a607-052e2ec5f162">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtOS0xLTEtNjg3NjY_dbfef8d7-d2f0-4994-bb17-90c5798b20fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMTEtMS0xLTY4NzY2_d83c8d68-525b-49b8-a25e-11d2af91a883">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMTMtMS0xLTY4NzY2_ca509288-7117-458c-8068-541610f7099d">750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtMS0xLTEtNjg3NjY_52bf824d-e44b-494f-b3eb-68d77d3e4149">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtMy0xLTEtNjg3NjY_37ff9531-2aaa-4969-a7ea-2eca975bca2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtNS0xLTEtNjg3NjY_8a052aa3-f656-420b-a840-21943c2e08ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtNy0xLTEtNjg3NjY_b9cd7954-ca0f-4327-b631-e2c9965c0b6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtOS0xLTEtNjg3NjY_7f43c338-bdd6-4058-8054-d2532f73e96d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtMTEtMS0xLTY4NzY2_fb368c98-41b4-4295-abf1-56768b2df788">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtMTMtMS0xLTY4NzY2_8febd8c1-6e23-4c66-99fb-4044110e953e">2,200</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our debt is held at the parent which is reported in the Other segment. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI3NDA_c84ff8fa-f85a-4a8a-946a-c693d0b7a41d" continuedAt="i8feed63704de4cf1b1492834c936d108" escape="true">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</ix:nonNumeric></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><ix:continuation id="i8feed63704de4cf1b1492834c936d108"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzktMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjozYmUzMzhmMTRlMjA0NGViOThmM2E0ZDE5MjgwNjA0ZV80_a703ac38-9997-4647-a9bd-fc863bbebef9">4.375</ix:nonFraction>% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzktMS0xLTEtNjg3NjY_679704d2-51b1-4081-9777-d365d1928c6c">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71d56b2727844c739f8fc7c6c248b44d_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzktMy0xLTEtNjg3NjY_18d9661d-747c-43df-a778-d51ada99c13a">800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246ZGM3NDNjMjYzZWRmNDRmM2I4YTI5Nzg1ZGYxMDUxNDdfNA_981093a5-53dc-4dd4-bee6-323c907b5574">3.875</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEwLTEtMS0xLTY4NzY2_05fb42bb-75fc-4d8c-b32f-e4d15c16113d">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02c779ff61241edbb85961d0ca9c5eb_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEwLTMtMS0xLTY4NzY2_5a78aa46-2467-4fb5-8102-e4e5910bd548">650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzExLTAtMS0xLTY4NzY2L3RleHRyZWdpb246N2QyNGVlZmQxYjI3NDdhMzk1ZTE5NTBjZTM5YjRmZWNfNA_f0731975-5da3-49e5-a53d-eac52e0cb078">3.875</ix:nonFraction>% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzExLTEtMS0xLTY4NzY2_9632a681-383b-4326-8ec8-19d22955fa79">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd32afbbde514f44b74fc5c5bac8e578_I20211231" decimals="-6" name="moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzExLTMtMS0xLTY4NzY2_9f2660df-b0c2-4d32-9ac1-b27b89fb0d68">750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEyLTEtMS0xLTY4NzY2_e528c89f-6bf9-473b-a43f-06fd6ea54bdc">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEyLTMtMS0xLTY4NzY2_f64da1ea-5a84-45e7-876b-6692b2d467c1">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEzLTEtMS0xLTY4NzY2_df9e11cd-4d0e-418a-9d6c-749fe63b30ec">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEzLTMtMS0xLTY4NzY2_3f494480-cf80-444c-8d09-53c7514d0fd7">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (the &#8220;Credit Agreement&#8221;) which includes a revolving credit facility (&#8220;Credit Facility&#8221;) of $<ix:nonFraction unitRef="usd" contextRef="i0a8a1bfa4d2646619b114fd4ca9f2f3c_I20221231" decimals="INF" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzUyNQ_006f7fd1-6484-4311-9e98-32b2ba2255af">1.0</ix:nonFraction> billion, among other provisions. The Credit Agreement has a term of <ix:nonNumeric contextRef="i894911675af3435aaff732b2e986f5cb_D20220101-20221231" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzU4OA_7a54d8b6-e1d7-4dd6-a2a1-6249e9921be5">five years</ix:nonNumeric>, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i47f1d59f117d40109c915fda6ec30ef7" continuedAt="i3ddb90ce89b24a029007d3914cfd8871"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of December&#160;31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of December&#160;31, 2022, <ix:nonFraction unitRef="usd" contextRef="i0a8a1bfa4d2646619b114fd4ca9f2f3c_I20221231" decimals="INF" name="us-gaap:LineOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzEyMjA_dc5c66fb-1309-4a32-bcb9-4b8b593d7e2f">no</ix:nonFraction> amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzE4NTU_a703ac38-9997-4647-a9bd-fc863bbebef9">4.375</ix:nonFraction>% Notes due 2028. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have $<ix:nonFraction unitRef="usd" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzE4ODI_9960008d-e9be-425f-b50d-9d98e8920799">800</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzE5MzQ_a703ac38-9997-4647-a9bd-fc863bbebef9">4.375</ix:nonFraction>% Notes&#8221;) outstanding as of December 31, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIwNTk_a703ac38-9997-4647-a9bd-fc863bbebef9">4.375</ix:nonFraction>% per annum, is payable semiannually in arrears on June 15 and December 15. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIxMzc_981093a5-53dc-4dd4-bee6-323c907b5574">3.875</ix:nonFraction>% Notes due 2030. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have $<ix:nonFraction unitRef="usd" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIxNjQ_e43a32fa-e2ca-4b5e-9c37-bbae57c3967b">650</ix:nonFraction> million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIyMTY_981093a5-53dc-4dd4-bee6-323c907b5574">3.875</ix:nonFraction>% Notes due 2030&#8221;) outstanding as of December 31, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIzNTQ_981093a5-53dc-4dd4-bee6-323c907b5574">3.875</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"><ix:continuation id="i3ddb90ce89b24a029007d3914cfd8871" continuedAt="id469f8eb8a444f2d8a091d63db31a784"><ix:nonFraction unitRef="number" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI0MzA_f0731975-5da3-49e5-a53d-eac52e0cb078">3.875</ix:nonFraction>% Notes due 2032.</ix:continuation></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="id469f8eb8a444f2d8a091d63db31a784"> We have $<ix:nonFraction unitRef="usd" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="-6" name="us-gaap:DebtInstrumentCarryingAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI0NTc_79f7e3dc-8db9-4f6b-8931-d5a7adf17cff">750</ix:nonFraction>&#160;million aggregate principal amount of senior notes (the &#8220;<ix:nonFraction unitRef="number" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI1MDk_f0731975-5da3-49e5-a53d-eac52e0cb078">3.875</ix:nonFraction>% Notes due 2032&#8221;) outstanding as of December 31, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of <ix:nonFraction unitRef="number" contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI2NDI_e2f91aab-38e9-4c84-bc47-aacf1109257c">3.875</ix:nonFraction>% per annum, is payable semiannually in arrears on May 15 and November 15.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_172"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2NzI_d288e239-fb0a-4160-9ef2-22ef39d4d69b" continuedAt="i969be9b95ccc4ce1b7d6511b478363a8" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="i969be9b95ccc4ce1b7d6511b478363a8" continuedAt="ic81316058fd64e9e856ec6acc7380826"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2Mjk_fff08f00-9ff7-4a16-969c-c8ebb36c1a76" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for continuing operations consisted of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzUtMS0xLTEtNjg3NjY_ba25c051-0c06-4496-807f-7b63e77bfc96">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzUtMy0xLTEtNjg3NjY_88d793db-e625-4ef5-96bc-0ef1a68f8d55">209</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzUtNS0xLTEtNjg3NjY_c479704e-81ee-4a1f-b6fe-638ecb62dc58">281</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzYtMS0xLTEtNjg3NjY_bca9ae94-701d-4ded-ac2a-184358cd0812">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzYtMy0xLTEtNjg3NjY_416fa5eb-fa17-46c0-b69a-a2582a70a3c3">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzYtNS0xLTEtNjg3NjY_4b0d71a1-1472-475c-b44f-e739c0ce253c">26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzgtMS0xLTEtNjg3NjY_5479eb75-8347-4de9-a15c-6d85632cb7c2">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzgtMy0xLTEtNjg3NjY_12872700-1fd8-4cfc-9193-1b4a559c360d">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzgtNS0xLTEtNjg3NjY_976ae34b-8fc1-4e41-8cb6-eb401954bed3">307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEwLTEtMS0xLTY4NzY2_3b927445-c222-4052-a875-b10380d184e7">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEwLTMtMS0xLTY4NzY2_28e7795d-238b-42ea-8f55-d2ef0ea95da0">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEwLTUtMS0xLTY4NzY2_1550ba99-fce0-408b-8124-d76e81a0c3a0">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzExLTEtMS0xLTY4NzY2_ab083e05-4793-4f16-a7c5-d096675afead">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzExLTMtMS0xLTY4NzY2_be3f564d-1b61-4784-b7c4-59ca53523691">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzExLTUtMS0xLTY4NzY2_ad3cd2c6-4671-48fb-9230-ecb84317974a">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEyLTEtMS0xLTY4NzY2_b30fdc50-162c-4d07-b6e0-6ab5aa1ae793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEyLTMtMS0xLTY4NzY2_6155e7ea-20d9-4142-8a78-b31e298b4888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEyLTUtMS0xLTY4NzY2_fd83a00b-1b29-4ef6-9593-cc7b1485d4d8">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEzLTEtMS0xLTY4NzY2_1c5330e9-f634-4b0d-bfff-6e21aca379df">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEzLTMtMS0xLTY4NzY2_c388186a-551d-42bf-adb8-4f1f603fadb6">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEzLTUtMS0xLTY4NzY2_c215b5d0-978a-4853-965e-58de07d414d6">19</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzE0LTEtMS0xLTY4NzY2_7c616015-4918-4e99-88db-8cccb21f7cd9">271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzE0LTMtMS0xLTY4NzY2_2a219bbc-5c77-43ca-b8f8-588310aebeae">216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzE0LTUtMS0xLTY4NzY2_e112fe34-c769-4352-ae21-8e1921e16a85">288</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2NTA_e163a890-dea3-4e38-a0b3-7f1c7bf2f8e2" escape="true"><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate for continuing operations is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory federal tax (benefit) rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzItMS0xLTEtNjg3NjY_c67264ed-abe8-44c3-9897-bb2e032bab42">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzItMy0xLTEtNjg3NjY_8e2d3c9f-c425-436a-9f12-cadf97270b94">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzItNS0xLTEtNjg3NjY_ce0ca12b-e088-4c3d-bcbe-1c92913e5f6e">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income provision (benefit), net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzMtMS0xLTEtNjg3NjY_995426c2-3ec5-4f8e-8e3d-dff8ffc83de5">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzMtMy0xLTEtNjg3NjY_e15c225f-b949-4350-a525-9d873ea60763">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzMtNS0xLTEtNjg3NjY_5cc292ce-f4d3-4c70-b051-8b89794c73b1">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible health insurer fee (&#8220;HIF&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="3" name="moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzUtMS0xLTEtNjg3NjY_e2afb186-5187-4567-9028-0c95bc63e36e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="3" name="moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzUtMy0xLTEtNjg3NjY_3e28f713-4aed-4f71-8f19-2d7d90f62f25">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="3" name="moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzUtNS0xLTEtNjg3NjY_00016ebf-431c-42e1-9aa6-40234ee0aac0">6.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzYtMS0xLTEtNjg3NjY_6977a189-b7d6-49c6-8a57-d0fd56cddfa9">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzYtMy0xLTEtNjg3NjY_64ac5ca8-1c74-4bf0-bf66-45b5a68c2e7d">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzYtNS0xLTEtNjg3NjY_2d8f3aaa-8346-47c1-8cd0-419a74b3f66c">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzgtMS0xLTEtNjg3NjY_c404dbdd-6884-45fd-9284-11bf754bf1a9">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzgtMy0xLTEtNjg3NjY_91ab957d-2417-40b3-92bb-d8793c66f92b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzgtNS0xLTEtNjg3NjY_8072aefa-3eff-43d6-80e1-b525cd1da42b">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective tax expense rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzktMS0xLTEtNjg3NjY_f60e5b85-e300-410b-b507-c0b1c0be54a9">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzktMy0xLTEtNjg3NjY_6af1dff3-0128-43a9-a301-97478c90819e">24.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzktNS0xLTEtNjg3NjY_d2bb60fe-fb8f-4791-bc24-e49a46663f03">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic81316058fd64e9e856ec6acc7380826" continuedAt="i5408a8e4967c4e4eb4455895fbfb8e02"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was not impacted by the HIF in 2022 and 2021 given it was repealed for years after 2020. Our effective tax rate is based on expected income, statutory tax rates, and tax planning opportunities available to us in the various jurisdictions in which we operate. Management estimates and judgments are required in determining our effective tax rate. We are routinely under audit by federal, state, or local authorities regarding the timing and amount of deductions, nexus of income among various tax jurisdictions, and compliance with federal, state, foreign, and local tax laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are classified as non-current. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2Mzk_4f65fd76-72ea-4616-99f4-afa5312c673e" continuedAt="ic5d3e45e64e244a6b702fdaeb7a646ea" escape="true">Significant components of our deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:1pt;margin-top:6pt"><ix:continuation id="ic5d3e45e64e244a6b702fdaeb7a646ea"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and reserve liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzQtMS0xLTEtNjg3NjY_57aa728a-5d25-4663-a0ee-b15160da9c7a">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzQtMy0xLTEtNjg3NjY_1bc982d7-4e92-480d-8fbc-b4b20b28665f">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued medical costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzUtMS0xLTEtNjg3NjY_19206740-de74-4cf0-9b5a-be248e4ebad2">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzUtMy0xLTEtNjg3NjY_89fda064-511d-420b-a9a1-7a6ddc994be6">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzYtMS0xLTEtNjg3NjY_4fc4a11a-9169-415b-b732-c1217decd818">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzYtMy0xLTEtNjg3NjY_1d93e8ce-b833-41d3-ba4d-439b3d15ae17">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzgtMS0xLTEtNjg3NjY_702024b6-24b4-426d-a485-728680c99a44">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzgtMy0xLTEtNjg3NjY_a87342ce-5eb4-445f-b45c-35f12342386d">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease financing obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzktMS0xLTEtNjg3NjY_563d4701-8b93-4200-85fb-cc9e396e127c">40</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzktMy0xLTEtNjg3NjY_f90d3984-d6d5-468b-8ada-6cbabe029db1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzktMS0xLTEtNzYyNjI_47a568ec-2003-47d0-bedc-c4ff232bdead">49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzktMy0xLTEtNzYyNjI_6458bec5-56e3-48e1-8eb1-c26b86374bb5">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets and intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:DeferredTaxAssetsFixedAssetsAndIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzExLTEtMS0xLTc2MjQ5_377c3410-a087-4cbf-a44b-5a319dd584d6">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:DeferredTaxAssetsFixedAssetsAndIntangibles" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzExLTMtMS0xLTc2MjQ5_5c8c8262-39e0-4962-91c2-e7ba4d2eb58b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credit carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEwLTEtMS0xLTY4NzY2_f94f10a3-6781-4c91-8550-2fae8f7cbd49">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEwLTMtMS0xLTY4NzY2_924acac0-6b1a-490f-b787-08861445ed5b">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzExLTEtMS0xLTY4NzY2_46df43fc-4752-4059-86f1-f413dece9d65">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzExLTMtMS0xLTY4NzY2_d1b9b787-dfaa-4f33-b13c-a8c0f0f3cb04">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEyLTEtMS0xLTY4NzY2_e26a4c64-6211-46bb-9c7e-aa1bd591d032">18</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEyLTMtMS0xLTY4NzY2_8b8926a4-2ff6-43e4-8dba-791a74566927">10</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax assets, net of valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEzLTEtMS0xLTY4NzY2_3d361c30-21d4-4d4d-9393-f4bd4c764e01">235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEzLTMtMS0xLTY4NzY2_39560853-edbc-485a-a829-4698bb90deb3">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets and intangibles</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="moh:DeferredTaxLiabilitiesFixedAssetsAndIntangibles" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE0LTEtMS0xLTY4NzY2_9e04018e-b8f8-4aec-a753-a658428d79aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="moh:DeferredTaxLiabilitiesFixedAssetsAndIntangibles" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE0LTMtMS0xLTY4NzY2_6b76d660-05f3-41bd-a065-ff46447ec953">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE1LTEtMS0xLTY4NzY2_c58ca582-4c4e-4b28-9957-fa50ea33f92f">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE1LTMtMS0xLTY4NzY2_7c7a7156-bad9-4f58-af5c-0b676b6499ce">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE4LTEtMS0xLTY4NzY2_504592e7-43f8-49a2-b06b-91dc6535b9d6">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE4LTMtMS0xLTY4NzY2_f7961210-724c-4892-bfb8-8d789ac6b6f4">14</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE5LTEtMS0xLTY4NzY2_cc22ad2a-6e0f-450f-899b-7274482fc292">220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE5LTMtMS0xLTY4NzY2_423bdf41-567b-44d6-8018-1ad39f31e7c0">106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had state net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="ia92d461677b3467aad6b5cb1343d01b8_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzEwNzE_d015b4cc-c31c-4a1c-94d9-13eef0233cd2">95</ix:nonFraction>&#160;million, which begin expiring in 2036.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had foreign net operating loss carryforwards of $<ix:nonFraction unitRef="usd" contextRef="i7209f6abd53942d2b14fad2f133eb977_I20221231" decimals="-6" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzExNjM_c6813111-fffd-4f85-8618-ede05cf6b08e">8</ix:nonFraction>&#160;million, which expire in 2032. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had foreign tax credit carryovers of $<ix:nonFraction unitRef="usd" contextRef="i7209f6abd53942d2b14fad2f133eb977_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzEyMzc_f3579c99-952d-4238-95fc-97e298491c87">5</ix:nonFraction>&#160;million, which expire in 2030.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the need for a valuation allowance taking into consideration the ability to carry back and carry forward tax credits and losses, available tax planning strategies and future income, including reversal of temporary differences. We have determined that as of December&#160;31, 2022, $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:TaxCreditCarryforwardValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzE1MzY_77e8d575-c530-487f-b121-e4f1e162a866">18</ix:nonFraction> million of deferred tax assets did not satisfy the recognition criteria. Therefore, we increased our valuation allowance by $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzE2NTU_0b895f97-8ec4-4321-bac3-a9467c25a0cd">8</ix:nonFraction> million, from $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzE2NjQ_98cea435-ee51-4647-b5fd-d0d66a270b5d">10</ix:nonFraction> million at December&#160;31, 2021, to $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzE2Nzc_645c585c-fd9f-432d-933d-0828b476c52e">18</ix:nonFraction> million as of December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits only if the tax position is more likely than not to be sustained. We are subject to income taxes in the United States, Puerto Rico, and numerous state jurisdictions. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. We establish reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these reserves in light of changing facts and circumstances, such as the outcome of tax audits. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5408a8e4967c4e4eb4455895fbfb8e02" continuedAt="i41c777495927444a85dcfa66b65bef76"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2NDU_0fa7a091-5aa2-42e1-8d6b-eec0ae80aff1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The roll forward of our unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzQtMS0xLTEtNjg3NjY_82c71ca3-5a62-4bf3-aa2d-d7c2c21c49bf">15</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzQtMy0xLTEtNjg3NjY_b60ceabd-03a5-48c0-9a58-17827eb0f672">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzQtNS0xLTEtNjg3NjY_a80845d4-b61e-4942-9123-4e6ff0fcd78e">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzktMS0xLTEtNjg3NjY_760693f1-8bd8-4bda-bb68-a3486433aa40">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzktMy0xLTEtNjg3NjY_8b9384ce-fd5f-4976-9149-0695ba79f0eb">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzktNS0xLTEtNjg3NjY_a8fbb30d-52a1-4149-af20-00a9fcef8160">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzEwLTEtMS0xLTY4NzY2_bbef2222-e9c5-4f73-a8f7-e0854bd18e56">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzEwLTMtMS0xLTY4NzY2_2b66cddd-b8cc-44b0-8428-4352edc20ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzEwLTUtMS0xLTY4NzY2_4aa764d7-852e-4bf6-b9d6-3949a86c721d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzExLTEtMS0xLTY4NzY2_6fd9e9f5-de31-42fc-895e-b648f707a861">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzExLTMtMS0xLTY4NzY2_022cd1e8-af10-48f7-aa8d-9a3fc24a8240">15</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzExLTUtMS0xLTY4NzY2_ae065a44-7dea-4d58-aa12-6627907d217e">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits at December&#160;31, 2022, 2021 and 2020 that, if recognized, would affect the effective tax rates is $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzI4NjI_269821e2-91d3-41f0-b292-b220193cc466">5</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzI4NjY_08516455-4be9-40a9-b515-8a8d846f59d2">15</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzI4NzQ_771f08d1-dc99-4126-bc25-cca58f9d77bd">20</ix:nonFraction> million, respectively. We expect that during the next 12 months it is reasonably possible that unrecognized tax benefit liabilities may decrease by $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzMwMjg_bf70b3f3-7128-43eb-9e18-071a721cd980">5</ix:nonFraction> million due to resolution of a state refund claim. The state refund claim will not result in a cash payment for income taxes if our claim is denied. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continuing practice is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense. Amounts accrued for the payment of interest and penalties as of December&#160;31, 2022, 2021 and 2020 were insignificant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to examination by the IRS for calendar years after 2018. With a few exceptions, which are immaterial in the aggregate, we no longer are subject to state, local, and Puerto Rico tax examinations for years before 2018. </span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i41c777495927444a85dcfa66b65bef76">On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for the tax years beginning on or after January 1, 2023. We do not expect such tax provisions to have a material impact on our consolidated financial results.</ix:continuation> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_175"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ1MTY_aff4c520-6ddb-4f80-a539-2d112bb6004d" continuedAt="i3664e2c82f62464182587cde39367b14" escape="true">Stockholders' Equity</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:continuation id="i3664e2c82f62464182587cde39367b14" continuedAt="ida66c45a9174406f80ec1a9af1f70ad9"> </ix:continuation></span></div><ix:continuation id="ida66c45a9174406f80ec1a9af1f70ad9" continuedAt="i9764a494f9884ece9da347644db559d0"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Programs</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, our board of directors authorized the purchase of up to $<ix:nonFraction unitRef="usd" contextRef="if0857a373c3b4a04a563c80433da37a7_I20221130" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3Xzc2OTY1ODE0MDAxODg_bb1014f9-9675-48df-ac5b-8d4328813611">500</ix:nonFraction>&#160;million, in the aggregate, of our common stock. This new program supersedes the stock purchase program previously approved by our board of directors in September 2021, as described below. This new program will be funded with cash on hand and extends through December 31, 2023. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately <ix:nonFraction unitRef="shares" contextRef="i231fe0f403304e04821105e21c970d54_D20221001-20221231" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzcxNDY4MjU1ODY5ODI_ef831229-e7cc-41d9-8214-411f0349c839">590,000</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="i231fe0f403304e04821105e21c970d54_D20221001-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzcxNDY4MjU1ODY5Njg_6f57e73e-beb3-47df-9c0e-81851d1c32b6">200</ix:nonFraction>&#160;million in the fourth quarter of 2022 (average cost of $<ix:nonFraction unitRef="usdPerShare" contextRef="i231fe0f403304e04821105e21c970d54_D20221001-20221231" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzcxNDY4MjU1ODY5NTk_cd78829d-e96b-43e0-8534-56c86a0525d5">339.06</ix:nonFraction> per share). <ix:nonFraction unitRef="shares" contextRef="ic666c8c846a6470fa80b6fd8546e1fb8_D20230101-20230213" decimals="INF" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQzOTgwNDY1MTkwMTA_99e04cf8-61c2-4000-b7c6-44e3284071e6">No</ix:nonFraction> shares have been purchased in 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, our board of directors authorized the purchase of up to $<ix:nonFraction unitRef="usd" contextRef="i0d872067ad8c4dfdb6ad4e01a7b702fc_I20210930" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzExMg_6628e404-ecf7-4de5-ab49-d158fd0f0f2c">500</ix:nonFraction>&#160;million, in the aggregate, of our common stock. This program was funded with cash on hand. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately <ix:nonFraction unitRef="shares" contextRef="icf47a0c9203348a4a82289677971cd52_D20220401-20220630" decimals="-3" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzcyMw_776241d2-51ba-47a4-98f8-0ffa59f59e56">658,000</ix:nonFraction> shares for $<ix:nonFraction unitRef="usd" contextRef="icf47a0c9203348a4a82289677971cd52_D20220401-20220630" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzczNw_f35bb311-10d5-462d-83b1-df76f84e33cf">200</ix:nonFraction>&#160;million in the second quarter of 2022 (average cost of $<ix:nonFraction unitRef="usdPerShare" contextRef="icf47a0c9203348a4a82289677971cd52_D20220401-20220630" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3Xzc4Nw_8826a3b6-3ec0-4e04-a994-bff0e522e812">304.13</ix:nonFraction> per share). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our employee stock plans, approximately <ix:nonFraction unitRef="shares" contextRef="i71b7d1ac171e4a1480d0d094dfc1146d_D20220101-20221231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3Xzg4Nw_0962cd75-5d83-4d3c-8def-931ff1253e7f">755,000</ix:nonFraction> shares and <ix:nonFraction unitRef="shares" contextRef="i748536bf845448ec8b3a8851a8779612_D20210101-20211231" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzkwMQ_f4a666d4-6476-4c7d-ac34-ac46b3e578aa">429,000</ix:nonFraction> shares of common stock were issued, net of shares used to settle employees&#8217; income tax obligations, during the years ended December&#160;31, 2022, and 2021, respectively. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ1MDU_6fdbeacc-dbbb-4cb4-95ef-a23572da1f78" continuedAt="i37431f0cbb364cb6b67cdfffaf3b42e6" escape="true">Total share-based compensation expense is reported in &#8220;General and administrative expenses&#8221; in the accompanying consolidated statements of income, and summarized below.</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:center"><ix:continuation id="i37431f0cbb364cb6b67cdfffaf3b42e6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.190%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs and PSUs (defined below)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730ca96dd7ca4ca290d11ea041a783c7_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtMS0xLTEtNjg3NjY_04298830-ec7d-4b27-b779-f9548a21892a">97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730ca96dd7ca4ca290d11ea041a783c7_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtMy0xLTEtNjg3NjY_e37d0d37-1828-4d29-95ac-d51ad2576f73">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d9217daf844c889c548acff4d0a65a_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtNS0xLTEtNjg3NjY_54a2c1f0-d29e-4f7f-bb00-ac8298fe1e14">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07d9217daf844c889c548acff4d0a65a_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtNy0xLTEtNjg3NjY_a532fa53-b382-4a3e-bda7-34e3260b5587">62</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic983aeae5acc408cb7dab92ea09a8f01_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtOS0xLTEtNjg3NjY_915c2b06-c85e-4ad1-a8cc-e543e648eac3">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic983aeae5acc408cb7dab92ea09a8f01_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtMTEtMS0xLTY4NzY2_f776e283-5fda-4d30-b773-582c0d8c2681">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan and stock options </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31147c355a2444291af45d631a17138_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtMS0xLTEtNjg3NjY_f1cedd72-d091-4fa2-801d-c049f1d97e04">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31147c355a2444291af45d631a17138_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtMy0xLTEtNjg3NjY_d6494a8e-5049-48a4-a803-d7c7f8d7e7b6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b98d941fd8447b4b70e3c1c0b270359_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtNS0xLTEtNjg3NjY_115f5275-d53f-491f-b606-0c0d43857f46">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b98d941fd8447b4b70e3c1c0b270359_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtNy0xLTEtNjg3NjY_237d75de-6f95-4c3c-beee-205919faaf9f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49563c89a0044495a4024b953890bdec_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtOS0xLTEtNjg3NjY_cd6bdba9-9a1f-414f-ad21-e6dee00fe683">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i49563c89a0044495a4024b953890bdec_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtMTEtMS0xLTY4NzY2_d9647ade-afb4-4dea-98ae-5de95a8f8af1">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctMS0xLTEtNjg3NjY_1f86c11d-b94e-432c-8625-00cbc7f713ce">103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctMy0xLTEtNjg3NjY_63609a0f-6c48-42c3-afbc-905ca1a315e1">96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctNS0xLTEtNjg3NjY_d5409122-f1e5-4b5d-aa05-ba80424a80cf">72</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctNy0xLTEtNjg3NjY_b826e812-55ec-4518-9d5a-821271cd4ca9">68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctOS0xLTEtNjg3NjY_45662c36-a795-4558-a863-61ebee7f043a">57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctMTEtMS0xLTY4NzY2_863e5cd1-5ee6-4e2e-a13d-bf832e17efdb">53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9764a494f9884ece9da347644db559d0" continuedAt="i2f30c5a56d7a4158a0f230041ed49dc5"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had employee equity incentives outstanding under our 2019 Equity Incentive Plan (the &#8220;2019 EIP&#8221;). The 2019 EIP provides for awards, in the form of restricted stock awards (&#8220;RSAs&#8221;), performance units (&#8220;PSUs&#8221;), stock options, and other stock&#8211; or cash&#8211;based awards, to eligible persons who perform services for us. The 2019 EIP provides for the issuance of up to <ix:nonFraction unitRef="shares" contextRef="i808268ffa68b43739052deba1dced859_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzE2NDM_94b3581f-ef4a-4050-82c5-dd1943484b99">2.9</ix:nonFraction> million shares of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. RSAs and PSUs are granted with a fair value equal to the market price of our common stock on the date of grant, and generally vest in equal annual installments over periods up to <ix:nonNumeric contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzE4Nzk_312452ee-231b-4ad1-a832-0c1bf7e8257c">four years</ix:nonNumeric> from the date of grant. PSUs vest in their entirety at the end of <ix:nonNumeric contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ1MTg_964dd54d-1a33-4c38-8e3e-a44371c1419f">three-year</ix:nonNumeric> performance periods, if their performance conditions are met. We generally recognize expense for RSAs and PSUs on a straight-line basis. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0OTA_43ea4779-4fb3-4dac-beec-41b289fa3721" continuedAt="i6f2717f829c3418782074d2e724cd4bb" escape="true">Activity for stock-based awards in the year ended December&#160;31, 2022, is summarized below.</ix:nonNumeric></span></div><div style="margin-top:6pt"><ix:continuation id="i6f2717f829c3418782074d2e724cd4bb"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:40.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.038%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.041%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1e073e88099741bfbc940e573293e498_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzEtMS0xLTEtNjg3NjY_2acef134-2e08-4b82-9bc7-203d8405c1e1">539,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1e073e88099741bfbc940e573293e498_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzEtMy0xLTEtNjg3NjY_98d6b75b-1a1b-42a2-914e-a571a389920a">169.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i290c59f46b35464aaccca35307808b88_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzEtNS0xLTEtNjg3NjY_2fed292a-8f0e-4345-b40d-689bde5160a9">275,050</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i290c59f46b35464aaccca35307808b88_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzEtNy0xLTEtNjg3NjY_4819f9a6-7e2b-4e5c-b6a7-72fe0013e8c9">129.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzItMS0xLTEtNjg3NjY_ad6862c0-e2f9-446b-a918-335a49dfcef3">237,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzItMy0xLTEtNjg3NjY_fee5a0ea-cac9-4764-89c2-0f7c86504daf">312.27</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzItNS0xLTEtNjg3NjY_02263c42-309d-440f-b1bd-cda68625f3f6">271,270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzItNy0xLTEtNjg3NjY_960184b7-9697-4dd0-b01a-2b6d8f543670">214.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzMtMS0xLTEtNjg3NjY_d538f9cd-7f3e-4bad-9911-3adda20448cc">224,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzMtMy0xLTEtNjg3NjY_d2529df9-a5ca-4325-b82b-cf5f34ce43fc">156.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzMtNS0xLTEtNjg3NjY_474be74f-1227-4445-98c3-67f75e07f620">219,674</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzMtNy0xLTEtNjg3NjY_37139b63-5250-4cb8-a860-56ba5acf0949">137.54</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzQtMS0xLTEtNjg3NjY_0d51948c-47b5-489f-870f-25207aae9c6e">41,257</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzQtMy0xLTEtNjg3NjY_53b5789b-85d5-424b-be9a-dd556c056787">224.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzQtNS0xLTEtNjg3NjY_1b344029-409c-4238-86f8-4bec4eb4c0eb">13,816</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzQtNy0xLTEtNjg3NjY_e33d7b5f-688e-45e1-9aa4-d612adaa215b">249.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia92853bb15c348949754087573c60ee1_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzUtMS0xLTEtNjg3NjY_7b5d5ee0-050d-4d46-a431-c2e88316e335">511,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia92853bb15c348949754087573c60ee1_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzUtMy0xLTEtNjg3NjY_bf7d0d06-324e-4f8b-868e-a9321174c701">237.10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i781d050a46354e80ade11c0f5bf7feda_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzUtNS0xLTEtNjg3NjY_f73d15ad-3a32-4fe7-8cb8-e8b33efabe0b">312,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i781d050a46354e80ade11c0f5bf7feda_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzUtNy0xLTEtNjg3NjY_52df243f-2bd4-4370-94d1-36b5013a5734">193.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></ix:continuation></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation expense related to unvested RSAs and PSUs was $<ix:nonFraction unitRef="usd" contextRef="ia92853bb15c348949754087573c60ee1_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzIyNzY_feb24c38-a1f9-44d5-8c0d-d7054df4e7ee">74</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="i781d050a46354e80ade11c0f5bf7feda_I20221231" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzIyODQ_3a5a90c1-118c-491f-9c9c-57b6fd590550">31</ix:nonFraction> million, respectively, which we expect to recognize over a remaining weighted-average period of <ix:nonNumeric contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzIzNzU_f9e4cb2f-00b1-4ec4-b51a-94ca81f55920">2.0</ix:nonNumeric> years, and <ix:nonNumeric contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzIzODM_ed28f414-09ad-48a6-9567-f58c2e830797">0.7</ix:nonNumeric> years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of <ix:nonFraction unitRef="number" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="3" name="moh:UnrecognizedCompensationForfeitedRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzI0Nzc_b6de3406-f582-41c3-847f-503e4dedd473">9.2</ix:nonFraction>% for non-executive employees as of December&#160;31, 2022, based on actual forfeitures over the last <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzI1NjA_b553b8d6-14cf-4a5e-8e22-c8af7747ce61">4</ix:nonNumeric> years. </span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ1MDI_18f9d423-65ad-4962-b88f-6418e4b4eae7" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value of awards granted and vested is presented in the following table.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:64.492%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzUtMS0xLTEtNjg3NjY_3ba41f75-993d-48f4-bbf6-357e615b4d05">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd67479e4964d2fa6a1a3d75f41f688_D20210101-20211231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzUtMy0xLTEtNjg3NjY_88e16328-2172-41b0-8430-ae3fba0df509">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e2d29204efe4a1ca22aeb31da2ce2ac_D20200101-20201231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzUtNS0xLTEtNjg3NjY_c74d725c-588f-4d5a-a2fe-304032d862c5">44</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzYtMS0xLTEtNjg3NjY_d22a1813-fe61-40cc-ac6d-6d115c850f3c">43</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ee1afc55d64732912318aa5e962ea8_D20210101-20211231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzYtMy0xLTEtNjg3NjY_db7bfdc9-6ac5-4edf-8547-ce0f1e0e3843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if47f80d012ad40879d50cdef41999002_D20200101-20201231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzYtNS0xLTEtNjg3NjY_a29f867e-efad-49b3-8ffd-753e00f1d541">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total granted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzctMS0xLTEtNjg3NjY_b31ae6e8-a245-4e1b-b6a9-963c99a0879e">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzctMy0xLTEtNjg3NjY_d9d0586a-ce5c-4c02-a23c-c796f34ac530">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzctNS0xLTEtNjg3NjY_17440b84-fce0-4333-b198-7f171ec4f297">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzktMS0xLTEtNjg3NjY_cd089b93-10f3-4bad-91c8-5d16a2f3a91f">70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbd67479e4964d2fa6a1a3d75f41f688_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzktMy0xLTEtNjg3NjY_5090b2fd-9853-440e-9689-fd24f6118549">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e2d29204efe4a1ca22aeb31da2ce2ac_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzktNS0xLTEtNjg3NjY_d667e27f-61cd-4de2-9337-450eb0125b67">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzEwLTEtMS0xLTY4NzY2_8f619007-da56-4026-b6cc-54c40251e000">69</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1ee1afc55d64732912318aa5e962ea8_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzEwLTMtMS0xLTY4NzY2_7a4ab5f0-28bf-4d74-964c-341c699311ea">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if47f80d012ad40879d50cdef41999002_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzEwLTUtMS0xLTY4NzY2_8c779076-494d-4968-9c17-54043dec6340">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total vested</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzExLTEtMS0xLTY4NzY2_ddd9e216-fefc-4cca-ba73-2215882799ad">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzExLTMtMS0xLTY4NzY2_9ae036fa-858f-40d6-8f7b-e6e78e14a5e7">124</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzExLTUtMS0xLTY4NzY2_b4e52554-5dc7-4c3b-a248-791dff8f7f60">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to <ix:nonNumeric contextRef="i3d6e9c94477f48d3bda9237fd401466b_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM0MzE_2487ba68-b939-4175-9f7c-53e8dcfe8d2f">four years</ix:nonNumeric> from the date of grant, and have a maximum term of <ix:nonNumeric contextRef="i3d6e9c94477f48d3bda9237fd401466b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM0ODU_f73588df-d4c6-4d0b-959d-d9a24bae8023">ten years</ix:nonNumeric> from the date of grant. Stock option activity for the year ended December&#160;31, 2022, is summarized below.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.724%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.402%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.502%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual term</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Per share)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzMtMS0xLTEtNjg3NjY_55537420-29c1-45e4-a7ba-68940c98227d">395,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzMtMy0xLTEtNjg3NjY_7ee71989-2326-405d-b455-fc2e93cb67a5">65.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzQtMS0xLTEtNjg3NjY_192b9017-13a7-432a-a37b-bcd93d96bbf5">390,000</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzQtMy0xLTEtNjg3NjY_e8d86db3-dbb7-4673-9150-83906b10227b">66.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, vested, and exercisable as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzUtMS0xLTEtNjg3NjY_07cc177f-acfc-4676-ac93-f4217c8039be">5,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzUtMy0xLTEtNjg3NjY_5cc16fa5-5c4c-4731-a57f-482be0a395bb">33.02</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzUtNS0xLTEtNjg3NjY_17c2e2ad-3057-46bb-90fd-7e5c0f149ac9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzUtNy0xLTEtNjg3NjY_42534f1f-4416-4de3-8d52-52582ba4434b">0.2</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM1OTM_6ef84d8f-c84b-4576-9131-64736ce7fd26"><ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM1OTM_8c11630a-5093-4c48-bb0c-ea7b3efbdf56"><ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM1OTM_f66559a0-31f0-416f-8fa9-4fee45bf0d7b">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> stock options were granted in 2022, 2021, or 2020, and <ix:nonFraction unitRef="shares" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM2NDU_4fb994ac-916d-4ead-b897-bbe5f794285a"><ix:nonFraction unitRef="shares" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM2NDU_59629280-3c12-495e-a78c-0943f5bc1587">no</ix:nonFraction></ix:nonFraction> stock options were exercised in 2020. As of December&#160;31, 2022, there was <ix:nonFraction unitRef="shares" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM3MTE_8221bd09-64e9-4c05-83bc-7d06866cbca0">no</ix:nonFraction> unrecognized compensation expense related to unvested stock options.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i2f30c5a56d7a4158a0f230041ed49dc5"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Stock Purchase Plans (&#8220;ESPP&#8221;)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our ESPP, eligible employees may purchase common shares at <ix:nonFraction unitRef="number" contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" decimals="INF" name="moh:FairMarketValueOfCommonStockPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM4ODc_0cb35148-60cf-49b2-bf67-2e25202c10d1">85</ix:nonFraction>% of the lower of the fair market value of our common stock on either the first or last trading day of each <ix:nonNumeric contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" name="us-gaap:StockRepurchaseProgramPeriodInForce1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0OTM_77b3845e-2163-4a4b-a815-9a0264d68b65">six-month</ix:nonNumeric> offering period. Each participant is limited to a maximum purchase of $<ix:nonFraction unitRef="usd" contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" decimals="INF" name="moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQwNzU_c6d4cbec-39ce-48cf-ac15-a92ee8dd565c">25,000</ix:nonFraction> (as measured by the fair value of the stock acquired) per year through payroll deductions. We estimate the fair value of the stock issued using a standard option pricing model. For the years ended December&#160;31, 2022, 2021, and 2020, the inputs to this model were as follows: risk-free interest rates of approximately <ix:nonFraction unitRef="number" contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQzNzU_19a53967-010c-4af9-85ca-02036908c255">0.1</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQzODE_4e784145-7110-4513-900c-79dd7aebc896">2.5</ix:nonFraction>%; expected volatility of approximately <ix:nonFraction unitRef="number" contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0MjI_94afc44b-d61c-46ab-b5b9-6316f69bdd84">29</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0Mjg_595a6ee5-7df2-4fcd-a26d-d43937588385">54</ix:nonFraction>%, dividend yields of <ix:nonFraction unitRef="number" contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0NTE_5a4815ed-2901-49ab-867d-4aa2f5b4511a">0</ix:nonFraction>%, and an average expected life of <ix:nonNumeric contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0ODc_75945e50-ddd6-4665-abf3-fcd6f7500406">0.5</ix:nonNumeric> years.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_178"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzgxNw_29286b1b-94c4-4def-b689-42e4c3c17ec6" continuedAt="i1a04dc57530c406190c046606f4d53a2" escape="true">Employee Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="i1a04dc57530c406190c046606f4d53a2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor defined contribution 401(k) plans that cover substantially all employees of our company and its subsidiaries. Eligible employees are permitted to contribute up to the maximum amount allowed by law. We match up to the first <ix:nonFraction unitRef="number" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzI0Ng_ff5f43db-680b-425d-a265-4cd5bcd2be46">4</ix:nonFraction>% of compensation contributed by employees. Expense recognized in connection with our contributions to the 401(k) plans amounted to $<ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzM3OQ_2174951b-36de-4818-9d57-3d3bf70ec640">45</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzM4Mw_af2820d5-c38a-45de-b38c-68dd9e161f5e">41</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzM5MQ_c2ae37ea-66a0-449c-b5dd-922d4f55bd01">28</ix:nonFraction> million in the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a non-qualified deferred compensation plan for certain key employees. Under this plan, eligible participants may defer portions of their base salary and bonus to provide tax-deferred growth. The deferrals are distributable based upon termination of employment or other periods, as elected under the plan and were $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5Xzc3MA_5675932c-87b0-44b9-9d59-f54f11303ca1">26</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i863e60c11f294d5382a62b168dc11650_I20211231" decimals="-6" name="us-gaap:DeferredCompensationPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5Xzc3Nw_85a0731f-ec4f-4c35-a63d-1d1de7199417">23</ix:nonFraction>&#160;million as of December&#160;31, 2022 and 2021, respectively.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_181"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzQ5Mjg_3c23b71a-f67e-4e05-aeb7-e2eac9a9b9c4" continuedAt="i4acdf96462534d5c9cf484d24db839f6" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i4acdf96462534d5c9cf484d24db839f6" continuedAt="id7f0192a6cdb4e42894b1211880d3575"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Capital Requirements and Dividend Restrictions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health plans, which are generally operated by our respective wholly owned subsidiaries in those states in which our health plans operate, are subject to state laws and regulations that, among other things, require the maintenance of minimum levels of statutory capital, as defined by each state. The National Association of Insurance Commissioners (&#8220;NAIC&#8221;), has adopted rules which, if implemented by the states, set minimum capitalization requirements for insurance companies, HMOs, and other entities bearing risk for healthcare coverage. The requirements take the form of risk-based capital (&#8220;RBC&#8221;) rules which may vary from state to state. Regulators in some states may also enforce capital requirements that require the retention of net worth in excess of amounts formally required by statute or regulation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the states in which our health plans operate, except California, Florida, Massachusetts and New York, have adopted the RBC rules. The minimum statutory capital requirements in these states is based on a percentage of annualized premium revenue, a percentage of annualized health care costs, a percentage of certain liabilities, or other financial ratios. The RBC rules, if adopted by California, Florida, Massachusetts or New York, could increase the minimum capital required for those states. Our Massachusetts health plan maintains a $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-6" name="us-gaap:SpecialAssessmentBond" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzEyMDc_f40eb991-ca4d-4390-a905-2556746ee963">35</ix:nonFraction>&#160;million performance bond, effective through December 31, 2023, to partially satisfy minimum net worth requirements in that state.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutes, regulations and informal capital requirements also restrict the timing, payment, and amount of dividends and other distributions that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based on current statutes and regulations, the net assets in these subsidiaries, which may not be transferable to us in the form of loans, advances, or cash dividends was approximately $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-8" name="us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzE4NDA_a6380136-ec56-42ec-8f5f-6fec71af0854">3.1</ix:nonFraction> billion at December&#160;31, 2022. Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments held by the parent company&#8212;Molina Healthcare, Inc. Such cash, cash equivalents and investments amounted to $<ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzIyMjA_c1aa0b10-112c-41cf-acd7-0e16724bd486">375</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzIyMjc_b8c4aef9-ce9b-4f43-8fe9-56ee793b1762">348</ix:nonFraction> million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our health plans had aggregate statutory capital and surplus of approximately $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzIzNDk_faee2582-453c-44b7-8525-4d4e63176467">3.3</ix:nonFraction> billion, which was in excess of the required minimum aggregate statutory capital and surplus of approximately $<ix:nonFraction unitRef="usd" contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231" decimals="-8" name="us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzI0NTQ_c0808833-4e32-4954-a9e7-3f48a3ebeb53">2.3</ix:nonFraction> billion. We have the ability and commitment to provide additional capital to each of our health plans when necessary to ensure that statutory capital and surplus continue to meet regulatory requirements. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id7f0192a6cdb4e42894b1211880d3575"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic and, as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously billed and collected revenues. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&#160; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. On September 9, 2022, the Kentucky Court of Appeals ruled that, with regard to the earlier Circuit Court ruling granting Anthem relief, the Circuit Court should not have invalidated the 2020 procurement and thus should not have awarded a contract to Anthem. Anthem has sought discretionary review by the Kentucky Supreme Court of the ruling by the Court of Appeals. Pending further Court order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#8220;MHPR&#8221;) filed a complaint asserting, among other claims, breach of contract against Puerto Rico Health Insurance Administration (&#8220;ASES&#8221;). On September 13, 2021, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. This matter remains subject to significant additional proceedings, and no prediction can be made as to the outcome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Professional Liability Insurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry medical professional liability insurance for healthcare services rendered in the primary care institutions that we manage. In addition, we carry managed care errors and omissions insurance for all managed care services that we provide.</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_184"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16. <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90ZXh0cmVnaW9uOjZiMzRjZmRjNDA4MDQ5ZWI5ODRlN2UxM2QxYzJiZDM2XzIxMDk_85e552af-a5ca-4046-97e2-de6801b310c4" continuedAt="i5229d27ffde142d0b69f41bfa6ee8cd9" escape="true">Segments </ix:nonNumeric></span></div><ix:continuation id="i5229d27ffde142d0b69f41bfa6ee8cd9" continuedAt="i954a7fe79cf442cb9c41a106b51f3ae9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have <ix:nonFraction unitRef="segment" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90ZXh0cmVnaW9uOjZiMzRjZmRjNDA4MDQ5ZWI5ODRlN2UxM2QxYzJiZDM2XzIxMjE_4dc4206e-d596-4dc3-b529-37f7fd5cf75b">four</ix:nonFraction> reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes long-term services and supports consultative services in Wisconsin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i954a7fe79cf442cb9c41a106b51f3ae9"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment since this is not a metric used to assess segment performance or allocate resources.</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90ZXh0cmVnaW9uOjZiMzRjZmRjNDA4MDQ5ZWI5ODRlN2UxM2QxYzJiZDM2XzIxMzc_cada62c5-9a79-4974-9997-3c1e3ac8e1a4" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:59.280%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.622%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzUtMS0xLTEtNjg3NjY_ff269a74-246e-4aee-a2b1-7febdc46499f">25,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzUtMy0xLTEtNjg3NjY_54cae4fc-30df-47d5-8d70-c7cd50ad44e0">21,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzUtNS0xLTEtNjg3NjY_e03fadeb-a161-444a-bae2-3e7b7e0a0f3c">15,217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzYtMS0xLTEtNjg3NjY_7fda5472-9d29-4b2b-aca0-9bf159693dda">3,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzYtMy0xLTEtNjg3NjY_27c675aa-437f-48e0-8daf-efc72af4c53a">3,379</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzYtNS0xLTEtNjg3NjY_447a8e79-1226-41bf-9a92-8b9aed117994">2,529</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzctMS0xLTEtNjg3NjY_d4f0dccc-53e9-45fa-bda4-250334bcdc56">2,296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzctMy0xLTEtNjg3NjY_baa0a165-9601-4e35-92ff-db3dd2297517">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzctNS0xLTEtNjg3NjY_0c3fa5d6-9632-4a38-ab93-46119d051838">1,677</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0e6e336cc2457895f26a4b547de184_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzgtMS0xLTEtNjg3NjY_9ffd397b-cd61-4971-9361-1a0a3e0af4af">71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83f163bbbec4901a4db9c0cd3b6beae_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzgtMy0xLTEtNjg3NjY_b75f7d59-87ce-41b8-995c-9ec78ddb1ddf">70</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0d5667fa1324091ae2ef23e403af7b3_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzgtNS0xLTEtNjg3NjY_d5a14577-a3c5-4180-b9a6-f1fa0a210f14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzktMS0xLTEtNjg3NjY_c3d9f34f-4d28-4caa-a56d-000c4e1e1867">31,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzktMy0xLTEtNjg3NjY_8d18e691-cdb8-47d9-87d2-2b0361fbd3bc">27,771</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzktNS0xLTEtNjg3NjY_f1f80ffd-ea19-4a1c-881f-70b39ce81a57">19,423</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income tax expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzUtMS0xLTEtNjg3NjY_63814a28-b33a-4c36-ab13-740f81a41d17">2,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzUtMy0xLTEtNjg3NjY_c6cf4cfa-4908-4226-9a17-2994868a1142">2,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzUtNS0xLTEtNjg3NjY_4d0faecb-b191-42ef-ba49-17cf44edd337">1,804</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzYtMS0xLTEtNjg3NjY_eb9f429e-7d9a-47a9-b3dc-045c5d146602">437</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzYtMy0xLTEtNjg3NjY_4a7c8bef-7a3f-466a-85dc-7eb77e1aee3d">430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzYtNS0xLTEtNjg3NjY_ac2952d2-928c-452f-85fb-051890d643ed">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzctMS0xLTEtNjg3NjY_dac43ecf-1f4b-4c30-ad6b-9cb5c7265fbb">290</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzctMy0xLTEtNjg3NjY_d501c79a-1fb5-41a3-9ad0-6c370ab3038e">399</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzctNS0xLTEtNjg3NjY_42c30783-227d-45ca-b4e3-2b4197b3c9b5">324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba0e6e336cc2457895f26a4b547de184_D20220101-20221231" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzgtMS0xLTEtNjg3NjY_8cb87cbd-d79d-4eae-89aa-4c63dc34ae7b">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83f163bbbec4901a4db9c0cd3b6beae_D20210101-20211231" decimals="-6" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzgtMy0xLTEtNjg3NjY_4237a644-28d4-4c5c-8bd2-db85d7ae0546">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0d5667fa1324091ae2ef23e403af7b3_D20200101-20201231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzgtNS0xLTEtNjg3NjY_17cd5d1b-94fc-42f9-9b82-491b2935fefb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63c5437de6ea46768cb132375cf8d34c_D20220101-20221231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzktMS0xLTEtNjg3NjY_49f2f414-38e4-4580-a108-292f968e021a">3,719</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e239d54c717494dbfa7e61bb51ad771_D20210101-20211231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzktMy0xLTEtNjg3NjY_b54e3155-961a-4d63-bd3e-8fab3af9e5a0">3,165</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i077768d476524c85ac1e4304def5f128_D20200101-20201231" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzktNS0xLTEtNjg3NjY_862957d5-8a7a-4bb2-bebf-1c9d30c9eca1">2,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fdd93fd019b4782acece4fa6c2d7a43_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEwLTEtMS0xLTY4NzY2_54692b9d-c303-4dea-8f06-691018ceaf2a">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fcaf49be0f49c4851f37e732bfb025_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEwLTMtMS0xLTY4NzY2_64e2a37b-7142-4e41-98cb-fd6de5cf6d77">846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8578fffd2f7a460688cbe76bc35b7b1a_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEwLTUtMS0xLTY4NzY2_1683686a-31d6-4502-b49a-d286b3ac0e2e">1,124</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9fdd93fd019b4782acece4fa6c2d7a43_D20220101-20221231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzExLTEtMS0xLTY4NzY2_d11d8b7a-81f7-414b-bd25-4db02200a417">3,566</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41fcaf49be0f49c4851f37e732bfb025_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzExLTMtMS0xLTY4NzY2_6fd8829d-9d43-46b7-a484-5a9faa2f3315">2,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8578fffd2f7a460688cbe76bc35b7b1a_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzExLTUtMS0xLTY4NzY2_f09bd8ad-c785-4ed2-8e42-5ca7357e6830">2,525</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEyLTEtMS0xLTY4NzY2_4c18caf1-9d24-4f03-83db-65a16d48b274">1,173</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEyLTMtMS0xLTY4NzY2_0e8e3b73-7593-4ff1-b97c-c897c81c41cd">1,020</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEyLTUtMS0xLTY4NzY2_224527f7-04cf-4ba5-91f3-49436d4a57b5">1,078</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEzLTEtMS0xLTY4NzY2_4f8dd8a5-8e70-4add-b5a6-efc175b54b0a">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEzLTMtMS0xLTY4NzY2_98b0e8b1-0648-4ce8-9ffb-fccef1b46b10">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEzLTUtMS0xLTY4NzY2_4f351aa7-0f95-47dc-b0a2-7c670c726970">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzE0LTEtMS0xLTY4NzY2_ce635ff6-ef85-4886-93ca-c548e260f1d9">1,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzE0LTMtMS0xLTY4NzY2_f3d4da33-5f48-4035-bc29-3627a98ae08f">875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzE0LTUtMS0xLTY4NzY2_535b31ba-da56-4857-8d7f-826ff2ca8b3e">961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, Marketplace risk corridor judgment, investment income and other revenue.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment, and other costs.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 80</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.&#160;<ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzUxMQ_b6a06b33-d583-4429-af23-734be140c6ff" continuedAt="i50fd1c70ad1546de8914dd973de7d831" escape="true">Condensed Financial Information of Registrant </ix:nonNumeric></span></div><ix:continuation id="i50fd1c70ad1546de8914dd973de7d831" continuedAt="i4aa32b8b3a214549a597dd67a0086035"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed balance sheets as of December&#160;31, 2022 and 2021, and the related condensed statements of income, comprehensive income and cash flows for each of the three years in the period ended December&#160;31, 2022 for our parent company Molina Healthcare, Inc. (the &#8220;Registrant&#8221;), are presented below.</span></div><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="srt:ScheduleOfCondensedBalanceSheetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzU0MA_27ae3605-194b-434b-87b0-827787a969d2" escape="true"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:72.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.365%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share data)</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzYtMS0xLTEtNjg3NjY_cc5b741c-5933-4cc0-9bc1-99748498a7b7">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzYtMy0xLTEtNjg3NjY_528c4fc0-fc12-45c4-8608-bea699b61921">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzctMS0xLTEtNjg3NjY_5bb70373-99ed-4a77-8b19-5e7ed6b17a4e">46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzctMy0xLTEtNjg3NjY_006ba09d-4b43-4a70-b6f4-3dea37c4bed5">74</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzktMS0xLTEtNjg3NjY_0cfbf608-5c3a-47f1-90c1-92741b5a1180">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzktMy0xLTEtNjg3NjY_08f3e322-85b2-40ba-a716-eff3aaf87e1f">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEwLTEtMS0xLTY4NzY2_3e2c76ab-6efe-430b-9c70-935f635447f5">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEwLTMtMS0xLTY4NzY2_866ffe45-d6ad-40b5-bda6-d3ba2857153a">142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzExLTEtMS0xLTY4NzY2_586a6bf7-7d7d-4c66-8a9c-85235bb3821a">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:AssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzExLTMtMS0xLTY4NzY2_877aa4ff-9f26-4454-b3f1-fa16ce63e99a">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEyLTEtMS0xLTY4NzY2_03b103f5-e90c-4d22-8ced-a4701df20b6a">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEyLTMtMS0xLTY4NzY2_80f2ce10-04f8-44f9-a3f5-9de2f0612163">349</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill and intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEzLTEtMS0xLTY4NzY2_090c6595-abbb-4a3d-9d08-061dc2b92bbc">731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEzLTMtMS0xLTY4NzY2_555450d2-f690-4b6a-b4c1-6cfb39e4dc6d">699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE0LTEtMS0xLTY4NzY2_ea99d0bb-a611-4ecc-89b2-767f4a9e9283">4,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE0LTMtMS0xLTY4NzY2_406cd64b-8c47-4416-b836-5d81b757729c">3,772</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE1LTEtMS0xLTY4NzY2_9c7376b8-de19-451c-9de9-470dabfbd39b">37</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE1LTMtMS0xLTY4NzY2_40dd62a8-daad-4ce6-a469-bdbeb9073a93">18</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advances to related parties and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="moh:AdvancesToRelatedPartiesAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE2LTEtMS0xLTY4NzY2_4dea8eb9-25a5-4861-964c-6fe0c0a5aecd">78</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="moh:AdvancesToRelatedPartiesAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE2LTMtMS0xLTY4NzY2_fccc50ee-b2f7-470e-9a10-fd3fd56f9474">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE3LTEtMS0xLTY4NzY2_0b94a1f0-246f-4a27-90d7-3b153c7870bc">5,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE3LTMtMS0xLTY4NzY2_d6f26fdf-6d0d-4228-a859-8ff5c1322b4d">5,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIwLTEtMS0xLTY4NzY2_ec2e2f31-6b89-4876-a67d-a88a91314e87">448</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIwLTMtMS0xLTY4NzY2_9beea65a-c2db-4d84-bdd3-2e1cc98e7644">378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIxLTEtMS0xLTY4NzY2_a4ed08f8-9c67-4347-aae7-d2e529db09d7">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIxLTMtMS0xLTY4NzY2_091d2b19-bf38-40eb-9782-22d2f309017e">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIyLTEtMS0xLTY4NzY2_c6b3e0fa-200e-4cab-905e-675ff3c5a386">2,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIyLTMtMS0xLTY4NzY2_e7e2a2d5-bea2-4556-93b3-a811ef82dbfe">2,173</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIzLTEtMS0xLTY4NzY2_2a767364-8702-4ad4-b7c9-94e4fdb75d89">215</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIzLTMtMS0xLTY4NzY2_f8d6c236-a329-486e-be72-9fe3b46b407f">219</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI0LTEtMS0xLTY4NzY2_ed0994e9-4d8e-4791-8e44-a37c27f0bb03">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI0LTMtMS0xLTY4NzY2_57bf0619-cdbf-40fb-9c43-b2e677020d40">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI1LTEtMS0xLTY4NzY2_103df7be-c166-4d55-acfe-e04d082fcd5f">2,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI1LTMtMS0xLTY4NzY2_9ce09c5d-fa9c-4a54-ac89-52d61cb9ad6a">2,804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfMTk_5cb3d7e9-8f49-422f-a2ae-9059388c27ff"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfMTk_e4b5327b-2345-46dc-a0c5-af56c1960aa8">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfMzM_04a31c0e-160b-457c-84c6-08f3c9957460"><ix:nonFraction unitRef="shares" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfMzM_4e210ee2-8e4c-41af-8e7c-bc3bfabff900">150</ix:nonFraction></ix:nonFraction> million shares authorized; outstanding: <ix:nonFraction unitRef="shares" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfNjg_7b787f45-6942-40dc-8dd5-7521f48a55ca">58</ix:nonFraction> million shares at each of December 31, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTEtMS0xLTY4NzY2_877f7029-7c80-4f7c-be28-e77893fdc00d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:CommonStockValueOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTMtMS0xLTY4NzY2_6d790d07-9d70-45cd-afd0-935349931945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfMjI_a7a31557-e923-4970-9da4-564bc3be6ec2"><ix:nonFraction unitRef="usdPerShare" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfMjI_ff2c75d0-8629-4022-870c-b73963246cc1">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfMzY_cda6ec6e-3a68-40ca-ad18-2ed1bce7a19a"><ix:nonFraction unitRef="shares" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfMzY_dc26d6bc-d910-43c6-a2bb-2f36e2521ee3">20</ix:nonFraction></ix:nonFraction> million shares authorized, <ix:nonFraction unitRef="shares" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfNTg_c7d6716c-0bac-4234-beec-65fc2fdd9101"><ix:nonFraction unitRef="shares" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfNTg_e51f8e49-8280-44c2-8b09-5bac41cec5f6"><ix:nonFraction unitRef="shares" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfNTg_f5737322-676c-4eee-a0e9-351dbf32cfc1"><ix:nonFraction unitRef="shares" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfNTg_fb2b9740-96bc-4a82-b8df-5667d869d61a">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTEtMS0xLTY4NzY2_8e86df5c-d497-4ef7-9f9e-df1fdab62648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTMtMS0xLTY4NzY2_9180644a-9578-43cf-a5de-c06f1a1aa398">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI5LTEtMS0xLTY4NzY2_c4affc98-c815-4b86-a0b6-5bac74e265d5">328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI5LTMtMS0xLTY4NzY2_f09eeaa2-7063-4dcc-95b3-f033f6e7ea22">236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMwLTEtMS0xLTY4NzY2_79ad123d-57e5-4728-bc06-0942f39385de">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMwLTMtMS0xLTY4NzY2_de0648d3-d012-48d9-a653-9af25e04b2f4">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMxLTEtMS0xLTY4NzY2_e7745f4b-98f7-4b50-9dbb-19cc602ad29f">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMxLTMtMS0xLTY4NzY2_3ad213df-96d8-48b9-a5e7-6133be6b662d">2,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMyLTEtMS0xLTY4NzY2_0ccbbc11-6544-4293-97b2-4341cc227dce">2,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMyLTMtMS0xLTY4NzY2_82bd1990-5d19-4b65-afa2-3997152109a7">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMzLTEtMS0xLTY4NzY2_f2bf54db-18e3-4a33-b089-be5782d9ee1e">5,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMzLTMtMS0xLTY4NzY2_95d79646-404c-4854-8b6f-e27504cb9062">5,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4aa32b8b3a214549a597dd67a0086035" continuedAt="i62150ef57631446a9953c0f9551b9477"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="srt:ScheduleOfCondensedIncomeStatementTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzUyMw_bc34911b-a46e-4956-9ec2-6a69768f6f04" escape="true"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Income</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Administrative services fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:InsuranceAgencyManagementFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzUtMS0xLTEtNjg3NjY_1ceb96cb-2497-4a6c-8b27-5da9932f2730">1,826</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:InsuranceAgencyManagementFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzUtMy0xLTEtNjg3NjY_c04efdaf-dd9b-4fc7-b6b9-3a4c48baf314">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:InsuranceAgencyManagementFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzUtNS0xLTEtNjg3NjY_a7f31f5d-3147-41c1-99bc-7740d8caf239">1,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzYtMS0xLTEtNjg3NjY_e277ae9d-ef93-4f5a-8c6d-f52d4c191f16">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzYtMy0xLTEtNjg3NjY_f22d9f0c-4dae-4eeb-a7b6-06ad3bd8cd8a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:InterestAndDividendIncomeOperating" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzYtNS0xLTEtNjg3NjY_9b393f7a-4ffe-4924-84b9-79d7886582de">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzctMS0xLTEtNjg3NjY_86eb7e15-f632-440d-a444-3d5a8851b4be">1,834</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzctMy0xLTEtNjg3NjY_78975df0-f6ae-4066-aa33-aee88ac83b4b">1,507</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzctNS0xLTEtNjg3NjY_03159917-7abb-433e-a337-e765b904a87e">1,221</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzktMS0xLTEtNjg3NjY_1c6e556a-0bb8-491a-bc3b-6c7ff4276388">1,721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzktMy0xLTEtNjg3NjY_59ec243c-1b3c-4680-95d3-e6d98b0f31de">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzktNS0xLTEtNjg3NjY_b8866364-0d0d-4d82-b600-7c78a802a334">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEwLTEtMS0xLTY4NzY2_a44dddd2-a500-4de6-bfe8-d4a85805ea4d">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEwLTMtMS0xLTY4NzY2_4db39455-f7f0-4710-a011-a7aa674c004a">98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:DepreciationAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEwLTUtMS0xLTY4NzY2_9cfcdd1a-44bd-4ae3-8cd3-1d156ef8e505">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTEtMS0xLTc1Mjcw_5e27487f-7a95-4ef6-af75-131d09d40d93">138</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTMtMS0xLTc1Mjcw_f59f9921-725e-42d1-b90e-df2ce35f2903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTUtMS0xLTc1Mjcw_59a7493b-d72e-4731-860a-6af97ab8cf5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTEtMS0xLTY4NzY2_f8b2c509-b708-4f15-8156-2bf724cacb97">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTMtMS0xLTY4NzY2_038760f6-a5c7-413b-ae37-e655cea093e1">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTUtMS0xLTY4NzY2_916b6bba-77f4-42bc-b75d-31a3d51e0c5a">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEyLTEtMS0xLTY4NzY2_36d4c0ba-dd8a-4cd7-bd32-8d305753ada2">2,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEyLTMtMS0xLTY4NzY2_1816407f-baea-4a20-bd1d-6c8912865076">1,527</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEyLTUtMS0xLTY4NzY2_57e77d54-ca7b-46a3-8b1f-883c278dcde0">1,180</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEzLTEtMS0xLTY4NzY2_2a30064a-707f-43ce-974a-0c1abf600359">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEzLTMtMS0xLTY4NzY2_2abcc5de-d689-4b09-b80d-245fc35624d6">20</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEzLTUtMS0xLTY4NzY2_904c3f54-3ce8-49a6-87df-74350f19bf1a">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE0LTEtMS0xLTY4NzY2_06972586-38c0-4c6a-ab6b-289c4fa68a6c">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE0LTMtMS0xLTY4NzY2_bccf4a2e-668e-4460-a799-e7d65be1b631">120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE0LTUtMS0xLTY4NzY2_240c1dcb-3eaf-47c5-89bc-10a8f0c591b2">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE1LTEtMS0xLTY4NzY2_36777b9e-be3b-4692-8005-eb5a8feac83f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE1LTMtMS0xLTY4NzY2_2b6acfd8-1778-40a4-a329-84c1401dd90a">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE1LTUtMS0xLTY4NzY2_f051d4d5-c9b6-465d-9f98-71890f6473f1">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:OtherExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE2LTEtMS0xLTY4NzY2_d1ed5ad9-7a7d-41c2-b27c-e3e4a035c293">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:OtherExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE2LTMtMS0xLTY4NzY2_4260b2e7-40d0-433c-a488-ccf17334a679">145</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:OtherExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE2LTUtMS0xLTY4NzY2_b53a289a-4627-4e18-acc5-42a78bb263fa">117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax benefit and equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE3LTEtMS0xLTY4NzY2_85b7e085-457b-4b07-9206-3ffb4bde8b74">276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE3LTMtMS0xLTY4NzY2_2be757eb-d932-4a12-9bbe-f3bdb3aa30a6">165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" sign="-" name="moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE3LTUtMS0xLTY4NzY2_4a44d28a-c176-4e01-a0e6-07262f877c9b">76</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE4LTEtMS0xLTY4NzY2_91f59dd4-7969-4980-8f92-5791f19f7e87">42</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE4LTMtMS0xLTY4NzY2_3a1a902d-e749-460e-b319-41a72dbb9593">21</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE4LTUtMS0xLTY4NzY2_6241efbb-a135-496c-8d69-b7e522e3e618">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss before equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE5LTEtMS0xLTY4NzY2_57f20d90-5092-4fd6-9363-f80a5921ca91">234</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE5LTMtMS0xLTY4NzY2_66dd6115-6c2a-487a-b546-cda58db4e967">144</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" sign="-" name="moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE5LTUtMS0xLTY4NzY2_867e1fd1-b971-431e-9ab8-1b75a8c97e31">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIwLTEtMS0xLTY4NzY2_6fe30b87-494d-4e4e-8d56-2e3b682f67b2">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIwLTMtMS0xLTY4NzY2_bd12a045-4830-4487-92eb-40e0c5b5ea98">803</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:IncomeLossFromSubsidiariesNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIwLTUtMS0xLTY4NzY2_f609f1c3-0016-42ba-bb47-f165e6313d01">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIxLTEtMS0xLTY4NzY2_d99fdc40-0ec0-44b3-9956-31e7bee0fbe0">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIxLTMtMS0xLTY4NzY2_fdd32f49-9ed4-4251-ba8f-b20a11c2b12b">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIxLTUtMS0xLTY4NzY2_2e7f05c6-61f7-4b60-9385-24eeff718bf4">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzUxNQ_24e4f862-4fc9-446b-a463-c60eb53fea64" escape="true"><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Comprehensive Income</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzQtMS0xLTEtNjg3NjY_d99fdc40-0ec0-44b3-9956-31e7bee0fbe0">792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzQtMy0xLTEtNjg3NjY_fdd32f49-9ed4-4251-ba8f-b20a11c2b12b">659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzQtNS0xLTEtNjg3NjY_2e7f05c6-61f7-4b60-9385-24eeff718bf4">673</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized investment (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzYtMS0xLTEtNjg3NjY_f6b2df23-0e2f-4d32-9acc-20e226619345">204</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzYtMy0xLTEtNjg3NjY_797febcb-dc94-4653-b5ce-f15ce0d53af0">55</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzYtNS0xLTEtNjg3NjY_6c955bab-e450-461b-8adc-6d296e7b03b6">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: effect of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzctMS0xLTEtNjg3NjY_192d356b-e605-4d09-a2b3-a292c6628faf">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzctMy0xLTEtNjg3NjY_2856f618-64aa-4560-9379-8d3e2202a5f0">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzctNS0xLTEtNjg3NjY_b9efcb4d-db56-4d4e-842d-f8e164238090">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzgtMS0xLTEtNjg3NjY_d3fe85d3-bee6-4a97-b03d-1e954db58a70">155</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzgtMy0xLTEtNjg3NjY_f43f6ad8-005f-41f1-8fee-b6c7637cbc0b">42</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzgtNS0xLTEtNjg3NjY_7f19bcd4-d090-4c60-bc83-7251a18e5f0e">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzktMS0xLTEtNjg3NjY_400aadb6-e6ea-4f11-9b28-18f6c65537c5">637</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzktMy0xLTEtNjg3NjY_1e38c71a-914e-451e-8744-c3d5d276d2b3">617</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzktNS0xLTEtNjg3NjY_c619c11b-61a8-4073-bfb0-0fe6f36af224">706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div></ix:continuation><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i62150ef57631446a9953c0f9551b9477" continuedAt="id0004ff57e44433696417a12c8d04bfb"><ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="srt:ScheduleOfCondensedCashFlowStatementTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzQ5OA_9fca3ddc-4ec9-440f-bcdf-9353db2221e3" escape="true"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:59.222%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzUtMS0xLTEtNjg3NjY_01d2c612-8c9a-4bee-9fbc-777937b491cb">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzUtMy0xLTEtNjg3NjY_68c89eaa-6860-4c18-8f89-b67d2b520362">60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzUtNS0xLTEtNjg3NjY_82838605-2e75-47de-8048-ade50b4e2f9a">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital contributions to subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzctMS0xLTEtNjg3NjY_3cdb9c65-4e2a-4aee-a578-eb832d1df7d6">159</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzctMy0xLTEtNjg3NjY_7e8aae39-4b00-4201-bbb7-ee7a5db98374">440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzctNS0xLTEtNjg3NjY_a4d723ba-a4e2-4994-89c2-5e2e45bb9652">107</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends received from subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromDividendsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzgtMS0xLTEtNjg3NjY_49c1e5ff-23f7-40c2-8f04-d60f51c3012f">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromDividendsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzgtMy0xLTEtNjg3NjY_78ec2e26-fe2b-4ada-a6c8-efbee3ed9948">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromDividendsReceived" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzgtNS0xLTEtNjg3NjY_a3163a76-3f92-4514-b4d3-8c6b1197bc30">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzktMS0xLTEtNjg3NjY_113fa636-3fb7-48e1-882f-b2f2be1d60a0">29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzktMy0xLTEtNjg3NjY_2d64b50f-1404-44a8-b6d7-c8bd9459320a">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzktNS0xLTEtNjg3NjY_f6afed71-6ad8-4463-84a5-ea2dfd9d4ef1">188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEwLTEtMS0xLTY4NzY2_00727869-3b3f-4ed1-ba3e-8718b210600f">49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEwLTMtMS0xLTY4NzY2_1c491f8e-cf60-46a0-a175-66086b3ae776">21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEwLTUtMS0xLTY4NzY2_5ddc2a98-ce49-4d26-bd9d-207fd7d5c0ee">282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, equipment and capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzExLTEtMS0xLTY4NzY2_36420700-9a16-4de2-8c45-9e640d720a4b">86</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzExLTMtMS0xLTY4NzY2_7677df44-1826-4acc-8dbe-37cc96ddac89">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzExLTUtMS0xLTY4NzY2_3f52a5dc-fcd9-4cf3-ba21-1473bb107b5e">74</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid in business combinations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEyLTEtMS0xLTY4NzY2_f8e5c026-497f-41fa-8307-ef0859fc1be7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEyLTMtMS0xLTY4NzY2_aa0fc9f1-f534-486f-b952-ce96f8742481">263</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEyLTUtMS0xLTY4NzY2_a2e4e921-d63e-48df-9052-f6b8b2f3398a">1,028</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in amounts due to/from affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="moh:ChangesInAmountsDueToAndDueFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEzLTEtMS0xLTY4NzY2_25dcacad-4878-461a-8296-45bce07385c7">69</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="moh:ChangesInAmountsDueToAndDueFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEzLTMtMS0xLTY4NzY2_2ed20148-60b7-438c-b8a8-fbd1de43b5e2">40</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" sign="-" name="moh:ChangesInAmountsDueToAndDueFromAffiliates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEzLTUtMS0xLTY4NzY2_bdb3d554-17e9-49c0-9b0b-dcfa85ff16dd">68</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE0LTEtMS0xLTY4NzY2_1a28aed4-9e8f-404f-a85c-4c7968f2d490">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE0LTMtMS0xLTY4NzY2_158046f1-f19f-4283-a2b4-d476e6a9a7d6">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE0LTUtMS0xLTY4NzY2_d81c4139-659d-4296-9525-040cd40d6b1e">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE1LTEtMS0xLTY4NzY2_8cb4dae0-b0b7-4de1-a08d-323443f382ef">377</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE1LTMtMS0xLTY4NzY2_efddeb04-7fa3-4f8f-aa22-33657e11be29">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE1LTUtMS0xLTY4NzY2_89997f7e-e2d4-403f-93ac-a7535d804121">545</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE3LTEtMS0xLTY4NzY2_be8b0168-1174-44ef-af43-1507ca70595c">400</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE3LTMtMS0xLTY4NzY2_669364eb-6311-4f08-8c70-b91bd18e7f8d">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE3LTUtMS0xLTY4NzY2_7c6d7b39-36ce-4549-ace0-f4b87f084b2b">606</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld to settle employee tax obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE4LTEtMS0xLTY4NzY2_dbdd82f9-ef6b-4c75-90be-16cacd6fc8fb">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE4LTMtMS0xLTY4NzY2_13b34bc3-2a7f-434d-8c3d-639882deb762">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="moh:CommonStockWithheldToSettleEmployeeTaxObligations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE4LTUtMS0xLTY4NzY2_de44933f-b07a-4fc8-88d6-33c127df77d5">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE5LTEtMS0xLTY4NzY2_0b98a425-1fd0-4985-b964-e892aec0b4ba">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE5LTMtMS0xLTY4NzY2_daf4ac8f-a96f-450f-aee6-4c41ad9b7f60">20</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE5LTUtMS0xLTY4NzY2_ca9a799d-2bff-4361-aa30-bb5e16b33b6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from senior notes offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIwLTEtMS0xLTY4NzY2_8f47d663-12e9-4bb4-ad81-5c16f95e968c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIwLTMtMS0xLTY4NzY2_73d7c2e5-06b9-4321-8b0d-1aee8a854fcd">740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIwLTUtMS0xLTY4NzY2_d063440e-4454-44e5-b4cd-4e358fbefc4b">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIxLTEtMS0xLTY4NzY2_79941092-a777-4c9f-8e54-2437feb9b568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIxLTMtMS0xLTY4NzY2_f3c62ef8-0eb6-433a-917d-9de48948be24">723</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfSeniorDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIxLTUtMS0xLTY4NzY2_5d19530a-92a4-422e-a9bc-1f16f2d06014">338</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIyLTEtMS0xLTY4NzY2_c823802b-1600-4957-af58-6241dccdf0f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIyLTMtMS0xLTY4NzY2_5020554c-b82b-4b24-aa9d-ef1b71c04130">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfLongTermLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIyLTUtMS0xLTY4NzY2_ccdf182a-23fc-4525-aa2a-cfc12ce55ade">600</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan facility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIzLTEtMS0xLTY4NzY2_058a6127-a4f6-4d02-9435-0f7c070a86eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIzLTMtMS0xLTY4NzY2_dac23c8d-9661-4a2a-86c4-80b1ecedf4df">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromLinesOfCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIzLTUtMS0xLTY4NzY2_ca0777c2-04d5-439b-903c-7cf54f3ae127">380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial termination of warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI0LTEtMS0xLTY4NzY2_b095cab1-a8de-45b3-9a4c-a5106e04199e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfWarrants" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI0LTMtMS0xLTY4NzY2_efa9f84a-d3f4-400d-890f-0af9b86b55d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfWarrants" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI0LTUtMS0xLTY4NzY2_0f918b60-1a0f-4cde-a76f-763cc1706364">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial settlement of conversion option</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="moh:CashPaidForSettlementOfConversionOption" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI1LTEtMS0xLTY4NzY2_a51f5649-210a-4122-a2c2-da9ea9e6bdda">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="moh:CashPaidForSettlementOfConversionOption" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI1LTMtMS0xLTY4NzY2_5ac72677-a5b9-4cab-b73b-fbbb2a2a5e02">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="moh:CashPaidForSettlementOfConversionOption" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI1LTUtMS0xLTY4NzY2_0c797484-9104-4f84-9833-c26d1bc8dbe0">27</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for partial settlement of call option</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI2LTEtMS0xLTY4NzY2_74340786-90f2-477b-86ab-db7b024df88c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI2LTMtMS0xLTY4NzY2_8fa0ce51-2a9b-4ca7-a156-5f9ab01786a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI2LTUtMS0xLTY4NzY2_2e84cecb-f9eb-460a-80ec-3fa758fef209">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of principal amount of convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI3LTEtMS0xLTY4NzY2_9b9abf29-be1b-4fb6-883a-605255476b9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI3LTMtMS0xLTY4NzY2_84a07c2e-eaa9-460e-a971-b61168f7e2d6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI3LTUtMS0xLTY4NzY2_482d465b-bf62-4a38-bda7-1097ca5a0041">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI4LTEtMS0xLTY4NzY2_36837f07-851c-4431-bd7d-d4d0379c9a51">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI4LTMtMS0xLTY4NzY2_75c84eae-5c31-458f-b0c3-d6da3b817357">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI4LTUtMS0xLTY4NzY2_e7037a5b-27b5-4d32-8401-4383c57996a9">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI5LTEtMS0xLTY4NzY2_a3a9a522-c9c8-46b1-942c-7f5c104353b1">441</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI5LTMtMS0xLTY4NzY2_138f9274-f02b-4272-ac81-2823d40d9fe1">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI5LTUtMS0xLTY4NzY2_433a7514-78dd-4bd4-b508-475f5e22ad2e">217</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMwLTEtMS0xLTY4NzY2_e7d1694a-88ab-4225-aa08-e58232bf9820">55</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMwLTMtMS0xLTY4NzY2_6a14df89-3987-4a65-8afe-5a4d545caa03">301</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMwLTUtMS0xLTY4NzY2_2a7807b7-d90a-4790-b9f5-da4336d809e5">261</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMxLTEtMS0xLTY4NzY2_41850366-097a-44ca-861c-a8d5eac009cc">274</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2480da1aa27740debeb057251b13ddd3_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMxLTMtMS0xLTY4NzY2_1fdbf6b0-764c-4d11-8908-3ef16d316aed">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e83845445404707a8b2523b0d438117_I20191231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMxLTUtMS0xLTY4NzY2_2a935a52-fa7d-4742-b1ec-f68b89031498">836</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMyLTEtMS0xLTY4NzY2_223faf75-e171-4156-a82a-7c15b9bdf16d">329</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMyLTMtMS0xLTY4NzY2_22efac1e-58e0-46d3-9ebe-3ed84d489f3b">274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2480da1aa27740debeb057251b13ddd3_I20201231" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMyLTUtMS0xLTY4NzY2_59904c3c-21fb-46f2-9812-57b71dbe3f82">575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span><br/></span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_190"></div><ix:continuation id="id0004ff57e44433696417a12c8d04bfb" continuedAt="i435fd4748a164806ad967f8a9c135756"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Financial Information of Registrant </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;A&#160;- Basis of Presentation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant was incorporated in 2002. Prior to that date, Molina Healthcare of California (formerly known as Molina Medical Centers) operated as a California health plan and as the parent company for three other state health plans. In June 2003, the employees and operations of the corporate entity were transferred from Molina Healthcare of California to the Registrant. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries since the date of acquisition. The accompanying condensed financial information of the Registrant should be read in conjunction with the consolidated financial statements and accompanying notes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;B&#160;- Transactions with Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant provides certain centralized medical and administrative services to our subsidiaries pursuant to administrative services agreements that include, but are not limited to, information technology, product development </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i435fd4748a164806ad967f8a9c135756" continuedAt="i32079ca2b8584dfb941e4ba07c42e756"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administration, underwriting, claims processing, customer service, certain care management services, human resources, marketing, purchasing, risk management, actuarial, finance, accounting, compliance, legal and public relations. Fees are based on the fair market value of services rendered and are recorded as operating revenue. Payment is subordinated to the subsidiaries&#8217; ability to comply with minimum capital and other restrictive financial requirements of the states in which they operate. Charges in 2022, 2021, and 2020 for these services amounted to $<ix:nonFraction unitRef="usd" contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xOTAvZnJhZzplZGJiMGFkNWRmNmE0NjYxOGI4MmFlMjA0MjMxZDJkZS90ZXh0cmVnaW9uOmVkYmIwYWQ1ZGY2YTQ2NjE4YjgyYWUyMDQyMzFkMmRlXzExNzE_0f6f20bf-3736-4660-bf60-5e658850314d">1,826</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xOTAvZnJhZzplZGJiMGFkNWRmNmE0NjYxOGI4MmFlMjA0MjMxZDJkZS90ZXh0cmVnaW9uOmVkYmIwYWQ1ZGY2YTQ2NjE4YjgyYWUyMDQyMzFkMmRlXzExNzU_936a9954-e487-4267-afcc-d924a85a90ae">1,496</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231" decimals="-6" name="us-gaap:RevenueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xOTAvZnJhZzplZGJiMGFkNWRmNmE0NjYxOGI4MmFlMjA0MjMxZDJkZS90ZXh0cmVnaW9uOmVkYmIwYWQ1ZGY2YTQ2NjE4YjgyYWUyMDQyMzFkMmRlXzExODM_add51dbf-7c53-4c7b-94bf-4822a308bab7">1,208</ix:nonFraction> million, respectively, and are included in operating revenue. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant and its subsidiaries are included in the consolidated federal and state income tax returns filed by the Registrant. Income taxes are allocated to each subsidiary in accordance with an intercompany tax allocation agreement. The agreement allocates income taxes in an amount generally equivalent to the amount which would be expensed by the subsidiary if it filed a separate tax return. Net operating loss benefits are paid to the subsidiary by the Registrant to the extent such losses are utilized in the consolidated tax returns.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;C&#160;- Dividends and Capital Contributions </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Registrant receives dividends from its subsidiaries, such amounts are recorded as a reduction to the investments in the respective subsidiaries.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i32079ca2b8584dfb941e4ba07c42e756">For all periods presented, the Registrant made capital contributions to certain subsidiaries primarily to comply with minimum net worth requirements and to fund business combinations. Such amounts have been recorded as an increase in investment in the respective subsidiaries.</ix:continuation> </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 84</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S EVALUATION OF DISCLOSURE CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain disclosure controls and procedures, as defined in Rule 13a-15(e) and Rule 15d-15(e) under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), that are designed to provide reasonable assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to provide reasonable assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer or persons performing similar functions, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of any possible controls and procedures.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the supervision and with the participation of our management, including our chief executive officer and our chief financial officer, we carried out an evaluation of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Form 10-K pursuant to Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act. Based on this evaluation, our chief executive officer and our chief financial officer concluded that our disclosure controls and procedures were effective as of December&#160;31, 2022, at the reasonable assurance level. In addition, management concluded that our consolidated financial statements included in this Annual Report on Form 10-K are fairly stated in all material respects in accordance with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) for each of the periods presented herein.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANAGEMENT&#8217;S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rule&#160;13a-15(f) under the Exchange Act. Our internal control over financial reporting includes those policies and procedures that (1)&#160;pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (2)&#160;provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and (3)&#160;provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on our financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements prepared for external purposes in accordance with GAAP. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the effectiveness of our internal control over financial reporting to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management concluded that we maintained effective internal control over financial reporting as of December&#160;31, 2022, based on criteria described in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#8220;COSO&#8221;).</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ernst &amp; Young, LLP, the independent registered public accounting firm who audited our Consolidated Financial Statements included in this Form 10-K, has issued a report on our internal control over financial reporting, which is included herein.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) during the quarter ended December 31, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 85</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Molina Healthcare, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Molina Healthcare, Inc.&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the &#8220;COSO criteria&#8221;). In our opinion, Molina Healthcare, Inc. (the &#8220;Company&#8221;) maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2022, based on the COSO criteria.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the consolidated balance sheets of the Company as of December&#160;31, 2022 and 2021, the related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2022, and the related notes and our report dated February&#160;13, 2023, expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control Over Financial Reporting</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Ernst&#160;&amp; Young LLP</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Angeles, California</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;13, 2023 </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 86</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">To the Stockholders and the Board of Directors of Molina Healthcare, Inc.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Molina Healthcare, Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, the&#160;related consolidated statements of income, comprehensive income, stockholders&#8217; equity and cash flows for each of the three years in the period ended December&#160;31, 2022, and the&#160;related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In&#160;our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2022, in conformity with U.S. generally accepted accounting principles. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (&#8220;PCAOB&#8221;), the Company&#8217;s internal control over financial reporting as of December&#160;31, 2022, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework), and our report dated February&#160;13, 2023, expressed an unqualified opinion thereon.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company&#8216;s management. Our&#160;responsibility is to express an opinion on the Company&#8216;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="margin-bottom:2pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current period audit of the financial statements that&#160;were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that&#160;are material to the financial statements and (2)&#160;involved our especially challenging, subjective or complex judgments. The&#160;communication of the critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Incurred but not paid (IBNP) claims reverses</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Description of the matter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">As of December&#160;31, 2022, the Company&#8217;s liability for fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;), comprised $2,597 million of the $3,528 million of Medical Claims and Benefits Payable. The Company&#8217;s IBNP liability is determined using actuarial methods that include a number of factors and assumptions, including completion factors, which seek to measure the cumulative percentage of claims expense that will have been paid for a given month of service as of the reporting date, based on historical payment patterns, and assumed health care cost trend factors, which represent an estimate of claims expense based on recent claims expense levels and healthcare cost levels. There is significant uncertainty inherent in determining management&#8217;s best estimate of completion and trend factors, which are used to calculate actuarial estimates of incurred but not paid claims.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.431%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:82.381%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">How we addressed the matter in our audit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:110%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of the Company&#8217;s controls over the process for estimating the IBNP liability. This included testing management review controls over completion and trend factor assumptions, and management&#8217;s review and approval of actuarial methods used to calculate IBNP liability, including the data inputs and outputs of those models.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:107%">To test IBNP liability, our audit procedures included, among others, testing the completeness and accuracy of data used in the calculation by testing reconciliations of underlying claims and membership data recorded in source systems to the actuarial reserving calculations, and comparing a sample of claims to source documentation. With the assistance of EY actuarial specialists, we evaluated the Company&#8217;s selection and weighting of actuarial methods by comparing the weightings used in the current estimate to those used in prior periods and those used in the industry for the specific types of insurance. To evaluate significant assumptions used by management in the actuarial methods, we compared assumptions to current and historical claims trends, to those used historically and to current industry benchmarks. We also compared management&#8217;s recorded IBNP liability to a range of reasonable IBNP estimates calculated independently by our EY actuarial specialists. Additionally, we performed a review of the prior period estimates using subsequent claims development, and we reviewed and evaluated management&#8217;s disclosures surrounding fee-for-service claims IBNP.</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:6pt;text-indent:24.75pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/&#160;Ernst&#160;&amp; Young LLP</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2000. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Los Angeles, California</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;13, 2023 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 88</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">OTHER INFORMATION</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_205"></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by Item 10 of Part III will be included in our Proxy Statement relating to our 2023 Annual Meeting of Stockholders (the &#8220;2023 Proxy Statement&#8221;), and is incorporated herein by reference. This information will be included in the following sections of the 2023 Proxy Statement:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PROPOSAL 1 - Election of Directors</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Information About Director Nominees</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Information About Directors Continuing in Office</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Additional Information About Directors</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Corporate Governance and Board of Directors Matters</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Information About the Executive Officers of the Company</span></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Section 16(a) Beneficial Ownership Reporting Compliance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information relating to our Code of Business Conduct and Ethics and compliance with Section 16(a) of the Exchange Act will be set forth in the 2023 Proxy Statement and is incorporated herein by reference. To the extent permissible under NYSE rules, we intend to disclose amendments to our Code of Business Conduct and Ethics, as well as waivers of the provisions thereof, on our investor relations website under the heading &#8220;Investor Information&#8212;Corporate Governance&#8221; at molinahealthcare.com. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by Item 11 of Part III will be included in the 2023 Proxy Statement in the section entitled &#8220;Executive Compensation,&#8221; and is incorporated herein by reference. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED SHAREHOLDER MATTERS</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by Item 12 of Part III will be included in the 2023 Proxy Statement in the section entitled &#8220;Security Ownership of Certain Beneficial Owners and Management,&#8221; and is incorporated herein by reference. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by Item 13 of Part III will be included in the 2023 Proxy Statement in the sections entitled &#8220;Related Party Transactions,&#8221; and &#8220;Corporate Governance and Board of Directors Matters&#8212;Director Independence,&#8221; and is incorporated herein by reference.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent registered public accounting firm is <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8yMDUvZnJhZzpmNTY3ZGYyMzlhNTg0ODBjOGU0Mzc4NTY1ODNhOWIzMi90ZXh0cmVnaW9uOmY1NjdkZjIzOWE1ODQ4MGM4ZTQzNzg1NjU4M2E5YjMyXzI0MDA_deca1926-9dd4-4a27-833f-20c098d0b293">Ernst&#160;&amp; Young LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8yMDUvZnJhZzpmNTY3ZGYyMzlhNTg0ODBjOGU0Mzc4NTY1ODNhOWIzMi90ZXh0cmVnaW9uOmY1NjdkZjIzOWE1ODQ4MGM4ZTQzNzg1NjU4M2E5YjMyXzI0MDE_4b62bdcc-df4b-4c24-ae74-66c79295687d">Los Angeles, CA</ix:nonNumeric>, Auditor Firm ID: <ix:nonNumeric contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8yMDUvZnJhZzpmNTY3ZGYyMzlhNTg0ODBjOGU0Mzc4NTY1ODNhOWIzMi90ZXh0cmVnaW9uOmY1NjdkZjIzOWE1ODQ4MGM4ZTQzNzg1NjU4M2E5YjMyXzI0MDI_b5e33f85-08e8-4b1d-a202-dbede762cb6a">42</ix:nonNumeric>. </span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information required by Item 14 of Part III will be included in the 2023 Proxy Statement in the section entitled &#8220;Fees Paid to Independent Registered Public Accounting Firm,&#8221; and is incorporated herein by reference.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:5pt;margin-top:5pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 89</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-bottom:6pt;margin-top:7.5pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The consolidated financial statements are included in this report in the section entitled &#8220;Financial Statements and Supplementary Data.&#8221;</span></div><div style="margin-bottom:6pt;margin-top:7.5pt;padding-left:47.25pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Financial Statement Schedules: </span></div><div style="margin-bottom:5pt;margin-top:5pt;padding-left:49.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Schedules for which provision is made in the applicable accounting regulations of the SEC are not required under the related instructions, are inapplicable, or the required information is included in the consolidated financial statements, and therefore have been omitted.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#828282;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBITS</span></div><div style="margin-bottom:6pt;margin-top:7.5pt;padding-left:24.75pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference is made to the accompanying &#8220;Index to Exhibits.&#8221; </span></div><div style="margin-bottom:6pt;margin-top:7.5pt;padding-left:24.75pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-bottom:6pt;margin-top:8pt"><span><br/></span></div><div style="margin-bottom:17pt;margin-top:17pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 90</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:8pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the undersigned registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on the 13th day of February, 2023.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:40.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.610%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MOLINA HEALTHCARE, INC.</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Joseph M. Zubretsky</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer<br/>(Principal Executive Officer)</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities as indicated, as of February&#160;13, 2023. </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:61.657%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td></tr><tr style="height:12pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Joseph M. Zubretsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief&#160;Executive&#160;Officer,&#160;President and Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mark L. Keim</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Maurice S. Hebert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Accounting Officer</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maurice S. Hebert</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Barbara L. Brasier</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Barbara L. Brasier</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel Cooperman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Daniel Cooperman</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Stephen H. Lockhart</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stephen H. Lockhart</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Steven J. Orlando</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Steven J. Orlando</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Ronna E. Romney</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ronna E. Romney</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard M. Schapiro</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Richard M. Schapiro</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Dale B. Wolf</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Dale B. Wolf</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Richard C. Zoretic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Richard C. Zoretic</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">                                                                                                                                                         </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 91</span></div></div></div><div id="ia6131cdf4d354d56b8257b8e26eb9181_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-bottom:6pt;margin-top:6pt"><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEX TO EXHIBITS</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits, which are furnished with this Annual Report on Form 10-K (this &#8220;Form 10-K&#8221;) or incorporated herein by reference, are filed as part of this annual report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The agreements included or incorporated by reference as exhibits to this Form&#160;10-K may contain representations and warranties by each of the parties to the applicable agreement. These representations and warranties were made solely for the benefit of the other parties to the applicable agreement and (i)&#160;were not intended to be treated as categorical statements of fact, but rather as a way of allocating the risk to one of the parties if those statements prove to be inaccurate; (ii)&#160;may have been qualified in such agreement by disclosures that were made to the other party in connection with the negotiation of the applicable agreement; (iii)&#160;may apply contract standards of &#8220;materiality&#8221; that are different from &#8220;materiality&#8221; under the applicable securities laws; and (iv)&#160;were made only as of the date of the applicable agreement or such other date or dates as may be specified in the agreement. The Company acknowledges that, notwithstanding the inclusion of the foregoing cautionary statements, it is responsible for considering whether additional specific disclosures of material information regarding material contractual provisions are required to make the statements in this Form&#160;10-K not misleading.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method&#160;of&#160;Filing</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000089843002004683/dex32.txt">Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit&#160;3.2 to registrant&#8217;s Registration Statement on Form&#160;S-1 filed December&#160;30, 2002</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000119312513124378/d494218ddef14a.htm">Certificate of Amendment to Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Appendix A to registrant&#8217;s Definitive Proxy Statement on Form DEF 14A filed March 25, 2013</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000060/a2019definitiveproxy.htm">Certificate of Amendment to Certificate of Incorporation</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Appendix A to registrant&#8217;s Definitive Proxy Statement on Form DEF 14A filed March 25, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000032/moh-12312018xex33.htm">Sixth Amended and Restated Bylaws of Molina Healthcare, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 3.3 to registrant&#8217;s Form 10-K filed February 19, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000115752320000848/a52229102ex4_1.htm">Indenture, dated as of June 2, 2020, by and between Molina Healthcare, Inc. and U.S. Bank National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 4.1 to registrant&#8217;s Form 8-K filed June 2, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000115752320000848/a52229102ex4_1.htm">Form of 4.375% Notes (included in Exhibit 4.1).</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 4.2 to registrant&#8217;s Form 8-K filed June 2, 2020 (Included in Exhibit 4.1 to registrant&#8217;s Form 8-K filed June 2, 2020)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000115752320001511/a52328971ex4_1.htm">Indenture, dated as of November 17, 2020, by and between Molina Healthcare, Inc. and U.S. Bank National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 4.1 to registrant&#8217;s Form 8-K filed November 17, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000115752320001511/a52328971ex4_1.htm">Form of 3.875% Notes due 2030 (included in Exhibit 4.3)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 4.2 to registrant&#8217;s Form 8-K filed November 17, 2020 (Included in Exhibit 4.1 to registrant&#8217;s Form 8-K filed November 17, 2020)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992921000178/molina-indenturexfinal.htm">Indenture, dated as of November 16, 2021, by and between Molina Healthcare, Inc. and U.S. Bank National Association, as Trustee</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 4.1 to registrant&#8217;s Form 8-K filed November 16, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992921000178/molina-indenturexfinal.htm">Form of 3.875% Notes due 2032 (included in Exhibit 4.5)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:112%">Filed as Exhibit 4.2 to registrant&#8217;s Form 8-K filed November 16, 2021 (Included in Exhibit 4.1 to registrant&#8217;s Form 8-K filed November 16, 2021)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001179929/000117992921000024/descriptionofregistrantsse.htm">Description of Registrant&#8217;s Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 4.9 to registrant&#8217;s Form 10-K filed February 16, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000115752320000874/a52231626ex10_1.htm">Credit Agreement, dated as of June 8, 2020, by and among Molina Healthcare, Inc., as the Borrower, Truist Bank, as Administrative Agent, Issuing Bank and Swingline Lender, and the Lenders party thereto</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.1 to registrant&#8217;s Form 8-K filed June 8, 2020</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000060/a2019definitiveproxy.htm">2019 Employee Stock Purchase Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Appendix C to registrant&#8217;s Definitive Proxy Statement on Form DEF 14A filed March 25, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000060/a2019definitiveproxy.htm">Molina Healthcare, Inc. 2019 Equity Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Appendix B to registrant&#8217;s Definitive Proxy Statement on Form DEF 14A filed March 25, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000134/ex101_2019-rsa.htm">2019 Equity Incentive Plan - Form of Restricted Stock Award Agreement (Employee/Officer with No Employment Agreement)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.1 to registrant&#8217;s Form 10-Q filed July 31, 2019</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.523%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Method&#160;of&#160;Filing</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000134/a2019equityincentiveplan.htm">2019 Equity Incentive Plan - Form of Performance Stock Unit Award Agreement (Employee/Officer with No Employment Agreement)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.2 to registrant&#8217;s Form 10-Q filed July 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.6</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000134/ex103_2019eip-rsa.htm">2019 Equity Incentive Plan - Form of Restricted Stock Award Agreement (Officer with Employment Agreement)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.3 to registrant&#8217;s Form 10-Q filed July 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.7</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000134/ex104_2019eip-psu.htm">2019 Equity Incentive Plan - Form of Performance Stock Unit Award Agreement (Officer with Employment Agreement)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.4 to registrant&#8217;s Form 10-Q filed July 31, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0001179929/000117992921000024/a2ndamendedchangeincontrol.htm">Molina Healthcare, Inc. Second Amended and Restated Change in Control Severance Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.14 to registrant&#8217;s Form 10-K filed February 16, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.9</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000119312507054663/dex1014.htm">Form of Indemnification Agreement</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.14 to registrant&#8217;s Form 10-K filed March 14, 2007</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1179929/000117992922000025/moh4q21_examendedandrestat.htm">Molina Healthcare, Inc. Amended and Restated Deferred Compensation Plan (2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.10 to registrant&#8217;s Form 10-K filed February 14, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000119312513259609/d554295dex103.htm">Employment Agreement with Jeff Barlow dated June 14, 2013</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.3 to registrant&#8217;s Form 8-K filed June 14, 2013</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.12</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000144530513000387/moh-12312012x10kex1016.htm">Change in Control Agreement with Jeff D. Barlow, dated as of September 18, 2012</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.16 to registrant&#8217;s Form 10-K filed February 28, 2013</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001179929/000115752321001130/a52488491ex10_1.htm">Amended and Restated Employment Agreement, dated September 8, 2021, by and between Molina Healthcare, Inc. and Joseph M. Zubretsky</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.1 to registrant&#8217;s Form 8-K filed September 9, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*10.14</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1179929/000117992922000028/exhibit101_amendedemployme.htm">Amendment of Employment Agreement, dated February 16, 2022, by and between Molina Healthcare, Inc. and Joseph M. Zubretsky</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.1 to registrant&#8217;s Form 8-K filed February 16, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+10.15</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000032/moh-12312018xex1036.htm">Master Services Agreement for Information Technology Services, dated February 4, 2019, by and between Molina Healthcare, Inc. and Infosys Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.36 to registrant&#8217;s Form 10-K filed February 19, 2019<br/></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.16</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992919000160/moh-09302019ex101.htm">First Amendment, dated August 1, 2019, to the Master Services Agreement for Information Technology Services, dated February 4, 2019, by and between Molina Healthcare, Inc. and Infosys Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.1 to registrant&#8217;s Form 10-Q filed October 30, 2019</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+10.17</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/1179929/000117992922000172/exhibit101_changexreques.htm">Change Request #7 to the Master Services Agreement dated February 2, 2019, by and between Molina Healthcare, Inc. and Infosys Limited</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed as Exhibit 10.1 to registrant&#8217;s Form 10-Q filed October 27, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh4q22_ex211.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh4q22_ex231.htm">Consent of Independent Registered Public Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh4q22_ex311.htm">Section 302 Certification of Chief Executive Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh4q22_ex312.htm">Section 302 Certification of Chief Financial Officer</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh4q22_ex321.htm">Certificate of Chief Executive Officer pursuant to 18&#160;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0f7c7f;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="moh4q22_ex322.htm">Certificate of Chief Financial Officer pursuant to 18&#160;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the inline XBRL document.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cover Page Interactive Data file (formatted as Inline XBRL and embedded within Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Filed herewith</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:7.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.262%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Management contract or compensatory plan or arrangement required to be filed (and/or incorporated by reference) as an exhibit to this Annual Report on Form 10-K pursuant to Item&#160;15(b) of Form 10-K.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certain portions of this agreement have been omitted in accordance with Item 601(b)(10) of Regulation S-K. A copy of any omitted portion will be furnished to the Securities and Exchange Commission upon request. </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portions of this exhibit have been omitted pursuant to a request for confidential treatment filed with the Securities and Exchange Commission under Rule 24b-2. The omitted confidential material has been filed separately. The location of the redacted confidential information is indicated in the exhibit as &#8220;[redacted]&#8221;.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. 2022 Form 10-K | 94</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>2
<FILENAME>moh4q22_ex211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i213aab101009496b95de7852758dfe66_1"></div><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 21.1</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIST OF SUBSIDIARIES </font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.520%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.280%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Jurisdiction of Incorporation</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028 West Broadway, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MHAZ, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare Data Center, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Arizona, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Arizona</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of California</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Florida, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Georgia, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Georgia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Illinois, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Illinois</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Indiana, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Iowa, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Iowa</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Kentucky, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kentucky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Louisiana, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Louisiana</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Michigan, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Mississippi, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mississippi</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Nebraska, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nebraska</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Nevada, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nevada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of New Mexico, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Mexico</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of New York, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Ohio, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Oklahoma, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oklahoma </font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Pennsylvania, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Puerto Rico, Inc. </font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Puerto Rico&#47;Nevada</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Rhode Island Holding Company, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Rhode Island, Inc.+*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rhode Island</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of South Carolina, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">South Carolina</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Tennessee, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Texas, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Texas Insurance Company</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Utah, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Virginia, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Virginia</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Washington, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Wisconsin, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Healthcare of Wisconsin CMO, Inc.*</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Clinical Services, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Molina Care Connections, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oceangate Reinsurance, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Utah</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SWH Holdings, Inc.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Health Holdings, LLC++</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Health Holdings, Inc.+++</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AlphaCare Holdings, Inc.++++</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Whole Health of New York, Inc.+++++</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Whole Health, LLC++++</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Management Group, LLC</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wisconsin</font></td></tr></table></div><div style="margin-top:2.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 21.1</font></div><div style="text-align:right"><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;    Non-operational entity</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;    Wholly owned subsidiary of Molina Healthcare of Rhode Island Holding Company, Inc.</font></div><div style="margin-top:6pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;    Wholly owned subsidiary of SWH Holdings, Inc.</font></div><div style="margin-top:6pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+++&#160;&#160;&#160;&#160;    Wholly owned subsidiary of Senior Health Holdings, LLC</font></div><div style="margin-top:6pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++++    Wholly owned subsidiary of Senior Health Holdings, Inc. </font></div><div style="margin-top:6pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+++++  Wholly owned subsidiary of AlphaCare Holdings, Inc.</font></div><div style="margin-top:7.5pt;padding-left:24.75pt;text-align:justify"><font><br></font></div><div style="margin-top:7.5pt;padding-left:24.75pt;text-align:justify;text-indent:-22.5pt"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>moh4q22_ex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ieeea4616e32c45438ab688fda97d71eb_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">EXHIBIT 23.1  </font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:174%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-231385) pertaining to the Molina Healthcare, Inc. 2019 Equity Incentive Plan and 2019 Employee Stock Purchase Plan of our reports dated February&#160;13, 2023, with respect to the consolidated financial statements of Molina Healthcare, Inc., and to the effectiveness of internal control over financial reporting of Molina Healthcare, Inc., included in this Annual Report (Form&#160;10-K) for the year ended December&#160;31,&#160;2022. </font></div><div style="text-align:justify;text-indent:24.75pt"><font><br></font></div><div style="padding-left:54pt;padding-right:54pt;text-align:center;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">&#47;s&#47;&#160;ERNST&#160;&#38; YOUNG LLP </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">Los Angeles, California </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:174%">February&#160;13, 2023 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>moh4q22_ex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i77fbfbe336de40f4a197f234c95a1619_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph M. Zubretsky, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed the report on Form 10-Q for the period ended December&#160;31, 2022, of Molina Healthcare, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:1pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; February 13, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>moh4q22_ex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i91cf31c32b8c4c3e9690dfeb74f0e340_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a)&#47;15d-14(a)</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">UNDER THE SECURITIES EXCHANGE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ACT OF 1934, AS AMENDED</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Mark L. Keim, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed the report on Form 10-Q for the period ended December&#160;31, 2022, of Molina Healthcare, Inc.&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, the report does not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in the report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in the report&#59;</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended), and internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) of the Securities Exchange Act of 1934, as amended), for the registrant and have&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period for which this report is being prepared&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in the report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by the report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d) Disclosed in the report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and to the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.848%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.850%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; February 13, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark L. Keim</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>moh4q22_ex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i67df6d20f311445da48e2072a00d47d1_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended December&#160;31, 2022 (the &#8220;Report&#8221;), I, Joseph M. Zubretsky, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; February 13, 2023</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Joseph M. Zubretsky</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President and Director</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>moh4q22_ex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ib3afda9784434ed385c358ee6eb71661_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.2 </font></div><div style="margin-top:18pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATE PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the report of Molina Healthcare, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the period ended December&#160;31, 2022 (the &#8220;Report&#8221;), I, Mark L. Keim, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section&#160;1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:6pt;text-indent:49.5pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:43.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.622%"></td><td style="width:0.1%"></td></tr><tr style="height:39pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated&#58; February 13, 2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Mark L. Keim</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mark L. Keim</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Chief Financial Officer and Treasurer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>moh-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a6be6ee9-88ed-425c-ba06-deafc74c4611,g:0568f791-801e-41fa-b039-5982169b2ced-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:moh="http://www.molinahealthcare.com/20221231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.molinahealthcare.com/20221231">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2022" schemaLocation="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="moh-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.molinahealthcare.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.molinahealthcare.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofIncome" roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome">
        <link:definition>0000003 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000004 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000005 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000007 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000008 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentation" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation">
        <link:definition>0000009 - Disclosure - Organization and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies">
        <link:definition>0000010 - Disclosure - Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShare">
        <link:definition>0000011 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinations" roleURI="http://www.molinahealthcare.com/role/BusinessCombinations">
        <link:definition>0000012 - Disclosure - Business Combinations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements">
        <link:definition>0000013 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.molinahealthcare.com/role/Investments">
        <link:definition>0000014 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandCapitalizedSoftwareNet" roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNet">
        <link:definition>0000015 - Disclosure - Property, Equipment, and Capitalized Software, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.molinahealthcare.com/role/Leases">
        <link:definition>0000016 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNet" roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNet">
        <link:definition>0000017 - Disclosure - Goodwill and Intangible Assets, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayable" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable">
        <link:definition>0000018 - Disclosure - Medical Claims and Benefits Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://www.molinahealthcare.com/role/Debt">
        <link:definition>0000019 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.molinahealthcare.com/role/IncomeTaxes">
        <link:definition>0000020 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.molinahealthcare.com/role/StockholdersEquity">
        <link:definition>0000021 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.molinahealthcare.com/role/EmployeeBenefitPlans">
        <link:definition>0000022 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies">
        <link:definition>0000023 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Segments" roleURI="http://www.molinahealthcare.com/role/Segments">
        <link:definition>0000024 - Disclosure - Segments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedFinancialInformationofRegistrant" roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrant">
        <link:definition>0000025 - Disclosure - Condensed Financial Information of Registrant</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesPolicies" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies">
        <link:definition>0000026 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesTables" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables">
        <link:definition>0000027 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareTables">
        <link:definition>0000028 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsTables" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsTables">
        <link:definition>0000029 - Disclosure - Business Combinations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables">
        <link:definition>0000030 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.molinahealthcare.com/role/InvestmentsTables">
        <link:definition>0000031 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandCapitalizedSoftwareNetTables" roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetTables">
        <link:definition>0000032 - Disclosure - Property, Equipment, and Capitalized Software, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.molinahealthcare.com/role/LeasesTables">
        <link:definition>0000033 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetTables" roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetTables">
        <link:definition>0000034 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableTables" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables">
        <link:definition>0000035 - Disclosure - Medical Claims and Benefits Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://www.molinahealthcare.com/role/DebtTables">
        <link:definition>0000036 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.molinahealthcare.com/role/IncomeTaxesTables">
        <link:definition>0000037 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityTables">
        <link:definition>0000038 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsTables" roleURI="http://www.molinahealthcare.com/role/SegmentsTables">
        <link:definition>0000039 - Disclosure - Segments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedFinancialInformationofRegistrantTables" roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables">
        <link:definition>0000040 - Disclosure - Condensed Financial Information of Registrant (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandBasisofPresentationDetails" roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails">
        <link:definition>0000041 - Disclosure - Organization and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>0000042 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>0000043 - Disclosure - Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesReceivablesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails">
        <link:definition>0000044 - Disclosure - Significant Accounting Policies - Receivables (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails">
        <link:definition>0000045 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareDetails" roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails">
        <link:definition>0000046 - Disclosure - Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails">
        <link:definition>0000047 - Disclosure - Business Combinations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessCombinationsIntangibleAssetsDetails" roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails">
        <link:definition>0000048 - Disclosure - Business Combinations - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAdditionalInformationDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails">
        <link:definition>0000049 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails">
        <link:definition>0000050 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails">
        <link:definition>0000051 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsScheduleofInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails">
        <link:definition>0000052 - Disclosure - Investments - Schedule of Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsContractualMaturitiesDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails">
        <link:definition>0000053 - Disclosure - Investments - Contractual Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails">
        <link:definition>0000054 - Disclosure - Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsAvailableforSaleDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails">
        <link:definition>0000055 - Disclosure - Investments - Available-for-Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsBalancesofRestrictedInvestmentsDetails" roleURI="http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails">
        <link:definition>0000056 - Disclosure - Investments - Balances of Restricted Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails" roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails">
        <link:definition>0000057 - Disclosure - Property, Equipment, and Capitalized Software, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails" roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails">
        <link:definition>0000058 - Disclosure - Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails" roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails">
        <link:definition>0000059 - Disclosure - Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/LeasesNarrativeDetails">
        <link:definition>0000060 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>0000061 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowDetails" roleURI="http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails">
        <link:definition>0000062 - Disclosure - Leases - Supplemental Cash Flow (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>0000063 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseMaturitiesDetails" roleURI="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails">
        <link:definition>0000064 - Disclosure - Leases - Lease Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesLeaseMaturitiesDetails_1" roleURI="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1">
        <link:definition>0000064 - Disclosure - Leases - Lease Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails" roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails">
        <link:definition>0000065 - Disclosure - Goodwill and Intangible Assets, Net - Balances of Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails" roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails">
        <link:definition>0000066 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillandIntangibleAssetsNetAdditionalInformationDetails" roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails">
        <link:definition>0000067 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails">
        <link:definition>0000068 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableAdditionalInformationDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableAdditionalInformationDetails">
        <link:definition>0000069 - Disclosure - Medical Claims and Benefits Payable - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails">
        <link:definition>0000070 - Disclosure - Medical Claims and Benefits Payable - Components of the Change (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails">
        <link:definition>0000071 - Disclosure - Medical Claims and Benefits Payable - Medical Claims Reserve Development by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails">
        <link:definition>0000072 - Disclosure - Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails">
        <link:definition>0000073 - Disclosure - Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails" roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails">
        <link:definition>0000074 - Disclosure - Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtMaturitiesDetails" roleURI="http://www.molinahealthcare.com/role/DebtMaturitiesDetails">
        <link:definition>0000075 - Disclosure - Debt - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleofLongTermDebtDetails" roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails">
        <link:definition>0000076 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtCreditAgreementDetails" roleURI="http://www.molinahealthcare.com/role/DebtCreditAgreementDetails">
        <link:definition>0000077 - Disclosure - Debt - Credit Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtSeniorNotesDetails" roleURI="http://www.molinahealthcare.com/role/DebtSeniorNotesDetails">
        <link:definition>0000078 - Disclosure - Debt - Senior Notes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>0000079 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails" roleURI="http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails">
        <link:definition>0000080 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" roleURI="http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails">
        <link:definition>0000081 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>0000082 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitsDetails" roleURI="http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails">
        <link:definition>0000083 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityAdditionalInformationDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails">
        <link:definition>0000084 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityComponentsofSharebasedCompensationDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails">
        <link:definition>0000085 - Disclosure - Stockholders' Equity - Components of Share-based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityRestrictedandPerformanceStockActivityDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails">
        <link:definition>0000086 - Disclosure - Stockholders' Equity - Restricted and Performance Stock Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityFairValueofAwardsGrantedandVestedDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails">
        <link:definition>0000087 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityStockOptionActivityDetails" roleURI="http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails">
        <link:definition>0000088 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansDetails" roleURI="http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails">
        <link:definition>0000089 - Disclosure - Employee Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails">
        <link:definition>0000090 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsNarrativeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails">
        <link:definition>0000091 - Disclosure - Segments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsScheduleofOperatingSegmentInformationDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails">
        <link:definition>0000092 - Disclosure - Segments - Schedule of Operating Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
        <link:definition>0000093 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails">
        <link:definition>0000094 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails" roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails">
        <link:definition>0000095 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails">
        <link:definition>0000096 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails" roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails">
        <link:definition>0000097 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails">
        <link:definition>0000098 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails" roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails">
        <link:definition>0000099 - Disclosure - Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="moh_BasisOfPresentationTable" abstract="true" name="BasisOfPresentationTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthCareOrganizationRevenuePercentage" abstract="false" name="HealthCareOrganizationRevenuePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moh_RestrictionsOnInvestmentsTableTextBlock" abstract="false" name="RestrictionsOnInvestmentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_OtherClaimsPayable" abstract="false" name="OtherClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_WeightedAverageNumberofSharesShareBasedCompensation" abstract="false" name="WeightedAverageNumberofSharesShareBasedCompensation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moh_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_GainLossOnDebtRepayment" abstract="false" name="GainLossOnDebtRepayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthPlansSegmentMember" abstract="true" name="HealthPlansSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" abstract="false" name="MedicalPremiumsLiabilityMedicalCareCostsThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicaidMember" abstract="true" name="MedicaidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles" abstract="false" name="DeferredTaxLiabilitiesFixedAssetsAndIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthPlansMember" abstract="true" name="HealthPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_OperatingAndFinanceLeaseImpairmentLoss" abstract="false" name="OperatingAndFinanceLeaseImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OperatingLeaseLiabilitiesLesseeAbstract" abstract="true" name="OperatingLeaseLiabilitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_MemberListsMember" abstract="true" name="MemberListsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_PharmacyClaimsPayable" abstract="false" name="PharmacyClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" abstract="false" name="PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" abstract="false" name="AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesOther" abstract="false" name="AmountsDuetoGovernmentAgenciesOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_DepreciationAndAmortizationOfCapitalizedSoftware" abstract="false" name="DepreciationAndAmortizationOfCapitalizedSoftware" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PassportHealthPlanIncMember" abstract="true" name="PassportHealthPlanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_GovernmentReceivablesMember" abstract="true" name="GovernmentReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_UnrecognizedCompensationForfeitedRate" abstract="false" name="UnrecognizedCompensationForfeitedRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moh_EmployeeStockPurchasePlanandStockOptionsMember" abstract="true" name="EmployeeStockPurchasePlanandStockOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_HealthCareOrganizationPremiumTaxRevenue" abstract="false" name="HealthCareOrganizationPremiumTaxRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthPlanContractTerm" abstract="false" name="HealthPlanContractTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AffinityHealthPlanIncMember" abstract="true" name="AffinityHealthPlanIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_EquityIncentivePlanMember" abstract="true" name="EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_ThreePointEightSevenFivePercentSeniorNotesMember" abstract="true" name="ThreePointEightSevenFivePercentSeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" abstract="false" name="IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicareMember" abstract="true" name="MedicareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" abstract="false" name="LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ProviderNetworkMember" abstract="true" name="ProviderNetworkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" abstract="false" name="HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_FinanceLeaseLiabilitiesLesseeAbstract" abstract="true" name="FinanceLeaseLiabilitiesLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_TaxesBasedOnPremiumsPolicyTextBlock" abstract="false" name="TaxesBasedOnPremiumsPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" abstract="false" name="AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_SharesOutstandingExcludingRestrictedStockAwards" abstract="false" name="SharesOutstandingExcludingRestrictedStockAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="moh_MunicipalSecuritiesMember" abstract="true" name="MunicipalSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidOther" abstract="false" name="AmountsDueToGovernmentAgenciesMedicaidOther" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicalPremiumLiabilityDueToAgency" abstract="false" name="MedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_SummarizedPremiumRevenueTableTextBlock" abstract="false" name="SummarizedPremiumRevenueTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_CompleteCareMember" abstract="true" name="CompleteCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_CashPaidForSettlementOfConversionOption" abstract="false" name="CashPaidForSettlementOfConversionOption" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MyChoiceWisconsinMember" abstract="true" name="MyChoiceWisconsinMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" abstract="false" name="ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_OperatingLeaseAssetsLesseeAbstract" abstract="true" name="OperatingLeaseAssetsLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_OtherSecuritiesMember" abstract="true" name="OtherSecuritiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_HealthAndHumanServicesMember" abstract="true" name="HealthAndHumanServicesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" abstract="false" name="MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OtherProgramMember" abstract="true" name="OtherProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AgeWellNewYorkMember" abstract="true" name="AgeWellNewYorkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" abstract="false" name="OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" abstract="false" name="BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_FairMarketValueOfCommonStockPercentage" abstract="false" name="FairMarketValueOfCommonStockPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moh_OtherReceivablesMember" abstract="true" name="OtherReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicareProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" abstract="false" name="IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthPlanExtensionOptionPeriod" abstract="false" name="HealthPlanExtensionOptionPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_ProviderNetworksMember" abstract="true" name="ProviderNetworksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MarketplaceMember" abstract="true" name="MarketplaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" abstract="false" name="AmountsDuetoGovernmentAgenciesRiskAdjustment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_HealthCareOrganizationInsurerFeeRevenue" abstract="false" name="HealthCareOrganizationInsurerFeeRevenue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" abstract="false" name="AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_OtherMedicareProgram" abstract="false" name="OtherMedicareProgram" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ContractRightsandLicensingAgreementsMember" abstract="true" name="ContractRightsandLicensingAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_DeferredTaxAssetsFixedAssetsAndIntangibles" abstract="false" name="DeferredTaxAssetsFixedAssetsAndIntangibles" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" abstract="false" name="ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PercentageOfAdditionalIncrementalRevenueEarned" abstract="false" name="PercentageOfAdditionalIncrementalRevenueEarned" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" abstract="false" name="LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PharmacyRebateReceivablesMember" abstract="true" name="PharmacyRebateReceivablesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_FinanceLeaseCost" abstract="false" name="FinanceLeaseCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_A3875SeniorNotesMember" abstract="true" name="A3875SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_BusinessCombinationNumberOfBusinessCombinations" abstract="false" name="BusinessCombinationNumberOfBusinessCombinations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" abstract="false" name="NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_InvestmentsAverageMaturityPeriod" abstract="false" name="InvestmentsAverageMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_PropertyAndEquipmentMember" abstract="true" name="PropertyAndEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AdvancesToRelatedPartiesAndOtherAssets" abstract="false" name="AdvancesToRelatedPartiesAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" abstract="false" name="NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="moh_HealthCareOrganizationInsurerFeeExpense" abstract="false" name="HealthCareOrganizationInsurerFeeExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_PremiumTaxExpenses" abstract="false" name="PremiumTaxExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_CashPaidDuringThePeriodAbstract" abstract="true" name="CashPaidDuringThePeriodAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_OperatingIncomeGuaranteeMember" abstract="true" name="OperatingIncomeGuaranteeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_MedicalClaimsAndBenefitsPayable" abstract="false" name="MedicalClaimsAndBenefitsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_FinanceLeaseAssetsLesseeAbstract" abstract="true" name="FinanceLeaseAssetsLesseeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_RecordedInDepreciationAndAmortizationAbstract" abstract="true" name="RecordedInDepreciationAndAmortizationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" abstract="true" name="CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" abstract="false" name="LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_RestrictedandPerformanceStockMember" abstract="true" name="RestrictedandPerformanceStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_MinimumMemberEnrollmentTargetsMember" abstract="true" name="MinimumMemberEnrollmentTargetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_BasisOfPresentationLineItems" abstract="true" name="BasisOfPresentationLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract" abstract="true" name="RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_ChangesInAmountsDueToAndDueFromAffiliates" abstract="false" name="ChangesInAmountsDueToAndDueFromAffiliates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_InvestmentsMaturityPeriod" abstract="false" name="InvestmentsMaturityPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="moh_DepreciationandAmortizationContinuingOperations" abstract="false" name="DepreciationandAmortizationContinuingOperations" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_RisksAndUncertaintiesPolicyTextBlock" abstract="false" name="RisksAndUncertaintiesPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="moh_CapitationClaimsPayable" abstract="false" name="CapitationClaimsPayable" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="moh_A4375SeniorNotesMember" abstract="true" name="A4375SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" abstract="true" name="AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="moh_CommonStockWithheldToSettleEmployeeTaxObligations" abstract="false" name="CommonStockWithheldToSettleEmployeeTaxObligations" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>moh-20221231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a6be6ee9-88ed-425c-ba06-deafc74c4611,g:0568f791-801e-41fa-b039-5982169b2ced-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c647d921-8e9b-4caa-a1d2-85d74c632c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_0acf6d3b-c2fd-4d2b-8ac8-54a0a375d836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c647d921-8e9b-4caa-a1d2-85d74c632c33" xlink:to="loc_us-gaap_OperatingIncomeLoss_0acf6d3b-c2fd-4d2b-8ac8-54a0a375d836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_baa27933-26f3-42c9-b36f-e7b3cf02e5fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c647d921-8e9b-4caa-a1d2-85d74c632c33" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_baa27933-26f3-42c9-b36f-e7b3cf02e5fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f1f86b9-1d56-4568-a27a-27793308e1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b19d1506-2374-494b-9566-474742932507" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8f1f86b9-1d56-4568-a27a-27793308e1d5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b19d1506-2374-494b-9566-474742932507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85d2cea2-1b1b-4c69-becb-20086f2625d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8f1f86b9-1d56-4568-a27a-27793308e1d5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_85d2cea2-1b1b-4c69-becb-20086f2625d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5c6d7989-0b9f-492a-a524-7e23aa8be742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue_e6859392-823f-4b65-b8fc-e16151790928" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5c6d7989-0b9f-492a-a524-7e23aa8be742" xlink:to="loc_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue_e6859392-823f-4b65-b8fc-e16151790928" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_e53fce39-800e-4910-a4d0-2971a47b7e26" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5c6d7989-0b9f-492a-a524-7e23aa8be742" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_e53fce39-800e-4910-a4d0-2971a47b7e26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_58d617b1-82e3-4a7f-bfa7-70f9a1e1824e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5c6d7989-0b9f-492a-a524-7e23aa8be742" xlink:to="loc_us-gaap_NetInvestmentIncome_58d617b1-82e3-4a7f-bfa7-70f9a1e1824e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_ea0a7483-390b-48f4-8d8a-97d2c6ef988a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5c6d7989-0b9f-492a-a524-7e23aa8be742" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_ea0a7483-390b-48f4-8d8a-97d2c6ef988a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue_a33ea18d-533d-4176-80da-20a3f7aa930d" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5c6d7989-0b9f-492a-a524-7e23aa8be742" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeRevenue_a33ea18d-533d-4176-80da-20a3f7aa930d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_d9189386-67d5-4be7-aacc-1c9529352825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_5c6d7989-0b9f-492a-a524-7e23aa8be742" xlink:to="loc_us-gaap_PremiumsEarnedNet_d9189386-67d5-4be7-aacc-1c9529352825" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_ee61032b-e2a7-49ca-9526-f74b4575b4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4e4c5698-ab8a-4749-99ef-d71a027cd908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ee61032b-e2a7-49ca-9526-f74b4575b4b0" xlink:to="loc_us-gaap_CostsAndExpenses_4e4c5698-ab8a-4749-99ef-d71a027cd908" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_5a2d1835-d4e1-42ba-b74c-8da1305d49f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_ee61032b-e2a7-49ca-9526-f74b4575b4b0" xlink:to="loc_us-gaap_Revenues_5a2d1835-d4e1-42ba-b74c-8da1305d49f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_f8277f4c-5da8-4125-8e42-59484e131f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_b7ff7039-8bb5-4936-950a-601fd9b8a945" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f8277f4c-5da8-4125-8e42-59484e131f74" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_b7ff7039-8bb5-4936-950a-601fd9b8a945" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_13a54233-c560-42be-9ea2-03ce752958af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f8277f4c-5da8-4125-8e42-59484e131f74" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_13a54233-c560-42be-9ea2-03ce752958af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5e224055-835d-4836-b8ce-c581d1834ad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f8277f4c-5da8-4125-8e42-59484e131f74" xlink:to="loc_us-gaap_DepreciationAndAmortization_5e224055-835d-4836-b8ce-c581d1834ad0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_fec22eb3-cd0f-40c5-bc7d-35fda35bacf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f8277f4c-5da8-4125-8e42-59484e131f74" xlink:to="loc_us-gaap_AssetImpairmentCharges_fec22eb3-cd0f-40c5-bc7d-35fda35bacf4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_3395ad22-d343-41c8-a598-75fa68055c08" xlink:href="moh-20221231.xsd#moh_PremiumTaxExpenses"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f8277f4c-5da8-4125-8e42-59484e131f74" xlink:to="loc_moh_PremiumTaxExpenses_3395ad22-d343-41c8-a598-75fa68055c08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense_6c0d8ebb-df9c-4f8e-8975-3f3e99eea8a6" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f8277f4c-5da8-4125-8e42-59484e131f74" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeExpense_6c0d8ebb-df9c-4f8e-8975-3f3e99eea8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_de50ec84-3302-468a-836a-1bb54bac4f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_f8277f4c-5da8-4125-8e42-59484e131f74" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_de50ec84-3302-468a-836a-1bb54bac4f72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_ae6d1af0-0319-496b-97c3-3a9550655df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_539475d8-42e0-4c39-bf4a-8765cac27c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ae6d1af0-0319-496b-97c3-3a9550655df9" xlink:to="loc_us-gaap_InterestExpense_539475d8-42e0-4c39-bf4a-8765cac27c02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_64115358-9965-42c6-8fb1-04332e96024d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_ae6d1af0-0319-496b-97c3-3a9550655df9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_64115358-9965-42c6-8fb1-04332e96024d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_61dc0805-2e8b-484b-8ce9-563a95b5c99e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_ccc4208e-a288-483a-9c54-a71cca3b74c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_61dc0805-2e8b-484b-8ce9-563a95b5c99e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_ccc4208e-a288-483a-9c54-a71cca3b74c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_9b994985-3afb-46fe-acb8-30f012142010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_61dc0805-2e8b-484b-8ce9-563a95b5c99e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_9b994985-3afb-46fe-acb8-30f012142010" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_7d63892a-222b-42c0-bb52-e1b1538f5185" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_be732540-bf1a-4f67-b4ae-9760ba51b42f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7d63892a-222b-42c0-bb52-e1b1538f5185" xlink:to="loc_us-gaap_NetIncomeLoss_be732540-bf1a-4f67-b4ae-9760ba51b42f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6dddc5b0-e538-4fb5-a497-94370b24cf91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_7d63892a-222b-42c0-bb52-e1b1538f5185" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6dddc5b0-e538-4fb5-a497-94370b24cf91" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_abba1e93-6f43-483b-ad72-13936acf84f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e323bd06-ca39-4a0a-bb1e-88cff4118913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abba1e93-6f43-483b-ad72-13936acf84f2" xlink:to="loc_us-gaap_LiabilitiesCurrent_e323bd06-ca39-4a0a-bb1e-88cff4118913" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_dc61ca36-90fb-4786-8619-643e83f88da1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abba1e93-6f43-483b-ad72-13936acf84f2" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_dc61ca36-90fb-4786-8619-643e83f88da1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dca21c1e-f908-4535-bc17-4286b391a8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abba1e93-6f43-483b-ad72-13936acf84f2" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_dca21c1e-f908-4535-bc17-4286b391a8a6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c3829df9-a5db-47e9-9054-512f9292d111" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_abba1e93-6f43-483b-ad72-13936acf84f2" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c3829df9-a5db-47e9-9054-512f9292d111" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a14b47eb-d10a-4e36-a1c4-e6402116f2fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_bbf28742-90c2-458f-bb3e-3b9999254f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14b47eb-d10a-4e36-a1c4-e6402116f2fd" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_bbf28742-90c2-458f-bb3e-3b9999254f56" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fbc8afec-f4ad-4e00-8a52-9b8c45ed3bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14b47eb-d10a-4e36-a1c4-e6402116f2fd" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_fbc8afec-f4ad-4e00-8a52-9b8c45ed3bc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_d05c72bd-f9e7-4bda-82c0-6a0f9430b620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14b47eb-d10a-4e36-a1c4-e6402116f2fd" xlink:to="loc_us-gaap_ReceivablesNetCurrent_d05c72bd-f9e7-4bda-82c0-6a0f9430b620" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_374f70c3-3d39-40ff-b722-1992df7b36e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14b47eb-d10a-4e36-a1c4-e6402116f2fd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_374f70c3-3d39-40ff-b722-1992df7b36e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_08604555-4427-4109-8c0a-d73cc1135320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14b47eb-d10a-4e36-a1c4-e6402116f2fd" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_08604555-4427-4109-8c0a-d73cc1135320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_bb134d63-4274-48fc-9013-8e76712d8d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6525d814-7021-4214-9d7c-77d48afdc8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb134d63-4274-48fc-9013-8e76712d8d0b" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_6525d814-7021-4214-9d7c-77d48afdc8b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bef4ada4-9b28-4bce-b09c-27efacb88f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb134d63-4274-48fc-9013-8e76712d8d0b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_bef4ada4-9b28-4bce-b09c-27efacb88f2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_62600a45-e9b1-4b42-bf7f-3ba321ba6a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb134d63-4274-48fc-9013-8e76712d8d0b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_62600a45-e9b1-4b42-bf7f-3ba321ba6a6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_c08073f1-05fb-4e59-a5fe-b0a17f10cd1e" xlink:href="moh-20221231.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_bb134d63-4274-48fc-9013-8e76712d8d0b" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_c08073f1-05fb-4e59-a5fe-b0a17f10cd1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_51b4e3f4-a243-4e59-9da2-f9b07ebb5e17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_029fd66c-31b5-4532-a0b1-fb22565b95d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b4e3f4-a243-4e59-9da2-f9b07ebb5e17" xlink:to="loc_us-gaap_PreferredStockValue_029fd66c-31b5-4532-a0b1-fb22565b95d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25053a5e-b539-4c09-8863-f2d7e44610a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b4e3f4-a243-4e59-9da2-f9b07ebb5e17" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_25053a5e-b539-4c09-8863-f2d7e44610a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1c1e7802-1411-40c4-891b-3f906e177e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b4e3f4-a243-4e59-9da2-f9b07ebb5e17" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_1c1e7802-1411-40c4-891b-3f906e177e11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dd77a7a1-56d7-49dc-b7be-b85c00b3527b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b4e3f4-a243-4e59-9da2-f9b07ebb5e17" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dd77a7a1-56d7-49dc-b7be-b85c00b3527b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_b0e2eb79-5836-44fd-81e0-08f5b50ecddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_51b4e3f4-a243-4e59-9da2-f9b07ebb5e17" xlink:to="loc_us-gaap_CommonStockValueOutstanding_b0e2eb79-5836-44fd-81e0-08f5b50ecddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd6b9759-b669-4c0f-999f-e494b4b873e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_b91a638c-7524-4268-9289-261a9870e75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd6b9759-b669-4c0f-999f-e494b4b873e1" xlink:to="loc_us-gaap_Liabilities_b91a638c-7524-4268-9289-261a9870e75f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_eb3499ae-6c9e-487a-88d0-fad6de6c6085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_dd6b9759-b669-4c0f-999f-e494b4b873e1" xlink:to="loc_us-gaap_StockholdersEquity_eb3499ae-6c9e-487a-88d0-fad6de6c6085" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_58f708ce-b301-43cf-bb5a-cc10b0c52703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a0816ae0-0f78-469b-98e7-8a276611145c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58f708ce-b301-43cf-bb5a-cc10b0c52703" xlink:to="loc_us-gaap_AssetsCurrent_a0816ae0-0f78-469b-98e7-8a276611145c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_773c0dde-8683-42d1-9b27-49dc0b986d30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58f708ce-b301-43cf-bb5a-cc10b0c52703" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_773c0dde-8683-42d1-9b27-49dc0b986d30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_af18bccc-daa3-4614-9953-4870f78e4ec6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58f708ce-b301-43cf-bb5a-cc10b0c52703" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_af18bccc-daa3-4614-9953-4870f78e4ec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_74464683-eb48-43af-94ee-575d1406c174" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58f708ce-b301-43cf-bb5a-cc10b0c52703" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_74464683-eb48-43af-94ee-575d1406c174" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_315a61cc-4831-4027-b175-085e2d1f883d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58f708ce-b301-43cf-bb5a-cc10b0c52703" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_315a61cc-4831-4027-b175-085e2d1f883d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0ccaba63-ec03-476f-8c0a-47d3a36339bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_58f708ce-b301-43cf-bb5a-cc10b0c52703" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_0ccaba63-ec03-476f-8c0a-47d3a36339bc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f82f5138-c7cc-4887-8369-62e768ab3a14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab8f01e6-b387-4ce5-9170-1d14889b35b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f82f5138-c7cc-4887-8369-62e768ab3a14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ab8f01e6-b387-4ce5-9170-1d14889b35b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5869f81c-7178-419f-afce-51138e2fa1a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f82f5138-c7cc-4887-8369-62e768ab3a14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5869f81c-7178-419f-afce-51138e2fa1a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f3c5042-80b1-4fc0-b6c3-89dfcefa420c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_f82f5138-c7cc-4887-8369-62e768ab3a14" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_0f3c5042-80b1-4fc0-b6c3-89dfcefa420c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_40f596ab-16e7-4804-809e-3d8502e6e0bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_40f596ab-16e7-4804-809e-3d8502e6e0bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_5bd54d13-f698-4016-acae-10496be07472" xlink:href="moh-20221231.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_5bd54d13-f698-4016-acae-10496be07472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidForSettlementOfConversionOption_db450d1b-362b-44af-a010-761190f7bec1" xlink:href="moh-20221231.xsd#moh_CashPaidForSettlementOfConversionOption"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_moh_CashPaidForSettlementOfConversionOption_db450d1b-362b-44af-a010-761190f7bec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_b5794f17-496f-49ef-ae92-3173309ec1da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_b5794f17-496f-49ef-ae92-3173309ec1da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_a9c7016e-2f68-433b-bb9f-75f0a27370f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_a9c7016e-2f68-433b-bb9f-75f0a27370f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_14c67f61-74a4-4b49-9dd0-81b8c56694fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_14c67f61-74a4-4b49-9dd0-81b8c56694fb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_32126532-da5c-482c-93df-29473587ab02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_32126532-da5c-482c-93df-29473587ab02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_7af9a4e4-f8bc-4bd8-b3f8-24a2a359269e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_7af9a4e4-f8bc-4bd8-b3f8-24a2a359269e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_2a8e8290-cfc3-41ef-9d15-38ef1c4e8da7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_2a8e8290-cfc3-41ef-9d15-38ef1c4e8da7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_47b489ca-624b-497a-8aff-f1b5a049301e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_47b489ca-624b-497a-8aff-f1b5a049301e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_500bc87f-8bd9-4674-9966-c88f1d44a9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_500bc87f-8bd9-4674-9966-c88f1d44a9b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_cb131ea7-6ffe-4487-8493-a83edbb7e5f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_113a7d01-1d69-444d-a02f-548d51e36b30" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_cb131ea7-6ffe-4487-8493-a83edbb7e5f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_915ad024-5e5b-433b-afd7-6c14f1f87b77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_ShareBasedCompensation_915ad024-5e5b-433b-afd7-6c14f1f87b77" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_35ade88c-ae09-42dd-b5b8-e7093d972cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_35ade88c-ae09-42dd-b5b8-e7093d972cba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_6a5d8fce-eebd-4fa3-a43d-ab275f657221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_6a5d8fce-eebd-4fa3-a43d-ab275f657221" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_807669d7-e329-4937-8623-43751effbfcb" xlink:href="moh-20221231.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_807669d7-e329-4937-8623-43751effbfcb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6af4295b-a832-424f-9c9c-68b536f662fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6af4295b-a832-424f-9c9c-68b536f662fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_c83a0845-0d12-4907-aa0f-f47b7a25dac8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_c83a0845-0d12-4907-aa0f-f47b7a25dac8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_db718db0-592a-43c6-899d-30477bfb1fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_db718db0-592a-43c6-899d-30477bfb1fe0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3fa4825f-efcb-4dc4-a19f-4042b51b19c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_NetIncomeLoss_3fa4825f-efcb-4dc4-a19f-4042b51b19c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9d87f172-895f-4be0-ad51-bae628a636a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_9d87f172-895f-4be0-ad51-bae628a636a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_6ee9606c-26cc-4032-9596-4758f2677af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_6ee9606c-26cc-4032-9596-4758f2677af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_af6da6e4-5f03-4484-bd28-d66eb78202ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_af6da6e4-5f03-4484-bd28-d66eb78202ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GainLossOnDebtRepayment_7696185e-aaba-4622-a7ae-95eddd18547a" xlink:href="moh-20221231.xsd#moh_GainLossOnDebtRepayment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_moh_GainLossOnDebtRepayment_7696185e-aaba-4622-a7ae-95eddd18547a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_ccb7e93e-84d3-4249-9ca1-b4cc2f79f3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_ccb7e93e-84d3-4249-9ca1-b4cc2f79f3c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_1b1570ba-bcac-494a-8ed4-7cece946c731" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b1e0be3b-3f8a-4655-9894-f742e0be8346" xlink:to="loc_us-gaap_AssetImpairmentCharges_1b1570ba-bcac-494a-8ed4-7cece946c731" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_467d3943-d02b-46e9-bc6f-954e9e01d48a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9271ce94-8ada-41a3-a6db-fdd252ce7468" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_467d3943-d02b-46e9-bc6f-954e9e01d48a" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9271ce94-8ada-41a3-a6db-fdd252ce7468" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4428c10c-93c7-4255-ab46-757c1f65a510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_467d3943-d02b-46e9-bc6f-954e9e01d48a" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4428c10c-93c7-4255-ab46-757c1f65a510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_66613757-e43d-49ca-ac5a-b80556027707" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_467d3943-d02b-46e9-bc6f-954e9e01d48a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_66613757-e43d-49ca-ac5a-b80556027707" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ef8e499a-4131-4872-a988-862acf210741" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_467d3943-d02b-46e9-bc6f-954e9e01d48a" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_ef8e499a-4131-4872-a988-862acf210741" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9bd86042-cb3f-4962-8610-55e1f34b6884" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_467d3943-d02b-46e9-bc6f-954e9e01d48a" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9bd86042-cb3f-4962-8610-55e1f34b6884" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a878b94-9cb7-457e-b75e-ede513b33b83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_d4329425-f80f-4f01-8de5-2c594f81d86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a878b94-9cb7-457e-b75e-ede513b33b83" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_d4329425-f80f-4f01-8de5-2c594f81d86e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ec34805-4737-435f-b108-09d22e93a973" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9a878b94-9cb7-457e-b75e-ede513b33b83" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ec34805-4737-435f-b108-09d22e93a973" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:href="moh-20221231.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_ea59edfd-a504-48d4-b308-b08c5c3c2610" xlink:href="moh-20221231.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_ea59edfd-a504-48d4-b308-b08c5c3c2610" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_8771afed-33d7-44a4-8a03-cdd78ee754ea" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_8771afed-33d7-44a4-8a03-cdd78ee754ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_4886f7b8-0a75-4679-af3a-ac1ee0b1da21" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_4886f7b8-0a75-4679-af3a-ac1ee0b1da21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_61145ee9-5081-4414-8a04-c3014a114324" xlink:href="moh-20221231.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_61145ee9-5081-4414-8a04-c3014a114324" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_ee45fae7-4a87-48df-8510-c041c3bf01a4" xlink:href="moh-20221231.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_ee45fae7-4a87-48df-8510-c041c3bf01a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_703ecc93-70a6-48b1-86be-9c1a9e1f6b5c" xlink:href="moh-20221231.xsd#moh_OtherMedicareProgram"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:to="loc_moh_OtherMedicareProgram_703ecc93-70a6-48b1-86be-9c1a9e1f6b5c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_669c326e-bb6d-4c92-a85c-017ed87c20df" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_669c326e-bb6d-4c92-a85c-017ed87c20df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_160de39d-7e85-41f1-87c6-72978576bc45" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency_ddf74bcb-6ff5-49d5-a6b3-09f06fc89a3d" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_160de39d-7e85-41f1-87c6-72978576bc45" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#NetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b87fe08-1752-4b77-b6ee-b6f4ae3641f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_300c7d68-e39d-4571-aab3-e924fe1b8acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b87fe08-1752-4b77-b6ee-b6f4ae3641f2" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_300c7d68-e39d-4571-aab3-e924fe1b8acd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea85221e-fea5-4eba-8e39-4f66173e574e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_5b87fe08-1752-4b77-b6ee-b6f4ae3641f2" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_ea85221e-fea5-4eba-8e39-4f66173e574e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_951a8571-6d7e-4949-bee4-2224fa1edc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_68548253-a7d7-440f-9ca8-a4327817ca24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_951a8571-6d7e-4949-bee4-2224fa1edc93" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_68548253-a7d7-440f-9ca8-a4327817ca24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_2e914191-1155-46cd-b10e-49b179b274fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b1460e91-5a5f-4439-8860-04c1fb08cede" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_2e914191-1155-46cd-b10e-49b179b274fe" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_b1460e91-5a5f-4439-8860-04c1fb08cede" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsScheduleofInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_e211ce31-5c8e-4115-b530-034aae13cbd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_44291183-95fa-4dea-862c-1a427cbd2a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_e211ce31-5c8e-4115-b530-034aae13cbd4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_44291183-95fa-4dea-862c-1a427cbd2a96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_97394d15-f855-4bd8-ab93-59ec9c356cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_e211ce31-5c8e-4115-b530-034aae13cbd4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_97394d15-f855-4bd8-ab93-59ec9c356cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c6ad6504-de9b-4a08-b84f-99a9ca4db364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_e211ce31-5c8e-4115-b530-034aae13cbd4" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_c6ad6504-de9b-4a08-b84f-99a9ca4db364" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_da80b9a9-a19e-44fb-8e1d-df25059e769f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_a4f7befb-c284-4926-ad73-a52a4671a766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_da80b9a9-a19e-44fb-8e1d-df25059e769f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_a4f7befb-c284-4926-ad73-a52a4671a766" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_e24bc219-858a-4df0-853c-dd5bf7acfa29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_da80b9a9-a19e-44fb-8e1d-df25059e769f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_e24bc219-858a-4df0-853c-dd5bf7acfa29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_444f14c4-2c25-4771-9282-4240da1bc407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_da80b9a9-a19e-44fb-8e1d-df25059e769f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_444f14c4-2c25-4771-9282-4240da1bc407" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_10ccfec7-63f7-4182-b97e-9da6d8eaa651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_da80b9a9-a19e-44fb-8e1d-df25059e769f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_10ccfec7-63f7-4182-b97e-9da6d8eaa651" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2d28f0e-1779-400b-826e-8e29c8850d61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_aace7641-e62f-4204-9674-2c6e9362857f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2d28f0e-1779-400b-826e-8e29c8850d61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_aace7641-e62f-4204-9674-2c6e9362857f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a36b65fc-44a5-4e94-9b83-6725494a3508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2d28f0e-1779-400b-826e-8e29c8850d61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a36b65fc-44a5-4e94-9b83-6725494a3508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_1094b6d3-dda4-4219-b685-e9f59a2137c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2d28f0e-1779-400b-826e-8e29c8850d61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_1094b6d3-dda4-4219-b685-e9f59a2137c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_1079ae2b-7c6b-4f7c-847e-b0630243539c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_f2d28f0e-1779-400b-826e-8e29c8850d61" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_1079ae2b-7c6b-4f7c-847e-b0630243539c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8ea43e39-37bd-4ad1-92f0-2e9b9c8627f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_9db8196c-b58d-4513-9a99-458f501f14dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8ea43e39-37bd-4ad1-92f0-2e9b9c8627f3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_9db8196c-b58d-4513-9a99-458f501f14dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b2413cea-c70a-44bd-a219-fcd7317b5d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8ea43e39-37bd-4ad1-92f0-2e9b9c8627f3" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_b2413cea-c70a-44bd-a219-fcd7317b5d50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_46078bab-8710-4b0b-a7c4-b6433afa77db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_8ea43e39-37bd-4ad1-92f0-2e9b9c8627f3" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_46078bab-8710-4b0b-a7c4-b6433afa77db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18af4064-0550-41b2-930a-b281c991d5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_7881c052-cc4b-48db-bc79-203024775ae9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18af4064-0550-41b2-930a-b281c991d5d1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_7881c052-cc4b-48db-bc79-203024775ae9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_676149e2-d96a-4dcb-831a-5f879e4a452d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_18af4064-0550-41b2-930a-b281c991d5d1" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_676149e2-d96a-4dcb-831a-5f879e4a452d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_DepreciationandAmortizationContinuingOperations_cd352daf-9b42-4ef2-8ec6-54e914f1686a" xlink:href="moh-20221231.xsd#moh_DepreciationandAmortizationContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DepreciationAndAmortizationOfCapitalizedSoftware_c084333f-bf28-4778-b381-13db61208dd9" xlink:href="moh-20221231.xsd#moh_DepreciationAndAmortizationOfCapitalizedSoftware"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_DepreciationandAmortizationContinuingOperations_cd352daf-9b42-4ef2-8ec6-54e914f1686a" xlink:to="loc_moh_DepreciationAndAmortizationOfCapitalizedSoftware_c084333f-bf28-4778-b381-13db61208dd9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_151806e2-f576-43ec-818b-17960428586b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_DepreciationandAmortizationContinuingOperations_cd352daf-9b42-4ef2-8ec6-54e914f1686a" xlink:to="loc_us-gaap_Depreciation_151806e2-f576-43ec-818b-17960428586b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_4acc64bf-0420-452d-b399-548a59b52753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_DepreciationandAmortizationContinuingOperations_cd352daf-9b42-4ef2-8ec6-54e914f1686a" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_4acc64bf-0420-452d-b399-548a59b52753" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_86b576a9-ba10-426b-ae22-b93b6c227745" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_DepreciationandAmortizationContinuingOperations_cd352daf-9b42-4ef2-8ec6-54e914f1686a" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_86b576a9-ba10-426b-ae22-b93b6c227745" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_FinanceLeaseCost_e2dd7b4a-2569-49cb-bc4d-c6b2b7037d40" xlink:href="moh-20221231.xsd#moh_FinanceLeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_58703df7-605e-4a1b-90ea-ac4c9168567e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_FinanceLeaseCost_e2dd7b4a-2569-49cb-bc4d-c6b2b7037d40" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_58703df7-605e-4a1b-90ea-ac4c9168567e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_b9fb8bc8-0e1a-4eaa-b79f-f522be3f468b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_FinanceLeaseCost_e2dd7b4a-2569-49cb-bc4d-c6b2b7037d40" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_b9fb8bc8-0e1a-4eaa-b79f-f522be3f468b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_d217f1f8-5868-4bfb-9151-934477b1961d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_36df703c-b40e-4f6f-8850-96753165373b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_d217f1f8-5868-4bfb-9151-934477b1961d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_36df703c-b40e-4f6f-8850-96753165373b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9d5e9212-6810-42cf-b30c-a2cd4f8789fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_d217f1f8-5868-4bfb-9151-934477b1961d" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_9d5e9212-6810-42cf-b30c-a2cd4f8789fd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesLeaseMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce0db257-3bc6-4dec-9fe8-5ab6076874e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_833a814a-13a1-423f-9c8f-e7701ee13875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce0db257-3bc6-4dec-9fe8-5ab6076874e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_833a814a-13a1-423f-9c8f-e7701ee13875" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d5aa4870-213d-4493-9c83-3af508d3f377" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce0db257-3bc6-4dec-9fe8-5ab6076874e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d5aa4870-213d-4493-9c83-3af508d3f377" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d580b346-f779-4e80-ad70-8a58501f3b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce0db257-3bc6-4dec-9fe8-5ab6076874e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_d580b346-f779-4e80-ad70-8a58501f3b2e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b3113739-ea0b-48fc-9c40-9edec65bb72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce0db257-3bc6-4dec-9fe8-5ab6076874e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b3113739-ea0b-48fc-9c40-9edec65bb72a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_513f9365-b2a1-4863-b268-aefdce78093e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce0db257-3bc6-4dec-9fe8-5ab6076874e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_513f9365-b2a1-4863-b268-aefdce78093e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_79e32baa-8be8-47bf-9e9e-42ea5afd71f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_ce0db257-3bc6-4dec-9fe8-5ab6076874e7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_79e32baa-8be8-47bf-9e9e-42ea5afd71f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a551ca5-8e8b-46fb-9dc8-02d8f8d7d3ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_4dc3cb50-fddc-4778-a47b-db673f1cd9d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a551ca5-8e8b-46fb-9dc8-02d8f8d7d3ee" xlink:to="loc_us-gaap_FinanceLeaseLiability_4dc3cb50-fddc-4778-a47b-db673f1cd9d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_59ebe89c-c62e-4c08-8d97-54e792670051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6a551ca5-8e8b-46fb-9dc8-02d8f8d7d3ee" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_59ebe89c-c62e-4c08-8d97-54e792670051" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesLeaseMaturitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1f84dd28-89de-49e6-87cb-0b4e5f6ad8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_794541a5-cf4b-44fe-80ba-8dc31e02f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1f84dd28-89de-49e6-87cb-0b4e5f6ad8d3" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_794541a5-cf4b-44fe-80ba-8dc31e02f8c5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_975cf9cf-eebe-4f16-a078-b053aed9fc39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1f84dd28-89de-49e6-87cb-0b4e5f6ad8d3" xlink:to="loc_us-gaap_OperatingLeaseLiability_975cf9cf-eebe-4f16-a078-b053aed9fc39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6915571a-f8a4-4ac0-a17b-30b4ae9732fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_4d5f354b-6b54-44a6-bd9d-249ccf3e39a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6915571a-f8a4-4ac0-a17b-30b4ae9732fd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_4d5f354b-6b54-44a6-bd9d-249ccf3e39a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9061ac97-563b-43b5-84b0-ec55cf97b909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6915571a-f8a4-4ac0-a17b-30b4ae9732fd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_9061ac97-563b-43b5-84b0-ec55cf97b909" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d7d16cd9-8b03-41ba-9d2b-57a8026fd860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6915571a-f8a4-4ac0-a17b-30b4ae9732fd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_d7d16cd9-8b03-41ba-9d2b-57a8026fd860" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_938bd0bc-ebff-4224-911b-5434679f4658" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6915571a-f8a4-4ac0-a17b-30b4ae9732fd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_938bd0bc-ebff-4224-911b-5434679f4658" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_625d43e7-38b6-498c-8a94-e7b2e498f159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6915571a-f8a4-4ac0-a17b-30b4ae9732fd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_625d43e7-38b6-498c-8a94-e7b2e498f159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_390496f7-ed71-4729-8fb1-f6ddccdd8f97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_6915571a-f8a4-4ac0-a17b-30b4ae9732fd" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_390496f7-ed71-4729-8fb1-f6ddccdd8f97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4560e966-737f-4264-a719-6feccef695c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a2fa60a-a98d-44f9-a63c-980121d2174d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4560e966-737f-4264-a719-6feccef695c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_9a2fa60a-a98d-44f9-a63c-980121d2174d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e3a510ef-3cd5-4cd8-a336-9e920b403349" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4560e966-737f-4264-a719-6feccef695c6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e3a510ef-3cd5-4cd8-a336-9e920b403349" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2fd3792b-9d4f-435b-923a-0b3b1619be5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_2871af34-c524-45e1-8516-06d4f5c2d43f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2fd3792b-9d4f-435b-923a-0b3b1619be5c" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_2871af34-c524-45e1-8516-06d4f5c2d43f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_bf5b69a1-7d9d-4d24-8abb-9924213daa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_2fd3792b-9d4f-435b-923a-0b3b1619be5c" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_bf5b69a1-7d9d-4d24-8abb-9924213daa28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_5ec4c4b9-6187-4e73-9ab2-d891f325cc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_fe211ef8-b1da-45d3-bfbb-cf822e1ff991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_5ec4c4b9-6187-4e73-9ab2-d891f325cc83" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_fe211ef8-b1da-45d3-bfbb-cf822e1ff991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_db6644ff-fc2e-4fbf-9254-9f639b3e4f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_5ec4c4b9-6187-4e73-9ab2-d891f325cc83" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_db6644ff-fc2e-4fbf-9254-9f639b3e4f96" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e3e6c4b-ee3b-4f6b-b2e2-db9113736fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears_b0094a03-0692-43cc-9d3a-844128bc039d" xlink:href="moh-20221231.xsd#moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e3e6c4b-ee3b-4f6b-b2e2-db9113736fc4" xlink:to="loc_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears_b0094a03-0692-43cc-9d3a-844128bc039d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems_518744e2-bd76-46e3-a165-b64e4fe412a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e3e6c4b-ee3b-4f6b-b2e2-db9113736fc4" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems_518744e2-bd76-46e3-a165-b64e4fe412a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_3326e977-617c-4d90-b13f-669c5c26f3f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e3e6c4b-ee3b-4f6b-b2e2-db9113736fc4" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_3326e977-617c-4d90-b13f-669c5c26f3f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_f09fd382-54d0-432d-9499-376cfd193ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_1e3e6c4b-ee3b-4f6b-b2e2-db9113736fc4" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_f09fd382-54d0-432d-9499-376cfd193ebc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtMaturitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_f90a3889-191b-4ecf-86ad-23cfb3c2cc32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7e9a011f-f877-479d-af09-6faa0cc2c625" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f90a3889-191b-4ecf-86ad-23cfb3c2cc32" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_7e9a011f-f877-479d-af09-6faa0cc2c625" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_03734a7e-9500-4826-aaa5-6af655f811ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f90a3889-191b-4ecf-86ad-23cfb3c2cc32" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_03734a7e-9500-4826-aaa5-6af655f811ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ffec37b9-1398-434c-b3e8-c51d2c698ba7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f90a3889-191b-4ecf-86ad-23cfb3c2cc32" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ffec37b9-1398-434c-b3e8-c51d2c698ba7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8e370772-6727-4789-93d8-8ec62a6c473c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f90a3889-191b-4ecf-86ad-23cfb3c2cc32" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_8e370772-6727-4789-93d8-8ec62a6c473c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_38643645-0199-468b-b781-f361c3dfc232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f90a3889-191b-4ecf-86ad-23cfb3c2cc32" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_38643645-0199-468b-b781-f361c3dfc232" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e6dad8de-7094-46eb-8a58-3437626fef16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_f90a3889-191b-4ecf-86ad-23cfb3c2cc32" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_e6dad8de-7094-46eb-8a58-3437626fef16" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_856a5a60-68d3-49d8-abef-1f89172031fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_41e01e15-58b2-4e13-968f-cdfe19b9d320" xlink:href="moh-20221231.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_856a5a60-68d3-49d8-abef-1f89172031fa" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_41e01e15-58b2-4e13-968f-cdfe19b9d320" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d4ecd57c-623c-49da-88b3-cefa986a0bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_856a5a60-68d3-49d8-abef-1f89172031fa" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_d4ecd57c-623c-49da-88b3-cefa986a0bd6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2bc85ec6-fca5-4cd4-a1ad-198815611094" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7bdb5314-22c6-4951-a7cc-ae2b23e266dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2bc85ec6-fca5-4cd4-a1ad-198815611094" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7bdb5314-22c6-4951-a7cc-ae2b23e266dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_52458af3-e9e1-4d66-8b2f-eb29149024da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2bc85ec6-fca5-4cd4-a1ad-198815611094" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_52458af3-e9e1-4d66-8b2f-eb29149024da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_af155415-20a2-4310-8b64-8613343c49bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_2bc85ec6-fca5-4cd4-a1ad-198815611094" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_af155415-20a2-4310-8b64-8613343c49bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5a6c2537-7e7f-44fe-910e-f62ebf4ac537" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ce3edaf3-a381-4b7e-a37c-d81ea15619c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5a6c2537-7e7f-44fe-910e-f62ebf4ac537" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_ce3edaf3-a381-4b7e-a37c-d81ea15619c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_eb234cc2-b738-4010-8ed7-d5432f68d2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_5a6c2537-7e7f-44fe-910e-f62ebf4ac537" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_eb234cc2-b738-4010-8ed7-d5432f68d2e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_463b7552-a55c-4a5b-9ea3-01149512e6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_aa7fe5eb-dd00-4666-8704-dd2e7d3182c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_463b7552-a55c-4a5b-9ea3-01149512e6ab" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_aa7fe5eb-dd00-4666-8704-dd2e7d3182c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b3c2bf90-d82d-437c-acc6-a9c3d3a18fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_463b7552-a55c-4a5b-9ea3-01149512e6ab" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b3c2bf90-d82d-437c-acc6-a9c3d3a18fa1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ed41717d-342e-44eb-b1b3-366c5ff1bb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d97f4b59-d403-4774-903b-b5ce82d9e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ed41717d-342e-44eb-b1b3-366c5ff1bb6a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_d97f4b59-d403-4774-903b-b5ce82d9e0fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a467577b-bfc2-42be-a1ef-b8a669bb146f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ed41717d-342e-44eb-b1b3-366c5ff1bb6a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_a467577b-bfc2-42be-a1ef-b8a669bb146f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_852bbeff-cf4a-4280-8b4d-1d2b14901725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ed41717d-342e-44eb-b1b3-366c5ff1bb6a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_852bbeff-cf4a-4280-8b4d-1d2b14901725" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0a98c49f-3d54-4ac8-a728-11a4042aae93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ed41717d-342e-44eb-b1b3-366c5ff1bb6a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_0a98c49f-3d54-4ac8-a728-11a4042aae93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent_687ea844-48e2-47cd-a4e2-21cc3a29d892" xlink:href="moh-20221231.xsd#moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ed41717d-342e-44eb-b1b3-366c5ff1bb6a" xlink:to="loc_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent_687ea844-48e2-47cd-a4e2-21cc3a29d892" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b536f8d2-d56a-4c7f-a614-c55a19a98766" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_c9f9ffcb-34da-4313-b58c-45ddb7c22294" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b536f8d2-d56a-4c7f-a614-c55a19a98766" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_c9f9ffcb-34da-4313-b58c-45ddb7c22294" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_ccc2ca3a-6735-4551-916e-8d3d33ccec40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_b536f8d2-d56a-4c7f-a614-c55a19a98766" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_ccc2ca3a-6735-4551-916e-8d3d33ccec40" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2a1506a4-fc02-47f6-bf94-2c0d17bfb86e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_85bff7a1-a8e5-4879-813c-2924e5e8e959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_2a1506a4-fc02-47f6-bf94-2c0d17bfb86e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_85bff7a1-a8e5-4879-813c-2924e5e8e959" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles_94ce0b2c-03bd-4d0d-b662-2160e7793a60" xlink:href="moh-20221231.xsd#moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_2a1506a4-fc02-47f6-bf94-2c0d17bfb86e" xlink:to="loc_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles_94ce0b2c-03bd-4d0d-b662-2160e7793a60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_450ed429-0483-4151-9762-b04cb01cea9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_450ed429-0483-4151-9762-b04cb01cea9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_aab725a0-caaf-4252-8a34-08f2f3a45fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_aab725a0-caaf-4252-8a34-08f2f3a45fc0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4f8b68e0-d3af-4bbd-9a47-841b40cc3e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4f8b68e0-d3af-4bbd-9a47-841b40cc3e84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_ae343e3c-8770-409a-924f-32288da0ff8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_ae343e3c-8770-409a-924f-32288da0ff8f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_b785c79f-82a4-46f6-b56a-16315b6d1e76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_b785c79f-82a4-46f6-b56a-16315b6d1e76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_929ed6f0-47c8-4276-ae35-e06d7e737f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_929ed6f0-47c8-4276-ae35-e06d7e737f83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_4efe1bcb-6806-4a9c-8d68-ec3098b524ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_4efe1bcb-6806-4a9c-8d68-ec3098b524ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e85afefe-6483-4c2b-9f7c-b66acbe54e51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_e85afefe-6483-4c2b-9f7c-b66acbe54e51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_1518c2cd-8868-48e7-a98e-b6c87a833b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_1518c2cd-8868-48e7-a98e-b6c87a833b6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DeferredTaxAssetsFixedAssetsAndIntangibles_923a527b-cdd2-49d6-b1fd-05760c016acb" xlink:href="moh-20221231.xsd#moh_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_d77576b0-f93f-48dc-8102-3ce16c47cfd3" xlink:to="loc_moh_DeferredTaxAssetsFixedAssetsAndIntangibles_923a527b-cdd2-49d6-b1fd-05760c016acb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"/>
  <link:calculationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1a08c476-4cb7-40f1-86ca-91a427f25c63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_2eb3256d-b926-40f2-9acc-b36848ed8368" xlink:href="moh-20221231.xsd#moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1a08c476-4cb7-40f1-86ca-91a427f25c63" xlink:to="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_2eb3256d-b926-40f2-9acc-b36848ed8368" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_80f6050c-e2cf-4690-a689-68bb0ef691d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_1a08c476-4cb7-40f1-86ca-91a427f25c63" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_80f6050c-e2cf-4690-a689-68bb0ef691d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_27efc2b5-1d59-469d-9c53-f4516e3a8497" xlink:href="moh-20221231.xsd#moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_377ed25c-017e-4e26-88fd-02f550c0de63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_27efc2b5-1d59-469d-9c53-f4516e3a8497" xlink:to="loc_us-gaap_OperatingIncomeLoss_377ed25c-017e-4e26-88fd-02f550c0de63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_e017a3a1-4f49-4a59-a26f-5f986e275e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_27efc2b5-1d59-469d-9c53-f4516e3a8497" xlink:to="loc_us-gaap_InterestExpense_e017a3a1-4f49-4a59-a26f-5f986e275e2c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_2fde6eee-f7f6-467d-b48f-f48c87918cfc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_27efc2b5-1d59-469d-9c53-f4516e3a8497" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_2fde6eee-f7f6-467d-b48f-f48c87918cfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_275f1284-9012-4edb-ba99-03376b949b3b" xlink:href="moh-20221231.xsd#moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_a5c79eb8-f907-4d68-ae64-c5d4f656b193" xlink:href="moh-20221231.xsd#moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_275f1284-9012-4edb-ba99-03376b949b3b" xlink:to="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_a5c79eb8-f907-4d68-ae64-c5d4f656b193" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_32ba73a6-aba1-4564-bf65-92d69e7bf4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_275f1284-9012-4edb-ba99-03376b949b3b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_32ba73a6-aba1-4564-bf65-92d69e7bf4f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a9b54c32-f035-48b6-978f-1e3c4fc6e804" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6cfdbe38-8fd2-4d99-a177-b0358e90a1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9b54c32-f035-48b6-978f-1e3c4fc6e804" xlink:to="loc_us-gaap_DepreciationAndAmortization_6cfdbe38-8fd2-4d99-a177-b0358e90a1b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_eecfb9bf-5694-4810-b813-32506f53b003" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9b54c32-f035-48b6-978f-1e3c4fc6e804" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_eecfb9bf-5694-4810-b813-32506f53b003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_a018d9f9-3795-4e1f-a449-f496c25104cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9b54c32-f035-48b6-978f-1e3c4fc6e804" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_a018d9f9-3795-4e1f-a449-f496c25104cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_cbf17453-cf2b-4207-8fc1-5fa8a52074cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a9b54c32-f035-48b6-978f-1e3c4fc6e804" xlink:to="loc_us-gaap_AssetImpairmentCharges_cbf17453-cf2b-4207-8fc1-5fa8a52074cc" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>moh-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a6be6ee9-88ed-425c-ba06-deafc74c4611,g:0568f791-801e-41fa-b039-5982169b2ced-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="ic9599c4a69804fca9c46e4a2e89b478a_ConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c5647097-c862-4b84-9867-6d76ff514130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c5647097-c862-4b84-9867-6d76ff514130" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b390087d-dbfc-4a6b-ae49-1abb12546f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_SharesOutstanding_b390087d-dbfc-4a6b-ae49-1abb12546f71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b70eab4b-3ffa-4ba6-a1f4-c1c22d2e874d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockholdersEquity_b70eab4b-3ffa-4ba6-a1f4-c1c22d2e874d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a1851a2-de46-417e-866b-7dabc1f47066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_NetIncomeLoss_3a1851a2-de46-417e-866b-7dabc1f47066" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_045f7504-3bac-492a-8f63-4006eced1f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_045f7504-3bac-492a-8f63-4006eced1f52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_1cbe5b9e-b6bf-4194-b925-b0c7e2990d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_1cbe5b9e-b6bf-4194-b925-b0c7e2990d7f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_49f49d7d-cbb5-4afd-879b-3c2f129106b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_49f49d7d-cbb5-4afd-879b-3c2f129106b1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3362eac-4805-4028-8aae-8fdfab4f2542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3362eac-4805-4028-8aae-8fdfab4f2542" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d899547e-3ec8-499f-abd3-c5c89f046f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d899547e-3ec8-499f-abd3-c5c89f046f28" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7dfb3fe8-fe12-42db-836d-7e79a9b7bd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7dfb3fe8-fe12-42db-836d-7e79a9b7bd33" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0ed7d390-ee54-4e19-8d39-47b3701272af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb63f805-f8db-4aea-95a1-73eef06c1912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9eec1ef7-4f38-45ff-99fa-c79d61f533a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c5647097-c862-4b84-9867-6d76ff514130" xlink:to="loc_us-gaap_StatementTable_9eec1ef7-4f38-45ff-99fa-c79d61f533a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_9eec1ef7-4f38-45ff-99fa-c79d61f533a9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d" xlink:to="loc_us-gaap_EquityComponentDomain_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d" xlink:to="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bade57bc-5ae4-44f2-8261-0364ab9f2fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:to="loc_us-gaap_CommonStockMember_bade57bc-5ae4-44f2-8261-0364ab9f2fc3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1a41fd1b-bbe5-452d-9d19-8ad1b1e55fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1a41fd1b-bbe5-452d-9d19-8ad1b1e55fe7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8077ce45-f4e0-461b-826f-3c7d7ab1ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8077ce45-f4e0-461b-826f-3c7d7ab1ee05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7c0cdf1a-10af-4f1a-99bb-e09da0ca48dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:to="loc_us-gaap_RetainedEarningsMember_7c0cdf1a-10af-4f1a-99bb-e09da0ca48dc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended" id="i236f679553d843c385c30c325541c680_OrganizationandBasisofPresentationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:href="moh-20221231.xsd#moh_BasisOfPresentationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c872ba8c-d255-4d5e-8a47-d7bf135925eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_us-gaap_NumberOfReportableSegments_c872ba8c-d255-4d5e-8a47-d7bf135925eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_594fc052-5632-49f5-8885-5e6206ea2c57" xlink:href="moh-20221231.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_594fc052-5632-49f5-8885-5e6206ea2c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_276d433f-f47d-4070-af08-2a6cfe2e36ee" xlink:href="moh-20221231.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_276d433f-f47d-4070-af08-2a6cfe2e36ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_92ca709d-372e-464e-af15-4d782eb68aa4" xlink:href="moh-20221231.xsd#moh_HealthPlanContractTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_HealthPlanContractTerm_92ca709d-372e-464e-af15-4d782eb68aa4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod_5dbff06a-3bf6-45cd-8a12-9688d97d88d5" xlink:href="moh-20221231.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_HealthPlanExtensionOptionPeriod_5dbff06a-3bf6-45cd-8a12-9688d97d88d5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a6e69d6e-8343-4a78-843c-f8bd0a1e323e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a6e69d6e-8343-4a78-843c-f8bd0a1e323e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:href="moh-20221231.xsd#moh_BasisOfPresentationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be0679c9-9089-4c7a-9022-eb411e777fd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_srt_RangeAxis_be0679c9-9089-4c7a-9022-eb411e777fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_be0679c9-9089-4c7a-9022-eb411e777fd1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_be0679c9-9089-4c7a-9022-eb411e777fd1" xlink:to="loc_srt_RangeMember_be0679c9-9089-4c7a-9022-eb411e777fd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3a1c296-acdb-4c5c-9e42-4676d998744d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_be0679c9-9089-4c7a-9022-eb411e777fd1" xlink:to="loc_srt_RangeMember_d3a1c296-acdb-4c5c-9e42-4676d998744d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d184487d-3687-4a3c-9a44-2c91cc2b585e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3a1c296-acdb-4c5c-9e42-4676d998744d" xlink:to="loc_srt_MinimumMember_d184487d-3687-4a3c-9a44-2c91cc2b585e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87b9bc0b-8329-4b58-959e-a1f655f7c3ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d3a1c296-acdb-4c5c-9e42-4676d998744d" xlink:to="loc_srt_MaximumMember_87b9bc0b-8329-4b58-959e-a1f655f7c3ed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2ab184ad-e718-4957-9b3b-325bd494406b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2ab184ad-e718-4957-9b3b-325bd494406b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2ab184ad-e718-4957-9b3b-325bd494406b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ab184ad-e718-4957-9b3b-325bd494406b" xlink:to="loc_us-gaap_SegmentDomain_2ab184ad-e718-4957-9b3b-325bd494406b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c3a298fe-55a6-4aa3-8318-b037a1b53206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ab184ad-e718-4957-9b3b-325bd494406b" xlink:to="loc_us-gaap_SegmentDomain_c3a298fe-55a6-4aa3-8318-b037a1b53206" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_0a51dd3d-d47d-4d98-9c17-fa99ed2a4cfa" xlink:href="moh-20221231.xsd#moh_HealthPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c3a298fe-55a6-4aa3-8318-b037a1b53206" xlink:to="loc_moh_HealthPlansMember_0a51dd3d-d47d-4d98-9c17-fa99ed2a4cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthAndHumanServicesMember_5fedf1c5-926f-40ec-bfd0-2baca4738ce0" xlink:href="moh-20221231.xsd#moh_HealthAndHumanServicesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c3a298fe-55a6-4aa3-8318-b037a1b53206" xlink:to="loc_moh_HealthAndHumanServicesMember_5fedf1c5-926f-40ec-bfd0-2baca4738ce0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59cf225e-51de-48f6-949c-77e603d59dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59cf225e-51de-48f6-949c-77e603d59dd5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59cf225e-51de-48f6-949c-77e603d59dd5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59cf225e-51de-48f6-949c-77e603d59dd5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_59cf225e-51de-48f6-949c-77e603d59dd5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8072090b-7132-44b3-bde4-bbb85c4b1a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59cf225e-51de-48f6-949c-77e603d59dd5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8072090b-7132-44b3-bde4-bbb85c4b1a5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MyChoiceWisconsinMember_058d7b10-75fa-4105-9660-3131ce1826af" xlink:href="moh-20221231.xsd#moh_MyChoiceWisconsinMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8072090b-7132-44b3-bde4-bbb85c4b1a5b" xlink:to="loc_moh_MyChoiceWisconsinMember_058d7b10-75fa-4105-9660-3131ce1826af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2445b063-bbbe-4a22-bc12-6a09c7664356" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_srt_StatementGeographicalAxis_2445b063-bbbe-4a22-bc12-6a09c7664356" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2445b063-bbbe-4a22-bc12-6a09c7664356_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_2445b063-bbbe-4a22-bc12-6a09c7664356" xlink:to="loc_srt_SegmentGeographicalDomain_2445b063-bbbe-4a22-bc12-6a09c7664356_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_2445b063-bbbe-4a22-bc12-6a09c7664356" xlink:to="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NE_cdd63e29-a11f-4648-a838-24c43b4a90e0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:to="loc_stpr_NE_cdd63e29-a11f-4648-a838-24c43b4a90e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA_2796c459-2d0c-4233-ad83-9fa35132a2aa" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:to="loc_stpr_IA_2796c459-2d0c-4233-ad83-9fa35132a2aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS_dca2d73b-6ddf-4e8d-9ba0-1d93fdcbbb0b" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:to="loc_stpr_MS_dca2d73b-6ddf-4e8d-9ba0-1d93fdcbbb0b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" id="i4b93b6a085774adca4c4996ea9efaef8_SignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_8ee48aeb-b4fc-4aff-b4f8-f332e5b4943d" xlink:href="moh-20221231.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_InvestmentsMaturityPeriod_8ee48aeb-b4fc-4aff-b4f8-f332e5b4943d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_73b819e3-2d6e-4e42-aef7-1419c3b6c8e0" xlink:href="moh-20221231.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_73b819e3-2d6e-4e42-aef7-1419c3b6c8e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_4196c96b-7eba-4dd5-a29a-cfc586e7d713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_InterestReceivable_4196c96b-7eba-4dd5-a29a-cfc586e7d713" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ae6274f0-5eea-46cd-99ef-8db47a35114b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ae6274f0-5eea-46cd-99ef-8db47a35114b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_352b5b32-a164-489a-a8c3-0edd222ec0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_352b5b32-a164-489a-a8c3-0edd222ec0a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b6def90e-7335-4b18-9168-615bbb5f1989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b6def90e-7335-4b18-9168-615bbb5f1989" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingAndFinanceLeaseImpairmentLoss_f0f8f57f-6370-4862-b685-e7edc563d0b4" xlink:href="moh-20221231.xsd#moh_OperatingAndFinanceLeaseImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_OperatingAndFinanceLeaseImpairmentLoss_f0f8f57f-6370-4862-b685-e7edc563d0b4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_194b5f40-84fa-414c-86ca-0f47048c536f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_194b5f40-84fa-414c-86ca-0f47048c536f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_45354830-d61e-4c0f-ad9e-074cdea2f9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_45354830-d61e-4c0f-ad9e-074cdea2f9f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_5820c32d-6496-4dab-ac88-edd4cdeef8f4" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_5820c32d-6496-4dab-ac88-edd4cdeef8f4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_c293d52e-2fe2-438c-87d6-6ae8f28d5948" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_c293d52e-2fe2-438c-87d6-6ae8f28d5948" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_baf545f3-3ce4-4bda-bf78-39aeaed86d78" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_baf545f3-3ce4-4bda-bf78-39aeaed86d78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned_1723be8e-eaee-4e93-8db3-a7f5b27057ea" xlink:href="moh-20221231.xsd#moh_PercentageOfAdditionalIncrementalRevenueEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned_1723be8e-eaee-4e93-8db3-a7f5b27057ea" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidReinsurancePremiums_c515cf13-71a2-4c6f-aa8f-b8476914579c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_PrepaidReinsurancePremiums_c515cf13-71a2-4c6f-aa8f-b8476914579c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_9c59f632-4db2-45f8-a587-ff90f0a9f612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_InsuranceRecoveries_9c59f632-4db2-45f8-a587-ff90f0a9f612" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ba399caa-6925-45fc-8dc8-10a10b104959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ba399caa-6925-45fc-8dc8-10a10b104959" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationRevenuePercentage_6be397df-10a9-436b-8d1a-4a278ac100ce" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationRevenuePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_HealthCareOrganizationRevenuePercentage_6be397df-10a9-436b-8d1a-4a278ac100ce" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38a9f64e-027a-4ff8-b19d-05d4bd83c51c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_srt_RangeAxis_38a9f64e-027a-4ff8-b19d-05d4bd83c51c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_38a9f64e-027a-4ff8-b19d-05d4bd83c51c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_38a9f64e-027a-4ff8-b19d-05d4bd83c51c" xlink:to="loc_srt_RangeMember_38a9f64e-027a-4ff8-b19d-05d4bd83c51c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41092e16-19be-45a1-b28a-d9dd9248522b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_38a9f64e-027a-4ff8-b19d-05d4bd83c51c" xlink:to="loc_srt_RangeMember_41092e16-19be-45a1-b28a-d9dd9248522b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fab0e871-c847-4fcf-b345-50b4d125be96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41092e16-19be-45a1-b28a-d9dd9248522b" xlink:to="loc_srt_MinimumMember_fab0e871-c847-4fcf-b345-50b4d125be96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_49c28dc9-2d29-487a-a2d3-202229fc151f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_41092e16-19be-45a1-b28a-d9dd9248522b" xlink:to="loc_srt_MaximumMember_49c28dc9-2d29-487a-a2d3-202229fc151f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_35fa36b9-0e0d-4781-a6d9-e8229c70b2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_35fa36b9-0e0d-4781-a6d9-e8229c70b2da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_35fa36b9-0e0d-4781-a6d9-e8229c70b2da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_35fa36b9-0e0d-4781-a6d9-e8229c70b2da" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_35fa36b9-0e0d-4781-a6d9-e8229c70b2da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_f8b51cc1-b4bf-409e-a06d-b224940b7e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_35fa36b9-0e0d-4781-a6d9-e8229c70b2da" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_f8b51cc1-b4bf-409e-a06d-b224940b7e3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_a8381698-c154-4854-a2c1-c4b259b37ee1" xlink:href="moh-20221231.xsd#moh_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_f8b51cc1-b4bf-409e-a06d-b224940b7e3f" xlink:to="loc_moh_COVID19Member_a8381698-c154-4854-a2c1-c4b259b37ee1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1dad6942-47df-4a9a-a932-cf15afdd26af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_srt_ProductOrServiceAxis_1dad6942-47df-4a9a-a932-cf15afdd26af" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1dad6942-47df-4a9a-a932-cf15afdd26af_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1dad6942-47df-4a9a-a932-cf15afdd26af" xlink:to="loc_srt_ProductsAndServicesDomain_1dad6942-47df-4a9a-a932-cf15afdd26af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f78e3801-3791-4590-b092-b43c5bb4ce5e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1dad6942-47df-4a9a-a932-cf15afdd26af" xlink:to="loc_srt_ProductsAndServicesDomain_f78e3801-3791-4590-b092-b43c5bb4ce5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePremiumMember_bc5ff555-17e6-4c71-b988-f60cd7f806c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePremiumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_f78e3801-3791-4590-b092-b43c5bb4ce5e" xlink:to="loc_us-gaap_HealthCarePremiumMember_bc5ff555-17e6-4c71-b988-f60cd7f806c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_724abe94-7c9b-4000-8f19-a148d4700f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_724abe94-7c9b-4000-8f19-a148d4700f0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724abe94-7c9b-4000-8f19-a148d4700f0a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_724abe94-7c9b-4000-8f19-a148d4700f0a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_724abe94-7c9b-4000-8f19-a148d4700f0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da461a25-94ea-40b6-ae06-b9557a7ef911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_724abe94-7c9b-4000-8f19-a148d4700f0a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da461a25-94ea-40b6-ae06-b9557a7ef911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_09d7bbfd-a1c6-443a-a6e4-026fa009d9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da461a25-94ea-40b6-ae06-b9557a7ef911" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_09d7bbfd-a1c6-443a-a6e4-026fa009d9c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_55eb6330-8a21-4e13-ad85-52ffb862fccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_55eb6330-8a21-4e13-ad85-52ffb862fccb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_babb9b52-8dd1-4f18-b27e-606a28a72b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_55eb6330-8a21-4e13-ad85-52ffb862fccb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_babb9b52-8dd1-4f18-b27e-606a28a72b46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_873c57b0-445d-445a-84a3-1e11028bdd51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_srt_StatementGeographicalAxis_873c57b0-445d-445a-84a3-1e11028bdd51" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_873c57b0-445d-445a-84a3-1e11028bdd51_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_873c57b0-445d-445a-84a3-1e11028bdd51" xlink:to="loc_srt_SegmentGeographicalDomain_873c57b0-445d-445a-84a3-1e11028bdd51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_873c57b0-445d-445a-84a3-1e11028bdd51" xlink:to="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_652d6ccd-845a-4369-9564-cea1866bce11" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:to="loc_stpr_NY_652d6ccd-845a-4369-9564-cea1866bce11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_c63bbc7f-f0b3-4537-9439-91bd777033f5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:to="loc_stpr_TX_c63bbc7f-f0b3-4537-9439-91bd777033f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_0c41e208-93fb-44d5-9cbc-bdf18909c0af" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:to="loc_stpr_WA_0c41e208-93fb-44d5-9cbc-bdf18909c0af" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended" id="i202cd9c6589740bbb9f0e747d063b6b8_SignificantAccountingPoliciesReceivablesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_57b03462-ecbc-4d4c-bf34-5ce7a403a308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_9d3c31c4-609b-43b6-8493-ce4168d72cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_57b03462-ecbc-4d4c-bf34-5ce7a403a308" xlink:to="loc_us-gaap_ReceivablesNetCurrent_9d3c31c4-609b-43b6-8493-ce4168d72cb6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1a0afaef-ac84-4c3c-972f-8001d7491a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_57b03462-ecbc-4d4c-bf34-5ce7a403a308" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1a0afaef-ac84-4c3c-972f-8001d7491a33" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3fb7468-b3ce-42be-b8bf-81f020a13691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1a0afaef-ac84-4c3c-972f-8001d7491a33" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3fb7468-b3ce-42be-b8bf-81f020a13691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_f3fb7468-b3ce-42be-b8bf-81f020a13691_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3fb7468-b3ce-42be-b8bf-81f020a13691" xlink:to="loc_us-gaap_ReceivableTypeDomain_f3fb7468-b3ce-42be-b8bf-81f020a13691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3fb7468-b3ce-42be-b8bf-81f020a13691" xlink:to="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_cb95f93b-613a-4e22-8990-80008e10a3d3" xlink:href="moh-20221231.xsd#moh_GovernmentReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:to="loc_moh_GovernmentReceivablesMember_cb95f93b-613a-4e22-8990-80008e10a3d3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_a79283d9-90f7-4a77-b596-585e48ece34f" xlink:href="moh-20221231.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:to="loc_moh_PharmacyRebateReceivablesMember_a79283d9-90f7-4a77-b596-585e48ece34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_af93e9ae-055c-4fd2-adaa-bc9afbb143c4" xlink:href="moh-20221231.xsd#moh_OtherReceivablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:to="loc_moh_OtherReceivablesMember_af93e9ae-055c-4fd2-adaa-bc9afbb143c4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended" id="if812930eb9b646b78d47bdd27f01cf73_BusinessCombinationsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfBusinessCombinations_1ebbe413-c0fb-44e3-bfb3-2b7f6b06e0c5" xlink:href="moh-20221231.xsd#moh_BusinessCombinationNumberOfBusinessCombinations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_moh_BusinessCombinationNumberOfBusinessCombinations_1ebbe413-c0fb-44e3-bfb3-2b7f6b06e0c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_ed85b604-260d-4a9f-b328-263cb685f0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_AcquisitionCosts_ed85b604-260d-4a9f-b328-263cb685f0fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3a242f71-17f0-4d6a-8d68-44deab820733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3a242f71-17f0-4d6a-8d68-44deab820733" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_d8b90886-0aa9-4ab4-87f6-2d6c280dd245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_d8b90886-0aa9-4ab4-87f6-2d6c280dd245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b9ff2ad6-dd1c-4e6c-9ee2-0946ed247881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b9ff2ad6-dd1c-4e6c-9ee2-0946ed247881" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_5686b1be-1135-442f-9b3c-134e4e4b049c" xlink:href="moh-20221231.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_5686b1be-1135-442f-9b3c-134e4e4b049c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_575a9287-a0fb-44e1-84ba-bbe1083e7b89" xlink:href="moh-20221231.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_575a9287-a0fb-44e1-84ba-bbe1083e7b89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e4da9071-faaa-4730-81b2-5987a2bf4da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e4da9071-faaa-4730-81b2-5987a2bf4da8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4da9071-faaa-4730-81b2-5987a2bf4da8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4da9071-faaa-4730-81b2-5987a2bf4da8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e4da9071-faaa-4730-81b2-5987a2bf4da8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4da9071-faaa-4730-81b2-5987a2bf4da8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AgeWellNewYorkMember_4e108307-6188-4c3e-bbc2-7c9c250f72fe" xlink:href="moh-20221231.xsd#moh_AgeWellNewYorkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:to="loc_moh_AgeWellNewYorkMember_4e108307-6188-4c3e-bbc2-7c9c250f72fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_6793d972-e8fb-43f9-9a52-cf5e17a54788" xlink:href="moh-20221231.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:to="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_6793d972-e8fb-43f9-9a52-cf5e17a54788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember_979fd4b6-3610-474a-954c-df48239f4523" xlink:href="moh-20221231.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:to="loc_moh_AffinityHealthPlanIncMember_979fd4b6-3610-474a-954c-df48239f4523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50305da0-4a6c-4430-8910-1ecfa1ee62ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50305da0-4a6c-4430-8910-1ecfa1ee62ed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_50305da0-4a6c-4430-8910-1ecfa1ee62ed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50305da0-4a6c-4430-8910-1ecfa1ee62ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_50305da0-4a6c-4430-8910-1ecfa1ee62ed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2be34ecd-0ddd-4d24-9f28-736d25a2cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50305da0-4a6c-4430-8910-1ecfa1ee62ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2be34ecd-0ddd-4d24-9f28-736d25a2cf10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember_d48b530d-ed7f-4d2b-a933-ada75e42ca58" xlink:href="moh-20221231.xsd#moh_MemberListsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2be34ecd-0ddd-4d24-9f28-736d25a2cf10" xlink:to="loc_moh_MemberListsMember_d48b530d-ed7f-4d2b-a933-ada75e42ca58" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#BusinessCombinationsIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="extended" id="if09a9790eba645648eb2c7dff7fa0832_BusinessCombinationsIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e3590b94-a67f-48b2-8452-99cde60d4e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e3590b94-a67f-48b2-8452-99cde60d4e4f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_20e1015d-41c7-4e82-9dbb-908c659728d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_20e1015d-41c7-4e82-9dbb-908c659728d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_015a3411-9f11-4328-ae34-80621bfe924b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_015a3411-9f11-4328-ae34-80621bfe924b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_17170016-d6fa-4a2d-ba19-4b2763f0c789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_17170016-d6fa-4a2d-ba19-4b2763f0c789" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_df9e72e2-4321-427c-a1f2-1978ed4758d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_df9e72e2-4321-427c-a1f2-1978ed4758d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df9e72e2-4321-427c-a1f2-1978ed4758d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df9e72e2-4321-427c-a1f2-1978ed4758d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_df9e72e2-4321-427c-a1f2-1978ed4758d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d221ebe6-b372-4935-9573-7a1516c2adf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df9e72e2-4321-427c-a1f2-1978ed4758d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d221ebe6-b372-4935-9573-7a1516c2adf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansSegmentMember_9e3eb52f-86a5-4b31-bfea-170eb79eda7a" xlink:href="moh-20221231.xsd#moh_HealthPlansSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d221ebe6-b372-4935-9573-7a1516c2adf2" xlink:to="loc_moh_HealthPlansSegmentMember_9e3eb52f-86a5-4b31-bfea-170eb79eda7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_56ca9b0e-8fdd-4153-9667-6b62dd819f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_56ca9b0e-8fdd-4153-9667-6b62dd819f78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56ca9b0e-8fdd-4153-9667-6b62dd819f78_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_56ca9b0e-8fdd-4153-9667-6b62dd819f78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_56ca9b0e-8fdd-4153-9667-6b62dd819f78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32de939d-a88d-4463-a7e2-2511d1ccec60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_56ca9b0e-8fdd-4153-9667-6b62dd819f78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32de939d-a88d-4463-a7e2-2511d1ccec60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_da817e7c-5200-42ff-a35d-e53b3ad1cdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32de939d-a88d-4463-a7e2-2511d1ccec60" xlink:to="loc_us-gaap_ContractualRightsMember_da817e7c-5200-42ff-a35d-e53b3ad1cdaf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworkMember_791966be-ce25-493d-a95e-6c6aea19dfb4" xlink:href="moh-20221231.xsd#moh_ProviderNetworkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32de939d-a88d-4463-a7e2-2511d1ccec60" xlink:to="loc_moh_ProviderNetworkMember_791966be-ce25-493d-a95e-6c6aea19dfb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a43f288-4c6b-4631-82cc-ba5f5332b80c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:to="loc_srt_RangeAxis_7a43f288-4c6b-4631-82cc-ba5f5332b80c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7a43f288-4c6b-4631-82cc-ba5f5332b80c_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7a43f288-4c6b-4631-82cc-ba5f5332b80c" xlink:to="loc_srt_RangeMember_7a43f288-4c6b-4631-82cc-ba5f5332b80c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49cede5f-a36e-458e-9c3a-99210d8e974a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7a43f288-4c6b-4631-82cc-ba5f5332b80c" xlink:to="loc_srt_RangeMember_49cede5f-a36e-458e-9c3a-99210d8e974a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_98d15b1c-c234-454d-a8e3-59f1c7d31181" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49cede5f-a36e-458e-9c3a-99210d8e974a" xlink:to="loc_srt_MinimumMember_98d15b1c-c234-454d-a8e3-59f1c7d31181" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_729d9a56-b0da-41d9-a5cb-403a46840722" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_49cede5f-a36e-458e-9c3a-99210d8e974a" xlink:to="loc_srt_MaximumMember_729d9a56-b0da-41d9-a5cb-403a46840722" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended" id="i1287378ca9a6483a9f8551bfef89afca_FairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_ea8d17df-b5af-4ebf-842b-01df920e40f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_ea8d17df-b5af-4ebf-842b-01df920e40f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fe68fccd-d8c7-42a3-9d49-4281ba5a6787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fe68fccd-d8c7-42a3-9d49-4281ba5a6787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_856d4ace-3311-4318-8fcb-2efe03b5e4cd" xlink:href="moh-20221231.xsd#moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_856d4ace-3311-4318-8fcb-2efe03b5e4cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_544954f8-c891-4478-9c79-82895575b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_544954f8-c891-4478-9c79-82895575b80e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_088cadb7-e856-4254-9834-3fd15d5f4fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_088cadb7-e856-4254-9834-3fd15d5f4fe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4b528282-f220-4bd4-b054-929d9bbc23c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4b528282-f220-4bd4-b054-929d9bbc23c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b528282-f220-4bd4-b054-929d9bbc23c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b528282-f220-4bd4-b054-929d9bbc23c0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_4b528282-f220-4bd4-b054-929d9bbc23c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47a6afe3-37bb-41bd-95c9-b61a365c4aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b528282-f220-4bd4-b054-929d9bbc23c0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47a6afe3-37bb-41bd-95c9-b61a365c4aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_a01e6907-429e-4c2f-bffa-e0137aa600db" xlink:href="moh-20221231.xsd#moh_PassportHealthPlanIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47a6afe3-37bb-41bd-95c9-b61a365c4aae" xlink:to="loc_moh_PassportHealthPlanIncMember_a01e6907-429e-4c2f-bffa-e0137aa600db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af646c11-cb88-46dc-93d6-a64cfcdf7cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af646c11-cb88-46dc-93d6-a64cfcdf7cf0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_af646c11-cb88-46dc-93d6-a64cfcdf7cf0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af646c11-cb88-46dc-93d6-a64cfcdf7cf0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_af646c11-cb88-46dc-93d6-a64cfcdf7cf0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3525b93a-8fee-4924-9243-8152e2226c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af646c11-cb88-46dc-93d6-a64cfcdf7cf0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3525b93a-8fee-4924-9243-8152e2226c72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_05a3b316-d567-4330-82f3-5c4779e01a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3525b93a-8fee-4924-9243-8152e2226c72" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_05a3b316-d567-4330-82f3-5c4779e01a8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c0850367-02ff-4aec-81b8-e8bed03a11d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c0850367-02ff-4aec-81b8-e8bed03a11d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MinimumMemberEnrollmentTargetsMember_c8127242-3812-4983-bc92-4f52c9a0abcf" xlink:href="moh-20221231.xsd#moh_MinimumMemberEnrollmentTargetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c0850367-02ff-4aec-81b8-e8bed03a11d0" xlink:to="loc_moh_MinimumMemberEnrollmentTargetsMember_c8127242-3812-4983-bc92-4f52c9a0abcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingIncomeGuaranteeMember_c56e3224-8546-40a5-b5a3-26243b00a194" xlink:href="moh-20221231.xsd#moh_OperatingIncomeGuaranteeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c0850367-02ff-4aec-81b8-e8bed03a11d0" xlink:to="loc_moh_OperatingIncomeGuaranteeMember_c56e3224-8546-40a5-b5a3-26243b00a194" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended" id="ia722b280430840fdb35c27bbf7994a61_FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_23b19fb1-ad00-45a0-8750-7cf203be61b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_23b19fb1-ad00-45a0-8750-7cf203be61b5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_67a3bf43-8723-49fc-adb3-4ecba5fdc04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_67a3bf43-8723-49fc-adb3-4ecba5fdc04f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7e7fe93c-d9e4-4add-8fdd-42b9cd2a99da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7e7fe93c-d9e4-4add-8fdd-42b9cd2a99da" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d561646d-97c4-4229-b9cf-f9f329d19f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d561646d-97c4-4229-b9cf-f9f329d19f56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_96cbf9f3-9e19-4088-a084-14994debe8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_96cbf9f3-9e19-4088-a084-14994debe8a6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_23b19fb1-ad00-45a0-8750-7cf203be61b5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62a43300-481c-4c01-833b-fdd30535845f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62a43300-481c-4c01-833b-fdd30535845f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62a43300-481c-4c01-833b-fdd30535845f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62a43300-481c-4c01-833b-fdd30535845f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_62a43300-481c-4c01-833b-fdd30535845f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62a43300-481c-4c01-833b-fdd30535845f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b51e2e1b-d4be-46f2-a007-cf492f2f7453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b51e2e1b-d4be-46f2-a007-cf492f2f7453" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_505f1d1a-a457-4523-aa1d-57349c424910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_505f1d1a-a457-4523-aa1d-57349c424910" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_acc76ea1-187a-4e43-8dff-93d0b45c3295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_acc76ea1-187a-4e43-8dff-93d0b45c3295" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_152f190e-12b6-4c91-9b8e-51239980221a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_152f190e-12b6-4c91-9b8e-51239980221a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b0df19fa-e70d-4f85-a41f-a3da8866d93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b0df19fa-e70d-4f85-a41f-a3da8866d93a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2e1e27a7-5302-4068-806d-6c6ea23bc6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2e1e27a7-5302-4068-806d-6c6ea23bc6cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_509f0963-966e-4e31-974c-60d5cf89ec68" xlink:href="moh-20221231.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_moh_MunicipalSecuritiesMember_509f0963-966e-4e31-974c-60d5cf89ec68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_fc1492de-8996-45aa-a6b7-0c079a40ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_fc1492de-8996-45aa-a6b7-0c079a40ad54" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_dc45ecec-b4f0-4253-8190-b2df7b3dbd68" xlink:href="moh-20221231.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_moh_OtherSecuritiesMember_dc45ecec-b4f0-4253-8190-b2df7b3dbd68" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended" id="ibb9c32f8ccde44c1a14d043e107b22aa_FairValueMeasurementsLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b01bbba0-6246-4a50-869f-90d65f283df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8cfc22e0-7e78-4b5d-8c44-5f0180d19652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b01bbba0-6246-4a50-869f-90d65f283df3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8cfc22e0-7e78-4b5d-8c44-5f0180d19652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5545b41b-3c29-4118-89a1-013408175104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b01bbba0-6246-4a50-869f-90d65f283df3" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5545b41b-3c29-4118-89a1-013408175104" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b01bbba0-6246-4a50-869f-90d65f283df3" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7927ce36-8c6f-4b25-a356-5df5983e9d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7927ce36-8c6f-4b25-a356-5df5983e9d2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7927ce36-8c6f-4b25-a356-5df5983e9d2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7927ce36-8c6f-4b25-a356-5df5983e9d2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7927ce36-8c6f-4b25-a356-5df5983e9d2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1d8ec47d-f0a6-44ba-8ae9-91891ba952b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7927ce36-8c6f-4b25-a356-5df5983e9d2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1d8ec47d-f0a6-44ba-8ae9-91891ba952b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_75ab6828-390b-4fd0-a36f-3611e38c7f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1d8ec47d-f0a6-44ba-8ae9-91891ba952b5" xlink:to="loc_us-gaap_SeniorNotesMember_75ab6828-390b-4fd0-a36f-3611e38c7f6b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8ed5e058-2653-43bd-8065-5984c1c70cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:to="loc_us-gaap_DebtInstrumentAxis_8ed5e058-2653-43bd-8065-5984c1c70cda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_8ed5e058-2653-43bd-8065-5984c1c70cda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ed5e058-2653-43bd-8065-5984c1c70cda" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_8ed5e058-2653-43bd-8065-5984c1c70cda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ed5e058-2653-43bd-8065-5984c1c70cda" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_866d67b3-8580-44ac-b830-36f3b07b27c5" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:to="loc_moh_A4375SeniorNotesMember_866d67b3-8580-44ac-b830-36f3b07b27c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_61069795-ba9e-4161-a7bc-63fe2df6b613" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_61069795-ba9e-4161-a7bc-63fe2df6b613" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_9a16a8a7-1a14-448d-bd78-eb1993404b01" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:to="loc_moh_A3875SeniorNotesMember_9a16a8a7-1a14-448d-bd78-eb1993404b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_434e3a0b-0e07-4eb5-822c-d2aad712f574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_434e3a0b-0e07-4eb5-822c-d2aad712f574" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_434e3a0b-0e07-4eb5-822c-d2aad712f574_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_434e3a0b-0e07-4eb5-822c-d2aad712f574" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_434e3a0b-0e07-4eb5-822c-d2aad712f574_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_403fb6fe-7286-4701-870e-2aee26e352eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_434e3a0b-0e07-4eb5-822c-d2aad712f574" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_403fb6fe-7286-4701-870e-2aee26e352eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_432da0df-a608-49e5-a671-e64fa770a72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_403fb6fe-7286-4701-870e-2aee26e352eb" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_432da0df-a608-49e5-a671-e64fa770a72b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e4f23ce9-c38c-4522-8aad-cc73540dd383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_432da0df-a608-49e5-a671-e64fa770a72b" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e4f23ce9-c38c-4522-8aad-cc73540dd383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b920462b-4d35-41b9-a28e-35ee042c4a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_432da0df-a608-49e5-a671-e64fa770a72b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b920462b-4d35-41b9-a28e-35ee042c4a94" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsScheduleofInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="extended" id="i4d3bd28f56a846a2ba785a4cd9b73a9d_InvestmentsScheduleofInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_fbdea1ab-f5b4-4d7c-a917-e864543f2f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_fbdea1ab-f5b4-4d7c-a917-e864543f2f24" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f9d70d17-f3af-4d26-9873-39f01cee0326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f9d70d17-f3af-4d26-9873-39f01cee0326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b5aa6465-1749-4154-ab9f-6d88a5cae1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b5aa6465-1749-4154-ab9f-6d88a5cae1b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_86194007-91ab-4a16-baab-f3d18865b73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_86194007-91ab-4a16-baab-f3d18865b73d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5dd6e9cb-b679-470e-a823-82b702c9ce70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5dd6e9cb-b679-470e-a823-82b702c9ce70" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7aa141c9-b7ab-4f9f-b222-473cb10588fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5dd6e9cb-b679-470e-a823-82b702c9ce70" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7aa141c9-b7ab-4f9f-b222-473cb10588fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7aa141c9-b7ab-4f9f-b222-473cb10588fd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7aa141c9-b7ab-4f9f-b222-473cb10588fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7aa141c9-b7ab-4f9f-b222-473cb10588fd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7aa141c9-b7ab-4f9f-b222-473cb10588fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_669ee2e8-cee2-434b-958d-920af289f853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_669ee2e8-cee2-434b-958d-920af289f853" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_c404ae0f-1107-4ea2-bf61-cd8c5edcd519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_c404ae0f-1107-4ea2-bf61-cd8c5edcd519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_69cfed87-65ba-4fcf-a856-f3187e217bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_69cfed87-65ba-4fcf-a856-f3187e217bbc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_97777ce9-a615-436c-827a-961337e2523c" xlink:href="moh-20221231.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_moh_MunicipalSecuritiesMember_97777ce9-a615-436c-827a-961337e2523c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_ffb2836b-1332-449b-bccd-21f0dbe63eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_ffb2836b-1332-449b-bccd-21f0dbe63eac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_302b7302-6958-4031-ad6d-2c91e4d53909" xlink:href="moh-20221231.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_moh_OtherSecuritiesMember_302b7302-6958-4031-ad6d-2c91e4d53909" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsAvailableforSaleDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails" xlink:type="extended" id="i550984a8e28d4123bb2a7dba7e3c80e4_InvestmentsAvailableforSaleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ccd3b8dc-15d8-4523-ba1f-d43aebb0f416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ccd3b8dc-15d8-4523-ba1f-d43aebb0f416" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f3377ce-9a1b-45e8-b582-48433ae0c31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f3377ce-9a1b-45e8-b582-48433ae0c31e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_cee802fc-5c39-41db-acf4-cad6e03e88d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_cee802fc-5c39-41db-acf4-cad6e03e88d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bca367f4-e37d-4760-9172-5a1ef1eb204a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bca367f4-e37d-4760-9172-5a1ef1eb204a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a9f1da7e-3a3e-4ede-8be6-8cd623b3bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a9f1da7e-3a3e-4ede-8be6-8cd623b3bbcf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3942fa46-ec64-45ba-b899-da5f023c5be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3942fa46-ec64-45ba-b899-da5f023c5be4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dcd9a2bc-8e70-48ad-9f24-59f366fc85d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dcd9a2bc-8e70-48ad-9f24-59f366fc85d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4f063582-2ad8-4ced-abc3-ad41cc24b221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dcd9a2bc-8e70-48ad-9f24-59f366fc85d7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4f063582-2ad8-4ced-abc3-ad41cc24b221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f063582-2ad8-4ced-abc3-ad41cc24b221_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f063582-2ad8-4ced-abc3-ad41cc24b221" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4f063582-2ad8-4ced-abc3-ad41cc24b221_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f063582-2ad8-4ced-abc3-ad41cc24b221" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_58819122-825d-41fc-9a65-0e26bb35779e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_58819122-825d-41fc-9a65-0e26bb35779e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_fd76084f-223e-4740-a501-a953d590363f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_fd76084f-223e-4740-a501-a953d590363f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e5cf20cf-8391-4461-9ee9-9ec391e0fa82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e5cf20cf-8391-4461-9ee9-9ec391e0fa82" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_27d441e7-ace8-429a-a682-ae3ee57c54e2" xlink:href="moh-20221231.xsd#moh_MunicipalSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_moh_MunicipalSecuritiesMember_27d441e7-ace8-429a-a682-ae3ee57c54e2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_83254571-72d1-4e68-9194-d5abac5d667d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_83254571-72d1-4e68-9194-d5abac5d667d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_cc0665c5-57c6-4ec9-819a-2c19a91b0007" xlink:href="moh-20221231.xsd#moh_OtherSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_moh_OtherSecuritiesMember_cc0665c5-57c6-4ec9-819a-2c19a91b0007" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsBalancesofRestrictedInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails" xlink:type="extended" id="ib81bda2451e0415b8d5959ce17937a84_InvestmentsBalancesofRestrictedInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_46530532-acab-4c8a-9b41-8cbfbc9076aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_d571384c-9318-43c5-bd11-8393473d5c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_46530532-acab-4c8a-9b41-8cbfbc9076aa" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_d571384c-9318-43c5-bd11-8393473d5c97" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_71ac35da-549a-49e9-804d-20b801f62427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_46530532-acab-4c8a-9b41-8cbfbc9076aa" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_71ac35da-549a-49e9-804d-20b801f62427" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_71ac35da-549a-49e9-804d-20b801f62427" xlink:to="loc_us-gaap_FinancialInstrumentAxis_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_dca42daa-22c5-474d-b134-12b0d28af913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_dca42daa-22c5-474d-b134-12b0d28af913" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_ac4a3da2-85ef-4452-8133-33238ca0c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_ac4a3da2-85ef-4452-8133-33238ca0c3b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_dee1946d-cf37-43f0-9d18-de84d43b76da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_dee1946d-cf37-43f0-9d18-de84d43b76da" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails" xlink:type="extended" id="ibee8547d57044db7adcbfb595a762200_PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca6734a1-32d0-40d8-991d-99dda006b929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a66b78c9-e5f5-460e-8728-2eccbdd7576f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca6734a1-32d0-40d8-991d-99dda006b929" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a66b78c9-e5f5-460e-8728-2eccbdd7576f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_450cdd07-1f84-443b-9521-efd5aa1d8633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca6734a1-32d0-40d8-991d-99dda006b929" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_450cdd07-1f84-443b-9521-efd5aa1d8633" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca6734a1-32d0-40d8-991d-99dda006b929" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7942a08-3698-4ab9-9af6-2c8d11092053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7942a08-3698-4ab9-9af6-2c8d11092053" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7942a08-3698-4ab9-9af6-2c8d11092053_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7942a08-3698-4ab9-9af6-2c8d11092053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a7942a08-3698-4ab9-9af6-2c8d11092053_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7942a08-3698-4ab9-9af6-2c8d11092053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PropertyAndEquipmentMember_ea164a78-dfe5-4583-a6d9-be0a5067539f" xlink:href="moh-20221231.xsd#moh_PropertyAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:to="loc_moh_PropertyAndEquipmentMember_ea164a78-dfe5-4583-a6d9-be0a5067539f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_d2ae6893-984f-4b2b-adb4-3ef1924c3a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_d2ae6893-984f-4b2b-adb4-3ef1924c3a45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_967adda4-8769-4d10-8cfa-917ea6b9a52c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_967adda4-8769-4d10-8cfa-917ea6b9a52c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_f0857e00-defd-45fa-9c7b-ec2e74e1a04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_f0857e00-defd-45fa-9c7b-ec2e74e1a04f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fb573883-0830-42f4-9416-0d05597743e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:to="loc_srt_RangeAxis_fb573883-0830-42f4-9416-0d05597743e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fb573883-0830-42f4-9416-0d05597743e1_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fb573883-0830-42f4-9416-0d05597743e1" xlink:to="loc_srt_RangeMember_fb573883-0830-42f4-9416-0d05597743e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ba3bb65-9eba-4003-a554-e913f7e5b7ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fb573883-0830-42f4-9416-0d05597743e1" xlink:to="loc_srt_RangeMember_0ba3bb65-9eba-4003-a554-e913f7e5b7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7fc4cd06-1af5-4a1f-9309-5e7b573f21c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0ba3bb65-9eba-4003-a554-e913f7e5b7ca" xlink:to="loc_srt_MinimumMember_7fc4cd06-1af5-4a1f-9309-5e7b573f21c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_13da56fe-c7ec-4c54-ba6d-d14c329fdaaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_0ba3bb65-9eba-4003-a554-e913f7e5b7ca" xlink:to="loc_srt_MaximumMember_13da56fe-c7ec-4c54-ba6d-d14c329fdaaa" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails" xlink:type="extended" id="i347029aebc71426f89be9e2bae5d70f1_PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1b7d2b1e-a749-4496-b1bc-3f3f5a055806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1b7d2b1e-a749-4496-b1bc-3f3f5a055806" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_cc420174-6ec3-45e8-8626-371d77e29684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_cc420174-6ec3-45e8-8626-371d77e29684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_058f7512-9e70-44d6-84fd-be3efb1ab039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_058f7512-9e70-44d6-84fd-be3efb1ab039" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_febf85fb-93e2-44b5-a40a-b14402a27520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_febf85fb-93e2-44b5-a40a-b14402a27520" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_97dfc79a-2c0b-4762-a55d-79c14f36221c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_97dfc79a-2c0b-4762-a55d-79c14f36221c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5ac1dedc-106d-412a-863f-3575675b91b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5ac1dedc-106d-412a-863f-3575675b91b8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_828886a4-853d-48de-ad47-000a7367e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_828886a4-853d-48de-ad47-000a7367e0ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acfd0e53-839e-438c-8714-baf4abc34454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_828886a4-853d-48de-ad47-000a7367e0ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acfd0e53-839e-438c-8714-baf4abc34454" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_acfd0e53-839e-438c-8714-baf4abc34454_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acfd0e53-839e-438c-8714-baf4abc34454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_acfd0e53-839e-438c-8714-baf4abc34454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acfd0e53-839e-438c-8714-baf4abc34454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e0969b86-3cf1-4719-8f26-c8983399e028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e0969b86-3cf1-4719-8f26-c8983399e028" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PropertyAndEquipmentMember_94bbce1d-53b6-4e77-bf96-9b2b30b134bb" xlink:href="moh-20221231.xsd#moh_PropertyAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:to="loc_moh_PropertyAndEquipmentMember_94bbce1d-53b6-4e77-bf96-9b2b30b134bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_4fa4bb6b-6acb-4ec4-9f50-ea5a3976c1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_4fa4bb6b-6acb-4ec4-9f50-ea5a3976c1f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_231565e6-29c6-49dc-a43c-33d880337f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:to="loc_us-gaap_LandMember_231565e6-29c6-49dc-a43c-33d880337f54" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails" xlink:type="extended" id="iaf580bd9107145baaa2fc4f78bfff07d_GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_1b4424a5-679d-4337-b5ab-87b80b3dbe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1b4424a5-679d-4337-b5ab-87b80b3dbe1c" xlink:to="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4476ca4f-c2df-490c-8a19-f36a15e5466c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:to="loc_us-gaap_Goodwill_4476ca4f-c2df-490c-8a19-f36a15e5466c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_45c7a035-edfe-4900-b54a-0e72a0de7941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_45c7a035-edfe-4900-b54a-0e72a0de7941" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_25d67f7a-4024-44c7-857a-8356215979f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_390ad8b5-510b-47d9-ac7f-226f9658091c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_1b4424a5-679d-4337-b5ab-87b80b3dbe1c" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_390ad8b5-510b-47d9-ac7f-226f9658091c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_15035e97-536d-474b-b6cc-86ef9ae2ec81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_390ad8b5-510b-47d9-ac7f-226f9658091c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_15035e97-536d-474b-b6cc-86ef9ae2ec81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_15035e97-536d-474b-b6cc-86ef9ae2ec81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_15035e97-536d-474b-b6cc-86ef9ae2ec81" xlink:to="loc_us-gaap_SegmentDomain_15035e97-536d-474b-b6cc-86ef9ae2ec81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_15035e97-536d-474b-b6cc-86ef9ae2ec81" xlink:to="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_618d9607-3d18-4f3e-b2f8-6814c8429b33" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:to="loc_moh_MedicaidMember_618d9607-3d18-4f3e-b2f8-6814c8429b33" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_3ae84e3a-b2a3-48d4-9d2c-6b832f7fba2b" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:to="loc_moh_MedicareMember_3ae84e3a-b2a3-48d4-9d2c-6b832f7fba2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_63ea76a6-cd72-46c7-98a4-ade47526c0b0" xlink:href="moh-20221231.xsd#moh_OtherProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:to="loc_moh_OtherProgramMember_63ea76a6-cd72-46c7-98a4-ade47526c0b0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails" xlink:type="extended" id="ida9c89aefe6c4fa79d1aa2e4ded4d33f_GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_617602c1-9285-42cb-b78c-c0fc8702cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_617602c1-9285-42cb-b78c-c0fc8702cef7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_342069c6-9ced-4e3b-9df7-9839c4bbe3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_342069c6-9ced-4e3b-9df7-9839c4bbe3af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7b899019-5f60-4e65-931a-ae5d450a0cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7b899019-5f60-4e65-931a-ae5d450a0cec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08ffff62-990e-4c93-a765-50af93ecd3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08ffff62-990e-4c93-a765-50af93ecd3d3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_423668de-bbeb-40a2-b255-ee8e21828158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08ffff62-990e-4c93-a765-50af93ecd3d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_423668de-bbeb-40a2-b255-ee8e21828158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_423668de-bbeb-40a2-b255-ee8e21828158_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_423668de-bbeb-40a2-b255-ee8e21828158" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_423668de-bbeb-40a2-b255-ee8e21828158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_423668de-bbeb-40a2-b255-ee8e21828158" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ContractRightsandLicensingAgreementsMember_3f8179da-e472-4756-9c6b-b8bb2c4d3426" xlink:href="moh-20221231.xsd#moh_ContractRightsandLicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:to="loc_moh_ContractRightsandLicensingAgreementsMember_3f8179da-e472-4756-9c6b-b8bb2c4d3426" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworksMember_476b1be7-7452-44aa-8e80-6f8ffd866a72" xlink:href="moh-20221231.xsd#moh_ProviderNetworksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:to="loc_moh_ProviderNetworksMember_476b1be7-7452-44aa-8e80-6f8ffd866a72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_bc4d4d4e-c9e3-473e-89ef-a881eccfae30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:to="loc_us-gaap_TradeNamesMember_bc4d4d4e-c9e3-473e-89ef-a881eccfae30" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails" xlink:type="extended" id="i955f165a28f54930ab2244191d6b175a_MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_f9bed94a-9398-469e-962a-9f42e950d86f" xlink:href="moh-20221231.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_f9bed94a-9398-469e-962a-9f42e950d86f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_d7818148-5642-4a4c-86a4-ea953b2157c4" xlink:href="moh-20221231.xsd#moh_PharmacyClaimsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_moh_PharmacyClaimsPayable_d7818148-5642-4a4c-86a4-ea953b2157c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_53e0fd00-ce19-462f-94c0-acf5a28d71c5" xlink:href="moh-20221231.xsd#moh_CapitationClaimsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_moh_CapitationClaimsPayable_53e0fd00-ce19-462f-94c0-acf5a28d71c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_5dd0ab0d-9b60-4d15-94b9-dae92d94a245" xlink:href="moh-20221231.xsd#moh_OtherClaimsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_moh_OtherClaimsPayable_5dd0ab0d-9b60-4d15-94b9-dae92d94a245" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9eaa8352-042b-46da-ac08-e78ce9d655fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9eaa8352-042b-46da-ac08-e78ce9d655fd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_6265f526-a859-4c52-acc1-754fb668872f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_6265f526-a859-4c52-acc1-754fb668872f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_479d4a36-fe5d-41cf-a90d-10ec861e9de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_6265f526-a859-4c52-acc1-754fb668872f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_479d4a36-fe5d-41cf-a90d-10ec861e9de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_479d4a36-fe5d-41cf-a90d-10ec861e9de0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_479d4a36-fe5d-41cf-a90d-10ec861e9de0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_479d4a36-fe5d-41cf-a90d-10ec861e9de0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5096d3f-4ef7-4139-a769-23fc2eea68ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_479d4a36-fe5d-41cf-a90d-10ec861e9de0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5096d3f-4ef7-4139-a769-23fc2eea68ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CompleteCareMember_bed04d74-6123-43d8-9ee5-abf1f26bc3bd" xlink:href="moh-20221231.xsd#moh_CompleteCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5096d3f-4ef7-4139-a769-23fc2eea68ef" xlink:to="loc_moh_CompleteCareMember_bed04d74-6123-43d8-9ee5-abf1f26bc3bd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails" xlink:type="extended" id="ifc526546e0434851a2e447767d802447_MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_647dcd7c-7d30-4b16-8ce0-e56e1c3756fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_647dcd7c-7d30-4b16-8ce0-e56e1c3756fa" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bc8d60ae-75cb-4e83-bd4e-fd3488b5352f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bc8d60ae-75cb-4e83-bd4e-fd3488b5352f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_b70eccd7-bd11-40c6-96cd-2498dd9b0756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_b70eccd7-bd11-40c6-96cd-2498dd9b0756" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_49d358b9-6840-441c-8d02-ff81fc70e22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_49d358b9-6840-441c-8d02-ff81fc70e22a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_60661b7c-c1e0-43b1-b41d-e1141aa46e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_60661b7c-c1e0-43b1-b41d-e1141aa46e56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0b35c9ef-28e7-4bdf-8c03-64d37fafb674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0b35c9ef-28e7-4bdf-8c03-64d37fafb674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_12ad8087-a94f-4929-9399-ae4dd56e6107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_12ad8087-a94f-4929-9399-ae4dd56e6107" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_9483be90-1194-4d6d-a755-00ae324a04aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_9483be90-1194-4d6d-a755-00ae324a04aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_387c0f54-8e88-45c3-9fc9-6a9fb88b2e88" xlink:href="moh-20221231.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_387c0f54-8e88-45c3-9fc9-6a9fb88b2e88" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_a2077db1-6084-4ec1-9f6a-1f4e8036d8eb" xlink:href="moh-20221231.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_a2077db1-6084-4ec1-9f6a-1f4e8036d8eb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9b22442e-4331-4195-81f2-1b12dc566785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_46cc5bf2-6eed-4753-af76-dd2c63916c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_647dcd7c-7d30-4b16-8ce0-e56e1c3756fa" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_46cc5bf2-6eed-4753-af76-dd2c63916c66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f97f4691-8bc4-41d0-a5df-ac2b794b0981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_46cc5bf2-6eed-4753-af76-dd2c63916c66" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f97f4691-8bc4-41d0-a5df-ac2b794b0981" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f97f4691-8bc4-41d0-a5df-ac2b794b0981_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f97f4691-8bc4-41d0-a5df-ac2b794b0981" xlink:to="loc_us-gaap_SegmentDomain_f97f4691-8bc4-41d0-a5df-ac2b794b0981_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f97f4691-8bc4-41d0-a5df-ac2b794b0981" xlink:to="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_8b0956c5-f710-4bf2-9d1a-c4967450943d" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:to="loc_moh_MedicaidMember_8b0956c5-f710-4bf2-9d1a-c4967450943d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_b36d788c-dda0-4a78-bd9f-71e2ece439a1" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:to="loc_moh_MedicareMember_b36d788c-dda0-4a78-bd9f-71e2ece439a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_6935db7c-fef8-4c3a-9aba-01cb0334f6fb" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:to="loc_moh_MarketplaceMember_6935db7c-fef8-4c3a-9aba-01cb0334f6fb" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails" xlink:type="extended" id="i174b4d96ca4e42e7ad931dd692d71070_MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_d735514c-3c52-4edd-b296-9abbc0998c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_cbb478b5-21b6-4d6f-b359-b596c8f8a88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_d735514c-3c52-4edd-b296-9abbc0998c26" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_cbb478b5-21b6-4d6f-b359-b596c8f8a88c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_e0929860-2f14-4953-a59c-eb21b2ac09f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_d735514c-3c52-4edd-b296-9abbc0998c26" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_e0929860-2f14-4953-a59c-eb21b2ac09f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_e0929860-2f14-4953-a59c-eb21b2ac09f1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c" xlink:to="loc_us-gaap_SegmentDomain_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c" xlink:to="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_6be29dc5-377f-4b6f-ae0b-39f975ecb92b" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:to="loc_moh_MedicaidMember_6be29dc5-377f-4b6f-ae0b-39f975ecb92b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_ccbb1002-112c-4ab9-9e46-e797f60a9278" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:to="loc_moh_MedicareMember_ccbb1002-112c-4ab9-9e46-e797f60a9278" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_1a4da684-6a78-4e28-8855-3e77674f3e08" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:to="loc_moh_MarketplaceMember_1a4da684-6a78-4e28-8855-3e77674f3e08" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails" xlink:type="extended" id="i9cfdaf1104ce43488845362b88646856_MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_962b9c90-a7b5-44d0-a73f-d9ebcf6a1fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_962b9c90-a7b5-44d0-a73f-d9ebcf6a1fd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment_67dbae9b-a39a-451a-9391-5753ad0fdb99" xlink:href="moh-20221231.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment_67dbae9b-a39a-451a-9391-5753ad0fdb99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_c10ade16-88f7-4807-a088-1a6a54f6f83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_c10ade16-88f7-4807-a088-1a6a54f6f83a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_6571ea63-754e-480b-8cb1-b10eeafe8ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_6571ea63-754e-480b-8cb1-b10eeafe8ce5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_27247a47-f517-4656-9120-2f2f76f9490b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_27247a47-f517-4656-9120-2f2f76f9490b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_ba9089a3-edc3-4c6e-a5e9-24e859d9e735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_27247a47-f517-4656-9120-2f2f76f9490b" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_ba9089a3-edc3-4c6e-a5e9-24e859d9e735" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_ba9089a3-edc3-4c6e-a5e9-24e859d9e735_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_ba9089a3-edc3-4c6e-a5e9-24e859d9e735" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_ba9089a3-edc3-4c6e-a5e9-24e859d9e735_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_ba9089a3-edc3-4c6e-a5e9-24e859d9e735" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_4bc1d4ae-0e4f-4bc5-9ef8-dfaea7701d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_4bc1d4ae-0e4f-4bc5-9ef8-dfaea7701d9b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_7f58a152-48a9-434a-a6fc-0ba34407def6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_7f58a152-48a9-434a-a6fc-0ba34407def6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_f2520cac-2c1b-4e91-954d-a789fba751d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_f2520cac-2c1b-4e91-954d-a789fba751d8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails" xlink:type="extended" id="i2b0e96134c1a4eb8b826309d5680769f_MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_ad390960-fec9-4ced-a547-8df477f09d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e1e2f959-33c6-4bb8-ac8c-4b23758d4a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductInformationLineItems_ad390960-fec9-4ced-a547-8df477f09d29" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e1e2f959-33c6-4bb8-ac8c-4b23758d4a22" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_21723bf1-5022-41ea-b3f9-2fa11abfbe4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ProductInformationLineItems_ad390960-fec9-4ced-a547-8df477f09d29" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_21723bf1-5022-41ea-b3f9-2fa11abfbe4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_21723bf1-5022-41ea-b3f9-2fa11abfbe4b" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_2bfb38e3-dac0-4e9a-b858-ae2fec565c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2020Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_2bfb38e3-dac0-4e9a-b858-ae2fec565c48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_ddaf99cd-c6da-4673-b45b-8b9fc2f492fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2021Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_ddaf99cd-c6da-4673-b45b-8b9fc2f492fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_cc52e845-d4ac-462c-9f43-169e771bbae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_cc52e845-d4ac-462c-9f43-169e771bbae0" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtMaturitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtMaturitiesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtMaturitiesDetails" xlink:type="extended" id="i8c8eee1f62a64507a9b264164bb32c3b_DebtMaturitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e964848-b3e4-4eec-8497-0a4c87a29e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e964848-b3e4-4eec-8497-0a4c87a29e45" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_01153644-5171-4754-bc90-584724170311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_01153644-5171-4754-bc90-584724170311" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_89d289f9-6d13-400d-af4e-4360c529d4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_89d289f9-6d13-400d-af4e-4360c529d4c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_47b2f57b-231f-42d5-ae35-2955f2325b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_47b2f57b-231f-42d5-ae35-2955f2325b8d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ba499caa-ed46-4a3f-b9e9-dc8204dbc035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ba499caa-ed46-4a3f-b9e9-dc8204dbc035" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e2bd08a7-5654-4786-a65d-1e636fe1bc52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e2bd08a7-5654-4786-a65d-1e636fe1bc52" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2a787a31-e690-447b-aa6f-206159b12249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2a787a31-e690-447b-aa6f-206159b12249" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7cad52cc-db17-4f21-a66d-d4fe95078096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7cad52cc-db17-4f21-a66d-d4fe95078096" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_28937912-f686-4539-a37d-1c6ace176ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_28937912-f686-4539-a37d-1c6ace176ec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_28937912-f686-4539-a37d-1c6ace176ec0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_28937912-f686-4539-a37d-1c6ace176ec0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_28937912-f686-4539-a37d-1c6ace176ec0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2f2baa53-6a30-4bc0-992a-81391bf05566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_28937912-f686-4539-a37d-1c6ace176ec0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2f2baa53-6a30-4bc0-992a-81391bf05566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_21395a13-66ae-4d04-82f9-3fdb93aa590e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2f2baa53-6a30-4bc0-992a-81391bf05566" xlink:to="loc_us-gaap_SeniorNotesMember_21395a13-66ae-4d04-82f9-3fdb93aa590e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7351ab86-438b-4a28-84f7-61c7c7b3051e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:to="loc_us-gaap_DebtInstrumentAxis_7351ab86-438b-4a28-84f7-61c7c7b3051e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7351ab86-438b-4a28-84f7-61c7c7b3051e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7351ab86-438b-4a28-84f7-61c7c7b3051e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7351ab86-438b-4a28-84f7-61c7c7b3051e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7351ab86-438b-4a28-84f7-61c7c7b3051e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_c758cb09-6e70-44f6-91d0-4559992d3d80" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:to="loc_moh_A4375SeniorNotesMember_c758cb09-6e70-44f6-91d0-4559992d3d80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e529111e-5459-433d-88e1-b7365d82801b" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e529111e-5459-433d-88e1-b7365d82801b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_d2e57057-d2ee-4707-bf74-e87dd90efc3d" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:to="loc_moh_A3875SeniorNotesMember_d2e57057-d2ee-4707-bf74-e87dd90efc3d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended" id="i9fa732750ecd4ca6b3ec5ae505fc64be_DebtScheduleofLongTermDebtDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36bc1fd9-a577-4aaf-93c2-80469372abcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36bc1fd9-a577-4aaf-93c2-80469372abcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_86fb6daf-f9e3-45c9-b2af-2d060c71c967" xlink:href="moh-20221231.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_86fb6daf-f9e3-45c9-b2af-2d060c71c967" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_0ba03ed2-2b49-4693-9d0f-3a1ea07450d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_0ba03ed2-2b49-4693-9d0f-3a1ea07450d6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_73eacb91-80ee-4a05-abfb-6ab364b4c167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_73eacb91-80ee-4a05-abfb-6ab364b4c167" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_533e2b78-8a2e-478b-a26b-71133a028e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_533e2b78-8a2e-478b-a26b-71133a028e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_533e2b78-8a2e-478b-a26b-71133a028e22_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_533e2b78-8a2e-478b-a26b-71133a028e22" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_533e2b78-8a2e-478b-a26b-71133a028e22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5b37858c-e5ce-42eb-8f54-0a252afc7c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_533e2b78-8a2e-478b-a26b-71133a028e22" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5b37858c-e5ce-42eb-8f54-0a252afc7c33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1a7b80ab-0ce2-44c8-a88b-7864a0588013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5b37858c-e5ce-42eb-8f54-0a252afc7c33" xlink:to="loc_us-gaap_SeniorNotesMember_1a7b80ab-0ce2-44c8-a88b-7864a0588013" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9357f18e-cc82-4e4f-8613-5250cf37cf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:to="loc_us-gaap_DebtInstrumentAxis_9357f18e-cc82-4e4f-8613-5250cf37cf0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9357f18e-cc82-4e4f-8613-5250cf37cf0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9357f18e-cc82-4e4f-8613-5250cf37cf0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9357f18e-cc82-4e4f-8613-5250cf37cf0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9357f18e-cc82-4e4f-8613-5250cf37cf0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_12651c16-b73f-4007-84d9-d140c3da8c58" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:to="loc_moh_A4375SeniorNotesMember_12651c16-b73f-4007-84d9-d140c3da8c58" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e7ddc461-deca-4902-a997-e341250ead1b" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e7ddc461-deca-4902-a997-e341250ead1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_a9bdb99c-6cf0-45b5-aa0e-267f063bc4d6" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:to="loc_moh_A3875SeniorNotesMember_a9bdb99c-6cf0-45b5-aa0e-267f063bc4d6" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtCreditAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" xlink:type="extended" id="i9b45b58e355a42058e6528c194720ad0_DebtCreditAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3ef1e451-dc0f-4b01-88b4-97fcf52bbade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3ef1e451-dc0f-4b01-88b4-97fcf52bbade" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_df4c49f0-0af6-429c-982a-f9d81ab16be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:to="loc_us-gaap_DebtInstrumentTerm_df4c49f0-0af6-429c-982a-f9d81ab16be1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_fb3f0cee-e456-44c5-989e-3a98ab353b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:to="loc_us-gaap_LineOfCredit_fb3f0cee-e456-44c5-989e-3a98ab353b44" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7abcbdee-5738-4354-96aa-9f6c9ceff7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7abcbdee-5738-4354-96aa-9f6c9ceff7f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_7abcbdee-5738-4354-96aa-9f6c9ceff7f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7abcbdee-5738-4354-96aa-9f6c9ceff7f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_7abcbdee-5738-4354-96aa-9f6c9ceff7f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_358a24c7-d6f3-4de5-995a-a4bca6ec6f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7abcbdee-5738-4354-96aa-9f6c9ceff7f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_358a24c7-d6f3-4de5-995a-a4bca6ec6f27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cf18a401-3f90-4080-9403-c81523218686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_358a24c7-d6f3-4de5-995a-a4bca6ec6f27" xlink:to="loc_us-gaap_LineOfCreditMember_cf18a401-3f90-4080-9403-c81523218686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:to="loc_us-gaap_CreditFacilityAxis_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d" xlink:to="loc_us-gaap_CreditFacilityDomain_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e6ffe991-195b-4730-9c87-581484410269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d" xlink:to="loc_us-gaap_CreditFacilityDomain_e6ffe991-195b-4730-9c87-581484410269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_239c6bd5-20c9-4ff6-bd0c-1e23e2a38bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e6ffe991-195b-4730-9c87-581484410269" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_239c6bd5-20c9-4ff6-bd0c-1e23e2a38bae" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtSeniorNotesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtSeniorNotesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/DebtSeniorNotesDetails" xlink:type="extended" id="i1d02a7b168814ea79f21b80116129607_DebtSeniorNotesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f9edf746-afe9-4387-a360-830949765d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f9edf746-afe9-4387-a360-830949765d0d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c3a52dfa-c13c-4836-9588-b74e2e501411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c3a52dfa-c13c-4836-9588-b74e2e501411" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c5acc054-6f28-4b4c-b495-6084baaf3326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c5acc054-6f28-4b4c-b495-6084baaf3326" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:to="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_50ea58a7-f420-4c4b-8557-761ff2ff89a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_50ea58a7-f420-4c4b-8557-761ff2ff89a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_50ea58a7-f420-4c4b-8557-761ff2ff89a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_50ea58a7-f420-4c4b-8557-761ff2ff89a1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_50ea58a7-f420-4c4b-8557-761ff2ff89a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3cf24f72-2cd2-4c90-9099-636237da6fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_50ea58a7-f420-4c4b-8557-761ff2ff89a1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3cf24f72-2cd2-4c90-9099-636237da6fa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b3455055-098e-4161-aa52-5b646f6e93db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3cf24f72-2cd2-4c90-9099-636237da6fa8" xlink:to="loc_us-gaap_SeniorNotesMember_b3455055-098e-4161-aa52-5b646f6e93db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b0dc5d7c-4166-4f24-8576-2d2c53c04df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:to="loc_us-gaap_DebtInstrumentAxis_b0dc5d7c-4166-4f24-8576-2d2c53c04df0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b0dc5d7c-4166-4f24-8576-2d2c53c04df0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b0dc5d7c-4166-4f24-8576-2d2c53c04df0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b0dc5d7c-4166-4f24-8576-2d2c53c04df0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b0dc5d7c-4166-4f24-8576-2d2c53c04df0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_072fc66e-a312-4695-950e-534a8efe66c9" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:to="loc_moh_A4375SeniorNotesMember_072fc66e-a312-4695-950e-534a8efe66c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_92eaadda-9316-4ba2-9e14-228905587c8b" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_92eaadda-9316-4ba2-9e14-228905587c8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_3597229f-dc38-434f-875d-6b9b851bec41" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:to="loc_moh_A3875SeniorNotesMember_3597229f-dc38-434f-875d-6b9b851bec41" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended" id="i7c0e068639ca48408cca9df395632c16_IncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e052a519-7300-4191-813f-075c8b7d213d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e052a519-7300-4191-813f-075c8b7d213d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_37e2cb58-2cb4-45b3-a590-fadad1f5aa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_37e2cb58-2cb4-45b3-a590-fadad1f5aa3d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_fa563822-96cc-46a0-bce4-fc5653d9312c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_fa563822-96cc-46a0-bce4-fc5653d9312c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_df6a8ed5-df8a-496e-bae2-d8a00e7a0236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_df6a8ed5-df8a-496e-bae2-d8a00e7a0236" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e3875cd-d1f7-4aba-a278-5038db8bb306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e3875cd-d1f7-4aba-a278-5038db8bb306" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c381d7ba-40dc-4430-a267-671a93f75d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c381d7ba-40dc-4430-a267-671a93f75d20" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_581fa5c7-fab6-4318-a185-8a78cb3d675d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_581fa5c7-fab6-4318-a185-8a78cb3d675d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_81600119-d0a4-4452-a256-9330f6b77f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_81600119-d0a4-4452-a256-9330f6b77f0d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_81600119-d0a4-4452-a256-9330f6b77f0d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_fb8a3a5f-3d37-43c3-b35a-fec7ba16b71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_fb8a3a5f-3d37-43c3-b35a-fec7ba16b71e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6ba61035-23aa-47f8-836c-59058b2da689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_fb8a3a5f-3d37-43c3-b35a-fec7ba16b71e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6ba61035-23aa-47f8-836c-59058b2da689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_00131b0a-132b-4a88-91fb-5b6229077429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_fb8a3a5f-3d37-43c3-b35a-fec7ba16b71e" xlink:to="loc_us-gaap_ForeignCountryMember_00131b0a-132b-4a88-91fb-5b6229077429" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended" id="i3b63e27ce24442749c2d7fc94cf7de1a_StockholdersEquityAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2f7d7254-259b-43f6-8abf-6589f3f5dbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2f7d7254-259b-43f6-8abf-6589f3f5dbed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_8fbacd5d-6048-42f3-ad09-77e7d0435413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_8fbacd5d-6048-42f3-ad09-77e7d0435413" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a185d0ec-5202-4549-b977-21b0d15c18d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a185d0ec-5202-4549-b977-21b0d15c18d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_6875a263-4f3a-45fc-b2d5-caf67699d039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_6875a263-4f3a-45fc-b2d5-caf67699d039" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_659da748-53bf-4224-8997-03181b2e1f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_659da748-53bf-4224-8997-03181b2e1f07" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6b67a58f-2b12-4d8e-a1c7-339422b8bc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6b67a58f-2b12-4d8e-a1c7-339422b8bc6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_252a6058-46e8-44b3-93c7-4fd9a73657fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_252a6058-46e8-44b3-93c7-4fd9a73657fe" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_13cbec61-7d13-451b-a95a-e8dc1f424219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_13cbec61-7d13-451b-a95a-e8dc1f424219" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_420c202c-019e-40ae-8392-cc2418d7830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_420c202c-019e-40ae-8392-cc2418d7830e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_UnrecognizedCompensationForfeitedRate_968969d7-1422-4c83-b947-198cb8ba8a23" xlink:href="moh-20221231.xsd#moh_UnrecognizedCompensationForfeitedRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_moh_UnrecognizedCompensationForfeitedRate_968969d7-1422-4c83-b947-198cb8ba8a23" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a7cab588-24af-42e4-9fe8-ffb804f7c9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a7cab588-24af-42e4-9fe8-ffb804f7c9c2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cbdf886d-ca8c-4879-8da7-40371b1b1c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cbdf886d-ca8c-4879-8da7-40371b1b1c20" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a9c123dd-9b55-4333-b279-2359286fc080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a9c123dd-9b55-4333-b279-2359286fc080" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c1b9d565-2b69-48b1-a8d0-85aafbab63f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c1b9d565-2b69-48b1-a8d0-85aafbab63f8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FairMarketValueOfCommonStockPercentage_083a15d9-43b2-46ca-8554-f12bbeaef16e" xlink:href="moh-20221231.xsd#moh_FairMarketValueOfCommonStockPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_moh_FairMarketValueOfCommonStockPercentage_083a15d9-43b2-46ca-8554-f12bbeaef16e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_07cc1255-5a0a-4b16-b2e3-e0f3276b17c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_07cc1255-5a0a-4b16-b2e3-e0f3276b17c3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee_79b869f5-cee3-4352-b5cb-0dee4a206458" xlink:href="moh-20221231.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee_79b869f5-cee3-4352-b5cb-0dee4a206458" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_32b9aceb-3606-4778-99b8-c561ccf767b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_32b9aceb-3606-4778-99b8-c561ccf767b3" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fd51a3ba-5031-45fe-8cbe-1b2a1e7e239f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fd51a3ba-5031-45fe-8cbe-1b2a1e7e239f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a31f7e3a-d2f7-4dea-9647-37735a29d252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a31f7e3a-d2f7-4dea-9647-37735a29d252" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e26e3a59-1458-480f-b5a4-8b76f2f84d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e26e3a59-1458-480f-b5a4-8b76f2f84d3b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f6669914-38b6-46ab-84bb-b62977ff8cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f6669914-38b6-46ab-84bb-b62977ff8cf2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_755af6c9-f562-4aa0-9a31-646f6e1a2644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_755af6c9-f562-4aa0-9a31-646f6e1a2644" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b8665157-e302-40d3-89e2-a8a34546e50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b8665157-e302-40d3-89e2-a8a34546e50f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b8665157-e302-40d3-89e2-a8a34546e50f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b8665157-e302-40d3-89e2-a8a34546e50f" xlink:to="loc_us-gaap_EquityComponentDomain_b8665157-e302-40d3-89e2-a8a34546e50f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4c51108f-3d00-4f78-809d-cf1a8481714b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b8665157-e302-40d3-89e2-a8a34546e50f" xlink:to="loc_us-gaap_EquityComponentDomain_4c51108f-3d00-4f78-809d-cf1a8481714b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b1243474-a94c-4db6-be42-d18668bbe2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4c51108f-3d00-4f78-809d-cf1a8481714b" xlink:to="loc_us-gaap_CommonStockMember_b1243474-a94c-4db6-be42-d18668bbe2ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_PlanNameAxis_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8" xlink:to="loc_us-gaap_PlanNameDomain_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1da559c4-7910-4c28-9aa5-32fa39b47225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8" xlink:to="loc_us-gaap_PlanNameDomain_1da559c4-7910-4c28-9aa5-32fa39b47225" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EquityIncentivePlanMember_ff9c3875-6e61-4d68-8195-27d87b902e10" xlink:href="moh-20221231.xsd#moh_EquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1da559c4-7910-4c28-9aa5-32fa39b47225" xlink:to="loc_moh_EquityIncentivePlanMember_ff9c3875-6e61-4d68-8195-27d87b902e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a2c842f1-e89a-489e-8975-5e5c14ee0691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_AwardTypeAxis_a2c842f1-e89a-489e-8975-5e5c14ee0691" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2c842f1-e89a-489e-8975-5e5c14ee0691_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a2c842f1-e89a-489e-8975-5e5c14ee0691" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2c842f1-e89a-489e-8975-5e5c14ee0691_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a2c842f1-e89a-489e-8975-5e5c14ee0691" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_31f9baef-f10b-4c82-8968-acba2314d8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:to="loc_us-gaap_EmployeeStockMember_31f9baef-f10b-4c82-8968-acba2314d8e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_dbf7afd8-27a3-4620-beeb-cff5db42c678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:to="loc_us-gaap_RestrictedStockMember_dbf7afd8-27a3-4620-beeb-cff5db42c678" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d4f2502e-5e1e-4f64-b286-c1b089430059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:to="loc_us-gaap_PerformanceSharesMember_d4f2502e-5e1e-4f64-b286-c1b089430059" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0728c242-fb9b-4bb5-bcb0-96c84d95c158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0728c242-fb9b-4bb5-bcb0-96c84d95c158" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8e03ceb7-caca-4c9d-be2f-2675ae833ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8e03ceb7-caca-4c9d-be2f-2675ae833ff6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_8e03ceb7-caca-4c9d-be2f-2675ae833ff6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8e03ceb7-caca-4c9d-be2f-2675ae833ff6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_8e03ceb7-caca-4c9d-be2f-2675ae833ff6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_12340b47-a61d-4af2-9316-1fb3a359fb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8e03ceb7-caca-4c9d-be2f-2675ae833ff6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_12340b47-a61d-4af2-9316-1fb3a359fb49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_668718cd-3549-46a8-80d7-0e9554feb7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_12340b47-a61d-4af2-9316-1fb3a359fb49" xlink:to="loc_us-gaap_SubsequentEventMember_668718cd-3549-46a8-80d7-0e9554feb7b7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityComponentsofSharebasedCompensationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails" xlink:type="extended" id="i33a08d9ad0784107982dfe01e60807ae_StockholdersEquityComponentsofSharebasedCompensationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_574ff2a9-863b-4b27-a002-e65b37ab849c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b4f5238a-a945-4e55-a40c-15a4616190ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_574ff2a9-863b-4b27-a002-e65b37ab849c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b4f5238a-a945-4e55-a40c-15a4616190ff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_312b96df-ef72-458d-b660-961c8b0eb4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_574ff2a9-863b-4b27-a002-e65b37ab849c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_312b96df-ef72-458d-b660-961c8b0eb4ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c16f76-c38a-4d0d-a9b1-48dc9bdea1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_574ff2a9-863b-4b27-a002-e65b37ab849c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c16f76-c38a-4d0d-a9b1-48dc9bdea1bd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9340d8f2-e260-4c2a-8b69-c9c9330254f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c16f76-c38a-4d0d-a9b1-48dc9bdea1bd" xlink:to="loc_us-gaap_AwardTypeAxis_9340d8f2-e260-4c2a-8b69-c9c9330254f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9340d8f2-e260-4c2a-8b69-c9c9330254f5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_9340d8f2-e260-4c2a-8b69-c9c9330254f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9340d8f2-e260-4c2a-8b69-c9c9330254f5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9431dd-c1a8-4f94-a199-e01e7e4e78c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_9340d8f2-e260-4c2a-8b69-c9c9330254f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9431dd-c1a8-4f94-a199-e01e7e4e78c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RestrictedandPerformanceStockMember_26b99318-cee2-47a1-b77f-af043e27ba31" xlink:href="moh-20221231.xsd#moh_RestrictedandPerformanceStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9431dd-c1a8-4f94-a199-e01e7e4e78c0" xlink:to="loc_moh_RestrictedandPerformanceStockMember_26b99318-cee2-47a1-b77f-af043e27ba31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EmployeeStockPurchasePlanandStockOptionsMember_70771f5d-9b53-4bd4-a849-69343e55fd7d" xlink:href="moh-20221231.xsd#moh_EmployeeStockPurchasePlanandStockOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9431dd-c1a8-4f94-a199-e01e7e4e78c0" xlink:to="loc_moh_EmployeeStockPurchasePlanandStockOptionsMember_70771f5d-9b53-4bd4-a849-69343e55fd7d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityRestrictedandPerformanceStockActivityDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails" xlink:type="extended" id="i0065201a2d244e3b99ab5a3208a4e59c_StockholdersEquityRestrictedandPerformanceStockActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a0f1618-d560-4103-9447-0c503fe5eacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a0f1618-d560-4103-9447-0c503fe5eacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c871f89d-85c3-4f78-a3ab-8f46ba94d20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c871f89d-85c3-4f78-a3ab-8f46ba94d20a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_95e84c8b-190d-45ba-bd47-e6b83a6d3d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_95e84c8b-190d-45ba-bd47-e6b83a6d3d03" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ef3cf870-d64a-459b-b779-ceffef86d2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ef3cf870-d64a-459b-b779-ceffef86d2fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67e75dd5-dcb7-4781-b4d4-8ce2701f2e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67e75dd5-dcb7-4781-b4d4-8ce2701f2e1b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc4dd52f-5b1b-4570-9942-78da21cc11d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a0f1618-d560-4103-9447-0c503fe5eacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b949bea-e50e-4e9b-b37c-578e9a61aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b949bea-e50e-4e9b-b37c-578e9a61aed0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65999cd1-4bbd-4c3b-9642-90d79db50994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65999cd1-4bbd-4c3b-9642-90d79db50994" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f5d0f1bc-bca8-4ed6-ade3-da6735eecd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f5d0f1bc-bca8-4ed6-ade3-da6735eecd15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_316adfbb-74ce-45e1-aef5-508fdb6161bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_316adfbb-74ce-45e1-aef5-508fdb6161bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5dc158c-0b26-4875-8545-cc5431345c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cb60cac-48a6-4f5b-aac9-fdee75cd165c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a0f1618-d560-4103-9447-0c503fe5eacc" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cb60cac-48a6-4f5b-aac9-fdee75cd165c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ea7a0154-72d3-4dba-a618-e28fb450e510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cb60cac-48a6-4f5b-aac9-fdee75cd165c" xlink:to="loc_us-gaap_AwardTypeAxis_ea7a0154-72d3-4dba-a618-e28fb450e510" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea7a0154-72d3-4dba-a618-e28fb450e510_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ea7a0154-72d3-4dba-a618-e28fb450e510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ea7a0154-72d3-4dba-a618-e28fb450e510_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d99d2af-fa57-434d-9612-be36e9466b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ea7a0154-72d3-4dba-a618-e28fb450e510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d99d2af-fa57-434d-9612-be36e9466b66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c5820d70-6507-453e-ba45-80c9ce16be50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d99d2af-fa57-434d-9612-be36e9466b66" xlink:to="loc_us-gaap_RestrictedStockMember_c5820d70-6507-453e-ba45-80c9ce16be50" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0c3e6488-2759-4cc9-9d7f-b842cb1a3d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d99d2af-fa57-434d-9612-be36e9466b66" xlink:to="loc_us-gaap_PerformanceSharesMember_0c3e6488-2759-4cc9-9d7f-b842cb1a3d9a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityFairValueofAwardsGrantedandVestedDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="extended" id="ifea9203680bd47b4a5e91a0a1be1e799_StockholdersEquityFairValueofAwardsGrantedandVestedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8322cb6b-6f77-4f34-a153-39b41bc04a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_579179e6-0cb1-408d-b754-c1c508d42ec0" xlink:href="moh-20221231.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8322cb6b-6f77-4f34-a153-39b41bc04a01" xlink:to="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_579179e6-0cb1-408d-b754-c1c508d42ec0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_966ebd81-8c88-47c1-8deb-fde3243be207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8322cb6b-6f77-4f34-a153-39b41bc04a01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_966ebd81-8c88-47c1-8deb-fde3243be207" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc11c859-28b2-4995-80f0-55554356ccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8322cb6b-6f77-4f34-a153-39b41bc04a01" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc11c859-28b2-4995-80f0-55554356ccc8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc11c859-28b2-4995-80f0-55554356ccc8" xlink:to="loc_us-gaap_AwardTypeAxis_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c1ddfa9-8cc6-4f81-bc45-9a315942afa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c1ddfa9-8cc6-4f81-bc45-9a315942afa0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c9091692-d578-4d7f-a103-f21481b5a921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c1ddfa9-8cc6-4f81-bc45-9a315942afa0" xlink:to="loc_us-gaap_RestrictedStockMember_c9091692-d578-4d7f-a103-f21481b5a921" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6e24d4b1-b85b-494a-b058-c887156ba840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c1ddfa9-8cc6-4f81-bc45-9a315942afa0" xlink:to="loc_us-gaap_PerformanceSharesMember_6e24d4b1-b85b-494a-b058-c887156ba840" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails" xlink:type="extended" id="i8f33a87c3adc471d915f782be9bc52db_CommitmentsandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SpecialAssessmentBond_453a5dfd-8be0-43d6-80a7-08a6d601485c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SpecialAssessmentBond"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_SpecialAssessmentBond_453a5dfd-8be0-43d6-80a7-08a6d601485c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_e0c74f2d-de57-49bd-b859-d23217240e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_e0c74f2d-de57-49bd-b859-d23217240e7c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b9d1016c-7c84-4476-bf63-d57941c053f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b9d1016c-7c84-4476-bf63-d57941c053f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_b4a4f8ae-2b23-4373-b588-a872359a26d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_b4a4f8ae-2b23-4373-b588-a872359a26d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_5e8ad321-4b24-417a-9337-b49ef3a28127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_5e8ad321-4b24-417a-9337-b49ef3a28127" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable_06dbe28d-afd0-4995-8bbe-b5d13f0bf64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_StatutoryAccountingPracticesTable_06dbe28d-afd0-4995-8bbe-b5d13f0bf64c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_39febeff-d66d-4951-8a76-8d7ef82cf632" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_06dbe28d-afd0-4995-8bbe-b5d13f0bf64c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_39febeff-d66d-4951-8a76-8d7ef82cf632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_39febeff-d66d-4951-8a76-8d7ef82cf632_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_39febeff-d66d-4951-8a76-8d7ef82cf632" xlink:to="loc_srt_ConsolidatedEntitiesDomain_39febeff-d66d-4951-8a76-8d7ef82cf632_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6b53d3dc-d4c2-40f2-aa18-c14c925dcd98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_39febeff-d66d-4951-8a76-8d7ef82cf632" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6b53d3dc-d4c2-40f2-aa18-c14c925dcd98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_9878f3d8-4ed3-4cab-88b2-daa100606b1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_6b53d3dc-d4c2-40f2-aa18-c14c925dcd98" xlink:to="loc_srt_ParentCompanyMember_9878f3d8-4ed3-4cab-88b2-daa100606b1b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SegmentsScheduleofOperatingSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="extended" id="ia7266ad2460542b5ae7df9f3af6a8060_SegmentsScheduleofOperatingSegmentInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_791fa018-b04a-40dc-9991-bd48aea2b911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e4e5790c-2135-4116-9a95-229715e71d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_791fa018-b04a-40dc-9991-bd48aea2b911" xlink:to="loc_us-gaap_Revenues_e4e5790c-2135-4116-9a95-229715e71d74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a38b83e8-10d5-40cb-9a39-eba380998e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_791fa018-b04a-40dc-9991-bd48aea2b911" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a38b83e8-10d5-40cb-9a39-eba380998e04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_32cf5989-d0e1-41f7-8484-ab00026c2e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a38b83e8-10d5-40cb-9a39-eba380998e04" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_32cf5989-d0e1-41f7-8484-ab00026c2e48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_32cf5989-d0e1-41f7-8484-ab00026c2e48_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32cf5989-d0e1-41f7-8484-ab00026c2e48" xlink:to="loc_us-gaap_SegmentDomain_32cf5989-d0e1-41f7-8484-ab00026c2e48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32cf5989-d0e1-41f7-8484-ab00026c2e48" xlink:to="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_d59902ed-b19e-4103-80a0-c2fdd7ca4605" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:to="loc_moh_MedicaidMember_d59902ed-b19e-4103-80a0-c2fdd7ca4605" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_77548af7-e722-4dc7-959e-5855f7ae733c" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:to="loc_moh_MedicareMember_77548af7-e722-4dc7-959e-5855f7ae733c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_3d90d3af-eb18-43df-9b0f-572412cd738d" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:to="loc_moh_MarketplaceMember_3d90d3af-eb18-43df-9b0f-572412cd738d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_8e7cdd81-c443-40b9-be99-de30cf4f2aa6" xlink:href="moh-20221231.xsd#moh_OtherProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:to="loc_moh_OtherProgramMember_8e7cdd81-c443-40b9-be99-de30cf4f2aa6" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended" id="ic8543abe557c4c1cbe589c76e626dd79_SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_45a58c0d-ab0f-403e-9d51-1ecfae3d204c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_GrossProfit_45a58c0d-ab0f-403e-9d51-1ecfae3d204c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ee635e5e-c053-4263-b163-1cccab6f3221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_Revenues_ee635e5e-c053-4263-b163-1cccab6f3221" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_85a49886-5c4a-418d-840e-3fdb4584ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_CostsAndExpenses_85a49886-5c4a-418d-840e-3fdb4584ad6c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f9796cf-17b4-43b2-9a1b-e165d944a974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f9796cf-17b4-43b2-9a1b-e165d944a974" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_454cc8c1-f586-4906-b26d-e9390509049f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_454cc8c1-f586-4906-b26d-e9390509049f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e39bdaa-7ee6-4453-b3ff-a782570a6b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e39bdaa-7ee6-4453-b3ff-a782570a6b6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_4abecf57-fab4-4152-a40b-cb583d4c2b5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:to="loc_srt_ConsolidationItemsAxis_4abecf57-fab4-4152-a40b-cb583d4c2b5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_4abecf57-fab4-4152-a40b-cb583d4c2b5b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_4abecf57-fab4-4152-a40b-cb583d4c2b5b" xlink:to="loc_srt_ConsolidationItemsDomain_4abecf57-fab4-4152-a40b-cb583d4c2b5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a8974a3c-9f62-45fc-87f0-b570f28d0958" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_4abecf57-fab4-4152-a40b-cb583d4c2b5b" xlink:to="loc_srt_ConsolidationItemsDomain_a8974a3c-9f62-45fc-87f0-b570f28d0958" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_b476580e-c3c6-4817-9610-57c02b4f4e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a8974a3c-9f62-45fc-87f0-b570f28d0958" xlink:to="loc_us-gaap_OperatingSegmentsMember_b476580e-c3c6-4817-9610-57c02b4f4e3f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_cd55ba18-98ac-424b-8fb9-72b3426687b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_a8974a3c-9f62-45fc-87f0-b570f28d0958" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_cd55ba18-98ac-424b-8fb9-72b3426687b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2403fa0c-2b8e-47de-b32c-f5466d266f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2403fa0c-2b8e-47de-b32c-f5466d266f9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2403fa0c-2b8e-47de-b32c-f5466d266f9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2403fa0c-2b8e-47de-b32c-f5466d266f9c" xlink:to="loc_us-gaap_SegmentDomain_2403fa0c-2b8e-47de-b32c-f5466d266f9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2403fa0c-2b8e-47de-b32c-f5466d266f9c" xlink:to="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_9f94ba15-d341-4f8e-bd92-0f78de8d256f" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:to="loc_moh_MedicaidMember_9f94ba15-d341-4f8e-bd92-0f78de8d256f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_fd7100ab-4e0a-4f43-8464-9afbcea4f2b7" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:to="loc_moh_MedicareMember_fd7100ab-4e0a-4f43-8464-9afbcea4f2b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_68785192-bdf2-420b-91e4-3b4ffba77193" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:to="loc_moh_MarketplaceMember_68785192-bdf2-420b-91e4-3b4ffba77193" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_ee372685-4c93-4cf7-858e-547b0c48d8fb" xlink:href="moh-20221231.xsd#moh_OtherProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:to="loc_moh_OtherProgramMember_ee372685-4c93-4cf7-858e-547b0c48d8fb" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="extended" id="i3d755e0b0d8d478c80ffda2962dc430f_CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_822747f9-f2e7-4184-87c3-861217a6205e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f10c775c-5291-46c0-ba84-bc0c4451f2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_822747f9-f2e7-4184-87c3-861217a6205e" xlink:to="loc_us-gaap_StatementOfFinancialPositionAbstract_f10c775c-5291-46c0-ba84-bc0c4451f2e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f10c775c-5291-46c0-ba84-bc0c4451f2e9" xlink:to="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_98b1ca4a-b250-4ad2-b10f-21d04ca2296a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_98b1ca4a-b250-4ad2-b10f-21d04ca2296a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_fa5ac37d-d8df-45a3-9ac5-3e9c16309300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_fa5ac37d-d8df-45a3-9ac5-3e9c16309300" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_d1dd8d62-4e6c-4bb3-a1d5-159ef4b8b919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_d1dd8d62-4e6c-4bb3-a1d5-159ef4b8b919" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_93f516f6-949f-4eaa-973d-baf6baaa4b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_93f516f6-949f-4eaa-973d-baf6baaa4b1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6d850f40-50eb-4bc4-a3f7-b5ac75d8c4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_AssetsCurrent_6d850f40-50eb-4bc4-a3f7-b5ac75d8c4ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_25abedda-9699-4825-b9da-9dc35a049264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_25abedda-9699-4825-b9da-9dc35a049264" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e9abf1a9-793a-479e-9f3c-2776e24d2301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e9abf1a9-793a-479e-9f3c-2776e24d2301" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_67d8310a-dc0c-4686-ac2b-56d99aa8c106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_67d8310a-dc0c-4686-ac2b-56d99aa8c106" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e1447196-a7a4-44a4-adba-acd3e9dd4574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e1447196-a7a4-44a4-adba-acd3e9dd4574" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AdvancesToRelatedPartiesAndOtherAssets_1c6a48f3-7daa-43bb-82bc-b34551c5b8a5" xlink:href="moh-20221231.xsd#moh_AdvancesToRelatedPartiesAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_moh_AdvancesToRelatedPartiesAndOtherAssets_1c6a48f3-7daa-43bb-82bc-b34551c5b8a5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_afe40ad4-bb16-4ac7-9174-147e4de84af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_Assets_afe40ad4-bb16-4ac7-9174-147e4de84af8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f10c775c-5291-46c0-ba84-bc0c4451f2e9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5784347d-05da-4637-8671-4338dd014700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5784347d-05da-4637-8671-4338dd014700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1a3df7de-75d1-431f-81df-2747f84572ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5784347d-05da-4637-8671-4338dd014700" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1a3df7de-75d1-431f-81df-2747f84572ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_29e5c63e-5df8-46ca-9cd6-9c71856303ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5784347d-05da-4637-8671-4338dd014700" xlink:to="loc_us-gaap_LiabilitiesCurrent_29e5c63e-5df8-46ca-9cd6-9c71856303ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4b57936b-db52-4d29-a227-0dec25747365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4b57936b-db52-4d29-a227-0dec25747365" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1734a280-f7ee-4267-8c1d-89a6f855e67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1734a280-f7ee-4267-8c1d-89a6f855e67c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d984b0d8-41ff-4104-bfb4-dd8091db4a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d984b0d8-41ff-4104-bfb4-dd8091db4a8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c3965147-6836-4127-b90a-62ef949dbe34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_Liabilities_c3965147-6836-4127-b90a-62ef949dbe34" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_8a086252-24cb-4cfa-ade0-f3ce9891a071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_CommonStockValueOutstanding_8a086252-24cb-4cfa-ade0-f3ce9891a071" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b5abdb05-2c9a-4dc9-8284-552b8fffc15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_PreferredStockValue_b5abdb05-2c9a-4dc9-8284-552b8fffc15c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f04434d4-559b-4910-afc2-c2ecb309f77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f04434d4-559b-4910-afc2-c2ecb309f77c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5da7c668-9cc5-4515-b8f0-1b4278b56a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5da7c668-9cc5-4515-b8f0-1b4278b56a4c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_938fa109-24c1-401e-8c56-134e6a39096b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_938fa109-24c1-401e-8c56-134e6a39096b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_78867c8e-ac38-4ced-b9cf-913c77ebbbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_StockholdersEquity_78867c8e-ac38-4ced-b9cf-913c77ebbbb7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_25e97fe6-097f-47e6-9091-0b1aab8be20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_25e97fe6-097f-47e6-9091-0b1aab8be20b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_a58e066f-baf4-4dbe-b1df-c9864f92b981" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_822747f9-f2e7-4184-87c3-861217a6205e" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_a58e066f-baf4-4dbe-b1df-c9864f92b981" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_111ccf16-2b43-49c5-88fc-0eb26dcf0b78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_a58e066f-baf4-4dbe-b1df-c9864f92b981" xlink:to="loc_srt_ConsolidatedEntitiesAxis_111ccf16-2b43-49c5-88fc-0eb26dcf0b78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_111ccf16-2b43-49c5-88fc-0eb26dcf0b78_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_111ccf16-2b43-49c5-88fc-0eb26dcf0b78" xlink:to="loc_srt_ConsolidatedEntitiesDomain_111ccf16-2b43-49c5-88fc-0eb26dcf0b78_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6ba25c2c-4576-435c-a166-753cd4a902f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_111ccf16-2b43-49c5-88fc-0eb26dcf0b78" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6ba25c2c-4576-435c-a166-753cd4a902f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_dac5b9ab-fe89-450f-ab18-58921a6d87bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_6ba25c2c-4576-435c-a166-753cd4a902f5" xlink:to="loc_srt_ParentCompanyMember_dac5b9ab-fe89-450f-ab18-58921a6d87bc" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails" xlink:type="extended" id="i30fcb36a6efe4775bdbc0d18a1106c0d_CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23034d25-deb2-486b-b108-39e0480650f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23034d25-deb2-486b-b108-39e0480650f0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b6b0c603-2cb3-4f45-9c27-20ea7d6869b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b6b0c603-2cb3-4f45-9c27-20ea7d6869b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cf931e64-f721-4e27-b438-8945575ff103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cf931e64-f721-4e27-b438-8945575ff103" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2a80471f-d1af-48a7-a6e5-ae10ed913c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2a80471f-d1af-48a7-a6e5-ae10ed913c2f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4013f4e2-0b5c-4928-916b-0491ae060875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4013f4e2-0b5c-4928-916b-0491ae060875" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9582b201-5658-45a7-be18-f40b63e0b5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9582b201-5658-45a7-be18-f40b63e0b5f2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fc99d1ce-64f7-4e24-b910-4f0fd9806850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fc99d1ce-64f7-4e24-b910-4f0fd9806850" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_15236ba6-c154-4ad5-acd6-8056c866d19d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_15236ba6-c154-4ad5-acd6-8056c866d19d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_584703de-b6f7-4247-8bd2-53e2bf2cf389" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_15236ba6-c154-4ad5-acd6-8056c866d19d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_584703de-b6f7-4247-8bd2-53e2bf2cf389" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_584703de-b6f7-4247-8bd2-53e2bf2cf389_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_584703de-b6f7-4247-8bd2-53e2bf2cf389" xlink:to="loc_srt_ConsolidatedEntitiesDomain_584703de-b6f7-4247-8bd2-53e2bf2cf389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1e25de69-ca3b-4959-8d90-b320ab462704" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_584703de-b6f7-4247-8bd2-53e2bf2cf389" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1e25de69-ca3b-4959-8d90-b320ab462704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_444826b4-b30a-431f-9307-7f1cb8e74210" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1e25de69-ca3b-4959-8d90-b320ab462704" xlink:to="loc_srt_ParentCompanyMember_444826b4-b30a-431f-9307-7f1cb8e74210" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="extended" id="i174c061d172b49589b306bcd3bbbc3c7_CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_346dc697-406c-4f26-91f3-044605961f4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_346dc697-406c-4f26-91f3-044605961f4e" xlink:to="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAgencyManagementFee_dc679990-c03a-41db-bacf-c51ab9666b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAgencyManagementFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:to="loc_us-gaap_InsuranceAgencyManagementFee_dc679990-c03a-41db-bacf-c51ab9666b59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_8751a13b-75a2-4d58-83ce-52327fc72e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_8751a13b-75a2-4d58-83ce-52327fc72e98" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bc657718-99c1-4b6d-990d-e965cfcb6008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:to="loc_us-gaap_Revenues_bc657718-99c1-4b6d-990d-e965cfcb6008" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6df5c54b-58ae-4fab-9734-ce22db3e6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6df5c54b-58ae-4fab-9734-ce22db3e6c45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b2e385e7-8060-4b09-b3a9-22dcaa793344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_DepreciationAndAmortization_b2e385e7-8060-4b09-b3a9-22dcaa793344" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e742a376-2c4f-4cba-ae93-5ee79e1540e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_AssetImpairmentCharges_e742a376-2c4f-4cba-ae93-5ee79e1540e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_2960a956-6c26-4db7-89ac-9cbab9d2b8da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_2960a956-6c26-4db7-89ac-9cbab9d2b8da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b8915095-58c5-4c06-8060-39f0dc352dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_CostsAndExpenses_b8915095-58c5-4c06-8060-39f0dc352dc3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20a54de0-abaf-4815-83d0-3a57b0c0067c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_OperatingIncomeLoss_20a54de0-abaf-4815-83d0-3a57b0c0067c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_03c1c573-4323-44d9-8383-d1e7ebf29051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_InterestExpense_03c1c573-4323-44d9-8383-d1e7ebf29051" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f595ab87-9f97-44e0-80b6-dca4004c0356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f595ab87-9f97-44e0-80b6-dca4004c0356" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_37b1e319-7e4f-458c-86c5-a7ce4366f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_OtherExpenses_37b1e319-7e4f-458c-86c5-a7ce4366f6f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_e1ee2ee5-70f4-42f1-a870-29819412a231" xlink:href="moh-20221231.xsd#moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_e1ee2ee5-70f4-42f1-a870-29819412a231" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70000d26-571d-4480-b3bc-444149e98438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70000d26-571d-4480-b3bc-444149e98438" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_a81bba8a-7b09-4405-8850-f485a81486cd" xlink:href="moh-20221231.xsd#moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_a81bba8a-7b09-4405-8850-f485a81486cd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_7307d437-fbee-424f-a948-9dc3a323d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_7307d437-fbee-424f-a948-9dc3a323d91b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c97b2b16-2165-4b3e-9241-ed612ab78cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_NetIncomeLoss_c97b2b16-2165-4b3e-9241-ed612ab78cff" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_275e8e0f-b26d-49d6-b4e0-46acb5909c5e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_346dc697-406c-4f26-91f3-044605961f4e" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_275e8e0f-b26d-49d6-b4e0-46acb5909c5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c541a115-df57-4c19-8fcb-e088fd743303" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_275e8e0f-b26d-49d6-b4e0-46acb5909c5e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c541a115-df57-4c19-8fcb-e088fd743303" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_c541a115-df57-4c19-8fcb-e088fd743303_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c541a115-df57-4c19-8fcb-e088fd743303" xlink:to="loc_srt_ConsolidatedEntitiesDomain_c541a115-df57-4c19-8fcb-e088fd743303_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_04c8891e-d35f-41b7-b182-9acf548517db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c541a115-df57-4c19-8fcb-e088fd743303" xlink:to="loc_srt_ConsolidatedEntitiesDomain_04c8891e-d35f-41b7-b182-9acf548517db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_a297e293-0483-4e87-a529-a8128556fc70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_04c8891e-d35f-41b7-b182-9acf548517db" xlink:to="loc_srt_ParentCompanyMember_a297e293-0483-4e87-a529-a8128556fc70" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails" xlink:type="extended" id="i58e7433b73d145bcaa27cb4b7447c5f1_CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5f1a253d-3f41-452d-9ce9-fa5bacb49cf4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ca553a6-c1dc-4f89-a15e-6fa7a446f1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5f1a253d-3f41-452d-9ce9-fa5bacb49cf4" xlink:to="loc_us-gaap_NetIncomeLoss_3ca553a6-c1dc-4f89-a15e-6fa7a446f1c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5f1a253d-3f41-452d-9ce9-fa5bacb49cf4" xlink:to="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_b7f640f0-330d-4bcc-8b6e-ad8e489918d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_b7f640f0-330d-4bcc-8b6e-ad8e489918d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_010d6c30-68aa-4227-8c94-a1eeeeab46df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_010d6c30-68aa-4227-8c94-a1eeeeab46df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_227024be-76bd-4854-9e47-dde75572d016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_227024be-76bd-4854-9e47-dde75572d016" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f036ecb6-8732-4781-8abb-274683151e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f036ecb6-8732-4781-8abb-274683151e48" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_14119185-c4ef-44f6-b8a7-fcf747ed618f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5f1a253d-3f41-452d-9ce9-fa5bacb49cf4" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_14119185-c4ef-44f6-b8a7-fcf747ed618f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b21dff0a-a85c-4476-935f-e3cbdcbf8e28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_14119185-c4ef-44f6-b8a7-fcf747ed618f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b21dff0a-a85c-4476-935f-e3cbdcbf8e28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_b21dff0a-a85c-4476-935f-e3cbdcbf8e28_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b21dff0a-a85c-4476-935f-e3cbdcbf8e28" xlink:to="loc_srt_ConsolidatedEntitiesDomain_b21dff0a-a85c-4476-935f-e3cbdcbf8e28_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8ac32329-54ed-43cb-8b31-d088c55962b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b21dff0a-a85c-4476-935f-e3cbdcbf8e28" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8ac32329-54ed-43cb-8b31-d088c55962b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_8bdc30d6-a0ef-4493-ad9a-7f2ac90aca92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8ac32329-54ed-43cb-8b31-d088c55962b2" xlink:to="loc_srt_ParentCompanyMember_8bdc30d6-a0ef-4493-ad9a-7f2ac90aca92" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="extended" id="ice5d093509764dea89c8705f404d188e_CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_27aa926c-65d0-4f1b-aaff-faf1927104a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_27aa926c-65d0-4f1b-aaff-faf1927104a8" xlink:to="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e4fd0c3a-38b1-4ed2-814a-0b59ab4a533e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e4fd0c3a-38b1-4ed2-814a-0b59ab4a533e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67bc58aa-15e1-4cbc-97be-2472ec5eee1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e4fd0c3a-38b1-4ed2-814a-0b59ab4a533e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67bc58aa-15e1-4cbc-97be-2472ec5eee1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2cb833fa-5645-4ec7-a766-83b1b04eabff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2cb833fa-5645-4ec7-a766-83b1b04eabff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDividendsReceived_f62323b0-3e3d-4b08-9e9e-7ff5cc0dd19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_ProceedsFromDividendsReceived_f62323b0-3e3d-4b08-9e9e-7ff5cc0dd19c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c237986a-ac6b-4532-a469-a076fe851cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c237986a-ac6b-4532-a469-a076fe851cea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2c9335b0-fe32-4caa-8984-413e24d698de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2c9335b0-fe32-4caa-8984-413e24d698de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25476ab8-c3fb-4aca-bd66-f0885708c706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25476ab8-c3fb-4aca-bd66-f0885708c706" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_80de9d21-5ae2-4403-9ea6-4a030bbe4ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_80de9d21-5ae2-4403-9ea6-4a030bbe4ca1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ChangesInAmountsDueToAndDueFromAffiliates_3d4e9b0a-0cc9-4b8a-a699-76c71314d3b1" xlink:href="moh-20221231.xsd#moh_ChangesInAmountsDueToAndDueFromAffiliates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_moh_ChangesInAmountsDueToAndDueFromAffiliates_3d4e9b0a-0cc9-4b8a-a699-76c71314d3b1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_82052a16-47ed-45ac-a92d-7f0749275019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_82052a16-47ed-45ac-a92d-7f0749275019" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f7b6648-94e0-48f1-9ce8-a0185a4ad356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f7b6648-94e0-48f1-9ce8-a0185a4ad356" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b09450bc-fa0c-4b06-9dce-61bb45578f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b09450bc-fa0c-4b06-9dce-61bb45578f07" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_f6524a7b-589f-4b0b-bf58-bda56c09a11c" xlink:href="moh-20221231.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_f6524a7b-589f-4b0b-bf58-bda56c09a11c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b24bc9be-2c55-4dc1-b3bd-b2fdfd2b33a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b24bc9be-2c55-4dc1-b3bd-b2fdfd2b33a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b48e57dc-d2c0-4f2b-b926-149516a84b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b48e57dc-d2c0-4f2b-b926-149516a84b8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_f6c9a2cc-4145-476b-b3c3-9ff1d48f36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_f6c9a2cc-4145-476b-b3c3-9ff1d48f36d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_6bbfd323-21db-40da-9a0b-baac54c7c9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_6bbfd323-21db-40da-9a0b-baac54c7c9d3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_7ef282bd-3b41-4a79-b53c-908c9b3256e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_7ef282bd-3b41-4a79-b53c-908c9b3256e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_c7f49d58-809b-4964-974a-d2c9331fe067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_c7f49d58-809b-4964-974a-d2c9331fe067" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidForSettlementOfConversionOption_c0bce64c-ad95-4080-aa7f-f9eb7faedadb" xlink:href="moh-20221231.xsd#moh_CashPaidForSettlementOfConversionOption"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_moh_CashPaidForSettlementOfConversionOption_c0bce64c-ad95-4080-aa7f-f9eb7faedadb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_c40ff545-ac8d-4111-b3cd-c360b6780fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_c40ff545-ac8d-4111-b3cd-c360b6780fe6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_4eebed86-62e2-4d15-91a9-25f37a933f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_4eebed86-62e2-4d15-91a9-25f37a933f9b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c7e47f8e-43b0-4316-a9bb-1feda9b44310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c7e47f8e-43b0-4316-a9bb-1feda9b44310" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5924dc16-de94-4f8b-88e9-82736056be50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5924dc16-de94-4f8b-88e9-82736056be50" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_729eee80-3c5e-485e-b1fc-eb52857a98a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_729eee80-3c5e-485e-b1fc-eb52857a98a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66f18a45-5b87-4ff2-9995-e8e6b8528088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66f18a45-5b87-4ff2-9995-e8e6b8528088" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5af777c2-4b6d-4d85-b525-4cb6219748b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_3aae4a44-a985-4eae-b49b-e99658e5910a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_27aa926c-65d0-4f1b-aaff-faf1927104a8" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_3aae4a44-a985-4eae-b49b-e99658e5910a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_acf547b8-d27c-4e63-b584-715e8eb60d97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_3aae4a44-a985-4eae-b49b-e99658e5910a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_acf547b8-d27c-4e63-b584-715e8eb60d97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_acf547b8-d27c-4e63-b584-715e8eb60d97_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_acf547b8-d27c-4e63-b584-715e8eb60d97" xlink:to="loc_srt_ConsolidatedEntitiesDomain_acf547b8-d27c-4e63-b584-715e8eb60d97_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_21d96617-0bdc-4c42-9d00-bae2ba277199" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_acf547b8-d27c-4e63-b584-715e8eb60d97" xlink:to="loc_srt_ConsolidatedEntitiesDomain_21d96617-0bdc-4c42-9d00-bae2ba277199" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_6812bc16-00cd-4a1f-a0b5-a461505a206c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_21d96617-0bdc-4c42-9d00-bae2ba277199" xlink:to="loc_srt_ParentCompanyMember_6812bc16-00cd-4a1f-a0b5-a461505a206c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails" xlink:type="extended" id="i268ebe997d644a2f9c20789a981d72f1_CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b7ae8044-dca5-4e49-91a5-77cdf444217f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_0d823dc9-0eeb-4562-abf7-8de6c3ea09f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b7ae8044-dca5-4e49-91a5-77cdf444217f" xlink:to="loc_us-gaap_RevenueFromRelatedParties_0d823dc9-0eeb-4562-abf7-8de6c3ea09f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dd8ad312-a0d7-4584-b8ae-2c0a645593f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b7ae8044-dca5-4e49-91a5-77cdf444217f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dd8ad312-a0d7-4584-b8ae-2c0a645593f3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6349160b-e36b-4ae2-8a47-f92365011804" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dd8ad312-a0d7-4584-b8ae-2c0a645593f3" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6349160b-e36b-4ae2-8a47-f92365011804" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6349160b-e36b-4ae2-8a47-f92365011804_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6349160b-e36b-4ae2-8a47-f92365011804" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6349160b-e36b-4ae2-8a47-f92365011804_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e100bbc6-cd94-492e-9d20-481225daf78b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6349160b-e36b-4ae2-8a47-f92365011804" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e100bbc6-cd94-492e-9d20-481225daf78b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_b2ec3478-213b-496e-8a05-d3235ead69df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_e100bbc6-cd94-492e-9d20-481225daf78b" xlink:to="loc_srt_ParentCompanyMember_b2ec3478-213b-496e-8a05-d3235ead69df" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>moh-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a6be6ee9-88ed-425c-ba06-deafc74c4611,g:0568f791-801e-41fa-b039-5982169b2ced-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_dceff5e4-a432-4509-b657-e11ac2731520_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_09cd5ce0-5212-4205-b50c-b537a780f65b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d93c8f7-800e-4fc2-a20c-70773ada53a4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_89567330-c9ac-41f3-9ea0-4935558ffc5a_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal - undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_87826c71-b7f8-4c8d-bc85-70e78e04e5e7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_8f2a9b39-f157-4b48-9ba3-d986e92fd94d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_290e426b-ccb5-480d-ac82-66fd5c08407e_totalLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_365085d2-9ab9-4152-adf7-6653e7f9cdb4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net carrying amount of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationRevenuePercentage_fea5e547-9e2f-4670-9d74-d9c808f7cb18_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium revenue percentage</link:label>
    <link:label id="lab_moh_HealthCareOrganizationRevenuePercentage_label_en-US" xlink:label="lab_moh_HealthCareOrganizationRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Percentage</link:label>
    <link:label id="lab_moh_HealthCareOrganizationRevenuePercentage_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationRevenuePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Revenue Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationRevenuePercentage" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationRevenuePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationRevenuePercentage" xlink:to="lab_moh_HealthCareOrganizationRevenuePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_04c4174d-c697-4b20-8bcc-814c5ece9520_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of available-for-sale investments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherClaimsPayable_22e84929-ce50-4ba7-9bac-5f4c42bf2840_terseLabel_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_label_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:label id="lab_moh_OtherClaimsPayable_documentation_en-US" xlink:label="lab_moh_OtherClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable" xlink:href="moh-20221231.xsd#moh_OtherClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherClaimsPayable" xlink:to="lab_moh_OtherClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OperatingLeaseLiabilitiesLesseeAbstract_e6018751-095a-4ea7-ad35-27385a97e618_terseLabel_en-US" xlink:label="lab_moh_OperatingLeaseLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_moh_OperatingLeaseLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_moh_OperatingLeaseLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liabilities, Lessee [Abstract]</link:label>
    <link:label id="lab_moh_OperatingLeaseLiabilitiesLesseeAbstract_documentation_en-US" xlink:label="lab_moh_OperatingLeaseLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingLeaseLiabilitiesLesseeAbstract" xlink:href="moh-20221231.xsd#moh_OperatingLeaseLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OperatingLeaseLiabilitiesLesseeAbstract" xlink:to="lab_moh_OperatingLeaseLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_b114c236-5d1d-4d79-ad32-bda309e2b97b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_17c3592d-eeeb-4475-8dd9-ea5c04388a89_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets - finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_9732b450-5b3e-40c0-b3ec-41e3c09eacaf_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment, and capitalized software, net</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, after Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAsset" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_d9871bba-dae6-4a16-951e-4117beb3f62c_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from affiliates</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Due from (to) Related Party, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:to="lab_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_8a4d2b5a-107d-43f3-a5c1-bca9eead89c5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_8fc49b31-e7fb-4b2e-a276-6a1cb6f5a1c3_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_80dd666a-cf87-4f9b-a751-06ea3e298111_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_435624d0-b964-477f-822c-9502d590030e_verboseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits roll forward</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_404846fa-4134-4fbd-98da-b2bb99393956_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment_56e7a7f0-26d3-436e-8827-d1133ec58722_terseLabel_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred Claims and Allocated Claims Adjustment Expenses</link:label>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment_label_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense, Incurred Claims Including Acquisition Adjustment</link:label>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment_documentation_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability For Unpaid Claims And Claims Adjustment Expense, Incurred Claims Including Acquisition Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" xlink:href="moh-20221231.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" xlink:to="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MinimumMemberEnrollmentTargetsMember_811c8eef-d5ac-406f-a524-53d8355d3b89_terseLabel_en-US" xlink:label="lab_moh_MinimumMemberEnrollmentTargetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Member Enrollment Targets</link:label>
    <link:label id="lab_moh_MinimumMemberEnrollmentTargetsMember_label_en-US" xlink:label="lab_moh_MinimumMemberEnrollmentTargetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Member Enrollment Targets [Member]</link:label>
    <link:label id="lab_moh_MinimumMemberEnrollmentTargetsMember_documentation_en-US" xlink:label="lab_moh_MinimumMemberEnrollmentTargetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Member Enrollment Targets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MinimumMemberEnrollmentTargetsMember" xlink:href="moh-20221231.xsd#moh_MinimumMemberEnrollmentTargetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MinimumMemberEnrollmentTargetsMember" xlink:to="lab_moh_MinimumMemberEnrollmentTargetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_b17f4410-db02-4a3c-9347-929cf2e3b581_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of liability for unpaid claims and claims adjustment expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_b1130ef1-c260-451b-9214-746b13063de8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy" xlink:to="lab_us-gaap_BusinessCombinationsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_6a180453-e951-47cc-ac7a-7e19536b34ce_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_57e5f638-4052-490e-bf40-783a21bad378_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_34da98cc-863a-4dc3-a8b1-0574bf3dd49a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability" xlink:to="lab_us-gaap_FinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_640adde0-c4f4-45c8-bd19-310aab06c197_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_e2c24ae8-1ee0-4014-a12c-7f894663500a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_c0195af7-7b1f-46cb-8a5b-0b5dc461ae64_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:label id="lab_us-gaap_ReceivableTypeDomain_label_en-US" xlink:label="lab_us-gaap_ReceivableTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivableTypeDomain" xlink:to="lab_us-gaap_ReceivableTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_834cb6ee-80e3-4917-b28e-a261e5071012_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_9ec108ce-3af5-4975-ba59-ef5c655343c0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_8a39c0c2-20cf-4446-873c-37cdfc35a1f4_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized software</link:label>
    <link:label id="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_label_en-US" xlink:label="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software and Software Development Costs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="lab_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_6d606b90-a154-47d6-afa8-d4bfcc69c6a2_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_836e50c0-2f20-4a3c-b79d-686ca9aaaf86_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_a7f4b41d-cd40-4e6e-a2ba-24882f106609_totalLabel_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total amounts due government agencies</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_MedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:href="moh-20221231.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_MedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_69520051-c11a-4ace-acbe-41eca446fb0c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net:</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_99a2c641-707d-47e2-b430-c42da2389044_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_cff04d83-70da-4871-b779-24aefd2a65ea_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_5285f5b8-6d00-474b-a1b1-94169194e041_periodStartLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, beginning balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9fa6c674-4be1-4517-9f11-65f938c4ae97_periodEndLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, ending balance</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_0862b3d7-079f-4fb4-b237-6bc9c68f5189_netLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable, total reserve development</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_36fd355d-5bd8-4742-ab6f-a88c3bbf64b9_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_8a19c83a-6c69-415a-a3ac-120bc95cc633_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_bac9d0c1-d600-4d8f-9bed-96f94bfba5ac_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation plan</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationPlanAssets_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationPlanAssets" xlink:to="lab_us-gaap_DeferredCompensationPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_363dc067-af8a-4fd4-97ae-f70c5b818d2c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_d5b44f27-d40b-493d-b16e-ba155d2fcc5a_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlansSegmentMember_d3146c19-e995-4b31-a8de-4d810ae390a0_terseLabel_en-US" xlink:label="lab_moh_HealthPlansSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans Segment</link:label>
    <link:label id="lab_moh_HealthPlansSegmentMember_label_en-US" xlink:label="lab_moh_HealthPlansSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans Segment [Member]</link:label>
    <link:label id="lab_moh_HealthPlansSegmentMember_documentation_en-US" xlink:label="lab_moh_HealthPlansSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansSegmentMember" xlink:href="moh-20221231.xsd#moh_HealthPlansSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlansSegmentMember" xlink:to="lab_moh_HealthPlansSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_1eab5613-e3c1-4cf5-8927-f771d784492a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_66285394-1eeb-4a1c-94e9-bf683c463729_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_ecbcadd9-0600-4842-9155-509af1a5c82d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_372ee02e-f542-440f-9914-27530067c11f_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property, equipment, building, and improvements</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3e6e8cfd-8e53-44de-a4ad-d6ad8acf5abb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7fd90c05-2298-4d56-b556-9afbc6df6638_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_9461b224-dff1-482b-9c3f-939cec74ab83_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred income tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_b146b99a-9bb9-414b-8d1f-fc12e5ececb2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_05fe64b7-f291-4a0a-9474-0fabcad46f9a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_99b0455d-ccef-45bb-b3af-5318b944f3fa_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contractual interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_62cedafe-877b-48b3-8a9d-d5763caf654e_netLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of contractual interest rate on notes</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_3b88254a-6400-4002-bbf3-4e4a44168461_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_10255cda-7537-4380-ba90-08761c29a149_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_2d79091c-08d0-4a51-a0b1-9e783e6a7a58_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse in statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_41611f93-6dcb-45d1-afdb-3d3f8dfc4b68_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_SummarizedPremiumRevenueTableTextBlock_281b50d5-3a7d-4c83-8ea9-699d75d573bf_terseLabel_en-US" xlink:label="lab_moh_SummarizedPremiumRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized premium revenue</link:label>
    <link:label id="lab_moh_SummarizedPremiumRevenueTableTextBlock_label_en-US" xlink:label="lab_moh_SummarizedPremiumRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SummarizedPremiumRevenue [Table Text Block]</link:label>
    <link:label id="lab_moh_SummarizedPremiumRevenueTableTextBlock_documentation_en-US" xlink:label="lab_moh_SummarizedPremiumRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Premium Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SummarizedPremiumRevenueTableTextBlock" xlink:href="moh-20221231.xsd#moh_SummarizedPremiumRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_SummarizedPremiumRevenueTableTextBlock" xlink:to="lab_moh_SummarizedPremiumRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6b86cf37-8e92-4e14-bbcc-79af1d44c88c_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_6f859d9e-08c3-491b-b7ad-3d27781d3a57_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_c76cec32-1eed-4855-81cd-64cbde6fae58_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment, and capitalized software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_ba131658-1aab-487f-b85b-6ea48efdf332_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment, and capitalized software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_20a9cad1-1892-48dc-b124-5258fb8ffc9c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, equipment, and capitalized software, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ca6b0632-1c6a-4536-ab82-45427fca37a4_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_56e0c5ba-cb5e-4099-a70d-ae7f78576f80_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_5413cc11-67c8-4d2f-9b5f-cb04b88ba788_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_13189897-baab-41ec-8f32-3b1297c77ff4_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_701b4b2c-c896-4293-ba6c-8992b6b96e62_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_bfc3a9b2-0b6f-47c0-966a-a9174352f758_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_ad167d1d-05f9-4d64-a787-bda2bc56d0ab_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed statements of income</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Income Statement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedIncomeStatementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_52ef20e1-7551-4d72-878e-b76c03b636b3_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_286e7fe2-f389-43aa-be3f-679e00e7365c_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_2bbab892-ae48-4487-982d-01f9bfbedb41_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_2404ee5d-7e25-4e43-b1f2-ad4e221f2ad3_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of long-term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_55b73a0e-872e-4c07-b560-5ff8bc6428fc_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_1754d389-0199-4ee0-b97d-85af54e63cde_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_2215dd9d-c1e2-41b1-814e-f7f84c31a2d8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b6de5dad-8837-46a3-9f72-608699697754_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentIncome_ff6868da-feb1-4dc7-9e65-ab412aeb44ce_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income</link:label>
    <link:label id="lab_us-gaap_NetInvestmentIncome_label_en-US" xlink:label="lab_us-gaap_NetInvestmentIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentIncome" xlink:to="lab_us-gaap_NetInvestmentIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_b790d88c-70c7-4986-86ec-82dee94e2925_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_36943483-f667-4eeb-92f4-2ceb605596fa_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_0f45fc6c-e9cc-4910-aa19-71af68908249_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_3131ba64-8882-42ed-b819-426c9bb68860_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_949ebc3b-4c61-4637-b9f5-2bf1897c0f5c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_91630346-15f7-4235-9d4c-803eceb65337_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_83cbb996-992c-46db-81a2-2d808f316061_verboseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits roll forward</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_b311d8cf-583a-461b-9d56-e2e3408abfc3_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_0669c0fb-e11b-450f-ac8c-fdef75002b65_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of ROU assets</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:to="lab_us-gaap_FinanceLeaseRightOfUseAssetAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_UnrecognizedCompensationForfeitedRate_64880461-e1d8-45de-9d0d-398a88e2cd9f_terseLabel_en-US" xlink:label="lab_moh_UnrecognizedCompensationForfeitedRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeiture rate</link:label>
    <link:label id="lab_moh_UnrecognizedCompensationForfeitedRate_label_en-US" xlink:label="lab_moh_UnrecognizedCompensationForfeitedRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Compensation Forfeited Rate</link:label>
    <link:label id="lab_moh_UnrecognizedCompensationForfeitedRate_documentation_en-US" xlink:label="lab_moh_UnrecognizedCompensationForfeitedRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation forfeited rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_UnrecognizedCompensationForfeitedRate" xlink:href="moh-20221231.xsd#moh_UnrecognizedCompensationForfeitedRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_UnrecognizedCompensationForfeitedRate" xlink:to="lab_moh_UnrecognizedCompensationForfeitedRate" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A3875SeniorNotesMember_e3e2888d-cf70-4959-91bb-59b56335e1f3_terseLabel_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes due 2032</link:label>
    <link:label id="lab_moh_A3875SeniorNotesMember_label_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A3875SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A3875SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A3875SeniorNotesMember" xlink:to="lab_moh_A3875SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_f3a40cbe-8949-4f5a-be51-96237b69489c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_67be36ac-c2b8-4f76-8754-c752007cb3f1_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_87b7c3e0-9fb6-4114-af39-0a9770540be5_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net-of-Tax Amount</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_80d21bed-721e-4ac7-9e1b-ae85797b2311_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AssetsAndLiabilitiesLesseeTableTextBlock_1a01ff54-ce8c-4b44-aed8-bfff425c73f6_terseLabel_en-US" xlink:label="lab_moh_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental lease information</link:label>
    <link:label id="lab_moh_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_moh_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_moh_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_moh_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="moh-20221231.xsd#moh_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_moh_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_4e2a2c4c-c909-42c9-92e2-d3bb584cbae4_terseLabel_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension period</link:label>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_label_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Extension Option, Period</link:label>
    <link:label id="lab_moh_HealthPlanExtensionOptionPeriod_documentation_en-US" xlink:label="lab_moh_HealthPlanExtensionOptionPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Extension Option, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod" xlink:href="moh-20221231.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanExtensionOptionPeriod" xlink:to="lab_moh_HealthPlanExtensionOptionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_a876b3d2-61fb-4b57-b3c1-5a552b8f6c5c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ec8830ab-269b-4ba5-8615-f5dead6e845f_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_15d85aa2-368c-4b36-8c66-356a2e6e857d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_374e3124-7717-4439-844e-8cccd7434b95_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total IBNP</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OperatingIncomeGuaranteeMember_db0f2cbc-391e-476d-b64f-42f458d32ce6_terseLabel_en-US" xlink:label="lab_moh_OperatingIncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Guarantee</link:label>
    <link:label id="lab_moh_OperatingIncomeGuaranteeMember_label_en-US" xlink:label="lab_moh_OperatingIncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Guarantee [Member]</link:label>
    <link:label id="lab_moh_OperatingIncomeGuaranteeMember_documentation_en-US" xlink:label="lab_moh_OperatingIncomeGuaranteeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income Guarantee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingIncomeGuaranteeMember" xlink:href="moh-20221231.xsd#moh_OperatingIncomeGuaranteeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OperatingIncomeGuaranteeMember" xlink:to="lab_moh_OperatingIncomeGuaranteeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_e859f234-3bca-4c58-a268-cfc4dcffed42_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0134d461-bd30-4a4b-8e8f-f30ece42890b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_37527226-d6e5-4700-b993-586ab2a20818_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCredit_4bd93ef8-a874-4d4f-b281-5595a2b4010e_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount outstanding under Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCredit_label_en-US" xlink:label="lab_us-gaap_LineOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Line of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCredit" xlink:to="lab_us-gaap_LineOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_7582cc34-0499-4dd4-bf4e-3c1ab04c4977_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value per share; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022, and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_3438bb32-5754-485a-9238-2bd5efda15fd_netLabel_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022 and December 31, 2021</link:label>
    <link:label id="lab_us-gaap_CommonStockValueOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockValueOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValueOutstanding" xlink:to="lab_us-gaap_CommonStockValueOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_39808adf-4ed0-40b4-80b2-e972edf5cea7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_47e81a0b-f1d3-46b4-810f-af9d03c8b1c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_cd10aac2-53d1-4471-afc2-3b1ae711b826_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidReinsurancePremiums_bf0fcb2e-f188-4e8f-8883-655503bec066_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidReinsurancePremiums" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid reinsurance premiums</link:label>
    <link:label id="lab_us-gaap_PrepaidReinsurancePremiums_label_en-US" xlink:label="lab_us-gaap_PrepaidReinsurancePremiums" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Reinsurance Premiums</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidReinsurancePremiums" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidReinsurancePremiums" xlink:to="lab_us-gaap_PrepaidReinsurancePremiums" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_c9e99135-c2c1-4854-933a-ebed85c336cd_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_edbf7ff6-59d0-4644-8c81-8899d69c1b55_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_414a4110-c9e2-4e24-90fc-3f9fb3db8e95_terseLabel_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</link:label>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_label_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan [Member]</link:label>
    <link:label id="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_documentation_en-US" xlink:label="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:href="moh-20221231.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:to="lab_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_095aec22-2a55-4f23-ade8-4ed43a4be12a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_99c7b749-b8ab-4a22-88d5-7509a25d56f9_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_70872bad-8558-4110-a80e-6763a1e1b185_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities (current)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_733f461e-dbd8-4e25-bbe2-ee173352ce17_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems_label_en-US" xlink:label="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts, Notes, Loans and Financing Receivable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:to="lab_us-gaap_AccountsNotesAndLoansReceivableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_6b271c84-9961-4ca3-8235-ff86d40cdfa4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred and paid claims development</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Claims Development [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_e2f5562a-becc-4371-99b9-6738fca9f061_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_80e0a568-e36a-483e-b2eb-fbde25bbd49d_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8793fadb-d960-465b-bd84-2cf09a2f0be8_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_404cafe4-f92a-4a11-a290-b4fbc685c66b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_882a6930-ff74-428b-875f-3ca3a434523d_netLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_f1cee332-6740-441b-b7f6-50bea535d9a8_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_cd1e65ef-de7f-4568-a767-9278e31dbbf6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_2034e885-ee83-406d-8107-29159f900fdd_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:label id="lab_srt_CondensedFinancialStatementsCaptionsLineItems_label_en-US" xlink:label="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements, Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:to="lab_srt_CondensedFinancialStatementsCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_18df9d84-b741-415d-ae10-d385de028f41_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease financing obligation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_6de09633-29d5-4133-86e2-a4ab024cd9b6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5ab91387-8e17-4826-a2ad-0db554317e5c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_FinanceLeaseLiabilitiesLesseeAbstract_0a4e27e4-babb-469e-8e0b-fd8f04ff4dcf_terseLabel_en-US" xlink:label="lab_moh_FinanceLeaseLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_moh_FinanceLeaseLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_moh_FinanceLeaseLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liabilities, Lessee [Abstract]</link:label>
    <link:label id="lab_moh_FinanceLeaseLiabilitiesLesseeAbstract_documentation_en-US" xlink:label="lab_moh_FinanceLeaseLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FinanceLeaseLiabilitiesLesseeAbstract" xlink:href="moh-20221231.xsd#moh_FinanceLeaseLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_FinanceLeaseLiabilitiesLesseeAbstract" xlink:to="lab_moh_FinanceLeaseLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_9e1c4daf-60da-4fc0-aea7-54be63846fbe_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_73a1257a-6bc1-402f-a66f-48ac862d9dfd_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_c54cc014-ee9a-4999-917b-0483dded4ab6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Purchase Accounting Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4449c2b6-cf0a-4e78-9503-cbcc734bf14c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_885c8433-0d5f-4ff0-82f8-31210fbe2370_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_cb54e07d-6bfa-451e-93ab-d979377e6066_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:to="lab_us-gaap_LesseeFinanceLeaseRenewalTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_33f9d440-48b0-4972-a4a1-01334fa9f9bf_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_0c293239-f5cd-44e3-881d-d24b511d8c8b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred claims and allocated claims adjustment expenses</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e92e3cc9-2a88-4f3c-90f1-600fb57ed9aa_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8f83ed1e-fcb4-4ac0-b613-4bb4c8f62750_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_c41dee35-2353-4a3c-b3ee-9da6f0668476_terseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_c96b56ff-7efa-424e-9c5f-7e4616dd5998_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of property and equipment and depreciation and amortization recognized</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_6503ae43-da60-443e-ac26-cd4cc9518ff9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_817b6d29-a6e2-41a5-b463-3f669173f094_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_2d89e19f-a686-4679-b8ab-b18a17ecc3e2_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_cf28b491-9703-4683-ac67-16d7c300559e_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_5fe8730e-ce9d-45f3-af5a-b243dcc1ac92_terseLabel_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of states with programs</link:label>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_label_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States With Government-Sponsored Healthcare Programs</link:label>
    <link:label id="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_documentation_en-US" xlink:label="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of States With Government-Sponsored Healthcare Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:href="moh-20221231.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:to="lab_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_af0c68b5-066e-4aa7-9625-d496e0cc3287_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_463edfa9-eb57-4789-9ad0-010bcc3e9293_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life of property plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_c053a3a2-2dae-4af7-85ac-559ae6bd01e6_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtTextBlock_label_en-US" xlink:label="lab_us-gaap_LongTermDebtTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtTextBlock" xlink:to="lab_us-gaap_LongTermDebtTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_f43ef4fa-8277-41d7-91d0-38930df672b1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs and PSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_d6696bc6-1ed3-4308-b4ca-010088da9788_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_c7779401-dd13-4a36-a21f-db1672e3e053_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_8cf68942-509e-40e8-90b5-7e4a5c733615_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payable</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:href="moh-20221231.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_2562aa56-f80d-4905-bdf2-2c99eb8c8eb3_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_89a369cc-3801-4ab0-bd1e-ef07a700dc94_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_61b47a20-4af5-436e-9ec1-623f8fc2bbe9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_3a226153-afd7-4dea-b616-19626eb9b0e6_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease expense:</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_2f64a078-d12a-4f3b-bbe4-9664ddf4226f_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_2be8aed1-46eb-4e31-957c-eb077ecd6cd2_verboseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_79ea883a-37cc-4c42-939f-8d12d79ac8f8_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_ddc3d815-f1af-4dd5-b950-b253fd75a086_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_6a023dcd-6807-4f58-8423-a2d4be21a81e_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a3e54ad8-df71-45fd-bbc2-2e39e2cf04a7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5b9aee6a-dd39-4bc0-b142-357cf48aa9c9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_bbee72f7-3d6e-49c8-9805-adfecdd4e240_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_b0e71a93-0d3e-456b-bea1-89166696cb56_verboseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, Due in one year or less</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_2cd786b6-7c43-429d-86ea-30d4f2d5db59_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_77d57a2d-eb28-455a-a1c9-0fa5fe1c4a76_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized loss</link:label>
    <link:label id="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Fair Value Hedges Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:to="lab_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_58874ef1-739a-481f-9231-b2c1825c4fdc_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_4994a049-20c7-4e7a-a091-72edf929526f_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationNumberOfBusinessCombinations_a751b4d5-c23c-4341-86ce-b4bb9c00b754_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business combinations</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfBusinessCombinations_label_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Business Combinations</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfBusinessCombinations_documentation_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Business Combinations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:href="moh-20221231.xsd#moh_BusinessCombinationNumberOfBusinessCombinations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:to="lab_moh_BusinessCombinationNumberOfBusinessCombinations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_64e983d8-3626-4563-ba04-36e94b85613d_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_EmployeeStockPurchasePlanandStockOptionsMember_5aa4aac7-88fe-47c4-b614-82de0287d100_terseLabel_en-US" xlink:label="lab_moh_EmployeeStockPurchasePlanandStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan and stock options</link:label>
    <link:label id="lab_moh_EmployeeStockPurchasePlanandStockOptionsMember_label_en-US" xlink:label="lab_moh_EmployeeStockPurchasePlanandStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan and Stock Options [Member]</link:label>
    <link:label id="lab_moh_EmployeeStockPurchasePlanandStockOptionsMember_documentation_en-US" xlink:label="lab_moh_EmployeeStockPurchasePlanandStockOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan and Stock Options [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EmployeeStockPurchasePlanandStockOptionsMember" xlink:href="moh-20221231.xsd#moh_EmployeeStockPurchasePlanandStockOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_EmployeeStockPurchasePlanandStockOptionsMember" xlink:to="lab_moh_EmployeeStockPurchasePlanandStockOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_7e81a30b-498b-47b0-861f-3b1e58e6d0bb_terseLabel_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsAverageMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsAverageMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Average Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod" xlink:href="moh-20221231.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsAverageMaturityPeriod" xlink:to="lab_moh_InvestmentsAverageMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_ae582a07-898e-491b-b816-5f5da48ccf32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_bb198fe2-3487-4929-8ac3-c0247d4458ed_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemAxis_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis" xlink:to="lab_us-gaap_UnusualOrInfrequentItemAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_52d5acda-273c-487a-8b3e-2ca1e85d243a_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_97a2d9ca-0295-4ac7-829c-54eae829bb87_totalLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total paid</link:label>
    <link:label id="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:to="lab_us-gaap_PaymentsForLossesAndLossAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_0fe6e8f3-e003-452d-bead-4e126f787709_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_94c5b586-f8df-43da-8106-ab081e723495_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f0d74357-f084-4804-95cd-3235ae3267dc_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_260cb1f4-51bd-4217-938c-78fb61272b1d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value measurements of senior notes</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_45b9317c-773f-4663-88bf-8898de4d1f3d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized investment (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_5897f9d4-5c19-40f8-9e1b-8948cc3fbd3f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized investment (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_522aa598-fca2-4cb0-8464-10ba151e0ffa_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_410eef5c-0aa2-4dd9-a89d-83f13cfc42c1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held-to-maturity Securities [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Held-to-Maturity Securities [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlanContractTerm_0672633d-d3e0-467d-852c-ce5979b1d205_terseLabel_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_label_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:label id="lab_moh_HealthPlanContractTerm_documentation_en-US" xlink:label="lab_moh_HealthPlanContractTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plan, Contract Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm" xlink:href="moh-20221231.xsd#moh_HealthPlanContractTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlanContractTerm" xlink:to="lab_moh_HealthPlanContractTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_bb08d7a9-85af-4d87-88c8-41bd31e880ee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_06b16e33-940a-4fc7-be5c-f8cd25898a9b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_c9fa85aa-c61a-4d42-916b-52c1cb3f6545_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired membership with a preliminary fair value</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_2d845c80-2b81-4b56-bfca-8dae152917de_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MyChoiceWisconsinMember_2d095cb7-307e-4d1d-949c-00e016ef4bee_terseLabel_en-US" xlink:label="lab_moh_MyChoiceWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">My Choice Wisconsin</link:label>
    <link:label id="lab_moh_MyChoiceWisconsinMember_label_en-US" xlink:label="lab_moh_MyChoiceWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">My Choice Wisconsin [Member]</link:label>
    <link:label id="lab_moh_MyChoiceWisconsinMember_documentation_en-US" xlink:label="lab_moh_MyChoiceWisconsinMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">My Choice Wisconsin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MyChoiceWisconsinMember" xlink:href="moh-20221231.xsd#moh_MyChoiceWisconsinMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MyChoiceWisconsinMember" xlink:to="lab_moh_MyChoiceWisconsinMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_7262ca50-6878-4749-a3db-5cfb81640679_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_b3f7636e-44a9-4ae1-bd1c-e91028bf00f6_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock authorized</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_f1dd63b9-88b6-4338-b9cd-edbf093a715d_verboseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_b4115761-81d2-42e7-9348-47bd04c3d259_netLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_6349fc2f-08c6-4744-a0c4-88d6565fdae6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_75bfe3a4-c000-4c4d-b90a-93fdc782ec4c_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment, net payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_e2ae79c0-5c20-4578-83fe-673a35ae0b8b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9840596b-a67a-44fc-9276-b992b5ef093e_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_06b118ad-edbe-457c-9d48-51fb98061f5b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_fe7130f2-41cd-44c5-81e9-781c8506004b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_71f68bda-d227-4e1c-aeb7-0acdf42c40d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicareMember_ac50ea54-8362-4542-b2e9-c74a12cd4363_terseLabel_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:label id="lab_moh_MedicareMember_e5cf1082-2de6-4100-831c-5d364bd6efb3_verboseLabel_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare Segment</link:label>
    <link:label id="lab_moh_MedicareMember_label_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare [Member]</link:label>
    <link:label id="lab_moh_MedicareMember_documentation_en-US" xlink:label="lab_moh_MedicareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicareMember" xlink:to="lab_moh_MedicareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_aa8cf44b-5d89-459d-83c4-7c30fc9abf77_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_GovernmentReceivablesMember_a090728e-5699-402e-83fc-d2c7a1bd181e_terseLabel_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government receivables</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_label_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:label id="lab_moh_GovernmentReceivablesMember_documentation_en-US" xlink:label="lab_moh_GovernmentReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember" xlink:href="moh-20221231.xsd#moh_GovernmentReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_GovernmentReceivablesMember" xlink:to="lab_moh_GovernmentReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_5b4bad04-30ba-4d59-b091-053c6f3514aa_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MemberListsMember_a3b1a138-3c13-4a81-af3c-b432a112ac2f_terseLabel_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member list</link:label>
    <link:label id="lab_moh_MemberListsMember_label_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Lists [Member]</link:label>
    <link:label id="lab_moh_MemberListsMember_documentation_en-US" xlink:label="lab_moh_MemberListsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Member Lists</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember" xlink:href="moh-20221231.xsd#moh_MemberListsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MemberListsMember" xlink:to="lab_moh_MemberListsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_0b88439d-276a-4d53-853d-c77eab2aa260_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation expense</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_041f27e6-a647-4669-9f0f-b5ca305bb723_verboseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_737f1c21-6b47-4621-9370-1ed3a2db2635_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities (non-current)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_fc6e6b19-9a62-412c-8875-a400907d39ba_netLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_64129591-8649-4102-8466-55cb1945bdb1_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoverable</link:label>
    <link:label id="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_label_en-US" xlink:label="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Recoverable for Unpaid Claims and Claims Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:to="lab_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_f8a40280-486e-4e7f-8552-a90d3157f6e8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: effect of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_d685b59e-2cbc-4a14-98fd-544976d98529_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: effect of income taxes</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_156b4761-cb89-45cd-b98f-6a67a5334270_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_7fcdab07-db1b-4969-bd71-7415100bb42f_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AdvancesToRelatedPartiesAndOtherAssets_3c745caf-4e62-4135-ab4d-5ca41bca1c88_verboseLabel_en-US" xlink:label="lab_moh_AdvancesToRelatedPartiesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances to related parties and other assets</link:label>
    <link:label id="lab_moh_AdvancesToRelatedPartiesAndOtherAssets_label_en-US" xlink:label="lab_moh_AdvancesToRelatedPartiesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances To Related Parties And Other Assets</link:label>
    <link:label id="lab_moh_AdvancesToRelatedPartiesAndOtherAssets_documentation_en-US" xlink:label="lab_moh_AdvancesToRelatedPartiesAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advances to related parties and other assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AdvancesToRelatedPartiesAndOtherAssets" xlink:href="moh-20221231.xsd#moh_AdvancesToRelatedPartiesAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AdvancesToRelatedPartiesAndOtherAssets" xlink:to="lab_moh_AdvancesToRelatedPartiesAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_463a67d9-8d72-459f-8420-4208f6631a33_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5a62ec1e-cff8-43de-988c-4e7620a2512b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e850a550-bce1-4c15-b7de-d55ca65e7b47_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period for recognition</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_e4aac392-03df-4435-a7f2-4f053c99c349_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of identified intangible assets, by major class</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_fbbf07d8-304e-47ae-84c5-3ff52be902fa_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_fd4b4ff2-86db-4bcd-944e-b0e696679913_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid in business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_b18cfe15-6f77-40c0-9692-7e04eefea919_verboseLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f878f36d-2a7a-405c-8382-56f1aa6117fa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount_eafa5263-0780-440d-ac9b-e3fcac17f6d6_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized cost, due after five years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year 5 through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthPlansMember_c010c43d-dc9f-4eec-81c0-f35cc4d84826_terseLabel_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans</link:label>
    <link:label id="lab_moh_HealthPlansMember_label_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Plans [Member]</link:label>
    <link:label id="lab_moh_HealthPlansMember_documentation_en-US" xlink:label="lab_moh_HealthPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember" xlink:href="moh-20221231.xsd#moh_HealthPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthPlansMember" xlink:to="lab_moh_HealthPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_ceec907d-262b-4dd5-a995-6a6d9beba18f_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative number of reported claims (in claim)</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Cumulative Number of Reported Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_26085780-8187-4741-baf5-02773de9f333_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAbstract_9957706b-ca4d-4569-9e31-3cfe9faedca7_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:label id="lab_us-gaap_InsuranceAbstract_label_en-US" xlink:label="lab_us-gaap_InsuranceAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAbstract" xlink:to="lab_us-gaap_InsuranceAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_18e24d99-9966-4252-bb91-b16c99aa6863_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_466765f1-6246-401c-a459-e1da92586d2a_totalLabel_en-US" xlink:label="lab_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax benefit and equity in net earnings of subsidiaries</link:label>
    <link:label id="lab_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_label_en-US" xlink:label="lab_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Before Income Taxes And Equity In Net Income Of Subsidiaries</link:label>
    <link:label id="lab_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_documentation_en-US" xlink:label="lab_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Before Income Taxes And Equity In Net Income Of Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" xlink:href="moh-20221231.xsd#moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" xlink:to="lab_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_e3d06062-5753-4c7a-a53d-76311bb2ea62_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Year 2022</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_DepreciationandAmortizationContinuingOperations_b838c683-3aeb-476d-a958-18a135ef422f_totalLabel_en-US" xlink:label="lab_moh_DepreciationandAmortizationContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total depreciation and amortization recognized</link:label>
    <link:label id="lab_moh_DepreciationandAmortizationContinuingOperations_label_en-US" xlink:label="lab_moh_DepreciationandAmortizationContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Continuing Operations</link:label>
    <link:label id="lab_moh_DepreciationandAmortizationContinuingOperations_documentation_en-US" xlink:label="lab_moh_DepreciationandAmortizationContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DepreciationandAmortizationContinuingOperations" xlink:href="moh-20221231.xsd#moh_DepreciationandAmortizationContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_DepreciationandAmortizationContinuingOperations" xlink:to="lab_moh_DepreciationandAmortizationContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e67e694c-e22c-47fa-b766-2e89017f5d09_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e8ce6be9-83fd-4031-a8ff-630b94fee34d_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_2c3183cb-e870-4eae-8098-898b164bc906_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ChangesInAmountsDueToAndDueFromAffiliates_62504012-0d25-4d91-bf2a-65ed17e23b1f_verboseLabel_en-US" xlink:label="lab_moh_ChangesInAmountsDueToAndDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in amounts due to/from affiliates</link:label>
    <link:label id="lab_moh_ChangesInAmountsDueToAndDueFromAffiliates_label_en-US" xlink:label="lab_moh_ChangesInAmountsDueToAndDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Amounts Due To And Due From Affiliates</link:label>
    <link:label id="lab_moh_ChangesInAmountsDueToAndDueFromAffiliates_documentation_en-US" xlink:label="lab_moh_ChangesInAmountsDueToAndDueFromAffiliates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in amounts due to and due from affiliates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ChangesInAmountsDueToAndDueFromAffiliates" xlink:href="moh-20221231.xsd#moh_ChangesInAmountsDueToAndDueFromAffiliates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ChangesInAmountsDueToAndDueFromAffiliates" xlink:to="lab_moh_ChangesInAmountsDueToAndDueFromAffiliates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_83d13b17-0e59-4c77-85a4-30d30fca2183_verboseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Required minimum statutory capital surplus</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus Required</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_c81d6f45-ae04-4231-affe-147f7127d6b4_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_0379bcd8-61f2-4712-b7b5-6f161ddde599_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation and Presentation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_a51eb67c-ed06-4f19-996f-ee9f44a09641_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_9b3692d3-b47b-4ac2-a294-c8de4e38c00d_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_699ab9cb-5caa-4595-b690-21a41a1fc4e9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1b819773-ad35-4ca6-a0ff-c5d71837b1a8_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheets</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f44078db-2c18-4a2c-b2ac-7abfdd7122d0_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_7dc4a18a-0dd9-4db7-8c3f-a3294ad042b7_negatedLabel_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated amortization - capitalized software</link:label>
    <link:label id="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized Computer Software, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:to="lab_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_099aa1ab-ce65-47e6-a443-50ea0a346bc5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unearned premiums</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Unearned Premiums Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_69472a80-8ea1-4cd3-a11c-af91cabc50ab_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_0b213024-69dd-44a9-b4f9-0d684fc88775_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_b6377286-d396-4cdc-a423-90b67589d801_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a78ffa7a-0ede-4727-874b-1c32a5315724_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_d8a4da24-6f58-49bc-8b05-b66c1012dedf_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_f9341aa3-341e-409e-8e36-2c6f2c9fc3b2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_9686d035-fa4c-4a18-b110-3a553a451aa0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_9ebca62f-8c5f-4162-a3b6-6d81cda3ae7f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_e062b92a-a4cf-4a10-9c83-015d495d7fb5_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4b230aa3-d872-4a46-a99b-abe22e5a8472_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_4a5eecb4-32e6-4e0f-8669-82df3756fa3c_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average cost (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock_29d322b8-d6b2-429d-b6ef-b8f723afe838_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance and Deposit Contracts [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:to="lab_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_402fc475-8b8c-4210-b4db-1b5079a246e3_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization expense, 2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_FinanceLeaseAssetsLesseeAbstract_e089472f-f3cb-4681-b058-bb2c09e8164e_terseLabel_en-US" xlink:label="lab_moh_FinanceLeaseAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_moh_FinanceLeaseAssetsLesseeAbstract_label_en-US" xlink:label="lab_moh_FinanceLeaseAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Assets, Lessee [Abstract]</link:label>
    <link:label id="lab_moh_FinanceLeaseAssetsLesseeAbstract_documentation_en-US" xlink:label="lab_moh_FinanceLeaseAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Assets, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FinanceLeaseAssetsLesseeAbstract" xlink:href="moh-20221231.xsd#moh_FinanceLeaseAssetsLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_FinanceLeaseAssetsLesseeAbstract" xlink:to="lab_moh_FinanceLeaseAssetsLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_e1638485-06e1-4061-854f-b3cbe79da05b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_b3954668-3028-4c02-957a-e9f2aa0a79dc_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalents_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalents" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_15f68ef1-d514-445b-a631-fb8c95c07f8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_811b5536-cba7-43a6-88a4-568d02271617_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax expense rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems_e695b24b-9153-4b47-998a-04ba2d45e7d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-risk and other provider payables</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Aggregate Reconciling Items</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_760d0f43-5031-4789-85e7-dd3c260d6e28_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from borrowings under term loan facility</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLinesOfCredit" xlink:to="lab_us-gaap_ProceedsFromLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HealthCarePremiumMember_c02d362f-a119-4ac5-89bd-6bb0e2c5ec24_terseLabel_en-US" xlink:label="lab_us-gaap_HealthCarePremiumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium revenue</link:label>
    <link:label id="lab_us-gaap_HealthCarePremiumMember_label_en-US" xlink:label="lab_us-gaap_HealthCarePremiumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care, Premium [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePremiumMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePremiumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HealthCarePremiumMember" xlink:to="lab_us-gaap_HealthCarePremiumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_RisksAndUncertaintiesPolicyTextBlock_c3ddfd40-f890-4ad5-83b3-86f1480aff02_verboseLabel_en-US" xlink:label="lab_moh_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and Uncertainties</link:label>
    <link:label id="lab_moh_RisksAndUncertaintiesPolicyTextBlock_label_en-US" xlink:label="lab_moh_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks And Uncertainties [Policy Text Block]</link:label>
    <link:label id="lab_moh_RisksAndUncertaintiesPolicyTextBlock_documentation_en-US" xlink:label="lab_moh_RisksAndUncertaintiesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risks and uncertainties.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RisksAndUncertaintiesPolicyTextBlock" xlink:href="moh-20221231.xsd#moh_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_RisksAndUncertaintiesPolicyTextBlock" xlink:to="lab_moh_RisksAndUncertaintiesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_a2b6a5f2-cd15-4b4b-8bd8-f6c2fb0d95e2_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_ed8c929b-c762-45ea-b405-cdda97be8e45_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combinations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_db3b6a4c-75ad-4dc6-852d-de0228b55df7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ParentCompanyMember_767b736c-f449-497f-8fda-935cba3fa33b_terseLabel_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company</link:label>
    <link:label id="lab_srt_ParentCompanyMember_label_en-US" xlink:label="lab_srt_ParentCompanyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent Company [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ParentCompanyMember" xlink:to="lab_srt_ParentCompanyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_b41a7506-ee97-4459-80b2-8eaeacf89d8e_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Claims paid</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e8a5a82f-c3ed-433e-a8c5-5cb64cb4af92_negatedLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: cumulative paid claims and allocated claims adjustment expenses</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_09175158-4ddc-4555-a098-278e70b5c808_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_c01e5506-8f15-4d41-b736-97c21e260b64_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_f59add81-8d80-440d-9d98-f3b720cd957d_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Add: Other operating revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_e9578aeb-85c7-48fc-8f6e-d589ef15bd86_terseLabel_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance</link:label>
    <link:label id="lab_us-gaap_ReinsuranceAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReinsuranceAccountingPolicy" xlink:to="lab_us-gaap_ReinsuranceAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8ef8ded8-1adc-470b-bee6-1d05f943f3b4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum expected volatility rate inputs for fair value measurement</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_d8547463-16c5-428a-a2c4-e3670713891d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_c2dbd1d4-f74b-4d78-bf1a-0dfb569824a8_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_3cf99d8a-492b-48d1-ad6e-817b32ddeb9b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_6251a347-63a4-483c-bd45-a765f7cc8897_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_f4e7b836-d144-4ac2-8e67-a1e33311302d_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services revenue from subsidiaries</link:label>
    <link:label id="lab_us-gaap_RevenueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_RevenueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromRelatedParties" xlink:to="lab_us-gaap_RevenueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_f857ae10-e6b7-49a3-9e33-576c0d176168_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_7b9fbb58-177b-4ee8-bd0f-74cfe6b08300_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_e3d27ca5-048e-4c86-bc0d-8c0462ab6f98_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In a Continuous Loss Position for 12 Months or More, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_9d7a6844-6328-4359-8af9-700bff8efc83_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_d2980954-98e7-4489-9126-50f4e9cd1c34_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_dbf3f616-91b7-4cb0-adce-3309eaab1f97_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8ddfedac-d483-4226-b30a-042616a77a61_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_504e7e72-a595-490f-b74c-5ec83ffcb6e4_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_A4375SeniorNotesMember_f6b58238-67d4-4e73-86e7-6e433af45729_terseLabel_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2028</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_label_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes [Member]</link:label>
    <link:label id="lab_moh_A4375SeniorNotesMember_documentation_en-US" xlink:label="lab_moh_A4375SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_A4375SeniorNotesMember" xlink:to="lab_moh_A4375SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_80855cec-1a68-43a3-8f5c-13a00f3f624e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_493d670c-8817-4830-b5c8-91707384f9f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of restricted shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_6056b1b2-3ec7-492c-ab8d-6dde5ffdffaf_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_0c580a13-7c46-4b29-bec7-d0b8228eeedc_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_label_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</link:label>
    <link:label id="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_documentation_en-US" xlink:label="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:href="moh-20221231.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:to="lab_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_0d184885-1b6e-4e7f-a8a9-3d0b410c0ebe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_85de85e0-bda9-4b9d-bde5-8c04a064caa8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of principal amount of convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_3e8e8b39-3a03-418c-bece-5a600dbbbdb2_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of principal amount of convertible notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_362a2d57-3c55-4bd6-a341-1e333d18ef50_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_d3a6eb74-a003-475d-9b9c-acb44f7313a1_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_34eaef3d-cfb5-4a57-b2a3-acb0ab88a63f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_802c78f2-dd77-4c7c-9a59-b0086e4d0242_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_fdff398e-187b-44c8-8bc3-7e7b264e28cf_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryovers</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_d131a90f-44e2-4a28-b29b-af31649616c3_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Finance Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_4ba74c4d-ae93-4429-b2d2-9bde5d421f1c_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_58c107b5-ea6b-49f2-84f5-93aab31fa50d_terseLabel_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_label_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:label id="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_documentation_en-US" xlink:label="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:href="moh-20221231.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:to="lab_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_c746c57d-e335-4380-bbfe-6256c7233144_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_8c30c5b4-51ea-4a32-974d-01220a70d6fc_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityLineItems_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems" xlink:to="lab_us-gaap_LineOfCreditFacilityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_bd51ec84-a185-4592-9696-69473b070b7a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credit carryover</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesLineItems_1d764b87-3526-441f-b3f6-f79eed6d3da4_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesLineItems_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems" xlink:to="lab_us-gaap_StatutoryAccountingPracticesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_c2443107-9281-486f-bc7f-cffb9ca8a9bd_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_2e5407f8-5f89-448e-bd23-8de7906839ef_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other premium adjustments</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesOther_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:href="moh-20221231.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesOther" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5f06ab64-9bd3-4550-aa81-e95f1c1c59d7_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_defd8350-1fd5-422e-8cb5-2d455dd51e4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_CommercialMortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_CommercialMortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9f2ee81e-49d9-47da-b73b-816360a97407_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_c676ce71-2e83-46a4-a200-3985e4c4304a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueByBalanceSheetGroupingTable_label_en-US" xlink:label="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="lab_us-gaap_FairValueByBalanceSheetGroupingTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired_d0b28dc8-06ab-46d4-b83f-fd97ff6ed950_terseLabel_en-US" xlink:label="lab_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired_label_en-US" xlink:label="lab_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right Of Use Asset, Excluding Leases Acquired</link:label>
    <link:label id="lab_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired_documentation_en-US" xlink:label="lab_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease Right Of Use Asset, Excluding Leases Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" xlink:href="moh-20221231.xsd#moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" xlink:to="lab_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_a20c77e5-3996-4d65-9623-0b9fb811f016_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7a818eae-ecca-4cf7-9180-f6702062d2d1_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net of the effect of acquisitions:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b783fd78-b1e4-43d7-89ac-8b4ba04ad8fd_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization expense, 2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_7d8c1325-c3e6-4548-9b6e-cbbd0ffd493f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_9b6aca66-2067-4d66-8a2f-47fc31193e40_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_6d3d32fc-a0da-4abe-b9f3-e678da0d7845_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Year 2021</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2021 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2021Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_2d9a7611-f00b-466b-a7c3-37247cce6521_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_40eefaf8-4f56-4beb-b2ce-d9654efaa4dc_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_637d4705-9a58-497b-9852-a42f08631274_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_d29a47d6-0977-4c60-af49-c3748679995f_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_9c979a58-74f6-415c-8845-8cfad0a04590_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8359fa7a-93c0-445f-9541-d0d2c16759f5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive (loss) income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7e691fea-824d-4919-9028-039dfacc0595_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_58d3176d-e659-41da-ad18-64e1e9c4b215_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_label_en-US" xlink:label="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:to="lab_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_27fa9f36-0063-4ae3-b932-55bc77e52e5b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_73f0a7ad-9b3c-4de7-b7a3-373b7392b90c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_35f16845-5898-4249-8f12-5da86ee914f9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of lease expense and supplemental consolidated cash flow information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_e224132f-c970-45c8-963f-798f5b23c16c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_aadeaf16-85cc-4515-af95-801ac8868cc9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_5667c556-d3ac-4538-88c6-721847856491_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_62740727-1703-4112-a448-fb2dd85c8184_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_08354f9f-80e7-4b96-a381-98931509af41_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-risk provide payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayable_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:href="moh-20221231.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayable" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_39a89c78-085d-46ed-9183-33e33bfd3b86_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_f1fcd6a4-632a-41be-b7f3-9768113f82ed_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_9b7eab14-1f83-46a0-bfc1-eb2fc0876114_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_f65c7c78-546e-4175-a825-c84b7921b6e0_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_097e97c8-c14a-4c5d-a9ca-2112425cf1a2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_5aa83ca4-4a81-4d97-93e0-474b27ae98cc_terseLabel_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR, corridors, and profit sharing</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_label_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:label id="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_documentation_en-US" xlink:label="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Premiums Liability, Medical Care Costs Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:href="moh-20221231.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:to="lab_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_17032383-de89-401c-a361-d9d8283310aa_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_55c7d8bc-6e40-438d-81ed-bf8b3c17f21a_verboseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_7c8885ee-01f2-4b23-9bc4-d553665a494d_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total receivables</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ProviderNetworkMember_23c0ccb7-8132-45eb-ad41-a282d7e76ba0_terseLabel_en-US" xlink:label="lab_moh_ProviderNetworkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider network</link:label>
    <link:label id="lab_moh_ProviderNetworkMember_label_en-US" xlink:label="lab_moh_ProviderNetworkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Network [Member]</link:label>
    <link:label id="lab_moh_ProviderNetworkMember_documentation_en-US" xlink:label="lab_moh_ProviderNetworkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Network</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworkMember" xlink:href="moh-20221231.xsd#moh_ProviderNetworkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ProviderNetworkMember" xlink:to="lab_moh_ProviderNetworkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_3e2f0706-dde3-4aa8-ae20-0c3384e8c8d0_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_34841ace-0278-4aaf-81cd-dfea78ebebfe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities (non-current)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_6e459e98-93a6-466c-b936-3d592ae4d0ba_terseLabel_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of restricted shares granted</link:label>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_label_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</link:label>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_documentation_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:href="moh-20221231.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:to="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_41cbe1d5-d822-430a-aab9-4573288c2979_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense recognized in connection with contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_fcaa20bf-9125-4375-9d97-88533b3d7fbb_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherReceivablesMember_60c052c2-2ea1-4f1f-b32c-867fe7eb59f9_terseLabel_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_label_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:label id="lab_moh_OtherReceivablesMember_documentation_en-US" xlink:label="lab_moh_OtherReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember" xlink:href="moh-20221231.xsd#moh_OtherReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherReceivablesMember" xlink:to="lab_moh_OtherReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_678857b4-96c9-4012-86ae-6ed379d1ff73_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities settled</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_2452829a-b8de-4d43-941a-4a2d9f8e3bb8_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liabilities settled</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_d8e939d1-88ee-44f3-b040-f57b3d395a92_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted investments</link:label>
    <link:label id="lab_us-gaap_RestrictedInvestmentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Investments, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedInvestmentsNoncurrent" xlink:to="lab_us-gaap_RestrictedInvestmentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_afda3398-24c0-45d9-ad3d-ef2847df3291_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1e6e52b3-e02b-40cc-906e-48d42918f7ed_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_a90ec0f1-c939-4939-9663-b034b766eb26_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed statements of cash flows</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Cash Flow Statement [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_6aa7bfcb-e3f5-45d3-9b64-8afb1abac604_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_9d967e31-52a5-4c0f-90e5-c3d406323486_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicaidMember_865c5d2d-16ec-4ce8-a9f8-f253b8b934c4_terseLabel_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid</link:label>
    <link:label id="lab_moh_MedicaidMember_998ef93b-c8c9-4524-964f-0c0c866d5486_verboseLabel_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid Segment</link:label>
    <link:label id="lab_moh_MedicaidMember_label_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:label id="lab_moh_MedicaidMember_documentation_en-US" xlink:label="lab_moh_MedicaidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicaid [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicaidMember" xlink:to="lab_moh_MedicaidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_a3e7e2d4-502e-40f1-9ab6-f0d637b80d43_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for partial settlement of call option</link:label>
    <link:label id="lab_us-gaap_ProceedsFromConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromConvertibleDebt" xlink:to="lab_us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_329fe8a8-bb70-4d57-a221-6ceaa3d36bab_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_60f564f3-f778-403a-85dc-162c446bdb4c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_014a9c33-c236-419f-a8c5-8cc0c9d590c9_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_ef80f92d-a8ae-4d19-918f-9ca178b81b59_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_154a137d-64af-4352-bdad-098b67dee957_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_0f8a50ef-e511-4732-a731-59d8618283c6_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_d0ad93f0-3d19-4f21-b68f-e4ca01f8f074_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of intangible assets acquired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_dc142ac0-7f01-43dc-8ce9-c6b1549029f1_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_5ea1831a-ff02-45b8-887e-75c29dd0720a_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_7fda4533-8235-4c2c-9538-0420a717ba35_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_161303b6-c265-4bf0-b2ba-5fa0d815d72a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_bf4f2189-b146-4d96-9409-fa99beca664f_verboseLabel_en-US" xlink:label="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net assets of subsidiaries subject to restrictions</link:label>
    <link:label id="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_label_en-US" xlink:label="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:to="lab_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f89160cb-94e6-4c9c-8854-970a5121bfcc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_089a5d03-9daa-4f5c-a319-150514df8c3d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested balance, shares end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract_1102f592-1ff1-4bb1-9e2a-38019bbe3951_terseLabel_en-US" xlink:label="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="moh-20221231.xsd#moh_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_moh_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1435f2b5-3318-4475-abf2-a7b11357c4b4_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_28d1d499-a693-4fd3-8565-10998cc86068_negatedLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: other expenses, net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_6673534b-75cc-44b2-b5a3-97a9383e1228_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_dff03914-9723-4e5c-bb3d-3ed1a4e0ce04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OperatingAndFinanceLeaseImpairmentLoss_fbcaf436-1376-4290-a2e3-ddcdff6e1784_terseLabel_en-US" xlink:label="lab_moh_OperatingAndFinanceLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets impairments</link:label>
    <link:label id="lab_moh_OperatingAndFinanceLeaseImpairmentLoss_label_en-US" xlink:label="lab_moh_OperatingAndFinanceLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Impairment Loss</link:label>
    <link:label id="lab_moh_OperatingAndFinanceLeaseImpairmentLoss_documentation_en-US" xlink:label="lab_moh_OperatingAndFinanceLeaseImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating And Finance Lease, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingAndFinanceLeaseImpairmentLoss" xlink:href="moh-20221231.xsd#moh_OperatingAndFinanceLeaseImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OperatingAndFinanceLeaseImpairmentLoss" xlink:to="lab_moh_OperatingAndFinanceLeaseImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_765ee031-3b01-4d00-ac18-ba9867553133_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed balance sheets</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:to="lab_srt_ScheduleOfCondensedBalanceSheetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_de5eb7de-19b8-431f-91bb-869904a065a8_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3e465735-e480-4dc0-9184-0ec61bbc3d73_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_090c7f43-97d9-4aad-a9f5-dbadc4c38b92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9b1fda03-25c6-4a50-988c-bd925e73c993_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive (Loss) Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_DeferredTaxAssetsFixedAssetsAndIntangibles_4a26a66a-6e3d-4e08-a57a-83cf59d2f891_terseLabel_en-US" xlink:label="lab_moh_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets and intangibles</link:label>
    <link:label id="lab_moh_DeferredTaxAssetsFixedAssetsAndIntangibles_label_en-US" xlink:label="lab_moh_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Fixed Assets and Intangibles</link:label>
    <link:label id="lab_moh_DeferredTaxAssetsFixedAssetsAndIntangibles_documentation_en-US" xlink:label="lab_moh_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Fixed Assets and Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:href="moh-20221231.xsd#moh_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:to="lab_moh_DeferredTaxAssetsFixedAssetsAndIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_9ed57225-b20e-4fe4-a898-67bfde76a0bf_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_913d2c00-edb8-4484-b6d4-a80816931c24_terseLabel_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Notes due 2030</link:label>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_label_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Senior Notes [Member]</link:label>
    <link:label id="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember_documentation_en-US" xlink:label="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Three Point Eight Seven Five Percent Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:to="lab_moh_ThreePointEightSevenFivePercentSeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductInformationLineItems_bbb0c287-b846-44e2-a782-b1e78968da4c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_ProductInformationLineItems_label_en-US" xlink:label="lab_us-gaap_ProductInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductInformationLineItems" xlink:to="lab_us-gaap_ProductInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_0d6d46dc-f821-4b05-8e2a-2b2bdabfc489_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_d8329a72-af68-47bb-9d4b-cc87fd425e2c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_da38f5b6-15ae-447f-bb94-1ec1450d05f8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_1542c9cb-1714-425f-bfc3-deb68fdcea9a_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_ce3de72f-3328-4b64-ba8d-4739134fe37c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options, activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_08c9e1af-d02e-40af-bccc-e94650f5c9af_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a87b5883-be5f-4146-9c73-6533701d811f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating income</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b475d87c-152f-4645-a076-32a91fc85a64_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_f11d756b-bd2e-4d49-94c8-b2ed725bb324_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherCostAndExpenseOperating_label_en-US" xlink:label="lab_us-gaap_OtherCostAndExpenseOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Cost and Expense, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCostAndExpenseOperating" xlink:to="lab_us-gaap_OtherCostAndExpenseOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_61f6bab1-8154-4308-803b-33a82ff6f3f4_totalLabel_en-US" xlink:label="lab_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss before equity in net earnings of subsidiaries</link:label>
    <link:label id="lab_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) From Continuing Operations Before Equity Method Investments, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:label id="lab_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_documentation_en-US" xlink:label="lab_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) From Continuing Operations Before Equity Method Investments, Extraordinary Items, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" xlink:href="moh-20221231.xsd#moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_4de19dcc-5f67-4f47-81b2-70a6fd7a7e97_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_cf868984-2a5b-40f7-9e8a-2918a7b54666_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_310d55e7-b50f-4fec-b022-bbba97793417_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and reserve liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_bbd3c949-d9a0-423b-9f07-f20d64ab9a14_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares issued:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_19508cb6-c532-41c6-8c09-539fe41d967f_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_13ae32af-3cb3-4d86-a0d4-79de58d43a69_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_2aa8a5bb-3895-4d9a-a6ff-6f415ec09871_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in subsidiaries</link:label>
    <link:label id="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_label_en-US" xlink:label="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:to="lab_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_abcab61c-f1cd-47c3-805a-10ab44b6d905_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_53d25fe6-3dd4-4c93-8d6f-11fbad79345a_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_3c188412-537d-424c-9982-d3ff1009554b_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fees</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_label_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Expense</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeExpense_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationInsurerFeeExpense" xlink:to="lab_moh_HealthCareOrganizationInsurerFeeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_022eed5c-f802-4af8-9f31-6bb6f597331f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a9a2b91e-e362-48e2-ad80-27b588584bb2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_faefa5dc-d2d9-4d65-a558-fe6db21e5ce5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_aaf065a4-8b8a-4051-9968-1ff29660fe95_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3473a952-00a1-4f80-bb0b-36d3c6443e69_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_bfbe6062-79d8-44e5-9fdb-2cd238bd6c89_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Net</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_f9677027-5df1-4a63-b19c-2ed17d4952ea_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_59692d5b-60c8-4894-ac16-d337ac79ceda_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_257c0c1b-b1ca-45d7-aae7-d3e565788443_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_bb09f06d-46cb-4a41-8606-3b9e2c24f073_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_9b64447c-a1a4-4ef7-936a-be468dc7d106_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_02e41296-45e0-4ef3-9ef0-c427c519eed1_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_6f166d26-4358-49a3-9b4b-2c84a25a40a8_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets, including Intangible Assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_94b5e85c-fc32-44e3-836b-1d14a66aa6de_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd9fec9f-afff-45a1-9e8b-7d43e3533129_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b554ad52-8097-4419-ad64-dd54a0cebf6c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_1784cd7c-fc60-4c06-95dc-970414defe7f_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Statements of Income</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cde2771c-e809-479d-906d-e86a385c003c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_10dab9af-faa9-4e04-aca6-e16bbc724abe_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Marketplace Program [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_50fada65-78a0-4c0a-91bc-8c2675e0775d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4c9eeac6-9989-4a8c-a0da-d72a1fef322e_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_579b4286-0c5e-4210-a25c-f684f204929e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquisitionCosts_2157db3c-27b5-42ec-8d8c-1a0f89102b95_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition costs</link:label>
    <link:label id="lab_us-gaap_AcquisitionCosts_label_en-US" xlink:label="lab_us-gaap_AcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Costs, Period Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionCosts" xlink:to="lab_us-gaap_AcquisitionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_5fa1acb5-7618-4f68-aa30-5572e597e486_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_e43520a7-6f56-43e4-a368-f027582e8956_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical care costs</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_ec7d99a5-a3a9-42f4-8e72-8aa8b1501862_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a15cca55-badc-4a4a-9eab-1b1b9f350fd0_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ebe19944-8f9e-448b-b99d-88224ace9d2a_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_b8a4bad0-dcfb-4a44-a608-2f88df61795d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum expected volatility rate inputs for fair value measurement</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8c1f862e-65ac-44e7-a3d4-fba2791a2311_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_92e766dc-77cd-4c0c-8546-14ff79e3902b_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue_79795339-f3a3-4bab-8873-9376576815c9_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace risk corridor judgment</link:label>
    <link:label id="lab_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Marketplace Risk Corridor Judgment Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Marketplace Risk Corridor Judgment Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" xlink:to="lab_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_1415ee46-b77f-4a6b-8c3d-4502a33d2501_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in net earnings of subsidiaries</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Subsidiaries, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:to="lab_us-gaap_IncomeLossFromSubsidiariesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f9087fef-c70d-4cfc-884d-0ed8c82aceba_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term of awards</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_43c47933-8d2b-4fb4-9788-b94211a633a5_verboseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_a63d17c5-3847-4a51-9089-7043ec50a394_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Unrealized Currency Losses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:to="lab_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_ad5be2bf-99c2-4c0b-9f9b-42e1fa2487fe_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_25ba7895-d5f6-4262-8aaa-35bb942063ed_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_4530722d-1697-42fd-a481-42b43b144957_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_5d51c997-528a-42e3-89da-7f273de55808_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AuditInformationAbstract_label_en-US" xlink:label="lab_moh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_moh_AuditInformationAbstract_documentation_en-US" xlink:label="lab_moh_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AuditInformationAbstract" xlink:href="moh-20221231.xsd#moh_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AuditInformationAbstract" xlink:to="lab_moh_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_152b4549-e899-45f6-b2e2-8ca089e85105_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PassportHealthPlanIncMember_06a0bd9c-d36a-4efe-8fba-9536a148cadd_terseLabel_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc</link:label>
    <link:label id="lab_moh_PassportHealthPlanIncMember_label_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc [Member]</link:label>
    <link:label id="lab_moh_PassportHealthPlanIncMember_documentation_en-US" xlink:label="lab_moh_PassportHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Passport Health Plan Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember" xlink:href="moh-20221231.xsd#moh_PassportHealthPlanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PassportHealthPlanIncMember" xlink:to="lab_moh_PassportHealthPlanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_956ae038-6afb-42a1-aed0-b0ac299e2123_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable, accrued liabilities and other</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_d6e380ec-ef48-498e-89de-1744af2a4907_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_50a6a8e1-f169-408c-ada7-0f06955e788f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_a6a9d25b-f75e-4a13-b1ea-990216c78fff_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_0f1d3f11-e33b-4c25-bc2a-cf6c070230c5_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_4e081df9-a5bd-4cc3-95cc-7219764c1924_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CashPaidDuringThePeriodAbstract_f70cc4db-fa47-4c53-a0de-65908a0ba0bc_terseLabel_en-US" xlink:label="lab_moh_CashPaidDuringThePeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for:</link:label>
    <link:label id="lab_moh_CashPaidDuringThePeriodAbstract_label_en-US" xlink:label="lab_moh_CashPaidDuringThePeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During The Period [Abstract]</link:label>
    <link:label id="lab_moh_CashPaidDuringThePeriodAbstract_documentation_en-US" xlink:label="lab_moh_CashPaidDuringThePeriodAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During The Period [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidDuringThePeriodAbstract" xlink:href="moh-20221231.xsd#moh_CashPaidDuringThePeriodAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CashPaidDuringThePeriodAbstract" xlink:to="lab_moh_CashPaidDuringThePeriodAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_969ac64e-b5e9-40a4-a851-dc45adc44bcd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_70227069-e08d-413b-a3ac-90a6a4069fec_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_73dcb876-3da4-44ce-95c4-7dc65fd2ced2_verboseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for unrecognized tax benefits, potential decrease</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_DepreciationAndAmortizationOfCapitalizedSoftware_c57b3a04-55c7-4d88-96b4-004ccbf2cc86_verboseLabel_en-US" xlink:label="lab_moh_DepreciationAndAmortizationOfCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of capitalized software</link:label>
    <link:label id="lab_moh_DepreciationAndAmortizationOfCapitalizedSoftware_label_en-US" xlink:label="lab_moh_DepreciationAndAmortizationOfCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation And Amortization Of Capitalized Software</link:label>
    <link:label id="lab_moh_DepreciationAndAmortizationOfCapitalizedSoftware_documentation_en-US" xlink:label="lab_moh_DepreciationAndAmortizationOfCapitalizedSoftware" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, and amortization of capitalized software.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DepreciationAndAmortizationOfCapitalizedSoftware" xlink:href="moh-20221231.xsd#moh_DepreciationAndAmortizationOfCapitalizedSoftware"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_DepreciationAndAmortizationOfCapitalizedSoftware" xlink:to="lab_moh_DepreciationAndAmortizationOfCapitalizedSoftware" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_617094e8-79e0-41cc-bda3-dd0440f301b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d085a0d8-9a98-47c3-89ff-934b638053d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, and restricted cash and cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d49c9cbc-104b-4c46-b74c-d5b168d4d8a4_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1bb5c66d-1efd-4f82-9a6b-117e90bce9c9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_240acb45-3b8b-4b82-97f4-47ec1c4a9b0f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_5c2ce7d5-081d-4b24-be20-63ec0d1d8700_terseLabel_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturity period (less than)</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_label_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:label id="lab_moh_InvestmentsMaturityPeriod_documentation_en-US" xlink:label="lab_moh_InvestmentsMaturityPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Maturity Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod" xlink:href="moh-20221231.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_InvestmentsMaturityPeriod" xlink:to="lab_moh_InvestmentsMaturityPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ProviderNetworksMember_bd2550bc-0c7a-49bd-8a72-cc3dcf798e5e_netLabel_en-US" xlink:label="lab_moh_ProviderNetworksMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider networks</link:label>
    <link:label id="lab_moh_ProviderNetworksMember_label_en-US" xlink:label="lab_moh_ProviderNetworksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider Networks [Member]</link:label>
    <link:label id="lab_moh_ProviderNetworksMember_documentation_en-US" xlink:label="lab_moh_ProviderNetworksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provider networks.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworksMember" xlink:href="moh-20221231.xsd#moh_ProviderNetworksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ProviderNetworksMember" xlink:to="lab_moh_ProviderNetworksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_64c44333-eba0-44e2-9520-1416f9290bb0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Weighted Average Remaining Contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7d61c5b0-af8c-47ac-8968-ccf08ebdc3f2_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_f9900c33-2d1e-4f69-8064-6976138aa22c_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestExpense_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestExpense" xlink:to="lab_us-gaap_FinanceLeaseInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_72f76831-3be7-4dcf-ac8d-45901802fb20_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum matching contribution by employer under defined contribution plan</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_edc6ed0d-fc28-4468-ae13-162e50bea5ad_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and accrued liabilities (current)</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_61d10515-b25c-4a6b-b17a-30867cc96f38_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_fd4d02b5-8b8c-4412-9cdc-5a2a11e8dfed_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_945e0c7a-efbd-4f55-b57f-b0822faef483_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2b40cd0c-0139-493e-8597-fcead8ca2f9b_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_2e886a31-4193-461d-a95e-92ff4192f88c_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible asset useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_7bed364f-3838-4ee6-8692-e8ac8851d9e9_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_5ac55032-3908-4e60-adb2-e9da0eda87de_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease expense</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_35bb7ed0-012c-4ba8-8cae-0f858805c5b2_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate principal amount of notes outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_a15d4ba9-3563-48c5-b57c-7ac9efe93e97_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1eeaa865-5a20-4949-829a-cb3974f752af_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BasisOfPresentationTable_bf2a086e-9ca4-45a4-923d-97a5dbd0f013_terseLabel_en-US" xlink:label="lab_moh_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation [Table]</link:label>
    <link:label id="lab_moh_BasisOfPresentationTable_label_en-US" xlink:label="lab_moh_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation [Table]</link:label>
    <link:label id="lab_moh_BasisOfPresentationTable_documentation_en-US" xlink:label="lab_moh_BasisOfPresentationTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BasisOfPresentationTable" xlink:href="moh-20221231.xsd#moh_BasisOfPresentationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BasisOfPresentationTable" xlink:to="lab_moh_BasisOfPresentationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_bd653fd8-3f56-460d-935e-73a96297c811_terseLabel_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Year 2020</link:label>
    <link:label id="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_label_en-US" xlink:label="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contract, Accident Year 2020 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2020Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:to="lab_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_IA_a4f40216-cc37-46c7-8e2b-8be26392567a_terseLabel_en-US" xlink:label="lab_stpr_IA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Iowa</link:label>
    <link:label id="lab_stpr_IA_label_en-US" xlink:label="lab_stpr_IA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IOWA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_IA" xlink:to="lab_stpr_IA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_b430f9d3-d205-4c14-93ee-ffcebab09842_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and measurement period adjustments</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_8650aa76-e58f-4c71-9a84-5280c82db3eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of claims development to liability</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_042194e4-d672-4026-b2bf-7ceb26775058_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of operating segment information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7002b025-be06-4606-a42a-606063b97b96_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_9af6ba5a-3982-4744-b4f7-4e9cd171ad68_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_38d15503-799a-4c73-91a6-cfb8a8fa117d_terseLabel_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:label id="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_label_en-US" xlink:label="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:to="lab_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_c66f7fc4-3171-4c4b-88a8-c7598ec36483_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles_abb986e4-6f11-4765-a4c3-9876801de117_negatedTerseLabel_en-US" xlink:label="lab_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets and intangibles</link:label>
    <link:label id="lab_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles_label_en-US" xlink:label="lab_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangibles</link:label>
    <link:label id="lab_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles_documentation_en-US" xlink:label="lab_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Fixed Assets And Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles" xlink:href="moh-20221231.xsd#moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles" xlink:to="lab_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6e0f5130-61c1-4371-bab5-2653ba65b6ff_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_d41c0a90-dcfc-437f-a7d7-72c10b256a9d_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_13d432f9-0608-48f8-bcb5-1ac667493fe9_terseLabel_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment on property and equipment</link:label>
    <link:label id="lab_us-gaap_TangibleAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tangible Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TangibleAssetImpairmentCharges" xlink:to="lab_us-gaap_TangibleAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b849daac-3201-4594-b29f-117ba22f78de_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_75be43dc-7e21-4975-9aa8-6fa427d5d4df_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for medical care costs related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_6fbd8407-7eb0-4b98-90eb-71eeec120bb2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities, available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_85f09644-28e5-49b8-ba68-952430db2b2f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_ad8181c1-ca66-4ecd-a68e-389b95767ced_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Excluding Accrued Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_d474c708-27d7-4f75-8a55-8f787969f8e0_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health insurer fees reimbursed</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationInsurerFeeRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Insurer Fee Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:to="lab_moh_HealthCareOrganizationInsurerFeeRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a4d44031-c53a-40ad-baa9-19e7c3bcc10e_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory federal tax (benefit) rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_47f33abd-463d-4250-9960-4d911920ce79_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:label id="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_label_en-US" xlink:label="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Claims and Claims Adjustment Expense [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:to="lab_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_1294839f-3a70-447b-926d-5530e6fb167a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from senior notes offerings, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Senior Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_c51f8f87-7135-47de-83aa-2b3af9cdf8e9_terseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenue</link:label>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_3d7c7ac8-62a2-4f2c-9d15-a5727d3953a3_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment income and other revenue</link:label>
    <link:label id="lab_us-gaap_InterestAndDividendIncomeOperating_label_en-US" xlink:label="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest and Dividend Income, Operating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDividendIncomeOperating" xlink:to="lab_us-gaap_InterestAndDividendIncomeOperating" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CapitationClaimsPayable_4c8542b5-c81b-42c0-8c41-25feded91f25_terseLabel_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_label_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:label id="lab_moh_CapitationClaimsPayable_documentation_en-US" xlink:label="lab_moh_CapitationClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitation Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable" xlink:href="moh-20221231.xsd#moh_CapitationClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CapitationClaimsPayable" xlink:to="lab_moh_CapitationClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_TaxesBasedOnPremiumsPolicyTextBlock_ecd32ff4-2af2-4e92-b121-fab5478797ab_verboseLabel_en-US" xlink:label="lab_moh_TaxesBasedOnPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Based on Premiums</link:label>
    <link:label id="lab_moh_TaxesBasedOnPremiumsPolicyTextBlock_label_en-US" xlink:label="lab_moh_TaxesBasedOnPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Based On Premiums [Policy Text Block]</link:label>
    <link:label id="lab_moh_TaxesBasedOnPremiumsPolicyTextBlock_documentation_en-US" xlink:label="lab_moh_TaxesBasedOnPremiumsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes based on premiums.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_TaxesBasedOnPremiumsPolicyTextBlock" xlink:href="moh-20221231.xsd#moh_TaxesBasedOnPremiumsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_TaxesBasedOnPremiumsPolicyTextBlock" xlink:to="lab_moh_TaxesBasedOnPremiumsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_1fea5ec9-4099-4834-9509-af7535f4b0e2_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other premium adjustments</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicaid, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicaidOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a2f360e3-aef6-4b5a-b543-9c07426f9760_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_9b351c9b-c819-4107-9f49-0c1812fd6131_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_71f39b4d-c544-4496-bb06-c6497a6656ff_terseLabel_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding at the beginning of the period (in shares)</link:label>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_label_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Excluding Restricted Stock Awards</link:label>
    <link:label id="lab_moh_SharesOutstandingExcludingRestrictedStockAwards_documentation_en-US" xlink:label="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding, Excluding Restricted Stock Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:href="moh-20221231.xsd#moh_SharesOutstandingExcludingRestrictedStockAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:to="lab_moh_SharesOutstandingExcludingRestrictedStockAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_9d6dafee-1828-4aa0-92d0-190ba5c3e385_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical claims and benefits payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Health Care Insurance Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_7398300b-dbe2-4703-b590-2ac81fdddf32_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NE_6e40f9a2-1447-4848-96cf-dfc7abee540b_terseLabel_en-US" xlink:label="lab_stpr_NE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nebraska</link:label>
    <link:label id="lab_stpr_NE_label_en-US" xlink:label="lab_stpr_NE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEBRASKA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NE" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NE" xlink:to="lab_stpr_NE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_7b7c9bd8-b2b0-419a-bc3d-a7c2830e4d84_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Other Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_705c5ca3-7bad-40c9-8c66-3725e3951224_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_6d64820c-0bbe-4c7e-afe8-2a23840d42e0_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_e9395bb0-dbf8-4cf9-bec9-49e1b349960a_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_db27df05-2407-4fd2-9360-2df1535a0241_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In a Continuous Loss Position for Less than 12 Months, Total Number of Positions</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_26ad1b3f-fa44-4182-812e-0225ad661e0e_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_3070d1b6-6946-4906-a521-ce1b681bf2c1_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income provision (benefit), net of federal benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_0038856a-55d7-4034-acd4-696819e16aae_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_4a24b2e2-ccd8-4dfc-94cf-739db0603619_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MS_1ee9a198-f675-4a8e-af80-553b1faafa34_terseLabel_en-US" xlink:label="lab_stpr_MS" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mississippi</link:label>
    <link:label id="lab_stpr_MS_label_en-US" xlink:label="lab_stpr_MS" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MISSISSIPPI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MS" xlink:to="lab_stpr_MS" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_df8e1a44-fc1f-4612-8a8b-5a2742b19ef6_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_885e1ac6-c315-44ad-9cc9-cb408316c38f_terseLabel_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of long-term debt</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_label_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:label id="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_documentation_en-US" xlink:label="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:href="moh-20221231.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:to="lab_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_2aa0e06f-ad31-42ee-abc9-678d102575ba_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsAbstract_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract" xlink:to="lab_us-gaap_PostemploymentBenefitsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_8f5ee94f-624d-4869-a197-6d20f17bc790_verboseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate statutory capital and surplus</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices, Statutory Capital and Surplus, Balance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:to="lab_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_8c052872-5612-4a36-9020-98ffbc141a4a_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_9f9fd8db-d927-437a-bf46-5f45995700e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDividendsReceived_1f6a9bbb-c85f-4764-9529-22958ab8ee7c_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends received from subsidiaries</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDividendsReceived_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDividendsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Dividends Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDividendsReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDividendsReceived" xlink:to="lab_us-gaap_ProceedsFromDividendsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_b0533ec3-5275-43c1-956d-d271f5e84de0_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_b9e82e50-b866-48a2-8acc-cf65c9044205_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_5e1f60e0-d2bd-40b6-874a-d15b7ebfa9b1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other expenses, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ContractRightsandLicensingAgreementsMember_2276a153-7ce7-484c-babc-60d2e4226ac5_terseLabel_en-US" xlink:label="lab_moh_ContractRightsandLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract rights and licenses</link:label>
    <link:label id="lab_moh_ContractRightsandLicensingAgreementsMember_label_en-US" xlink:label="lab_moh_ContractRightsandLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Rights and Licensing Agreements [Member]</link:label>
    <link:label id="lab_moh_ContractRightsandLicensingAgreementsMember_documentation_en-US" xlink:label="lab_moh_ContractRightsandLicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Rights and Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ContractRightsandLicensingAgreementsMember" xlink:href="moh-20221231.xsd#moh_ContractRightsandLicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ContractRightsandLicensingAgreementsMember" xlink:to="lab_moh_ContractRightsandLicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c10780bf-b763-46bd-aebf-2913e1bacd11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_d6db535c-979a-492b-afc6-3b9a75143630_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_0dea7b89-67d7-42df-8cea-86885fb27ecd_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardValuationAllowance_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:to="lab_us-gaap_TaxCreditCarryforwardValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9c9a4171-5270-4895-a101-6f37b4643f91_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c52a658a-176d-4311-9206-b5ec4046a7d0_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8f745961-b15c-400d-982e-b88ae1a476f3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44da35bd-a0f6-494b-bde8-309ea71aa970_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_4591a0dd-4e38-4c49-99e7-1264b847420a_verboseLabel_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information of Registrant</link:label>
    <link:label id="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Information of Parent Company Only Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:to="lab_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee_7abe781c-2208-4a16-ab7a-92b9cc16e5d9_terseLabel_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum annual contribution per employee</link:label>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee_label_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Per Employee</link:label>
    <link:label id="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee_documentation_en-US" xlink:label="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation arrangement by share based payment award maximum amount per employee.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" xlink:href="moh-20221231.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" xlink:to="lab_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_a5590754-3bf8-411d-ae7b-bb3129b220f2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_a3772a42-72a1-42c3-a31a-c61ff20ba226_verboseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New York</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c0c2b1eb-5c08-4438-8fb6-e9d138949938_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a877af74-e6c2-46b2-90af-4617409be3af_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5e26a24d-b82a-4d0c-b91b-43eaf9d488dc_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_1e589648-4242-466b-bb65-9bf089b867ee_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_0b13198f-fd17-47ed-bd0c-f8e810897cd6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_a7c0fb0c-b057-4e7f-9172-fea56a6a78cd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_c6ab55f4-7f9a-4887-92cd-a117d0733020_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_20c90910-4d44-4be0-b4f8-b218497b902b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_4bb5d6eb-3d38-44cc-8d01-11a90619bbf9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_5a0a91d1-6bcc-4cd6-a592-36d06e3d8883_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_358c62e7-709a-49ef-8a11-255b3ef687a4_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_f17eeead-7ed4-49dd-83a0-9fa445bb362d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_79a1468c-fec8-4082-ae0b-1f4dce606ca9_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_844cc0b4-dfe1-4eb2-a5da-38a04b691a6a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_7233aafd-6633-4ccd-bb7c-659119e0c340_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_ff4079e0-8966-4843-8218-4edec8952d6b_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum MLR and profit sharing</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_21c0b170-606d-4d9e-a0b5-7c877c23ca86_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityTable_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityTable" xlink:to="lab_us-gaap_LineOfCreditFacilityTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_396efcae-4e58-4f84-ba8b-b0d30145b5de_terseLabel_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in non-risk and other provider payables</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_label_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims And Benefits Payable, Adjustments, Change In Provider</link:label>
    <link:label id="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_documentation_en-US" xlink:label="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Claims and Benefits Payable, Adjustments, Change in Provider</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:href="moh-20221231.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:to="lab_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_091b53ad-a6a3-46af-ab76-a173e19527db_terseLabel_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:label id="lab_us-gaap_UnusualOrInfrequentItemDomain_label_en-US" xlink:label="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unusual or Infrequent Item, or Both [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain" xlink:to="lab_us-gaap_UnusualOrInfrequentItemDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_58c0b9ce-694f-48b4-ba5e-2451b2b33cc8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of fair value of assets measured on recurring basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_0c206722-ea91-4806-8e1d-81d79e656a60_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_bd51908d-1f9e-469c-a728-1d7ea76c6f07_verboseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_39aa4bc2-7bc0-41d7-b6b4-ad2d1dc2ff27_terseLabel_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium revenue</link:label>
    <link:label id="lab_us-gaap_PremiumsEarnedNet_label_en-US" xlink:label="lab_us-gaap_PremiumsEarnedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premiums Earned, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PremiumsEarnedNet" xlink:to="lab_us-gaap_PremiumsEarnedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_44856934-d3fa-4836-be8d-fb1723f133ed_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_074abf0f-a42a-4bce-b56d-f6776c0522b5_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_3e847379-32e3-436d-88fd-662714bfbc59_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_46110c6c-f58f-4a70-8711-a4a4c921335e_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Equipment, and Capitalized Software, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PropertyAndEquipmentMember_f2349c34-6546-4910-ad3f-2624f8605a84_terseLabel_en-US" xlink:label="lab_moh_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_moh_PropertyAndEquipmentMember_label_en-US" xlink:label="lab_moh_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property And Equipment [Member]</link:label>
    <link:label id="lab_moh_PropertyAndEquipmentMember_documentation_en-US" xlink:label="lab_moh_PropertyAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property And Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PropertyAndEquipmentMember" xlink:href="moh-20221231.xsd#moh_PropertyAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PropertyAndEquipmentMember" xlink:to="lab_moh_PropertyAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_4e7af796-05dd-4722-9c21-af4049338499_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f93e4003-f8e9-46b1-9701-042764f9ef55_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_fda275ba-2429-4b4c-bcb3-4b13d7aaffc5_verboseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesTable_0cc65bca-f99b-426a-821d-77fb08d72d22_terseLabel_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Table]</link:label>
    <link:label id="lab_us-gaap_StatutoryAccountingPracticesTable_label_en-US" xlink:label="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory Accounting Practices [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable" xlink:to="lab_us-gaap_StatutoryAccountingPracticesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_4d8f4c75-c9c5-4075-86ea-d0e696629daa_verboseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost, Due one year through five years</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears_c5c1238d-3e92-4d5f-a832-dea1e08a8b0b_terseLabel_en-US" xlink:label="lab_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All outstanding liabilities before 2020</link:label>
    <link:label id="lab_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears_label_en-US" xlink:label="lab_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Outstanding Liabilities Relating to Prior Years</link:label>
    <link:label id="lab_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears_documentation_en-US" xlink:label="lab_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Outstanding Liabilities Relating to Prior Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" xlink:href="moh-20221231.xsd#moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" xlink:to="lab_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_077c5025-bc98-44e1-94ac-b88eabbc3f8e_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_65b3857f-2dd5-4774-9e94-d63e0d08d095_verboseLabel_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Condensed Financial Statements [Table]</link:label>
    <link:label id="lab_srt_ScheduleOfCondensedFinancialStatementsTable_label_en-US" xlink:label="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed Financial Statements [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:to="lab_srt_ScheduleOfCondensedFinancialStatementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_95dc3067-d949-4b59-9dec-dd16ea2e0908_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_3ba83759-d36e-40e8-8525-273f6711f4b4_terseLabel_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts due government agencies</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_label_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Medical Premium Liability Due To Agency</link:label>
    <link:label id="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_documentation_en-US" xlink:label="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Medical Premium Liability Due to Agency</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:href="moh-20221231.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:to="lab_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_c1640f31-052a-4c0e-86f1-2014d2139545_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeOperatingLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_4ad27bb0-eb3f-4d47-a49b-43e5e9417b1b_terseLabel_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc</link:label>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_label_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc [Member]</link:label>
    <link:label id="lab_moh_AffinityHealthPlanIncMember_documentation_en-US" xlink:label="lab_moh_AffinityHealthPlanIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affinity Health Plan, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember" xlink:href="moh-20221231.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffinityHealthPlanIncMember" xlink:to="lab_moh_AffinityHealthPlanIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_d6da2e55-9a2f-4dfb-9b9f-3f6ab0c79148_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_623f7dfb-96fa-4da8-9dfb-56882cf196c8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Other operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_RecordedInDepreciationAndAmortizationAbstract_3f14c461-e448-45fd-8b6f-067c885af316_terseLabel_en-US" xlink:label="lab_moh_RecordedInDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded in depreciation and amortization:</link:label>
    <link:label id="lab_moh_RecordedInDepreciationAndAmortizationAbstract_label_en-US" xlink:label="lab_moh_RecordedInDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded In Depreciation And Amortization [Abstract]</link:label>
    <link:label id="lab_moh_RecordedInDepreciationAndAmortizationAbstract_documentation_en-US" xlink:label="lab_moh_RecordedInDepreciationAndAmortizationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recorded In Depreciation And Amortization [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RecordedInDepreciationAndAmortizationAbstract" xlink:href="moh-20221231.xsd#moh_RecordedInDepreciationAndAmortizationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_RecordedInDepreciationAndAmortizationAbstract" xlink:to="lab_moh_RecordedInDepreciationAndAmortizationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_ea92081e-d773-40d5-aef3-c3ead1d87dfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_3f7ecd3f-a624-4223-b884-0c6e2ed7dd69_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_01dffef9-9363-4161-8746-cbff74b5aff5_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_4f451260-b420-4b14-b7b9-5d278f848fd3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyClaimsPayable_5e5ba2dd-a786-4b77-bdff-326000f90664_terseLabel_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_label_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:label id="lab_moh_PharmacyClaimsPayable_documentation_en-US" xlink:label="lab_moh_PharmacyClaimsPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Claims Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable" xlink:href="moh-20221231.xsd#moh_PharmacyClaimsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyClaimsPayable" xlink:to="lab_moh_PharmacyClaimsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_eefbd77c-d050-4c45-a3c0-9c5299e4166e_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_cce5427e-bdb2-4b9c-adc5-e7f81ffedc70_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal - undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OperatingLeaseAssetsLesseeAbstract_a93a1073-0cce-475e-b489-290d2f156eac_terseLabel_en-US" xlink:label="lab_moh_OperatingLeaseAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_moh_OperatingLeaseAssetsLesseeAbstract_label_en-US" xlink:label="lab_moh_OperatingLeaseAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets, Lessee [Abstract]</link:label>
    <link:label id="lab_moh_OperatingLeaseAssetsLesseeAbstract_documentation_en-US" xlink:label="lab_moh_OperatingLeaseAssetsLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Assets, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingLeaseAssetsLesseeAbstract" xlink:href="moh-20221231.xsd#moh_OperatingLeaseAssetsLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OperatingLeaseAssetsLesseeAbstract" xlink:to="lab_moh_OperatingLeaseAssetsLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_848de0d9-b4e5-40ee-93fc-61f771004433_verboseLabel_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the change in medical claims and benefits payable</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_label_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:label id="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_documentation_en-US" xlink:label="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:href="moh-20221231.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:to="lab_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_a9e6ef99-90eb-42ab-bd9b-550be5770912_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease maturities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_744c464d-f389-4fb0-9966-7df47e615758_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_fdb0b781-a452-44b6-8450-9d9fe2369321_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for partial termination of warrants</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfWarrants_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_9a9c5f3a-7363-4eee-9a04-72a494544df6_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination of warrants</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Additional Paid in Capital, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_a9b45496-83c0-41cc-ab27-e2728f65d98b_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_FinanceLeaseCost_2cbe367a-a5f0-4f77-add8-48b16d8e1b03_totalLabel_en-US" xlink:label="lab_moh_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total finance lease expense</link:label>
    <link:label id="lab_moh_FinanceLeaseCost_label_en-US" xlink:label="lab_moh_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:label id="lab_moh_FinanceLeaseCost_documentation_en-US" xlink:label="lab_moh_FinanceLeaseCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FinanceLeaseCost" xlink:href="moh-20221231.xsd#moh_FinanceLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_FinanceLeaseCost" xlink:to="lab_moh_FinanceLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_5b0c7e98-1096-479c-827a-c43e7653db4b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_3b97d1de-bf14-477b-a3e0-1780a3d7d48c_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_991aee08-cd83-41ec-97a0-025742163441_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_25350697-a64e-4238-84b6-b2e20c0ff754_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned_66d91cef-93e9-444c-8b9f-018d42cf180f_verboseLabel_en-US" xlink:label="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional incremental revenue earned</link:label>
    <link:label id="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned_label_en-US" xlink:label="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Additional Incremental Revenue Earned</link:label>
    <link:label id="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned_documentation_en-US" xlink:label="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of additional incremental revenue earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:href="moh-20221231.xsd#moh_PercentageOfAdditionalIncrementalRevenueEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:to="lab_moh_PercentageOfAdditionalIncrementalRevenueEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_33654776-970b-41e2-800e-5fdbbf0f7b97_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BasisOfPresentationLineItems_d0306918-b78a-45c1-be66-9fac546abe70_terseLabel_en-US" xlink:label="lab_moh_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_moh_BasisOfPresentationLineItems_label_en-US" xlink:label="lab_moh_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation [Line Items]</link:label>
    <link:label id="lab_moh_BasisOfPresentationLineItems_documentation_en-US" xlink:label="lab_moh_BasisOfPresentationLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BasisOfPresentationLineItems" xlink:href="moh-20221231.xsd#moh_BasisOfPresentationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BasisOfPresentationLineItems" xlink:to="lab_moh_BasisOfPresentationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_2170aaad-0e16-4623-8857-f38631e42270_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4ab8f018-4386-4517-923b-7c5ccaca868e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractualRightsMember_3b719b08-4bda-40df-9f2a-032d32072439_terseLabel_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract rights - member list</link:label>
    <link:label id="lab_us-gaap_ContractualRightsMember_label_en-US" xlink:label="lab_us-gaap_ContractualRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractualRightsMember" xlink:to="lab_us-gaap_ContractualRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherExpenses_f61a915b-b07d-45af-8ef3-d21ba9201e5d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other expenses, net</link:label>
    <link:label id="lab_us-gaap_OtherExpenses_label_en-US" xlink:label="lab_us-gaap_OtherExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherExpenses" xlink:to="lab_us-gaap_OtherExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_1388572e-0a72-4d4e-919c-64300be95135_terseLabel_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_label_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:label id="lab_moh_HealthCareOrganizationPremiumTaxRevenue_documentation_en-US" xlink:label="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health Care Organization, Premium Tax Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:to="lab_moh_HealthCareOrganizationPremiumTaxRevenue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_f0c18b82-fef6-4b50-862f-351fc32d7796_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_7d9779fc-8991-4ee5-a5b4-8ee4524928d5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-maturity [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_29cecdd0-352d-4170-86fe-27b7d15a276e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent_22d0901b-3569-489d-b97e-6a34ed3e8a8b_terseLabel_en-US" xlink:label="lab_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nondeductible health insurer fee (&#8220;HIF&#8221;)</link:label>
    <link:label id="lab_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent_label_en-US" xlink:label="lab_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent</link:label>
    <link:label id="lab_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent_documentation_en-US" xlink:label="lab_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" xlink:href="moh-20221231.xsd#moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" xlink:to="lab_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_193bd2a9-79c2-4122-89d0-aeaabc0992f7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_023d3151-43ca-44b2-bf93-af2ae79d0549_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of contractual maturities of investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_2d807a89-b0c5-4608-b851-804ea18cb78d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfProductInformationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfProductInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Product Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable" xlink:to="lab_us-gaap_ScheduleOfProductInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_4f48c713-affe-4afb-b32f-cacfbacbefff_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PremiumTaxExpenses_236699b8-be12-4b1a-83ca-aed1cc97dafd_terseLabel_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium tax expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_label_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Premium Tax Expenses</link:label>
    <link:label id="lab_moh_PremiumTaxExpenses_documentation_en-US" xlink:label="lab_moh_PremiumTaxExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">An assessment levied by a state government on the net premium income collected.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses" xlink:href="moh-20221231.xsd#moh_PremiumTaxExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PremiumTaxExpenses" xlink:to="lab_moh_PremiumTaxExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_4659ee77-7b75-4fc7-b87b-4debd9e8df21_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_56ff2906-bda6-4d32-a852-d9925d134615_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4e4590e8-9747-4e1d-86d2-3eaab521083e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator for basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_8b3c3757-e2f8-4358-b29a-0efe792b7fdf_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_0cb9053a-b94a-46b4-873e-75480f35b75a_terseLabel_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation (in shares)</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_label_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:label id="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation_documentation_en-US" xlink:label="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Share Based Compensation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:href="moh-20221231.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:to="lab_moh_WeightedAverageNumberofSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherSecuritiesMember_72b85d88-48a5-41ff-885b-cbba80bdec71_verboseLabel_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_d23bb329-61bc-4d7f-a610-534362919bda_terseLabel_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_label_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Securities [Member]</link:label>
    <link:label id="lab_moh_OtherSecuritiesMember_documentation_en-US" xlink:label="lab_moh_OtherSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember" xlink:href="moh-20221231.xsd#moh_OtherSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherSecuritiesMember" xlink:to="lab_moh_OtherSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_cfa18aca-602a-4de0-89cf-287ede2ae5e5_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior period claims, favorable development</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_861b0121-3cca-4cc9-8114-d691d2043bcc_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior years</link:label>
    <link:label id="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_label_en-US" xlink:label="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior Year Claims and Claims Adjustment Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:to="lab_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CompleteCareMember_a2e4e47a-29d4-4416-9b16-facad8d59e75_terseLabel_en-US" xlink:label="lab_moh_CompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Magellan Complete Care acquisition opening balance</link:label>
    <link:label id="lab_moh_CompleteCareMember_label_en-US" xlink:label="lab_moh_CompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complete Care [Member]</link:label>
    <link:label id="lab_moh_CompleteCareMember_documentation_en-US" xlink:label="lab_moh_CompleteCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Complete Care</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CompleteCareMember" xlink:href="moh-20221231.xsd#moh_CompleteCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CompleteCareMember" xlink:to="lab_moh_CompleteCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_b20997ff-3241-4eef-9ac8-790b498656fb_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax Charges</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_04a59311-5d30-4cbc-bd56-598472105ba8_netLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_d4d16210-05b0-4531-9224-c5159b29b018_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury notes</link:label>
    <link:label id="lab_us-gaap_USTreasuryNotesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Notes Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryNotesSecuritiesMember" xlink:to="lab_us-gaap_USTreasuryNotesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceAgencyManagementFee_c537c57d-811f-4cdc-9757-6b5680f1e766_verboseLabel_en-US" xlink:label="lab_us-gaap_InsuranceAgencyManagementFee" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative services fees</link:label>
    <link:label id="lab_us-gaap_InsuranceAgencyManagementFee_label_en-US" xlink:label="lab_us-gaap_InsuranceAgencyManagementFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Agency Management Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAgencyManagementFee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAgencyManagementFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceAgencyManagementFee" xlink:to="lab_us-gaap_InsuranceAgencyManagementFee" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3141b272-b066-4c60-95fb-f74fb1e7220e_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_ad5d83df-6cd6-43e8-b933-e38adf3e6470_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0c635a90-c679-47d9-86ac-0fc072e91916_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, outstanding (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_HealthAndHumanServicesMember_854bef6d-85ca-47c5-8428-1744cc6e0087_terseLabel_en-US" xlink:label="lab_moh_HealthAndHumanServicesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health and human services</link:label>
    <link:label id="lab_moh_HealthAndHumanServicesMember_label_en-US" xlink:label="lab_moh_HealthAndHumanServicesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health And Human Services [Member]</link:label>
    <link:label id="lab_moh_HealthAndHumanServicesMember_documentation_en-US" xlink:label="lab_moh_HealthAndHumanServicesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Health And Human Services</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthAndHumanServicesMember" xlink:href="moh-20221231.xsd#moh_HealthAndHumanServicesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_HealthAndHumanServicesMember" xlink:to="lab_moh_HealthAndHumanServicesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_93fd97d7-7aa9-4568-9402-aa9795dc75d5_terseLabel_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medicare program:</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_label_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program [Abstract]</link:label>
    <link:label id="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_documentation_en-US" xlink:label="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due To Government Agencies Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:to="lab_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_72966c7a-f36e-4652-9bbe-62d26011eef0_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_3eaf6788-1e0b-4ac8-af22-4309ff203e9f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="lab_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_5066f35a-f637-4e14-b6ff-1fe676996ef1_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value per share; 20 million shares authorized, no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_a613007d-f3f4-4e2c-90a5-8b75dfe416a7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_8a5fcd4b-7569-4398-8364-9cabf2e18920_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_30461e5d-9f75-410c-9429-d32050500e18_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_3b635e0f-1009-43de-955d-3560ed59cdc8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_9b61b80d-ef43-4f27-838d-7dd5dd1da011_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_5027c327-2496-499e-b838-b42d30803248_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_2de38119-279a-4771-a127-34740a812819_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining half of contingent consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_3340469b-ff0f-46bf-b451-01742c494ec0_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_983bf87a-39fe-416d-9247-61f066372211_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_b48af7e8-1ecb-405b-99c9-f75ca4f78639_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_3dbf4d4f-84ab-4cf3-9ead-fef0b5518510_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_378f598d-78c1-4ffc-943d-f41a5b7d16bc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_b12f1b12-4603-4938-a4ba-ef77c62167bf_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AgeWellNewYorkMember_3706ceef-2614-482c-b11d-82fb7348c5ad_terseLabel_en-US" xlink:label="lab_moh_AgeWellNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AgeWell New York</link:label>
    <link:label id="lab_moh_AgeWellNewYorkMember_label_en-US" xlink:label="lab_moh_AgeWellNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AgeWell New York [Member]</link:label>
    <link:label id="lab_moh_AgeWellNewYorkMember_documentation_en-US" xlink:label="lab_moh_AgeWellNewYorkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AgeWell New York</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AgeWellNewYorkMember" xlink:href="moh-20221231.xsd#moh_AgeWellNewYorkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AgeWellNewYorkMember" xlink:to="lab_moh_AgeWellNewYorkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_ebb1f498-279b-4c7e-a5c5-abd6f9b1aeae_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_c924dada-2250-4f46-a613-8b92d5890d24_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_12db9753-7039-4c42-8269-fef6a530d125_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases, weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_7baa7635-857c-4c3f-84ea-d14c9c54931b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_115fb67d-95bc-4cde-b55b-9be350c6322a_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Offering period</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramPeriodInForce1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Period in Force</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:to="lab_us-gaap_StockRepurchaseProgramPeriodInForce1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_04b7c39d-070d-443c-8824-76050bca6337_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of medical care costs related to:</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_01db6bd4-6b45-4771-9eef-49b993bc5c16_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_930f3499-560c-40d0-a3d2-5ed09333612d_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_c34ba036-d5d0-4467-9ba5-3313791085f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_6d052e80-5bd2-45e2-bda0-c7639a7f74b1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_141ddb86-a83a-40f8-813f-cdde33f3c3eb_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current year</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_3273ae51-c3bb-47e8-be4c-e702cbeaf8aa_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant components of deferred tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a1c48ab0-e5e0-45f8-8970-4a63f2ca3a4c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_f52eefe8-c578-4ca9-9fbb-a177fd99b3a6_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_a62d9d0d-a1f5-4812-bad2-a9612003deca_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_f4b4d152-3cbf-4b70-9c4f-39b1e18923bf_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_88670864-d4d6-4893-af0a-a1115ed9495a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Lines of Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:to="lab_us-gaap_RepaymentsOfLongTermLinesOfCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_484b025d-2268-45e7-a93d-2da94d8461b5_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_683398ff-464c-471a-8af7-968cbff0b343_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_f2aae878-8544-42cd-8311-5b04db910125_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0a44f88b-e9dd-4cf4-adcd-9ff54bd63df1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_1960b451-c639-42bd-9e8d-93372661da78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid in business combinations</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_88865161-64b8-4d7e-9bf2-80d7ad49d983_terseLabel_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_label_en-US" xlink:label="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Policyholder Benefits and Claims Incurred, Net, Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:to="lab_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_1c327266-67df-45ee-8e5a-6b357bf241f9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_3c395fb1-f392-4bfb-8f98-4bb195f10e61_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_7b49ab47-e286-4086-95a1-98a549cb8d59_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized investment gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_42b4be5e-f718-4b0a-a73d-9283be07ba47_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_fb994d19-107e-4672-ad53-033787424bbc_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_b2308146-6084-4014-be3d-dedc35b9eebe_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_7c18ff0e-ce98-47e9-8b3b-bb106fc87411_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_aa433423-2921-43bb-ba2d-8c6bd887f722_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c9ef205f-4bd3-43cc-83c9-e76026f06987_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_1dbbef0e-f430-4d14-856b-c915c741e068_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_832552ed-c4aa-412e-b332-49b9ab73d6b4_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_c584516e-1407-42d4-a5d2-c55b1fa218f1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_ab60ffaf-3931-4072-a957-dd3210bc8ebd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_ce0f7e92-ad11-424f-a3e3-c0c6f485d987_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases:</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Finance Lease, Description [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:to="lab_us-gaap_LesseeFinanceLeaseDescriptionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherMedicareProgram_c7e74e5c-831a-4fff-b432-51841f3dcd73_terseLabel_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other premium adjustments</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_label_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:label id="lab_moh_OtherMedicareProgram_documentation_en-US" xlink:label="lab_moh_OtherMedicareProgram" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Medicare Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram" xlink:href="moh-20221231.xsd#moh_OtherMedicareProgram"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherMedicareProgram" xlink:to="lab_moh_OtherMedicareProgram" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_4e3eaf9a-44cd-484d-a0b0-60774a349034_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_33efbd5b-31f9-45c6-908a-3557aa9862a7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_f30a4f4d-51ee-4b42-b76e-f3f183b1ae5f_terseLabel_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace risk adjustment payables</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_label_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:label id="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_documentation_en-US" xlink:label="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:to="lab_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_c8b94c51-f769-46cd-b993-6e15b2a17b07_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of receivables</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b59d020a-45df-41d2-a601-6038f5da83ef_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrecognized tax benefits at beginning of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_fc4cbbd2-4ce9-4060-8275-c5f0425c3079_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrecognized tax benefits at end of period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_0504dbb0-99a2-4168-9595-665e5bde4b74_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax assets, net of valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract_b208696e-3f19-4252-80de-b9e54fcac5da_terseLabel_en-US" xlink:label="lab_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets recognized in exchange for lease obligations:</link:label>
    <link:label id="lab_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract_label_en-US" xlink:label="lab_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability [Abstract]</link:label>
    <link:label id="lab_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract_documentation_en-US" xlink:label="lab_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract" xlink:href="moh-20221231.xsd#moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract" xlink:to="lab_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_GainLossOnDebtRepayment_94deef9e-6cd3-4fe6-983f-70a08813f39c_negatedLabel_en-US" xlink:label="lab_moh_GainLossOnDebtRepayment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on debt repayment</link:label>
    <link:label id="lab_moh_GainLossOnDebtRepayment_label_en-US" xlink:label="lab_moh_GainLossOnDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Debt Repayment</link:label>
    <link:label id="lab_moh_GainLossOnDebtRepayment_documentation_en-US" xlink:label="lab_moh_GainLossOnDebtRepayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Debt Repayment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GainLossOnDebtRepayment" xlink:href="moh-20221231.xsd#moh_GainLossOnDebtRepayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_GainLossOnDebtRepayment" xlink:to="lab_moh_GainLossOnDebtRepayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_2a32f0de-3383-4c4e-bab8-92da1b13be16_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impact on effective tax rate if tax benefits are recognized</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_b8543dd5-5932-4339-8160-7f8b54ca89f0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_OtherProgramMember_f493603d-69f4-4577-9348-f9b4f80bd710_terseLabel_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_moh_OtherProgramMember_label_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Program [Member]</link:label>
    <link:label id="lab_moh_OtherProgramMember_documentation_en-US" xlink:label="lab_moh_OtherProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember" xlink:href="moh-20221231.xsd#moh_OtherProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_OtherProgramMember" xlink:to="lab_moh_OtherProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_e13e653c-9c80-400d-81a9-8095131f0591_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_c9f37b87-df6f-4e39-a13d-ad749304eae7_netLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_3e8bf63d-49a4-4c42-9e9d-5774ba9bfa21_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6df86e26-fef6-4d81-af97-7f586bded23d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_79f41111-33b3-4e61-8ec3-2c04bd3df697_terseLabel_en-US" xlink:label="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration paid to seller included in financing and operating activities</link:label>
    <link:label id="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_label_en-US" xlink:label="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Financing And Operating Activities</link:label>
    <link:label id="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_documentation_en-US" xlink:label="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment For Contingent Consideration Liability, Financing And Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:href="moh-20221231.xsd#moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:to="lab_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_63d7d80a-98c1-462f-bdbd-ca1b788d08e0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease maturities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_54aa23f9-ac93-4deb-9de6-5997ae077541_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_fadb87c0-eabf-41c2-a8c1-73db6be1bc87_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_5b4a4cb4-679b-4d25-b18c-7c6d35b46f2e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_527fd0d6-ca0f-4a1a-8806-ec94012b2e6e_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_COVID19Member_81c6bef5-44fa-401f-ac5a-6f85b4b680f5_terseLabel_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_moh_COVID19Member_label_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_moh_COVID19Member_documentation_en-US" xlink:label="lab_moh_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member" xlink:href="moh-20221231.xsd#moh_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_COVID19Member" xlink:to="lab_moh_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_f25280db-5481-4dc8-a95e-d6ded0544fa2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contributions to subsidiaries</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Additional Interest in Subsidiaries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:to="lab_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_ae7863e2-9850-451c-a2cb-1b11135862f2_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_b0566d84-3e9d-435d-9793-d35ccf99e78a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increased in deferred tax asset valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_afab7552-52e9-4db2-a259-96a2e62485e4_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases, weighted average remaining lease term</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2a7d669e-78ef-4a74-8a1a-9ecdfbd5fcf4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_ca2d80dd-c4ee-43d0-bd89-560e88baa49b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred Claims and Allocated Claims Adjustment Expenses</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_ceaf8b29-30bf-47c6-af28-44649effdc4c_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incurred Claims and Allocated Claims Adjustment Expenses</link:label>
    <link:label id="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_label_en-US" xlink:label="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:to="lab_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_f897e1fc-0ac9-4810-8f16-bdb04af3eaeb_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TradeNamesMember_b6b134fe-ed7f-4f5a-9707-d8c73dce6655_terseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade names</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember" xlink:to="lab_us-gaap_TradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_8c1ff02d-5cc3-470c-8267-6b3eeb02cfc1_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InsuranceRecoveries_77601ba9-bab6-4b19-a0a3-b5d38a7ffee2_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reinsurance recoveries</link:label>
    <link:label id="lab_us-gaap_InsuranceRecoveries_label_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries" xlink:to="lab_us-gaap_InsuranceRecoveries" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SpecialAssessmentBond_fa8d4708-b708-4873-af1a-302abb877c13_terseLabel_en-US" xlink:label="lab_us-gaap_SpecialAssessmentBond" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance bond</link:label>
    <link:label id="lab_us-gaap_SpecialAssessmentBond_label_en-US" xlink:label="lab_us-gaap_SpecialAssessmentBond" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Special Assessment Bond</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SpecialAssessmentBond" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SpecialAssessmentBond"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SpecialAssessmentBond" xlink:to="lab_us-gaap_SpecialAssessmentBond" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_e6d9fe58-30e6-45d2-b575-cdee1433e950_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long term debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_7c6675aa-2c54-405b-8d9f-fc7313e5fde3_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_1bd8079f-9288-4374-a6e7-f7252f31bd94_terseLabel_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs, approximately</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_label_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Number Of Members Eligible For The Health Care Programs</link:label>
    <link:label id="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_documentation_en-US" xlink:label="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of members eligible for the health care programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:href="moh-20221231.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:to="lab_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5ddc6323-5fa5-4afa-9352-59460347b364_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_FairMarketValueOfCommonStockPercentage_a0e3b215-ee99-4898-84f2-cabb39de9c51_terseLabel_en-US" xlink:label="lab_moh_FairMarketValueOfCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee purchase price as a percentage of stock price</link:label>
    <link:label id="lab_moh_FairMarketValueOfCommonStockPercentage_label_en-US" xlink:label="lab_moh_FairMarketValueOfCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Market Value Of Common Stock Percentage</link:label>
    <link:label id="lab_moh_FairMarketValueOfCommonStockPercentage_documentation_en-US" xlink:label="lab_moh_FairMarketValueOfCommonStockPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair market value of common stock, Percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FairMarketValueOfCommonStockPercentage" xlink:href="moh-20221231.xsd#moh_FairMarketValueOfCommonStockPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_FairMarketValueOfCommonStockPercentage" xlink:to="lab_moh_FairMarketValueOfCommonStockPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CashPaidForSettlementOfConversionOption_b7ef084f-37a8-4def-99ea-d2de277994e8_negatedTerseLabel_en-US" xlink:label="lab_moh_CashPaidForSettlementOfConversionOption" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for partial settlement of conversion option</link:label>
    <link:label id="lab_moh_CashPaidForSettlementOfConversionOption_label_en-US" xlink:label="lab_moh_CashPaidForSettlementOfConversionOption" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Settlement Of Conversion Option</link:label>
    <link:label id="lab_moh_CashPaidForSettlementOfConversionOption_documentation_en-US" xlink:label="lab_moh_CashPaidForSettlementOfConversionOption" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid For Settlement Of Conversion Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidForSettlementOfConversionOption" xlink:href="moh-20221231.xsd#moh_CashPaidForSettlementOfConversionOption"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CashPaidForSettlementOfConversionOption" xlink:to="lab_moh_CashPaidForSettlementOfConversionOption" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_88f94ee3-e2d8-439e-8af7-2dafbc0479fa_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a541197e-366a-433c-acde-f4d4901ce8cc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MarketplaceMember_7c412178-0326-4ba3-b718-e7fb57d7c244_terseLabel_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace Segment</link:label>
    <link:label id="lab_moh_MarketplaceMember_label_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace [Member]</link:label>
    <link:label id="lab_moh_MarketplaceMember_documentation_en-US" xlink:label="lab_moh_MarketplaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketplace</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MarketplaceMember" xlink:to="lab_moh_MarketplaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_b3602c0e-e690-49ec-8b48-9b8adcf5ef5d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted and performance stock activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Nonvested Share Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_d15b1571-4a43-4cd1-8e02-388156fa5e87_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in premiums</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Premiums Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInPremiumsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_49bae0aa-6267-4c26-b644-90a5e989a6b2_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued medical costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_cc1a0dfa-6798-4a15-a7d2-009565bcad3a_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_316430de-a81a-44dd-b546-657ce7e5b20b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation and amortization - property, equipment, building, and improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant, and Equipment, Owned, Accumulated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WA_e47ff37a-e860-4eb9-be60-4eb1453255a4_verboseLabel_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Washington</link:label>
    <link:label id="lab_stpr_WA_label_en-US" xlink:label="lab_stpr_WA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WASHINGTON</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WA" xlink:to="lab_stpr_WA" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_EquityIncentivePlanMember_398056df-d528-4c9b-82c2-1707469d0f09_terseLabel_en-US" xlink:label="lab_moh_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2019 EIP</link:label>
    <link:label id="lab_moh_EquityIncentivePlanMember_label_en-US" xlink:label="lab_moh_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_moh_EquityIncentivePlanMember_documentation_en-US" xlink:label="lab_moh_EquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Incentive Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EquityIncentivePlanMember" xlink:href="moh-20221231.xsd#moh_EquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_EquityIncentivePlanMember" xlink:to="lab_moh_EquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_cd3d004d-046a-421f-8cd4-5056aa7b64c3_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_e221368e-38f8-4632-98ff-0e8f12cedefc_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance leases</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Interest Payment on Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:to="lab_us-gaap_FinanceLeaseInterestPaymentOnLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_MunicipalSecuritiesMember_ed0820e1-3d33-4f89-87b6-0b8988058a60_terseLabel_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_label_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Securities [Member]</link:label>
    <link:label id="lab_moh_MunicipalSecuritiesMember_documentation_en-US" xlink:label="lab_moh_MunicipalSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember" xlink:href="moh-20221231.xsd#moh_MunicipalSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_MunicipalSecuritiesMember" xlink:to="lab_moh_MunicipalSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_bd48daa2-1848-40b0-967b-5bd05fe75234_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation to the statutory federal income tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_6e0e3df2-de2e-4352-bbc3-b220ecc697e8_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_RestrictionsOnInvestmentsTableTextBlock_55c10780-f946-4751-94ff-f934c6a672e5_terseLabel_en-US" xlink:label="lab_moh_RestrictionsOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of balances of restricted investments</link:label>
    <link:label id="lab_moh_RestrictionsOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_moh_RestrictionsOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions On Investments [Table Text Block]</link:label>
    <link:label id="lab_moh_RestrictionsOnInvestmentsTableTextBlock_documentation_en-US" xlink:label="lab_moh_RestrictionsOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions On Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RestrictionsOnInvestmentsTableTextBlock" xlink:href="moh-20221231.xsd#moh_RestrictionsOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_RestrictionsOnInvestmentsTableTextBlock" xlink:to="lab_moh_RestrictionsOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d71ea729-80cb-4dfb-a6fb-131aee77296a_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization expense, 2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c876d2ae-0056-4c4f-810e-3aa2a7cf60cc_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_446a8171-e39a-4d41-b05b-e928ed7ab2c9_terseLabel_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_label_en-US" xlink:label="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Duration Insurance Contracts, Accident Year [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:to="lab_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_d7445d80-cf08-4814-85ba-d1bef8c45f07_terseLabel_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy rebate receivables</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_label_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:label id="lab_moh_PharmacyRebateReceivablesMember_documentation_en-US" xlink:label="lab_moh_PharmacyRebateReceivablesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmacy Rebate Receivables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember" xlink:href="moh-20221231.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_PharmacyRebateReceivablesMember" xlink:to="lab_moh_PharmacyRebateReceivablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_cdfa6f7f-12cf-41e2-aa10-44177b6a4583_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Grant&#160;Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_9691721c-3343-49f0-bab5-fd1d0512b877_terseLabel_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of amounts due to government agencies</link:label>
    <link:label id="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves Reported to Other Agencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:to="lab_us-gaap_ReservesReportedToOtherAgenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_76395062-30e5-4c77-b438-7679d20234d1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fddd3585-e851-4d6e-9fc4-e059c2be3ad8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_7f9556f0-5394-400f-b3f4-a9dd1eee6362_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_d7d6850e-d64a-437d-8442-6dd80eac50db_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Condensed statements of comprehensive income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_17ae41b9-eab1-494c-b625-27264dd94159_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_6c15e204-0c74-48fc-abfe-6d8d7d44f00f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_6501d644-dc26-4b6a-8d83-413a4bcfb418_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_5b7b1a38-609b-4208-bdf9-cabafd1887b6_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_c0cca4cf-6417-41da-8919-faf04b143109_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_6d453974-4671-4821-a305-b79e50328501_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_70724c63-de28-42dc-8472-1ca692bc999e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_4ad06435-d3b4-4230-9225-695b5e19e090_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_c93d0e6a-155d-4c2e-a94f-5b1efecf7297_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bddd2a48-7d70-4e43-810a-e2427a2b9881_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c6999ed7-7085-4044-872f-3641d413e7fa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash used in financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_32a244b9-6517-432a-9228-631bc1f02a47_terseLabel_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage-backed securities</link:label>
    <link:label id="lab_us-gaap_MortgageBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateralized Mortgage-Backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MortgageBackedSecuritiesMember" xlink:to="lab_us-gaap_MortgageBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_9d53d8a0-1323-49f7-8ce3-226fb8cb1002_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_71b6546f-4172-404f-b20f-0b69e2569fea_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_f78ff119-df4d-45ee-bdb7-dd059087f32e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_03b8b4bd-3cbd-4ce7-9a6b-a3a7d1d150fb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_83170fd6-5ae4-4ca2-9796-5a20a4d0fc6b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e390d98a-2fa7-4cd4-b22e-0e9d26834834_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_3e15fe04-f630-4528-b415-b309479e2bdd_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and capitalized software</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_0161f3fa-d013-4064-9626-c6c1fcdd5ab7_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_05875663-0e4f-43ea-8564-9a566bae8059_terseLabel_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_label_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:label id="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_documentation_en-US" xlink:label="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Due to Government Agencies, Risk Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:href="moh-20221231.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:to="lab_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_4f98395f-32c2-43da-95b3-dbe2bbf4ee83_terseLabel_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired balances, net of post-acquisition adjustments</link:label>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_label_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</link:label>
    <link:label id="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_documentation_en-US" xlink:label="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:href="moh-20221231.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:to="lab_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3cb8db72-374b-4b70-9e0e-c236401be238_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_d859ef50-6a77-405a-8e0c-eafb1c35e0b5_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c39466e3-8ef3-48e5-be3a-933beb431c8b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of denominators for the computation of basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_15a9c91a-d9a2-438c-a3cf-e7ef3e8d9bb9_negatedTerseLabel_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock withheld to settle employee tax obligations</link:label>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_label_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:label id="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations_documentation_en-US" xlink:label="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Withheld to Settle Employee Tax Obligations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:href="moh-20221231.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:to="lab_moh_CommonStockWithheldToSettleEmployeeTaxObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_TX_83a97218-4888-4479-82c3-82ba79778769_verboseLabel_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Texas</link:label>
    <link:label id="lab_stpr_TX_label_en-US" xlink:label="lab_stpr_TX" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TEXAS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_TX" xlink:to="lab_stpr_TX" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_01de04ed-7fb9-4052-9ea4-d598543d3e2e_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_8b7c53d6-0684-478e-96f5-ca1af5b61974_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross realized investment loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_moh_RestrictedandPerformanceStockMember_24e5e746-ebbd-4a1c-8666-40088a623ba5_terseLabel_en-US" xlink:label="lab_moh_RestrictedandPerformanceStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RSAs and PSUs (defined below)</link:label>
    <link:label id="lab_moh_RestrictedandPerformanceStockMember_label_en-US" xlink:label="lab_moh_RestrictedandPerformanceStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted and Performance Stock [Member]</link:label>
    <link:label id="lab_moh_RestrictedandPerformanceStockMember_documentation_en-US" xlink:label="lab_moh_RestrictedandPerformanceStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted and Performance Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RestrictedandPerformanceStockMember" xlink:href="moh-20221231.xsd#moh_RestrictedandPerformanceStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_moh_RestrictedandPerformanceStockMember" xlink:to="lab_moh_RestrictedandPerformanceStockMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>moh-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:a6be6ee9-88ed-425c-ba06-deafc74c4611,g:0568f791-801e-41fa-b039-5982169b2ced-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CoverPage" xlink:type="simple" xlink:href="moh-20221231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_af71fb1d-4321-417d-9404-f8b0387b636e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_DocumentType_af71fb1d-4321-417d-9404-f8b0387b636e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_04e71a12-4bf6-443c-81c1-ec221e28ae78" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_DocumentAnnualReport_04e71a12-4bf6-443c-81c1-ec221e28ae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6cffc417-4475-43fb-88ce-edf53b3bf2c3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_DocumentPeriodEndDate_6cffc417-4475-43fb-88ce-edf53b3bf2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_1015ac17-672c-4548-9dcb-1024c75e89d3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_CurrentFiscalYearEndDate_1015ac17-672c-4548-9dcb-1024c75e89d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_788a4dda-d7af-4c92-8b60-525873033969" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_DocumentTransitionReport_788a4dda-d7af-4c92-8b60-525873033969" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_88ea10d6-0337-47f1-bc7b-deae350f7e6a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityFileNumber_88ea10d6-0337-47f1-bc7b-deae350f7e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4c7486d0-e866-4eec-af91-3797afba6171" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityRegistrantName_4c7486d0-e866-4eec-af91-3797afba6171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_4929fc40-94c5-4f3c-93b1-e0418c20afe9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityIncorporationStateCountryCode_4929fc40-94c5-4f3c-93b1-e0418c20afe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_f1f0b746-31be-4321-8ef9-6ed31aba3a11" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityTaxIdentificationNumber_f1f0b746-31be-4321-8ef9-6ed31aba3a11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_baa8c639-b7fa-4c26-b5b8-9d6811657ca8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityAddressAddressLine1_baa8c639-b7fa-4c26-b5b8-9d6811657ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_217efa3f-2c54-49f2-8f7b-ec0c38ea5270" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityAddressAddressLine2_217efa3f-2c54-49f2-8f7b-ec0c38ea5270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_d65782d5-ef0d-4a7b-8662-e8b093a815cc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityAddressCityOrTown_d65782d5-ef0d-4a7b-8662-e8b093a815cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_be9ee196-6645-45bd-9b58-52c88434cd98" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityAddressStateOrProvince_be9ee196-6645-45bd-9b58-52c88434cd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d7abfbae-c7a1-4d4e-ac11-f8a9a8d11f53" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityAddressPostalZipCode_d7abfbae-c7a1-4d4e-ac11-f8a9a8d11f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_78f4048c-e319-48a4-93da-f8f756bf47d5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_CityAreaCode_78f4048c-e319-48a4-93da-f8f756bf47d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_23749243-66c7-4efb-b00c-f3cc4535b117" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_LocalPhoneNumber_23749243-66c7-4efb-b00c-f3cc4535b117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_b97b03ea-0ecf-4efa-8da9-d6428eba4bff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_Security12bTitle_b97b03ea-0ecf-4efa-8da9-d6428eba4bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1c13f147-bcb7-4878-820c-d148a7e9a376" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_TradingSymbol_1c13f147-bcb7-4878-820c-d148a7e9a376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_a707d7d5-c3a0-435d-b55d-065e31f8ec9f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_SecurityExchangeName_a707d7d5-c3a0-435d-b55d-065e31f8ec9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_bbeae926-aeac-483d-bef0-8b76c90b8063" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_bbeae926-aeac-483d-bef0-8b76c90b8063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_78827bad-8bd9-4c08-8efc-2b582f5460bf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityVoluntaryFilers_78827bad-8bd9-4c08-8efc-2b582f5460bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_3d56f728-1783-40ab-901c-2c278d41c217" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityCurrentReportingStatus_3d56f728-1783-40ab-901c-2c278d41c217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_ca448f08-8f53-4fbd-a3ce-fc935fc9e4e6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityInteractiveDataCurrent_ca448f08-8f53-4fbd-a3ce-fc935fc9e4e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ac2ded35-e918-4287-8233-2d1c452b8c7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityFilerCategory_ac2ded35-e918-4287-8233-2d1c452b8c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_709647ae-c50e-4e79-b85e-fd08657d6dcb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntitySmallBusiness_709647ae-c50e-4e79-b85e-fd08657d6dcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_ecde6e6e-7aee-41b9-8829-24ea6c2e2a5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityEmergingGrowthCompany_ecde6e6e-7aee-41b9-8829-24ea6c2e2a5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_794d0a2b-6526-434b-9e54-410ad5a241e3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_IcfrAuditorAttestationFlag_794d0a2b-6526-434b-9e54-410ad5a241e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e64ec84d-33b4-470c-88e2-9c4a824f314a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityShellCompany_e64ec84d-33b4-470c-88e2-9c4a824f314a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_494c3368-1bb6-4ee2-bbcd-08444727cdd8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityPublicFloat_494c3368-1bb6-4ee2-bbcd-08444727cdd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bd4159d5-39d4-4532-a2e2-d72d2f2593a5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bd4159d5-39d4-4532-a2e2-d72d2f2593a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fec265ed-3cb0-4f65-8e25-a70d7625ef08" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fec265ed-3cb0-4f65-8e25-a70d7625ef08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_451bb163-a72b-4658-841d-13c448aafeaf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_EntityCentralIndexKey_451bb163-a72b-4658-841d-13c448aafeaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_84025802-984c-4f76-b073-2f18573a8483" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_AmendmentFlag_84025802-984c-4f76-b073-2f18573a8483" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9bc60832-b691-4fa6-b3aa-b832b4befac2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_DocumentFiscalYearFocus_9bc60832-b691-4fa6-b3aa-b832b4befac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_8ba5a02f-6256-4d66-91f3-5e6a148842ab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_258843be-2ff5-4959-ba43-a5315b42cb71" xlink:to="loc_dei_DocumentFiscalPeriodFocus_8ba5a02f-6256-4d66-91f3-5e6a148842ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/AuditInformation" xlink:type="simple" xlink:href="moh-20221231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_moh_AuditInformationAbstract_c82e6554-6541-43a9-919e-15ea4c38d626" xlink:href="moh-20221231.xsd#moh_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_a554cdba-5e7f-4422-8104-0926540d3f68" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AuditInformationAbstract_c82e6554-6541-43a9-919e-15ea4c38d626" xlink:to="loc_dei_AuditorName_a554cdba-5e7f-4422-8104-0926540d3f68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_0fe4e2ce-b88e-4c9c-bab8-35f480a3c6ff" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AuditInformationAbstract_c82e6554-6541-43a9-919e-15ea4c38d626" xlink:to="loc_dei_AuditorLocation_0fe4e2ce-b88e-4c9c-bab8-35f480a3c6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_83ba7895-578a-45c9-8e76-be510458a387" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AuditInformationAbstract_c82e6554-6541-43a9-919e-15ea4c38d626" xlink:to="loc_dei_AuditorFirmId_83ba7895-578a-45c9-8e76-be510458a387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:to="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PremiumsEarnedNet_2ae6be8c-ea23-4530-a4af-61b599ca4444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PremiumsEarnedNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:to="loc_us-gaap_PremiumsEarnedNet_2ae6be8c-ea23-4530-a4af-61b599ca4444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationPremiumTaxRevenue_8b86cd3b-0b17-459d-a458-32d62405e66e" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationPremiumTaxRevenue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:to="loc_moh_HealthCareOrganizationPremiumTaxRevenue_8b86cd3b-0b17-459d-a458-32d62405e66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeRevenue_7db086e2-93a9-4bb3-9243-ff4bf65d891a" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationInsurerFeeRevenue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeRevenue_7db086e2-93a9-4bb3-9243-ff4bf65d891a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue_67dc53f2-5a1b-4bba-8198-3930b1b6c5d7" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:to="loc_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue_67dc53f2-5a1b-4bba-8198-3930b1b6c5d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentIncome_e76eeb67-f1d8-414f-8f58-19ae963141d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetInvestmentIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:to="loc_us-gaap_NetInvestmentIncome_e76eeb67-f1d8-414f-8f58-19ae963141d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_8f78522a-efd1-4c2c-b303-b4f6673a613e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_8f78522a-efd1-4c2c-b303-b4f6673a613e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cbb8c6f3-506c-4f46-9211-ad37f3e4a600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_b3baf3cc-383c-43f3-b01c-adf38b3c17f1" xlink:to="loc_us-gaap_Revenues_cbb8c6f3-506c-4f46-9211-ad37f3e4a600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_265beb3f-e557-4435-9d4f-4b756613b288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_265beb3f-e557-4435-9d4f-4b756613b288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_1a0762e3-6aef-4d18-b664-65501394ecb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_1a0762e3-6aef-4d18-b664-65501394ecb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PremiumTaxExpenses_cbe17d33-cf5a-4edf-8db8-d4c1ff91c92c" xlink:href="moh-20221231.xsd#moh_PremiumTaxExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_moh_PremiumTaxExpenses_cbe17d33-cf5a-4edf-8db8-d4c1ff91c92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationInsurerFeeExpense_23632028-a6ea-4c57-97bc-ab2291ead627" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationInsurerFeeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_moh_HealthCareOrganizationInsurerFeeExpense_23632028-a6ea-4c57-97bc-ab2291ead627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_6bca5aa9-0ed9-4994-8996-f7cbe37276a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_us-gaap_DepreciationAndAmortization_6bca5aa9-0ed9-4994-8996-f7cbe37276a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_9be072db-7864-4614-aaf6-8ab90022900b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_us-gaap_AssetImpairmentCharges_9be072db-7864-4614-aaf6-8ab90022900b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCostAndExpenseOperating_037cb99d-302d-4d94-94f1-c405cdf1f51b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCostAndExpenseOperating"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_us-gaap_OtherCostAndExpenseOperating_037cb99d-302d-4d94-94f1-c405cdf1f51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_36317de8-081e-4f27-8bd0-74d0fb7dbf1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_us-gaap_CostsAndExpenses_36317de8-081e-4f27-8bd0-74d0fb7dbf1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_9813f6d3-f878-4196-9901-cb3c22f0a208" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_c4d38aea-abfb-47e0-9c32-c5bb190c0c03" xlink:to="loc_us-gaap_OperatingIncomeLoss_9813f6d3-f878-4196-9901-cb3c22f0a208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bdf250c-3026-41b8-ae07-3a4f506d053f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeAndExpensesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:to="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bdf250c-3026-41b8-ae07-3a4f506d053f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b38be2cf-9c81-466f-b275-a54f585c6503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bdf250c-3026-41b8-ae07-3a4f506d053f" xlink:to="loc_us-gaap_InterestExpense_b38be2cf-9c81-466f-b275-a54f585c6503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_db3718f7-7ac2-42df-9766-2fee1b02ab0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bdf250c-3026-41b8-ae07-3a4f506d053f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_db3718f7-7ac2-42df-9766-2fee1b02ab0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9567c511-43ef-47ad-8458-c5f35d7e7e69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0bdf250c-3026-41b8-ae07-3a4f506d053f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9567c511-43ef-47ad-8458-c5f35d7e7e69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b807a28d-4d59-4474-ae29-e69985413863" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_b807a28d-4d59-4474-ae29-e69985413863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_b0194c4a-54fb-46cb-a68b-0f140c124a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_b0194c4a-54fb-46cb-a68b-0f140c124a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a9306f8d-1cac-4093-82da-f86dc59c2098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:to="loc_us-gaap_NetIncomeLoss_a9306f8d-1cac-4093-82da-f86dc59c2098" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_702d26a8-e036-4966-9fad-06c7f0cbbd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_702d26a8-e036-4966-9fad-06c7f0cbbd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_056153e4-1982-4b17-97bd-dab0975063e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_702d26a8-e036-4966-9fad-06c7f0cbbd0b" xlink:to="loc_us-gaap_EarningsPerShareBasic_056153e4-1982-4b17-97bd-dab0975063e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_352192aa-7339-4bad-8ee3-2898f3838bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_702d26a8-e036-4966-9fad-06c7f0cbbd0b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_352192aa-7339-4bad-8ee3-2898f3838bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b6aa3303-51b9-443d-a97e-2db22c05dd9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_88197fc8-fc99-40bf-a18b-bf017a40b9f5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b6aa3303-51b9-443d-a97e-2db22c05dd9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_139a0b3f-a23b-4889-b18a-47ae247b2286" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b6aa3303-51b9-443d-a97e-2db22c05dd9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_139a0b3f-a23b-4889-b18a-47ae247b2286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_baa027c6-c9ad-41ea-ba2e-88c9e7e2e87d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_b6aa3303-51b9-443d-a97e-2db22c05dd9f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_baa027c6-c9ad-41ea-ba2e-88c9e7e2e87d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_690d3d8b-39c1-46ee-9fda-ec96f16ed4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_579f82ee-8ada-4f3f-9dea-d706ce8ac9e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_690d3d8b-39c1-46ee-9fda-ec96f16ed4f5" xlink:to="loc_us-gaap_NetIncomeLoss_579f82ee-8ada-4f3f-9dea-d706ce8ac9e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_28a675ab-ba0f-47d9-a305-318e77075600" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_690d3d8b-39c1-46ee-9fda-ec96f16ed4f5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_28a675ab-ba0f-47d9-a305-318e77075600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_f42980f3-0e49-4436-9f22-d12466453a74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_28a675ab-ba0f-47d9-a305-318e77075600" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_f42980f3-0e49-4436-9f22-d12466453a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_c244f568-a5b6-43cf-a5d2-1beb25bbfa8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_28a675ab-ba0f-47d9-a305-318e77075600" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_c244f568-a5b6-43cf-a5d2-1beb25bbfa8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7a49ba33-12e7-4a6e-8366-251bb332e4b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_28a675ab-ba0f-47d9-a305-318e77075600" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7a49ba33-12e7-4a6e-8366-251bb332e4b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_a4917cef-6b52-4184-af6b-7db62cbe96a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_690d3d8b-39c1-46ee-9fda-ec96f16ed4f5" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_a4917cef-6b52-4184-af6b-7db62cbe96a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_4997f119-10e3-40cd-9ae5-055f65290242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4997f119-10e3-40cd-9ae5-055f65290242" xlink:to="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_a7e33973-b73e-4b04-b39e-14c17ad2a7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:to="loc_us-gaap_AssetsCurrentAbstract_a7e33973-b73e-4b04-b39e-14c17ad2a7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7cd1233a-e27f-4e61-a65d-eb526e88e65a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7e33973-b73e-4b04-b39e-14c17ad2a7aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_7cd1233a-e27f-4e61-a65d-eb526e88e65a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_ae54a2ef-73ed-4f35-8829-00b5e4d83b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7e33973-b73e-4b04-b39e-14c17ad2a7aa" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_ae54a2ef-73ed-4f35-8829-00b5e4d83b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_6e60c48c-a55d-47e3-8df8-3c41cc036f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7e33973-b73e-4b04-b39e-14c17ad2a7aa" xlink:to="loc_us-gaap_ReceivablesNetCurrent_6e60c48c-a55d-47e3-8df8-3c41cc036f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c91057e8-fe7e-4028-a264-cd75e6e5d154" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7e33973-b73e-4b04-b39e-14c17ad2a7aa" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c91057e8-fe7e-4028-a264-cd75e6e5d154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_8cade351-6c7d-44e4-86a0-10757f6f2b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_a7e33973-b73e-4b04-b39e-14c17ad2a7aa" xlink:to="loc_us-gaap_AssetsCurrent_8cade351-6c7d-44e4-86a0-10757f6f2b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e212042e-7ff2-47f6-897b-a5da56779735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_e212042e-7ff2-47f6-897b-a5da56779735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_dfc630ca-8e1b-4435-a9dd-f75c9e10ff10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_dfc630ca-8e1b-4435-a9dd-f75c9e10ff10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_c01ddf9c-d90f-49de-b9b1-01732aed4ecc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_c01ddf9c-d90f-49de-b9b1-01732aed4ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_93df8e99-3664-4f64-a623-372ee46e3232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_93df8e99-3664-4f64-a623-372ee46e3232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_8495aa29-7f3a-4ed3-860d-c805fb4808df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_8495aa29-7f3a-4ed3-860d-c805fb4808df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_d1055c5d-4c7d-46b8-8e88-5ca2dd936267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_9d003052-fe0d-43fc-abc5-816c5e70a118" xlink:to="loc_us-gaap_Assets_d1055c5d-4c7d-46b8-8e88-5ca2dd936267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4997f119-10e3-40cd-9ae5-055f65290242" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_f263e805-d0ae-457b-9dcd-ef5c05c2f28e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_f263e805-d0ae-457b-9dcd-ef5c05c2f28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8c06ed99-b4eb-44b7-ad1e-e23e405d01f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f263e805-d0ae-457b-9dcd-ef5c05c2f28e" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_8c06ed99-b4eb-44b7-ad1e-e23e405d01f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_25c136fd-daa3-4a6b-b146-ab3295abc89c" xlink:href="moh-20221231.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f263e805-d0ae-457b-9dcd-ef5c05c2f28e" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_25c136fd-daa3-4a6b-b146-ab3295abc89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2b7fb899-8d06-4cda-9b06-82580f762887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f263e805-d0ae-457b-9dcd-ef5c05c2f28e" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_2b7fb899-8d06-4cda-9b06-82580f762887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_42c3bd1d-0313-462e-8be3-c478fcf1ec9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f263e805-d0ae-457b-9dcd-ef5c05c2f28e" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_42c3bd1d-0313-462e-8be3-c478fcf1ec9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_87f3c701-ed28-4bad-b6b8-996863bfd215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_f263e805-d0ae-457b-9dcd-ef5c05c2f28e" xlink:to="loc_us-gaap_LiabilitiesCurrent_87f3c701-ed28-4bad-b6b8-996863bfd215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_cbb1887e-d26e-4026-8424-29bd9276cc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_cbb1887e-d26e-4026-8424-29bd9276cc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_609864bd-094e-4491-a8dd-9f03f8e91d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_609864bd-094e-4491-a8dd-9f03f8e91d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7805cedf-158a-4f41-a5d5-528e934333c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7805cedf-158a-4f41-a5d5-528e934333c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_49110faa-5d50-4344-803a-bf37a3a89dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:to="loc_us-gaap_Liabilities_49110faa-5d50-4344-803a-bf37a3a89dd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_b27922f1-645e-42ec-985c-d087e07e85db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:to="loc_us-gaap_StockholdersEquityAbstract_b27922f1-645e-42ec-985c-d087e07e85db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_63436d1e-c52b-4952-a342-40b0cda9985b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b27922f1-645e-42ec-985c-d087e07e85db" xlink:to="loc_us-gaap_CommonStockValueOutstanding_63436d1e-c52b-4952-a342-40b0cda9985b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_3d46aa71-3add-409b-8ce4-7b61570503bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b27922f1-645e-42ec-985c-d087e07e85db" xlink:to="loc_us-gaap_PreferredStockValue_3d46aa71-3add-409b-8ce4-7b61570503bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2eb40211-ffa7-4d51-a28e-95e532724032" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b27922f1-645e-42ec-985c-d087e07e85db" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2eb40211-ffa7-4d51-a28e-95e532724032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_240b1580-b3bd-4dcb-8329-963d12cc581c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b27922f1-645e-42ec-985c-d087e07e85db" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_240b1580-b3bd-4dcb-8329-963d12cc581c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32818c48-62e3-47cc-8d8d-1d104c666722" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b27922f1-645e-42ec-985c-d087e07e85db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_32818c48-62e3-47cc-8d8d-1d104c666722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a71c7b1c-9eca-49d3-b33d-8b27c7117b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_b27922f1-645e-42ec-985c-d087e07e85db" xlink:to="loc_us-gaap_StockholdersEquity_a71c7b1c-9eca-49d3-b33d-8b27c7117b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_c95e31bd-1a30-4521-9488-ea22ad1a1441" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_ad182fbb-ed7b-42ea-91bf-9388216dbe10" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_c95e31bd-1a30-4521-9488-ea22ad1a1441" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_208d8ebb-5d7d-4431-a31f-25c3eecef49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_4997f119-10e3-40cd-9ae5-055f65290242" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_208d8ebb-5d7d-4431-a31f-25c3eecef49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_86f852aa-3654-4fcf-8915-b1a77fa63921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_1321b2cf-fd0f-4023-86c5-f2fc6ac6472b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f852aa-3654-4fcf-8915-b1a77fa63921" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_1321b2cf-fd0f-4023-86c5-f2fc6ac6472b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_759afd02-d96b-4f2c-97b9-4d7da45e5b8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f852aa-3654-4fcf-8915-b1a77fa63921" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_759afd02-d96b-4f2c-97b9-4d7da45e5b8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f48c3e5c-b9c9-4ac2-ad37-deb38e8ef793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f852aa-3654-4fcf-8915-b1a77fa63921" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f48c3e5c-b9c9-4ac2-ad37-deb38e8ef793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_41b6fc96-8b8f-4b80-8693-c5c170dd976b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f852aa-3654-4fcf-8915-b1a77fa63921" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_41b6fc96-8b8f-4b80-8693-c5c170dd976b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_d719b2a1-ded5-46a2-bebf-8e1a75ffebca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f852aa-3654-4fcf-8915-b1a77fa63921" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_d719b2a1-ded5-46a2-bebf-8e1a75ffebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_26ed3613-fd95-46d7-ac50-537abf70ced2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f852aa-3654-4fcf-8915-b1a77fa63921" xlink:to="loc_us-gaap_PreferredStockSharesIssued_26ed3613-fd95-46d7-ac50-537abf70ced2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_6c085960-e395-48cc-a532-435131f07f15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_86f852aa-3654-4fcf-8915-b1a77fa63921" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_6c085960-e395-48cc-a532-435131f07f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_e71b628c-0d3a-4aeb-a57c-415bbde952c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_9eec1ef7-4f38-45ff-99fa-c79d61f533a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_e71b628c-0d3a-4aeb-a57c-415bbde952c5" xlink:to="loc_us-gaap_StatementTable_9eec1ef7-4f38-45ff-99fa-c79d61f533a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9eec1ef7-4f38-45ff-99fa-c79d61f533a9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_8ff2c3d1-8c5e-48a8-b9b1-e9e61cd1669d" xlink:to="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_bade57bc-5ae4-44f2-8261-0364ab9f2fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:to="loc_us-gaap_CommonStockMember_bade57bc-5ae4-44f2-8261-0364ab9f2fc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1a41fd1b-bbe5-452d-9d19-8ad1b1e55fe7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1a41fd1b-bbe5-452d-9d19-8ad1b1e55fe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8077ce45-f4e0-461b-826f-3c7d7ab1ee05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8077ce45-f4e0-461b-826f-3c7d7ab1ee05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_7c0cdf1a-10af-4f1a-99bb-e09da0ca48dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_28f90a68-886e-4cc4-9f71-7c450e178043" xlink:to="loc_us-gaap_RetainedEarningsMember_7c0cdf1a-10af-4f1a-99bb-e09da0ca48dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c5647097-c862-4b84-9867-6d76ff514130" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_9eec1ef7-4f38-45ff-99fa-c79d61f533a9" xlink:to="loc_us-gaap_StatementLineItems_c5647097-c862-4b84-9867-6d76ff514130" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c5647097-c862-4b84-9867-6d76ff514130" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_b390087d-dbfc-4a6b-ae49-1abb12546f71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_SharesOutstanding_b390087d-dbfc-4a6b-ae49-1abb12546f71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b70eab4b-3ffa-4ba6-a1f4-c1c22d2e874d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockholdersEquity_b70eab4b-3ffa-4ba6-a1f4-c1c22d2e874d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3a1851a2-de46-417e-866b-7dabc1f47066" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_NetIncomeLoss_3a1851a2-de46-417e-866b-7dabc1f47066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_045f7504-3bac-492a-8f63-4006eced1f52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_045f7504-3bac-492a-8f63-4006eced1f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_1cbe5b9e-b6bf-4194-b925-b0c7e2990d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_1cbe5b9e-b6bf-4194-b925-b0c7e2990d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_49f49d7d-cbb5-4afd-879b-3c2f129106b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_49f49d7d-cbb5-4afd-879b-3c2f129106b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3362eac-4805-4028-8aae-8fdfab4f2542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b3362eac-4805-4028-8aae-8fdfab4f2542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d899547e-3ec8-499f-abd3-c5c89f046f28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_d899547e-3ec8-499f-abd3-c5c89f046f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7dfb3fe8-fe12-42db-836d-7e79a9b7bd33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_7dfb3fe8-fe12-42db-836d-7e79a9b7bd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_0ed7d390-ee54-4e19-8d39-47b3701272af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_SharesOutstanding_0ed7d390-ee54-4e19-8d39-47b3701272af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fb63f805-f8db-4aea-95a1-73eef06c1912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8d727844-53ed-450f-886b-af73466a6020" xlink:to="loc_us-gaap_StockholdersEquity_fb63f805-f8db-4aea-95a1-73eef06c1912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="moh-20221231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d54c9572-6cc6-47b0-889a-89fbf8944af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d275debb-10ed-45e5-b5d4-dfdfd78d67d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d54c9572-6cc6-47b0-889a-89fbf8944af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d275debb-10ed-45e5-b5d4-dfdfd78d67d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_45e780f9-7b0c-4a92-9351-01b7be3bfea1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d275debb-10ed-45e5-b5d4-dfdfd78d67d0" xlink:to="loc_us-gaap_NetIncomeLoss_45e780f9-7b0c-4a92-9351-01b7be3bfea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d275debb-10ed-45e5-b5d4-dfdfd78d67d0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b633e5d3-f98c-40e3-ae93-8855af785d6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b633e5d3-f98c-40e3-ae93-8855af785d6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_be81f960-0b26-43cc-8824-d4e9ee51a71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_be81f960-0b26-43cc-8824-d4e9ee51a71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9146bf9c-7f01-44ea-9ab7-c3a12f887150" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:to="loc_us-gaap_ShareBasedCompensation_9146bf9c-7f01-44ea-9ab7-c3a12f887150" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GainLossOnDebtRepayment_45decd60-8e0b-4ce1-b3df-172f8aa466e1" xlink:href="moh-20221231.xsd#moh_GainLossOnDebtRepayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:to="loc_moh_GainLossOnDebtRepayment_45decd60-8e0b-4ce1-b3df-172f8aa466e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_bad51ae3-6907-4275-acb6-7d193154f66d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:to="loc_us-gaap_AssetImpairmentCharges_bad51ae3-6907-4275-acb6-7d193154f66d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_0faee8ed-3edc-4646-a5a1-009aea3c226e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_0faee8ed-3edc-4646-a5a1-009aea3c226e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_76a6424a-d93a-4c84-b92d-a0d75cc17528" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInReceivables_7d82ce17-08e6-493a-ab35-8b3e5b3af1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInReceivables_7d82ce17-08e6-493a-ab35-8b3e5b3af1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c1eb75f7-8b6d-4ff4-9fb9-f78c19f31a07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c1eb75f7-8b6d-4ff4-9fb9-f78c19f31a07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_5da3a83e-b846-4ccc-a0d5-5e1e9546a44e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities_5da3a83e-b846-4ccc-a0d5-5e1e9546a44e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_982d8b06-29e4-4590-baae-169ef6dd6f6e" xlink:href="moh-20221231.xsd#moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:to="loc_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency_982d8b06-29e4-4590-baae-169ef6dd6f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_996e97df-1931-40bb-b80d-84f1ba881909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_996e97df-1931-40bb-b80d-84f1ba881909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19043c57-5ce8-4b75-bb00-dbc422578a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_19043c57-5ce8-4b75-bb00-dbc422578a4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_811ae1b4-db8a-49ae-900b-b4658a2e05a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7f0b6255-c0d6-4c82-866b-dabcefe0fc7d" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_811ae1b4-db8a-49ae-900b-b4658a2e05a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3ac87919-19fc-4605-9878-e4af3fe168e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_d275debb-10ed-45e5-b5d4-dfdfd78d67d0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3ac87919-19fc-4605-9878-e4af3fe168e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d3292dd-721c-4ff0-b5e4-49d2fb0207a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d54c9572-6cc6-47b0-889a-89fbf8944af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d3292dd-721c-4ff0-b5e4-49d2fb0207a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b7d84f4d-2684-4d5b-8095-156fe77a95d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d3292dd-721c-4ff0-b5e4-49d2fb0207a6" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_b7d84f4d-2684-4d5b-8095-156fe77a95d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9acb784f-12ce-40d5-993a-15ff5795d679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d3292dd-721c-4ff0-b5e4-49d2fb0207a6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_9acb784f-12ce-40d5-993a-15ff5795d679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_49effef3-a6e8-4547-b19c-176564754771" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d3292dd-721c-4ff0-b5e4-49d2fb0207a6" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_49effef3-a6e8-4547-b19c-176564754771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bd17ab68-4448-4a2f-8fd6-b6a16a6074b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d3292dd-721c-4ff0-b5e4-49d2fb0207a6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bd17ab68-4448-4a2f-8fd6-b6a16a6074b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9124a7bf-db57-4528-9b82-bed1996ac72a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d3292dd-721c-4ff0-b5e4-49d2fb0207a6" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_9124a7bf-db57-4528-9b82-bed1996ac72a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a1d3994-28ed-42a1-9e3f-a1c482ea830f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8d3292dd-721c-4ff0-b5e4-49d2fb0207a6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_1a1d3994-28ed-42a1-9e3f-a1c482ea830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d54c9572-6cc6-47b0-889a-89fbf8944af7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7240c30-933e-425e-9237-17e1fab620b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_d7240c30-933e-425e-9237-17e1fab620b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_a3bacad4-b11c-4dc7-ad50-134b821a1ed7" xlink:href="moh-20221231.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_a3bacad4-b11c-4dc7-ad50-134b821a1ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f11ca092-5abb-4a03-a7a2-fb0752ed292e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_f11ca092-5abb-4a03-a7a2-fb0752ed292e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_a3e4edfc-eb0b-4fe2-bf38-f4fef62dd8b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_a3e4edfc-eb0b-4fe2-bf38-f4fef62dd8b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_0ce4f1a4-3c55-4cd1-bbfc-80105f59b271" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_0ce4f1a4-3c55-4cd1-bbfc-80105f59b271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_5639af19-2c61-413f-88bf-ed0253bb4990" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_5639af19-2c61-413f-88bf-ed0253bb4990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_a10108ed-8bef-4295-952a-69e49b08bdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_a10108ed-8bef-4295-952a-69e49b08bdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8be25d28-c302-45ea-beb1-516886b0b5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_8be25d28-c302-45ea-beb1-516886b0b5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidForSettlementOfConversionOption_3c928fd9-fe44-48e2-a27f-ddd52bd44209" xlink:href="moh-20221231.xsd#moh_CashPaidForSettlementOfConversionOption"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_moh_CashPaidForSettlementOfConversionOption_3c928fd9-fe44-48e2-a27f-ddd52bd44209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_15bae39a-a2b4-4441-b671-edc3d17100a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_15bae39a-a2b4-4441-b671-edc3d17100a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_4f2ab9c1-6a25-45da-959b-dac89a635022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_4f2ab9c1-6a25-45da-959b-dac89a635022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d65c9b08-1099-4525-b6f3-44078c824956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_d65c9b08-1099-4525-b6f3-44078c824956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df707091-0837-451e-9d93-20ae5026aff2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5938bc8e-b9f2-45bf-9828-80cec9200e92" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_df707091-0837-451e-9d93-20ae5026aff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a7e18bef-b98d-45cc-9196-a5cd82907491" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d54c9572-6cc6-47b0-889a-89fbf8944af7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_a7e18bef-b98d-45cc-9196-a5cd82907491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa512919-0905-4b49-8988-66086e47ad19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d54c9572-6cc6-47b0-889a-89fbf8944af7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fa512919-0905-4b49-8988-66086e47ad19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1058e982-400b-4fa2-9f93-899b06670d77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d54c9572-6cc6-47b0-889a-89fbf8944af7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1058e982-400b-4fa2-9f93-899b06670d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_fec51a78-09b0-418c-8103-3123dea6fb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d54c9572-6cc6-47b0-889a-89fbf8944af7" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_fec51a78-09b0-418c-8103-3123dea6fb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidDuringThePeriodAbstract_22fc19cd-bc8d-4b83-b6ef-c481c106cf25" xlink:href="moh-20221231.xsd#moh_CashPaidDuringThePeriodAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_fec51a78-09b0-418c-8103-3123dea6fb6d" xlink:to="loc_moh_CashPaidDuringThePeriodAbstract_22fc19cd-bc8d-4b83-b6ef-c481c106cf25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_45ec9504-5da4-48c5-91b8-45a9577321d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_CashPaidDuringThePeriodAbstract_22fc19cd-bc8d-4b83-b6ef-c481c106cf25" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_45ec9504-5da4-48c5-91b8-45a9577321d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_920ee189-323c-4ff4-8edb-b0062e7661a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_CashPaidDuringThePeriodAbstract_22fc19cd-bc8d-4b83-b6ef-c481c106cf25" xlink:to="loc_us-gaap_InterestPaidNet_920ee189-323c-4ff4-8edb-b0062e7661a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="simple" xlink:href="moh-20221231.xsd#OrganizationandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d50a1ec-3406-4b94-afc3-b7d74d79ddf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_39607a7f-9895-428c-9947-661a65bd2fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3d50a1ec-3406-4b94-afc3-b7d74d79ddf2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_39607a7f-9895-428c-9947-661a65bd2fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c785a581-bc75-474f-848d-100d71973b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_712ccae6-38d7-4a9f-84c6-fe67cb0a8056" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c785a581-bc75-474f-848d-100d71973b5e" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_712ccae6-38d7-4a9f-84c6-fe67cb0a8056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="moh-20221231.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4e3230a6-4df9-4b60-8585-df3dc2a6c8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_a75c2a93-2b7b-4537-b66b-b2e086f9bde9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4e3230a6-4df9-4b60-8585-df3dc2a6c8b8" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_a75c2a93-2b7b-4537-b66b-b2e086f9bde9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="simple" xlink:href="moh-20221231.xsd#BusinessCombinations"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0154e708-b8bf-40ef-825b-e2a440b773fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_35578422-f9d1-4a03-bcd6-dbeb61e6ae4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0154e708-b8bf-40ef-825b-e2a440b773fe" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_35578422-f9d1-4a03-bcd6-dbeb61e6ae4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b5489c98-db42-4369-b9bd-3516c82eb0c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_39721724-ee3e-4908-930d-5635e6c2535a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b5489c98-db42-4369-b9bd-3516c82eb0c7" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_39721724-ee3e-4908-930d-5635e6c2535a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Investments" xlink:type="simple" xlink:href="moh-20221231.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9b9382d6-ded1-4a1d-8698-20621df8265b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_acaf5b19-3727-4b16-ba3f-80259ca7fc92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9b9382d6-ded1-4a1d-8698-20621df8265b" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_acaf5b19-3727-4b16-ba3f-80259ca7fc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNet" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNet"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0f7ec42d-f5f1-4fc6-8dac-681f8484cfdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b76fbcfc-a8ca-460e-a39a-06fc7a792449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0f7ec42d-f5f1-4fc6-8dac-681f8484cfdd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_b76fbcfc-a8ca-460e-a39a-06fc7a792449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Leases" xlink:type="simple" xlink:href="moh-20221231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_4f36b87e-e431-4849-b283-61d327f2aae4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_0e585f3f-6d4e-41cf-b686-3018a60f1225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4f36b87e-e431-4849-b283-61d327f2aae4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_0e585f3f-6d4e-41cf-b686-3018a60f1225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_8da6777c-109a-43c0-a8c2-b6dd5ee1791d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeasesTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_4f36b87e-e431-4849-b283-61d327f2aae4" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_8da6777c-109a-43c0-a8c2-b6dd5ee1791d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNet" xlink:type="simple" xlink:href="moh-20221231.xsd#GoodwillandIntangibleAssetsNet"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68ef0f0b-a491-4dbd-917c-172a954778af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2bc1a6d1-e4b2-45e1-9629-f21370edf50a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_68ef0f0b-a491-4dbd-917c-172a954778af" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2bc1a6d1-e4b2-45e1-9629-f21370edf50a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayable"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_6037d772-d6ac-4979-9939-e60706247a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock_5d71ba8f-6212-4c85-887d-1d55af4d7287" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_6037d772-d6ac-4979-9939-e60706247a71" xlink:to="loc_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock_5d71ba8f-6212-4c85-887d-1d55af4d7287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Debt" xlink:type="simple" xlink:href="moh-20221231.xsd#Debt"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_61b84aba-055c-47b3-ab5c-3e9bd749d9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtTextBlock_c66057b6-4b29-4437-8306-3c4d443b56bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_61b84aba-055c-47b3-ab5c-3e9bd749d9c5" xlink:to="loc_us-gaap_LongTermDebtTextBlock_c66057b6-4b29-4437-8306-3c4d443b56bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxes" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_17347ddc-eb54-4b68-a3c6-ba2c9782a152" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_9ddf5ca1-ab0f-4f4e-b229-99a4018346bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_17347ddc-eb54-4b68-a3c6-ba2c9782a152" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_9ddf5ca1-ab0f-4f4e-b229-99a4018346bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_30626c3f-3d53-447b-83a1-ba4775675d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_eb81cb96-ca24-4100-94f7-33549af9a02c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_30626c3f-3d53-447b-83a1-ba4775675d9f" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_eb81cb96-ca24-4100-94f7-33549af9a02c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="moh-20221231.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_9520e6f8-a741-4ae5-9b23-d196dc867ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_25bff39c-c082-4174-89af-0dc252167656" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_9520e6f8-a741-4ae5-9b23-d196dc867ffc" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_25bff39c-c082-4174-89af-0dc252167656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="moh-20221231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac739594-8491-4591-a618-c51583ba210e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fedc793b-1472-49fb-a43f-0e09c1c4b99d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_ac739594-8491-4591-a618-c51583ba210e" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_fedc793b-1472-49fb-a43f-0e09c1c4b99d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/Segments" xlink:type="simple" xlink:href="moh-20221231.xsd#Segments"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/Segments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_150496d2-f29f-47c3-b71e-dcfb6bb0b41b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_e53f3c1d-3fa8-4227-9242-a024489f27be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_150496d2-f29f-47c3-b71e-dcfb6bb0b41b" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_e53f3c1d-3fa8-4227-9242-a024489f27be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrant" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrant"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrant" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c676c6e6-2b59-47b8-a05c-22fe473543f6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_0ea874bc-9691-4efd-a604-07cda9a7c4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c676c6e6-2b59-47b8-a05c-22fe473543f6" xlink:to="loc_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock_0ea874bc-9691-4efd-a604-07cda9a7c4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_f1c01a33-4f52-456e-a776-321e1878e426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_f1c01a33-4f52-456e-a776-321e1878e426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b58dca3b-fc36-49da-96fa-b7be2ff5b1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_UseOfEstimates_b58dca3b-fc36-49da-96fa-b7be2ff5b1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_600b4819-5008-416b-a250-f9b7f7883978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_600b4819-5008-416b-a250-f9b7f7883978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_899d25a1-c4c6-404f-bbf1-9f704b667cd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_899d25a1-c4c6-404f-bbf1-9f704b667cd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_c3801d87-2dcf-4f41-8524-f31bb021c21b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_c3801d87-2dcf-4f41-8524-f31bb021c21b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_2f7ffb69-82ba-45e4-bca5-7adb30669d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationsPolicy"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_2f7ffb69-82ba-45e4-bca5-7adb30669d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7fe9b174-745b-4d54-897c-21433f864550" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_7fe9b174-745b-4d54-897c-21433f864550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_75a5cf9a-66aa-4272-932b-db58b7425975" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_75a5cf9a-66aa-4272-932b-db58b7425975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_e37ffc40-a797-42df-b45c-957ae4ebda05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_e37ffc40-a797-42df-b45c-957ae4ebda05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_42bf0504-2110-4df0-a4d7-7120a2c67dca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_42bf0504-2110-4df0-a4d7-7120a2c67dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_381712c2-0a5d-4722-91cd-ed5b07b001eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_381712c2-0a5d-4722-91cd-ed5b07b001eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceAccountingPolicy_10ed610d-53be-44ae-aa6d-b7c289e77575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceAccountingPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_ReinsuranceAccountingPolicy_10ed610d-53be-44ae-aa6d-b7c289e77575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_5156ca8f-c854-4c36-a61d-fde1a385f96c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_5156ca8f-c854-4c36-a61d-fde1a385f96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_TaxesBasedOnPremiumsPolicyTextBlock_c9749d74-df2e-47d4-adcc-067230080cda" xlink:href="moh-20221231.xsd#moh_TaxesBasedOnPremiumsPolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_moh_TaxesBasedOnPremiumsPolicyTextBlock_c9749d74-df2e-47d4-adcc-067230080cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_1d008421-442d-4504-9524-9de8cf2d7d2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_1d008421-442d-4504-9524-9de8cf2d7d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RisksAndUncertaintiesPolicyTextBlock_f1459f7d-ce88-443f-b37a-522768b5d90c" xlink:href="moh-20221231.xsd#moh_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_moh_RisksAndUncertaintiesPolicyTextBlock_f1459f7d-ce88-443f-b37a-522768b5d90c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b82f404c-208a-437c-ad28-b9c705e238cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b82f404c-208a-437c-ad28-b9c705e238cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4767c17c-f6cb-43c0-b2e4-8398dd4294bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a949c07d-3df9-4ccf-ad1c-cb7be10fec9e" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_4767c17c-f6cb-43c0-b2e4-8398dd4294bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_12b67628-26fb-4ba9-afe6-2bf1afc2a2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_00afcf11-2c98-42b4-99f9-5d9dee18e901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b67628-26fb-4ba9-afe6-2bf1afc2a2b2" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_00afcf11-2c98-42b4-99f9-5d9dee18e901" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4e4db5b7-c46e-4209-bc00-6b9fa5662a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b67628-26fb-4ba9-afe6-2bf1afc2a2b2" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_4e4db5b7-c46e-4209-bc00-6b9fa5662a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_22856a83-8fce-4e39-b482-7535899f226d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b67628-26fb-4ba9-afe6-2bf1afc2a2b2" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock_22856a83-8fce-4e39-b482-7535899f226d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_0afd24f6-25cc-45e0-b4e9-3fbe9effbe11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReservesReportedToOtherAgenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b67628-26fb-4ba9-afe6-2bf1afc2a2b2" xlink:to="loc_us-gaap_ReservesReportedToOtherAgenciesTextBlock_0afd24f6-25cc-45e0-b4e9-3fbe9effbe11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SummarizedPremiumRevenueTableTextBlock_76ed13d5-83c2-41d0-ab6b-003bf3b1c155" xlink:href="moh-20221231.xsd#moh_SummarizedPremiumRevenueTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_12b67628-26fb-4ba9-afe6-2bf1afc2a2b2" xlink:to="loc_moh_SummarizedPremiumRevenueTableTextBlock_76ed13d5-83c2-41d0-ab6b-003bf3b1c155" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="moh-20221231.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a3adf35f-6795-46a4-94c9-e6f9bf98cfe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c17fcb64-42ea-4c6d-8aee-d26e539e8080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a3adf35f-6795-46a4-94c9-e6f9bf98cfe3" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_c17fcb64-42ea-4c6d-8aee-d26e539e8080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsTables" xlink:type="simple" xlink:href="moh-20221231.xsd#BusinessCombinationsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_92978dd4-367b-425b-85c3-ce4c7384e74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_70ec12ac-d1b3-499e-b349-345fa366ea3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_92978dd4-367b-425b-85c3-ce4c7384e74e" xlink:to="loc_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock_70ec12ac-d1b3-499e-b349-345fa366ea3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_bc83fc51-3156-4615-bfbc-4a3f04c5b9c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_249d71c5-5122-4533-a5a5-930cf5e5751d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc83fc51-3156-4615-bfbc-4a3f04c5b9c7" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_249d71c5-5122-4533-a5a5-930cf5e5751d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f9688e3b-d6cb-45ee-9374-95f797a0c20d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_bc83fc51-3156-4615-bfbc-4a3f04c5b9c7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_f9688e3b-d6cb-45ee-9374-95f797a0c20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a8129b8e-4733-49b2-920f-34276a82047f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_8aae9a87-9ffe-4b32-acc6-ea0ac533004a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a8129b8e-4733-49b2-920f-34276a82047f" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_8aae9a87-9ffe-4b32-acc6-ea0ac533004a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2770c6b2-1e5b-4bcd-bf93-edb0f75ba9a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a8129b8e-4733-49b2-920f-34276a82047f" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_2770c6b2-1e5b-4bcd-bf93-edb0f75ba9a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_73facf56-3f54-4d5c-b0e1-c531d4c79175" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a8129b8e-4733-49b2-920f-34276a82047f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_73facf56-3f54-4d5c-b0e1-c531d4c79175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RestrictionsOnInvestmentsTableTextBlock_57543a6a-55b2-4beb-9d1c-73d89c7f8d4e" xlink:href="moh-20221231.xsd#moh_RestrictionsOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a8129b8e-4733-49b2-920f-34276a82047f" xlink:to="loc_moh_RestrictionsOnInvestmentsTableTextBlock_57543a6a-55b2-4beb-9d1c-73d89c7f8d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetTables" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNetTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23ee9cb9-ff04-45a5-9ea2-1c350c978ba3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ad886bda-9325-4977-999a-c3d7d9e49f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23ee9cb9-ff04-45a5-9ea2-1c350c978ba3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_ad886bda-9325-4977-999a-c3d7d9e49f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesTables" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1d43b195-59e0-4eef-bf0d-35a501db8a13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_510ed78e-c479-4fe6-90d7-b8807a39227a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d43b195-59e0-4eef-bf0d-35a501db8a13" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_510ed78e-c479-4fe6-90d7-b8807a39227a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AssetsAndLiabilitiesLesseeTableTextBlock_7dc0a798-4ab6-4897-84c4-a982052d47db" xlink:href="moh-20221231.xsd#moh_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d43b195-59e0-4eef-bf0d-35a501db8a13" xlink:to="loc_moh_AssetsAndLiabilitiesLesseeTableTextBlock_7dc0a798-4ab6-4897-84c4-a982052d47db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4664bfc8-6d6b-4e81-906c-db560782c2bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d43b195-59e0-4eef-bf0d-35a501db8a13" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_4664bfc8-6d6b-4e81-906c-db560782c2bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_e681146f-aeb1-4f6f-9b95-e75c1ddad440" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1d43b195-59e0-4eef-bf0d-35a501db8a13" xlink:to="loc_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock_e681146f-aeb1-4f6f-9b95-e75c1ddad440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="simple" xlink:href="moh-20221231.xsd#GoodwillandIntangibleAssetsNetTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cb6cbda1-3471-4f7a-8ab5-969bef311952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_ac2bc602-43e5-43ca-a7a7-4eccd0f92e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cb6cbda1-3471-4f7a-8ab5-969bef311952" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_ac2bc602-43e5-43ca-a7a7-4eccd0f92e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_943c198d-f65b-4e7d-a0e2-e160e0c6a608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_cb6cbda1-3471-4f7a-8ab5-969bef311952" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_943c198d-f65b-4e7d-a0e2-e160e0c6a608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_f701181a-6cd5-4c48-985e-b00acc773d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_1aac2f0f-166e-43e5-9cab-3ace5e9f4cae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_f701181a-6cd5-4c48-985e-b00acc773d67" xlink:to="loc_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense_1aac2f0f-166e-43e5-9cab-3ace5e9f4cae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_29cd0d59-b34c-4af8-bb75-9d03911c857e" xlink:href="moh-20221231.xsd#moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_f701181a-6cd5-4c48-985e-b00acc773d67" xlink:to="loc_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock_29cd0d59-b34c-4af8-bb75-9d03911c857e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_01940ec9-2bf0-4fa7-a8fa-b50be8311f14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_f701181a-6cd5-4c48-985e-b00acc773d67" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock_01940ec9-2bf0-4fa7-a8fa-b50be8311f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_1d7ffaf2-bf52-43d7-961b-7af1931151f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_f701181a-6cd5-4c48-985e-b00acc773d67" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock_1d7ffaf2-bf52-43d7-961b-7af1931151f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtTables" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_208c7168-a2ec-4370-8bdb-ef7268df0251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e0cb253c-ecef-4c11-8a6f-4be68367e3df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_208c7168-a2ec-4370-8bdb-ef7268df0251" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_e0cb253c-ecef-4c11-8a6f-4be68367e3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fce4af08-c5e2-49c7-b80f-6c011d8b1474" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_208c7168-a2ec-4370-8bdb-ef7268df0251" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_fce4af08-c5e2-49c7-b80f-6c011d8b1474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ac47516e-08d4-4bd1-a707-61783a102831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d0cc7f19-246c-459d-aa8f-6b4c7467c27f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac47516e-08d4-4bd1-a707-61783a102831" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_d0cc7f19-246c-459d-aa8f-6b4c7467c27f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f9aed45c-4711-487f-88b3-45515c79ff69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac47516e-08d4-4bd1-a707-61783a102831" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_f9aed45c-4711-487f-88b3-45515c79ff69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b52c2c32-5c8b-470e-a3de-0ade61b7efb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac47516e-08d4-4bd1-a707-61783a102831" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_b52c2c32-5c8b-470e-a3de-0ade61b7efb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_7d82299c-e807-4d8b-8e3e-a0bd4a51c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ac47516e-08d4-4bd1-a707-61783a102831" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_7d82299c-e807-4d8b-8e3e-a0bd4a51c90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_333baf7e-27d1-446f-9f0d-3d8a6f274b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_e5b0a398-9fe6-4955-8687-578b0a42052e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_333baf7e-27d1-446f-9f0d-3d8a6f274b62" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_e5b0a398-9fe6-4955-8687-578b0a42052e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_83b9b9d0-adbf-4b34-98ac-f60bba7cffc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_333baf7e-27d1-446f-9f0d-3d8a6f274b62" xlink:to="loc_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock_83b9b9d0-adbf-4b34-98ac-f60bba7cffc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_994757e0-faa8-445e-baef-69eeb2844c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_333baf7e-27d1-446f-9f0d-3d8a6f274b62" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_994757e0-faa8-445e-baef-69eeb2844c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="simple" xlink:href="moh-20221231.xsd#SegmentsTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_176b0d7a-d7dc-4f20-959f-85e2aec9066d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7e98e8b4-5a00-4194-8051-d33d28af8beb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_176b0d7a-d7dc-4f20-959f-85e2aec9066d" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7e98e8b4-5a00-4194-8051-d33d28af8beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantTables"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c7e75b8b-1c14-45d4-b895-c27148d52442" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_b38b8c08-c565-426b-be6f-3a9f8f2c4680" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedBalanceSheetTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c7e75b8b-1c14-45d4-b895-c27148d52442" xlink:to="loc_srt_ScheduleOfCondensedBalanceSheetTableTextBlock_b38b8c08-c565-426b-be6f-3a9f8f2c4680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_977ab999-d0d0-4dd3-bb6e-310306c912b9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedIncomeStatementTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c7e75b8b-1c14-45d4-b895-c27148d52442" xlink:to="loc_srt_ScheduleOfCondensedIncomeStatementTableTextBlock_977ab999-d0d0-4dd3-bb6e-310306c912b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_ab8b4967-722c-42e8-ad17-8363163f1024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c7e75b8b-1c14-45d4-b895-c27148d52442" xlink:to="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_ab8b4967-722c-42e8-ad17-8363163f1024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_45a33e47-d002-4138-b753-f353d379e965" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedCashFlowStatementTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_c7e75b8b-1c14-45d4-b895-c27148d52442" xlink:to="loc_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock_45a33e47-d002-4138-b753-f353d379e965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#OrganizationandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7569af54-ed10-4ee9-8495-ad79d9c84454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:href="moh-20221231.xsd#moh_BasisOfPresentationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7569af54-ed10-4ee9-8495-ad79d9c84454" xlink:to="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_be0679c9-9089-4c7a-9022-eb411e777fd1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_srt_RangeAxis_be0679c9-9089-4c7a-9022-eb411e777fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d3a1c296-acdb-4c5c-9e42-4676d998744d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_be0679c9-9089-4c7a-9022-eb411e777fd1" xlink:to="loc_srt_RangeMember_d3a1c296-acdb-4c5c-9e42-4676d998744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d184487d-3687-4a3c-9a44-2c91cc2b585e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3a1c296-acdb-4c5c-9e42-4676d998744d" xlink:to="loc_srt_MinimumMember_d184487d-3687-4a3c-9a44-2c91cc2b585e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_87b9bc0b-8329-4b58-959e-a1f655f7c3ed" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d3a1c296-acdb-4c5c-9e42-4676d998744d" xlink:to="loc_srt_MaximumMember_87b9bc0b-8329-4b58-959e-a1f655f7c3ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2ab184ad-e718-4957-9b3b-325bd494406b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2ab184ad-e718-4957-9b3b-325bd494406b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c3a298fe-55a6-4aa3-8318-b037a1b53206" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ab184ad-e718-4957-9b3b-325bd494406b" xlink:to="loc_us-gaap_SegmentDomain_c3a298fe-55a6-4aa3-8318-b037a1b53206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansMember_0a51dd3d-d47d-4d98-9c17-fa99ed2a4cfa" xlink:href="moh-20221231.xsd#moh_HealthPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c3a298fe-55a6-4aa3-8318-b037a1b53206" xlink:to="loc_moh_HealthPlansMember_0a51dd3d-d47d-4d98-9c17-fa99ed2a4cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthAndHumanServicesMember_5fedf1c5-926f-40ec-bfd0-2baca4738ce0" xlink:href="moh-20221231.xsd#moh_HealthAndHumanServicesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c3a298fe-55a6-4aa3-8318-b037a1b53206" xlink:to="loc_moh_HealthAndHumanServicesMember_5fedf1c5-926f-40ec-bfd0-2baca4738ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_59cf225e-51de-48f6-949c-77e603d59dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_59cf225e-51de-48f6-949c-77e603d59dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8072090b-7132-44b3-bde4-bbb85c4b1a5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_59cf225e-51de-48f6-949c-77e603d59dd5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8072090b-7132-44b3-bde4-bbb85c4b1a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MyChoiceWisconsinMember_058d7b10-75fa-4105-9660-3131ce1826af" xlink:href="moh-20221231.xsd#moh_MyChoiceWisconsinMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8072090b-7132-44b3-bde4-bbb85c4b1a5b" xlink:to="loc_moh_MyChoiceWisconsinMember_058d7b10-75fa-4105-9660-3131ce1826af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_2445b063-bbbe-4a22-bc12-6a09c7664356" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_srt_StatementGeographicalAxis_2445b063-bbbe-4a22-bc12-6a09c7664356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_2445b063-bbbe-4a22-bc12-6a09c7664356" xlink:to="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NE_cdd63e29-a11f-4648-a838-24c43b4a90e0" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:to="loc_stpr_NE_cdd63e29-a11f-4648-a838-24c43b4a90e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_IA_2796c459-2d0c-4233-ad83-9fa35132a2aa" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_IA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:to="loc_stpr_IA_2796c459-2d0c-4233-ad83-9fa35132a2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MS_dca2d73b-6ddf-4e8d-9ba0-1d93fdcbbb0b" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_MS"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_171cd5bd-5de5-441b-b0da-8314a8dda147" xlink:to="loc_stpr_MS_dca2d73b-6ddf-4e8d-9ba0-1d93fdcbbb0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:href="moh-20221231.xsd#moh_BasisOfPresentationLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationTable_5af2c4da-8631-4a12-9cd2-d63eb7b18deb" xlink:to="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_c872ba8c-d255-4d5e-8a47-d7bf135925eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_us-gaap_NumberOfReportableSegments_c872ba8c-d255-4d5e-8a47-d7bf135925eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_594fc052-5632-49f5-8885-5e6206ea2c57" xlink:href="moh-20221231.xsd#moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms_594fc052-5632-49f5-8885-5e6206ea2c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_276d433f-f47d-4070-af08-2a6cfe2e36ee" xlink:href="moh-20221231.xsd#moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms_276d433f-f47d-4070-af08-2a6cfe2e36ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanContractTerm_92ca709d-372e-464e-af15-4d782eb68aa4" xlink:href="moh-20221231.xsd#moh_HealthPlanContractTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_HealthPlanContractTerm_92ca709d-372e-464e-af15-4d782eb68aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlanExtensionOptionPeriod_5dbff06a-3bf6-45cd-8a12-9688d97d88d5" xlink:href="moh-20221231.xsd#moh_HealthPlanExtensionOptionPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_moh_HealthPlanExtensionOptionPeriod_5dbff06a-3bf6-45cd-8a12-9688d97d88d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a6e69d6e-8343-4a78-843c-f8bd0a1e323e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_BasisOfPresentationLineItems_1cea16cc-7a78-4044-966f-2909f16b78b4" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_a6e69d6e-8343-4a78-843c-f8bd0a1e323e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_36d0220b-5c84-4fb2-b231-2bbc571d9a34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_02dd88be-d5a4-4b13-9c4a-1135acb96afe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_36d0220b-5c84-4fb2-b231-2bbc571d9a34" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_02dd88be-d5a4-4b13-9c4a-1135acb96afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalents_96e379ed-37df-4093-883b-41d5d8c0820a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_36d0220b-5c84-4fb2-b231-2bbc571d9a34" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalents_96e379ed-37df-4093-883b-41d5d8c0820a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233f4fac-fb92-430a-bfcc-432111c96e34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_36d0220b-5c84-4fb2-b231-2bbc571d9a34" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_233f4fac-fb92-430a-bfcc-432111c96e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_593bc310-624b-4125-8a00-d66bfe41626a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_593bc310-624b-4125-8a00-d66bfe41626a" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_38a9f64e-027a-4ff8-b19d-05d4bd83c51c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_srt_RangeAxis_38a9f64e-027a-4ff8-b19d-05d4bd83c51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_41092e16-19be-45a1-b28a-d9dd9248522b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_38a9f64e-027a-4ff8-b19d-05d4bd83c51c" xlink:to="loc_srt_RangeMember_41092e16-19be-45a1-b28a-d9dd9248522b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_fab0e871-c847-4fcf-b345-50b4d125be96" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41092e16-19be-45a1-b28a-d9dd9248522b" xlink:to="loc_srt_MinimumMember_fab0e871-c847-4fcf-b345-50b4d125be96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_49c28dc9-2d29-487a-a2d3-202229fc151f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_41092e16-19be-45a1-b28a-d9dd9248522b" xlink:to="loc_srt_MaximumMember_49c28dc9-2d29-487a-a2d3-202229fc151f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemAxis_35fa36b9-0e0d-4781-a6d9-e8229c70b2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_us-gaap_UnusualOrInfrequentItemAxis_35fa36b9-0e0d-4781-a6d9-e8229c70b2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnusualOrInfrequentItemDomain_f8b51cc1-b4bf-409e-a06d-b224940b7e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnusualOrInfrequentItemDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemAxis_35fa36b9-0e0d-4781-a6d9-e8229c70b2da" xlink:to="loc_us-gaap_UnusualOrInfrequentItemDomain_f8b51cc1-b4bf-409e-a06d-b224940b7e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_COVID19Member_a8381698-c154-4854-a2c1-c4b259b37ee1" xlink:href="moh-20221231.xsd#moh_COVID19Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_UnusualOrInfrequentItemDomain_f8b51cc1-b4bf-409e-a06d-b224940b7e3f" xlink:to="loc_moh_COVID19Member_a8381698-c154-4854-a2c1-c4b259b37ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1dad6942-47df-4a9a-a932-cf15afdd26af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_srt_ProductOrServiceAxis_1dad6942-47df-4a9a-a932-cf15afdd26af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f78e3801-3791-4590-b092-b43c5bb4ce5e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1dad6942-47df-4a9a-a932-cf15afdd26af" xlink:to="loc_srt_ProductsAndServicesDomain_f78e3801-3791-4590-b092-b43c5bb4ce5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HealthCarePremiumMember_bc5ff555-17e6-4c71-b988-f60cd7f806c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HealthCarePremiumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_f78e3801-3791-4590-b092-b43c5bb4ce5e" xlink:to="loc_us-gaap_HealthCarePremiumMember_bc5ff555-17e6-4c71-b988-f60cd7f806c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_724abe94-7c9b-4000-8f19-a148d4700f0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_724abe94-7c9b-4000-8f19-a148d4700f0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da461a25-94ea-40b6-ae06-b9557a7ef911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_724abe94-7c9b-4000-8f19-a148d4700f0a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da461a25-94ea-40b6-ae06-b9557a7ef911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_09d7bbfd-a1c6-443a-a6e4-026fa009d9c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_da461a25-94ea-40b6-ae06-b9557a7ef911" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_09d7bbfd-a1c6-443a-a6e4-026fa009d9c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_55eb6330-8a21-4e13-ad85-52ffb862fccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_0628ff1c-5b7c-4b41-9f6a-7a4d041ace6c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_55eb6330-8a21-4e13-ad85-52ffb862fccb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_babb9b52-8dd1-4f18-b27e-606a28a72b46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_55eb6330-8a21-4e13-ad85-52ffb862fccb" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_babb9b52-8dd1-4f18-b27e-606a28a72b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_873c57b0-445d-445a-84a3-1e11028bdd51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_srt_StatementGeographicalAxis_873c57b0-445d-445a-84a3-1e11028bdd51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_873c57b0-445d-445a-84a3-1e11028bdd51" xlink:to="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_652d6ccd-845a-4369-9564-cea1866bce11" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_NY"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:to="loc_stpr_NY_652d6ccd-845a-4369-9564-cea1866bce11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_TX_c63bbc7f-f0b3-4537-9439-91bd777033f5" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_TX"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:to="loc_stpr_TX_c63bbc7f-f0b3-4537-9439-91bd777033f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WA_0c41e208-93fb-44d5-9cbc-bdf18909c0af" xlink:href="https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd#stpr_WA"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_fb06ecb9-6d0f-41b5-9937-92b36f1296d3" xlink:to="loc_stpr_WA_0c41e208-93fb-44d5-9cbc-bdf18909c0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_5991a442-e5e9-4d56-a288-e6afccba6f3c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsMaturityPeriod_8ee48aeb-b4fc-4aff-b4f8-f332e5b4943d" xlink:href="moh-20221231.xsd#moh_InvestmentsMaturityPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_InvestmentsMaturityPeriod_8ee48aeb-b4fc-4aff-b4f8-f332e5b4943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_InvestmentsAverageMaturityPeriod_73b819e3-2d6e-4e42-aef7-1419c3b6c8e0" xlink:href="moh-20221231.xsd#moh_InvestmentsAverageMaturityPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_InvestmentsAverageMaturityPeriod_73b819e3-2d6e-4e42-aef7-1419c3b6c8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_4196c96b-7eba-4dd5-a29a-cfc586e7d713" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_InterestReceivable_4196c96b-7eba-4dd5-a29a-cfc586e7d713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ae6274f0-5eea-46cd-99ef-8db47a35114b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_ae6274f0-5eea-46cd-99ef-8db47a35114b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_352b5b32-a164-489a-a8c3-0edd222ec0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_352b5b32-a164-489a-a8c3-0edd222ec0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b6def90e-7335-4b18-9168-615bbb5f1989" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b6def90e-7335-4b18-9168-615bbb5f1989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingAndFinanceLeaseImpairmentLoss_f0f8f57f-6370-4862-b685-e7edc563d0b4" xlink:href="moh-20221231.xsd#moh_OperatingAndFinanceLeaseImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_OperatingAndFinanceLeaseImpairmentLoss_f0f8f57f-6370-4862-b685-e7edc563d0b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_194b5f40-84fa-414c-86ca-0f47048c536f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_194b5f40-84fa-414c-86ca-0f47048c536f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_45354830-d61e-4c0f-ad9e-074cdea2f9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPremiumsReceivable"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_IncreaseDecreaseInPremiumsReceivable_45354830-d61e-4c0f-ad9e-074cdea2f9f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_5820c32d-6496-4dab-ac88-edd4cdeef8f4" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable_5820c32d-6496-4dab-ac88-edd4cdeef8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_c293d52e-2fe2-438c-87d6-6ae8f28d5948" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable_c293d52e-2fe2-438c-87d6-6ae8f28d5948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_baf545f3-3ce4-4bda-bf78-39aeaed86d78" xlink:href="moh-20221231.xsd#moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable_baf545f3-3ce4-4bda-bf78-39aeaed86d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned_1723be8e-eaee-4e93-8db3-a7f5b27057ea" xlink:href="moh-20221231.xsd#moh_PercentageOfAdditionalIncrementalRevenueEarned"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_PercentageOfAdditionalIncrementalRevenueEarned_1723be8e-eaee-4e93-8db3-a7f5b27057ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidReinsurancePremiums_c515cf13-71a2-4c6f-aa8f-b8476914579c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidReinsurancePremiums"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_PrepaidReinsurancePremiums_c515cf13-71a2-4c6f-aa8f-b8476914579c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceRecoveries_9c59f632-4db2-45f8-a587-ff90f0a9f612" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceRecoveries"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_InsuranceRecoveries_9c59f632-4db2-45f8-a587-ff90f0a9f612" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ba399caa-6925-45fc-8dc8-10a10b104959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments_ba399caa-6925-45fc-8dc8-10a10b104959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthCareOrganizationRevenuePercentage_6be397df-10a9-436b-8d1a-4a278ac100ce" xlink:href="moh-20221231.xsd#moh_HealthCareOrganizationRevenuePercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_88c508e0-ca65-4fb2-bd44-4d9009cf01a1" xlink:to="loc_moh_HealthCareOrganizationRevenuePercentage_6be397df-10a9-436b-8d1a-4a278ac100ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesReceivablesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ef5019dd-7227-4c8f-ab5c-44f9dd13cf03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1a0afaef-ac84-4c3c-972f-8001d7491a33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ef5019dd-7227-4c8f-ab5c-44f9dd13cf03" xlink:to="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1a0afaef-ac84-4c3c-972f-8001d7491a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3fb7468-b3ce-42be-b8bf-81f020a13691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1a0afaef-ac84-4c3c-972f-8001d7491a33" xlink:to="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3fb7468-b3ce-42be-b8bf-81f020a13691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivableTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis_f3fb7468-b3ce-42be-b8bf-81f020a13691" xlink:to="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_GovernmentReceivablesMember_cb95f93b-613a-4e22-8990-80008e10a3d3" xlink:href="moh-20221231.xsd#moh_GovernmentReceivablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:to="loc_moh_GovernmentReceivablesMember_cb95f93b-613a-4e22-8990-80008e10a3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyRebateReceivablesMember_a79283d9-90f7-4a77-b596-585e48ece34f" xlink:href="moh-20221231.xsd#moh_PharmacyRebateReceivablesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:to="loc_moh_PharmacyRebateReceivablesMember_a79283d9-90f7-4a77-b596-585e48ece34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherReceivablesMember_af93e9ae-055c-4fd2-adaa-bc9afbb143c4" xlink:href="moh-20221231.xsd#moh_OtherReceivablesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReceivableTypeDomain_0e886024-96ab-47e6-8c44-cea4abc7011b" xlink:to="loc_moh_OtherReceivablesMember_af93e9ae-055c-4fd2-adaa-bc9afbb143c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_57b03462-ecbc-4d4c-bf34-5ce7a403a308" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsNotesAndLoansReceivableLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable_1a0afaef-ac84-4c3c-972f-8001d7491a33" xlink:to="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_57b03462-ecbc-4d4c-bf34-5ce7a403a308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_9d3c31c4-609b-43b6-8493-ce4168d72cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsNotesAndLoansReceivableLineItems_57b03462-ecbc-4d4c-bf34-5ce7a403a308" xlink:to="loc_us-gaap_ReceivablesNetCurrent_9d3c31c4-609b-43b6-8493-ce4168d72cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_64007ca6-6701-4e96-b3a0-e5d46033246f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_bb755f4b-2d0f-4cef-9328-a9ef28a87b45" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64007ca6-6701-4e96-b3a0-e5d46033246f" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_bb755f4b-2d0f-4cef-9328-a9ef28a87b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_f1ccc1d1-5e35-4cde-babe-1e7b5a263426" xlink:href="moh-20221231.xsd#moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_bb755f4b-2d0f-4cef-9328-a9ef28a87b45" xlink:to="loc_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold_f1ccc1d1-5e35-4cde-babe-1e7b5a263426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_67275258-4ab7-4ca6-9e9d-20d308b2e085" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicaidOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract_bb755f4b-2d0f-4cef-9328-a9ef28a87b45" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicaidOther_67275258-4ab7-4ca6-9e9d-20d308b2e085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_4550d636-2db1-486e-9068-6cff55ecf4ad" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64007ca6-6701-4e96-b3a0-e5d46033246f" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_4550d636-2db1-486e-9068-6cff55ecf4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_d97fff3a-39df-4d39-b1c9-f8799987ffc8" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_4550d636-2db1-486e-9068-6cff55ecf4ad" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing_d97fff3a-39df-4d39-b1c9-f8799987ffc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_93883fe8-271e-452d-97a9-1ed1c835dc2b" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_4550d636-2db1-486e-9068-6cff55ecf4ad" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold_93883fe8-271e-452d-97a9-1ed1c835dc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherMedicareProgram_e7f5d0ee-50f3-4370-9ba0-b3464ad5b03e" xlink:href="moh-20221231.xsd#moh_OtherMedicareProgram"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract_4550d636-2db1-486e-9068-6cff55ecf4ad" xlink:to="loc_moh_OtherMedicareProgram_e7f5d0ee-50f3-4370-9ba0-b3464ad5b03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_7a1bdf26-d945-498a-81c9-806b6d402a63" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64007ca6-6701-4e96-b3a0-e5d46033246f" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_7a1bdf26-d945-498a-81c9-806b6d402a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_39a48009-76d9-4390-9071-22c5f3cbea42" xlink:href="moh-20221231.xsd#moh_AmountsDuetoGovernmentAgenciesRiskAdjustment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_7a1bdf26-d945-498a-81c9-806b6d402a63" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment_39a48009-76d9-4390-9071-22c5f3cbea42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_c02cc96f-51eb-4b66-acb8-48dd89d9203d" xlink:href="moh-20221231.xsd#moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_7a1bdf26-d945-498a-81c9-806b6d402a63" xlink:to="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold_c02cc96f-51eb-4b66-acb8-48dd89d9203d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AmountsDuetoGovernmentAgenciesOther_c1da6904-77ea-40b5-a18e-524ac30fc3cf" xlink:href="moh-20221231.xsd#moh_AmountsDuetoGovernmentAgenciesOther"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract_7a1bdf26-d945-498a-81c9-806b6d402a63" xlink:to="loc_moh_AmountsDuetoGovernmentAgenciesOther_c1da6904-77ea-40b5-a18e-524ac30fc3cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalPremiumLiabilityDueToAgency_8c14fe2f-202e-42bf-b0e7-30c336f8d4d5" xlink:href="moh-20221231.xsd#moh_MedicalPremiumLiabilityDueToAgency"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_64007ca6-6701-4e96-b3a0-e5d46033246f" xlink:to="loc_moh_MedicalPremiumLiabilityDueToAgency_8c14fe2f-202e-42bf-b0e7-30c336f8d4d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#NetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/NetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_27a44e5c-4d36-4fe9-a277-facdb0c933b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_b9906fb9-a67e-45ed-9430-3d7a9b05a338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27a44e5c-4d36-4fe9-a277-facdb0c933b5" xlink:to="loc_us-gaap_NetIncomeLossAbstract_b9906fb9-a67e-45ed-9430-3d7a9b05a338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_48d16f2e-071c-4ac0-a8b3-6e52cc57c060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_b9906fb9-a67e-45ed-9430-3d7a9b05a338" xlink:to="loc_us-gaap_NetIncomeLoss_48d16f2e-071c-4ac0-a8b3-6e52cc57c060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_276f9105-473b-4ead-a0c3-5e2f667c7ffc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27a44e5c-4d36-4fe9-a277-facdb0c933b5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_276f9105-473b-4ead-a0c3-5e2f667c7ffc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_SharesOutstandingExcludingRestrictedStockAwards_4d6ecce1-8362-4bfc-bebb-d0b9d9b88f93" xlink:href="moh-20221231.xsd#moh_SharesOutstandingExcludingRestrictedStockAwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_276f9105-473b-4ead-a0c3-5e2f667c7ffc" xlink:to="loc_moh_SharesOutstandingExcludingRestrictedStockAwards_4d6ecce1-8362-4bfc-bebb-d0b9d9b88f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5b14f260-7528-48a3-87d0-484f9fd33c21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_276f9105-473b-4ead-a0c3-5e2f667c7ffc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5b14f260-7528-48a3-87d0-484f9fd33c21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_da2d9976-97c6-487d-aac8-7bf6535a3c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5b14f260-7528-48a3-87d0-484f9fd33c21" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_da2d9976-97c6-487d-aac8-7bf6535a3c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_cb3a2b15-f22b-40dc-ab26-80d183fb6d5e" xlink:href="moh-20221231.xsd#moh_WeightedAverageNumberofSharesShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5b14f260-7528-48a3-87d0-484f9fd33c21" xlink:to="loc_moh_WeightedAverageNumberofSharesShareBasedCompensation_cb3a2b15-f22b-40dc-ab26-80d183fb6d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e33b20d8-ed23-49ff-a1b4-01bc74f1d619" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_5b14f260-7528-48a3-87d0-484f9fd33c21" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e33b20d8-ed23-49ff-a1b4-01bc74f1d619" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_e7a730b6-f609-42b5-8f78-0a40698ff11e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_276f9105-473b-4ead-a0c3-5e2f667c7ffc" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_e7a730b6-f609-42b5-8f78-0a40698ff11e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_be9df247-8832-4acc-bc56-0f433b373822" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_e7a730b6-f609-42b5-8f78-0a40698ff11e" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_be9df247-8832-4acc-bc56-0f433b373822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b9aab833-6dfb-4f3a-a09b-d1798f0ddf30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_e7a730b6-f609-42b5-8f78-0a40698ff11e" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b9aab833-6dfb-4f3a-a09b-d1798f0ddf30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_f7c7ee35-da40-4c29-9b1a-dca4cf6913a9" xlink:href="moh-20221231.xsd#moh_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_27a44e5c-4d36-4fe9-a277-facdb0c933b5" xlink:to="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_f7c7ee35-da40-4c29-9b1a-dca4cf6913a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_149c004a-e4a9-4dc5-a419-de42b3fd3c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_f7c7ee35-da40-4c29-9b1a-dca4cf6913a9" xlink:to="loc_us-gaap_EarningsPerShareBasic_149c004a-e4a9-4dc5-a419-de42b3fd3c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_ce9c4bcd-3ab1-4b5b-b792-d5502ec056e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_EarningsPerShareBasicAndDilutedEPSAbstract_f7c7ee35-da40-4c29-9b1a-dca4cf6913a9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_ce9c4bcd-3ab1-4b5b-b792-d5502ec056e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#BusinessCombinationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_84eacd41-557a-45b5-9f08-141f753a39d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_84eacd41-557a-45b5-9f08-141f753a39d3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e4da9071-faaa-4730-81b2-5987a2bf4da8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e4da9071-faaa-4730-81b2-5987a2bf4da8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e4da9071-faaa-4730-81b2-5987a2bf4da8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AgeWellNewYorkMember_4e108307-6188-4c3e-bbc2-7c9c250f72fe" xlink:href="moh-20221231.xsd#moh_AgeWellNewYorkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:to="loc_moh_AgeWellNewYorkMember_4e108307-6188-4c3e-bbc2-7c9c250f72fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_6793d972-e8fb-43f9-9a52-cf5e17a54788" xlink:href="moh-20221231.xsd#moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:to="loc_moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember_6793d972-e8fb-43f9-9a52-cf5e17a54788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AffinityHealthPlanIncMember_979fd4b6-3610-474a-954c-df48239f4523" xlink:href="moh-20221231.xsd#moh_AffinityHealthPlanIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_272e3f3d-d915-44d9-bc26-503c688f9f22" xlink:to="loc_moh_AffinityHealthPlanIncMember_979fd4b6-3610-474a-954c-df48239f4523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50305da0-4a6c-4430-8910-1ecfa1ee62ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50305da0-4a6c-4430-8910-1ecfa1ee62ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2be34ecd-0ddd-4d24-9f28-736d25a2cf10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_50305da0-4a6c-4430-8910-1ecfa1ee62ed" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2be34ecd-0ddd-4d24-9f28-736d25a2cf10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MemberListsMember_d48b530d-ed7f-4d2b-a933-ada75e42ca58" xlink:href="moh-20221231.xsd#moh_MemberListsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2be34ecd-0ddd-4d24-9f28-736d25a2cf10" xlink:to="loc_moh_MemberListsMember_d48b530d-ed7f-4d2b-a933-ada75e42ca58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_86fe4534-8fb3-47de-ac05-9c94a3a6ad79" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationNumberOfBusinessCombinations_1ebbe413-c0fb-44e3-bfb3-2b7f6b06e0c5" xlink:href="moh-20221231.xsd#moh_BusinessCombinationNumberOfBusinessCombinations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_moh_BusinessCombinationNumberOfBusinessCombinations_1ebbe413-c0fb-44e3-bfb3-2b7f6b06e0c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_ed85b604-260d-4a9f-b328-263cb685f0fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_AcquisitionCosts_ed85b604-260d-4a9f-b328-263cb685f0fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3a242f71-17f0-4d6a-8d68-44deab820733" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_3a242f71-17f0-4d6a-8d68-44deab820733" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_d8b90886-0aa9-4ab4-87f6-2d6c280dd245" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_d8b90886-0aa9-4ab4-87f6-2d6c280dd245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b9ff2ad6-dd1c-4e6c-9ee2-0946ed247881" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_b9ff2ad6-dd1c-4e6c-9ee2-0946ed247881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_5686b1be-1135-442f-9b3c-134e4e4b049c" xlink:href="moh-20221231.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable_5686b1be-1135-442f-9b3c-134e4e4b049c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_575a9287-a0fb-44e1-84ba-bbe1083e7b89" xlink:href="moh-20221231.xsd#moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_e38fde9a-ed0b-4bad-846e-009982c8e6d3" xlink:to="loc_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables_575a9287-a0fb-44e1-84ba-bbe1083e7b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#BusinessCombinationsIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_43781e24-c8e5-4b4b-a3dd-93b924a67556" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_43781e24-c8e5-4b4b-a3dd-93b924a67556" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_df9e72e2-4321-427c-a1f2-1978ed4758d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_df9e72e2-4321-427c-a1f2-1978ed4758d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d221ebe6-b372-4935-9573-7a1516c2adf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_df9e72e2-4321-427c-a1f2-1978ed4758d3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d221ebe6-b372-4935-9573-7a1516c2adf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_HealthPlansSegmentMember_9e3eb52f-86a5-4b31-bfea-170eb79eda7a" xlink:href="moh-20221231.xsd#moh_HealthPlansSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_d221ebe6-b372-4935-9573-7a1516c2adf2" xlink:to="loc_moh_HealthPlansSegmentMember_9e3eb52f-86a5-4b31-bfea-170eb79eda7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_56ca9b0e-8fdd-4153-9667-6b62dd819f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_56ca9b0e-8fdd-4153-9667-6b62dd819f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32de939d-a88d-4463-a7e2-2511d1ccec60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_56ca9b0e-8fdd-4153-9667-6b62dd819f78" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32de939d-a88d-4463-a7e2-2511d1ccec60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractualRightsMember_da817e7c-5200-42ff-a35d-e53b3ad1cdaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractualRightsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32de939d-a88d-4463-a7e2-2511d1ccec60" xlink:to="loc_us-gaap_ContractualRightsMember_da817e7c-5200-42ff-a35d-e53b3ad1cdaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworkMember_791966be-ce25-493d-a95e-6c6aea19dfb4" xlink:href="moh-20221231.xsd#moh_ProviderNetworkMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_32de939d-a88d-4463-a7e2-2511d1ccec60" xlink:to="loc_moh_ProviderNetworkMember_791966be-ce25-493d-a95e-6c6aea19dfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7a43f288-4c6b-4631-82cc-ba5f5332b80c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:to="loc_srt_RangeAxis_7a43f288-4c6b-4631-82cc-ba5f5332b80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_49cede5f-a36e-458e-9c3a-99210d8e974a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7a43f288-4c6b-4631-82cc-ba5f5332b80c" xlink:to="loc_srt_RangeMember_49cede5f-a36e-458e-9c3a-99210d8e974a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_98d15b1c-c234-454d-a8e3-59f1c7d31181" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49cede5f-a36e-458e-9c3a-99210d8e974a" xlink:to="loc_srt_MinimumMember_98d15b1c-c234-454d-a8e3-59f1c7d31181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_729d9a56-b0da-41d9-a5cb-403a46840722" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_49cede5f-a36e-458e-9c3a-99210d8e974a" xlink:to="loc_srt_MaximumMember_729d9a56-b0da-41d9-a5cb-403a46840722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable_3953da90-b953-486a-9b60-e9185d30c548" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e3590b94-a67f-48b2-8452-99cde60d4e4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_e3590b94-a67f-48b2-8452-99cde60d4e4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_20e1015d-41c7-4e82-9dbb-908c659728d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_20e1015d-41c7-4e82-9dbb-908c659728d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_015a3411-9f11-4328-ae34-80621bfe924b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_015a3411-9f11-4328-ae34-80621bfe924b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_17170016-d6fa-4a2d-ba19-4b2763f0c789" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems_e985c848-f4f2-42b9-9b42-92ceb6426425" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_17170016-d6fa-4a2d-ba19-4b2763f0c789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_366a427f-0f6b-47b0-8425-2329d8cf481a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_366a427f-0f6b-47b0-8425-2329d8cf481a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4b528282-f220-4bd4-b054-929d9bbc23c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4b528282-f220-4bd4-b054-929d9bbc23c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47a6afe3-37bb-41bd-95c9-b61a365c4aae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4b528282-f220-4bd4-b054-929d9bbc23c0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47a6afe3-37bb-41bd-95c9-b61a365c4aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PassportHealthPlanIncMember_a01e6907-429e-4c2f-bffa-e0137aa600db" xlink:href="moh-20221231.xsd#moh_PassportHealthPlanIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_47a6afe3-37bb-41bd-95c9-b61a365c4aae" xlink:to="loc_moh_PassportHealthPlanIncMember_a01e6907-429e-4c2f-bffa-e0137aa600db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af646c11-cb88-46dc-93d6-a64cfcdf7cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af646c11-cb88-46dc-93d6-a64cfcdf7cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3525b93a-8fee-4924-9243-8152e2226c72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_af646c11-cb88-46dc-93d6-a64cfcdf7cf0" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3525b93a-8fee-4924-9243-8152e2226c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_05a3b316-d567-4330-82f3-5c4779e01a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3525b93a-8fee-4924-9243-8152e2226c72" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_05a3b316-d567-4330-82f3-5c4779e01a8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c0850367-02ff-4aec-81b8-e8bed03a11d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_dd7256a7-63ba-4ed8-aa5a-158aa47d3ba0" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c0850367-02ff-4aec-81b8-e8bed03a11d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MinimumMemberEnrollmentTargetsMember_c8127242-3812-4983-bc92-4f52c9a0abcf" xlink:href="moh-20221231.xsd#moh_MinimumMemberEnrollmentTargetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c0850367-02ff-4aec-81b8-e8bed03a11d0" xlink:to="loc_moh_MinimumMemberEnrollmentTargetsMember_c8127242-3812-4983-bc92-4f52c9a0abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingIncomeGuaranteeMember_c56e3224-8546-40a5-b5a3-26243b00a194" xlink:href="moh-20221231.xsd#moh_OperatingIncomeGuaranteeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_c0850367-02ff-4aec-81b8-e8bed03a11d0" xlink:to="loc_moh_OperatingIncomeGuaranteeMember_c56e3224-8546-40a5-b5a3-26243b00a194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_760116c8-0a22-4829-bad4-3e89250b2d0e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_ea8d17df-b5af-4ebf-842b-01df920e40f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings_ea8d17df-b5af-4ebf-842b-01df920e40f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fe68fccd-d8c7-42a3-9d49-4281ba5a6787" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_fe68fccd-d8c7-42a3-9d49-4281ba5a6787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_856d4ace-3311-4318-8fcb-2efe03b5e4cd" xlink:href="moh-20221231.xsd#moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities_856d4ace-3311-4318-8fcb-2efe03b5e4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_544954f8-c891-4478-9c79-82895575b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities_544954f8-c891-4478-9c79-82895575b80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_088cadb7-e856-4254-9834-3fd15d5f4fe9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_7074470f-8329-4276-9678-57afaa2a7048" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_088cadb7-e856-4254-9834-3fd15d5f4fe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a94cec21-ecf4-4200-b840-d223742824dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a94cec21-ecf4-4200-b840-d223742824dd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62a43300-481c-4c01-833b-fdd30535845f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62a43300-481c-4c01-833b-fdd30535845f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_62a43300-481c-4c01-833b-fdd30535845f" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b51e2e1b-d4be-46f2-a007-cf492f2f7453" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b51e2e1b-d4be-46f2-a007-cf492f2f7453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_505f1d1a-a457-4523-aa1d-57349c424910" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_505f1d1a-a457-4523-aa1d-57349c424910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_acc76ea1-187a-4e43-8dff-93d0b45c3295" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2f3bc841-c8f9-424f-89f9-3b0e9ec16b23" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_acc76ea1-187a-4e43-8dff-93d0b45c3295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:to="loc_us-gaap_FinancialInstrumentAxis_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_8fbb59a3-fc5c-4d91-bb74-0e4894e0494f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_152f190e-12b6-4c91-9b8e-51239980221a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_152f190e-12b6-4c91-9b8e-51239980221a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b0df19fa-e70d-4f85-a41f-a3da8866d93a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialMortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_us-gaap_CommercialMortgageBackedSecuritiesMember_b0df19fa-e70d-4f85-a41f-a3da8866d93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_2e1e27a7-5302-4068-806d-6c6ea23bc6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_2e1e27a7-5302-4068-806d-6c6ea23bc6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_509f0963-966e-4e31-974c-60d5cf89ec68" xlink:href="moh-20221231.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_moh_MunicipalSecuritiesMember_509f0963-966e-4e31-974c-60d5cf89ec68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_fc1492de-8996-45aa-a6b7-0c079a40ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_fc1492de-8996-45aa-a6b7-0c079a40ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_dc45ecec-b4f0-4253-8190-b2df7b3dbd68" xlink:href="moh-20221231.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_9e24c3a4-5d62-4ac8-954e-26c36c98ddba" xlink:to="loc_moh_OtherSecuritiesMember_dc45ecec-b4f0-4253-8190-b2df7b3dbd68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_23b19fb1-ad00-45a0-8750-7cf203be61b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_0ba88594-21d8-43f0-913a-716171953620" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_23b19fb1-ad00-45a0-8750-7cf203be61b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_23b19fb1-ad00-45a0-8750-7cf203be61b5" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_67a3bf43-8723-49fc-adb3-4ecba5fdc04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_67a3bf43-8723-49fc-adb3-4ecba5fdc04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_7e7fe93c-d9e4-4add-8fdd-42b9cd2a99da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_7e7fe93c-d9e4-4add-8fdd-42b9cd2a99da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d561646d-97c4-4229-b9cf-f9f329d19f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d561646d-97c4-4229-b9cf-f9f329d19f56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_96cbf9f3-9e19-4088-a084-14994debe8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_00697932-ff89-4899-8f5a-714ca1e1701d" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_96cbf9f3-9e19-4088-a084-14994debe8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#FairValueMeasurementsLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_17fab29a-8736-4156-b8fc-99b33b54cee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_17fab29a-8736-4156-b8fc-99b33b54cee0" xlink:to="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7927ce36-8c6f-4b25-a356-5df5983e9d2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7927ce36-8c6f-4b25-a356-5df5983e9d2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_1d8ec47d-f0a6-44ba-8ae9-91891ba952b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7927ce36-8c6f-4b25-a356-5df5983e9d2e" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_1d8ec47d-f0a6-44ba-8ae9-91891ba952b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_75ab6828-390b-4fd0-a36f-3611e38c7f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_1d8ec47d-f0a6-44ba-8ae9-91891ba952b5" xlink:to="loc_us-gaap_SeniorNotesMember_75ab6828-390b-4fd0-a36f-3611e38c7f6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_8ed5e058-2653-43bd-8065-5984c1c70cda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:to="loc_us-gaap_DebtInstrumentAxis_8ed5e058-2653-43bd-8065-5984c1c70cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_8ed5e058-2653-43bd-8065-5984c1c70cda" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_866d67b3-8580-44ac-b830-36f3b07b27c5" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:to="loc_moh_A4375SeniorNotesMember_866d67b3-8580-44ac-b830-36f3b07b27c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_61069795-ba9e-4161-a7bc-63fe2df6b613" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_61069795-ba9e-4161-a7bc-63fe2df6b613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_9a16a8a7-1a14-448d-bd78-eb1993404b01" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_1ac95157-e10b-4bb2-a698-25ea9655253b" xlink:to="loc_moh_A3875SeniorNotesMember_9a16a8a7-1a14-448d-bd78-eb1993404b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_434e3a0b-0e07-4eb5-822c-d2aad712f574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_434e3a0b-0e07-4eb5-822c-d2aad712f574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_403fb6fe-7286-4701-870e-2aee26e352eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_434e3a0b-0e07-4eb5-822c-d2aad712f574" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_403fb6fe-7286-4701-870e-2aee26e352eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_432da0df-a608-49e5-a671-e64fa770a72b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_403fb6fe-7286-4701-870e-2aee26e352eb" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_432da0df-a608-49e5-a671-e64fa770a72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e4f23ce9-c38c-4522-8aad-cc73540dd383" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_432da0df-a608-49e5-a671-e64fa770a72b" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_e4f23ce9-c38c-4522-8aad-cc73540dd383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b920462b-4d35-41b9-a28e-35ee042c4a94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_432da0df-a608-49e5-a671-e64fa770a72b" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_b920462b-4d35-41b9-a28e-35ee042c4a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b01bbba0-6246-4a50-869f-90d65f283df3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByBalanceSheetGroupingTable_46d4e0ab-b43e-49b6-97a1-acbc7bbdd866" xlink:to="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b01bbba0-6246-4a50-869f-90d65f283df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8cfc22e0-7e78-4b5d-8c44-5f0180d19652" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b01bbba0-6246-4a50-869f-90d65f283df3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_8cfc22e0-7e78-4b5d-8c44-5f0180d19652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_5545b41b-3c29-4118-89a1-013408175104" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_b01bbba0-6246-4a50-869f-90d65f283df3" xlink:to="loc_us-gaap_DebtInstrumentFairValue_5545b41b-3c29-4118-89a1-013408175104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsScheduleofInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e9767f77-6e32-4d90-881a-18724b63f980" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5dd6e9cb-b679-470e-a823-82b702c9ce70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e9767f77-6e32-4d90-881a-18724b63f980" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5dd6e9cb-b679-470e-a823-82b702c9ce70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7aa141c9-b7ab-4f9f-b222-473cb10588fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5dd6e9cb-b679-470e-a823-82b702c9ce70" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7aa141c9-b7ab-4f9f-b222-473cb10588fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7aa141c9-b7ab-4f9f-b222-473cb10588fd" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_669ee2e8-cee2-434b-958d-920af289f853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_669ee2e8-cee2-434b-958d-920af289f853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_c404ae0f-1107-4ea2-bf61-cd8c5edcd519" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_c404ae0f-1107-4ea2-bf61-cd8c5edcd519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_69cfed87-65ba-4fcf-a856-f3187e217bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_69cfed87-65ba-4fcf-a856-f3187e217bbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_97777ce9-a615-436c-827a-961337e2523c" xlink:href="moh-20221231.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_moh_MunicipalSecuritiesMember_97777ce9-a615-436c-827a-961337e2523c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_ffb2836b-1332-449b-bccd-21f0dbe63eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_ffb2836b-1332-449b-bccd-21f0dbe63eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_302b7302-6958-4031-ad6d-2c91e4d53909" xlink:href="moh-20221231.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_8b3287b5-95a8-4a8d-b85a-68e659f9c444" xlink:to="loc_moh_OtherSecuritiesMember_302b7302-6958-4031-ad6d-2c91e4d53909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_5dd6e9cb-b679-470e-a823-82b702c9ce70" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_fbdea1ab-f5b4-4d7c-a917-e864543f2f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_fbdea1ab-f5b4-4d7c-a917-e864543f2f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f9d70d17-f3af-4d26-9873-39f01cee0326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f9d70d17-f3af-4d26-9873-39f01cee0326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b5aa6465-1749-4154-ab9f-6d88a5cae1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b5aa6465-1749-4154-ab9f-6d88a5cae1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_86194007-91ab-4a16-baab-f3d18865b73d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_9604ac35-bf41-4d61-bd8e-ae6f066758b9" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_86194007-91ab-4a16-baab-f3d18865b73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_afa09ff3-1f71-46b8-ac32-30f825e9d3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d6eba33d-cb10-4671-9ce2-f3210d3c8bcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_afa09ff3-1f71-46b8-ac32-30f825e9d3ef" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d6eba33d-cb10-4671-9ce2-f3210d3c8bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0dec8bde-74eb-41e8-83b9-3b7576b1f8c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d6eba33d-cb10-4671-9ce2-f3210d3c8bcf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_0dec8bde-74eb-41e8-83b9-3b7576b1f8c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_44eb55bd-6bd6-457a-8991-b59fee18c51d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d6eba33d-cb10-4671-9ce2-f3210d3c8bcf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_44eb55bd-6bd6-457a-8991-b59fee18c51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_56a9b1c4-6aba-4e3d-ae06-2e076ad439d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d6eba33d-cb10-4671-9ce2-f3210d3c8bcf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_56a9b1c4-6aba-4e3d-ae06-2e076ad439d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_f2a23449-4feb-4642-a9c8-44c4f8c427a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d6eba33d-cb10-4671-9ce2-f3210d3c8bcf" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost_f2a23449-4feb-4642-a9c8-44c4f8c427a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_9959ff88-06c3-4566-a7e4-13ae9ee4776a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_d6eba33d-cb10-4671-9ce2-f3210d3c8bcf" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss_9959ff88-06c3-4566-a7e4-13ae9ee4776a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_ea2e74d5-60ee-412f-8fb9-587d05e1d5f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_afa09ff3-1f71-46b8-ac32-30f825e9d3ef" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_ea2e74d5-60ee-412f-8fb9-587d05e1d5f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_504812f0-a1da-4940-97b2-d4a4646c6dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_ea2e74d5-60ee-412f-8fb9-587d05e1d5f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_504812f0-a1da-4940-97b2-d4a4646c6dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5b6ef564-9880-46aa-a889-edf02dc2343c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_ea2e74d5-60ee-412f-8fb9-587d05e1d5f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_5b6ef564-9880-46aa-a889-edf02dc2343c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_924587b4-6621-4282-bd99-5e340e23d97d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_ea2e74d5-60ee-412f-8fb9-587d05e1d5f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_924587b4-6621-4282-bd99-5e340e23d97d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_209bc046-2994-41ae-8c3b-7c77ea590171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_ea2e74d5-60ee-412f-8fb9-587d05e1d5f0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_209bc046-2994-41ae-8c3b-7c77ea590171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_eacf65b4-3412-4c35-a6db-ef6bc0f2bc3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_ea2e74d5-60ee-412f-8fb9-587d05e1d5f0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_eacf65b4-3412-4c35-a6db-ef6bc0f2bc3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_347999f8-6996-4079-9cd4-53535cfbcb0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_b473664c-3cd5-4b58-956c-44b1d7f1c9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_347999f8-6996-4079-9cd4-53535cfbcb0b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_b473664c-3cd5-4b58-956c-44b1d7f1c9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a69adf92-21f0-4833-9c01-538eafdc78ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_347999f8-6996-4079-9cd4-53535cfbcb0b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_a69adf92-21f0-4833-9c01-538eafdc78ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_4d5b0026-a292-4b42-a77e-dbfbf017f52b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_347999f8-6996-4079-9cd4-53535cfbcb0b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount_4d5b0026-a292-4b42-a77e-dbfbf017f52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_30d0404a-1e97-4eee-92d1-d90d818eea26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_347999f8-6996-4079-9cd4-53535cfbcb0b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount_30d0404a-1e97-4eee-92d1-d90d818eea26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount_75d24eb3-c27e-493b-84e3-7248e9b3c86d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_347999f8-6996-4079-9cd4-53535cfbcb0b" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount_75d24eb3-c27e-493b-84e3-7248e9b3c86d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsAvailableforSaleDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3229e01c-46b1-4c4b-86a0-0bc8c5b49aca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dcd9a2bc-8e70-48ad-9f24-59f366fc85d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3229e01c-46b1-4c4b-86a0-0bc8c5b49aca" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dcd9a2bc-8e70-48ad-9f24-59f366fc85d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_4f063582-2ad8-4ced-abc3-ad41cc24b221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dcd9a2bc-8e70-48ad-9f24-59f366fc85d7" xlink:to="loc_us-gaap_FinancialInstrumentAxis_4f063582-2ad8-4ced-abc3-ad41cc24b221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_4f063582-2ad8-4ced-abc3-ad41cc24b221" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_58819122-825d-41fc-9a65-0e26bb35779e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_58819122-825d-41fc-9a65-0e26bb35779e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MortgageBackedSecuritiesMember_fd76084f-223e-4740-a501-a953d590363f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MortgageBackedSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_us-gaap_MortgageBackedSecuritiesMember_fd76084f-223e-4740-a501-a953d590363f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_e5cf20cf-8391-4461-9ee9-9ec391e0fa82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_e5cf20cf-8391-4461-9ee9-9ec391e0fa82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MunicipalSecuritiesMember_27d441e7-ace8-429a-a682-ae3ee57c54e2" xlink:href="moh-20221231.xsd#moh_MunicipalSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_moh_MunicipalSecuritiesMember_27d441e7-ace8-429a-a682-ae3ee57c54e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_83254571-72d1-4e68-9194-d5abac5d667d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_83254571-72d1-4e68-9194-d5abac5d667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherSecuritiesMember_cc0665c5-57c6-4ec9-819a-2c19a91b0007" xlink:href="moh-20221231.xsd#moh_OtherSecuritiesMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80af369a-5926-48be-81ff-3d89cb45c244" xlink:to="loc_moh_OtherSecuritiesMember_cc0665c5-57c6-4ec9-819a-2c19a91b0007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_dcd9a2bc-8e70-48ad-9f24-59f366fc85d7" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ccd3b8dc-15d8-4523-ba1f-d43aebb0f416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_ccd3b8dc-15d8-4523-ba1f-d43aebb0f416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f3377ce-9a1b-45e8-b582-48433ae0c31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_2f3377ce-9a1b-45e8-b582-48433ae0c31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_cee802fc-5c39-41db-acf4-cad6e03e88d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions_cee802fc-5c39-41db-acf4-cad6e03e88d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bca367f4-e37d-4760-9172-5a1ef1eb204a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_bca367f4-e37d-4760-9172-5a1ef1eb204a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a9f1da7e-3a3e-4ede-8be6-8cd623b3bbcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_a9f1da7e-3a3e-4ede-8be6-8cd623b3bbcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3942fa46-ec64-45ba-b899-da5f023c5be4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_d4e03c87-df4c-4c16-99ee-1475b154db48" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions_3942fa46-ec64-45ba-b899-da5f023c5be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#InvestmentsBalancesofRestrictedInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7d556bc2-11a9-432e-afe3-dfba1e856188" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_71ac35da-549a-49e9-804d-20b801f62427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7d556bc2-11a9-432e-afe3-dfba1e856188" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_71ac35da-549a-49e9-804d-20b801f62427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_71ac35da-549a-49e9-804d-20b801f62427" xlink:to="loc_us-gaap_FinancialInstrumentAxis_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_35c4d69a-4c6a-412c-a8eb-2bb1852e0c07" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_dca42daa-22c5-474d-b134-12b0d28af913" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_dca42daa-22c5-474d-b134-12b0d28af913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryNotesSecuritiesMember_ac4a3da2-85ef-4452-8133-33238ca0c3b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryNotesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:to="loc_us-gaap_USTreasuryNotesSecuritiesMember_ac4a3da2-85ef-4452-8133-33238ca0c3b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_dee1946d-cf37-43f0-9d18-de84d43b76da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_a7b70d9a-0c9a-4fbf-85c5-a28d6fd5c928" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_dee1946d-cf37-43f0-9d18-de84d43b76da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_46530532-acab-4c8a-9b41-8cbfbc9076aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesTable_71ac35da-549a-49e9-804d-20b801f62427" xlink:to="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_46530532-acab-4c8a-9b41-8cbfbc9076aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedInvestmentsNoncurrent_d571384c-9318-43c5-bd11-8393473d5c97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedInvestmentsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems_46530532-acab-4c8a-9b41-8cbfbc9076aa" xlink:to="loc_us-gaap_RestrictedInvestmentsNoncurrent_d571384c-9318-43c5-bd11-8393473d5c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f6f39da2-0f40-4973-8223-8992625e123d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_f6f39da2-0f40-4973-8223-8992625e123d" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7942a08-3698-4ab9-9af6-2c8d11092053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7942a08-3698-4ab9-9af6-2c8d11092053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a7942a08-3698-4ab9-9af6-2c8d11092053" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PropertyAndEquipmentMember_ea164a78-dfe5-4583-a6d9-be0a5067539f" xlink:href="moh-20221231.xsd#moh_PropertyAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:to="loc_moh_PropertyAndEquipmentMember_ea164a78-dfe5-4583-a6d9-be0a5067539f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_d2ae6893-984f-4b2b-adb4-3ef1924c3a45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_d2ae6893-984f-4b2b-adb4-3ef1924c3a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_967adda4-8769-4d10-8cfa-917ea6b9a52c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_967adda4-8769-4d10-8cfa-917ea6b9a52c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_f0857e00-defd-45fa-9c7b-ec2e74e1a04f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b92b67fe-8aaa-49f6-bd4b-31c2464c13a6" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_f0857e00-defd-45fa-9c7b-ec2e74e1a04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fb573883-0830-42f4-9416-0d05597743e1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:to="loc_srt_RangeAxis_fb573883-0830-42f4-9416-0d05597743e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0ba3bb65-9eba-4003-a554-e913f7e5b7ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fb573883-0830-42f4-9416-0d05597743e1" xlink:to="loc_srt_RangeMember_0ba3bb65-9eba-4003-a554-e913f7e5b7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7fc4cd06-1af5-4a1f-9309-5e7b573f21c7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0ba3bb65-9eba-4003-a554-e913f7e5b7ca" xlink:to="loc_srt_MinimumMember_7fc4cd06-1af5-4a1f-9309-5e7b573f21c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_13da56fe-c7ec-4c54-ba6d-d14c329fdaaa" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_0ba3bb65-9eba-4003-a554-e913f7e5b7ca" xlink:to="loc_srt_MaximumMember_13da56fe-c7ec-4c54-ba6d-d14c329fdaaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca6734a1-32d0-40d8-991d-99dda006b929" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_02adc9ee-a959-44ca-ac11-b3d560b73902" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca6734a1-32d0-40d8-991d-99dda006b929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a66b78c9-e5f5-460e-8728-2eccbdd7576f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca6734a1-32d0-40d8-991d-99dda006b929" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_a66b78c9-e5f5-460e-8728-2eccbdd7576f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TangibleAssetImpairmentCharges_450cdd07-1f84-443b-9521-efd5aa1d8633" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TangibleAssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_ca6734a1-32d0-40d8-991d-99dda006b929" xlink:to="loc_us-gaap_TangibleAssetImpairmentCharges_450cdd07-1f84-443b-9521-efd5aa1d8633" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2daaf9a2-4842-4b73-9395-3ff4d8d5b3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_828886a4-853d-48de-ad47-000a7367e0ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2daaf9a2-4842-4b73-9395-3ff4d8d5b3fc" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_828886a4-853d-48de-ad47-000a7367e0ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acfd0e53-839e-438c-8714-baf4abc34454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_828886a4-853d-48de-ad47-000a7367e0ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acfd0e53-839e-438c-8714-baf4abc34454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_acfd0e53-839e-438c-8714-baf4abc34454" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e0969b86-3cf1-4719-8f26-c8983399e028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:to="loc_us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_e0969b86-3cf1-4719-8f26-c8983399e028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PropertyAndEquipmentMember_94bbce1d-53b6-4e77-bf96-9b2b30b134bb" xlink:href="moh-20221231.xsd#moh_PropertyAndEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:to="loc_moh_PropertyAndEquipmentMember_94bbce1d-53b6-4e77-bf96-9b2b30b134bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_4fa4bb6b-6acb-4ec4-9f50-ea5a3976c1f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_4fa4bb6b-6acb-4ec4-9f50-ea5a3976c1f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_231565e6-29c6-49dc-a43c-33d880337f54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6ff43d0f-b9eb-4974-ad4e-1ce76641bb28" xlink:to="loc_us-gaap_LandMember_231565e6-29c6-49dc-a43c-33d880337f54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_828886a4-853d-48de-ad47-000a7367e0ed" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_1b7d2b1e-a749-4496-b1bc-3f3f5a055806" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_1b7d2b1e-a749-4496-b1bc-3f3f5a055806" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_cc420174-6ec3-45e8-8626-371d77e29684" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization_cc420174-6ec3-45e8-8626-371d77e29684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_058f7512-9e70-44d6-84fd-be3efb1ab039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation_058f7512-9e70-44d6-84fd-be3efb1ab039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_febf85fb-93e2-44b5-a40a-b14402a27520" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_febf85fb-93e2-44b5-a40a-b14402a27520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_97dfc79a-2c0b-4762-a55d-79c14f36221c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_97dfc79a-2c0b-4762-a55d-79c14f36221c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5ac1dedc-106d-412a-863f-3575675b91b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_61cf5fe0-a5e7-432d-bbc6-e3c6cd5c18ec" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_5ac1dedc-106d-412a-863f-3575675b91b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2cac0bc5-b716-4717-a0c9-62e555097d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RecordedInDepreciationAndAmortizationAbstract_1e2407f9-c826-45af-beb1-73668aae95c7" xlink:href="moh-20221231.xsd#moh_RecordedInDepreciationAndAmortizationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2cac0bc5-b716-4717-a0c9-62e555097d5a" xlink:to="loc_moh_RecordedInDepreciationAndAmortizationAbstract_1e2407f9-c826-45af-beb1-73668aae95c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_41a1cae9-daba-4314-a28c-67d58a937d10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_RecordedInDepreciationAndAmortizationAbstract_1e2407f9-c826-45af-beb1-73668aae95c7" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_41a1cae9-daba-4314-a28c-67d58a937d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DepreciationAndAmortizationOfCapitalizedSoftware_018e5169-429f-43e9-a912-0cc30438a1e2" xlink:href="moh-20221231.xsd#moh_DepreciationAndAmortizationOfCapitalizedSoftware"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_RecordedInDepreciationAndAmortizationAbstract_1e2407f9-c826-45af-beb1-73668aae95c7" xlink:to="loc_moh_DepreciationAndAmortizationOfCapitalizedSoftware_018e5169-429f-43e9-a912-0cc30438a1e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e42c55b8-4376-4f07-8d21-c1e318bd931c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_RecordedInDepreciationAndAmortizationAbstract_1e2407f9-c826-45af-beb1-73668aae95c7" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_e42c55b8-4376-4f07-8d21-c1e318bd931c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_7fc45abc-ff1d-42a6-ba49-76a993d66925" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_RecordedInDepreciationAndAmortizationAbstract_1e2407f9-c826-45af-beb1-73668aae95c7" xlink:to="loc_us-gaap_Depreciation_7fc45abc-ff1d-42a6-ba49-76a993d66925" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DepreciationandAmortizationContinuingOperations_1453f5ef-65d4-4b8a-a95b-6c59e9d32b31" xlink:href="moh-20221231.xsd#moh_DepreciationandAmortizationContinuingOperations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_RecordedInDepreciationAndAmortizationAbstract_1e2407f9-c826-45af-beb1-73668aae95c7" xlink:to="loc_moh_DepreciationandAmortizationContinuingOperations_1453f5ef-65d4-4b8a-a95b-6c59e9d32b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_034279d4-772a-469c-b25c-add50c2b196f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_034279d4-772a-469c-b25c-add50c2b196f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ec10fb4e-59fa-44f0-b191-495b9401f072" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_ec10fb4e-59fa-44f0-b191-495b9401f072" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_412ab22b-133b-4e6d-9e9b-a99676fe3ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_412ab22b-133b-4e6d-9e9b-a99676fe3ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_065d4094-8dd8-44e8-9fa6-f7cbfce3917e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm_065d4094-8dd8-44e8-9fa6-f7cbfce3917e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_329838a0-fea9-4d20-bca7-5b1fa081644a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseRenewalTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_us-gaap_LesseeFinanceLeaseRenewalTerm1_329838a0-fea9-4d20-bca7-5b1fa081644a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_16bb1e79-23ee-4a03-a20b-f8e479f7b63f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1_16bb1e79-23ee-4a03-a20b-f8e479f7b63f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingAndFinanceLeaseImpairmentLoss_d1f57a21-47e2-4841-9c96-7d9b6113abad" xlink:href="moh-20221231.xsd#moh_OperatingAndFinanceLeaseImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_moh_OperatingAndFinanceLeaseImpairmentLoss_d1f57a21-47e2-4841-9c96-7d9b6113abad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637d1ed5-cbcb-446e-8f9b-2c4d0609ddd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_637d1ed5-cbcb-446e-8f9b-2c4d0609ddd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a8f6c1ec-a4b4-4834-bf17-09ce7343f8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3e4ed8d1-0479-40cb-a9d3-905401630628" xlink:to="loc_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent_a8f6c1ec-a4b4-4834-bf17-09ce7343f8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b445baf6-c32b-4af2-bef5-cbf1824fc7e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_24c77212-d22c-474f-b616-2691b5620be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b445baf6-c32b-4af2-bef5-cbf1824fc7e5" xlink:to="loc_us-gaap_OperatingLeaseCost_24c77212-d22c-474f-b616-2691b5620be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_c09329f7-b6ec-4557-9e9f-1a9878937390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b445baf6-c32b-4af2-bef5-cbf1824fc7e5" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_c09329f7-b6ec-4557-9e9f-1a9878937390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_96a7d9fb-24b6-45d7-86ea-5053790eabd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAssetAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_c09329f7-b6ec-4557-9e9f-1a9878937390" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAssetAmortization_96a7d9fb-24b6-45d7-86ea-5053790eabd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestExpense_a3957bbd-2447-4d5c-956c-b9e79c6a6f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_c09329f7-b6ec-4557-9e9f-1a9878937390" xlink:to="loc_us-gaap_FinanceLeaseInterestExpense_a3957bbd-2447-4d5c-956c-b9e79c6a6f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FinanceLeaseCost_47f716a3-c65d-49b3-95cf-9c073a1c94a0" xlink:href="moh-20221231.xsd#moh_FinanceLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_c09329f7-b6ec-4557-9e9f-1a9878937390" xlink:to="loc_moh_FinanceLeaseCost_47f716a3-c65d-49b3-95cf-9c073a1c94a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesSupplementalCashFlowDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d62163e3-077c-43ba-841b-b3adaf202ed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8b114de0-c448-4c21-b8df-fec469bfef9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d62163e3-077c-43ba-841b-b3adaf202ed4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8b114de0-c448-4c21-b8df-fec469bfef9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_da77b9ec-1a78-4b13-b5c2-838506eaf661" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8b114de0-c448-4c21-b8df-fec469bfef9d" xlink:to="loc_us-gaap_OperatingLeasePayments_da77b9ec-1a78-4b13-b5c2-838506eaf661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_1e4d3d57-640a-4183-9e11-e21e21c53f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseInterestPaymentOnLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_8b114de0-c448-4c21-b8df-fec469bfef9d" xlink:to="loc_us-gaap_FinanceLeaseInterestPaymentOnLiability_1e4d3d57-640a-4183-9e11-e21e21c53f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2396f58-33fc-4028-9120-89520a35938a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d62163e3-077c-43ba-841b-b3adaf202ed4" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2396f58-33fc-4028-9120-89520a35938a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_0f897aba-5e89-4545-80a7-6df6fcfc8ab6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c2396f58-33fc-4028-9120-89520a35938a" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_0f897aba-5e89-4545-80a7-6df6fcfc8ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract_5c29099b-8d5b-476c-93ff-3bed171cb98e" xlink:href="moh-20221231.xsd#moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d62163e3-077c-43ba-841b-b3adaf202ed4" xlink:to="loc_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract_5c29099b-8d5b-476c-93ff-3bed171cb98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c489d05e-eca0-405c-8919-fd0bed3da584" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract_5c29099b-8d5b-476c-93ff-3bed171cb98e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_c489d05e-eca0-405c-8919-fd0bed3da584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_18c3727a-7ae0-4778-8cdc-55fe09496a3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract_5c29099b-8d5b-476c-93ff-3bed171cb98e" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability_18c3727a-7ae0-4778-8cdc-55fe09496a3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_cfc602b9-0412-4e06-89a4-d19149892553" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_ac26de31-671d-43b9-b2ec-bf82cbe31510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseDescriptionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfc602b9-0412-4e06-89a4-d19149892553" xlink:to="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_ac26de31-671d-43b9-b2ec-bf82cbe31510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingLeaseAssetsLesseeAbstract_32822e0f-574d-45ce-be08-360b9788203b" xlink:href="moh-20221231.xsd#moh_OperatingLeaseAssetsLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_ac26de31-671d-43b9-b2ec-bf82cbe31510" xlink:to="loc_moh_OperatingLeaseAssetsLesseeAbstract_32822e0f-574d-45ce-be08-360b9788203b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired_f7f94f25-703b-4de3-b3d6-e065014055cf" xlink:href="moh-20221231.xsd#moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_OperatingLeaseAssetsLesseeAbstract_32822e0f-574d-45ce-be08-360b9788203b" xlink:to="loc_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired_f7f94f25-703b-4de3-b3d6-e065014055cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OperatingLeaseLiabilitiesLesseeAbstract_0d953631-b974-48db-98ea-d06fd9eba2e9" xlink:href="moh-20221231.xsd#moh_OperatingLeaseLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeOperatingLeaseDescriptionAbstract_ac26de31-671d-43b9-b2ec-bf82cbe31510" xlink:to="loc_moh_OperatingLeaseLiabilitiesLesseeAbstract_0d953631-b974-48db-98ea-d06fd9eba2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_fd2bb24b-2f6e-4895-841f-b7a2c14b798d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_OperatingLeaseLiabilitiesLesseeAbstract_0d953631-b974-48db-98ea-d06fd9eba2e9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_fd2bb24b-2f6e-4895-841f-b7a2c14b798d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_298cf943-d26c-4405-9c08-1f0a24506f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_OperatingLeaseLiabilitiesLesseeAbstract_0d953631-b974-48db-98ea-d06fd9eba2e9" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_298cf943-d26c-4405-9c08-1f0a24506f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_458d0d8f-0dd0-4e00-9e79-c9055f24dd35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_OperatingLeaseLiabilitiesLesseeAbstract_0d953631-b974-48db-98ea-d06fd9eba2e9" xlink:to="loc_us-gaap_OperatingLeaseLiability_458d0d8f-0dd0-4e00-9e79-c9055f24dd35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_15e06a89-03cf-40ec-9536-a78f87f7c9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeFinanceLeaseDescriptionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfc602b9-0412-4e06-89a4-d19149892553" xlink:to="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_15e06a89-03cf-40ec-9536-a78f87f7c9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FinanceLeaseAssetsLesseeAbstract_49b8f325-b9ff-424b-a694-361dd5ff960d" xlink:href="moh-20221231.xsd#moh_FinanceLeaseAssetsLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_15e06a89-03cf-40ec-9536-a78f87f7c9ef" xlink:to="loc_moh_FinanceLeaseAssetsLesseeAbstract_49b8f325-b9ff-424b-a694-361dd5ff960d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseRightOfUseAsset_f03bae9d-0bb9-4833-8b4f-fe46e31f0c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_FinanceLeaseAssetsLesseeAbstract_49b8f325-b9ff-424b-a694-361dd5ff960d" xlink:to="loc_us-gaap_FinanceLeaseRightOfUseAsset_f03bae9d-0bb9-4833-8b4f-fe46e31f0c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FinanceLeaseLiabilitiesLesseeAbstract_54e86057-939c-42fb-93a2-85620fd2c099" xlink:href="moh-20221231.xsd#moh_FinanceLeaseLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeFinanceLeaseDescriptionAbstract_15e06a89-03cf-40ec-9536-a78f87f7c9ef" xlink:to="loc_moh_FinanceLeaseLiabilitiesLesseeAbstract_54e86057-939c-42fb-93a2-85620fd2c099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_aac26d3b-5011-4d3f-986a-a1585cc3210d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_FinanceLeaseLiabilitiesLesseeAbstract_54e86057-939c-42fb-93a2-85620fd2c099" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_aac26d3b-5011-4d3f-986a-a1585cc3210d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ffab7820-b165-4746-b486-4e88e336fa1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_FinanceLeaseLiabilitiesLesseeAbstract_54e86057-939c-42fb-93a2-85620fd2c099" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_ffab7820-b165-4746-b486-4e88e336fa1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_6f8050d0-2787-474e-950d-b1888812d38a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_moh_FinanceLeaseLiabilitiesLesseeAbstract_54e86057-939c-42fb-93a2-85620fd2c099" xlink:to="loc_us-gaap_FinanceLeaseLiability_6f8050d0-2787-474e-950d-b1888812d38a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e0b36d0d-6fd4-4106-a2e8-e1cccf125a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfc602b9-0412-4e06-89a4-d19149892553" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_e0b36d0d-6fd4-4106-a2e8-e1cccf125a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_4cc308dd-6f6b-4269-b200-8ab50b55717b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfc602b9-0412-4e06-89a4-d19149892553" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_4cc308dd-6f6b-4269-b200-8ab50b55717b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_08beb07c-2ac8-4f58-9918-5060882a54c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfc602b9-0412-4e06-89a4-d19149892553" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_08beb07c-2ac8-4f58-9918-5060882a54c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_fedd133c-eb3a-40cf-bb6c-b407ef74bb01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_cfc602b9-0412-4e06-89a4-d19149892553" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_fedd133c-eb3a-40cf-bb6c-b407ef74bb01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesLeaseMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2892d60a-5c68-4de1-bfd3-30a219015c51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2892d60a-5c68-4de1-bfd3-30a219015c51" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ab33db64-e1fd-4a78-8deb-16b7bc22f6e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ab33db64-e1fd-4a78-8deb-16b7bc22f6e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a79e6a4e-12bf-49a8-8ab3-52c3a0a23b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_a79e6a4e-12bf-49a8-8ab3-52c3a0a23b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ecfe5728-a793-4faf-aefc-72f4bc12e937" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ecfe5728-a793-4faf-aefc-72f4bc12e937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d0b739e9-d97f-49d9-8afd-4b1df6d66a12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_d0b739e9-d97f-49d9-8afd-4b1df6d66a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_98c33b91-d0db-4bb0-abe6-53e92f1cc7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_98c33b91-d0db-4bb0-abe6-53e92f1cc7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c8813e6b-7f59-44b3-ac10-1cf7a2175807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c8813e6b-7f59-44b3-ac10-1cf7a2175807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b52fd443-bb8c-4b06-ba40-dc9dd234d113" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b52fd443-bb8c-4b06-ba40-dc9dd234d113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_39ae2d49-a988-44af-ad85-e0dd6fcebad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_39ae2d49-a988-44af-ad85-e0dd6fcebad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_fdaef0d3-33be-44b7-b2e7-e657f12721ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_5f9526e5-8890-4dd5-a4e8-85e0dda83ecf" xlink:to="loc_us-gaap_OperatingLeaseLiability_fdaef0d3-33be-44b7-b2e7-e657f12721ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2892d60a-5c68-4de1-bfd3-30a219015c51" xlink:to="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_92a8a932-9abb-47fb-ab22-db192c97471f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths_92a8a932-9abb-47fb-ab22-db192c97471f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cc814aca-fe9a-4287-ac09-06df34027fc2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo_cc814aca-fe9a-4287-ac09-06df34027fc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_69b32288-460b-4ce6-8342-5ebdbcb4f0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree_69b32288-460b-4ce6-8342-5ebdbcb4f0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_23dc4736-12d9-48bc-a168-768b389a01b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour_23dc4736-12d9-48bc-a168-768b389a01b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_40d261f1-8fdc-42e1-b5b7-5e7f81716e70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive_40d261f1-8fdc-42e1-b5b7-5e7f81716e70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_e61e4d11-95f3-499f-9370-a47bb7a640c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive_e61e4d11-95f3-499f-9370-a47bb7a640c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_77695095-3c01-4065-8d3c-662b90b08694" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiabilityPaymentsDue_77695095-3c01-4065-8d3c-662b90b08694" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_0f72d415-87dc-40b6-82ec-910abc2d6b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount_0f72d415-87dc-40b6-82ec-910abc2d6b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiability_1dc6461c-7d37-4bb6-8759-9e7b4fe96edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract_f49144ec-7c0c-40ee-8718-c6519cf4b235" xlink:to="loc_us-gaap_FinanceLeaseLiability_1dc6461c-7d37-4bb6-8759-9e7b4fe96edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1" xlink:type="simple" xlink:href="moh-20221231.xsd#LeasesLeaseMaturitiesDetails_1"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ab346339-54dc-4f43-8247-05db796edaf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_390ad8b5-510b-47d9-ac7f-226f9658091c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ab346339-54dc-4f43-8247-05db796edaf4" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_390ad8b5-510b-47d9-ac7f-226f9658091c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_15035e97-536d-474b-b6cc-86ef9ae2ec81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_390ad8b5-510b-47d9-ac7f-226f9658091c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_15035e97-536d-474b-b6cc-86ef9ae2ec81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_15035e97-536d-474b-b6cc-86ef9ae2ec81" xlink:to="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_618d9607-3d18-4f3e-b2f8-6814c8429b33" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:to="loc_moh_MedicaidMember_618d9607-3d18-4f3e-b2f8-6814c8429b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_3ae84e3a-b2a3-48d4-9d2c-6b832f7fba2b" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:to="loc_moh_MedicareMember_3ae84e3a-b2a3-48d4-9d2c-6b832f7fba2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_63ea76a6-cd72-46c7-98a4-ade47526c0b0" xlink:href="moh-20221231.xsd#moh_OtherProgramMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_fce87fb9-a153-430f-b273-32c202068518" xlink:to="loc_moh_OtherProgramMember_63ea76a6-cd72-46c7-98a4-ade47526c0b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_1b4424a5-679d-4337-b5ab-87b80b3dbe1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_390ad8b5-510b-47d9-ac7f-226f9658091c" xlink:to="loc_us-gaap_GoodwillLineItems_1b4424a5-679d-4337-b5ab-87b80b3dbe1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1b4424a5-679d-4337-b5ab-87b80b3dbe1c" xlink:to="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_4476ca4f-c2df-490c-8a19-f36a15e5466c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:to="loc_us-gaap_Goodwill_4476ca4f-c2df-490c-8a19-f36a15e5466c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_45c7a035-edfe-4900-b54a-0e72a0de7941" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_45c7a035-edfe-4900-b54a-0e72a0de7941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_25d67f7a-4024-44c7-857a-8356215979f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_49287524-4589-4952-85df-b82dcefe54bf" xlink:to="loc_us-gaap_Goodwill_25d67f7a-4024-44c7-857a-8356215979f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8806d8d2-92c8-459e-a6c3-d3984fd02b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08ffff62-990e-4c93-a765-50af93ecd3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_8806d8d2-92c8-459e-a6c3-d3984fd02b44" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08ffff62-990e-4c93-a765-50af93ecd3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_423668de-bbeb-40a2-b255-ee8e21828158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08ffff62-990e-4c93-a765-50af93ecd3d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_423668de-bbeb-40a2-b255-ee8e21828158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_423668de-bbeb-40a2-b255-ee8e21828158" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ContractRightsandLicensingAgreementsMember_3f8179da-e472-4756-9c6b-b8bb2c4d3426" xlink:href="moh-20221231.xsd#moh_ContractRightsandLicensingAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:to="loc_moh_ContractRightsandLicensingAgreementsMember_3f8179da-e472-4756-9c6b-b8bb2c4d3426" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ProviderNetworksMember_476b1be7-7452-44aa-8e80-6f8ffd866a72" xlink:href="moh-20221231.xsd#moh_ProviderNetworksMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:to="loc_moh_ProviderNetworksMember_476b1be7-7452-44aa-8e80-6f8ffd866a72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TradeNamesMember_bc4d4d4e-c9e3-473e-89ef-a881eccfae30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_aebb1eee-39b9-4bd0-bea9-38480fc478bc" xlink:to="loc_us-gaap_TradeNamesMember_bc4d4d4e-c9e3-473e-89ef-a881eccfae30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_08ffff62-990e-4c93-a765-50af93ecd3d3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_617602c1-9285-42cb-b78c-c0fc8702cef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_617602c1-9285-42cb-b78c-c0fc8702cef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_342069c6-9ced-4e3b-9df7-9839c4bbe3af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_342069c6-9ced-4e3b-9df7-9839c4bbe3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7b899019-5f60-4e65-931a-ae5d450a0cec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c9411bb8-98a3-4f67-bad0-1d9105756c60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7b899019-5f60-4e65-931a-ae5d450a0cec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#GoodwillandIntangibleAssetsNetAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ae1c15c-6adf-4b6e-b3ee-0bc392009955" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3f4b8174-17c5-44f3-8d82-0540e0c1cdc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ae1c15c-6adf-4b6e-b3ee-0bc392009955" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_3f4b8174-17c5-44f3-8d82-0540e0c1cdc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c1b5a546-0f20-429b-97a5-759625f16f90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ae1c15c-6adf-4b6e-b3ee-0bc392009955" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_c1b5a546-0f20-429b-97a5-759625f16f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d677b3b7-33aa-46be-ac6c-f07e24f40498" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ae1c15c-6adf-4b6e-b3ee-0bc392009955" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_d677b3b7-33aa-46be-ac6c-f07e24f40498" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_98696adf-f84e-4d67-bb7c-b03bb74ae31f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ae1c15c-6adf-4b6e-b3ee-0bc392009955" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_98696adf-f84e-4d67-bb7c-b03bb74ae31f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_22df6ec0-95b2-47ee-bf2a-f25f7bf3f253" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1ae1c15c-6adf-4b6e-b3ee-0bc392009955" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_22df6ec0-95b2-47ee-bf2a-f25f7bf3f253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_996fb01c-df9e-4fc1-a257-2cda2d38e7c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_6265f526-a859-4c52-acc1-754fb668872f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_996fb01c-df9e-4fc1-a257-2cda2d38e7c7" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_6265f526-a859-4c52-acc1-754fb668872f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_479d4a36-fe5d-41cf-a90d-10ec861e9de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_6265f526-a859-4c52-acc1-754fb668872f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_479d4a36-fe5d-41cf-a90d-10ec861e9de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5096d3f-4ef7-4139-a769-23fc2eea68ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_479d4a36-fe5d-41cf-a90d-10ec861e9de0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5096d3f-4ef7-4139-a769-23fc2eea68ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CompleteCareMember_bed04d74-6123-43d8-9ee5-abf1f26bc3bd" xlink:href="moh-20221231.xsd#moh_CompleteCareMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e5096d3f-4ef7-4139-a769-23fc2eea68ef" xlink:to="loc_moh_CompleteCareMember_bed04d74-6123-43d8-9ee5-abf1f26bc3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable_6265f526-a859-4c52-acc1-754fb668872f" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_f9bed94a-9398-469e-962a-9f42e950d86f" xlink:href="moh-20221231.xsd#moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount_f9bed94a-9398-469e-962a-9f42e950d86f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_PharmacyClaimsPayable_d7818148-5642-4a4c-86a4-ea953b2157c4" xlink:href="moh-20221231.xsd#moh_PharmacyClaimsPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_moh_PharmacyClaimsPayable_d7818148-5642-4a4c-86a4-ea953b2157c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CapitationClaimsPayable_53e0fd00-ce19-462f-94c0-acf5a28d71c5" xlink:href="moh-20221231.xsd#moh_CapitationClaimsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_moh_CapitationClaimsPayable_53e0fd00-ce19-462f-94c0-acf5a28d71c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherClaimsPayable_5dd0ab0d-9b60-4d15-94b9-dae92d94a245" xlink:href="moh-20221231.xsd#moh_OtherClaimsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_moh_OtherClaimsPayable_5dd0ab0d-9b60-4d15-94b9-dae92d94a245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9eaa8352-042b-46da-ac08-e78ce9d655fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems_ebf8b1c8-8e2d-4ecf-aeb9-d80c446a4c9d" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9eaa8352-042b-46da-ac08-e78ce9d655fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_a24b1cab-e91d-4b54-b7db-822ea3a9923c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayable_686980f0-61b3-4a91-9bca-11fdbc439887" xlink:href="moh-20221231.xsd#moh_MedicalClaimsAndBenefitsPayable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_a24b1cab-e91d-4b54-b7db-822ea3a9923c" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayable_686980f0-61b3-4a91-9bca-11fdbc439887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_9efe80d1-79e5-4d5d-9cf8-997d22fe7305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_a24b1cab-e91d-4b54-b7db-822ea3a9923c" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_9efe80d1-79e5-4d5d-9cf8-997d22fe7305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_257a6a29-03df-4325-8971-ea1a7741724a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_46cc5bf2-6eed-4753-af76-dd2c63916c66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_257a6a29-03df-4325-8971-ea1a7741724a" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_46cc5bf2-6eed-4753-af76-dd2c63916c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f97f4691-8bc4-41d0-a5df-ac2b794b0981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_46cc5bf2-6eed-4753-af76-dd2c63916c66" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f97f4691-8bc4-41d0-a5df-ac2b794b0981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f97f4691-8bc4-41d0-a5df-ac2b794b0981" xlink:to="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_8b0956c5-f710-4bf2-9d1a-c4967450943d" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:to="loc_moh_MedicaidMember_8b0956c5-f710-4bf2-9d1a-c4967450943d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_b36d788c-dda0-4a78-bd9f-71e2ece439a1" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:to="loc_moh_MedicareMember_b36d788c-dda0-4a78-bd9f-71e2ece439a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_6935db7c-fef8-4c3a-9aba-01cb0334f6fb" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_66779e84-c335-427b-ab54-89f89ecbb34a" xlink:to="loc_moh_MarketplaceMember_6935db7c-fef8-4c3a-9aba-01cb0334f6fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_647dcd7c-7d30-4b16-8ce0-e56e1c3756fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_46cc5bf2-6eed-4753-af76-dd2c63916c66" xlink:to="loc_us-gaap_ProductInformationLineItems_647dcd7c-7d30-4b16-8ce0-e56e1c3756fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_647dcd7c-7d30-4b16-8ce0-e56e1c3756fa" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bc8d60ae-75cb-4e83-bd4e-fd3488b5352f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_bc8d60ae-75cb-4e83-bd4e-fd3488b5352f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_b70eccd7-bd11-40c6-96cd-2498dd9b0756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense_b70eccd7-bd11-40c6-96cd-2498dd9b0756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_49d358b9-6840-441c-8d02-ff81fc70e22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:to="loc_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense_49d358b9-6840-441c-8d02-ff81fc70e22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_60661b7c-c1e0-43b1-b41d-e1141aa46e56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract_197baf52-9032-4e74-b407-54e0c00f32ea" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_60661b7c-c1e0-43b1-b41d-e1141aa46e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0b35c9ef-28e7-4bdf-8c03-64d37fafb674" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1_0b35c9ef-28e7-4bdf-8c03-64d37fafb674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_12ad8087-a94f-4929-9399-ae4dd56e6107" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1_12ad8087-a94f-4929-9399-ae4dd56e6107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_9483be90-1194-4d6d-a755-00ae324a04aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLossesAndLossAdjustmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract_13bbf3b2-c03c-43b3-b531-b2dc6795dc82" xlink:to="loc_us-gaap_PaymentsForLossesAndLossAdjustmentExpense_9483be90-1194-4d6d-a755-00ae324a04aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_387c0f54-8e88-45c3-9fc9-6a9fb88b2e88" xlink:href="moh-20221231.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments_387c0f54-8e88-45c3-9fc9-6a9fb88b2e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_a2077db1-6084-4ec1-9f6a-1f4e8036d8eb" xlink:href="moh-20221231.xsd#moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider_a2077db1-6084-4ec1-9f6a-1f4e8036d8eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9b22442e-4331-4195-81f2-1b12dc566785" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract_ca668002-e1d8-40fb-af8e-b3377e9ba2b3" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_9b22442e-4331-4195-81f2-1b12dc566785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_97241178-c881-4360-af9c-162687d2dd38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_e0929860-2f14-4953-a59c-eb21b2ac09f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_97241178-c881-4360-af9c-162687d2dd38" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_e0929860-2f14-4953-a59c-eb21b2ac09f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_e0929860-2f14-4953-a59c-eb21b2ac09f1" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_0a3f41f1-904b-4b99-9d4a-f2fbdd85e54c" xlink:to="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_6be29dc5-377f-4b6f-ae0b-39f975ecb92b" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:to="loc_moh_MedicaidMember_6be29dc5-377f-4b6f-ae0b-39f975ecb92b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_ccbb1002-112c-4ab9-9e46-e797f60a9278" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:to="loc_moh_MedicareMember_ccbb1002-112c-4ab9-9e46-e797f60a9278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_1a4da684-6a78-4e28-8855-3e77674f3e08" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_391b44e2-9776-46ae-92d1-9fef7a97784b" xlink:to="loc_moh_MarketplaceMember_1a4da684-6a78-4e28-8855-3e77674f3e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_d735514c-3c52-4edd-b296-9abbc0998c26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_e0929860-2f14-4953-a59c-eb21b2ac09f1" xlink:to="loc_us-gaap_ProductInformationLineItems_d735514c-3c52-4edd-b296-9abbc0998c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_cbb478b5-21b6-4d6f-b359-b596c8f8a88c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_d735514c-3c52-4edd-b296-9abbc0998c26" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_cbb478b5-21b6-4d6f-b359-b596c8f8a88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_af90fad1-d242-4a99-8ff4-f5f1c078e8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_27247a47-f517-4656-9120-2f2f76f9490b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_af90fad1-d242-4a99-8ff4-f5f1c078e8c2" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_27247a47-f517-4656-9120-2f2f76f9490b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_ba9089a3-edc3-4c6e-a5e9-24e859d9e735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_27247a47-f517-4656-9120-2f2f76f9490b" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_ba9089a3-edc3-4c6e-a5e9-24e859d9e735" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_ba9089a3-edc3-4c6e-a5e9-24e859d9e735" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_4bc1d4ae-0e4f-4bc5-9ef8-dfaea7701d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_4bc1d4ae-0e4f-4bc5-9ef8-dfaea7701d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_7f58a152-48a9-434a-a6fc-0ba34407def6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_7f58a152-48a9-434a-a6fc-0ba34407def6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_f2520cac-2c1b-4e91-954d-a789fba751d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_3e96b379-0c62-4022-b434-034ebd095e87" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_f2520cac-2c1b-4e91-954d-a789fba751d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_27247a47-f517-4656-9120-2f2f76f9490b" xlink:to="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_962b9c90-a7b5-44d0-a73f-d9ebcf6a1fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1_962b9c90-a7b5-44d0-a73f-d9ebcf6a1fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment_67dbae9b-a39a-451a-9391-5753ad0fdb99" xlink:href="moh-20221231.xsd#moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment_67dbae9b-a39a-451a-9391-5753ad0fdb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_c10ade16-88f7-4807-a088-1a6a54f6f83a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount_c10ade16-88f7-4807-a088-1a6a54f6f83a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_6571ea63-754e-480b-8cb1-b10eeafe8ce5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_f82c5ddc-39bd-47b5-bead-16fcecce8de8" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims_6571ea63-754e-480b-8cb1-b10eeafe8ce5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_3695e475-2014-4765-862d-50e427c7bcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfProductInformationTable_21723bf1-5022-41ea-b3f9-2fa11abfbe4b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfProductInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_3695e475-2014-4765-862d-50e427c7bcc0" xlink:to="loc_us-gaap_ScheduleOfProductInformationTable_21723bf1-5022-41ea-b3f9-2fa11abfbe4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_21723bf1-5022-41ea-b3f9-2fa11abfbe4b" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsAccidentYearDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis_f5f01c98-09c3-46af-94c6-d22ecfbd0dbb" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_2bfb38e3-dac0-4e9a-b858-ae2fec565c48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2020Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2020Member_2bfb38e3-dac0-4e9a-b858-ae2fec565c48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_ddaf99cd-c6da-4673-b45b-8b9fc2f492fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2021Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2021Member_ddaf99cd-c6da-4673-b45b-8b9fc2f492fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_cc52e845-d4ac-462c-9f43-169e771bbae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortDurationInsuranceContractAccidentYear2022Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortdurationInsuranceContractsAccidentYearDomain_a22bec75-467a-4e4f-b432-6059242bdddc" xlink:to="loc_us-gaap_ShortDurationInsuranceContractAccidentYear2022Member_cc52e845-d4ac-462c-9f43-169e771bbae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductInformationLineItems_ad390960-fec9-4ced-a547-8df477f09d29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfProductInformationTable_21723bf1-5022-41ea-b3f9-2fa11abfbe4b" xlink:to="loc_us-gaap_ProductInformationLineItems_ad390960-fec9-4ced-a547-8df477f09d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e1e2f959-33c6-4bb8-ac8c-4b23758d4a22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductInformationLineItems_ad390960-fec9-4ced-a547-8df477f09d29" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_e1e2f959-33c6-4bb8-ac8c-4b23758d4a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAbstract_fa1184f5-76f1-4666-b928-a16421488dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_ebc0dda5-c093-456c-889e-2d5190147e40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_fa1184f5-76f1-4666-b928-a16421488dcc" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet_ebc0dda5-c093-456c-889e-2d5190147e40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_3420b4e4-d58e-4d81-93bc-a06db7d07112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_fa1184f5-76f1-4666-b928-a16421488dcc" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet_3420b4e4-d58e-4d81-93bc-a06db7d07112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears_dca539b0-2a41-4689-9f63-8237c16b14a1" xlink:href="moh-20221231.xsd#moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_fa1184f5-76f1-4666-b928-a16421488dcc" xlink:to="loc_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears_dca539b0-2a41-4689-9f63-8237c16b14a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems_e2138e06-bdd2-434b-a662-a767df40f8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_fa1184f5-76f1-4666-b928-a16421488dcc" xlink:to="loc_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems_e2138e06-bdd2-434b-a662-a767df40f8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7d2aa38c-e54e-4a83-b55b-c49cec2e4320" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InsuranceAbstract_fa1184f5-76f1-4666-b928-a16421488dcc" xlink:to="loc_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense_7d2aa38c-e54e-4a83-b55b-c49cec2e4320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtMaturitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f9382a8f-62bb-4f3f-8743-ba81f602624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f9382a8f-62bb-4f3f-8743-ba81f602624b" xlink:to="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_28937912-f686-4539-a37d-1c6ace176ec0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_28937912-f686-4539-a37d-1c6ace176ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2f2baa53-6a30-4bc0-992a-81391bf05566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_28937912-f686-4539-a37d-1c6ace176ec0" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2f2baa53-6a30-4bc0-992a-81391bf05566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_21395a13-66ae-4d04-82f9-3fdb93aa590e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2f2baa53-6a30-4bc0-992a-81391bf05566" xlink:to="loc_us-gaap_SeniorNotesMember_21395a13-66ae-4d04-82f9-3fdb93aa590e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7351ab86-438b-4a28-84f7-61c7c7b3051e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:to="loc_us-gaap_DebtInstrumentAxis_7351ab86-438b-4a28-84f7-61c7c7b3051e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7351ab86-438b-4a28-84f7-61c7c7b3051e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_c758cb09-6e70-44f6-91d0-4559992d3d80" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:to="loc_moh_A4375SeniorNotesMember_c758cb09-6e70-44f6-91d0-4559992d3d80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e529111e-5459-433d-88e1-b7365d82801b" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e529111e-5459-433d-88e1-b7365d82801b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_d2e57057-d2ee-4707-bf74-e87dd90efc3d" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_74e50c22-c61c-4583-a9c6-93773ecf58e3" xlink:to="loc_moh_A3875SeniorNotesMember_d2e57057-d2ee-4707-bf74-e87dd90efc3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_5997e9ff-6b3c-4623-a2e2-ce74501d292b" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e964848-b3e4-4eec-8497-0a4c87a29e45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_5e964848-b3e4-4eec-8497-0a4c87a29e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_01153644-5171-4754-bc90-584724170311" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_01153644-5171-4754-bc90-584724170311" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_89d289f9-6d13-400d-af4e-4360c529d4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_89d289f9-6d13-400d-af4e-4360c529d4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_47b2f57b-231f-42d5-ae35-2955f2325b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_47b2f57b-231f-42d5-ae35-2955f2325b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ba499caa-ed46-4a3f-b9e9-dc8204dbc035" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_ba499caa-ed46-4a3f-b9e9-dc8204dbc035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e2bd08a7-5654-4786-a65d-1e636fe1bc52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_e2bd08a7-5654-4786-a65d-1e636fe1bc52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2a787a31-e690-447b-aa6f-206159b12249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_2a787a31-e690-447b-aa6f-206159b12249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7cad52cc-db17-4f21-a66d-d4fe95078096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e08fb501-33aa-44cd-bb2c-49c5486eeb1f" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_7cad52cc-db17-4f21-a66d-d4fe95078096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1438a932-4eff-43f0-a998-f1c40a6bc82e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1438a932-4eff-43f0-a998-f1c40a6bc82e" xlink:to="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_533e2b78-8a2e-478b-a26b-71133a028e22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_533e2b78-8a2e-478b-a26b-71133a028e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5b37858c-e5ce-42eb-8f54-0a252afc7c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_533e2b78-8a2e-478b-a26b-71133a028e22" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5b37858c-e5ce-42eb-8f54-0a252afc7c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1a7b80ab-0ce2-44c8-a88b-7864a0588013" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_5b37858c-e5ce-42eb-8f54-0a252afc7c33" xlink:to="loc_us-gaap_SeniorNotesMember_1a7b80ab-0ce2-44c8-a88b-7864a0588013" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_9357f18e-cc82-4e4f-8613-5250cf37cf0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:to="loc_us-gaap_DebtInstrumentAxis_9357f18e-cc82-4e4f-8613-5250cf37cf0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9357f18e-cc82-4e4f-8613-5250cf37cf0b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_12651c16-b73f-4007-84d9-d140c3da8c58" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:to="loc_moh_A4375SeniorNotesMember_12651c16-b73f-4007-84d9-d140c3da8c58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e7ddc461-deca-4902-a997-e341250ead1b" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_e7ddc461-deca-4902-a997-e341250ead1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_a9bdb99c-6cf0-45b5-aa0e-267f063bc4d6" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_736ccc8c-5288-49b7-aa78-3de33a87d54d" xlink:to="loc_moh_A3875SeniorNotesMember_a9bdb99c-6cf0-45b5-aa0e-267f063bc4d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3b5d903c-4fd5-433f-a459-1d15bfe6214d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36bc1fd9-a577-4aaf-93c2-80469372abcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_36bc1fd9-a577-4aaf-93c2-80469372abcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_86fb6daf-f9e3-45c9-b2af-2d060c71c967" xlink:href="moh-20221231.xsd#moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount_86fb6daf-f9e3-45c9-b2af-2d060c71c967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_0ba03ed2-2b49-4693-9d0f-3a1ea07450d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_0ba03ed2-2b49-4693-9d0f-3a1ea07450d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_73eacb91-80ee-4a05-abfb-6ab364b4c167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a1346900-933f-4d57-ac67-d393da73852a" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_73eacb91-80ee-4a05-abfb-6ab364b4c167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtCreditAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtCreditAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dd130acd-1cee-4d5e-9438-0c84ab42e63b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dd130acd-1cee-4d5e-9438-0c84ab42e63b" xlink:to="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_7abcbdee-5738-4354-96aa-9f6c9ceff7f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_7abcbdee-5738-4354-96aa-9f6c9ceff7f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_358a24c7-d6f3-4de5-995a-a4bca6ec6f27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_7abcbdee-5738-4354-96aa-9f6c9ceff7f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_358a24c7-d6f3-4de5-995a-a4bca6ec6f27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_cf18a401-3f90-4080-9403-c81523218686" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_358a24c7-d6f3-4de5-995a-a4bca6ec6f27" xlink:to="loc_us-gaap_LineOfCreditMember_cf18a401-3f90-4080-9403-c81523218686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:to="loc_us-gaap_CreditFacilityAxis_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e6ffe991-195b-4730-9c87-581484410269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_a71ce070-8fb0-4078-a52e-8ea1d9e46f2d" xlink:to="loc_us-gaap_CreditFacilityDomain_e6ffe991-195b-4730-9c87-581484410269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_239c6bd5-20c9-4ff6-bd0c-1e23e2a38bae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e6ffe991-195b-4730-9c87-581484410269" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_239c6bd5-20c9-4ff6-bd0c-1e23e2a38bae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityTable_5167db9c-ed54-4ca0-b60e-fbb3a0eaea50" xlink:to="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3ef1e451-dc0f-4b01-88b4-97fcf52bbade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_3ef1e451-dc0f-4b01-88b4-97fcf52bbade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_df4c49f0-0af6-429c-982a-f9d81ab16be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:to="loc_us-gaap_DebtInstrumentTerm_df4c49f0-0af6-429c-982a-f9d81ab16be1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCredit_fb3f0cee-e456-44c5-989e-3a98ab353b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCredit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LineOfCreditFacilityLineItems_26b7bfe7-955c-4c2f-b66c-26b56805b0a5" xlink:to="loc_us-gaap_LineOfCredit_fb3f0cee-e456-44c5-989e-3a98ab353b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/DebtSeniorNotesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#DebtSeniorNotesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/DebtSeniorNotesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e432556e-704c-4a0e-aea8-24c950993af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e432556e-704c-4a0e-aea8-24c950993af8" xlink:to="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_50ea58a7-f420-4c4b-8557-761ff2ff89a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_50ea58a7-f420-4c4b-8557-761ff2ff89a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3cf24f72-2cd2-4c90-9099-636237da6fa8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_50ea58a7-f420-4c4b-8557-761ff2ff89a1" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3cf24f72-2cd2-4c90-9099-636237da6fa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_b3455055-098e-4161-aa52-5b646f6e93db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3cf24f72-2cd2-4c90-9099-636237da6fa8" xlink:to="loc_us-gaap_SeniorNotesMember_b3455055-098e-4161-aa52-5b646f6e93db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b0dc5d7c-4166-4f24-8576-2d2c53c04df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:to="loc_us-gaap_DebtInstrumentAxis_b0dc5d7c-4166-4f24-8576-2d2c53c04df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b0dc5d7c-4166-4f24-8576-2d2c53c04df0" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A4375SeniorNotesMember_072fc66e-a312-4695-950e-534a8efe66c9" xlink:href="moh-20221231.xsd#moh_A4375SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:to="loc_moh_A4375SeniorNotesMember_072fc66e-a312-4695-950e-534a8efe66c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_92eaadda-9316-4ba2-9e14-228905587c8b" xlink:href="moh-20221231.xsd#moh_ThreePointEightSevenFivePercentSeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:to="loc_moh_ThreePointEightSevenFivePercentSeniorNotesMember_92eaadda-9316-4ba2-9e14-228905587c8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_A3875SeniorNotesMember_3597229f-dc38-434f-875d-6b9b851bec41" xlink:href="moh-20221231.xsd#moh_A3875SeniorNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_28c266d1-e3e3-4ad1-b7db-2c1f51d696c1" xlink:to="loc_moh_A3875SeniorNotesMember_3597229f-dc38-434f-875d-6b9b851bec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_887878cc-9314-46f8-a687-2f91e22e0e23" xlink:to="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f9edf746-afe9-4387-a360-830949765d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_f9edf746-afe9-4387-a360-830949765d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_c3a52dfa-c13c-4836-9588-b74e2e501411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_c3a52dfa-c13c-4836-9588-b74e2e501411" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_c5acc054-6f28-4b4c-b495-6084baaf3326" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_26269309-0a8e-428e-bd70-0fb16940c5ac" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_c5acc054-6f28-4b4c-b495-6084baaf3326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9a37b88a-3037-486d-b030-d5a7d96417a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ff161b9f-2e98-4d11-889d-93b5cea3d19b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9a37b88a-3037-486d-b030-d5a7d96417a3" xlink:to="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ff161b9f-2e98-4d11-889d-93b5cea3d19b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_185aee6b-ed17-40de-851f-8521ae662c8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ff161b9f-2e98-4d11-889d-93b5cea3d19b" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_185aee6b-ed17-40de-851f-8521ae662c8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_910b248f-bc21-485b-813a-f42735077c34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_185aee6b-ed17-40de-851f-8521ae662c8d" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_910b248f-bc21-485b-813a-f42735077c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9d8db45c-1d7d-44e4-afa5-10fad5094ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_185aee6b-ed17-40de-851f-8521ae662c8d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_9d8db45c-1d7d-44e4-afa5-10fad5094ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2829a04-4dc1-4efa-9162-6cf343700102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_185aee6b-ed17-40de-851f-8521ae662c8d" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c2829a04-4dc1-4efa-9162-6cf343700102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_61392a2d-bf87-46ff-bfaa-c70e30cd604a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ff161b9f-2e98-4d11-889d-93b5cea3d19b" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_61392a2d-bf87-46ff-bfaa-c70e30cd604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ef483b51-99c8-40b5-8e6d-b812002ca269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_61392a2d-bf87-46ff-bfaa-c70e30cd604a" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_ef483b51-99c8-40b5-8e6d-b812002ca269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8a4198e5-a516-43c3-8771-a6cfaa167ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_61392a2d-bf87-46ff-bfaa-c70e30cd604a" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_8a4198e5-a516-43c3-8771-a6cfaa167ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f6e58ca4-6d63-4f46-9fb4-d9792cfebc83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_61392a2d-bf87-46ff-bfaa-c70e30cd604a" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f6e58ca4-6d63-4f46-9fb4-d9792cfebc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f605f078-b827-42ad-9798-0f5fef24f449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_61392a2d-bf87-46ff-bfaa-c70e30cd604a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_f605f078-b827-42ad-9798-0f5fef24f449" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_513c7bdb-9e01-4d60-a2f8-cb2baf825168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract_ff161b9f-2e98-4d11-889d-93b5cea3d19b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_513c7bdb-9e01-4d60-a2f8-cb2baf825168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d652e11e-5c6d-449a-ac3e-90d5dd7a7812" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_32204c03-31ee-4da3-9a80-597f16045cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d652e11e-5c6d-449a-ac3e-90d5dd7a7812" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_32204c03-31ee-4da3-9a80-597f16045cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4ca46b8b-8a6a-4717-99d6-bec4a5c84a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d652e11e-5c6d-449a-ac3e-90d5dd7a7812" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_4ca46b8b-8a6a-4717-99d6-bec4a5c84a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent_460c9205-5d08-4ed3-baf9-7b57150da0dd" xlink:href="moh-20221231.xsd#moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d652e11e-5c6d-449a-ac3e-90d5dd7a7812" xlink:to="loc_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent_460c9205-5d08-4ed3-baf9-7b57150da0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_cd6cae7e-8a13-4ddd-9e64-ef0f8ac2df5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d652e11e-5c6d-449a-ac3e-90d5dd7a7812" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_cd6cae7e-8a13-4ddd-9e64-ef0f8ac2df5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1b8fec3c-9ed4-4b2a-943a-b4f5137404c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d652e11e-5c6d-449a-ac3e-90d5dd7a7812" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_1b8fec3c-9ed4-4b2a-943a-b4f5137404c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b1b3aa1c-68bd-4066-9aa4-b3ff865dfa5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d652e11e-5c6d-449a-ac3e-90d5dd7a7812" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_b1b3aa1c-68bd-4066-9aa4-b3ff865dfa5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_33993efc-11dd-470a-bdf2-530420b6d9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_33993efc-11dd-470a-bdf2-530420b6d9ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d3d1e150-b6e1-40a7-a64d-7e52af829840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_d3d1e150-b6e1-40a7-a64d-7e52af829840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0a54b6a0-2bdd-4200-827f-4e1f24d29775" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0a54b6a0-2bdd-4200-827f-4e1f24d29775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_83922399-231f-4f30-ab83-2a2b95592650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve_83922399-231f-4f30-ab83-2a2b95592650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_040b8c1f-6d51-4d73-be47-411cfd958225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent_040b8c1f-6d51-4d73-be47-411cfd958225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_1b0f1b70-d90b-4f0b-8883-93d0bd713cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses_1b0f1b70-d90b-4f0b-8883-93d0bd713cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DeferredTaxAssetsFixedAssetsAndIntangibles_3abac76d-3d9a-481a-b5d1-da1c0a80e5aa" xlink:href="moh-20221231.xsd#moh_DeferredTaxAssetsFixedAssetsAndIntangibles"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_moh_DeferredTaxAssetsFixedAssetsAndIntangibles_3abac76d-3d9a-481a-b5d1-da1c0a80e5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ff3fb923-8d40-4451-beef-10a9d92ec39d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ff3fb923-8d40-4451-beef-10a9d92ec39d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3e7efde2-16d0-44f6-a4ab-8cce7c536c88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3e7efde2-16d0-44f6-a4ab-8cce7c536c88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_458fa86f-b2fe-4cfd-a07c-afd815494222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_458fa86f-b2fe-4cfd-a07c-afd815494222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_14fbc253-18b1-4f68-b598-0fa42b79e3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_14fbc253-18b1-4f68-b598-0fa42b79e3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles_920e2e3e-b4d8-4592-92ce-4cc10d60cabc" xlink:href="moh-20221231.xsd#moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles_920e2e3e-b4d8-4592-92ce-4cc10d60cabc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_84643de3-16b4-4dbb-9ba2-3a6d10d9cb07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_84643de3-16b4-4dbb-9ba2-3a6d10d9cb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_456e0610-012b-47e5-8ee5-02e7a5e2c2da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_456e0610-012b-47e5-8ee5-02e7a5e2c2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2c5011fb-dac3-4078-ab93-43fcf0632860" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d9d531f4-2834-4a5e-a665-d1dd1093d115" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_2c5011fb-dac3-4078-ab93-43fcf0632860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_87b0e67b-bedb-4a51-9052-b2f0425b1df0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_81600119-d0a4-4452-a256-9330f6b77f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_87b0e67b-bedb-4a51-9052-b2f0425b1df0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_81600119-d0a4-4452-a256-9330f6b77f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_81600119-d0a4-4452-a256-9330f6b77f0d" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_fb8a3a5f-3d37-43c3-b35a-fec7ba16b71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_cd92efd9-e6b1-4324-8ef7-f1a1403d5b16" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_fb8a3a5f-3d37-43c3-b35a-fec7ba16b71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6ba61035-23aa-47f8-836c-59058b2da689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_fb8a3a5f-3d37-43c3-b35a-fec7ba16b71e" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6ba61035-23aa-47f8-836c-59058b2da689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_00131b0a-132b-4a88-91fb-5b6229077429" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_fb8a3a5f-3d37-43c3-b35a-fec7ba16b71e" xlink:to="loc_us-gaap_ForeignCountryMember_00131b0a-132b-4a88-91fb-5b6229077429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_81600119-d0a4-4452-a256-9330f6b77f0d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_e052a519-7300-4191-813f-075c8b7d213d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_OperatingLossCarryforwards_e052a519-7300-4191-813f-075c8b7d213d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_37e2cb58-2cb4-45b3-a590-fadad1f5aa3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_37e2cb58-2cb4-45b3-a590-fadad1f5aa3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_fa563822-96cc-46a0-bce4-fc5653d9312c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_TaxCreditCarryforwardValuationAllowance_fa563822-96cc-46a0-bce4-fc5653d9312c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_df6a8ed5-df8a-496e-bae2-d8a00e7a0236" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_df6a8ed5-df8a-496e-bae2-d8a00e7a0236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e3875cd-d1f7-4aba-a278-5038db8bb306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_5e3875cd-d1f7-4aba-a278-5038db8bb306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c381d7ba-40dc-4430-a267-671a93f75d20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_c381d7ba-40dc-4430-a267-671a93f75d20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_581fa5c7-fab6-4318-a185-8a78cb3d675d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_ca81b542-45f0-4707-baba-7fb7012d055f" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_581fa5c7-fab6-4318-a185-8a78cb3d675d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#IncomeTaxesUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1190d914-bf02-4a31-88fc-f675bb52dd46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e2af173-c723-4c9d-91a6-f4805cc0912e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1190d914-bf02-4a31-88fc-f675bb52dd46" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e2af173-c723-4c9d-91a6-f4805cc0912e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_c0144c49-bf27-4746-bae0-d426252f2028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e2af173-c723-4c9d-91a6-f4805cc0912e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_c0144c49-bf27-4746-bae0-d426252f2028" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_83521229-7cfa-4f68-a6eb-1cf8e1b66b33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e2af173-c723-4c9d-91a6-f4805cc0912e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities_83521229-7cfa-4f68-a6eb-1cf8e1b66b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_dbf094a0-8fab-4bf5-9520-e46c15837d67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e2af173-c723-4c9d-91a6-f4805cc0912e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_dbf094a0-8fab-4bf5-9520-e46c15837d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_659527f3-8d9d-4a5a-abb6-96100d869d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5e2af173-c723-4c9d-91a6-f4805cc0912e" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_659527f3-8d9d-4a5a-abb6-96100d869d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_6609ba5f-af91-43bd-b7b1-84ab11ce8f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6609ba5f-af91-43bd-b7b1-84ab11ce8f39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b8665157-e302-40d3-89e2-a8a34546e50f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b8665157-e302-40d3-89e2-a8a34546e50f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4c51108f-3d00-4f78-809d-cf1a8481714b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b8665157-e302-40d3-89e2-a8a34546e50f" xlink:to="loc_us-gaap_EquityComponentDomain_4c51108f-3d00-4f78-809d-cf1a8481714b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b1243474-a94c-4db6-be42-d18668bbe2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4c51108f-3d00-4f78-809d-cf1a8481714b" xlink:to="loc_us-gaap_CommonStockMember_b1243474-a94c-4db6-be42-d18668bbe2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_PlanNameAxis_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_1da559c4-7910-4c28-9aa5-32fa39b47225" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1ba743a4-3790-4a08-a0e5-24a32fa0f0a8" xlink:to="loc_us-gaap_PlanNameDomain_1da559c4-7910-4c28-9aa5-32fa39b47225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EquityIncentivePlanMember_ff9c3875-6e61-4d68-8195-27d87b902e10" xlink:href="moh-20221231.xsd#moh_EquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1da559c4-7910-4c28-9aa5-32fa39b47225" xlink:to="loc_moh_EquityIncentivePlanMember_ff9c3875-6e61-4d68-8195-27d87b902e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a2c842f1-e89a-489e-8975-5e5c14ee0691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_AwardTypeAxis_a2c842f1-e89a-489e-8975-5e5c14ee0691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a2c842f1-e89a-489e-8975-5e5c14ee0691" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_31f9baef-f10b-4c82-8968-acba2314d8e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:to="loc_us-gaap_EmployeeStockMember_31f9baef-f10b-4c82-8968-acba2314d8e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_dbf7afd8-27a3-4620-beeb-cff5db42c678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:to="loc_us-gaap_RestrictedStockMember_dbf7afd8-27a3-4620-beeb-cff5db42c678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_d4f2502e-5e1e-4f64-b286-c1b089430059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:to="loc_us-gaap_PerformanceSharesMember_d4f2502e-5e1e-4f64-b286-c1b089430059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_0728c242-fb9b-4bb5-bcb0-96c84d95c158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_22784202-a2e5-4242-be8b-aba6e2e72c4f" xlink:to="loc_us-gaap_EmployeeStockOptionMember_0728c242-fb9b-4bb5-bcb0-96c84d95c158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_8e03ceb7-caca-4c9d-be2f-2675ae833ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_8e03ceb7-caca-4c9d-be2f-2675ae833ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_12340b47-a61d-4af2-9316-1fb3a359fb49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_8e03ceb7-caca-4c9d-be2f-2675ae833ff6" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_12340b47-a61d-4af2-9316-1fb3a359fb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_668718cd-3549-46a8-80d7-0e9554feb7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_12340b47-a61d-4af2-9316-1fb3a359fb49" xlink:to="loc_us-gaap_SubsequentEventMember_668718cd-3549-46a8-80d7-0e9554feb7b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9ea9c91a-416d-4264-abf4-69f51b06a44c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2f7d7254-259b-43f6-8abf-6589f3f5dbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_2f7d7254-259b-43f6-8abf-6589f3f5dbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_8fbacd5d-6048-42f3-ad09-77e7d0435413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_8fbacd5d-6048-42f3-ad09-77e7d0435413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a185d0ec-5202-4549-b977-21b0d15c18d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_a185d0ec-5202-4549-b977-21b0d15c18d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_6875a263-4f3a-45fc-b2d5-caf67699d039" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_6875a263-4f3a-45fc-b2d5-caf67699d039" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_659da748-53bf-4224-8997-03181b2e1f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_659da748-53bf-4224-8997-03181b2e1f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6b67a58f-2b12-4d8e-a1c7-339422b8bc6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_6b67a58f-2b12-4d8e-a1c7-339422b8bc6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_252a6058-46e8-44b3-93c7-4fd9a73657fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_252a6058-46e8-44b3-93c7-4fd9a73657fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_13cbec61-7d13-451b-a95a-e8dc1f424219" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_13cbec61-7d13-451b-a95a-e8dc1f424219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_420c202c-019e-40ae-8392-cc2418d7830e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_420c202c-019e-40ae-8392-cc2418d7830e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_UnrecognizedCompensationForfeitedRate_968969d7-1422-4c83-b947-198cb8ba8a23" xlink:href="moh-20221231.xsd#moh_UnrecognizedCompensationForfeitedRate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_moh_UnrecognizedCompensationForfeitedRate_968969d7-1422-4c83-b947-198cb8ba8a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a7cab588-24af-42e4-9fe8-ffb804f7c9c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a7cab588-24af-42e4-9fe8-ffb804f7c9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cbdf886d-ca8c-4879-8da7-40371b1b1c20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_cbdf886d-ca8c-4879-8da7-40371b1b1c20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a9c123dd-9b55-4333-b279-2359286fc080" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_a9c123dd-9b55-4333-b279-2359286fc080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c1b9d565-2b69-48b1-a8d0-85aafbab63f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_c1b9d565-2b69-48b1-a8d0-85aafbab63f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_FairMarketValueOfCommonStockPercentage_083a15d9-43b2-46ca-8554-f12bbeaef16e" xlink:href="moh-20221231.xsd#moh_FairMarketValueOfCommonStockPercentage"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_moh_FairMarketValueOfCommonStockPercentage_083a15d9-43b2-46ca-8554-f12bbeaef16e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_07cc1255-5a0a-4b16-b2e3-e0f3276b17c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramPeriodInForce1"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_StockRepurchaseProgramPeriodInForce1_07cc1255-5a0a-4b16-b2e3-e0f3276b17c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee_79b869f5-cee3-4352-b5cb-0dee4a206458" xlink:href="moh-20221231.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee_79b869f5-cee3-4352-b5cb-0dee4a206458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_32b9aceb-3606-4778-99b8-c561ccf767b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_32b9aceb-3606-4778-99b8-c561ccf767b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fd51a3ba-5031-45fe-8cbe-1b2a1e7e239f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_fd51a3ba-5031-45fe-8cbe-1b2a1e7e239f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a31f7e3a-d2f7-4dea-9647-37735a29d252" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_a31f7e3a-d2f7-4dea-9647-37735a29d252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e26e3a59-1458-480f-b5a4-8b76f2f84d3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_e26e3a59-1458-480f-b5a4-8b76f2f84d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f6669914-38b6-46ab-84bb-b62977ff8cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_f6669914-38b6-46ab-84bb-b62977ff8cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_755af6c9-f562-4aa0-9a31-646f6e1a2644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f3e212c9-61fb-407b-8b50-512de0d899bb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_755af6c9-f562-4aa0-9a31-646f6e1a2644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityComponentsofSharebasedCompensationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_848cc91b-4a7d-42a4-9034-2c9766c582a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c16f76-c38a-4d0d-a9b1-48dc9bdea1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_848cc91b-4a7d-42a4-9034-2c9766c582a7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c16f76-c38a-4d0d-a9b1-48dc9bdea1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_9340d8f2-e260-4c2a-8b69-c9c9330254f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c16f76-c38a-4d0d-a9b1-48dc9bdea1bd" xlink:to="loc_us-gaap_AwardTypeAxis_9340d8f2-e260-4c2a-8b69-c9c9330254f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9431dd-c1a8-4f94-a199-e01e7e4e78c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_9340d8f2-e260-4c2a-8b69-c9c9330254f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9431dd-c1a8-4f94-a199-e01e7e4e78c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_RestrictedandPerformanceStockMember_26b99318-cee2-47a1-b77f-af043e27ba31" xlink:href="moh-20221231.xsd#moh_RestrictedandPerformanceStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9431dd-c1a8-4f94-a199-e01e7e4e78c0" xlink:to="loc_moh_RestrictedandPerformanceStockMember_26b99318-cee2-47a1-b77f-af043e27ba31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_EmployeeStockPurchasePlanandStockOptionsMember_70771f5d-9b53-4bd4-a849-69343e55fd7d" xlink:href="moh-20221231.xsd#moh_EmployeeStockPurchasePlanandStockOptionsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7d9431dd-c1a8-4f94-a199-e01e7e4e78c0" xlink:to="loc_moh_EmployeeStockPurchasePlanandStockOptionsMember_70771f5d-9b53-4bd4-a849-69343e55fd7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_574ff2a9-863b-4b27-a002-e65b37ab849c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d7c16f76-c38a-4d0d-a9b1-48dc9bdea1bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_574ff2a9-863b-4b27-a002-e65b37ab849c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_b4f5238a-a945-4e55-a40c-15a4616190ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_574ff2a9-863b-4b27-a002-e65b37ab849c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_b4f5238a-a945-4e55-a40c-15a4616190ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_312b96df-ef72-458d-b660-961c8b0eb4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_574ff2a9-863b-4b27-a002-e65b37ab849c" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_312b96df-ef72-458d-b660-961c8b0eb4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityRestrictedandPerformanceStockActivityDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9b7eebb9-a8cd-4803-9522-ac0fc7f4f4f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cb60cac-48a6-4f5b-aac9-fdee75cd165c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9b7eebb9-a8cd-4803-9522-ac0fc7f4f4f8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cb60cac-48a6-4f5b-aac9-fdee75cd165c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ea7a0154-72d3-4dba-a618-e28fb450e510" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cb60cac-48a6-4f5b-aac9-fdee75cd165c" xlink:to="loc_us-gaap_AwardTypeAxis_ea7a0154-72d3-4dba-a618-e28fb450e510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d99d2af-fa57-434d-9612-be36e9466b66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ea7a0154-72d3-4dba-a618-e28fb450e510" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d99d2af-fa57-434d-9612-be36e9466b66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c5820d70-6507-453e-ba45-80c9ce16be50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d99d2af-fa57-434d-9612-be36e9466b66" xlink:to="loc_us-gaap_RestrictedStockMember_c5820d70-6507-453e-ba45-80c9ce16be50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_0c3e6488-2759-4cc9-9d7f-b842cb1a3d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0d99d2af-fa57-434d-9612-be36e9466b66" xlink:to="loc_us-gaap_PerformanceSharesMember_0c3e6488-2759-4cc9-9d7f-b842cb1a3d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a0f1618-d560-4103-9447-0c503fe5eacc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_3cb60cac-48a6-4f5b-aac9-fdee75cd165c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a0f1618-d560-4103-9447-0c503fe5eacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a0f1618-d560-4103-9447-0c503fe5eacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c871f89d-85c3-4f78-a3ab-8f46ba94d20a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c871f89d-85c3-4f78-a3ab-8f46ba94d20a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_95e84c8b-190d-45ba-bd47-e6b83a6d3d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_95e84c8b-190d-45ba-bd47-e6b83a6d3d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ef3cf870-d64a-459b-b779-ceffef86d2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_ef3cf870-d64a-459b-b779-ceffef86d2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67e75dd5-dcb7-4781-b4d4-8ce2701f2e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_67e75dd5-dcb7-4781-b4d4-8ce2701f2e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc4dd52f-5b1b-4570-9942-78da21cc11d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ac7dd70f-0038-4a0a-b46a-fd86f6bb0073" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_bc4dd52f-5b1b-4570-9942-78da21cc11d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a0f1618-d560-4103-9447-0c503fe5eacc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b949bea-e50e-4e9b-b37c-578e9a61aed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8b949bea-e50e-4e9b-b37c-578e9a61aed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65999cd1-4bbd-4c3b-9642-90d79db50994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65999cd1-4bbd-4c3b-9642-90d79db50994" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f5d0f1bc-bca8-4ed6-ade3-da6735eecd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f5d0f1bc-bca8-4ed6-ade3-da6735eecd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_316adfbb-74ce-45e1-aef5-508fdb6161bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_316adfbb-74ce-45e1-aef5-508fdb6161bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5dc158c-0b26-4875-8545-cc5431345c60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_50e93299-cc9a-484d-a1c4-7c0325d8d79c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d5dc158c-0b26-4875-8545-cc5431345c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityFairValueofAwardsGrantedandVestedDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_c413058c-15c5-4915-8d3b-777685df6b71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc11c859-28b2-4995-80f0-55554356ccc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_c413058c-15c5-4915-8d3b-777685df6b71" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc11c859-28b2-4995-80f0-55554356ccc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc11c859-28b2-4995-80f0-55554356ccc8" xlink:to="loc_us-gaap_AwardTypeAxis_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c1ddfa9-8cc6-4f81-bc45-9a315942afa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7d8abaeb-5395-4fc9-bb96-f4a4d2f8c5cd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c1ddfa9-8cc6-4f81-bc45-9a315942afa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_c9091692-d578-4d7f-a103-f21481b5a921" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c1ddfa9-8cc6-4f81-bc45-9a315942afa0" xlink:to="loc_us-gaap_RestrictedStockMember_c9091692-d578-4d7f-a103-f21481b5a921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6e24d4b1-b85b-494a-b058-c887156ba840" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c1ddfa9-8cc6-4f81-bc45-9a315942afa0" xlink:to="loc_us-gaap_PerformanceSharesMember_6e24d4b1-b85b-494a-b058-c887156ba840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8322cb6b-6f77-4f34-a153-39b41bc04a01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_fc11c859-28b2-4995-80f0-55554356ccc8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8322cb6b-6f77-4f34-a153-39b41bc04a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_579179e6-0cb1-408d-b754-c1c508d42ec0" xlink:href="moh-20221231.xsd#moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8322cb6b-6f77-4f34-a153-39b41bc04a01" xlink:to="loc_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_579179e6-0cb1-408d-b754-c1c508d42ec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_966ebd81-8c88-47c1-8deb-fde3243be207" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8322cb6b-6f77-4f34-a153-39b41bc04a01" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_966ebd81-8c88-47c1-8deb-fde3243be207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#StockholdersEquityStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_a4c49c71-b925-4024-9dce-eee1b404ad89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_12f2ff9a-e3a3-4501-92ca-7fadde94a228" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a4c49c71-b925-4024-9dce-eee1b404ad89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_12f2ff9a-e3a3-4501-92ca-7fadde94a228" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6c33e137-5cbb-41ca-8ce1-6f26e21ef9b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_12f2ff9a-e3a3-4501-92ca-7fadde94a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6c33e137-5cbb-41ca-8ce1-6f26e21ef9b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27bc9a18-3a0d-4021-8e76-cc91abb99390" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_12f2ff9a-e3a3-4501-92ca-7fadde94a228" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_27bc9a18-3a0d-4021-8e76-cc91abb99390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_385c2ace-fc15-4a20-8645-f00b03a0e027" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_12f2ff9a-e3a3-4501-92ca-7fadde94a228" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_385c2ace-fc15-4a20-8645-f00b03a0e027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c12ff982-53d8-4d97-9281-99fb565733ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a4c49c71-b925-4024-9dce-eee1b404ad89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c12ff982-53d8-4d97-9281-99fb565733ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a141fe69-d7c1-4667-952f-5c25ddb46169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c12ff982-53d8-4d97-9281-99fb565733ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_a141fe69-d7c1-4667-952f-5c25ddb46169" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d3bcbc78-43b7-4352-b7a7-19b96225a6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c12ff982-53d8-4d97-9281-99fb565733ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_d3bcbc78-43b7-4352-b7a7-19b96225a6fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2b0c4c6-ee3e-4af0-ab34-a9eb5626ddc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_c12ff982-53d8-4d97-9281-99fb565733ee" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_d2b0c4c6-ee3e-4af0-ab34-a9eb5626ddc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2b33e99e-053b-425c-aa19-5262bd137d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a4c49c71-b925-4024-9dce-eee1b404ad89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_2b33e99e-053b-425c-aa19-5262bd137d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c3045b92-dddc-44b4-b494-09fcfba7e112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_a4c49c71-b925-4024-9dce-eee1b404ad89" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_c3045b92-dddc-44b4-b494-09fcfba7e112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#EmployeeBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsAbstract_8ce9ecd8-6f94-4b6f-9abf-9573069f655d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_cd509e14-64e6-4571-a03d-1077e9cc5115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_8ce9ecd8-6f94-4b6f-9abf-9573069f655d" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_cd509e14-64e6-4571-a03d-1077e9cc5115" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_720c5908-d616-4176-85e0-4455a1586c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_8ce9ecd8-6f94-4b6f-9abf-9573069f655d" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_720c5908-d616-4176-85e0-4455a1586c3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationPlanAssets_cd255c0d-801c-4cd6-b6b4-9eb57e10f88e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PostemploymentBenefitsAbstract_8ce9ecd8-6f94-4b6f-9abf-9573069f655d" xlink:to="loc_us-gaap_DeferredCompensationPlanAssets_cd255c0d-801c-4cd6-b6b4-9eb57e10f88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d351dbe3-ba58-47b4-a2c2-56dcefbc0235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesTable_06dbe28d-afd0-4995-8bbe-b5d13f0bf64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_d351dbe3-ba58-47b4-a2c2-56dcefbc0235" xlink:to="loc_us-gaap_StatutoryAccountingPracticesTable_06dbe28d-afd0-4995-8bbe-b5d13f0bf64c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_39febeff-d66d-4951-8a76-8d7ef82cf632" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_06dbe28d-afd0-4995-8bbe-b5d13f0bf64c" xlink:to="loc_srt_ConsolidatedEntitiesAxis_39febeff-d66d-4951-8a76-8d7ef82cf632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6b53d3dc-d4c2-40f2-aa18-c14c925dcd98" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_39febeff-d66d-4951-8a76-8d7ef82cf632" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6b53d3dc-d4c2-40f2-aa18-c14c925dcd98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_9878f3d8-4ed3-4cab-88b2-daa100606b1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_6b53d3dc-d4c2-40f2-aa18-c14c925dcd98" xlink:to="loc_srt_ParentCompanyMember_9878f3d8-4ed3-4cab-88b2-daa100606b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesTable_06dbe28d-afd0-4995-8bbe-b5d13f0bf64c" xlink:to="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SpecialAssessmentBond_453a5dfd-8be0-43d6-80a7-08a6d601485c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SpecialAssessmentBond"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_SpecialAssessmentBond_453a5dfd-8be0-43d6-80a7-08a6d601485c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_e0c74f2d-de57-49bd-b859-d23217240e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries_e0c74f2d-de57-49bd-b859-d23217240e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b9d1016c-7c84-4476-bf63-d57941c053f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_b9d1016c-7c84-4476-bf63-d57941c053f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_b4a4f8ae-2b23-4373-b588-a872359a26d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance_b4a4f8ae-2b23-4373-b588-a872359a26d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_5e8ad321-4b24-417a-9337-b49ef3a28127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatutoryAccountingPracticesLineItems_6a19f00e-3eed-4be7-a259-ce06e82c54d0" xlink:to="loc_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired_5e8ad321-4b24-417a-9337-b49ef3a28127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SegmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f60a7490-59d3-4b32-9275-795d814ce98c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7c1a2ca7-5b9a-49fa-acac-752afd813f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f60a7490-59d3-4b32-9275-795d814ce98c" xlink:to="loc_us-gaap_NumberOfReportableSegments_7c1a2ca7-5b9a-49fa-acac-752afd813f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SegmentsScheduleofOperatingSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6e375226-8c0c-4685-9b61-9afa91760fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a38b83e8-10d5-40cb-9a39-eba380998e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6e375226-8c0c-4685-9b61-9afa91760fd7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a38b83e8-10d5-40cb-9a39-eba380998e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_32cf5989-d0e1-41f7-8484-ab00026c2e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a38b83e8-10d5-40cb-9a39-eba380998e04" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_32cf5989-d0e1-41f7-8484-ab00026c2e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_32cf5989-d0e1-41f7-8484-ab00026c2e48" xlink:to="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_d59902ed-b19e-4103-80a0-c2fdd7ca4605" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:to="loc_moh_MedicaidMember_d59902ed-b19e-4103-80a0-c2fdd7ca4605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_77548af7-e722-4dc7-959e-5855f7ae733c" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:to="loc_moh_MedicareMember_77548af7-e722-4dc7-959e-5855f7ae733c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_3d90d3af-eb18-43df-9b0f-572412cd738d" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:to="loc_moh_MarketplaceMember_3d90d3af-eb18-43df-9b0f-572412cd738d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_8e7cdd81-c443-40b9-be99-de30cf4f2aa6" xlink:href="moh-20221231.xsd#moh_OtherProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_af0cb07d-e6ec-4b18-b1b6-99cf0ddf1eae" xlink:to="loc_moh_OtherProgramMember_8e7cdd81-c443-40b9-be99-de30cf4f2aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_791fa018-b04a-40dc-9991-bd48aea2b911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_a38b83e8-10d5-40cb-9a39-eba380998e04" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_791fa018-b04a-40dc-9991-bd48aea2b911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e4e5790c-2135-4116-9a95-229715e71d74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_791fa018-b04a-40dc-9991-bd48aea2b911" xlink:to="loc_us-gaap_Revenues_e4e5790c-2135-4116-9a95-229715e71d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_2eba1517-3047-4cb6-ada6-f4a6d2482352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_2eba1517-3047-4cb6-ada6-f4a6d2482352" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_4abecf57-fab4-4152-a40b-cb583d4c2b5b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:to="loc_srt_ConsolidationItemsAxis_4abecf57-fab4-4152-a40b-cb583d4c2b5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_a8974a3c-9f62-45fc-87f0-b570f28d0958" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_4abecf57-fab4-4152-a40b-cb583d4c2b5b" xlink:to="loc_srt_ConsolidationItemsDomain_a8974a3c-9f62-45fc-87f0-b570f28d0958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_b476580e-c3c6-4817-9610-57c02b4f4e3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a8974a3c-9f62-45fc-87f0-b570f28d0958" xlink:to="loc_us-gaap_OperatingSegmentsMember_b476580e-c3c6-4817-9610-57c02b4f4e3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_cd55ba18-98ac-424b-8fb9-72b3426687b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_a8974a3c-9f62-45fc-87f0-b570f28d0958" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_cd55ba18-98ac-424b-8fb9-72b3426687b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2403fa0c-2b8e-47de-b32c-f5466d266f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2403fa0c-2b8e-47de-b32c-f5466d266f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2403fa0c-2b8e-47de-b32c-f5466d266f9c" xlink:to="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicaidMember_9f94ba15-d341-4f8e-bd92-0f78de8d256f" xlink:href="moh-20221231.xsd#moh_MedicaidMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:to="loc_moh_MedicaidMember_9f94ba15-d341-4f8e-bd92-0f78de8d256f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MedicareMember_fd7100ab-4e0a-4f43-8464-9afbcea4f2b7" xlink:href="moh-20221231.xsd#moh_MedicareMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:to="loc_moh_MedicareMember_fd7100ab-4e0a-4f43-8464-9afbcea4f2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_MarketplaceMember_68785192-bdf2-420b-91e4-3b4ffba77193" xlink:href="moh-20221231.xsd#moh_MarketplaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:to="loc_moh_MarketplaceMember_68785192-bdf2-420b-91e4-3b4ffba77193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_OtherProgramMember_ee372685-4c93-4cf7-858e-547b0c48d8fb" xlink:href="moh-20221231.xsd#moh_OtherProgramMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9080c5c8-a43f-4f44-831c-ae652e0e7560" xlink:to="loc_moh_OtherProgramMember_ee372685-4c93-4cf7-858e-547b0c48d8fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_9ad5f6d5-5f4f-4a91-9dcd-72300b907534" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_45a58c0d-ab0f-403e-9d51-1ecfae3d204c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_GrossProfit_45a58c0d-ab0f-403e-9d51-1ecfae3d204c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ee635e5e-c053-4263-b163-1cccab6f3221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_Revenues_ee635e5e-c053-4263-b163-1cccab6f3221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_85a49886-5c4a-418d-840e-3fdb4584ad6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_CostsAndExpenses_85a49886-5c4a-418d-840e-3fdb4584ad6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3f9796cf-17b4-43b2-9a1b-e165d944a974" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_OperatingIncomeLoss_3f9796cf-17b4-43b2-9a1b-e165d944a974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_454cc8c1-f586-4906-b26d-e9390509049f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_454cc8c1-f586-4906-b26d-e9390509049f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e39bdaa-7ee6-4453-b3ff-a782570a6b6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d5d29511-d6ae-4775-9b82-151bb2afa232" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0e39bdaa-7ee6-4453-b3ff-a782570a6b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_d2343cfb-e4fd-419b-89d3-f85a27750741" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_a58e066f-baf4-4dbe-b1df-c9864f92b981" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_d2343cfb-e4fd-419b-89d3-f85a27750741" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_a58e066f-baf4-4dbe-b1df-c9864f92b981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_111ccf16-2b43-49c5-88fc-0eb26dcf0b78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_a58e066f-baf4-4dbe-b1df-c9864f92b981" xlink:to="loc_srt_ConsolidatedEntitiesAxis_111ccf16-2b43-49c5-88fc-0eb26dcf0b78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_6ba25c2c-4576-435c-a166-753cd4a902f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_111ccf16-2b43-49c5-88fc-0eb26dcf0b78" xlink:to="loc_srt_ConsolidatedEntitiesDomain_6ba25c2c-4576-435c-a166-753cd4a902f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_dac5b9ab-fe89-450f-ab18-58921a6d87bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_6ba25c2c-4576-435c-a166-753cd4a902f5" xlink:to="loc_srt_ParentCompanyMember_dac5b9ab-fe89-450f-ab18-58921a6d87bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_822747f9-f2e7-4184-87c3-861217a6205e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_a58e066f-baf4-4dbe-b1df-c9864f92b981" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_822747f9-f2e7-4184-87c3-861217a6205e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f10c775c-5291-46c0-ba84-bc0c4451f2e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_822747f9-f2e7-4184-87c3-861217a6205e" xlink:to="loc_us-gaap_StatementOfFinancialPositionAbstract_f10c775c-5291-46c0-ba84-bc0c4451f2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f10c775c-5291-46c0-ba84-bc0c4451f2e9" xlink:to="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_98b1ca4a-b250-4ad2-b10f-21d04ca2296a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_98b1ca4a-b250-4ad2-b10f-21d04ca2296a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_fa5ac37d-d8df-45a3-9ac5-3e9c16309300" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_fa5ac37d-d8df-45a3-9ac5-3e9c16309300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_d1dd8d62-4e6c-4bb3-a1d5-159ef4b8b919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent_d1dd8d62-4e6c-4bb3-a1d5-159ef4b8b919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_93f516f6-949f-4eaa-973d-baf6baaa4b1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_93f516f6-949f-4eaa-973d-baf6baaa4b1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_6d850f40-50eb-4bc4-a3f7-b5ac75d8c4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_e4d07dc5-6cbc-4aec-80bd-c3e9d00e84d5" xlink:to="loc_us-gaap_AssetsCurrent_6d850f40-50eb-4bc4-a3f7-b5ac75d8c4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_25abedda-9699-4825-b9da-9dc35a049264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization_25abedda-9699-4825-b9da-9dc35a049264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e9abf1a9-793a-479e-9f3c-2776e24d2301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_e9abf1a9-793a-479e-9f3c-2776e24d2301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_67d8310a-dc0c-4686-ac2b-56d99aa8c106" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures_67d8310a-dc0c-4686-ac2b-56d99aa8c106" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_e1447196-a7a4-44a4-adba-acd3e9dd4574" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_e1447196-a7a4-44a4-adba-acd3e9dd4574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_AdvancesToRelatedPartiesAndOtherAssets_1c6a48f3-7daa-43bb-82bc-b34551c5b8a5" xlink:href="moh-20221231.xsd#moh_AdvancesToRelatedPartiesAndOtherAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_moh_AdvancesToRelatedPartiesAndOtherAssets_1c6a48f3-7daa-43bb-82bc-b34551c5b8a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_afe40ad4-bb16-4ac7-9174-147e4de84af8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_a3b0203b-7fc5-4d4f-a6d0-af490fad45e0" xlink:to="loc_us-gaap_Assets_afe40ad4-bb16-4ac7-9174-147e4de84af8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f10c775c-5291-46c0-ba84-bc0c4451f2e9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_5784347d-05da-4637-8671-4338dd014700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_5784347d-05da-4637-8671-4338dd014700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1a3df7de-75d1-431f-81df-2747f84572ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5784347d-05da-4637-8671-4338dd014700" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_1a3df7de-75d1-431f-81df-2747f84572ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_29e5c63e-5df8-46ca-9cd6-9c71856303ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_5784347d-05da-4637-8671-4338dd014700" xlink:to="loc_us-gaap_LiabilitiesCurrent_29e5c63e-5df8-46ca-9cd6-9c71856303ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4b57936b-db52-4d29-a227-0dec25747365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4b57936b-db52-4d29-a227-0dec25747365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1734a280-f7ee-4267-8c1d-89a6f855e67c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1734a280-f7ee-4267-8c1d-89a6f855e67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_d984b0d8-41ff-4104-bfb4-dd8091db4a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_d984b0d8-41ff-4104-bfb4-dd8091db4a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c3965147-6836-4127-b90a-62ef949dbe34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_Liabilities_c3965147-6836-4127-b90a-62ef949dbe34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValueOutstanding_8a086252-24cb-4cfa-ade0-f3ce9891a071" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValueOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_CommonStockValueOutstanding_8a086252-24cb-4cfa-ade0-f3ce9891a071" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_b5abdb05-2c9a-4dc9-8284-552b8fffc15c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_PreferredStockValue_b5abdb05-2c9a-4dc9-8284-552b8fffc15c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f04434d4-559b-4910-afc2-c2ecb309f77c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_f04434d4-559b-4910-afc2-c2ecb309f77c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5da7c668-9cc5-4515-b8f0-1b4278b56a4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_5da7c668-9cc5-4515-b8f0-1b4278b56a4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_938fa109-24c1-401e-8c56-134e6a39096b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_938fa109-24c1-401e-8c56-134e6a39096b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_78867c8e-ac38-4ced-b9cf-913c77ebbbb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_10d5ac0b-e7d1-4f90-98ba-05a6f3dcb3ef" xlink:to="loc_us-gaap_StockholdersEquity_78867c8e-ac38-4ced-b9cf-913c77ebbbb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_25e97fe6-097f-47e6-9091-0b1aab8be20b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_20dae3d8-c517-4179-b5a4-7fa8f58b5cd7" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_25e97fe6-097f-47e6-9091-0b1aab8be20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_5169fced-023f-4433-a584-f8cca592e206" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_15236ba6-c154-4ad5-acd6-8056c866d19d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_5169fced-023f-4433-a584-f8cca592e206" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_15236ba6-c154-4ad5-acd6-8056c866d19d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_584703de-b6f7-4247-8bd2-53e2bf2cf389" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_15236ba6-c154-4ad5-acd6-8056c866d19d" xlink:to="loc_srt_ConsolidatedEntitiesAxis_584703de-b6f7-4247-8bd2-53e2bf2cf389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1e25de69-ca3b-4959-8d90-b320ab462704" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_584703de-b6f7-4247-8bd2-53e2bf2cf389" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1e25de69-ca3b-4959-8d90-b320ab462704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_444826b4-b30a-431f-9307-7f1cb8e74210" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_1e25de69-ca3b-4959-8d90-b320ab462704" xlink:to="loc_srt_ParentCompanyMember_444826b4-b30a-431f-9307-7f1cb8e74210" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_15236ba6-c154-4ad5-acd6-8056c866d19d" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_23034d25-deb2-486b-b108-39e0480650f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_23034d25-deb2-486b-b108-39e0480650f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_b6b0c603-2cb3-4f45-9c27-20ea7d6869b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_b6b0c603-2cb3-4f45-9c27-20ea7d6869b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_cf931e64-f721-4e27-b438-8945575ff103" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_cf931e64-f721-4e27-b438-8945575ff103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2a80471f-d1af-48a7-a6e5-ae10ed913c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_2a80471f-d1af-48a7-a6e5-ae10ed913c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_4013f4e2-0b5c-4928-916b-0491ae060875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_4013f4e2-0b5c-4928-916b-0491ae060875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_9582b201-5658-45a7-be18-f40b63e0b5f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_PreferredStockSharesIssued_9582b201-5658-45a7-be18-f40b63e0b5f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_fc99d1ce-64f7-4e24-b910-4f0fd9806850" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_1b57fda6-cbd7-4357-9817-a3cda347c8d1" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_fc99d1ce-64f7-4e24-b910-4f0fd9806850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_277f8313-8bbe-4273-813a-55f9fab850d9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_275e8e0f-b26d-49d6-b4e0-46acb5909c5e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_277f8313-8bbe-4273-813a-55f9fab850d9" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_275e8e0f-b26d-49d6-b4e0-46acb5909c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_c541a115-df57-4c19-8fcb-e088fd743303" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_275e8e0f-b26d-49d6-b4e0-46acb5909c5e" xlink:to="loc_srt_ConsolidatedEntitiesAxis_c541a115-df57-4c19-8fcb-e088fd743303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_04c8891e-d35f-41b7-b182-9acf548517db" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_c541a115-df57-4c19-8fcb-e088fd743303" xlink:to="loc_srt_ConsolidatedEntitiesDomain_04c8891e-d35f-41b7-b182-9acf548517db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_a297e293-0483-4e87-a529-a8128556fc70" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_04c8891e-d35f-41b7-b182-9acf548517db" xlink:to="loc_srt_ParentCompanyMember_a297e293-0483-4e87-a529-a8128556fc70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_346dc697-406c-4f26-91f3-044605961f4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_275e8e0f-b26d-49d6-b4e0-46acb5909c5e" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_346dc697-406c-4f26-91f3-044605961f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_346dc697-406c-4f26-91f3-044605961f4e" xlink:to="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InsuranceAgencyManagementFee_dc679990-c03a-41db-bacf-c51ab9666b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InsuranceAgencyManagementFee"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:to="loc_us-gaap_InsuranceAgencyManagementFee_dc679990-c03a-41db-bacf-c51ab9666b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestAndDividendIncomeOperating_8751a13b-75a2-4d58-83ce-52327fc72e98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestAndDividendIncomeOperating"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:to="loc_us-gaap_InterestAndDividendIncomeOperating_8751a13b-75a2-4d58-83ce-52327fc72e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_bc657718-99c1-4b6d-990d-e965cfcb6008" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_a1249891-261a-4e46-9ae3-672f3f157f78" xlink:to="loc_us-gaap_Revenues_bc657718-99c1-4b6d-990d-e965cfcb6008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_6df5c54b-58ae-4fab-9734-ce22db3e6c45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_6df5c54b-58ae-4fab-9734-ce22db3e6c45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_b2e385e7-8060-4b09-b3a9-22dcaa793344" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_DepreciationAndAmortization_b2e385e7-8060-4b09-b3a9-22dcaa793344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_e742a376-2c4f-4cba-ae93-5ee79e1540e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_AssetImpairmentCharges_e742a376-2c4f-4cba-ae93-5ee79e1540e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_2960a956-6c26-4db7-89ac-9cbab9d2b8da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare_2960a956-6c26-4db7-89ac-9cbab9d2b8da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b8915095-58c5-4c06-8060-39f0dc352dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_8a5bc52c-00b7-4550-8658-f67542ead7d7" xlink:to="loc_us-gaap_CostsAndExpenses_b8915095-58c5-4c06-8060-39f0dc352dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_20a54de0-abaf-4815-83d0-3a57b0c0067c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_OperatingIncomeLoss_20a54de0-abaf-4815-83d0-3a57b0c0067c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_03c1c573-4323-44d9-8383-d1e7ebf29051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_InterestExpense_03c1c573-4323-44d9-8383-d1e7ebf29051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_f595ab87-9f97-44e0-80b6-dca4004c0356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_f595ab87-9f97-44e0-80b6-dca4004c0356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherExpenses_37b1e319-7e4f-458c-86c5-a7ce4366f6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherExpenses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_OtherExpenses_37b1e319-7e4f-458c-86c5-a7ce4366f6f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_e1ee2ee5-70f4-42f1-a870-29819412a231" xlink:href="moh-20221231.xsd#moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries_e1ee2ee5-70f4-42f1-a870-29819412a231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_70000d26-571d-4480-b3bc-444149e98438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_70000d26-571d-4480-b3bc-444149e98438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_a81bba8a-7b09-4405-8850-f485a81486cd" xlink:href="moh-20221231.xsd#moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest_a81bba8a-7b09-4405-8850-f485a81486cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_7307d437-fbee-424f-a948-9dc3a323d91b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromSubsidiariesNetOfTax"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_IncomeLossFromSubsidiariesNetOfTax_7307d437-fbee-424f-a948-9dc3a323d91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_c97b2b16-2165-4b3e-9241-ed612ab78cff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_a17e4f46-1d6f-4ae0-a3e5-0c58f7e0bc59" xlink:to="loc_us-gaap_NetIncomeLoss_c97b2b16-2165-4b3e-9241-ed612ab78cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_8713fcef-7633-4d3e-bd1e-3452a116ee92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_14119185-c4ef-44f6-b8a7-fcf747ed618f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_8713fcef-7633-4d3e-bd1e-3452a116ee92" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_14119185-c4ef-44f6-b8a7-fcf747ed618f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_b21dff0a-a85c-4476-935f-e3cbdcbf8e28" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_14119185-c4ef-44f6-b8a7-fcf747ed618f" xlink:to="loc_srt_ConsolidatedEntitiesAxis_b21dff0a-a85c-4476-935f-e3cbdcbf8e28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_8ac32329-54ed-43cb-8b31-d088c55962b2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_b21dff0a-a85c-4476-935f-e3cbdcbf8e28" xlink:to="loc_srt_ConsolidatedEntitiesDomain_8ac32329-54ed-43cb-8b31-d088c55962b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_8bdc30d6-a0ef-4493-ad9a-7f2ac90aca92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_8ac32329-54ed-43cb-8b31-d088c55962b2" xlink:to="loc_srt_ParentCompanyMember_8bdc30d6-a0ef-4493-ad9a-7f2ac90aca92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5f1a253d-3f41-452d-9ce9-fa5bacb49cf4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_14119185-c4ef-44f6-b8a7-fcf747ed618f" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5f1a253d-3f41-452d-9ce9-fa5bacb49cf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3ca553a6-c1dc-4f89-a15e-6fa7a446f1c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5f1a253d-3f41-452d-9ce9-fa5bacb49cf4" xlink:to="loc_us-gaap_NetIncomeLoss_3ca553a6-c1dc-4f89-a15e-6fa7a446f1c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfOtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_5f1a253d-3f41-452d-9ce9-fa5bacb49cf4" xlink:to="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_b7f640f0-330d-4bcc-8b6e-ad8e489918d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_b7f640f0-330d-4bcc-8b6e-ad8e489918d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_010d6c30-68aa-4227-8c94-a1eeeeab46df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_010d6c30-68aa-4227-8c94-a1eeeeab46df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_227024be-76bd-4854-9e47-dde75572d016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_227024be-76bd-4854-9e47-dde75572d016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_f036ecb6-8732-4781-8abb-274683151e48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfOtherComprehensiveIncomeAbstract_9ab820da-9ec4-4655-98f3-1f629b5113c6" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_f036ecb6-8732-4781-8abb-274683151e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_0cd71816-4191-47c6-bcbf-5dbed1d3ac6f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfCondensedFinancialStatementsTable_3aae4a44-a985-4eae-b49b-e99658e5910a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScheduleOfCondensedFinancialStatementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_0cd71816-4191-47c6-bcbf-5dbed1d3ac6f" xlink:to="loc_srt_ScheduleOfCondensedFinancialStatementsTable_3aae4a44-a985-4eae-b49b-e99658e5910a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_acf547b8-d27c-4e63-b584-715e8eb60d97" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_3aae4a44-a985-4eae-b49b-e99658e5910a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_acf547b8-d27c-4e63-b584-715e8eb60d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_21d96617-0bdc-4c42-9d00-bae2ba277199" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_acf547b8-d27c-4e63-b584-715e8eb60d97" xlink:to="loc_srt_ConsolidatedEntitiesDomain_21d96617-0bdc-4c42-9d00-bae2ba277199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_6812bc16-00cd-4a1f-a0b5-a461505a206c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_21d96617-0bdc-4c42-9d00-bae2ba277199" xlink:to="loc_srt_ParentCompanyMember_6812bc16-00cd-4a1f-a0b5-a461505a206c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialStatementsCaptionsLineItems_27aa926c-65d0-4f1b-aaff-faf1927104a8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialStatementsCaptionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfCondensedFinancialStatementsTable_3aae4a44-a985-4eae-b49b-e99658e5910a" xlink:to="loc_srt_CondensedFinancialStatementsCaptionsLineItems_27aa926c-65d0-4f1b-aaff-faf1927104a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialStatementsCaptionsLineItems_27aa926c-65d0-4f1b-aaff-faf1927104a8" xlink:to="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e4fd0c3a-38b1-4ed2-814a-0b59ab4a533e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e4fd0c3a-38b1-4ed2-814a-0b59ab4a533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67bc58aa-15e1-4cbc-97be-2472ec5eee1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_e4fd0c3a-38b1-4ed2-814a-0b59ab4a533e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_67bc58aa-15e1-4cbc-97be-2472ec5eee1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2cb833fa-5645-4ec7-a766-83b1b04eabff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries_2cb833fa-5645-4ec7-a766-83b1b04eabff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDividendsReceived_f62323b0-3e3d-4b08-9e9e-7ff5cc0dd19c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDividendsReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_ProceedsFromDividendsReceived_f62323b0-3e3d-4b08-9e9e-7ff5cc0dd19c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c237986a-ac6b-4532-a469-a076fe851cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_c237986a-ac6b-4532-a469-a076fe851cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2c9335b0-fe32-4caa-8984-413e24d698de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_2c9335b0-fe32-4caa-8984-413e24d698de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25476ab8-c3fb-4aca-bd66-f0885708c706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_25476ab8-c3fb-4aca-bd66-f0885708c706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_80de9d21-5ae2-4403-9ea6-4a030bbe4ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_80de9d21-5ae2-4403-9ea6-4a030bbe4ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_ChangesInAmountsDueToAndDueFromAffiliates_3d4e9b0a-0cc9-4b8a-a699-76c71314d3b1" xlink:href="moh-20221231.xsd#moh_ChangesInAmountsDueToAndDueFromAffiliates"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_moh_ChangesInAmountsDueToAndDueFromAffiliates_3d4e9b0a-0cc9-4b8a-a699-76c71314d3b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_82052a16-47ed-45ac-a92d-7f0749275019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_82052a16-47ed-45ac-a92d-7f0749275019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f7b6648-94e0-48f1-9ce8-a0185a4ad356" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_25796537-0e44-4c35-a049-a06db17cc4c7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7f7b6648-94e0-48f1-9ce8-a0185a4ad356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b09450bc-fa0c-4b06-9dce-61bb45578f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_b09450bc-fa0c-4b06-9dce-61bb45578f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_f6524a7b-589f-4b0b-bf58-bda56c09a11c" xlink:href="moh-20221231.xsd#moh_CommonStockWithheldToSettleEmployeeTaxObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_moh_CommonStockWithheldToSettleEmployeeTaxObligations_f6524a7b-589f-4b0b-bf58-bda56c09a11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b24bc9be-2c55-4dc1-b3bd-b2fdfd2b33a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_b24bc9be-2c55-4dc1-b3bd-b2fdfd2b33a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b48e57dc-d2c0-4f2b-b926-149516a84b8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt_b48e57dc-d2c0-4f2b-b926-149516a84b8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_f6c9a2cc-4145-476b-b3c3-9ff1d48f36d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_f6c9a2cc-4145-476b-b3c3-9ff1d48f36d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_6bbfd323-21db-40da-9a0b-baac54c7c9d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermLinesOfCredit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_RepaymentsOfLongTermLinesOfCredit_6bbfd323-21db-40da-9a0b-baac54c7c9d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromLinesOfCredit_7ef282bd-3b41-4a79-b53c-908c9b3256e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromLinesOfCredit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_ProceedsFromLinesOfCredit_7ef282bd-3b41-4a79-b53c-908c9b3256e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfWarrants_c7f49d58-809b-4964-974a-d2c9331fe067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfWarrants_c7f49d58-809b-4964-974a-d2c9331fe067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_moh_CashPaidForSettlementOfConversionOption_c0bce64c-ad95-4080-aa7f-f9eb7faedadb" xlink:href="moh-20221231.xsd#moh_CashPaidForSettlementOfConversionOption"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_moh_CashPaidForSettlementOfConversionOption_c0bce64c-ad95-4080-aa7f-f9eb7faedadb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromConvertibleDebt_c40ff545-ac8d-4111-b3cd-c360b6780fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromConvertibleDebt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_ProceedsFromConvertibleDebt_c40ff545-ac8d-4111-b3cd-c360b6780fe6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_4eebed86-62e2-4d15-91a9-25f37a933f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_4eebed86-62e2-4d15-91a9-25f37a933f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c7e47f8e-43b0-4316-a9bb-1feda9b44310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_c7e47f8e-43b0-4316-a9bb-1feda9b44310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5924dc16-de94-4f8b-88e9-82736056be50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_596d47b8-ebdf-4f3e-a40c-e8fb2a27faa3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5924dc16-de94-4f8b-88e9-82736056be50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_729eee80-3c5e-485e-b1fc-eb52857a98a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_729eee80-3c5e-485e-b1fc-eb52857a98a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66f18a45-5b87-4ff2-9995-e8e6b8528088" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_66f18a45-5b87-4ff2-9995-e8e6b8528088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5af777c2-4b6d-4d85-b525-4cb6219748b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_d335dffd-c348-4140-9166-86ae179da890" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5af777c2-4b6d-4d85-b525-4cb6219748b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails" xlink:type="simple" xlink:href="moh-20221231.xsd#CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_d435c827-24d7-43b9-b00f-2aa63340781f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dd8ad312-a0d7-4584-b8ae-2c0a645593f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract_d435c827-24d7-43b9-b00f-2aa63340781f" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dd8ad312-a0d7-4584-b8ae-2c0a645593f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_6349160b-e36b-4ae2-8a47-f92365011804" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dd8ad312-a0d7-4584-b8ae-2c0a645593f3" xlink:to="loc_srt_ConsolidatedEntitiesAxis_6349160b-e36b-4ae2-8a47-f92365011804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_e100bbc6-cd94-492e-9d20-481225daf78b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_6349160b-e36b-4ae2-8a47-f92365011804" xlink:to="loc_srt_ConsolidatedEntitiesDomain_e100bbc6-cd94-492e-9d20-481225daf78b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ParentCompanyMember_b2ec3478-213b-496e-8a05-d3235ead69df" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ParentCompanyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_e100bbc6-cd94-492e-9d20-481225daf78b" xlink:to="loc_srt_ParentCompanyMember_b2ec3478-213b-496e-8a05-d3235ead69df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_b7ae8044-dca5-4e49-91a5-77cdf444217f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_dd8ad312-a0d7-4584-b8ae-2c0a645593f3" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_b7ae8044-dca5-4e49-91a5-77cdf444217f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromRelatedParties_0d823dc9-0eeb-4562-abf7-8de6c3ea09f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromRelatedParties"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_b7ae8044-dca5-4e49-91a5-77cdf444217f" xlink:to="loc_us-gaap_RevenueFromRelatedParties_0d823dc9-0eeb-4562-abf7-8de6c3ea09f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>moh-20221231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 moh-20221231_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #] E@# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MSSBNNL=0M=4M4N;.YBN[=QE)H) Z-]"#@U^3]=3X ^)GB+X9ZLE_H.H26QW
MRVS$M!./[KIT/'?J.Q%>G4R1<O[N>OF?*87CV3J)8JBN7O%ZKY/?[T?I_17
M_!OXMZ=\8/"::G:+]FOH2(KVRW9,$F.WJIZ@_4=0:[ZOF*D)4Y.$U9H_6</B
M*6*I1KT97C+5,****@Z HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M574Z=/0_H;),KCD^"CAD[RWD^[?]67H%%%%<1[P4444 %%%% !1110 4444
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M^![6]M9&AFAD&&1U."#^-5:^I_LG"O57^\_(9<9YO%V;C=?W3[A_X;B\"?\
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M&X!(#JZLI )&5."1S7X?_MD>(/\ A)OVIOB?>;MWEZY<68..T#>0.W_3/_\
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M#C[R;QR*\1OO^"R%I'<,++X3S7$'9Y_$ B8_\!%LP].]>&_L/_L(7?[1C?\
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M&*5ISLDNR\_-]NE@HHHKP3]$/B']MKPM!I/Q$TS6($6,ZM9_OL?Q21';N/\
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M [RL:_1:@C8X?PG\&_#7A#7FUV&._P!4UXQ&!=4UO4KC4+B*(XS'&TSMY2G
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M[:_\$[?C./B]^S;HUO=S^;K?AD_V+>;FRS+&H,#^N#$47)ZLCT!(^GJ***"
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH ^*/VYE'_"Q-!..?[* S_P!M
MI*^;J^F/VZ( OC;PW-GE]/9,?20G_P!F_2OF>OT++O\ =8>A_-/$RMF^(]?T
M04445Z)\P%>N_LHZM+I?QRT!(V81WBSVTJK_ !*8F8#_ +Z53^%>15Z=^S-_
MR73PG_UWD_\ 1,E<N*5Z%1/L_P CU\GDXYCAVOYX_P#I2/6OV\/^0MX/_P"N
M%S_Z%'7RO7U1^WA_R%O!_P#UPN?_ $*.OE>N7+/]TA\_S9ZO%?\ R.:_R_\
M24%%%%>H?)A1110!Z=^S-_R73PG_ -=Y/_1,E>M?MX?\A;P?_P!<+G_T*.O)
M?V9O^2Z>$_\ KO)_Z)DKUK]O#_D+>#_^N%S_ .A1UX5;_D94O\+_ %/T'!_\
MDMBO\:_]L/E>BBBO=/SX**** "O3OV9O^2Z>$_\ KO)_Z)DKS&O3OV9O^2Z>
M$_\ KO)_Z)DKFQ/\"IZ/\CU<I_Y&&'_QQ_\ 2D?HU7Y5?\%@/%7V[XI^!/#@
M?<--T>6^*@_=:XF*?GBV'Z5^JM?)W[07_!/7P[^T9\4-1\9Z_P"+]8L9Y[:&
MUMK.QAB"0+&@')8$MEMS=OO8[9K\U/ZI18_X)DZ:;']D+PQ-L*_;+R_GR3G=
MBYDCR/3_ %>/PKZIKS_X"?""S^ OPGT'P)I]]+J=II(G"74Z!'D\R>28D@$C
M.9"/P[=*] H$?C!_P4F^ S?"+X^7.O6%L(?#GB\-J5OY:X2.Y! N8_KO(D],
M2@=J[/\ X)5_ ?\ X3?XK7_Q$U*W+:5X57R[/</EDOI5(!]_+C+,1V+QFOT,
M_:>_9KT']J#P#;^&]9NY=+EM;R.\M-2MXU>6!AE7 !ZAD+ C/7:>=HK6_9Y^
M!>C_ +.GPMT[P7HT\E[%;R23SWTR!)+J9VRSL!P.-J@>B"@J^AZ57QO_ ,%6
MM-%]^RW',0I-GK]G.-W492:/CW_>?EFOLBO,OVC/@?9_M$_"N_\ !-_J<ND6
MUY/!,UY!"LCIY<BO@ D#)QC/;-!)_/S7[E?\$^_$G_"3_LA_#^9GW36D$]BX
M.?E\FXEC4?\ ?"H?QKP^/_@D!\/Q:%9/''B1KK!Q(L=N$SV.W83CI_%S[5]/
M?LR?L^V_[-/PYF\'V6NW.OV7V^6]AFNH5C>(.B Q_*2"-RLV>/OXQQDA3:*?
M[5O[-6D?M/?#"?P]>.ECK5JQNM(U,KDVUQC&&P,F-Q\K =L'JHK\1/BK\)/%
M7P5\877AGQ?I,VE:G 25WC,<Z9P)(GZ.AQP1]#@@BOZ(JY'XE?"7P?\ &+0#
MHOC/P]9>(-.R2D=TGSQ,>"T<@P\;8_B0@^] D['YV_L.?\%%-+\#^&=/^'OQ
M2N);?3+!!!I/B%8VE$,0^[!<*N6VKPJNH.!@$ #=7Z%Z)\;/A[XDT^.^TOQS
MX<O[20966#58&'T.&X/L>17QO\0_^"0_@O6+B:X\'>,]4\-;LLMIJ%NM_"I_
MNJP:-P/J6/UZ5Y)J'_!'_P >QS8LO'7ARXA_OW$5Q$W7T"MV]Z!Z'V7\;OV]
MOA)\%])N63Q%:^+M=4$0Z/H%PEP[.!P))5)2(9QG<=V.BMTK\>OCE\;/$G[0
M7Q(U#Q?XDE#7ESB*WM(<^3:0+G9#&#T49/N26)Y)K[8\+?\ !'?5I9HV\2?$
MBSMH1@O%I>FO,S>H#R.F._.T_2OJ_P"!O[!7PD^!=U;:E8Z,_B+Q# 0Z:OKS
M+<21,,',<8 CC(/(8+N']XT#T1\A_L&_\$_=1UK5]-^(WQ.TR2PT>V9;G2M
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M![F5P?Y#\J^:J_0<N_W6']=3^:N*'?.,1ZK\D%%%%>D?+A7IW[,W_)=/"?\
MUWD_]$R5YC7IW[,W_)=/"?\ UWD_]$R5S8G^!4]'^1ZN4_\ (PP_^./_ *4C
MUK]O#_D+>#_^N%S_ .A1U\KU]4?MX?\ (6\'_P#7"Y_]"CKY7KDRS_=(?/\
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M&U?PO^TYIWAFVN)3H_B6TNH+RUW'R]T,$D\<NWIN!B*@^DC#O7ZX_$*VDOO
M/B:WA&Z6;3+F-!G&6,3 4":/&X_^"@'[/\T:2+\1[,*P# -97:GGU!BR#[&G
M_P##?OP _P"BD6/_ ("77_QJOQG^!7AW3O&'QN^'N@ZO;?;-)U3Q%IUC>6^]
MD\V&6YC21-RD,,JQ&001G@U^OMY_P38_9ZNE41^")K0@Y+0ZS?$GV.Z9J!M)
M'T!X(\;:+\1_"NG^)/#M[_:.BWZL]M=")XQ*H8J2%=0V,J<$CD<C@@UNUS7P
MW^'^D?"OP1I/A/05FCT?2XC#:I<2F5U0L6P6/)QN('L!72T$A1110 4444 %
M%%% !1110 4444 %%%% !1110!\4_MS?\E"T#_L%_P#M:2OFVOI+]N;_ )*%
MH'_8+_\ :TE?-M?H67_[K#T/YHXF_P"1OB/7]$%%%%>B?,A7IW[,W_)=/"?_
M %WD_P#1,E>8UZ=^S-_R73PG_P!=Y/\ T3)7-B?X%3T?Y'JY3_R,,/\ XX_^
ME(]:_;P_Y"W@_P#ZX7/_ *%'7RO7U1^WA_R%O!__ %PN?_0HZ^5ZY,L_W2'S
M_-GK\5_\CFO\O_24%%%%>H?)A1110!Z=^S-_R73PG_UWD_\ 1,E>M?MX?\A;
MP?\ ]<+G_P!"CKR7]F;_ )+IX3_Z[R?^B9*]:_;P_P"0MX/_ .N%S_Z%'7A5
MO^1E2_PO]3]!P?\ R2V*_P :_P#;#Y7HHHKW3\^"BBB@ KT[]F;_ )+IX3_Z
M[R?^B9*\QKT[]F;_ )+IX3_Z[R?^B9*YL3_ J>C_ "/5RG_D88?_ !Q_]*1^
MC5?C-_P5*_Y.PO\ _L$V7_H+5^S-?C-_P5*_Y.PO_P#L$V7_ *"U?FI_54=S
ML/V??VK/VE? /PC\,Z!X+^#Q\2^$[&)UL]27PUJ=R;A#*[,1-%($;#,PRHXQ
M[5WFO?MK?M:7EG=Q#X!R6EE)"R2-+X3U9F52I#'=Y@ X]J^J_P!@+_DT#X;_
M /7I/_Z535[?XG_Y%O5O^O2;_P! - 'X$_LR_P#)R7PH_P"QMTG_ -+(J_H)
MK^?;]F=E3]H_X4LQ"JOBS222> !]LBK^@F@)'X@?\%'?^3SOB'_W#O\ TW6U
M>[_!O_@H9X]^'GPI\)^&;#X+WFM66DZ;#9PZBDUP!<*B "0 0$<XSP3]:\(_
MX*._\GG?$/\ [AW_ *;K:OUB_9$_Y-?^%O\ V+MG_P"BEH'T.-_8W_:@\0_M
M+6OC";7_  BOA%]%N((88 TC,X<2%MQ=5Y78!P.]?1Q(7))P.]+7SC^WY\:O
M^%*_LX:_-:3^5KFO#^Q=/VMAE:56\R0=QLB$A![-L]:"3YI^ EI!^V-^WIXU
M^(][&NI>"O"41MM.20;XI1AX+88/9@)Y_9L5\5_%SPCJG[+_ .TIJ^F:=(T%
MYX7UI+O2YF)),099K9S[E#&3[Y%?8G[*/[.7[4GP_P#A?;7W@#Q)X,\+:3XC
M$6K&WUB-I+M@\2[-Y^RR;1MQ\N[@D\<FO&?V[?@;\;/#MYIWQ!^+&H^']>:Z
M,>CKJ'A]2B@JLDB+(ODQ\XW@-C^''84%=3]=/AGX]T_XH_#[P]XMTILV&LV,
M5Y&N<E-Z@LA_VE;*GW4UI^)_^1;U;_KTF_\ 0#7PM_P25^,W_"0?#O7_ (;W
MTP-YX?F^WV"LW+6LS'S% ]$ER3_UV%?=/B?_ )%O5O\ KTF_] -!/4_ G]F7
M_DY+X4?]C;I/_I9%7]!-?S[?LR_\G)?"C_L;=)_]+(J_H)H'(*_/O_@L)_R3
M;X??]A:?_P!$U^@E?GW_ ,%A/^2;?#[_ +"T_P#Z)H$MS,_X(Y_\BW\4/^OO
M3_\ T">OT7K\Z/\ @CG_ ,BW\4/^OO3_ /T">OT7H![GYT?\%C/^1;^%_P#U
M]ZA_Z!!7S7^Q[\>OC;\(/#?B&S^%7PZ_X3;3[R[CEO;C^P[Z_P#(D"85=UO(
MH7(YPW-?2G_!8S_D6_A?_P!?>H?^@05I_P#!'O\ Y)M\0?\ L+0?^B:"NA@W
M'[;W[7#0Q"#]GZ:.4#]XTGA/5W5CCL!(,=^YKX&^-WBGQ)XV^+'B;7?&&D?V
M#XFOKLRW^F_9I;;[/)@ KY<I+KP!PQ)K^ANOP<_;<_Y.P^)O_86;_P! 6@$?
MM7\"_P#DB7P^_P"Q>T__ -)HZ_'/_@H9XHF\4?M=>.C)(7AT^2WT^!3G"+'!
M&& _X&7;ZL:_8SX%_P#)$OA]_P!B]I__ *31U^1__!2[X<W?@?\ :GUW4WA*
MZ=XD@@U.TD"X4GRUBE7(&-PDC8GOAU)ZY(*.Y^CW_!/KPU;^&?V1O *0HJR7
ML$U_,Z]7>6>1@3P.0NQ?HH'/6OHJODO_ ()D_$ZS\<_LQ:5HBS!M5\+W$VGW
M<1/S!'D>6%\?W2C[1[QMZ5]:4"8445XE^V5\:/\ A1/[/?BCQ%;S>3K%Q%_9
MNEE<;OM4P*HPSW0;Y/\ MF:!'R9X39?VOO\ @I%J&MOMO?!?P[3;;<AHW:W<
MK$0>AWW+/*#W6,#/2OC?]J7X9W7[.W[2WB72-+WZ?!97ZZGHTT8V^7!(1-#L
M/^QG9GUC-?4'['7[._[3/A3X<+XF^&_B'PCX6TSQ9'#?,NN(TES/&N\1,?\
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M;*\!^(O&6I>%WT+1;[5DMX;@2M:0M($):/ ..F<'\J^<?^%&_$'_ *$W6?\
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M'*KI6_/_ #/<H\+X>CEU3+54?+-IWTOI;_(_,_\ X4;\0?\ H3=9_P# -_\
M"C_A1OQ!_P"A-UG_ , W_P *_3"BNS^VZO\ (OQ/#_U"P?\ S^E^!^9__"C?
MB#_T)NL_^ ;_ .%'_"C?B#_T)NL_^ ;_ .%?IA11_;=7^1?B'^H6#_Y_2_ _
M,_\ X4;\0?\ H3=9_P# -_\ "O0_V?\ X3^,_#_QB\-:AJ7AC5+&Q@FD,MQ/
M;,J(#$X!)(XY(_.ONVBLZF<5:D)0<5JK'3AN"<+AJ\*\:LFXM/IT=PK\I?\
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M5^MWC[S-5^&?B/[);7$\USI%SY-LL+"9V:%MJ!"-VXD@;2,YXKJ** N?A?\
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>moh-20221231_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 moh-20221231_g2.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %I DP# 2(  A$! Q$!_\0
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M8\]":DO(DHI*6H.D**2EH ***2@!:*** "BBB@ HHHH **** "BBB@ HHHH
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MJ#P/_P!"?H7_ (+8/_B::_PC\$8X\):.O_7/3XE_DM'NBYJG\OX_\ Z_)[4
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MYCII0<8^]N.HHHJ3<;Z5SGCG79_#?AV6]M8DGO#-!;0I*VU/,EF2%2Q_NAI
MWX5T=<;\5>?"L1_ZBFF_^ET%5'<QJMQ@VBQX;\(R:9?S:MJ=\VL:W-'Y+73Q
MK''#'NW>7#'_ ,LX]W/WF9MJ[F;:NWJOX:08P*7I4_$7&*BK(=124M!8444E
M "TE+10!$V-ISTKX!^-_BR?QO\7/$5U,\C6FEW#:790NN!$L?RR8]VF61MW]
MW;_=K[^9>_8"OSE\<1PQ_$;QG';2F:W&MWA61EZLTS-(O_ 9&D7_ (#7TF10
MC*O*4NQ^0>)=:I2RN%.+]V4M3&HHHK[P_EL.U=1\*_&U_P##OXC:'J=E>"VM
MKR[M]/U*"9\036\DRIN;^ZT?F>8K?[R_=9JYC^&H;NVCOK.2WE7='(NUEKFK
MT8UZ<J<CULJQT\MQE/%P^RS]-U.5!;&33MW;I7Q1X-_:M\;>$+5K;6+6+QI
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M)=/:#3;6,6<5II>R#;"J^6NZS9L#I\S$^]=+_P *X\2X_P"2I>*=W_7II/\
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M_9J>LV'_ (E=]Y/W;:X9C%_L/_$O_ OO+_P*M*HB:UH\LN;N%%%%6<P4444
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MUO\ \TXTVY_ZX^)5_P#9K=:B3XA_$9?];\*9C_UPU^U;_P!"VT<K(^LP\_\
MP%_Y'J&?:C)]*\ZA^(WB]?\ CX^%FNK_ -<=2TU__0KE:M#XA>(?^B9^)O\
MP*TO_P"3*7*RO;P\_N?^1W/H3UK@?V@/^2%_$/'_ $+VH?\ I-)4I^('B'K_
M ,*S\2[O^OK2_P#Y-KDOBMXN\0ZU\,_%VG-\.O$D O-'O(#*]QIK*FZ%ER0M
MXS=^RU4(OF1E6JQ=.2UV[,]?TV[74+&VN4^[-&LB_BN:L]C7+_"^^_M+X;^%
M+K_GXTJUD_[ZA4UU-9RT9U4WS13%I:2C(]:1H%%&X>M&X>M KG!_%;X<V_Q2
M\%7^@3R_8Y)3'/!>I$LC0S1LK(V&^\,KM8<;E9ER,YKX%,,EO+=03/!--:SS
M6LCVKYA=HY&C9HSW5MNY?]FOTQ("K@'&*^)_VK?ASH'P]U:QU7P[-)#J^MWC
MR/HS7*K:K'Y<C33*GWE_>>7WV_>V[=U?19/C'1J>REM(_(?$'(EF&$CC:5E*
M&_I_PYX7K\SWBR:7!$TDTD2R,VY57;N_VO\ =;_OI:VSR:YN;4],T_S+R?4X
MKV^@B;8K7"C^'[JJO]ZO:K']FWXG7UTJPZ5I$EC-'')%J']ILL!5E5NC1^9_
MY#K[">+HT?XDN4_!L/D>/S*/+@:,I*/Z_P##'G/'K25Z_P#\,B_$J5E_TGPO
M O\ $?MUQ+_[;K75>&_V*KN8[_$GC&1?[L&AVBQX_P"VDWF9_!5KDJ9O@XZ\
MQ[6'X"SZM+EE1Y?5H^=MIHKZM7]B?PD[JUQXD\47 7^'[5;Q#_R' M=!!^R+
M\,X;=4DTG4;EA]YYM9O-S?\ ?,RBN.6?8=?#%GO4_#'-I_'4A'[_ /(^,NE9
M>JZ]%:3+;)+#]K;[WG-MCB7^\W_Q-?>VD?LO_"W16)A\%:;<MZZ@AO/_ $<6
MKIM%^%/@SPW=+<:3X2T/3+E>5FL]-BA8?\"5:YI<01^S3/;P_A;54N:MB%]Q
M^=/A>R%Y(]OI$-QKM\Y:69M-M)+B1V^]]V-6KH/^$5\4'4-.LE\):T+O4+C[
M/:07%M]G:5MNYMJS,K;55=S-]U?XJ^\?&?Q-\,?#M[.+7M4BTR6Z&8HV5F.U
M<;I&V@[8URNZ1L*N>6KC?"^@:M\3/&FB?$34+J;2=(L!,=%T80+YDMO-%M::
MX8_,K/\ *RQK]U47=\S,!S_VU6Y>:,>5'J0\.<!S\M2O*I/KLCP'2OV6_B;J
M]L)9;#1]&8M_JK[46,H_[]1R+_X]7:Z;^Q7J4C0-JWC.../'[Z'3=,^?_=62
M21A_Y#KZMYIK)]*\VIFV,G]H^NPO >0X;_ESS>K9X9HO['_P_P!/CD_M#^UM
M?=FW[[^_:/'_  &'RU_-:]-\-_#3PGX+D,NA^'-*TF8IL:6RLHXY&7T9E7+5
MU"KBD;Z5YTZ]6I\<CZ[#97@<'_N]&,?1#]H]!^5%+16!ZI@>+O#MKXN\.W^D
M7YD6SNXS%*T+;753W5OX6]^U<=XB^"_AK7O#5Y::;:6^F:C<QD1:U&GG76_G
MYFF;YY%;<RMN;YE9ES\U;GC[Q;-X7L<GPIK7B:SE1A,=)BAF\L=-K1M(LC9_
MV5:O*/A9X7T+30FCWGA[6/"MQ/%>:FLT&HR6<*VZW"[8W\N=9-RK,JJTD:_*
MC?W:Z*=[7N>77E"53DE&_P#7H)KFAV-WHJ>+]8U5=+M]/\0:7Y+PQ-(LWV2[
M^RM)+M^\\S%EW?PJMON^Y7T1GH!TKYSU*X3XO6NC>&/ .CS2>#-,U&.XNO$%
MW,R65P(V9ML#-NDN#YGS>8/EW)][YMU?12XZ9ZBE4#"6YI<J]W37N^I+2TE+
M6!Z@4444 %%%% !1110 RN?\56F@ZEI9TSQ!]C>QU!A:?9[TJ%G=L[8US]YN
M. .?EK7OK4W=G/$LKV[O&RK-']Y,@_,OO7FX^"L>K>$8=$\1ZU?:S/#.TZ7Q
M8B2/=&8V1?,:1MNUF^\S89MR[=J;=(V[G-64G'E4>8^>?C!^SIK'P\FN=3T&
M&?7/"ZJTC;6WW-BO\2LOWI%_VE^;^]]W<WD"2+)&C1LK*WS*R_Q5^FFW*@$Y
MKY@^/W[.(6.?Q/X)L)3<[_,O]&MU4K,OWFFA7^&3_97[W\*[OO?59?F__+K$
M?>?A?%G *Y98[*H_XH?_ "/^1\UT5'%*MQ&LB-N6I*^R/Y]:=-\DPHHHH,RM
M?68OK5HB?+;[R2+]Y&_A:J&DSRWU_)).GER6L7D,NW_EHS;F9?\ 9VK'_P!]
M5L5G1LL.N3*5V_:88V#?WF5FW?\ H2UG+XCT*,_W4X&C1116AYX4444 %%%%
M !5&Q7=?ZB_WOWJQ_P#?*+_\4U7JHZ*J_99)%^;SKB5MW][YVV_^.UG]LZJ?
M\*<B]1116ARA1110 4444 %%%% '8_!GXU7/PA\0^)6MM!CUPWT-G$VZ]^S^
M7Y9F;_GFV[_7?[/W:]=@_;9N5_X^/ <R'_ICJL;?^A1K7R_IL975]7D_VXU_
M\AK_ /%5J,3(PXKQ:F5T,1*52I'WC]%PO&>;952IX7"S7)&/9>I].Q_ML6!^
M_P"#-63_ ';FW;_V>K,?[:VA'[_A+Q O^Z;5O_:]?*]%9?V'A#T/^(DYW_=^
MX^R_A[^U%H/Q"\867AR#0]:T^\NUD:&6]6W\L^6I9ON3,W;^[7M##I_>[5\&
M?LZ<_'SPGG^Y>?\ HAJ^\\]STKY+,,/#"U_90/W;@_.,3GF6?6L5\7,UH24M
M%%>6?<!1110 5#-"EQ \;J&1U*E6[BIJ2@#P'X,^#O$%_P" +2P'Q'\16-YH
M<DFAW-K:P::T<4ELWD_+YEFS[655D7<S-MD7YFKO?^%<^(^/^+I^*O\ P$TG
M_P"0:S_#\XT;X\>*M+C,GD:MI5GK+*7^5;A6DMI&"_[4<=N/^V=>G[ATK6<G
M<\[#T8\G+KIIN^AYC>?!W6[S[_Q6\;+_ -<FTZ/_ -!LZI-\!+F;_6_$WQ[+
M_P!Q2./_ - A6O6]E)AAW%'.S?ZK3EO^;/*%_9ZM?^6OCKQY-_W,DZ?^@[:M
M6_P"TBW'S^(_&ER?^FGBW41_Z#,M>GXH*C!J?:3[A]5I=CPGX=^*+;PW\//&
MGBV\O]3OO!)OIY]*-W>S75ZUK'&D+;)))-VV2:.1H_F^[(O(W?*WX-_LW^%-
M)\"Z8/%'@719_$<B;[Z:_MX[Z5Y-WWFDD\SYF&UFVMMW,VVN1^(7[/O@?4-5
MTSP/X6TF]CU1I(;F]NTU&Z>/2;%9/O+YDC1K*VW;&NUOXFV[5KZA"E.%/R]!
MCM6\Y\J]WJ>;AZ'M)_OXI\GSU>_0R]"\*Z-X7M3!I&DV.E6YY,5E;)"O_?*K
M6S_#1QW-&X8ZUSW;W/8C&--6BK#J*;N7U'YU6O+ZWL(7GN;B.")?O22R;5%2
M7=%BEY]*XFZ^,G@*P?9<^-?#MNW]V75(%_FU9M]^T-\-K#9GQEI5VS=%L)_M
M;?\ ?,6XU?)/L<\L11CO-?>>C#MQ7DOCCXD)XFDOO!W@B\FO/$EQ<?V==WUC
M%))%HZ-N$TTDP_=K)&JOMCW;O,VKMZU6\<_'1)/!E[/X+T_6]5UMO+%HK>&=
M2:!MTBJS;O)56"JS-][^&L_PCXIU;P#\--/L=+\ :Z]EIMM^^U'7KFSTR-MH
MW37$VZ9I$W-ND;]W_$U:Q@UJSCK8A3?)%^[U:U_([SP/\-;7P7>:A>?VGJFN
MZE>+' ;[6+@3S1V\6[RH%;:ORJ7=LMEF9V9F8UVORQ\  >O-?'FJ_MD>+=3D
M;^Q?#^BZ5;*S*LUS+<7GGKVD52MNRJ?]I<^U>2^,/%_B#XA7CW/B75[K4\ME
M+17:&TA_V5A7Y?\ @3;F_O,U>O1RC$U_>G[J/@,PX]R?+4Z=#]Y)=O\ -GWS
MK'Q*\):#,T.J>)]'TV=#AH[J_BB8?@S4S0?B?X/\57YL=%\4Z+JM]M+_ &:Q
MU"&:3:.K;58FOSJM]+L[7_56L,?^[&M3RQ*TD,T;O!=6SK-!/"=LD$BMN616
M_A96KT?]7_=_B'R4?%1NI'FPWN^O_ /TVW;<9/%!8=%:OSKU;XA^,M<N&FO_
M !CKTKLNW$.H-:QC_@$/EK_X[61X=U/4O!>K'5?#NHW&C:I_%<PMN\[_ &9%
M;Y9%_P!ZN7^PJ_+?F/9?B?EWM8P5*7+WT_(_2W-+7SG\,?VL=-\020:5XRB@
M\.ZH[;8[Y7/V&;C^\W^J;_9DXZ;68_*/4_B1XSF\$Z+'>6$4&I7\C;8=(:1E
MN+[^]';[0V9.<_=V\?,R+EU\&KAZM&?LZD3]0P>;8/,,/]9PM3FB.U[Q'?ZE
MK%QH7A^:*T:U3=J>L3)O2Q#+N6-5/#3%3N^;Y44JS;MRJWEWA_X=_P#"U]6N
M+N\MKZU\ 1S*^-1+?;/$LT?W;BXW?,MJO_+.+Y5;[VU5V5Z5\)?#NK^'_A_I
M=GXE6WDU^=9+G4O(7Y&FE=I),_,V6^;:2#MZ[0JX4=WZC-3S\GNQ-_8?6%&I
M5^[]/\^_IH/50J\"EHI:Q/1"BBB@ HHHH **** "BBB@!O\ %7)>.O&5SX,L
M["XM]"U'7?M%XEL\6G)O:%6W?.WMQMY^7<R[F4?-76^]-(#4T1)-K06N2F\>
M0+XZB\*_V;J#7<EM]J6^6$?9=N6R-V[=GY?[NW+*-WS5UIKE_!:>)H].N/\
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M%%%%:'*%%%% !1110 4444#6Y2T?_CS+#^*>?_T:U7:S/#/_ " [4G^(,?\
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MY'Q7'^QSX\L9[KR=3T&^269G$DEQ-"Q7HHV^2VWY1V:OIKX/>![CX??#S2-
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M7YZ?U@+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MS"^$W[-OAKX;E;ZYA@\0^(VF:9M2EM$C5&W_ /+&%?W<.W_9^;K]*]E"A>@
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MZ\6O[R.21EV_-M4KGYF^5HZ]K0;5'.:48!IQ%9RES&M*BJ8M%%%2= 4E+10
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MA=6GVMOE7=Y:,K1M_L_-N;WKZD!+>X-<!\8O"OB+QEX)NM'\-:A9V-S<DPW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>moh-20221231_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 moh-20221231_g3.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YO<G1H=V%Y
M+"!!;&EC:6$    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,S
M,@  DI(  @    ,S,@  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ^(_^A:C_P#!BG_Q-']J^(_^A:C_ /!BG_Q-;]%',OY5^/\ F'L9_P#/Q_\
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M .A:C_\ !BG_ ,31_:OB/_H6H_\ P8I_\36_11S+^5?C_F'L9_\ /Q_^2_\
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MJ^(_^A:C_P#!BG_Q-']J^(_^A:C_ /!BG_Q-;]%',OY5^/\ F'L9_P#/Q_\
MDO\ \B8']J^(_P#H6H__  8I_P#$T?VKXC_Z%J/_ ,&*?_$UOT4<R_E7X_YA
M[&?_ #\?_DO_ ,B8']J^(_\ H6H__!BG_P 31_:OB/\ Z%J/_P &*?\ Q-;]
M%',OY5^/^8>QG_S\?_DO_P B8']J^(_^A:C_ /!BG_Q-']J^(_\ H6H__!BG
M_P 36_11S+^5?C_F'L9_\_'_ .2__(F!_:OB/_H6H_\ P8I_\31_:OB/_H6H
M_P#P8I_\36_11S+^5?C_ )A[&?\ S\?_ )+_ /(F!_:OB/\ Z%J/_P &*?\
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MYH **,C.,\^E(6 ."1F@!:**3<"< C/UH 6BC..M'7I0 444 @]#F@ HHHH
M**** "BBC(SC/- !10#GI10 444=* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH S=(\0:9KKWB:5=+.UC.UO<*%*F.0=000/SZ4-X@TQ/$::"U
MVO\ :<D!N%MPI)\L'&2<8'XFO M"UZ]\#>.O$7BAU>?1)=8GL;^*,9*-DM&_
MYDC_ /74_A'4-5M?BM<^*O$",9[[0[C4DM^\<0/R)_WRH_.E%II-]KO[K_\
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M> W$]C+>QQ+;ID@;I&X+$#./>I+OP!KEU#X3-WK":A<Z3J/VR\N+@E2X_NH
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M=3LKC[3%/'EXMXD9E!R <8;TJ74_!7C#6+/2=6N]5TV'Q1I$\C02PHQMY(V
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MX9LV\-1EG"22D7,D2G!<<X'0]OSK:U#QQXBUB;38O .BQW,5Y9"\>^U .L"
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/EI_<7\J/+3^XOY57+$R]M4\OZ^9>_MW2?\ H*67_@0G^-']NZ3_ -!2R_\
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M]IWJ^(].NYA#,T-EY4MJ3T?"9!3U)I+4KET.WHKGM6\=>&M#U$V.IZK%#<@
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MZV_7;\/O*]VR2Z7_ $W_ *Z#?^%DW,.E^(KB_P##\EI<:&(O,MGN03(7]P"
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ML?3?^@=:?]^%_P *.8/8>90HJ_\ V/IO_0.M/^_"_P"%']CZ;_T#K3_OPO\
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MP>P\RA15_P#L?3?^@=:?]^%_PH_L?3?^@=:?]^%_PHY@]AYE"BK_ /8^F_\
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M_P#"0VI\7'P[Y<WVL6?VS?@;-F_9C.<YS[4=; :M%%% !1110 4444 %%%%
M!1110!RUUX5FO/B,=;N/(DTY](:PDA8G>S&3<>,8VX]ZR;OX8VUCX;TS2/#
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MT<&:7;M#N6Z8!Z"J4?PYU2/PVD4-_;V^KV6L3:G93 %X_G8D(X(!Y!P<=*]
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MYG+D$+SMQ@$X'3(KIJ*%HK ]7<YG5O#=UJ'C_0M;1X?LFGP7$4T;D[F,B@#
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MWMN+Z"WU%==DU>PG0%U1B<J'! [9!Q4EIX;\:W7C6QU_7KK1<V5G/!%#:"3
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MXJUK4/%&H:?)8375O%86TRI#"D8( D0CYBP[GUJ/09;W6T\)>%_[9NM&L/[
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MFO3ZQQ563FN5Z=#MRC!4H47[2'OZIW_K:WWG@?C;P3+X3N(Y8YUGLIV(B9B
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ****  =16W6(.HK;J)'30ZD%Y_QZ/\ A_.LNM2]
M#FS?RHVE?C"*0">?<@5D[+W_ *!MQ_WW%_\ %T1:L*K&3EH.HINR]_Z!MQ_W
MW%_\71LO?^@;<?\ ?<7_ ,7571E[.78=13=E[_T#;C_ON+_XNC9>_P#0-N/^
M^XO_ (NBZ#V<NPZBF[+W_H&W'_?<7_Q=&R]_Z!MQ_P!]Q?\ Q=%T'LY=AU%-
MV7O_ $#;C_ON+_XNC9>_] VX_P"^XO\ XNBZ#V<NPZBF[+W_ *!MQ_WW%_\
M%T;+W_H&W'_?<7_Q=%T'LY=AU%-V7O\ T#;C_ON+_P"+HV7O_0-N/^^XO_BZ
M+H/9R[#J*;LO?^@;<?\ ?<7_ ,71LO?^@;<?]]Q?_%T70>SEV'44W9>_] VX
M_P"^XO\ XNC9>_\ 0-N/^^XO_BZ+H/9R[#J*;LO?^@;<?]]Q?_%T;+W_ *!M
MQ_WW%_\ %T70>SEV'44W9>_] VX_[[B_^+HV7O\ T#;C_ON+_P"+HN@]G+L.
MHINR]_Z!MQ_WW%_\71LO?^@;<?\ ?<7_ ,71=![.78=13=E[_P! VX_[[B_^
M+HV7O_0-N/\ ON+_ .+HN@]G+L.HINR]_P"@;<?]]Q?_ !=&R]_Z!MQ_WW%_
M\71=![.78=13=E[_ - VX_[[B_\ BZ-E[_T#;C_ON+_XNBZ#V<NPZBF[+W_H
M&W'_ 'W%_P#%T;+W_H&W'_?<7_Q=%T'LY=AU%-V7O_0-N/\ ON+_ .+HV7O_
M $#;C_ON+_XNBZ#V<NPZBF[+W_H&W'_?<7_Q=&R]_P"@;<?]]Q?_ !=%T'LY
M=AU%-V7O_0-N/^^XO_BZ-E[_ - VX_[[B_\ BZ+H/9R[#J*;LO?^@;<?]]Q?
M_%T;+W_H&W'_ 'W%_P#%T70>SEV'44W9>_\ 0-N/^^XO_BZ-E[_T#;C_ +[B
M_P#BZ+H/9R[#J*;LO?\ H&W'_?<7_P 71LO?^@;<?]]Q?_%T70>SEV'44W9>
M_P#0-N/^^XO_ (NC9>_] VX_[[B_^+HN@]G+L.HINR]_Z!MQ_P!]Q?\ Q=&R
M]_Z!MQ_WW%_\71=![.78=13=E[_T#;C_ +[B_P#BZ-E[_P! VX_[[B_^+HN@
M]G+L.HINR]_Z!MQ_WW%_\71LO?\ H&W'_?<7_P 71=![.78=13=E[_T#;C_O
MN+_XNC9>_P#0-N/^^XO_ (NBZ#V<NPZBF[+W_H&W'_?<7_Q=&R]_Z!MQ_P!]
MQ?\ Q=%T'LY=AU%-V7O_ $#;C_ON+_XNC9>_] VX_P"^XO\ XNBZ#V<NPZBF
M[+W_ *!MQ_WW%_\ %T;+W_H&W'_?<7_Q=%T'LY=AU%-V7O\ T#;C_ON+_P"+
MHV7O_0-N/^^XO_BZ+H/9R[#J*;LO?^@;<?\ ?<7_ ,71LO?^@;<?]]Q?_%T7
M0>SEV'44W9>_] VX_P"^XO\ XNC9>_\ 0-N/^^XO_BZ+H/9R[#J*;LO?^@;<
M?]]Q?_%T;+W_ *!MQ_WW%_\ %T70>SEV'44W9>_] VX_[[B_^+HV7O\ T#;C
M_ON+_P"+HN@]G+L.HINR]_Z!MQ_WW%_\71LO?^@;<?\ ?<7_ ,71=![.78=1
M3=E[_P! VX_[[B_^+HV7O_0-N/\ ON+_ .+HN@]G+L.HINR]_P"@;<?]]Q?_
M !=&R]_Z!MQ_WW%_\71=![.78=13=E[_ - VX_[[B_\ BZ-E[_T#;C_ON+_X
MNBZ#V<NPZBF[+W_H&W'_ 'W%_P#%T;+W_H&W'_?<7_Q=%T'LY=AU%-V7O_0-
MN/\ ON+_ .+HV7O_ $#;C_ON+_XNBZ#V<NPZBF[+W_H&W'_?<7_Q=&R]_P"@
M;<?]]Q?_ !=%T'LY=APZBMNL(+>[A_Q+KC_ON+_XNMVHDS>C%J]PHHHJ3<**
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BO.M6\?7.A?&>WT*^?\ XD]W9Q@-L&(9F9@I+8SAL8Y/I1XW\?7.
ME^//#OAO1GP]Q>1?VA($#!(W.%CY'!;!/K@4+6UNKL#TO?HKGHM%<[K?CWPS
MX=U%;#6-6BM[E@&,>UF* ]"VT':/KBHY?B+X5@TFPU.?5HX[/4-XMIGC<"39
MG=VXZ=^O:CI<=GL=-17$V?BUKOXC&"*^7^PVT);]-Z! "9"-Y) 8?+V-:Q\<
M^'4\.IKDFHK'ITC[(II(W7S6S_ I&6_ '-'2_P#6]OT%UM_6USH**X_5_B/H
MEOX)O==TF^CN?)5XXAY,C8FVDJKJ!N4<=\?6H]#^)FAWW@X:UJ-V8!;0PM?-
M]EE5(W? PN5Y&[N,_6COY!V.THKGM$\=^&O$6H-9:/JL5Q<JI;R]K(6'JNX#
M</<9K)\)^, /!^H:QXJU&..*VU*Y@\Z0*@"+(55< <G''J:/^'_3]0.WHKF]
M$^(/ACQ'J'V'1]46XN?*:8Q^4ZE4! ).X#'4=:-/^(7A75-:_LFPUF":\+%5
M0!@KD=0K$;6/T)H\@.DHKG=5\?>&-$U7^SM3U>&&Z&-Z89A'GIO(!"_B170H
MZR1J\;!E895@<@CUHZ7#R%HKSKQGX]NO"?Q*T.SG;.C7=NWVL;!^Z)<*LF<9
M !(![<T?$_Q_<>&Y])TO1)!]OO;B)II H?R8"X4DY!'S$X'XT+6UNKL#TOY*
MYZ+16#KOC7P]X:N([?6M2CMYY%WB(*SL%_O$*"0/<\5/J'BO0]+T./6+[4X(
M]/E ,4X;<),]-N,EC["CI<.MC7HKSBQ\?+K_ (IUY-&UI!I-KHPGCE^SY^SR
M[F#,5(#'  .TUT"^,-)T3PAI>I>(-;BD6Z@0I<^24-R2H.Y8P-W.<XQQ1TO_
M %NU^@=;?UT?ZG3T5CVGBS0K[P^^N6VIV[:;&"9+@MM5,=0<\@^QYK/TCXD>
M%-=U2#3M*U99[NXW>7%Y,BD[1DGE1@8[GKVHZV#I<ZBBN5T7Q/9VGA2YU;6_
M$,%W;PW4T;79@, 7#D"/:>21TXZUDZ1\0+?Q)\3;6PT#4UN=+.F22S1>5M(E
M#@ G< PX/TH6KLOZTN#T3?\ 6]CT"BBB@ HHHH **** "BBB@ HHHH ****
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M.BCE#V_D7/[<TS_G\C_.C^W-,_Y_(_SJG11RA[?R+G]N:9_S^1_G1_;FF?\
M/Y'^=4Z*.4/;^1<_MS3/^?R/\Z/[<TS_ )_(_P ZIT4<H>W\BY_;FF?\_D?Y
MT?VYIG_/Y'^=4Z*.4/;^1<_MS3/^?R/\Z/[<TS_G\C_.J=%'*'M_(N?VYIG_
M #^1_G1_;FF?\_D?YU3HHY0]OY%S^W-,_P"?R/\ .C^W-,_Y_(_SJG11RA[?
MR+G]N:9_S^1_G1_;FF?\_D?YU3HHY0]OY%S^W-,_Y_(_SH_MS3/^?R/\ZIT4
M<H>W\BY_;FF?\_D?YT?VYIG_ #^1_G5.BCE#V_D7/[<TS_G\C_.C^W-,_P"?
MR/\ .J=%'*'M_(N?VYIG_/Y'^=']N:9_S^1_G5.BCE#V_D7/[<TS_G\C_.C^
MW-,_Y_(_SJG11RA[?R+G]N:9_P _D?YT?VYIG_/Y'^=4Z*.4/;^1<_MS3/\
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MFAU(+S_CT?\ #^=9=:EY_P >C_A_.LNG'8BM\05!=V5K?VY@OK>*YA)#&.9
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M)Y9,VX-#TJUOFO;;3+2&Z?.Z>.!5<YZY8#-%WH>E7]R+B^TRTN9PNT2RP*S
M>F2,U@Z3\1=*U74K2T^QZC9B^&;2>[MC''<'&<*V>3BF:=XETO2['Q!?WFH7
MSP6>I212?:\-L?Y?DB"\E>1@=:-.O]?U<=I'1S:-IEQI\=C<:=:RVD0 2W>%
M3&@'3"XP*<VEV#VL-LUE;F"!E>*(Q+MC8="HQ@$>U8NC>.-/U?4&L'M+_3KS
MRC-'!?VYB:5!U9>QH\+>-[#Q<2=+L[](E0LT\\&V,,#C9NS@MWXS3ZDV:1O-
M9VSWJ7CV\37,:%$F* NJGJ W4 ^E5'\.Z*\\DSZ18M+(P=W-LA9F!R"3CDYY
MK 34+C2?BM<V=Y=2M8ZG8"XMTDD)2*2(X<*#P,J<G%<[X \7W]UXGU>36YY/
ML&I1/J&G"1R0D4;LA"@]. #@?6I36GS_  _X9E\KL_E^)Z+=Z)I5_=)<WVFV
MES/']R66!69?H2,BI+[2[#5(5BU*RM[N-3D)/$K@'Z$5Y/'XBU*QT;P[K^HW
MNH-'JFM2SM;QN[DPE6"1! >1P"!TYKT#1_&VF:LM\)([K39M/3S+F"_B\IXT
MQD/CGCBGI;7I_DF)QDGI_6K1N"SMA9_9!;Q"VV[/)"#9M],=,5!!H^FVNGO8
MVVGVL5I)G?;I"JQMGKE0,&N?T[XC:1J.H6UN;;4+2*\;9:7=U:F.&Y/8*WOV
MSBJ.A>)8]+A\67VNWLK6UIK$D48=BY487:B#ZG@"CU_K;_,.65OZ\_\ (ZHZ
M!HYTX:>=*LC9AMPM_LZ^6#Z[<8JW:VEO8VZV]E!';PI]V.) JK] *Q=#\866
MM:@]@;2^T^]6/S5M[Z#RVDCSC<O)!&:Z"F2[[,****!!1110 4444 %%%% !
M1110 45YC\,O&5S<2:CI?B&=RR2S7%G<3OGS(5<AQD_W2/R-'@WQE<ZUXX\0
M:AJ$TEOH\5DLUJDC$(L(9AYF/4X)SZ4DT[>:N7*FU?RT_$].HKE=+^(&EZGJ
M%M;?9=0M$O219W%U;&.*Y.,X1O<<C.,U1\1_$*PM[?5K.PMM3N7M8I(Y;RSM
MBT5O)M/#..A!].E*3LKA&#;L=Q17 ^'=4\T>"EO=0U)KN[TYWV!P8IB$4EI<
M\D\\5?NOB3HUK>S1>1J$UI;R^3<:A#;%K>%\X(9_8^@-4]';^NQ*BVKHZ^BN
M<UKQMI^CW\5C';7NIWDD7G>1I\'G,D?9SZ"L>]\9Z9KWA<:A;S:M80Q:K':%
MH56.5GW 8()^Z<\YY]J6[_KO8?*[7.[HKF=8\=:?I.K/IL=GJ&HW,*![A;"V
M,OD*>A?T^G)JM\,=0GU3P-#=W5Q-</)<3XDF8LVWS&P.>>!VH3OL#BTKLZ^B
MN%^*VIZKI.@Z9/H4DBWAU.)51&(\WAOD/J#Z57\4_$%?^%=07^@[FU'5(V2W
MC4_-$P!,A/IL /XXI.5DWV*5-MKS/0J*XG2O&,&D^"_#OV_[9J.I7UFC)!;H
M9IIL*"S')_,DUIQ>.=%?PY<ZS+++;PVLGE3PS1E98Y/[A3KNY%4]&UV(46TO
M,Z.BO.?^$QDUKXC>&[6WMM6TR-EN6FM[R)H1,-@VMC.& (/TK4TOQ1I>E:#J
MNHW=_J$\,.IS0'[6 \ADW >7&%ZKGH*7]?C8?*_Z^?\ D=E17.Z-XUT[5Y[F
MWE@O-,N;:+SW@U"'RF\O^^.Q%9+_ !6T=$CF&FZNUI-*L4%Y]DQ#,6; *L2.
M._..E/K8.5G<45S+>.M/_P"$LF\/16>H37L$D:R&*#=&@< [RP/"C/.<?C5=
MOB3HJW3#R;YK%)O(;4Q;DVROG&-_UXSC%):ARLZZBD!STI:9(4444 %%%% !
M1110 4444 %%%% !1110 4444 %<]XQ\0'P_IUM+&1YDMP@V^J Y;]!C\:S_
M !)XFU[P[,7?3;>>S8X2X4MCZ,.QKS_Q+XGN?$L\#W,20K I"HA)&2>3S]!^
M5=='#N34GL>-CLQA3A*$;J?H>WHZRQJ\;!D8 J1W!IU>3Z5\1=2L["VL([**
MX:)!$A);<V. ,#\J[JVN_$L^CM<R6-G#='!CMG9LD>YSP?;\\5G.A*&YU4,?
M2KKW+M]=#>KG- \1C5O$6L6.X%+:0>3[J/E;\-PS_P "KE;SXE:O:RRVUQI<
M-O.N5(;=E3ZX-<GH6N7&@ZL+^W42/M965R<,#Z_C@_A6T,++E=_D<%?-::JP
M4'HGKH>\T5PFA>,]?\077E6.E6VQ3^\F=F")]3Z^U7_$OB#7O#^9ET^WNK/_
M )[IN&W_ 'AGCZ]*P=&2ER]3T5CJ4J;JJ_+WLR]XQUI]"\//<P'$[R+'%]<Y
M/Z UL6MREY9PW,)S'-&LB_0C(KQCQ+XMNO$J6Z7$,<"0%B%C).XG')S]/UK0
MT;X@W^DZ5!I\=I#.(055F)W$$Y X^N*W>%E[-6W/-CFU+ZQ*[]RRMZ_T_P #
MUVBL?0+S6+^V^T:Q9PV2L/W<2DE_J<]/IU^E;%<<ERNQ[D)J<5)!1112+"BB
MB@ HHHH !U%;=8@ZBMNHD=-#J07G_'H_X?SK+K4O/^/1_P /YUETX[$5OB"B
MBBJ,3B=89O#_ ,3;#6ID8V&IVPTZ:11GRI=^Z,GV.<5'J<'BFTU&^@DT.T\4
MZ9<R&2V$TR1M; CE&##!'ICFNY*AOO 'G/-+4VTMZ_CK^9?-K<\MD^'6JQ^!
M=,MHV1K^PU!KX6L-PT2A6)S$D@Y4@'@^M'_"':K>:%X@GDT::VU"ZL#:6R7.
MJFZED!.<%F.U1GIS7J55-3U.TT;3)]0U*7R;6W7=))M+;1]!DT-*S_KI;\AJ
M<KJW]:W_ #.:UW0M0O+;PDMM;[FTZ^@EN?G4>6BH0QY///IFL>;P7K%UI.N*
MD<<-V=?_ +3LEE<%)E7:0&QG .#UKO+W5K+3]'DU2\F\NSBB\UY=I.%ZYP!G
M]*L0S)<6\<T+;HY%#J<8R",BJ>[?]=/\B8R:BET_X?\ S.)MM.\1>(?%EAJ^
MN:7#I$.EPRK%"MRLSSO(NTG(X"@>M:WP_P!*O-$\#Z?I^I0^1=0A_,CW!L9=
MB.02.A%=)2,P52S< #)I;(')O0X?XG^&M5U[2;.?PVN=3M9653O"_NI%*/R2
M.Q!_"L[QQX#U&?PQHEKX54"[T^,V;$,%S Z;)#DD?6NXL_$.DW^F6NH6]]%]
MEO'\NWDD/E^8V2-H#8.<@\5+<:O96FJV>FSS;+N]#F"/:3O"#+<XP, ]Z7*M
MO/\ K^O,I3DK>5SG=8\-W'VCPC#I=OOM=)NU,IW ;(Q&5!P3SSCI577?"5[K
M?BW66V^397^A_8UN-PXEWDX(SGI[5U>L:Q::%I<FH:D[);1%0[JA;;D@9..W
M/6K<<B31))$P='4,K*<@@]#3:YKW\_Q5A*3C:W]6=SSLZ3XKUZ'1M&U?2;73
M[33+B&::]CN0_G^5T$: 97/O45_X%U74]&\0P;!!/-KG]H6>Z7 F50N/F4Y7
M//N#7IE%#UU_KI_D@4VM%_6_^9P7A+P[?+XD&JZMI%Q8M;PM'$]UJSWCDMUP
M,D!?UKO:**?2Q+=W<****!!1110 4444 %%%% !1110!YI8_#1]6\&PV&MF3
M3KR#4+B9)(F#,8I'.5R#T935R]\$W%YKNOV\,(M=-O=&BL;:4,,*RYXV@YP.
M.U=_14\JM;^MK%^TE>_];W_,\NT#PAJQU/2X=9T>=(=.=9#=2ZU)-&7084QQ
M9X^AQ@58.D^+- L-:T32=&M]3M-0EGE@O#=K&8_-SE74C)()[5Z313:OO_5_
M^&!3:=_ZT. TCPSJUKJ'@F2>UV)I>GRPWA\Q3Y;M&H X//(/3-06&F>,/#NG
MW'A[2M)LKNUDN'>#4IIQM1'?<?,C/+$9/2O1J*;U=_ZWN)2LK'#WNF>(- \7
MW&MZ)IL.LQ:A:Q0SP^>L#Q/'P&4GC:<]*Q8?"OB.;PC=PWFG)'?7'B);\Q1S
M*5$?F*Q(.?8\=?:O4J*2T=_ZWO\ H/F=K?UM8X62P\2>&_%6KWNAZ3!J]IJ[
MI*=UR(7MY NTYR.5XSQS4?@XZQX7TG0]$U'35^U7UU=-/MG!\A=S/N&,Y'('
M4=17?44)6!RNK'+^-](OM7CT0:?#YIM=6@N9OF"[8U)W'D\]>@YK.F^'-I9W
MNO:IIY>6>^M9DMK5L!('D4[RN3@;CCTKN:*3BFFO7\5;] 4VK?UUN>67?@C6
M8K'PU?P6LT]UI^FBRNK*"_-M)T!RLBG'!SD9P:LCP+J$_A*X>&T2QU9[^._2
M&XO'N?,:,_*)'/<C(XXZ5Z513ZW_ *WO^8<[LE_78\_B@\5:UX\T'4]5T"/3
M;33UG60B\25LNF,\8XR..OO50>#-:;0;DQ0Q1W]MXADU2UAF<%)TSP"1G&03
MUZ5Z711Z?UJG^:#G?]?/_,XV.U\1^)X]2BUW3;;1;2>R>UC195FF+MU;>O 4
M>E<[J&F>-;WPK8>&Y/#UMY=C-;AKV.\3$J1N.50X(.!DY]Z]4HHZW]/PU#F.
M7T/1KRU\9>*+VZA\NVU!H/L\FX'>%CVMP#D8/K7#VOP_UBTM_P"P)]+FOK$S
M'_2_[9DC@,1;=\T(/WO8#&:]@HHLM YV-C01QJB]%  _"G444R HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH AO&@2RF:[56@6-FD##(*@9.1]*\(MM-O
M-:O)_P"R[)Y -TA2,<(O7'^ [U[CJNG_ -J:9-9-*T*3 *[(.=N>0/J./QI=
M.TVTTFS6UT^!88E[#J3ZD]S731K*E%VW9Y>,P3Q=2*;M%?>>:?#-X(O$D]O=
M0+]H:(^4SK\R,IY ]"03^5>K5DWGAVSNM7MM4B'V>]@<-YL8_P!8O0JP[Y&1
MGK_*M:HK3527,C;!8>6&INE+H]&>=_%26V$5C#Y49NF9F\S'S*@XQGT)/Z5P
MEWH^H6%K#<WEG+##.,QNZX!_P_&O:9?#MG<Z^=6O1]HE152!''RQ >W<Y).:
MT;FVAO+=X+J)98I!AD<9!K:&)5.*BE<X,1EDL34G4D[=O^"9OA:6VG\+V$ME
M$D,;1#*(, ,.&_4&M60(8V$NTI@[MW3'?-9^BZ-%H=M+:VCLUNTIDC1^3'G&
M5SW&>?QJSJ%JU]IT]JLIA\Y#&7 R0#P<>^,US2LYZ;'K4U.-)*2U2/#VLIM<
MURY71+)F5Y&=(HQPB9X]A6U\/_*M?&2VVH6P$S(R1^:N#'(.>_0X!%>HZ5H]
MEHMF+;3X1&G\3=6<^I/<U6U3P[9ZE>07P'D7UNZO'<(.3@]&'<5URQ*DG&VA
MXU/*ITY1JIWDG=KI\C7HHHKA/H HHHH **** "BBB@ '45MUB#J*VZB1TT.I
M!>?\>C_A_.LNM2\_X]'_  _G673CL16^(****HQ"BBB@ KE/B=_R3+7/^O;_
M -F%=76?KNC6_B#0KK2KQY$@NDV.T1 8#.>,@CMZ5,TW%I%TVHS39YKXGUWQ
M9-\-;VWN_!ZVUFUB%>Z_M.-]JX'S; ,GZ5:U/Q9J$.J:?H-C?R:7##ID-Q+<
MPZ>UW([,,!0H! '')-=]J>AVVJ^&YM$N'E6VF@\AF0@.%QC()&,\>E9NI^";
M#4FM)H[J^L+NU@%NEW93^7(T8_A8XP1WZ4Y7YF_ZZ_YH<7'E2:[_ *?Y,YE/
M&NOW/AG3[=(TM]7OM2.GI=SV[1H5 SYPC;!R5[>M6["Z\2Z;X_30]:UM-3M)
M=+EN5*VJ0MN# <X].>E;UQX*TJZ\-1Z+<&YDBB<2I</.QF63.=X?KNJOI'@*
MQTC7/[7.I:I?7AMVMC)>W'F90D'TXQCM2:;O_73_ #U'S1M_7?\ RT/-4L=0
MG^'_ ((DM=6>UB;4TB2(0HP20RR8ER1DD=,=*Z?Q-I^MIXQ\'V=MK*OJ6R[!
MU":V7@;02=BX&<<"NF/@32CX/M_#K27)MK9_,AG$@6:-PQ8,& &""3VJ:U\(
M6UO>:3=RW]_=W&E"812W,P=I/,Z[SCG';&*KK\[_ ( YK?\ KJ9GAJ\U&^O_
M !!X8\3SQ:D;(1C[2(1'YT4J$X91P",'I3_A;-)+\/[-)'+BWDE@C8GJB2,%
M_08_"K6K>&;E#K=_X>N?)U35XXHG><_NXE4;=R@#.=I)Y/7%:V@Z/;^']!M-
M+L\F*VC"!CU8]V/N3DTEY_U_7ZDR:MI_6G^?Y&A1113("BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH ****  =16W6(.HK;J)'30ZE>_
M;;92':[=.$0L>H[#FL;[1_TPN_\ P%D_^)KH:*E.QI*FI.[.>^T?],+O_P !
M9/\ XFC[1_TPN_\ P%D_^)KH:*?,R?8Q.>^T?],+O_P%D_\ B:/M'_3"[_\
M 63_ .)KH:*.9A[&)SWVC_IA=_\ @+)_\31]H_Z87?\ X"R?_$UT-%',P]C$
MY[[1_P!,+O\ \!9/_B:/M'_3"[_\!9/_ (FNAHHYF'L8G/?:/^F%W_X"R?\
MQ-'VC_IA=_\ @+)_\370T4<S#V,3GOM'_3"[_P# 63_XFC[1_P!,+O\ \!9/
M_B:Z&BCF8>QB<]]H_P"F%W_X"R?_ !-'VC_IA=_^ LG_ ,370T4<S#V,3GOM
M'_3"[_\  63_ .)H^T?],+O_ ,!9/_B:Z&BCF8>QB<]]H_Z87?\ X"R?_$T?
M:/\ IA=_^ LG_P 370T4<S#V,3GOM'_3"[_\!9/_ (FC[1_TPN__  %D_P#B
M:Z&BCF8>QB<]]H_Z87?_ ("R?_$T?:/^F%W_ . LG_Q-=#11S,/8Q.>^T?\
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M%D_^)H^T?],+O_P%D_\ B:Z&BCF8>QB<]]H_Z87?_@+)_P#$T?:/^F%W_P"
MLG_Q-=#11S,/8Q.>^T?],+O_ ,!9/_B:/M'_ $PN_P#P%D_^)KH:*.9A[&)S
MWVC_ *87?_@+)_\ $T?:/^F%W_X"R?\ Q-=#11S,/8Q.>^T?],+O_P !9/\
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MA=_^ LG_ ,31]H_Z87?_ ("R?_$UT-%',P]C$Y[[1_TPN_\ P%D_^)H^T?\
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M_P#KTE_] ->5_#;Q\?#WP]EM/%#'SM/LDO+(D\W,#\(J^I#?+^5*^_E_P?\
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MP)W-T!P3[57TG5=5U/XV61US1)-'N(]%E B:X697!E7D,OY4+5K^NEP>B?\
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M85PVJ^"==T;2XM0OK,B!QE]AW&'TWCM_GOQ7NZ:)8KKDFKM%YEZZA%D?GRU
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MZ!TW_?Q/\:/[:F_Z!TW_ '\3_&HJ*.5![:1+_;4W_0.F_P"_B?XT?VU-_P!
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M$*?>DE8*J_4FI 00"#D'H17G&K^+KN7P7XCM]<TJQ?4]'>))[=P9+>8.RE7
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MB@ HHHH ****  =16W6(.HK;J)'30ZD%]O\ L;^7&TK<81<9/(]2!61_I?\
MT#KG\X__ (JMZBI3:-94U)W9@_Z7_P! ZY_./_XJC_2_^@=<_G'_ /%5O44^
M9D>QB8/^E_\ 0.N?SC_^*H_TO_H'7/YQ_P#Q5;U%',P]C$P?]+_Z!US^<?\
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MKG\X_P#XJC_2_P#H'7/YQ_\ Q5;U%',P]C$P?]+_ .@=<_G'_P#%4?Z7_P!
MZY_./_XJMZBCF8>QB8/^E_\ 0.N?SC_^*H_TO_H'7/YQ_P#Q5;U%',P]C$P?
M]+_Z!US^<?\ \51_I?\ T#KG\X__ (JMZBCF8>QB8/\ I?\ T#KG\X__ (JC
M_2_^@=<_G'_\56]11S,/8Q,'_2_^@=<_G'_\51_I?_0.N?SC_P#BJWJ*.9A[
M&)@_Z7_T#KG\X_\ XJC_ $O_ *!US^<?_P 56]11S,/8Q,'_ $O_ *!US^<?
M_P 51_I?_0.N?SC_ /BJWJ*.9A[&)@_Z7_T#KG\X_P#XJC_2_P#H'7/YQ_\
MQ5;U%',P]C$P?]+_ .@=<_G'_P#%4?Z7_P! ZY_./_XJMZBCF8>QB8/^E_\
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MFJZNS!6!*'# '[IQG!_ C\Z.9A[*!A_Z7_T#KG\X_P#XJC_2_P#H'7/YQ_\
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MM[),@L;R.\C\H@9=,X!R#QS6M10!1O='L[ZUOHGB6-K^$PSS1J!(RE2O7'.
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MU+45:GM)<W4VP>%^JT_9)W5]/\CRWXDQ7_B;Q59:#I$+3M;1>9+CA49^['L
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M -_C4U%%D'/+N0^3+_S_ %W_ -_C1Y,O_/\ 7?\ W^-34460<\NY#Y,O_/\
M7?\ W^-'DR_\_P!=_P#?XU-119!SR[D/DR_\_P!=_P#?XT>3+_S_ %W_ -_C
M4U%%D'/+N0^3+_S_ %W_ -_C1Y,O_/\ 7?\ W^-34460<\NY#Y,O_/\ 7?\
MW^-'DR_\_P!=_P#?XU-119!SR[D/DR_\_P!=_P#?XT>3+_S_ %W_ -_C4U%%
MD'/+N0^3+_S_ %W_ -_C1Y,O_/\ 7?\ W^-34460<\NY#Y,O_/\ 7?\ W^-'
MDR_\_P!=_P#?XU-119!SR[D/DR_\_P!=_P#?XT>3+_S_ %W_ -_C4U%%D'/+
MN0^3+_S_ %W_ -_C1Y,O_/\ 7?\ W^-34460<\NY#Y,O_/\ 7?\ W^-'DR_\
M_P!=_P#?XU-119!SR[D/DR_\_P!=_P#?XT>3+_S_ %W_ -_C4U%%D'/+N0^3
M+_S_ %W_ -_C1Y,O_/\ 7?\ W^-34460<\NY#Y,O_/\ 7?\ W^-'DR_\_P!=
M_P#?XU-119!SR[D/DR_\_P!=_P#?XT>3+_S_ %W_ -_C4U%%D'/+N0^3+_S_
M %W_ -_C1Y,O_/\ 7?\ W^-34460<\NY#Y,O_/\ 7?\ W^-'DR_\_P!=_P#?
MXU-119!SR[D/DR_\_P!=_P#?XT>3+_S_ %W_ -_C4U4=5U6WT>UCGNCA9)DB
M'U8XS^ R?PIJ-W9"E5<5S2>A8\F7_G^N_P#O\:/)E_Y_KO\ [_&IJ*5D/GEW
M(?)E_P"?Z[_[_&CR9?\ G^N_^_QJ:J-EJL%]?WUI"<R64BH_/7*Y_GD?A3Y;
MB=5II-[ECR9?^?Z[_P"_QH\F7_G^N_\ O\:FHI60^>7<A\F7_G^N_P#O\:/)
ME_Y_KO\ [_&H-7U2'1M+EOKGF.,J" >3D@?UJX"& (.0>01WI\NEQ>U;ERWU
M(O)E_P"?Z[_[_&CR9?\ G^N_^_QJ:BE9#YY=R'R9?^?Z[_[_ !H\F7_G^N_^
M_P :FHHL@YY=R'R9?^?Z[_[_ !H\F7_G^N_^_P :FHHL@YY=R'R9?^?Z[_[_
M !H\F7_G^N_^_P :FHHL@YY=R$0R[A_IMWU_YZFNAK$'45MU$CHHR;O<@O/^
M/1_P_G676I>?\>C_ (?SK+JH[&=;X@HHHJC$**** "BBB@ KC-1\4:[J7B"[
MT?P78V<K6!"W=[?NPA1R,[ %Y)Q^5=G7G%KK,/P\\2:W#XBBGBTW4KPWMMJ"
M0M(F6 W1MM!(((XJ>NI<5H[*[-C1_%NHO=7^C^(K&*RUFSMC<IY3EH;F/^\A
M//7@@\U:\(^+K77M"TV2\O;)-3NX!(]K'* P/LA).*YVUN)/%WBN[\26EM-!
MI-CI<MK;S31E#<N_)8 \[0!7.'0=,L?@AI&KV=C##J4<EO.+I$Q+O,H!.[KT
M/2G&_7R_%M?E9E.*V7]:(]5M[Z[D\47EE))8FUB@C>-(Y2;@,<Y+KV7C@U8M
MM8TR\O)+2TU"UGN8_OPQS*SK]0#D5P6KP7]UXQ\90Z26%[)H<*P[3@EOGX'O
M6' V@WR>&;'P?IDEOKUI=0M<LMJT;P(O^M\UR!G//4G-*+O9?UNU^%A.*U?]
M;)_B>S44451F%%%% !1110 4444 %%%% !1110 4444 <?=>.!8?%&'PO>I&
MEO=6BR038.[S26^4G.,$#CWH\5^.!H7BC0M"LTCENM2N46;?D^5$3C/!ZD]/
MH:P?$.@+XD^)FK6.[RIQHL4MM,.L4RRDJP_']*S;O0-2L9M U;Q*4DUS4=?@
M,Y0Y6-%5@J#V[_C4PN^6_?\ ]NM_7D;.,=?3]+_UYGJ=YK&FZ?-'#?ZA:VTL
MO^K2:94+_0$\TS^W=(\B";^U+/RKC=Y,GGKMDV_>VG/.,<XZ5YO<2^']+\5^
M)%\=V!GNKR;=8R36K3"6#: J1D X(.?2LK0]-M-4T3X<V=_;+-;-<79:&0<'
M&X@$?4#BB+NON_'_ "$X)?C^5STFW\2O=>/#I$#6\NGG2UO4G0Y+$R;?O9P5
MQ[5K+K6EOI[WR:C:-:(Q5K@3*8U(Z@MG%>7^-=%UF_\ B!/IGA1H;0'00LB@
M;,QB0_NUQTR<#Z56UJ\@U+0/"]YIMI#::1ILTD-_:3VS31VDP4 >9&I!(!SS
M[YH3T_KN_P#AA\BO_7;]3TW5_%6EZ7X9N-:6]M9X(XV,1%PH69P"0@;D9./>
MH]'\8:-JV@QZG_:-E$OE1O<+]J0BW9QPK'L<\<XKA-!T:/5_#WBR>Q:VO8+V
M B"&WT]X(!,(V&Z,.3R<CD=ZHZEJ>AWGP1N;338E6[M(;.._B%N8W#AU!!X&
M3D'UIWW^7X_U^0N1.R\_\CUNSU?3=1EDBT_4+6ZDB_UBPS*Y3Z@'BLCPKXDD
MUC0;O4-5-O;BWO)X"R_*@1'(!))/;K7'6TN@ZIXT\.GP)9>3+9NQOY8;5H5C
MAV$%),@9).,#FLL6[2>";>:ZMY;K2;?Q)<2ZC#$I8M$';DJ.J@X)%*^O]=UK
M^(<JM_79Z?@>LV>NZ3J,RQ:?J=G=2,I=4AG5R5!P3@'I3H=8TRXOGLK?4+66
MZC^_ DREU^J@Y%>4Q3:1JOCZZ;P! ENTF@7"))#;F!7EW#&,@<CCFI_#LWA)
MX?#^G6FBW/\ PD%M+'YXB@:*:!P/G>60@97.>YS36MOZZM?H*4+)_P!=+GI]
MSK&FV5W':WFH6L%Q+_JXI9E5G^@)R:NUX7J\/V76_$MIXA>QBN;ZZ<P-=:7+
M<32Q$83R75@!CT'0BO5?#FH0P0VGA^>[DGU.TL(I)C)$REE(P&.>,\=,YHB[
MJ_\ 7](4X\K,[Q!XX'A[Q]H^BWB1K9:C"V9CG=')NPO.<;3TZ=Z/'OC@>$AI
MMM:I'+?:A<I&L<F2%CW ,QP1ZX'O65XNT6W\0_$RRTR\'[NXT6=0PZHV]2K#
MW!P:YS6O#6L6GATZQXMD2?5GO[.TB*'(2!)%P1[L?F-*+;M?O^%[?UY%N,?P
M_2_]?\$]<OM6T[3-G]I7]M:>8<)Y\JIN/MD\U+<7MK:6ANKJXBAMU&3+(X50
M/7)XKR7Q8&T_XB:K=:ZU@EI<V\2V4NHZ=)=(5"X9$VD;6W=1U.:)]-_LOP]X
M/EUY9]1\/VDLSW(:V8! V?*+QG)VKTY]J$[JXO9K^O2YV2>,)+WQ)JMCI<^G
MS6EKI:W<%R9,H9"6'S.#C:,#I6W:ZO%#X?M=0UF\L8/,B5I)DF'D%B/X6/4>
ME>8V%QHEWXB\83^&;=8;%]!XV0&)7;YLLJD#CWQVIY%G:0^"]1\46S7&@1:.
MJ9:$RQPW!5<,Z@'JO .*$]/Z[R_R&X*_]=H_YGK$-[:W%F+N"YBDMBNX3(X*
M$>N>E5;7Q!HU].D-EJUE<2R$A$BN$9F(&3@ \XKS?4K>SOO 5_-X7TF^BT=]
M4CFN(%4K]I@!'F&).H4^F!G!IME?>%K_ .*?AF3PC:1Q*D5RL[PVAA4_N^%.
M0,D<_G36KM_6UR>32_J>AZ+JLL^CS7FKW.G#RYI%:6TFW1*JM@98]&'?WK/@
M\7)?>.[72=,N+.[L)K![AIH7WD.KA<;@<8P?2O/TMVD\!64UU;RW6DV_B&>7
M48(E+%HA(_)4=5!P2*U?#EWX=OOC!#/X3MDAM3I,@D>*V,*.WF+T! S@=\4H
MN[7]?9N.44E+^OM6/4Z***HR"BBB@ HHHH **** "BBB@ HHHH **** ,.Z\
M8Z%8W3V]W>F&:,X9'@D!'_CM<)\0/$]GK7V.VTN?SH(LR.P5ERW0#! Z#/YU
MZ!KWAO3_ !#:[+V/;*H_=SIPZ?XCVKPZ=$CN)$B?S$5R%?&-PSP<5WX6%.3Y
MENCYS-:V(IQ]G*W++MOI\SUO2?'VBMI%K_:%_P"7=")1*IC<_,!@G(&.>M:L
M?BK1Y;"2]CN9&M8VVO*+>3:I^NVO,_ OA^RU_594U"1ML""00KQY@S@Y/8#C
M\Z]?BMH(+9;>&)$A5=HC50% ],5E7A3A*RN=N K8FO3YY62Z;W^>I@OX^\.+
M&S+J&\@$A1"^3[?=K@O!_B9-/\4W%WJDVR&]#F9\$X;.X' YZY'XU=^(7AK3
MM($-]8'R&N)"IM@/EZ9+#T[<>]<-751I4W!\O4\?&XS$PKQ4[7AKIM^9[9'X
MX\.RR+'%J&]V.%58)"2?3&VIKSQ=HFGW)M[Z\:"51DH\$@/_ *#5+P?X8TW2
M].M[Z#_2+F>)7^T..@89PH[=?K6KK6@V&O6GD:A%N(^Y(O#H?8_TZ5PM4E.V
MMCWX2Q<J/,^7F[:V^^YP7C_Q58:OI]K9Z3<^>GF&24A&7&!A1R!ZG\JV_#OC
MK1X_#UG%J=[Y5U%&(W4QN?N\ Y /4 5YAJ-M'9ZE<VT,OG)#*R+)C&X XS6O
MX,T.TU_7/LU],R1I&9-B\&3!'RY[=:[Y4::I6>RU/GJ6-Q,L4W%+FEI;I^9Z
MWI>O:=K6_P#LR=IQ']YA$Z@>V2 ,^U:-0VEI;V-JEO9PI##&,*B# %35Y<K7
MT/K8<_*N??R"BBBD6%%%% !1110 #J*VZQ!U%;=1(Z:'4@O/^/1_P_G676I>
M?\>C_A_.LNG'8BM\044451B%%%% !1110 4A /49I:* $HP,8QQ2T4 )1@#H
M*6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 3'.>]&,]:6B@!" >HH
MP/3I2T4 )CG/>C ]*6B@! ,=.*QO%7A\>)O#L^EBX^R^:\;>;Y>[&UPW3(],
M5M44#3:=T(JA0 *,#TI:*!"  = !1@9SCFEHH 0@'J*KQV%M%J$U\D>+F=%2
M20DDE5S@>PY/3UJS10 F*,9ZTM% "$ ]1FC%+10 F!Z"C QC'%+10 F*-H'0
M#\J6B@!,#TH  Z "EHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,_7
M!=MH=U'IT>^YE3RXQG&"W&<]L Y_"L/P]X!T[2K<MJ"1WUU(N'+KE%!ZA0?Y
M]?I7645:J2C'E1SSP].I452:NUL<7;^#I/#WBJWU+129+-V,<UN3\T:MQD'N
M <'UX[UVE%%$YN?Q#HT(44U#1/6QR'B#PQ<^*/$D7VIS;Z;:(%!!^:5CRVWT
M[#)]*M:IX$T:_P!,2UMX%M)(EQ%-&/F'^]_>_&NEHJO:S5DGL9_4Z+<G*-W+
M>YA^$[*^TS11IVHJ-]K(R1R*<K(AY!'YD8]JTM2DN(]-N&LHS)<^61$H[N>!
MU[9JU14.5Y<S-H4U"FJ:>VAQWAKP!9Z8HN-6"7MVPY5AF-,^@/4^YJ*;P6VC
M>(K76/#^3%')^^M2>0AX;:3UX)X/X5VU%:>VG=MO<Y_J-!048QM;5/K<****
MQ.T**** "BBB@ HHHH !U%;=8@ZBMNHD=-#J,FABN(C%/&DL;=4=00?P-5O[
M'TS_ *!UK_WX7_"KE%0=!3_L?3/^@=:_]^%_PH_L?3/^@=:_]^%_PJY10!3_
M +'TS_H'6O\ WX7_  H_L?3/^@=:_P#?A?\ "KE% %/^Q],_Z!UK_P!^%_PH
M_L?3/^@=:_\ ?A?\*N44 4_['TS_ *!UK_WX7_"C^Q],_P"@=:_]^%_PJY10
M!3_L?3/^@=:_]^%_PH_L?3/^@=:_]^%_PJY10!3_ +'TS_H'6O\ WX7_  H_
ML?3/^@=:_P#?A?\ "KE% %/^Q],_Z!UK_P!^%_PH_L?3/^@=:_\ ?A?\*N44
M 4_['TS_ *!UK_WX7_"C^Q],_P"@=:_]^%_PJY10!3_L?3/^@=:_]^%_PH_L
M?3/^@=:_]^%_PJY10!3_ +'TS_H'6O\ WX7_  H_L?3/^@=:_P#?A?\ "KE%
M %/^Q],_Z!UK_P!^%_PH_L?3/^@=:_\ ?A?\*N44 4_['TS_ *!UK_WX7_"C
M^Q],_P"@=:_]^%_PJY10!3_L?3/^@=:_]^%_PH_L?3/^@=:_]^%_PJY10!3_
M +'TS_H'6O\ WX7_  H_L?3/^@=:_P#?A?\ "KE% %/^Q],_Z!UK_P!^%_PH
M_L?3/^@=:_\ ?A?\*N44 4_['TS_ *!UK_WX7_"C^Q],_P"@=:_]^%_PJY10
M!3_L?3/^@=:_]^%_PH_L?3/^@=:_]^%_PJY10!3_ +'TS_H'6O\ WX7_  H_
ML?3/^@=:_P#?A?\ "KE% %/^Q],_Z!UK_P!^%_PH_L?3/^@=:_\ ?A?\*N44
M 4_['TS_ *!UK_WX7_"C^Q],_P"@=:_]^%_PJY10!3_L?3/^@=:_]^%_PH_L
M?3/^@=:_]^%_PJY10!3_ +'TS_H'6O\ WX7_  H_L?3/^@=:_P#?A?\ "KE%
M %/^Q],_Z!UK_P!^%_PH_L?3/^@=:_\ ?A?\*N44 4_['TS_ *!UK_WX7_"C
M^Q],_P"@=:_]^%_PJY10!3_L?3/^@=:_]^%_PH_L?3/^@=:_]^%_PJY10!3_
M +'TS_H'6O\ WX7_  H_L?3/^@=:_P#?A?\ "KE% %/^Q],_Z!UK_P!^%_PH
M_L?3/^@=:_\ ?A?\*N44 4_['TS_ *!UK_WX7_"C^Q],_P"@=:_]^%_PJY10
M!3_L?3/^@=:_]^%_PH_L?3/^@=:_]^%_PJY10!3_ +'TS_H'6O\ WX7_  H_
ML?3/^@=:_P#?A?\ "KE% %/^Q],_Z!UK_P!^%_PH_L?3/^@=:_\ ?A?\*N44
M 4_['TS_ *!UK_WX7_"C^Q],_P"@=:_]^%_PJY45W<QV5E/=3G$4$;2.?0 9
M/\J!-I*[(/['TS_H'6O_ 'X7_"C^Q],_Z!UK_P!^%_PJQ;SQW5K%<0-NCE0.
MC>H(R#4E *S5T4_['TS_ *!UK_WX7_"C^Q],_P"@=:_]^%_PJY54ZC;C5ETT
MO_I+0&<)_L!@N?S/Z4[-B;2W&_V/IG_0.M?^_"_X4?V/IG_0.M?^_"_X5<HI
M%%/^Q],_Z!UK_P!^%_PH_L?3/^@=:_\ ?A?\*M.ZQ1L\C!44$LQZ #O4-A>P
MZEI\%[:MNAN(Q(A/H1W]Z>MKBNKVZD?]CZ9_T#K7_OPO^%']CZ9_T#K7_OPO
M^%7**0RG_8^F?] ZU_[\+_A1_8^F?] ZU_[\+_A3;S5[>RU2PL)CB6^9Q'Z?
M*N3_ $'XU>IV:)4HMM+H4_['TS_H'6O_ 'X7_"C^Q],_Z!UK_P!^%_PJY12*
M*?\ 8^F?] ZU_P"_"_X4?V/IG_0.M?\ OPO^%7** *?]CZ9_T#K7_OPO^%']
MCZ9_T#K7_OPO^%7** *?]CZ:.FGVO_?E?\*N444 %%%% !574]0M])TNZU"]
M8K;VL32R$#)"J,FK597BB6"'PIJ<EW8R7]N+9_-MHOO2ICY@/?&:F3:BVBHJ
M[2.3A^)>I):6NK:IX2N[/0;ID$=\+E)'57.%=XARH.1W.*] W# .1STKPT:O
M%X6T.POO WC=]3MY)8HXM O&2>1E9@/+&/G3;GT[5J:E%X?UGQ[XCB^(NH&U
M^QK'_9L,UVT")$4R9(\$;FW9]>E6[+\?T_S)1Z_FH+Z\CL+"XNYLE+>)I7"]
M2 ,\>_%>-:1J]Q OP\UCQ'=.MJDU[ +VZ.W<C*1"SD],@=35WR]'\;>+?'R0
MF+5;5;"V\HQMN4RHCXP1UP?2IG=)V\_P*BDWKY?G8[?4O&]O:_#AO%UG://"
M;=+A+>1PC$,0 "1NP>?>ND@E$T*2# W*&QG.,BO"X;/PS#^SWJ$FB&U&J2Z=
M#]O$4N9 P<#YES\O.>U=')X;LO!?B_P=<Z"]S%)J4[6U\9+AY/M(,1;+!B1D
M$9XJVES->9"?N)^OX6/0?$?B&Q\+Z)+J>ILPBC(54C7<\CDX5%'<DUR9^)&J
MZ<L5[XG\'7NDZ1*ZJ+TW"2F+<< R1CE!_*IOBI!,FE:/JR0/<VVCZI#>74*+
MN)B7(+8[XSFD\0_$GPK)X<(L9;/Q%/>;8X-*C<.UPS$85EP=H]<BH7?S_P O
MS*[([E9$9%=6!5AD$'@BEW#U'I7DVLPZ-J?Q'ET[Q_,MAIMOIL+Z;9O=&&W+
M'/F$,"H+*0 /:N5@MK2[^'\MII]Y,]G+XT6*&Y24ES&6 #!^N<=Z:U=OZW2%
MLK_UM<^@\C&<C'K6)XP\1_\ "*>&)]7%M]K\EXU\KS-F=SA>N#TSGI7!^)M'
MT33/%.@>&]8FDL?"C6TTH22Z=(Y[G<#B20G/0D@$]:YW4I8U\"^,['1KJ2[\
M.VE]9KI\CR&15)=#(B,>J@XH6K7]=;#V/:;?4+V77;FSETUHK.*%)([TRJ1*
MQZKMZC'K6@&!Z$?G7F.H$_\ "=>-_P#L7(O_ $&2N;@\-V7ASX>^$O%.E274
M>KO/9"6X:X=O,20@-&5)QMP< 8[41UM\OQ;7Z">B_KHD_P!3W(D#J0*4'/3F
MO';F+PYJ_C'Q0WQ"U(VUW8S[=/BFO&@$4&P%7B (R2<YZ\UU7P<(/PHT<ABP
MQ+@D\G]ZU$=8W]/Q"6CL=Q1110 4444 %%%% !1110!S$GC>T@^)">$;F+RI
MIK,7,$Y?B1LG*8QP<#/7FCQ1XWM/#6MZ'I+1?:+S5[I84C#[?+0G!<\'N1QW
MKA_%_AZ7Q#\6=173W\K5++18;NPE_N3),2!]#R#]:R[S3-5O-6\.^+?%-J;7
M5=0U^VABM6_Y=8$#87ZDY8_A1#7EOW_#FM_7D.6E[=OQM<]R) ZD"C</4?G7
MCUS%X<U?QCXH;XA:D;:[L9]NGQ37C0"*#8"KQ $9).<]>:Q-%TR#6_#/PSL+
MF:<6\]Q>AVBE*,ZC<<;ASSC!]C0M5?T_$&K-_/\  ]@7Q)N\>OX;^R_=T\7O
MVCS.N7V;=N/QSFMS<,9R,>M>)^-8=<T?X@2:=X#LB9%\-K%E7^:"%96)*D]6
M.,#W-0ZY=Z=_PBO@ZV\/*O\ PC=U+)]M2XNVMA),%&$GE )!+;LYZD4+5+^N
MK_R^\&K/^NR9[1JNI0Z1H]WJ5R&:&UA>9PF"Q"@D@9[\4FEZG!J^D6FHVP98
M;J%)D#X# ,,@''?FO'].T&/5O"7B^S9+&YTN"'SK&QM+][M;2X$;9VN0.O!Q
MS56^MO"]M^S_ '$OA^2U2YEM[)M0-O-EU;>N2PR2ISNH[_+\?Z_JX=OG^A[J
M"#T(-8GA/Q)_PD^EW%Y]E^R^3>36NWS-^?+;;NS@=<=*\]M8?#VC^.?#(^'M
M_P"?/?2,-1A@NVG62#829),DX(.,'BLA;AHO <$%U<S6FCW/BFYBU.>%BI6$
MR-P6'(4G )HZ_P!;W2_473^NS?Z'N@8'H0?QHR,XR,UXC%!HVC_$6[7X<W"7
M+Q>'+F1(H+DSHDVX;<9)P3P<9JQX9A\'1V_AO5+/7KK_ (22[FC%PT5PTL]Q
M(1^\26,DX7.<G QBFM?Z\VOT!Z?UY)_J>S$@'!(I:^?M8DDU'Q!XI?7OL2:A
M;7;QV<]YK+VCV<8'[MHHPI!'?(ZU[-X9U+S=)L+'4;^VN-8CLHI;E(I,L<C&
M_'7!/?%*.L;A+1V*>K>-[31O'FE>&[V+9_:D+/%<E^ X. A&._KGK1XV\;VG
M@RUL6GB^T7-_=);P0!]I.2 S9P> #_*N1^('AZ/Q1\4=.TUG,4S:-/);S#K%
M*LBE&'T(KF/$.F:]JVC+XG\:6IMK^"^L["TMST15E7S)1_OM^E$->6_?\.:W
M]?>.6E[=OQM<][) ZG%+G'6O$_&,AOOB=J]KXAALY[2VMHFL(K_5FLD12N6D
M3"D,V[OVQ2W,US)X;\%V'C#5M^A74TZWEY#<MLF SY"/+P<'H3QG%"U5P:L_
MZ[7/2)?%4H\5:GH=KIQN);+3EO8V68#SF8L!'@C Z=<]ZV=.N9[K2[:YO;4V
M<\L:M);LX8Q,1RN1P<5XWIUMH-EXH\:P>%+E9["/P[QY=P9DC;Y\JK$GCOC/
M<U)FRO+?P)IGBR[:V\.3:(LA#3&**>X"KA78$=%Y SUH6J_KO+_('O\ UVC_
M )GM6>,TFX'H0?QKQW5+JRT_X=ZE#X2UF_FT5-5B@N+A69OLEN2/-$4G5E''
M.3C)IEC8>$=.^+GA2/P7>QS*\5TUQ'#>-.H_=_*QR3@GG\J:U?\ 7:XGHOZ[
MV/5M%O[W4+%YM2TUM-E65T$3RK)E0<!LCU'.*I2^)1'X[MO#@MMWGV+WGVCS
M/N[7"[=N/?KFO*$N7C^'=E#=W,UIH]SXFN(M3GB8J5A,K\%AR%)P":U_#%CX
M8T_XV6\'@ZZCFM1HTAD2&Z,Z1MYB]"2<9'.,THZM?U]FXY:)_P!?:L>NT444
M""BBB@ HHHH **** "BBB@ HHHH HW.MZ593F&\U.SMY5&3'+<(K#\":X[XC
M^*M//@^6UTS4+6YFNW6(B"97*IU)X/MC\:Z;Q'X6TWQ/9^3J$6)5'[JX3AX_
MH>X]CQ7@GB'1F\/Z]<Z9).D[0$?O$X!! (X['!Y%=V%ITYR3OJCY[-\5B:%-
MQY5RRTOU^X]9^'GBO3F\'6]OJ6HVMM/:L8=L\ZH64<J0">F"!^%=4GB'19=W
MEZO8/M4LVVY0X [GGI7S]X;T-O$6O6^F).EN9LDNXS@ 9.!W. :]Z\/^%],\
M-V)M[" %G&)9G&7E^I]/;I1B:=.$KWU893BL3B*2CRKECI?T\B7_ (2;0?\
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MF^'K+3["ZO9(GDD$0C$FV0,=Q5<DX!_.NOHHZW HZ?HFEZ7(\NG:=:6DLO\
MK'@A5"_U('-/CTK3XK.6TBL;9+:9F:2%8E".6.6)&,$GO5NB@#.L?#VC:9,L
MVFZ396DJJ45X+=$8*3D@$#H33X-#TJVU![^VTVTBO),[[A(%61L^K 9-7J*
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MGW$^TZE_S]P_]^/_ +*C[3J7_/W#_P!^/_LJ6BCE0>TGW$^TZE_S]P_]^/\
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MJ/M.I?\ /W#_ -^/_LJ6BCE0>TGW$^TZE_S]P_\ ?C_[*C[3J7_/W#_WX_\
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MWZUT%%%EL',^Y2TK2+'1-/2RTJV2VMT)(1?4]22>2?<U=HHIB"BBB@ HHHH
M**** "BBB@ HHHH **** *2Z18IKDFKK#B^D@%NTNX\Q@Y QG'7OBDU#1['5
M6M&OX/--G.MQ!\Q79(.AX//7H>*O44!=F!K'@CP[KVH+>ZKI<4]R  9-S*6
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M^?VW_P# 9O\ XNC^RK[_ )_;?_P&;_XNM>BB[#V<>QD?V5??\_MO_P" S?\
MQ=']E7W_ #^V_P#X#-_\76O11=A[./8R/[*OO^?VW_\  9O_ (NC^RK[_G]M
M_P#P&;_XNM>BB[#V<>QD?V5??\_MO_X#-_\ %T?V5??\_MO_ . S?_%UKT47
M8>SCV,C^RK[_ )_;?_P&;_XNC^RK[_G]M_\ P&;_ .+K7HHNP]G'L9']E7W_
M #^V_P#X#-_\71_95]_S^V__ (#-_P#%UKT478>SCV,C^RK[_G]M_P#P&;_X
MNC^RK[_G]M__  &;_P"+K7HHNP]G'L9']E7W_/[;_P#@,W_Q=']E7W_/[;_^
M S?_ !=:]%%V'LX]C(_LJ^_Y_;?_ ,!F_P#BZ/[*OO\ G]M__ 9O_BZUZ*+L
M/9Q[&1_95]_S^V__ (#-_P#%T?V5??\ /[;_ /@,W_Q=:]%%V'LX]C(_LJ^_
MY_;?_P !F_\ BZ/[*OO^?VW_ / 9O_BZUZ*+L/9Q[&1_95]_S^V__@,W_P 7
M1_95]_S^V_\ X#-_\76O11=A[./8R/[*OO\ G]M__ 9O_BZ/[*OO^?VW_P#
M9O\ XNM>BB[#V<>QD?V5??\ /[;_ /@,W_Q=']E7W_/[;_\ @,W_ ,76O11=
MA[./8R/[*OO^?VW_ / 9O_BZ/[*OO^?VW_\  9O_ (NM>BB[#V<>QD?V5??\
M_MO_ . S?_%T?V5??\_MO_X#-_\ %UKT478>SCV,C^RK[_G]M_\ P&;_ .+H
M_LJ^_P"?VW_\!F_^+K7HHNP]G'L9']E7W_/[;_\ @,W_ ,71_95]_P _MO\
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M1_95]_S^V_\ X#-_\71_95]_S^V__@,W_P 76O11=A[./8R/[*OO^?VW_P#
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M\8&<=J]:I_97S_-B^T_E^2"BBBD 4444 %%%% !1110 4444 %%%% !1110
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M?:M2H+.RMM.LX[6Q@2"",85$& *GKR)6O[NQ]O3Y^5>TM?RV"BBBI- HHHH
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M_P#;NG?\_'_CC?X4?V[IW_/Q_P".-_A0%T:%%9_]NZ=_S\?^.-_A1_;NG?\
M/Q_XXW^% 71H48YSWK/_ +=T[_GX_P#'&_PH_MW3O^?C_P <;_"@+HT",]:0
M@'J :H?V[IW_ #\?^.-_A1_;NG?\_'_CC?X4!=&@0",$4FT#L/RJA_;NG?\
M/Q_XXW^%']NZ=_S\?^.-_A0%T7\ C! Q2XXQVK/_ +=T[_GX_P#'&_PH_MW3
MO^?C_P <;_"@+HOA0.@ _"EP,8QQZ5G_ -NZ=_S\?^.-_A1_;NG?\_'_ (XW
M^% 71?"@= !^%+6?_;NG?\_'_CC?X4?V[IW_ #\?^.-_A0%T:%%9_P#;NG?\
M_'_CC?X4?V[IW_/Q_P".-_A0%T:%%9_]NZ=_S\?^.-_A1_;NG?\ /Q_XXW^%
M 71H45G_ -NZ=_S\?^.-_A1_;NG?\_'_ (XW^% 71H45G_V[IW_/Q_XXW^%'
M]NZ=_P _'_CC?X4!=&A16?\ V[IW_/Q_XXW^%']NZ=_S\?\ CC?X4!=&A16?
M_;NG?\_'_CC?X4?V[IW_ #\?^.-_A0%T:%%9_P#;NG?\_'_CC?X4?V[IW_/Q
M_P".-_A0%T:%%9_]NZ=_S\?^.-_A1_;NG?\ /Q_XXW^% 71H45G_ -NZ=_S\
M?^.-_A1_;NG?\_'_ (XW^% 71H45G_V[IW_/Q_XXW^%']NZ=_P _'_CC?X4!
M=#?$0O7\/7D6EQ^9=S1F*(9Q@M\N[/; )/X5SOACX:Z7HUJ6U../4;R1=KM(
MN40'J%!_F>?I72?V[IW_ #\?^.-_A1_;NG?\_'_CC?X5I&I*,>5'-4PU&I55
M6:NUMV1R-KX%E\,>,K75M +26,CF*XMF;YHT;C(/\2@X/KQWKOJS_P"W=._Y
M^/\ QQO\*/[=T[_GX_\ '&_PHG.4[.0Z&'IX=-4]$W>W^1S'B?PA=^,/%4)O
M)&MM)LHPH(.6F=N6VCL,;1D^G>K>K_#C0=2TF.SMK9;&2%<13Q#YA_O?WA]>
M?>MS^W=._P"?C_QQO\*/[=T[_GX_\<;_  JO;5%9)VL9/ X>3FYQNY;W_K2Q
MG^"[#4-(\/C2]55?,LY&2.1#E9(SR"#^)&/:M759+F+2;E]/C,MUY9$*#'+D
M87KVSBHO[=T[_GX_\<;_  H_MW3O^?C_ ,<;_"H<FY<S.B%-4Z2I1>RMYG+>
M$_AI8Z0@NM:6/4+YARKKNCCSZ _>/N:@F\ MH/BFSUWPSDPQR_O[,GD(>&V$
M]>">#^'I78?V[IW_ #\?^.-_A1_;NG?\_'_CC?X5I[>HVVWN<G]G850C",;6
MU3ZW[W-"BL_^W=._Y^/_ !QO\*/[=T[_ )^/_'&_PK ]"Z-"BL_^W=._Y^/_
M !QO\*/[=T[_ )^/_'&_PH"Z-"BL_P#MW3O^?C_QQO\ "C^W=._Y^/\ QQO\
M* NC0HK/_MW3O^?C_P <;_"C^W=._P"?C_QQO\* NC0HK/&NZ<3@7'_CC?X5
MH4#(+S_CT?\ #^=9=:EY_P >C_A_.LNM([')6^(****HQ"BBB@ HHI,T +12
M$XZ\49H 6BBB@ HI,YZ4M !1110 4444 %%%% !1110 4444 %%%% !1110
M44E&<=: %HHHH **3/..]+0 4444 %%%)G/2@!:*** "BBB@ HI,T9QUH 6B
MBB@ HI,TM !1110 44F<]*,\X[T +1110 4444 %%%% !1110 4444 %%%%
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M6.\% Y!R-PY[U9TC0/&-HVGZ==ZQ8KI6GLH$MO$PN+A%X5&S\JC&,D4UTO\
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MRVE;^O>_R.UHHHJC(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M**C^T0_\]H_^^A1]HA_Y[1_]]"@"2BH_M$/_ #VC_P"^A1]HA_Y[1_\ ?0H
MDKF=2^'7A35]6;4]0T:&6Z=@SMN95D([LH(#?B#71?:(?^>T?_?0H^T0_P#/
M:/\ [Z%'6X#T18XU2-0J* %51@ >E+4?VB'_ )[1_P#?0H^T0_\ /:/_ +Z%
M $E%1_:(?^>T?_?0H^T0_P#/:/\ [Z% $E%1_:(?^>T?_?0H^T0_\]H_^^A0
M!)14?VB'_GM'_P!]"C[1#_SVC_[Z% $E%1_:(?\ GM'_ -]"C[1#_P ]H_\
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M!=D'V&T_Y]8?^_8H^PVG_/K#_P!^Q4]% 79!]AM/^?6'_OV*/L-I_P ^L/\
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M/^?6'_OV*/L-I_SZP_\ ?L5/10%V0?8;3_GUA_[]BC[#:?\ /K#_ -^Q4]%
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M1]AM/^?6'_OV*GHI%W9!]AM/^?6'_OV*/L-I_P ^L/\ W[%4O$>LKH.BRWS
M,RLJHA_B)/3\LG\*T8Y$FB26)@R.H96'<'H:?*[7(51.;A?5$?V&T_Y]8?\
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MF7B7'E*R1CRG;$VTE5=0-R].^/K3=&^(FC7GA,:O?W7D"WBB-XWV:55C=\#
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M,'N*%M_7>7_ &XJ_]=HG=VWB?1;S0GUFWU&!M/C!+SEL!,=0<\@^QYJAI7Q
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MT0_\]4_[Z% $E%1_:(?^>J?]]"C[1#_SU3_OH4 245']HA_YZI_WT*/M$/\
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M% $E%1_:(?\ GJG_ 'T*/M$/_/5/^^A0!)14?VB'_GJG_?0H^T0_\]4_[Z%
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M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\
MA1_9MC_SYV__ 'Z7_"K-% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-
M% %;^S;'_GSM_P#OTO\ A1_9MC_SYV__ 'Z7_"K-% %;^SK(=+.W_P"_2_X5
&9HHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>moh-20221231_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 moh-20221231_g4.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#^17AI9@  34T *@    @ ! $[  (
M   1   (2H=I  0    !   (7)R=  $    B   0U.H<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $YO<G1H=V%Y
M+"!!;&EC:6$    %D ,  @   !0  !"JD 0  @   !0  !"^DI$  @    ,T
M.0  DI(  @    ,T.0  ZAP !P  " P   B>     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                            ,C R,SHP,CHP,2 R,#HU.3HT,0 R,#(S
M.C R.C Q(#(P.C4Y.C0Q    3@!O '( = !H '< 80!Y "P ( !! &P :0!C
M &D 80   /_A"R-H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A
M8VME="!B96=I;CTG[[N_)R!I9#TG5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED
M)S\^#0H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS.FUE=&$O(CX\<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/CQR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2)U
M=6ED.F9A9C5B9&0U+6)A,V0M,3%D82UA9#,Q+60S,V0W-3$X,F8Q8B(@>&UL
M;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(B\^/')D
M9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S9"TQ
M,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA
M9&]B92YC;VTO>&%P+S$N,"\B/CQX;7 Z0W)E871E1&%T93XR,#(S+3 R+3 Q
M5#(P.C4Y.C0Q+C0Y,3PO>&UP.D-R96%T941A=&4^/"]R9&8Z1&5S8W)I<'1I
M;VX^/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M
M8F$S9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO
M+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/CQD8SIC<F5A=&]R/CQR9&8Z
M4V5Q('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^/')D9CIL:3Y.;W)T:'=A>2P@06QI8VEA/"]R9&8Z
M;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T
M:6]N/CPO<F1F.E)$1CX\+W@Z>&UP;65T83X-"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/#]X<&%C:V5T(&5N9#TG=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*
M$0L*"0D*%0\0#!$8%1H9&!48%QL>)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR
M)RHK*O_; $,!!P@("@D*% L+%"H<&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*O_  !$( BD"PP,!(@ "$0$#
M$0'_Q  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,#
M @0#!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S
M8G*""0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H
M:6IS='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZ
MPL/$Q<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 #
M 0$! 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  !
M G<  0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q
M%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X
M>7J"@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(
MR<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&
MBBB@ HHHH **** "BBB@ HHHH *SM7\0Z+H"1/KVKV&F+,2(VO;E(0Y'7&XC
M.,BM&OGCX<>"]'^,6M>)_%WCR.;4F&HO9VMH;B2-+>-0&&"C \!@ ,XZGDG-
M 'T!97UIJ5E%>:==0W=K,-T<\$@=''J&'!K.U3Q=X;T.\%KK7B'2M.N2H<0W
M=['$Y4]#M9@<<'GVK@]/\$0_!;P?XTUCP]J5U<0R027=K83X,5LR(=O7)8YX
M+9&5"@@D9KF/A;\%_"WBSP);>)O&D$^M:MK+/=2SRW4J;,NPXV,,DXR2<\GT
MH ]SGU"SM=.:_NKN"&S2/S&N9)0L:IC.XL3C'O4.DZYI.O6SW&AZG9ZE C['
MEL[A)E5L [25) ."#CWKYSTY+GPMX9^+/@!;Z:]TO2+0S6)F;+1*X)*^G\2Y
MP -P8X&35/X0>)'^'OA3Q 9W^6]\/_VW9JQP/-21X, ^I;9GKTH ^C['Q;X<
MU.ZGMM-U_2[N>W1I)HK>]CD:)%(#,P!R "0"3TS5+_A8_@C_ *'+P_\ ^#2#
M_P"*KYR^#6CRZ#\2/%&GW!)F7PF\DF>S2+;R$?@7(KDO#&M?"FU\#/:^*O#.
MK7WB(K+MN[:8I'DY\O\ Y:@#''\!^AH ^UY;VU@L'OIKF&.TCB,SW#R 1K&!
MDN6Z!<<YZ8J+2]8TS7+/[7HNHVFHVVXIYUI.LJ;AU&Y21GD<5\Y3S^(/#G[,
M&D>%KR.6#6/$=^;&SMILK(D#R;B"#T!^[@]I!74_">T/PV^+6O\ P\FD8V5Y
M!'J6FNY^^0H#@>YY_P"_1H ]4O\ QMX5TJ^DLM4\3:/97<6!)!<W\4<B9&1E
M68$<$'\:NZ3KVD:] \VA:K9:E%&VQY+.X295;&<$J3@XKY<\<ZAX(T[]HCQ9
M)\1='O=6L6CA6"*S<JR2>5%\QQ(G&,CJ?I74_!72[>[^+=WXB\!Z%JFB^#)=
M-,8-_NVW$FX A"6;=AE8\,<;3DC(% 'OFF:SI>MPR3:-J5IJ$44ABD>TG654
M<<E25)P>1Q[U3TSQAX9UJ\%IHWB+2=0N2I80VE]'*Y ZG:K$XKYW\&:-K6O_
M +.WCK3_  V)'O9-;<^3$<--&HB+H/<J#QWZ=ZP;6+X97#:5ID?]L_#GQ9IS
MQ//J-]#).GGK@;2ID!0EB'W%448.<# H ^N;N\MM/LY;N_N(K6VA4O+-,X1$
M4=26/ 'UJCI/B;0=?DE30M;T[4WA ,BV=W',4!Z$[2<5X_\ $6Q;XC?'?0O
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M?M$J["B,5^4,%.#ZB@#KX?'_ (.N9"EOXLT.5PC.5CU*%B%52S-@-T"@DGL
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MOPJTOX9^,/!6NP>$?#M[8Z5>S+;:A!>3R;IB@W+@B5B -_8B@#NO^%C^"/\
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MKJSG-O=6=VJB6!\!@#M9E(*LK JQ!##G.0':9KMMJNI:M8VZ3++I-RMM.9
MK,T22 K@G(PXZXYS0!YU\-_ /BD^-KSQ_P#$FXA.M7,)M[:P@(9+.,GID9'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[:)I97P3M11DG Y/ [5S]M\0?#]T]J!)J,"7CHD$]WI-W;PNS_<'FR1*GS<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\XU7X87_B#Q[;ZKXAUU;[2;2=;FVMQ;"*X1E\S;$9$(
M!13(3G&XX )XR?1Z* .#T?X3Z5H'CJUU_1[R]M[6TTLV$.GF[GD"'S-P;>\A
M^0#CRB-N<-U%-N?AK<Z_>0OXUU\ZU%:6UW:VOEV2VTH6Y4H[2,K%681G:"J(
M.^":[ZB@#C_"7@:;P_JYU35=575+U--@TN"1+;R EO$21D;VW.Q.2W ]%%=7
M<VMO>0^5=P13QYSLE0,,_0U+10!F>'XTATIHXD5(TNKE511@*!.^ !V%:=9V
MA_\ (/E_Z_+K_P!'R5HT %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 45SFL?$/P?H!(U?Q)IMLZ]8C<JTG_? RWZ5S3?';PA.Q70H]
M8UY@<8TS3)7Y_P"!!: /2**\V_X6GKUW_P @CX8>)Y0>GVY$M/\ T(FC_A,_
MB?<?\>WPMC@7LUSKT'/X 9H ])HKS;_A(?BV_P!WP/HT7^_JX/\ (4?VM\8G
M^[X:\,Q_[]_(?Y"@#TFBO-O[6^,0Z^&O#+?2_D']*/[:^+Z]?"7AYO\ =U)A
M_2@#TFBO-O\ A(OBVGWO NCR?[FK@?S%'_"5_%5?O?#:Q?\ W==B'\Q0!Z31
M7FW_  EWQ3_Z)C:_^#^'_P")H_X2[XIG_FF-J/<Z_#_\30!Z37-_\+'\$?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 445S'C3Q[I'@FTB^W&2ZU&Z.VRTVU7?<73] %4=L]SQ^/% &YJFJV&B:
M9-J.KW<5G9P+NDFF;:JC_'VZFO,/MOB7XQNJZ4UUX:\$,2)+S[EYJB^D8_Y9
MQD=^I]^0+6D^ ]8\;:I;>(OBL8V6$^98^&XCNM[7T:7_ )Z2?7C^0]/5510J
M *JC  & !0!F>'?#>D^%-%ATK0+*.SM(APB#ECW9B>6)]3S6I110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q$
MGPPL;GQO'X@O]6U*]BAF%U;Z?<RB2."<;\,KD;PHWL53. 3QQ@#MZ* .6TOP
M#9Z?KEMJEWJNK:M/8QRQ6 U*X67[&LIR^Q@H=B0 NYV9L#&:@@^&NEFZ636-
M0U378XH+BWMH=4N!*+>.?(E4,%#ME3MR[,0O -=A10!S7ACP-8>%[M[J&\O;
M^Y-K%91S7KHS16\6=D2[$7@9)R<L3U)KI:** ,[0_P#D'R_]?EU_Z/DK1K.T
M/_D'R_\ 7Y=?^CY*T: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HIDT\5M!)/<2)%%&I9Y)&"JH'))
M)Z"O*[SQ5K_Q1NI-*^',LFEZ!'(8[WQ*ZX:3'5+93U/;?V]N,@&OXM^(T\>K
MR>%? -FNM>)R/W@_Y=]/!XWSOVQ_=Z_H#;\%_#F#P[?2:]KMY)KGBBZ7%SJ=
MP/N#^Y$O1$'3CK].!L^$_!VB^"M'&G:!:^4C'?-,YW2SOW=VZL?\C%;E !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%>%:7J.H:1^T%=0^.+W6;*>]NV729XIMUE<P,S"&!EY5<@
M'C ;>I.[).0#W6BO-+!+OPM\5+73)M:U:>TO-.N) =7O#.=2G5@Y,2CY(A&K
M$$!8\@KA6P2.&M_&^O:+X=\/^(UU*]NKSQ!HFL7EU'<3M)"DL*^;"R1L2L87
M.W"@ C&03S0!]"45Y?X"OKZQ\>0:%+J%_?VUYX6M-6D>]N7G*W!D9'92Y.T,
M,':/E!' %>EW-REK#YDJRLN<8BB:0_DH)H IZ'_R#Y?^ORZ_]'R5HUF>'W$N
ME-(H8!KJY8!E*GF=^H/(/L:TZ "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "L;Q1XLT;P=HSZGX@O4M8%X0'E
MY6_NHO5F]A7/>+OB5#I&JKX<\+63>(/%$PPEC WR6_\ MSOT11Z=?IG-5_"W
MPUF&L1>*/B#>C7O$@&8@1_HM@#SMA0\<?WCSWX/) ,BWT#Q#\6[B'4?&D4VB
M>$U;S+;0%<K->CJKW)'0?[ _^N?4[.SMM/LXK2Q@CMK:%0D<,2!511T  Z"I
MJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "N(D^&%C<^-X_$%_JVI7L4,PNK?3[F421P3C?
MAE<C>%&]BJ9P">., =O10!RVE> K/3M=M=5NM5U75Y[&.6.P&I3K+]D64Y?:
MVT.Q( 7<[,<#&:J:=\+/#^GRD,;J[LH[:XM+6PN70PVD-PVZ5(]JAL-G'S,Q
M X! KM** .:\,>!K#PO=O=0WE[?W)M8K*.:]=&:*WBSLB78B\#).3EB>I-=+
M110!G:'_ ,@^7_K\NO\ T?)6C6=H?_(/E_Z_+K_T?)6C0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%>%ZMKOAF[\>>*=
M/L/!EEXW\27&I1_9U-G%+'#$+.W7,D[ A$$BR#&>"#TS0![5J6IV.C:=-?ZK
M=PV=I"NZ2:9PJJ/J:\S?Q/XJ^*,C6W@)9= \-DXE\0W,96:X7N+:,]/]\_H1
M6%X-^$5I<?$'49/'5EI<T\%E9WL>F:7;+;V,+2/<KM:-0/-*^5PS?WB#GBO<
M41(HUCC5410%55&  .P% &#X0\$Z)X(TLV>AVQ5I&WW%U*=\UP_=G?J3^@["
MN@HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "H_M$)NC;":/SP@D,6X;@I.-V.N,@
MC-25X#;V1\&_M R2^+M/^W#6]0W:9K-M<,LL+3%UBBD ()4*K)C[H"@X] #W
MZBO%_"4>F7?QL2#X=Z>+70]!M[B'6=20EO[1N)""(V=B6E*,-VYB3][M@MC7
M]KJWPPMKC^U;/0[G7=<L-9O8]5L+1A=6LZ(TQS.W+KM; ^5,$#KW /H&BO)/
MAU;PZ-\1K;2]'A2#3[KP?97URL7W9+GS&7S6]79>K=3C)S7JUS<I:P^9*LK+
MG&(HFD/Y*": *>A_\@^7_K\NO_1\E:-9GA]Q+I32*& :ZN6 92IYG?J#R#[&
MM.@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ&M:[I?
MAW2Y-1UV_@L+2/[TL[A1GT'J?8<F@"_7,>+_ (@^'_!4*#5KII+V;_CWTZU7
MS;FX/8*@_F<#WKDCXM\8_$@^3\/K1M!T)^&\0ZE#^\F7UMX3U]F;CZ&NG\(?
M#;0O"$TE] DNH:S/S<ZM?OYMS*2.?F/W0?0?CF@#F/[%\<_$P;_%$\OA#PXY
MXTJRDS>W*Y_Y:R_P C^$?0CO71Z;\*?">BPM%HMMJ.FQOM+I8ZQ>6ZN0H4,5
M24 G &3C)[UV-% &1HWAC3=!NKFZL/MCW%TD<<TMY?SW3LJ%RB@RNQ !D<X&
M/O&M>BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N3C^&?A>+Q5+K\=BZW4C
M&4Q"=Q"LI# S"/.T2$,WS#U)ZDD]910!S'ASX=^&_"6P>'K>\LX4+$6PU.Y>
M EA@DQ-(4)]R/>GZ3\/_  QHEP9=.TM5_=R1)'+-)+%"DC;G2.-V*QJQ/*H
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M:;;0VEK"NV.&% B(/0 <"K%      , = **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ J/[1";HVPFC\\()#%N&X*3C=CKC((S4E> V]D?!O
M[0,DOB[3_MPUO4-VF:S;7#++"TQ=8HI ""5"JR8^Z H./0 ]^HKQ7PNFFW/Q
MF\KX;Z<+;1O#]M<Q:QJ*$M_:-Q)RL3.26E*,-VYB3][M@MR-MJ=WHOA3PSX@
MT9C'JVL^'M<N=3O(S^\G=%\Q))#U8JY.TGD#CH,4 ?3%%>2?#JWAT;XC6VEZ
M/"D&GW7@^ROKE8ONR7/F,OFMZNR]6ZG&3FO5KF9X(=\5O+<MG'EQ%0?_ !X@
M?K0!3T/_ )!\O_7Y=?\ H^2M&LSP^Q?2F9D:,M=7)*-C*_OWX."1GZ&M.@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***CGGAM8'GN94ABC&YY)&"JH]23TH DHKSB
M_P#C!9WU[)IGP\TJZ\7:BIVL]I\EI"?5YV^7'3ID'UJM_P *]\5^-#YOQ+\2
M-#8OS_86AL88<?W9)?O/[CID<&@#1UWXN:1::DVC>%+2X\5ZX./L>F?,D9_Z
M:3?=0>O4CN!6;_P@?B[QW^]^)>M_8=-?G_A']%<I&P])IOO/[@<>A%=_H7AW
M1_#&FK8:!IUO86R_P0)C<?4GJQ]SDUI4 9^B:!I7AO34T_0=/M["U3I% @4$
M^I[D^YYK0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBJ.KZUIVA6:76KW26L#S) KN"<N[!5''N>3T R3@ F@"]1110 44
M44 %%,EFB@3?-(D:_P!YV %44\1:))>QV<>L6#74IVQP+=(7<^@7.30!HT5A
M^(?&GAOPHT2^(]9M-.>92T:3OAG ZD#J:YFX^/'PUMFP_B>)SZ16TTF?^^4-
M 'H5%8NJ>*M.TKPF/$3K=7-@T4<J?9K9Y)'5\;2$QG^(=<8[UR'_  NO39/^
M//PCXQO!ZP:,Q_FPH ])HK$\*^)6\4:9)>/H>KZ*4E,?D:M;""1L '<%R?EY
MQGU!KE)?B#XV:>1+'X5ZE*%8J&GU*"'/OW'ZF@#T:BN/\,>(/&^JZOY?B3P5
M#H5AY9(F_M:.X?=Q@;4'UI/$\WQ'&L;/!UKX:;3_ "UQ+JDL_F;^<\(,8].M
M '8USM_X]\-Z;>SVMUJ)#VK!;EX[>62*W)[22*I2,_[Q%<Y;V/QAENHVO=8\
M)6T0<%UMK2>3*YY W$=O<57\/^(M/\,Z#I>CZSJ@TG4-,ED&HV$MLTDNILP<
M;HN,N'D99<H&_NG&30!Z7%+'/"DL+K)'(H9'0Y# \@@]Q3JY[P'8W.G>";&W
MO+9K1\RR):L<FVC>5GCB/NB,J_\  :Z&@ HHHH *Y./X9^%XO%4NOQV+K=2,
M93$)W$*RD,#,(\[1(0S?,/4GJ23UE% ',^&_AYX<\(-'_P ([!>V4499EMQJ
M=T\&6&"3$TA0GW(]#VJ?3O WAS2K^>[LM,59)DDC*/*\D:)(V^14C9BD:LQR
M0@ />M^B@#%\/^$-$\+F4Z+:-"TJ)$S27$DS"- 0D:F1F*HH)PHPHSP*VJ**
M ,[0_P#D'R_]?EU_Z/DK1K.T/_D'R_\ 7Y=?^CY*T: "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDTT5
MO$TL\B11KU=V  _$T /K$U#QKX5TB_DL=5\2Z/8W<6/,M[F_BCD3(!&59@1D
M$'Z&L;6OB]X#T)C'>>);.68' ALV-PY/IB,'!^M<9H/Q \2ZKK7B5_ W@B\O
MH[W4TE%UJ<JV<<&+.W3#*<L3\F[ YVNI[T >JZ1XCT/Q!YW]@ZSI^I^1M\W[
M%=)-Y>[.-VTG&<'&?0UG^)?'WA;P?&3XBURTLY ,B ONE/TC7+'\J\YM?!OC
M+Q5X]U6+QEXK?2W_ +,LGGMO#9,*R1-+=!(S(WS?*5DSZ[_:N]\-?#'P?X3<
M3:/HEN+O.XWEP#-.3W.]\D9]L4 <Y_PGOC3Q>=GP^\)M9V;\#6/$.88\?WDA
M'SM['IZBGP?" :U.EY\2O$-_XIG4[A:,QM[.,_[,2'G'J3SCD5Z710!6T_3;
M+2;&.STNT@L[6(82&",(B_0#BK-%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%5K_4K'2K1KK4[RWL[=/O2W$HC4?B>*YG5?B;X>TW6++2H
M#>:I>WJ1RPQZ9:O< Q.<+)O7Y=O4Y!/ H Z^BN0@UOQK>^+Y[$>%8-.T2%I4
M&IW-\LCS8!V.D2<X)VG!(X)Z$8K-7PWKPT'5$^(GCYA;WBJ VGQQZ>+/:VX[
M9?O'(&#GMF@#MM2U73]'M#=:M?6UC;@X,MS,L:Y],L0*YG7/BKX3T*:R@DOI
M;Z>_A6>UBTZW>Y,L9) <% 1C(/?M6/X5T'X8:U92Z!I,UGXF73YS>2"[F-X5
MD<;=VYL@Y"XP...F34E]K7CT:A-H_@GP-8:?8V;F"&^U.Z6.%E!P"D47S;<#
M(]NP/% &RWC+47\:#0[;P?K+VJRA)=5D1([< KG<I)RP[<<YK/A\0^.S'J4V
MN:3H/ARVCMW^QSWFI>:#-D;"^T ;,9SR#TJ3P[H'Q!77H=2\6>,+.2UCW;M)
MT[3U6)\@@9E;Y^#@_A6CXA^'/A3Q7K,.J>(M(CU"Z@B$49FE?8%!)QL#;3R3
MSC/Y"@#SJY^)EU::)>6>L_$SPO;ZO)/']FFT>PDO5C7G>I49SGC![8/KQQ'B
M+PUXP\9)J5U>WEYK][I.HS:7)Y&GQ.&;YAQ$[!(E"!&WJ"Q:8@_=!KZ0TKPU
MH>A*%T71K"P _P"?:V2,_F!6%K?PG\">(KXWFJ^&+&2Y:1I'EB4PM(Y.2SF,
MKO)/)+9H \4\(7?QNUA!IV@ZE'!%HDWV.?[=/!(2RG/SG:S,/X<@D?*0#D&O
M6=/\/_%&:X-UJ_C;2[7SD?=8V>DB2*W8J0NQW(9L'#?-[CD5U^B^&=#\.)(O
MA_1[#3!*%$OV2V2(R;<[=Q4#=C)Z^I]:TZ /&)_A[\7KW[9_:'Q'#*+=OLHL
MU%L6EXVA]L?RKUR1D]*L^#M&^(O@G0=1O;^SO?%6KRS1QQVESXBW(8N=SJ9$
M 0@X&.^?;GUZB@#P[7] \%CR?$OC3X7^(7U#5)99+I;=Y+P6S CE]DN%#9XP
M/; K<TZ3X.>%/$VGVD-CIND:U+'%/;+=6;I*GF#Y/G=<*W.,9R.]>JU%/:6]
MR4-S!%,8SN0R(&VGU&>E &>Z>']=O&61=-U*YLR48,(YG@.>1W*\BKT%C:6H
M MK6&$#H(XPN/RK!_P"%=^$U\1-KT.B6]OJK>86N[?,3DR*5=CM(^8ACSUY)
MZUF:?\.[S0-+U&W\-^,]=@ENHU6V?495OH[(ALY1' ZC(()[T =Q17#2/\2M
M#\-1E8M(\4ZFMT?,"L;+=!M&,9RN_=GT&".#R:74OB2WAV/31XH\+:Y9R7=N
MLDSV=N+R"UD+$&)I(SRW&>%Y!'TH [BBL*#QMX9N?$,N@Q:Y8G58G\MK)I@L
MI;&=H4\DX[#-;H.1D4 %%%% !1110 4444 %%%% !4?VB$W1MA-'YX02&+<-
MP4G&['7&01FI*\"MK-O!?[03S>+M/^W?VUJ._3-8M[@B2%IBZQ12*""5"JR8
M^Z HX] #WVBO*O!>EW>D_'3Q%#J.KW6KW,FCVTLES<X')D?Y44<(@[*.G/7-
M<G?VNK?#"VN/[5L]#N==URPUF]CU6PM&%U:SHC3',[<NNUL#Y4P0.O< ^@:*
M\D^'5O#HWQ&MM+T>%(-/NO!]E?7*Q?=DN?,9?-;U=EZMU.,G->K7,SP0[XK>
M6Y;./+B*@_\ CQ _6@"GH?\ R#Y?^ORZ_P#1\E:-9GA]B^E,S(T9:ZN24;&5
M_?OP<$C/T-:= !1110 4444 %%%% !1110 4444 %%%4=4US2M$A\[6=3L]/
MCQG?=3K&/_'B* +U9&J^+/#F@W2VNN:_I>FW#H)%BO+V.%V4D@, Q!QD$9]C
M7)WGQR\"P3FWT[4;C6;KM!I=I).Q^A V_K7.VGCWQ9JGC[5;GPK\/=1=YM,L
MHRFL3I9-"BRW161E.20Q=@ .?D- 'IVE>+/#FO736NAZ_I>I7"(9&BL[V.9U
M4$ L0I)QD@9]Q6O7C5W#\6-3\?:4+FZ\-:'=-IEZ8&MXY;@I%YMKY@8-P6R8
ML8XP&SVK;_X5OXQU'_D8/BEK#@]5TNUBLL>P*Y/XT >E57NM1LK%<WMY;VP]
M9I53^9KS[_A1WA^?_D*ZUXFU7U^VZO(V?^^<59M?@7\.+1MR>&896[M/<2RY
M_P"^G- '07'C_P '6F?M/BO1(B.SZC$#^6ZLNX^,/P^ML^9XMTUL?\\Y?,_]
M!!JY;_#+P-:X\GPAHF1T+V$;G\R#6G;^%] M,?9=#TV#'3R[2-?Y"@#CY?CY
M\-8VVKXC$K]EBLKA\_DE1_\ "]O"4G_'E;ZW>^GV?2I3G\P*]&BAB@7;#$D8
M]$4"GT >;?\ "Y4F_P"0?X"\;7?HRZ/M3\RU'_"R_%=Q_P @_P"%FN/Z?:KB
M*#^>:])HH \V_P"$F^+%]_QZ> -,TP'H;_6%EQ]1&*/LGQFOO]?J?A'2E/\
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M?!^@6WASXW^);337N)GDT6WFDGNIC++-*TCY=F;N<#T''05YXCWO_"!>#CI
M?[;_ ,(SX@-YY:GS,XYW=\^=G@_Q9[T ?1NEZYI.MI*VBZI9:BL+[)3:7"2B
M-O1MI.#[&KU>3^ BI^)MC_9FS[ / VG^9Y0^7?YC>7G_ (!G'M57XV6FG7OB
MOPG!JE@-3=[>_6RT\CBZN6:V6)"<@JNYMS$?PJ<\9H ]1T/_ )!\O_7Y=?\
MH^2M&OCN'PMXX\'_ !(TR'PKH=M;ZE/=7JZ5<RM 7N1%&T<F1NV)A=[;3@9;
MN%4#LHO!GQ4UGS[GX@Z-JVNQ(O\ R#X_$<%K',21G"1C:,#)ZCVH ]IU_P")
MG@SPQN&M>(["&5>L*2^;*/\ @"9;]*YW_A;6I:U\O@;P'KFL!ONW5VHLK=O<
M._7\A7&'3_&OA*WM;WP+\(= L0X*M%,XNKN%E/5I ZY4]L$GKGM5J^\8_'*R
MNK!9_#&GR1W4:2N;"QDE\C)YC;,HPPQSVYZT =1_9/Q;\1_\A+7]'\*6S?\
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MZWID+&TDTVX"."S*N&X*M%NV%LJP 7..* *.G_%K3O#_ (JN](LD\4>(-/\
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M:);OK#.)/M<FYV# 8# $X!P.H'O6S9Z7I^G,YT^QMK4R'+F"%4W?7 YJU10
M5S][X(T:^U>ZU.1M4AN[O9Y[6FL7=LK[5VK\L<JKP!Z>OJ:Z"B@##TKPAI.C
M:LVIV?\ :$EXT!MS+>:G<W7[O<&V@2R,!R,Y'/7U-;E%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5DQ^%=!B\2OXACTBS35W38UZL($A&,=?7'&>N..E:U% %=-/LX]1DOTM(%O)
M8Q')<B("1T!R%+8R0,GBH;30])T_4+F_L-+LK6\NSFXN8;=$DF.<_.P&6Y]:
MO44 4=+T/2=$25=%TNRTY9GWRBTMTB$C>K;0,GW-<S\0/A?H_P 1Y=+EUB^U
M*SDTLR&!]/F2,Y?9DDLC=-@QC'>NTHH \F\+?!/2;+7[;Q)_PDGB6XU"ROI6
M4W%['(LFR5TP^8\D,I8'D?>;&,UZS6=H?_(/E_Z_+K_T?)6C0 4444 %%%%
M!39(HYDV3(LB_P!UAD4ZB@"K/I>GW4D<ES8VTSQ@!&DA5B@'3!(XJ(Z%I)U/
M^T3I=E]NSN^U?9T\W.,9WXSTXZU?HH QH/!_AFV:Y-MX=TF$W4;17!CL8U\Y
M&^\K87Y@>X/!J)? WA./39]/C\,Z0EG<.LDUNEC&L<C+]TE0,$C)QZ9K>HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M^%A_X'/_ /&J//UK_GPL/_ Y_P#XU0!HT5G>?K7_ #X6'_@<_P#\:H\_6O\
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M\_6O^?"P_P# Y_\ XU0!HT5G>?K7_/A8?^!S_P#QJCS]:_Y\+#_P.?\ ^-4
M:-%9WGZU_P ^%A_X'/\ _&J//UK_ )\+#_P.?_XU0!HT5G>?K7_/A8?^!S__
M !JCS]:_Y\+#_P #G_\ C5 &C16=Y^M?\^%A_P"!S_\ QJCS]:_Y\+#_ ,#G
M_P#C5 &C16=Y^M?\^%A_X'/_ /&J@OEUN\TZYMDM+&)IHFC$@O7)0D$9_P!5
MVS0!L45G>?K7_/A8?^!S_P#QJCS]:_Y\+#_P.?\ ^-4 :-%9WGZU_P ^%A_X
M'/\ _&J//UK_ )\+#_P.?_XU0!HT5G>?K7_/A8?^!S__ !JCS]:_Y\+#_P #
MG_\ C5 &C16=Y^M?\^%A_P"!S_\ QJCS]:_Y\+#_ ,#G_P#C5 &C16=Y^M?\
M^%A_X'/_ /&J//UK_GPL/_ Y_P#XU0!HT5G>?K7_ #X6'_@<_P#\:H\_6O\
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MH T:*SO/UK_GPL/_  .?_P"-4>?K7_/A8?\ @<__ ,:H T:*SO/UK_GPL/\
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MS=&(L#)/(@.X9P./?T + 'M5%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &5JWBGP_H,Z0Z[KN
MFZ;+(N]([R\CA9ESC(#$9&:H?\+'\$?]#EX?_P#!I!_\55_5O"WA_7ITFUW0
MM-U*6-=B27EG',RKG. 6!P,U0_X5QX(_Z$WP_P#^"N#_ .)H Y_7/B=I3:_I
MUAX?\;>$[6WFM;B:YN[R5;E%9&A5(QMGC"EA)(>2<[#@<&C0_B=I2Z_J-AX@
M\;>$[JWAM;>:VN[.5;9&9VF5XSNGD#%1'&>",;QD<BK.L_!WPAJEU;7%GIEG
MI#VZ2(18Z99%)0Y0_.DL+J2-G! !&YAGDT:-\'?"&EW5S<7FF6>KO<)&@%]I
MED$B"%S\B10HH)W\D@D[5&>!0!K_ /"Q_!'_ $.7A_\ \&D'_P 54UIX[\(Z
MA>16EAXIT6ZN9F"10PZC$[NQ[!0V2?I4/_"N/!'_ $)OA_\ \%<'_P 34UIX
M$\(Z?>17=AX6T6UN86#Q30Z=$CHP[A@N0?I0!YM\9?B!XF\&>-M 70[WRM,6
M$W>I6_D1N9HDE4.,E2P^4G[I'&35:]^)VOM^T+;:1:ZI'%X329K:5?*B*R.E
MMYLC;RNX %EZ-VKKO'/PZN_%_B^WO_.MET]=&O-/E5V;S-\RX5E 4C //7\*
MX_1/@1J=II?AJUU2]LY7MI]1EUB6.:0M-]IB$2^62G)"*N=VW!Z9H [#0_C1
MX=US6K2QCL=:LK;4)6AT[4[VQ,5I?.&P%B?.26Y(R!TP<'BN:U+Q_K5K<>,1
M<ZY<6<.FZ_:6=H]OI\,[1QR#E-K%003U8DD=JGTGX8>,ICX<T3Q3JVC2^&O#
M%XEW9O8Q2+=W319$(E#?*HVL<[2?3G[P?KGPGUS4O^$H\B[T]?[7URTU&#?(
MXVQQ?>#83AO0#(]Q0!J:W\<- T/5=6L9=&\079T:98K^>TL1)% ",AV??A5/
M(&<$X/%:'BKXJ:?X55)G\/\ B/5+)K5;IK_3M-+V\<9&1ND8J!QR?3/-9=U\
M-]8FT[XC6Z7-B'\4R;K(F1\1CR]O[SY>.?3=6#X@^$WC35XWTW^U=#NM(FTF
MWM5CU&.69M/FBAV%K9,!06;DR'Y@&.!Q@@'J]WJJ7'A&;5M*FWQR6+7-M,%Z
M@Q[E;!'T."*\.D_:#LO^%*CR_$W_ !7'V8?\N#?ZWS.?^6?E?<_#\:]FTO0[
MNT^'%IH-PT/VR'2DLG9&)CWB()D$@'&1Z9]JY.7X<:N_[/8\""XLO[4^R+!Y
MQ=_(W"4/G.W=C'^S0!;U?XM:3X<DAL[RPUC5+F&RCNM1ETRQ\Z.Q1ESYDQR
MH(W-QG@'VJ7Q/\6-,\-0170T+Q%J^GR6BWG]HZ9IYDMDB89!,C,H^[@^P/-<
M/XU^!.H:WXM;6]/M] U+[7;017,.L37<8A>*-8]T9@9=P95&=W3''6K7B3X0
M^*M1:XTG3M1T.;P[+IL-K;P:C%/(=-DCB*;K:,LP4L?^6C,S@,1SM^8 LZU\
M5[[1?%7B*]M%FUC1+/0+;4+*T@A RTK#]XS;=P3!!.<X&3BJ2?&/5&U[P?=7
M.G:LEIJFDSS7&DVVF[Y[J=0"&B7EMAY93N *\FM"#X3:VUOJT=Q>:?']O\)P
M:(AC=WVSQH%+'*#Y,CKU]JN^%_ /BFR\2>$=4\03Z0?[!TN;3I%L7E^=<!8R
M-R\G:!N.1ST% &U#\6/#DOP\;Q@PO8K-93;_ &5X/]),X;:(0@)&\G&.<<\D
M<XCT_P"+&F:EH^J74.@^(EO]+>-;C17TT_;L.,HPB!/RD9.21TYZC//?\*DU
M=_ %_I?]H64.JKXBDUW3IAO>(/NRBR< \\@X!QG//2K.I^%OBMK?A^X>]\3Z
M1::G]M@E@L+!98[,PIG>CRX\XAR02,X^7'1C@ M?\+P\.1>'-2U:_P!-UO3S
MI=W%:WEE=V8CN(3*,HY3=C:>>^>#QTS/=?%_3[2SL2_ACQ2^HWH>1-'CTS=>
M)$C;3*\>[Y4SP#G)STQ7&Q_!3Q(--UR$R^'K>35;[3[T0V$<EO;P&#<9(U3:
M<#YOE/\ %R2%S6S\6?A#=>./$UCKVF1Z3>3P6GV.6SUB2XCA*!F=75H&#;@6
M88/!!]J /2/#VOZ=XH\/VFM:+/Y]E>)OB?&#U((([$$$$>H-<SX]\1:IHOBC
MP7::9=>1!JFK?9[M/+5O-CV$[<D$CGN,&H_".CZUX-D\/^&;*PTU-(6TGFU!
MK5+@K#,6W 1O*[?*2W0DL<$X4<"[XS\)WWB+Q#X3O[*6WCBT74OM=P)F8,Z;
M<83 .3]<?6@# B^/'AN2[5#I.OI:_;SI\NH&Q!MH)MVW:\@8CG(.!DX(XJ]K
MGQD\.Z%X@NM,GLM8N8;"2.+4-3M;(O:6+N< 2R9&,9&< ]<#)R*P9?A/KLGP
MJO\ PR+O3_MMQKAU%)#(_EB,S!\$[,[L#IC&>]6Y/ WCW1/$VMGP/K>C66D:
M]?"^N)[N!Y+NTD8CS/*7!C?(&1N]<<8R0#U)65U#(0RL,@@Y!%+67I*ZZM[J
M"ZTU@]H)5&GM;;_-:/')FS\N[/\ =XK4H **** "BBB@ HHHH **** "BBB@
M#*N?%/A^RU==*O-=TRWU%RJK9RWD:S,6^Z A.[G/''--B\6^')]4DTV#Q!I<
ME_%N\RU2]C,J;1ELH#D8 .>.,4MUX3\.WNKC5;W0-+N-15E87DMG&\P*XVG>
M1G(P,<\8I(/"7ARVU274K;P_I<-_,7,EU'91K*Y?.\EP,G=DYYYSS0!F:G\1
M_#%GX;U/5K#7-,U)=.BWO':WT3_,QVHI(;"[FPH)P*K^&/B-HVI>$5U36]:T
M:TD@N&L[N9+U!;F=>\;EB"K##J,DX//(-5==^%FEW<UB?#NG^'=*@@=Y+FUE
MT-9HKLE=J;U1X\A<L<'(R0<945'H_P +;.UU2XEUJT\-7FFSPHITRTT 6\'G
M(6VS;7ED7>%=UR "01D\4 =+<>-O"MI:VUU=>)M'@M[I2UO+)?Q*DP!P2I+8
M8 \<5:7Q#HKZPNDIJ]@VI,GF+9BY0S%<;MP3.[&.<XZ<U5N/!?A:[M;6VNO#
M6CSP6:E;:*2PB98 3DA 5PH)YXJS%X<T.#5EU2#1M/CU!4$:WB6J"8*%VA0X
M&<;1C&>G% 'G?QE\9ZSX6U'P];6FMMX9TF^>87>MC31?>4ZKE(C&>F[GMDXX
MX5J/$OBWQ/X?^ O]N'6]'O-5C9(WU;3V26&6,R[?-C5MJ-)M_AZ;@<>@Z/QW
MHOC'4W@/A2[T2>S>-H;W2->M3);3@\A]R*7R.FW[IZ]N>)MO@SK^D^$]&_LC
M4]*.NZ7J\FK+:SQ/_9X>0 &-0/G"IMRIQG.>F<@ Z'X:>(_$&L^"-9U'4]4&
MKVT4LO\ 9>KFR6U:\C5>7\KL X(&0,XYKS&P^)GBZV\&:5XG;XE:;K&H3SQK
M)X6^P6PFD#2;"N8_G!Q\WW1_CU_@SX/^(_#WBZ\\0WVH:(AU*UNX;G3K*WE$
M-L9""OD,QR 2,MD<#*@'(*]7\./ACI?A#PMI,6IZ/HTNO62MYFHV]JK.6+-@
MB0H'^Z0,\4 6OBQXGO/"/PRU75M*D,>H(J16K",.1([JH(4@@XR3R.U>8:?\
M3/$]IX/UJ.Y\17MSXD>^LM.@M=9T**PDTUI\_OBB,1("IR-W0H"5(;!]@\<Z
M'JOB#PG<6?AW5Y='U166:UND=E7>ISL?;R4;E3UZYP<8/G]W\)?$OB&QUS5_
M$>JZ7'XJO9K6:R^Q1N;.V-L<Q@[OG(;)!)SC.1GI0 V/X@^)?!NF^/-/\2W]
MOKNH^&K:"YL[XVP@%P)U^4/&A  5\=#D@GGO6CX&U[Q;IWCZ'PQXRUN'71J.
MBKJEO=):);M"X<*T6$ ##G.X\\=!2V7PNU?6M*\8R>.=0L?[7\40Q0,=,C=K
M>T2)<1E0^&;YL,03SCKWJUX'\$^*K7Q</$GCN^TN>\M=*72K.'2Q)Y?EA@S2
M.7 .\D8XXY/3B@#T>BBB@ HHHH **** "BBB@ HHHH *RM6\4^']!G2#7==T
MS399%WI'>7D<+,N<9 8C(SWK5K)U;PIX>UZX2XUS0=,U*:--B27EG',RKG.
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MR5YSS7#C]GNXN/ MU8RVOA_3M5:^ANXX;&6]>UG$2N DK2R%P")7Y0*1ZGL
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MN+>)(E*HJ[_F/!.<_KUH [>BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
; **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143054400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> shares in Thousands, $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 10, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-31719<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MOLINA HEALTHCARE, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-4204626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Oceangate<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Long Beach<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">90802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">435-3666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 Par Value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MOH<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text">Portions of the registrant&#8217;s Proxy Statement for the 2023 Annual Meeting of Stockholders to be held on May 3, 2023, are incorporated by reference into Part III of this Form 10-K, to the extent described therein.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001179929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144140192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Los Angeles, CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143918064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PremiumsEarnedNet', window );">Premium revenue</a></td>
<td class="nump">$ 30,883<span></span>
</td>
<td class="nump">$ 26,855<span></span>
</td>
<td class="nump">$ 18,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthCareOrganizationPremiumTaxRevenue', window );">Premium tax revenue</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthCareOrganizationInsurerFeeRevenue', window );">Health insurer fees reimbursed</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue', window );">Marketplace risk corridor judgment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetInvestmentIncome', window );">Investment income</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">52<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Other revenue</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">31,974<span></span>
</td>
<td class="nump">27,771<span></span>
</td>
<td class="nump">19,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Medical care costs</a></td>
<td class="nump">27,175<span></span>
</td>
<td class="nump">23,704<span></span>
</td>
<td class="nump">15,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,311<span></span>
</td>
<td class="nump">2,068<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PremiumTaxExpenses', window );">Premium tax expenses</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">787<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthCareOrganizationInsurerFeeExpense', window );">Health insurer fees</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCostAndExpenseOperating', window );">Other</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,801<span></span>
</td>
<td class="nump">26,751<span></span>
</td>
<td class="nump">18,345<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other expenses, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other expenses, net</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax expense</a></td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="nump">$ 11.40<span></span>
</td>
<td class="nump">$ 11.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 13.55<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="nump">$ 11.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">58.5<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationInsurerFeeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Insurer Fee Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationInsurerFeeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationInsurerFeeRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Insurer Fee Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationInsurerFeeRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Marketplace Risk Corridor Judgment Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationPremiumTaxRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Premium Tax Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationPremiumTaxRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PremiumTaxExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An assessment levied by a state government on the net premium income collected.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PremiumTaxExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetInvestmentIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetInvestmentIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCostAndExpenseOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCostAndExpenseOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PremiumsEarnedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 235<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.12-17(Column E))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401096&amp;loc=d3e574992-122915<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486672&amp;loc=d3e27261-158547<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PremiumsEarnedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143899872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized investment (loss) income</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Less: effect of income taxes</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144023616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,006<span></span>
</td>
<td class="nump">$ 4,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Receivables</a></td>
<td class="nump">2,302<span></span>
</td>
<td class="nump">2,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,084<span></span>
</td>
<td class="nump">10,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and intangible assets, net</a></td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">238<span></span>
</td>
<td class="nump">212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">123<span></span>
</td>
<td class="nump">179<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,314<span></span>
</td>
<td class="nump">12,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable</a></td>
<td class="nump">3,528<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="nump">2,079<span></span>
</td>
<td class="nump">2,472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">842<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">359<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,855<span></span>
</td>
<td class="nump">7,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,350<span></span>
</td>
<td class="nump">9,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value per share; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022, and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value per share; 20 million shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">2,796<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 12,314<span></span>
</td>
<td class="nump">$ 12,209<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common Stock, Shares, Outstanding</a></td>
<td class="nump">58<span></span>
</td>
<td class="nump">58<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143025616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">58,000,000<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140702896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive (Loss) Income</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning Balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 1,960<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(605)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(594)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">Termination of warrants</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2020</a></td>
<td class="nump">2,096<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">659<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(120)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2021</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">792<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Common stock purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Common stock purchases</a></td>
<td class="num">(400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(395)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net</a></td>
<td class="num">(155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(155)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending Balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance at Dec. 31, 2022</a></td>
<td class="nump">$ 2,964<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 328<span></span>
</td>
<td class="num">$ (160)<span></span>
</td>
<td class="nump">$ 2,796<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140619104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_GainLossOnDebtRepayment', window );">Loss on debt repayment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other, net</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of the effect of acquisitions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Receivables</a></td>
<td class="num">(95)<span></span>
</td>
<td class="num">(415)<span></span>
</td>
<td class="num">(100)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="num">(124)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities', window );">Medical claims and benefits payable</a></td>
<td class="nump">153<span></span>
</td>
<td class="nump">471<span></span>
</td>
<td class="nump">544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency', window );">Amounts due government agencies</a></td>
<td class="num">(428)<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="nump">446<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="nump">126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income taxes</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">773<span></span>
</td>
<td class="nump">2,119<span></span>
</td>
<td class="nump">1,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments</a></td>
<td class="num">(1,913)<span></span>
</td>
<td class="num">(2,713)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Net cash paid in business combinations</a></td>
<td class="num">(134)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="num">(755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and capitalized software</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(790)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations', window );">Common stock withheld to settle employee tax obligations</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from senior notes offerings, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(723)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of term loan facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings under term loan facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Cash paid for partial termination of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CashPaidForSettlementOfConversionOption', window );">Cash paid for partial settlement of conversion option</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash received for partial settlement of call option</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of principal amount of convertible senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents</a></td>
<td class="num">(458)<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">4,048<span></span>
</td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CashPaidDuringThePeriodAbstract', window );"><strong>Cash paid during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">340<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="nump">321<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="nump">$ 127<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CashPaidDuringThePeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During The Period [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CashPaidDuringThePeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CashPaidForSettlementOfConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For Settlement Of Conversion Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CashPaidForSettlementOfConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Withheld to Settle Employee Tax Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CommonStockWithheldToSettleEmployeeTaxObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_GainLossOnDebtRepayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Debt Repayment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_GainLossOnDebtRepayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in health care insurance liability balances during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812230615600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization and Basis of Presentation</a></td>
<td class="text">Organization and Basis of Presentation <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization and Operations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#8220;Marketplace&#8221;). Molina was founded in 1980 as a provider organization serving low-income families in Southern California and reincorporated in Delaware in 2002. We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2022, we served approximately 5.3 million members eligible for government-sponsored healthcare programs, located across 19 states. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our state Medicaid contracts typically have terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzY3OA_6f2a845c-6f22-4bcc-9cb4-a0ec1e4ca0c4">three</span> to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#8220;RFP&#8221;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#8220;ABD&#8221;); and regions or service areas.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Medicare, we enter into Medicare Advantage-Part D contracts with the Centers for Medicare and Medicaid Services (&#8220;CMS&#8221;) annually, and for dual-eligible plans, we enter into contracts with CMS, in partnership with each state&#8217;s department of health and human services. Such contracts typically have terms of <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzEwOTk1MTE2NDU4MTc_95927849-eb03-4285-a11c-36386eebadfb">one</span> to three years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Marketplace, we enter into contracts with CMS, which end on December 31 of each year, and must be renewed annually. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 27, 2023, the Texas Health and Human Services Commission posted a notice on its website indicating that it was issuing a Notice of Intent to Award to Molina Healthcare of Texas, Inc. a STAR+PLUS ABD contract in each of Bexar, Dallas, El Paso, Harris, Hidalgo, Jefferson, Northeast Texas, and Tarrant Service Areas. The notice follows a proposal that we submitted in June 2022 to continue serving STAR+PLUS members in the same service areas, in response to an RFP posted in March 2022. The start of operations for the new contract is expected to begin in February 2024. Further, in December 2022, the RFP was posted for the TANF and CHIP programs (known as the STAR &amp; CHIP programs, and both existing contracts for Molina), with awards expected in February 2024 and the start of operations in February 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">California Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, we announced that the California Department of Health Care Services (&#8220;DHCS&#8221;) had confirmed our California health plan&#8217;s footprint as originally announced in August 2022, including Medi-Cal contract awards in each of Riverside, San Bernardino, Sacramento, and San Diego Counties. In Los Angeles County, we will share membership equally with the current commercial incumbent. The Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand our footprint in Los Angeles County. DHCS has also agreed to grant Molina a contract to offer EAE-SNP products for dual eligible members in Los Angeles County.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">New York Acquisition&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York (&#8220;AgeWell&#8221;). See Note 4, &#8220;Business Combinations,&#8221; for further information. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nebraska Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, we announced that our Nebraska health plan had been selected by the Nebraska Department of Health and Human Services to provide health care services to Nebraskans under the state&#8217;s Medicaid managed care program. The new five-year contract is expected to begin on January 1, 2024, and may be extended for an additional two-years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Iowa Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Iowa health plan had been notified by the Iowa Department of Health and Human Services (&#8220;Iowa HHS&#8221;) of its intent to award a Medicaid managed care contract pursuant to the RFP issued by Iowa HHS in February 2022. The new four-year contract is expected to begin on July 1, 2023, and may be extended for an additional four years.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mississippi Procurement&#8212;Medicaid. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, we announced that our Mississippi health plan had been notified by the Mississippi Division of Medicaid (&#8220;DOM&#8221;) of its intent to award a Medicaid Coordinated Care Contract for its Mississippi Coordinated Access Program and Mississippi Children&#8217;s Health Insurance Program pursuant to the Request for Qualifications issued by DOM in December 2021. The four-year contract is expected to begin on July 1, 2023, and may be extended for an additional two years. The award enables us to continue serving Medicaid members across the state.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Wisconsin Acquisition&#8212;Medicaid and Medicare. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#8220;MCW&#8221;). The purchase price for the transaction is approximately $150&#160;million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in mid-2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Nevada Procurement&#8212;Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. This new contract is four years with a potential two-year extension.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Texas Acquisition&#8212;Medicaid and Medicare.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan (&#8220;MMP&#8221;) contracts, along with certain operating assets. See Note 4, &#8220;Business Combinations,&#8221; for further information.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div>The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143020704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text">Significant Accounting Policies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#8220;AFS&#8221;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#8217; equity as other comprehensive income, net of applicable income taxes. Held-to-maturity (&#8220;HTM&#8221;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses arising from credit-related factors with respect to AFS </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy requires that all of our investments have final maturities of less than 15 years, or less than 15 years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In general, our AFS securities are classified as current assets without regard to the securities&#8217; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment. For comprehensive discussions of the fair value and classification of our investments, see Note&#160;5, &#8220;Fair Value Measurements,&#8221; and Note&#160;6, &#8220;Investments.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued interest receivable relating to our AFS and HTM securities is presented within &#8220;Prepaid expenses and other current assets&#8221; in the accompanying consolidated balance sheets, and amounted to $35 million and $11 million at December 31, 2022, and 2021, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write offs as a reversal of investment income. No accrued interest was written off during the year ended December 31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Combinations</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for business combinations using the acquisition method of accounting, which requires us to recognize the assets acquired and the liabilities assumed at their acquisition date fair values. As discussed below, the excess of the purchase consideration transferred over the fair value of the net tangible and intangible assets acquired is recorded as goodwill. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated results of operations. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The purchase price for the acquisition of certain assets of Passport Health Plan, Inc. in 2020 included contingent consideration payable to seller relating to guarantees for minimum operating income in the post-acquisition period in 2020 and minimum membership targets in 2021. The liabilities are recorded at fair value on a recurring basis, which totaled $8 million as of December 31, 2022. For the amounts paid in the year ended December 31, 2022, $20&#160;million has been presented in &#8220;Financing activities&#8221; in the accompanying consolidated statements of cash flows, with the balance reflected in &#8220;Operating activities.&#8221; We paid the remaining balance of the liabilities, reported in &#8220;Accounts payable, accrued liabilities and other&#8221; in the accompanying consolidated balance sheets, in January 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 4, &#8220;Business Combinations,&#8221; and Note 9, &#8220;Goodwill and Intangible Assets, Net,&#8221; for further details.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets, including Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, &#8220;Property, Equipment, and Capitalized Software, Net&#8221;), and intangible assets resulting from acquisitions. Long-lived assets are subject to impairment tests when events or circumstances indicate that the asset&#8217;s (or asset group&#8217;s) carrying value may not be recoverable. Refer to the discussion in &#8220;Leases&#8221; below for impairment charges related to leasehold improvements and other property and equipment associated with the reduction in leased space used in our business operations. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3Nzg_99b8badb-97fb-4a1c-8779-f7186aae231d">five</span> and 16 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair value of separately identifiable intangible assets requires management to make estimates, which are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Determining the useful life of an intangible asset also requires judgment, as different types of intangible assets will have different useful lives. The most significant intangible asset we typically record in a business combination is contract rights associated with membership assumed. In determining the estimated fair value of the intangible assets, we typically apply the income approach, which discounts the projected future net cash flows using an appropriate discount rate that reflects the risk associated with such projected future cash flows. The most critical assumptions used in determining the fair value of contract rights include forecasted operating margins and the weighted average cost of capital.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset&#8217;s (or asset group&#8217;s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment. Refer to Note 9, &#8220;Goodwill and Intangible Assets, Net,&#8221; for further details.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase consideration over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Impairment indicators may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of our reporting units exceed their estimated fair values. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. We performed a qualitative goodwill assessment of our reporting units, and did not identify any factors indicating that the carrying value of our reporting units exceeded their estimated fair values. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows. The base year in the reporting units&#8217; discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly-traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units&#8217; fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use (&#8220;ROU&#8221;) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2022, we recognized $192&#160;million of ROU asset impairments in connection with the reduction in leased space to accommodate our move to a remote work environment, including vacating and abandonment of various leased properties. We assessed the ROU assets for impairment as a result of the reduction in leased space used in our business operations, and we engaged a third-party real estate specialist to determine the recoverability of the leased properties, based on estimated fair values. The valuation primarily considered comparable leased properties in each market and the assessment of actual and potential future rental income generated by the ROU assets. For further information, including the amount and location of the ROU assets and lease liabilities recognized in the accompanying consolidated balance sheets, see Note 8, &#8220;Leases.&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recognized $16&#160;million in impairment charges related to leasehold improvements and other property and equipment associated with the reduction in leased space used in our business operations. Please refer to Note 7, &#8220;Property, Equipment, and Capitalized Software, Net&#8221; for further discussion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Claims and Benefits Payable</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (&#8220;IBNP&#8221;). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period in which the adjustments are determined. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10, &#8220;Medical Claims and Benefits Payable,&#8221; for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates, including certain components of premium revenue that are subject to accounting estimates and are described below, under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#8220;Amounts due government agencies&#8221; in the accompanying consolidated balance sheets. Categorized by program, such amounts due government agencies included the following:</span></div><div style="margin-bottom:1pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR, corridors, and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Medical Cost Corridors. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs as a percentage of premium revenue, or minimum medical loss ratio (&#8220;Minimum MLR&#8221;). Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. We have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the year ended December 31, 2022, we recognized approximately $197&#160;million related to such risk corridors, primarily in the Medicaid segment, compared to $323&#160;million recognized in the year ended December 31, 2021.The decrease in 2022 is due to the elimination of most of the COVID-19 risk corridors. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit Sharing. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium revenues on a retroactive basis for rate changes and changes in membership and eligibility data. In certain states, adjustments are made based on the health status of our members (as measured through a risk score). In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#8217; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#8217; health status, risk scores and CMS practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Affordable Care Act (&#8220;ACA&#8221;) established a Minimum MLR of 85% for Medicare. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of December&#160;31, 2022, Marketplace risk adjustment payables amounted to $230 million and related receivables amounted to $135 million, for a net payable of $95 million. As of December 31, 2021, Marketplace risk adjustment payables amounted to $902 million and related receivables amounted to $7 million, for a net payable of $895 million.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Incentives</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. Recognition of quality incentive premium revenue is subject to the use of estimates. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bear underwriting and reserving risks associated with our health plan subsidiaries. In certain cases, we limit our risk of significant catastrophic losses by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#8220;third-party reinsurer&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we remain liable for losses in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#8217;s financial condition, including its ability to maintain high credit ratings. Intercompany transactions with our captive are eliminated in consolidation.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $2 million, $2 million, and $9 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. Reinsurance recoveries amounted to $35 million, $33 million, and $23 million for the years ended December 31, 2022, 2021, and 2020, respectively. Reinsurance recoverable of $27 million, $51 million, and $30 million, as of December 31, 2022, 2021, and 2020, respectively, is included in &#8220;Receivables&#8221; in the accompanying consolidated balance sheets.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Deficiency Reserves on Loss Contracts</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assess the profitability of our contracts to determine if it is probable that a loss will be incurred in the future by reviewing current results and forecasts. For purposes of this assessment, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. A premium deficiency reserve (&#8220;PDR&#8221;) is recognized if anticipated future medical care and administrative costs exceed anticipated future premium revenue, investment income and reinsurance recoveries.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. For further discussion and disclosure, see Note 12, &#8220;Income Taxes.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Taxes Based on Premiums</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health Insurer Fee (&#8220;HIF&#8221;). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Affordable Care Act, the federal government imposed an annual fee, or excise tax, on health insurers for each calendar year (the &#8220;HIF&#8221;). The Further Consolidated Appropriations Act, 2020 repealed the HIF effective for years after 2020.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Premium and Use Tax. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our health plans are assessed a tax based on premium revenue collected. The premium revenues we receive from these states include reimbursement for the premium tax assessment. We have reported these taxes on a gross basis, as premium tax revenue and as premium tax expenses in the consolidated statements of income. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in healthcare practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate health plans primarily as a direct contractor with the states, and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a relatively small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive the majority of our revenues under contracts or subcontracts with state Medicaid managed care programs, which are considered individual external customers. Instances where these contracts were at least 10% of our total premium revenue for the year ended December 31, 2022 were New York with 10.0%, Texas with 12.0% and Washington with 13.6%.</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812230625856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income Per Share</a></td>
<td class="text">Net Income Per Share <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.55&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.23&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income per share because to do so would have been anti-dilutive.</span></div>(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812230631936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combinations</a></td>
<td class="text">Business Combinations <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, we closed on two business combinations primarily in the Medicaid segment, consistent with our growth strategy. For these transactions, we applied the acquisition method of accounting, where the total purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed, based on their fair values as of the acquisition date. The proforma effects of these acquisitions for prior periods were not material to our consolidated results of operations. Costs to complete acquisitions amounted to $2 million in the aggregate for the year ended December 31, 2022, and were recorded as &#8220;General and administrative expenses&#8221; in the accompanying consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">AgeWell. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York for purchase consideration of approximately $134&#160;million. We acquired membership and a provider network with a fair value of approximately $47 million. We allocated the remaining $87 million of purchase consideration to goodwill, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership. The goodwill is deductible for income tax purposes.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cigna.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On January 1, 2022, we closed on our acquisition of Cigna Corporation&#8217;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $60&#160;million. Because the closing date fell on a holiday, the purchase price was paid on December 31, 2021 and was recorded to prepaid expenses and other assets. We acquired membership and a provider network with a fair value of approximately $35&#160;million. We allocated the remaining $25&#160;million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents intangible assets acquired, by major class, for the AgeWell and Cigna acquisitions. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights - member list</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider network</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div>Affinity. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for purchase consideration of approximately $176&#160;million. In the year ended December 31, 2022, we recorded various measurement period adjustments, including an increase of $12&#160;million to &#8220;Medical claims and benefits payable,&#8221; and an increase of $4&#160;million to &#8220;Amounts due government agencies&#8221; net of &#8220;Receivables.&#8221; In the aggregate, we recorded a net increase of $21&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments, which have been finalized as of December 31, 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812146883600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to a three-tier fair value hierarchy as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 &#8212; Observable Inputs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 financial instruments are actively traded and therefore the fair value for these securities is based on quoted market prices for identical securities in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 &#8212; Directly or Indirectly Observable Inputs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value for these investments is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 3 &#8212; Unobservable Inputs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3 financial instruments are valued using unobservable inputs that represent management&#8217;s best estimate of what market participants would use in pricing the financial instrument at the measurement date. As of December 31, 2022 and 2021, our Level 3 financial instruments consisted of contingent consideration liabilities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net changes in fair value of Level 3 financial instruments are reported in &#8220;Other&#8221; operating expenses in our consolidated statements of income. In the years ended December 31, 2022 and 2021, we recognized a loss of $4&#160;million and $24&#160;million, respectively, primarily for the increase in the fair value of the contingent consideration liability described below. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Level 3 Contingent Consideration Liabilities</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Level 3 financial instruments at December 31, 2022 are comprised solely of contingent consideration liabilities of $8 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Refer to Note 2, &#8220;Significant Accounting Policies&#8212;Business Combinations&#8221;, for further details. Such liabilities are recorded at fair value on a recurring basis. In 2022, the estimated fair value of contingent purchase consideration increased by approximately $4&#160;million, relating to an operating income guarantee.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2022, we paid the seller $43&#160;million, of which $23&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $20&#160;million was for the first payment of the consideration due for the operating income guarantee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value Measurements &#8211; Disclosure Only</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812146914512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">Investments <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Available-for-Sale</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of December&#160;31, 2022 are summarized below:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted $1 million, $10 million and $6&#160;million in the years ended December&#160;31, 2022, 2021 and 2020, respectively, and were reclassified into earnings from other comprehensive income on a net-of-tax basis. Gross realized investment losses amounted to $7 million in the year ended December&#160;31, 2022, and were reclassified into earnings from other comprehensive income on a net-of-tax basis. Gross realized investment losses were insignificant in the years ended December 31, 2021 and 2020. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have determined that unrealized losses at December&#160;31, 2022 and 2021 primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience realized losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,858&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Investments Held-to-Maturity</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value, of which $193 million will mature in one year or less, $37 million will mature in one through five years, and $8 million will mature after five years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balances of restricted investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812151657328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment, and Capitalized Software, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment, and Capitalized Software, Net</a></td>
<td class="text">Property, Equipment, and Capitalized Software, Net <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Software developed for internal use is capitalized. Property and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM1OA_a83fded9-5651-4fc9-bbd0-f88b865ee371">three</span> to seven years. Software is generally amortized over its estimated useful life of three years. Leasehold improvements are amortized over the term of the lease, or over their useful lives from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzUzNQ_5c091379-9c3b-4ddb-b0f8-72f24ac68c1e">five</span> to 10 years, whichever is shorter. Buildings are depreciated over their estimated useful lives of 31.5 to 40&#160;years.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2, &#8220;Significant Accounting Policies&#8221;, the Company recognized an impairment on property and equipment of $16 million associated with our reduction in leased space used in our business operations, in the quarter ended December 31, 2022.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of property, equipment, and capitalized software is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated amortization - capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization - property, equipment, building, and improvements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(695)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets - finance leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents all depreciation and amortization recognized in our consolidated statements of income:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recorded in depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of property, equipment, building, and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation and amortization recognized</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812150134592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to 13 years, some of which include options to extend the leases for up to 10 years. As of December&#160;31, 2022, the weighted average remaining operating lease term is 8 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our finance leases have remaining lease terms up to 16 years, some of which include options to extend the leases for up to 25 years. As of December&#160;31, 2022, the weighted average remaining finance lease term is 13 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2, &#8220;Significant Accounting Policies&#8221;, the Company recognized $192 million of ROU asset impairments associated with our reduction in leased space used in our business operations in the quarter ended December 31, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted-average discount rate used to compute the present value of lease payments was 4.4% for operating lease liabilities, and 6.3% for finance lease liabilities. The components of lease expense for the years ended December&#160;31, 2022, 2021, and 2020 are presented in the following table.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease expense: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated cash flow information related to leases follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets recognized in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c">Other assets</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84">Accounts payable and accrued liabilities (current)</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df">Other long-term liabilities (non-current)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ROU assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8">Accounts payable and accrued liabilities (current)</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (non-current)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:92.25pt;text-indent:-76.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal - undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases <div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to 13 years, some of which include options to extend the leases for up to 10 years. As of December&#160;31, 2022, the weighted average remaining operating lease term is 8 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our finance leases have remaining lease terms up to 16 years, some of which include options to extend the leases for up to 25 years. As of December&#160;31, 2022, the weighted average remaining finance lease term is 13 years.</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 2, &#8220;Significant Accounting Policies&#8221;, the Company recognized $192 million of ROU asset impairments associated with our reduction in leased space used in our business operations in the quarter ended December 31, 2022. </span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, the weighted-average discount rate used to compute the present value of lease payments was 4.4% for operating lease liabilities, and 6.3% for finance lease liabilities. The components of lease expense for the years ended December&#160;31, 2022, 2021, and 2020 are presented in the following table.</span></div><div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease expense: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated cash flow information related to leases follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets recognized in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c">Other assets</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84">Accounts payable and accrued liabilities (current)</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df">Other long-term liabilities (non-current)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ROU assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8">Accounts payable and accrued liabilities (current)</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (non-current)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:92.25pt;text-indent:-76.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal - undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142915728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill and Intangible Assets, Net</a></td>
<td class="text">Goodwill and Intangible Assets, Net <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and measurement period adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and measurement period adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The changes in the carrying amounts of both goodwill and intangible assets, net, in 2022, were due to the </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquisitions and purchase price adjustments described in Note 4, &#8220;Business Combinations.&#8221; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of identified intangible assets, by major class, for the periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:23.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.505%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights and licenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>As of December&#160;31, 2022, we estimate that our intangible asset amortization will be approximately $84 million in 2023, $67 million in 2024, $64 million in 2025, $25 million in 2026, and $13 million in 2027.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812240574528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock', window );">Medical Claims and Benefits Payable</a></td>
<td class="text">Medical Claims and Benefits Payable <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Other&#8221; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $228 million, $226 million and $235 million, as of December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amounts presented for &#8220;Components of medical care costs related to: Prior years&#8221; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our estimates of medical claims and benefits payable recorded at December 31, 2022, 2021 and 2020 developed favorably by approximately $284&#160;million, $239&#160;million and $119&#160;million in 2022, 2021 and 2020, respectively. The favorable prior year development recognized in 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance, mainly in the Medicaid segment. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our estimates in 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior year development recognized in 2021 was primarily due to lower than expected utilization of medical services by our Medicaid members, and to a lesser extent our Medicare and Marketplace members, and improved operating performance. Consequently, the ultimate costs recognized in 2021 were lower than our original estimates in 2020, which was not discernible until additional information was provided, and as claims payments were processed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The favorable prior year development recognized in 2020 was primarily due to lower than expected utilization of medical services by our Medicaid members, and improved operating performance. Consequently, the ultimate costs recognized in 2020 were lower than our original estimates in 2019, which was not discernible until additional information was provided, and as claims payments were processed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide information about our consolidated incurred and paid claims development as of December&#160;31, 2022, as well as cumulative claims frequency and the total of incurred but not paid claims liabilities. The pattern of incurred and paid claims development is consistent across each of our segments. The cumulative claim frequency is measured by claim event, and includes claims covered under capitated arrangements.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.544%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Claims and Allocated Claims Adjustment Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total IBNP</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative number of reported claims</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,438&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.462%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claims Adjustment Expenses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incurred claims and allocated claims adjustment expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: cumulative paid claims and allocated claims adjustment expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All outstanding liabilities before 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-risk and other provider payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for insurance products considered to be short-duration contracts because the contract provides insurance protection for a fixed period of short duration and enables the insurer to cancel the contract or to adjust the provisions of the contract at the end of any contract period, such as adjusting the amount of premiums charged or coverage provided, and on contracts on which amounts are paid but insurance risk is not transferred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143043728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Debt</a></td>
<td class="text">Debt <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt, as of December&#160;31, 2022, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All our debt is held at the parent which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to a credit agreement (the &#8220;Credit Agreement&#8221;) which includes a revolving credit facility (&#8220;Credit Facility&#8221;) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary non-financial and financial covenants. As of December&#160;31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of December&#160;31, 2022, no amounts were outstanding under the Credit Facility.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Senior Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">4.375% Notes due 2028. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have $800 million aggregate principal amount of senior notes (the &#8220;4.375% Notes&#8221;) outstanding as of December 31, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">3.875% Notes due 2030. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have $650 million aggregate principal amount of senior notes (the &#8220;3.875% Notes due 2030&#8221;) outstanding as of December 31, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.</span></div>3.875% Notes due 2032. We have $750&#160;million aggregate principal amount of senior notes (the &#8220;3.875% Notes due 2032&#8221;) outstanding as of December 31, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812240573136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for continuing operations consisted of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate for continuing operations is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory federal tax (benefit) rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income provision (benefit), net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible health insurer fee (&#8220;HIF&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective tax expense rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effective tax rate was not impacted by the HIF in 2022 and 2021 given it was repealed for years after 2020. Our effective tax rate is based on expected income, statutory tax rates, and tax planning opportunities available to us in the various jurisdictions in which we operate. Management estimates and judgments are required in determining our effective tax rate. We are routinely under audit by federal, state, or local authorities regarding the timing and amount of deductions, nexus of income among various tax jurisdictions, and compliance with federal, state, foreign, and local tax laws.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are classified as non-current. Significant components of our deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and reserve liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued medical costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease financing obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets and intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credit carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax assets, net of valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets and intangibles</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had state net operating loss carryforwards of $95&#160;million, which begin expiring in 2036.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had foreign net operating loss carryforwards of $8&#160;million, which expire in 2032. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had foreign tax credit carryovers of $5&#160;million, which expire in 2030.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We evaluate the need for a valuation allowance taking into consideration the ability to carry back and carry forward tax credits and losses, available tax planning strategies and future income, including reversal of temporary differences. We have determined that as of December&#160;31, 2022, $18 million of deferred tax assets did not satisfy the recognition criteria. Therefore, we increased our valuation allowance by $8 million, from $10 million at December&#160;31, 2021, to $18 million as of December&#160;31, 2022.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize tax benefits only if the tax position is more likely than not to be sustained. We are subject to income taxes in the United States, Puerto Rico, and numerous state jurisdictions. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. We establish reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these reserves in light of changing facts and circumstances, such as the outcome of tax audits. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The roll forward of our unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total amount of unrecognized tax benefits at December&#160;31, 2022, 2021 and 2020 that, if recognized, would affect the effective tax rates is $5 million, $15 million, and $20 million, respectively. We expect that during the next 12 months it is reasonably possible that unrecognized tax benefit liabilities may decrease by $5 million due to resolution of a state refund claim. The state refund claim will not result in a cash payment for income taxes if our claim is denied. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continuing practice is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense. Amounts accrued for the payment of interest and penalties as of December&#160;31, 2022, 2021 and 2020 were insignificant.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to examination by the IRS for calendar years after 2018. With a few exceptions, which are immaterial in the aggregate, we no longer are subject to state, local, and Puerto Rico tax examinations for years before 2018. </span></div>On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for the tax years beginning on or after January 1, 2023. We do not expect such tax provisions to have a material impact on our consolidated financial results.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812151657328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">Stockholders' Equity <div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Purchase Programs</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This new program supersedes the stock purchase program previously approved by our board of directors in September 2021, as described below. This new program will be funded with cash on hand and extends through December 31, 2023. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 590,000 shares for $200&#160;million in the fourth quarter of 2022 (average cost of $339.06 per share). No shares have been purchased in 2023. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This program was funded with cash on hand. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 658,000 shares for $200&#160;million in the second quarter of 2022 (average cost of $304.13 per share). </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-Based Compensation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our employee stock plans, approximately 755,000 shares and 429,000 shares of common stock were issued, net of shares used to settle employees&#8217; income tax obligations, during the years ended December&#160;31, 2022, and 2021, respectively. Total share-based compensation expense is reported in &#8220;General and administrative expenses&#8221; in the accompanying consolidated statements of income, and summarized below.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs and PSUs (defined below)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan and stock options </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Incentive Plan</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2022, we had employee equity incentives outstanding under our 2019 Equity Incentive Plan (the &#8220;2019 EIP&#8221;). The 2019 EIP provides for awards, in the form of restricted stock awards (&#8220;RSAs&#8221;), performance units (&#8220;PSUs&#8221;), stock options, and other stock&#8211; or cash&#8211;based awards, to eligible persons who perform services for us. The 2019 EIP provides for the issuance of up to 2.9 million shares of our common stock.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. RSAs and PSUs are granted with a fair value equal to the market price of our common stock on the date of grant, and generally vest in equal annual installments over periods up to four years from the date of grant. PSUs vest in their entirety at the end of three-year performance periods, if their performance conditions are met. We generally recognize expense for RSAs and PSUs on a straight-line basis. Activity for stock-based awards in the year ended December&#160;31, 2022, is summarized below.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:40.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,816)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">511,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, total unrecognized compensation expense related to unvested RSAs and PSUs was $74 million, and $31 million, respectively, which we expect to recognize over a remaining weighted-average period of 2.0 years, and 0.7 years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of 9.2% for non-executive employees as of December&#160;31, 2022, based on actual forfeitures over the last 4 years. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value of awards granted and vested is presented in the following table.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total granted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total vested</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to four years from the date of grant, and have a maximum term of ten years from the date of grant. Stock option activity for the year ended December&#160;31, 2022, is summarized below.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual term</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, vested, and exercisable as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt;margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No stock options were granted in 2022, 2021, or 2020, and no stock options were exercised in 2020. As of December&#160;31, 2022, there was no unrecognized compensation expense related to unvested stock options.</span></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Employee Stock Purchase Plans (&#8220;ESPP&#8221;)</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our ESPP, eligible employees may purchase common shares at 85% of the lower of the fair market value of our common stock on either the first or last trading day of each six-month offering period. Each participant is limited to a maximum purchase of $25,000 (as measured by the fair value of the stock acquired) per year through payroll deductions. We estimate the fair value of the stock issued using a standard option pricing model. For the years ended December&#160;31, 2022, 2021, and 2020, the inputs to this model were as follows: risk-free interest rates of approximately 0.1% to 2.5%; expected volatility of approximately 29% to 54%, dividend yields of 0%, and an average expected life of 0.5 years.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812230654000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">Employee Benefit Plans<div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We sponsor defined contribution 401(k) plans that cover substantially all employees of our company and its subsidiaries. Eligible employees are permitted to contribute up to the maximum amount allowed by law. We match up to the first 4% of compensation contributed by employees. Expense recognized in connection with our contributions to the 401(k) plans amounted to $45 million, $41 million, and $28 million in the years ended December&#160;31, 2022, 2021, and 2020, respectively.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also have a non-qualified deferred compensation plan for certain key employees. Under this plan, eligible participants may defer portions of their base salary and bonus to provide tax-deferred growth. The deferrals are distributable based upon termination of employment or other periods, as elected under the plan and were $26 million and $23&#160;million as of December&#160;31, 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -URI https://asc.fasb.org/topic&amp;trid=2197446<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142868224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory Capital Requirements and Dividend Restrictions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our health plans, which are generally operated by our respective wholly owned subsidiaries in those states in which our health plans operate, are subject to state laws and regulations that, among other things, require the maintenance of minimum levels of statutory capital, as defined by each state. The National Association of Insurance Commissioners (&#8220;NAIC&#8221;), has adopted rules which, if implemented by the states, set minimum capitalization requirements for insurance companies, HMOs, and other entities bearing risk for healthcare coverage. The requirements take the form of risk-based capital (&#8220;RBC&#8221;) rules which may vary from state to state. Regulators in some states may also enforce capital requirements that require the retention of net worth in excess of amounts formally required by statute or regulation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the states in which our health plans operate, except California, Florida, Massachusetts and New York, have adopted the RBC rules. The minimum statutory capital requirements in these states is based on a percentage of annualized premium revenue, a percentage of annualized health care costs, a percentage of certain liabilities, or other financial ratios. The RBC rules, if adopted by California, Florida, Massachusetts or New York, could increase the minimum capital required for those states. Our Massachusetts health plan maintains a $35&#160;million performance bond, effective through December 31, 2023, to partially satisfy minimum net worth requirements in that state.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Statutes, regulations and informal capital requirements also restrict the timing, payment, and amount of dividends and other distributions that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based on current statutes and regulations, the net assets in these subsidiaries, which may not be transferable to us in the form of loans, advances, or cash dividends was approximately $3.1 billion at December&#160;31, 2022. Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments held by the parent company&#8212;Molina Healthcare, Inc. Such cash, cash equivalents and investments amounted to $375&#160;million and $348 million as of December&#160;31, 2022 and 2021, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2022, our health plans had aggregate statutory capital and surplus of approximately $3.3 billion, which was in excess of the required minimum aggregate statutory capital and surplus of approximately $2.3 billion. We have the ability and commitment to provide additional capital to each of our health plans when necessary to ensure that statutory capital and surplus continue to meet regulatory requirements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">COVID-19 Pandemic</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic and, as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously billed and collected revenues. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&#160; </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Kentucky RFP.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. On September 9, 2022, the Kentucky Court of Appeals ruled that, with regard to the earlier Circuit Court ruling granting Anthem relief, the Circuit Court should not have invalidated the 2020 procurement and thus should not have awarded a contract to Anthem. Anthem has sought discretionary review by the Kentucky Supreme Court of the ruling by the Court of Appeals. Pending further Court order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Puerto Rico.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#8220;MHPR&#8221;) filed a complaint asserting, among other claims, breach of contract against Puerto Rico Health Insurance Administration (&#8220;ASES&#8221;). On September 13, 2021, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. This matter remains subject to significant additional proceedings, and no prediction can be made as to the outcome.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Professional Liability Insurance</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We carry medical professional liability insurance for healthcare services rendered in the primary care institutions that we manage. In addition, we carry managed care errors and omissions insurance for all managed care services that we provide.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812149802192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments</a></td>
<td class="text">Segments <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes long-term services and supports consultative services in Wisconsin.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment since this is not a metric used to assess segment performance or allocate resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income tax expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, Marketplace risk corridor judgment, investment income and other revenue.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment, and other costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142950656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of Registrant<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock', window );">Condensed Financial Information of Registrant</a></td>
<td class="text">Condensed Financial Information of Registrant <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed balance sheets as of December&#160;31, 2022 and 2021, and the related condensed statements of income, comprehensive income and cash flows for each of the three years in the period ended December&#160;31, 2022 for our parent company Molina Healthcare, Inc. (the &#8220;Registrant&#8221;), are presented below.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share data)</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill and intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advances to related parties and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $0.001 par value; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Income</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Administrative services fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax benefit and equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss before equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Comprehensive Income</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized investment (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: effect of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital contributions to subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends received from subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, equipment and capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid in business combinations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in amounts due to/from affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld to settle employee tax obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from senior notes offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan facility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial termination of warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial settlement of conversion option</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for partial settlement of call option</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of principal amount of convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Condensed Financial Information of Registrant </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;A&#160;- Basis of Presentation </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant was incorporated in 2002. Prior to that date, Molina Healthcare of California (formerly known as Molina Medical Centers) operated as a California health plan and as the parent company for three other state health plans. In June 2003, the employees and operations of the corporate entity were transferred from Molina Healthcare of California to the Registrant. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant&#8217;s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries since the date of acquisition. The accompanying condensed financial information of the Registrant should be read in conjunction with the consolidated financial statements and accompanying notes. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;B&#160;- Transactions with Subsidiaries</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant provides certain centralized medical and administrative services to our subsidiaries pursuant to administrative services agreements that include, but are not limited to, information technology, product development </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and administration, underwriting, claims processing, customer service, certain care management services, human resources, marketing, purchasing, risk management, actuarial, finance, accounting, compliance, legal and public relations. Fees are based on the fair market value of services rendered and are recorded as operating revenue. Payment is subordinated to the subsidiaries&#8217; ability to comply with minimum capital and other restrictive financial requirements of the states in which they operate. Charges in 2022, 2021, and 2020 for these services amounted to $1,826 million, $1,496 million, and $1,208 million, respectively, and are included in operating revenue. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Registrant and its subsidiaries are included in the consolidated federal and state income tax returns filed by the Registrant. Income taxes are allocated to each subsidiary in accordance with an intercompany tax allocation agreement. The agreement allocates income taxes in an amount generally equivalent to the amount which would be expensed by the subsidiary if it filed a separate tax return. Net operating loss benefits are paid to the subsidiary by the Registrant to the extent such losses are utilized in the consolidated tax returns.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Note&#160;C&#160;- Dividends and Capital Contributions </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Registrant receives dividends from its subsidiaries, such amounts are recorded as a reduction to the investments in the respective subsidiaries.</span></div>For all periods presented, the Registrant made capital contributions to certain subsidiaries primarily to comply with minimum net worth requirements and to fund business combinations. Such amounts have been recorded as an increase in investment in the respective subsidiaries.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.5-04(Schedule I))<br> -URI https://asc.fasb.org/extlink&amp;oid=126898705&amp;loc=d3e5864-122674<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=d3e5283-111683<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143184704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation and Presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text">Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text">Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#8220;AFS&#8221;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#8217; equity as other comprehensive income, net of applicable income taxes. Held-to-maturity (&#8220;HTM&#8221;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses arising from credit-related factors with respect to AFS </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment policy requires that all of our investments have final maturities of less than 15 years, or less than 15 years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.</span></div>In general, our AFS securities are classified as current assets without regard to the securities&#8217; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivables</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Receivables</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text">Business CombinationsWe account for business combinations using the acquisition method of accounting, which requires us to recognize the assets acquired and the liabilities assumed at their acquisition date fair values. As discussed below, the excess of the purchase consideration transferred over the fair value of the net tangible and intangible assets acquired is recorded as goodwill. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated results of operations.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Long-Lived Assets, including Intangible Assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets, including Intangible Assets</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, &#8220;Property, Equipment, and Capitalized Software, Net&#8221;), and intangible assets resulting from acquisitions. Long-lived assets are subject to impairment tests when events or circumstances indicate that the asset&#8217;s (or asset group&#8217;s) carrying value may not be recoverable. Refer to the discussion in &#8220;Leases&#8221; below for impairment charges related to leasehold improvements and other property and equipment associated with the reduction in leased space used in our business operations. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3Nzg_99b8badb-97fb-4a1c-8779-f7186aae231d">five</span> and 16 years.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Determining the fair value of separately identifiable intangible assets requires management to make estimates, which are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Determining the useful life of an intangible asset also requires judgment, as different types of intangible assets will have different useful lives. The most significant intangible asset we typically record in a business combination is contract rights associated with membership assumed. In determining the estimated fair value of the intangible assets, we typically apply the income approach, which discounts the projected future net cash flows using an appropriate discount rate that reflects the risk associated with such projected future cash flows. The most critical assumptions used in determining the fair value of contract rights include forecasted operating margins and the weighted average cost of capital.</span></div>Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Software developed for internal use is capitalized. Property and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM1OA_a83fded9-5651-4fc9-bbd0-f88b865ee371">three</span> to seven years. Software is generally amortized over its estimated useful life of three years. Leasehold improvements are amortized over the term of the lease, or over their useful lives from <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzUzNQ_5c091379-9c3b-4ddb-b0f8-72f24ac68c1e">five</span> to 10 years, whichever is shorter. Buildings are depreciated over their estimated useful lives of 31.5 to 40&#160;years.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text">Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset&#8217;s (or asset group&#8217;s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill represents the excess of the purchase consideration over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Impairment indicators may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of our reporting units exceed their estimated fair values. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. We performed a qualitative goodwill assessment of our reporting units, and did not identify any factors indicating that the carrying value of our reporting units exceeded their estimated fair values. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows. The base year in the reporting units&#8217; discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly-traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units&#8217; fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Right-of-use (&#8220;ROU&#8221;) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.</span></div>The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Medical Claims and Benefits Payable</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Medical Claims and Benefits Payable</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (&#8220;IBNP&#8221;). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the period in which the adjustments are determined. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note 10, &#8220;Medical Claims and Benefits Payable,&#8221; for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Premium Revenue Recognition and Amounts Due Government Agencies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#8220;PMPM&#8221;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates, including certain components of premium revenue that are subject to accounting estimates and are described below, under &#8220;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#8221; and &#8220;Quality Incentives.&#8221;</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Provisions That May Adjust or Limit Revenue or Profit</span></div>Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.<div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicaid Program</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR and Medical Cost Corridors. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs as a percentage of premium revenue, or minimum medical loss ratio (&#8220;Minimum MLR&#8221;). Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.</span></div>Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#8217; fiscal years in 2019. We have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable.<div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit Sharing. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Premium Adjustments. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">State Medicaid programs periodically adjust premium revenues on a retroactive basis for rate changes and changes in membership and eligibility data. In certain states, adjustments are made based on the health status of our members (as measured through a risk score). In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Medicare Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Adjustment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#8217; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#8217; health status, risk scores and CMS practices.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Affordable Care Act (&#8220;ACA&#8221;) established a Minimum MLR of 85% for Medicare. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-bottom:6pt;margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Marketplace Program</span></div>Risk Adjustment. Under this program, our health plans&#8217; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Minimum MLR.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Quality Incentives</span></div>At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. Recognition of quality incentive premium revenue is subject to the use of estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceAccountingPolicy', window );">Reinsurance</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reinsurance</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We bear underwriting and reserving risks associated with our health plan subsidiaries. In certain cases, we limit our risk of significant catastrophic losses by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#8220;third-party reinsurer&#8221;).</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we remain liable for losses in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#8217;s financial condition, including its ability to maintain high credit ratings. Intercompany transactions with our captive are eliminated in consolidation.</span></div>We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text">Income TaxesWe account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_TaxesBasedOnPremiumsPolicyTextBlock', window );">Taxes Based on Premiums</a></td>
<td class="text">Taxes Based on PremiumsHealth Insurer Fee (&#8220;HIF&#8221;). Under the Affordable Care Act, the federal government imposed an annual fee, or excise tax, on health insurers for each calendar year (the &#8220;HIF&#8221;).<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text">Concentrations of Credit RiskFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in healthcare practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.</span></div>We operate health plans primarily as a direct contractor with the states, and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a relatively small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#8220;SEC&#8221;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to a three-tier fair value hierarchy as follows:</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 1 &#8212; Observable Inputs.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1 financial instruments are actively traded and therefore the fair value for these securities is based on quoted market prices for identical securities in active markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Level 2 &#8212; Directly or Indirectly Observable Inputs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value for these investments is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets. </span></div>Level 3 &#8212; Unobservable Inputs. Level 3 financial instruments are valued using unobservable inputs that represent management&#8217;s best estimate of what market participants would use in pricing the financial instrument at the measurement date. As of December 31, 2022 and 2021, our Level 3 financial instruments consisted of contingent consideration liabilities.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_TaxesBasedOnPremiumsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Taxes based on premiums.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_TaxesBasedOnPremiumsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144439<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27830-158548<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 605<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99379264&amp;loc=d3e27758-158548<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -URI https://asc.fasb.org/topic&amp;trid=2303980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812139312272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash and cash equivalents</a></td>
<td class="text">The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restricted cash and cash equivalents</a></td>
<td class="text">The restricted cash and cash equivalents presented below are included in &#8220;Restricted investments&#8221; in the accompanying consolidated balance sheets. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.864%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.869%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:27pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,048&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,223&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock', window );">Schedule of receivables</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:72.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.694%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.695%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government receivables</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,702&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy rebate receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total receivables</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock', window );">Schedule of amounts due to government agencies</a></td>
<td class="text">Categorized by program, such amounts due government agencies included the following:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.206%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid program:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR, corridors, and profit sharing</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">482&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">263&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment and Part D risk sharing</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR and profit sharing </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace program:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk adjustment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">902&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minimum MLR</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other premium adjustments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total amounts due government agencies</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,079&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,472&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_SummarizedPremiumRevenueTableTextBlock', window );">Summarized premium revenue</a></td>
<td class="text"><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant Customers</span></div><div style="margin-bottom:5pt;margin-top:5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive the majority of our revenues under contracts or subcontracts with state Medicaid managed care programs, which are considered individual external customers. Instances where these contracts were at least 10% of our total premium revenue for the year ended December 31, 2022 were New York with 10.0%, Texas with 12.0% and Washington with 13.6%.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_SummarizedPremiumRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summarized Premium Revenue</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_SummarizedPremiumRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReservesReportedToOtherAgenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of reserves reported to other federal agencies or authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReservesReportedToOtherAgenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3,4)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812149913728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Summary of denominators for the computation of basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the calculation of basic and diluted net income per share:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:56.462%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except net income per share)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shares outstanding at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average number of shares issued:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock purchases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for basic net income per share</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denominator for diluted net income per share</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Basic </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.72&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share - Diluted </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.55&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.25&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.23&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">_______________________________&#160;</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income per share because to do so would have been anti-dilutive.</span></div>(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812230789216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock', window );">Summary of intangible assets acquired</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents intangible assets acquired, by major class, for the AgeWell and Cigna acquisitions. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.572%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.623%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Life</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights - member list</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider network</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.0</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.7</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144767808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of fair value of assets measured on recurring basis</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2022, were as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.923%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Schedule of fair value measurements of senior notes</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:49.779%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.632%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">729&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">791&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">829&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">643&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">741&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,912&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,264&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142925744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of investments</a></td>
<td class="text">The following tables summarize our current investments as of the dates indicated:<div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,303&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Losses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,833&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">616&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,208&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,202&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of contractual maturities of investments</a></td>
<td class="text"><div style="margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of our current investments as of December&#160;31, 2022 are summarized below:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">364&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due after ten years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,709&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,499&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of available-for-sale investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2022:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:24.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.826%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">371&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,858&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,116&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:24.744%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.647%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.651%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;Less&#160;than&#160;12&#160;Months</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">In&#160;a&#160;Continuous&#160;Loss Position<br/>for&#160;12&#160;Months or More</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Positions</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mortgage-backed securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">408&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">677&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_RestrictionsOnInvestmentsTableTextBlock', window );">Schedule of balances of restricted investments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the balances of restricted investments:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. Treasury notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total restricted investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">238&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_RestrictionsOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restrictions On Investments [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_RestrictionsOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812149730624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment, and Capitalized Software, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment and depreciation and amortization recognized</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of property, equipment, and capitalized software is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized software</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">615&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">547&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">221&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Building and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">822&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated amortization - capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(482)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(427)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: accumulated depreciation and amortization - property, equipment, building, and improvements</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(695)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets - finance leases</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents all depreciation and amortization recognized in our consolidated statements of income:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Recorded in depreciation and amortization:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of capitalized software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of property, equipment, building, and improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total depreciation and amortization recognized</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">131&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143017248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of lease expense and supplemental consolidated cash flow information</a></td>
<td class="text">The components of lease expense for the years ended December&#160;31, 2022, 2021, and 2020 are presented in the following table.<div style="margin-bottom:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease expense</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease expense: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of ROU assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental consolidated cash flow information related to leases follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:56.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.516%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.519%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash used in financing activities: </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ROU assets recognized in exchange for lease obligations:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating leases</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance leases</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Supplemental lease information</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.122%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.498%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating leases:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ROU assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c">Other assets</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84">Accounts payable and accrued liabilities (current)</span></span></span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df">Other long-term liabilities (non-current)</span></span></span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Finance leases:</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ROU assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8">Accounts payable and accrued liabilities (current)</span></span></span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities (non-current)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:92.25pt;text-indent:-76.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total finance lease liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">234&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Operating lease maturities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal - undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock', window );">Finance lease maturities</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of lease liabilities as of December&#160;31, 2022, were as follows:</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:70.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.536%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.537%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Operating </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Finance</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subtotal - undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(25)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">118&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144174240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">161&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">692&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and measurement period adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">280&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">769&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">982&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions and measurement period adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance, December 31, 2022</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Summary of identified intangible assets, by major class</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of identified intangible assets, by major class, for the periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:23.569%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.381%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.500%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.505%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying Amount </span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract rights and licenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">507&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Provider networks</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trade names</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">501&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140610112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense', window );">Schedule of liability for unpaid claims and claims adjustment expense</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the details of our medical claims and benefits payable as of the dates indicated.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,597&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,486&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmacy payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitation payable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">82&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">528&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Magellan Complete Care acquisition opening balance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock', window );">Components of the change in medical claims and benefits payable</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,097&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,972&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(251)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(32)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,358&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,971&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,175&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">361&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,621&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,305&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,089&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,015&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,815&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">452&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,652&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(182)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(239)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,139&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,931&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,704&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,573&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,601&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,080&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,885&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,913&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,430&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,228&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,580&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">379&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,363&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicaid </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Medicare </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketplace</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Consolidated</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,465&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">267&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,854&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Components of medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,545&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,939&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(84)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total medical care costs</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,461&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,161&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,820&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for medical care costs related to:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current year</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,940&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,047&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prior years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">233&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total paid</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,116&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,145&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired balances, net of post-acquisition adjustments</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">294&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in non-risk and other provider payables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable, ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,129&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">392&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,696&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock', window );">Incurred and paid claims development</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.737%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.541%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.544%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incurred Claims and Allocated Claims Adjustment Expenses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total IBNP</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative number of reported claims</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,233&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,056&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,167&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,459&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,453&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,438&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,588&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.462%"/><td style="width:0.1%"/></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cumulative Paid Claims and Allocated Claims Adjustment Expenses</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Benefit Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Unaudited)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64,189&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock', window );">Reconciliation of claims development to liability</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Incurred claims and allocated claims adjustment expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: cumulative paid claims and allocated claims adjustment expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(64,189)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All outstanding liabilities before 2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-risk and other provider payables</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical claims and benefits payable </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,528&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Components Of Change In Medical Claims And Benefits Payable [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140700480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Maturities of long-term debt</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual maturities of debt, as of December&#160;31, 2022, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.046%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.998%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Thereafter</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,200&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Long term debt</a></td>
<td class="text">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-current long-term debt:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.375% Notes due 2028</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2030</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">650&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.875% Notes due 2032</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: unamortized debt issuance costs </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143798864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for income taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense for continuing operations consisted of the following:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">281&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">216&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">288&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Effective income tax rate reconciliation to the statutory federal income tax rate</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate for continuing operations is as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statutory federal tax (benefit) rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income provision (benefit), net of federal benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible health insurer fee (&#8220;HIF&#8221;)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective tax expense rate</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Significant components of deferred tax assets and liabilities</a></td>
<td class="text">Significant components of our deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:72.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and reserve liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other accrued medical costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating losses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unearned premiums</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease financing obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized losses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets and intangibles</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credit carryover</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax assets, net of valuation allowance </span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">235&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets and intangibles</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred income tax liabilities </span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(14)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred income tax asset</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">220&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Unrecognized tax benefits roll forward</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The roll forward of our unrecognized tax benefits is as follows:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at beginning of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lapse in statute of limitations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross unrecognized tax benefits at end of period</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(15)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144808064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Stock based compensation expense</a></td>
<td class="text">Total share-based compensation expense is reported in &#8220;General and administrative expenses&#8221; in the accompanying consolidated statements of income, and summarized below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.190%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.726%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Pretax<br/>Charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net-of-Tax<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs and PSUs (defined below)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee stock purchase plan and stock options </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock', window );">Restricted and performance stock activity</a></td>
<td class="text">Activity for stock-based awards in the year ended December&#160;31, 2022, is summarized below.<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:40.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.038%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.041%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">RSAs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">PSUs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted<br/>Average<br/>Grant&#160;Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">539,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169.39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">275,050&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312.27&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(224,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">156.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(219,674)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137.54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,257)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,816)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">249.09&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unvested balance, December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">511,105&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">237.10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">312,830&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock options, activity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total grant date fair value of awards granted and vested is presented in the following table.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:64.492%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.880%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total granted</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RSAs</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PSUs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total vested</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="margin-bottom:6pt;margin-top:7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Options.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to four years from the date of grant, and have a maximum term of ten years from the date of grant. Stock option activity for the year ended December&#160;31, 2022, is summarized below.</span></div><div style="margin-bottom:1pt;margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.724%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.402%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.502%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average Remaining Contractual term</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Per share)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding as of December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">395,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(390,000)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, vested, and exercisable as of December 31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.02&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.2</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144750208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of operating segment information</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.280%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.622%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,217&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,379&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,529&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,974&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,771&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,423&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table reconciles margin by segment to consolidated income before income tax expense:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Margin:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicaid</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,981&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,804&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medicare</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketplace</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">399&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total margin</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,719&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,165&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Add: other operating revenues </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,124&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other operating expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,566)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,525)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,173&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,020&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,078&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,063&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">875&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">961&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating revenues include premium tax revenue, health insurer fees reimbursed, Marketplace risk corridor judgment, investment income and other revenue.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt">Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment, and other costs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142979728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of Registrant (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract', window );"><strong>Condensed Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock', window );">Condensed balance sheets</a></td>
<td class="text"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Balance Sheets</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:72.946%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.656%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.365%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except per-share data)</span></div></td></tr><tr><td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from affiliates</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, equipment, and capitalized software, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">349&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill and intangible assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">731&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments in subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(18)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Advances to related parties and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable, accrued liabilities and other</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,173&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">215&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">219&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,804&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $0.001 par value; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022 and December 31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">328&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,796&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,964&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,836&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,434&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock', window );">Condensed statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Income</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Administrative services fees</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,826&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,208&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment income and other revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,834&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,507&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,221&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,721&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Impairment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,000&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,527&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,180&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating (loss) income</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other expenses, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other expenses, net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax benefit and equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(165)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(21)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss before equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(234)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(144)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in net earnings of subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">803&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock', window );">Condensed statements of comprehensive income</a></td>
<td class="text"><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Comprehensive Income</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">659&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized investment (loss) income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(204)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(55)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: effect of income taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(155)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">617&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">706&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock', window );">Condensed statements of cash flows</a></td>
<td class="text"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Condensed Statements of Cash Flows</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:59.222%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capital contributions to subsidiaries</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(159)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends received from subsidiaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">282&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property, equipment and capitalized software</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(86)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid in business combinations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(263)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,028)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in amounts due to/from affiliates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(68)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">377&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(545)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock purchases</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(400)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(606)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock withheld to settle employee tax obligations </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration liabilities settled</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from senior notes offering, net of issuance costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">740&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of senior notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(723)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(338)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of term loan facility</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(600)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from borrowings under term loan facility</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial termination of warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for partial settlement of conversion option</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for partial settlement of call option</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:15.75pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of principal amount of convertible notes</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(441)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">217&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(301)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(261)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at beginning of period</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">836&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at end of period</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">329&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">274&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedCashFlowStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedCashFlowStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfCondensedIncomeStatementTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Paragraph (a)<br> -Subsection 04<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfCondensedIncomeStatementTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e526-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812138903136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Basis of Presentation (Details)<br> member in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 13, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>segment </div>
<div>member </div>
<div>state</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NE', window );">Nebraska</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_IA', window );">Iowa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_MS', window );">Mississippi</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanExtensionOptionPeriod', window );">Extension period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_MyChoiceWisconsinMember', window );">My Choice Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price | $</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember', window );">Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms', window );">Number of members eligible for the health care programs, approximately | member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms', window );">Number of states with programs | state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Health and human services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Health Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Health and human services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BasisOfPresentationLineItems', window );"><strong>Basis Of Presentation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthPlanContractTerm', window );">Contract term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis Of Presentation [Line Items]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of members eligible for the health care programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanContractTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Contract Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanContractTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthPlanExtensionOptionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Plan, Extension Option, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthPlanExtensionOptionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of States With Government-Sponsored Healthcare Programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_IA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_IA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_MS">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_MS</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_MyChoiceWisconsinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_MyChoiceWisconsinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_HealthPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_HealthAndHumanServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_HealthAndHumanServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143973776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,006<span></span>
</td>
<td class="nump">$ 4,438<span></span>
</td>
<td class="nump">$ 4,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">69<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows</a></td>
<td class="nump">$ 4,048<span></span>
</td>
<td class="nump">$ 4,506<span></span>
</td>
<td class="nump">$ 4,223<span></span>
</td>
<td class="nump">$ 2,508<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812145262704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_InvestmentsMaturityPeriod', window );">Maturity period (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_InvestmentsAverageMaturityPeriod', window );">Average maturity period (less than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OperatingAndFinanceLeaseImpairmentLoss', window );">ROU assets impairments</a></td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable', window );">Marketplace risk adjustment payables</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable', window );">Risk adjustment receivable</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable', window );">Risk adjustment, net payable</a></td>
<td class="nump">95<span></span>
</td>
<td class="nump">95<span></span>
</td>
<td class="nump">895<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidReinsurancePremiums', window );">Prepaid reinsurance premiums</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Reinsurance recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments', window );">Reinsurance recoverable</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_NY', window );">New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthCareOrganizationRevenuePercentage', window );">Premium revenue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_TX', window );">Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthCareOrganizationRevenuePercentage', window );">Premium revenue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=stpr_WA', window );">Washington</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_HealthCareOrganizationRevenuePercentage', window );">Premium revenue percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment on property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member', window );">COVID-19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPremiumsReceivable', window );">Reduction in premiums</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Premium revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PercentageOfAdditionalIncrementalRevenueEarned', window );">Percentage of additional incremental revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Premium revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PercentageOfAdditionalIncrementalRevenueEarned', window );">Percentage of additional incremental revenue earned</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_HealthCareOrganizationRevenuePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Health Care Organization, Revenue Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_HealthCareOrganizationRevenuePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsAverageMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments, Average Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsAverageMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_InvestmentsMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments, Maturity Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_InvestmentsMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OperatingAndFinanceLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OperatingAndFinanceLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PercentageOfAdditionalIncrementalRevenueEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of additional incremental revenue earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PercentageOfAdditionalIncrementalRevenueEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPremiumsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The change in the premium receivable balance on the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPremiumsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidReinsurancePremiums">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The unexpired portion of premiums ceded on policies in force as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 340<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6485982&amp;loc=d3e22818-158507<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123600520&amp;loc=SL75241803-196195<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidReinsurancePremiums</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 310<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=99404803&amp;loc=d3e21412-158489<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=99397103&amp;loc=d3e6824-158387<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_TX">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_TX</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualOrInfrequentItemAxis=moh_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_HealthCarePremiumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_HealthCarePremiumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142937520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Receivables (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 2,302<span></span>
</td>
<td class="nump">$ 2,177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember', window );">Government receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">1,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember', window );">Pharmacy rebate receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">291<span></span>
</td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsNotesAndLoansReceivableLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Total receivables</a></td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">$ 335<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesAndLoansReceivableLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesAndLoansReceivableLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_GovernmentReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_PharmacyRebateReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis=moh_OtherReceivablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144126304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Amounts Due To Government Agencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract', window );"><strong>Medicaid program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold', window );">Minimum MLR, corridors, and profit sharing</a></td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="nump">$ 1,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther', window );">Other premium adjustments</a></td>
<td class="nump">482<span></span>
</td>
<td class="nump">263<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract', window );"><strong>Medicare program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing', window );">Risk adjustment and Part D risk sharing</a></td>
<td class="nump">76<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold', window );">Minimum MLR and profit sharing</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OtherMedicareProgram', window );">Other premium adjustments</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract', window );"><strong>Marketplace program:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment', window );">Risk adjustment</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">902<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold', window );">Minimum MLR</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AmountsDuetoGovernmentAgenciesOther', window );">Other premium adjustments</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">48<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalPremiumLiabilityDueToAgency', window );">Total amounts due government agencies</a></td>
<td class="nump">$ 2,079<span></span>
</td>
<td class="nump">$ 2,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Marketplace Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicaid Program [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due To Government Agencies Medicare Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AmountsDuetoGovernmentAgenciesRiskAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts Due to Government Agencies, Risk Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AmountsDuetoGovernmentAgenciesRiskAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumLiabilityDueToAgency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Premium Liability Due to Agency</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumLiabilityDueToAgency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Premiums Liability, Medical Care Costs Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherMedicareProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Medicare Program</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherMedicareProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142766656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_SharesOutstandingExcludingRestrictedStockAwards', window );">Shares outstanding at the beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.9<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average number of shares issued:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Stock purchases (in shares)</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_WeightedAverageNumberofSharesShareBasedCompensation', window );">Stock-based compensation (in shares)</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Denominator for basic net income per share (in shares)</a></td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">57.8<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Share-based compensation (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Denominator for diluted net income per share (in shares)</a></td>
<td class="nump">58.5<span></span>
</td>
<td class="nump">58.6<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - Basic (in dollars per share)</a></td>
<td class="nump">$ 13.72<span></span>
</td>
<td class="nump">$ 11.40<span></span>
</td>
<td class="nump">$ 11.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - Diluted (in dollars per share)</a></td>
<td class="nump">$ 13.55<span></span>
</td>
<td class="nump">$ 11.25<span></span>
</td>
<td class="nump">$ 11.23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_SharesOutstandingExcludingRestrictedStockAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shares, Outstanding, Excluding Restricted Stock Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_SharesOutstandingExcludingRestrictedStockAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_WeightedAverageNumberofSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted Average Number of Shares, Share Based Compensation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_WeightedAverageNumberofSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140635248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>combination</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BusinessCombinationNumberOfBusinessCombinations', window );">Number of business combinations | combination</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_AgeWellNewYorkMember', window );">AgeWell New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="nump">$ 134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_AgeWellNewYorkMember', window );">AgeWell New York | Member list</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquired membership with a preliminary fair value</a></td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember', window );">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember', window );">Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan | Member list</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Acquired membership with a preliminary fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember', window );">Affinity Health Plan, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable', window );">Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables', window );">Receivables</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationNumberOfBusinessCombinations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Number Of Business Combinations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationNumberOfBusinessCombinations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126954596&amp;loc=d3e511914-122862<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126954596&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e961-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_AgeWellNewYorkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_AgeWellNewYorkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_MemberListsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_MemberListsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_AffinityHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142809840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combinations - Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember', window );">Health Plans Segment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 82<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average life</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember', window );">Health Plans Segment | Contract rights - member list</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets value</a></td>
<td class="nump">$ 81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average life</a></td>
<td class="text">3 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember', window );">Health Plans Segment | Contract rights - member list | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember', window );">Health Plans Segment | Contract rights - member list | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember', window );">Health Plans Segment | Provider network</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets value</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted-average life</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember', window );">Health Plans Segment | Provider network | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember', window );">Health Plans Segment | Provider network | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems', window );"><strong>Acquired Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible asset useful life</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI https://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_HealthPlansSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ContractualRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144002512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings', window );">Recognized loss</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities', window );">Contingent consideration paid to seller included in financing and operating activities</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan Inc | Minimum Member Enrollment Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities', window );">Remaining half of contingent consideration paid</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember', window );">Passport Health Plan Inc | Operating Income Guarantee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payment For Contingent Consideration Liability, Financing And Operating Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (ee)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_PassportHealthPlanIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=moh_MinimumMemberEnrollmentTargetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=moh_MinimumMemberEnrollmentTargetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=moh_OperatingIncomeGuaranteeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=moh_OperatingIncomeGuaranteeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140419888">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Instruments on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="nump">$ 3,202<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total liabilities</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Fair value of assets measured on recurring basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Debt securities, available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialMortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143225344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 2,176<span></span>
</td>
<td class="nump">$ 2,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 1,912<span></span>
</td>
<td class="nump">2,264<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 643<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 554<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032 | Carrying Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 741<span></span>
</td>
<td class="nump">740<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032 | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Fair value of debt</a></td>
<td class="nump">$ 629<span></span>
</td>
<td class="nump">$ 760<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812138856016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Schedule of Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 3,709<span></span>
</td>
<td class="nump">$ 3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">212<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">2,303<span></span>
</td>
<td class="nump">1,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">1,833<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">787<span></span>
</td>
<td class="nump">616<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">614<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">288<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">45<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 42<span></span>
</td>
<td class="nump">$ 32<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143187872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Contractual Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Amortized Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">2,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost', window );">Due after ten years</a></td>
<td class="nump">778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">3,709<span></span>
</td>
<td class="nump">$ 3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">2,127<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Due after ten years</a></td>
<td class="nump">712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Amortized Cost</a></td>
<td class="nump">$ 3,499<span></span>
</td>
<td class="nump">$ 3,202<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812146813184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized investment gains</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized investment loss</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount', window );">Amortized Cost, Due in one year or less</a></td>
<td class="nump">193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount', window );">Amortized Cost, Due one year through five years</a></td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount', window );">Amortized cost, due after five years</a></td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143125648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Available-for-Sale (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>position</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>position</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 1,858<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In a Continuous Loss Position for Less than 12 Months, Total Number of Positions | position</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In a Continuous Loss Position for 12 Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 1,398<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 135<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 1,124<span></span>
</td>
<td class="nump">$ 1,063<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In a Continuous Loss Position for Less than 12 Months, Total Number of Positions | position</a></td>
<td class="nump">683<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In a Continuous Loss Position for 12 Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 887<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 76<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">371<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember', window );">Mortgage-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">$ 408<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 20<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In a Continuous Loss Position for Less than 12 Months, Total Number of Positions | position</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In a Continuous Loss Position for 12 Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 319<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">131<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset-backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 161<span></span>
</td>
<td class="nump">$ 166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In a Continuous Loss Position for Less than 12 Months, Total Number of Positions | position</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In a Continuous Loss Position for 12 Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 118<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 69<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In a Continuous Loss Position for Less than 12 Months, Total Number of Positions | position</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">61<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In a Continuous Loss Position for 12 Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 57<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In a Continuous Loss Position for Less than 12 Months, Total Number of Positions | position</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In a Continuous Loss Position for 12 Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;Less&#160;than&#160;12&#160;Months, Estimated Fair Value</a></td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions', window );">In a Continuous Loss Position for Less than 12 Months, Total Number of Positions | position</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In a Continuous Loss Position for 12 Months or More, Estimated Fair Value</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions', window );">In&#160;a&#160;Continuous&#160;Loss Position for&#160;12&#160;Months or More, Total Number of Positions | position</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MortgageBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_MunicipalSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=moh_OtherSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143999536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments - Balances of Restricted Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">$ 238<span></span>
</td>
<td class="nump">$ 212<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember', window );">U.S. Treasury notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems', window );"><strong>Schedule of Held-to-maturity Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedInvestmentsNoncurrent', window );">Restricted investments</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedInvestmentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=127002003&amp;loc=SL6242269-115581<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedInvestmentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryNotesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812139580384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment, and Capitalized Software, Net - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=moh_PropertyAndEquipmentMember', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment on property and equipment</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=moh_PropertyAndEquipmentMember', window );">Property and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=moh_PropertyAndEquipmentMember', window );">Property and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TangibleAssetImpairmentCharges', window );">Impairment on property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">31 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life of property plant and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">40 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TangibleAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TangibleAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=moh_PropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=moh_PropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143173504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">$ 882<span></span>
</td>
<td class="nump">$ 822<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization', window );">Less: accumulated amortization - capitalized software</a></td>
<td class="num">(482)<span></span>
</td>
<td class="num">(427)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation', window );">Less: accumulated depreciation and amortization - property, equipment, building, and improvements</a></td>
<td class="num">(213)<span></span>
</td>
<td class="num">(205)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Total accumulated depreciation and amortization</a></td>
<td class="num">(695)<span></span>
</td>
<td class="num">(632)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">ROU assets - finance leases</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Capitalized software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">615<span></span>
</td>
<td class="nump">547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=moh_PropertyAndEquipmentMember', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total cost</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of depreciation (related to long-lived, depreciable flight assets owned by the entity and used in the entity's principle business operations and capitalized assets classified as property, plant and equipment that are owned by the entity) that has been recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=moh_PropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=moh_PropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142967824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_RecordedInDepreciationAndAmortizationAbstract', window );"><strong>Recorded in depreciation and amortization:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_DepreciationAndAmortizationOfCapitalizedSoftware', window );">Amortization of capitalized software</a></td>
<td class="nump">54<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of finance leases</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation and amortization of property, equipment, building, and improvements</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_DepreciationandAmortizationContinuingOperations', window );">Total depreciation and amortization recognized</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">$ 88<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_DepreciationAndAmortizationOfCapitalizedSoftware">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation, and amortization of capitalized software.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_DepreciationAndAmortizationOfCapitalizedSoftware</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_DepreciationandAmortizationContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation and Amortization, Continuing Operations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_DepreciationandAmortizationContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_RecordedInDepreciationAndAmortizationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Recorded In Depreciation And Amortization [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_RecordedInDepreciationAndAmortizationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812146738528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Operating lease, remaining lease term</a></td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases, weighted average remaining lease term</a></td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm', window );">Finance lease, remaining lease term</a></td>
<td class="text">16 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeaseRenewalTerm1', window );">Finance lease renewal term</a></td>
<td class="text">25 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1', window );">Finance leases, weighted average remaining lease term</a></td>
<td class="text">13 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OperatingAndFinanceLeaseImpairmentLoss', window );">ROU assets impairments</a></td>
<td class="nump">$ 192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating leases, weighted average discount rate</a></td>
<td class="nump">4.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent', window );">Finance leases, weighted average discount rate</a></td>
<td class="nump">6.30%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OperatingAndFinanceLeaseImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Lease, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OperatingAndFinanceLeaseImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for finance lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeaseRenewalTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeaseRenewalTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812146712624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease expense</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance lease expense:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization', window );">Amortization of ROU assets</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_FinanceLeaseCost', window );">Total finance lease expense</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_FinanceLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_FinanceLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812145160240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating leases</a></td>
<td class="nump">$ 31<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseInterestPaymentOnLiability', window );">Finance leases</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash used in financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Finance leases</a></td>
<td class="nump">15<span></span>
</td>
<td class="nump">18<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract', window );"><strong>ROU assets recognized in exchange for lease obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating leases</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">86<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability', window );">Finance leases</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset Obtained in Exchange for Operating Lease Liability [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseInterestPaymentOnLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest paid on finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseInterestPaymentOnLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142811376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OperatingLeaseAssetsLesseeAbstract', window );"><strong>ROU assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired', window );">Other assets</a></td>
<td class="nump">$ 43<span></span>
</td>
<td class="nump">$ 128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OperatingLeaseLiabilitiesLesseeAbstract', window );"><strong>Lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Accounts payable and accrued liabilities (current)</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Other long-term liabilities (non-current)</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_FinanceLeaseAssetsLesseeAbstract', window );"><strong>ROU assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseRightOfUseAsset', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">206<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_FinanceLeaseLiabilitiesLesseeAbstract', window );"><strong>Lease liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Accounts payable and accrued liabilities (current)</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities (non-current)</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">219<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accounts Payable and Accrued Liabilities, Current<span></span>
</td>
<td class="text">Accounts Payable and Accrued Liabilities, Current<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Accounts Payable and Accrued Liabilities, Current<span></span>
</td>
<td class="text">Accounts Payable and Accrued Liabilities, Current<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other long-term liabilities<span></span>
</td>
<td class="text">Other long-term liabilities<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_FinanceLeaseAssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Assets, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_FinanceLeaseAssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_FinanceLeaseLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finance Lease, Liabilities, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_FinanceLeaseLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OperatingLeaseAssetsLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Assets, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OperatingLeaseAssetsLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OperatingLeaseLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liabilities, Lessee [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OperatingLeaseLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Right Of Use Asset, Excluding Leases Acquired</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of right-of-use asset from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812139940800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Lease Maturities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Subtotal - undiscounted lease payments</a></td>
<td class="nump">143<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">$ 134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Finance</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityPaymentsDue', window );">Subtotal - undiscounted lease payments</a></td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(119)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Total finance lease liabilities</a></td>
<td class="nump">$ 237<span></span>
</td>
<td class="nump">$ 234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140649808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Balances of Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 982<span></span>
</td>
<td class="nump">$ 692<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions and measurement period adjustments</a></td>
<td class="nump">133<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">1,115<span></span>
</td>
<td class="nump">982<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">769<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions and measurement period adjustments</a></td>
<td class="nump">130<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">899<span></span>
</td>
<td class="nump">769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">169<span></span>
</td>
<td class="nump">161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions and measurement period adjustments</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">172<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Acquisitions and measurement period adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 44<span></span>
</td>
<td class="nump">$ 44<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812139422752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 583<span></span>
</td>
<td class="nump">$ 501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">308<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ContractRightsandLicensingAgreementsMember', window );">Contract rights and licenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">507<span></span>
</td>
<td class="nump">426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">279<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount</a></td>
<td class="nump">228<span></span>
</td>
<td class="nump">216<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworksMember', window );">Provider networks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">19<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Carrying Amount</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ContractRightsandLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ContractRightsandLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=moh_ProviderNetworksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143729472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Goodwill and Intangible Assets, Net - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Future amortization expense, 2023</a></td>
<td class="nump">$ 84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Future amortization expense, 2024</a></td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Future amortization expense, 2025</a></td>
<td class="nump">64<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Future amortization expense, 2026</a></td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Future amortization expense, 2027</a></td>
<td class="nump">$ 13<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812145235584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount', window );">Fee-for-service claims incurred but not paid (&#8220;IBNP&#8221;)</a></td>
<td class="nump">$ 2,597<span></span>
</td>
<td class="nump">$ 2,486<span></span>
</td>
<td class="nump">$ 1,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_PharmacyClaimsPayable', window );">Pharmacy payable</a></td>
<td class="nump">206<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CapitationClaimsPayable', window );">Capitation payable</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_OtherClaimsPayable', window );">Other</a></td>
<td class="nump">631<span></span>
</td>
<td class="nump">576<span></span>
</td>
<td class="nump">528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total</a></td>
<td class="nump">3,528<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=moh_CompleteCareMember', window );">Magellan Complete Care acquisition opening balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems', window );"><strong>Liability for Claims and Claims Adjustment Expense [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CapitationClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitation Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CapitationClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_OtherClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_OtherClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_PharmacyClaimsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Pharmacy Claims Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_PharmacyClaimsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=moh_CompleteCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=moh_CompleteCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143827248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayable', window );">Non-risk provide payables</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 226<span></span>
</td>
<td class="nump">$ 235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior period claims, favorable development</a></td>
<td class="num">$ (284)<span></span>
</td>
<td class="num">$ (239)<span></span>
</td>
<td class="num">$ (119)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812139883104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Components of the Change (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">27,459<span></span>
</td>
<td class="nump">23,943<span></span>
</td>
<td class="nump">15,939<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(284)<span></span>
</td>
<td class="num">(239)<span></span>
</td>
<td class="num">(119)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">27,175<span></span>
</td>
<td class="nump">23,704<span></span>
</td>
<td class="nump">15,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">24,345<span></span>
</td>
<td class="nump">21,148<span></span>
</td>
<td class="nump">13,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">2,670<span></span>
</td>
<td class="nump">2,080<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">27,015<span></span>
</td>
<td class="nump">23,228<span></span>
</td>
<td class="nump">15,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">197<span></span>
</td>
<td class="nump">294<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="nump">106<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">3,528<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
<td class="nump">2,696<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">22,097<span></span>
</td>
<td class="nump">18,321<span></span>
</td>
<td class="nump">12,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(251)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">21,846<span></span>
</td>
<td class="nump">18,139<span></span>
</td>
<td class="nump">12,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">19,655<span></span>
</td>
<td class="nump">16,284<span></span>
</td>
<td class="nump">10,940<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">1,966<span></span>
</td>
<td class="nump">1,601<span></span>
</td>
<td class="nump">1,176<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">21,621<span></span>
</td>
<td class="nump">17,885<span></span>
</td>
<td class="nump">12,116<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">2,815<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">404<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">3,390<span></span>
</td>
<td class="nump">2,970<span></span>
</td>
<td class="nump">2,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">3,358<span></span>
</td>
<td class="nump">2,931<span></span>
</td>
<td class="nump">2,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">2,944<span></span>
</td>
<td class="nump">2,573<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">340<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">3,305<span></span>
</td>
<td class="nump">2,913<span></span>
</td>
<td class="nump">2,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(8)<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="num">(5)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">392<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract', window );"><strong>Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, beginning balance</a></td>
<td class="nump">379<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="nump">122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract', window );"><strong>Components of medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense', window );">Current year</a></td>
<td class="nump">1,972<span></span>
</td>
<td class="nump">2,652<span></span>
</td>
<td class="nump">1,205<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense', window );">Prior years</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">1,971<span></span>
</td>
<td class="nump">2,634<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract', window );"><strong>Payments for medical care costs related to:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1', window );">Current year</a></td>
<td class="nump">1,746<span></span>
</td>
<td class="nump">2,291<span></span>
</td>
<td class="nump">1,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1', window );">Prior years</a></td>
<td class="nump">343<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">98<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense', window );">Total paid</a></td>
<td class="nump">2,089<span></span>
</td>
<td class="nump">2,430<span></span>
</td>
<td class="nump">1,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments', window );">Acquired balances, net of post-acquisition adjustments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider', window );">Change in non-risk and other provider payables</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, ending balance</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Medical Claims and Benefits Payable, Adjustments, Change in Provider</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLossesAndLossAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLossesAndLossAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144125488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Medical Claims Reserve Development by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, total reserve development</a></td>
<td class="nump">$ 3,528<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, total reserve development</a></td>
<td class="nump">2,815<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
<td class="nump">2,129<span></span>
</td>
<td class="nump">1,465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, total reserve development</a></td>
<td class="nump">452<span></span>
</td>
<td class="nump">404<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">267<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable, total reserve development</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 379<span></span>
</td>
<td class="nump">$ 175<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143839280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)<br> claim in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>claim</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">$ 27,175<span></span>
</td>
<td class="nump">$ 23,704<span></span>
</td>
<td class="nump">$ 15,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">67,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount', window );">Total IBNP</a></td>
<td class="nump">2,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2020Member', window );">Benefit Year 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">16,000<span></span>
</td>
<td class="nump">16,056<span></span>
</td>
<td class="nump">$ 16,233<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount', window );">Total IBNP</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Cumulative number of reported claims (in claim) | claim</a></td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member', window );">Benefit Year 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">$ 23,979<span></span>
</td>
<td class="nump">$ 24,167<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount', window );">Total IBNP</a></td>
<td class="nump">$ 108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Cumulative number of reported claims (in claim) | claim</a></td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member', window );">Benefit Year 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1', window );">Incurred Claims and Allocated Claims Adjustment Expenses</a></td>
<td class="nump">$ 27,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount', window );">Total IBNP</a></td>
<td class="nump">$ 2,453<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims', window );">Cumulative number of reported claims (in claim) | claim</a></td>
<td class="nump">264<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability For Unpaid Claims And Claims Adjustment Expense, Incurred Claims Including Acquisition Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.W)<br> -URI https://asc.fasb.org/extlink&amp;oid=27015833&amp;loc=d3e570705-122907<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cumulative number of reported claims for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671317-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143938784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Claims paid</a></td>
<td class="nump">$ 64,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2020Member', window );">Benefit Year 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Claims paid</a></td>
<td class="nump">15,973<span></span>
</td>
<td class="nump">$ 16,004<span></span>
</td>
<td class="nump">$ 13,871<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member', window );">Benefit Year 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Claims paid</a></td>
<td class="nump">23,871<span></span>
</td>
<td class="nump">$ 21,148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member', window );">Benefit Year 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProductInformationLineItems', window );"><strong>Product Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Claims paid</a></td>
<td class="nump">$ 24,345<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsAccidentYearAxis=us-gaap_ShortDurationInsuranceContractAccidentYear2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140409568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAbstract', window );"><strong>Insurance [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Incurred claims and allocated claims adjustment expenses</a></td>
<td class="nump">$ 67,438<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet', window );">Less: cumulative paid claims and allocated claims adjustment expenses</a></td>
<td class="num">(64,189)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears', window );">All outstanding liabilities before 2020</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems', window );">Non-risk and other provider payables</a></td>
<td class="nump">270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense', window );">Medical claims and benefits payable</a></td>
<td class="nump">$ 3,528<span></span>
</td>
<td class="nump">$ 3,363<span></span>
</td>
<td class="nump">$ 2,696<span></span>
</td>
<td class="nump">$ 1,854<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Outstanding Liabilities Relating to Prior Years</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (cc)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884095&amp;loc=d3e14764-158437<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671311-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of aggregate reconciling items for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=116884468&amp;loc=SL65671315-158438<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812139520400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 2,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate</a></td>
<td class="nump">4.375%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount</a></td>
<td class="nump">$ 750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">Thereafter</a></td>
<td class="nump">$ 750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140652848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule of Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Less: unamortized debt issuance costs</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total</a></td>
<td class="nump">$ 2,176<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 650<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount', window );">Non-current portion of long-term debt</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143729728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt - Credit Agreement (Details) - Term Loan Facility<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Agreement term</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember', window );">Term Loan Facility</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityLineItems', window );"><strong>Line of Credit Facility [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Maximum borrowing capacity</a></td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Amount outstanding under Letter of Credit</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812145211600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Senior Notes (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount of debt</a></td>
<td class="nump">$ 2,200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 4.375% Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">4.375%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate principal amount of notes outstanding</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount of debt</a></td>
<td class="nump">$ 800,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount of debt</a></td>
<td class="nump">$ 650,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | 3.875% Notes due 2032</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Percentage of contractual interest rate on notes</a></td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Net carrying amount of debt</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A4375SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_ThreePointEightSevenFivePercentSeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=moh_A3875SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142800576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 209<span></span>
</td>
<td class="nump">$ 281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="nump">307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 271<span></span>
</td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">$ 288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143183920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory federal tax (benefit) rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income provision (benefit), net of federal benefit</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent', window );">Nondeductible health insurer fee (&#8220;HIF&#8221;)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nondeductible compensation</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax expense rate</a></td>
<td class="nump">25.50%<span></span>
</td>
<td class="nump">24.70%<span></span>
</td>
<td class="nump">30.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812143149536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses and reserve liabilities</a></td>
<td class="nump">$ 96<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Other accrued medical costs</a></td>
<td class="nump">24<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating losses</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve', window );">Unearned premiums</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent', window );">Lease financing obligation</a></td>
<td class="nump">40<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses', window );">Unrealized losses</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_DeferredTaxAssetsFixedAssetsAndIntangibles', window );">Fixed assets and intangibles</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credit carryover</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(18)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income tax assets, net of valuation allowance</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">120<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles', window );">Fixed assets and intangibles</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(15)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred income tax asset</a></td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">$ 106<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_DeferredTaxAssetsFixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Fixed Assets and Intangibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_DeferredTaxAssetsFixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Fixed Assets And Intangibles</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the unearned premiums reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144158944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardValuationAllowance', window );">Deferred tax assets</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increased in deferred tax asset valuation allowance</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Impact on effective tax rate if tax benefits are recognized</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Liability for unrecognized tax benefits, potential decrease</a></td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryovers</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812139412352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized tax benefits roll forward</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at beginning of period</a></td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse in statute of limitations</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Gross unrecognized tax benefits at end of period</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="num">$ (15)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140228752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000,000<span></span>
</td>
<td class="nump">$ 128,000,000<span></span>
</td>
<td class="nump">$ 606,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_UnrecognizedCompensationForfeitedRate', window );">Forfeiture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_FairMarketValueOfCommonStockPercentage', window );">Employee purchase price as a percentage of stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramPeriodInForce1', window );">Offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee', window );">Maximum annual contribution per employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Minimum expected volatility rate inputs for fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Maximum expected volatility rate inputs for fair value measurement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Maximum award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Maximum award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Maximum award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=moh_EquityIncentivePlanMember', window );">2019 EIP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares issued under ESPP (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Common stock authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">590,000<span></span>
</td>
<td class="nump">658,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Average cost (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 339.06<span></span>
</td>
<td class="nump">$ 304.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of common stock (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">755,000<span></span>
</td>
<td class="nump">429,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_FairMarketValueOfCommonStockPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair market value of common stock, Percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_FairMarketValueOfCommonStockPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award maximum amount per employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_UnrecognizedCompensationForfeitedRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized compensation forfeited rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_UnrecognizedCompensationForfeitedRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramPeriodInForce1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramPeriodInForce1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=moh_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=moh_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140658960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Components of Share-based Compensation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pretax Charges</a></td>
<td class="nump">$ 103<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
<td class="nump">$ 57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Net-of-Tax Amount</a></td>
<td class="nump">96<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=moh_RestrictedandPerformanceStockMember', window );">RSAs and PSUs (defined below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pretax Charges</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Net-of-Tax Amount</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=moh_EmployeeStockPurchasePlanandStockOptionsMember', window );">Employee stock purchase plan and stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Pretax Charges</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Net-of-Tax Amount</a></td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=moh_RestrictedandPerformanceStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=moh_RestrictedandPerformanceStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=moh_EmployeeStockPurchasePlanandStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=moh_EmployeeStockPurchasePlanandStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142837568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Restricted and Performance Stock Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSAs and PSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, beginning of period (in shares) | shares</a></td>
<td class="nump">539,117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">237,590<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(224,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(41,257)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, shares end of period (in shares) | shares</a></td>
<td class="nump">511,105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 169.39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">312.27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">156.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">224.96<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 237.10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>RSAs and PSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, beginning of period (in shares) | shares</a></td>
<td class="nump">275,050<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">271,270<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(219,674)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(13,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested balance, shares end of period (in shares) | shares</a></td>
<td class="nump">312,830<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant&#160;Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 129.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">214.94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">137.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">249.09<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested balance, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 193.09<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812151175648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Fair Value of Awards Granted and Vested (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Fair value of restricted shares granted</a></td>
<td class="nump">$ 117<span></span>
</td>
<td class="nump">$ 65<span></span>
</td>
<td class="nump">$ 67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted shares vested</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Fair value of restricted shares granted</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">65<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted shares vested</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Fair value of restricted shares granted</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair value of restricted shares vested</a></td>
<td class="nump">$ 69<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812146809808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance, outstanding (in shares)</a></td>
<td class="nump">395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(390,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance, outstanding (in shares)</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">395,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance, outstanding (in dollars per share)</a></td>
<td class="nump">$ 65.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="nump">66.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance, outstanding (in dollars per share)</a></td>
<td class="nump">$ 33.02<span></span>
</td>
<td class="nump">$ 65.59<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Outstanding, Aggregate Intrinsic Value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Outstanding, Weighted Average Remaining Contractual term</a></td>
<td class="text">2 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142910416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsAbstract', window );"><strong>Postemployment Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Maximum matching contribution by employer under defined contribution plan</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Expense recognized in connection with contributions</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationPlanAssets', window );">Deferred compensation plan</a></td>
<td class="nump">$ 26<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812145225776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SpecialAssessmentBond', window );">Performance bond</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries', window );">Net assets of subsidiaries subject to restrictions</a></td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance', window );">Aggregate statutory capital and surplus</a></td>
<td class="nump">3,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired', window );">Required minimum statutory capital surplus</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatutoryAccountingPracticesLineItems', window );"><strong>Statutory Accounting Practices [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and investments</a></td>
<td class="nump">$ 375<span></span>
</td>
<td class="nump">$ 348<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(3)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SpecialAssessmentBond">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a type of municipal bond typically used to fund a development project. Also called special assessment limited liability bond, special district bond, special purpose bond, special tax bond and community development obligation. Interest owed to lenders is paid by taxes levied on the community benefiting from the particular bond-funded project. For example, if a bond of this sort was issued to pay for sidewalks to be repaved in a certain community, an additional tax would be levied on homeowners in the area benefiting from this project.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SpecialAssessmentBond</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24708-158529<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 505<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6486098&amp;loc=d3e24708-158529<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812149822336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812138870272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Schedule of Operating Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 31,974<span></span>
</td>
<td class="nump">$ 27,771<span></span>
</td>
<td class="nump">$ 19,423<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">25,783<span></span>
</td>
<td class="nump">21,231<span></span>
</td>
<td class="nump">15,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">3,824<span></span>
</td>
<td class="nump">3,379<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 71<span></span>
</td>
<td class="nump">$ 70<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812145376544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments - Reconciliation of Gross Margin to Consolidated Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: Other operating revenues</a></td>
<td class="nump">$ 31,974<span></span>
</td>
<td class="nump">$ 27,771<span></span>
</td>
<td class="nump">$ 19,423<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: Other operating expenses</a></td>
<td class="num">(30,801)<span></span>
</td>
<td class="num">(26,751)<span></span>
</td>
<td class="num">(18,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Less: other expenses, net</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax expense</a></td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">875<span></span>
</td>
<td class="nump">961<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember', window );">Medicaid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">2,981<span></span>
</td>
<td class="nump">2,322<span></span>
</td>
<td class="nump">1,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: Other operating revenues</a></td>
<td class="nump">25,783<span></span>
</td>
<td class="nump">21,231<span></span>
</td>
<td class="nump">15,217<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember', window );">Medicare</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">437<span></span>
</td>
<td class="nump">430<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: Other operating revenues</a></td>
<td class="nump">3,824<span></span>
</td>
<td class="nump">3,379<span></span>
</td>
<td class="nump">2,529<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember', window );">Marketplace Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">290<span></span>
</td>
<td class="nump">399<span></span>
</td>
<td class="nump">324<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: Other operating revenues</a></td>
<td class="nump">2,296<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
<td class="nump">1,677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: Other operating revenues</a></td>
<td class="nump">71<span></span>
</td>
<td class="nump">70<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Total margin</a></td>
<td class="nump">3,719<span></span>
</td>
<td class="nump">3,165<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other Operating</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Add: Other operating revenues</a></td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="nump">1,124<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Less: Other operating expenses</a></td>
<td class="num">$ (3,566)<span></span>
</td>
<td class="num">$ (2,991)<span></span>
</td>
<td class="num">$ (2,525)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicaidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MedicareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_MarketplaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=moh_OtherProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812144968480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of Registrant - Condensed Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 4,006<span></span>
</td>
<td class="nump">$ 4,438<span></span>
</td>
<td class="nump">$ 4,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">3,499<span></span>
</td>
<td class="nump">3,202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">277<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">10,084<span></span>
</td>
<td class="nump">10,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">259<span></span>
</td>
<td class="nump">396<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and intangible assets, net</a></td>
<td class="nump">1,390<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">12,314<span></span>
</td>
<td class="nump">12,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">889<span></span>
</td>
<td class="nump">842<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,855<span></span>
</td>
<td class="nump">7,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">104<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">9,350<span></span>
</td>
<td class="nump">9,579<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">2,796<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">$ 2,096<span></span>
</td>
<td class="nump">$ 1,960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">12,314<span></span>
</td>
<td class="nump">12,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">329<span></span>
</td>
<td class="nump">274<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Investments</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent', window );">Due from affiliates</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">106<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization', window );">Property, equipment, and capitalized software, net</a></td>
<td class="nump">224<span></span>
</td>
<td class="nump">349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Goodwill and intangible assets, net</a></td>
<td class="nump">731<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures', window );">Investments in subsidiaries</a></td>
<td class="nump">4,142<span></span>
</td>
<td class="nump">3,772<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred income taxes</a></td>
<td class="nump">37<span></span>
</td>
<td class="num">(18)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_AdvancesToRelatedPartiesAndOtherAssets', window );">Advances to related parties and other assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">5,836<span></span>
</td>
<td class="nump">5,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable, accrued liabilities and other</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">448<span></span>
</td>
<td class="nump">378<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">2,176<span></span>
</td>
<td class="nump">2,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">219<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,872<span></span>
</td>
<td class="nump">2,804<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValueOutstanding', window );">Common stock, $0.001 par value; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022 and December 31, 2021</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">328<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">2,796<span></span>
</td>
<td class="nump">2,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,964<span></span>
</td>
<td class="nump">2,630<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 5,836<span></span>
</td>
<td class="nump">$ 5,434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_AdvancesToRelatedPartiesAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Advances to related parties and other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_AdvancesToRelatedPartiesAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity method investee and investment in and advance to affiliate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812138870608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">58,000,000<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares, outstanding (in shares)</a></td>
<td class="nump">58,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">20,000,000<span></span>
</td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140400416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of Registrant - Condensed Statements of Operations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Investment income and other revenue</a></td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 77<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">31,974<span></span>
</td>
<td class="nump">27,771<span></span>
</td>
<td class="nump">19,423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">2,311<span></span>
</td>
<td class="nump">2,068<span></span>
</td>
<td class="nump">1,480<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">176<span></span>
</td>
<td class="nump">131<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="nump">208<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">30,801<span></span>
</td>
<td class="nump">26,751<span></span>
</td>
<td class="nump">18,345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="nump">1,173<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="nump">1,078<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">271<span></span>
</td>
<td class="nump">216<span></span>
</td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InsuranceAgencyManagementFee', window );">Administrative services fees</a></td>
<td class="nump">1,826<span></span>
</td>
<td class="nump">1,496<span></span>
</td>
<td class="nump">1,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestAndDividendIncomeOperating', window );">Investment income and other revenue</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,834<span></span>
</td>
<td class="nump">1,507<span></span>
</td>
<td class="nump">1,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">1,721<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">1,527<span></span>
</td>
<td class="nump">1,180<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating income</a></td>
<td class="num">(166)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expenses, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherExpenses', window );">Total other expenses, net</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries', window );">Loss before income tax benefit and equity in net earnings of subsidiaries</a></td>
<td class="num">(276)<span></span>
</td>
<td class="num">(165)<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest', window );">Net loss before equity in net earnings of subsidiaries</a></td>
<td class="num">(234)<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax', window );">Equity in net earnings of subsidiaries</a></td>
<td class="nump">1,026<span></span>
</td>
<td class="nump">803<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) Before Income Taxes And Equity In Net Income Of Subsidiaries</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net Income (Loss) From Continuing Operations Before Equity Method Investments, Extraordinary Items, Noncontrolling Interest</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromSubsidiariesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) of subsidiary attributable to the parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromSubsidiariesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceAgencyManagementFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fees earned during the period for providing management services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceAgencyManagementFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDividendIncomeOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.1-5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDividendIncomeOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4,6)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.5)<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812138878400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract', window );"><strong>Statement of Other Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized investment (loss) income</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Less: effect of income taxes</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">637<span></span>
</td>
<td class="nump">617<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CondensedFinancialStatementsCaptionsLineItems', window );"><strong>Condensed Financial Statements, Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">659<span></span>
</td>
<td class="nump">673<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract', window );"><strong>Statement of Other Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized investment (loss) income</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Less: effect of income taxes</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive (loss) income, net of tax</a></td>
<td class="num">(155)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CondensedFinancialStatementsCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CondensedFinancialStatementsCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812140324384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">$ 773<span></span>
</td>
<td class="nump">$ 2,119<span></span>
</td>
<td class="nump">$ 1,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments</a></td>
<td class="num">(1,913)<span></span>
</td>
<td class="num">(2,713)<span></span>
</td>
<td class="num">(670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">1,398<span></span>
</td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and capitalized software</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="num">(50)<span></span>
</td>
<td class="num">(63)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(790)<span></span>
</td>
<td class="num">(1,653)<span></span>
</td>
<td class="num">(400)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations', window );">Common stock withheld to settle employee tax obligations</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from senior notes offerings, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(723)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of term loan facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings under term loan facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Cash paid for partial termination of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CashPaidForSettlementOfConversionOption', window );">Cash paid for partial settlement of conversion option</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash received for partial settlement of call option</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of principal amount of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents</a></td>
<td class="num">(458)<span></span>
</td>
<td class="nump">283<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">4,048<span></span>
</td>
<td class="nump">4,506<span></span>
</td>
<td class="nump">4,223<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">119<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries', window );">Capital contributions to subsidiaries</a></td>
<td class="num">(159)<span></span>
</td>
<td class="num">(440)<span></span>
</td>
<td class="num">(107)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDividendsReceived', window );">Dividends received from subsidiaries</a></td>
<td class="nump">668<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="nump">635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of investments</a></td>
<td class="num">(29)<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">282<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and capitalized software</a></td>
<td class="num">(86)<span></span>
</td>
<td class="num">(70)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Net cash paid in business combinations</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(263)<span></span>
</td>
<td class="num">(1,028)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_ChangesInAmountsDueToAndDueFromAffiliates', window );">Change in amounts due to/from affiliates</a></td>
<td class="num">(69)<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="num">(68)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other, net</a></td>
<td class="nump">3<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">377<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Common stock purchases</a></td>
<td class="num">(400)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations', window );">Common stock withheld to settle employee tax obligations</a></td>
<td class="num">(54)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration liabilities settled</a></td>
<td class="num">(20)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt', window );">Proceeds from senior notes offerings, net of issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">740<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayment of senior notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(723)<span></span>
</td>
<td class="num">(338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermLinesOfCredit', window );">Repayment of term loan facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(600)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromLinesOfCredit', window );">Proceeds from borrowings under term loan facility</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfWarrants', window );">Cash paid for partial termination of warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_moh_CashPaidForSettlementOfConversionOption', window );">Cash paid for partial settlement of conversion option</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Cash received for partial settlement of call option</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Repayment of principal amount of convertible notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other, net</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(441)<span></span>
</td>
<td class="num">(183)<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents</a></td>
<td class="nump">55<span></span>
</td>
<td class="num">(301)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">$ 329<span></span>
</td>
<td class="nump">$ 274<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CashPaidForSettlementOfConversionOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid For Settlement Of Conversion Option</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CashPaidForSettlementOfConversionOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_ChangesInAmountsDueToAndDueFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in amounts due to and due from affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_ChangesInAmountsDueToAndDueFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_moh_CommonStockWithheldToSettleEmployeeTaxObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Withheld to Settle Employee Tax Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">moh_CommonStockWithheldToSettleEmployeeTaxObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>moh_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of noncontrolling interest during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDividendsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Dividends received on equity and other investments during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3337-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDividendsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermLinesOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermLinesOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139812142924960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember', window );">Parent Company</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Services revenue from subsidiaries</a></td>
<td class="nump">$ 1,826<span></span>
</td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="nump">$ 1,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=srt_ParentCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>moh-20221231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:moh="http://www.molinahealthcare.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="moh-20221231.xsd" xlink:type="simple"/>
    <context id="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0aedc9af750a409fa2db8df9d13e5fae_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1d4e025ccdc84d63b8840e2ad276c200_I20230210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2023-02-10</instant>
        </period>
    </context>
    <context id="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e1fafef562c4c43a4e635c589f60bc2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i863e60c11f294d5382a62b168dc11650_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i999be11240344aa48da9e906b939d685_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i199fd9ed80d34939adcf4df9bd792f0d_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8771041280f54d5e8602cbc70ecac436_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="iff8f933345f844fa938f287ea4acbefa_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i8df5a01609344460bb17a1e2311459c7_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i6cdb516bfdef4a8f9b6c6c031e73cef1_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i0ec77d8e31ee46229cf16bffe3977e23_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i6e5861f8a1be489fbadca2791aa90afe_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ifc10bd10790d4245a58fd5f3eb995125_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i4c5174cdc8a543aab6a82650213fae42_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if519cf6d7ba746faa633b1d247f21140_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="if419e645396c4411a00a65c9c61e8f4b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iaa1000dd422a4091b6562e182ae3a5e6_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i202e4db7009b4cf9bdcf1f64e749b198_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="iad023f53ea0d4a398b072037f4fa5a28_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i0a1b426cbcba4d009021f4ffbe5138b1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie888b7a86e1749beb1747431a08efb69_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i20ffea858f7a413e84d7c60bd51a39ad_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i579cf48f5d864bddb56457fa28bb2587_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c46a6c267b9418ea1b14da3214406ec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i587b2eb5aff244fbb08b0618fb285d59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia7a7caae068640048ce1c869c4207d7f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa9ec9408e524d0c9ce56cae77d8fddc_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iac9f15a52524444587078e926f065feb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i790f6598096b4e42affcce597dc39434_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i014d76748d9c435e8c2252256e738466_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i8454949eb924409fbf2446822fa8d947_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie1db3a5ad94a4885a560d39ee09283e7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1426d89bce2644bcb46ee222394ca3ab_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95d5fbc5f32e4d71bf63e8a5e693b170_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i85e7dfbb25714e6fa1e9c665d5b451ed_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i406902950217439984d39e91eadf0f62_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0401c2aac1bd43f18925d12817958d7a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia8b74ae9eb6d45a8ba7fcf53e5356106_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i99e5c5b493404f65b708b3004c6d9e12_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:HealthAndHumanServicesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i880dcbd954c94606b002149fe2d46983_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5d1626275dac4e1fb93d80b9a4189fb4_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:IA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i0f69658aa2554010bae3200d5bca4c4d_D20220801-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:MS</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-01</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i307d98a799304ec9b2ea5e24af4f8721_D20220713-20220713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:MyChoiceWisconsinMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-13</startDate>
            <endDate>2022-07-13</endDate>
        </period>
    </context>
    <context id="ie3076577c633490db40aa71614578a1e_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5986c52b45c34430a4e46e84fd09578e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4e1b19ab0d1440b7bfda152e607a2ac4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:GovernmentReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1ac7e7cce7c7488f856cfee3ee520a77_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i95f4006db8de462884c07a9ec0cebfd1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:PharmacyRebateReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i283a40999d534f9f8762d3200d2894ff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i72c7bccfd8ca4bf18d2185d8ddf074de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis">moh:OtherReceivablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i386078af04c247fa901c709fe93c58dd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ieb8a1f0e16d84ec0a669cac6d07c2042_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1a3656d06a5b43eaa3ec5dfdecceaac7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i01aae92c76f5467c8edb776a572ee453_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3f1d77f589974a46b23eddba5474dc63_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i04d52aa82e834517bbc667b377f4ad2c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2133a1cf36b14bcf8da5c42ae85115a7_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualOrInfrequentItemAxis">moh:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i5d0d8ea348c241a4b9f809ef2b12dfa2_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePremiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i7eaace7d309845f986541d1f02db8612_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:HealthCarePremiumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i889ea50e28bb4eed8c94a76a4a8d2cfb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic15c81fc6ee74eb7b1b3e900ac2e9c64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:TX</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ida4424c349994a84985daff56e365e13_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id9fa89e4cd2b4b9e91fa9ccde542996c_D20221001-20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AgeWellNewYorkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="i634b4c45a645473796839899d286be1f_D20221001-20221001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AgeWellNewYorkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:MemberListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-10-01</endDate>
        </period>
    </context>
    <context id="i61710d4352384e94a9ce3f422ff24847_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="id1c23ba3104a41408eac767b2e726ada_D20220101-20220101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:MemberListsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="ibebb703fd4a9457dbfd3f97701ae04f3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0385a25993b0446c89a46930f0f91bde_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id5c65081a30c46cf8460d6a803e1f17a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1f9337e55d484c09b5a1513d389ccf3b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ContractualRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ide3af300aa304f619ca228fba2ff8fa4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i29148aa5c5964b8f8d10939beb34fe33_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i4d53aea5bdb946b5b111b4810dc4fa29_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1c870ec0a4794f988790a6078f3f01f9_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idda4ab8b08044fecb8346dffcc274008_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3c7feed041254360ad5d3019f6a744aa_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:HealthPlansSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i18ece6617d5c496d9258ce72e661253f_D20211025-20211025">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-25</startDate>
            <endDate>2021-10-25</endDate>
        </period>
    </context>
    <context id="i2ac9097825cf45b8aee7acbbe22e2785_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:AffinityHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9d8d5c0a352f4015825c1a2b0847caff_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5816b9d063fd4d4f9679ec48c22e7f0a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8a831368a2374281bb348964ee80005f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7194e3bc65f34309acccfe5e8eebc910_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2225551d260b4fff8b1fcd8b2225a4d5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f5ae5c597454f189bef195ea3021a0e_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i02199c67baf944d3a3c45249783e8405_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i349d4816275045dfaa89200a39cfc5ef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if032025c0fb244a08e3b1ef2e3941040_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86889d94e8904988ac5e365d286d4a7b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i962ee0b812d44a069fd6c87304d4bc42_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7ca41013f9c540f28757acf9f49962e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1bd8a5c0011b40b3bcaa8d6d87dd0520_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ed1689dee4a41eda03bdc9c92c02453_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic9e4ac3e01c944c0b4c5b9718ba2c91c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i777ac9767d8c4e58a9ba5410baae7037_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib5fcc352ead24246b3f108ce7dd02772_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib53a75ae39b14988836f4967971ce19b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie00e6ad84a254b709450ec9c3505658d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i335b83f184544942bc8b176a2ac44633_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2d1b7f1d31c442bfa81f382822fcd6b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iba848d4237f8438e92d576eea416786f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic804f30bbe1941a5bd3069bece3d95c1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9e5e68ad6d9c4c8ea513343c44695691_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3d9f57cf49eb4b3d93701dd1a0ade3fd_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7e3a24c60394b48a399eb0153944cd5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1c35ad3ddab44e749e3b1e84bd0af3d1_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i960d1aa66067454ba42f52aed1e487bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0945f141b7f04212b9df4d20cbd510cc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i30c11d9f4dee4390998e42cc33eb779e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8d46c859e204a6a80f2c36c08a46f8e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie4a239b8e14f435d944f2c1891cd59f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59f46e8b96ab457584d0f833330e5f53_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialMortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i576bade46abf49a3a06593cc4f8c1b09_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i63aa4f07c83c4604ab411ba61e492802_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67dd714df638487ea61a28b66c207c9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3697cd3591404f5ab704c339859f4118_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib12a73884b8842b28e11041aea7f7b00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icaaa9d3cee0f4342b73d5a8600dde796_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:MunicipalSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4319bd7e084d4fe6bbe30097e8b6ea2a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id9e1553afa264028b0cd457a33f5a149_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8ab0ae951a4e4b62b8083cf3e819c96a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryNotesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9677ef65e67d487cabd070ff51ef3d1c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ada07a36a9546358030aaca313e8c59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5bb2d39305ab437ebcfcb31c936ff8e7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cba98a86a954f7e8b177f14d18360bd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">moh:OtherSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e93ce10aaba4d8b9c22ff0c09bacdc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i14f045e80bf74bfdb5641b6aed955093_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibbd8a7e880f542339bc89afd0861bdf2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7757357193c94ad298e824f0d0518470_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i16c45403f97a4dfb89f109633839fb86_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">moh:MinimumMemberEnrollmentTargetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i016cfea50f2e421f88790001362b8498_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:PassportHealthPlanIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">moh:OperatingIncomeGuaranteeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i73f9280e97a540afba84f71174ad29c4_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9cdbd3860d6c488798e272302d58dcf7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib074c81f11e84dd0a6eb9b5acffd5118_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9641bb00844a4cbb9f0155ed3c8b8bed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieada9e735cbd4500babf6903ca597d7e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i562391d3973d4bd18a2b1c897b6c4610_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4446a6c953714ca891cd94c12831bb57_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia5acbc39836d44c0877b4659cfa91af9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7548748313094c9dbe3ac25160bfe723_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i396dfc81f74a4ecfa6a338862899d231_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i32599e3034534c39973f424bf0a0d5a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3a98f51b9a6349488555f9c9a14a3df0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i597b3ae4dd8e4818b13a24f5c890394d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icbc3bf6d7b6442e59a8c61f5a4fcd73f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2790faed091468abda4356c61276b5a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i88055e4dad2440acb86c85055d57ae20_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i48bac014b28a4af083ee0516405e8d5a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3dde019b6c3e473c978eda9b0c5c1d4a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i34ceb7d8e4e84d52bcad92498c815f6e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id18ca73ccc5f4614a083a4e53496fb4b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia9b5c6207fdc407187736e67b43692ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MortgageBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78c795544d9047bab9b654c5a011d8fe_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib20d5076d1754f178426259e52222452_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8df844efd93545ae81dc29ce059d9765_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3dfbd2fd237c43bc9219d4395d0474dd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i59d9a78c5ed049d0817ec4ff2cc838cd_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i55b78cda26784d3785265b3a4fef2f5a_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6a82111ac8a5487a824e9ddb07e72a1e_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="icd312c63a968473280db7fe49cdb0016_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="if6864266f9a2488da514854481f1778b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i54050094325c4beba6d8861066ebb7a0_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6b87a358731a498a8531fb81dfa9704f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i15dba481187544f8ba4896f21c4e17cd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4a482fdc9d8b4a328f48fa2052fe7c15_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ifd2a2696dfc6483caf233c53d8331a83_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">moh:PropertyAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibf0ed51712cb44a1a1fc04300c9d5c82_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibdcfd494f0b044d6a63a13ddfb1e9737_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib470bce1e1e7439682a2b7cf6079bc24_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i54f8881d1acd421683ecb16c150ac455_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13f72b45b4644a468fe3bf237a344ae5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie051c5fdd0164b7692de987d735b5614_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ica8010c73a874479be005b5c0efe2f9b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic83f163bbbec4901a4db9c0cd3b6beae_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i35d2514974d648b4a321860ce0da423a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a8d5443c6c445b7b1df9e882c954e13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i471861f0bd924c028fddde43043e03e5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba0e6e336cc2457895f26a4b547de184_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i277bd722f8d244c98c6cb91f7a6d9c98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4ded5b162e2f49728c0e31ad73edfaeb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie099f36d881c40a3badd49fcbe24a158_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iffc025417eb148d5848c4dc550d72cf1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ContractRightsandLicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a10f9e2abb34524aa6d8bc510e1aa4e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ContractRightsandLicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4767b4d9b3f84070acc01bf02ca7feef_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id4f6a981430a48419a3e8f282bae5cee_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">moh:ProviderNetworksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8398f04c5a124683b46e82729ddf8f33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i390ee1c0be844452a70fa034460742a3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iea3d5b8372df4c6abfbb27c274bc673a_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0023c6ef83664597b60b89a484a483bc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i791cb3b2e1414dc995d8c3832e970a59_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">moh:CompleteCareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e256b4d3f8045d6a0d60842042e5330_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i837aaf36681849538dfa8df0d8740876_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i628668ecbc2f46759154eeb9586c550c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0f8bd3d713d84b16b5d4c1c2e0b0602f_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i050e8b37615f4e679be531c2520a8320_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="iec5b1cb8aec941ee8481b1247d22f717_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i048dd0bf323147f88d1ce251936a8002_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i2c45749706a94b278c9d69ee05c26153_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicaidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MedicareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:MarketplaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id90f37a0e7ed48588693d942d7439522_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="iaa1f11b3a0464f1c8a8e9399866f72eb_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i3e82750ee1ba4f92ba421980442e025f_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0d21f0289d0f4503a608e0c544fa3528_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibc6e982b4b304fa2849be3b24940489a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8d09c2e933d841399382aeaf45b11f51_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ib60f70f36c784daabd311b0746a76015_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i9ce51eb40d964399bcbf595c78a3712c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0ca478154d99467c8fbc5952a0a6af98_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iacb62ab94ca7487b9f7d98e6acaec0bd_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i820c538fe10a42b88e632ca56ab2d10e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id22d0b329d7a4bb5a67d6402f8b59ed8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortdurationInsuranceContractsAccidentYearAxis">us-gaap:ShortDurationInsuranceContractAccidentYear2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i71d56b2727844c739f8fc7c6c248b44d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A4375SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia02c779ff61241edbb85961d0ca9c5eb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:ThreePointEightSevenFivePercentSeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icd32afbbde514f44b74fc5c5bac8e578_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">moh:A3875SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0a8a1bfa4d2646619b114fd4ca9f2f3c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i894911675af3435aaff732b2e986f5cb_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ia92d461677b3467aad6b5cb1343d01b8_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i7209f6abd53942d2b14fad2f133eb977_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if0857a373c3b4a04a563c80433da37a7_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i231fe0f403304e04821105e21c970d54_D20221001-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ic666c8c846a6470fa80b6fd8546e1fb8_D20230101-20230213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-02-13</endDate>
        </period>
    </context>
    <context id="i0d872067ad8c4dfdb6ad4e01a7b702fc_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="icf47a0c9203348a4a82289677971cd52_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i71b7d1ac171e4a1480d0d094dfc1146d_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i748536bf845448ec8b3a8851a8779612_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i730ca96dd7ca4ca290d11ea041a783c7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:RestrictedandPerformanceStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i07d9217daf844c889c548acff4d0a65a_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:RestrictedandPerformanceStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ic983aeae5acc408cb7dab92ea09a8f01_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:RestrictedandPerformanceStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="if31147c355a2444291af45d631a17138_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:EmployeeStockPurchasePlanandStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i5b98d941fd8447b4b70e3c1c0b270359_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:EmployeeStockPurchasePlanandStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i49563c89a0044495a4024b953890bdec_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">moh:EmployeeStockPurchasePlanandStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i808268ffa68b43739052deba1dced859_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">moh:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8b40040b80904e3398625faca74b79ac_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i1e073e88099741bfbc940e573293e498_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i290c59f46b35464aaccca35307808b88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia92853bb15c348949754087573c60ee1_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i781d050a46354e80ade11c0f5bf7feda_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idbd67479e4964d2fa6a1a3d75f41f688_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i6e2d29204efe4a1ca22aeb31da2ce2ac_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="ib1ee1afc55d64732912318aa5e962ea8_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="if47f80d012ad40879d50cdef41999002_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i3d6e9c94477f48d3bda9237fd401466b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="id0cb083a718842129d8611165782b40b_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="iba3d39cbcb0e429cbc30596a5203c015_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d4b8ac4a365441ab7791c3a476b369f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if0d5667fa1324091ae2ef23e403af7b3_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">moh:OtherProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i63c5437de6ea46768cb132375cf8d34c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i0e239d54c717494dbfa7e61bb51ad771_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i077768d476524c85ac1e4304def5f128_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i9fdd93fd019b4782acece4fa6c2d7a43_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i41fcaf49be0f49c4851f37e732bfb025_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i8578fffd2f7a460688cbe76bc35b7b1a_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i2480da1aa27740debeb057251b13ddd3_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6e83845445404707a8b2523b0d438117_I20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001179929</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">srt:ParentCompanyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>moh:segment</measure>
    </unit>
    <unit id="member">
        <measure>moh:member</measure>
    </unit>
    <unit id="state">
        <measure>moh:state</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="combination">
        <measure>moh:combination</measure>
    </unit>
    <unit id="position">
        <measure>moh:position</measure>
    </unit>
    <unit id="claim">
        <measure>moh:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV80L2ZyYWc6YzY1YWE0NjM1OTkwNGQzNWI2NTc1ZWI5NWZlMmUzZmUvdGFibGU6MmQ0MzU4MDAyMDM1NDMyZTk4NmY4NjcyYmUwNTE0MWUvdGFibGVyYW5nZToyZDQzNTgwMDIwMzU0MzJlOTg2Zjg2NzJiZTA1MTQxZV8xLTEtMS0xLTY4NzY2_5c6acd97-1f47-4bb6-adf0-b6366a53d8f2">0001179929</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV80L2ZyYWc6YzY1YWE0NjM1OTkwNGQzNWI2NTc1ZWI5NWZlMmUzZmUvdGFibGU6MmQ0MzU4MDAyMDM1NDMyZTk4NmY4NjcyYmUwNTE0MWUvdGFibGVyYW5nZToyZDQzNTgwMDIwMzU0MzJlOTg2Zjg2NzJiZTA1MTQxZV8yLTEtMS0xLTY4NzY2_6b8d2278-8a74-40a9-bd62-ae12e9af7081">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV80L2ZyYWc6YzY1YWE0NjM1OTkwNGQzNWI2NTc1ZWI5NWZlMmUzZmUvdGFibGU6MmQ0MzU4MDAyMDM1NDMyZTk4NmY4NjcyYmUwNTE0MWUvdGFibGVyYW5nZToyZDQzNTgwMDIwMzU0MzJlOTg2Zjg2NzJiZTA1MTQxZV8zLTEtMS0xLTY4NzY2_aab69003-a8ea-4bd2-9f67-96607ba371a3">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV80L2ZyYWc6YzY1YWE0NjM1OTkwNGQzNWI2NTc1ZWI5NWZlMmUzZmUvdGFibGU6MmQ0MzU4MDAyMDM1NDMyZTk4NmY4NjcyYmUwNTE0MWUvdGFibGVyYW5nZToyZDQzNTgwMDIwMzU0MzJlOTg2Zjg2NzJiZTA1MTQxZV80LTEtMS0xLTY4NzY2_a24e127f-0ae8-4d1d-9f74-53fbb20d2bc4">FY</dei:DocumentFiscalPeriodFocus>
    <moh:HealthPlanContractTerm
      contextRef="i406902950217439984d39e91eadf0f62_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzY3OA_6f2a845c-6f22-4bcc-9cb4-a0ec1e4ca0c4">P3Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanContractTerm
      contextRef="ia8b74ae9eb6d45a8ba7fcf53e5356106_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzEwOTk1MTE2NDU4MTc_95927849-eb03-4285-a11c-36386eebadfb">P1Y</moh:HealthPlanContractTerm>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ieb8a1f0e16d84ec0a669cac6d07c2042_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3Nzg_99b8badb-97fb-4a1c-8779-f7186aae231d">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i8df844efd93545ae81dc29ce059d9765_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM1OA_a83fded9-5651-4fc9-bbd0-f88b865ee371">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i55b78cda26784d3785265b3a4fef2f5a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzUzNQ_5c091379-9c3b-4ddb-b0f8-72f24ac68c1e">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8">http://fasb.org/us-gaap/2022#AccountsPayableAndAccruedLiabilitiesCurrent</us-gaap:FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <dei:DocumentType
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc2_3c6dd4f5-23c8-4628-9b80-d72ce34b157b">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6NDU4ZmFhNGVhZmI4NDMzYzg3NjFiOTI2M2VkY2U0NmMvdGFibGVyYW5nZTo0NThmYWE0ZWFmYjg0MzNjODc2MWI5MjYzZWRjZTQ2Y18wLTAtMS0xLTY4NzY2_5e79791b-f30e-47cd-99c2-bda8348c488c">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8xMjg_1404695d-2199-4ddf-83f4-24630aa83948">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8xMjg_c3b089e9-e1b7-4acc-8646-02ded351ea54">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6YWExYzBmZTEwMWVkNGIwZjlkYjQ2ZjUwODEyMjYwMGEvdGFibGVyYW5nZTphYTFjMGZlMTAxZWQ0YjBmOWRiNDZmNTA4MTIyNjAwYV8wLTAtMS0xLTY4NzY2_6177eacf-ae42-43aa-829d-a18579130ece">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjgz_73ab9dc4-567a-4bfe-a66a-056cc7d89fc6">1-31719</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjg0_41d89fc0-b30d-44a0-82b2-a21c86944037">MOLINA HEALTHCARE, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6YWJhY2I5ZWEyMGE1NDVjYjljNTIyODA5NjRjMzk0YWQvdGFibGVyYW5nZTphYmFjYjllYTIwYTU0NWNiOWM1MjI4MDk2NGMzOTRhZF8wLTAtMS0xLTY4NzY2_135cabc2-5f0e-44af-9239-1168b74d05dc">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6YWJhY2I5ZWEyMGE1NDVjYjljNTIyODA5NjRjMzk0YWQvdGFibGVyYW5nZTphYmFjYjllYTIwYTU0NWNiOWM1MjI4MDk2NGMzOTRhZF8wLTItMS0xLTY4NzY2_75182737-5dc2-4779-aaba-3cb28fe45f93">13-4204626</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc3_d72dec33-bdf9-4fd5-a641-a3bdbc76d946">200 Oceangate</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc4_8d5b8481-4edd-4ac6-9277-e2164efb0310">Suite 100</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjcy_cfaf8de2-cd0c-43ad-82c0-27d4b85965eb">Long Beach</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjcz_0932a667-9ec6-450e-80bf-e6859394b21f">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc5_fe243628-8a10-4445-9909-43637188612c">90802</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjcw_7aaf0425-465e-45e5-ae7f-4daac8ae01ef">562</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc0_03dabde5-91a3-4eaf-b5d5-cecb75dff260">435-3666</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6NDk5MDFmNjhkYWYxNDA0ODliYjc4NmQyZGI0ZDkzMzUvdGFibGVyYW5nZTo0OTkwMWY2OGRhZjE0MDQ4OWJiNzg2ZDJkYjRkOTMzNV8xLTAtMS0xLTY4NzY2_426c1939-7806-404d-8122-b48611daead5">Common Stock, $0.001 Par Value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6NDk5MDFmNjhkYWYxNDA0ODliYjc4NmQyZGI0ZDkzMzUvdGFibGVyYW5nZTo0OTkwMWY2OGRhZjE0MDQ4OWJiNzg2ZDJkYjRkOTMzNV8xLTEtMS0xLTY4NzY2_4e97d985-90fa-491c-91b3-9471b2e6afdf">MOH</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6NDk5MDFmNjhkYWYxNDA0ODliYjc4NmQyZGI0ZDkzMzUvdGFibGVyYW5nZTo0OTkwMWY2OGRhZjE0MDQ4OWJiNzg2ZDJkYjRkOTMzNV8xLTItMS0xLTY4NzY2_88e36d65-5dd4-4a53-bc1a-20ddacdc8dd9">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjcx_ae592f38-923d-4f8a-b2c0-feafec73c338">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjgx_3f76ce78-212d-4f7b-a6a9-54bd958f9cc5">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjgy_bdb6766f-74c3-4ff2-91ef-a2d4c9fa285e">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjY4_242ddb91-6af9-45e0-ac7e-b5b1baeb02fb">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6MzM2NGUwNTk0NDdkNGQ0MWE3ZGY5MmQ4ZWIxODU4ZDMvdGFibGVyYW5nZTozMzY0ZTA1OTQ0N2Q0ZDQxYTdkZjkyZDhlYjE4NThkM18wLTAtMS0xLTY4NzY2_7e69146f-0304-4d16-82a7-34e3f939ed19">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6MzM2NGUwNTk0NDdkNGQ0MWE3ZGY5MmQ4ZWIxODU4ZDMvdGFibGVyYW5nZTozMzY0ZTA1OTQ0N2Q0ZDQxYTdkZjkyZDhlYjE4NThkM18wLTctMS0xLTY4NzY2_0441609b-822a-4898-a944-0614f501dea6">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGFibGU6MzM2NGUwNTk0NDdkNGQ0MWE3ZGY5MmQ4ZWIxODU4ZDMvdGFibGVyYW5nZTozMzY0ZTA1OTQ0N2Q0ZDQxYTdkZjkyZDhlYjE4NThkM18wLTktMS0xLTY4NzY2_fafeee24-7a3c-489a-99aa-e680409d9f48">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjc1_ad6ae94a-7979-4508-8ee0-f11464549e59">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjY5_ed135c6c-9a2c-4da8-b916-b57d55c672ff">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i0aedc9af750a409fa2db8df9d13e5fae_I20220630"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8yNzYy_c29c40be-d399-4745-862a-5d9b0027ff2a"
      unitRef="usd">16100000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i1d4e025ccdc84d63b8840e2ad276c200_I20230210"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8yOTI5_a37c6296-3592-416c-b746-f85dcfbe0a67"
      unitRef="shares">57900000</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xL2ZyYWc6MDY3MTViYjZlMjMyNGM4YjhhMWQxYzZmODEyYWNiMWUvdGV4dHJlZ2lvbjowNjcxNWJiNmUyMzI0YzhiOGExZDFjNmY4MTJhY2IxZV8zMjg1_e3aecd35-33a5-4a66-b6ae-224839dfc0dc">Portions of the registrant&#x2019;s Proxy Statement for the 2023 Annual Meeting of Stockholders to be held on May 3, 2023, are incorporated by reference into Part III of this Form 10-K, to the extent described therein.</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:PremiumsEarnedNet
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzUtMS0xLTEtNjg3NjY_35ee02db-516d-4839-a6d0-cd297d5b0ab4"
      unitRef="usd">30883000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzUtMy0xLTEtNjg3NjY_a6cfad03-36e0-4388-90ae-14fc880a36a1"
      unitRef="usd">26855000000</us-gaap:PremiumsEarnedNet>
    <us-gaap:PremiumsEarnedNet
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzUtNS0xLTEtNjg3NjY_0205a88c-2798-49bf-93fe-092c748600ae"
      unitRef="usd">18299000000</us-gaap:PremiumsEarnedNet>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzYtMS0xLTEtNjg3NjY_33aff803-5d27-4b3e-abb3-b295becb62a7"
      unitRef="usd">873000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzYtMy0xLTEtNjg3NjY_fe453aed-ee9f-4010-8b4c-d86fd2b99d12"
      unitRef="usd">787000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationPremiumTaxRevenue
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzYtNS0xLTEtNjg3NjY_12125efb-8f23-497d-b44a-c8449a95e63b"
      unitRef="usd">649000000</moh:HealthCareOrganizationPremiumTaxRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzctMS0xLTEtNjg3NjY_37ac83ea-a39f-413f-9394-8bd21bdba3ed"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzctMy0xLTEtNjg3NjY_bfe910a0-2d80-4c3b-86b8-2ec07e04d73d"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeRevenue>
    <moh:HealthCareOrganizationInsurerFeeRevenue
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzctNS0xLTEtNjg3NjY_5578af4e-ce3b-4b30-b55e-688e0f1e1a5e"
      unitRef="usd">271000000</moh:HealthCareOrganizationInsurerFeeRevenue>
    <moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzgtMS0xLTEtNjg3NjY_0a46d7e5-7110-4e60-8e52-c490669b1063"
      unitRef="usd">0</moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue>
    <moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzgtMy0xLTEtNjg3NjY_769eb87a-9ab7-4176-9bac-6644ddae332c"
      unitRef="usd">0</moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue>
    <moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzgtNS0xLTEtNjg3NjY_569fc31a-421a-4ceb-8131-3543a6d5ff68"
      unitRef="usd">128000000</moh:HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue>
    <us-gaap:NetInvestmentIncome
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzktMS0xLTEtNjg3NjY_9c037b72-25d9-44ff-b884-2e805334effd"
      unitRef="usd">143000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzktMy0xLTEtNjg3NjY_ec6c5e1f-19fc-4f90-94e6-bb3ff631ad0e"
      unitRef="usd">52000000</us-gaap:NetInvestmentIncome>
    <us-gaap:NetInvestmentIncome
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzktNS0xLTEtNjg3NjY_315517ae-e67e-46bb-92e2-f95468eddff2"
      unitRef="usd">59000000</us-gaap:NetInvestmentIncome>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEwLTEtMS0xLTY4NzY2_d4dabae9-9457-4c2a-909a-fe26daff3454"
      unitRef="usd">75000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEwLTMtMS0xLTY4NzY2_1fc815d3-23d8-4d13-947b-acff3a0e0b20"
      unitRef="usd">77000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEwLTUtMS0xLTY4NzY2_4ebe8afe-f512-470b-8e8f-628193f8e717"
      unitRef="usd">17000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:Revenues
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzExLTEtMS0xLTY4NzY2_cfe5217f-d603-4330-95fb-b7a1d8b3ac15"
      unitRef="usd">31974000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzExLTMtMS0xLTY4NzY2_18e4dfa5-b0e2-47ba-982c-5951e117326e"
      unitRef="usd">27771000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzExLTUtMS0xLTY4NzY2_f3e43a82-a0d7-4783-89c2-13dc2ee562e9"
      unitRef="usd">19423000000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEzLTEtMS0xLTY4NzY2_98b2fb43-6761-427e-8edb-a11580510221"
      unitRef="usd">27175000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEzLTMtMS0xLTY4NzY2_08ffbefd-11c9-4065-a676-02b69a997c4b"
      unitRef="usd">23704000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzEzLTUtMS0xLTY4NzY2_7d58af61-326a-4d29-9d35-fc73616774a9"
      unitRef="usd">15820000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE0LTEtMS0xLTY4NzY2_f602e943-23b9-42e5-8252-0b4d8d5a54d6"
      unitRef="usd">2311000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE0LTMtMS0xLTY4NzY2_771e5272-14cb-4d5c-ba36-d386d2103f5c"
      unitRef="usd">2068000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE0LTUtMS0xLTY4NzY2_4a6be338-dfa2-4d67-97a9-8f50c51d019f"
      unitRef="usd">1480000000</us-gaap:GeneralAndAdministrativeExpense>
    <moh:PremiumTaxExpenses
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE1LTEtMS0xLTY4NzY2_f137f477-5dd9-4dc5-8908-740eda754f9d"
      unitRef="usd">873000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE1LTMtMS0xLTY4NzY2_9555e604-9f6c-41e9-bb3a-6a68aa017c9d"
      unitRef="usd">787000000</moh:PremiumTaxExpenses>
    <moh:PremiumTaxExpenses
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE1LTUtMS0xLTY4NzY2_54d0f20b-832b-450c-a194-d57481d511f1"
      unitRef="usd">649000000</moh:PremiumTaxExpenses>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE2LTEtMS0xLTY4NzY2_a940c22a-04f7-440c-b9ff-0c3cf556fcb5"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeExpense>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE2LTMtMS0xLTY4NzY2_5783d02c-eea9-49f8-8d27-b7fcf33444ad"
      unitRef="usd">0</moh:HealthCareOrganizationInsurerFeeExpense>
    <moh:HealthCareOrganizationInsurerFeeExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE2LTUtMS0xLTY4NzY2_e44fdb10-49b3-45dd-8f01-5819ad290860"
      unitRef="usd">277000000</moh:HealthCareOrganizationInsurerFeeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE3LTEtMS0xLTY4NzY2_02cbde01-cdc6-4f16-a744-7af88dfa1c14"
      unitRef="usd">176000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE3LTMtMS0xLTY4NzY2_64cb518f-9615-4428-9e7a-6d15c7a77728"
      unitRef="usd">131000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE3LTUtMS0xLTY4NzY2_e450d9b8-d81a-4fc4-8252-1c21302804ea"
      unitRef="usd">88000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTEtMS0xLTcxNzUw_b1eba8d8-03bc-48dc-a58c-6480be8313f4"
      unitRef="usd">208000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTMtMS0xLTcxNzUw_7460f495-57d8-4d7f-9b9c-f3652d289c89"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTUtMS0xLTcxNzUw_d83244d2-4dbd-4e8b-9bd8-e32218ec3a4e"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTEtMS0xLTY4NzY2_e4de5c3e-9965-4c51-9977-187fc9cd4892"
      unitRef="usd">58000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTMtMS0xLTY4NzY2_35eed9ff-80d9-4dab-b9f9-37f78c434e54"
      unitRef="usd">61000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:OtherCostAndExpenseOperating
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE4LTUtMS0xLTY4NzY2_2dc677bf-6caa-477b-8217-9c97d5f4edba"
      unitRef="usd">31000000</us-gaap:OtherCostAndExpenseOperating>
    <us-gaap:CostsAndExpenses
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE5LTEtMS0xLTY4NzY2_fb97ea50-d5db-4e91-a7c5-72f8b378ab47"
      unitRef="usd">30801000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE5LTMtMS0xLTY4NzY2_3e554f36-0333-4d4e-857f-db023f7c15d1"
      unitRef="usd">26751000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzE5LTUtMS0xLTY4NzY2_478d25c0-a438-40e5-a36b-fb6dc9c477a5"
      unitRef="usd">18345000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIwLTEtMS0xLTY4NzY2_8c389bce-09e9-47cf-9080-835076fd12c1"
      unitRef="usd">1173000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIwLTMtMS0xLTY4NzY2_c4dab664-bdba-426d-8cbc-f4c8cf91dae5"
      unitRef="usd">1020000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIwLTUtMS0xLTY4NzY2_4a5ec5bd-5e3b-4e97-9a26-88274ba364bb"
      unitRef="usd">1078000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIyLTEtMS0xLTY4NzY2_d448f41e-6f00-48fe-91e6-bc380d107968"
      unitRef="usd">110000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIyLTMtMS0xLTY4NzY2_f4bbd85f-881d-4125-991b-de5c3fe2b27d"
      unitRef="usd">120000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIyLTUtMS0xLTY4NzY2_6401e640-22c5-437c-8d4a-eaaa5c71c8a2"
      unitRef="usd">102000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIzLTEtMS0xLTY4NzY2_cf1c3889-9095-4c8e-b180-a7d9c4986b6d"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIzLTMtMS0xLTY4NzY2_900e6832-4656-4e23-a371-e95bae6c997d"
      unitRef="usd">-25000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzIzLTUtMS0xLTY4NzY2_31003c80-b964-41db-b03b-538630cafef3"
      unitRef="usd">-15000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI0LTEtMS0xLTY4NzY2_a761530a-c644-4bb7-9ecf-74040babfc38"
      unitRef="usd">-110000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI0LTMtMS0xLTY4NzY2_5e9ce231-e6d3-40b2-a3e4-f6b478fcfa41"
      unitRef="usd">-145000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI0LTUtMS0xLTY4NzY2_7fbe7ccb-55a8-432e-af8a-bc23c30284cf"
      unitRef="usd">-117000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI1LTEtMS0xLTY4NzY2_bc993dda-96a9-4c4f-92e4-c339d5db1448"
      unitRef="usd">1063000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI1LTMtMS0xLTY4NzY2_99c13d9b-a158-4f52-887b-d091b60c9deb"
      unitRef="usd">875000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI1LTUtMS0xLTY4NzY2_8b690aa5-e198-4db4-b159-1ae75028106d"
      unitRef="usd">961000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI2LTEtMS0xLTY4NzY2_47180281-12f3-4f2c-ae07-b6fa289a5e77"
      unitRef="usd">271000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI2LTMtMS0xLTY4NzY2_83414551-63e6-4b27-b4e6-84dc1864480c"
      unitRef="usd">216000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI2LTUtMS0xLTY4NzY2_b15cb40f-7845-4663-aba0-ef5157bf3c07"
      unitRef="usd">288000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI3LTEtMS0xLTY4NzY2_6b8c9fa1-024f-4195-86f2-8525f10b658d"
      unitRef="usd">792000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI3LTMtMS0xLTY4NzY2_cc2f757c-223d-42ce-b803-55903ae444a5"
      unitRef="usd">659000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzI3LTUtMS0xLTY4NzY2_528163d5-1254-4c49-b590-9b4134987e06"
      unitRef="usd">673000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMwLTEtMS0xLTY4NzY2_15476e39-e4ad-4718-8039-ef0806aabf9e"
      unitRef="usdPerShare">13.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMwLTMtMS0xLTY4NzY2_8f4f7f61-3ec9-4109-9227-80ba02fe7c4a"
      unitRef="usdPerShare">11.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMwLTUtMS0xLTY4NzY2_f51a01aa-1f7f-4385-800b-130f1b29f947"
      unitRef="usdPerShare">11.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMxLTEtMS0xLTY4NzY2_691c704c-f4ef-4095-8b43-514de19e658c"
      unitRef="usdPerShare">13.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMxLTMtMS0xLTY4NzY2_bee9ff1b-fea9-4ffe-9ec1-0244caa9d4dd"
      unitRef="usdPerShare">11.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMxLTUtMS0xLTY4NzY2_30cb36f4-7b93-4b13-8561-f1209a660a1a"
      unitRef="usdPerShare">11.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMzLTEtMS0xLTY4NzY2_4bcd198d-31d5-42e7-9da0-e6d2507b9871"
      unitRef="shares">57800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMzLTMtMS0xLTY4NzY2_2c7c422c-7640-48be-b4ea-46fcd2629988"
      unitRef="shares">57800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzMzLTUtMS0xLTY4NzY2_b6e873c7-0213-4034-91b2-832d82c1bd00"
      unitRef="shares">59000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzM0LTEtMS0xLTY4NzY2_462bf50e-7004-4f84-9034-f9f8ab27a739"
      unitRef="shares">58500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzM0LTMtMS0xLTY4NzY2_e5773359-eb55-465f-a696-b056553cd72e"
      unitRef="shares">58600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDYvZnJhZzozOTYzYTA4MzZiMDA0YWJkYTdhZDQ4Y2NkNzIzYTA3My90YWJsZTplYWZjOWYxOTlhYjI0YjRlYjZjOTZmNDRiYjczZWJkNi90YWJsZXJhbmdlOmVhZmM5ZjE5OWFiMjRiNGViNmM5NmY0NGJiNzNlYmQ2XzM0LTUtMS0xLTY4NzY2_bf26eb9b-c9bc-4b0d-b503-8a269e5d2374"
      unitRef="shares">59900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzQtMS0xLTEtNjg3NjY_73e8b16e-4082-41b0-9c63-8980b069a798"
      unitRef="usd">792000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzQtMy0xLTEtNjg3NjY_151e1d84-8d3b-4334-840c-0ddb6489f1e6"
      unitRef="usd">659000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzQtNS0xLTEtNjg3NjY_b78c6c7c-d4c2-438e-b2a7-9a578b1fc2b3"
      unitRef="usd">673000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzYtMS0xLTEtNjg3NjY_90775e8a-a27e-4cc5-baf1-c0fd9144e6f0"
      unitRef="usd">-204000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzYtMy0xLTEtNjg3NjY_6740c33a-ed08-4a5c-9f28-f3b323938663"
      unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzYtNS0xLTEtNjg3NjY_42d918cc-d005-4e91-ad16-d807be81e9f2"
      unitRef="usd">44000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzctMS0xLTEtNjg3NjY_3955267b-0bb5-4306-a856-e2015b098297"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzctMy0xLTEtNjg3NjY_d05be2aa-cad1-410a-94be-459da16c13e5"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzctNS0xLTEtNjg3NjY_210eae81-cb12-48a7-8717-bd8e474fedb1"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzgtMS0xLTEtNjg3NjY_00684a3e-3290-4445-b1e0-e8ac2f38fc49"
      unitRef="usd">-155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzgtMy0xLTEtNjg3NjY_5c0af1d8-b0b3-4c33-9577-081426409862"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzgtNS0xLTEtNjg3NjY_c828d9f7-76fd-4ccc-9327-0cfe323cc568"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzktMS0xLTEtNjg3NjY_0f37ac0d-a68d-4d08-903c-65962c43570c"
      unitRef="usd">637000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzktMy0xLTEtNjg3NjY_570a4cfa-c843-4f30-8b9c-9c0d2d49592c"
      unitRef="usd">617000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMDkvZnJhZzo3YTE3NTc2ZTAzYTI0ZjA0OWEzZTRjNGU1MWRkZjExNC90YWJsZTo3MWRjOTQxNTYxMGQ0NzJiYTlmNjFhYmRlZDgyY2FiZi90YWJsZXJhbmdlOjcxZGM5NDE1NjEwZDQ3MmJhOWY2MWFiZGVkODJjYWJmXzktNS0xLTEtNjg3NjY_2149d352-6391-4f6a-aa28-cc5622823b58"
      unitRef="usd">706000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzYtMS0xLTEtNjg3NjY_fbb3446b-1a30-43fc-89c2-79f3a411ee7b"
      unitRef="usd">4006000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzYtMy0xLTEtNjg3NjY_5eb865f0-b711-476b-b659-f957019a2c4f"
      unitRef="usd">4438000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzctMS0xLTEtNjg3NjY_27b768a4-10ad-401c-b413-04b1a75335a7"
      unitRef="usd">3499000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzctMy0xLTEtNjg3NjY_7378dcf4-b747-446e-b0a7-b1ea00b58048"
      unitRef="usd">3202000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzgtMS0xLTEtNjg3NjY_8d0cb1d1-f501-499b-9cc1-bbee8e7be416"
      unitRef="usd">2302000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzgtMy0xLTEtNjg3NjY_8e934f2f-9d45-4306-9e1f-377290f72af2"
      unitRef="usd">2177000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzktMS0xLTEtNjg3NjY_524aab03-3373-4353-80a4-cdf7e3c0db5c"
      unitRef="usd">277000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzktMy0xLTEtNjg3NjY_370fae1d-176b-4db9-a464-e6b752fdde6f"
      unitRef="usd">247000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEwLTEtMS0xLTY4NzY2_1805afd3-34bc-4cdf-bd9e-8ea1df6f8e14"
      unitRef="usd">10084000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEwLTMtMS0xLTY4NzY2_2c2e8fa0-0c62-4504-a8ba-34e6cd22e628"
      unitRef="usd">10064000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzExLTEtMS0xLTY4NzY2_ff8891d7-7026-4e0f-9dec-2c9a758cb83e"
      unitRef="usd">259000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzExLTMtMS0xLTY4NzY2_150fc824-450f-4bba-9875-d91387c9b638"
      unitRef="usd">396000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEyLTEtMS0xLTY4NzY2_f5da65e2-b5a4-486d-83d3-bfe02fd4bd15"
      unitRef="usd">1390000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEyLTMtMS0xLTY4NzY2_ff40c2dc-cc39-4e7f-bb75-ff4a3995cdc1"
      unitRef="usd">1252000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEzLTEtMS0xLTY4NzY2_85e35d04-8991-4ce1-ad5b-a001a85af4f6"
      unitRef="usd">238000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzEzLTMtMS0xLTY4NzY2_ea047b5a-d3dd-4e5b-8476-6d53d5ccb8a0"
      unitRef="usd">212000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE0LTEtMS0xLTY4NzY2_d2de0b68-9dd2-44c3-8327-09c9278bc92d"
      unitRef="usd">220000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE0LTMtMS0xLTY4NzY2_5a01756c-2f72-4988-b4fa-a2a41968d36e"
      unitRef="usd">106000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE1LTEtMS0xLTY4NzY2_07d079a8-c7f2-4ae4-96b0-3403e692064d"
      unitRef="usd">123000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE1LTMtMS0xLTY4NzY2_de0c3d08-6b53-4dfe-8264-fc4d34022ad0"
      unitRef="usd">179000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE2LTEtMS0xLTY4NzY2_15b29fe7-454f-4e3d-a715-636c1d653d2d"
      unitRef="usd">12314000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzE2LTMtMS0xLTY4NzY2_fc0447eb-2e50-4138-9829-d2d811bc8ed8"
      unitRef="usd">12209000000</us-gaap:Assets>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIwLTEtMS0xLTY4NzY2_238a54d7-f8e6-4b2d-96bd-73130c2784cf"
      unitRef="usd">3528000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIwLTMtMS0xLTY4NzY2_c4cd4ad7-1c16-49e0-b29f-5cd9dac4dadd"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIxLTEtMS0xLTY4NzY2_9ec139df-a5a1-4ea9-925f-f67e221c3018"
      unitRef="usd">2079000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIxLTMtMS0xLTY4NzY2_403f36e3-56d5-48d8-8575-9d4d98ed9b65"
      unitRef="usd">2472000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIyLTEtMS0xLTY4NzY2_f053531e-1a99-42ac-ade9-afd332bde3de"
      unitRef="usd">889000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIyLTMtMS0xLTY4NzY2_4bd5aa0d-11f4-4933-9bab-905f3408abfc"
      unitRef="usd">842000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIzLTEtMS0xLTY4NzY2_15730e6d-d26a-4622-9b13-1b15803ed57c"
      unitRef="usd">359000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzIzLTMtMS0xLTY4NzY2_5a5954d8-fe50-4e66-8d39-b4ec8b26a130"
      unitRef="usd">370000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI0LTEtMS0xLTY4NzY2_4f316107-92d2-4cd7-8922-b86870b2c625"
      unitRef="usd">6855000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI0LTMtMS0xLTY4NzY2_c0cc31f7-1114-41c8-a02e-9fcbf7118e1c"
      unitRef="usd">7047000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI1LTEtMS0xLTY4NzY2_018f1f2a-0122-49f8-a3ee-854d11d25f70"
      unitRef="usd">2176000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI1LTMtMS0xLTY4NzY2_d257789f-acf7-4ac6-bbd0-a0ff545d2fcd"
      unitRef="usd">2173000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI2LTEtMS0xLTY4NzY2_4657eab9-b049-448e-9158-8425d708700a"
      unitRef="usd">215000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI2LTMtMS0xLTY4NzY2_4fd8d9dd-9a89-4186-9424-9280d76ce60b"
      unitRef="usd">219000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI3LTEtMS0xLTY4NzY2_e2c8bcc8-ea3c-475e-bf9d-de72c1c37533"
      unitRef="usd">104000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI3LTMtMS0xLTY4NzY2_18bde2c6-add7-4468-bf0a-cd5564b5f70c"
      unitRef="usd">140000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI4LTEtMS0xLTY4NzY2_f3e2c8bf-b5de-46ef-a8a7-65565d556227"
      unitRef="usd">9350000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzI4LTMtMS0xLTY4NzY2_cf10cfda-8f60-4971-be9a-dfcd13210b00"
      unitRef="usd">9579000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTIzNw_7e6c3393-c427-473a-b6b2-854e86014d5f"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTIzNw_e3410e44-b49c-4806-a3a4-3e851bdc76ef"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTI0MQ_0b4abc0e-4e9d-4a0d-84ef-5289b755bd04"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTI0MQ_d98dd6b5-e438-4252-96a0-8f9f5913dcd2"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTI0NQ_8243a8da-3c18-4a4b-860b-4ce7ca7e402f"
      unitRef="shares">58000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MzYzODYxNTNhY2EwNDA1NGIwMjNkZjU3NzdlNDI1YmNfNDM5ODA0NjUxMTI0NQ_a4ee601f-8a75-47b4-b290-07c69abafc4c"
      unitRef="shares">58000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTEtMS0xLTY4NzY2_6977ae0f-db24-4fd7-a906-fbbadf6239b5"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMwLTMtMS0xLTY4NzY2_c33f1e3f-1bcb-4bea-8c24-36d125179364"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIwNA_11c27540-eb43-4722-9cd7-4d58e997c982"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIwNA_29526d31-f90d-4b7b-a538-9d06a37c1693"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIwOA_c73dbffd-ff4f-4a0c-b0dc-4032cb60e177"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIwOA_ceb831b4-7743-4adf-a097-9dbe1989a715"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIxNA_1697c283-2b34-4151-9ec4-ca0969ba1c76"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIxNA_65608097-4278-449f-837f-bb3e913bbc3c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIxNA_6fed0128-aae4-4975-82df-84bef82f9c62"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTE1ZTNkYzhjYjk3NDBmNGE4YmJhODExMTRkOTA4YjRfNDM5ODA0NjUxMTIxNA_ef2a5b4e-25bb-4627-9e79-306761a077ab"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTEtMS0xLTY4NzY2_457c41fd-693d-40f9-ba89-6cd66fa7a23a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMxLTMtMS0xLTY4NzY2_676274e7-17d0-4e7d-b1c3-ce53277a3ab1"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMyLTEtMS0xLTY4NzY2_e43f860c-755c-4edb-a088-7fffb60b7d57"
      unitRef="usd">328000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMyLTMtMS0xLTY4NzY2_ff6cdda5-df02-44a4-9fc7-7a96c3e73060"
      unitRef="usd">236000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMzLTEtMS0xLTY4NzY2_23fa9ba4-9cb1-421a-a31b-44352052bab0"
      unitRef="usd">-160000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzMzLTMtMS0xLTY4NzY2_92d993d5-3a5c-4d9d-ae22-5cacf4d5fc96"
      unitRef="usd">-5000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM0LTEtMS0xLTY4NzY2_ab39a348-d00b-4d5a-a063-02f25cd4c4b0"
      unitRef="usd">2796000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM0LTMtMS0xLTY4NzY2_d635a271-4e97-4c57-92b7-32ecef76187e"
      unitRef="usd">2399000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM1LTEtMS0xLTY4NzY2_eb15b30f-06a4-4f87-8a5a-944dc4c5eab1"
      unitRef="usd">2964000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM1LTMtMS0xLTY4NzY2_f844babb-0002-4014-b60b-b43669ccc3ef"
      unitRef="usd">2630000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM2LTEtMS0xLTY4NzY2_c86a0791-aa56-4015-b51e-a495800a40c3"
      unitRef="usd">12314000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTIvZnJhZzowNGExODU3NDRhNDM0OGUyOWNjMTI2YjZkMGIwYzMxYi90YWJsZTplOGZjNjZiNjM3ZDA0NzdkYTFjYmNkOTA1NDFlYjhiNC90YWJsZXJhbmdlOmU4ZmM2NmI2MzdkMDQ3N2RhMWNiY2Q5MDU0MWViOGI0XzM2LTMtMS0xLTY4NzY2_238037de-46ff-485b-8b47-beb431719e6e"
      unitRef="usd">12209000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="i999be11240344aa48da9e906b939d685_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtMS0xLTEtNjg3NjY_215116c4-c0ae-46d9-8a9b-c0174ad3a7bb"
      unitRef="shares">62000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i999be11240344aa48da9e906b939d685_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtMy0xLTEtNjg3NjY_f3c23ac9-a82d-4d59-b0bc-84b24d50e4cf"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i199fd9ed80d34939adcf4df9bd792f0d_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtNS0xLTEtNjg3NjY_a1efa1c0-0076-466a-98c6-60efa53d2a72"
      unitRef="usd">175000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8771041280f54d5e8602cbc70ecac436_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtNy0xLTEtNjg3NjY_6162c387-3d41-479f-81c5-3bc377f81185"
      unitRef="usd">4000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iff8f933345f844fa938f287ea4acbefa_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtOS0xLTEtNjg3NjY_d95ea62c-17ee-4efa-a77c-fa01d06e1e76"
      unitRef="usd">1781000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQtMTEtMS0xLTY4NzY2_b41794f1-3f08-487e-9819-ec3e4c2bb2db"
      unitRef="usd">1960000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i6cdb516bfdef4a8f9b6c6c031e73cef1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzUtOS0xLTEtNjg3NjY_6d67ab64-0585-4934-a8ce-6daf4e131a26"
      unitRef="usd">673000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzUtMTEtMS0xLTY4NzY2_a9dfe792-3ce3-4714-86cc-04776e4a5a9f"
      unitRef="usd">673000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0ec77d8e31ee46229cf16bffe3977e23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzYtMS0xLTEtNjg3NjY_4617b92c-17a4-4d2c-b1ab-3eca5340687a"
      unitRef="shares">4000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6e5861f8a1be489fbadca2791aa90afe_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzYtNS0xLTEtNjg3NjY_778e353b-62a2-4741-9a85-63b3be524a59"
      unitRef="usd">11000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i6cdb516bfdef4a8f9b6c6c031e73cef1_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzYtOS0xLTEtNjg3NjY_c8a74504-5bc7-45df-8899-9438053c277b"
      unitRef="usd">594000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzYtMTEtMS0xLTY4NzY2_0d91678a-8963-43f4-8a96-6a30be524f34"
      unitRef="usd">605000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="i6e5861f8a1be489fbadca2791aa90afe_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzctNS0xLTEtNjg3NjY_000936c0-3f5d-40ef-919f-5c31053a2da8"
      unitRef="usd">-30000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzctMTEtMS0xLTY4NzY2_036f0801-f002-4616-a8d3-df2803ab9171"
      unitRef="usd">-30000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ifc10bd10790d4245a58fd5f3eb995125_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE1LTctMS0xLTY4NzY2_94612f4a-f16f-4ada-b1d9-5da18d2fbe4c"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE1LTExLTEtMS02ODc2Ng_7706174b-0af0-46f4-a28c-5cb4dce46871"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i0ec77d8e31ee46229cf16bffe3977e23_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE2LTEtMS0xLTY4NzY2_d3f2b254-df46-409f-8148-3a67d6ff8468"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6e5861f8a1be489fbadca2791aa90afe_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE2LTUtMS0xLTY4NzY2_d912001b-7e73-4eac-bc28-15eea45ad1ce"
      unitRef="usd">65000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE2LTExLTEtMS02ODc2Ng_58278636-44d8-4735-af0d-51e84d20515e"
      unitRef="usd">65000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i4c5174cdc8a543aab6a82650213fae42_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTEtMS0xLTY4NzY2_067b690d-0a52-4448-bbe1-7d5d2e7ba112"
      unitRef="shares">59000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i4c5174cdc8a543aab6a82650213fae42_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTMtMS0xLTY4NzY2_9fc845ed-42e3-4962-b7f9-5a2414eb1822"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if519cf6d7ba746faa633b1d247f21140_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTUtMS0xLTY4NzY2_b477deb6-bc6e-4463-8697-4d754bacf870"
      unitRef="usd">199000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if419e645396c4411a00a65c9c61e8f4b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTctMS0xLTY4NzY2_e23c2efc-c5f6-4c8f-a420-da28e509d502"
      unitRef="usd">37000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa1000dd422a4091b6562e182ae3a5e6_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTktMS0xLTY4NzY2_2bea48a6-a3a1-4ac9-aea2-559e9f357aa9"
      unitRef="usd">1860000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE3LTExLTEtMS02ODc2Ng_8aab55d7-b2f0-400f-ae71-9e37bf393402"
      unitRef="usd">2096000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iad023f53ea0d4a398b072037f4fa5a28_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE4LTktMS0xLTY4NzY2_2461052a-490b-40a0-8981-7e748494bb1d"
      unitRef="usd">659000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE4LTExLTEtMS02ODc2Ng_490b577c-f527-4929-a0c3-bf3883601a8d"
      unitRef="usd">659000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i0a1b426cbcba4d009021f4ffbe5138b1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE5LTEtMS0xLTY4NzY2_dd604ce0-f8a3-46e7-b9df-e88bf3495fa0"
      unitRef="shares">1000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie888b7a86e1749beb1747431a08efb69_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE5LTUtMS0xLTY4NzY2_5b347bdb-8b7f-4c9e-a952-69cf164a66b5"
      unitRef="usd">2000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iad023f53ea0d4a398b072037f4fa5a28_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE5LTktMS0xLTY4NzY2_dac7d361-a97d-4298-8cd5-2f4df8476da1"
      unitRef="usd">120000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzE5LTExLTEtMS02ODc2Ng_c01ad99e-0614-4823-b815-46b68da5cc14"
      unitRef="usd">122000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i20ffea858f7a413e84d7c60bd51a39ad_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzI4LTctMS0xLTY4NzY2_53f34220-6e13-48e5-8987-929ac01456f0"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzI4LTExLTEtMS02ODc2Ng_babdd6a4-3bac-4bf7-a901-30d510870311"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ie888b7a86e1749beb1747431a08efb69_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzI5LTUtMS0xLTY4NzY2_bbe6bfa3-ad80-47a9-87c5-eda7ac00362f"
      unitRef="usd">39000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzI5LTExLTEtMS02ODc2Ng_5759a027-02f4-4ff0-b5f4-9d345e8e70cf"
      unitRef="usd">39000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i579cf48f5d864bddb56457fa28bb2587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTEtMS0xLTY4NzY2_3dd080ab-4b7d-4929-9f4c-c2dd10a6c978"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i579cf48f5d864bddb56457fa28bb2587_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTMtMS0xLTY4NzY2_c0c8f0e9-4974-4264-88de-d831656b800f"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6c46a6c267b9418ea1b14da3214406ec_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTUtMS0xLTY4NzY2_2f15c31d-5177-41f5-b344-8ac53ce1ed7d"
      unitRef="usd">236000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i587b2eb5aff244fbb08b0618fb285d59_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTctMS0xLTY4NzY2_31dc3a13-6bd9-4292-9a40-4b0d0eacacc8"
      unitRef="usd">-5000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7a7caae068640048ce1c869c4207d7f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTktMS0xLTY4NzY2_37abe088-25a0-4642-8efa-8ec0badfd6b6"
      unitRef="usd">2399000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMwLTExLTEtMS02ODc2Ng_485b65cd-bd8b-490e-8c34-3b34864ea7c9"
      unitRef="usd">2630000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="iaa9ec9408e524d0c9ce56cae77d8fddc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMxLTktMS0xLTY4NzY2_8ef7758e-2858-4c7b-a775-96347217b90d"
      unitRef="usd">792000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMxLTExLTEtMS02ODc2Ng_eb0e063d-fa6c-46b3-b0c2-33d0d135e875"
      unitRef="usd">792000000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="iac9f15a52524444587078e926f065feb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMyLTEtMS0xLTY4NzY2_38399935-5f6a-4aeb-8761-5272230e44a6"
      unitRef="shares">1000000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i790f6598096b4e42affcce597dc39434_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMyLTUtMS0xLTY4NzY2_c7512a57-d9f6-47a1-a999-96cf90c8c44d"
      unitRef="usd">5000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="iaa9ec9408e524d0c9ce56cae77d8fddc_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMyLTktMS0xLTY4NzY2_3fa148b4-dbfe-43dd-b3aa-6657f4055d7d"
      unitRef="usd">395000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzMyLTExLTEtMS02ODc2Ng_9e82aaab-4eda-4ffb-b80c-a0b6771cd4cc"
      unitRef="usd">400000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i014d76748d9c435e8c2252256e738466_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQxLTctMS0xLTY4NzY2_4e96afc0-bf7c-4da4-8b58-745bd82dd24a"
      unitRef="usd">-155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQxLTExLTEtMS02ODc2Ng_9136f628-6a23-4e66-ba75-cd299e9b3bb7"
      unitRef="usd">-155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="iac9f15a52524444587078e926f065feb_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQyLTEtMS0xLTY4NzY2_ffffeece-884a-497b-9b3c-904d2e102dbb"
      unitRef="shares">1000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i790f6598096b4e42affcce597dc39434_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQyLTUtMS0xLTY4NzY2_78483fa6-277b-448e-9927-b6513018a642"
      unitRef="usd">97000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQyLTExLTEtMS02ODc2Ng_081263a8-ccba-4972-86d2-0c8a66469e47"
      unitRef="usd">97000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:SharesOutstanding
      contextRef="i8454949eb924409fbf2446822fa8d947_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTEtMS0xLTY4NzY2_b9af51f8-1791-4a1c-b1fc-aa855dd88d16"
      unitRef="shares">58000000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i8454949eb924409fbf2446822fa8d947_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTMtMS0xLTY4NzY2_f257421c-ff41-4394-9526-e09636d3f0ab"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie1db3a5ad94a4885a560d39ee09283e7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTUtMS0xLTY4NzY2_125a055c-8787-44e4-af2f-e1782a54d4c1"
      unitRef="usd">328000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1426d89bce2644bcb46ee222394ca3ab_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTctMS0xLTY4NzY2_edfe1472-3d42-4d57-bc12-17bdf5a89482"
      unitRef="usd">-160000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i95d5fbc5f32e4d71bf63e8a5e693b170_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTktMS0xLTY4NzY2_25321a94-9fc5-45cd-93dd-3423b22f3cd6"
      unitRef="usd">2796000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTUvZnJhZzo3OGMxM2UwMmM0N2M0MGQ4Yjg4ODQ3ZjAyNzY1MjI5Ni90YWJsZTo4OTQzYTljM2ZlNGE0ZDBkYmVlODUwNWEzMDc5NzhlMy90YWJsZXJhbmdlOjg5NDNhOWMzZmU0YTRkMGRiZWU4NTA1YTMwNzk3OGUzXzQzLTExLTEtMS02ODc2Ng_a4058fdb-cda2-4bc4-8f10-9888a1c7a846"
      unitRef="usd">2964000000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzUtMS0xLTEtNjg3NjY_75eed8b0-a9c0-4f6e-9d50-149afd804ce9"
      unitRef="usd">792000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzUtMy0xLTEtNjg3NjY_2d674381-752a-42a4-85cb-d1193d4709f5"
      unitRef="usd">659000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzUtNS0xLTEtNjg3NjY_297b3eb7-b09f-469c-940c-fabc1947257f"
      unitRef="usd">673000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzctMS0xLTEtNjg3NjY_436bd5f0-ed35-4ec0-876a-46334d1adf10"
      unitRef="usd">176000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzctMy0xLTEtNjg3NjY_8872ae9a-bf2d-43e6-b1f0-e46fbbea9fd3"
      unitRef="usd">131000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzctNS0xLTEtNjg3NjY_40b4c37a-0fe6-487c-be9d-44d6c5ad6f19"
      unitRef="usd">88000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzgtMS0xLTEtNjg3NjY_876ad958-1a27-4b1e-9097-9ce3dea59ea5"
      unitRef="usd">66000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzgtMy0xLTEtNjg3NjY_247db1e2-b596-4ed3-a410-4bef386cc81b"
      unitRef="usd">24000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzgtNS0xLTEtNjg3NjY_95ee6880-7790-4991-9ae2-39389fb5fcf2"
      unitRef="usd">19000000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzktMS0xLTEtNjg3NjY_0e04b96a-e6a5-4808-957e-277e8e5ed608"
      unitRef="usd">103000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzktMy0xLTEtNjg3NjY_669eaee7-63fd-45ab-b2cd-d3fbdde336b2"
      unitRef="usd">72000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzktNS0xLTEtNjg3NjY_0440ea2e-e7ee-4129-ace0-7aa9f9da9018"
      unitRef="usd">57000000</us-gaap:ShareBasedCompensation>
    <moh:GainLossOnDebtRepayment
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEwLTEtMS0xLTY4NzY2_501b3254-8d9e-4584-b001-58d098ea96ae"
      unitRef="usd">0</moh:GainLossOnDebtRepayment>
    <moh:GainLossOnDebtRepayment
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEwLTMtMS0xLTY4NzY2_24d75c5b-c017-40e1-98c6-01a5ce65ca7a"
      unitRef="usd">-25000000</moh:GainLossOnDebtRepayment>
    <moh:GainLossOnDebtRepayment
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEwLTUtMS0xLTY4NzY2_ee9a3e05-eada-4808-91fc-4201f5ca1022"
      unitRef="usd">-15000000</moh:GainLossOnDebtRepayment>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTEtMS0xLTcxOTI1_901edcaf-f9fc-49d5-bdba-67065b39ceeb"
      unitRef="usd">208000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTMtMS0xLTcxOTMz_a17fd5ae-bd69-435d-a033-83fd6ef417e9"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTUtMS0xLTcxOTMz_999b05c7-285f-4366-8cdb-2d049b6b7a9b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTEtMS0xLTY4NzY2_9e099e1d-cdc8-4817-ac47-2d01278d8ee9"
      unitRef="usd">8000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTMtMS0xLTY4NzY2_24947f9b-87ce-43a1-9775-f6770f4d8d56"
      unitRef="usd">33000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzExLTUtMS0xLTY4NzY2_18758465-84cd-4e1a-b6ca-1be9246fc6bd"
      unitRef="usd">12000000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEzLTEtMS0xLTY4NzY2_6f6bbd57-764c-4c57-a4b3-85370fb30d82"
      unitRef="usd">95000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEzLTMtMS0xLTY4NzY2_75b36088-fffd-49c2-93ea-4c07fa2157c5"
      unitRef="usd">415000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzEzLTUtMS0xLTY4NzY2_83a2c355-d67f-42f6-881e-7679ae975aa2"
      unitRef="usd">100000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE0LTEtMS0xLTY4NzY2_93c5308c-3a56-45e6-bab0-5944752204d3"
      unitRef="usd">124000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE0LTMtMS0xLTY4NzY2_55520bd5-adaa-4be4-aae1-497389480ef8"
      unitRef="usd">19000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE0LTUtMS0xLTY4NzY2_10db9452-46c0-4309-9922-8e6b56878785"
      unitRef="usd">16000000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE1LTEtMS0xLTY4NzY2_49490f55-aea6-4ce6-878b-496841ee01d6"
      unitRef="usd">153000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE1LTMtMS0xLTY4NzY2_4c4b2239-56f9-4f5d-9a95-be532061a627"
      unitRef="usd">471000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE1LTUtMS0xLTY4NzY2_722e7aa2-d605-4ccd-b8b9-949e7823019d"
      unitRef="usd">544000000</us-gaap:IncreaseDecreaseInHealthCareInsuranceLiabilities>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE2LTEtMS0xLTY4NzY2_9337e127-3c9b-4e20-b2c8-ce2187d0f343"
      unitRef="usd">-428000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE2LTMtMS0xLTY4NzY2_d0f857e5-74e6-45ea-90e1-a4e2ab16849d"
      unitRef="usd">1046000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE2LTUtMS0xLTY4NzY2_02c750e2-8daa-431e-b7cb-506fb84a7f6f"
      unitRef="usd">446000000</moh:IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE3LTEtMS0xLTY4NzY2_a74e93b8-61c6-4f8c-9640-85c190411fd8"
      unitRef="usd">55000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE3LTMtMS0xLTY4NzY2_9207e240-68bc-45c7-b45b-dd237bda04c4"
      unitRef="usd">138000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE3LTUtMS0xLTY4NzY2_27cc3576-6528-46ef-a2c6-5127664991fb"
      unitRef="usd">86000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE4LTEtMS0xLTY4NzY2_8c7d6722-e764-402c-b330-9ebe8bc568de"
      unitRef="usd">-11000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE4LTMtMS0xLTY4NzY2_3b1372f1-4be6-41b3-9ca4-2b48d9e7e686"
      unitRef="usd">-5000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE4LTUtMS0xLTY4NzY2_052f567c-4a79-4995-85e6-d24cecd9bddf"
      unitRef="usd">126000000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE5LTEtMS0xLTY4NzY2_03dc2421-48de-4964-a1b6-2b8cf5d29278"
      unitRef="usd">2000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE5LTMtMS0xLTY4NzY2_441fd06a-6f52-40ab-816a-950560abe73f"
      unitRef="usd">7000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzE5LTUtMS0xLTY4NzY2_20a539c4-6c9f-48b3-83f3-3105a1c86a0f"
      unitRef="usd">-14000000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIwLTEtMS0xLTY4NzY2_118a4fcf-bcf2-430c-84d0-7fcf48080370"
      unitRef="usd">773000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIwLTMtMS0xLTY4NzY2_2249d4d1-8dda-483e-9c25-24626c248003"
      unitRef="usd">2119000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIwLTUtMS0xLTY4NzY2_55385322-24cb-4e5e-8612-35c6f2238017"
      unitRef="usd">1898000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIyLTEtMS0xLTY4NzY2_fdfa09b5-d122-42c3-b8e3-5a6513acbf63"
      unitRef="usd">1913000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIyLTMtMS0xLTY4NzY2_43be6761-544f-4deb-9f28-2152c330a514"
      unitRef="usd">2713000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIyLTUtMS0xLTY4NzY2_3e03c95c-946b-46e2-b413-735e0c728f10"
      unitRef="usd">670000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIzLTEtMS0xLTY4NzY2_5f1624b2-a54b-4b99-abf2-e61ead477ccd"
      unitRef="usd">1398000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIzLTMtMS0xLTY4NzY2_a72dbe7a-6b39-49e0-b2d1-a3161d7604ea"
      unitRef="usd">1329000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzIzLTUtMS0xLTY4NzY2_10b54943-6c7c-401f-8b93-6328c9faf61c"
      unitRef="usd">1097000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI0LTEtMS0xLTY4NzY2_3d662238-c300-4cef-8a5f-cf91d267f64a"
      unitRef="usd">134000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI0LTMtMS0xLTY4NzY2_9ab9efb2-6881-456d-a432-55a5cab72f5d"
      unitRef="usd">129000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI0LTUtMS0xLTY4NzY2_a59a3c15-e16c-434a-934b-c072be4f7c14"
      unitRef="usd">755000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI1LTEtMS0xLTY4NzY2_a7905d86-39a8-430c-9fb5-7091065f543a"
      unitRef="usd">91000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI1LTMtMS0xLTY4NzY2_3cdb7546-66a6-4d8f-8baa-2fe0e97ffd0f"
      unitRef="usd">77000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI1LTUtMS0xLTY4NzY2_5d520445-3ae0-4c7e-b9e1-ef134365df80"
      unitRef="usd">74000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI2LTEtMS0xLTY4NzY2_7c41a4a5-734e-4335-a80a-ac27d319612f"
      unitRef="usd">50000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI2LTMtMS0xLTY4NzY2_8fe4aa5e-2712-44dc-bad6-81a8c69f3eb4"
      unitRef="usd">63000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI2LTUtMS0xLTY4NzY2_1f5494d4-1ca2-4d58-b226-995fff1ae4cc"
      unitRef="usd">-2000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI3LTEtMS0xLTY4NzY2_3fa306c7-4df9-4777-a250-a8de21afc464"
      unitRef="usd">-790000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI3LTMtMS0xLTY4NzY2_0d540e2b-f548-45f8-aaa6-f6c3f6a041b2"
      unitRef="usd">-1653000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI3LTUtMS0xLTY4NzY2_1e4d3878-0c42-438b-b5c8-7a137a2d8724"
      unitRef="usd">-400000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI5LTEtMS0xLTY4NzY2_e7526db5-5637-4fdb-848d-2747ebfa9fd7"
      unitRef="usd">400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI5LTMtMS0xLTY4NzY2_00b1e35f-c728-4189-ad80-40164e7bf82a"
      unitRef="usd">128000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzI5LTUtMS0xLTY4NzY2_2e9da017-1332-4538-8deb-cf2acfed54fa"
      unitRef="usd">606000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMwLTEtMS0xLTY4NzY2_948d6ce1-657a-4406-b45a-85e05ac5dcdb"
      unitRef="usd">54000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMwLTMtMS0xLTY4NzY2_4d7b0519-c77c-4b53-be20-abdedf2ae0b5"
      unitRef="usd">53000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMwLTUtMS0xLTY4NzY2_9e3c9d7c-42bd-436f-9a12-bd841eaebe0c"
      unitRef="usd">8000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMxLTEtMS0xLTY4NzY2_0d25a0e2-09e2-4999-beb2-28e7ac4344c1"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMxLTMtMS0xLTY4NzY2_d9b547c4-6000-4a94-80ec-b3915e517364"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMxLTUtMS0xLTY4NzY2_43068e4a-cc9f-4e63-a667-1db5e20747cc"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMyLTEtMS0xLTY4NzY2_9b7bafe8-7a00-42a6-b5f5-b5b353a02cce"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMyLTMtMS0xLTY4NzY2_34e9d090-2448-4849-99ba-2a5b44d1c375"
      unitRef="usd">740000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMyLTUtMS0xLTY4NzY2_52e5688f-e93d-4c5f-8d8f-de4de768b1b2"
      unitRef="usd">1429000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMzLTEtMS0xLTY4NzY2_ddb513da-342d-4af3-bb41-86d5f7a7047e"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMzLTMtMS0xLTY4NzY2_837837f1-5a3b-4123-b4fd-6b7e6a581ffe"
      unitRef="usd">723000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzMzLTUtMS0xLTY4NzY2_803b22fa-2560-4ed7-ba02-455bd8cc1fe3"
      unitRef="usd">338000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM0LTEtMS0xLTY4NzY2_20bf4d77-9395-4a52-8b5d-7df75c111913"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM0LTMtMS0xLTY4NzY2_122bc83b-b4d9-4a35-adcd-c8ccd7e486f2"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM0LTUtMS0xLTY4NzY2_547d4c56-0a65-4431-8ca2-31d2b9ce87ac"
      unitRef="usd">600000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM1LTEtMS0xLTY4NzY2_5a6dae7c-a8cf-42fd-b2fe-0669f91288bb"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM1LTMtMS0xLTY4NzY2_14506bc2-7cde-48f8-90e0-e555f2779340"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM1LTUtMS0xLTY4NzY2_8125fff4-81af-4483-82a4-5cf7d5e937ae"
      unitRef="usd">380000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM2LTEtMS0xLTY4NzY2_d13ee961-3e61-4c9a-ab12-081a30b735de"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM2LTMtMS0xLTY4NzY2_861be610-e585-4528-bb42-881d99fece6d"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM2LTUtMS0xLTY4NzY2_2c7339f0-67f3-41a3-98af-7982bfd48c1d"
      unitRef="usd">30000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <moh:CashPaidForSettlementOfConversionOption
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM3LTEtMS0xLTY4NzY2_460de9d9-7eee-4639-8e05-8cf98e719c2a"
      unitRef="usd">0</moh:CashPaidForSettlementOfConversionOption>
    <moh:CashPaidForSettlementOfConversionOption
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM3LTMtMS0xLTY4NzY2_75b8511c-0d78-43c2-9dbe-c0be34128c20"
      unitRef="usd">0</moh:CashPaidForSettlementOfConversionOption>
    <moh:CashPaidForSettlementOfConversionOption
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM3LTUtMS0xLTY4NzY2_643a5951-0c6e-4166-bb60-0f019dcd0f12"
      unitRef="usd">27000000</moh:CashPaidForSettlementOfConversionOption>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM4LTEtMS0xLTY4NzY2_41e246e2-f198-4688-9c77-46fa6bddd52c"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM4LTMtMS0xLTY4NzY2_9820b9af-9f61-4d8e-b0db-20b0772303bb"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM4LTUtMS0xLTY4NzY2_dababf54-5212-40f5-abcd-28718bddd2f6"
      unitRef="usd">27000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM5LTEtMS0xLTY4NzY2_3d2da302-6b20-41c9-9269-25d63c321cbd"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM5LTMtMS0xLTY4NzY2_5dd911da-5f51-4b66-9f25-0a0e30d572b5"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzM5LTUtMS0xLTY4NzY2_a1c26a62-05d9-4fb8-8fcb-ecf82c2aee33"
      unitRef="usd">12000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQwLTEtMS0xLTY4NzY2_4fe0d0c4-565f-4082-9e51-819d910c9546"
      unitRef="usd">33000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQwLTMtMS0xLTY4NzY2_4158842d-3491-4e08-9a1a-4767b9231a1c"
      unitRef="usd">1000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQwLTUtMS0xLTY4NzY2_a59486b8-8a5f-4956-8a8d-935a31f4381e"
      unitRef="usd">2000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQxLTEtMS0xLTY4NzY2_6eb731d3-15f2-42ca-8e89-f1e8e5b3ef03"
      unitRef="usd">-441000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQxLTMtMS0xLTY4NzY2_a33b267c-2aa0-4fba-af35-e76095fccd88"
      unitRef="usd">-183000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQxLTUtMS0xLTY4NzY2_5f654541-441f-480c-a400-d10d5429c67b"
      unitRef="usd">217000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQyLTEtMS0xLTY4NzY2_5fe38af6-62ac-42c7-be1c-b27be04cb173"
      unitRef="usd">-458000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQyLTMtMS0xLTY4NzY2_aadd85b0-3e54-4c98-b2ab-4f43cab88ef3"
      unitRef="usd">283000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQyLTUtMS0xLTY4NzY2_61303348-88fb-4f23-9d99-56191197b17a"
      unitRef="usd">1715000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQzLTEtMS0xLTY4NzY2_9e316368-65c9-4f5f-ad8d-edfcaae79be4"
      unitRef="usd">4506000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQzLTMtMS0xLTY4NzY2_6f404e3f-2831-4e2a-a64b-0ca03940275f"
      unitRef="usd">4223000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQzLTUtMS0xLTY4NzY2_d0628b18-1a4a-4a3e-b454-f40dfecd3b5b"
      unitRef="usd">2508000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQ0LTEtMS0xLTY4NzY2_49673cd4-f3d6-4d3e-b6a3-5c88fe48987e"
      unitRef="usd">4048000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQ0LTMtMS0xLTY4NzY2_5bae440f-b98e-4c97-b67f-8f0899431afd"
      unitRef="usd">4506000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZToyMjIwNjU2NzhiOTU0MGRlYTZmN2YyNjY0ZmVmNjk0NS90YWJsZXJhbmdlOjIyMjA2NTY3OGI5NTQwZGVhNmY3ZjI2NjRmZWY2OTQ1XzQ0LTUtMS0xLTY4NzY2_d7f9bef8-9ee9-4ccf-ac19-aecc42e7a8c6"
      unitRef="usd">4223000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzYtMS0xLTEtNjg3NjY_3dbdfd61-f9e9-432f-abe4-1434357e7f9a"
      unitRef="usd">340000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzYtMy0xLTEtNjg3NjY_403d879c-9480-4c75-8f18-0c17ccbddf1c"
      unitRef="usd">235000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzYtNS0xLTEtNjg3NjY_145ace0b-c3f3-457b-8cb1-e319cf0112a1"
      unitRef="usd">321000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzctMS0xLTEtNjg3NjY_ac386aec-2bae-4a60-abe1-d3437afd081c"
      unitRef="usd">108000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzctMy0xLTEtNjg3NjY_ec6dbd44-c47e-4611-87eb-63c972d7de63"
      unitRef="usd">127000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMTgvZnJhZzo2ZmY1NzA0ZjNiNjU0MzNiODcwZWQ2YjY1MTY4ZGNjNS90YWJsZTowNmJmNmFlOTU5NDA0ZTFiYWE4NjY4NDBiOGJmZmM0OC90YWJsZXJhbmdlOjA2YmY2YWU5NTk0MDRlMWJhYTg2Njg0MGI4YmZmYzQ4XzctNS0xLTEtNjg3NjY_074c2dc9-fbc9-4e16-ae98-c9749c32167b"
      unitRef="usd">112000000</us-gaap:InterestPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwNTg_c689c14f-bae2-40eb-acc7-54c7809c2154">Organization and Basis of Presentation &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Organization and Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Molina Healthcare, Inc. provides managed healthcare services under the Medicaid and Medicare programs, and through the state insurance marketplaces (the &#x201c;Marketplace&#x201d;). Molina was founded in 1980 as a provider organization serving low-income families in Southern California and reincorporated in Delaware in 2002. We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2022, we served approximately 5.3 million members eligible for government-sponsored healthcare programs, located across 19 states. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our state Medicaid contracts typically have terms of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzY3OA_6f2a845c-6f22-4bcc-9cb4-a0ec1e4ca0c4"&gt;three&lt;/span&gt; to five years, contain renewal options exercisable by the state Medicaid agency, and allow either the state or the health plan to terminate the contract with or without cause. Such contracts are subject to risk of loss in states that issue requests for proposal (&#x201c;RFP&#x201d;) open to competitive bidding by other health plans. If one of our health plans is not a successful responsive bidder to a state RFP, its contract may not be renewed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to contract renewal, our state Medicaid contracts may be periodically amended to include or exclude certain health benefits (such as pharmacy services, behavioral health services, or long-term care services); populations such as the aged, blind or disabled (&#x201c;ABD&#x201d;); and regions or service areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Medicare, we enter into Medicare Advantage-Part D contracts with the Centers for Medicare and Medicaid Services (&#x201c;CMS&#x201d;) annually, and for dual-eligible plans, we enter into contracts with CMS, in partnership with each state&#x2019;s department of health and human services. Such contracts typically have terms of &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzEwOTk1MTE2NDU4MTc_95927849-eb03-4285-a11c-36386eebadfb"&gt;one&lt;/span&gt; to three years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In Marketplace, we enter into contracts with CMS, which end on December 31 of each year, and must be renewed annually. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Developments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 27, 2023, the Texas Health and Human Services Commission posted a notice on its website indicating that it was issuing a Notice of Intent to Award to Molina Healthcare of Texas, Inc. a STAR+PLUS ABD contract in each of Bexar, Dallas, El Paso, Harris, Hidalgo, Jefferson, Northeast Texas, and Tarrant Service Areas. The notice follows a proposal that we submitted in June 2022 to continue serving STAR+PLUS members in the same service areas, in response to an RFP posted in March 2022. The start of operations for the new contract is expected to begin in February 2024. Further, in December 2022, the RFP was posted for the TANF and CHIP programs (known as the STAR &amp;amp; CHIP programs, and both existing contracts for Molina), with awards expected in February 2024 and the start of operations in February 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;California Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, we announced that the California Department of Health Care Services (&#x201c;DHCS&#x201d;) had confirmed our California health plan&#x2019;s footprint as originally announced in August 2022, including Medi-Cal contract awards in each of Riverside, San Bernardino, Sacramento, and San Diego Counties. In Los Angeles County, we will share membership equally with the current commercial incumbent. The Medi-Cal contracts are expected to commence on January 1, 2024, which enables us to continue serving Medi-Cal members in our existing counties and expand our footprint in Los Angeles County. DHCS has also agreed to grant Molina a contract to offer EAE-SNP products for dual eligible members in Los Angeles County.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;New York Acquisition&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York (&#x201c;AgeWell&#x201d;). See Note 4, &#x201c;Business Combinations,&#x201d; for further information. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nebraska Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, we announced that our Nebraska health plan had been selected by the Nebraska Department of Health and Human Services to provide health care services to Nebraskans under the state&#x2019;s Medicaid managed care program. The new five-year contract is expected to begin on January 1, 2024, and may be extended for an additional two-years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Iowa Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we announced that our Iowa health plan had been notified by the Iowa Department of Health and Human Services (&#x201c;Iowa HHS&#x201d;) of its intent to award a Medicaid managed care contract pursuant to the RFP issued by Iowa HHS in February 2022. The new four-year contract is expected to begin on July 1, 2023, and may be extended for an additional four years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Mississippi Procurement&#x2014;Medicaid. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, we announced that our Mississippi health plan had been notified by the Mississippi Division of Medicaid (&#x201c;DOM&#x201d;) of its intent to award a Medicaid Coordinated Care Contract for its Mississippi Coordinated Access Program and Mississippi Children&#x2019;s Health Insurance Program pursuant to the Request for Qualifications issued by DOM in December 2021. The four-year contract is expected to begin on July 1, 2023, and may be extended for an additional two years. The award enables us to continue serving Medicaid members across the state.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Wisconsin Acquisition&#x2014;Medicaid and Medicare. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 13, 2022, we announced a definitive agreement to acquire substantially all the assets of My Choice Wisconsin (&#x201c;MCW&#x201d;). The purchase price for the transaction is approximately $150&#160;million, net of expected tax benefits and required regulatory capital, which we intend to fund with cash on hand. The transaction is subject to receipt of applicable federal and state regulatory approvals, and the satisfaction of other customary closing conditions. We currently expect the transaction to close in mid-2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Nevada Procurement&#x2014;Medicaid.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our new contract in Clark and Washoe Counties commenced on January 1, 2022, and offers health coverage to TANF, CHIP and Medicaid Expansion beneficiaries. This new contract is four years with a potential two-year extension.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Texas Acquisition&#x2014;Medicaid and Medicare.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On January 1, 2022, we closed on our acquisition of Cigna Corporation&#x2019;s Texas Medicaid and Medicare-Medicaid Plan (&#x201c;MMP&#x201d;) contracts, along with certain operating assets. See Note 4, &#x201c;Business Combinations,&#x201d; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1ODY_a4362266-9afb-4b4c-9ff4-6ff84ec170a7"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms
      contextRef="i85e7dfbb25714e6fa1e9c665d5b451ed_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzUzMg_ed0ce3bb-6533-406c-a7ca-1a4b8b3f4893"
      unitRef="member">5300000</moh:BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms>
    <moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms
      contextRef="i85e7dfbb25714e6fa1e9c665d5b451ed_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzYxMw_8e9dc130-5f85-4b3e-9ce3-e71fe77967d3"
      unitRef="state">19</moh:NumberOfStatesWithGovernmentSponsoredHealthcarePrograms>
    <moh:HealthPlanContractTerm
      contextRef="i0401c2aac1bd43f18925d12817958d7a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzY4NA_300c2ee7-bf79-4f89-b7b3-3d57bdf4fac3">P5Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanContractTerm
      contextRef="i99e5c5b493404f65b708b3004c6d9e12_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQzOTgwNDY1MjkxNTY_56f8afa9-78f8-4f36-9016-79faa63b3293">P3Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanContractTerm
      contextRef="i880dcbd954c94606b002149fe2d46983_D20220901-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1Nzk_da260b0b-204d-4b63-9359-377c5b013e1c">P5Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="i880dcbd954c94606b002149fe2d46983_D20220901-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1NjU_2aea2302-3648-4a6a-aed2-1de3812bb7ec">P2Y</moh:HealthPlanExtensionOptionPeriod>
    <moh:HealthPlanContractTerm
      contextRef="i5d1626275dac4e1fb93d80b9a4189fb4_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1NTI_cdec4946-ebdc-4aa1-9001-d365f2ffbd98">P4Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="i5d1626275dac4e1fb93d80b9a4189fb4_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1MzQ_870fb43f-0412-4fbd-9008-4ca4829999d9">P4Y</moh:HealthPlanExtensionOptionPeriod>
    <moh:HealthPlanContractTerm
      contextRef="i0f69658aa2554010bae3200d5bca4c4d_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY1MTA_907f4f42-be52-4262-a8aa-bb3c197a14fd">P4Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="i0f69658aa2554010bae3200d5bca4c4d_D20220801-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY0OTI_b9832065-bdb8-48e6-9944-db32c8692ea1">P2Y</moh:HealthPlanExtensionOptionPeriod>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i307d98a799304ec9b2ea5e24af4f8721_D20220713-20220713"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2Xzc2OTY1ODE0MDY0NjY_f3623eb1-cf34-4156-ae1a-b66015bb1e28"
      unitRef="usd">150000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <moh:HealthPlanContractTerm
      contextRef="ie3076577c633490db40aa71614578a1e_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwODE_402ee0cf-6136-44c7-8261-0d3d96375487">P4Y</moh:HealthPlanContractTerm>
    <moh:HealthPlanExtensionOptionPeriod
      contextRef="ie3076577c633490db40aa71614578a1e_D20210901-20210930"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwODY_b372c107-265b-44c3-9a3c-1387a478e4ab">P2Y</moh:HealthPlanExtensionOptionPeriod>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwNTQ_6eaf0968-d22b-4166-97c2-872413da59d2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Molina Healthcare, Inc., and its subsidiaries. All significant inter-company balances and transactions have been eliminated in consolidation. Financial information related to subsidiaries acquired during any year is included only for periods subsequent to their acquisition. In the opinion of management, all adjustments considered necessary for a fair presentation of the results as of the date and for the periods presented have been included; such adjustments consist of normal recurring adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjQvZnJhZzo2ODk3OTZhOWU4Y2Y0OTBkOGQ5M2Y2YjQzZDcyZTkzNi90ZXh0cmVnaW9uOjY4OTc5NmE5ZThjZjQ5MGQ4ZDkzZjZiNDNkNzJlOTM2XzQwODQ_8f69c872-0086-4b63-a6f6-634f274d3de0">Use of EstimatesThe preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates.</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDI4_966c8a67-0ed9-4159-9fe0-0ce26659e4f1">Significant Accounting Policies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows. The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#x201c;AFS&#x201d;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#x2019; equity as other comprehensive income, net of applicable income taxes. Held-to-maturity (&#x201c;HTM&#x201d;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses arising from credit-related factors with respect to AFS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment policy requires that all of our investments have final maturities of less than 15 years, or less than 15 years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In general, our AFS securities are classified as current assets without regard to the securities&#x2019; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment. For comprehensive discussions of the fair value and classification of our investments, see Note&#160;5, &#x201c;Fair Value Measurements,&#x201d; and Note&#160;6, &#x201c;Investments.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued interest receivable relating to our AFS and HTM securities is presented within &#x201c;Prepaid expenses and other current assets&#x201d; in the accompanying consolidated balance sheets, and amounted to $35 million and $11 million at December 31, 2022, and 2021, respectively. We do not measure an allowance for credit losses on accrued interest receivable. Instead, we write off accrued interest receivable that has not been collected within 90 days of the interest payment due date. We recognize such write offs as a reversal of investment income. No accrued interest was written off during the year ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for business combinations using the acquisition method of accounting, which requires us to recognize the assets acquired and the liabilities assumed at their acquisition date fair values. As discussed below, the excess of the purchase consideration transferred over the fair value of the net tangible and intangible assets acquired is recorded as goodwill. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated results of operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The purchase price for the acquisition of certain assets of Passport Health Plan, Inc. in 2020 included contingent consideration payable to seller relating to guarantees for minimum operating income in the post-acquisition period in 2020 and minimum membership targets in 2021. The liabilities are recorded at fair value on a recurring basis, which totaled $8 million as of December 31, 2022. For the amounts paid in the year ended December 31, 2022, $20&#160;million has been presented in &#x201c;Financing activities&#x201d; in the accompanying consolidated statements of cash flows, with the balance reflected in &#x201c;Operating activities.&#x201d; We paid the remaining balance of the liabilities, reported in &#x201c;Accounts payable, accrued liabilities and other&#x201d; in the accompanying consolidated balance sheets, in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 4, &#x201c;Business Combinations,&#x201d; and Note 9, &#x201c;Goodwill and Intangible Assets, Net,&#x201d; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets, including Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, &#x201c;Property, Equipment, and Capitalized Software, Net&#x201d;), and intangible assets resulting from acquisitions. Long-lived assets are subject to impairment tests when events or circumstances indicate that the asset&#x2019;s (or asset group&#x2019;s) carrying value may not be recoverable. Refer to the discussion in &#x201c;Leases&#x201d; below for impairment charges related to leasehold improvements and other property and equipment associated with the reduction in leased space used in our business operations. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3Nzg_99b8badb-97fb-4a1c-8779-f7186aae231d"&gt;five&lt;/span&gt; and 16 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining the fair value of separately identifiable intangible assets requires management to make estimates, which are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Determining the useful life of an intangible asset also requires judgment, as different types of intangible assets will have different useful lives. The most significant intangible asset we typically record in a business combination is contract rights associated with membership assumed. In determining the estimated fair value of the intangible assets, we typically apply the income approach, which discounts the projected future net cash flows using an appropriate discount rate that reflects the risk associated with such projected future cash flows. The most critical assumptions used in determining the fair value of contract rights include forecasted operating margins and the weighted average cost of capital.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset&#x2019;s (or asset group&#x2019;s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment. Refer to Note 9, &#x201c;Goodwill and Intangible Assets, Net,&#x201d; for further details.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase consideration over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Impairment indicators may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of our reporting units exceed their estimated fair values. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. We performed a qualitative goodwill assessment of our reporting units, and did not identify any factors indicating that the carrying value of our reporting units exceeded their estimated fair values. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows. The base year in the reporting units&#x2019; discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly-traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units&#x2019; fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use (&#x201c;ROU&#x201d;) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fourth quarter of 2022, we recognized $192&#160;million of ROU asset impairments in connection with the reduction in leased space to accommodate our move to a remote work environment, including vacating and abandonment of various leased properties. We assessed the ROU assets for impairment as a result of the reduction in leased space used in our business operations, and we engaged a third-party real estate specialist to determine the recoverability of the leased properties, based on estimated fair values. The valuation primarily considered comparable leased properties in each market and the assessment of actual and potential future rental income generated by the ROU assets. For further information, including the amount and location of the ROU assets and lease liabilities recognized in the accompanying consolidated balance sheets, see Note 8, &#x201c;Leases.&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also recognized $16&#160;million in impairment charges related to leasehold improvements and other property and equipment associated with the reduction in leased space used in our business operations. Please refer to Note 7, &#x201c;Property, Equipment, and Capitalized Software, Net&#x201d; for further discussion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Claims and Benefits Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (&#x201c;IBNP&#x201d;). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the period in which the adjustments are determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 10, &#x201c;Medical Claims and Benefits Payable,&#x201d; for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Amounts Due Government Agencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates, including certain components of premium revenue that are subject to accounting estimates and are described below, under &#x201c;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#x201d; and &#x201c;Quality Incentives.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions. Liabilities accrued for premiums to be returned under such provisions are reported in the aggregate as &#x201c;Amounts due government agencies&#x201d; in the accompanying consolidated balance sheets. Categorized by program, such amounts due government agencies included the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR, corridors, and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other premium adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other premium adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other premium adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Medical Cost Corridors. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs as a percentage of premium revenue, or minimum medical loss ratio (&#x201c;Minimum MLR&#x201d;). Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#x2019; fiscal years in 2019. We have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable. For the year ended December 31, 2022, we recognized approximately $197&#160;million related to such risk corridors, primarily in the Medicaid segment, compared to $323&#160;million recognized in the year ended December 31, 2021.The decrease in 2022 is due to the elimination of most of the COVID-19 risk corridors. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit Sharing. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium revenues on a retroactive basis for rate changes and changes in membership and eligibility data. In certain states, adjustments are made based on the health status of our members (as measured through a risk score). In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#x2019; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#x2019; health status, risk scores and CMS practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Affordable Care Act (&#x201c;ACA&#x201d;) established a Minimum MLR of 85% for Medicare. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income. As of December&#160;31, 2022, Marketplace risk adjustment payables amounted to $230 million and related receivables amounted to $135 million, for a net payable of $95 million. As of December 31, 2021, Marketplace risk adjustment payables amounted to $902 million and related receivables amounted to $7 million, for a net payable of $895 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Quality Incentives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. Recognition of quality incentive premium revenue is subject to the use of estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reinsurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We bear underwriting and reserving risks associated with our health plan subsidiaries. In certain cases, we limit our risk of significant catastrophic losses by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#x201c;third-party reinsurer&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because we remain liable for losses in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#x2019;s financial condition, including its ability to maintain high credit ratings. Intercompany transactions with our captive are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs. In certain cases, we participate in state-run reinsurance programs for which no reinsurance premium is paid. Reinsurance premiums amounted to $2 million, $2 million, and $9 million for the years ended December&#160;31, 2022, 2021, and 2020, respectively. Reinsurance recoveries amounted to $35 million, $33 million, and $23 million for the years ended December 31, 2022, 2021, and 2020, respectively. Reinsurance recoverable of $27 million, $51 million, and $30 million, as of December 31, 2022, 2021, and 2020, respectively, is included in &#x201c;Receivables&#x201d; in the accompanying consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Deficiency Reserves on Loss Contracts&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We assess the profitability of our contracts to determine if it is probable that a loss will be incurred in the future by reviewing current results and forecasts. For purposes of this assessment, contracts are grouped in a manner consistent with our method of acquiring, servicing and measuring the profitability of such contracts. A premium deficiency reserve (&#x201c;PDR&#x201d;) is recognized if anticipated future medical care and administrative costs exceed anticipated future premium revenue, investment income and reinsurance recoveries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized. For further discussion and disclosure, see Note 12, &#x201c;Income Taxes.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Taxes Based on Premiums&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Health Insurer Fee (&#x201c;HIF&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Affordable Care Act, the federal government imposed an annual fee, or excise tax, on health insurers for each calendar year (the &#x201c;HIF&#x201d;). The Further Consolidated Appropriations Act, 2020 repealed the HIF effective for years after 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Premium and Use Tax. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain of our health plans are assessed a tax based on premium revenue collected. The premium revenues we receive from these states include reimbursement for the premium tax assessment. We have reported these taxes on a gross basis, as premium tax revenue and as premium tax expenses in the consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in healthcare practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate health plans primarily as a direct contractor with the states, and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a relatively small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive the majority of our revenues under contracts or subcontracts with state Medicaid managed care programs, which are considered individual external customers. Instances where these contracts were at least 10% of our total premium revenue for the year ended December 31, 2022 were New York with 10.0%, Texas with 12.0% and Washington with 13.6%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTEw_fdf7275b-3493-4f7b-8b4e-8561db4dd038">Cash and Cash EquivalentsCash and cash equivalents consist of cash and short-term, highly liquid investments that are both readily convertible into known amounts of cash and have a maturity of three months or less on the date of purchase. The following table provides a reconciliation of cash, cash equivalents, and restricted cash and cash equivalents reported within the accompanying consolidated balance sheets that sum to the total of the same such amounts presented in the accompanying consolidated statements of cash flows.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDAx_f0ea0e2e-e9eb-4580-b0bb-698bf8bd578a">The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets. &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDIx_b309cf23-af51-47ca-975b-44ed4180b825">The restricted cash and cash equivalents presented below are included in &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets. &lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.835%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.869%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:27pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,223&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzQtMS0xLTEtNjg3NjY_58fcda56-92df-43a9-b8e4-89412a1f774c"
      unitRef="usd">4006000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzQtMy0xLTEtNjg3NjY_aed9434a-b8d6-4011-a045-211e790ef211"
      unitRef="usd">4438000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzQtNS0xLTEtNjg3NjY_7b695711-5422-47f0-b3b4-ca7f214f8fbf"
      unitRef="usd">4154000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzUtMS0xLTEtNjg3NjY_204b050f-ebc9-4be6-affc-0af9cbd926ad"
      unitRef="usd">42000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzUtMy0xLTEtNjg3NjY_67c12b9f-0f78-49a0-8bd7-d280ef71939d"
      unitRef="usd">68000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzUtNS0xLTEtNjg3NjY_81393f82-46b2-4175-a21d-c6b965c64c94"
      unitRef="usd">69000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzYtMS0xLTEtNjg3NjY_197ec672-2920-41fe-8a14-77dd4cf8850c"
      unitRef="usd">4048000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzYtMy0xLTEtNjg3NjY_270fc3e0-d3a0-4edd-b669-e3cbd4ffbd83"
      unitRef="usd">4506000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTo3NDhkNDQ5MDA5ZDc0NDE3ODU1M2I4ODFkZjhhN2ZjOS90YWJsZXJhbmdlOjc0OGQ0NDkwMDlkNzQ0MTc4NTUzYjg4MWRmOGE3ZmM5XzYtNS0xLTEtNjg3NjY_6b6a4b81-a4e1-42ae-bd86-fbe451931777"
      unitRef="usd">4223000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTEx_6c094b85-65c4-4681-87a2-5c89a33dc1be">&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments are principally held in debt securities, which are grouped into two separate categories for accounting and reporting purposes: available-for-sale securities, and held-to-maturity securities. Available-for-sale (&#x201c;AFS&#x201d;) securities are recorded at fair value and unrealized gains and losses, if any, are recorded in stockholders&#x2019; equity as other comprehensive income, net of applicable income taxes. Held-to-maturity (&#x201c;HTM&#x201d;) securities are recorded at amortized cost, which approximates fair value, and unrealized holding gains or losses are not generally recognized. Realized gains and losses and unrealized losses arising from credit-related factors with respect to AFS &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and HTM securities are included in the determination of net income. The cost of securities sold is determined using the specific-identification method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investment policy requires that all of our investments have final maturities of less than 15 years, or less than 15 years average life for structured securities. Investments and restricted investments are subject to interest rate risk and will decrease in value if market rates increase. Declines in interest rates over time will reduce our investment income.&lt;/span&gt;&lt;/div&gt;In general, our AFS securities are classified as current assets without regard to the securities&#x2019; contractual maturity dates because they may be readily liquidated. We monitor our investments for credit-related impairment.</us-gaap:InvestmentPolicyTextBlock>
    <moh:InvestmentsMaturityPeriod
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzE2Mzc_88f3fda5-745d-48bb-a168-1c701578e830">P15Y</moh:InvestmentsMaturityPeriod>
    <moh:InvestmentsAverageMaturityPeriod
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzE2NjA_68e11dab-7d0e-498f-a624-1d396c7a4cd2">P15Y</moh:InvestmentsAverageMaturityPeriod>
    <us-gaap:InterestReceivable
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NDU_ae89e370-76bc-4219-81e0-ad3963881dac"
      unitRef="usd">35000000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NTI_79992818-3e8e-48af-ad7c-a555b552a45e"
      unitRef="usd">11000000</us-gaap:InterestReceivable>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDI5_c00e4d2d-0068-4500-9ca6-b920b84e9d44">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Receivables&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Receivables consist primarily of premium amounts due from government agencies, which are subject to potential retroactive adjustments. Because substantially all of our receivable amounts are readily determinable and substantially all of our creditors are governmental authorities, our allowance for credit losses is insignificant. Any amounts determined to be uncollectible are charged to expense when such determination is made.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTcw_2b7493bc-e1b4-43fe-9b06-b9f9d2a37aa9">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.694%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,702&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy rebate receivables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total receivables&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i5986c52b45c34430a4e46e84fd09578e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzQtMS0xLTEtNjg3NjY_b5ef705a-b68c-4f2b-8bb1-a58f4e268587"
      unitRef="usd">1702000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i4e1b19ab0d1440b7bfda152e607a2ac4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzQtMy0xLTEtNjg3NjY_0d893443-9500-4578-a891-2b1e596e25d0"
      unitRef="usd">1566000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i1ac7e7cce7c7488f856cfee3ee520a77_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzUtMS0xLTEtNjg3NjY_94953fa1-6026-496f-950e-09a4b0931afd"
      unitRef="usd">291000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i95f4006db8de462884c07a9ec0cebfd1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzUtMy0xLTEtNjg3NjY_3db4f214-c3cd-4339-abd7-426a8a957061"
      unitRef="usd">276000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i283a40999d534f9f8762d3200d2894ff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzctMS0xLTEtNjg3NjY_5dfc46c7-2a46-4478-8b65-bcac11f1867b"
      unitRef="usd">309000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i72c7bccfd8ca4bf18d2185d8ddf074de_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzctMy0xLTEtNjg3NjY_d7269126-f03e-469a-ac56-06c820f92e98"
      unitRef="usd">335000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzgtMS0xLTEtNjg3NjY_a0797a69-169d-496e-8839-9e7bf2c054e1"
      unitRef="usd">2302000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTozMmM1ZTY0NDExMTM0N2NiOTQ2MjQ4YzhjMzk2NWQ3MS90YWJsZXJhbmdlOjMyYzVlNjQ0MTExMzQ3Y2I5NDYyNDhjOGMzOTY1ZDcxXzgtMy0xLTEtNjg3NjY_eb393800-f335-4504-bf7a-c63ae86fc536"
      unitRef="usd">2177000000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTQ2_5a612965-703e-4436-bfb6-fd2e2c54fe46">Business CombinationsWe account for business combinations using the acquisition method of accounting, which requires us to recognize the assets acquired and the liabilities assumed at their acquisition date fair values. As discussed below, the excess of the purchase consideration transferred over the fair value of the net tangible and intangible assets acquired is recorded as goodwill. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date, our estimates are inherently uncertain and subject to refinement. As a result, during the measurement period, which may be up to one year from the acquisition date, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill. Measurement period adjustments are recorded in the period in which they are determined, as if they had been completed at the acquisition date. Upon the conclusion of the final determination of the values of assets acquired or liabilities assumed, or one year after the date of acquisition, whichever comes first, any subsequent adjustments are recorded within our consolidated results of operations.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i386078af04c247fa901c709fe93c58dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzQ2ODI_beae4cf5-278c-4504-93c4-df5672ba22e1"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzc2OTY1ODE0MzQ5Njk_d746f52e-66ba-4ba4-bbf2-e264b91b2706"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTY2_c4bd7a78-d133-4528-880c-bdae6ab30533">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets, including Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets consist primarily of property, equipment, capitalized software (see Note 7, &#x201c;Property, Equipment, and Capitalized Software, Net&#x201d;), and intangible assets resulting from acquisitions. Long-lived assets are subject to impairment tests when events or circumstances indicate that the asset&#x2019;s (or asset group&#x2019;s) carrying value may not be recoverable. Refer to the discussion in &#x201c;Leases&#x201d; below for impairment charges related to leasehold improvements and other property and equipment associated with the reduction in leased space used in our business operations. Finite-lived, separately-identified intangible assets acquired in business combinations are assets that represent future expected benefits but lack physical substance (such as purchased contract rights and provider contracts). Intangible assets are initially recorded at fair value and are then amortized on a straight-line basis over their expected useful lives, generally between &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3Nzg_99b8badb-97fb-4a1c-8779-f7186aae231d"&gt;five&lt;/span&gt; and 16 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Determining the fair value of separately identifiable intangible assets requires management to make estimates, which are based on all available information and in some cases assumptions with respect to the timing and amount of future revenues and expenses associated with an asset. Determining the useful life of an intangible asset also requires judgment, as different types of intangible assets will have different useful lives. The most significant intangible asset we typically record in a business combination is contract rights associated with membership assumed. In determining the estimated fair value of the intangible assets, we typically apply the income approach, which discounts the projected future net cash flows using an appropriate discount rate that reflects the risk associated with such projected future cash flows. The most critical assumptions used in determining the fair value of contract rights include forecasted operating margins and the weighted average cost of capital.&lt;/span&gt;&lt;/div&gt;Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Software developed for internal use is capitalized. Property and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM1OA_a83fded9-5651-4fc9-bbd0-f88b865ee371"&gt;three&lt;/span&gt; to seven years. Software is generally amortized over its estimated useful life of three years. Leasehold improvements are amortized over the term of the lease, or over their useful lives from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzUzNQ_5c091379-9c3b-4ddb-b0f8-72f24ac68c1e"&gt;five&lt;/span&gt; to 10 years, whichever is shorter. Buildings are depreciated over their estimated useful lives of 31.5 to 40&#160;years.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1a3656d06a5b43eaa3ec5dfdecceaac7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzU3ODU_ad375fb2-1f0b-41e4-8ceb-01e5db429e74">P16Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDEx_afaf5599-3990-492d-bcd0-168506442a7d">Our intangible assets are subject to impairment tests when events or circumstances indicate that a finite-lived intangible asset&#x2019;s (or asset group&#x2019;s) carrying value may not be recoverable. Consideration is given to a number of potential impairment indicators, including the ability of our health plan subsidiaries to obtain the renewal by amendment of their contracts in each state prior to the actual expiration of their contracts. However, there can be no assurance that these contracts will continue to be renewed. Following the identification of any potential impairment indicators, to determine whether an impairment exists, we would compare the carrying amount of a finite-lived intangible asset with the greater of the undiscounted cash flows that are expected to result from the use of the asset or related group of assets, or its value under the asset liquidation method. If it is determined that the carrying amount of the asset is not recoverable, the amount by which the carrying value exceeds the estimated fair value is recorded as an impairment.</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTYw_2a8b6e95-ffec-4cc1-9a7e-e581b2ec6af5">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill represents the excess of the purchase consideration over the fair value of net assets acquired in business combinations. Goodwill is not amortized but is tested for impairment on an annual basis and more frequently if impairment indicators are present. Impairment indicators may include experienced or expected operating cash-flow deterioration or losses, significant losses of membership, loss of state funding, loss of state contracts, and other factors. Goodwill is impaired if the carrying amount of the reporting unit exceeds its estimated fair value. This excess is recorded as an impairment loss and adjusted if necessary for the impact of tax-deductible goodwill. The loss recognized may not exceed the total goodwill allocated to the reporting unit. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When testing goodwill for impairment, we may first assess qualitative factors, such as industry and market factors, the dynamic economic and political environments in which we operate, cost factors, and changes in overall performance, to determine if it is more likely than not that the carrying value of our reporting units exceed their estimated fair values. If our qualitative assessment indicates that it is more likely than not that the carrying value of a reporting unit exceeds its estimated fair value, we perform the quantitative assessment. We may also elect to bypass the qualitative assessment and proceed directly to the quantitative assessment. We performed a qualitative goodwill assessment of our reporting units, and did not identify any factors indicating that the carrying value of our reporting units exceeded their estimated fair values. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If performing a quantitative assessment, we generally estimate the fair values of our reporting units by applying the income approach, using discounted cash flows. The base year in the reporting units&#x2019; discounted cash flows is derived from the annual financial planning cycle, which commences in the fourth quarter of the year. As part of a quantitative assessment, we may also apply the asset liquidation method to estimate the fair value of individual reporting units, which is computed as total assets minus total liabilities, excluding intangible assets and deferred taxes. Finally, we apply a market approach to reconcile the value of our reporting units to our consolidated market value. Under the market approach, we consider publicly-traded comparable company information to determine revenue and earnings multiples which are used to estimate our reporting units&#x2019; fair values. The assumptions used are consistent with those used in our long-range business plan and annual planning process. However, if these assumptions differ from actual results, the outcome of our goodwill impairment tests could be adversely affected.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTI0_8ebcdcd1-46c2-454d-85bd-75f84db4492e">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Right-of-use (&#x201c;ROU&#x201d;) assets represent our right to use the underlying assets over the lease term, and lease liabilities represent our obligation for lease payments arising from the related leases. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. Lease terms may include options to extend or terminate the lease when we believe it is reasonably certain that we will exercise such options. If applicable, we account for lease and non-lease components within a lease as a single lease component.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because most of our leases do not provide an implicit interest rate, we generally use our incremental borrowing rate to determine the present value of lease payments. Lease expenses for operating lease payments are recognized on a straight-line basis over the lease term, and the related ROU assets and liabilities are reduced to the present value of the remaining lease payments at the end of each period. Finance lease payments reduce finance lease liabilities, the related ROU assets are amortized on a straight-line basis over the lease term, and interest expense is recognized using the effective interest method.&lt;/span&gt;&lt;/div&gt;The significant majority of our operating leases consist of long-term operating leases for office space. Short-term leases (those with terms of 12 months or less) are not recorded as ROU assets or liabilities in the consolidated balance sheets. For certain leases that represent a portfolio of similar assets, such as a fleet of vehicles, we apply a portfolio approach to account for the related ROU assets and liabilities, rather than account for such assets and the related liabilities individually. A nominal number of our lease agreements include rental payments that adjust periodically for inflation. Our lease agreements do not contain any material residual value guarantees or material restrictive covenants.</us-gaap:LesseeLeasesPolicyTextBlock>
    <moh:OperatingAndFinanceLeaseImpairmentLoss
      contextRef="i01aae92c76f5467c8edb776a572ee453_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk1OTA_8154da02-1e90-45a4-b7db-6fa576c67b1c"
      unitRef="usd">192000000</moh:OperatingAndFinanceLeaseImpairmentLoss>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i3f1d77f589974a46b23eddba5474dc63_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk1Nzc_1b2ba620-fda3-4f8f-9443-4ca38197dd6c"
      unitRef="usd">16000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTE0_c89ddfe2-c210-484e-b8e1-183ed8467d35">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Medical Claims and Benefits Payable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical care costs are recognized in the period in which services are provided and include fee-for-service claims, pharmacy benefits, capitation payments to providers, and various other medically-related costs. Under fee-for-service claims arrangements with providers, we retain the financial responsibility for medical care provided and incur costs based on actual utilization of hospital and physician services. Such medical care costs include amounts paid by us as well as estimated medical claims and benefits payable for costs that were incurred but not paid as of the reporting date (&#x201c;IBNP&#x201d;). Pharmacy benefits represent payments for members' prescription drug costs, net of rebates from drug manufacturers. We estimate pharmacy rebates based on historical and current utilization of prescription drugs and contractual provisions. Capitation payments represent monthly contractual fees paid to providers, who are responsible for providing medical care to members, which could include medical or ancillary costs like dental, vision and other supplemental health benefits. Such capitation costs are fixed in advance of the periods covered and are not subject to significant accounting estimates. Other medical care costs include all medically-related administrative costs, amounts due to providers pursuant to risk-sharing or other incentive arrangements, provider claims, and other healthcare expenses. Examples of medically-related administrative costs include expenses relating to health education, quality assurance, case management, care coordination, disease management, and 24-hour on-call nurses. Additionally, we include an estimate for the cost of settling claims incurred through the reporting date in our medical claims and benefits payable liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Medical claims and benefits payable consist mainly of fee-for-service IBNP, unpaid pharmacy claims, capitation costs, other medical costs, including amounts payable to providers pursuant to risk-sharing or other incentive arrangements and amounts payable to providers on behalf of certain state agencies for certain state assessments in which we assume no financial risk&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IBNP includes the costs of claims incurred as of the balance sheet date which have been reported to us, and our best estimate of the cost of claims incurred but not yet reported to us. We also include an additional reserve to ensure that our overall IBNP liability is sufficient under moderately adverse &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;conditions. We reflect changes in these estimates in the consolidated results of operations in the period in which they are determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimation of the IBNP liability requires a significant degree of judgment in applying actuarial methods, determining the appropriate assumptions and considering numerous factors. Of those factors, we consider estimated completion factors and the assumed healthcare cost trend to be the most critical assumptions. Other relevant factors also include, but are not limited to, healthcare service utilization trends, claim inventory levels, changes in membership, product mix, seasonality, benefit changes or changes in Medicaid fee schedules, provider contract changes, prior authorizations and the incidence of catastrophic or pandemic cases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because of the significant degree of judgment involved in estimation of our IBNP liability, there is considerable variability and uncertainty inherent in such estimates. Each reporting period, the recognized IBNP liability represents our best estimate of the total amount of unpaid claims incurred as of the balance sheet date using a consistent methodology in estimating our IBNP liability. We believe our current estimates are reasonable and adequate; however, the development of our estimate is a continuous process that we monitor and update as more complete claims payment information and healthcare cost trend data becomes available. Actual medical care costs may be less than we previously estimated (favorable development) or more than we previously estimated (unfavorable development), and any differences could be material. Any adjustments to reflect favorable development would be recognized as a decrease to medical care costs, and any adjustments to reflect unfavorable development would be recognized as an increase to medical care costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in the period in which the adjustments are determined. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to Note 10, &#x201c;Medical Claims and Benefits Payable,&#x201d; for a table presenting the components of the change in our medical claims and benefits payable, for all periods presented in the accompanying consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Premium Revenue Recognition and Amounts Due Government Agencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Premium revenue is generated from our contracts with state and federal agencies, in connection with our participation in the Medicaid, Medicare, and Marketplace programs. Premium revenue is generally received based on per member per month (&#x201c;PMPM&#x201d;) rates established in advance of the periods covered. These premium revenues are recognized in the month that members are entitled to receive healthcare services, and premiums collected in advance are deferred. State Medicaid programs and the federal Medicare program periodically adjust premium rates, including certain components of premium revenue that are subject to accounting estimates and are described below, under &#x201c;Contractual Provisions That May Adjust or Limit Revenue or Profit,&#x201d; and &#x201c;Quality Incentives.&#x201d;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contractual Provisions That May Adjust or Limit Revenue or Profit&lt;/span&gt;&lt;/div&gt;Many of our contracts contain provisions that may adjust or limit revenue or profit, as described below. Consequently, we recognize premium revenue as it is earned under such provisions.&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicaid Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR and Medical Cost Corridors. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A portion of our premium revenue may be returned if certain minimum amounts are not spent on defined medical care costs as a percentage of premium revenue, or minimum medical loss ratio (&#x201c;Minimum MLR&#x201d;). Under certain medical cost corridor provisions, the health plans may receive additional premiums if amounts spent on medical care costs exceed a defined maximum threshold.&lt;/span&gt;&lt;/div&gt;Beginning in 2020, various states enacted temporary risk corridors in response to the reduced demand for medical services stemming from COVID-19, which have resulted in a reduction of our medical margin. In some cases, these risk corridors were retroactive to earlier periods in 2020, or as early as the beginning of the states&#x2019; fiscal years in 2019. We have recognized risk corridors that we believe to be probable, and where the ultimate premium amount is reasonably estimable.&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;It is possible that certain states could change the structure of existing risk corridors, implement new risk corridors in the future or discontinue existing risk corridors. Due to these uncertainties, the ultimate outcomes could differ materially from our estimates as a result of changes in facts or further developments, which could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit Sharing. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our contracts with certain states contain profit sharing provisions under which we refund amounts to the states if our health plans generate profit above a certain specified percentage. In some cases, we are limited in the amount of administrative costs that we may deduct in calculating the refund, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Premium Adjustments. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;State Medicaid programs periodically adjust premium revenues on a retroactive basis for rate changes and changes in membership and eligibility data. In certain states, adjustments are made based on the health status of our members (as measured through a risk score). In these cases, we adjust our premium revenue in the period in which we determine that the adjustment is probable and reasonably estimable, based on our best estimate of the ultimate premium we expect to realize for the period being adjusted. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Medicare Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk Adjustment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Our Medicare premiums are subject to retroactive increase or decrease based on the health status of our Medicare members (as measured by member risk score). We estimate our members&#x2019; risk scores and the related amount of Medicare revenue that will ultimately be realized for the periods presented based on our knowledge of our members&#x2019; health status, risk scores and CMS practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Affordable Care Act (&#x201c;ACA&#x201d;) established a Minimum MLR of 85% for Medicare. Federal regulations define what constitutes medical costs and premium revenue. If the Minimum MLR is not met, we may be required to pay rebates to the federal government. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Marketplace Program&lt;/span&gt;&lt;/div&gt;Risk Adjustment. Under this program, our health plans&#x2019; composite risk scores are compared with the overall average risk score for the relevant state and market pool. Generally, our health plans will make a risk adjustment payment into the pool if their composite risk scores are below the average risk score (risk adjustment payable), and will receive a risk adjustment payment from the pool if their composite risk scores are above the average risk score (risk adjustment receivable). We estimate our ultimate premium based on insurance policy year-to-date experience, and recognize estimated premiums relating to the risk adjustment program as an adjustment to premium revenue in our consolidated statements of income.&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Minimum MLR.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The ACA established a Minimum MLR of 80% for the Marketplace. If the Minimum MLR is not met, we may be required to pay rebates to our Marketplace policyholders. The Marketplace risk adjustment program is taken into consideration when computing the Minimum MLR. We recognize estimated rebates under the Minimum MLR as an adjustment to premium revenue in our consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Quality Incentives&lt;/span&gt;&lt;/div&gt;At many of our health plans, revenue ranging from approximately 1% to 4% of certain health plan premiums is earned only if certain performance measures are met. Such performance measures are generally found in our Medicaid and MMP contracts. Recognition of quality incentive premium revenue is subject to the use of estimates.</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ReservesReportedToOtherAgenciesTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDMw_71b3dc3a-8d81-4519-aa04-f8eb1cf862a1">Categorized by program, such amounts due government agencies included the following:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.204%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR, corridors, and profit sharing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other premium adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;482&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;263&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment and Part D risk sharing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR and profit sharing &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other premium adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace program:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk adjustment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Minimum MLR&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other premium adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total amounts due government agencies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,079&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ReservesReportedToOtherAgenciesTextBlock>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzUtMS0xLTEtNjg3NjY_ff0c02cc-4713-4bca-984c-b08591c40294"
      unitRef="usd">1145000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzUtMy0xLTEtNjg3NjY_5c2e93b3-3895-41a5-b650-12f743be3bd9"
      unitRef="usd">1016000000</moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzYtMS0xLTEtNjg3NjY_6c536c22-8b39-40c9-882a-22b4bd4cda1f"
      unitRef="usd">482000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesMedicaidOther
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzYtMy0xLTEtNjg3NjY_e8d66f43-0377-446b-8eef-de14ccea346c"
      unitRef="usd">263000000</moh:AmountsDueToGovernmentAgenciesMedicaidOther>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzgtMS0xLTEtNjg3NjY_5b4c025f-5055-47f4-afe3-f4b80ac4a344"
      unitRef="usd">76000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzgtMy0xLTEtNjg3NjY_73886576-bcba-43bc-babd-d28b37d6c577"
      unitRef="usd">89000000</moh:AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzktMS0xLTEtNjg3NjY_91a638a5-2e20-46f7-b7dd-247c7bece16a"
      unitRef="usd">84000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzktMy0xLTEtNjg3NjY_7daf7630-5409-476c-978c-e36ab83969b5"
      unitRef="usd">101000000</moh:AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold>
    <moh:OtherMedicareProgram
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEwLTEtMS0xLTY4NzY2_4d635a2c-31fc-4423-b004-3e0c171dedd1"
      unitRef="usd">27000000</moh:OtherMedicareProgram>
    <moh:OtherMedicareProgram
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEwLTMtMS0xLTY4NzY2_4ab650a8-dccc-479c-ae97-55c491e6c621"
      unitRef="usd">35000000</moh:OtherMedicareProgram>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEyLTEtMS0xLTY4NzY2_83a35e36-dccf-4447-a91f-a8ceeba483d9"
      unitRef="usd">230000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDuetoGovernmentAgenciesRiskAdjustment
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEyLTMtMS0xLTY4NzY2_4d8bba47-9814-43bb-ae87-ca22353cd6f7"
      unitRef="usd">902000000</moh:AmountsDuetoGovernmentAgenciesRiskAdjustment>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEzLTEtMS0xLTY4NzY2_5c92308a-ca47-48b5-be82-e3e7cbc18cf1"
      unitRef="usd">2000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzEzLTMtMS0xLTY4NzY2_dfa91086-2811-4cde-8c67-7e9479b8a775"
      unitRef="usd">18000000</moh:AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzE0LTEtMS0xLTY4NzY2_7ac5a4fb-a1d7-4691-aded-55e13ad56c54"
      unitRef="usd">33000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:AmountsDuetoGovernmentAgenciesOther
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzE0LTMtMS0xLTY4NzY2_f8ed344b-dbee-40e8-89f9-9f65f88e4e60"
      unitRef="usd">48000000</moh:AmountsDuetoGovernmentAgenciesOther>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzE2LTEtMS0xLTY4NzY2_f2866935-d855-41ef-a699-d2255739cf9a"
      unitRef="usd">2079000000</moh:MedicalPremiumLiabilityDueToAgency>
    <moh:MedicalPremiumLiabilityDueToAgency
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90YWJsZTpmN2NjNzYzZDhkNTU0NWYzOTVlZTY2Mjg0NzVjYTk0Yi90YWJsZXJhbmdlOmY3Y2M3NjNkOGQ1NTQ1ZjM5NWVlNjYyODQ3NWNhOTRiXzE2LTMtMS0xLTY4NzY2_284fe3b9-78f7-4c23-a776-7d8593f3809a"
      unitRef="usd">2472000000</moh:MedicalPremiumLiabilityDueToAgency>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="i04d52aa82e834517bbc667b377f4ad2c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIwMzQ0_5077317d-a114-4202-8d0a-485e3582ec46"
      unitRef="usd">-197000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <us-gaap:IncreaseDecreaseInPremiumsReceivable
      contextRef="i2133a1cf36b14bcf8da5c42ae85115a7_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzc2OTY1ODE0MzQ5ODI_4f8af1e3-f282-405b-8489-15f6d1946a42"
      unitRef="usd">-323000000</us-gaap:IncreaseDecreaseInPremiumsReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyNzc1_2fdbee9e-7407-44eb-8fc5-756e69dae2a0"
      unitRef="usd">230000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyODE0_d2523038-4272-4314-a3a2-b14b1b455d11"
      unitRef="usd">135000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyODM5_78466b7b-5dcf-4393-8aed-8f2699ca9dd2"
      unitRef="usd">95000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyOTE1_67c0e1ec-a192-4596-9678-e64e8b1da77c"
      unitRef="usd">902000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyOTU0_7222c048-a8b7-4368-945e-5d9269a2930c"
      unitRef="usd">7000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable>
    <moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIyOTc5_22db1ff6-2901-4a32-9047-d9d400205ba9"
      unitRef="usd">895000000</moh:AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable>
    <moh:PercentageOfAdditionalIncrementalRevenueEarned
      contextRef="i5d0d8ea348c241a4b9f809ef2b12dfa2_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIzNDc0_6bf5c7ef-13dc-4543-8403-01cd89e262cd"
      unitRef="number">0.01</moh:PercentageOfAdditionalIncrementalRevenueEarned>
    <moh:PercentageOfAdditionalIncrementalRevenueEarned
      contextRef="i7eaace7d309845f986541d1f02db8612_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzIzNDgw_a7a2b2f1-f0d0-4ed7-a0e6-1cc701fa5d12"
      unitRef="number">0.04</moh:PercentageOfAdditionalIncrementalRevenueEarned>
    <us-gaap:ReinsuranceAccountingPolicy
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDUz_b37b063f-835c-45a7-a1ec-3331316be163">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Reinsurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We bear underwriting and reserving risks associated with our health plan subsidiaries. In certain cases, we limit our risk of significant catastrophic losses by maintaining high deductible reinsurance coverage with a highly-rated, unaffiliated insurance company (the &#x201c;third-party reinsurer&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Because we remain liable for losses in the event the third-party reinsurer is unable to pay its portion of the losses, we continually monitor the third-party reinsurer&#x2019;s financial condition, including its ability to maintain high credit ratings. Intercompany transactions with our captive are eliminated in consolidation.&lt;/span&gt;&lt;/div&gt;We report reinsurance premiums as a reduction to premium revenue, while related reinsurance recoveries are reported as a reduction to medical care costs.</us-gaap:ReinsuranceAccountingPolicy>
    <us-gaap:PrepaidReinsurancePremiums
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NTUy_cc398590-61e7-4b4e-b891-ac1cefa359f9"
      unitRef="usd">2000000</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:PrepaidReinsurancePremiums
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NTU2_da2ed8d6-bc9c-4638-a474-5fd537015437"
      unitRef="usd">2000000</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:PrepaidReinsurancePremiums
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NTY0_01fbff26-2bd7-4e09-b29b-9e48d8dbfea2"
      unitRef="usd">9000000</us-gaap:PrepaidReinsurancePremiums>
    <us-gaap:InsuranceRecoveries
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NjY1_330ddf5a-da45-4da7-9079-6219eac9317b"
      unitRef="usd">35000000</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0NjY5_bf51a17f-e645-4862-a582-f16f15989573"
      unitRef="usd">33000000</us-gaap:InsuranceRecoveries>
    <us-gaap:InsuranceRecoveries
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0Njc3_e8766a8e-de8f-472a-b51e-2b024c934a5e"
      unitRef="usd">23000000</us-gaap:InsuranceRecoveries>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0Nzcw_79108872-82b1-4076-a651-a407d4b17a83"
      unitRef="usd">27000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0Nzc0_d09f9922-3c73-4724-82b2-771aaf1fc495"
      unitRef="usd">51000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI0Nzgy_25129166-0cbc-48d1-9b03-36614a112e54"
      unitRef="usd">30000000</us-gaap:ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDQ1_233450d7-af80-40d2-a5fe-da8dbcdbfab1">Income TaxesWe account for income taxes under the asset and liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates expected to be in effect during the year in which the basis differences reverse. Valuation allowances are established when management determines it is more likely than not that some portion, or all, of the deferred tax assets will not be realized.</us-gaap:IncomeTaxPolicyTextBlock>
    <moh:TaxesBasedOnPremiumsPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDE3_e58f4a13-7c3e-4e57-b368-3ceb5320bd75">Taxes Based on PremiumsHealth Insurer Fee (&#x201c;HIF&#x201d;). Under the Affordable Care Act, the federal government imposed an annual fee, or excise tax, on health insurers for each calendar year (the &#x201c;HIF&#x201d;).</moh:TaxesBasedOnPremiumsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTU4_88785eb1-818d-4e5b-9efd-c133d7594798">Concentrations of Credit RiskFinancial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, investments, receivables, and restricted investments. Our investments and a portion of our cash equivalents are managed by professional portfolio managers operating under documented investment guidelines. Our portfolio managers must obtain our prior approval before selling investments where the loss position of those investments exceeds certain levels. Our investments consist primarily of investment-grade debt securities with final maturities of less than 15 years, or less than 15 years average life for structured securities. Restricted investments are invested principally in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. Concentration of credit risk with respect to accounts receivable is limited because our payors consist principally of the federal government, and governments of each state in which our health plan subsidiaries operate.</us-gaap:ConcentrationRiskCreditRisk>
    <moh:InvestmentsMaturityPeriod
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI3MzE1_88f3fda5-745d-48bb-a168-1c701578e830">P15Y</moh:InvestmentsMaturityPeriod>
    <moh:InvestmentsAverageMaturityPeriod
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI3MzIw_68e11dab-7d0e-498f-a624-1d396c7a4cd2">P15Y</moh:InvestmentsAverageMaturityPeriod>
    <moh:RisksAndUncertaintiesPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTE5_20b34364-d94b-4cb4-aceb-6c5a6127da27">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our profitability depends in large part on our ability to accurately predict and effectively manage medical care costs. We continually review our medical costs in light of our underlying claims experience and revised actuarial data. However, several factors could adversely affect medical care costs. These factors, which include changes in healthcare practices, inflation, new technologies, major epidemics, natural disasters, and malpractice litigation, are beyond our control and may have an adverse effect on our ability to accurately predict and effectively control medical care costs. Costs in excess of those anticipated could have a material adverse effect on our financial condition, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;We operate health plans primarily as a direct contractor with the states, and in Los Angeles County, California, as a subcontractor to another health plan holding a direct contract with the state. We are therefore dependent upon a relatively small number of contracts to support our revenue. The loss of any one of those contracts could have a material adverse effect on our financial position, results of operations, or cash flows. In addition, our ability to arrange for the provision of medical services to our members is dependent upon our ability to develop and maintain adequate provider networks. Our inability to develop or maintain such networks might, in certain circumstances, have a material adverse effect on our financial position, results of operations, or cash flows.</moh:RisksAndUncertaintiesPolicyTextBlock>
    <moh:SummarizedPremiumRevenueTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzMwMDAw_b8748863-7928-4ee0-8327-0f4e93a74d27">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive the majority of our revenues under contracts or subcontracts with state Medicaid managed care programs, which are considered individual external customers. Instances where these contracts were at least 10% of our total premium revenue for the year ended December 31, 2022 were New York with 10.0%, Texas with 12.0% and Washington with 13.6%.&lt;/span&gt;&lt;/div&gt;</moh:SummarizedPremiumRevenueTableTextBlock>
    <moh:HealthCareOrganizationRevenuePercentage
      contextRef="i889ea50e28bb4eed8c94a76a4a8d2cfb_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk2MDQ_06642c12-8bc9-4c90-b5a9-439b349c4727"
      unitRef="number">0.100</moh:HealthCareOrganizationRevenuePercentage>
    <moh:HealthCareOrganizationRevenuePercentage
      contextRef="ic15c81fc6ee74eb7b1b3e900ac2e9c64_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk2MTg_a319fd4d-f003-40d3-a1ba-e9421cda968a"
      unitRef="number">0.120</moh:HealthCareOrganizationRevenuePercentage>
    <moh:HealthCareOrganizationRevenuePercentage
      contextRef="ida4424c349994a84985daff56e365e13_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzcxNDY4MjU2Mjk2MTE_3965eb56-6704-4dbb-9fb2-b47097b82483"
      unitRef="number">0.136</moh:HealthCareOrganizationRevenuePercentage>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMjcvZnJhZzo0MzQ3MmNlOTY3NGE0M2M2YTZmMjE2ZjQyMDkzMTk4Yy90ZXh0cmVnaW9uOjQzNDcyY2U5Njc0YTQzYzZhNmYyMTZmNDIwOTMxOThjXzI5OTY5_001e943c-f918-4f02-b8da-4c43b4033a15">&lt;div style="margin-bottom:5pt;margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force), the American Institute of Certified Public Accountants, and the Securities and Exchange Commission (&#x201c;SEC&#x201d;) did not have, nor does management expect such pronouncements to have, a significant impact on our present or future consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90ZXh0cmVnaW9uOjFlMjQ2MmE0MjBlYTQ4MmI5NGYzZDlmZjMwNzRkZjFiXzQ4Mg_2fe16245-a852-4998-9e25-f71f43120fe0">Net Income Per Share &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of basic and diluted net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income per share because to do so would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90ZXh0cmVnaW9uOjFlMjQ2MmE0MjBlYTQ4MmI5NGYzZDlmZjMwNzRkZjFiXzQ2Nw_291e1a8b-488d-4946-ac02-8d148db1493a">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the calculation of basic and diluted net income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except net income per share)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Shares outstanding at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares issued:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock purchases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for basic net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Denominator for diluted net income per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Basic &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income per share - Diluted &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;_______________________________&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;The dilutive effect of all potentially dilutive common shares is calculated using the treasury stock method. Certain potentially dilutive common shares issuable are not included in the computation of diluted net income per share because to do so would have been anti-dilutive.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Source data for calculations in thousands.</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzUtMS0xLTEtNjg3NjY_36fb960c-7e8e-4410-b6f7-bb700a3ed2b6"
      unitRef="usd">792000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzUtMy0xLTEtNjg3NjY_018ef386-2554-4c11-9662-fe3610f60208"
      unitRef="usd">659000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzUtNS0xLTEtNjg3NjY_feeda5ae-7665-4b12-8353-45d14d7120a1"
      unitRef="usd">673000000</us-gaap:NetIncomeLoss>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzctMS0xLTEtNjg3NjY_e4ed94bf-9555-418a-b8ef-a2b3f142b210"
      unitRef="shares">57900000</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzctMy0xLTEtNjg3NjY_59a2d9f2-a52a-4af8-81b9-394ce3ecb5a2"
      unitRef="shares">58000000.0</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <moh:SharesOutstandingExcludingRestrictedStockAwards
      contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzctNS0xLTEtNjg3NjY_11536b63-ed2a-4fdf-b83f-5c276ff3fded"
      unitRef="shares">61900000</moh:SharesOutstandingExcludingRestrictedStockAwards>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzktMS0xLTEtNjg3NjY_042c0bae-188c-4b91-aa64-ac7de14b8b36"
      unitRef="shares">500000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzktMy0xLTEtNjg3NjY_d3f9fd77-b0a6-4c8c-85ce-203c99bef62e"
      unitRef="shares">500000</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzktNS0xLTEtNjg3NjY_e068576b-adcb-420b-9241-12b9d84104c6"
      unitRef="shares">3000000.0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEwLTEtMS0xLTY4NzY2_75e18257-9ae3-434c-b1cf-0a1ce203113e"
      unitRef="shares">400000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEwLTMtMS0xLTY4NzY2_be7316be-ad44-4a19-917e-f6e5b1e02ad6"
      unitRef="shares">300000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <moh:WeightedAverageNumberofSharesShareBasedCompensation
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEwLTUtMS0xLTY4NzY2_7a5878b3-ef03-4a2d-889b-67cd66f6bcb4"
      unitRef="shares">100000</moh:WeightedAverageNumberofSharesShareBasedCompensation>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzExLTEtMS0xLTY4NzY2_dc010192-2678-4622-9e9a-dc89a2cbe732"
      unitRef="shares">57800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzExLTMtMS0xLTY4NzY2_208178b9-e8af-492e-b8bf-920f28c92b16"
      unitRef="shares">57800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzExLTUtMS0xLTY4NzY2_6c934db8-ab9d-438f-9bf4-a9f298aa27c5"
      unitRef="shares">59000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEzLTEtMS0xLTY4NzY2_d8380370-578b-43b2-b0b0-32355e5d1373"
      unitRef="shares">700000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEzLTMtMS0xLTY4NzY2_4c635d47-49e9-42a8-9ea0-a3af65b24507"
      unitRef="shares">800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzEzLTUtMS0xLTY4NzY2_b0f9633d-7f4a-45b6-9d93-4b91862359d9"
      unitRef="shares">900000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE1LTEtMS0xLTY4NzY2_7fa0e84c-41c1-4cf0-8327-d8591396e1f5"
      unitRef="shares">58500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE1LTMtMS0xLTY4NzY2_1808d1eb-a3ba-4901-acdc-af9cd9108cf1"
      unitRef="shares">58600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE1LTUtMS0xLTY4NzY2_76965e98-d7ee-4a33-9af0-8c5de8479d3a"
      unitRef="shares">59900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE3LTEtMS0xLTY4NzY2_38f6a358-42b3-4b0c-b8fc-fb2df8aad76b"
      unitRef="usdPerShare">13.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE3LTMtMS0xLTY4NzY2_8d635d5c-616b-4ce4-8b53-2dcd0f8aa908"
      unitRef="usdPerShare">11.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE3LTUtMS0xLTY4NzY2_b447e99c-a55b-4374-8c69-97a3e8ce412e"
      unitRef="usdPerShare">11.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE4LTEtMS0xLTY4NzY2_8b3dd3bc-63e2-4ebb-a2be-7965193140b1"
      unitRef="usdPerShare">13.55</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE4LTMtMS0xLTY4NzY2_6c3d75f5-751c-488f-a56a-b24de006f2e2"
      unitRef="usdPerShare">11.25</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzAvZnJhZzoxZTI0NjJhNDIwZWE0ODJiOTRmM2Q5ZmYzMDc0ZGYxYi90YWJsZTpjODkzMDY5NjExZmE0NDI1ODlkNDQ5Nzk1NDIyZDc2ZS90YWJsZXJhbmdlOmM4OTMwNjk2MTFmYTQ0MjU4OWQ0NDk3OTU0MjJkNzZlXzE4LTUtMS0xLTY4NzY2_be245a35-eaba-47fa-b4ea-5b49aacd28f3"
      unitRef="usdPerShare">11.23</us-gaap:EarningsPerShareDiluted>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzI1MzI_977563dc-6f90-4b3f-a14d-8550b30f2bbc">Business Combinations &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, we closed on two business combinations primarily in the Medicaid segment, consistent with our growth strategy. For these transactions, we applied the acquisition method of accounting, where the total purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed, based on their fair values as of the acquisition date. The proforma effects of these acquisitions for prior periods were not material to our consolidated results of operations. Costs to complete acquisitions amounted to $2 million in the aggregate for the year ended December 31, 2022, and were recorded as &#x201c;General and administrative expenses&#x201d; in the accompanying consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;AgeWell. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 1, 2022, we closed on our acquisition of the Medicaid Managed Long Term Care business of AgeWell New York for purchase consideration of approximately $134&#160;million. We acquired membership and a provider network with a fair value of approximately $47 million. We allocated the remaining $87 million of purchase consideration to goodwill, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership. The goodwill is deductible for income tax purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Cigna.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On January 1, 2022, we closed on our acquisition of Cigna Corporation&#x2019;s Texas Medicaid and Medicare-Medicaid Plan contracts, along with certain operating assets, for purchase consideration of approximately $60&#160;million. Because the closing date fell on a holiday, the purchase price was paid on December 31, 2021 and was recorded to prepaid expenses and other assets. We acquired membership and a provider network with a fair value of approximately $35&#160;million. We allocated the remaining $25&#160;million of purchase consideration to goodwill, primarily in the Medicaid segment, which relates to future economic benefits arising from expected synergies from the use of our existing infrastructure to support the added membership, and from the assembled workforce. The goodwill is deductible for income tax purposes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents intangible assets acquired, by major class, for the AgeWell and Cigna acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract rights - member list&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provider network&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Affinity. On October 25, 2021, we closed on our acquisition of substantially all of the assets of Affinity Health Plan, Inc., a Medicaid health plan in New York, for purchase consideration of approximately $176&#160;million. In the year ended December 31, 2022, we recorded various measurement period adjustments, including an increase of $12&#160;million to &#x201c;Medical claims and benefits payable,&#x201d; and an increase of $4&#160;million to &#x201c;Amounts due government agencies&#x201d; net of &#x201c;Receivables.&#x201d; In the aggregate, we recorded a net increase of $21&#160;million to goodwill for these measurement period adjustments and various purchase price adjustments, which have been finalized as of December 31, 2022.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <moh:BusinessCombinationNumberOfBusinessCombinations
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzMz_bc15aa2f-8e76-446d-938a-67e7e149de1a"
      unitRef="combination">2</moh:BusinessCombinationNumberOfBusinessCombinations>
    <us-gaap:AcquisitionCosts
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzg1Mg_4d133def-2cd0-40a8-816e-468735f58b96"
      unitRef="usd">2000000</us-gaap:AcquisitionCosts>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="id9fa89e4cd2b4b9e91fa9ccde542996c_D20221001-20221001"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzA2MTI_89159501-f0a9-4bc0-b1b3-acabc5b32bb0"
      unitRef="usd">134000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="i634b4c45a645473796839899d286be1f_D20221001-20221001"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzc2OTY1ODEzOTc3MTY_1807f219-7dc4-491c-a700-f4dd44f4f61d"
      unitRef="usd">47000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="id9fa89e4cd2b4b9e91fa9ccde542996c_D20221001-20221001"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzc2OTY1ODEzOTc3MTc_8db49608-8437-4c58-a5c3-36e2144d3322"
      unitRef="usd">87000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i61710d4352384e94a9ce3f422ff24847_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzNzI_8dd1e80f-bf70-4b2d-904a-75c7ba33b5b1"
      unitRef="usd">60000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="id1c23ba3104a41408eac767b2e726ada_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzODU_ad2f986f-33b9-4301-a22d-a00222076586"
      unitRef="usd">35000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i61710d4352384e94a9ce3f422ff24847_D20220101-20220101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzOTg_275ba32a-a47a-431a-a714-074861a2a2ee"
      unitRef="usd">25000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzI1MzM_d0e7906a-e185-4017-b56f-d89928e2898b">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents intangible assets acquired, by major class, for the AgeWell and Cigna acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:4.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.623%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Life&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract rights - member list&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provider network&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.7&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ibebb703fd4a9457dbfd3f97701ae04f3_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzMtMS0xLTEtNjg3NjY_2332bd48-71e0-48bd-953f-39a331533b87"
      unitRef="usd">81000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0385a25993b0446c89a46930f0f91bde_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzMtMy0xLTEtNjg3NjY_0d3e7fe6-d921-4ec1-a18e-e148cde4781b">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="id5c65081a30c46cf8460d6a803e1f17a_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzMtNS0xLTEtNzMzODE_656d14bc-6fd8-4bdc-b6ee-a5eb1b1ab320">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1f9337e55d484c09b5a1513d389ccf3b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzMtNy0xLTEtNzMyNjk_bed72d57-b9df-48b8-bcf0-682a45d31ae7">P3Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="ide3af300aa304f619ca228fba2ff8fa4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzQtMS0xLTEtNjg3NjY_398f879f-87d2-4837-9acb-338e3f9464d7"
      unitRef="usd">1000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i29148aa5c5964b8f8d10939beb34fe33_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzQtMy0xLTEtNjg3NjY_10e35f05-429a-4c21-8b08-fce2032d4aa6">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4d53aea5bdb946b5b111b4810dc4fa29_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzQtNS0xLTEtNzMzODE_48ca7791-585a-45c9-aa90-4ae3fbf9eea8">P5Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i1c870ec0a4794f988790a6078f3f01f9_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzQtNy0xLTEtNzMyOTQ_cdfe5fb9-0aab-427c-812b-5cf87e80b0cb">P4Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="idda4ab8b08044fecb8346dffcc274008_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzYtMS0xLTEtNjg3NjY_9a37df09-8b90-4a9e-9b07-df28993a36f7"
      unitRef="usd">82000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="i3c7feed041254360ad5d3019f6a744aa_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90YWJsZTo2YTExZmUyNDRhNzA0MjNkOTI5ODY3ZDE2ZmUzYTc3NC90YWJsZXJhbmdlOjZhMTFmZTI0NGE3MDQyM2Q5Mjk4NjdkMTZmZTNhNzc0XzUtNy0xLTEtNzMzMDI_e2b73595-8b1d-432e-9349-45f9e6833e4c">P3Y8M12D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i18ece6617d5c496d9258ce72e661253f_D20211025-20211025"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzMjI_c0a6cf50-20f9-4075-97f3-641ed43fef4e"
      unitRef="usd">176000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable
      contextRef="i2ac9097825cf45b8aee7acbbe22e2785_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzNjA_56689a3b-571a-4b0c-bcaf-3bf70938edd5"
      unitRef="usd">12000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable>
    <moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables
      contextRef="i2ac9097825cf45b8aee7acbbe22e2785_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzMzY_deba9a25-534a-4e61-87a4-2a3e22e91311"
      unitRef="usd">4000000</moh:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables>
    <us-gaap:GoodwillPurchaseAccountingAdjustments
      contextRef="i2ac9097825cf45b8aee7acbbe22e2785_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzMvZnJhZzpiZjlkNjUwYjM2MjE0NmFjYjUyOWU2OTUxMWYzZDg0YS90ZXh0cmVnaW9uOmJmOWQ2NTBiMzYyMTQ2YWNiNTI5ZTY5NTExZjNkODRhXzEwOTk1MTE2MzAzNDg_cb5c99c8-7578-4d0a-b399-a4ae6574592f"
      unitRef="usd">21000000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzI5OTI_74e64f4d-71db-4196-993e-fc05d42c6e8d">Fair Value Measurements &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to a three-tier fair value hierarchy as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Observable Inputs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 financial instruments are actively traded and therefore the fair value for these securities is based on quoted market prices for identical securities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Directly or Indirectly Observable Inputs. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value for these investments is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 3 &#x2014; Unobservable Inputs. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3 financial instruments are valued using unobservable inputs that represent management&#x2019;s best estimate of what market participants would use in pricing the financial instrument at the measurement date. As of December 31, 2022 and 2021, our Level 3 financial instruments consisted of contingent consideration liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net changes in fair value of Level 3 financial instruments are reported in &#x201c;Other&#x201d; operating expenses in our consolidated statements of income. In the years ended December 31, 2022 and 2021, we recognized a loss of $4&#160;million and $24&#160;million, respectively, primarily for the increase in the fair value of the contingent consideration liability described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Level 3 Contingent Consideration Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Level 3 financial instruments at December 31, 2022 are comprised solely of contingent consideration liabilities of $8 million, in connection with our 2020 acquisition of certain assets of Passport Health Plan, Inc., a Medicaid health plan in Kentucky. Refer to Note 2, &#x201c;Significant Accounting Policies&#x2014;Business Combinations&#x201d;, for further details. Such liabilities are recorded at fair value on a recurring basis. In 2022, the estimated fair value of contingent purchase consideration increased by approximately $4&#160;million, relating to an operating income guarantee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the year ended December 31, 2022, we paid the seller $43&#160;million, of which $23&#160;million was for the remaining half of the consideration due for minimum member enrollment targets and $20&#160;million was for the first payment of the consideration due for the operating income guarantee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Fair Value Measurements &#x2013; Disclosure Only&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts and estimated fair values of our notes payable are classified as Level 2 financial instruments. Fair value for these securities is determined using a market approach based on quoted market prices for similar securities in active markets or quoted prices for identical securities in inactive markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzMwMTA_72fd5f70-3325-4a6b-a85b-e5a90f6da4f9">Fair Value Measurements &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider the carrying amounts of current assets and current liabilities to approximate their fair values because of the relatively short period of time between the origination of these instruments and their expected realization or payment. For our financial instruments measured at fair value on a recurring basis, we prioritize the inputs used in measuring fair value according to a three-tier fair value hierarchy as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 1 &#x2014; Observable Inputs.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1 financial instruments are actively traded and therefore the fair value for these securities is based on quoted market prices for identical securities in active markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Level 2 &#x2014; Directly or Indirectly Observable Inputs. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value for these investments is determined using a market approach based on quoted prices for similar securities in active markets or quoted prices for identical securities in inactive markets. &lt;/span&gt;&lt;/div&gt;Level 3 &#x2014; Unobservable Inputs. Level 3 financial instruments are valued using unobservable inputs that represent management&#x2019;s best estimate of what market participants would use in pricing the financial instrument at the measurement date. As of December 31, 2022 and 2021, our Level 3 financial instruments consisted of contingent consideration liabilities.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzE0Nzk_d71d74c6-a6b6-4365-8a32-45a52045dec5"
      unitRef="usd">-4000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzE0ODY_4fd6f735-1606-410e-88de-469ba13ae6f0"
      unitRef="usd">-24000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzMwMDQ_c7fe00bd-c7b1-450b-aa3f-fea088757c1c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our financial instruments measured at fair value on a recurring basis at December&#160;31, 2021, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.923%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.595%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.602%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzMtMS0xLTEtNjg3NjY_f472ce6f-5575-41b8-a95f-7cca8372aa00"
      unitRef="usd">2184000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9d8d5c0a352f4015825c1a2b0847caff_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzMtMy0xLTEtNjg3NjY_c6919f6a-d3c2-4d79-9127-6d33029e6144"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5816b9d063fd4d4f9679ec48c22e7f0a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzMtNS0xLTEtNjg3NjY_d74b32d1-24bf-4bd6-aeef-183f9c4f43ef"
      unitRef="usd">2184000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8a831368a2374281bb348964ee80005f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzMtNy0xLTEtNjg3NjY_53cc092a-7d09-42ef-87be-e16ff2b88c02"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7194e3bc65f34309acccfe5e8eebc910_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzQtMS0xLTEtNjg3NjY_824149c6-1d04-4ef1-98b0-14849b3b9acc"
      unitRef="usd">731000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2225551d260b4fff8b1fcd8b2225a4d5_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzQtMy0xLTEtNjg3NjY_e24444ec-752c-4c44-99ce-75b749ac8025"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1f5ae5c597454f189bef195ea3021a0e_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzQtNS0xLTEtNjg3NjY_4d144aee-0fc5-4fb0-86fc-7027dd471535"
      unitRef="usd">731000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i02199c67baf944d3a3c45249783e8405_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzQtNy0xLTEtNjg3NjY_0de06d7b-7360-4df4-a3cd-710a7aa2ea6c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzUtMS0xLTEtNjg3NjY_e9cecd7c-2246-4751-81fb-3349e43c47fb"
      unitRef="usd">288000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="if032025c0fb244a08e3b1ef2e3941040_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzUtMy0xLTEtNjg3NjY_dce27a2c-cebe-42b5-baf5-98fb27589455"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i86889d94e8904988ac5e365d286d4a7b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzUtNS0xLTEtNjg3NjY_8433367e-ee6b-4b33-a1b2-2e2168c38557"
      unitRef="usd">288000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i962ee0b812d44a069fd6c87304d4bc42_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzUtNy0xLTEtNjg3NjY_568282a7-dce1-4ebc-b0c9-397a7c303a4a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzYtMS0xLTEtNjg3NjY_84407169-4859-47a9-bfcb-1e6996cf03dd"
      unitRef="usd">149000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1bd8a5c0011b40b3bcaa8d6d87dd0520_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzYtMy0xLTEtNjg3NjY_345ecb85-592a-4753-a8c1-d4e63425058d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4ed1689dee4a41eda03bdc9c92c02453_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzYtNS0xLTEtNjg3NjY_1b59911d-0ef2-4269-aad8-fd66b23c2b8c"
      unitRef="usd">149000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic9e4ac3e01c944c0b4c5b9718ba2c91c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzYtNy0xLTEtNjg3NjY_1f0002a9-e578-4d1a-9a0f-0d88bf6013c7"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzctMS0xLTEtNjg3NjY_70941158-146f-4aad-98fe-777e31ff05e0"
      unitRef="usd">105000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib5fcc352ead24246b3f108ce7dd02772_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzctMy0xLTEtNjg3NjY_4fb5665d-546a-4236-b6f1-3b610767faf3"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib53a75ae39b14988836f4967971ce19b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzctNS0xLTEtNjg3NjY_e1e7cabf-b963-4f70-a727-ea4dbe0f1938"
      unitRef="usd">105000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie00e6ad84a254b709450ec9c3505658d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzctNy0xLTEtNjg3NjY_b24e21cc-ee64-4158-b1db-f2c880b07768"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEwLTEtMS0xLTY4NzY2_ead8c210-b76d-46b4-ae81-352a3cbcde03"
      unitRef="usd">42000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i2d1b7f1d31c442bfa81f382822fcd6b8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEwLTMtMS0xLTY4NzY2_bae6dfb3-a59f-48ce-a62f-9f3b5198d638"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="iba848d4237f8438e92d576eea416786f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEwLTUtMS0xLTY4NzY2_b7baadc9-a6cd-4d54-8f88-44022c4212e8"
      unitRef="usd">42000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ic804f30bbe1941a5bd3069bece3d95c1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEwLTctMS0xLTY4NzY2_fed85f49-4f42-49c9-a08c-dea7821960c5"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzExLTEtMS0xLTY4NzY2_4ce63c28-4317-41e8-b573-7a2e7b4dbec8"
      unitRef="usd">3499000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i9e5e68ad6d9c4c8ea513343c44695691_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzExLTMtMS0xLTY4NzY2_bd1628e3-03a3-420d-aed9-e5c460d1e983"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i3d9f57cf49eb4b3d93701dd1a0ade3fd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzExLTUtMS0xLTY4NzY2_b0df9849-ac29-4925-ac08-f73f6eb1a76b"
      unitRef="usd">3499000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i386078af04c247fa901c709fe93c58dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzExLTctMS0xLTY4NzY2_a58709eb-e634-4f0e-8c5f-1b9a421e173f"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEzLTEtMS0xLTY4NzY2_4b078208-eb53-4dc7-a4d7-f95f245f8afd"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9e5e68ad6d9c4c8ea513343c44695691_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEzLTMtMS0xLTY4NzY2_41c886dc-9018-4b30-960f-f17ae3154da2"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3d9f57cf49eb4b3d93701dd1a0ade3fd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEzLTUtMS0xLTY4NzY2_31c37662-25ae-42a2-b839-2c1ef83b3b86"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i386078af04c247fa901c709fe93c58dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzEzLTctMS0xLTY4NzY2_beae4cf5-278c-4504-93c4-df5672ba22e1"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzE0LTEtMS0xLTY4NzY2_76f1c96b-5af7-42c4-8bab-4d1c1bef8e35"
      unitRef="usd">8000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i9e5e68ad6d9c4c8ea513343c44695691_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzE0LTMtMS0xLTY4NzY2_0c8adb53-87a0-4e6f-ac71-9d1c7e358b4c"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i3d9f57cf49eb4b3d93701dd1a0ade3fd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzE0LTUtMS0xLTY4NzY2_5f6c04e2-8b9f-41f9-b785-7e2106928975"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i386078af04c247fa901c709fe93c58dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo5Y2VjMDZkMzNmNTg0ZjRhODg4ZDQ5NTI1MjBkY2FiMy90YWJsZXJhbmdlOjljZWMwNmQzM2Y1ODRmNGE4ODhkNDk1MjUyMGRjYWIzXzE0LTctMS0xLTY4NzY2_1b969e9f-70e9-4890-985b-7304faeb4d41"
      unitRef="usd">8000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzMtMS0xLTEtNjg3NjY_4a126fbd-bb81-4bc8-85cb-26fc6cc75d5a"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i1c35ad3ddab44e749e3b1e84bd0af3d1_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzMtMy0xLTEtNjg3NjY_37ba2713-6802-4b22-bb20-c05559395738"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i960d1aa66067454ba42f52aed1e487bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzMtNS0xLTEtNjg3NjY_f31b9931-d24b-4d98-b185-eccb2fe9cef9"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i0945f141b7f04212b9df4d20cbd510cc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzMtNy0xLTEtNjg3NjY_e25289a2-5d10-4de3-8c2c-5a57e1e538ca"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i30c11d9f4dee4390998e42cc33eb779e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzQtMS0xLTEtNjg3NjY_843bf2a9-79e7-4cb0-bcf0-4ce07cc8f436"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id8d46c859e204a6a80f2c36c08a46f8e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzQtMy0xLTEtNjg3NjY_cb2278b6-1594-4eb7-b232-5a94e7211716"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie4a239b8e14f435d944f2c1891cd59f4_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzQtNS0xLTEtNjg3NjY_861a7595-9d0e-4a9b-9fdc-5a0273cd37e7"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i59f46e8b96ab457584d0f833330e5f53_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzQtNy0xLTEtNjg3NjY_d6bdf682-9561-4551-91c4-927b8dd54a98"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzUtMS0xLTEtNjg3NjY_18b2e577-1a26-4ad6-9b9e-c202155bdba2"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i576bade46abf49a3a06593cc4f8c1b09_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzUtMy0xLTEtNjg3NjY_f4389e45-ca0b-4745-b276-c7ece2dc85b4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i63aa4f07c83c4604ab411ba61e492802_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzUtNS0xLTEtNjg3NjY_f2951d88-9722-47ce-9a50-dcfc382c545a"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i67dd714df638487ea61a28b66c207c9d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzUtNy0xLTEtNjg3NjY_cacc918a-dcc1-4a61-8504-d47a8ffd9650"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzYtMS0xLTEtNjg3NjY_b14da10f-83b9-4c33-bb6d-3f4a70e9b5d2"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i3697cd3591404f5ab704c339859f4118_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzYtMy0xLTEtNjg3NjY_c7939efd-0481-4005-be4b-f38ce58313c0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib12a73884b8842b28e11041aea7f7b00_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzYtNS0xLTEtNjg3NjY_94d75c98-b570-4b9c-971f-952fb683edc8"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="icaaa9d3cee0f4342b73d5a8600dde796_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzYtNy0xLTEtNjg3NjY_085cd1f4-8b6b-4c18-8a40-ff5a25e8bb1f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzctMS0xLTEtNjg3NjY_b9b9599e-a8b0-40b6-b9fc-8f037be2a780"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i4319bd7e084d4fe6bbe30097e8b6ea2a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzctMy0xLTEtNjg3NjY_a9497038-3511-42f9-9103-a6cf8aee8c7c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id9e1553afa264028b0cd457a33f5a149_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzctNS0xLTEtNjg3NjY_d34ea15e-b3b9-4a95-b23c-993d01b80fcd"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i8ab0ae951a4e4b62b8083cf3e819c96a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzctNy0xLTEtNjg3NjY_7f733110-cc66-4645-aaee-01e63f839e7a"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEwLTEtMS0xLTY4NzY2_5ffa7994-57a9-4844-a0e5-926ff94fc050"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7ada07a36a9546358030aaca313e8c59_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEwLTMtMS0xLTY4NzY2_7600a122-ec46-42ee-a1d1-5ca2a26cc844"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i5bb2d39305ab437ebcfcb31c936ff8e7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEwLTUtMS0xLTY4NzY2_0732f089-54ed-486b-ab2f-9eaa89a889fa"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7cba98a86a954f7e8b177f14d18360bd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEwLTctMS0xLTY4NzY2_26a81257-676c-4c0c-8a36-3b93626a2a06"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzExLTEtMS0xLTY4NzY2_62cb66d7-9f5e-4223-9d36-00a9df67a3bd"
      unitRef="usd">3202000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i8e93ce10aaba4d8b9c22ff0c09bacdc7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzExLTMtMS0xLTY4NzY2_4e484b95-f293-4eba-a8f9-1d26915b4933"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i14f045e80bf74bfdb5641b6aed955093_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzExLTUtMS0xLTY4NzY2_bd29cf44-e2dc-4ead-94a5-9435c2131d48"
      unitRef="usd">3202000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibbd8a7e880f542339bc89afd0861bdf2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzExLTctMS0xLTY4NzY2_5a1b0ff7-9730-4080-92db-99993d207d88"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEzLTEtMS0xLTY4NzY2_c757aba1-064e-47fc-ba5f-4f80dc3b2758"
      unitRef="usd">47000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8e93ce10aaba4d8b9c22ff0c09bacdc7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEzLTMtMS0xLTY4NzY2_aefe8a7c-ff92-40f2-a40b-f3f3250f2fbe"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i14f045e80bf74bfdb5641b6aed955093_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEzLTUtMS0xLTY4NzY2_8cb57571-b07c-4085-8f38-9755cfc1ba9f"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibbd8a7e880f542339bc89afd0861bdf2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzEzLTctMS0xLTY4NzY2_99faeea9-255a-4f76-a70f-44de8dd10c8b"
      unitRef="usd">47000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzE0LTEtMS0xLTY4NzY2_1e30a203-5104-4c53-9b3b-bbdc387261b0"
      unitRef="usd">47000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i8e93ce10aaba4d8b9c22ff0c09bacdc7_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzE0LTMtMS0xLTY4NzY2_26ad5ca4-b44c-4ed3-ba31-9240ffa377f6"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i14f045e80bf74bfdb5641b6aed955093_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzE0LTUtMS0xLTY4NzY2_ec89bd1f-cef7-4f5a-9c77-869dceddd19d"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ibbd8a7e880f542339bc89afd0861bdf2_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTplNGM1MzE2M2Q2ZTQ0NTI3YTMxNmI1NTUxOGYzNmI2OC90YWJsZXJhbmdlOmU0YzUzMTYzZDZlNDQ1MjdhMzE2YjU1NTE4ZjM2YjY4XzE0LTctMS0xLTY4NzY2_490f786f-3636-4a1f-9ffe-fce1155f2a17"
      unitRef="usd">47000000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i386078af04c247fa901c709fe93c58dd_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzE5NjU_beae4cf5-278c-4504-93c4-df5672ba22e1"
      unitRef="usd">8000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzIzMjQ_d71d74c6-a6b6-4365-8a32-45a52045dec5"
      unitRef="usd">-4000000</us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings>
    <moh:PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities
      contextRef="i7757357193c94ad298e824f0d0518470_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzc2OTY1ODEzOTg2NjI_db71f12d-b81b-49ac-813a-07105689eece"
      unitRef="usd">43000000</moh:PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities
      contextRef="i16c45403f97a4dfb89f109633839fb86_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzI0MDg_f08dc642-dbb4-483b-a640-98ae7251fdff"
      unitRef="usd">23000000</us-gaap:PaymentForContingentConsiderationLiabilityOperatingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i016cfea50f2e421f88790001362b8498_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzc2OTY1ODEzOTg2NzU_296ee8c0-9971-47a8-9567-708cf740eb3b"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90ZXh0cmVnaW9uOmY0YTQ5NGNmOGY0YTQ5MzA4NzI1MmZkZjY4ZGE5NTljXzMwMTY_0014d766-8ce3-4d01-b8ac-0c298901fcc9">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.779%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.632%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;729&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;643&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;675&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;741&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjo4ZTBkNjY3ODdlOTg0MjI2YjhlZTBlMzNiNGU1ZWZjMl80_a703ac38-9997-4647-a9bd-fc863bbebef9"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9cdbd3860d6c488798e272302d58dcf7_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtMS0xLTEtNjg3NjY_9998311e-77b0-467f-ab71-54fd4d238f11"
      unitRef="usd">792000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ib074c81f11e84dd0a6eb9b5acffd5118_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtMy0xLTEtNjg3NjY_4fb1c643-d7a4-460c-be4e-8be0926ee21f"
      unitRef="usd">729000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i9641bb00844a4cbb9f0155ed3c8b8bed_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtNS0xLTEtNjg3NjY_0a7bba35-9ba3-4f1b-9013-c9726e15ef10"
      unitRef="usd">791000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ieada9e735cbd4500babf6903ca597d7e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzQtNy0xLTEtNjg3NjY_a844f1c3-593a-4497-b359-f88bd60a5d05"
      unitRef="usd">829000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjo3ZDYyNDlhODA2MzQ0OTAxOGU5MGU5MzIyNzU4YzBlNF80_981093a5-53dc-4dd4-bee6-323c907b5574"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i4446a6c953714ca891cd94c12831bb57_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtMS0xLTEtNjg3NjY_67c5def8-cb55-4b75-8d01-3bdd12d00f11"
      unitRef="usd">643000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ia5acbc39836d44c0877b4659cfa91af9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtMy0xLTEtNjg3NjY_71b9e606-d649-4f7e-ab4e-52e44ac3b3bb"
      unitRef="usd">554000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i7548748313094c9dbe3ac25160bfe723_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtNS0xLTEtNjg3NjY_90406f69-eab3-460b-9b67-bc30647c613f"
      unitRef="usd">642000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i396dfc81f74a4ecfa6a338862899d231_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzUtNy0xLTEtNjg3NjY_591d9c4a-3395-42e1-84d1-e13917cce259"
      unitRef="usd">675000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjo4ZTA0ODQzNWZhYzQ0N2Y5YWNiYjJiNTA1MDI3OGVlN180_f0731975-5da3-49e5-a53d-eac52e0cb078"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i3a98f51b9a6349488555f9c9a14a3df0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtMS0xLTEtNjg3NjY_508a2981-34e0-4414-ad37-f8165c0f6ee1"
      unitRef="usd">741000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i597b3ae4dd8e4818b13a24f5c890394d_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtMy0xLTEtNjg3NjY_8d801c77-9065-4b86-8a5b-8a34bb2368df"
      unitRef="usd">629000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="icbc3bf6d7b6442e59a8c61f5a4fcd73f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtNS0xLTEtNjg3NjY_0f831fa6-8d56-4fa4-93ac-e6676ae135cd"
      unitRef="usd">740000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="ic2790faed091468abda4356c61276b5a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzYtNy0xLTEtNjg3NjY_4c108b47-2e92-469e-ad42-0ad52453dd48"
      unitRef="usd">760000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i88055e4dad2440acb86c85055d57ae20_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzctMS0xLTEtNjg3NjY_6a921429-5070-49c2-9cec-a010dd75dbd7"
      unitRef="usd">2176000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i48bac014b28a4af083ee0516405e8d5a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzctMy0xLTEtNjg3NjY_f4f901ac-9923-4eda-b8af-a5cf9bbf5387"
      unitRef="usd">1912000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i3dde019b6c3e473c978eda9b0c5c1d4a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzctNS0xLTEtNjg3NjY_4ce2791b-6250-439b-abe5-50b15b126c6c"
      unitRef="usd">2173000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i34ceb7d8e4e84d52bcad92498c815f6e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzYvZnJhZzpmNGE0OTRjZjhmNGE0OTMwODcyNTJmZGY2OGRhOTU5Yy90YWJsZTo3MjM5ODFmMDVmMTI0N2Y3YjVjOWIzOGE2ZGJkZmI1ZC90YWJsZXJhbmdlOjcyMzk4MWYwNWYxMjQ3ZjdiNWM5YjM4YTZkYmRmYjVkXzctNy0xLTEtNjg3NjY_dfddbf3a-aa9e-42ba-bf05-5396f35177a3"
      unitRef="usd">2264000000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzExNjM_b87f3203-170d-48e6-a5ac-5a4300a64e86">Investments &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Available-for-Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consider all of our investments classified as current assets to be available-for-sale. The following tables summarize our current investments as of the dates indicated:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our current investments as of December&#160;31, 2022 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gross realized gains and losses from sales of available-for-sale securities are calculated under the specific identification method and are included in investment income. Gross realized investment gains amounted $1 million, $10 million and $6&#160;million in the years ended December&#160;31, 2022, 2021 and 2020, respectively, and were reclassified into earnings from other comprehensive income on a net-of-tax basis. Gross realized investment losses amounted to $7 million in the year ended December&#160;31, 2022, and were reclassified into earnings from other comprehensive income on a net-of-tax basis. Gross realized investment losses were insignificant in the years ended December 31, 2021 and 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have determined that unrealized losses at December&#160;31, 2022 and 2021 primarily resulted from fluctuating interest rates, rather than a deterioration of the creditworthiness of the issuers. Therefore, we determined that an allowance for credit losses was not necessary. So long as we maintain the intent and ability to hold these securities to maturity, we are unlikely to experience realized losses. In the event that we dispose of these securities before maturity, we expect that realized losses, if any, will be insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;Less&#160;than&#160;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;12&#160;Months or More&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;Less&#160;than&#160;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;12&#160;Months or More&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Investments Held-to-Maturity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the regulations governing our state health plan subsidiaries, we maintain statutory deposits and deposits required by government authorities primarily in cash, cash equivalents, U.S. Treasury securities, and corporate debt securities. We also maintain restricted investments as protection against the insolvency of certain capitated providers. The use of these funds is limited as required by regulations in the various states in which we operate, or as needed in the event of insolvency of capitated providers. Therefore, such investments are reported as &#x201c;Restricted investments&#x201d; in the accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have the ability to hold these restricted investments until maturity, and as a result, we would not expect the value of these investments to decline significantly due to a sudden change in market interest rates. Our held-to-maturity restricted investments are carried at amortized cost, which approximates fair value, of which $193 million will mature in one year or less, $37 million will mature in one through five years, and $8 million will mature after five years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the balances of restricted investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzExODY_7c5c72e0-2a62-48fa-b7dd-8acfdcb7dff7">The following tables summarize our current investments as of the dates indicated:&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:21pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,833&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;353&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzUtMS0xLTEtNjg3NjY_4cb5f0a2-1c24-4c7c-9b2f-571cd347adfd"
      unitRef="usd">2303000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzUtMy0xLTEtNjg3NjY_61485221-62c3-4e59-b3d8-78dbfdca14d6"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzUtNS0xLTEtNjg3NjY_f9cc3a87-4bbf-4e85-bc88-2c41f5e92902"
      unitRef="usd">121000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzUtNy0xLTEtNjg3NjY_8b4c2bdd-945a-4edd-8110-f9fdf840f6f0"
      unitRef="usd">2184000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzYtMS0xLTEtNjg3NjY_5ea8f4c5-b7cd-4a8e-b2eb-6625e9fb3327"
      unitRef="usd">787000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzYtMy0xLTEtNjg3NjY_ccdaa0f3-9877-41d1-acbc-2999814a27dd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzYtNS0xLTEtNjg3NjY_01ea9aa6-5291-4d2c-9359-809f7a4de324"
      unitRef="usd">56000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzYtNy0xLTEtNjg3NjY_e4c61a5b-79d3-4001-8e19-22a80872d94a"
      unitRef="usd">731000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzctMS0xLTEtNjg3NjY_cf8cd2f5-8d3b-481a-8214-a947e3f2c79a"
      unitRef="usd">308000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzctMy0xLTEtNjg3NjY_b956c110-fafb-44b4-8bb9-99796a89e49d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzctNS0xLTEtNjg3NjY_f16e8c0d-9fb5-4039-ae0d-af58f1221cfb"
      unitRef="usd">20000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzctNy0xLTEtNjg3NjY_58f0a03d-2f6c-41ae-8b9d-e1029cc645b3"
      unitRef="usd">288000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzgtMS0xLTEtNjg3NjY_19772ea0-c986-4f9c-ae09-61150b9435a5"
      unitRef="usd">160000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzgtMy0xLTEtNjg3NjY_a6d9b8c7-36f8-4845-8364-126ed0078b88"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzgtNS0xLTEtNjg3NjY_ad38094e-237c-4323-a253-1a8fd24efdd2"
      unitRef="usd">11000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzgtNy0xLTEtNjg3NjY_31ea4776-00a4-45d5-878c-aaf94c2339a6"
      unitRef="usd">149000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzktMS0xLTEtNjg3NjY_3a76dfd1-2163-4df0-9e46-21f3f8acdbca"
      unitRef="usd">106000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzktMy0xLTEtNjg3NjY_d0794f0d-e1d0-4d05-97f7-9285f63de541"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzktNS0xLTEtNjg3NjY_41c6290d-5d19-4bdf-af45-876c92cf8e72"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzktNy0xLTEtNjg3NjY_639cf7e2-d5ac-4814-9a85-08be89c22b62"
      unitRef="usd">105000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEyLTEtMS0xLTY4NzY2_643aa208-0ce2-4825-86af-7b5c2b3b62ca"
      unitRef="usd">45000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEyLTMtMS0xLTY4NzY2_2499377c-fffe-4e32-af0b-a4113d7a9a98"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEyLTUtMS0xLTY4NzY2_f9e63ef7-f80d-4273-ae82-13b45a51cd44"
      unitRef="usd">3000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEyLTctMS0xLTY4NzY2_c3aa3732-e083-419d-bee3-8d0323fc6eae"
      unitRef="usd">42000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEzLTEtMS0xLTY4NzY2_ee85bec3-451f-4bfe-9734-ce9c9d623bb4"
      unitRef="usd">3709000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEzLTMtMS0xLTY4NzY2_aacc22d4-f237-4539-9d8b-eb532e03cda2"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEzLTUtMS0xLTY4NzY2_54e05762-981c-4078-950e-8173814fe46f"
      unitRef="usd">212000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTowNWE4MzBmOTVmNzU0NjM0OGE0YTgwNjg4MTE3MDJmNC90YWJsZXJhbmdlOjA1YTgzMGY5NWY3NTQ2MzQ4YTRhODA2ODgxMTcwMmY0XzEzLTctMS0xLTY4NzY2_37362c4b-3873-42eb-b678-8ec6b65d33b9"
      unitRef="usd">3499000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzUtMS0xLTEtNjg3NjY_d817ca45-71d1-47ac-b8df-da0da7679adf"
      unitRef="usd">1836000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzUtMy0xLTEtNjg3NjY_91e8a1db-1ad9-4422-94c3-993e1b76b9aa"
      unitRef="usd">9000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzUtNS0xLTEtNjg3NjY_a0b79f01-4827-46ae-a477-921c0e780e97"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzUtNy0xLTEtNjg3NjY_10900f18-65f3-4cff-ac6f-3b88a0fde5ce"
      unitRef="usd">1833000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzYtMS0xLTEtNjg3NjY_eb2d0558-9a59-43a4-89b0-46c31b54e312"
      unitRef="usd">616000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzYtMy0xLTEtNjg3NjY_96886863-56c2-4c6e-9f06-a2473b431c97"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzYtNS0xLTEtNjg3NjY_e0e225d8-1d23-4d1f-b61d-c86ded36fae7"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzYtNy0xLTEtNjg3NjY_69de191b-749e-4b8f-9eee-20d9314117f5"
      unitRef="usd">614000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzctMS0xLTEtNjg3NjY_976f558e-c82a-4793-bddf-4edd1356fdb9"
      unitRef="usd">248000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzctMy0xLTEtNjg3NjY_161cd061-0a5e-4979-89a8-674a3a118284"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzctNS0xLTEtNjg3NjY_991f8ea1-423f-4da1-9455-e3e6e0122ee9"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzctNy0xLTEtNjg3NjY_8e6eaa39-a5c9-4af8-ad1d-5ba72496d247"
      unitRef="usd">247000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzgtMS0xLTEtNjg3NjY_6a92fde4-aacd-4cbb-a552-fc8d3552b0fc"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzgtMy0xLTEtNjg3NjY_d95b1781-00ac-4fdf-9d36-cc46818dc2ec"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzgtNS0xLTEtNjg3NjY_3a24ed0e-5459-4601-9e5a-c5a14f410bd1"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzgtNy0xLTEtNjg3NjY_c71ac507-449d-4be2-8235-946d00be50c5"
      unitRef="usd">123000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzktMS0xLTEtNjg3NjY_8c2752dd-6c37-406d-a851-bb11024291c1"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzktMy0xLTEtNjg3NjY_e30c9ec3-cde8-4ca2-84c3-82098632cf8c"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzktNS0xLTEtNjg3NjY_7eece9ba-344a-4186-aa99-2b10b8ae9939"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzktNy0xLTEtNjg3NjY_77e6b6b0-382e-417e-926c-9adc93c2c6d5"
      unitRef="usd">353000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEyLTEtMS0xLTY4NzY2_1ebf822e-037d-4464-aa0d-e783ea9e3be2"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEyLTMtMS0xLTY4NzY2_39519103-698f-4efc-96b8-3cc13f3137e2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEyLTUtMS0xLTY4NzY2_ec4729a3-ab01-40c6-9ea8-8efc3f27451d"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i9677ef65e67d487cabd070ff51ef3d1c_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEyLTctMS0xLTY4NzY2_4f82bf6a-57fc-42e4-b724-9adcb42caa87"
      unitRef="usd">32000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEzLTEtMS0xLTY4NzY2_48135072-ea82-4872-9460-1d43e5c705be"
      unitRef="usd">3208000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEzLTMtMS0xLTY4NzY2_d223a980-8bcd-4131-a5d5-0796ef7025b4"
      unitRef="usd">12000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEzLTUtMS0xLTY4NzY2_338e631b-20bf-4d75-a27f-814f4b889e32"
      unitRef="usd">18000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTpmYTBkYmUzODc3ZTE0YjdhYTQ5ODVjNTgxMmU1MWE1OS90YWJsZXJhbmdlOmZhMGRiZTM4NzdlMTRiN2FhNDk4NWM1ODEyZTUxYTU5XzEzLTctMS0xLTY4NzY2_7aebb4b3-d305-434c-bf91-eb30ec51b5a2"
      unitRef="usd">3202000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzExNzg_4fc0d6a1-40dc-41f8-b500-7ec75744c248">&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of our current investments as of December&#160;31, 2022 are summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due after ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,709&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzMtMS0xLTEtNjg3NjY_d2ec794a-f17f-438e-b847-49166613c267"
      unitRef="usd">318000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzMtMy0xLTEtNjg3NjY_84e6a30c-d95c-4b88-9c55-0b8b7363079b"
      unitRef="usd">315000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzQtMS0xLTEtNjg3NjY_28c439d3-4e62-463e-868d-92897889f772"
      unitRef="usd">2249000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzQtMy0xLTEtNjg3NjY_bfb84064-96d5-400f-8964-67ecb3cfd837"
      unitRef="usd">2127000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzUtMS0xLTEtNjg3NjY_48ab26c3-8900-4fa8-858a-a566a8baf51b"
      unitRef="usd">364000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzUtMy0xLTEtNjg3NjY_0aae4796-444d-4d78-bee9-0736d2030130"
      unitRef="usd">345000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzYtMS0xLTEtNjg3NjY_848e957a-23f7-41f4-94b3-56993f351f2e"
      unitRef="usd">778000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzYtMy0xLTEtNjg3NjY_7accd511-3ef8-4b69-9627-5a89ad014cc1"
      unitRef="usd">712000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzctMS0xLTEtNjg3NjY_38066898-a958-455f-a683-6cb27d72415d"
      unitRef="usd">3709000000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90YWJsZTphMjYyN2I1MmVhMDA0MDNlYTgwODAyNWQ5ZDAwZTdjNC90YWJsZXJhbmdlOmEyNjI3YjUyZWEwMDQwM2VhODA4MDI1ZDlkMDBlN2M0XzctMy0xLTEtNjg3NjY_8e8d8315-f9df-4c9a-bbe6-414c4a25f009"
      unitRef="usd">3499000000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzUxMA_6da28897-cbc5-4560-a96c-350efe5555d5"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzUxNA_5e922cb4-7140-4abe-9d00-3592e98eea30"
      unitRef="usd">10000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzUyMQ_ffc33a47-7592-44b4-8e0b-c119e605aacc"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xMzkvZnJhZzo2NzkzNzc3OTNiMzU0ODEzYjEyNzU1ZWI4ODcyZmU2NS90ZXh0cmVnaW9uOjY3OTM3Nzc5M2IzNTQ4MTNiMTI3NTVlYjg4NzJmZTY1XzcxNDY4MjU1ODE4Nzg_6d7fa201-2757-4dc5-a2ab-ffaec76a92a0"
      unitRef="usd">7000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90ZXh0cmVnaW9uOjgxMzBkMmZlZGRlNTRmZGI4NGViMDI3YTM5YmFkOWE2XzcxNDY4MjU1ODEwMDY_04e3b8e3-9ee7-40e4-baf5-0fe4d8cfc07d">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.559%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.633%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;Less&#160;than&#160;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;12&#160;Months or More&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;371&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,858&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table segregates those available-for-sale investments that have been in a continuous loss position for less than 12 months, and those that have been in a continuous loss position for 12 months or more as of December&#160;31, 2021:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.744%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.647%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.651%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;Less&#160;than&#160;12&#160;Months&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;In&#160;a&#160;Continuous&#160;Loss Position&lt;br/&gt;for&#160;12&#160;Months or More&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total Number of Positions&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Mortgage-backed securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;408&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Asset-backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtMS0xLTEtNjg3NjY_5d19718f-496b-4e47-8ce8-e10076ab69fb"
      unitRef="usd">1124000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtMy0xLTEtNjg3NjY_dbccdbe1-ffb7-4899-935f-e1d08b91137a"
      unitRef="usd">45000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtNS0xLTEtNjg3NjY_90314169-7f63-4354-91ae-cec6858d83a7"
      unitRef="position">683</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtNy0xLTEtNjg3NjY_de3f94a3-073a-4b2e-8502-058e435c4224"
      unitRef="usd">887000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtOS0xLTEtNjg3NjY_c4079f6e-9f0d-4a5d-bb7c-c998d5ded283"
      unitRef="usd">76000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzMtMTEtMS0xLTY4NzY2_43227f18-b1e7-4da1-8058-927d8cf8236a"
      unitRef="position">371</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtMS0xLTEtNjg3NjY_e7bef40b-94aa-4e82-be04-83450de8b3ac"
      unitRef="usd">395000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtMy0xLTEtNjg3NjY_bd67eb8b-6645-411a-ba7b-058f6b02a5ec"
      unitRef="usd">20000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtNS0xLTEtNjg3NjY_84c20ee8-0f21-4d10-9065-50fc1aa67175"
      unitRef="position">220</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtNy0xLTEtNjg3NjY_dcd42163-9079-4544-8e67-d1201fd5e45b"
      unitRef="usd">319000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtOS0xLTEtNjg3NjY_e0263a51-77e5-414f-a010-bf92f5dd3665"
      unitRef="usd">36000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="id18ca73ccc5f4614a083a4e53496fb4b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzQtMTEtMS0xLTY4NzY2_729a3060-03bb-4214-bc9a-4a174400e8e7"
      unitRef="position">131</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtMS0xLTEtNjg3NjY_f1444d95-64ca-4da0-9f89-023b4848f20b"
      unitRef="usd">161000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtMy0xLTEtNjg3NjY_4c7badbe-bd2d-4c3f-9551-b1cd89955d3f"
      unitRef="usd">6000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtNS0xLTEtNjg3NjY_9c5c7b2c-f280-427f-b0d9-e68867eac934"
      unitRef="position">108</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtNy0xLTEtNjg3NjY_05801b7b-a136-4193-b78b-f862af7bd72a"
      unitRef="usd">118000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtOS0xLTEtNjg3NjY_c570ceb3-a42b-4efd-9be2-66204c94593b"
      unitRef="usd">14000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i349d4816275045dfaa89200a39cfc5ef_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzUtMTEtMS0xLTY4NzY2_009c10ff-b3cb-4bf6-b051-67d6921a48b9"
      unitRef="position">59</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtMS0xLTEtNjg3NjY_45297078-80e5-4383-bf1f-83d89ef503cd"
      unitRef="usd">75000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtMy0xLTEtNjg3NjY_da1f1edf-3d32-4300-978c-a94f9fd065a5"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtNS0xLTEtNjg3NjY_542452d4-cd40-4d70-aead-4ed4ed434413"
      unitRef="position">83</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtNy0xLTEtNjg3NjY_b5270ccd-2fb4-478b-a2ba-634fb9d5fd6e"
      unitRef="usd">57000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtOS0xLTEtNjg3NjY_4463376b-0fcc-4345-be41-463276b7b53a"
      unitRef="usd">7000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i7ca41013f9c540f28757acf9f49962e0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzYtMTEtMS0xLTY4NzY2_5b41c35c-4f76-4021-9a6d-a9025f46a8f5"
      unitRef="position">57</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctMS0xLTEtNjg3NjY_be09b7d4-2321-4b33-b8b1-b49aa4e61c44"
      unitRef="usd">88000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctMy0xLTEtNjg3NjY_f6957126-dc44-49dc-896f-e3131fa2d855"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctNS0xLTEtNjg3NjY_f1e9016d-5907-4936-bf26-b39acb51212e"
      unitRef="position">6</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctNy0xLTEtNjg3NjY_9f72f958-30f9-4a32-8753-696e18a7bac0"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctOS0xLTEtNjg3NjY_c9de1035-453f-41eb-addd-8d9539213fb4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzctMTEtMS0xLTY4NzY2_482ab9c2-b8c2-427d-ba7f-e6c6d6804732"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktMS0xLTEtNjg3NjY_611aeb1c-73e8-478f-be51-552280ca2913"
      unitRef="usd">15000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktMy0xLTEtNjg3NjY_b14a0f65-f102-4daf-9385-dea72fc76965"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktNS0xLTEtNjg3NjY_6e5f264e-07db-4fd7-bf95-53fed127c8f0"
      unitRef="position">16</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktNy0xLTEtNjg3NjY_14cb3f56-f9aa-47f7-83bc-21f2e88dd2eb"
      unitRef="usd">17000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktOS0xLTEtNjg3NjY_c3a4eae0-fbb3-4ad6-ae93-d8f141b30532"
      unitRef="usd">2000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i335b83f184544942bc8b176a2ac44633_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzktMTEtMS0xLTY4NzY2_9f05dd59-b074-4939-8bf5-db1e8d3955e6"
      unitRef="position">6</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTEtMS0xLTY4NzY2_8961fbea-e0fd-49ca-bfd9-7feebde41314"
      unitRef="usd">1858000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTMtMS0xLTY4NzY2_8327bf94-4d6a-42ed-911e-4c2b6141e408"
      unitRef="usd">77000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTUtMS0xLTY4NzY2_59bdb784-fc75-49ae-a5f5-81ce85b2867b"
      unitRef="position">1116</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTctMS0xLTY4NzY2_e418c64d-8ded-4604-8c10-65bcb56bfaf7"
      unitRef="usd">1398000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTktMS0xLTY4NzY2_3b4e82d6-79ed-4a0a-8ea2-90251ff2ffbf"
      unitRef="usd">135000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTphMWJjNmM2Yjc4NzE0YjZhOTViZjM2NzFhMDZiOGRmNS90YWJsZXJhbmdlOmExYmM2YzZiNzg3MTRiNmE5NWJmMzY3MWEwNmI4ZGY1XzExLTExLTEtMS02ODc2Ng_e66972cc-6389-4873-8821-ddf1622e2519"
      unitRef="position">624</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtMS0xLTEtNjg3NjY_bc32e996-06f9-4d57-b600-40bba8459b52"
      unitRef="usd">1063000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtMy0xLTEtNjg3NjY_5a5bd94d-316c-426f-aa7b-925c7b4e432a"
      unitRef="usd">12000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtNS0xLTEtNjg3NjY_7c6ed610-40a1-4c45-a62a-9be11f92f69c"
      unitRef="position">395</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtNy0xLTEtNjg3NjY_d3fbf8ee-c0db-4200-bddf-5c8bafe0de53"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtOS0xLTEtNjg3NjY_0dc1c806-8b85-4e09-abee-4902cc8b2272"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzMtMTEtMS0xLTY4NzY2_0a312766-c3d9-4c10-a947-8ae8ae9757f6"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtMS0xLTEtNjg3NjY_c36791fe-14b0-4971-af54-893e845d4b82"
      unitRef="usd">408000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtMy0xLTEtNjg3NjY_8eb10cfc-df9c-4d76-a283-150379c08945"
      unitRef="usd">4000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtNS0xLTEtNjg3NjY_7bed27bc-29ed-48e3-a2f6-9e52433f52eb"
      unitRef="position">146</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtNy0xLTEtNjg3NjY_c2eb8457-71dc-41b1-9937-0d3bb075dab9"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtOS0xLTEtNjg3NjY_c2954041-4897-4ee4-9d56-5271f0f2069f"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ia9b5c6207fdc407187736e67b43692ac_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzQtMTEtMS0xLTY4NzY2_c5a4d314-8152-4e73-b0b5-4177cef68dce"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtMS0xLTEtNjg3NjY_2ab742e9-9ecd-459f-b359-a319bd8b3dca"
      unitRef="usd">166000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtMy0xLTEtNjg3NjY_55b05180-77b9-43c4-b38d-2a9a149fd007"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtNS0xLTEtNjg3NjY_b006919e-d7f2-407a-883b-0c5cb6f0792d"
      unitRef="position">75</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtNy0xLTEtNjg3NjY_ab66ad60-4ce8-4e12-9012-1fd91b2c2511"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtOS0xLTEtNjg3NjY_48101fad-c3e9-4c7c-8199-d3e89469dd0d"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="ib5fbf8d01f1444d6b4a0bd117325d158_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzUtMTEtMS0xLTY4NzY2_3a4b1f41-f81e-47cc-aa93-1cc323f09957"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctMS0xLTEtNjg3NjY_166e7eb8-41d0-44cd-b212-b7b6acb57e73"
      unitRef="usd">69000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctMy0xLTEtNjg3NjY_1e11acec-e793-4c5c-b035-0509db18c7a1"
      unitRef="usd">1000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctNS0xLTEtNjg3NjY_f0f0b83b-8c94-466b-b10b-f74add386f24"
      unitRef="position">61</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctNy0xLTEtNjg3NjY_63307357-5296-4cce-97eb-61ff55d6eec6"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctOS0xLTEtNjg3NjY_cf3b4c07-6f82-4ee4-85e9-5be326dbf260"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="idfd3f2e409304f2f9663a5c18e8b56e3_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzctMTEtMS0xLTY4NzY2_998a0eae-a7be-4c17-9a41-9ec763275d09"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTEtMS0xLTY4NzY2_af4cbe4a-f09f-48be-98fd-6a5e51404990"
      unitRef="usd">1706000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTMtMS0xLTY4NzY2_2067b95c-aac3-4800-8a47-322861af6a62"
      unitRef="usd">18000000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTUtMS0xLTY4NzY2_461bca0e-4848-4a4e-ae65-b359ff8fd1db"
      unitRef="position">677</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTctMS0xLTY4NzY2_dcd2edd5-b3ad-4bc6-bd1d-5a24fb03a70c"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTktMS0xLTY4NzY2_9042fd2b-00e2-4908-ad7d-50668e37f705"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDUvZnJhZzo4MTMwZDJmZWRkZTU0ZmRiODRlYjAyN2EzOWJhZDlhNi90YWJsZTpkMmI1MzJiZDM1NTE0OWRiYjY3ODVmNGFhZDdhNGU2MC90YWJsZXJhbmdlOmQyYjUzMmJkMzU1MTQ5ZGJiNjc4NWY0YWFkN2E0ZTYwXzExLTExLTEtMS02ODc2Ng_28f05e7c-1ea6-4e83-8cbf-15f11ffb4ad5"
      unitRef="position">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90ZXh0cmVnaW9uOmMzYWZlZmZjZWU0NjQ3NWM4OGIxZDI2NjJmMTdjNjQwXzk5MQ_5ff2e7b5-8d6f-48e3-bc5f-0fedca1b78ef"
      unitRef="usd">193000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90ZXh0cmVnaW9uOmMzYWZlZmZjZWU0NjQ3NWM4OGIxZDI2NjJmMTdjNjQwXzEwMzE_96763720-06bd-493a-8827-151abddc46de"
      unitRef="usd">37000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90ZXh0cmVnaW9uOmMzYWZlZmZjZWU0NjQ3NWM4OGIxZDI2NjJmMTdjNjQwXzEwOTk1MTE2MjkwMTg_e64e25c5-a2f6-4eab-b9e3-81c04a00dba3"
      unitRef="usd">8000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount>
    <moh:RestrictionsOnInvestmentsTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90ZXh0cmVnaW9uOmMzYWZlZmZjZWU0NjQ3NWM4OGIxZDI2NjJmMTdjNjQwXzExNDQ_60581fec-2ab0-4713-8d02-aeb793db26cf">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the balances of restricted investments:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. Treasury notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total restricted investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;238&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moh:RestrictionsOnInvestmentsTableTextBlock>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i78c795544d9047bab9b654c5a011d8fe_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzQtMS0xLTEtNjg3NjY_2b2db4ca-e1f3-4fb0-81b0-47a4907b211d"
      unitRef="usd">42000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="ib20d5076d1754f178426259e52222452_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzQtMy0xLTEtNjg3NjY_c23372e7-ab88-494c-bf76-d9e8b8b4db9d"
      unitRef="usd">68000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i777ac9767d8c4e58a9ba5410baae7037_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzUtMS0xLTEtNjg3NjY_5b8d1883-0cf0-472f-b83c-194479838924"
      unitRef="usd">159000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i599d71ee55bc40e0a7e1904196a5fdfd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzUtMy0xLTEtNjg3NjY_1553f397-f501-4b39-bc7c-d9463eabcedf"
      unitRef="usd">144000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="ie70ca4fa0e024a9da6a28a215ebf6089_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzYtMS0xLTEtNzAzNzk_c58515f5-138d-4804-ab22-71ba636a7180"
      unitRef="usd">37000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="id7e3a24c60394b48a399eb0153944cd5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzYtMy0xLTEtNzAzNzk_d60960d1-fffb-4b49-a5b7-cf591b05446d"
      unitRef="usd">0</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzctMS0xLTEtNjg3NjY_ec3bee80-a062-49c2-b85b-3c41acbe1e11"
      unitRef="usd">238000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:RestrictedInvestmentsNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNDgvZnJhZzpjM2FmZWZmY2VlNDY0NzVjODhiMWQyNjYyZjE3YzY0MC90YWJsZTpjZDg0NThlOTljOTA0MjlkYmEyN2Q3YzUzZWZkY2E4MS90YWJsZXJhbmdlOmNkODQ1OGU5OWM5MDQyOWRiYTI3ZDdjNTNlZmRjYTgxXzctMy0xLTEtNjg3NjY_6f44406c-cbf0-49cf-a300-f2c2f7a3dcd4"
      unitRef="usd">212000000</us-gaap:RestrictedInvestmentsNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzg1Mg_b1bf7b66-4089-4577-95fe-664bd162dcb2">Property, Equipment, and Capitalized Software, Net &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are stated at historical cost. Replacements and major improvements are capitalized, and repairs and maintenance are charged to expense as incurred. Software developed for internal use is capitalized. Property and equipment are generally depreciated using the straight-line method over estimated useful lives ranging from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM1OA_a83fded9-5651-4fc9-bbd0-f88b865ee371"&gt;three&lt;/span&gt; to seven years. Software is generally amortized over its estimated useful life of three years. Leasehold improvements are amortized over the term of the lease, or over their useful lives from &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzUzNQ_5c091379-9c3b-4ddb-b0f8-72f24ac68c1e"&gt;five&lt;/span&gt; to 10 years, whichever is shorter. Buildings are depreciated over their estimated useful lives of 31.5 to 40&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 2, &#x201c;Significant Accounting Policies&#x201d;, the Company recognized an impairment on property and equipment of $16 million associated with our reduction in leased space used in our business operations, in the quarter ended December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of property, equipment, and capitalized software is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization - capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization - property, equipment, building, and improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU assets - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, equipment, and capitalized software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents all depreciation and amortization recognized in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recorded in depreciation and amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization of property, equipment, building, and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i3dfbd2fd237c43bc9219d4395d0474dd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzM2NA_445ee1e5-9e04-4cc3-a94c-ecc3495e09dc">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i59d9a78c5ed049d0817ec4ff2cc838cd_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzQzNA_e38466bf-90f1-4634-8fa0-25f9f50b4556">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i6a82111ac8a5487a824e9ddb07e72a1e_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzU0MQ_e22affef-e01d-4469-a8a0-0d51214e77eb">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icd312c63a968473280db7fe49cdb0016_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzYzNg_3980e66b-8788-4454-ad8f-d141faa5f593">P31Y6M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if6864266f9a2488da514854481f1778b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzY0Mg_7166141c-1e51-44c8-b4d3-82e14cdfed5e">P40Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:TangibleAssetImpairmentCharges
      contextRef="i54050094325c4beba6d8861066ebb7a0_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzc2OTY1ODEzOTgwNjM_9807b76b-a5b8-4403-91f8-f1b046c8b26c"
      unitRef="usd">16000000</us-gaap:TangibleAssetImpairmentCharges>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90ZXh0cmVnaW9uOjc3MTdiNzRjMjEyOTRiNGNiNmI0NTFmN2E3YzM4YmZiXzg2MQ_f011aa6b-b69a-410e-9d16-43be1831c486">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of property, equipment, and capitalized software is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;615&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;547&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Building and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;822&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated amortization - capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(482)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(427)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation and amortization - property, equipment, building, and improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(695)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU assets - finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, equipment, and capitalized software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents all depreciation and amortization recognized in our consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Recorded in depreciation and amortization:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16pt;text-align:left;text-indent:-9pt;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization of property, equipment, building, and improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total depreciation and amortization recognized&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6b87a358731a498a8531fb81dfa9704f_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzQtMS0xLTEtNjg3NjY_c8000c5c-a1dc-42b6-bdd7-b15128f9b0c1"
      unitRef="usd">615000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i15dba481187544f8ba4896f21c4e17cd_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzQtMy0xLTEtNjg3NjY_5bac0b6d-1e33-4ff4-bb56-86a38fc68452"
      unitRef="usd">547000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i4a482fdc9d8b4a328f48fa2052fe7c15_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzUtMS0xLTEtNjg3NjY_39cb7a29-2812-4188-b6be-ef7a7ca3a749"
      unitRef="usd">221000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifd2a2696dfc6483caf233c53d8331a83_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzUtMy0xLTEtNjg3NjY_06bc01f6-d2a4-449e-8323-6f0edbf616f9"
      unitRef="usd">237000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibf0ed51712cb44a1a1fc04300c9d5c82_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzYtMS0xLTEtNjg3NjY_9a26c727-5a30-47b0-8b5f-5c09bba47891"
      unitRef="usd">41000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibdcfd494f0b044d6a63a13ddfb1e9737_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzYtMy0xLTEtNjg3NjY_81dfb84e-6bfb-4fc1-9ee9-7ef98b748c3c"
      unitRef="usd">37000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib470bce1e1e7439682a2b7cf6079bc24_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzctMS0xLTEtNjg3NjY_5e792a3d-4576-47ae-bf2a-8d7444185d1d"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i54f8881d1acd421683ecb16c150ac455_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzctMy0xLTEtNjg3NjY_ec185fc4-ef64-41f3-abc5-54647f3fa76c"
      unitRef="usd">1000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzktMS0xLTEtNjg3NjY_8c89d4d0-f8dc-429a-bc02-252c5e21bc15"
      unitRef="usd">882000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzktMy0xLTEtNjg3NjY_208cea98-e1b7-4b9f-bd45-e6ec633562b0"
      unitRef="usd">822000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEwLTEtMS0xLTY4NzY2_83b147ad-b0f9-4205-9c2d-69c0b112e633"
      unitRef="usd">482000000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEwLTMtMS0xLTY4NzY2_59362999-6ba8-4a08-8f5b-739b5c6c4b4a"
      unitRef="usd">427000000</us-gaap:CapitalizedComputerSoftwareAccumulatedAmortization>
    <us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzExLTEtMS0xLTY4NzY2_b97c0201-9dd6-49ee-a25c-c4b4daa64708"
      unitRef="usd">213000000</us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation>
    <us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzExLTMtMS0xLTY4NzY2_c5b7e519-5a9a-4d3b-aa7e-df88c6c5abba"
      unitRef="usd">205000000</us-gaap:PropertyPlantAndEquipmentOwnedAccumulatedDepreciation>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEyLTEtMS0xLTY4NzY2_6ce22a34-44d7-4d94-a6e4-f7f7992783b8"
      unitRef="usd">695000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEyLTMtMS0xLTY4NzY2_20925c43-63de-45b6-8223-68c125a0d6ac"
      unitRef="usd">632000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEzLTEtMS0xLTY4NzY2_cffcc193-0045-4738-937d-6050f90bc27a"
      unitRef="usd">72000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzEzLTMtMS0xLTY4NzY2_8a5f27c4-4c33-4639-b048-2443ed02d06d"
      unitRef="usd">206000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzE0LTEtMS0xLTY4NzY2_649dba46-b138-4333-b34a-b3430b6e341c"
      unitRef="usd">259000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTpiYmYyNzBmNzZiNDU0ZTNmYjU0OTc0ZTM1MTg1NDAxYS90YWJsZXJhbmdlOmJiZjI3MGY3NmI0NTRlM2ZiNTQ5NzRlMzUxODU0MDFhXzE0LTMtMS0xLTY4NzY2_113acb1f-861b-4251-ac7b-b8a55afea7e2"
      unitRef="usd">396000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzUtMS0xLTEtNjg3NjY_9e8d6297-bec4-416a-aebd-ed9972dd9cf3"
      unitRef="usd">77000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzUtMy0xLTEtNjg3NjY_75801e94-7eba-4f65-9db8-e793c4be4da0"
      unitRef="usd">49000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzUtNS0xLTEtNjg3NjY_ff3b0172-83cf-454e-84a3-8d6008ceb1e9"
      unitRef="usd">15000000</us-gaap:AmortizationOfIntangibleAssets>
    <moh:DepreciationAndAmortizationOfCapitalizedSoftware
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzYtMS0xLTEtNjg3NjY_db99fbec-843a-4444-8287-0301bdd39693"
      unitRef="usd">54000000</moh:DepreciationAndAmortizationOfCapitalizedSoftware>
    <moh:DepreciationAndAmortizationOfCapitalizedSoftware
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzYtMy0xLTEtNjg3NjY_a014f20c-ac20-4129-96ac-21f13fea6a17"
      unitRef="usd">41000000</moh:DepreciationAndAmortizationOfCapitalizedSoftware>
    <moh:DepreciationAndAmortizationOfCapitalizedSoftware
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzYtNS0xLTEtNjg3NjY_d41f9304-37e4-4e82-9f92-285e2c162246"
      unitRef="usd">38000000</moh:DepreciationAndAmortizationOfCapitalizedSoftware>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzctMS0xLTEtNjg3NjY_d990a999-fe4f-4f8b-87a7-682dc74ce95f"
      unitRef="usd">28000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzctMy0xLTEtNjg3NjY_9b244c2b-2090-47cc-9e4f-868d19acb05b"
      unitRef="usd">25000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzctNS0xLTEtNjg3NjY_087ffb99-5aee-4a63-915d-eb6777b7891d"
      unitRef="usd">19000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:Depreciation
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzgtMS0xLTEtNjg3NjY_7b5c8df4-1381-4c5b-84da-4f9140f5eb6e"
      unitRef="usd">17000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzgtMy0xLTEtNjg3NjY_e709f9d7-0184-42f8-abda-e112b24706f6"
      unitRef="usd">16000000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzgtNS0xLTEtNjg3NjY_436f21b6-146b-41fd-803d-b1e150c1fa4a"
      unitRef="usd">16000000</us-gaap:Depreciation>
    <moh:DepreciationandAmortizationContinuingOperations
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzktMS0xLTEtNjg3NjY_366c9157-0596-41b3-8995-f91ea958f984"
      unitRef="usd">176000000</moh:DepreciationandAmortizationContinuingOperations>
    <moh:DepreciationandAmortizationContinuingOperations
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzktMy0xLTEtNjg3NjY_85a9d6d0-0c88-4596-b664-ecf90adc34a5"
      unitRef="usd">131000000</moh:DepreciationandAmortizationContinuingOperations>
    <moh:DepreciationandAmortizationContinuingOperations
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTEvZnJhZzo3NzE3Yjc0YzIxMjk0YjRjYjZiNDUxZjdhN2MzOGJmYi90YWJsZTo0MWRhMDFiMmJhZjI0NTdkODc5ODM0YzIyNjYwN2YwYS90YWJsZXJhbmdlOjQxZGEwMWIyYmFmMjQ1N2Q4Nzk4MzRjMjI2NjA3ZjBhXzktNS0xLTEtNjg3NjY_51b73e7d-d98c-4e8d-98a9-b1461bb47170"
      unitRef="usd">88000000</moh:DepreciationandAmortizationContinuingOperations>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTI_13f2dab5-8230-4161-bf78-952df77885b8">Leases &lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to 13 years, some of which include options to extend the leases for up to 10 years. As of December&#160;31, 2022, the weighted average remaining operating lease term is 8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our finance leases have remaining lease terms up to 16 years, some of which include options to extend the leases for up to 25 years. As of December&#160;31, 2022, the weighted average remaining finance lease term is 13 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 2, &#x201c;Significant Accounting Policies&#x201d;, the Company recognized $192 million of ROU asset impairments associated with our reduction in leased space used in our business operations in the quarter ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the weighted-average discount rate used to compute the present value of lease payments was 4.4% for operating lease liabilities, and 6.3% for finance lease liabilities. The components of lease expense for the years ended December&#160;31, 2022, 2021, and 2020 are presented in the following table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease expense: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated cash flow information related to leases follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in financing activities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU assets recognized in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84"&gt;Accounts payable and accrued liabilities (current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df"&gt;Other long-term liabilities (non-current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, equipment, and capitalized software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8"&gt;Accounts payable and accrued liabilities (current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:92.25pt;text-indent:-76.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal - undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTM_5505a3ea-d3a2-4a90-a52f-a690d95eb00f">Leases &lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are a party to operating and finance leases primarily for our corporate and health plan offices. Our operating leases have remaining lease terms up to 13 years, some of which include options to extend the leases for up to 10 years. As of December&#160;31, 2022, the weighted average remaining operating lease term is 8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our finance leases have remaining lease terms up to 16 years, some of which include options to extend the leases for up to 25 years. As of December&#160;31, 2022, the weighted average remaining finance lease term is 13 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As discussed in Note 2, &#x201c;Significant Accounting Policies&#x201d;, the Company recognized $192 million of ROU asset impairments associated with our reduction in leased space used in our business operations in the quarter ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, the weighted-average discount rate used to compute the present value of lease payments was 4.4% for operating lease liabilities, and 6.3% for finance lease liabilities. The components of lease expense for the years ended December&#160;31, 2022, 2021, and 2020 are presented in the following table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease expense: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated cash flow information related to leases follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in financing activities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU assets recognized in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84"&gt;Accounts payable and accrued liabilities (current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df"&gt;Other long-term liabilities (non-current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, equipment, and capitalized software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8"&gt;Accounts payable and accrued liabilities (current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:92.25pt;text-indent:-76.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal - undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzE2Nw_59b4080a-06dd-402d-9c84-8126d9324eb4">P13Y</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzIzMg_bc396386-5f7b-45a8-8fff-352962d97bb8">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzMwMQ_06e20dff-19b8-4376-9042-c39536af3c2a">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LesseeFinanceLeaseRemainingLeaseTerm
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzM1Nw_5cdc2451-9373-4e1d-8312-f97fa61ed284">P16Y</us-gaap:LesseeFinanceLeaseRemainingLeaseTerm>
    <us-gaap:LesseeFinanceLeaseRenewalTerm1
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzQyMg_e4fb484a-c31d-451a-bc0c-c87754b04731">P25Y</us-gaap:LesseeFinanceLeaseRenewalTerm1>
    <us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzQ4OQ_1fd415af-d066-42da-9616-ad7cd47a1913">P13Y</us-gaap:FinanceLeaseWeightedAverageRemainingLeaseTerm1>
    <moh:OperatingAndFinanceLeaseImpairmentLoss
      contextRef="i01aae92c76f5467c8edb776a572ee453_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzE0MTgx_da26ea2c-0b55-4491-9a60-ec9109aab2d8"
      unitRef="usd">192000000</moh:OperatingAndFinanceLeaseImpairmentLoss>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzU5NA_18731d3d-5eae-4ba1-9e5b-0a3b26030097"
      unitRef="number">0.044</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzYzNA_383e2286-88bc-452d-843e-7a00c7c156ef"
      unitRef="number">0.063</us-gaap:FinanceLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTQ_239776c7-1ac9-4d91-9a7b-6ffbd11a8be8">The components of lease expense for the years ended December&#160;31, 2022, 2021, and 2020 are presented in the following table.&lt;div style="margin-bottom:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease expense: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization of ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental consolidated cash flow information related to leases follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.516%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.385%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash used in financing activities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ROU assets recognized in exchange for lease obligations:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzQtMy0xLTEtNjg3NjY_98c5daf5-82ce-48cd-9881-5ca6d7250a8f"
      unitRef="usd">31000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzQtNS0xLTEtNjg3NjY_01f70c90-3c82-4f24-861f-17c1b2d67f96"
      unitRef="usd">34000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzQtNS0xLTEtNzIxMTk_ff4c8ef9-c65c-4101-b086-0b0eabd7a51e"
      unitRef="usd">28000000</us-gaap:OperatingLeaseCost>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzctMy0xLTEtNjg3NjY_cc52736b-1d4e-4b04-9f7d-6514400e9c08"
      unitRef="usd">28000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzctNS0xLTEtNjg3NjY_98d792f5-a20e-418b-bc59-c5b5ebbe0938"
      unitRef="usd">25000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseRightOfUseAssetAmortization
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzctNS0xLTEtNzIxMjc_13b78104-e41c-4173-9478-0b8932e12490"
      unitRef="usd">19000000</us-gaap:FinanceLeaseRightOfUseAssetAmortization>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzgtMy0xLTEtNjg3NjY_bdd7da1e-8c30-483f-8560-fcfb98ff73b7"
      unitRef="usd">15000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzgtNS0xLTEtNjg3NjY_09bec621-3a03-42cf-80d3-fd3ae12dda92"
      unitRef="usd">15000000</us-gaap:FinanceLeaseInterestExpense>
    <us-gaap:FinanceLeaseInterestExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzgtNS0xLTEtNzIxMjc_ebc35e32-375b-4be4-9f7e-aa99aa3b00b6"
      unitRef="usd">15000000</us-gaap:FinanceLeaseInterestExpense>
    <moh:FinanceLeaseCost
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzktMy0xLTEtNjg3NjY_2c23c997-76d7-4d89-a64c-884d37de09ab"
      unitRef="usd">43000000</moh:FinanceLeaseCost>
    <moh:FinanceLeaseCost
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzktNS0xLTEtNjg3NjY_ddeff039-aa9f-4768-a586-1be85086556e"
      unitRef="usd">40000000</moh:FinanceLeaseCost>
    <moh:FinanceLeaseCost
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo5OGRkNGE5ZWI2Mzg0MTZmOWUyMWY5NGViNGYzY2IxZC90YWJsZXJhbmdlOjk4ZGQ0YTllYjYzODQxNmY5ZTIxZjk0ZWI0ZjNjYjFkXzktNS0xLTEtNzIxMjc_32577b57-0f19-405d-8980-ff57f0b62987"
      unitRef="usd">34000000</moh:FinanceLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzUtMS0xLTEtNjg3NjY_1225e9df-cd35-472a-a660-5b7bce55112c"
      unitRef="usd">31000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzUtMy0xLTEtNjg3NjY_f5d52e25-a398-4178-82c0-6e6c227e73dd"
      unitRef="usd">33000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzUtNS0xLTEtNzIxNDg_30167b8f-5aad-4e57-8d78-ca40f37548b6"
      unitRef="usd">30000000</us-gaap:OperatingLeasePayments>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzYtMS0xLTEtNjg3NjY_fcbcd697-ab93-4e86-b63a-16ea9b0117dd"
      unitRef="usd">15000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzYtMy0xLTEtNjg3NjY_72a071ea-fa1b-42bf-80d2-11fbb83ef317"
      unitRef="usd">15000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeaseInterestPaymentOnLiability
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzYtNS0xLTEtNzIxNDg_7a9edbbc-df7c-4773-b26d-b763c463e8d6"
      unitRef="usd">15000000</us-gaap:FinanceLeaseInterestPaymentOnLiability>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzgtMS0xLTEtNjg3NjY_d52fd281-f2f4-4aa9-8012-162eb3cd29ab"
      unitRef="usd">15000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzgtMy0xLTEtNjg3NjY_c71c96f1-ddb9-4a29-b942-2aed789fb098"
      unitRef="usd">18000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzgtNS0xLTEtNzIxNDg_8e35903c-e592-488a-809f-aef38b065f00"
      unitRef="usd">9000000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzEwLTEtMS0xLTY4NzY2_df877f6f-d596-4576-9610-ce77ec96ee68"
      unitRef="usd">10000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzEwLTMtMS0xLTY4NzY2_8d038629-099f-46b1-9e71-d2f4d55a34c5"
      unitRef="usd">86000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzEwLTUtMS0xLTcyMTQ4_7cb92f2b-57a8-4f50-af92-6f21b0ab0ed7"
      unitRef="usd">28000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzExLTEtMS0xLTY4NzY2_01e10868-afb1-444d-a9f8-0135bb9b0c98"
      unitRef="usd">18000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzExLTMtMS0xLTY4NzY2_5a844c6c-9f85-4ced-8eca-c1920af6435e"
      unitRef="usd">18000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyNTZkNTcxNzhmYTA0ZTI1ODc0MjkyN2Q3YTEzZWE3MS90YWJsZXJhbmdlOjI1NmQ1NzE3OGZhMDRlMjU4NzQyOTI3ZDdhMTNlYTcxXzExLTUtMS0xLTcyMTQ4_1c02a45a-e8e8-439a-99a2-cfe1526e282a"
      unitRef="usd">7000000</us-gaap:RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability>
    <moh:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTY_b42a2d90-ef61-4333-9e27-fc4ad9b2c89c">&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental information related to leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.496%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.498%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_3ecdee13-b439-4da9-8842-9c3d34eb003d"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMC0xLTEtNjg3NjY_689a9ca9-e69d-410f-8847-51bfe682632c"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_199fecd7-23a5-4f88-ab80-685d978daf63"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTAtMS0xLTY4NzY2_e75dd101-8721-4b09-90ec-84ce91833b84"&gt;Accounts payable and accrued liabilities (current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_1d2933ac-81c6-40fb-adcd-ddcb4682ceb9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTAtMS0xLTY4NzY2_edb1df51-4fe2-459d-828f-8c48ddced7df"&gt;Other long-term liabilities (non-current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;77&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Finance leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ROU assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, equipment, and capitalized software, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_2767aebd-8c1c-4679-861e-99685d02d996"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTAtMS0xLTY4NzY2_c19dd465-05b4-414a-8c6b-906e767681e8"&gt;Accounts payable and accrued liabilities (current)&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities (non-current)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:92.25pt;text-indent:-76.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total finance lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</moh:AssetsAndLiabilitiesLesseeTableTextBlock>
    <moh:OperatingLeaseRightOfUseAssetExcludingLeasesAcquired
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMS0xLTEtNjg3NjY_831824d5-40ff-40b4-aa1e-64c447245ad0"
      unitRef="usd">43000000</moh:OperatingLeaseRightOfUseAssetExcludingLeasesAcquired>
    <moh:OperatingLeaseRightOfUseAssetExcludingLeasesAcquired
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzYtMy0xLTEtNjg3NjY_483505ac-c1ae-4b9c-8f53-388387ff669d"
      unitRef="usd">128000000</moh:OperatingLeaseRightOfUseAssetExcludingLeasesAcquired>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTEtMS0xLTY4NzY2_c60010ea-0302-4b12-a0ae-c88f7bbd284e"
      unitRef="usd">41000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEwLTMtMS0xLTY4NzY2_d7e70490-ad48-432a-84c1-a59bc7c5d918"
      unitRef="usd">35000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTEtMS0xLTY4NzY2_e98b7914-bc48-42d2-b547-f9727f5a886b"
      unitRef="usd">77000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzExLTMtMS0xLTY4NzY2_d0d6563c-97b1-4acd-b023-8a314d56cd15"
      unitRef="usd">99000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEzLTEtMS0xLTY4NzY2_97d71b7a-7ab7-4aa5-9272-041d2db30d89"
      unitRef="usd">118000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzEzLTMtMS0xLTY4NzY2_b2be4c86-f90c-41fd-87b3-8653b00084ff"
      unitRef="usd">134000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE2LTEtMS0xLTY4NzY2_cffcc193-0045-4738-937d-6050f90bc27a"
      unitRef="usd">72000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseRightOfUseAsset
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE2LTMtMS0xLTY4NzY2_b3d034f0-cb03-47ff-a777-83b5e395e2c3"
      unitRef="usd">206000000</us-gaap:FinanceLeaseRightOfUseAsset>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTEtMS0xLTY4NzY2_178c16a9-e1b7-4b4d-bc5e-fd495f810147"
      unitRef="usd">22000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE4LTMtMS0xLTY4NzY2_aabe057f-2c05-4802-93ea-a124d1a932f1"
      unitRef="usd">15000000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE5LTEtMS0xLTY4NzY2_1efa6866-d0ad-4b10-bd15-e286a5c68860"
      unitRef="usd">215000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzE5LTMtMS0xLTY4NzY2_679b300d-bca8-45c6-888f-b1b404296af9"
      unitRef="usd">219000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzIwLTEtMS0xLTY4NzY2_295f3a87-7818-42af-979a-b67253ecbb8a"
      unitRef="usd">237000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZTo2M2I4ZjU3ZDdlNjc0MDQ1YTQ0OTZjZmY2MmIzZDY4NC90YWJsZXJhbmdlOjYzYjhmNTdkN2U2NzQwNDVhNDQ5NmNmZjYyYjNkNjg0XzIwLTMtMS0xLTY4NzY2_29951991-0ba7-4d2c-b9a9-737400810db3"
      unitRef="usd">234000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTc_0fb4a9c7-e47f-473a-92d9-6a2647c8a7a5">&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal - undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90ZXh0cmVnaW9uOjVjNWJkZDQ2OTZmNTQ1YjNhZTQ3Y2U0MDhlZDEzNTBhXzEwNTg_a112948b-7676-41d0-b29b-e4e27632e429">&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of lease liabilities as of December&#160;31, 2022, were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:70.894%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.537%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Operating &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Finance&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Subtotal - undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(25)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;118&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzQtMS0xLTEtNjg3NjY_657bf088-ba9c-4bad-a207-ce0cda45d46d"
      unitRef="usd">28000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzQtMy0xLTEtNjg3NjY_20e2f1c1-1592-4900-8144-a9bb72fad0cb"
      unitRef="usd">34000000</us-gaap:FinanceLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzUtMS0xLTEtNjg3NjY_95637015-c62d-483c-9139-ddee69ee489a"
      unitRef="usd">22000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzUtMy0xLTEtNjg3NjY_9c24520e-5a60-42fc-805d-7ac15893b7fd"
      unitRef="usd">30000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzYtMS0xLTEtNjg3NjY_a0a15910-fedf-400b-8e99-3e308408635e"
      unitRef="usd">18000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzYtMy0xLTEtNjg3NjY_0bcc9ee2-309f-47a2-b201-3b6a73fb6576"
      unitRef="usd">26000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzctMS0xLTEtNjg3NjY_50b7c7c6-e80b-42ea-942b-f3938c773c1b"
      unitRef="usd">11000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzctMy0xLTEtNjg3NjY_b8277ead-9447-4a3e-b5f9-4f6dc5b4973f"
      unitRef="usd">23000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzgtMS0xLTEtNjg3NjY_d9897c03-b421-4d82-bb9d-3e946204b375"
      unitRef="usd">9000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzgtMy0xLTEtNjg3NjY_dbeced38-1dc6-4c99-bedd-574dfb74ef29"
      unitRef="usd">24000000</us-gaap:FinanceLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzktMS0xLTEtNjg3NjY_6fa44eb4-7753-4e95-804f-70752a84def9"
      unitRef="usd">55000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzktMy0xLTEtNjg3NjY_05a66849-2506-4d6d-bec1-52d1e05d2d3e"
      unitRef="usd">219000000</us-gaap:FinanceLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzEwLTEtMS0xLTY4NzY2_775b713e-9c19-4f59-939b-ea8f76e0b21d"
      unitRef="usd">143000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:FinanceLeaseLiabilityPaymentsDue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzEwLTMtMS0xLTY4NzY2_f6a671f6-d4dd-46e9-9b5c-6ae38cfcb9da"
      unitRef="usd">356000000</us-gaap:FinanceLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzExLTEtMS0xLTY4NzY2_ab9984b8-11ad-4f35-88b0-9674d886ec25"
      unitRef="usd">25000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzExLTMtMS0xLTY4NzY2_048a1c7c-b86c-4438-bada-2a461a9e60da"
      unitRef="usd">119000000</us-gaap:FinanceLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzEyLTEtMS0xLTY4NzY2_d7ec32da-a960-44e7-9237-745a7da58455"
      unitRef="usd">118000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNTQvZnJhZzo1YzViZGQ0Njk2ZjU0NWIzYWU0N2NlNDA4ZWQxMzUwYS90YWJsZToyY2E1ZmNiMzE4OWM0YWViODQwNDk5NTg5MTc2MDY2MS90YWJsZXJhbmdlOjJjYTVmY2IzMTg5YzRhZWI4NDA0OTk1ODkxNzYwNjYxXzEyLTMtMS0xLTY4NzY2_0ff1f772-2419-4093-bdd9-ab9b8ef38d8b"
      unitRef="usd">237000000</us-gaap:FinanceLeaseLiability>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzYwNA_6f14da1d-1f71-4fec-bd4e-6d8815838c70">Goodwill and Intangible Assets, Net &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions and measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions and measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The changes in the carrying amounts of both goodwill and intangible assets, net, in 2022, were due to the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquisitions and purchase price adjustments described in Note 4, &#x201c;Business Combinations.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of identified intangible assets, by major class, for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract rights and licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provider networks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;As of December&#160;31, 2022, we estimate that our intangible asset amortization will be approximately $84 million in 2023, $67 million in 2024, $64 million in 2025, $25 million in 2026, and $13 million in 2027.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzYwOA_153b0033-78b3-4ad7-afb7-00f42a219407">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the changes in the carrying amounts of goodwill by segment, for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;692&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions and measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquisitions and measurement period adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,115&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i13f72b45b4644a468fe3bf237a344ae5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzMtMS0xLTEtNjg3NjY_71f00c45-598e-42b8-a4a7-dd286abfe1d5"
      unitRef="usd">489000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie051c5fdd0164b7692de987d735b5614_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzMtMy0xLTEtNjg3NjY_ec52e083-cf50-4160-974a-0ef3dbcb006f"
      unitRef="usd">161000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ica8010c73a874479be005b5c0efe2f9b_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzMtNS0xLTEtNjg3NjY_b0fc05e1-0dbe-4ce6-b283-e7189e58125b"
      unitRef="usd">42000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzMtNy0xLTEtNjg3NjY_c21b99c5-0176-42e3-95ff-e87261d628c0"
      unitRef="usd">692000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzQtMS0xLTEtNjg3NjY_b752dbba-c931-4117-b367-050e3c71a29d"
      unitRef="usd">280000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzQtMy0xLTEtNjg3NjY_1134ec01-d100-4f72-b8d1-e84cbeaadd4d"
      unitRef="usd">8000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic83f163bbbec4901a4db9c0cd3b6beae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzQtNS0xLTEtNjg3NjY_faeade68-4fbd-4d34-8080-1f2ce0647c8c"
      unitRef="usd">2000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzQtNy0xLTEtNjg3NjY_3c9eb38f-fa22-4d0b-8f61-ada14379ea6f"
      unitRef="usd">290000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i35d2514974d648b4a321860ce0da423a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzctMS0xLTEtNjg3NjY_40e3a006-b391-47c4-a4cb-1cd7cae392ec"
      unitRef="usd">769000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0a8d5443c6c445b7b1df9e882c954e13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzctMy0xLTEtNjg3NjY_726f1832-30e5-4f19-989a-dd5f4c302159"
      unitRef="usd">169000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i471861f0bd924c028fddde43043e03e5_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzctNS0xLTEtNjg3NjY_46297c30-8d8d-4c5a-bb78-d0203aea6beb"
      unitRef="usd">44000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzctNy0xLTEtNjg3NjY_85072e81-f73d-4d3d-9d75-03decbf7fddb"
      unitRef="usd">982000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzEyLTEtMS0xLTY4NzY2_e60cb4d8-8429-49f9-9be8-20da2cef095f"
      unitRef="usd">130000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzEyLTMtMS0xLTY4NzY2_3c79806e-4ef3-4d6a-bfdc-76ce64df01c6"
      unitRef="usd">3000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="iba0e6e336cc2457895f26a4b547de184_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzEyLTUtMS0xLTY4NzY2_32f31f56-f214-42cf-b775-dffd2c9344bd"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzEyLTctMS0xLTY4NzY2_daec0278-8aa0-49bb-a8b5-f25f31aba960"
      unitRef="usd">133000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:Goodwill
      contextRef="i277bd722f8d244c98c6cb91f7a6d9c98_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzE1LTEtMS0xLTY4NzY2_f4e8a89e-8365-4a81-91a9-b0af70def893"
      unitRef="usd">899000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i4ded5b162e2f49728c0e31ad73edfaeb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzE1LTMtMS0xLTY4NzY2_1ff35f5f-fac5-4ae2-a5f9-af1e2b65d871"
      unitRef="usd">172000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ie099f36d881c40a3badd49fcbe24a158_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzE1LTUtMS0xLTY4NzY2_7c802cf9-04da-4b36-99ec-65fc3db716ba"
      unitRef="usd">44000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmNWZkNzI4MzY1NjA0NGFiOGJjYWE5NWFiZTU0MTExMS90YWJsZXJhbmdlOmY1ZmQ3MjgzNjU2MDQ0YWI4YmNhYTk1YWJlNTQxMTExXzE1LTctMS0xLTY4NzY2_1305d4de-9738-43d9-a013-64d48c1f5af3"
      unitRef="usd">1115000000</us-gaap:Goodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzYwMA_a9b4105f-44e1-48ff-b03d-5dfa1a731188">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of identified intangible assets, by major class, for the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:23.569%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.206%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.381%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.500%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.969%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying Amount &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract rights and licenses&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Provider networks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iffc025417eb148d5848c4dc550d72cf1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtMS0xLTEtNjg3NjY_d36c7f79-df6a-4046-8eb2-f3bdf2442d5c"
      unitRef="usd">507000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iffc025417eb148d5848c4dc550d72cf1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtMy0xLTEtNjg3NjY_ae98d261-edab-4b2b-aa84-b9eae480aea7"
      unitRef="usd">279000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iffc025417eb148d5848c4dc550d72cf1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtNS0xLTEtNjg3NjY_513df4cd-7748-4f27-88e4-5ddf0450031f"
      unitRef="usd">228000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6a10f9e2abb34524aa6d8bc510e1aa4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtNy0xLTEtNjg3NjY_57767190-472f-4777-8b40-c5bd80c45d1a"
      unitRef="usd">426000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6a10f9e2abb34524aa6d8bc510e1aa4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtOS0xLTEtNjg3NjY_cc51ac04-9e24-4c18-be97-05e4f1b42366"
      unitRef="usd">210000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6a10f9e2abb34524aa6d8bc510e1aa4e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzQtMTEtMS0xLTY4NzY2_19f4a5c1-e926-4be8-85c8-6301662f51d3"
      unitRef="usd">216000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i4767b4d9b3f84070acc01bf02ca7feef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtMS0xLTEtNjg3NjY_1011f520-2444-481b-ac20-74752ae606bd"
      unitRef="usd">57000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4767b4d9b3f84070acc01bf02ca7feef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtMy0xLTEtNjg3NjY_46034ccc-0a09-4f9f-abf2-d1bc2900611b"
      unitRef="usd">24000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i4767b4d9b3f84070acc01bf02ca7feef_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtNS0xLTEtNjg3NjY_cd07a48b-1053-48b2-b6c1-2338dc028b30"
      unitRef="usd">33000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="id4f6a981430a48419a3e8f282bae5cee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtNy0xLTEtNjg3NjY_af779f19-67e4-412a-b115-ba658ebeeab9"
      unitRef="usd">56000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id4f6a981430a48419a3e8f282bae5cee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtOS0xLTEtNjg3NjY_ad2eb927-8fef-4cc0-a920-ffe8f6fabb2d"
      unitRef="usd">19000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="id4f6a981430a48419a3e8f282bae5cee_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzUtMTEtMS0xLTY4NzY2_2d9ffb65-618a-4bb1-8892-f13d24a8b788"
      unitRef="usd">37000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i8398f04c5a124683b46e82729ddf8f33_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtMS0xLTEtNjg3NjY_d4570345-b025-4b51-a272-13ef04f63b25"
      unitRef="usd">19000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i8398f04c5a124683b46e82729ddf8f33_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtMy0xLTEtNjg3NjY_969ee5ec-0f0d-4273-8243-90319d37e38b"
      unitRef="usd">5000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i8398f04c5a124683b46e82729ddf8f33_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtNS0xLTEtNjg3NjY_96aa5e96-6769-4937-909f-07b772b7e317"
      unitRef="usd">14000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i390ee1c0be844452a70fa034460742a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtNy0xLTEtNjg3NjY_08a05569-c808-432e-837b-1f61c305293a"
      unitRef="usd">19000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i390ee1c0be844452a70fa034460742a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtOS0xLTEtNjg3NjY_69752b9d-26d0-484d-852c-1f1b2ec3afe1"
      unitRef="usd">2000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i390ee1c0be844452a70fa034460742a3_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzYtMTEtMS0xLTY4NzY2_d39925b7-6628-4d3c-b38f-4896b2c36d7a"
      unitRef="usd">17000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctMS0xLTEtNjg3NjY_37a25891-9ac0-4538-bd87-df046e06c8dc"
      unitRef="usd">583000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctMy0xLTEtNjg3NjY_4ea370cb-08b0-463c-8d6b-0d3f4fa3ad80"
      unitRef="usd">308000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctNS0xLTEtNjg3NjY_e63b2420-dbff-4af0-b925-25c0be9c0b5e"
      unitRef="usd">275000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctNy0xLTEtNjg3NjY_7873b8a5-cc64-43e3-9501-be191cea6f23"
      unitRef="usd">501000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctOS0xLTEtNjg3NjY_20e5cb3e-2d9d-4e1b-94f8-49ab63fa59f0"
      unitRef="usd">231000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90YWJsZTpmODgyMzc0YTAwMTQ0MDJiYTdlMGVkZmI5NTYzMWZkYS90YWJsZXJhbmdlOmY4ODIzNzRhMDAxNDQwMmJhN2UwZWRmYjk1NjMxZmRhXzctMTEtMS0xLTY4NzY2_c7debf9c-4c1c-4a10-8927-3e470d466fa7"
      unitRef="usd">270000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU0Mg_f55802a0-454b-40eb-a454-634673e1ab6a"
      unitRef="usd">84000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU1Mg_5f1abf52-7061-479f-8aee-ce450d3223e1"
      unitRef="usd">67000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU2Mg_ba51f733-32eb-45b5-8450-f4f6cf66e577"
      unitRef="usd">64000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU3Mg_7f6ef36e-d849-4f56-aa43-6dd06bd01e1f"
      unitRef="usd">25000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjAvZnJhZzoyMjhjYzYyYWMyNmY0NmViODRlODQ2ZGY5ZDE4MGNiZS90ZXh0cmVnaW9uOjIyOGNjNjJhYzI2ZjQ2ZWI4NGU4NDZkZjlkMTgwY2JlXzU4Ng_f46a7349-7f19-4ed4-af94-603f10d46205"
      unitRef="usd">13000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwOTg_e116ffc2-3467-4904-ae63-ce49078639a2">Medical Claims and Benefits Payable &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fee-for-service claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Magellan Complete Care acquisition opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x201c;Other&#x201d; medical claims and benefits payable include amounts payable to certain providers for which we act as an intermediary on behalf of various government agencies without assuming financial risk. Such receipts and payments do not impact our consolidated statements of income. Non-risk provider payables amounted to $228 million, $226 million and $235 million, as of December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amounts presented for &#x201c;Components of medical care costs related to: Prior years&#x201d; represent the amount by which our original estimate of medical claims and benefits payable at the beginning of the year varied from the actual liabilities, based on information (principally the payment of claims) developed since those liabilities were first reported.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our estimates of medical claims and benefits payable recorded at December 31, 2022, 2021 and 2020 developed favorably by approximately $284&#160;million, $239&#160;million and $119&#160;million in 2022, 2021 and 2020, respectively. The favorable prior year development recognized in 2022 was primarily due to lower than expected utilization of medical services by our members and improved operating performance, mainly in the Medicaid segment. Consequently, the ultimate costs recognized in 2022, as claims payments were processed, were lower than our estimates in 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The favorable prior year development recognized in 2021 was primarily due to lower than expected utilization of medical services by our Medicaid members, and to a lesser extent our Medicare and Marketplace members, and improved operating performance. Consequently, the ultimate costs recognized in 2021 were lower than our original estimates in 2020, which was not discernible until additional information was provided, and as claims payments were processed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The favorable prior year development recognized in 2020 was primarily due to lower than expected utilization of medical services by our Medicaid members, and improved operating performance. Consequently, the ultimate costs recognized in 2020 were lower than our original estimates in 2019, which was not discernible until additional information was provided, and as claims payments were processed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables provide information about our consolidated incurred and paid claims development as of December&#160;31, 2022, as well as cumulative claims frequency and the total of incurred but not paid claims liabilities. The pattern of incurred and paid claims development is consistent across each of our segments. The cumulative claim frequency is measured by claim event, and includes claims covered under capitated arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred Claims and Allocated Claims Adjustment Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total IBNP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative number of reported claims&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Benefit Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims and Allocated Claims Adjustment Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Benefit Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Incurred claims and allocated claims adjustment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: cumulative paid claims and allocated claims adjustment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All outstanding liabilities before 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock>
    <us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwOTA_7e151859-cf77-4ab0-a268-b92060d5f70a">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the details of our medical claims and benefits payable as of the dates indicated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fee-for-service claims incurred but not paid (&#x201c;IBNP&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,486&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pharmacy payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;157&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitation payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Magellan Complete Care acquisition opening balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzQtMS0xLTEtNjg3NjY_318af1b4-b4dc-4ca0-a35c-088621bdfead"
      unitRef="usd">2597000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzQtMy0xLTEtNjg3NjY_5ac1fbd3-d843-4c84-baa2-055d1f495b68"
      unitRef="usd">2486000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzQtNS0xLTEtNjg3NjY_0ae0cfe0-4066-4a82-8f2c-0c113e549400"
      unitRef="usd">1647000000</moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount>
    <moh:PharmacyClaimsPayable
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzUtMS0xLTEtNjg3NjY_d086b78e-e0a3-4648-8726-60446491939b"
      unitRef="usd">206000000</moh:PharmacyClaimsPayable>
    <moh:PharmacyClaimsPayable
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzUtMy0xLTEtNjg3NjY_e4c71d79-1ac5-48e8-b8d7-ca6901c2540c"
      unitRef="usd">219000000</moh:PharmacyClaimsPayable>
    <moh:PharmacyClaimsPayable
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzUtNS0xLTEtNjg3NjY_ca5b94ff-89b7-4d4a-92f7-4563b50e8f2b"
      unitRef="usd">157000000</moh:PharmacyClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzYtMS0xLTEtNjg3NjY_4b4c88c1-5a17-471c-80ab-f0fe4299fcce"
      unitRef="usd">94000000</moh:CapitationClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzYtMy0xLTEtNjg3NjY_cf47c005-d51b-40ad-b9b9-2957a34e01b3"
      unitRef="usd">82000000</moh:CapitationClaimsPayable>
    <moh:CapitationClaimsPayable
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzYtNS0xLTEtNjg3NjY_0e4069a5-6d80-429b-8289-6da35df0303d"
      unitRef="usd">70000000</moh:CapitationClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzctMS0xLTEtNjg3NjY_eee98646-404a-4439-a6d6-6097eddbf97f"
      unitRef="usd">631000000</moh:OtherClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzctMy0xLTEtNjg3NjY_485efcba-21bc-4d1c-bcc8-f986cd900357"
      unitRef="usd">576000000</moh:OtherClaimsPayable>
    <moh:OtherClaimsPayable
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzctNS0xLTEtNjg3NjY_b246dd14-a277-4f2e-b0c8-31a8bcb78840"
      unitRef="usd">528000000</moh:OtherClaimsPayable>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iea3d5b8372df4c6abfbb27c274bc673a_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzgtMS0xLTEtNjg3NjY_13eccec0-39b1-4942-b66d-c51294f0cd81"
      unitRef="usd">0</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i0023c6ef83664597b60b89a484a483bc_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzgtMy0xLTEtNjg3NjY_67c3ee28-2cfc-4d7e-a2a0-c7d410cadb46"
      unitRef="usd">0</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i791cb3b2e1414dc995d8c3832e970a59_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzgtNS0xLTEtNjg3NjY_0519cb9d-5d7b-49c4-aef1-1535934eb1c9"
      unitRef="usd">294000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzktMS0xLTEtNjg3NjY_b131e0c4-a2d9-4ee0-aedd-480b0fa1f324"
      unitRef="usd">3528000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzktMy0xLTEtNjg3NjY_ec8b80a4-4800-4611-b6ef-02c0ab42de1f"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTphODJlNDlhNTlhNjk0ZWZhOTJlZGU2YjlkMzljZjhkZS90YWJsZXJhbmdlOmE4MmU0OWE1OWE2OTRlZmE5MmVkZTZiOWQzOWNmOGRlXzktNS0xLTEtNjg3NjY_55ca9e9d-da2f-4f34-addc-f7971d5e1522"
      unitRef="usd">2696000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzQ0NA_910d97c1-cf50-4907-8fc7-dedcfbca982d"
      unitRef="usd">228000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzQ0OA_538f50ed-ddba-4fb0-a1c5-7a1f5fd31fe5"
      unitRef="usd">226000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:MedicalClaimsAndBenefitsPayable
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzQ1NQ_8103df8e-7121-48d9-a4bf-17450b3500e7"
      unitRef="usd">235000000</moh:MedicalClaimsAndBenefitsPayable>
    <moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwODU_9e795a64-8603-451d-9754-1f8445e67956">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present the components of the change in our medical claims and benefits payable for the periods indicated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(251)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(32)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(284)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,358&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,670&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(182)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(239)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,284&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,601&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;340&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,080&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicaid &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Medicare &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 5.5pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Components of medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,939&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(84)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total medical care costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,161&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,820&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Payments for medical care costs related to:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,940&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total paid&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,116&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Acquired balances, net of post-acquisition adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;294&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable, ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i35d2514974d648b4a321860ce0da423a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzQtMS0xLTEtNjg3NjY_a47268f9-3238-4d75-9e2f-67ef8a7d7552"
      unitRef="usd">2580000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i0a8d5443c6c445b7b1df9e882c954e13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzQtMy0xLTEtNjg3NjY_af831916-d8dc-44e6-ade0-f58902906eb0"
      unitRef="usd">404000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6e256b4d3f8045d6a0d60842042e5330_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzQtNS0xLTEtNjg3NjY_1b8ccc17-c2bc-4d88-a29f-ffd4fdd3906a"
      unitRef="usd">379000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzQtNy0xLTEtNjg3NjY_b6b14728-fe98-43bc-b123-2ee82d439208"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzYtMS0xLTEtNjg3NjY_9b97e904-5aae-4caa-9e27-fa22ac2673a0"
      unitRef="usd">22097000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzYtMy0xLTEtNjg3NjY_9026c483-2c06-4d47-a492-315fd4a9deea"
      unitRef="usd">3390000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzYtNS0xLTEtNjg3NjY_9cadd429-274f-408f-b23e-409f8c418d42"
      unitRef="usd">1972000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzYtNy0xLTEtNjg3NjY_b89de130-a8c1-459d-9218-e7ba3a1ab460"
      unitRef="usd">27459000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzctMS0xLTEtNjg3NjY_eed3cd02-2660-4c57-84d6-15f9bf52860b"
      unitRef="usd">-251000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzctMy0xLTEtNjg3NjY_c0485e68-f113-4a60-ba15-9da8132dbf40"
      unitRef="usd">-32000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzctNS0xLTEtNjg3NjY_5765ede2-2518-49cf-82a9-125cf1536b76"
      unitRef="usd">-1000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzctNy0xLTEtNjg3NjY_29ae7d24-3016-40db-97e7-80a0267ce441"
      unitRef="usd">-284000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzgtMS0xLTEtNjg3NjY_6248bd89-f92b-4dfe-9b1c-9a9eb624aa6b"
      unitRef="usd">21846000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzgtMy0xLTEtNjg3NjY_b108ccdd-9c0e-45ab-82f4-205e3cc7c2a1"
      unitRef="usd">3358000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzgtNS0xLTEtNjg3NjY_aa5fff0a-07b8-4952-9513-4e0942a7e98f"
      unitRef="usd">1971000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzgtNy0xLTEtNjg3NjY_132e58bc-6646-4119-839a-ce3b9876cb0d"
      unitRef="usd">27175000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEwLTEtMS0xLTY4NzY2_85491e71-8628-419b-ab7e-c66c1bd8b0b6"
      unitRef="usd">19655000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEwLTMtMS0xLTY4NzY2_e47720ef-8153-4a96-a2dd-af54af7bb772"
      unitRef="usd">2944000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEwLTUtMS0xLTY4NzY2_ad1d4ede-b335-438a-8b49-9623656ef01d"
      unitRef="usd">1746000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEwLTctMS0xLTY4NzY2_19538566-2af2-4af1-a3cd-70170c88f71f"
      unitRef="usd">24345000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzExLTEtMS0xLTY4NzY2_c817e34d-06d0-491c-b3dc-b56477a4a14f"
      unitRef="usd">1966000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzExLTMtMS0xLTY4NzY2_12b74e64-74de-4379-a597-bf62e9ef5ebc"
      unitRef="usd">361000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzExLTUtMS0xLTY4NzY2_68ee3389-5441-4692-ba95-7e0839a7564a"
      unitRef="usd">343000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzExLTctMS0xLTY4NzY2_357b1264-b951-4059-a66d-c469fdfc31be"
      unitRef="usd">2670000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEyLTEtMS0xLTY4NzY2_a03b3d2d-b88f-44ff-b090-2350266a7733"
      unitRef="usd">21621000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEyLTMtMS0xLTY4NzY2_2094cbe6-833a-4575-901f-ed3b3f5afe3d"
      unitRef="usd">3305000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEyLTUtMS0xLTY4NzY2_ee7d29d9-29c4-4862-a2e9-305f6920dcbd"
      unitRef="usd">2089000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEyLTctMS0xLTY4NzY2_4435e11f-d463-48b9-b94e-38884dd69a32"
      unitRef="usd">27015000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEzLTEtMS0xLTc1NjU3_e9332d00-b979-46e5-90ac-9b903eae1858"
      unitRef="usd">12000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEzLTMtMS0xLTc1NjU3_f0b46bf1-cdb5-4195-969c-b04faff31a4e"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEzLTUtMS0xLTc1NjU3_814b5a09-18bf-4aa0-b901-321ea771e6cf"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzEzLTctMS0xLTc1NjU3_855b43d5-db65-4ebb-929b-5657a883d7e0"
      unitRef="usd">12000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE0LTEtMS0xLTY4NzY2_6798cccf-d9a9-4ac8-a9e7-e7d6b3e90d13"
      unitRef="usd">-2000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE0LTMtMS0xLTY4NzY2_ce0e3569-940e-4fc7-9cb5-991af18fda89"
      unitRef="usd">-5000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE0LTUtMS0xLTY4NzY2_ab565605-895f-4eae-8c7e-3294e3532c73"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE0LTctMS0xLTY4NzY2_65d94bd3-d9a6-4605-a7a7-35dc3338d1ea"
      unitRef="usd">-7000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i277bd722f8d244c98c6cb91f7a6d9c98_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE1LTEtMS0xLTY4NzY2_262d4c77-cb93-44f6-8ba5-fbe021d631b4"
      unitRef="usd">2815000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i4ded5b162e2f49728c0e31ad73edfaeb_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE1LTMtMS0xLTY4NzY2_75c7f16e-5a57-484b-8595-35c713372cec"
      unitRef="usd">452000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i628668ecbc2f46759154eeb9586c550c_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE1LTUtMS0xLTY4NzY2_55f602aa-1812-41c9-9b3e-93f1f6c6ba30"
      unitRef="usd">261000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo4YTZmMzI4ZWViYzM0YjZjOTkxY2RlOTU1OTJiN2U5ZC90YWJsZXJhbmdlOjhhNmYzMjhlZWJjMzRiNmM5OTFjZGU5NTU5MmI3ZTlkXzE1LTctMS0xLTY4NzY2_d59ce5f2-f158-40d6-bf85-30024b585bf7"
      unitRef="usd">3528000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i13f72b45b4644a468fe3bf237a344ae5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzQtMS0xLTEtNjg3NjY_958e8fb5-3555-4516-a3f4-950d598eb8f9"
      unitRef="usd">2129000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie051c5fdd0164b7692de987d735b5614_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzQtMy0xLTEtNjg3NjY_156504a1-5a10-48ba-866f-e5c2cff50834"
      unitRef="usd">392000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i0f8bd3d713d84b16b5d4c1c2e0b0602f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzQtNS0xLTEtNjg3NjY_046e915a-74f9-4cbc-9dd6-074955a44d8c"
      unitRef="usd">175000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzQtNy0xLTEtNjg3NjY_e7cfbc4d-9451-4f90-8a11-3cccc8103b4b"
      unitRef="usd">2696000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzYtMS0xLTEtNjg3NjY_14bf18fa-9444-4057-acd9-32de0704a773"
      unitRef="usd">18321000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzYtMy0xLTEtNjg3NjY_e49c44bc-aa6d-45b1-a4ac-7d25dcc7936d"
      unitRef="usd">2970000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzYtNS0xLTEtNjg3NjY_ca6b030b-f579-4ba7-80a2-1807bb6a6cd5"
      unitRef="usd">2652000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzYtNy0xLTEtNjg3NjY_395ce464-4626-44bc-8dc5-b3f39529aa54"
      unitRef="usd">23943000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzctMS0xLTEtNjg3NjY_a68936a3-cccf-44cf-9c92-faebe6336a67"
      unitRef="usd">-182000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzctMy0xLTEtNjg3NjY_a5dd5aee-814e-473b-83eb-3d6d4596fd68"
      unitRef="usd">-39000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzctNS0xLTEtNjg3NjY_c3269f2e-c197-49de-bc8f-6ab4340299e7"
      unitRef="usd">-18000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzctNy0xLTEtNjg3NjY_fe6e5bf0-6806-40bd-b44d-b0f3dddc65f6"
      unitRef="usd">-239000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzgtMS0xLTEtNjg3NjY_2e835aaf-6fd3-4c23-8d46-65c1235ec373"
      unitRef="usd">18139000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzgtMy0xLTEtNjg3NjY_285e2927-20a5-46fb-bd1c-615be4c79b11"
      unitRef="usd">2931000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzgtNS0xLTEtNjg3NjY_e94cc89a-70fe-4610-9050-69e014ecb05f"
      unitRef="usd">2634000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzgtNy0xLTEtNjg3NjY_ba317561-6276-429d-b848-16bc74bf47c6"
      unitRef="usd">23704000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEwLTEtMS0xLTY4NzY2_d97452d2-ce50-4f1f-ad7e-9cc5083135d1"
      unitRef="usd">16284000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEwLTMtMS0xLTY4NzY2_f884e064-8667-4808-8adc-42bfa8551484"
      unitRef="usd">2573000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEwLTUtMS0xLTY4NzY2_e6123831-4550-44ea-ad7f-ce7392d17819"
      unitRef="usd">2291000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEwLTctMS0xLTY4NzY2_584107d8-f520-4046-bf03-0b491fd07f20"
      unitRef="usd">21148000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzExLTEtMS0xLTY4NzY2_8c62e93f-7d11-4011-9189-5a067691c8d3"
      unitRef="usd">1601000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzExLTMtMS0xLTY4NzY2_fd41dbf5-c93b-4144-8e91-5379daaa05ee"
      unitRef="usd">340000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzExLTUtMS0xLTY4NzY2_3f60f795-28d5-4b0e-bc0b-7c796649fc6b"
      unitRef="usd">139000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzExLTctMS0xLTY4NzY2_c0936c69-347a-44c6-b3e2-80d783ec4dad"
      unitRef="usd">2080000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEyLTEtMS0xLTY4NzY2_09929729-0af3-4139-af86-14e3ba256433"
      unitRef="usd">17885000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEyLTMtMS0xLTY4NzY2_76ec88f1-4a5a-4bc2-b279-a47869f40ffa"
      unitRef="usd">2913000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEyLTUtMS0xLTY4NzY2_e02697c7-cabe-4734-92b7-e2149b8031c7"
      unitRef="usd">2430000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEyLTctMS0xLTY4NzY2_eeb90d66-4390-4a21-997b-ce3f71f8e518"
      unitRef="usd">23228000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEzLTEtMS0xLTY4NzY2_f0ba9277-d007-4527-b895-99a452cf770f"
      unitRef="usd">205000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEzLTMtMS0xLTY4NzY2_06a319a6-c96c-4f60-8354-e7bb09a6df22"
      unitRef="usd">-8000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEzLTUtMS0xLTY4NzY2_3d984dc7-be86-4c7c-a025-a1f6cd9b4e92"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzEzLTctMS0xLTY4NzY2_cb310b3d-7e6c-46cb-bcaf-9ed3f77780ff"
      unitRef="usd">197000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE0LTEtMS0xLTY4NzY2_cdc09b9b-0e5c-4024-80d8-bf5bc4f9a48c"
      unitRef="usd">-8000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE0LTMtMS0xLTY4NzY2_fbc4e979-0a69-488a-a933-8070516eb26c"
      unitRef="usd">2000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE0LTUtMS0xLTY4NzY2_3315c8a2-7785-4b6e-ae62-edd8bacf7fb8"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE0LTctMS0xLTY4NzY2_2b087ee6-1e0c-41c2-8db2-de11fa7d8764"
      unitRef="usd">-6000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i35d2514974d648b4a321860ce0da423a_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE1LTEtMS0xLTY4NzY2_a95dd40a-5d90-4473-9406-ceb066feb6ab"
      unitRef="usd">2580000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i0a8d5443c6c445b7b1df9e882c954e13_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE1LTMtMS0xLTY4NzY2_f10aeb4f-1d61-4668-9f78-b59d9d1ade5f"
      unitRef="usd">404000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6e256b4d3f8045d6a0d60842042e5330_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE1LTUtMS0xLTY4NzY2_aef556ad-1a48-4998-82ab-27635699a777"
      unitRef="usd">379000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpmYzQwZWMyZGIzNzc0YTRlYTEyODNiYThjYmZhN2E2Yi90YWJsZXJhbmdlOmZjNDBlYzJkYjM3NzRhNGVhMTI4M2JhOGNiZmE3YTZiXzE1LTctMS0xLTY4NzY2_072c39b6-4a7e-4518-aa25-1b0923c1395f"
      unitRef="usd">3363000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="iec5b1cb8aec941ee8481b1247d22f717_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzQtMS0xLTEtNjg3NjY_3cf38db6-7738-4c71-9e50-beb35a2382e4"
      unitRef="usd">1465000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i048dd0bf323147f88d1ce251936a8002_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzQtMy0xLTEtNjg3NjY_32a3e0dc-fb27-4507-a111-686a8f65b272"
      unitRef="usd">267000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i2c45749706a94b278c9d69ee05c26153_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzQtNS0xLTEtNjg3NjY_9f77c6c6-8daf-477c-99d9-664722d1c079"
      unitRef="usd">122000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzQtNy0xLTEtNjg3NjY_49ddb950-9e1f-4f7d-921a-1da67272783e"
      unitRef="usd">1854000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzYtMS0xLTEtNjg3NjY_5f188688-52a0-47e3-a6e6-81091c410837"
      unitRef="usd">12545000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzYtMy0xLTEtNjg3NjY_83587ccb-d193-4475-9b1a-d0937401450f"
      unitRef="usd">2189000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzYtNS0xLTEtNjg3NjY_1d0f7197-6bb3-42c6-93b2-cd1687aefd0b"
      unitRef="usd">1205000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzYtNy0xLTEtNjg3NjY_2f2a53a8-9a1c-4d2a-a921-c61e05de5b47"
      unitRef="usd">15939000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzctMS0xLTEtNjg3NjY_a77711f7-3456-4221-aa45-96cee809814a"
      unitRef="usd">-84000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzctMy0xLTEtNjg3NjY_0476c185-ec1c-4045-bb1e-217e3c9527af"
      unitRef="usd">-28000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzctNS0xLTEtNjg3NjY_b3849d27-b936-4f10-bd33-e54329216694"
      unitRef="usd">-7000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzctNy0xLTEtNjg3NjY_5cb04071-5dfe-402c-a14d-8b751992cdbe"
      unitRef="usd">-119000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzgtMS0xLTEtNjg3NjY_b8df035a-5a8c-4185-9a12-75d017f985fd"
      unitRef="usd">12461000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzgtMy0xLTEtNjg3NjY_a9a15a16-b994-435d-98b4-6a245c632952"
      unitRef="usd">2161000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzgtNS0xLTEtNjg3NjY_968012a6-fd53-4918-8535-880d133494f5"
      unitRef="usd">1198000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzgtNy0xLTEtNjg3NjY_ef318bc4-2cd5-4b8b-9cd3-00343f5caacb"
      unitRef="usd">15820000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEwLTEtMS0xLTY4NzY2_b44ebf01-e460-42eb-95a1-13f1021faf2b"
      unitRef="usd">10940000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEwLTMtMS0xLTY4NzY2_fead3f4b-d6ff-4298-a167-21399739e762"
      unitRef="usd">1884000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEwLTUtMS0xLTY4NzY2_dad0f114-b506-4505-91b4-1ab66afe9b3c"
      unitRef="usd">1047000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEwLTctMS0xLTY4NzY2_2f6d08b1-e831-4216-a7e4-e54b7086d7c3"
      unitRef="usd">13871000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzExLTEtMS0xLTY4NzY2_ba5de47a-27de-4730-b46d-cb6ebe8bd716"
      unitRef="usd">1176000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzExLTMtMS0xLTY4NzY2_5dd9c910-990d-4590-9a5e-9174912f176b"
      unitRef="usd">233000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzExLTUtMS0xLTY4NzY2_e266549f-8e87-4d57-a069-586eebeb79d6"
      unitRef="usd">98000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzExLTctMS0xLTY4NzY2_3938b528-b38d-4087-8485-07a6f089a31b"
      unitRef="usd">1507000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEyLTEtMS0xLTY4NzY2_bfcb8f4f-afe4-4ff6-8198-98d8252c5dc9"
      unitRef="usd">12116000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEyLTMtMS0xLTY4NzY2_5142b210-32af-450d-b43d-45c91f263005"
      unitRef="usd">2117000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEyLTUtMS0xLTY4NzY2_044a8af4-b55f-4202-8f0d-3d393b70a4ee"
      unitRef="usd">1145000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <us-gaap:PaymentsForLossesAndLossAdjustmentExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEyLTctMS0xLTY4NzY2_db87acab-3986-46a4-80e6-5ab81ec11d68"
      unitRef="usd">15378000000</us-gaap:PaymentsForLossesAndLossAdjustmentExpense>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEzLTEtMS0xLTY4NzY2_1a9a4eae-fe40-4c8f-bf80-3f4550a1158b"
      unitRef="usd">215000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEzLTMtMS0xLTY4NzY2_3c225331-357f-46d0-8f9a-3805039a0d5a"
      unitRef="usd">79000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEzLTUtMS0xLTY4NzY2_0544509f-1daf-40ed-a43f-7369f67c7720"
      unitRef="usd">0</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzEzLTctMS0xLTY4NzY2_ddd592dc-c6b1-485d-a7a0-f32777f52f40"
      unitRef="usd">294000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE0LTEtMS0xLTY4NzY2_548b0569-fb8b-46e3-bedd-115d43e59c44"
      unitRef="usd">104000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE0LTMtMS0xLTY4NzY2_0c350fb3-5c6b-4dae-9b83-da75ab287e41"
      unitRef="usd">2000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE0LTUtMS0xLTY4NzY2_17a954ad-1155-400d-ad9b-98bf26457ab1"
      unitRef="usd">0</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE0LTctMS0xLTY4NzY2_19d90c7e-1f23-4670-a33c-936ae838b975"
      unitRef="usd">106000000</moh:MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i13f72b45b4644a468fe3bf237a344ae5_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE1LTEtMS0xLTY4NzY2_26156093-0ad6-4d89-a78b-38cffe52fc51"
      unitRef="usd">2129000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="ie051c5fdd0164b7692de987d735b5614_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE1LTMtMS0xLTY4NzY2_c0797871-dd35-4d6b-9b48-356e87ff4c4c"
      unitRef="usd">392000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i0f8bd3d713d84b16b5d4c1c2e0b0602f_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE1LTUtMS0xLTY4NzY2_aa414216-cf19-4c78-86c7-2fceb509f988"
      unitRef="usd">175000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZToxMzk1NDc5OGE5NDk0OGNjYWMxNmNiZjhiY2U4ZjZmNS90YWJsZXJhbmdlOjEzOTU0Nzk4YTk0OTQ4Y2NhYzE2Y2JmOGJjZThmNmY1XzE1LTctMS0xLTY4NzY2_a679bd23-4a0c-49fd-a9f0-d71f36189482"
      unitRef="usd">2696000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzExODQ_29ae7d24-3016-40db-97e7-80a0267ce441"
      unitRef="usd">-284000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzExODg_fe6e5bf0-6806-40bd-b44d-b0f3dddc65f6"
      unitRef="usd">-239000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzExOTU_5cb04071-5dfe-402c-a14d-8b751992cdbe"
      unitRef="usd">-119000000</us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense>
    <us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwNzc_3c96da77-28eb-4e89-9739-482617a2cc64">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.444%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.737%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.541%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Incurred Claims and Allocated Claims Adjustment Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total IBNP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative number of reported claims&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Benefit Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,233&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,167&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;108&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cumulative Paid Claims and Allocated Claims Adjustment Expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Benefit Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Unaudited)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="id90f37a0e7ed48588693d942d7439522_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtMi0xLTEtNjg3NjY_c8632ea8-bdf9-4f60-bba2-82dcabd23abc"
      unitRef="usd">16233000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="iaa1f11b3a0464f1c8a8e9399866f72eb_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtNC0xLTEtNjg3NjY_75b049b4-ec66-4d57-bdc5-88398706b5d7"
      unitRef="usd">16056000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i3e82750ee1ba4f92ba421980442e025f_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtNi0xLTEtNjg3NjY_66ef3640-3049-4522-9447-61802d84ca7b"
      unitRef="usd">16000000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
      contextRef="i0d21f0289d0f4503a608e0c544fa3528_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtOC0xLTEtNjg3NjY_e227932d-8f52-411c-bfb8-e09bbb172a37"
      unitRef="usd">27000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="i0d21f0289d0f4503a608e0c544fa3528_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzUtMTAtMS0xLTY4NzY2_179c5fd3-9861-4999-97c6-696c43b154d9"
      unitRef="claim">138000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="ibc6e982b4b304fa2849be3b24940489a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzYtNC0xLTEtNjg3NjY_cf2d7011-e4dc-402d-bdce-76b04f8939fa"
      unitRef="usd">24167000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i8d09c2e933d841399382aeaf45b11f51_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzYtNi0xLTEtNjg3NjY_8eb780fa-ba22-4641-999d-76164c79525c"
      unitRef="usd">23979000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
      contextRef="ib60f70f36c784daabd311b0746a76015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzYtOC0xLTEtNjg3NjY_eb83efdf-7a3b-4b22-b318-55863b6a4358"
      unitRef="usd">108000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="ib60f70f36c784daabd311b0746a76015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzYtMTAtMS0xLTY4NzY2_1b1aebfb-bfbc-4880-a5d5-9fe746725f83"
      unitRef="claim">236000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1
      contextRef="i9ce51eb40d964399bcbf595c78a3712c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzctNi0xLTEtNjg3NjY_d4fdc872-57d3-452e-8087-b9b219ad92df"
      unitRef="usd">27459000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
      contextRef="i0ca478154d99467c8fbc5952a0a6af98_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzctOC0xLTEtNjg3NjY_29b15fdf-3d63-48e8-a552-839438654599"
      unitRef="usd">2453000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount>
    <us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims
      contextRef="i0ca478154d99467c8fbc5952a0a6af98_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzctMTAtMS0xLTY4NzY2_5994f84c-ea62-4f68-8da3-a2ddb3a015a3"
      unitRef="claim">264000000</us-gaap:ShortdurationInsuranceContractsNumberOfReportedClaims>
    <moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzgtNi0xLTEtNjg3NjY_f2565838-6e74-411e-8a57-9867870623c3"
      unitRef="usd">67438000000</moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment>
    <us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTozZmIzZjdkY2Y0Y2Y0Mjk0OTRkMGNiYzIxYTYxMTc1Ny90YWJsZXJhbmdlOjNmYjNmN2RjZjRjZjQyOTQ5NGQwY2JjMjFhNjExNzU3XzgtOC0xLTEtNjg3NjY_bd44a3da-7426-4432-a0da-123815bc7df1"
      unitRef="usd">2588000000</us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="iacb62ab94ca7487b9f7d98e6acaec0bd_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzUtMi0xLTEtNjg3NjY_3ae2ff0c-3c22-440b-9ec0-efe5b0f2fad9"
      unitRef="usd">13871000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i820c538fe10a42b88e632ca56ab2d10e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzUtNC0xLTEtNjg3NjY_b6db45e8-c2bd-478a-9946-29d259a2dc50"
      unitRef="usd">16004000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i0d21f0289d0f4503a608e0c544fa3528_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzUtNi0xLTEtNjg3NjY_ab1635b6-9a7d-4dac-91a7-b6229b0a201f"
      unitRef="usd">15973000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="id22d0b329d7a4bb5a67d6402f8b59ed8_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzYtNC0xLTEtNjg3NjY_95074b69-6cec-4aa9-be62-2fb13da733e0"
      unitRef="usd">21148000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="ib60f70f36c784daabd311b0746a76015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzYtNi0xLTEtNjg3NjY_c7b99eac-7581-4f03-96ae-05b5dc6b78ce"
      unitRef="usd">23871000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i0ca478154d99467c8fbc5952a0a6af98_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzctNi0xLTEtNjg3NjY_83d0f094-61b4-43f7-9369-8315f5f2b525"
      unitRef="usd">24345000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTo1ZWY4N2EyMzlkNDk0NDQ3YjRhOGJjYWM0ZGRkMWE3Yi90YWJsZXJhbmdlOjVlZjg3YTIzOWQ0OTQ0NDdiNGE4YmNhYzRkZGQxYTdiXzgtNi0xLTEtNjg3NjY_788556f1-afa5-445e-a523-f01acc254f96"
      unitRef="usd">64189000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90ZXh0cmVnaW9uOmM2NTM0MzMyZjcwNzQ3YzA5ODNhZDliNTUxYmNiZmY5XzMwODg_a19f90a2-c04a-4ad5-8521-e4a3499c0b4e">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents a reconciliation of claims development to the aggregate carrying amount of the liability for medical claims and benefits payable.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.712%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.462%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Incurred claims and allocated claims adjustment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: cumulative paid claims and allocated claims adjustment expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(64,189)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;All outstanding liabilities before 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-risk and other provider payables&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medical claims and benefits payable &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,528&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzMtNi0xLTEtNjg3NjY_4c71fd93-20de-4aca-a840-4da7c12335fa"
      unitRef="usd">67438000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzQtNi0xLTEtNjg3NjY_6c6aeab0-c073-4883-a9ef-d25a25507260"
      unitRef="usd">64189000000</us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet>
    <moh:ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzUtNi0xLTEtNjg3NjY_c42f0c9c-c27c-41c1-be6a-96e1a38a62cc"
      unitRef="usd">9000000</moh:ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears>
    <us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzctNi0xLTEtNjg3NjY_d8b1d617-add7-49a2-ab47-2fb1579f5524"
      unitRef="usd">270000000</us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems>
    <us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjMvZnJhZzpjNjUzNDMzMmY3MDc0N2MwOTgzYWQ5YjU1MWJjYmZmOS90YWJsZTpkODQ5OGVhZjA0N2I0MzY0OTY0MTdjZWI2Nzg4YTE4Mi90YWJsZXJhbmdlOmQ4NDk4ZWFmMDQ3YjQzNjQ5NjQxN2NlYjY3ODhhMTgyXzgtNi0xLTEtNjg3NjY_d4fd3864-a717-4751-8f95-98dc84136799"
      unitRef="usd">3528000000</us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense>
    <us-gaap:LongTermDebtTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI3MzU_ee386cf7-6257-45c7-a5c1-359fb0dffce3">Debt &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of debt, as of December&#160;31, 2022, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All our debt is held at the parent which is reported in the Other segment. The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-current long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Credit Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are party to a credit agreement (the &#x201c;Credit Agreement&#x201d;) which includes a revolving credit facility (&#x201c;Credit Facility&#x201d;) of $1.0 billion, among other provisions. The Credit Agreement has a term of five years, and all amounts outstanding will be due and payable on June 8, 2025. Borrowings under the Credit Agreement bear interest based, at our election, on a base rate or other defined rate, plus in each case, the applicable margin. In addition to interest &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;payable on the principal amount of indebtedness outstanding from time to time under the Credit Agreement, we are required to pay a quarterly commitment fee. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Credit Agreement contains customary non-financial and financial covenants. As of December&#160;31, 2022, we were in compliance with all financial and non-financial covenants under the Credit Agreement and other long-term debt. As of December&#160;31, 2022, no amounts were outstanding under the Credit Facility.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our senior notes are described below. Each of these notes are senior unsecured obligations of Molina and rank equally in right of payment with all existing and future senior debt, and senior to all existing and future subordinated debt of Molina. In addition, each of the notes contain customary non-financial covenants and change of control provisions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The indentures governing the senior notes contain cross-default provisions that are triggered upon default by us or any of our subsidiaries on any indebtedness in excess of the amount specified in the applicable indenture. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;4.375% Notes due 2028. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have $800 million aggregate principal amount of senior notes (the &#x201c;4.375% Notes&#x201d;) outstanding as of December 31, 2022, which are due June 15, 2028, unless earlier redeemed. Interest, at a rate of 4.375% per annum, is payable semiannually in arrears on June 15 and December 15. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;3.875% Notes due 2030. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have $650 million aggregate principal amount of senior notes (the &#x201c;3.875% Notes due 2030&#x201d;) outstanding as of December 31, 2022, which are due November 15, 2030, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.&lt;/span&gt;&lt;/div&gt;3.875% Notes due 2032. We have $750&#160;million aggregate principal amount of senior notes (the &#x201c;3.875% Notes due 2032&#x201d;) outstanding as of December 31, 2022, which are due May 15, 2032, unless earlier redeemed. Interest, at a rate of 3.875% per annum, is payable semiannually in arrears on May 15 and November 15.</us-gaap:LongTermDebtTextBlock>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI3Mjc_fa1dfad8-2f3b-4dd7-a870-dd181cf9d1b7">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contractual maturities of debt, as of December&#160;31, 2022, are illustrated in the following table. All amounts represent the principal amounts of the debt instruments outstanding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.046%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.998%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjphNWM3NGMwODM3MWM0NmRkODUwNDY4NGNjM2ZhZTVjZF80_a703ac38-9997-4647-a9bd-fc863bbebef9"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMS0xLTEtNjg3NjY_5c085cac-2121-4cd3-b5fb-e988537e5370"
      unitRef="usd">800000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMy0xLTEtNjg3NjY_34714666-d32b-405a-a281-4ca504c7e2fd"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtNS0xLTEtNjg3NjY_852f95cb-d106-4839-a2e5-452deda54f99"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtNy0xLTEtNjg3NjY_387fc85a-d630-4307-a63e-d7b4ebbe1c22"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtOS0xLTEtNjg3NjY_6b23d9e4-4a8e-4f73-a667-85fa01d60177"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMTEtMS0xLTY4NzY2_d1307908-6936-4255-8a02-a3df123b6de8"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzMtMTMtMS0xLTY4NzY2_21a6d41e-033f-4e2e-8d8d-cc6410394c77"
      unitRef="usd">800000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjphODM3YmM3Yzc0ZDg0NWE4YjU0NzFmMjExMDJiYmFlMF80_981093a5-53dc-4dd4-bee6-323c907b5574"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMS0xLTEtNjg3NjY_e43a32fa-e2ca-4b5e-9c37-bbae57c3967b"
      unitRef="usd">650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMy0xLTEtNjg3NjY_afe84437-fc78-468e-bc7b-69a318bdfe4b"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtNS0xLTEtNjg3NjY_173b892e-f3b8-4118-97ae-34a83e08d0f0"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtNy0xLTEtNjg3NjY_ae1d1ab7-160e-4953-afab-79b69f69b617"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtOS0xLTEtNjg3NjY_9cceb408-2055-419c-99ca-3744517c6782"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMTEtMS0xLTY4NzY2_6e7969b8-28a7-4d6d-acdc-b1d5d3b6c9d6"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzQtMTMtMS0xLTY4NzY2_4b79ea21-2b9f-47a7-9014-f362495dae77"
      unitRef="usd">650000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjpjODU1Y2FmNTYwMzE0OTIxOWM4ODgwYjU4ODgwNjNiMl80_f0731975-5da3-49e5-a53d-eac52e0cb078"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMS0xLTEtNjg3NjY_01800a9b-b895-4fe9-a7a6-8b5f6afcfc67"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMy0xLTEtNjg3NjY_d957f2ae-7f62-436e-ad22-0fe63c8b59a4"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtNS0xLTEtNjg3NjY_207eaffb-6800-4a48-82ff-806230b08bc0"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtNy0xLTEtNjg3NjY_0c96a1a1-bef3-4e93-a607-052e2ec5f162"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtOS0xLTEtNjg3NjY_dbfef8d7-d2f0-4994-bb17-90c5798b20fb"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMTEtMS0xLTY4NzY2_d83c8d68-525b-49b8-a25e-11d2af91a883"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzUtMTMtMS0xLTY4NzY2_ca509288-7117-458c-8068-541610f7099d"
      unitRef="usd">750000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtMS0xLTEtNjg3NjY_52bf824d-e44b-494f-b3eb-68d77d3e4149"
      unitRef="usd">2200000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtMy0xLTEtNjg3NjY_37ff9531-2aaa-4969-a7ea-2eca975bca2c"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtNS0xLTEtNjg3NjY_8a052aa3-f656-420b-a840-21943c2e08ff"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtNy0xLTEtNjg3NjY_b9cd7954-ca0f-4327-b631-e2c9965c0b6a"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtOS0xLTEtNjg3NjY_7f43c338-bdd6-4058-8054-d2532f73e96d"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtMTEtMS0xLTY4NzY2_fb368c98-41b4-4295-abf1-56768b2df788"
      unitRef="usd">0</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTo5YmJjMjI3YmJkN2U0MWNkOTAwZTA5MzhiZTc2NDc5NC90YWJsZXJhbmdlOjliYmMyMjdiYmQ3ZTQxY2Q5MDBlMDkzOGJlNzY0Nzk0XzYtMTMtMS0xLTY4NzY2_8febd8c1-6e23-4c66-99fb-4044110e953e"
      unitRef="usd">2200000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI3NDA_c84ff8fa-f85a-4a8a-946a-c693d0b7a41d">The following table summarizes our outstanding debt obligations, all of which are non-current as of the dates reported below:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-current long-term debt:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.875% Notes due 2032&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: unamortized debt issuance costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzktMC0xLTEtNjg3NjYvdGV4dHJlZ2lvbjozYmUzMzhmMTRlMjA0NGViOThmM2E0ZDE5MjgwNjA0ZV80_a703ac38-9997-4647-a9bd-fc863bbebef9"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzktMS0xLTEtNjg3NjY_679704d2-51b1-4081-9777-d365d1928c6c"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i71d56b2727844c739f8fc7c6c248b44d_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzktMy0xLTEtNjg3NjY_18d9661d-747c-43df-a778-d51ada99c13a"
      unitRef="usd">800000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEwLTAtMS0xLTY4NzY2L3RleHRyZWdpb246ZGM3NDNjMjYzZWRmNDRmM2I4YTI5Nzg1ZGYxMDUxNDdfNA_981093a5-53dc-4dd4-bee6-323c907b5574"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEwLTEtMS0xLTY4NzY2_05fb42bb-75fc-4d8c-b32f-e4d15c16113d"
      unitRef="usd">650000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="ia02c779ff61241edbb85961d0ca9c5eb_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEwLTMtMS0xLTY4NzY2_5a78aa46-2467-4fb5-8102-e4e5910bd548"
      unitRef="usd">650000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzExLTAtMS0xLTY4NzY2L3RleHRyZWdpb246N2QyNGVlZmQxYjI3NDdhMzk1ZTE5NTBjZTM5YjRmZWNfNA_f0731975-5da3-49e5-a53d-eac52e0cb078"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzExLTEtMS0xLTY4NzY2_9632a681-383b-4326-8ec8-19d22955fa79"
      unitRef="usd">750000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount
      contextRef="icd32afbbde514f44b74fc5c5bac8e578_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzExLTMtMS0xLTY4NzY2_9f2660df-b0c2-4d32-9ac1-b27b89fb0d68"
      unitRef="usd">750000000</moh:LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEyLTEtMS0xLTY4NzY2_e528c89f-6bf9-473b-a43f-06fd6ea54bdc"
      unitRef="usd">24000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEyLTMtMS0xLTY4NzY2_f64da1ea-5a84-45e7-876b-6692b2d467c1"
      unitRef="usd">27000000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEzLTEtMS0xLTY4NzY2_df9e11cd-4d0e-418a-9d6c-749fe63b30ec"
      unitRef="usd">2176000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90YWJsZTozNWU3NTI2NzIwNmM0OTgxODY3NGFjM2Q1MjFmNjk1Mi90YWJsZXJhbmdlOjM1ZTc1MjY3MjA2YzQ5ODE4Njc0YWMzZDUyMWY2OTUyXzEzLTMtMS0xLTY4NzY2_3f494480-cf80-444c-8d09-53c7514d0fd7"
      unitRef="usd">2173000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i0a8a1bfa4d2646619b114fd4ca9f2f3c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzUyNQ_006f7fd1-6484-4311-9e98-32b2ba2255af"
      unitRef="usd">1000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentTerm
      contextRef="i894911675af3435aaff732b2e986f5cb_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzU4OA_7a54d8b6-e1d7-4dd6-a2a1-6249e9921be5">P5Y</us-gaap:DebtInstrumentTerm>
    <us-gaap:LineOfCredit
      contextRef="i0a8a1bfa4d2646619b114fd4ca9f2f3c_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzEyMjA_dc5c66fb-1309-4a32-bcb9-4b8b593d7e2f"
      unitRef="usd">0</us-gaap:LineOfCredit>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzE4NTU_a703ac38-9997-4647-a9bd-fc863bbebef9"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzE4ODI_9960008d-e9be-425f-b50d-9d98e8920799"
      unitRef="usd">800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzE5MzQ_a703ac38-9997-4647-a9bd-fc863bbebef9"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i73f9280e97a540afba84f71174ad29c4_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIwNTk_a703ac38-9997-4647-a9bd-fc863bbebef9"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIxMzc_981093a5-53dc-4dd4-bee6-323c907b5574"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIxNjQ_e43a32fa-e2ca-4b5e-9c37-bbae57c3967b"
      unitRef="usd">650000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIyMTY_981093a5-53dc-4dd4-bee6-323c907b5574"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i562391d3973d4bd18a2b1c897b6c4610_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzIzNTQ_981093a5-53dc-4dd4-bee6-323c907b5574"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI0MzA_f0731975-5da3-49e5-a53d-eac52e0cb078"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI0NTc_79f7e3dc-8db9-4f6b-8931-d5a7adf17cff"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI1MDk_f0731975-5da3-49e5-a53d-eac52e0cb078"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i32599e3034534c39973f424bf0a0d5a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNjkvZnJhZzo0MDU3OWJjM2I5ZDc0M2E2YjBiNjNhZmNlYTM5ZWNjNS90ZXh0cmVnaW9uOjQwNTc5YmMzYjlkNzQzYTZiMGI2M2FmY2VhMzllY2M1XzI2NDI_e2f91aab-38e9-4c84-bc47-aacf1109257c"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2NzI_d288e239-fb0a-4160-9ef2-22ef39d4d69b">Income Taxes &lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense for continuing operations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate for continuing operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Statutory federal tax (benefit) rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income provision (benefit), net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nondeductible health insurer fee (&#x201c;HIF&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nondeductible compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective tax expense rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effective tax rate was not impacted by the HIF in 2022 and 2021 given it was repealed for years after 2020. Our effective tax rate is based on expected income, statutory tax rates, and tax planning opportunities available to us in the various jurisdictions in which we operate. Management estimates and judgments are required in determining our effective tax rate. We are routinely under audit by federal, state, or local authorities regarding the timing and amount of deductions, nexus of income among various tax jurisdictions, and compliance with federal, state, foreign, and local tax laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are classified as non-current. Significant components of our deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and reserve liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued medical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unearned premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credit carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets, net of valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had state net operating loss carryforwards of $95&#160;million, which begin expiring in 2036.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had foreign net operating loss carryforwards of $8&#160;million, which expire in 2032. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had foreign tax credit carryovers of $5&#160;million, which expire in 2030.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We evaluate the need for a valuation allowance taking into consideration the ability to carry back and carry forward tax credits and losses, available tax planning strategies and future income, including reversal of temporary differences. We have determined that as of December&#160;31, 2022, $18 million of deferred tax assets did not satisfy the recognition criteria. Therefore, we increased our valuation allowance by $8 million, from $10 million at December&#160;31, 2021, to $18 million as of December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognize tax benefits only if the tax position is more likely than not to be sustained. We are subject to income taxes in the United States, Puerto Rico, and numerous state jurisdictions. Significant judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. We establish reserves for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. These reserves are established when we believe that certain positions might be challenged despite our belief that our tax return positions are fully supportable. We adjust these reserves in light of changing facts and circumstances, such as the outcome of tax audits. The provision for income taxes includes the impact of reserve provisions and changes to reserves that are considered appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The roll forward of our unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total amount of unrecognized tax benefits at December&#160;31, 2022, 2021 and 2020 that, if recognized, would affect the effective tax rates is $5 million, $15 million, and $20 million, respectively. We expect that during the next 12 months it is reasonably possible that unrecognized tax benefit liabilities may decrease by $5 million due to resolution of a state refund claim. The state refund claim will not result in a cash payment for income taxes if our claim is denied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our continuing practice is to recognize interest and/or penalties related to unrecognized tax benefits in income tax expense. Amounts accrued for the payment of interest and penalties as of December&#160;31, 2022, 2021 and 2020 were insignificant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may be subject to examination by the IRS for calendar years after 2018. With a few exceptions, which are immaterial in the aggregate, we no longer are subject to state, local, and Puerto Rico tax examinations for years before 2018. &lt;/span&gt;&lt;/div&gt;On August 16, 2022, the Inflation Reduction Act was signed into law. The Inflation Reduction Act includes various tax provisions, which are effective for the tax years beginning on or after January 1, 2023. We do not expect such tax provisions to have a material impact on our consolidated financial results.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2Mjk_fff08f00-9ff7-4a16-969c-c8ebb36c1a76">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Income tax expense for continuing operations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;281&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;216&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;288&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzUtMS0xLTEtNjg3NjY_ba25c051-0c06-4496-807f-7b63e77bfc96"
      unitRef="usd">297000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzUtMy0xLTEtNjg3NjY_88d793db-e625-4ef5-96bc-0ef1a68f8d55"
      unitRef="usd">209000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzUtNS0xLTEtNjg3NjY_c479704e-81ee-4a1f-b6fe-638ecb62dc58"
      unitRef="usd">281000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzYtMS0xLTEtNjg3NjY_bca9ae94-701d-4ded-ac2a-184358cd0812"
      unitRef="usd">40000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzYtMy0xLTEtNjg3NjY_416fa5eb-fa17-46c0-b69a-a2582a70a3c3"
      unitRef="usd">31000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzYtNS0xLTEtNjg3NjY_4b0d71a1-1472-475c-b44f-e739c0ce253c"
      unitRef="usd">26000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzgtMS0xLTEtNjg3NjY_5479eb75-8347-4de9-a15c-6d85632cb7c2"
      unitRef="usd">337000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzgtMy0xLTEtNjg3NjY_12872700-1fd8-4cfc-9193-1b4a559c360d"
      unitRef="usd">240000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzgtNS0xLTEtNjg3NjY_976ae34b-8fc1-4e41-8cb6-eb401954bed3"
      unitRef="usd">307000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEwLTEtMS0xLTY4NzY2_3b927445-c222-4052-a875-b10380d184e7"
      unitRef="usd">-66000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEwLTMtMS0xLTY4NzY2_28e7795d-238b-42ea-8f55-d2ef0ea95da0"
      unitRef="usd">-17000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEwLTUtMS0xLTY4NzY2_1550ba99-fce0-408b-8124-d76e81a0c3a0"
      unitRef="usd">-13000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzExLTEtMS0xLTY4NzY2_ab083e05-4793-4f16-a7c5-d096675afead"
      unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzExLTMtMS0xLTY4NzY2_be3f564d-1b61-4784-b7c4-59ca53523691"
      unitRef="usd">-7000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzExLTUtMS0xLTY4NzY2_ad3cd2c6-4671-48fb-9230-ecb84317974a"
      unitRef="usd">-7000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEyLTEtMS0xLTY4NzY2_b30fdc50-162c-4d07-b6e0-6ab5aa1ae793"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEyLTMtMS0xLTY4NzY2_6155e7ea-20d9-4142-8a78-b31e298b4888"
      unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEyLTUtMS0xLTY4NzY2_fd83a00b-1b29-4ef6-9593-cc7b1485d4d8"
      unitRef="usd">1000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEzLTEtMS0xLTY4NzY2_1c5330e9-f634-4b0d-bfff-6e21aca379df"
      unitRef="usd">-66000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEzLTMtMS0xLTY4NzY2_c388186a-551d-42bf-adb8-4f1f603fadb6"
      unitRef="usd">-24000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzEzLTUtMS0xLTY4NzY2_c215b5d0-978a-4853-965e-58de07d414d6"
      unitRef="usd">-19000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzE0LTEtMS0xLTY4NzY2_7c616015-4918-4e99-88db-8cccb21f7cd9"
      unitRef="usd">271000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzE0LTMtMS0xLTY4NzY2_2a219bbc-5c77-43ca-b8f8-588310aebeae"
      unitRef="usd">216000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToxZjczYmNlNTdlMTg0MTYyOTM2ZmQxODdlMzcxOWFmYS90YWJsZXJhbmdlOjFmNzNiY2U1N2UxODQxNjI5MzZmZDE4N2UzNzE5YWZhXzE0LTUtMS0xLTY4NzY2_e112fe34-c769-4352-ae21-8e1921e16a85"
      unitRef="usd">288000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2NTA_e163a890-dea3-4e38-a0b3-7f1c7bf2f8e2">&lt;div style="margin-bottom:6pt;margin-top:7pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the combined effective income tax rate for continuing operations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Statutory federal tax (benefit) rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income provision (benefit), net of federal benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nondeductible health insurer fee (&#x201c;HIF&#x201d;)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nondeductible compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective tax expense rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzItMS0xLTEtNjg3NjY_c67264ed-abe8-44c3-9897-bb2e032bab42"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzItMy0xLTEtNjg3NjY_8e2d3c9f-c425-436a-9f12-cadf97270b94"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzItNS0xLTEtNjg3NjY_ce0ca12b-e088-4c3d-bcbe-1c92913e5f6e"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzMtMS0xLTEtNjg3NjY_995426c2-3ec5-4f8e-8e3d-dff8ffc83de5"
      unitRef="number">0.030</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzMtMy0xLTEtNjg3NjY_e15c225f-b949-4350-a525-9d873ea60763"
      unitRef="number">0.022</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzMtNS0xLTEtNjg3NjY_5cc292ce-f4d3-4c70-b051-8b89794c73b1"
      unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzUtMS0xLTEtNjg3NjY_e2afb186-5187-4567-9028-0c95bc63e36e"
      unitRef="number">0</moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent>
    <moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzUtMy0xLTEtNjg3NjY_3e28f713-4aed-4f71-8f19-2d7d90f62f25"
      unitRef="number">0</moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent>
    <moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzUtNS0xLTEtNjg3NjY_00016ebf-431c-42e1-9aa6-40234ee0aac0"
      unitRef="number">0.061</moh:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzYtMS0xLTEtNjg3NjY_6977a189-b7d6-49c6-8a57-d0fd56cddfa9"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzYtMy0xLTEtNjg3NjY_64ac5ca8-1c74-4bf0-bf66-45b5a68c2e7d"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzYtNS0xLTEtNjg3NjY_2d8f3aaa-8346-47c1-8cd0-419a74b3f66c"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzgtMS0xLTEtNjg3NjY_c404dbdd-6884-45fd-9284-11bf754bf1a9"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzgtMy0xLTEtNjg3NjY_91ab957d-2417-40b3-92bb-d8793c66f92b"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzgtNS0xLTEtNjg3NjY_8072aefa-3eff-43d6-80e1-b525cd1da42b"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzktMS0xLTEtNjg3NjY_f60e5b85-e300-410b-b507-c0b1c0be54a9"
      unitRef="number">0.255</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzktMy0xLTEtNjg3NjY_6af1dff3-0128-43a9-a301-97478c90819e"
      unitRef="number">0.247</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTozMDAyOGEzZjJkYWY0NGJjYTYwZWMzZWY5YTEwOWQzOC90YWJsZXJhbmdlOjMwMDI4YTNmMmRhZjQ0YmNhNjBlYzNlZjlhMTA5ZDM4XzktNS0xLTEtNjg3NjY_d2bb60fe-fb8f-4791-bc24-e49a46663f03"
      unitRef="number">0.300</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2Mzk_4f65fd76-72ea-4616-99f4-afa5312c673e">Significant components of our deferred tax assets and liabilities as of December&#160;31, 2022 and 2021 were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued expenses and reserve liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other accrued medical costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unearned premiums&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credit carryover&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred income tax assets, net of valuation allowance &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred income tax liabilities &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred income tax asset&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;220&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzQtMS0xLTEtNjg3NjY_57aa728a-5d25-4663-a0ee-b15160da9c7a"
      unitRef="usd">96000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzQtMy0xLTEtNjg3NjY_1bc982d7-4e92-480d-8fbc-b4b20b28665f"
      unitRef="usd">57000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzUtMS0xLTEtNjg3NjY_19206740-de74-4cf0-9b5a-be248e4ebad2"
      unitRef="usd">24000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzUtMy0xLTEtNjg3NjY_89fda064-511d-420b-a9a1-7a6ddc994be6"
      unitRef="usd">23000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzYtMS0xLTEtNjg3NjY_4fc4a11a-9169-415b-b732-c1217decd818"
      unitRef="usd">9000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzYtMy0xLTEtNjg3NjY_1d93e8ce-b833-41d3-ba4d-439b3d15ae17"
      unitRef="usd">13000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzgtMS0xLTEtNjg3NjY_702024b6-24b4-426d-a485-728680c99a44"
      unitRef="usd">16000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzgtMy0xLTEtNjg3NjY_a87342ce-5eb4-445f-b45c-35f12342386d"
      unitRef="usd">17000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzktMS0xLTEtNjg3NjY_563d4701-8b93-4200-85fb-cc9e396e127c"
      unitRef="usd">40000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzktMy0xLTEtNjg3NjY_f90d3984-d6d5-468b-8ada-6cbabe029db1"
      unitRef="usd">9000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzktMS0xLTEtNzYyNjI_47a568ec-2003-47d0-bedc-c4ff232bdead"
      unitRef="usd">49000000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzktMy0xLTEtNzYyNjI_6458bec5-56e3-48e1-8eb1-c26b86374bb5"
      unitRef="usd">2000000</us-gaap:DeferredTaxAssetsUnrealizedCurrencyLosses>
    <moh:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzExLTEtMS0xLTc2MjQ5_377c3410-a087-4cbf-a44b-5a319dd584d6"
      unitRef="usd">9000000</moh:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <moh:DeferredTaxAssetsFixedAssetsAndIntangibles
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzExLTMtMS0xLTc2MjQ5_5c8c8262-39e0-4962-91c2-e7ba4d2eb58b"
      unitRef="usd">0</moh:DeferredTaxAssetsFixedAssetsAndIntangibles>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEwLTEtMS0xLTY4NzY2_f94f10a3-6781-4c91-8550-2fae8f7cbd49"
      unitRef="usd">5000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEwLTMtMS0xLTY4NzY2_924acac0-6b1a-490f-b787-08861445ed5b"
      unitRef="usd">5000000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzExLTEtMS0xLTY4NzY2_46df43fc-4752-4059-86f1-f413dece9d65"
      unitRef="usd">5000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzExLTMtMS0xLTY4NzY2_d1b9b787-dfaa-4f33-b13c-a8c0f0f3cb04"
      unitRef="usd">4000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEyLTEtMS0xLTY4NzY2_e26a4c64-6211-46bb-9c7e-aa1bd591d032"
      unitRef="usd">18000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEyLTMtMS0xLTY4NzY2_8b8926a4-2ff6-43e4-8dba-791a74566927"
      unitRef="usd">10000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEzLTEtMS0xLTY4NzY2_3d361c30-21d4-4d4d-9393-f4bd4c764e01"
      unitRef="usd">235000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzEzLTMtMS0xLTY4NzY2_39560853-edbc-485a-a829-4698bb90deb3"
      unitRef="usd">120000000</us-gaap:DeferredTaxAssetsNet>
    <moh:DeferredTaxLiabilitiesFixedAssetsAndIntangibles
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE0LTEtMS0xLTY4NzY2_9e04018e-b8f8-4aec-a753-a658428d79aa"
      unitRef="usd">0</moh:DeferredTaxLiabilitiesFixedAssetsAndIntangibles>
    <moh:DeferredTaxLiabilitiesFixedAssetsAndIntangibles
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE0LTMtMS0xLTY4NzY2_6b76d660-05f3-41bd-a065-ff46447ec953"
      unitRef="usd">1000000</moh:DeferredTaxLiabilitiesFixedAssetsAndIntangibles>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE1LTEtMS0xLTY4NzY2_c58ca582-4c4e-4b28-9957-fa50ea33f92f"
      unitRef="usd">15000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE1LTMtMS0xLTY4NzY2_7c7a7156-bad9-4f58-af5c-0b676b6499ce"
      unitRef="usd">13000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE4LTEtMS0xLTY4NzY2_504592e7-43f8-49a2-b06b-91dc6535b9d6"
      unitRef="usd">15000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE4LTMtMS0xLTY4NzY2_f7961210-724c-4892-bfb8-8d789ac6b6f4"
      unitRef="usd">14000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE5LTEtMS0xLTY4NzY2_cc22ad2a-6e0f-450f-899b-7274482fc292"
      unitRef="usd">220000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZTo0NjE4MjJjMTg0NzM0NDc5ODI2ODFmMzIwNDRlNGU4Mi90YWJsZXJhbmdlOjQ2MTgyMmMxODQ3MzQ0Nzk4MjY4MWYzMjA0NGU0ZTgyXzE5LTMtMS0xLTY4NzY2_423bdf41-567b-44d6-8018-1ad39f31e7c0"
      unitRef="usd">106000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards
      contextRef="ia92d461677b3467aad6b5cb1343d01b8_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzEwNzE_d015b4cc-c31c-4a1c-94d9-13eef0233cd2"
      unitRef="usd">95000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i7209f6abd53942d2b14fad2f133eb977_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzExNjM_c6813111-fffd-4f85-8618-ede05cf6b08e"
      unitRef="usd">8000000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i7209f6abd53942d2b14fad2f133eb977_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzEyMzc_f3579c99-952d-4238-95fc-97e298491c87"
      unitRef="usd">5000000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardValuationAllowance
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzE1MzY_77e8d575-c530-487f-b121-e4f1e162a866"
      unitRef="usd">18000000</us-gaap:TaxCreditCarryforwardValuationAllowance>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzE2NTU_0b895f97-8ec4-4321-bac3-a9467c25a0cd"
      unitRef="usd">-8000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzE2NjQ_98cea435-ee51-4647-b5fd-d0d66a270b5d"
      unitRef="usd">10000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzE2Nzc_645c585c-fd9f-432d-933d-0828b476c52e"
      unitRef="usd">18000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzM2NDU_0fa7a091-5aa2-42e1-8d6b-eec0ae80aff1">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The roll forward of our unrecognized tax benefits is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lapse in statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross unrecognized tax benefits at end of period&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(15)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzQtMS0xLTEtNjg3NjY_82c71ca3-5a62-4bf3-aa2d-d7c2c21c49bf"
      unitRef="usd">15000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzQtMy0xLTEtNjg3NjY_b60ceabd-03a5-48c0-9a58-17827eb0f672"
      unitRef="usd">20000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i8df5a01609344460bb17a1e2311459c7_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzQtNS0xLTEtNjg3NjY_a80845d4-b61e-4942-9123-4e6ff0fcd78e"
      unitRef="usd">20000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzktMS0xLTEtNjg3NjY_760693f1-8bd8-4bda-bb68-a3486433aa40"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzktMy0xLTEtNjg3NjY_8b9384ce-fd5f-4976-9149-0695ba79f0eb"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzktNS0xLTEtNjg3NjY_a8fbb30d-52a1-4149-af20-00a9fcef8160"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzEwLTEtMS0xLTY4NzY2_bbef2222-e9c5-4f73-a8f7-e0854bd18e56"
      unitRef="usd">10000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzEwLTMtMS0xLTY4NzY2_2b66cddd-b8cc-44b0-8428-4352edc20ceb"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzEwLTUtMS0xLTY4NzY2_4aa764d7-852e-4bf6-b9d6-3949a86c721d"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzExLTEtMS0xLTY4NzY2_6fd9e9f5-de31-42fc-895e-b648f707a861"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzExLTMtMS0xLTY4NzY2_022cd1e8-af10-48f7-aa8d-9a3fc24a8240"
      unitRef="usd">15000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90YWJsZToyZjUyMDVkNjhhZjQ0MjE2YTEyOTA4NWM3N2Q1ZjY3OS90YWJsZXJhbmdlOjJmNTIwNWQ2OGFmNDQyMTZhMTI5MDg1Yzc3ZDVmNjc5XzExLTUtMS0xLTY4NzY2_ae065a44-7dea-4d58-aa12-6627907d217e"
      unitRef="usd">20000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzI4NjI_269821e2-91d3-41f0-b292-b220193cc466"
      unitRef="usd">5000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzI4NjY_08516455-4be9-40a9-b515-8a8d846f59d2"
      unitRef="usd">15000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
      contextRef="i202e4db7009b4cf9bdcf1f64e749b198_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzI4NzQ_771f08d1-dc99-4126-bc25-cca58f9d77bd"
      unitRef="usd">20000000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzIvZnJhZzo5ODdlN2RjNjVmYTI0YTVhYTE1NWJlN2VlYWNhM2JkOS90ZXh0cmVnaW9uOjk4N2U3ZGM2NWZhMjRhNWFhMTU1YmU3ZWVhY2EzYmQ5XzMwMjg_bf70b3f3-7128-43eb-9e18-071a721cd980"
      unitRef="usd">5000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ1MTY_aff4c520-6ddb-4f80-a539-2d112bb6004d">Stockholders' Equity &lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Purchase Programs&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This new program supersedes the stock purchase program previously approved by our board of directors in September 2021, as described below. This new program will be funded with cash on hand and extends through December 31, 2023. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 590,000 shares for $200&#160;million in the fourth quarter of 2022 (average cost of $339.06 per share). No shares have been purchased in 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, our board of directors authorized the purchase of up to $500&#160;million, in the aggregate, of our common stock. This program was funded with cash on hand. Under this program, pursuant to a Rule 10b5-1 trading plan, we purchased approximately 658,000 shares for $200&#160;million in the second quarter of 2022 (average cost of $304.13 per share). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our employee stock plans, approximately 755,000 shares and 429,000 shares of common stock were issued, net of shares used to settle employees&#x2019; income tax obligations, during the years ended December&#160;31, 2022, and 2021, respectively. Total share-based compensation expense is reported in &#x201c;General and administrative expenses&#x201d; in the accompanying consolidated statements of income, and summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pretax&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net-of-Tax&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pretax&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net-of-Tax&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pretax&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net-of-Tax&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs and PSUs (defined below)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan and stock options &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Equity Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2022, we had employee equity incentives outstanding under our 2019 Equity Incentive Plan (the &#x201c;2019 EIP&#x201d;). The 2019 EIP provides for awards, in the form of restricted stock awards (&#x201c;RSAs&#x201d;), performance units (&#x201c;PSUs&#x201d;), stock options, and other stock&#x2013; or cash&#x2013;based awards, to eligible persons who perform services for us. The 2019 EIP provides for the issuance of up to 2.9 million shares of our common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock-based awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. RSAs and PSUs are granted with a fair value equal to the market price of our common stock on the date of grant, and generally vest in equal annual installments over periods up to four years from the date of grant. PSUs vest in their entirety at the end of three-year performance periods, if their performance conditions are met. We generally recognize expense for RSAs and PSUs on a straight-line basis. Activity for stock-based awards in the year ended December&#160;31, 2022, is summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;539,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(219,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested balance, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;511,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, total unrecognized compensation expense related to unvested RSAs and PSUs was $74 million, and $31 million, respectively, which we expect to recognize over a remaining weighted-average period of 2.0 years, and 0.7 years, respectively. This unrecognized compensation cost assumes an estimated forfeiture rate of 9.2% for non-executive employees as of December&#160;31, 2022, based on actual forfeitures over the last 4 years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant date fair value of awards granted and vested is presented in the following table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to four years from the date of grant, and have a maximum term of ten years from the date of grant. Stock option activity for the year ended December&#160;31, 2022, is summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options outstanding as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(390,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options outstanding, vested, and exercisable as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No stock options were granted in 2022, 2021, or 2020, and no stock options were exercised in 2020. As of December&#160;31, 2022, there was no unrecognized compensation expense related to unvested stock options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Employee Stock Purchase Plans (&#x201c;ESPP&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our ESPP, eligible employees may purchase common shares at 85% of the lower of the fair market value of our common stock on either the first or last trading day of each six-month offering period. Each participant is limited to a maximum purchase of $25,000 (as measured by the fair value of the stock acquired) per year through payroll deductions. We estimate the fair value of the stock issued using a standard option pricing model. For the years ended December&#160;31, 2022, 2021, and 2020, the inputs to this model were as follows: risk-free interest rates of approximately 0.1% to 2.5%; expected volatility of approximately 29% to 54%, dividend yields of 0%, and an average expected life of 0.5 years.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="if0857a373c3b4a04a563c80433da37a7_I20221130"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3Xzc2OTY1ODE0MDAxODg_bb1014f9-9675-48df-ac5b-8d4328813611"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="i231fe0f403304e04821105e21c970d54_D20221001-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzcxNDY4MjU1ODY5ODI_ef831229-e7cc-41d9-8214-411f0349c839"
      unitRef="shares">590000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i231fe0f403304e04821105e21c970d54_D20221001-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzcxNDY4MjU1ODY5Njg_6f57e73e-beb3-47df-9c0e-81851d1c32b6"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="i231fe0f403304e04821105e21c970d54_D20221001-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzcxNDY4MjU1ODY5NTk_cd78829d-e96b-43e0-8534-56c86a0525d5"
      unitRef="usdPerShare">339.06</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic666c8c846a6470fa80b6fd8546e1fb8_D20230101-20230213"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQzOTgwNDY1MTkwMTA_99e04cf8-61c2-4000-b7c6-44e3284071e6"
      unitRef="shares">0</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i0d872067ad8c4dfdb6ad4e01a7b702fc_I20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzExMg_6628e404-ecf7-4de5-ab49-d158fd0f0f2c"
      unitRef="usd">500000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="icf47a0c9203348a4a82289677971cd52_D20220401-20220630"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzcyMw_776241d2-51ba-47a4-98f8-0ffa59f59e56"
      unitRef="shares">658000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="icf47a0c9203348a4a82289677971cd52_D20220401-20220630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzczNw_f35bb311-10d5-462d-83b1-df76f84e33cf"
      unitRef="usd">200000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="icf47a0c9203348a4a82289677971cd52_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3Xzc4Nw_8826a3b6-3ec0-4e04-a994-bff0e522e812"
      unitRef="usdPerShare">304.13</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i71b7d1ac171e4a1480d0d094dfc1146d_D20220101-20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3Xzg4Nw_0962cd75-5d83-4d3c-8def-931ff1253e7f"
      unitRef="shares">755000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i748536bf845448ec8b3a8851a8779612_D20210101-20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzkwMQ_f4a666d4-6476-4c7d-ac34-ac46b3e578aa"
      unitRef="shares">429000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ1MDU_6fdbeacc-dbbb-4cb4-95ef-a23572da1f78">Total share-based compensation expense is reported in &#x201c;General and administrative expenses&#x201d; in the accompanying consolidated statements of income, and summarized below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.190%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.726%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pretax&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net-of-Tax&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pretax&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net-of-Tax&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Pretax&lt;br/&gt;Charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net-of-Tax&lt;br/&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs and PSUs (defined below)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan and stock options &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i730ca96dd7ca4ca290d11ea041a783c7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtMS0xLTEtNjg3NjY_04298830-ec7d-4b27-b779-f9548a21892a"
      unitRef="usd">97000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i730ca96dd7ca4ca290d11ea041a783c7_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtMy0xLTEtNjg3NjY_e37d0d37-1828-4d29-95ac-d51ad2576f73"
      unitRef="usd">90000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i07d9217daf844c889c548acff4d0a65a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtNS0xLTEtNjg3NjY_54a2c1f0-d29e-4f7f-bb00-ac8298fe1e14"
      unitRef="usd">66000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i07d9217daf844c889c548acff4d0a65a_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtNy0xLTEtNjg3NjY_a532fa53-b382-4a3e-bda7-34e3260b5587"
      unitRef="usd">62000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic983aeae5acc408cb7dab92ea09a8f01_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtOS0xLTEtNjg3NjY_915c2b06-c85e-4ad1-a8cc-e543e648eac3"
      unitRef="usd">47000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="ic983aeae5acc408cb7dab92ea09a8f01_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzUtMTEtMS0xLTY4NzY2_f776e283-5fda-4d30-b773-582c0d8c2681"
      unitRef="usd">44000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if31147c355a2444291af45d631a17138_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtMS0xLTEtNjg3NjY_f1cedd72-d091-4fa2-801d-c049f1d97e04"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="if31147c355a2444291af45d631a17138_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtMy0xLTEtNjg3NjY_d6494a8e-5049-48a4-a803-d7c7f8d7e7b6"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5b98d941fd8447b4b70e3c1c0b270359_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtNS0xLTEtNjg3NjY_115f5275-d53f-491f-b606-0c0d43857f46"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i5b98d941fd8447b4b70e3c1c0b270359_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtNy0xLTEtNjg3NjY_237d75de-6f95-4c3c-beee-205919faaf9f"
      unitRef="usd">6000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i49563c89a0044495a4024b953890bdec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtOS0xLTEtNjg3NjY_cd6bdba9-9a1f-414f-ad21-e6dee00fe683"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i49563c89a0044495a4024b953890bdec_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzYtMTEtMS0xLTY4NzY2_d9647ade-afb4-4dea-98ae-5de95a8f8af1"
      unitRef="usd">9000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctMS0xLTEtNjg3NjY_1f86c11d-b94e-432c-8625-00cbc7f713ce"
      unitRef="usd">103000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctMy0xLTEtNjg3NjY_63609a0f-6c48-42c3-afbc-905ca1a315e1"
      unitRef="usd">96000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctNS0xLTEtNjg3NjY_d5409122-f1e5-4b5d-aa05-ba80424a80cf"
      unitRef="usd">72000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctNy0xLTEtNjg3NjY_b826e812-55ec-4518-9d5a-821271cd4ca9"
      unitRef="usd">68000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctOS0xLTEtNjg3NjY_45662c36-a795-4558-a863-61ebee7f043a"
      unitRef="usd">57000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpjMjU0YWY5ZWI1NzE0ODkxOGY2YzdmYmMzZmU4ODFkMy90YWJsZXJhbmdlOmMyNTRhZjllYjU3MTQ4OTE4ZjZjN2ZiYzNmZTg4MWQzXzctMTEtMS0xLTY4NzY2_863e5cd1-5ee6-4e2e-a13d-bf832e17efdb"
      unitRef="usd">53000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i808268ffa68b43739052deba1dced859_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzE2NDM_94b3581f-ef4a-4050-82c5-dd1943484b99"
      unitRef="shares">2900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzE4Nzk_312452ee-231b-4ad1-a832-0c1bf7e8257c">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ1MTg_964dd54d-1a33-4c38-8e3e-a44371c1419f">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0OTA_43ea4779-4fb3-4dac-beec-41b289fa3721">Activity for stock-based awards in the year ended December&#160;31, 2022, is summarized below.&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.038%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.536%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.041%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Grant&#160;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested balance, December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;539,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;275,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(224,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;156.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(219,674)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;137.54&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,816)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;249.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unvested balance, December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;511,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;237.10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;312,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNonvestedShareActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i1e073e88099741bfbc940e573293e498_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzEtMS0xLTEtNjg3NjY_2acef134-2e08-4b82-9bc7-203d8405c1e1"
      unitRef="shares">539117</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i1e073e88099741bfbc940e573293e498_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzEtMy0xLTEtNjg3NjY_98d6b75b-1a1b-42a2-914e-a571a389920a"
      unitRef="usdPerShare">169.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i290c59f46b35464aaccca35307808b88_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzEtNS0xLTEtNjg3NjY_2fed292a-8f0e-4345-b40d-689bde5160a9"
      unitRef="shares">275050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i290c59f46b35464aaccca35307808b88_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzEtNy0xLTEtNjg3NjY_4819f9a6-7e2b-4e5c-b6a7-72fe0013e8c9"
      unitRef="usdPerShare">129.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzItMS0xLTEtNjg3NjY_ad6862c0-e2f9-446b-a918-335a49dfcef3"
      unitRef="shares">237590</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzItMy0xLTEtNjg3NjY_fee5a0ea-cac9-4764-89c2-0f7c86504daf"
      unitRef="usdPerShare">312.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzItNS0xLTEtNjg3NjY_02263c42-309d-440f-b1bd-cda68625f3f6"
      unitRef="shares">271270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzItNy0xLTEtNjg3NjY_960184b7-9697-4dd0-b01a-2b6d8f543670"
      unitRef="usdPerShare">214.94</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzMtMS0xLTEtNjg3NjY_d538f9cd-7f3e-4bad-9911-3adda20448cc"
      unitRef="shares">224345</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzMtMy0xLTEtNjg3NjY_d2529df9-a5ca-4325-b82b-cf5f34ce43fc"
      unitRef="usdPerShare">156.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzMtNS0xLTEtNjg3NjY_474be74f-1227-4445-98c3-67f75e07f620"
      unitRef="shares">219674</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzMtNy0xLTEtNjg3NjY_37139b63-5250-4cb8-a860-56ba5acf0949"
      unitRef="usdPerShare">137.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzQtMS0xLTEtNjg3NjY_0d51948c-47b5-489f-870f-25207aae9c6e"
      unitRef="shares">41257</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzQtMy0xLTEtNjg3NjY_53b5789b-85d5-424b-be9a-dd556c056787"
      unitRef="usdPerShare">224.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzQtNS0xLTEtNjg3NjY_1b344029-409c-4238-86f8-4bec4eb4c0eb"
      unitRef="shares">13816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzQtNy0xLTEtNjg3NjY_e33d7b5f-688e-45e1-9aa4-d612adaa215b"
      unitRef="usdPerShare">249.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="ia92853bb15c348949754087573c60ee1_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzUtMS0xLTEtNjg3NjY_7b5d5ee0-050d-4d46-a431-c2e88316e335"
      unitRef="shares">511105</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="ia92853bb15c348949754087573c60ee1_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzUtMy0xLTEtNjg3NjY_bf7d0d06-324e-4f8b-868e-a9321174c701"
      unitRef="usdPerShare">237.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i781d050a46354e80ade11c0f5bf7feda_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzUtNS0xLTEtNjg3NjY_f73d15ad-3a32-4fe7-8cb8-e8b33efabe0b"
      unitRef="shares">312830</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i781d050a46354e80ade11c0f5bf7feda_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTpmYTczODQ3ZWM1NmY0MWMxOWNjZjQ4ZTJlMzA3NDA3NS90YWJsZXJhbmdlOmZhNzM4NDdlYzU2ZjQxYzE5Y2NmNDhlMmUzMDc0MDc1XzUtNy0xLTEtNjg3NjY_52df243f-2bd4-4370-94d1-36b5013a5734"
      unitRef="usdPerShare">193.09</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ia92853bb15c348949754087573c60ee1_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzIyNzY_feb24c38-a1f9-44d5-8c0d-d7054df4e7ee"
      unitRef="usd">74000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i781d050a46354e80ade11c0f5bf7feda_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzIyODQ_3a5a90c1-118c-491f-9c9c-57b6fd590550"
      unitRef="usd">31000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzIzNzU_f9e4cb2f-00b1-4ec4-b51a-94ca81f55920">P2Y</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzIzODM_ed28f414-09ad-48a6-9567-f58c2e830797">P0Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <moh:UnrecognizedCompensationForfeitedRate
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzI0Nzc_b6de3406-f582-41c3-847f-503e4dedd473"
      unitRef="number">0.092</moh:UnrecognizedCompensationForfeitedRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzI1NjA_b553b8d6-14cf-4a5e-8e22-c8af7747ce61">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ1MDI_18f9d423-65ad-4962-b88f-6418e4b4eae7">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total grant date fair value of awards granted and vested is presented in the following table.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.492%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total granted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;RSAs&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;PSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total vested&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stock Options.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Stock option awards generally have an exercise price equal to the fair market value of our common stock on the date of grant, vest in equal annual installments over periods up to four years from the date of grant, and have a maximum term of ten years from the date of grant. Stock option activity for the year ended December&#160;31, 2022, is summarized below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:1pt;margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.402%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.987%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.502%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average Remaining Contractual term&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Per share)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options outstanding as of December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;395,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;65.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(390,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options outstanding, vested, and exercisable as of December 31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzUtMS0xLTEtNjg3NjY_3ba41f75-993d-48f4-bbf6-357e615b4d05"
      unitRef="usd">74000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="idbd67479e4964d2fa6a1a3d75f41f688_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzUtMy0xLTEtNjg3NjY_88e16328-2172-41b0-8430-ae3fba0df509"
      unitRef="usd">65000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i6e2d29204efe4a1ca22aeb31da2ce2ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzUtNS0xLTEtNjg3NjY_c74d725c-588f-4d5a-a2fe-304032d862c5"
      unitRef="usd">44000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzYtMS0xLTEtNjg3NjY_d22a1813-fe61-40cc-ac6d-6d115c850f3c"
      unitRef="usd">43000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="ib1ee1afc55d64732912318aa5e962ea8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzYtMy0xLTEtNjg3NjY_db7bfdc9-6ac5-4edf-8547-ce0f1e0e3843"
      unitRef="usd">0</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="if47f80d012ad40879d50cdef41999002_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzYtNS0xLTEtNjg3NjY_a29f867e-efad-49b3-8ffd-753e00f1d541"
      unitRef="usd">23000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzctMS0xLTEtNjg3NjY_b31ae6e8-a245-4e1b-b6a9-963c99a0879e"
      unitRef="usd">117000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzctMy0xLTEtNjg3NjY_d9d0586a-ce5c-4c02-a23c-c796f34ac530"
      unitRef="usd">65000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzctNS0xLTEtNjg3NjY_17440b84-fce0-4333-b198-7f171ec4f297"
      unitRef="usd">67000000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i8b40040b80904e3398625faca74b79ac_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzktMS0xLTEtNjg3NjY_cd089b93-10f3-4bad-91c8-5d16a2f3a91f"
      unitRef="usd">70000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="idbd67479e4964d2fa6a1a3d75f41f688_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzktMy0xLTEtNjg3NjY_5090b2fd-9853-440e-9689-fd24f6118549"
      unitRef="usd">53000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i6e2d29204efe4a1ca22aeb31da2ce2ac_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzktNS0xLTEtNjg3NjY_d667e27f-61cd-4de2-9337-450eb0125b67"
      unitRef="usd">22000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i3e6314664391452a8f7cebf0a7779e99_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzEwLTEtMS0xLTY4NzY2_8f619007-da56-4026-b6cc-54c40251e000"
      unitRef="usd">69000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ib1ee1afc55d64732912318aa5e962ea8_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzEwLTMtMS0xLTY4NzY2_7a4ab5f0-28bf-4d74-964c-341c699311ea"
      unitRef="usd">71000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="if47f80d012ad40879d50cdef41999002_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzEwLTUtMS0xLTY4NzY2_8c779076-494d-4968-9c17-54043dec6340"
      unitRef="usd">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzExLTEtMS0xLTY4NzY2_ddd9e216-fefc-4cca-ba73-2215882799ad"
      unitRef="usd">139000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzExLTMtMS0xLTY4NzY2_9ae036fa-858f-40d6-8f7b-e6e78e14a5e7"
      unitRef="usd">124000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZToxMmVkM2I1YTgwZDc0MjM5OTg1MmZlNzUyMDMwM2Y4MC90YWJsZXJhbmdlOjEyZWQzYjVhODBkNzQyMzk5ODUyZmU3NTIwMzAzZjgwXzExLTUtMS0xLTY4NzY2_b4e52554-5dc7-4c3b-a248-791dff8f7f60"
      unitRef="usd">23000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3d6e9c94477f48d3bda9237fd401466b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM0MzE_2487ba68-b939-4175-9f7c-53e8dcfe8d2f">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3d6e9c94477f48d3bda9237fd401466b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM0ODU_f73588df-d4c6-4d0b-959d-d9a24bae8023">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzMtMS0xLTEtNjg3NjY_55537420-29c1-45e4-a7ba-68940c98227d"
      unitRef="shares">395000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzMtMy0xLTEtNjg3NjY_7ee71989-2326-405d-b455-fc2e93cb67a5"
      unitRef="usdPerShare">65.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzQtMS0xLTEtNjg3NjY_192b9017-13a7-432a-a37b-bcd93d96bbf5"
      unitRef="shares">390000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzQtMy0xLTEtNjg3NjY_e8d86db3-dbb7-4673-9150-83906b10227b"
      unitRef="usdPerShare">66.01</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzUtMS0xLTEtNjg3NjY_07cc177f-acfc-4676-ac93-f4217c8039be"
      unitRef="shares">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzUtMy0xLTEtNjg3NjY_5cc16fa5-5c4c-4731-a57f-482be0a395bb"
      unitRef="usdPerShare">33.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzUtNS0xLTEtNjg3NjY_17c2e2ad-3057-46bb-90fd-7e5c0f149ac9"
      unitRef="usd">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90YWJsZTplOTgyMzNhZGVjZjM0Y2QxYmE4NTNiNzc1NjRkYTRjYS90YWJsZXJhbmdlOmU5ODIzM2FkZWNmMzRjZDFiYTg1M2I3NzU2NGRhNGNhXzUtNy0xLTEtNjg3NjY_42534f1f-4416-4de3-8d52-52582ba4434b">P0Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM1OTM_6ef84d8f-c84b-4576-9131-64736ce7fd26"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM1OTM_8c11630a-5093-4c48-bb0c-ea7b3efbdf56"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM1OTM_f66559a0-31f0-416f-8fa9-4fee45bf0d7b"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM2NDU_4fb994ac-916d-4ead-b897-bbe5f794285a"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM2NDU_59629280-3c12-495e-a78c-0943f5bc1587"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM3MTE_8221bd09-64e9-4c05-83bc-7d06866cbca0"
      unitRef="shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <moh:FairMarketValueOfCommonStockPercentage
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzM4ODc_0cb35148-60cf-49b2-bf67-2e25202c10d1"
      unitRef="number">0.85</moh:FairMarketValueOfCommonStockPercentage>
    <us-gaap:StockRepurchaseProgramPeriodInForce1
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0OTM_77b3845e-2163-4a4b-a815-9a0264d68b65">P6M</us-gaap:StockRepurchaseProgramPeriodInForce1>
    <moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQwNzU_c6d4cbec-39ce-48cf-ac15-a92ee8dd565c"
      unitRef="usd">25000</moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQzNzU_19a53967-010c-4af9-85ca-02036908c255"
      unitRef="number">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQzODE_4e784145-7110-4513-900c-79dd7aebc896"
      unitRef="number">0.025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0MjI_94afc44b-d61c-46ab-b5b9-6316f69bdd84"
      unitRef="number">0.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0Mjg_595a6ee5-7df2-4fcd-a26d-d43937588385"
      unitRef="number">0.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0NTE_5a4815ed-2901-49ab-867d-4aa2f5b4511a"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="id0cb083a718842129d8611165782b40b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzUvZnJhZzpiMmRkNTRlODBhZDc0NWMzYjE4ZjdjOTIzMzU5NTFhNy90ZXh0cmVnaW9uOmIyZGQ1NGU4MGFkNzQ1YzNiMThmN2M5MjMzNTk1MWE3XzQ0ODc_75945e50-ddd6-4665-abf3-fcd6f7500406">P0Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzgxNw_29286b1b-94c4-4def-b689-42e4c3c17ec6">Employee Benefit Plans&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We sponsor defined contribution 401(k) plans that cover substantially all employees of our company and its subsidiaries. Eligible employees are permitted to contribute up to the maximum amount allowed by law. We match up to the first 4% of compensation contributed by employees. Expense recognized in connection with our contributions to the 401(k) plans amounted to $45 million, $41 million, and $28 million in the years ended December&#160;31, 2022, 2021, and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We also have a non-qualified deferred compensation plan for certain key employees. Under this plan, eligible participants may defer portions of their base salary and bonus to provide tax-deferred growth. The deferrals are distributable based upon termination of employment or other periods, as elected under the plan and were $26 million and $23&#160;million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzI0Ng_ff5f43db-680b-425d-a265-4cd5bcd2be46"
      unitRef="number">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzM3OQ_2174951b-36de-4818-9d57-3d3bf70ec640"
      unitRef="usd">45000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzM4Mw_af2820d5-c38a-45de-b38c-68dd9e161f5e"
      unitRef="usd">41000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5XzM5MQ_c2ae37ea-66a0-449c-b5dd-922d4f55bd01"
      unitRef="usd">28000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5Xzc3MA_5675932c-87b0-44b9-9d59-f54f11303ca1"
      unitRef="usd">26000000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:DeferredCompensationPlanAssets
      contextRef="i863e60c11f294d5382a62b168dc11650_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xNzgvZnJhZzpmYjRmM2RlODQ5ZjE0NzU3YjQwZTgzZWYwMjAwNDE0OS90ZXh0cmVnaW9uOmZiNGYzZGU4NDlmMTQ3NTdiNDBlODNlZjAyMDA0MTQ5Xzc3Nw_85a0731f-ec4f-4c35-a63d-1d1de7199417"
      unitRef="usd">23000000</us-gaap:DeferredCompensationPlanAssets>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzQ5Mjg_3c23b71a-f67e-4e05-aeb7-e2eac9a9b9c4">Commitments and Contingencies &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Regulatory Capital Requirements and Dividend Restrictions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our health plans, which are generally operated by our respective wholly owned subsidiaries in those states in which our health plans operate, are subject to state laws and regulations that, among other things, require the maintenance of minimum levels of statutory capital, as defined by each state. The National Association of Insurance Commissioners (&#x201c;NAIC&#x201d;), has adopted rules which, if implemented by the states, set minimum capitalization requirements for insurance companies, HMOs, and other entities bearing risk for healthcare coverage. The requirements take the form of risk-based capital (&#x201c;RBC&#x201d;) rules which may vary from state to state. Regulators in some states may also enforce capital requirements that require the retention of net worth in excess of amounts formally required by statute or regulation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the states in which our health plans operate, except California, Florida, Massachusetts and New York, have adopted the RBC rules. The minimum statutory capital requirements in these states is based on a percentage of annualized premium revenue, a percentage of annualized health care costs, a percentage of certain liabilities, or other financial ratios. The RBC rules, if adopted by California, Florida, Massachusetts or New York, could increase the minimum capital required for those states. Our Massachusetts health plan maintains a $35&#160;million performance bond, effective through December 31, 2023, to partially satisfy minimum net worth requirements in that state.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Statutes, regulations and informal capital requirements also restrict the timing, payment, and amount of dividends and other distributions that may be paid to us as the sole stockholder. To the extent our subsidiaries must comply with these regulations, they may not have the financial flexibility to transfer funds to us. Based on current statutes and regulations, the net assets in these subsidiaries, which may not be transferable to us in the form of loans, advances, or cash dividends was approximately $3.1 billion at December&#160;31, 2022. Because of the statutory restrictions that inhibit the ability of our health plans to transfer net assets to us, the amount of retained earnings readily available to pay dividends to our stockholders is generally limited to cash, cash equivalents and investments held by the parent company&#x2014;Molina Healthcare, Inc. Such cash, cash equivalents and investments amounted to $375&#160;million and $348 million as of December&#160;31, 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2022, our health plans had aggregate statutory capital and surplus of approximately $3.3 billion, which was in excess of the required minimum aggregate statutory capital and surplus of approximately $2.3 billion. We have the ability and commitment to provide additional capital to each of our health plans when necessary to ensure that statutory capital and surplus continue to meet regulatory requirements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;COVID-19 Pandemic&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We continue to monitor and assess the estimated operating and financial impact of the COVID-19 pandemic and, as it evolves, we continue to process, assemble, and assess member utilization information. We believe that our cash resources, borrowing capacity available under the Credit Agreement, and cash flow generated from operations will be sufficient to withstand the financial impact of the pandemic, and will enable us to continue to support our operations, regulatory requirements, debt repayment obligations, and capital expenditures for the foreseeable future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The healthcare industry is subject to numerous laws and regulations of federal, state, and local governments. Compliance with these laws and regulations can be subject to government review and interpretation, as well as regulatory actions unknown and unasserted at this time. Penalties associated with violations of these laws and regulations include significant fines and penalties, exclusion from participating in publicly funded programs, and the repayment of previously billed and collected revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are involved in legal actions in the ordinary course of business including, but not limited to, various employment claims, vendor disputes and provider claims. Some of these legal actions seek monetary damages, including claims for punitive damages, which may not be covered by insurance. We review legal matters and update our estimates of reasonably possible losses and related disclosures, as necessary. We have accrued liabilities for legal matters for which we deem the loss to be both probable and reasonably estimable. These liability estimates could change as a result of further developments of the matters. The outcome of legal actions is inherently uncertain. An adverse determination in one or more of these pending matters could have an adverse effect on our consolidated financial position, results of operations, or cash flows.&#160; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Kentucky RFP.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On September 4, 2020, Anthem Kentucky Managed Care Plan, Inc. brought an action in Franklin County Circuit Court against the Kentucky Finance and Administration Cabinet, the Kentucky Cabinet for Health and Family Services, and all of the five winning bidder health plans, including our Kentucky health plan. On September 9, 2022, the Kentucky Court of Appeals ruled that, with regard to the earlier Circuit Court ruling granting Anthem relief, the Circuit Court should not have invalidated the 2020 procurement and thus should not have awarded a contract to Anthem. Anthem has sought discretionary review by the Kentucky Supreme Court of the ruling by the Court of Appeals. Pending further Court order, our Kentucky health plan will continue to operate for the foreseeable future under its current Medicaid contract.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Puerto Rico.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On August 13, 2021, Molina Healthcare of Puerto Rico, Inc. (&#x201c;MHPR&#x201d;) filed a complaint asserting, among other claims, breach of contract against Puerto Rico Health Insurance Administration (&#x201c;ASES&#x201d;). On September 13, 2021, ASES filed a counterclaim and a third-party complaint against MHPR and the Company. This matter remains subject to significant additional proceedings, and no prediction can be made as to the outcome.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Professional Liability Insurance&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We carry medical professional liability insurance for healthcare services rendered in the primary care institutions that we manage. In addition, we carry managed care errors and omissions insurance for all managed care services that we provide.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:SpecialAssessmentBond
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzEyMDc_f40eb991-ca4d-4390-a905-2556746ee963"
      unitRef="usd">35000000</us-gaap:SpecialAssessmentBond>
    <us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzE4NDA_a6380136-ec56-42ec-8f5f-6fec71af0854"
      unitRef="usd">3100000000</us-gaap:AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzIyMjA_c1aa0b10-112c-41cf-acd7-0e16724bd486"
      unitRef="usd">375000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzIyMjc_b8c4aef9-ce9b-4f43-8fe9-56ee793b1762"
      unitRef="usd">348000000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzIzNDk_faee2582-453c-44b7-8525-4d4e63176467"
      unitRef="usd">3300000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance>
    <us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired
      contextRef="i6e1fafef562c4c43a4e635c589f60bc2_I20221231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODEvZnJhZzowZWZkMDk3ZDAwZDU0NzA4OGMwNDFkYjIyYjY1ODNjOC90ZXh0cmVnaW9uOjBlZmQwOTdkMDBkNTQ3MDg4YzA0MWRiMjJiNjU4M2M4XzI0NTQ_c0808833-4e32-4954-a9e7-3f48a3ebeb53"
      unitRef="usd">2300000000</us-gaap:StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90ZXh0cmVnaW9uOjZiMzRjZmRjNDA4MDQ5ZWI5ODRlN2UxM2QxYzJiZDM2XzIxMDk_85e552af-a5ca-4046-97e2-de6801b310c4">Segments &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We currently have four reportable segments consisting of: 1)&#160;Medicaid; 2)&#160;Medicare; 3)&#160;Marketplace; and 4)&#160;Other. Our reportable segments are consistent with how we currently manage the business and view the markets we serve. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which we offer managed healthcare services. The Other segment, which is insignificant to our consolidated results of operations, includes long-term services and supports consultative services in Wisconsin.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The key metrics used to assess the performance of our Medicaid, Medicare, and Marketplace segments are premium revenue, medical margin and MCR. MCR represents the amount of medical care costs as a percentage of premium revenue. Therefore, the underlying medical margin, or the amount earned by the Medicaid, Medicare, and Marketplace segments after medical costs are deducted from premium revenue, represents the most important measure of earnings reviewed by management, and is used by our chief executive officer to review results, assess performance, and allocate resources. The key metric used to assess the performance of our Other segment is &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;service margin. The service margin is equal to service revenue minus cost of service revenue. We do not report total assets by segment since this is not a metric used to assess segment performance or allocate resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin by segment to consolidated income before income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, health insurer fees reimbursed, Marketplace risk corridor judgment, investment income and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment, and other costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90ZXh0cmVnaW9uOjZiMzRjZmRjNDA4MDQ5ZWI5ODRlN2UxM2QxYzJiZDM2XzIxMjE_4dc4206e-d596-4dc3-b529-37f7fd5cf75b"
      unitRef="segment">4</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90ZXh0cmVnaW9uOjZiMzRjZmRjNDA4MDQ5ZWI5ODRlN2UxM2QxYzJiZDM2XzIxMzc_cada62c5-9a79-4974-9997-3c1e3ac8e1a4">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents total revenue by segment. Inter-segment revenue was insignificant for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.622%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,379&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,529&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,677&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,771&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,423&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table reconciles margin by segment to consolidated income before income tax expense:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Margin:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicaid&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,981&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Medicare&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;437&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketplace&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,719&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,165&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Add: other operating revenues &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,124&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other operating expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,525)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,020&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,078&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income before income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;875&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;______________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating revenues include premium tax revenue, health insurer fees reimbursed, Marketplace risk corridor judgment, investment income and other revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:7.02pt"&gt;Other operating expenses include general and administrative expenses, premium tax expenses, health insurer fees, depreciation and amortization, impairment, and other costs.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzUtMS0xLTEtNjg3NjY_ff269a74-246e-4aee-a2b1-7febdc46499f"
      unitRef="usd">25783000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzUtMy0xLTEtNjg3NjY_54cae4fc-30df-47d5-8d70-c7cd50ad44e0"
      unitRef="usd">21231000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzUtNS0xLTEtNjg3NjY_e03fadeb-a161-444a-bae2-3e7b7e0a0f3c"
      unitRef="usd">15217000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzYtMS0xLTEtNjg3NjY_7fda5472-9d29-4b2b-aca0-9bf159693dda"
      unitRef="usd">3824000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzYtMy0xLTEtNjg3NjY_27c675aa-437f-48e0-8daf-efc72af4c53a"
      unitRef="usd">3379000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzYtNS0xLTEtNjg3NjY_447a8e79-1226-41bf-9a92-8b9aed117994"
      unitRef="usd">2529000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzctMS0xLTEtNjg3NjY_d4f0dccc-53e9-45fa-bda4-250334bcdc56"
      unitRef="usd">2296000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzctMy0xLTEtNjg3NjY_baa0a165-9601-4e35-92ff-db3dd2297517"
      unitRef="usd">3091000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzctNS0xLTEtNjg3NjY_0c3fa5d6-9632-4a38-ab93-46119d051838"
      unitRef="usd">1677000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba0e6e336cc2457895f26a4b547de184_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzgtMS0xLTEtNjg3NjY_9ffd397b-cd61-4971-9361-1a0a3e0af4af"
      unitRef="usd">71000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic83f163bbbec4901a4db9c0cd3b6beae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzgtMy0xLTEtNjg3NjY_b75f7d59-87ce-41b8-995c-9ec78ddb1ddf"
      unitRef="usd">70000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0d5667fa1324091ae2ef23e403af7b3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzgtNS0xLTEtNjg3NjY_d5a14577-a3c5-4180-b9a6-f1fa0a210f14"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzktMS0xLTEtNjg3NjY_c3d9f34f-4d28-4caa-a56d-000c4e1e1867"
      unitRef="usd">31974000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzktMy0xLTEtNjg3NjY_8d18e691-cdb8-47d9-87d2-2b0361fbd3bc"
      unitRef="usd">27771000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTo1NDAzNWY5ZjljOWU0NGRkYjg0OTBlZGM4MmE0Mjg0Yi90YWJsZXJhbmdlOjU0MDM1ZjlmOWM5ZTQ0ZGRiODQ5MGVkYzgyYTQyODRiXzktNS0xLTEtNjg3NjY_f1f80ffd-ea19-4a1c-881f-70b39ce81a57"
      unitRef="usd">19423000000</us-gaap:Revenues>
    <us-gaap:GrossProfit
      contextRef="ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzUtMS0xLTEtNjg3NjY_63814a28-b33a-4c36-ab13-740f81a41d17"
      unitRef="usd">2981000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3c5d1788834d4c4e8503897c4eeb85a1_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzUtMy0xLTEtNjg3NjY_c6cf4cfa-4908-4226-9a17-2994868a1142"
      unitRef="usd">2322000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i92eca4b552a046b0875fbad22311f3b5_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzUtNS0xLTEtNjg3NjY_4d0faecb-b191-42ef-ba49-17cf44edd337"
      unitRef="usd">1804000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia4176f78a0434927aa419f25e2b3c477_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzYtMS0xLTEtNjg3NjY_eb9f429e-7d9a-47a9-b3dc-045c5d146602"
      unitRef="usd">437000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie2ca42ca2c844e76a46c2d38b5ec99b3_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzYtMy0xLTEtNjg3NjY_4a7c8bef-7a3f-466a-85dc-7eb77e1aee3d"
      unitRef="usd">430000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie0b91fd29f864568bec0ee1bc2b734d7_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzYtNS0xLTEtNjg3NjY_ac2952d2-928c-452f-85fb-051890d643ed"
      unitRef="usd">351000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i837aaf36681849538dfa8df0d8740876_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzctMS0xLTEtNjg3NjY_dac43ecf-1f4b-4c30-ad6b-9cb5c7265fbb"
      unitRef="usd">290000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i050e8b37615f4e679be531c2520a8320_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzctMy0xLTEtNjg3NjY_d501c79a-1fb5-41a3-9ad0-6c370ab3038e"
      unitRef="usd">399000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i8ed0a50cd14a462fbeebed406c39820c_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzctNS0xLTEtNjg3NjY_42c30783-227d-45ca-b4e3-2b4197b3c9b5"
      unitRef="usd">324000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iba0e6e336cc2457895f26a4b547de184_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzgtMS0xLTEtNjg3NjY_8cb87cbd-d79d-4eae-89aa-4c63dc34ae7b"
      unitRef="usd">11000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ic83f163bbbec4901a4db9c0cd3b6beae_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzgtMy0xLTEtNjg3NjY_4237a644-28d4-4c5c-8bd2-db85d7ae0546"
      unitRef="usd">14000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="if0d5667fa1324091ae2ef23e403af7b3_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzgtNS0xLTEtNjg3NjY_17cd5d1b-94fc-42f9-9b82-491b2935fefb"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i63c5437de6ea46768cb132375cf8d34c_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzktMS0xLTEtNjg3NjY_49f2f414-38e4-4580-a108-292f968e021a"
      unitRef="usd">3719000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0e239d54c717494dbfa7e61bb51ad771_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzktMy0xLTEtNjg3NjY_b54e3155-961a-4d63-bd3e-8fab3af9e5a0"
      unitRef="usd">3165000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i077768d476524c85ac1e4304def5f128_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzktNS0xLTEtNjg3NjY_862957d5-8a7a-4bb2-bebf-1c9d30c9eca1"
      unitRef="usd">2479000000</us-gaap:GrossProfit>
    <us-gaap:Revenues
      contextRef="i9fdd93fd019b4782acece4fa6c2d7a43_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEwLTEtMS0xLTY4NzY2_54692b9d-c303-4dea-8f06-691018ceaf2a"
      unitRef="usd">1020000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41fcaf49be0f49c4851f37e732bfb025_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEwLTMtMS0xLTY4NzY2_64e2a37b-7142-4e41-98cb-fd6de5cf6d77"
      unitRef="usd">846000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8578fffd2f7a460688cbe76bc35b7b1a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEwLTUtMS0xLTY4NzY2_1683686a-31d6-4502-b49a-d286b3ac0e2e"
      unitRef="usd">1124000000</us-gaap:Revenues>
    <us-gaap:CostsAndExpenses
      contextRef="i9fdd93fd019b4782acece4fa6c2d7a43_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzExLTEtMS0xLTY4NzY2_d11d8b7a-81f7-414b-bd25-4db02200a417"
      unitRef="usd">3566000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i41fcaf49be0f49c4851f37e732bfb025_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzExLTMtMS0xLTY4NzY2_6fd8829d-9d43-46b7-a484-5a9faa2f3315"
      unitRef="usd">2991000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i8578fffd2f7a460688cbe76bc35b7b1a_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzExLTUtMS0xLTY4NzY2_f09bd8ad-c785-4ed2-8e42-5ca7357e6830"
      unitRef="usd">2525000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEyLTEtMS0xLTY4NzY2_4c18caf1-9d24-4f03-83db-65a16d48b274"
      unitRef="usd">1173000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEyLTMtMS0xLTY4NzY2_0e8e3b73-7593-4ff1-b97c-c897c81c41cd"
      unitRef="usd">1020000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEyLTUtMS0xLTY4NzY2_224527f7-04cf-4ba5-91f3-49436d4a57b5"
      unitRef="usd">1078000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEzLTEtMS0xLTY4NzY2_4f8dd8a5-8e70-4add-b5a6-efc175b54b0a"
      unitRef="usd">-110000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEzLTMtMS0xLTY4NzY2_98b0e8b1-0648-4ce8-9ffb-fccef1b46b10"
      unitRef="usd">-145000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzEzLTUtMS0xLTY4NzY2_4f351aa7-0f95-47dc-b0a2-7c670c726970"
      unitRef="usd">-117000000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzE0LTEtMS0xLTY4NzY2_ce635ff6-ef85-4886-93ca-c548e260f1d9"
      unitRef="usd">1063000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3e0a1a7d943a4c4b8d38ae77fb9f8983_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzE0LTMtMS0xLTY4NzY2_f3d4da33-5f48-4035-bc29-3627a98ae08f"
      unitRef="usd">875000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="icfad9e70d1b94ba8b37a502ab7386b21_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODQvZnJhZzo2YjM0Y2ZkYzQwODA0OWViOTg0ZTdlMTNkMWMyYmQzNi90YWJsZTowMDBjNmJhZDBkYzA0NTdjOTkxZDU1YTM4NzJlYTFmNS90YWJsZXJhbmdlOjAwMGM2YmFkMGRjMDQ1N2M5OTFkNTVhMzg3MmVhMWY1XzE0LTUtMS0xLTY4NzY2_535b31ba-da56-4857-8d7f-826ff2ca8b3e"
      unitRef="usd">961000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzUxMQ_b6a06b33-d583-4429-af23-734be140c6ff">Condensed Financial Information of Registrant &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The condensed balance sheets as of December&#160;31, 2022 and 2021, and the related condensed statements of income, comprehensive income and cash flows for each of the three years in the period ended December&#160;31, 2022 for our parent company Molina Healthcare, Inc. (the &#x201c;Registrant&#x201d;), are presented below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except per-share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, equipment, and capitalized software, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill and intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investments in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Advances to related parties and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable, accrued liabilities and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock, $0.001 par value; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Administrative services fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment income and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income tax benefit and equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss before equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized investment (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: effect of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See accompanying notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital contributions to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividends received from subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from sales and maturities of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of property, equipment and capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash paid in business combinations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in amounts due to/from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash provided by (used in) investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock purchases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock withheld to settle employee tax obligations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from senior notes offering, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment of senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment of term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from borrowings under term loan facility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for partial termination of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for partial settlement of conversion option&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash received for partial settlement of call option&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment of principal amount of convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash (used in) provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Notes to Condensed Financial Information of Registrant &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note&#160;A&#160;- Basis of Presentation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Registrant was incorporated in 2002. Prior to that date, Molina Healthcare of California (formerly known as Molina Medical Centers) operated as a California health plan and as the parent company for three other state health plans. In June 2003, the employees and operations of the corporate entity were transferred from Molina Healthcare of California to the Registrant. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Registrant&#x2019;s investment in subsidiaries is stated at cost plus equity in undistributed earnings of subsidiaries since the date of acquisition. The accompanying condensed financial information of the Registrant should be read in conjunction with the consolidated financial statements and accompanying notes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note&#160;B&#160;- Transactions with Subsidiaries&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Registrant provides certain centralized medical and administrative services to our subsidiaries pursuant to administrative services agreements that include, but are not limited to, information technology, product development &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and administration, underwriting, claims processing, customer service, certain care management services, human resources, marketing, purchasing, risk management, actuarial, finance, accounting, compliance, legal and public relations. Fees are based on the fair market value of services rendered and are recorded as operating revenue. Payment is subordinated to the subsidiaries&#x2019; ability to comply with minimum capital and other restrictive financial requirements of the states in which they operate. Charges in 2022, 2021, and 2020 for these services amounted to $1,826 million, $1,496 million, and $1,208 million, respectively, and are included in operating revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Registrant and its subsidiaries are included in the consolidated federal and state income tax returns filed by the Registrant. Income taxes are allocated to each subsidiary in accordance with an intercompany tax allocation agreement. The agreement allocates income taxes in an amount generally equivalent to the amount which would be expensed by the subsidiary if it filed a separate tax return. Net operating loss benefits are paid to the subsidiary by the Registrant to the extent such losses are utilized in the consolidated tax returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Note&#160;C&#160;- Dividends and Capital Contributions &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When the Registrant receives dividends from its subsidiaries, such amounts are recorded as a reduction to the investments in the respective subsidiaries.&lt;/span&gt;&lt;/div&gt;For all periods presented, the Registrant made capital contributions to certain subsidiaries primarily to comply with minimum net worth requirements and to fund business combinations. Such amounts have been recorded as an increase in investment in the respective subsidiaries.</us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock>
    <srt:ScheduleOfCondensedBalanceSheetTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzU0MA_27ae3605-194b-434b-87b0-827787a969d2">&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Balance Sheets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.656%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.365%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:7.87pt;padding-right:7.87pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions, except per-share data)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;ASSETS&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Due from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property, equipment, and capitalized software, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;349&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Goodwill and intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investments in subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(18)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Advances to related parties and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accounts payable, accrued liabilities and other&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,173&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finance lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;215&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;219&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,804&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stockholders&#x2019; equity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock, $0.001 par value; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022 and December 31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;padding-right:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Additional paid-in capital&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;328&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Retained earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total liabilities and stockholders&#x2019; equity&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedBalanceSheetTableTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzYtMS0xLTEtNjg3NjY_cc5b741c-5933-4cc0-9bc1-99748498a7b7"
      unitRef="usd">329000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzYtMy0xLTEtNjg3NjY_528c4fc0-fc12-45c4-8608-bea699b61921"
      unitRef="usd">274000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzctMS0xLTEtNjg3NjY_5bb70373-99ed-4a77-8b19-5e7ed6b17a4e"
      unitRef="usd">46000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzctMy0xLTEtNjg3NjY_006ba09d-4b43-4a70-b6f4-3dea37c4bed5"
      unitRef="usd">74000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzktMS0xLTEtNjg3NjY_0cfbf608-5c3a-47f1-90c1-92741b5a1180"
      unitRef="usd">143000000</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
    <us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzktMy0xLTEtNjg3NjY_08f3e322-85b2-40ba-a716-eff3aaf87e1f"
      unitRef="usd">74000000</us-gaap:RelatedPartyTransactionDueFromToRelatedPartyCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEwLTEtMS0xLTY4NzY2_3e2c76ab-6efe-430b-9c70-935f635447f5"
      unitRef="usd">106000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEwLTMtMS0xLTY4NzY2_866ffe45-d6ad-40b5-bda6-d3ba2857153a"
      unitRef="usd">142000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzExLTEtMS0xLTY4NzY2_586a6bf7-7d7d-4c66-8a9c-85235bb3821a"
      unitRef="usd">624000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzExLTMtMS0xLTY4NzY2_877aa4ff-9f26-4454-b3f1-fa16ce63e99a"
      unitRef="usd">564000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEyLTEtMS0xLTY4NzY2_03b103f5-e90c-4d22-8ced-a4701df20b6a"
      unitRef="usd">224000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEyLTMtMS0xLTY4NzY2_80f2ce10-04f8-44f9-a3f5-9de2f0612163"
      unitRef="usd">349000000</us-gaap:PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEzLTEtMS0xLTY4NzY2_090c6595-abbb-4a3d-9d08-061dc2b92bbc"
      unitRef="usd">731000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzEzLTMtMS0xLTY4NzY2_555450d2-f690-4b6a-b4c1-6cfb39e4dc6d"
      unitRef="usd">699000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE0LTEtMS0xLTY4NzY2_ea99d0bb-a611-4ecc-89b2-767f4a9e9283"
      unitRef="usd">4142000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE0LTMtMS0xLTY4NzY2_406cd64b-8c47-4416-b836-5d81b757729c"
      unitRef="usd">3772000000</us-gaap:InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE1LTEtMS0xLTY4NzY2_9c7376b8-de19-451c-9de9-470dabfbd39b"
      unitRef="usd">37000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE1LTMtMS0xLTY4NzY2_40dd62a8-daad-4ce6-a469-bdbeb9073a93"
      unitRef="usd">-18000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <moh:AdvancesToRelatedPartiesAndOtherAssets
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE2LTEtMS0xLTY4NzY2_4dea8eb9-25a5-4861-964c-6fe0c0a5aecd"
      unitRef="usd">78000000</moh:AdvancesToRelatedPartiesAndOtherAssets>
    <moh:AdvancesToRelatedPartiesAndOtherAssets
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE2LTMtMS0xLTY4NzY2_fccc50ee-b2f7-470e-9a10-fd3fd56f9474"
      unitRef="usd">68000000</moh:AdvancesToRelatedPartiesAndOtherAssets>
    <us-gaap:Assets
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE3LTEtMS0xLTY4NzY2_0b94a1f0-246f-4a27-90d7-3b153c7870bc"
      unitRef="usd">5836000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzE3LTMtMS0xLTY4NzY2_d6f26fdf-6d0d-4228-a859-8ff5c1322b4d"
      unitRef="usd">5434000000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIwLTEtMS0xLTY4NzY2_ec2e2f31-6b89-4876-a67d-a88a91314e87"
      unitRef="usd">448000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIwLTMtMS0xLTY4NzY2_9beea65a-c2db-4d84-bdd3-2e1cc98e7644"
      unitRef="usd">378000000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIxLTEtMS0xLTY4NzY2_a4ed08f8-9c67-4347-aae7-d2e529db09d7"
      unitRef="usd">448000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIxLTMtMS0xLTY4NzY2_091d2b19-bf38-40eb-9782-22d2f309017e"
      unitRef="usd">378000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIyLTEtMS0xLTY4NzY2_c6b3e0fa-200e-4cab-905e-675ff3c5a386"
      unitRef="usd">2176000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIyLTMtMS0xLTY4NzY2_e7e2a2d5-bea2-4556-93b3-a811ef82dbfe"
      unitRef="usd">2173000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIzLTEtMS0xLTY4NzY2_2a767364-8702-4ad4-b7c9-94e4fdb75d89"
      unitRef="usd">215000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzIzLTMtMS0xLTY4NzY2_f8d6c236-a329-486e-be72-9fe3b46b407f"
      unitRef="usd">219000000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI0LTEtMS0xLTY4NzY2_ed0994e9-4d8e-4791-8e44-a37c27f0bb03"
      unitRef="usd">33000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI0LTMtMS0xLTY4NzY2_57bf0619-cdbf-40fb-9c43-b2e677020d40"
      unitRef="usd">34000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI1LTEtMS0xLTY4NzY2_103df7be-c166-4d55-acfe-e04d082fcd5f"
      unitRef="usd">2872000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI1LTMtMS0xLTY4NzY2_9ce09c5d-fa9c-4a54-ac89-52d61cb9ad6a"
      unitRef="usd">2804000000</us-gaap:Liabilities>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfMTk_5cb3d7e9-8f49-422f-a2ae-9059388c27ff"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfMTk_e4b5327b-2345-46dc-a0c5-af56c1960aa8"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfMzM_04a31c0e-160b-457c-84c6-08f3c9957460"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfMzM_4e210ee2-8e4c-41af-8e7c-bc3bfabff900"
      unitRef="shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTAtMS0xLTY4NzY2L3RleHRyZWdpb246MTcyNTMwNzEyZjUzNDkwY2IzZWQ1YjcyNTAyMmQ5YzZfNjg_7b787f45-6942-40dc-8dd5-7521f48a55ca"
      unitRef="shares">58000000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTEtMS0xLTY4NzY2_877f7029-7c80-4f7c-be28-e77893fdc00d"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:CommonStockValueOutstanding
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI3LTMtMS0xLTY4NzY2_6d790d07-9d70-45cd-afd0-935349931945"
      unitRef="usd">0</us-gaap:CommonStockValueOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfMjI_a7a31557-e923-4970-9da4-564bc3be6ec2"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfMjI_ff2c75d0-8629-4022-870c-b73963246cc1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfMzY_cda6ec6e-3a68-40ca-ad18-2ed1bce7a19a"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfMzY_dc26d6bc-d910-43c6-a2bb-2f36e2521ee3"
      unitRef="shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfNTg_c7d6716c-0bac-4234-beec-65fc2fdd9101"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfNTg_e51f8e49-8280-44c2-8b09-5bac41cec5f6"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfNTg_f5737322-676c-4eee-a0e9-351dbf32cfc1"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTAtMS0xLTY4NzY2L3RleHRyZWdpb246NDllZjdiZDU0NGI2NDczOTgzYzIzM2YyMGNhNWIwZDdfNTg_fb2b9740-96bc-4a82-b8df-5667d869d61a"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTEtMS0xLTY4NzY2_8e86df5c-d497-4ef7-9f9e-df1fdab62648"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI4LTMtMS0xLTY4NzY2_9180644a-9578-43cf-a5de-c06f1a1aa398"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI5LTEtMS0xLTY4NzY2_c4affc98-c815-4b86-a0b6-5bac74e265d5"
      unitRef="usd">328000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzI5LTMtMS0xLTY4NzY2_f09eeaa2-7063-4dcc-95b3-f033f6e7ea22"
      unitRef="usd">236000000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMwLTEtMS0xLTY4NzY2_79ad123d-57e5-4728-bc06-0942f39385de"
      unitRef="usd">-160000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMwLTMtMS0xLTY4NzY2_de0648d3-d012-48d9-a653-9af25e04b2f4"
      unitRef="usd">-5000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMxLTEtMS0xLTY4NzY2_e7745f4b-98f7-4b50-9dbb-19cc602ad29f"
      unitRef="usd">2796000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMxLTMtMS0xLTY4NzY2_3ad213df-96d8-48b9-a5e7-6133be6b662d"
      unitRef="usd">2399000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMyLTEtMS0xLTY4NzY2_0ccbbc11-6544-4293-97b2-4341cc227dce"
      unitRef="usd">2964000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMyLTMtMS0xLTY4NzY2_82bd1990-5d19-4b65-afa2-3997152109a7"
      unitRef="usd">2630000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMzLTEtMS0xLTY4NzY2_f2bf54db-18e3-4a33-b089-be5782d9ee1e"
      unitRef="usd">5836000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowM2MzZjg3MDk2MjM0ZmY4YTc4MmYzYjY3MmE5YTIzMS90YWJsZXJhbmdlOjAzYzNmODcwOTYyMzRmZjhhNzgyZjNiNjcyYTlhMjMxXzMzLTMtMS0xLTY4NzY2_95d79646-404c-4854-8b6f-e27504cb9062"
      unitRef="usd">5434000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <srt:ScheduleOfCondensedIncomeStatementTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzUyMw_bc34911b-a46e-4956-9ec2-6a69768f6f04">&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Administrative services fees&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment income and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,507&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,721&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,527&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,180&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total other expenses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income tax benefit and equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(165)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(21)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss before equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(234)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(144)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Equity in net earnings of subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;803&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedIncomeStatementTableTextBlock>
    <us-gaap:InsuranceAgencyManagementFee
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzUtMS0xLTEtNjg3NjY_1ceb96cb-2497-4a6c-8b27-5da9932f2730"
      unitRef="usd">1826000000</us-gaap:InsuranceAgencyManagementFee>
    <us-gaap:InsuranceAgencyManagementFee
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzUtMy0xLTEtNjg3NjY_c04efdaf-dd9b-4fc7-b6b9-3a4c48baf314"
      unitRef="usd">1496000000</us-gaap:InsuranceAgencyManagementFee>
    <us-gaap:InsuranceAgencyManagementFee
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzUtNS0xLTEtNjg3NjY_a7f31f5d-3147-41c1-99bc-7740d8caf239"
      unitRef="usd">1208000000</us-gaap:InsuranceAgencyManagementFee>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzYtMS0xLTEtNjg3NjY_e277ae9d-ef93-4f5a-8c6d-f52d4c191f16"
      unitRef="usd">8000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzYtMy0xLTEtNjg3NjY_f22d9f0c-4dae-4eeb-a7b6-06ad3bd8cd8a"
      unitRef="usd">11000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:InterestAndDividendIncomeOperating
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzYtNS0xLTEtNjg3NjY_9b393f7a-4ffe-4924-84b9-79d7886582de"
      unitRef="usd">13000000</us-gaap:InterestAndDividendIncomeOperating>
    <us-gaap:Revenues
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzctMS0xLTEtNjg3NjY_86eb7e15-f632-440d-a444-3d5a8851b4be"
      unitRef="usd">1834000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzctMy0xLTEtNjg3NjY_78975df0-f6ae-4066-aa33-aee88ac83b4b"
      unitRef="usd">1507000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzctNS0xLTEtNjg3NjY_03159917-7abb-433e-a337-e765b904a87e"
      unitRef="usd">1221000000</us-gaap:Revenues>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzktMS0xLTEtNjg3NjY_1c6e556a-0bb8-491a-bc3b-6c7ff4276388"
      unitRef="usd">1721000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzktMy0xLTEtNjg3NjY_59ec243c-1b3c-4680-95d3-e6d98b0f31de"
      unitRef="usd">1424000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzktNS0xLTEtNjg3NjY_b8866364-0d0d-4d82-b600-7c78a802a334"
      unitRef="usd">1089000000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEwLTEtMS0xLTY4NzY2_a44dddd2-a500-4de6-bfe8-d4a85805ea4d"
      unitRef="usd">141000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEwLTMtMS0xLTY4NzY2_4db39455-f7f0-4710-a011-a7aa674c004a"
      unitRef="usd">98000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEwLTUtMS0xLTY4NzY2_9cfcdd1a-44bd-4ae3-8cd3-1d156ef8e505"
      unitRef="usd">67000000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AssetImpairmentCharges
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTEtMS0xLTc1Mjcw_5e27487f-7a95-4ef6-af75-131d09d40d93"
      unitRef="usd">138000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTMtMS0xLTc1Mjcw_f59f9921-725e-42d1-b90e-df2ce35f2903"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTUtMS0xLTc1Mjcw_59a7493b-d72e-4731-860a-6af97ab8cf5c"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTEtMS0xLTY4NzY2_f8b2c509-b708-4f15-8156-2bf724cacb97"
      unitRef="usd">0</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTMtMS0xLTY4NzY2_038760f6-a5c7-413b-ae37-e655cea093e1"
      unitRef="usd">5000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzExLTUtMS0xLTY4NzY2_916b6bba-77f4-42bc-b75d-31a3d51e0c5a"
      unitRef="usd">24000000</us-gaap:PolicyholderBenefitsAndClaimsIncurredHealthCare>
    <us-gaap:CostsAndExpenses
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEyLTEtMS0xLTY4NzY2_36d4c0ba-dd8a-4cd7-bd32-8d305753ada2"
      unitRef="usd">2000000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEyLTMtMS0xLTY4NzY2_1816407f-baea-4a20-bd1d-6c8912865076"
      unitRef="usd">1527000000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEyLTUtMS0xLTY4NzY2_57e77d54-ca7b-46a3-8b1f-883c278dcde0"
      unitRef="usd">1180000000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEzLTEtMS0xLTY4NzY2_2a30064a-707f-43ce-974a-0c1abf600359"
      unitRef="usd">-166000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEzLTMtMS0xLTY4NzY2_2abcc5de-d689-4b09-b80d-245fc35624d6"
      unitRef="usd">-20000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzEzLTUtMS0xLTY4NzY2_904c3f54-3ce8-49a6-87df-74350f19bf1a"
      unitRef="usd">41000000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE0LTEtMS0xLTY4NzY2_06972586-38c0-4c6a-ab6b-289c4fa68a6c"
      unitRef="usd">110000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE0LTMtMS0xLTY4NzY2_bccf4a2e-668e-4460-a799-e7d65be1b631"
      unitRef="usd">120000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE0LTUtMS0xLTY4NzY2_240c1dcb-3eaf-47c5-89bc-10a8f0c591b2"
      unitRef="usd">102000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE1LTEtMS0xLTY4NzY2_36777b9e-be3b-4692-8005-eb5a8feac83f"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE1LTMtMS0xLTY4NzY2_2b6acfd8-1778-40a4-a329-84c1401dd90a"
      unitRef="usd">-25000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE1LTUtMS0xLTY4NzY2_f051d4d5-c9b6-465d-9f98-71890f6473f1"
      unitRef="usd">-15000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherExpenses
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE2LTEtMS0xLTY4NzY2_d1ed5ad9-7a7d-41c2-b27c-e3e4a035c293"
      unitRef="usd">110000000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE2LTMtMS0xLTY4NzY2_4260b2e7-40d0-433c-a488-ccf17334a679"
      unitRef="usd">145000000</us-gaap:OtherExpenses>
    <us-gaap:OtherExpenses
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE2LTUtMS0xLTY4NzY2_b53a289a-4627-4e18-acc5-42a78bb263fa"
      unitRef="usd">117000000</us-gaap:OtherExpenses>
    <moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE3LTEtMS0xLTY4NzY2_85b7e085-457b-4b07-9206-3ffb4bde8b74"
      unitRef="usd">-276000000</moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries>
    <moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE3LTMtMS0xLTY4NzY2_2be757eb-d932-4a12-9bbe-f3bdb3aa30a6"
      unitRef="usd">-165000000</moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries>
    <moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE3LTUtMS0xLTY4NzY2_4a44d28a-c176-4e01-a0e6-07262f877c9b"
      unitRef="usd">-76000000</moh:IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE4LTEtMS0xLTY4NzY2_91f59dd4-7969-4980-8f92-5791f19f7e87"
      unitRef="usd">-42000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE4LTMtMS0xLTY4NzY2_3a1a902d-e749-460e-b319-41a72dbb9593"
      unitRef="usd">-21000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE4LTUtMS0xLTY4NzY2_6241efbb-a135-496c-8d69-b7e522e3e618"
      unitRef="usd">-5000000</us-gaap:IncomeTaxExpenseBenefit>
    <moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE5LTEtMS0xLTY4NzY2_57f20d90-5092-4fd6-9363-f80a5921ca91"
      unitRef="usd">-234000000</moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest>
    <moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE5LTMtMS0xLTY4NzY2_66dd6115-6c2a-487a-b546-cda58db4e967"
      unitRef="usd">-144000000</moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest>
    <moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzE5LTUtMS0xLTY4NzY2_867e1fd1-b971-431e-9ab8-1b75a8c97e31"
      unitRef="usd">-71000000</moh:NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIwLTEtMS0xLTY4NzY2_6fe30b87-494d-4e4e-8d56-2e3b682f67b2"
      unitRef="usd">1026000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIwLTMtMS0xLTY4NzY2_bd12a045-4830-4487-92eb-40e0c5b5ea98"
      unitRef="usd">803000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:IncomeLossFromSubsidiariesNetOfTax
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIwLTUtMS0xLTY4NzY2_f609f1c3-0016-42ba-bb47-f165e6313d01"
      unitRef="usd">744000000</us-gaap:IncomeLossFromSubsidiariesNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIxLTEtMS0xLTY4NzY2_d99fdc40-0ec0-44b3-9956-31e7bee0fbe0"
      unitRef="usd">792000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIxLTMtMS0xLTY4NzY2_fdd32f49-9ed4-4251-ba8f-b20a11c2b12b"
      unitRef="usd">659000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTowNzVlNmE2YWFhMDU0YjcwYjdkYmFjNGEwODFkMWMyZS90YWJsZXJhbmdlOjA3NWU2YTZhYWEwNTRiNzBiN2RiYWM0YTA4MWQxYzJlXzIxLTUtMS0xLTY4NzY2_2e7f05c6-61f7-4b60-9385-24eeff718bf4"
      unitRef="usd">673000000</us-gaap:NetIncomeLoss>
    <us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzUxNQ_24e4f862-4fc9-446b-a463-c60eb53fea64">&lt;div style="margin-top:7pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Comprehensive Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized investment (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(204)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(55)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: effect of income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other comprehensive (loss) income, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(155)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;617&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzQtMS0xLTEtNjg3NjY_d99fdc40-0ec0-44b3-9956-31e7bee0fbe0"
      unitRef="usd">792000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzQtMy0xLTEtNjg3NjY_fdd32f49-9ed4-4251-ba8f-b20a11c2b12b"
      unitRef="usd">659000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzQtNS0xLTEtNjg3NjY_2e7f05c6-61f7-4b60-9385-24eeff718bf4"
      unitRef="usd">673000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzYtMS0xLTEtNjg3NjY_f6b2df23-0e2f-4d32-9acc-20e226619345"
      unitRef="usd">-204000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzYtMy0xLTEtNjg3NjY_797febcb-dc94-4653-b5ce-f15ce0d53af0"
      unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzYtNS0xLTEtNjg3NjY_6c955bab-e450-461b-8adc-6d296e7b03b6"
      unitRef="usd">44000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzctMS0xLTEtNjg3NjY_192d356b-e605-4d09-a2b3-a292c6628faf"
      unitRef="usd">-49000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzctMy0xLTEtNjg3NjY_2856f618-64aa-4560-9379-8d3e2202a5f0"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzctNS0xLTEtNjg3NjY_b9efcb4d-db56-4d4e-842d-f8e164238090"
      unitRef="usd">11000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzgtMS0xLTEtNjg3NjY_d3fe85d3-bee6-4a97-b03d-1e954db58a70"
      unitRef="usd">-155000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzgtMy0xLTEtNjg3NjY_f43f6ad8-005f-41f1-8fee-b6c7637cbc0b"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzgtNS0xLTEtNjg3NjY_7f19bcd4-d090-4c60-bc83-7251a18e5f0e"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzktMS0xLTEtNjg3NjY_400aadb6-e6ea-4f11-9b28-18f6c65537c5"
      unitRef="usd">637000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzktMy0xLTEtNjg3NjY_1e38c71a-914e-451e-8744-c3d5d276d2b3"
      unitRef="usd">617000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjNzZiMGQ4OWYzZDY0NmRjOWY5ZTljZDQ4YjE0MTRjNi90YWJsZXJhbmdlOmM3NmIwZDg5ZjNkNjQ2ZGM5ZjllOWNkNDhiMTQxNGM2XzktNS0xLTEtNjg3NjY_c619c11b-61a8-4073-bfb0-0fe6f36af224"
      unitRef="usd">706000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <srt:ScheduleOfCondensedCashFlowStatementTableTextBlock
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90ZXh0cmVnaW9uOmZiMmJmNjI3MGJiYzRjMTJiYzVmYWQ3YjM4Nzg4YjQ3XzQ5OA_9fca3ddc-4ec9-440f-bcdf-9353db2221e3">&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Condensed Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:59.222%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash provided by operating activities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capital contributions to subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(159)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(107)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Dividends received from subsidiaries&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from sales and maturities of investments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;282&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Purchases of property, equipment and capitalized software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(86)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(74)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash paid in business combinations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(263)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,028)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in amounts due to/from affiliates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(69)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(68)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash provided by (used in) investing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(178)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(545)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Financing activities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock purchases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(400)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(606)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock withheld to settle employee tax obligations &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(54)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contingent consideration liabilities settled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from senior notes offering, net of issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;740&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment of senior notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(723)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 16.75pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment of term loan facility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(600)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Proceeds from borrowings under term loan facility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for partial termination of warrants&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for partial settlement of conversion option&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash received for partial settlement of call option&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:15.75pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Repayment of principal amount of convertible notes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net cash (used in) provided by financing activities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(441)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net increase (decrease) in cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(301)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(261)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at beginning of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents at end of period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;329&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</srt:ScheduleOfCondensedCashFlowStatementTableTextBlock>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzUtMS0xLTEtNjg3NjY_01d2c612-8c9a-4bee-9fbc-777937b491cb"
      unitRef="usd">119000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzUtMy0xLTEtNjg3NjY_68c89eaa-6860-4c18-8f89-b67d2b520362"
      unitRef="usd">60000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzUtNS0xLTEtNjg3NjY_82838605-2e75-47de-8048-ade50b4e2f9a"
      unitRef="usd">67000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzctMS0xLTEtNjg3NjY_3cdb9c65-4e2a-4aee-a578-eb832d1df7d6"
      unitRef="usd">159000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzctMy0xLTEtNjg3NjY_7e8aae39-4b00-4201-bbb7-ee7a5db98374"
      unitRef="usd">440000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzctNS0xLTEtNjg3NjY_a4d723ba-a4e2-4994-89c2-5e2e45bb9652"
      unitRef="usd">107000000</us-gaap:PaymentsToAcquireAdditionalInterestInSubsidiaries>
    <us-gaap:ProceedsFromDividendsReceived
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzgtMS0xLTEtNjg3NjY_49c1e5ff-23f7-40c2-8f04-d60f51c3012f"
      unitRef="usd">668000000</us-gaap:ProceedsFromDividendsReceived>
    <us-gaap:ProceedsFromDividendsReceived
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzgtMy0xLTEtNjg3NjY_78ec2e26-fe2b-4ada-a6c8-efbee3ed9948"
      unitRef="usd">564000000</us-gaap:ProceedsFromDividendsReceived>
    <us-gaap:ProceedsFromDividendsReceived
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzgtNS0xLTEtNjg3NjY_a3163a76-3f92-4514-b4d3-8c6b1197bc30"
      unitRef="usd">635000000</us-gaap:ProceedsFromDividendsReceived>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzktMS0xLTEtNjg3NjY_113fa636-3fb7-48e1-882f-b2f2be1d60a0"
      unitRef="usd">29000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzktMy0xLTEtNjg3NjY_2d64b50f-1404-44a8-b6d7-c8bd9459320a"
      unitRef="usd">27000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzktNS0xLTEtNjg3NjY_f6afed71-6ad8-4463-84a5-ea2dfd9d4ef1"
      unitRef="usd">188000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEwLTEtMS0xLTY4NzY2_00727869-3b3f-4ed1-ba3e-8718b210600f"
      unitRef="usd">49000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEwLTMtMS0xLTY4NzY2_1c491f8e-cf60-46a0-a175-66086b3ae776"
      unitRef="usd">21000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEwLTUtMS0xLTY4NzY2_5ddc2a98-ce49-4d26-bd9d-207fd7d5c0ee"
      unitRef="usd">282000000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzExLTEtMS0xLTY4NzY2_36420700-9a16-4de2-8c45-9e640d720a4b"
      unitRef="usd">86000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzExLTMtMS0xLTY4NzY2_7677df44-1826-4acc-8dbe-37cc96ddac89"
      unitRef="usd">70000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzExLTUtMS0xLTY4NzY2_3f52a5dc-fcd9-4cf3-ba21-1473bb107b5e"
      unitRef="usd">74000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEyLTEtMS0xLTY4NzY2_f8e5c026-497f-41fa-8307-ef0859fc1be7"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEyLTMtMS0xLTY4NzY2_aa0fc9f1-f534-486f-b952-ce96f8742481"
      unitRef="usd">263000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEyLTUtMS0xLTY4NzY2_a2e4e921-d63e-48df-9052-f6b8b2f3398a"
      unitRef="usd">1028000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <moh:ChangesInAmountsDueToAndDueFromAffiliates
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEzLTEtMS0xLTY4NzY2_25dcacad-4878-461a-8296-45bce07385c7"
      unitRef="usd">-69000000</moh:ChangesInAmountsDueToAndDueFromAffiliates>
    <moh:ChangesInAmountsDueToAndDueFromAffiliates
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEzLTMtMS0xLTY4NzY2_2ed20148-60b7-438c-b8a8-fbd1de43b5e2"
      unitRef="usd">40000000</moh:ChangesInAmountsDueToAndDueFromAffiliates>
    <moh:ChangesInAmountsDueToAndDueFromAffiliates
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzEzLTUtMS0xLTY4NzY2_bdb3d554-17e9-49c0-9b0b-dcfa85ff16dd"
      unitRef="usd">-68000000</moh:ChangesInAmountsDueToAndDueFromAffiliates>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE0LTEtMS0xLTY4NzY2_1a28aed4-9e8f-404f-a85c-4c7968f2d490"
      unitRef="usd">-3000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE0LTMtMS0xLTY4NzY2_158046f1-f19f-4283-a2b4-d476e6a9a7d6"
      unitRef="usd">3000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE0LTUtMS0xLTY4NzY2_d81c4139-659d-4296-9525-040cd40d6b1e"
      unitRef="usd">-3000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE1LTEtMS0xLTY4NzY2_8cb4dae0-b0b7-4de1-a08d-323443f382ef"
      unitRef="usd">377000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE1LTMtMS0xLTY4NzY2_efddeb04-7fa3-4f8f-aa22-33657e11be29"
      unitRef="usd">-178000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE1LTUtMS0xLTY4NzY2_89997f7e-e2d4-403f-93ac-a7535d804121"
      unitRef="usd">-545000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE3LTEtMS0xLTY4NzY2_be8b0168-1174-44ef-af43-1507ca70595c"
      unitRef="usd">400000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE3LTMtMS0xLTY4NzY2_669364eb-6311-4f08-8c70-b91bd18e7f8d"
      unitRef="usd">128000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE3LTUtMS0xLTY4NzY2_7c6d7b39-36ce-4549-ace0-f4b87f084b2b"
      unitRef="usd">606000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE4LTEtMS0xLTY4NzY2_dbdd82f9-ef6b-4c75-90be-16cacd6fc8fb"
      unitRef="usd">54000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE4LTMtMS0xLTY4NzY2_13b34bc3-2a7f-434d-8c3d-639882deb762"
      unitRef="usd">53000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <moh:CommonStockWithheldToSettleEmployeeTaxObligations
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE4LTUtMS0xLTY4NzY2_de44933f-b07a-4fc8-88d6-33c127df77d5"
      unitRef="usd">8000000</moh:CommonStockWithheldToSettleEmployeeTaxObligations>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE5LTEtMS0xLTY4NzY2_0b98a425-1fd0-4985-b964-e892aec0b4ba"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE5LTMtMS0xLTY4NzY2_daf4ac8f-a96f-450f-aee6-4c41ad9b7f60"
      unitRef="usd">20000000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzE5LTUtMS0xLTY4NzY2_ca9a799d-2bff-4361-aa30-bb5e16b33b6e"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIwLTEtMS0xLTY4NzY2_8f47d663-12e9-4bb4-ad81-5c16f95e968c"
      unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIwLTMtMS0xLTY4NzY2_73d7c2e5-06b9-4321-8b0d-1aee8a854fcd"
      unitRef="usd">740000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIwLTUtMS0xLTY4NzY2_d063440e-4454-44e5-b4cd-4e358fbefc4b"
      unitRef="usd">1429000000</us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIxLTEtMS0xLTY4NzY2_79941092-a777-4c9f-8e54-2437feb9b568"
      unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIxLTMtMS0xLTY4NzY2_f3c62ef8-0eb6-433a-917d-9de48948be24"
      unitRef="usd">723000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIxLTUtMS0xLTY4NzY2_5d19530a-92a4-422e-a9bc-1f16f2d06014"
      unitRef="usd">338000000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIyLTEtMS0xLTY4NzY2_c823802b-1600-4957-af58-6241dccdf0f8"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIyLTMtMS0xLTY4NzY2_5020554c-b82b-4b24-aa9d-ef1b71c04130"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:RepaymentsOfLongTermLinesOfCredit
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIyLTUtMS0xLTY4NzY2_ccdf182a-23fc-4525-aa2a-cfc12ce55ade"
      unitRef="usd">600000000</us-gaap:RepaymentsOfLongTermLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIzLTEtMS0xLTY4NzY2_058a6127-a4f6-4d02-9435-0f7c070a86eb"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIzLTMtMS0xLTY4NzY2_dac23c8d-9661-4a2a-86c4-80b1ecedf4df"
      unitRef="usd">0</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:ProceedsFromLinesOfCredit
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzIzLTUtMS0xLTY4NzY2_ca0777c2-04d5-439b-903c-7cf54f3ae127"
      unitRef="usd">380000000</us-gaap:ProceedsFromLinesOfCredit>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI0LTEtMS0xLTY4NzY2_b095cab1-a8de-45b3-9a4c-a5106e04199e"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI0LTMtMS0xLTY4NzY2_efa9f84a-d3f4-400d-890f-0af9b86b55d8"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfWarrants>
    <us-gaap:PaymentsForRepurchaseOfWarrants
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI0LTUtMS0xLTY4NzY2_0f918b60-1a0f-4cde-a76f-763cc1706364"
      unitRef="usd">30000000</us-gaap:PaymentsForRepurchaseOfWarrants>
    <moh:CashPaidForSettlementOfConversionOption
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI1LTEtMS0xLTY4NzY2_a51f5649-210a-4122-a2c2-da9ea9e6bdda"
      unitRef="usd">0</moh:CashPaidForSettlementOfConversionOption>
    <moh:CashPaidForSettlementOfConversionOption
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI1LTMtMS0xLTY4NzY2_5ac72677-a5b9-4cab-b73b-fbbb2a2a5e02"
      unitRef="usd">0</moh:CashPaidForSettlementOfConversionOption>
    <moh:CashPaidForSettlementOfConversionOption
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI1LTUtMS0xLTY4NzY2_0c797484-9104-4f84-9833-c26d1bc8dbe0"
      unitRef="usd">27000000</moh:CashPaidForSettlementOfConversionOption>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI2LTEtMS0xLTY4NzY2_74340786-90f2-477b-86ab-db7b024df88c"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI2LTMtMS0xLTY4NzY2_8fa0ce51-2a9b-4ca7-a156-5f9ab01786a9"
      unitRef="usd">0</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:ProceedsFromConvertibleDebt
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI2LTUtMS0xLTY4NzY2_2e84cecb-f9eb-460a-80ec-3fa758fef209"
      unitRef="usd">27000000</us-gaap:ProceedsFromConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI3LTEtMS0xLTY4NzY2_9b9abf29-be1b-4fb6-883a-605255476b9a"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI3LTMtMS0xLTY4NzY2_84a07c2e-eaa9-460e-a971-b61168f7e2d6"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI3LTUtMS0xLTY4NzY2_482d465b-bf62-4a38-bda7-1097ca5a0041"
      unitRef="usd">12000000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI4LTEtMS0xLTY4NzY2_36837f07-851c-4431-bd7d-d4d0379c9a51"
      unitRef="usd">33000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI4LTMtMS0xLTY4NzY2_75c84eae-5c31-458f-b0c3-d6da3b817357"
      unitRef="usd">1000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI4LTUtMS0xLTY4NzY2_e7037a5b-27b5-4d32-8401-4383c57996a9"
      unitRef="usd">2000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI5LTEtMS0xLTY4NzY2_a3a9a522-c9c8-46b1-942c-7f5c104353b1"
      unitRef="usd">-441000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI5LTMtMS0xLTY4NzY2_138f9274-f02b-4272-ac81-2823d40d9fe1"
      unitRef="usd">-183000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzI5LTUtMS0xLTY4NzY2_433a7514-78dd-4bd4-b508-475f5e22ad2e"
      unitRef="usd">217000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMwLTEtMS0xLTY4NzY2_e7d1694a-88ab-4225-aa08-e58232bf9820"
      unitRef="usd">55000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMwLTMtMS0xLTY4NzY2_6a14df89-3987-4a65-8afe-5a4d545caa03"
      unitRef="usd">-301000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMwLTUtMS0xLTY4NzY2_2a7807b7-d90a-4790-b9f5-da4336d809e5"
      unitRef="usd">-261000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMxLTEtMS0xLTY4NzY2_41850366-097a-44ca-861c-a8d5eac009cc"
      unitRef="usd">274000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2480da1aa27740debeb057251b13ddd3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMxLTMtMS0xLTY4NzY2_1fdbf6b0-764c-4d11-8908-3ef16d316aed"
      unitRef="usd">575000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6e83845445404707a8b2523b0d438117_I20191231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMxLTUtMS0xLTY4NzY2_2a935a52-fa7d-4742-b1ec-f68b89031498"
      unitRef="usd">836000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="iba3d39cbcb0e429cbc30596a5203c015_I20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMyLTEtMS0xLTY4NzY2_223faf75-e171-4156-a82a-7c15b9bdf16d"
      unitRef="usd">329000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d4b8ac4a365441ab7791c3a476b369f_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMyLTMtMS0xLTY4NzY2_22efac1e-58e0-46d3-9ebe-3ed84d489f3b"
      unitRef="usd">274000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2480da1aa27740debeb057251b13ddd3_I20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xODcvZnJhZzpmYjJiZjYyNzBiYmM0YzEyYmM1ZmFkN2IzODc4OGI0Ny90YWJsZTpjOTEzODQwZTgwMmQ0ZGFiYTdhZWQ1NDg5MGNiN2E4NC90YWJsZXJhbmdlOmM5MTM4NDBlODAyZDRkYWJhN2FlZDU0ODkwY2I3YTg0XzMyLTUtMS0xLTY4NzY2_59904c3c-21fb-46f2-9812-57b71dbe3f82"
      unitRef="usd">575000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RevenueFromRelatedParties
      contextRef="id525b086f5334d17a80e67717fb01cb0_D20220101-20221231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xOTAvZnJhZzplZGJiMGFkNWRmNmE0NjYxOGI4MmFlMjA0MjMxZDJkZS90ZXh0cmVnaW9uOmVkYmIwYWQ1ZGY2YTQ2NjE4YjgyYWUyMDQyMzFkMmRlXzExNzE_0f6f20bf-3736-4660-bf60-5e658850314d"
      unitRef="usd">1826000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="i2084dd42a3bd406e9dfb2ea606aa9c85_D20210101-20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xOTAvZnJhZzplZGJiMGFkNWRmNmE0NjYxOGI4MmFlMjA0MjMxZDJkZS90ZXh0cmVnaW9uOmVkYmIwYWQ1ZGY2YTQ2NjE4YjgyYWUyMDQyMzFkMmRlXzExNzU_936a9954-e487-4267-afcc-d924a85a90ae"
      unitRef="usd">1496000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="id7eb17ee724846db8e6a15708fe3e511_D20200101-20201231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8xOTAvZnJhZzplZGJiMGFkNWRmNmE0NjYxOGI4MmFlMjA0MjMxZDJkZS90ZXh0cmVnaW9uOmVkYmIwYWQ1ZGY2YTQ2NjE4YjgyYWUyMDQyMzFkMmRlXzExODM_add51dbf-7c53-4c7b-94bf-4822a308bab7"
      unitRef="usd">1208000000</us-gaap:RevenueFromRelatedParties>
    <dei:AuditorName
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8yMDUvZnJhZzpmNTY3ZGYyMzlhNTg0ODBjOGU0Mzc4NTY1ODNhOWIzMi90ZXh0cmVnaW9uOmY1NjdkZjIzOWE1ODQ4MGM4ZTQzNzg1NjU4M2E5YjMyXzI0MDA_deca1926-9dd4-4a27-833f-20c098d0b293">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8yMDUvZnJhZzpmNTY3ZGYyMzlhNTg0ODBjOGU0Mzc4NTY1ODNhOWIzMi90ZXh0cmVnaW9uOmY1NjdkZjIzOWE1ODQ4MGM4ZTQzNzg1NjU4M2E5YjMyXzI0MDE_4b62bdcc-df4b-4c24-ae74-66c79295687d">Los Angeles, CA</dei:AuditorLocation>
    <dei:AuditorFirmId
      contextRef="i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmE2MTMxY2RmNGQzNTRkNTZiODI1N2I4ZTI2ZWI5MTgxL3NlYzphNjEzMWNkZjRkMzU0ZDU2YjgyNTdiOGUyNmViOTE4MV8yMDUvZnJhZzpmNTY3ZGYyMzlhNTg0ODBjOGU0Mzc4NTY1ODNhOWIzMi90ZXh0cmVnaW9uOmY1NjdkZjIzOWE1ODQ4MGM4ZTQzNzg1NjU4M2E5YjMyXzI0MDI_b5e33f85-08e8-4b1d-a202-dbede762cb6a">42</dei:AuditorFirmId>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>117
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M::G;*PCCH/</G*NC80[H&W;R%U!+ P04    " #'@DU6SWU^PT<&   K'P
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MBX9Z\G)C<(%$S-&O%P:.T9I,&/&#N4$'$!*AZ\UA1J33$L2N);HA/*[A""
ML-&9()1#AK4$HH*1!X%T6H*<T!*5FCO<CH^H8 H4$^2B8N*BWJ)+>3M.82<F
MB%U,W!>*:;_JD$4P?<#PQ\/N#H',.@! #ADI@TY$$+N( ,H I&$.>H,$H!B&
MJW4 @\<>R$XM$+M::%K,F43,00_<#P#D&5P@3R/SEG22@=@E0_/2[YFMN%:H
M=8?IZR"0DSGYL>,;W09Z76&0,D$+?V0(D$Y$$+N(N#^/AOWU0<," &%_R (
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M@/Y_Q;DZ')07:/?'E_\!4$L#!!0    ( ,>"3597<\@M-P,  !\+   8
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MRK//JG:L&@BZU W*C K9[NC77':PP!1 _C^G5&P':H&F)X[^ E!+ P04
M" #'@DU6;\N2+A<&  "I&0  &    'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;*V9;6_;-A#'OPKA%L4&)+%$6G[(@X$V0;<"*QHDZ_::EFB;J"2Z)&TG^_0[
M2HID2R<Z!?(FL>3CZ7\GWOU(^GJO] ^S%L*2IRS-S<U@;>WF<C@T\5IDW%RH
MC<CAFZ72&;=PJ5=#L]&")\6@+!W2(!@/,R[SP?RZN'>OY]=J:U.9BWM-S#;+
MN'[^)%*UOQF$@Y<;#W*UMN[&<'Z]X2OQ*.SWS;V&JV'M)9&9R(U4.=%B>3/X
M&%[>,NH&%!;_2+$W!Y^)"V6AU ]W\26Y&01.D4A%;)T+#O]VXE:DJ?,$.GY6
M3@?U,]W P\\OWC\7P4,P"V[$K4K_E8E=WPRF Y*()=^F]D'M_Q150)'S%ZO4
M%'_)OK(-!B3>&JNR:C HR&1>_N=/52(.!H2CG@&T&D!?.X!5 U@1:*FL".N.
M6SZ_UFI/M+,&;^Y#D9MB-$0C<_<:'ZV&;R6,L_-;E1N5RH1;D9!//.5Y+,BC
M<V?(.?G^>$=^>_\[,6NNA2$R)U]EFD+ZS1EY?WAY/;0@QKD<QM6#/Y4/ICT/
MOA/Q!6'A&:$!I<CPV]</#X^'#R$%=1YHG0=:^&-]>=AJ+7)+N#$0^B463^E@
MA#MPY79I-CP6-P.H)R/T3@SF']Z%X^ *B^Z-G!W%RNI8F<_[_):;->%Y0F+W
M0?S<RAU/(7CT+9:N)H4KUQ-V\Q%TB.OA[C :Q&C$IK71D<I1K7+D5?DEWPEC
MLSY=Y>#QP2/9:#9KZ4*,8+[@NJ):5^35]2!B 0E;I +5%74>2=G!(TM=B%$X
MF>"ZQK6NL5?7O18;+A,BGJ#%&ZA6]X:570L-?>1P<F.JQUU!!WI*T8C-J$?S
MI-8\\6K^6UF>OD+>I//H, BFHY9 U&H\PB5.:XG3$VD%9&K[?%84RL;-Q[.J
M>#82U,O_H'$:M;1[:)%G)!<6"V#:S5W4GJQ=&S8;X^)GM?B95_P?2B5[:-&%
M8)E;GJ\D3-PJT[UJ9]U$LEG0DHL8T:BGML*@P5%PHKJ,U3)V-)+^!E Y.JZT
M:4LD9A3VB3Q@9N@5>2>6 J:LDQBK3!#+G_!F4/DY>CQM)Q(Q"H.>%Q\V/ N]
M")E_*RJ_OZ2JX<?OC[6E(4:368^T!C^AGS]EU7ND,4Q:V"YWU(P&??(:[H2C
M5RT%4LD7,I56"GP]$'KY]:L+@K?R=AQT [703[6O(I&QZ\4IEUG)CH7(Q5+"
M.G##GQWNT!QT2<8BVJE"Q(J-6<^+:H 7^HGW,5-;: XDV0JR4CNA\ZS R$KD
ML>PI2 1BP:3=B3&KT:2O;32P"_VT^QC'I> JH<"1.-9;Z",'4ZW!-JJ_R[CI
MM",?,1KUJ6\X&/I!6#<]+78BW^+3 6%8AW.8T23HD=>0+O2C[G@I<9!05&<7
M7N-I%+6%=JTF0=^2AS:(HW[$_:7RU;D5.H/MY@+E+\6H-6DONG&KGJJB#=RH
M'VZ?95YL E,!N^-3B:0(X,)V'E&CGC9-#S9LKP%<6B?SE%($94$;*9C1J&=J
MTH9W]#6\.Z6O2[,9B]IK!<PJZB,R;9!'_<A[M"K^L59I(K3Y\&X*T^BJ6.[:
M9WPG_*;D>RMOQ[$WY*-^\MVJ+%,Y,2X%9^1]<!$$(71H36!3#&"!Q7]Y_'%%
MPB@@67G@\7(BPK=VK;3; UP1M;4&5MB)S%>7))IV3"T1/%X3M21WL(7,%N#X
MY?RCW%&T;X=H[KLL[4P2G\EQEAK6TI.[RZK]OR)1U),GV'2H^CS)&$>_@GA-
M\M"HNT3N1.TS.8ZZ(38]0>PDD>ZT$<K7[:W/9?ZR[4-%=KG+.FLAQ(BRGM4^
M;>!,_7"&I<4VVZ;%*5ZUYU<9E,O:';CNH(TK@W>=+HO/H;+:FA&KJ$=R VSJ
M!_:#L!QN)5 5.H?7CNOK(IA.9AT2(E9LUM,560-JY@=UV;=-;V]$C\L0*,_&
M;<Y@5F/6,UU9@V[F1W<'-$5I_6( 8><L#]M\H6:]FR_64)WYJ5YUX\>RR3P6
M?>*,?/-W!];%=M2N.[]-J79X<([N?L3XRO5*Y@:60DL8%%Q,H+'J\G>!\L*J
M37&TOE#6JJSXN!8<$NT,X/NE4O;EPIW6U[_.S/\'4$L#!!0    ( ,>"358.
M_ $XV0(  )L)   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULK99=;YLP
M%(;_BL6FJ96Z\)&0CRY!:E-5W<6DJ-&VBVD7#IP$J\9FMDFZ_?H=0XI"2_/1
M+1?!-N>\?A_[ !YOI'K0*8 ACQD7>N*DQN27KJOC%#*J.S('@7>64F748%>M
M7)TKH$F9E'$W\+R^FU$FG&A<CLU4-):%X4S 3!%=9!E5OZ^!R\W$\9VG@7NV
M2HT=<*-Q3E<P!_,UGRGLN;5*PC(0FDE!%"PGSI5_.1W9^#+@&X.-WFD32[*0
M\L%V/B<3Q[.&@$-LK +%RQJFP+D50AN_MII./:5-W&T_J=^6[,BRH!JFDG]G
MB4DGSM A"2QIP<V]W-S!EB>T>K'DNOPGFRHV'#@D+K21V389'61,5%?ZN%V'
MG02_]TI"L$T(CDWH;A.Z)6CEK,2ZH89&8R4W1-EH5+.-<FW*;*1APN[BW"B\
MRS#/1%,IM.0LH082<DTY%3&0N973Y&Q&%0B3@F$QY>?D(WE/7*)3'-5CU^#L
M5L.-MS-=5S,%K\QT W&'=/T+$GA!T)(^/3[=;Z:[R%R#!S5X4.IU7]&;&T3&
M<C1$+LDM$PC.*"<SJ5E97S^N%MHHK+*?;:B5=J]=VSYYESJG,4P<?+0TJ#4X
MT8=W?M_[U ;^G\0:R]"MEZ&[3QWW/\N0%NLL?K@@.55D37D!Y(P)DDC.J=(D
M!U7M^GG;4E3ZOE=.8%\:Z\CK>![NT7H7\F!8PWZOMM\[P7Y5FH06)I6*_<&*
MMAC5:*OW2KR_X\D/O>KWS/XQD0V"L"8(3R:X(/B^U8:*A(G5(8;PA;-PV(IP
M1&"#H%\3]/<2S/#%"TKA:O]#%?6/JZ*#80V"04TP.(W@Y$(:O%C;H+V.C@AL
M( QKA.&;$)C6Q6'[PQ>NGOO>%]$P/*H-C]YD^(3*'QUTO2^B<NWN?#KML>4+
M52LF-.&PQ!RO,\"G1E5'@:IC9%Y^31?2X+>Y;*9X>@)E _#^4DKSU+$?Z/H\
M%OT%4$L#!!0    ( ,>"35;'X>@$D08  "DS   8    >&PO=V]R:W-H965T
M<R]S:&5E=#<N>&ULO5M1DYLV$/XK&C?3YF;B& D;F]3GF9Z-IIEIVIN[I'WH
M]$$!W9D)( ?P.?GW%9@8$+(,UVU>;+"UWXK])*V^!98'D7[*MISGZ$L<)=GU
M:)OGNS>32>9O><RRUV+'$_G/@TACELO3]'&2[5+.@M(HCB;$LIQ)S,)DM%J6
MO]VFJZ78YU&8\-L49?LX9NG7&QZ)P_4(C[[]<!<^;O/BA\EJN6./_)[G'W:W
MJ3R;G%"",.9)%HH$I?SA>O0+?D-MJS H6_P9\D/6.$;%I7P4XE-Q\C:X'EE%
MCWC$_;R 8/+KB:]Y%!5(LA^?*]#1R6=AV#S^AD[+BY<7\Y%E?"VBO\(@WUZ/
M%B,4\ >VC_([<?B55Q<T*_!\$67E)SI4;:T1\O=9+N+*6/8@#I/C-_M2!:)A
M@.TS!J0R('T-[,K 5@S(_(S!M#*8*@93YXS!K#*8J5U:G#%P*@.GC/TQ6&6D
M-RQGJV4J#B@M6DNTXJ"DJ[26 0Z38F3=YZG\-Y1V^6HMDDQ$8<!R'J#[7'[)
M89-G2#S(,^%_VHHHX&GV$_(^[\/\*QJC#_<;]/+%%<JV+.49"A/T+HPB.4JR
M5^A%\W0YR64'"S<3O^K,S;$SY$QGWHN<11JSM=EL+>)8#M*ROQKKC=GZER (
MBT'.(G3+PF LKV#-=J&^)]X%+-_?Q_NH#.8?^9:G2/9-SOAM,16?.'KYF\BR
M*_0V\47,-?#4#'_'<[E62&R/I4F8/"HAGDCN3P. G 8 *3&G9S!O^&.8%&#H
MAD4L\64G902.Y%XAEJ,-]U\C&[]"Q,*NCE,C?K$ROLEVS.?7(QF(C*=/?+3Z
M\0?L6#_KF#Z".258L2H^K1RRG#PUZ83TYT&"42"P%H_VB4=[((]]N#MBSAOA
MQJYCM0.^[C926FPT,/-9NXW7;3-MMZ ZE 4^-6J%97H*R[2TLL^$14XUF7 S
M.:IE+,JCJV*-TJYM?]^)*$(R81U8&ORC"]<4<JA#@FT@P3Q(, H$UF)_=F)_
M9IP4O\NM67ANL;V9==>:N:V,?2/^4)(@P3Q(,&H.12OVSBGVCC'V55;.BIF&
M=OO4W\K)ES6SBXX3(^;0&>9TKFJLK#D;2'\>)!@% FMQ-S]Q-W\&=SJ^YMT0
M.Y:R]*^-SH9.(HU'C)5< ^F0:AS.W*E^<BQ. 5X8 _R>IW(SSTIQ);?:,N&D
M3&Z[=1%>=-W;:H8V.AL:X!X./4B'% BL181[(L(U$G'<I?NM7?HQ8Z"74;%9
M?X42GNMX<3MALM7D870]E!9(,.]RYRF0OQ8KV*IEJ67DY;Y($>.B9A"4[$AJ
MCK/E0OXPPPY-(!5:,T[*4K,!=>B!HE$HM#:'C=("?A:'6MYP=P>BIA&SNZ'S
MJ8='#]0CA4)KTU$+?6Q6^EX2])/YQ-(R!*KS<5?HSUQU:H$J?5 T"H76YK(6
M^]BL]A4N>_%G=R).+-=1Y]AEL:\!PJZKSIQN(WNN9!@=T*)1?6C'IE;\^'M*
M?@RJ^4'1-J!H'B@:A4)K#X):^./_HORQ1N^JR\_:[&$P5Z#B'Q2-7@A'FX):
M_^/_HP!@!AT\WS0E@,X.#K0& (I&H=#:%-9E  Q5!\ Z64Z(.J5 *P$ZGT3-
M0Z"E /U5GLM8=3$ FZL!SQ>A6"/6IYVH@Y8'0-&\/A= H5RVZ:E+!-A<(QBD
M8S3*NI-80.L"/3QZH!XI%%K[?F5=&B#FTD!_'8.UMRM!*P2D6R&8+=0;EJ E
M E T"H76YK(N$1!SB<"L8_3\=74[<3H5T:J52<?H@&Q%#WF:1F.E2D"U0.Z9
M_1-IW)@GWU''$-C;])!H&U T#Q2-0J&U!T$M](E9Z)MU#.DJZ+FKIG^SA\%<
M0:)YH&CT0CC:%-3U!&*4JL_4,6;0P?-M>EG'@'KT0-$H%%J;PKH:0,S5@/XZ
MAG2E\'AJ=;(+:&E YU.M1(-ZI#J/MCL[,U-JQ4_,BO_Y.H;H=/I,O0%@=C\X
M[*"ZO]<54"B?;8)J/4_,>OZY=]7,L(,7LZZ*[JQED X]4#0*A=;FL"X6$'.Q
M8(@:)5UU[<[5205:'>CAT0/U2*'0VG34Q0%B+@[T5Z-$RQ"D,E^3;BV@JT9!
M'R0 1:-0:.TG:.O*@CVHLM"'OPJQJ3.)ZRA/F:TUK3J/T':;V$3ASM,T&F/U
M>5VJZ].\<:?O&)U)XZ6!XB62=RQ]#),,1?Q!FEFOYW*/D![?RSB>Y&)7OD?P
M4>2YB,O#+6=2AA8-Y/\/0N3?3HI7$TYOQZS^!5!+ P04    " #'@DU6],1]
M/2T)  !B+0  &    'AL+W=O<FMS:&5E=',O<VAE970X+GAM;*V:89/B*!K'
MOPKE;5W-5K6C(6BTK]NJ&7-3VU4WNUW3M7>O,:)RDP27H#V]G_X@L47A =TZ
MWTQKY@_RAX>''X2'5R&_-QO&%/I1E77SV-LHM;T?#)IBPRK:?!1;5NO_60E9
M4:6_RO6@V4I&EVVAJAS@X7 \J"BO>[.']MFSG#V(G2IYS9XE:G951>7;9U:*
MU\=>TGM_\(VO-\H\&,P>MG3-7ICZ??LL];?!L98EKUC=<%$CR5:/O4_)?4XR
M4Z!5_)NSU^;D,S)6%D)\-U^>EH^]H6D1*UFA3!54_]FS.2M+4Y-NQQ^'2GO'
MWS0%3S^_U_ZE-:_-+&C#YJ+\#U^JS6-OTD-+MJ*[4GT3K[^P@Z&1J:\09=/^
MBUX/VF$/%;M&B>I06+>@XG7WE_XX=,1)@60<*( /!;!;@ 0*I(<"Z;4%R*$
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M4.7R$2@:!]Q90DJB%##[RI:\H"4J2LJKSMN"U6S%]>30"=:,&^AK!"1'=Y$
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ML\FN79*!G/1#6_9[_*[?M,XE6V;-IDTJU\'/&CYW29'U#J_9#6V^ 1$_23[
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MIISD?%K[LOOV)!2K@.%PW:4%/0^$D?'"'KG/!V#)FF#R$9]ZC-$OMBB&FF$
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M1ZE  XPS)/"CE1QA#R0@#;Q Y#R+>8P%" -OKN@.Z^51A"S:M;'7\B<Z(3:
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M*,EG<=@JK3B4"[\AB"67(]_GB!Y8G&&B6R<HGI?;H)U&0K4!IL*I4:H) )N
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M!/?)JZU7%1DACD9/!A4=AB$&KGW"2F@,9["U9C3(TAJ4?6#51W 5E9\C2V/
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M3S:)+Z&D?<@96!K#!/0AN:'RXJ@78[8<0TL5YBQXPS$LG11D4=*$5Q)HQVX
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M"6A<YQU$PZ +6C?HDJ/SR51@0_BM!3ODU[SJ[,R+&FX0-PG=/HD.W$% IJ#
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M.+2:S",8CVD8, M4LX\5]E;0<!"*<_)$^E%>X@G1"]$IQ7:(N>?.Z8&JBL9
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M<)$DNE#>4S=:BD1PZZ6B5X'%E<YRIM:X>*)1ZSL"'D23&+N4E-1PD?_'Z\_
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M"8[+)KR8"!=.Y_YEP$P[IS-_BH-LR@T)X/.YQJ&GO* %JK=#T[\!4$L#!!0
M   ( ,>"359WYK\;U0,  #L)   9    >&PO=V]R:W-H965T<R]S:&5E=#$W
M+GAM;)U6VW+;-A#]E1TFDVEG-"()ZD+9DF8DNQ<_./4D3OO0Z0-$KD0D(*
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M=?,"/)\;X[L+WJ#_;Y2;_P%02P,$%     @ QX)-5G;?8E_@"0  OAD  !D
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MX;\6^ =G5GQ#?V.<,Q7_7"J)M*(->#\WQG4/=$#_)YN+_P)02P,$%     @
MQX)-5K854Z2H P  (@@  !D   !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
MG5;?;^,V#/Y7"*\;=D O3IRT*[HD0'/787LX(+C;[1Z&/<@V$PN5)9\DQ\W^
M^B,EVTFWML#VXN@'^?$C*9)9=L8^N K1PV.MM%LEE??-;9JZHL):N(EI4-/-
MSMA:>-K:?>H:BZ(,2K5*L^GT.JV%U,EZ&<ZV=KTTK5=2X]:":^M:V.,&E>E6
MR2P9#C[*?>7Y(%TO&[''3^@_-UM+NW1$*66-VDFCP>)NE=S-;C<+E@\"?TCL
MW-D:V)/<F ?>_%:NDBD30H6%9P1!/P=\ATHQ$-'XVF,FHTE6/%\/Z+\$W\F7
M7#A\9]076?IJE=PD4.).M,I_--VOV/MSQ7B%42Y\H8NR\ZL$BM9Y4_?*Q*"6
M.OZ*QSX.9PHWTQ<4LEXA"[RCH<#RO?!BO;2F \O2A,:+X&K0)G)2<U(^>4NW
MDO3\^KYNE#DBP@8U[J2'K1+:+5-/V"R1%CW.)N)D+^#,,OA@M*\<W.L2RZ<
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MJ$!T+3_"H7 >+<#W*^=B^4 '#+\C7_P74$L#!!0    ( ,>"358&7K6,%08
M -(.   9    >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;)U7#6_;-A#]*P>W
M*%I M2W)MNQ\ 4F[8056M&B[%<,P#+1$VUPDT26I.-VOWSM2DNTT"=H5J2R2
M]_'NW?$HGNVTN;8;*1W=5F5MSP<;Y[8GHY'--[(2=JBWLL;*2IM*. S->F2W
M1HK"*U7E*!F/9Z-*J'IP<>;GWIN+,]VX4M7RO2';5)4P7Z]DJ7?G@WC037Q0
MZXWCB='%V5:LY4?I?MN^-QB->BN%JF1ME:[)R-7YX#(^N9JPO!?X7<F=/7@G
MCF2I]34/WA3G@S$#DJ7,'5L0^+F1KV19LB' ^-+:'/0N6?'PO;/^LX\=L2R%
ME:]T^5D5;G,^F ^HD"O1E.Z#WOTBVWBF;"_7I?5/V@799#&@O+%.5ZTR$%2J
M#K_BMN7A0&$^?D A:142CSLX\BA?"R<NSHS>D6%I6.,7'ZK7!CA5<U(^.H-5
M!3UW\5&N0;&S9R,':SPWREO-JZ"9/* 9)_16UVYCZ:>ZD,6Q@1%@]%B2#LM5
M\JC%US(?4AI'E(R3Y!%[:1];ZNVEC\=&'^16&Z?J-?UYN;3.H!+^NB_>8&UR
MOS7>'2=V*W)Y/D#Y6VENY.#BV9-X-CY]!.NDQSIYS/JC>?@^3?HL43#&X+W\
M2AMQ(VFE&X.=P]&+92G)=J*YQJZRGA*].J'X!;V5A<J%*DXIZ09&GE**@3#7
MTFU+1'Y*HBYH\H+>N8TT0WKW@'FH=BZ8_YUR&]J C]TAPDK4V/4$2[1L+(*R
MUIN_X:W,LY5W;%G+LSVD3YCM@$8]RLBK'<#< P$X3A4PL,&UOI&FYI67JX9K
MEC3:TQ9 M<%@:_3:B,H2KQG:;52^8>=ZM<(PP"UH(T7I-NS7HU*YM &8YZ1S
M';7JRI("#^M:K8"5<6CBI# [NE2%<# )B.@A%HX(S=8(;E<V@F)>-H6T5.IZ
M_=))4_4>?<2VV3+U(9LP(+B_[45439^5]6FH \)K"=:E,RI'C!:. 498R\0S
M/7#MFWR=2P\%,'^(;*8$=%>JJ1#2C:P;2%=>K^1DKH'(*[_Z,.3'/CO!OZAT
M X;@NE/*0R%9-HX_1IA#G,L&4G=\^1C1TC6#9'L^C>57+O)C%!'G_<"C%*8&
M&\NO?O+'8EXYKHT.;X *T"BN)N?<KHRNOF7E3N05]$A5?B,!3R6%;8R/D:$A
M *YDWA<!92C%4&:,3+7IQ)*OK8V2T+R5>>,K O6+@C"<[6"E*[BHR_Y!YH-%
M498Z1VVR)$SV-;ZOH.\LH*--P4#;\FPS$:P>S[&4_-* 3ECOEEKF^ 1LK.>9
M/=Q9'7(++#35VK5M"28<##%&4 U^.B38$SGW'MZ?UBN(!P+K-(Z",P\RM-)8
MV''-A9ZXS[-'TL6QAS*D-S5JZ&7GIY/8B;NM8Q7<,A*E"]N9EL60_D"=A&.8
M<(C*:@G2NX.4'S$_QO3\30T&RY+[RPOZ=(CHI*][>DK)-,KF*;_$49+&>(FG
M41)G_8Z@-)HG$SS3;$%)-$T61]LCB9+%#*OC14QQ-,NRM@ZRF+(Q/7LR3^+D
ME%X=]L"GC'>13=AI%F69=[J()DEZ+ZU&HK'EJD2?:ZOF(+E(WE%_1:YU!<Y]
M;^A&3MQBC^#;UB+V_\7?6^_XF+AH,8_];PI%1!#-QY,]:Y,TP_\QI=/XF*\%
MYA8+2L%I8"H&<9.>J9"I-M TRF*(1O%L"C\3)."R*$Y(>[WV_ !/;5XM/<?I
M'D<,?SZ9X2V&DU]1V=^JM'1 !=\ S]-H.IOA%S$M8O\[3:8X^GOQEDA8S-+6
M Y[9_,AZ9S.B&C>,.(;,9(K?#&7_>%8\?>,9E^$\F^*YF,7T][W_?(SO'B*@
M/4?[+LP^^DX<CG/>:>BXAE92<J]5U;(QZ /149J,LM>H+&-4@:WX3U.T1[VJ
M;Z1UH<.%,+B'AOC[UL2<WH78$]Y!7,L::V7HP06:G>+/5=_%]T0>QK&?O2>0
M",<0A',EP@6(C5;\)?ROGXCXR!'*[ ^2 -F?8L/[OFE'!_>,2IJUOTUQ.\8I
M&JX<_6Q_8;L,]Y2]>+CMA<V#;QNY@NIXF$T'X-??H,+ Z:V_M2RUPQW(OR)$
MG.@L@/65UJX;L(/^&GOQ'U!+ P04    " #'@DU6SV0NK90,  !Y(   &0
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M>SF.$C$:$SED'FVW0^9N34P,/<?K ON*7\DDU-QN&/8*"2S"UC@Y%]\JE6\
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M?B/$4"QK/(9*#3#@!ZM4?Y'N"%]E\&]=F"\="C3OLC7 2LNA5[.;@5%*<,Q
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M)5CF@CI<='3 HTF906E%%WU]X3DT-"!5<=S?M.3UBW=>288NO /P9 N32ZS
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M;5OD#'JO$\8= >M,2:O6JG7]T%92961GLM,YXLNP')-IM(PLYQMV^9P*9KM
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M0;PEH3G%Z4@VF! Q1D/XE6)*RKP)A.&@RMLQ9M -'6;0]4>CM@".Z@".WAQ
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M%O3? [43H/V=(O^U"W= ]V]F_3]02P,$%     @ QX)-5D==6M2M @  R@4
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MW>5+K[9N7SZ5BFQXP8J4,T%X@9$J*Z0TNIDY,0XK[MP6RX+)A'P-JDGH@!Q
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MPC@Y$A$%4)_PD<(6\!$)>H(;-A5B &3^OX#,A8-W1HH2&)O2]7*0>>H%]&$
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M8SSE5S;(Z@MX"HLD(?GLR2(=IR]^8L9VV6CQ-6:6P&R:]'H_&EGW%$H*\Y]
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M1 N9VW/9/'8M=H\3O"Z$1-NL3:#1? .Z*SK40YMQ)1-*[T(4!X[I3Z;HL3!
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M?.!X)B"@D"FC@/5K"4.@U CI,)X:3:?]I2&NMU_4;^W<]5RF6,*0TU\D5^7
MN7!0#@5>4'7/5]^@F8\-,.-4VB=:-5C/0=E"*EXU9!U!15C]QL^-#VL$/]I!
M"!I"<"@A; CAH82H(42'$N*&8*?NUG.WQJ58X:0O^ H)@]9JIF'=MVSM%V%F
MG4R4T%^)YJED0F:,%"3#3*'K+.,+I@B;H3&G)",@T1<TQ+(\M4\T>EJ0):;
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MN548K-"V8;#WT!8&R&X0()@6AD$5AH%UD)>Q8)(J9!DS8_R!WH7,Y/8-Y+B
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M+=^C"*\<690X9F_86?_^&YQZ?YAD[9,LZ),L[(FL$8!Q%8"QC5TO.*(7G"D
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MV0'F_5((_7QC$Y1'_I-_ 5!+ P04    " #'@DU6ZI9ORW$$  #V&   &0
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M$18X51RR%P,C5_FQ\[TT1J;YY1(H9L(:X/.YE&8SL"^H_NJ8_0]02P,$%
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MP4_=&9KQ75Y4CQ*3SA;Q\KML&#ZUN)AIIZC4U*VW@,.Q/KG[EZ J")&:6A!
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M</N6"R>U7*C4U(( EG KE@O7W93C$49#U&Q;?V[![18883/;$)<U;ID-I."
M%-R^]\))O1<J-;4@P"S<BO?"=5M%FV$L1,T6R(/CO@O,L(%YB&L:]\L&:G!
M#6[?A.&D)@R5FEH0@!QNQ83APXR#AJC9 N-PG'%:%^&1%B(N:-PL&UZ,!QCE
MV?=B/%*FHE)3"P),Y5GQ8CS=9CF>7C1$S1: Q\.!!Z9WI)&(ZQGWRH8_XP%
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M/JDO0Z6F%@3XQ;?BR_BZZ:*?1^P(ZCV/Z .)^&.\&=?,7,0UC7MF ST"0(_
MOCT3D-HS5&IJ00!W BOV3*"CC'XRL2NH]^,50#S!&(O&-3 8<4'CAMGP: *
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MSF4'KPY1M&G%0/&Y:5PF7&$;9!YC[&Q!: -<GW*N5@,=H.J5_;]02P,$%
M  @ QX)-5HQ%?<'N!@  AS@  !D   !X;"]W;W)K<VAE971S+W-H965T-34N
M>&ULU9MM;]LV$,>_"N$50P<TL?@@V>X< VVR;@6:+6B:[L6P%[+#Q$)ET1/I
MI!WVX4?9C"B)I!Q'4NR^B2WG>+K_2>+]1)W&]RS]PN>4"O!U$2?\I#<78OFZ
MW^>S.5V$_)@M:2+_<\/212CD9GK;Y\N4AM?K08NXCSPOZ"_"*.E-QNO?+M+)
MF*U$'"7T(@5\M5B$Z;>W-&;W)SW8>_CA8W0[%]D/_<EX&=[22RJNEA>IW.KG
M7JZC!4UXQ!*0TIN3WAOX^M0/L@%KB\\1O>>%[R"3,F7L2[;Q_OJDYV41T9C.
M1.8BE!]W])3&<>9)QO&/<MK+]YD-+'Y_\/YN+5Z*F8:<GK+XS^A:S$]ZPQZX
MIC?A*A8?V?UO5 GR,W\S%O/U7W"O;+T>F*VX8 LU6$:PB)+-9_A5):(P $/'
M *0&H,<.P&H 7@O=1+:6=1:*<#).V3U(,VOI+?NRSLUZM%03)=EAO!2I_&\D
MQXG)^^2.<B&/B^#@"+RY"Z,XG,;T2)X@1Y=A3,'+,RKDC_PG\ )$"3B/XEBF
MGX_[0NX]\]&?J3V]W>P).?9T1F?' ,-7 'D(@:O+,_#RQ4]@R7B4'4^+O]/'
M^X-;_/5E5O+4H#PU:+T#[-S!5(!+.ENETB/EKRK9X5EV_OH@!X'W@B[XW[:4
M;/9 ['O(+M'7?!G.Z$E/7H.<IG>T-_GQ!QAX/]ORT9*S4C)PG@Q<YUV>)QM7
MX>;CE"4B2E9LQ3?;'QCGX$+E'LCTJ)\I5P9B'BH/$&T^SZ6+N<SJ+UQ$\G*D
MU^!=&*7@<QBOJ"V5F_@&Z_BRR>EN H?^<-R_*Z;(8C3P@MRH))WDTLD6Z2 $
M6C PM(),)L@4 HC @ZY?T\SN*I&3:QS]*^5EXZCUPB%&U(-!19AI H=V67XN
MR^]"UB<FPAC\OEI,:0K833Z"@__J+N:WFV""H@ (@XI*TR@H9*(D,\AE!@UE
MYN* W#AG*7W\.1F81P6/JN>D:>39)0UR28/V)>UP.@XLJOR**-/&(6J8BQIV
M,,&4)Q.M]JEGZ= \ 1&I2#=M'-)'N?11K?13EBY9*D\WR1^RY/"\Y-@BK'6U
M:T5IR5E)-?0T>GB=%UBUBY;RT9:W<D(*+ 8/O,BJ $O7/C2N )N5%V#[50 U
M;\%:@GF&0JL"* 9.JC.;Q08BAS1-3W ;/CUKL571E.:Q(:X*-8WPR'<HU; $
MF])2@WH+30P:#JNH9#%R3-!0LQ)L"DO-2J[:?0D!JW!DL7'ITG $M]'1(51=
M%63I3!S JGS3R"5?@Q2L)RD9MK@-;^G1-)Q]D0>HOO36.]NYUK3DK2Q=XQ8<
M=E]\:Y%NYX2TY*V<$ UAL)["#J#XCHP+O#@AJRR91L1SW HBC6*HEFR>H?2J
M (IQ(Z^BS6)#',HT4Z%M3/6LE5=%4YRED*G3-(+$L4J!"LM53?&I0>5%)A5A
M.*KJ,HT<4S32Y(2:DE.SRHO,)2-<K;P6&Y<NS4EH&R<=0N5509;.1%RMO!8C
MEWP-5*@>J-[(XR$>5W;K/>V\B-J2M[)N#5PHZ'Y1N9;I=DY(2][*"=$(AK8M
M9NV[["++>E=@7 ,V(]>4K2$,;5OTZKSL#HVXC=G--($.81JFT#:8>MZJ.S*G
M,:^Z#FLQ&CAN=[$&)]P4G!H476SR$(3&(P_3R#$[8PU-N"DT-2NZV+* 5%UD
MLMBX=&E$PML0Z1"*K@JR>"+Z592RV+C4%Q[AU:/4^2J)9M%2QEQ?<.O=[%I?
MVO)6%JTY"Y/."RZN1;F=$]*2MW)"-'GA;4M9^RZXV++85;W-M=@$(\<%H.$+
M-WT6V+3<8O-AGS&O61X:.H1IB,)-GPBV6FY5-,7)R5A=MM@$+IV:EW!37FI2
M;4T.\JMKRQ8;U[2L60DW9:6&Q=9<,3)DF28.6423$=E&1H=0:U600=U!M=BX
MU&N"(O4$=75\>0P^R:/#5^DWD##AZ/RH];)K96G+6UFSIBO2?<,4:;5CJBUO
MY81HX"*'WC1%S)6K8?4&HE[$4Y-4Z*[:>WN5I7FJFH,NF(QH)B,'U8M%+'U6
MU81TL4Q&-*F1/79MD;J.+"6_BT4QHGF.[+?#B]2U;ZD,=/%XDFC2(]]#.QBI
MZ_52>>KBJ271\$CJX?$/,:>I-?16&\7:\E;N5-4LZ7??*>:WVBG6EK=R0C1>
M^H?>*>9;EO"J-_'U(IZ:),VC_K[[R7Q+KU@U!UT@J*\1U#^HQC/?["DSF[R[
MX$U?\Z:_QP8UWX*:U=O-^OB>JK_0]K_?5C;?7+E#U0QT 9>^ADO_>VAZ\\U^
M-N-*:95"^X6WQ+)7],[#]#:28<;T1KKWC@?RJ*2;M]XV&X(MUR^.39D0;+'^
M.J?A-4TS _G_&\;$PT;V+EK^[N'D?U!+ P04    " #'@DU6C;=4EA0#   K
M#0  &0   'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6R]5UUOFS 4_2L6JZ96
M6L-GOKH$:4TTM=(J5<VZ/4Q[<. FL6HPM4W2_OO:0"FD!#42ZDMBFWL.]QX?
M\&6R8_Q!;  D>HIH+*;&1LKDPC1%L($(BQY+(%975HQ'6*HI7YLBX8###!11
MT[&L@1EA$AO^)%N[Y?Z$I9*2&&XY$FD48?Y\"93MIH9MO"[<D?5&Z@73GR1X
M#0N0]\DM5S.S9 E)!+$@+$8<5E/CAWTQLQT-R"+^$-B)RACI4I:,/>C)=3@U
M+)T14 BDIL#J;PLSH%0SJ3P>"U*CO*<&5L>O[#^SXE4Q2RQ@QNA?$LK-U!@9
M*(053JF\8[LK* KJ:[Z 49']HET1:QDH2(5D40%6&40DSO_Q4R%$!6![!P!.
M 7 ^"G +@)L5FF>6E37'$OL3SG:(ZVC%I@>9-AE:54-BO8T+R=55HG#2OXZW
M(*3:%RG0.;K$%,<!",16Z$ZM<Q)("%$UZ'0.$A,JSE3X_6*.3D_.T DB,;HA
ME*J-$1-3JKPTNQD4.5SF.3@'<IA#T$.N_0TYEN,TP&<?A]MUN*G4*"5Q2DF<
MC,\]P+=0CTJ84M B7 $-SR4[5WY).9'/: &!'A"ET;]?"HBN)43B?U/1^5V\
MYKOHQ_-")#B J:&>/P%\"X;_]8L]L+XW2= 164T0MQ3$;6/W*TX@;TYH*CGG
M&68\^@6R]1UW-#&WU4H:8FRGC*DEZ)4)>JT)SK#8(!R'*- #>$S)%M-#.;92
M';LM'9'5JNZ75?<_Q:?]+@7IB*PFR* 49-"13W.>0<6#GK-GT_<A@U&S2X=E
M>L/6].Y[BQ[ZK<Y:D?)G%#,)C;FUDAR['1V1U>H=E?6./L6?HRX%Z8BL)LBX
M%&3<D3_'[\QG]\=[!FV(\;QFA]K66S=@M;])&4\8QQ)4*[242)2[U'BJMW(=
MNS-=L=4KK_1!]J>XM;A-5Z)TQ%87Y:T3LEO[BB,<6Q!5CW5WN.?8AAAKS[!F
MI9/5GQ$WF*])+!"%E<)8O:$Z7WC>F><3R9*LN5TRJ5KE;+A17S/ =8"ZOF+J
M/5M,=+]<?A_Y+U!+ P04    " #'@DU6LSH4?'$$   <'P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-RYX;6RU65UOVS84_2N$5@PMD$82_9G,-I"/%@O0
M%$:#; _#'AB+MHE2HDK2=C+LQX^B9-$:9*JRJ1=;E'B/[CF\I([$R8[Q[V*-
ML02O,4W$U%M+F5[[OEBL<8S$)4MQHJXL&8^15$V^\D7*,8IT4$Q]& 1#/T8D
M\683?6[.9Q.VD90D>,Z!V,0QXF^WF++=U N]_8EO9+66V0E_-DG1"C]A^9S.
MN6KY)4I$8IP(PA+ \7+JW837=_ J"] ]_B!X)PZ.04;EA;'O6>,AFGI!EA&F
M>"$S"*3^MO@.4YHAJ3Q^%*!>><\L\/!XC_Y9DU=D7I# =XS^22*YGGIC#T1X
MB394?F.[WW%!:)#A+1@5^A?LBKZ!!Q8;(5E<!*L,8I+D_^BU$.(@0.'4!\ B
M /X_8'PDH%<$]#31/#--ZQY)-)MPM@,\ZZW0L@.MC8Y6;$B2#>.3Y.HJ47%R
M-N>J(KA\NP"??FQ(J@9(7@"41. .I40B2O[!$7AB2[E#'%^ KZJP/H*;*"+9
M(" *'I*\E+(A>7^/)2)4?%!=GI_NP?MW'\ [0!+P2"A5'<3$ERKE[,;^HDCO
M-D\/'DFO!QY9(M<"?$HB'-7$W]GC0V@!\)56I6!P+]@MM"+>X\4EZ(47  80
MUB5T<G@EG5XY?CV-UV\8/SUF>#^$=4);<;+5XEJD:(&GGEH.!.9;[,U^_24<
M!K_5D70$5J'<+RGW-7JOL63G%"52,R^+%_SU174'#Q+'XN\Z&?HN97 $5I%A
M4,HPL([\0YPBPC5G-??2GZZ#''6D4;-%?CL+AQ-_>TC+>N,3:0U+6L,3"AK\
MJQ:1A,2;N(Z2%;'MF#H"JY ?E>1''9;VR*4,CL J,HQ+&<;6&G@6>+FA@)(E
M!FQI:CLM1;%6N!6\K0[V3'O@#2,N+)RO2LY7)]8]>CU6]U;$MD0=@57(AX&Q
M(4&'E5^ .U+"%5I5B@-'%G99_7;TUEK8<QTUUG\(#6]HQ=J[S%I2UM#6I!RA
M58D:RQ;VNJQUIT;.%5I5"F/E0JM%.KO6G;JYAER;U_K0>+?0;MZ^8/7JN68T
M B16I+<X8UC_?N3(C!44N[!VH?%VX;#+RG?J\URA5:4P3B^T.JB3[;L=MK4(
M(]O;0)6:<6^AW135%[?=PMLA6]-RA%85P%BY\*K+,G=JZURA53^6&%\'K6;I
MW 7>CMY6BX9<!XT+/#0F#MJ-T?$Y<-S.VR%;DW6$5A7 N#D(.YP#T*G?<X56
ME<+X/6C_1G?N''!J^!IR#8/F26#<';0[IML-H1%)5IKCSS\+[*BM"7?QD0X:
MIP<'7<X#I^[/%5I5"N/^H/W3WKGSP*G]:\BU%^;S  Q!K#<0; H8TP?MIL\Z
M(2P/!J>>SQ5:50/C#N&XRPGAU">Z0JM*87PBM'_S.W=".#6*#;GV+0\&_V#_
M,<9\I;=E!5BP32+SK<CR;+GU>Z,W/'W3/=\W?D1\11(!*%ZJT.!RI)8LGF_%
MY@W)4KV;^<*D9+$^7&,489YU4->7C,E]([M!N2$^^P]02P,$%     @ QX)-
M5N: )8@$!   >!,  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULM5AM
MC^(V$/XK5GJJ[B1V$R<08 M(7;953]IKT=)M/U3]X$V&Q;HDSMD&[N[7UTZR
M>2$F"VKV"^1EYN%Y9L:>P;,#XY_%%D"BKW&4B+FUE3*]L6T1;"$FXIJED*@W
M&\9C(M4M?[9%RH&$F5,<V:[C^'9,:&(M9MFS%5_,V$Y&-($51V(7QX1_NX6(
M'>86MEX>/-#GK=0/[,4L)<^P!OF8KKBZLTN4D,:0",H2Q&$SMW[&-TO7T0Z9
MQ5\4#J)VC;24)\8^ZYN/X=QR-".(() :@JBO/2PABC22XO&E +7*W]2.]>L7
M]%\S\4K,$Q&P9-'?-)3;N36Q4 @;LHOD SO\!H6@D<8+6"2R3W0H;!T+!3LA
M65PX*P8Q3?)O\K4(1,T!#T\XN(6#>ZZ#5SAXF="<62;KCDBRF'%V0%Q;*S1]
MD<4F\U9J:*+3N)9<O:7*3RY67%4$E]\&Z)<O.YJJ!,D!(DF(EB2EDD3T.X1H
MS3;R0#@,T.^JL*[0.L\Y8AMTD3]Z?P>2T$A\4""/ZSOT_MT'] [1!'VB4:2R
M*F:V5*(T-3LH!-SF MP3 NX@N$8>'B#7<5V#^_)\=]QTMU4HRWBZ93S=#,][
M-9ZKB"0R"T49&?3/O3)''R7$XE^3U!Q[:,;6*_I&I"2 N:66K "^!VOQXP_8
M=WXR">\)K!$&KPR#UX6^^).IW*. "6F2F?N.,U^]S^P7DXG*W;[.WF#C5C8-
M4L.2U+"3U#T(<:,VCF 7[R(B56&2F'%)OY-L1[E"0:UF15&S)O[YS_@U;E?#
ME@"3D3LV*QB5"D87*@A!92^@N0)=;$>2TK(>H5J?3SL:A31YSE<JC971'O0K
MX_H;M86XV#M2:S)R1F:U?JG6/Z.(SE9KXNZW:?G3T1%WDY%WHM;&)?=Q)_>'
M/QX1$0*D4$G8T(0D : (5,,QQGC<HC ^KJ>VB>OX9I*3DN2DD^3*5!PZK*:%
M,$ )&%?SI$UL-#TBW[;QIB?(3TORTT[RRS,7:R?*I7MJ3V -P=BI>K7SALVE
M .\I$GVA-4-1&UOP_V@PA7.]WGQ\O.P-1J/AB0T:5_T?=_;5,D=9<LIE9239
M:[?O"ZTIN^KWV'O+TNR<)BX.14]HS5!44P;N'C->*<WV7.#JR;-9F@8C[U1I
M5L,#[IX>;HNV?U;7[\:Z."4]H3655X,$]M^R.CO'E(M#T1-:,Q357(*[!Y-7
MJK,]90Q;Q=FV.5F;U22"NT>1>Y42(Z%.MXMCWQ-:4V0UL>#I6Y9AKY-,7VC-
M?\G5*.-VS@>OE&'A7/_W=]R]#2;XJ CMVK&(/I/Z1/@S380:PS?*Q[D>JTV)
MY\<\^8UD:792\L2D9'%VN042 M<&ZOV&,?ERHP]?RL.VQ7]02P,$%     @
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MN.0YTP5-<138[-"HEA@D[]_%O>A3 V"G!NPTJ2<W!;K#$3/@#O7$YH/+N'H
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M;*U676_;(!3]*\BKID[:ZJ]\+4LL)7&K55K5JEVWAVD/Q+E)4#%X0))NOWZ
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MFT'N9M!D/7Q06RP:'$VUAU;;U(+GL!=,W.<B_*H(]$>Y3 E5+T?5:R3?;D=
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M0)_?<JX>=\Q'BN:C5/(?4$L#!!0    ( ,>"359O\5\0T ,  (P2   9
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M?Q+[]U D-+1\B6 J_T7[(C;P4+)56F0%V"C(*#_\D^]%(8X >- !" M ^*N
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M&X#O5U*:P\2VK>ZCD_T!4$L#!!0    ( ,>"35;:?C*ON ,  ,0/   9
M>&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;+U776_;-A3]*X1:% FP1%^V;">V
M@$9RT !-:S3K]C#L@9:N;:Z4J))TG/S[D9*BV)*BN8:P%YN4SCF\]USQ:[IC
M_(?8 $CTE-!4S(R-E-F5:8IH PD6ERR#5+U9,9Y@J;I\;8J, XYS4D)-Q[(\
M,\$D-?QI_FS!_2G;2DI26' DMDF"^?,-4+:;&;;Q\N ;66^D?F#ZTPROX0'D
M]VS!5<^L5&*20"H(2Q&'U<SX:%_-;4L3<L0?!'9BKXUT*DO&?NC.73PS+!T1
M4(BDEL#J[Q$"H%0KJ3A^EJ)&-:8F[K=?U&_SY%4R2RP@8/1/$LO-S!@;*(85
MWE+YC>T^09G04.M%C(K\%^U*K&6@:"LD2TJRBB A:?&/GTHC]@CVX V"4Q*<
M8PEN27"/)0Q*PN!8PK DY*F;1>ZY<2&6V)]RMD-<HY6:;N3NYVSE%TGUA_(@
MN7I+%$_Z]Q"3"%,44$P2@7 :HQM(846D0 O\C)<4T 5J0=UNY9;#*_@L!(D)
M%><*_OTA1&?OS]%[1%)T3RA5GX28FE+%JT<UHS*VFR(VYXW80H@ND6O_AAS+
M<5KHP?%TNX4>'D^W6NCSH^GVY)!NJAI5A7*J0CFYGON&WF>"EX02^8S4ZK!?
MB++Y,?Y'?2UJ"DLT?U++B #TUV>E@>XD).+O-O>+ 0?M ^H5ZDID.(*9H98@
M ?P1#/_#.]NSKMMJT:=8V*?8O">Q@ZJY5=7<+G7_%N!"U>M"ZY((4%04BZ31
MEG.(T7(K4<HDRC")T=F'=V/'L:[O;KXL\J9]?=Y6MV+(43ZDW@@>?6<X&4W-
MQ_UZM( &8^\0%#9!MC>H*<T[,SS1OT'EWZ#3O\4&J]T@>E8&Y6M1FQV%@K>?
MJ55+-&C!Z%EY8$838P_K7G1&>Z(7P\J+8:<7 <Z(Q/GVVN'&L)'%9% SHPD9
M.S4OFI"15;.B,]@3K? J*[Q.*[[*#?"V[+U&W)YKU])O8H:C^L1HP3CCF@&=
M(9YHP*@R8-1IP.],8MIFP*@1N-N(/&@!N9Y;LZ )<KQ)S:?YJ+F C(>OW]M!
M;N,JMW%G;O?J@$HI3E' DHR"!!1@==+ T<\M$23__O4YF:1K=414N*AU'G2.
M\:N;6Y]B89]B\Y[$#@HUJ0HU^;^/)),^J]:G6-BGV+PGL8.JV=;KD=\Z;?$H
M>?O3N;;J!_\-"5L@3GT/FG>'^*L6F'L7('V_O<=\35*!**R4O'4Y4IL5+ZZ,
M14>R++\3+9E4-ZR\N5'7;. :H-ZO&),O'7W-JB[N_K]02P,$%     @ QX)-
M5EOU)QJ^ @  @@<  !D   !X;"]W;W)K<VAE971S+W-H965T-CDN>&ULK55=
M;]HP%/TK5UDUM5+;? ']&$0"LFE]8$*MNCU,>S#)!:PZ=F8;:/_];"=DP +J
MPU[BKW..[[F.K_L;(5_4$E'#:\&X&GA+K<M[WU?9$@NBKD6)W*S,A2R(-D.Y
M\%4ID>2.5# _"H*>7Q#*O:3OYJ8RZ8N59I3C5():%061;R-D8C/P0F\[\4@7
M2VTG_*1?D@4^H7XNI]*,_$8EIP5R104'B?.!-PSOTZ[%.\!WBANUTP?K9";$
MBQT\Y ,OL $APTQ;!6*:-8Z1,2MDPOA=:WK-EI:XV]^J?W'>C9<943@6[ ?-
M]7+@W7J0XYRLF'X4FZ]8^W$!9H(I]X5-C0T\R%9*BZ(FFP@*RJN6O-9YV"&$
MO2.$J"9$AX3.$4)<$^+W$CHUH>,R4UEQ>4B))DE?B@U(BS9JMN.2Z=C&/N7V
MV)^T-*O4\'0RP9QFA,&8$5HH(#R'$7*<4ZU@2M[(C"%<P3#/J3TF WS@U;]F
M#^T\14TH4Q<&\OR4POG9!9P!Y3"AC!F ZOO:Q&AW\K,ZGE$53W0DGC""B>!Z
MJ> SSS'?%_"-N<9AM'4XBDXJIIA=0QQ>0A1$44M X_?3PQ9Z^GYZ<,)-W)Q7
M[/3B(WH/7*TDX1G"S^%,:6GNS:^V+%<JG7856TON54DR''BF6"B4:_22CQ_"
M7O"I+4/_4RS]3V)[V>LTV>N<4D^^"7XEJ7J!4HHUS1'*ZA=O_5$KJ1LG9:OG
M.HFBV[Z_WLU,&Z:WCTE;,'&WP>SYZ#8^NB=]3"45$DHT30Z9N[J7,"=K(=V%
MS7%MZGEIJK-N,];])Z"KZ+9SX*P-%-\=6&L!A>'=@3=_ISH5*!>NRBO(Q(KK
MZAHWL\U#,G3U\V!^9!Z8ZCWX*U.]3A,B%Y0K8#@WDL'UC0E,5A6_&FA1NAHX
M$]I45-==FD<2I068];D0>CNP&S3/;O('4$L#!!0    ( ,>"359+!CIYJ0@
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M0[RUMR[SNON+G@=M,$/KQ[HI=T-CU8-=5O3_TZ]#((X:X'"B 1D:$+,!FVA
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M<VAE970W,2YX;6R]6&UOFSH8_2L6=YHV:2OO).E-(JV%Z5;:I*C5M@_3_>#
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M=@?S^5(8$W<K]BE?\Y V_@I02P,$%     @ QX)-5NRZ$FR= P  9A   !D
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M'/2G8DA==.3%R'$.A$5'5NS&]/B^;OF^/L6)_B0Z=*+O#-$UHIZZ($<"ZQ7
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MK2^TM20<QX^]0_VX+2FTO:8<ZL?^$S\.]OC1W3DDV@/W-Z:67&B2P )CO<X
M)Z7*,VS9,#(KSHTS:? 46ERN\-P/RG; YPN)ZU,U[%&T_B<1_0502P,$%
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M@E=U<M60;&8JQU<F51UJ'J?JVP*X!JCQ,6-RW= 3-%\KT7]02P,$%     @
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MH)T!OE\J99]NW'FA.A]._P502P,$%     @ QX)-5NG">FKT P  @A,  !D
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M![Q5J%648U3O\D<I*5U4_5I*?NPHN$+C^5S '"M WYD21(\A,?J)Z:JRF>7
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MWXO--ZCS&1B^1&3*_I)-97L9.B0IE19Y#<8(<L:K)]W6.NP!_.$)0% #@F/
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M-::&1@,EUT19:U2S Y<;YXTT3-A=G!J%;QGZF6@DTY09W!:C"14)&4EAF%B
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M\<:KHMLI)D9FKF&828/MAQLNL4$$90WP_5Q*\S*Q/4C9<D9_ 5!+ P04
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M-$V*/V)40D5[;O9R^ IC/;>.5TBN_1,-P7=N,Q:]-K(=@ZW=,A'>]'F\A[.
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MPQW$*3!E(,]O*!6GA;I -\4+_P=02P,$%     @ QX)-5F#%3L^5!0  *"(
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M/K;*%MEB&]:L=Y>$O&.#($;K>G1A;;)%MMB&A>W]+3'[V]<:1!L^7$K09Q.
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MG+"R JCO'SB7NX/J MW+(8O_ 5!+ P04    " #'@DU6'RV-[I8)  #$20
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M:IWIX<CLF(7#*IZ>#/WNQ6O:PC!M63ENNRQXBF'SE6OCT&EF;QS" 7N/K3Y
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M:X!ZOV),OMSH#U1G;O-_ %!+ P04    " #'@DU6^,(/Y3P)  #&-P  &0
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M1Y"2*U0<2J.0!(#HGN(K1:MWPA'!<U:*FT+J"*;\T%%OD^6E#%V%XC <A20
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MR9Z+G),)+)@VB@I#/I)OTH F1I+_ 8\S,)1Q?8*@^VE&CH].R!%A@MPQSC%
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M@]-S%*;J/E1/C*Q<99Y)@W7>#9?8ND'9 'P_EUAMFXG=H/TSD/X%4$L#!!0
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M1+V3@-Z9>F<!O3/US@)Z9^J=!?3.U#L+Z)VI=Q;0.U/O+*!WIMY90.],O;.
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
M  @ QX)-5E&+M0'5!P  :C   !@              ("!#0@  'AL+W=O<FMS
M:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,>"35;W^0%0.@(  +P%   8
M              " @1@0  !X;"]W;W)K<VAE971S+W-H965T,BYX;6Q02P$"
M% ,4    " #'@DU6SWU^PT<&   K'P  &               @(&($@  >&PO
M=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ QX)-5E=SR"TW P
M'PL  !@              ("!!1D  'AL+W=O<FMS:&5E=',O<VAE970T+GAM
M;%!+ 0(4 Q0    ( ,>"359ORY(N%P8  *D9   8              " @7(<
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #'@DU6#OP!
M.-D"  ";"0  &               @(&_(@  >&PO=V]R:W-H965T<R]S:&5E
M=#8N>&UL4$L! A0#%     @ QX)-5L?AZ 21!@  *3,  !@
M ("!SB4  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    ( ,>"
M35;TQ'T]+0D  &(M   8              " @94L  !X;"]W;W)K<VAE971S
M+W-H965T."YX;6Q02P$"% ,4    " #'@DU6'TY@X(\+  #J'@  &
M        @('X-0  >&PO=V]R:W-H965T<R]S:&5E=#DN>&UL4$L! A0#%
M  @ QX)-5LAD:K$9*0  @88  !D              ("!O4$  'AL+W=O<FMS
M:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4    " #'@DU6"!!@$K #  "F"
M&0              @($-:P  >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;%!+
M 0(4 Q0    ( ,>"359>WOK?@@4    .   9              " @?1N  !X
M;"]W;W)K<VAE971S+W-H965T,3(N>&UL4$L! A0#%     @ QX)-5@@WD7:
M!P  VA4  !D              ("!K70  'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q02P$"% ,4    " #'@DU6K&&*8[$(  !"&0  &0
M@(%D?   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    ( ,>"
M35;NJPQ)L 0  , +   9              " @4R%  !X;"]W;W)K<VAE971S
M+W-H965T,34N>&UL4$L! A0#%     @ QX)-5AZ%HW[A!0  *1H  !D
M         ("!,XH  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"% ,4
M    " #'@DU6=^:_&]4#   ["0  &0              @(%+D   >&PO=V]R
M:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( ,>"359OAF6=@ D  $X=
M   9              " @5>4  !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL
M4$L! A0#%     @ QX)-5E39*0!/!@  R1   !D              ("!#IX
M 'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #'@DU6CF"4
M<@ *  !2&0  &0              @(&4I   >&PO=V]R:W-H965T<R]S:&5E
M=#(P+GAM;%!+ 0(4 Q0    ( ,>"359VWV)?X D  +X9   9
M  " @<NN  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%     @
MQX)-5K854Z2H P  (@@  !D              ("!XK@  'AL+W=O<FMS:&5E
M=',O<VAE970R,BYX;6Q02P$"% ,4    " #'@DU6+=#/+PL,  !3'@  &0
M            @('!O   >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+ 0(4
M Q0    ( ,>"358&7K6,%08  -(.   9              " @0/)  !X;"]W
M;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ QX)-5L]D+JV4#
M>2   !D              ("!3\\  'AL+W=O<FMS:&5E=',O<VAE970R-2YX
M;6Q02P$"% ,4    " #'@DU6%CAA,WHA   S;@  &0              @($:
MW   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( ,>"35;P
M6W4!WP0   X/   9              " @<O]  !X;"]W;W)K<VAE971S+W-H
M965T,C<N>&UL4$L! A0#%     @ QX)-5NGQ<I[' P  V0@  !D
M     ("!X0(! 'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,>"358W@.:5N 0  (\.   9              "
M@507 0!X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @ QX)-
M5G2;53BE P  X@@  !D              ("!0QP! 'AL+W=O<FMS:&5E=',O
M<VAE970S-"YX;6Q02P$"% ,4    " #'@DU65MPJ$>8&   S%0  &0
M        @($?( $ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4 Q0
M   ( ,>"35;87)Y<80,  +0(   9              " @3PG 0!X;"]W;W)K
M<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ QX)-5N,%+DT^!0  (0X
M !D              ("!U"H! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX;6Q0
M2P$"% ,4    " #'@DU609L:MV@%   ;#0  &0              @(%), $
M>&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( ,>"35;(-U9K
M,@0  '()   9              " @>@U 0!X;"]W;W)K<VAE971S+W-H965T
M,SDN>&UL4$L! A0#%     @ QX)-5DQ ?X[6"   51<  !D
M ("!43H! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4    " #'
M@DU6+&,ZF]$&   <1@  &0              @(%>0P$ >&PO=V]R:W-H965T
M<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( ,>"35:^K<N'X (  )T)   9
M          " @69* 0!X;"]W;W)K<VAE971S+W-H965T-#(N>&UL4$L! A0#
M%     @ QX)-5GMAS8#9!P  ]$(  !D              ("!?4T! 'AL+W=O
M<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4    " #'@DU6,3S7//\"  #J
M#   &0              @(&-50$ >&PO=V]R:W-H965T<R]S:&5E=#0T+GAM
M;%!+ 0(4 Q0    ( ,>"358PJ=8R8 ,  $<,   9              " @<-8
M 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ QX)-5OZ=
M(VN6!   ;1<  !D              ("!6EP! 'AL+W=O<FMS:&5E=',O<VAE
M970T-BYX;6Q02P$"% ,4    " #'@DU6:\=$RC@%  "A)P  &0
M    @($G80$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0    (
M ,>"35;9$)]#$P0  /X7   9              " @99F 0!X;"]W;W)K<VAE
M971S+W-H965T-#@N>&UL4$L! A0#%     @ QX)-5NJ6;\MQ!   ]A@  !D
M             ("!X&H! 'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q02P$"
M% ,4    " #'@DU6$+.U'YH(  !X5   &0              @(&(;P$ >&PO
M=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( ,>"35;=\GUJ @4
M (TC   9              " @5EX 0!X;"]W;W)K<VAE971S+W-H965T-3$N
M>&UL4$L! A0#%     @ QX)-5G[AY^-S!0  *R(  !D              ("!
MDGT! 'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    " #'@DU6
MV^ UPR$#   B#0  &0              @($\@P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4S+GAM;%!+ 0(4 Q0    ( ,>"35;5#FQ &P,  #<+   9
M      " @92& 0!X;"]W;W)K<VAE971S+W-H965T-30N>&UL4$L! A0#%
M  @ QX)-5HQ%?<'N!@  AS@  !D              ("!YHD! 'AL+W=O<FMS
M:&5E=',O<VAE970U-2YX;6Q02P$"% ,4    " #'@DU6C;=4EA0#   K#0
M&0              @($+D0$ >&PO=V]R:W-H965T<R]S:&5E=#4V+GAM;%!+
M 0(4 Q0    ( ,>"35:S.A1\<00  !P?   9              " @5:4 0!X
M;"]W;W)K<VAE971S+W-H965T-3<N>&UL4$L! A0#%     @ QX)-5N: )8@$
M!   >!,  !D              ("!_I@! 'AL+W=O<FMS:&5E=',O<VAE970U
M."YX;6Q02P$"% ,4    " #'@DU6&=(HCC@#  !)"@  &0
M@($YG0$ >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    ( ,>"
M35:AR7OEW (  *P)   9              " @:B@ 0!X;"]W;W)K<VAE971S
M+W-H965T-C N>&UL4$L! A0#%     @ QX)-5@::2T $ P  ' H  !D
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M=#8U+GAM;%!+ 0(4 Q0    ( ,>"358'=K1_K@,  ,T1   9
M  " @7&V 0!X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%     @
MQX)-5M@(-PII @  @ 8  !D              ("!5KH! 'AL+W=O<FMS:&5E
M=',O<VAE970V-RYX;6Q02P$"% ,4    " #'@DU6VGXRK[@#  #$#P  &0
M            @('VO $ >&PO=V]R:W-H965T<R]S:&5E=#8X+GAM;%!+ 0(4
M Q0    ( ,>"359;]2<:O@(  (('   9              " @>7  0!X;"]W
M;W)K<VAE971S+W-H965T-CDN>&UL4$L! A0#%     @ QX)-5DL&.GFI"
M13H  !D              ("!VL,! 'AL+W=O<FMS:&5E=',O<VAE970W,"YX
M;6Q02P$"% ,4    " #'@DU6TM2^;90#  #5$P  &0              @(&Z
MS $ >&PO=V]R:W-H965T<R]S:&5E=#<Q+GAM;%!+ 0(4 Q0    ( ,>"35;5
MA3=0<00  # ;   9              " @870 0!X;"]W;W)K<VAE971S+W-H
M965T-S(N>&UL4$L! A0#%     @ QX)-5K/YXD%( P  T!   !D
M     ("!+=4! 'AL+W=O<FMS:&5E=',O<VAE970W,RYX;6Q02P$"% ,4
M" #'@DU68=B37DL#   !#0  &0              @(&LV $ >&PO=V]R:W-H
M965T<R]S:&5E=#<T+GAM;%!+ 0(4 Q0    ( ,>"35;MAI)PZ ,  + 5   9
M              " @2[< 0!X;"]W;W)K<VAE971S+W-H965T-S4N>&UL4$L!
M A0#%     @ QX)-5NRZ$FR= P  9A   !D              ("!3> ! 'AL
M+W=O<FMS:&5E=',O<VAE970W-BYX;6Q02P$"% ,4    " #'@DU6J>':-)0"
M   R!P  &0              @($AY $ >&PO=V]R:W-H965T<R]S:&5E=#<W
M+GAM;%!+ 0(4 Q0    ( ,>"35:3OU)(%P,  %4,   9              "
M@>SF 0!X;"]W;W)K<VAE971S+W-H965T-S@N>&UL4$L! A0#%     @ QX)-
M5I[#(S)* P  N0P  !D              ("!.NH! 'AL+W=O<FMS:&5E=',O
M<VAE970W.2YX;6Q02P$"% ,4    " #'@DU6;&G+/EP#  #Z"@  &0
M        @(&[[0$ >&PO=V]R:W-H965T<R]S:&5E=#@P+GAM;%!+ 0(4 Q0
M   ( ,>"358U97VAX ,  "L.   9              " @4[Q 0!X;"]W;W)K
M<VAE971S+W-H965T.#$N>&UL4$L! A0#%     @ QX)-5NG">FKT P  @A,
M !D              ("!9?4! 'AL+W=O<FMS:&5E=',O<VAE970X,BYX;6Q0
M2P$"% ,4    " #'@DU6E+TSKN8"   <"0  &0              @(&0^0$
M>&PO=V]R:W-H965T<R]S:&5E=#@S+GAM;%!+ 0(4 Q0    ( ,>"358A=(CU
M3 L  )>)   9              " @:W\ 0!X;"]W;W)K<VAE971S+W-H965T
M.#0N>&UL4$L! A0#%     @ QX)-5G-W7FRL P  'A   !D
M ("!, @" 'AL+W=O<FMS:&5E=',O<VAE970X-2YX;6Q02P$"% ,4    " #'
M@DU6;-4U>TD$  "U$P  &0              @($3# ( >&PO=V]R:W-H965T
M<R]S:&5E=#@V+GAM;%!+ 0(4 Q0    ( ,>"35:K'9W)E0,  &L0   9
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M970Y,2YX;6Q02P$"% ,4    " #'@DU6(3F"+[4#  #1$P  &0
M    @($?(0( >&PO=V]R:W-H965T<R]S:&5E=#DR+GAM;%!+ 0(4 Q0    (
M ,>"359@Q4[/E04  "@B   9              " @0LE @!X;"]W;W)K<VAE
M971S+W-H965T.3,N>&UL4$L! A0#%     @ QX)-5A\MC>Z6"0  Q$D  !D
M             ("!URH" 'AL+W=O<FMS:&5E=',O<VAE970Y-"YX;6Q02P$"
M% ,4    " #'@DU6L(F4.Z(#  !;$0  &0              @(&D- ( >&PO
M=V]R:W-H965T<R]S:&5E=#DU+GAM;%!+ 0(4 Q0    ( ,>"35;>8YV[608
M /D@   9              " @7TX @!X;"]W;W)K<VAE971S+W-H965T.38N
M>&UL4$L! A0#%     @ QX)-5O;53'TL!   ?Q,  !D              ("!
M#3\" 'AL+W=O<FMS:&5E=',O<VAE970Y-RYX;6Q02P$"% ,4    " #'@DU6
M^,(/Y3P)  #&-P  &0              @(%P0P( >&PO=V]R:W-H965T<R]S
M:&5E=#DX+GAM;%!+ 0(4 Q0    ( ,>"358&UR..NP(  !@(   9
M      " @>-, @!X;"]W;W)K<VAE971S+W-H965T.3DN>&UL4$L! A0#%
M  @ QX)-5H"]CN). P  KA4   T              ( !U4\" 'AL+W-T>6QE
M<RYX;6Q02P$"% ,4    " #'@DU6EXJ[',     3 @  "P
M@ %.4P( 7W)E;',O+G)E;'-02P$"% ,4    " #'@DU6+X9.>! '  #Y0
M#P              @ $W5 ( >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @
MQX)-5K?ZQO#1 @  ,CH  !H              ( !=%L" 'AL+U]R96QS+W=O
M<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ QX)-5A6+*+]4 @  .3@  !,
M             ( !?5X" %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&     &L
,:P!D'0   F$"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>270</ContextCount>
  <ElementCount>485</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>79</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Organization and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</Role>
      <ShortName>Organization and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Business Combinations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinations</Role>
      <ShortName>Business Combinations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Property, Equipment, and Capitalized Software, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNet</Role>
      <ShortName>Property, Equipment, and Capitalized Software, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Goodwill and Intangible Assets, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNet</Role>
      <ShortName>Goodwill and Intangible Assets, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Medical Claims and Benefits Payable</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</Role>
      <ShortName>Medical Claims and Benefits Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Segments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/Segments</Role>
      <ShortName>Segments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Condensed Financial Information of Registrant</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrant</Role>
      <ShortName>Condensed Financial Information of Registrant</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomePerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Business Combinations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsTables</Role>
      <ShortName>Business Combinations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/BusinessCombinations</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/FairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Investments</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Property, Equipment, and Capitalized Software, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetTables</Role>
      <ShortName>Property, Equipment, and Capitalized Software, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Leases</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Goodwill and Intangible Assets, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetTables</Role>
      <ShortName>Goodwill and Intangible Assets, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNet</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Medical Claims and Benefits Payable (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables</Role>
      <ShortName>Medical Claims and Benefits Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Debt</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/IncomeTaxes</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/StockholdersEquity</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Segments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsTables</Role>
      <ShortName>Segments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/Segments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Condensed Financial Information of Registrant (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables</Role>
      <ShortName>Condensed Financial Information of Registrant (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrant</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Organization and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails</Role>
      <ShortName>Organization and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Significant Accounting Policies - Receivables (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails</Role>
      <ShortName>Significant Accounting Policies - Receivables (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails</Role>
      <ShortName>Significant Accounting Policies - Amounts Due To Government Agencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/NetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/NetIncomePerShareTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Business Combinations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails</Role>
      <ShortName>Business Combinations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Business Combinations - Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails</Role>
      <ShortName>Business Combinations - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails</Role>
      <ShortName>Fair Value Measurements - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Investments - Schedule of Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails</Role>
      <ShortName>Investments - Schedule of Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Investments - Contractual Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails</Role>
      <ShortName>Investments - Contractual Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails</Role>
      <ShortName>Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Investments - Available-for-Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails</Role>
      <ShortName>Investments - Available-for-Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Investments - Balances of Restricted Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails</Role>
      <ShortName>Investments - Balances of Restricted Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Property, Equipment, and Capitalized Software, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails</Role>
      <ShortName>Property, Equipment, and Capitalized Software, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails</Role>
      <ShortName>Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails</Role>
      <ShortName>Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Leases - Supplemental Cash Flow (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Leases - Lease Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails</Role>
      <ShortName>Leases - Lease Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Goodwill and Intangible Assets, Net - Balances of Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Balances of Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails</Role>
      <ShortName>Goodwill and Intangible Assets, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Medical Claims and Benefits Payable - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableAdditionalInformationDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Medical Claims and Benefits Payable - Components of the Change (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Components of the Change (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Medical Claims and Benefits Payable - Medical Claims Reserve Development by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Medical Claims Reserve Development by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails</Role>
      <ShortName>Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Debt - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtMaturitiesDetails</Role>
      <ShortName>Debt - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Debt - Schedule of Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Debt - Schedule of Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Debt - Credit Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtCreditAgreementDetails</Role>
      <ShortName>Debt - Credit Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Debt - Senior Notes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.molinahealthcare.com/role/DebtSeniorNotesDetails</Role>
      <ShortName>Debt - Senior Notes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Stockholders' Equity - Components of Share-based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails</Role>
      <ShortName>Stockholders' Equity - Components of Share-based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Stockholders' Equity - Restricted and Performance Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails</Role>
      <ShortName>Stockholders' Equity - Restricted and Performance Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails</Role>
      <ShortName>Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails</Role>
      <ShortName>Stockholders' Equity - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Employee Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails</Role>
      <ShortName>Employee Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/EmployeeBenefitPlans</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.molinahealthcare.com/role/CommitmentsandContingencies</ParentRole>
      <Position>90</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Segments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsNarrativeDetails</Role>
      <ShortName>Segments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Segments - Schedule of Operating Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails</Role>
      <ShortName>Segments - Schedule of Operating Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails</Role>
      <ShortName>Segments - Reconciliation of Gross Margin to Consolidated Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails</Role>
      <ShortName>Condensed Financial Information of Registrant - Condensed Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails</Role>
      <ShortName>Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails</Role>
      <ShortName>Condensed Financial Information of Registrant - Condensed Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails</Role>
      <ShortName>Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails</Role>
      <ShortName>Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="moh-20221231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails</Role>
      <ShortName>Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 5 fact(s) appearing in ix:hidden were eligible for transformation: moh:HealthPlanContractTerm, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:PropertyPlantAndEquipmentUsefulLife -  moh-20221231.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="moh-20221231.htm">moh-20221231.htm</File>
    <File>moh-20221231.xsd</File>
    <File>moh-20221231_cal.xml</File>
    <File>moh-20221231_def.xml</File>
    <File>moh-20221231_lab.xml</File>
    <File>moh-20221231_pre.xml</File>
    <File>moh4q22_ex211.htm</File>
    <File>moh4q22_ex231.htm</File>
    <File>moh4q22_ex311.htm</File>
    <File>moh4q22_ex312.htm</File>
    <File>moh4q22_ex321.htm</File>
    <File>moh4q22_ex322.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>moh-20221231_g1.jpg</File>
    <File>moh-20221231_g2.jpg</File>
    <File>moh-20221231_g3.jpg</File>
    <File>moh-20221231_g4.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/srt/2022</BaseTaxonomy>
    <BaseTaxonomy items="1465">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>123
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "moh-20221231.htm": {
   "axisCustom": 0,
   "axisStandard": 24,
   "baseTaxonomies": {
    "http://fasb.org/srt/2022": 3,
    "http://fasb.org/us-gaap/2022": 1465,
    "http://xbrl.sec.gov/dei/2022": 38
   },
   "contextCount": 270,
   "dts": {
    "calculationLink": {
     "local": [
      "moh-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "moh-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "moh-20221231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "moh-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "moh-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "moh-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd"
     ]
    }
   },
   "elementCount": 733,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 11,
    "http://www.molinahealthcare.com/20221231": 2,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 17
   },
   "keyCustom": 67,
   "keyStandard": 418,
   "memberCustom": 32,
   "memberStandard": 47,
   "nsprefix": "moh",
   "nsuri": "http://www.molinahealthcare.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.molinahealthcare.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPolicies",
     "shortName": "Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Net Income Per Share",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Business Combinations",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinations",
     "shortName": "Business Combinations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Investments",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.molinahealthcare.com/role/Investments",
     "shortName": "Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Property, Equipment, and Capitalized Software, Net",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNet",
     "shortName": "Property, Equipment, and Capitalized Software, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.molinahealthcare.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Goodwill and Intangible Assets, Net",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNet",
     "shortName": "Goodwill and Intangible Assets, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Medical Claims and Benefits Payable",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable",
     "shortName": "Medical Claims and Benefits Payable",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortDurationInsuranceAndDepositContractsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Debt",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.molinahealthcare.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.molinahealthcare.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.molinahealthcare.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Stockholders' Equity",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Employee Benefit Plans",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.molinahealthcare.com/role/EmployeeBenefitPlans",
     "shortName": "Employee Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.molinahealthcare.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Segments",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.molinahealthcare.com/role/Segments",
     "shortName": "Segments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Condensed Financial Information of Registrant",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrant",
     "shortName": "Condensed Financial Information of Registrant",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "26",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables",
     "shortName": "Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Net Income Per Share (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Business Combinations (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsTables",
     "shortName": "Business Combinations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Statements of Income",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PremiumsEarnedNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Investments (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.molinahealthcare.com/role/InvestmentsTables",
     "shortName": "Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Property, Equipment, and Capitalized Software, Net (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetTables",
     "shortName": "Property, Equipment, and Capitalized Software, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.molinahealthcare.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Goodwill and Intangible Assets, Net (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetTables",
     "shortName": "Goodwill and Intangible Assets, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfGoodwillTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Medical Claims and Benefits Payable (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables",
     "shortName": "Medical Claims and Benefits Payable (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Debt (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.molinahealthcare.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.molinahealthcare.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Stockholders' Equity (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Segments (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.molinahealthcare.com/role/SegmentsTables",
     "shortName": "Segments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Condensed Financial Information of Registrant (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables",
     "shortName": "Condensed Financial Information of Registrant (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Organization and Basis of Presentation (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
     "shortName": "Organization and Basis of Presentation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "ie3076577c633490db40aa71614578a1e_D20210901-20210930",
      "decimals": null,
      "lang": "en-US",
      "name": "moh:HealthPlanContractTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Significant Accounting Policies - Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:InvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "moh:InvestmentsMaturityPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Significant Accounting Policies - Receivables (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails",
     "shortName": "Significant Accounting Policies - Receivables (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i5986c52b45c34430a4e46e84fd09578e_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ReceivablesNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails",
     "shortName": "Significant Accounting Policies - Amounts Due To Government Agencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalPremiumsLiabilityMedicalCareCostsThreshold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Net Income Per Share (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.molinahealthcare.com/role/NetIncomePerShareDetails",
     "shortName": "Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i863e60c11f294d5382a62b168dc11650_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "moh:SharesOutstandingExcludingRestrictedStockAwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moh:BusinessCombinationNumberOfBusinessCombinations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "combination",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Business Combinations - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
     "shortName": "Business Combinations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "moh:BusinessCombinationNumberOfBusinessCombinations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "combination",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i1a3656d06a5b43eaa3ec5dfdecceaac7_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Business Combinations - Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
     "shortName": "Business Combinations - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "idda4ab8b08044fecb8346dffcc274008_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnFairValueHedgesRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherAssetsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Financial Instruments on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i88055e4dad2440acb86c85055d57ae20_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Fair Value Measurements - Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails",
     "shortName": "Fair Value Measurements - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i88055e4dad2440acb86c85055d57ae20_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Investments - Schedule of Investments (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails",
     "shortName": "Investments - Schedule of Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Investments - Contractual Maturities (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails",
     "shortName": "Investments - Contractual Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Investments - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails",
     "shortName": "Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Investments - Available-for-Sale (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
     "shortName": "Investments - Available-for-Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedInvestmentsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Investments - Balances of Restricted Investments (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails",
     "shortName": "Investments - Balances of Restricted Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:RestrictionsOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i78c795544d9047bab9b654c5a011d8fe_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestrictedInvestmentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i54050094325c4beba6d8861066ebb7a0_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Property, Equipment, and Capitalized Software, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
     "shortName": "Property, Equipment, and Capitalized Software, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i54050094325c4beba6d8861066ebb7a0_D20221001-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TangibleAssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails",
     "shortName": "Property, Equipment, and Capitalized Software, Net - Summary of Property, Equipment, and Capitalized Software (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails",
     "shortName": "Property, Equipment, and Capitalized Software, Net - Depreciation and Amortization (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.molinahealthcare.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Leases - Components of Lease Expense (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Leases - Supplemental Cash Flow (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails",
     "shortName": "Leases - Supplemental Cash Flow (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:OperatingLeaseRightOfUseAssetExcludingLeasesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:OperatingLeaseRightOfUseAssetExcludingLeasesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Leases - Lease Maturities (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails",
     "shortName": "Leases - Lease Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i863e60c11f294d5382a62b168dc11650_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Goodwill and Intangible Assets, Net - Balances of Goodwill (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Balances of Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i202e4db7009b4cf9bdcf1f64e749b198_I20201231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Intangible Assets Balances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Goodwill and Intangible Assets, Net - Additional Information (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails",
     "shortName": "Goodwill and Intangible Assets, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails",
     "shortName": "Medical Claims and Benefits Payable - Medical Claims and Future Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Medical Claims and Benefits Payable - Additional Information (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableAdditionalInformationDetails",
     "shortName": "Medical Claims and Benefits Payable - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:MedicalClaimsAndBenefitsPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i999be11240344aa48da9e906b939d685_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Stockholders' Equity",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i999be11240344aa48da9e906b939d685_I20191231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i863e60c11f294d5382a62b168dc11650_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Medical Claims and Benefits Payable - Components of the Change (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
     "shortName": "Medical Claims and Benefits Payable - Components of the Change (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForClaimsAndClaimsAdjustmentExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Medical Claims and Benefits Payable - Medical Claims Reserve Development by Segment (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails",
     "shortName": "Medical Claims and Benefits Payable - Medical Claims Reserve Development by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "moh:ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails",
     "shortName": "Medical Claims and Benefits Payable - Incurred Claims and Allocated Adjustment Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "moh:LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
     "shortName": "Medical Claims and Benefits Payable - Cumulative Paid Claims and Allocated Claims Adjustment Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i0d21f0289d0f4503a608e0c544fa3528_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails",
     "shortName": "Medical Claims and Benefits Payable - Reconciliation of Claims Development (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Debt - Maturities (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
     "shortName": "Debt - Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Debt - Schedule of Long-Term Debt (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
     "shortName": "Debt - Schedule of Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsNoncurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i894911675af3435aaff732b2e986f5cb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Debt - Credit Agreement (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails",
     "shortName": "Debt - Credit Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i894911675af3435aaff732b2e986f5cb_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Debt - Senior Notes (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
     "shortName": "Debt - Senior Notes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i73f9280e97a540afba84f71174ad29c4_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails",
     "shortName": "Income Taxes - Reconciliation of the U.S. Federal Statutory Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails",
     "shortName": "Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Income Taxes - Additional Information (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TaxCreditCarryforwardValuationAllowance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i863e60c11f294d5382a62b168dc11650_I20211231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Income Taxes - Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i8df5a01609344460bb17a1e2311459c7_I20191231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "3",
      "lang": "en-US",
      "name": "moh:UnrecognizedCompensationForfeitedRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Stockholders' Equity - Components of Share-based Compensation (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails",
     "shortName": "Stockholders' Equity - Components of Share-based Compensation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i1e073e88099741bfbc940e573293e498_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Stockholders' Equity - Restricted and Performance Stock Activity (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails",
     "shortName": "Stockholders' Equity - Restricted and Performance Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i1e073e88099741bfbc940e573293e498_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
     "shortName": "Stockholders' Equity - Fair Value of Awards Granted and Vested (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "moh:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i863e60c11f294d5382a62b168dc11650_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Stockholders' Equity - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails",
     "shortName": "Stockholders' Equity - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Employee Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails",
     "shortName": "Employee Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Organization and Basis of Presentation",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation",
     "shortName": "Organization and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SpecialAssessmentBond",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - Commitments and Contingencies (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails",
     "shortName": "Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SpecialAssessmentBond",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Segments - Narrative (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails",
     "shortName": "Segments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Segments - Schedule of Operating Segment Information (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails",
     "shortName": "Segments - Schedule of Operating Segment Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
     "shortName": "Segments - Reconciliation of Gross Margin to Consolidated Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "ie1048aa4630b4b2c9254f8a188515094_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
     "shortName": "Condensed Financial Information of Registrant - Condensed Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "iba3d39cbcb0e429cbc30596a5203c015_I20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i6e1fafef562c4c43a4e635c589f60bc2_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
     "shortName": "Condensed Financial Information of Registrant - Condensed Balance Sheets - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedBalanceSheetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "iba3d39cbcb0e429cbc30596a5203c015_I20221231",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestAndDividendIncomeOperating",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Operations (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
     "shortName": "Condensed Financial Information of Registrant - Condensed Statements of Operations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedIncomeStatementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "id525b086f5334d17a80e67717fb01cb0_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InsuranceAgencyManagementFee",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
     "shortName": "Condensed Financial Information of Registrant - Condensed Statements of Comprehensive Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "id525b086f5334d17a80e67717fb01cb0_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "i2d46416c0f274c4fbf159c392301a68b_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
     "shortName": "Condensed Financial Information of Registrant - Condensed Statements of Cash Flows (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfCondensedCashFlowStatementTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "id525b086f5334d17a80e67717fb01cb0_D20220101-20221231",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:NetCashProvidedByUsedInOperatingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "id525b086f5334d17a80e67717fb01cb0_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails",
     "shortName": "Condensed Financial Information of Registrant - Notes to Condensed Financial Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "moh-20221231.htm",
      "contextRef": "id525b086f5334d17a80e67717fb01cb0_D20220101-20221231",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 79,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r717",
      "r718",
      "r719"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "moh_A3875SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.875% Senior Notes",
        "label": "3.875% Senior Notes [Member]",
        "terseLabel": "3.875% Notes due 2032"
       }
      }
     },
     "localname": "A3875SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_A4375SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Senior Notes",
        "label": "4.375% Senior Notes [Member]",
        "terseLabel": "4.375% Notes due 2028"
       }
      }
     },
     "localname": "A4375SeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AdvancesToRelatedPartiesAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advances to related parties and other assets.",
        "label": "Advances To Related Parties And Other Assets",
        "verboseLabel": "Advances to related parties and other assets"
       }
      }
     },
     "localname": "AdvancesToRelatedPartiesAndOtherAssets",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffinityHealthPlanIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affinity Health Plan, Inc",
        "label": "Affinity Health Plan, Inc [Member]",
        "terseLabel": "Affinity Health Plan, Inc"
       }
      }
     },
     "localname": "AffinityHealthPlanIncMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Net Payable",
        "terseLabel": "Risk adjustment, net payable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentNetPayable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, (Payable)",
        "terseLabel": "Marketplace risk adjustment payables"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentPayable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "label": "Affordable Care Act, Premium Stabilization Program, Risk Adjustment, Receivable",
        "terseLabel": "Risk adjustment receivable"
       }
      }
     },
     "localname": "AffordableCareActPremiumStabilizationProgramRiskAdjustmentReceivable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AgeWellNewYorkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AgeWell New York",
        "label": "AgeWell New York [Member]",
        "terseLabel": "AgeWell New York"
       }
      }
     },
     "localname": "AgeWellNewYorkMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 2.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "label": "Amounts Due To Government Agencies, Marketplace, Medical Loss Ratio Threshold",
        "terseLabel": "Minimum MLR"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceMedicalLossRatioThreshold",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Marketplace Program [Abstract]",
        "terseLabel": "Marketplace program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMarketplaceProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 3.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid, Other",
        "label": "Amounts Due To Government Agencies, Medicaid, Other",
        "terseLabel": "Other premium adjustments"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidOther",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicaidProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "label": "Amounts Due To Government Agencies, Medicaid Program [Abstract]",
        "terseLabel": "Medicaid program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicaidProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 7.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "label": "Amounts Due To Government Agencies, Medicare, Medical Loss Ratio And Profit Sharing, Threshold",
        "terseLabel": "Minimum MLR and profit sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareMedicalLossRatioAndProfitSharingThreshold",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesMedicareProgramAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due To Government Agencies Medicare Program",
        "label": "Amounts Due To Government Agencies Medicare Program [Abstract]",
        "terseLabel": "Medicare program:"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesMedicareProgramAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 8.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "label": "Amounts Due to Government Agencies, Risk Adjustment and Part D risk sharing",
        "terseLabel": "Risk adjustment and Part D risk sharing"
       }
      }
     },
     "localname": "AmountsDueToGovernmentAgenciesRiskAdjustmentAndPartDRiskSharing",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 4.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Other",
        "label": "Amounts Due to Government Agencies, Other",
        "terseLabel": "Other premium adjustments"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesOther",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AmountsDuetoGovernmentAgenciesRiskAdjustment": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 5.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts Due to Government Agencies, Risk Adjustment",
        "label": "Amounts Due to Government Agencies, Risk Adjustment",
        "terseLabel": "Risk adjustment"
       }
      }
     },
     "localname": "AmountsDuetoGovernmentAgenciesRiskAdjustment",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Supplemental lease information"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_AuditInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Audit Information",
        "label": "Audit Information [Abstract]"
       }
      }
     },
     "localname": "AuditInformationAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "xbrltype": "stringItemType"
    },
    "moh_BasisOfPresentationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Of Presentation [Line Items]",
        "label": "Basis Of Presentation [Line Items]",
        "terseLabel": "Basis Of Presentation [Line Items]"
       }
      }
     },
     "localname": "BasisOfPresentationLineItems",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_BasisOfPresentationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basis Of Presentation [Table]",
        "label": "Basis Of Presentation [Table]",
        "terseLabel": "Basis Of Presentation [Table]"
       }
      }
     },
     "localname": "BasisOfPresentationTable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_BusinessCombinationNumberOfBusinessCombinations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Number Of Business Combinations",
        "label": "Business Combination, Number Of Business Combinations",
        "terseLabel": "Number of business combinations"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfBusinessCombinations",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of members eligible for the health care programs.",
        "label": "Business Combination, Number Of Members Eligible For The Health Care Programs",
        "terseLabel": "Number of members eligible for the health care programs, approximately"
       }
      }
     },
     "localname": "BusinessCombinationNumberOfMembersEligibleForTheHealthCarePrograms",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Medical Claims and Benefits Payable",
        "terseLabel": "Payable"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentMedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Receivables",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentReceivables",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CapitationClaimsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Capitation Claims Payable",
        "label": "Capitation Claims Payable",
        "terseLabel": "Capitation payable"
       }
      }
     },
     "localname": "CapitationClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_CashPaidDuringThePeriodAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During The Period [Abstract]",
        "label": "Cash Paid During The Period [Abstract]",
        "terseLabel": "Cash paid during the period for:"
       }
      }
     },
     "localname": "CashPaidDuringThePeriodAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_CashPaidForSettlementOfConversionOption": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid For Settlement Of Conversion Option",
        "label": "Cash Paid For Settlement Of Conversion Option",
        "negatedTerseLabel": "Cash paid for partial settlement of conversion option"
       }
      }
     },
     "localname": "CashPaidForSettlementOfConversionOption",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ChangesInAmountsDueToAndDueFromAffiliates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in amounts due to and due from affiliates.",
        "label": "Changes In Amounts Due To And Due From Affiliates",
        "verboseLabel": "Change in amounts due to/from affiliates"
       }
      }
     },
     "localname": "ChangesInAmountsDueToAndDueFromAffiliates",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan",
        "label": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan [Member]",
        "terseLabel": "Cigna Corporation's Texas Medicaid and Medicare-Medicaid Plan"
       }
      }
     },
     "localname": "CignaCorporationsTexasMedicaidAndMedicareMedicaidPlanMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_CommonStockWithheldToSettleEmployeeTaxObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Withheld to Settle Employee Tax Obligations",
        "label": "Common Stock Withheld to Settle Employee Tax Obligations",
        "negatedTerseLabel": "Common stock withheld to settle employee tax obligations"
       }
      }
     },
     "localname": "CommonStockWithheldToSettleEmployeeTaxObligations",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_CompleteCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Complete Care",
        "label": "Complete Care [Member]",
        "terseLabel": "Magellan Complete Care acquisition opening balance"
       }
      }
     },
     "localname": "CompleteCareMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "label": "Components Of Change In Medical Claims And Benefits Payable [Table Text Block]",
        "verboseLabel": "Components of the change in medical claims and benefits payable"
       }
      }
     },
     "localname": "ComponentsOfChangeInMedicalClaimsAndBenefitsPayableTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_ContractRightsandLicensingAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Rights and Licensing Agreements [Member]",
        "label": "Contract Rights and Licensing Agreements [Member]",
        "terseLabel": "Contract rights and licenses"
       }
      }
     },
     "localname": "ContractRightsandLicensingAgreementsMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_DeferredTaxAssetsFixedAssetsAndIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Fixed Assets and Intangibles",
        "label": "Deferred Tax Assets, Fixed Assets and Intangibles",
        "terseLabel": "Fixed assets and intangibles"
       }
      }
     },
     "localname": "DeferredTaxAssetsFixedAssetsAndIntangibles",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_DeferredTaxLiabilitiesFixedAssetsAndIntangibles": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Fixed Assets And Intangibles",
        "label": "Deferred Tax Liabilities, Fixed Assets And Intangibles",
        "negatedTerseLabel": "Fixed assets and intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssetsAndIntangibles",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_DepreciationAndAmortizationOfCapitalizedSoftware": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails": {
       "order": 1.0,
       "parentTag": "moh_DepreciationandAmortizationContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation, and amortization of capitalized software.",
        "label": "Depreciation And Amortization Of Capitalized Software",
        "verboseLabel": "Amortization of capitalized software"
       }
      }
     },
     "localname": "DepreciationAndAmortizationOfCapitalizedSoftware",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_DepreciationandAmortizationContinuingOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation and Amortization, Continuing Operations",
        "label": "Depreciation and Amortization, Continuing Operations",
        "totalLabel": "Total depreciation and amortization recognized"
       }
      }
     },
     "localname": "DepreciationandAmortizationContinuingOperations",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic and Diluted EPS",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Health Insurance, Percent",
        "terseLabel": "Nondeductible health insurer fee (\u201cHIF\u201d)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseHealthInsurancePercent",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_EmployeeStockPurchasePlanandStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan and Stock Options [Member]",
        "label": "Employee Stock Purchase Plan and Stock Options [Member]",
        "terseLabel": "Employee stock purchase plan and stock options"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanandStockOptionsMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan [Member]",
        "label": "Equity Incentive Plan [Member]",
        "terseLabel": "2019 EIP"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_FairMarketValueOfCommonStockPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value of common stock, Percentage.",
        "label": "Fair Market Value Of Common Stock Percentage",
        "terseLabel": "Employee purchase price as a percentage of stock price"
       }
      }
     },
     "localname": "FairMarketValueOfCommonStockPercentage",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_FinanceLeaseAssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Assets, Lessee [Abstract]",
        "label": "Finance Lease, Assets, Lessee [Abstract]",
        "terseLabel": "ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseAssetsLesseeAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_FinanceLeaseCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Cost",
        "label": "Finance Lease, Cost",
        "totalLabel": "Total finance lease expense"
       }
      }
     },
     "localname": "FinanceLeaseCost",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_FinanceLeaseLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finance Lease, Liabilities, Lessee [Abstract]",
        "label": "Finance Lease, Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesLesseeAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_GainLossOnDebtRepayment": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Debt Repayment",
        "label": "Gain (Loss) On Debt Repayment",
        "negatedLabel": "Loss on debt repayment"
       }
      }
     },
     "localname": "GainLossOnDebtRepayment",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_GovernmentReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Receivables [Member]",
        "label": "Government Receivables [Member]",
        "terseLabel": "Government receivables"
       }
      }
     },
     "localname": "GovernmentReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthAndHumanServicesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health And Human Services",
        "label": "Health And Human Services [Member]",
        "terseLabel": "Health and human services"
       }
      }
     },
     "localname": "HealthAndHumanServicesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthCareOrganizationInsurerFeeExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Insurer Fee Expense",
        "label": "Health Care Organization, Insurer Fee Expense",
        "terseLabel": "Health insurer fees"
       }
      }
     },
     "localname": "HealthCareOrganizationInsurerFeeExpense",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationInsurerFeeRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Insurer Fee Revenue",
        "label": "Health Care Organization, Insurer Fee Revenue",
        "terseLabel": "Health insurer fees reimbursed"
       }
      }
     },
     "localname": "HealthCareOrganizationInsurerFeeRevenue",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Marketplace Risk Corridor Judgment Revenue",
        "label": "Health Care Organization, Marketplace Risk Corridor Judgment Revenue",
        "terseLabel": "Marketplace risk corridor judgment"
       }
      }
     },
     "localname": "HealthCareOrganizationMarketplaceRiskCorridorJudgmentRevenue",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationPremiumTaxRevenue": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Premium Tax Revenue",
        "label": "Health Care Organization, Premium Tax Revenue",
        "terseLabel": "Premium tax revenue"
       }
      }
     },
     "localname": "HealthCareOrganizationPremiumTaxRevenue",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_HealthCareOrganizationRevenuePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Care Organization, Revenue Percentage",
        "label": "Health Care Organization, Revenue Percentage",
        "terseLabel": "Premium revenue percentage"
       }
      }
     },
     "localname": "HealthCareOrganizationRevenuePercentage",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_HealthPlanContractTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plan, Contract Term",
        "label": "Health Plan, Contract Term",
        "terseLabel": "Contract term"
       }
      }
     },
     "localname": "HealthPlanContractTerm",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_HealthPlanExtensionOptionPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plan, Extension Option, Period",
        "label": "Health Plan, Extension Option, Period",
        "terseLabel": "Extension period"
       }
      }
     },
     "localname": "HealthPlanExtensionOptionPeriod",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_HealthPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health plans.",
        "label": "Health Plans [Member]",
        "terseLabel": "Health Plans"
       }
      }
     },
     "localname": "HealthPlansMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_HealthPlansSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Health Plans Segment",
        "label": "Health Plans Segment [Member]",
        "terseLabel": "Health Plans Segment"
       }
      }
     },
     "localname": "HealthPlansSegmentMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) Before Income Taxes And Equity In Net Income Of Subsidiaries",
        "label": "Income (Loss) Before Income Taxes And Equity In Net Income Of Subsidiaries",
        "totalLabel": "Loss before income tax benefit and equity in net earnings of subsidiaries"
       }
      }
     },
     "localname": "IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Medical Premium Liability Due to Agency",
        "label": "Increase (Decrease) In Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies"
       }
      }
     },
     "localname": "IncreaseDecreaseInMedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_InvestmentsAverageMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Average Maturity Period",
        "label": "Investments, Average Maturity Period",
        "terseLabel": "Average maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsAverageMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_InvestmentsMaturityPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments, Maturity Period",
        "label": "Investments, Maturity Period",
        "terseLabel": "Maturity period (less than)"
       }
      }
     },
     "localname": "InvestmentsMaturityPeriod",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Business Acquisitions, Net Of Post-Closing Adjustments",
        "terseLabel": "Acquired balances, net of post-acquisition adjustments"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseBusinessAcquisitionsNetOfPostClosingAdjustments",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability For Unpaid Claims And Claims Adjustment Expense, Incurred Claims Including Acquisition Adjustment",
        "label": "Liability For Unpaid Claims And Claims Adjustment Expense, Incurred Claims Including Acquisition Adjustment",
        "terseLabel": "Incurred Claims and Allocated Claims Adjustment Expenses"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsIncludingAcquisitionAdjustment",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Paid (IBNP), Fee-for-service Claims, Amount",
        "terseLabel": "Fee-for-service claims incurred but not paid (\u201cIBNP\u201d)"
       }
      }
     },
     "localname": "LiabilityforUnpaidClaimsandClaimsAdjustmentExpenseIncurredbutNotPaidIBNPFeeforserviceClaimsAmount",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "label": "Long-Term Debt, Noncurrent, Net Of Unamortized Debt Discount",
        "terseLabel": "Non-current portion of long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrentNetOfUnamortizedDebtDiscount",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MarketplaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketplace",
        "label": "Marketplace [Member]",
        "terseLabel": "Marketplace Segment"
       }
      }
     },
     "localname": "MarketplaceMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicaidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicaid [Member]",
        "label": "Medicaid [Member]",
        "terseLabel": "Medicaid",
        "verboseLabel": "Medicaid Segment"
       }
      }
     },
     "localname": "MedicaidMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable",
        "label": "Medical Claims And Benefits Payable",
        "terseLabel": "Non-risk provide payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Claims and Benefits Payable, Adjustments, Change in Provider",
        "label": "Medical Claims And Benefits Payable, Adjustments, Change In Provider",
        "terseLabel": "Change in non-risk and other provider payables"
       }
      }
     },
     "localname": "MedicalClaimsAndBenefitsPayableAdjustmentsChangeInProvider",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalPremiumLiabilityDueToAgency": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Premium Liability Due to Agency",
        "label": "Medical Premium Liability Due To Agency",
        "terseLabel": "Amounts due government agencies",
        "totalLabel": "Total amounts due government agencies"
       }
      }
     },
     "localname": "MedicalPremiumLiabilityDueToAgency",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicalPremiumsLiabilityMedicalCareCostsThreshold": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 1.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medical Premiums Liability, Medical Care Costs Threshold",
        "label": "Medical Premiums Liability, Medical Care Costs Threshold",
        "terseLabel": "Minimum MLR, corridors, and profit sharing"
       }
      }
     },
     "localname": "MedicalPremiumsLiabilityMedicalCareCostsThreshold",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_MedicareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Medicare",
        "label": "Medicare [Member]",
        "terseLabel": "Medicare",
        "verboseLabel": "Medicare Segment"
       }
      }
     },
     "localname": "MedicareMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MemberListsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Member Lists",
        "label": "Member Lists [Member]",
        "terseLabel": "Member list"
       }
      }
     },
     "localname": "MemberListsMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MinimumMemberEnrollmentTargetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Member Enrollment Targets",
        "label": "Minimum Member Enrollment Targets [Member]",
        "terseLabel": "Minimum Member Enrollment Targets"
       }
      }
     },
     "localname": "MinimumMemberEnrollmentTargetsMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MunicipalSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Municipal securities.",
        "label": "Municipal Securities [Member]",
        "terseLabel": "Municipal securities"
       }
      }
     },
     "localname": "MunicipalSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_MyChoiceWisconsinMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "My Choice Wisconsin",
        "label": "My Choice Wisconsin [Member]",
        "terseLabel": "My Choice Wisconsin"
       }
      }
     },
     "localname": "MyChoiceWisconsinMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net Income (Loss) From Continuing Operations Before Equity Method Investments, Extraordinary Items, Noncontrolling Interest",
        "label": "Net Income (Loss) From Continuing Operations Before Equity Method Investments, Extraordinary Items, Noncontrolling Interest",
        "totalLabel": "Net loss before equity in net earnings of subsidiaries"
       }
      }
     },
     "localname": "NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_NumberOfStatesWithGovernmentSponsoredHealthcarePrograms": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of States With Government-Sponsored Healthcare Programs",
        "label": "Number Of States With Government-Sponsored Healthcare Programs",
        "terseLabel": "Number of states with programs"
       }
      }
     },
     "localname": "NumberOfStatesWithGovernmentSponsoredHealthcarePrograms",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "moh_OperatingAndFinanceLeaseImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating And Finance Lease, Impairment Loss",
        "label": "Operating And Finance Lease, Impairment Loss",
        "terseLabel": "ROU assets impairments"
       }
      }
     },
     "localname": "OperatingAndFinanceLeaseImpairmentLoss",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OperatingIncomeGuaranteeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Income Guarantee",
        "label": "Operating Income Guarantee [Member]",
        "terseLabel": "Operating Income Guarantee"
       }
      }
     },
     "localname": "OperatingIncomeGuaranteeMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OperatingLeaseAssetsLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Assets, Lessee [Abstract]",
        "label": "Operating Lease, Assets, Lessee [Abstract]",
        "terseLabel": "ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseAssetsLesseeAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_OperatingLeaseLiabilitiesLesseeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liabilities, Lessee [Abstract]",
        "label": "Operating Lease, Liabilities, Lessee [Abstract]",
        "terseLabel": "Lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesLesseeAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_OperatingLeaseRightOfUseAssetExcludingLeasesAcquired": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease Right Of Use Asset, Excluding Leases Acquired",
        "label": "Operating Lease Right Of Use Asset, Excluding Leases Acquired",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetExcludingLeasesAcquired",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherClaimsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Claims Payable",
        "label": "Other Claims Payable",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherMedicareProgram": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails": {
       "order": 6.0,
       "parentTag": "moh_MedicalPremiumLiabilityDueToAgency",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Medicare Program",
        "label": "Other Medicare Program",
        "terseLabel": "Other premium adjustments"
       }
      }
     },
     "localname": "OtherMedicareProgram",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAmountsDueToGovernmentAgenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_OtherProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Program",
        "label": "Other Program [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherProgramMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Receivables [Member]",
        "label": "Other Receivables [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_OtherSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Securities",
        "label": "Other Securities [Member]",
        "terseLabel": "Other",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherSecuritiesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PassportHealthPlanIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Passport Health Plan Inc",
        "label": "Passport Health Plan Inc [Member]",
        "terseLabel": "Passport Health Plan Inc"
       }
      }
     },
     "localname": "PassportHealthPlanIncMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment For Contingent Consideration Liability, Financing And Operating Activities",
        "label": "Payment For Contingent Consideration Liability, Financing And Operating Activities",
        "terseLabel": "Contingent consideration paid to seller included in financing and operating activities"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingAndOperatingActivities",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_PercentageOfAdditionalIncrementalRevenueEarned": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of additional incremental revenue earned.",
        "label": "Percentage Of Additional Incremental Revenue Earned",
        "verboseLabel": "Percentage of additional incremental revenue earned"
       }
      }
     },
     "localname": "PercentageOfAdditionalIncrementalRevenueEarned",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_PharmacyClaimsPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Claims Payable",
        "label": "Pharmacy Claims Payable",
        "terseLabel": "Pharmacy payable"
       }
      }
     },
     "localname": "PharmacyClaimsPayable",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_PharmacyRebateReceivablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmacy Rebate Receivables [Member]",
        "label": "Pharmacy Rebate Receivables [Member]",
        "terseLabel": "Pharmacy rebate receivables"
       }
      }
     },
     "localname": "PharmacyRebateReceivablesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_PremiumTaxExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An assessment levied by a state government on the net premium income collected.",
        "label": "Premium Tax Expenses",
        "terseLabel": "Premium tax expenses"
       }
      }
     },
     "localname": "PremiumTaxExpenses",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_PropertyAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Property And Equipment",
        "label": "Property And Equipment [Member]",
        "terseLabel": "Property and equipment"
       }
      }
     },
     "localname": "PropertyAndEquipmentMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_ProviderNetworkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provider Network",
        "label": "Provider Network [Member]",
        "terseLabel": "Provider network"
       }
      }
     },
     "localname": "ProviderNetworkMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_ProviderNetworksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provider networks.",
        "label": "Provider Networks [Member]",
        "netLabel": "Provider networks"
       }
      }
     },
     "localname": "ProviderNetworksMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_RecordedInDepreciationAndAmortizationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recorded In Depreciation And Amortization [Abstract]",
        "label": "Recorded In Depreciation And Amortization [Abstract]",
        "terseLabel": "Recorded in depreciation and amortization:"
       }
      }
     },
     "localname": "RecordedInDepreciationAndAmortizationAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_RestrictedandPerformanceStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted and Performance Stock [Member]",
        "label": "Restricted and Performance Stock [Member]",
        "terseLabel": "RSAs and PSUs (defined below)"
       }
      }
     },
     "localname": "RestrictedandPerformanceStockMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_RestrictionsOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restrictions On Investments [Table Text Block]",
        "label": "Restrictions On Investments [Table Text Block]",
        "terseLabel": "Schedule of balances of restricted investments"
       }
      }
     },
     "localname": "RestrictionsOnInvestmentsTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability [Abstract]",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability [Abstract]",
        "terseLabel": "ROU assets recognized in exchange for lease obligations:"
       }
      }
     },
     "localname": "RightofUseAssetObtainedinExchangeforOperatingLeaseLiabilityAbstract",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "moh_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties.",
        "label": "Risks And Uncertainties [Policy Text Block]",
        "verboseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Granted In Period, Fair Value",
        "terseLabel": "Fair value of restricted shares granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award maximum amount per employee.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Maximum Amount Per Employee",
        "terseLabel": "Maximum annual contribution per employee"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumAmountPerEmployee",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_SharesOutstandingExcludingRestrictedStockAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares, Outstanding, Excluding Restricted Stock Awards",
        "label": "Shares, Outstanding, Excluding Restricted Stock Awards",
        "terseLabel": "Shares outstanding at the beginning of the period (in shares)"
       }
      }
     },
     "localname": "SharesOutstandingExcludingRestrictedStockAwards",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "moh_ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Outstanding Liabilities Relating to Prior Years",
        "label": "Short-duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Outstanding Liabilities Relating to Prior Years",
        "terseLabel": "All outstanding liabilities before 2020"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsLiabilityforUnpaidClaimsandClaimAdjustmentExpenseOutstandingLiabilitiesRelatingtoPriorYears",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "moh_SummarizedPremiumRevenueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarized Premium Revenue",
        "label": "SummarizedPremiumRevenue [Table Text Block]",
        "terseLabel": "Summarized premium revenue"
       }
      }
     },
     "localname": "SummarizedPremiumRevenueTableTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_TaxesBasedOnPremiumsPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Taxes based on premiums.",
        "label": "Taxes Based On Premiums [Policy Text Block]",
        "verboseLabel": "Taxes Based on Premiums"
       }
      }
     },
     "localname": "TaxesBasedOnPremiumsPolicyTextBlock",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "moh_ThreePointEightSevenFivePercentSeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Three Point Eight Seven Five Percent Senior Notes",
        "label": "Three Point Eight Seven Five Percent Senior Notes [Member]",
        "terseLabel": "3.875% Notes due 2030"
       }
      }
     },
     "localname": "ThreePointEightSevenFivePercentSeniorNotesMember",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "moh_UnrecognizedCompensationForfeitedRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized compensation forfeited rate.",
        "label": "Unrecognized Compensation Forfeited Rate",
        "terseLabel": "Forfeiture rate"
       }
      }
     },
     "localname": "UnrecognizedCompensationForfeitedRate",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "moh_WeightedAverageNumberofSharesShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted Average Number of Shares, Share Based Compensation",
        "label": "Weighted Average Number of Shares, Share Based Compensation",
        "terseLabel": "Stock-based compensation (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberofSharesShareBasedCompensation",
     "nsuri": "http://www.molinahealthcare.com/20221231",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Condensed Financial Information Disclosure [Abstract]",
        "terseLabel": "Condensed Financial Information Disclosure [Abstract]"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureAbstract",
     "nsuri": "http://fasb.org/srt/2022",
     "xbrltype": "stringItemType"
    },
    "srt_CondensedFinancialStatementsCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Condensed Financial Statements, Captions [Line Items]",
        "terseLabel": "Condensed Financial Statements, Captions [Line Items]"
       }
      }
     },
     "localname": "CondensedFinancialStatementsCaptionsLineItems",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r264",
      "r525",
      "r526",
      "r527",
      "r528",
      "r567",
      "r652",
      "r657",
      "r778",
      "r781",
      "r782",
      "r852",
      "r855",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by consolidated entity or group of entities.",
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r264",
      "r525",
      "r526",
      "r527",
      "r528",
      "r567",
      "r652",
      "r657",
      "r778",
      "r781",
      "r782",
      "r852",
      "r855",
      "r856"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity or group of entities consolidated into reporting entity.",
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r264",
      "r303",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r325",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r397",
      "r398",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r779",
      "r780",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by components, eliminations, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r264",
      "r303",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r325",
      "r387",
      "r388",
      "r389",
      "r390",
      "r392",
      "r393",
      "r395",
      "r397",
      "r398",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r779",
      "r780",
      "r853",
      "r854"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components, elimination, non-segment corporate-level activity and reconciling items used in consolidating a parent entity and its subsidiaries or its operating segments.",
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r453",
      "r599",
      "r626",
      "r653",
      "r654",
      "r693",
      "r701",
      "r710",
      "r783",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r453",
      "r599",
      "r626",
      "r653",
      "r654",
      "r693",
      "r701",
      "r710",
      "r783",
      "r831",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ParentCompanyMember": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The registrant that controls, directly or indirectly, another entity (or entities). The usual condition for control is ownership of a majority (over 50 percent) of the outstanding voting stock. The power to control may also exist with a lesser percentage of ownership, for example, by contract, lease, agreement with other stockholders or by court decree.",
        "label": "Parent Company [Member]",
        "terseLabel": "Parent Company"
       }
      }
     },
     "localname": "ParentCompanyMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r327",
      "r601",
      "r694",
      "r708",
      "r775",
      "r776",
      "r785",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r327",
      "r601",
      "r694",
      "r708",
      "r775",
      "r776",
      "r785",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r445",
      "r453",
      "r479",
      "r480",
      "r481",
      "r575",
      "r599",
      "r626",
      "r653",
      "r654",
      "r693",
      "r701",
      "r710",
      "r774",
      "r783",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r383",
      "r384",
      "r385",
      "r386",
      "r445",
      "r453",
      "r479",
      "r480",
      "r481",
      "r575",
      "r599",
      "r626",
      "r653",
      "r654",
      "r693",
      "r701",
      "r710",
      "r774",
      "r783",
      "r832",
      "r833",
      "r834",
      "r835",
      "r836"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r741",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.",
        "label": "Condensed Balance Sheet [Table Text Block]",
        "verboseLabel": "Condensed balance sheets"
       }
      }
     },
     "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedCashFlowStatementTableTextBlock": {
     "auth_ref": [
      "r741",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed cash flow statement, including, but not limited to, cash flow statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Cash Flow Statement [Table Text Block]",
        "verboseLabel": "Condensed statements of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCondensedCashFlowStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_ScheduleOfCondensedFinancialStatementsTable": {
     "auth_ref": [
      "r264",
      "r667",
      "r677",
      "r678",
      "r679",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about condensed financial statements, including, but not limited to, the balance sheet, income statement, and statement of cash flows.",
        "label": "Condensed Financial Statements [Table]",
        "terseLabel": "Condensed Financial Statements [Table]",
        "verboseLabel": "Schedule of Condensed Financial Statements [Table]"
       }
      }
     },
     "localname": "ScheduleOfCondensedFinancialStatementsTable",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": {
     "auth_ref": [
      "r741",
      "r851"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations.",
        "label": "Condensed Income Statement [Table Text Block]",
        "verboseLabel": "Condensed statements of income"
       }
      }
     },
     "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r328",
      "r329",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r656",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r695",
      "r709",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Geographical area.",
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r328",
      "r329",
      "r636",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r656",
      "r658",
      "r695",
      "r709",
      "r785"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by geographical components.",
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "stpr_IA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "IOWA",
        "terseLabel": "Iowa"
       }
      }
     },
     "localname": "IA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_MS": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "MISSISSIPPI",
        "terseLabel": "Mississippi"
       }
      }
     },
     "localname": "MS",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NE": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEBRASKA",
        "terseLabel": "Nebraska"
       }
      }
     },
     "localname": "NE",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_NY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NEW YORK",
        "verboseLabel": "New York"
       }
      }
     },
     "localname": "NY",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_TX": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "TEXAS",
        "verboseLabel": "Texas"
       }
      }
     },
     "localname": "TX",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "stpr_WA": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "WASHINGTON",
        "verboseLabel": "Washington"
       }
      }
     },
     "localname": "WA",
     "nsuri": "http://xbrl.sec.gov/stpr/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesAndLoansReceivableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accounts, Notes, Loans and Financing Receivable [Line Items]",
        "terseLabel": "Statutory Accounting Practices [Line Items]"
       }
      }
     },
     "localname": "AccountsNotesAndLoansReceivableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of receivable.",
        "label": "Receivable Type [Axis]",
        "terseLabel": "Receivable Type [Axis]"
       }
      }
     },
     "localname": "AccountsNotesLoansAndFinancingReceivableByReceivableTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "verboseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r93",
      "r230"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTotalLabel": "Total accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r25",
      "r27",
      "r28",
      "r236",
      "r616",
      "r631",
      "r632"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r24",
      "r28",
      "r152",
      "r566",
      "r627",
      "r628",
      "r728",
      "r729",
      "r730",
      "r742",
      "r743",
      "r744"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive (Loss) Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Acquired Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Acquired Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r83"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted-average life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AcquisitionCosts": {
     "auth_ref": [
      "r170",
      "r171"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.",
        "label": "Acquisition Costs, Period Cost",
        "terseLabel": "Acquisition costs"
       }
      }
     },
     "localname": "AcquisitionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r9"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "terseLabel": "Additional paid-in capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r742",
      "r743",
      "r744",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).",
        "label": "Adjustments to Additional Paid in Capital, Other",
        "terseLabel": "Termination of warrants"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r483"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "verboseLabel": "Pretax Charges"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "verboseLabel": "Net-of-Tax Amount"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r53",
      "r81",
      "r87"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails": {
       "order": 3.0,
       "parentTag": "moh_DepreciationandAmortizationContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries": {
     "auth_ref": [
      "r260"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of restricted net assets of consolidated and unconsolidated subsidiaries as of the end of the most recently completed fiscal year.",
        "label": "Amount of Restricted Net Assets for Consolidated and Unconsolidated Subsidiaries",
        "verboseLabel": "Net assets of subsidiaries subject to restrictions"
       }
      }
     },
     "localname": "AmountOfRestrictedNetAssetsForConsolidatedAndUnconsolidatedSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r696",
      "r752"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-Backed Securities [Member]",
        "netLabel": "Asset-backed securities",
        "terseLabel": "Asset-backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r53",
      "r90"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Impairment"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r175",
      "r189",
      "r234",
      "r261",
      "r311",
      "r317",
      "r323",
      "r349",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r525",
      "r527",
      "r540",
      "r707",
      "r779",
      "r780",
      "r829"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r226",
      "r237",
      "r261",
      "r349",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r525",
      "r527",
      "r540",
      "r707",
      "r779",
      "r780",
      "r829"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "terseLabel": "Fair value of assets measured on recurring basis"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "terseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r73",
      "r335",
      "r614"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r73",
      "r334",
      "r613"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "auth_ref": [
      "r73",
      "r336",
      "r615"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "terseLabel": "Due after ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r73",
      "r333",
      "r612"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and improvements",
        "verboseLabel": "Building and improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r521",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r136",
      "r137",
      "r521",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r143",
      "r144",
      "r146"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r142",
      "r145",
      "r524"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r138",
      "r139"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "terseLabel": "Intangible assets value"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combinations"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalizedComputerSoftwareAccumulatedAmortization": {
     "auth_ref": [
      "r843"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For each balance sheet presented, the amount of accumulated amortization for capitalized computer software costs.",
        "label": "Capitalized Computer Software, Accumulated Amortization",
        "negatedLabel": "Less: accumulated amortization - capitalized software"
       }
      }
     },
     "localname": "CapitalizedComputerSoftwareAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Amount"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r55",
      "r228",
      "r680"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "verboseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r727"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r49",
      "r55",
      "r58"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, and restricted cash and cash equivalents at end of period",
        "periodStartLabel": "Cash and cash equivalents, and restricted cash and cash equivalents at beginning of period",
        "totalLabel": "Total cash and cash equivalents, and restricted cash and cash equivalents presented in the consolidated statements of cash flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r163"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash and cash equivalents, and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialMortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r78",
      "r787"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by commercial real estate mortgage loans.",
        "label": "Commercial Mortgage-Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "CommercialMortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r97",
      "r381",
      "r382",
      "r639",
      "r777"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "verboseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r742",
      "r743",
      "r821"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r8",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "terseLabel": "Common Stock, Shares, Outstanding",
        "verboseLabel": "Common stock, shares, outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValueOutstanding": {
     "auth_ref": [
      "r8"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of all classes of common stock held by shareholders. May be all or portion of the number of common shares authorized. These shares exclude common shares repurchased by the entity and held as treasury shares.",
        "label": "Common Stock, Value, Outstanding",
        "netLabel": "Common stock, $0.001 par value; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022 and December 31, 2021",
        "verboseLabel": "Common stock, $0.001 par value per share; 150 million shares authorized; outstanding: 58 million shares at each of December 31, 2022, and December 31, 2021"
       }
      }
     },
     "localname": "CommonStockValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "auth_ref": [
      "r109",
      "r110",
      "r111",
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "verboseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/EmployeeBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ComponentsOfIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r29",
      "r243",
      "r245",
      "r252",
      "r606",
      "r619"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r705",
      "r771",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r186",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "verboseLabel": "Concentrations of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock": {
     "auth_ref": [
      "r223",
      "r264",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for condensed financial information, including the financial position, cash flows, and the results of operations of the registrant (parent company) as of the same dates or for the same periods for which audited consolidated financial statements are being presented. Alternatively, the details of this disclosure can be reported by the specific parent company taxonomy elements, indicating the appropriate date and period contexts in an instance document.",
        "label": "Condensed Financial Information of Parent Company Only Disclosure [Text Block]",
        "verboseLabel": "Condensed Financial Information of Registrant"
       }
      }
     },
     "localname": "CondensedFinancialInformationOfParentCompanyOnlyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrant"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r150",
      "r681"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation and Presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r433",
      "r434",
      "r443"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractualRightsMember": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights that arise from a contractual arrangement with a third party (not including franchise rights and license agreements).",
        "label": "Contractual Rights [Member]",
        "terseLabel": "Contract rights - member list"
       }
      }
     },
     "localname": "ContractualRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r696",
      "r698",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "netLabel": "Corporate debt securities",
        "terseLabel": "Corporate debt securities",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r35",
      "r601"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Medical care costs"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "negatedTerseLabel": "Less: Other operating expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r739",
      "r817",
      "r819"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r506",
      "r514",
      "r739"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r739",
      "r817",
      "r819"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r176",
      "r178",
      "r188",
      "r264",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r549",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r4",
      "r178",
      "r188",
      "r417"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-Term Debt, Gross",
        "terseLabel": "Net carrying amount of debt",
        "totalLabel": "Net carrying amount"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r165",
      "r167",
      "r400",
      "r549",
      "r689",
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "verboseLabel": "Aggregate principal amount of notes outstanding"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r408",
      "r539",
      "r689",
      "r690"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "terseLabel": "Fair value of debt"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r18",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "netLabel": "Percentage of contractual interest rate on notes",
        "terseLabel": "Debt instrument, interest rate, stated percentage",
        "verboseLabel": "Percentage of contractual interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r19",
      "r264",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r549",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r19",
      "r102",
      "r103",
      "r104",
      "r105",
      "r164",
      "r165",
      "r167",
      "r185",
      "r264",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r549",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Agreement term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss": {
     "auth_ref": [
      "r757"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, after Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r344",
      "r357",
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "In a Continuous Loss Position for 12 Months or More, Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r344",
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "terseLabel": "In a Continuous Loss Position for 12 Months or More, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Number of Positions",
        "terseLabel": "In\u00a0a\u00a0Continuous\u00a0Loss Position for\u00a012\u00a0Months or More, Total Number of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r344",
      "r357",
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "In\u00a0a\u00a0Continuous\u00a0Loss Position for\u00a0Less\u00a0than\u00a012\u00a0Months, Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r344",
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "terseLabel": "In a Continuous Loss Position for Less than 12 Months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without an allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, Less than 12 Months, Number of Positions",
        "terseLabel": "In a Continuous Loss Position for Less than 12 Months, Total Number of Positions"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r757"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestAfterAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Debt securities, available-for-sale",
        "totalLabel": "Amortized Cost",
        "verboseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsContractualMaturitiesDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "terseLabel": "Gross realized investment gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r345"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "terseLabel": "Gross realized investment loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r343",
      "r686",
      "r759"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "verboseLabel": "Schedule of available-for-sale investments"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r122"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "verboseLabel": "Liability for unrecognized tax benefits, potential decrease"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredCompensationPlanAssets": {
     "auth_ref": [
      "r724"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of assets held under deferred compensation agreements.",
        "label": "Deferred Compensation Plan Assets",
        "terseLabel": "Deferred compensation plan"
       }
      }
     },
     "localname": "DeferredCompensationPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r739",
      "r818",
      "r819"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r166"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Less: unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r133",
      "r739",
      "r818"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r491",
      "r492"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r53",
      "r133",
      "r507",
      "r513",
      "r514",
      "r739"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "verboseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r5",
      "r6",
      "r177",
      "r187",
      "r501"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Total deferred income tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r739",
      "r818",
      "r819"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r815"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred income tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r815"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred income tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r131",
      "r816"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "verboseLabel": "Net operating losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r131",
      "r816"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "auth_ref": [
      "r129",
      "r131",
      "r816"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "terseLabel": "Tax credit carryover"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "auth_ref": [
      "r131",
      "r816"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "verboseLabel": "Other accrued medical costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities": {
     "auth_ref": [
      "r131",
      "r816"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities",
        "verboseLabel": "Accrued expenses and reserve liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent": {
     "auth_ref": [
      "r131",
      "r816"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred rent.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Deferred Rent",
        "terseLabel": "Lease financing obligation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve": {
     "auth_ref": [
      "r131",
      "r816"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from the unearned premiums reserve.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Unearned Premiums Reserve",
        "verboseLabel": "Unearned premiums"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsUnearnedPremiumsReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsUnrealizedCurrencyLosses": {
     "auth_ref": [
      "r131",
      "r816"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from unrealized losses on foreign currency transactions.",
        "label": "Deferred Tax Assets, Unrealized Currency Losses",
        "terseLabel": "Unrealized losses"
       }
      }
     },
     "localname": "DeferredTaxAssetsUnrealizedCurrencyLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r502"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedTerseLabel": "Valuation allowance",
        "verboseLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid expenses"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesDeferredTaxAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "verboseLabel": "Expense recognized in connection with contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "verboseLabel": "Maximum matching contribution by employer under defined contribution plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/EmployeeBenefitPlansDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r53",
      "r91"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails": {
       "order": 2.0,
       "parentTag": "moh_DepreciationandAmortizationContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "verboseLabel": "Depreciation and amortization of property, equipment, building, and improvements"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r53",
      "r91"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r53",
      "r306"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "auth_ref": [
      "r112",
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of share-based payment arrangement.",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "verboseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r253",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r278",
      "r280",
      "r285",
      "r286",
      "r287",
      "r291",
      "r532",
      "r533",
      "r607",
      "r620",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income per share - Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r253",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r280",
      "r285",
      "r286",
      "r287",
      "r291",
      "r532",
      "r533",
      "r607",
      "r620",
      "r683"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income per share - Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r288",
      "r289",
      "r290",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Net Income Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r494"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax expense rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r262",
      "r494",
      "r515"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Statutory federal tax (benefit) rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r814",
      "r820"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "terseLabel": "Nondeductible compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r814",
      "r820"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r814",
      "r820"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income provision (benefit), net of federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesReconciliationoftheUSFederalStatutoryIncomeTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r484"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r101",
      "r222",
      "r247",
      "r248",
      "r249",
      "r265",
      "r266",
      "r267",
      "r269",
      "r275",
      "r277",
      "r293",
      "r350",
      "r432",
      "r485",
      "r486",
      "r487",
      "r509",
      "r510",
      "r531",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r566",
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r408",
      "r539",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r534",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r155",
      "r156",
      "r157",
      "r158",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Schedule of fair value measurements of senior notes"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r155",
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Schedule of fair value of assets measured on recurring basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r155",
      "r161",
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r408",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r535",
      "r572",
      "r573",
      "r574",
      "r689",
      "r690",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r155",
      "r160",
      "r408",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Fair Value, by Balance Sheet Grouping, Disclosure Item Amounts [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r408",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r408",
      "r446",
      "r451",
      "r535",
      "r572",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r408",
      "r446",
      "r451",
      "r535",
      "r573",
      "r689",
      "r690",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r408",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r535",
      "r574",
      "r689",
      "r690",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r408",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r572",
      "r573",
      "r574",
      "r689",
      "r690",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseInterestExpense": {
     "auth_ref": [
      "r553",
      "r558",
      "r706"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "moh_FinanceLeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense on finance lease liability.",
        "label": "Finance Lease, Interest Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseInterestPaymentOnLiability": {
     "auth_ref": [
      "r555",
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest paid on finance lease liability.",
        "label": "Finance Lease, Interest Payment on Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeaseInterestPaymentOnLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Finance lease expense:",
        "verboseLabel": "Finance"
       }
      }
     },
     "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails",
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r551",
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Total finance lease liabilities",
        "totalLabel": "Total finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails",
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Accounts payable and accrued liabilities (current)"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current finance lease liability.",
        "label": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position.",
        "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]",
        "terseLabel": "Finance lease maturities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "netLabel": "Finance lease liabilities",
        "terseLabel": "Finance lease liabilities (non-current)",
        "verboseLabel": "Finance lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, to be Paid",
        "totalLabel": "Subtotal - undiscounted lease payments"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": 5.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": 6.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": 3.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": 4.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finance Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease.",
        "label": "Finance Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r554",
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAsset": {
     "auth_ref": [
      "r550"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, after Accumulated Amortization",
        "terseLabel": "ROU assets - finance leases",
        "verboseLabel": "Property, equipment, and capitalized software, net"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseRightOfUseAssetAmortization": {
     "auth_ref": [
      "r553",
      "r558",
      "r706"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "moh_FinanceLeaseCost",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails": {
       "order": 4.0,
       "parentTag": "moh_DepreciationandAmortizationContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to right-of-use asset from finance lease.",
        "label": "Finance Lease, Right-of-Use Asset, Amortization",
        "terseLabel": "Amortization of finance leases",
        "verboseLabel": "Amortization of ROU assets"
       }
      }
     },
     "localname": "FinanceLeaseRightOfUseAssetAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetDepreciationandAmortizationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r563",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for finance lease calculated at point in time.",
        "label": "Finance Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Finance leases, weighted average discount rate"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r562",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Finance Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Finance leases, weighted average remaining lease term"
       }
      }
     },
     "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r340",
      "r341",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r358",
      "r359",
      "r416",
      "r430",
      "r529",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r686",
      "r753",
      "r754",
      "r755",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life",
        "verboseLabel": "Intangible asset useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r232",
      "r376"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table containing detailed characteristics of finite-lived intangible assets acquired during a business combination. Finite-lived intangible assets are assets that have no physical form, but have expected future economic benefit, and are expected to be used over a defined period. Acquired finite-lived intangible assets are disclosed by major class (assets that can be grouped together because they are similar, either by their nature or by their use in operations of the Entity) and in total. Additionally, any significant residual value (the expected value of the asset at the end of its useful life) and the weighted-average amortization period are also disclosed.",
        "label": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]",
        "terseLabel": "Finite-Lived Intangible Assets Acquired as Part of Business Combination [Table]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "verboseLabel": "Future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "verboseLabel": "Future amortization expense, 2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Future amortization expense, 2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "verboseLabel": "Future amortization expense, 2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r373",
      "r375",
      "r376",
      "r377",
      "r602",
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r86",
      "r603"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r82",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsIntangibleAssetsDetails",
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails",
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r86",
      "r602"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Carrying Amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r374"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Acquired membership with a preliminary fair value"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnFairValueHedgesRecognizedInEarnings": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of gain (loss) derived from fair value hedges recognized in earnings in the period.",
        "label": "Gain (Loss) on Fair Value Hedges Recognized in Earnings",
        "negatedLabel": "Recognized loss"
       }
      }
     },
     "localname": "GainLossOnFairValueHedgesRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "verboseLabel": "General and administrative expenses"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r231",
      "r360",
      "r604",
      "r687",
      "r707",
      "r760",
      "r767"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r362",
      "r687"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Acquisitions and measurement period adjustments"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Goodwill and Intangible Assets, Net"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": {
     "auth_ref": [
      "r371",
      "r372",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.",
        "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "auth_ref": [
      "r135",
      "r766"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from adjustments after acquisition date under purchase accounting of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Purchase Accounting Adjustments",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r34",
      "r261",
      "r311",
      "r316",
      "r322",
      "r325",
      "r349",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r540",
      "r685",
      "r779"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "verboseLabel": "Total margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HealthCarePremiumMember": {
     "auth_ref": [
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money received from insurance for service provided for maintenance, diagnosis and treatment of physical and mental health.",
        "label": "Health Care, Premium [Member]",
        "terseLabel": "Premium revenue"
       }
      }
     },
     "localname": "HealthCarePremiumMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount": {
     "auth_ref": [
      "r339",
      "r611"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year 5 through 10",
        "terseLabel": "Amortized cost, due after five years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterFiveThroughTenYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount": {
     "auth_ref": [
      "r338",
      "r610"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, after Year One through Five",
        "verboseLabel": "Amortized Cost, Due one year through five years"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount": {
     "auth_ref": [
      "r337",
      "r609"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity) with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, after Allowance for Credit Loss, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Amortized Cost, Due in one year or less"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearNetCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r30",
      "r172",
      "r180",
      "r198",
      "r311",
      "r316",
      "r322",
      "r325",
      "r608",
      "r685"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromSubsidiariesNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of income (loss) of subsidiary attributable to the parent entity.",
        "label": "Income (Loss) from Subsidiaries, Net of Tax",
        "terseLabel": "Equity in net earnings of subsidiaries"
       }
      }
     },
     "localname": "IncomeLossFromSubsidiariesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]",
        "verboseLabel": "Condensed Statements of Income"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r262",
      "r495",
      "r499",
      "r505",
      "r511",
      "r516",
      "r518",
      "r519",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r263",
      "r276",
      "r277",
      "r309",
      "r493",
      "r512",
      "r517",
      "r621"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "moh_NetIncomeLossFromContinuingOperationsBeforeEquityMethodInvestmentsExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax benefit",
        "totalLabel": "Income tax expense",
        "verboseLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r246",
      "r489",
      "r490",
      "r499",
      "r500",
      "r504",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r57"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "verboseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Accounts payable, accrued liabilities and other"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r600",
      "r736"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInHealthCareInsuranceLiabilities": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) in health care insurance liability balances during the period.",
        "label": "Increase (Decrease) in Health Care Insurance Liabilities",
        "verboseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInHealthCareInsuranceLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net of the effect of acquisitions:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPremiumsReceivable": {
     "auth_ref": [
      "r52"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The change in the premium receivable balance on the balance sheet.",
        "label": "Increase (Decrease) in Premiums Receivable",
        "negatedTerseLabel": "Reduction in premiums"
       }
      }
     },
     "localname": "IncreaseDecreaseInPremiumsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInReceivables": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Receivables",
        "negatedLabel": "Receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r287",
      "r456"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "verboseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_InsuranceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Insurance [Abstract]",
        "terseLabel": "Insurance [Abstract]"
       }
      }
     },
     "localname": "InsuranceAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InsuranceAgencyManagementFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fees earned during the period for providing management services.",
        "label": "Insurance Agency Management Fee",
        "verboseLabel": "Administrative services fees"
       }
      }
     },
     "localname": "InsuranceAgencyManagementFee",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InsuranceRecoveries": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.",
        "label": "Insurance Recoveries",
        "terseLabel": "Reinsurance recoveries"
       }
      }
     },
     "localname": "InsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Goodwill and intangible assets, net",
        "verboseLabel": "Goodwill and intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestAndDividendIncomeOperating": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total of interest and dividend income, including any amortization and accretion (as applicable) of discounts and premiums, earned from (1) loans and leases whether held-for-sale or held-in-portfolio; (2) investment securities; (3) federal funds sold; (4) securities purchased under agreements to resell; (5) investments in banker's acceptances, commercial paper, or certificates of deposit; (6) dividend income; or (7) other investments not otherwise specified herein.",
        "label": "Interest and Dividend Income, Operating",
        "terseLabel": "Other revenue",
        "verboseLabel": "Investment income and other revenue"
       }
      }
     },
     "localname": "InterestAndDividendIncomeOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r166",
      "r183",
      "r250",
      "r305",
      "r548"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 2.0,
       "parentTag": "moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries",
       "weight": -1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r254",
      "r256",
      "r257"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "verboseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r726"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r348",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Schedule of contractual maturities of investments"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures": {
     "auth_ref": [
      "r725"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity method investee and investment in and advance to affiliate.",
        "label": "Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures",
        "terseLabel": "Investments in subsidiaries"
       }
      }
     },
     "localname": "InvestmentsInAffiliatesSubsidiariesAssociatesAndJointVentures",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r173",
      "r184",
      "r221",
      "r655"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/Investments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r786"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r826"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of lease expense and supplemental consolidated cash flow information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Finance Lease, Description [Abstract]",
        "terseLabel": "Finance leases:"
       }
      }
     },
     "localname": "LesseeFinanceLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Remaining Lease Term",
        "terseLabel": "Finance lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeaseRenewalTerm1": {
     "auth_ref": [
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's finance lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Finance Lease, Renewal Term",
        "terseLabel": "Finance lease renewal term"
       }
      }
     },
     "localname": "LesseeFinanceLeaseRenewalTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseDescriptionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Description [Abstract]",
        "terseLabel": "Operating leases:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseDescriptionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r827"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Operating lease maturities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Subtotal - undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r564"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r823"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r824"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Operating lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r16",
      "r261",
      "r349",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r526",
      "r527",
      "r528",
      "r540",
      "r684",
      "r779",
      "r829",
      "r830"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r13",
      "r179",
      "r194",
      "r707",
      "r738",
      "r756",
      "r822"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "terseLabel": "Total liabilities and stockholders\u2019 equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r227",
      "r261",
      "r349",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r526",
      "r527",
      "r528",
      "r540",
      "r707",
      "r779",
      "r829",
      "r830"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r155"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r201",
      "r204"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount needed to reflect the estimated ultimate cost of settling claims relating to insured events that have occurred on or before the balance sheet date, whether or not reported to the insurer at that date.",
        "label": "Liability for Claims and Claims Adjustment Expense",
        "netLabel": "Medical claims and benefits payable, total reserve development",
        "periodEndLabel": "Medical claims and benefits payable, ending balance",
        "periodStartLabel": "Medical claims and benefits payable, beginning balance",
        "terseLabel": "Total",
        "totalLabel": "Medical claims and benefits payable",
        "verboseLabel": "Medical claims and benefits payable"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Liability for Claims and Claims Adjustment Expense [Line Items]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Line Items]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpenseTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the liability for claims and claims adjustment expense.",
        "label": "Liability for Claims and Claims Adjustment Expense [Table]",
        "terseLabel": "Liability for Claims and Claims Adjustment Expense [Table]"
       }
      }
     },
     "localname": "LiabilityForClaimsAndClaimsAdjustmentExpenseTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsandFutureBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid [Abstract]",
        "terseLabel": "Payments for medical care costs related to:"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in the current period and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Current Year",
        "verboseLabel": "Current year"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1": {
     "auth_ref": [
      "r203"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PaymentsForLossesAndLossAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle claims incurred in prior periods and related claims settlement costs.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid, Prior Years",
        "verboseLabel": "Prior years"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount": {
     "auth_ref": [
      "r210"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated costs as of the balance sheet date of settling insured claims and costs incurred in the claims settlement process for claims that have not yet been submitted to the insurance company for reimbursement.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred but Not Reported (IBNR) Claims, Amount",
        "verboseLabel": "Total IBNP"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred and costs incurred in the claim settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims",
        "terseLabel": "Incurred Claims and Allocated Claims Adjustment Expenses",
        "totalLabel": "Incurred Claims and Allocated Claims Adjustment Expenses"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Incurred Claims [Abstract]",
        "terseLabel": "Components of medical care costs related to:"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaimsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]",
        "terseLabel": "Liability for Unpaid Claims and Claims Adjustment Expense [Roll Forward]"
       }
      }
     },
     "localname": "LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCredit": {
     "auth_ref": [
      "r4",
      "r178",
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.",
        "label": "Long-Term Line of Credit",
        "terseLabel": "Amount outstanding under Letter of Credit"
       }
      }
     },
     "localname": "LineOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Line of Credit Facility [Line Items]",
        "terseLabel": "Line of Credit Facility [Line Items]"
       }
      }
     },
     "localname": "LineOfCreditFacilityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityTable": {
     "auth_ref": [
      "r14",
      "r737"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line.",
        "label": "Line of Credit Facility [Table]",
        "terseLabel": "Line of Credit Facility [Table]"
       }
      }
     },
     "localname": "LineOfCreditFacilityTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "verboseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r98",
      "r264",
      "r784"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "verboseLabel": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r98",
      "r264",
      "r411"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r98",
      "r264",
      "r411"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "verboseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r98",
      "r264",
      "r411"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "verboseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r98",
      "r264",
      "r411"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "verboseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r98",
      "r264",
      "r411"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtInstrumentCarryingAmount",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r235"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "netLabel": "Long-term debt",
        "totalLabel": "Total",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-Term Debt [Text Block]",
        "verboseLabel": "Debt"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails",
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r19",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails",
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other Operating"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MortgageBackedSecuritiesMember": {
     "auth_ref": [
      "r696",
      "r697",
      "r698",
      "r751",
      "r842"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities collateralized by mortgage loans.",
        "label": "Collateralized Mortgage-Backed Securities [Member]",
        "terseLabel": "Mortgage-backed securities"
       }
      }
     },
     "localname": "MortgageBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash (used in) provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash used in financing activities:",
        "verboseLabel": "Financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r255"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r51",
      "r54"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "terseLabel": "Net cash provided by operating activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash used in operating activities:",
        "verboseLabel": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r31",
      "r54",
      "r181",
      "r197",
      "r225",
      "r241",
      "r244",
      "r249",
      "r261",
      "r268",
      "r270",
      "r271",
      "r272",
      "r273",
      "r276",
      "r277",
      "r284",
      "r311",
      "r316",
      "r322",
      "r325",
      "r349",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r533",
      "r540",
      "r685",
      "r779"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetInvestmentIncome": {
     "auth_ref": [
      "r618"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.",
        "label": "Net Investment Income",
        "terseLabel": "Investment income"
       }
      }
     },
     "localname": "NetInvestmentIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "negatedLabel": "Less: other expenses, net",
        "negatedTotalLabel": "Total other expenses, net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r746"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "verboseLabel": "Expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r311",
      "r316",
      "r322",
      "r325",
      "r685"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 1.0,
       "parentTag": "moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "terseLabel": "Operating income",
        "totalLabel": "Operating income"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r559",
      "r706"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r551"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails_1": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesLeaseMaturitiesDetails",
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Accounts payable and accrued liabilities (current)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Other long-term liabilities (non-current)"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r556",
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r563",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating leases, weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r562",
      "r706"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases, weighted average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Loss Carryforwards [Line Items]",
        "terseLabel": "Operating Loss Carryforwards [Line Items]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Operating Loss Carryforwards [Table]",
        "terseLabel": "Operating Loss Carryforwards [Table]"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Organization and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r233"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r148",
      "r149",
      "r151",
      "r242",
      "r245"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net",
        "totalLabel": "Other comprehensive (loss) income, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive (loss) income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r238",
      "r240",
      "r346"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment and Tax",
        "terseLabel": "Unrealized investment (loss) income",
        "verboseLabel": "Unrealized investment (loss) income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r26",
      "r239"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Less: effect of income taxes",
        "verboseLabel": "Less: effect of income taxes"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCostAndExpenseOperating": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of other operating cost and expense items that are associated with the entity's normal revenue producing operation.",
        "label": "Other Cost and Expense, Operating",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherCostAndExpenseOperating",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenses": {
     "auth_ref": [
      "r38",
      "r200"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense classified as other.",
        "label": "Other Expenses",
        "terseLabel": "Total other expenses, net"
       }
      }
     },
     "localname": "OtherExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Income and Expenses [Abstract]",
        "terseLabel": "Other expenses, net:"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r20"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "moh_IncomeLossBeforeIncomeTaxesAndEquityInNetIncomeOfSubsidiaries",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other expenses, net",
        "negatedTerseLabel": "Other expenses, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities, Cash Flow Statement",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedTerseLabel": "Contingent consideration liabilities settled",
        "terseLabel": "Contingent consideration liabilities settled"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityOperatingActivities": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability exceeding amount recognized at acquisition date. Includes, but is not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Operating Activities",
        "terseLabel": "Remaining half of contingent consideration paid"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForLossesAndLossAdjustmentExpense": {
     "auth_ref": [
      "r50",
      "r203"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of payments to settle insured claims and pay costs incurred in the claims settlement process.",
        "label": "Liability for Unpaid Claims and Claims Adjustment Expense, Claims Paid",
        "totalLabel": "Total paid"
       }
      }
     },
     "localname": "PaymentsForLossesAndLossAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r731",
      "r732"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Common stock purchases",
        "terseLabel": "Common stock purchases"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfWarrants": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount paid by the entity to reacquire the right to purchase equity shares at a predetermined price, usually issued together with corporate debt.",
        "label": "Payments for Repurchase of Warrants",
        "negatedTerseLabel": "Cash paid for partial termination of warrants"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAdditionalInterestInSubsidiaries": {
     "auth_ref": [
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of noncontrolling interest during the period.",
        "label": "Payments to Acquire Additional Interest in Subsidiaries",
        "negatedTerseLabel": "Capital contributions to subsidiaries"
       }
      }
     },
     "localname": "PaymentsToAcquireAdditionalInterestInSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r42",
      "r523"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "negatedTerseLabel": "Net cash paid in business combinations"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedTerseLabel": "Net cash paid in business combinations"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and capitalized software"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r807",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyholderBenefitsAndClaimsIncurredHealthCare": {
     "auth_ref": [
      "r199"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effect of policies assumed or ceded, of expense related to provision for policy benefits and costs incurred for health insurance contracts.",
        "label": "Policyholder Benefits and Claims Incurred, Net, Health",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "PolicyholderBenefitsAndClaimsIncurredHealthCare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Postemployment Benefits [Abstract]",
        "terseLabel": "Postemployment Benefits [Abstract]"
       }
      }
     },
     "localname": "PostemploymentBenefitsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r7",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "verboseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r7",
      "r707"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 20 million shares authorized, no shares issued and outstanding",
        "verboseLabel": "Preferred stock, $0.001 par value per share; 20 million shares authorized, no shares issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PremiumsEarnedNet": {
     "auth_ref": [
      "r605",
      "r617",
      "r622",
      "r633"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after premiums ceded to other entities and premiums assumed by the entity, of premiums earned.",
        "label": "Premiums Earned, Net",
        "terseLabel": "Premium revenue"
       }
      }
     },
     "localname": "PremiumsEarnedNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r727"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidReinsurancePremiums": {
     "auth_ref": [
      "r623",
      "r634"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The unexpired portion of premiums ceded on policies in force as of the balance sheet date.",
        "label": "Prepaid Reinsurance Premiums",
        "terseLabel": "Prepaid reinsurance premiums"
       }
      }
     },
     "localname": "PrepaidReinsurancePremiums",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromConvertibleDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Proceeds from Convertible Debt",
        "terseLabel": "Cash received for partial settlement of call option"
       }
      }
     },
     "localname": "ProceedsFromConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDividendsReceived": {
     "auth_ref": [
      "r735"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Dividends received on equity and other investments during the current period.",
        "label": "Proceeds from Dividends Received",
        "terseLabel": "Dividends received from subsidiaries"
       }
      }
     },
     "localname": "ProceedsFromDividendsReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSeniorLongTermDebt": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing with the highest claim on the assets of the entity in case of bankruptcy or liquidation (with maturities initially due after one year or beyond the operating cycle, if longer).",
        "label": "Proceeds from Issuance of Senior Long-Term Debt",
        "terseLabel": "Proceeds from senior notes offerings, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSeniorLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLinesOfCredit": {
     "auth_ref": [
      "r44",
      "r737"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements.",
        "label": "Proceeds from Lines of Credit",
        "terseLabel": "Proceeds from borrowings under term loan facility"
       }
      }
     },
     "localname": "ProceedsFromLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r733",
      "r734"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from sales and maturities of investments",
        "verboseLabel": "Proceeds from sales and maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Product Information [Line Items]",
        "terseLabel": "Product Information [Line Items]"
       }
      }
     },
     "localname": "ProductInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": {
     "auth_ref": [
      "r773",
      "r825"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset.",
        "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization",
        "terseLabel": "Property, equipment, and capitalized software, net",
        "totalLabel": "Property, equipment, and capitalized software, net",
        "verboseLabel": "Property, equipment, and capitalized software, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r96",
      "r640",
      "r641",
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, Equipment, and Capitalized Software, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r92",
      "r229"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "verboseLabel": "Total cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentOwnedAccumulatedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of depreciation (related to long-lived, depreciable flight assets owned by the entity and used in the entity's principle business operations and capitalized assets classified as property, plant and equipment that are owned by the entity) that has been recognized in the income statement.",
        "label": "Property, Plant, and Equipment, Owned, Accumulated Depreciation",
        "negatedTerseLabel": "Less: accumulated depreciation and amortization - property, equipment, building, and improvements"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentOwnedAccumulatedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "verboseLabel": "Long-Lived Assets, including Intangible Assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Summary of property and equipment and depreciation and amortization recognized"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life of property plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivableTypeDomain": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financing arrangement representing a contractual right to receive money either on demand or on fixed and determinable dates.",
        "label": "Receivable [Domain]",
        "terseLabel": "Receivable [Domain]"
       }
      }
     },
     "localname": "ReceivableTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r195",
      "r219",
      "r707"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Total receivables",
        "verboseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r747",
      "r748",
      "r749",
      "r750"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Receivables"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "verboseLabel": "Unrecognized tax benefits roll forward"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReinsuranceAccountingPolicy": {
     "auth_ref": [
      "r635",
      "r711",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of reinsurance accounting policy, for example, but not limited to, description of the methodologies and assumptions underlying determination of reinsurance recoverables, reinsurance payables and retention policy.",
        "label": "Reinsurance Accounting Policy [Policy Text Block]",
        "terseLabel": "Reinsurance"
       }
      }
     },
     "localname": "ReinsuranceAccountingPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments": {
     "auth_ref": [
      "r201",
      "r204",
      "r838",
      "r840"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after valuation allowance, recoverable under reinsurance contracts for losses reported to the ceding insurer but not yet paid and amounts expected for incurred losses and settlement expenses, which have not yet been reported to the ceding insurer.",
        "label": "Reinsurance Recoverable for Unpaid Claims and Claims Adjustments",
        "terseLabel": "Reinsurance recoverable"
       }
      }
     },
     "localname": "ReinsuranceRecoverableForUnpaidClaimsAndClaimsAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionDueFromToRelatedPartyCurrent": {
     "auth_ref": [
      "r740",
      "r828"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date within one year where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.",
        "label": "Related Party Transaction, Due from (to) Related Party, Current",
        "terseLabel": "Due from affiliates"
       }
      }
     },
     "localname": "RelatedPartyTransactionDueFromToRelatedPartyCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedLabel": "Repayment of principal amount of convertible notes",
        "negatedTerseLabel": "Repayment of principal amount of convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermLinesOfCredit": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for the settlement of obligation drawn from a contractual arrangement with the lender, including letter of credit, standby letter of credit and revolving credit arrangements, under which borrowings can be made up to a specific amount at any point in time with maturities due beyond one year or the operating cycle, if longer.",
        "label": "Repayments of Long-Term Lines of Credit",
        "negatedLabel": "Repayment of term loan facility",
        "negatedTerseLabel": "Repayment of term loan facility"
       }
      }
     },
     "localname": "RepaymentsOfLongTermLinesOfCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "negatedTerseLabel": "Repayment of senior notes"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReservesReportedToOtherAgenciesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of reserves reported to other federal agencies or authorities.",
        "label": "Reserves Reported to Other Agencies [Table Text Block]",
        "terseLabel": "Schedule of amounts due to government agencies"
       }
      }
     },
     "localname": "ReservesReportedToOtherAgenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r55",
      "r58",
      "r174",
      "r191",
      "r228"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash and Cash Equivalents",
        "terseLabel": "Restricted cash and cash equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedInvestmentsNoncurrent": {
     "auth_ref": [
      "r637",
      "r638"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the noncurrent portion of investments which are not defined as or included in marketable (debt, equity, or other) securities that are pledged or subject to withdrawal restrictions.",
        "label": "Restricted Investments, Noncurrent",
        "verboseLabel": "Restricted investments"
       }
      }
     },
     "localname": "RestrictedInvestmentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r10",
      "r106",
      "r192",
      "r630",
      "r632",
      "r707"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r222",
      "r265",
      "r266",
      "r267",
      "r269",
      "r275",
      "r277",
      "r350",
      "r485",
      "r486",
      "r487",
      "r509",
      "r510",
      "r531",
      "r627",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r444",
      "r682"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r33",
      "r220",
      "r389",
      "r390",
      "r391",
      "r397",
      "r398",
      "r399"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "verboseLabel": "Services revenue from subsidiaries"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r251",
      "r261",
      "r302",
      "r303",
      "r315",
      "r320",
      "r321",
      "r327",
      "r328",
      "r331",
      "r349",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r394",
      "r396",
      "r398",
      "r399",
      "r540",
      "r608",
      "r779"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Revenues",
        "totalLabel": "Total revenue",
        "verboseLabel": "Add: Other operating revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue:",
        "verboseLabel": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofOperationsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "terseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtCreditAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability": {
     "auth_ref": [
      "r561",
      "r706"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for finance lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Finance Lease Liability",
        "terseLabel": "Finance leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r561",
      "r706"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating leases"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/LeasesSupplementalCashFlowDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]",
        "terseLabel": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesReceivablesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables.",
        "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]",
        "terseLabel": "Schedule of receivables"
       }
      }
     },
     "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the characteristics, including initial carrying value, residual amount, weighted average useful life, of finite-lived intangible assets acquired during the period by major class. A major class is composed of intangible assets that can be grouped together because they are similar, either by nature or by their use in the operations of the company.",
        "label": "Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]",
        "terseLabel": "Summary of intangible assets acquired"
       }
      }
     },
     "localname": "ScheduleOfAcquiredFiniteLivedIntangibleAssetsByMajorClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "verboseLabel": "Schedule of investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r136",
      "r137",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/BusinessCombinationsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "verboseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r23"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.",
        "label": "Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Condensed statements of comprehensive income"
       }
      }
     },
     "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r19",
      "r102",
      "r103",
      "r104",
      "r105",
      "r164",
      "r165",
      "r167",
      "r185",
      "r689",
      "r691",
      "r741"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "verboseLabel": "Long term debt"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "verboseLabel": "Significant components of deferred tax assets and liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r745"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Summary of denominators for the computation of basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Effective income tax rate reconciliation to the statutory federal income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r82",
      "r85",
      "r602"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r82",
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "verboseLabel": "Summary of identified intangible assets, by major class"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r687",
      "r760",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Held-to-Maturity Securities [Line Items]",
        "terseLabel": "Schedule of Held-to-maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfHeldToMaturitySecuritiesTable": {
     "auth_ref": [
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity [Table]",
        "terseLabel": "Debt Securities, Held-to-maturity [Table]"
       }
      }
     },
     "localname": "ScheduleOfHeldToMaturitySecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the activity in the reserve for settling insured claims and expenses incurred in the claims settlement process for the period. The estimated liability includes the amount of money that will be required for future payments of (a) claims that have been reported to the insurer, (b) claims related to insured events that have occurred but that have not been reported to the insurer as of the date the liability is estimated, and (c) claim adjustment expenses. Claim adjustment expenses include costs incurred in the claim settlement process such as legal fees; outside adjuster fees; and costs to record, process, and adjust claims.",
        "label": "Schedule of Liability for Unpaid Claims and Claims Adjustment Expense [Table Text Block]",
        "terseLabel": "Schedule of liability for unpaid claims and claims adjustment expense"
       }
      }
     },
     "localname": "ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "verboseLabel": "Maturities of long-term debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedShareActivityTableTextBlock": {
     "auth_ref": [
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested shares.",
        "label": "Schedule of Nonvested Share Activity [Table Text Block]",
        "verboseLabel": "Restricted and performance stock activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedShareActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfProductInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.",
        "label": "Schedule of Product Information [Table]",
        "terseLabel": "Schedule of Product Information [Table]"
       }
      }
     },
     "localname": "ScheduleOfProductInformationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r168",
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantNotestoCondensedFinancialInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r58",
      "r174",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of restricted cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r65",
      "r66",
      "r67",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Schedule of operating segment information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r454",
      "r455",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r113",
      "r115",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Stock options, activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r331",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r379",
      "r380",
      "r687",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r299",
      "r300",
      "r301",
      "r311",
      "r314",
      "r319",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r330",
      "r331",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/Segments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/DebtMaturitiesDetails",
      "http://www.molinahealthcare.com/role/DebtScheduleofLongTermDebtDetails",
      "http://www.molinahealthcare.com/role/DebtSeniorNotesDetails",
      "http://www.molinahealthcare.com/role/FairValueMeasurementsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Maximum award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Unvested balance, shares end of period (in shares)",
        "periodStartLabel": "Unvested balance, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "RSAs and PSUs"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Unvested balance, ending balance (in dollars per share)",
        "periodStartLabel": "Unvested balance, beginning balance (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "verboseLabel": "Weighted Average Grant\u00a0Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r475"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair value of restricted shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Maximum expected volatility rate inputs for fair value measurement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Minimum expected volatility rate inputs for fair value measurement"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r704"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares issued under ESPP (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Ending balance, outstanding (in shares)",
        "periodStartLabel": "Beginning balance, outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r460",
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Ending balance, outstanding (in dollars per share)",
        "periodStartLabel": "Beginning balance, outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r476"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r480",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityComponentsofSharebasedCompensationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityFairValueofAwardsGrantedandVestedDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityRestrictedandPerformanceStockActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r703"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Stock option expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term of awards"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Number of Shares",
        "terseLabel": "Unvested stock options (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Weighted Average Remaining Contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Ending Balance (in shares)",
        "periodStartLabel": "Beginning Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortDurationInsuranceAndDepositContractsTextBlock": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for insurance products considered to be short-duration contracts because the contract provides insurance protection for a fixed period of short duration and enables the insurer to cancel the contract or to adjust the provisions of the contract at the end of any contract period, such as adjusting the amount of premiums charged or coverage provided, and on contracts on which amounts are paid but insurance risk is not transferred.",
        "label": "Short-Duration Insurance and Deposit Contracts [Text Block]",
        "verboseLabel": "Medical Claims and Benefits Payable"
       }
      }
     },
     "localname": "ShortDurationInsuranceAndDepositContractsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayable"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2020Member": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year 2020 in which covered event occurs under terms of short-duration insurance contract.",
        "label": "Short-Duration Insurance Contract, Accident Year 2020 [Member]",
        "terseLabel": "Benefit Year 2020"
       }
      }
     },
     "localname": "ShortDurationInsuranceContractAccidentYear2020Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2021Member": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year 2021 in which covered event occurs under terms of short-duration insurance contract.",
        "label": "Short-Duration Insurance Contract, Accident Year 2021 [Member]",
        "terseLabel": "Benefit Year 2021"
       }
      }
     },
     "localname": "ShortDurationInsuranceContractAccidentYear2021Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortDurationInsuranceContractAccidentYear2022Member": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year 2022 in which covered event occurs under terms of short-duration insurance contract.",
        "label": "Short-Duration Insurance Contract, Accident Year 2022 [Member]",
        "terseLabel": "Benefit Year 2022"
       }
      }
     },
     "localname": "ShortDurationInsuranceContractAccidentYear2022Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearAxis": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by accident year in which a covered event occurs under the terms of the short-duration insurance contract.",
        "label": "Short-Duration Insurance Contracts, Accident Year [Axis]",
        "terseLabel": "Short-duration Insurance Contracts, Accident Year [Axis]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsAccidentYearAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsAccidentYearDomain": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accident year in which a covered event occurs under the terms of the short-duration insurance contract.",
        "label": "Short-Duration Insurance Contracts, Accident Year [Domain]",
        "terseLabel": "Short-duration Insurance Contracts, Accident Year [Domain]"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsAccidentYearDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted information about claims development by accident year for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Claims Development [Table Text Block]",
        "terseLabel": "Incurred and paid claims development"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsClaimsDevelopmentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "auth_ref": [
      "r206"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reinsurance, of paid claims and allocated claim adjustment expense used in claims development for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Cumulative Paid Claims and Allocated Claim Adjustment Expense, Net",
        "negatedLabel": "Less: cumulative paid claims and allocated claims adjustment expenses",
        "terseLabel": "Claims paid"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableCumulativePaidClaimsandAllocatedClaimsAdjustmentExpensesDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet": {
     "auth_ref": [
      "r207",
      "r208"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Undiscounted amount, after reinsurance, of the liability for unpaid claims and allocated claim adjustment expense for short-duration insurance contracts. Excludes unallocated claim adjustment expense.",
        "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Allocated Claim Adjustment Expense, Net",
        "verboseLabel": "Incurred claims and allocated claims adjustment expenses"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndAllocatedClaimAdjustmentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems": {
     "auth_ref": [
      "r208"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForClaimsAndClaimsAdjustmentExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of aggregate reconciling items for the reconciliation of the liability in the disclosure of claims development (in excess of) less than the liability for unpaid claims and claims adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Liability for Unpaid Claims and Claim Adjustment Expense, Aggregate Reconciling Items",
        "terseLabel": "Non-risk and other provider payables"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsLiabilityForUnpaidClaimsAndClaimAdjustmentExpenseAggregateReconcilingItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableReconciliationofClaimsDevelopmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsNumberOfReportedClaims": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative number of reported claims for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contract, Cumulative Number of Reported Claims",
        "terseLabel": "Cumulative number of reported claims (in claim)"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsNumberOfReportedClaims",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableIncurredClaimsandAllocatedAdjustmentExpenseDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for the reconciliation of claims development to the liability for unpaid claims and claim adjustment expense for short-duration insurance contracts.",
        "label": "Short-Duration Insurance Contracts, Reconciliation of Claims Development to Liability [Table Text Block]",
        "terseLabel": "Reconciliation of claims development to liability"
       }
      }
     },
     "localname": "ShortdurationInsuranceContractsReconciliationOfClaimsDevelopmentToLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r59",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "verboseLabel": "Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Capitalized software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetSummaryofPropertyEquipmentandCapitalizedSoftwareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SpecialAssessmentBond": {
     "auth_ref": [
      "r2",
      "r4",
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a type of municipal bond typically used to fund a development project. Also called special assessment limited liability bond, special district bond, special purpose bond, special tax bond and community development obligation. Interest owed to lenders is paid by taxes levied on the community benefiting from the particular bond-funded project. For example, if a bond of this sort was issued to pay for sidewalks to be repaved in a certain community, an additional tax would be levied on homeowners in the area benefiting from this project.",
        "label": "Special Assessment Bond",
        "terseLabel": "Performance bond"
       }
      }
     },
     "localname": "SpecialAssessmentBond",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r224",
      "r299",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r331",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r378",
      "r379",
      "r380",
      "r687",
      "r841"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetBalancesofGoodwillDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableMedicalClaimsReserveDevelopmentbySegmentDetails",
      "http://www.molinahealthcare.com/role/OrganizationandBasisofPresentationDetails",
      "http://www.molinahealthcare.com/role/SegmentsReconciliationofGrossMargintoConsolidatedIncomeDetails",
      "http://www.molinahealthcare.com/role/SegmentsScheduleofOperatingSegmentInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r21",
      "r101",
      "r222",
      "r247",
      "r248",
      "r249",
      "r265",
      "r266",
      "r267",
      "r269",
      "r275",
      "r277",
      "r293",
      "r350",
      "r432",
      "r485",
      "r486",
      "r487",
      "r509",
      "r510",
      "r531",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r566",
      "r627",
      "r628",
      "r629"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "verboseLabel": "Condensed Statements of Cash Flows"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofCashFlowsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]",
        "verboseLabel": "Condensed Balance Sheets"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Other Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Other Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedStatementsofComprehensiveIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r265",
      "r266",
      "r267",
      "r293",
      "r601"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statutory Accounting Practices [Line Items]",
        "terseLabel": "Statutory Accounting Practices [Line Items]"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance": {
     "auth_ref": [
      "r193",
      "r211"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of statutory capital and surplus (stockholders' equity) as of the balance sheet date using prescribed or permitted statutory accounting practices (rather than GAAP, if different) of the state or country.",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus, Balance",
        "verboseLabel": "Aggregate statutory capital and surplus"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusBalance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired": {
     "auth_ref": [
      "r212"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of statutory capital required to be maintained as of the balance sheet date under prescribed or permitted statutory accounting practices.",
        "label": "Statutory Accounting Practices, Statutory Capital and Surplus Required",
        "verboseLabel": "Required minimum statutory capital surplus"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesStatutoryCapitalAndSurplusRequired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatutoryAccountingPracticesTable": {
     "auth_ref": [
      "r196",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail by state, country, or other jurisdiction of domicile in which financial statements are filed reflecting statutory capital and surplus, net income and the differences between financial reports which are in conformity with generally accepted accounting principles and the statutory financial statements which also use state permitted or prescribed accounting practices.",
        "label": "Statutory Accounting Practices [Table]",
        "terseLabel": "Statutory Accounting Practices [Table]"
       }
      }
     },
     "localname": "StatutoryAccountingPracticesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CommitmentsandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r101",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r7",
      "r8",
      "r101",
      "r106",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Exercised (in shares)",
        "terseLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/StockholdersEquityStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r7",
      "r8",
      "r106",
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Common stock authorized"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramPeriodInForce1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which shares may be purchased under a stock repurchase plan authorized by an entity's Board of Directors, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Stock Repurchase Program, Period in Force",
        "terseLabel": "Offering period"
       }
      }
     },
     "localname": "StockRepurchaseProgramPeriodInForce1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r7",
      "r8",
      "r101",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedTerseLabel": "Common stock purchases (in shares)",
        "terseLabel": "Repurchases of common stock (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r7",
      "r8",
      "r101",
      "r106"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Common stock purchases"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r8",
      "r11",
      "r12",
      "r69",
      "r707",
      "r738",
      "r756",
      "r822"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets",
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/CondensedFinancialInformationofRegistrantCondensedBalanceSheetsDetails",
      "http://www.molinahealthcare.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r108",
      "r259",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r431",
      "r432",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "verboseLabel": "Stockholders' Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r547",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r547",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r547",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r121",
      "r125",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "verboseLabel": "Unrecognized tax benefits roll forward"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "verboseLabel": "Supplemental cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense for claims incurred in the current reporting period and related claims settlement costs.",
        "label": "Current Year Claims and Claims Adjustment Expense",
        "verboseLabel": "Current year"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense": {
     "auth_ref": [
      "r624"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after effects of reinsurance, of expense (reversal of expense) for claims incurred in prior reporting periods and related claims settlement costs.",
        "label": "Prior Year Claims and Claims Adjustment Expense",
        "terseLabel": "Prior years",
        "verboseLabel": "Prior period claims, favorable development"
       }
      }
     },
     "localname": "SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/MedicalClaimsandBenefitsPayableComponentsoftheChangeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TangibleAssetImpairmentCharges": {
     "auth_ref": [
      "r0",
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.",
        "label": "Tangible Asset Impairment Charges",
        "terseLabel": "Impairment on property and equipment"
       }
      }
     },
     "localname": "TangibleAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/PropertyEquipmentandCapitalizedSoftwareNetAdditionalInformationDetails",
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "verboseLabel": "Tax credit carryovers"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardValuationAllowance": {
     "auth_ref": [
      "r127"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from tax credit carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Tax Credit Carryforward, Valuation Allowance",
        "verboseLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "TaxCreditCarryforwardValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "terseLabel": "Trade names"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/GoodwillandIntangibleAssetsNetIntangibleAssetsBalancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r340",
      "r341",
      "r416",
      "r430",
      "r529",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r753",
      "r754",
      "r755",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Average cost (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/StockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_USTreasuryNotesSecuritiesMember": {
     "auth_ref": [
      "r837"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about negotiable debt securities issued by the United States Department of the Treasury which generally have maturities of one to ten years, are interest bearing, and are backed by the full faith and credit of the United States government.",
        "label": "US Treasury Notes Securities [Member]",
        "netLabel": "U.S. Treasury notes",
        "terseLabel": "U.S. Treasury notes"
       }
      }
     },
     "localname": "USTreasuryNotesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/FairValueMeasurementsFinancialInstrumentsonaRecurringBasisDetails",
      "http://www.molinahealthcare.com/role/InvestmentsAvailableforSaleDetails",
      "http://www.molinahealthcare.com/role/InvestmentsBalancesofRestrictedInvestmentsDetails",
      "http://www.molinahealthcare.com/role/InvestmentsScheduleofInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r488",
      "r496"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "negatedPeriodEndLabel": "Gross unrecognized tax benefits at end of period",
        "negatedPeriodStartLabel": "Gross unrecognized tax benefits at beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r124"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "terseLabel": "Lapse in statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "auth_ref": [
      "r498"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "verboseLabel": "Impact on effective tax rate if tax benefits are recognized"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualOrInfrequentItemAxis": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by an event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Axis]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Axis]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualOrInfrequentItemDomain": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event or transaction that is unusual in nature or infrequent in occurrence, or both.",
        "label": "Unusual or Infrequent Item, or Both [Domain]",
        "terseLabel": "Unusual or Infrequent Item, or Both [Domain]"
       }
      }
     },
     "localname": "UnusualOrInfrequentItemDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r62",
      "r63",
      "r64",
      "r294",
      "r295",
      "r297",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/SignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r503"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "negatedTerseLabel": "Increased in deferred tax asset valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r279",
      "r287"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "totalLabel": "Denominator for diluted net income per share (in shares)",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "negatedTerseLabel": "Stock purchases (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Denominator:",
        "verboseLabel": "Weighted average shares outstanding:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r278",
      "r287"
     ],
     "calculation": {
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Denominator for basic net income per share (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/ConsolidatedStatementsofIncome",
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "verboseLabel": "Weighted-average number of shares issued:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.molinahealthcare.com/role/NetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "712",
   "URI": "https://asc.fasb.org/topic&trid=2197446",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5047-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e961-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5419-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.1-5)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.23(c))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.5)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.7)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(cc)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671315-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671317-158438",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "40",
   "Subparagraph": "(SAB TOPIC 5.W)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=27015833&loc=d3e570705-122907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24708-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24746-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486098&loc=d3e24790-158529",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=82848697&loc=d3e24938-158530",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "505",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=82848697&loc=d3e24959-158530",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3,4)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-04(Schedule I))",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=126898705&loc=d3e5864-122674",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e526-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(3)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(3)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269825-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4,6)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=114868883&loc=SL114871943-224233",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(ee)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(c))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(d)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120401096&loc=d3e574992-122915",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "340",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6485982&loc=d3e22818-158507",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884095&loc=d3e14764-158437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671311-158438",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "605",
   "Subparagraph": "(c)(3)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=6486672&loc=d3e27261-158547",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "944",
   "URI": "https://asc.fasb.org/topic&trid=2303980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=127002003&loc=SL6242269-115581",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Footnote": "2",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Footnote": "4",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "29",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column B",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column C",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column D",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column E",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column F",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column G",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column H",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "Column I",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "28",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(A)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(B)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)(C)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "5",
   "Subparagraph": "Schedule I",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "c",
   "Publisher": "SEC",
   "Section": "7",
   "Subparagraph": "Schedule II",
   "Subsection": "05",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "9",
   "Subsection": "06",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99379264&loc=d3e27758-158548",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "605",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99379264&loc=d3e27830-158548",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r713": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r714": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r715": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r716": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r717": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r718": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r719": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r721": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r722": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=d3e5283-111683",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3337-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6283291-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99397103&loc=d3e6824-158387",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=99404803&loc=d3e21412-158489",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r844": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r845": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r846": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r847": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r848": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r849": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r851": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "04",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r852": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(i)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r853": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(ii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r854": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iii)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r855": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "01",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r856": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "13",
   "Subparagraph": "(4)(iv)",
   "Subsection": "02",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>124
<FILENAME>0001179929-23-000025-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001179929-23-000025-xbrl.zip
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MW*HR>@M:R;*@"YPP96V.S(!J,@ZR"/C>4PS\.30_PM0U)R=ID@U@E<D 1LK
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ML'/!#0#J]7!8SM@<#,?[L(^_0WR'J7%8"2&TUCP)PX+*.;O <TPNE-]!)=T
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M*MIJIQ++3M)_#'4^3P^;;\%9KAR:A> $G4-VB7%BHDHE$Q2PD A?*73BVBV
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M)_V8CW%[TL,';.)-OF/@GKD[&6'70M_%;9ESRX'[;]JV3F^_-1I&.G=P\-%
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MIV^C\%&Q@%6291MIJW3EC(!*)Q\8$S9G 2N/N7GP<4/B"Q0?MT*GVRUP_CU
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M:31FD4CR_*:-I$H VZ=VJSS'1;S&VR3^"?>LQ8X;) WDD60 3R;AHDD;&&S
M!CUR\PS+'_&^F=_PTAA"\XW-C1>,F@0TB<:$VX6V(!>!X$WX=NQ[H&_HE6Z7
MDV!#)U:Z<VFZ:&<,A^A63X<Z23'-*78)ADU?4: 9;MG4T9>BO"I4*\E_7ZNG
M/HY+FJ\;+[([-H[ZS<Q]5$YK!:TU*V-I+8PF0D-I(A3N,M6ZM0#8%WO]1K-L
MEM-U*A)A+R(O&Z3 #:T__:^,L=)TE;8)'I9Y7E[!((ZN[^2J-O,6;/Z?=UTC
M[0P9K=G/6_CENYYZ_''/7?OR!WWQM:;FLJ&\;L_,L^T#S 3F-2-QE)/O!/HC
MR5*:^=1@>](AHRI]4)5US<O \?1J[I=#>C@7:7C<-GT:4_3.8'-'1R2P(U,,
MYM&/NOYG[X[<P6Y;41^>_G;\9FOW5413E)I)-HA5).TKD@&=!<F #]RRJ2)5
M:SR^RE5:X,J"FT;BNHG!?T&P]$"#,%4&0L\"G54XAC'(9,"4I#FI\ER3HBS1
M= P9^UG@017K-WPVV'OT C>!-+91E4S<8WB/8U%I']<T@6F4I&CKSJ<BW0R0
ML1;#RZ=8H:_,A,:*#YN6TT82NJ\WTO\PTM]OTI&9T6*96JB8RD(T>S1BO+<H
M^!L%_=T1KS%MF&9 JFI(&Z<B94X'_V",ZX8-3F\Y]_#D6M5^9(8D^+-:Y!$W
MJPS0;F"ER__$#B ?IS;UZXW*>T"51W9$/9-3U<#$QTI-A( KG1<TH@'LQ:K"
M3K4+O^Q[^LG@RXBOVM)/&_+_>?U]/_2'?_0@32FW_C[$V0U7YL?O.^)OR\3.
M"L@$3=5ASYT]0KK&=F$='C<9.*MK/1GQ@RDJT@+0!W&$,CTX7OXWF'E9B7TN
M9T(T&)<9N19B+@6:WOD$JC38XO.'S;2<P:)*V :.T*.]*N$HD\Z',@A>2.IG
M3-]$K])S2P^CS='P@%J"/$:2B]K:&RV-S6Z(^4JN*I\&M [P#^@$\"<'>RMD
ML&"%ESRN3V9"W?0G&3OX3(]# C&E_S3RBG^3"/+QPZ;.M*R37$0%=R?]+,>Z
MTY76#8K8S*KXDF3P[R934V66T,\R[KJ92N"%GH#1946#(;/G&6'@9*=/S.:L
M>20IL@8E1*:96D$H79P&,G!(?Z8E+[(DCH[+JT26_(/I5TG])<$5M'"%^EEJ
M,"+G;P6F)2_.X#Y_>^:4'IDRJZ4G[JC 5WS-.[L3M> &9\O,C&#2Q:KZZ0W_
M,5&?4>K8Y54Y"7=MO>C]^+]!<GHC\QG>\@=S%?VKK+X(O'T>'?+1$WW.:A@Y
MV<99>*AU)5U=8XNA=,"=Z'H:0*D:>'WDMS:3B"OZ&Z-1TF8*M\+?G<+%+*=R
M.VW6@E8P\UPAX<(/E#J-7F)-!]+M$WC@-?G)<S;XZ!%0 =DE_RL(F@363=<2
MV:CXAQ(+L@J@C"\-.1"NMD0U^X3# 3EI;#K(-U/^2!I6P]YR&"90K379R]@+
MJ0'1(%;#Q8Z:&=WW'TG[L,,=;K>%/R*M49*QCPW%C[=!JLUB/M1B#N;DMVPE
MLQDYIK08B+"5DROXL.XW4G E,RI-D<5# )"<HV26(-PL%6! ^Z:L3R5EQRY;
MQO>0L-0FOY3(BK5[8973DI*63A'(YK24>&/"4DG_;Y("78'-W!1),QN7%7UZ
M"J?,LKN06)&=-3/\J)8"M_X<K3MGO<KH:IP-QOSZ*SJKV<4L6%8G] #^C;R[
MRZPJQ7.063,XZ>%X?)W*&R4F6&M"<G.R/Z"5'N@3T>,=TSQ4$XC(SC0JBZ5&
MB$[82E,ZXB5L-P-=1![5\WIF)N+NL^"!YE# %K#KRLB*EGU+,D4B-D$(6C.R
M%0YZFXE2P8*KAE19QZ4<8-L$QQ -<98QKF-S^CQ2RL1NYU*V\ZA!9I/LOJR^
M<8>'XH3T8W#.X-E9)0&$,5QWUEQ6:T5!6D;MBLW"/IQ9P8;TE%?6;69GU;-%
M$$11-#C/R1E:J0F.)EZ2E@F/'Q;L"(TADL))JV9D]0.NE&.(4P=P"7&J0*;F
MWA? 894@)2&J8&KS41(0W*)#<L Y[V)K1-XE_4O>L=$ CV1_RB$!.2G)E2?#
M<ZY&1'BB7]'2&$TB&L;'M.3*)WJB/"%YZ)MQIKK>71^(V\:Q>#S5CJ-[B@"O
MPU211M;F!7:KV31?66F^,%P0SC0#DP63;9B7S#"5I*2UN9,F^XI\'9XM0A.1
MUD%4D$]]D0IZ;M][(YI/%JN ;MBJ2>'PX5%54 N!?=#-.; 943M@%L*$624W
M;"3G(56"3^[@]- @37F%K##D!/ SR,"D 2R 89!6:G)@*]C0= ';$[WRY/VY
M#=RNGQ!]#[3Q'0M<'D<Z3TKZ+5&\"ZSP.#HN!MO1WL[>7@""^O^BW>L!T4^+
M;=[L]SN?% [L0_H>N"#:8:UC8%!659:6E>PH1@IS1(+.EJI,)&88;#$.)$O<
M6(R%B2'7,*6/'66:,)XZ;GP&Z-5-_W>%-'5.+01(E,9A)O'G(#Y!M@L@2PI!
M!O8)9UC#:FN:5 )T9=W%PR5[LXA4P&V6>7-N?&^+(YEML4YV1B.*"#VLR/N'
M(>(T5-,=B%PR& .U;*/5%L;];^Y1AU1RPHBHI0EG<I+*48'TE158>]H%;@YD
MQ\#7V0C+8V23;4 I(T."8<Q#=[PO9)%S>GR9T5J>9+3JHZ2(H]-Q5L;1!>F!
M,0!#O+MEK3^:KTD=H46SB J PVG#P$5#IVN&N#KL&3JBQUX%<O*1_U%MX ,/
M&YCDS 70/V)>JCX@9Q"%$2FCM8'4=DE(I/^Q)"T?T0)XL9-5Z7,)P>L-E/H!
M$X$,#^IKP4MM564SA=:^S,JFIDTTM=O%:5&?-U8U>O<-)'8O3(EL.-\LTXWY
M)M^-C(\U\<1\%G>6?(T$IZ'U%M;7IS7[+^?OYV:4U;FF>Q">;3]UDGW%)C5)
MA22!:&NQIK1VXLY!V\T*WTEK&M!X9Y;FT:]N@+52/);- 0)--2XG LUK:GI3
MS9F:;),[><#-5TZX6%R3718M6Q;#IN:M)":&6)K=(A3>: $&%E!F<HX6ZH0J
M4Y@K!.>"@I8!9\Q&9)ML#KR'6LQAE31I'%TE]4R*VQ+:-\@_,G]J'")AZ<),
MP$XX",T5_95$@?^4&[T<=HO#/V?%)>R=D4N+J@<]I)'%$7W;0%1O( [#RIC_
MF)C=;MWM0G'(E@X)6UEDJ"M%MD8L97FGPVRQC,PEOX(B/ 4$L".#7,S&5GH4
M3\97<W&VNY4\2PT=M(E Z]R?V2KFY%RK%DQRY869(=?:AEP/FUR2]J:PSE)E
MR3$E']<9P2(@GT.TXF3)19M#X:&$P4(>G.6L>72N,:4IIYD%N"<5,RI%_#OK
M-[)X=$O'I6&D999F2<4G]V:5'MYN'FI5E% 9A)@J1( 8],":D[>9KJ3+7\=6
M^\*7'810V@#H53$APV;Y'F[Y  Z(4CHK$UJM/,DF+;.)+#(ZQ:MR.J8ER?(<
MQN]&P3WD:4=; ODKC=[DCGN$SIJJG\TJ[TIVDGP<\S=XZ&8[/.R2C #; \L"
MEWA+2(;#V<XF"2-EW:BJK;NPL52.FXKE\#FI4?L[LU#0I6P&I#)1ME.YB%[+
M\60^!81>)92T6?D'7?EADN6*IV6/="Y&(/_)\>JXPPA^09$(N%A..P#.R:FQ
M7>PC93"0*>?TG/@^# P$C+29H=R8#\W:%!F*/LK[+>LF#G2WZ/DE+;5-786@
M/EUG16Z2ES!EICHAI>&P'Y,T(,N23'D8_S$6C*W)7OQ127L0?4_F"VN-E>G3
MGN<MS5[EC/'JHA8FQD@E)L/TX&-D_V[(<J61%J3Q-\#.Q]CRD 'U,K)"8?E7
MQF'X.&3/!5FHR=/(KXLB725T(E<;9?S@3H7N %+$B81J-4LM6/94@.TTB:3V
MJGD7.XWE6@#D!0%ZY7)CR+90V+ACEN9CL%00-L;O0RVQ![;2- <AP;JI%-X>
M(^=BH09)39?6"BS;+,(#:D!?LY 50]T99;%8I^B"7PQB8A\^."QO..$V>^8A
MEZLIA+"*M)^-/>+G7 CNM-E967#Y[Z24DPVKH_:EL<T>:R;=VZS,@VHS*>R8
M3,W,,V^BW+[,LU1VEA+B.=/!'E[;UZ[$/=EE'V<9CA*4*RKK&9O$%I>\'.G:
MH7Q<O*IS@7(@+K!/+EQ((MTBC]2?FQ9M8(,R>Z1IP.I&Z@JL;#0_N:2!<@:M
M70?19;@=N&/')>R/\@J$D6$,.::MF'.B M[@56:=\A2TBH[-40A0F=@T*ONY
M99854"?NH3W93--D9KY!-\G@*EPB=<PQ[60X)\R**' ^YC3-DZOK16F#N^[B
MKO<>A(AZ?[V(J)<]ZPY?^_R'A]-2C\.!??K;T?EOQT>?'UBGOMS#__<'A'7Y
M:'N_G'[Z&)V<OC_^T(O>'?7>?WQWV#L_6AC\"FP@LL6CMZ?G'S]].(H.=G;X
MK(-.^E'9F,'9G!1?2!7M[AW\Y$J5:^>PC=T#!4HZH+]YYNNEL-&@/$4LT(I9
M@3F-J_XZ^0R<OYT$M&W@#3>>0]O]P5;-;%O-?\4TOA@$5]/MOGJY(]DJESLN
MJU%2V&(9BX#-RRNRAF@"$$.@>1>J7('.DB\3Q(0UA(R+JRD(_>5%;TCI7HG_
M2GII9V\[^BR3 BH7I#Z_<M403>G!]GY$;\BEDD#(11.V_-Z8 ?];VBSM[\:L
MX6)'*J[HSMU7&B_>OMX4?T*CXC2,< _+<C:M,I1"W_R-J*3.\X83(CC[#*W(
M]@VN8?L#PZBI:XV53>C$K09T;3G>PEMV]_9W_V>TM_W[=/0#"*FO^4O[>-W?
MWYU^?=U6,5#LW4XC&(#\677^P;.=Z5<<$/=:G$?23F])*WTX/.Z]C]X=__KN
M/?U?WTE 0J/.1JAHLX ],D^FM?G9_L=K\!7FR?SGK."G\TWWF9Y7K[9?'NSC
M5-2F-?IB/3"W^<"T;5-:?WNQM_W\U=ZU?][9WKWV;S<]=G=W^_G^BWL]]N:_
M'>P_TF!?W>JQZ]X82#3%M8UT?'N]:TE/;_A$41:/^9$OO[4O^2/_99(J.N)3
MRVK(B)3C8JN=/^]"[G][(54I07'2%T;LB$<8[3HL,<Z9Q_WX6[0.^]-.[>ZR
MK=(]RA^F4]O=Y_"A%NEI!GE+O7/MH-9&0U\;.5PN=3\>%]:0KUT 9TISBX)[
M5RWYTUUT^.($#0;&W#Q!JZ'<SQ1@?2[@FJZBN\OW[40K^Y5_^T/?M8*M_?9W
MXI<O]Y>?S'>4R>B.WW@GY=5Y95?7;,1K-<5K[WG\\N#@Z<3KSNKVV^?1:DC*
MQW+&#?;NIFR7?-V?8C<L^ZX5W WDT+UZ\>R.NV&Y1#ZJLOV&M;D1K]44K[T7
M\8L7NT\G7M_;MGVH),KM9O=$T3/<>.>\S>)UZ-B[EO8/NN>X#K9?'MQB:$L2
MOW#NMO:W=Y<$8D%6+\V0?]S]J9. [.J(O;NMW=*]OB)[X^7+[9U',D-60YO]
M_5ZAI6^8U7]227@L?V<5)>%/:P%_,#,DL<O)QOQ=$_ODQ:N]C>V[D:U'^:#G
M!Z_^.H;O$^A8Q+6C-QDP@FET@?CV)L*['B&XW?WMIXS ;0*\?V[IVMW>>^KX
M[G\Q!NDVN-#O-#.,M/J?Y?_GZ4LT;C?\(#KPG=[9+L5XL;VSAR^V81?&C@IY
M>F70RIM1])/PK[8'!\">ID+>F!O\#+L-^QZZ...1H'JGG\ZCBZ-?3XX^>(C>
M*N$\/].,.YSP.+D$82SW5@%#J4 )S4B*';A'I?;0'?X<[?XD&L,"A%]'>ZU?
M0"Z[;W_Q6%\I#7FF?S@%,/>;2_D4$_,QP#['#O@L>.>P6:.;'B?0#(/VU9-;
M0\$QH]P5'8/+2BBRA/]7@-:^I'4XI'_>@,R60A:>-OOJ6&_G-D8UJ==L2&,5
MEG(E_-%B)^/Z6',%VD+#+'0T*6GOHHK(8\&9N%K:Z(@0T .$[\1=DA6^B>E*
MKN8Y"HTP(1]*97L]#&?EK6.2N'#%/3%?&^T^CRUB_4*7VI4SH?QGV%2\&-=T
M!=4U\NS;O@5$<,>F/.CVY4'[J]J68:7.'3USHI.CDU^.SB_>'9^M1S$CM-NP
M1,<LYA60$ZB9T(CH(;560'.Y!<IJP4*G&RQQ9;<I$SJ3R95QP<7/2XIV-B#Y
MOS)(_A88Q]6 ,MX(7.PMK\2Y#]C\-DC4VP!.5WBV;HO;?BCP[_I/UU(L]G7?
M:U5E42(I?=/,?*\K-P-^X@&O;\#<NGW7ZHM;)-)O5XFQRBGV9_&+@V<Q/?A^
M@<%;EZ(\94#ZK[:B^WNO5G5%_VSJ;^T&O+X@$AN<NY>^OFW*?T7V\.[!\WOL
MX-6#8/PIU^;9WM.NS9]?):V-">DS!'_$BEP7R=]_]O+^=L6:VH/KLC8O]IYX
M;1[([N!WOY H_<KM=Z[D^B/VQ_I[%P?QWL%]).VNU 7K8K7\&59T]]5]_,7O
MLJ)W)X?X7H0,-(8H+1MDF!Z,V.,IAGA'6-8J9#O/SH].CC^=1.='OQU]^/2T
M='W+,ID.\K2 R^B@F\+,YE!;5DQI'&5Z8V;SMHNSE&GMNR=%G^T>W#,I>O#B
M^:/D&5\]>Y2DZ,'C#/9VC_U+)44?@('K:7A[UB0IN.&^^K[YUA4T;_Y"I%CW
M'^W:L&7=FAOK+\* Y>B.-Y51ZU&[LO<L?KGW8NTCCQOQ6E'QVHF?/;\K'<OJ
M!4]73U(<E?Q?(6N['[]X==<"NTW.]ONLS/Z=M_>FZ'R3 .T>$_'>4YX2F_3G
M#1M\9_\)J5'_,LG/VSM,;6]=8\;=C,0?R)ZMQJ3<F9SE0>9C%3?@?<B)'W!.
M5IQK:+,-_AK;X%XDRBNP#:[) M^R+]VK'QXL=?Q(?>E.CB\NCD\_K$=U[&=N
M#5R5EX8SPL(/P#7E.=K'VKZRMB%9?QZE!G^ID((>TX.V_MW0(L_F ;7 M_N/
MK<9"_7:\5NMTE>5YE I?1I/58RQ,;7*L4B*=S=&M#FPG<31!]V8CW=0OC?:F
MRS/.Q^L:DR=5A(L9\$MX5HEU6LZ+C^>]CT>__FL]%A3M\#PU!BGI*UH3:7,W
M0OO729(5(/,8C)-B9%+NDW<%,IN"UK\Q()SH&U#:-)79 GYB^0(&A!^V^9YE
M]W!M&QMZ<D9O+YF1HRFR62:,%M+DF'L7\E:74<91/2\,31Q)XD"[,7K2$GY2
M,J,/\:)7-_6,/H>E3Z:\WHXP ?J]])AIE965O%B90WZ^94/Q?8<^^5.VK;YS
MD^I3[F,YL"*E"GQ0!A)@6)'C FQ\7K'"7$72:)/$8D RQ4"AED2@N3*6$?>8
MK\K; WG$4@OCB^V.;85BK)TOE1#(TKM$"2X4YA+280T_**DN#2TA?OTO-$%.
M?T\&"V.X;9?YC5"TA>)B5I&NB4X.SWG6?_V_DLGT=4]I@7BI:;NG%6_8;^[=
MS2+<;Q&.B[*]-VV7VV1 .T=F?/!O.MJ97:=F7JO-3-]GIL]-5I!=-!-5-4#'
MV4$R10<O:".82JX3;0EJLEE3L5K+>!^PVAJ7>0J+UZZ1Z++*D,*B([F^39?=
MU3 TVJC1+V:.J4CZ62ZGK9&MC3.B8X1L#F#Y)YZSK/O;[<7Q?7D5'9)%_KTW
MQP__^!GMIM70<^Y!Z '4EM--#O\!:?MR KD'1KC5J=MRO[6N\/V\R0IUEY_!
MM7!=,$[.7!>,+M6=):V[82]M1.U.HO:._A[]4UUR3'</3<;)NL;J]@:L"L%5
M%Q0W/Y$TAF&%MJ>:!$-.W)#9ATF$"Y&C3-$LF\@-JM/EU]K,H/<W(O50(G5N
M P<7UGJG*;\PR23'RAQ]116!*09/)4]"<+E$A<56O&++D0BYJVH?":F##TKH
M7_I)QGW2]2R*&QFZDPP=EI-)-D-9"NWD7YHL9RK+MPT97H:4D;='?G[(3DFW
MCZU)?$2'U;*/9N,$!V8^Q<A-43?,*#R9D@B1U\1N=4A[*BYR)(RW6GA#UB*+
MF+I/(HXPMEJ6:"ROTNA'3+_/>%A%.8ORC&:/)R^6EYNOH@^] Q=']2#)6:Q9
MG$<9_=?,#,8%S=UH#F[0*B'3KAE@SF4,27J9D)2G(#A,Z)<DG\^R0;V1^@>2
M>O6Z#]7U>(M$# O*$TDY8HHLG@F,? RM3R)3@'-X;,Q,!-"%!1,0-^N V=@C
M_<K;8NX$>#;>'+,/=LRR]7+B(S(?Z3R"TCGZ:@;-3 RF7\5%NUAPT;ZK'#&K
M-[V/C#/TLH;2B5%,R.S#$">.)"'LE[."E_.5LTP%B@WIA*[F]/5)*@XZO@_&
M7QB.PL=S9#(U@R253%1P,%\O=AM^XRZ_\;,-O_$MTD?_??2OZ,W1;T?O3\^6
M<^L_@4E"!ST9#ZEL!!@+-OV#N*QX1AK?%P9P/OX[81S)M(2[D]2Y<]478OY,
MO<XB=)74VKV>]D*2VPS4E0%YO+Q]V.1X&ADZ%7)6_VY,+=7%<.#*FLZ\RG N
MRLC9<H4[^V()"N]\&/!DTZ8L..@_7!:1(L53X]%I Z.EAGT5T9^*&O%J/( L
M*?H^&OU.[-GSH6/8I?R:3>@Q^3SZV^Y.U)<JI(@S#@4YS-V"Z9!S?=8>*89W
M2)L^P9&R^^)U3;KZ*PW-S:J++MJO'N0EUE'=U[XA(2^D[0'/=<P_]T;FL\GS
MUIMN\8#96%HLT$3]NTDJVKOZ3([:($ SCP[')1P=1ZF_]!TT#Z3.,;5TP?]I
M:*+PG.WH3.:1?N^;G*S6K(XFL'M3V+HL .Q]&T[7I#1[>3D546+%/Q!SN1[;
MK@;0PYA4&WCZ9KCQ>\=3[W2:__ /6?PSOX=8+/9<'XOM)SBE3VD%$Q)KVI=[
M+V(LY+X(F0SVG<=YO&M(*UC?OH[84ZMKR 7M8"QZ A<D$[V1(<-K^B0XQK(&
MR/Z YS)CE4$W<T(O0;<#OFU(Y]),<TR]JZ1B)W#A],)U/#@]QI+HXF/O_'^?
MO?]T$?5^>>,RC1!.DPPXL_D+75_%T9LDSW'?41Z=)37Y2.^2JLKHAW=9FN0C
M^N'_(,)4U>BD\*%$>P5RA>S;, D?Z0;X<S;$T4."4C24?KR$T&NQ8T2W+:@T
MV3>%$?W)"73-UG.D@2;%?Y(-?6GLJDXFIIT>A?X)U&<)@^O\[9E=%?KC25+1
M-,@>Q4A)EU>S=A\.%Z1%?M?/H,0X!NJ/LS;! ]^:?B4BL[/W;)O<<VY$P0-Q
MM>]>76$P6' =D'W3Q]Z'MSRGA^^.SWQ;DA^_%.5589$JF(>(DY#MRV0U:*./
MEZ28)2;-<O-3K$ #B%/P-=V/<#IPV=QT+CYXZ 9 WTT!'=)U-#=%EJR8%CH.
MM!!KH-8IP_L'BQ.,_XV9TD)-U 90-<6]M9V&LHF%-^\.+UQF89P 7%L,LVJ"
MSCATK@0/#?(=[L0>EN5L6F7:YX&L=Y*J/)^W#\%>,R)?167>FP.8TJU#])>R
M.TKE,%!-Y\!5U1DB.1<TW;^8JJ!+LJ+$OP<DZ_2)I8@[_OXF,R.TD"%W*D-N
MD6;N?5E'O6)D<M;*](<YSQ_#P"0;&?2M,(#AT?"]I:B0"SI\)Z;B3C3T 0W=
M4,Q$72Q\1<TV9Z@9^&8U&>U"[O)I\LRBB"1_R""B90K/O230=UB=8'?+)_-,
MT+OQ/[C KT^V;"JV(RP_&X1)7I-R'%5&QCQB1:['2^*7".8&AXK)ILW)/KN$
M)<B^&]UGBHKT.XM=39^/V2KH>;6@Y*S$'?6.MBX^^'26F**JF%+8D(:>ES%4
MPG_NLL&OJZ;Y0,?(O\KJ2]3S]N/W5RNJV9X^DK/([/[])H'\NB(Z'<Q*G,JR
M*??BP%4H9:-UW!:?L,U2#3:E)*&T$3\"AW@8 @5QO?5)W,+;O:!_L'OA#XAT
M"!__G=1M-IP_N93WJZ3^LH*GZ05YXZ$=MGB>8LW=^$.H+UFI=!QE4.&PVFK2
M1ZSF^W,6"G?/TA-XB:/@C^%W_A@F)6OSN_KN5J\Y[I>F+RILJSHUSV;&G<U.
M0&W;.GZ(VHAJE9,\#DF';\W!SW2S9;OL\))\S!P86I(^P_Q.T.*(:J9I)B&/
M:'95\@M6">QS1UD^+J]64(Y;AM5R(>:!AP(,$Z]O3,$>V3#SHLM7WE5L^:90
M=.FNC*-?UE5EFXXLB.72Z$2.$:S:'-&Z1?"!97SV-5UG8R\08_K:VXHQ@C*[
MUIV_G0QS]\TU%^(31"3H_Y].L[64Y7#\MQ+I\(8WV656Z_'M9-%IW].3.TCP
M85G"!V%^2#[J#ZW$06YP<_CB\&J%#IV)#A8@5WCI.,M3\C><"M<->(R$.0>=
M[9T+VR6(&C-N:<A!)?;/W2ZBK^P&(79E SWRYJ$#P.X=CE;SA-["Y1%]H3X
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M6N0;DJR0:P[EQ#U8H=H$RT?:G7S)097U+1?AZB0([TW9]23U$RI2PLRTC-9
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M=$SGFK!MSDID\9TQO0C#5MH$&\(,3L&L\-RD6HPIP^;68Y'R>HK=GYI:6GR
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M^3"5M"$;UR6.Q$1NR4( ;3*D7:G[6_8F3Z[&!LA 8N4VS"IXOJT9YP!"(M9
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M2K#0#5?(?J)R,""+TCE"DRS=LED$!BIQ<-KM$J&ML/WEF)@'BK.V%J]'M[D
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M2HY=RQ#]PJ0'0:TU^,3$9(+@6:A'VLK_)@.FAQ6F%_$WK4W;S:>R10';)1'
MBT@S<@:6G\ >ZJXRW!)85 +'UK&0R6KT[J$Q2VG[N%(IR\/&DP@ON7"F9>-3
MSM3"C[K#GXJ>D%7JF4(Y)=E8^IN );2#F)FI=^,=$SWA _M>4I2=WN9W-$0_
M9A,:"ZR!\Y*LQC]HDGY_*]B"-[AU 0?AN,:BAF>A,"R?*)<- :] F'IYL264
MHT[*/&)PV\A8]!CCCT16@NLR1:0+(89#PWXC[;*HS;^9>=E[+IF7%Z#77AF%
M]I=-O 0K:$U$3UKS2%D/LAE3QB-HS$TL") ^5YTP_D)R9(,ON#6^8'=G S"X
MC27+W)9E9R_<+G_D&I2'B8X6#WO]4QSXLBS6-SQ3Z@_<\7A36NHB*$'5D)CV
M5RW['.<BXRD\YUT69R%E%0L%#SH3T.:==Y[F0&AC,Q$M,"BG01!^Z0,=YY<.
M4(D)\610'5YSGW*E?I9(@34;AI6!(PGG@(%?GD\]K#X+QK<L*Y?40:U6R<7X
M[D^PBY),4J<ZT#1#,DQ:)*R.#W$G9;Z$D-#[U%EK:8'*L&&G./)L/+$CA9_9
M-!?KZ"UTY"8WO7O\2W64+Z4+>-U26*P9V7;,BC!&&76NL;FE#\&BT#WTZ]Q#
M,]^Z0/7;9("]MA"6L'C$MV\];[F-S$E#,RD%67;/Q2_^GNN[!"QAAVF%_&Q&
MZ2%2@DLFYA:I,$X+WRT7QO1?83[<EPK7[5/^5A,CZRH".)@/L(U="?&4#IJ6
MDZ>Q\U-D_@)SZDR0#G9Q3H_._(("\3%D8&W@<"PF]0/O@^1!:I1^.7E*9V*)
M*LG2__N'+'F^N[\[2(?/TOV#9^G!\_[+O8,7_9=F[[GIO]I]N?L_>P<_/)S^
M&;X8O!C>0?_LW2J+Z'IFG?4^O#DZ.3Y<#[79D^+=A8Y?+M?.N])<EODEN%Y
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M-(Y(.^:VD753>$)0B^5S&1VY1VVL.&JF@U(*CMR1/TE$G_&YD+9+<+DV9<I
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M2M,FG8&]#'W"\:7\*[]5K$!X/-5$X=RA*8NL4(JJX+&IM7$O:-,+S#OM=T6
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MH<^9R^_LWJ,ONN5]VC92(C"5E$@5OE,_K)V=U/#LE?."6TE6!2#W+P#97!6
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M%?N':AQQE0;'QAP6_E"(<EDO</]-<ZO,S7SSL4Z$00=F&-L0^X:'RL$X HJ
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M9=1-Z3]:RDOV\3P\A0^7]%2WP"KN"9VQ+GWXMHBS3_"F:!]/CVFTC]7"<&#
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MV,F_[!_C??LP?7'M#X?X.^P#)(R<*AS/^10V#YKF_.#]?[Z#J][M[\T>#[_
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M8\?#R9K1CD(&\TH(H\!U^!>#TS< B+9A%]XDUXCD=I.89_/Y+(:T0[^DH>&
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M?_LPJY)W "I8YZQ(9 BV">5<<99*O.[LY(-.V0 \:S. +D<E8<]%U_&P\FH
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M86"_9N"_8&TF55MITF*KO;FS]3-(4X91;)07MG=)7=YJLS8'^7TX2BP="??
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M -+0S%8P/V5X6Z;MR5-K-.SR_V?OW9O:2+*\X:]2P;J?ISM>I:;N%_>N(VC
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MM6HPK' #1-X,%!RNI7P$O0"=>X&_X[<1>F8B_PF>U-VLI^<M)0^?R5RVDE:
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M, <%&GTQ5DJ>J!I7!^XY*DIAC,O!]$+Y32=<APU>K7P&I^NTR"9?DLS>%^&
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MTT>%FDNN!Y(RD%+'G#+%UYC)@CN[ ,MF?-G73M(+.DPB]>\B>"V;V+-<F>8
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M\6I-L*@XI]6F7&YC715=5,GM5#1+S)F(9$AQ4(M)W!6EVUD1>-,RH*@L5B]
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M6A4!=IM/QGM"_BC3S#(#6R';W9)L/\)CA.*N%L(9>O&U_,#VR@/[(S^PC_+
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MO:E/:K]><2J&+\I++X<9PZVB) #FK5"Z@I57$R%PA N0A7CX ,<YR*D%L9B
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M=3S5P\>T8>7H.Y&SG,BQIDQ^L!!"QN$N(A:YQ(X-EU#/MHE'8]]G,34BPT8
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M0#\A'_(X&6?:-;U#.*QN1,36X;*ORK_\H(3 W?M1NB<H"%':Y0_LVT36Y"B
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M/SX[Q3J0]-'H\E/FA=R,( B^TJALP2SLV>JO:+NC?6\'\5'ULN<?U\4FJQ=
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MBFS:*9L[WSE<5KT;-B?FG1I"4Z4E UN"!XVX8@+9A ,2)&H>*!:P +9LW7N
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MJ<[5-7CQ<GMC^]G+C;]G*APL3MBK#CQ?:VP4-,W_76(N7CP*Y'$U<<IO'QW
M)7P#N1KG_>X[@T^VU_E>;V9[UN_5NQ[K/S9ZX=4@#O/>M_SG3IHTZK3=M_!)
MO2ENN-D9^FY_>#2(N_!,?W3[_LM=N^L_OSYUU^]L?F$[NQ_V=]Z_XWMT#^_L
M_O%EY\_78HO"7Y]??_^PZ4\^['[YOMTQ^,/_[F-_\.^>?6^.=C[O\9U=+[8/
MGHL/N_N?/WR&<_Y\S3]L?OG^X?.'SO;F]I?M[__J[NQNT?_]_OIX>_?31R^U
M\80GY&RDB./H$%"R0H)[I;'QE @^#J'4=2TV<J$D'!PUF'EB,.8B<<M@P@J9
MDK1610KK4QQZ>YCY<' $"].LJ.I:N7_886>8*^/."JJ:.O0G,V8.]?#=Y"G&
M1]?2^OF3G']R);#50DIA@N,I8D<"BU$SG500C,JURQ;+RUGDE[F\OLZ3S@B6
M"W\%1"T,XLYA'-1_#7]6'.6&7N"7%J/#<1?=875@>[!4A&K_](@*;O6UX^&[
MHUZ(@WI;X58,'9^W&N8W'O\!!\)%/@WLP:0:\VA_T#_ZM%\?/\P0KSH]@#9@
M/L)=!E_B")2D?-G?\A'_!91'\=.MLR_J3\C3WQ]7DX<^ML,JY5 1/%ZG5Q&C
M<04?V>G##ZK^K##JQP;MI=L_1IWQMK5Z(#MP2SC];?\([COH5<] TJD_Z'7L
MI(AT/GAPV <ICF^T"1K)<7X_^)UB3!]7[V/ECP8#@$CWI-JW7V-U::AS&#]E
M:FLV*>[E]HN%;LA'N8K&3GH3X<EK-?/M^,[#<Z748-[X7$[MN#\( /'3L"A^
M<#SKZ<[N'MG9?(ZW-O//O8^6,TFIE,C8W G+<8],2AP!;VD>/5'8JK5UF(&#
MA1@GS)KIL%<3B0^SQ(%/1^/&24\J\OLX$CK%SM.*GOMD$)]6;/K)&0R>UK.2
M3[[8R7/V<;5S-+CPEGF63FX+?U?'G=%^M=\_KHYG)^P8XC4NW=$0*&(XK._Q
MM1./ZT_'Z!SFLS*((B@-+:2RC7JIFM:/J1AY5*O4CTX?&]CI$*CA&X!F%.&]
M+\7H07V%^2*S(JJ0G ,MC_ HDR71>%BB@G!<D!@N*>$MIL \Z.\_^6,RO,_Z
M!PX8+-]UBM.M^I[#YV"4=$"$8 ?L[L<Q+3\#*;Z:4.F*U$&\=?2^^[[UZ6,,
MV$?F')*",5"2I$=6>9M[.SCM6.+:L+5U\7BQAN&T\$0U%OVPBA,YY.&N/O6_
MPL*0$86&AUF''9Q?$,_6.=!0ZU7"^D$?4'3Y*I#7OT8FV SUYQDVG4ZU#CU\
M#WC_\_3AWTZ?_6RU/YM6#Y;W][YM'7_4T01/&$8B:0%4SR(R,)505"1%I8Q4
M(2?XF<6)4TMRV$Y&S*O"6-,ZU<_RC,O//JQ&)X<YV66JL(SBX* FT'//E]4#
MU/F&]CLAQ-Z3AS0MV,[&1YFHU5QX6/(I6%W.@P;@'4<6P_(?N;?8@XT/BFV,
M$_E7H_X/+6K,,?'46D]<X"P1;:@(A&JBC-!!V1]8U!G>8^2^ZMIL2]>"W 6Y
M+6ITX6APJM$]-#SS[8V/#&-/8U3()97;\FF#G'(,L2"4"XDGZP'/J0,3_R3:
MP7#>IGU42\V"@@\Z4CRVW:I_6-MP5?P6![XSK-4L=S)CS)R90)]BSY^,;1[
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MNFG!G@E3 P_4UBY<K5,W2*ZG4OPV_M7'03UE)\/MX#8IC]MOPSQ5P#(^W+=
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MNW5.I^HTR6<VFCE1(6%F_LC!H#4.W@4CN#=<8NDPIH2;%'-&R[1T"<5FXF#
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MD:B4:WU=+](2/>UEO0<OVUOPIY_HQ8]M0'V_GO<VAK$?2R,,4V5*XAQSEM$
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MS4+;&(R6SR];Y^F^[YWG_[XF6F@P)GQ#LR\(9X:0B^?CR>?:I;'D"=@Q.#S
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M-42)& QZ9^,IC!;>/;AH+E&V"+'I^M4#J:]F X%>[%F%#7^QV^]T8D0UFUS
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M5,J)2%5"DLS$%"SS)(GC9R_XZI."?&2%. ,-^?^R]Z:];219NO!?(8S[ CV
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ME#BK/"F5&C.@EHMR$2'/)>#")E3ZSTG)###/9X;_S)M\ *-/O4'S;M-PWP)
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M=NS(W;=OU.9V?Q\)3&WNO__H$R09LB+<6/1W2PU5G!))8E;:< ^<)_;BE;U
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M>]5IX?!;\KT^E7TK^SXY^_[0YS<?CU7;FX^2C58P1;*+F<C@@'B?-#K$.-/
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MXA+D7P$:VIL)\G-!C<)*(XUS6@'3X$TDDI!F09N8!&8^;&RIDLU?\%QB_"L
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MR DC66W]E1:+.F:U"*0]<\97(=="KFM!KB40,B^=MFMTRJARR8!W%*1%G,:
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M]-6%GM6_?H@JM=YXG[4VLD?V^Z#7]=UX(6SUJK(:?IZ(6H%+Z@?PJ6Q=P%.
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M&;09C:TJL%+U#Q@3'B!X"G_GCTS+ K7^LKW3RCR9K# G]FPR E_M]V5F%IZ
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MZRP22IA!(<0H38Q<&[N>YT,*8)_$$"A ?210:^N_\90+, *0L!(C3I-'&HN
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M@&"T41XSY#@EB <-GH4S ;%HN*28.Z9RA; &.18E!M DP-[+ "A ?010:P9
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M%F'^DF2.BB;V^_8=JA>$WC="BXS>$&9K>K61)D81/<()!\2I8DA3SI#!C)C
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M&,A_?0C_18>VU/L6 SJ-XU'AI:5XZ=."Y$Y8A)7J,6*P.R!N.$5.2EC%@H!
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MTF@0 #])0W'P+H<]K&/=5.K*0@2K3 2-&S@*$3P2$=1,&)PS$0F( ##!#(C
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M@B@OE5Y< $_!=,%TV61>O#\]O<DLHS(P'0.HM56(!QF0]<$C1X((#,;6!%E
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MSWY\'6OU]X&%QYV?XQ^]5'-X!$CR=?Z*R2L<V=Y^JS-IJ01DC?^26Z=J8ET
M8@F^";(T0W:CW:[ )0.,N4'5ZE<'L1TJ.Z@&![$ZMCV 4'5RT/('^;->/.[V
M!C%4K4[]^3;\Z%7]N)^1ME;]X\HK7X4[#5QR(CU.5 '<$TRJPGAF*,/$PM2Z
MMYGAC@DFZ +W5Y'^AS^(8=B.V^EJF$U_!Y[RSW;7?WVA8/WRUP'V1W]V[&<S
MW#[\<-+<\0#<QMGN8?MK\^S#V2ZTL?';%FW0]T>[],^#QEF[O4L;Y*^S+=;<
MW-CSFJ>DDT4I5V;D5EMDN+3(2\,"=LIR,F;?5F<8PT;F/,!G#)(IS$/D/A%'
MN*&:<6^8# 3KE2H"!1Y#]T,O U)W8+A3M]WNG@!6JMK2J_[P" P7;*U?6U!W
M..@/;">#:61-70=0L1G2_=7*9CM+8UL"NZK 4I ?]FH+L_W\63:I8'-JC'-#
M<Q&>^/,,F*YDS+@MLN15Z9 3J<3>:,X:]TW=UI$-W=@_P$FC3AC3THA? *MM
M>]R//T]^^26T^L=M>_ISJU-CK_[2+U?;F4,KI^BE;N?HXU].6F%P\+,Q:UJP
M/,>.8SK'#QY]2M;JZ7>**T>?*;HF#;WV8[Q&KOWL1[<E9 WZYUZW_?%G@CU2
M8\VM;GM#W.R-,>YFYM(YNG5D?(\IV/04^ZNY@FTS^I@3&E6,K%Z9<!_:"Y><
MB>MFWCF3[S)V49Z.IK7(?5_S;707F6=)DX>/+V9U/SR-<=WB/H_ZR#?%*#]M
M=2JX5SO/^G^["Z5,)DJ8Y^./1^"IKBP-+@V^6X,7GO7P$59NYL.V>4F-M[N=
M?01D<E3+^)]O,_G=^T3@<][C&6H,3A$YRM=GQV0I%NGFYK:\7_G/DMLR+[^=
M-3]_8DUH0_-LZZ1YU,#;T([MS5W6_.T]W.<#:1R^/X)GD$9K>OFM0;[L>/@<
MWO9P@^Z>?1#;F^]X\]##=8TS:/-IX_,NW=[Y=/K7V=<;<EMVSW://ITUS@Z.
M&CL?VW _W/PMOR/\F[Z#]W\G&H<YM^4&_O*GQGM6868]T\@8HQ"77"%K7$#)
M:\F<BRXFL[+.U]B-N2VIGI_;\BX >TW+_J]H^?ZA58&/N@=7ENYA_AE//\TX
MV$Z?X*HN],99#/G3S5;?OZ:,G4]'#%,!(E*9O*1%D2".((XU048IA0*3(A 8
M42_]0DH!+S#3]!/M41;267[2(4%(1Q55FG.OF$DZ>04F2[EVG(>:=$@AG><F
MG:FH7J*#D9($I+CRB+.0D%5*HR"(#=883YA=-M)YAO3V+\\W*(7)EQZ-[T[^
ML[-Q96O^/^QC._[KX^F7S^'842Z__-9@S<WF(=SO[,MGZ*O-C^ 7;/'=G2W1
M/-LG7W[;_0[O][VY&5)S8UE*D[_>;$$/+>=2)KDG@M54Z" 6R7'J'%(B96!H
MCQRC"44>B/!$$L+"0HJXE/Q>2X98BZE7RJ0D">4D!N>T,*!WL+?&B^B*+%T2
MQ$[%J FKM+5<(I@%%>+)"023&P7$1F$(=D%PO6R(+6O6I1[3JX#C]YMT:9-^
M.&W^]F?[R]&'[[N'.=(M'#3.OL(SWHGFSC\/OT#;=P\_'D'[LRY=DHI,MUU,
M>GFSW$.S6)99[HE@-:5+C6342DT0T\SE,]42Z>@U(B90:H1(5IF%Y*Y<OB7?
M-XY8'V#DDW,A"L(3YT[QY(47T <Z"J6++ET2Q$[I4I.HE#@DY+"GX$DRBHSU
M!#FJG#;)X2#ULB%V0>NEHVRSR[CO\I_8[_\,:#NW^<F)B?[0=GR$E^X/^M6U
ML3*OR#/^Z5D2JZ8(S!/>MSJYMW_-G7V%C@KKW(UU3F=T0A14>Q@7)%TRB"L0
M"Y:SA+!,048KN M^99WR&=+Y6UFY>K'XU))%B3TAB1H>!-,@%:DC4@?XFQ3X
M)HE0\/EX^)Q2!4GR8$FT2%C-$1=1(:VD0U(:ZO+Q.N4)X%,M!SX7F7V>L#>3
M?OZ'1U7?[(GXN_7*$E+R,Y^+OV#B-W'J_:DX^FQ&0X5D(B$^@-.&(^(DG\0-
MTB/%32Z=ZQB.64.M$B6?XM3[G7"SY.%YA38+;3Z!D"VT^12T.25M6>*&<XV1
M3_"#<^Z1#M@@P;P2!+@T!36B3?9J:/-JRI"I' 3W2&VPZ*0A]7U^;H' ;?D?
MGQ^KTXC\"LY?:U!M[/=BS'NEDP%YC$0F\UM0W3LKQ)/F6_D<Z^P7Q[8W.*T&
MW<I6?M1U=M)UU4\Y$4;.,4;Q+]/]6O^9_/*W25*6CF\/0^S#;7KQ6[?]+2??
M&-\P6=]JM^ I/UV]U_OQW\]OU4W5_]R!:K'5EKAD>:"22TF,(X2GP+TUB2;F
M;[V[_A_HG.TT:M6D40W[O74T//IGM]>K4XW\:H_AD\'I[1C8O% &OG\&&'C^
MASV,95(I$"1Y7AI@A" 3C4:,.NHLI4+8M+).UF8W#"HW.JJ]6MDCF/FJ;IW1
MY[C7_=;JYQ/<:U5._#)MA-6!S197'Q$%X_E1WA]MN($)6$$+&&?"VI14;A8T
M3R;A;Y/WYVH01IZ<KQ@# -'_'(:]$V#L?NR\/0O@VQM[^116T$ZB2(+*4;D2
M66K!("@'2S"4N"A6UE/K6ZQ.H^WUIS/JP/AW0IVCQ];%ROI7LOF<@)%4+M;Q
M$?FZ8WM:Y[X!GOCWL!,KO9H/^XFUZARV?2 0F#_KE#XSUN.@!<!<HV":RME^
M#*LYY51.(A3;L;;,U7QS6W]8]>P GM4;&V>("7@CU']=K8[;PWY.1Q4ML*&'
MJU?K9]KC8YBWZD:.N'ZMVH+[P;1=LQOP[OGSIX(]9F;B2Q/)F,@Y':U''7?[
M]>U^[L4V7/PMCE/UC,7KI2^.IQY\\17K0%(,!]=_95I-/.DDU0"YT['5OZ)M
M#PX\S%>KT'U^+8\RK=X#]BJ"T?]6_U=E07:E^R[]/#C/^7%L]R-RO6B_(IMS
M\/ULVR?VM+_R]ZO3-,S(4ST\W3FC/EC_A^O]?7W>@^>F<N(JD2!,(D0%#DQC
MO"$B!2NC!W\\J>G46"P$9["/VCC*+:8&8Q68(=RGH+4B*\LK+BX!L\[?-LE\
M.$9U)NM6)^];QM")_:L@3[WN435H'<6,COJ_UT-XM3H9R9A>_.^P!1_F[\##
M ;'_'8*RB;WV*?3JT5%K4",^Q;AVHSY[C@Z;.[ME<["M3K_RPSX,JNV=ULG*
M4KVWT<J]"1QX\2_?_1;A]P%,EAMU'K-)4J61:\)(S8ZT[K,3X)Q,5] W0%#U
MQO%):W!0,^_5^U]]XODS?L2K^6LCCKR:P>&F=CVW]GNUZ8SO/ZF_.P5'>B]X
MX:5,#A$&WC"WC"+G'?SFM!.&!14IZ+I.=U;636;QVMXNHWS&?";">VUIW*<[
M>IY_Q$X+Q$$=P;F,%+,]S"DRZS9VZBC3S)O@LOE>RTTR'*Y5[[)^&>5 [,=+
M%XZ_.>R RAUFHKV45#%?/YZI,_1[MO.U CX&+CG-'%/+AGS-.!7N!=/$[ZW^
M(%M#363#P?#B09DO1F)P_(?LHE[WE6%>)8''#R;1,.<-NB*W5D?J;)SA<?1N
M8XZ]EF(O""\_T!_8SG[,=\C?ZW7;EUV491ST/*_DF;:3.ZI?[</;]#IUYLR#
M>-4:SCNBU^WWP:%-=M@>7'H]^ 9(XVP* QC0_9AM8'@,+#VYU)U6(('A?K9S
MFGLHJV@8F7XKM&ROE7-S=NJ/KDS\63%_][4$&(W*6"#TCX&T4^LBQ>LE(7W^
M/L\VE5_+#/,'H22Z6>89CC=W/BTTU\R%63[I:MZ!!:?Z+NMGCV1H,)''MU!I
M_"$F!VW?,T:")>B HG$1<2H2<@('9(+1X/-1K(R9GXU@DM>PLON@N??SJL0\
M#^L*O5]>RRU\M,S&(1IG'Q;!1Q?+ZI=DM[WB@%67?,+S?-B9QNK5-"+J#_4J
M&$@[3]'1]MHM^!9,_=G3"UE<C0:Q7C:SXP6R=+TC5PSL^0UL"Z[]^D #.XY9
MYL%HKN9T_)/5GGX\:N6_3H2_[?7R&N_Y\BP1M8@^MSXB7J>"*^E(GM:@OS?.
M_$+S@;P4!??0%!WS[>Q7P.TI3!9%Q/W8ZIJ''_8B9Y;19'-E6(NX$Q$9SQ1R
MSD:A/#-2N?E']Y]6Q!5*>EKC.&WL["Z4DAZBYIK=;Y,)=[6^V6,KNF)M3VMM
M\ X?'FAM=U9T#7LZ$727[&OM#KO82Z?P9K=L;]R"G=JR#5R:I*/3EG.>:- 6
M PXD"XX1JS0O"426&TBX<;;8#!YK\T(JGUI:SK?MFVVUNH\F?6AZCJ))'V*_
M<.V>,DG%/ ?HD/=HDW1(&T80]+ZR(1'E4_K1L?TG%::%X9[60DAC\^M"&>XA
MPG2D(6I-2A];DQ9#>UI#H\W-K;U(DR'6.L1T!"KR&C2ISTN-UB<"<I6"C_P4
MFG1Z#GYPC/Z\T+]\EWJ4K22,^)!X8(+G3.$:WM/I2&5TAFBR1Q1=65B BZ;Y
M_Q=^C('0M?&1EL>MIKK5\=VCN&._Y[P][6Y_V(M+4T?U;&N"&K&]&=I-^O&P
M>?CGT>[.%M[=^?-@=^<=:7[^-_S]S_;NY^9!@_[[Z_8,:K[R)OW$OOS6H,W/
M7PX:AQ\/FI_?'S1V/I'=(_C[9[@/?7>V>_1!_'76R&>>]@+58"S,H.2P1="_
M&)F8**(T)F8"#]*X:<_#P-^B<49X[[F/Q*D@!2&.*\TDLS-U5$?=7D&_QYPM
MYD=U3>>JQYN?=[5]7@,F)!8Z!<FCB5K(Z*7U7C&--97GGM'C5^W]M7MTW.V,
M:G*?6]^[[\>QTX__C)V86H.=S#1OV0P;AZ 24L(Z83"^E!3BED@$H^Z1!Z?!
M,>G!2Y#39G6]?W_Y6-KAL#]HI=,GC80:&_S ?J_B:*RS$S&QTBQ:NC#?C /:
MX*_]5C^'DXW#DLY+#O]\RPVK^:_[4DKU"K-&:2G5^[(:RZ__>)%UA8EX265
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M <TCH =N<!0"6A("FJX?&FE@WB3D>:X?RJ1%)A&*O W)Y$36SO!"0(6 GI^
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MY8CXZJ0U.)AI6!I5F1]=/&IBOE/;GO37;LI</M_VY1/;_J249=UNV^_'P6B
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M3X7%/LP33M7YE))ZW:,[F<:3GL\O8W_-V!]^V#/:1\N90#&*G!V#*^0$R.>
M@Y26*NQ$F'OV_IR%[#4J%'["7/L<TU,QBH<8!0A-R7.O"X]2,"D30C[WS +"
MFFK'E?2"QA]/33_2+,NJ-<=SY-E(X;G8B2F+P&ZG?5JU4CV-UM*OVQ_-HZU^
M=01S9]5N?8WM/,U"6_.\"U;O8M4?]@<VB[A:V-E>_HL[C+[^_&)O&71C:R10
M/P$P8.[](R_'@=[\?1A[<.7'EN^NUM(2C#3VNL/^>,'N<-AK]4.K[G<0CW_
M1-E*+6\[ _@H[!]%^ 5:V(O_';9&V]D3,5V7BH09_O++C-3K1'E.KCCN=;^U
M^OE=L^J^W.BU:G-8+P7EEG=[('&SG/7PI7[,(^^&?7CW/KQ'SH\V>O\CVX%>
MZL$@C:RE/U;?;3]LV]$?\F-&[DF^[[ ] #@.1MT^:9N=]/T08-S+75QW<.SG
MY=A6_P#>>%2]K;X9?!/U(MP>>N#\"W6LH!LIG4[^9OV4VF)/#F)N\*C'<QN
MG')/PDC4[8(/0JA[#*3\:/A.P.3S@(=AK!55/UXT(;_V><O@<7#[3I9:+K9;
MX!",]/VX59?&XB@;9KZG/P#Q%4'(Y+'I'X.!U.-2?SV-OCT9R5X$S^/R3?*S
MT[ -EMD?'H._42]7CXPQ'()QYM>[W%9H0;M^+G2#S^HI#V^"H1J/4ZOGAT?P
M+ME9685[PB !RNOQ'PYJR\BN39:AP^P\U7WQ PL:^T9Q=(O6T3$\*=]AW)Z+
M;XX?7^NY?AZ(\Q:/O"-XS8FWEP\,'\,7CX$/!G&*9V;7Z2\QSY@+.!W%OTYZ
M\>?:=EK?XB\GK3 XF&QB7?KB>!<"7WS%NGZW/1Q<_Y7IO88GY;E&%_YFJW]%
MVQX<@.<+TG^KX]=J8J[>PYQ8$8S^M_J_2HFI[KOT\Z W:>RQW8_(@=OP%=D$
M /W9MD_L:7_E[U=Y'4A]JH>G.V?4!^O_<#WXZIP'3PW>:%X6'&NK(S<@4WGD
MT7$N1-:R.:PJ8CK2%_"=&#;R5,^)5TIQ(TS>N^=6B^"3E=))X6)2\GQ_LIFY
MMN47X,Y<529_#(]@CCO=3N<!=K_6#=R/'0^DM //^F>[Z[^^.=T!UVR"(Y*L
MLM@0)*REB--<$"I(!]K48QLUMBE!ET909\<91[UA7%D6_9#)KM>%F6"RC@14
MEJEYV#F7%>&JKH IS.9)*DO2_L^WUT0UCU_03[W5">_6ML?]^//DEU\F!P5:
MG;JM]9=^&=]KS%D9AE/;G#4UC3X>(]28-2U8!NDXX&_\X#%^UVK\3NW<CCX3
M9HU2>NW'>(U<^]F/;DO(FF3J7K?]\6>"E<9*?OW'EV][0P3HC0'<1,Q<.R>"
MQX/RBKW'#%K14]A6<X-6=J/M5>\Z 1 \X]%<"5YX:+=<"K:Z0PC#,G99G@"O
M/8USQ]=\&]U%2G?=I;OP/.!-J7DVFB^?!(NWN,]K>^3;F@1^VNI,5K?Z?[L+
MZR_J. 2,S%-&:O[6RP$QU\M7.QA%!8T6BU)U#$_IAH><,'Y-4;S+'H?['(?+
M/EVR)?!\_SFVI!>_VCX.P#W]<OCIM+'YY]?FX<'!E\,/N''XCL)W3K=W-GCS
M<X,UZ0?RY7"7G7_G/ #WWT?-G:V3YN</=/NW]T?-S0^GC1WPF'?@73;WR>Z9
M9U\V_SQJ'GKPE#]<5#P_W&?-P]T]3;TBWC+PFB5XS2XQ!.YS0$%YZBGQW+C7
ME[.C$,O+)Q:@C<B#@_G6..Z3<<$GDB2/"DR6F%&,,"[$\F3$<GJ56!RP?K0N
M(,RL0%Q[C(P5&A&EJ8H.)ZGRR:>'Y&4OQ%*(Y1$42TC"8B*Q89QSB9TCRI((
M1$*X,+Z.5"6F$,M3$4MS2K%8C347@2,G243<\%S2F3+$HTP))Q]4CM1>%F)Y
M<0F!2E:DT@FE$UY"SJTE6_/Y(PX&[9A#AQZ62^NEI-AYVECF6VF+K7$0=O]C
M[.?XI\[^^U[WZ-+ ?&X-#N!Z^&!C.#CH]L:Y>5YWQO4G4BI?9]96E,32L$20
M=D$C[H)%SDF-+.-:<L:LY7C1"==?:,:M5PAZ%K$E5@638Y$]=SHP;:-2R9FD
MC68UZ,D$]/=? KTOZ NX[P;NJ?4-[0S3W$>4@DC@AB@);@@W"" OG%4FX;AD
MM>0+K!<!:Y]L,%'A7'28.ZL=4U9@:IUB6CI*:ECC":SOOP!9YO)GA?OLJD-R
MCN& !+4$\8QTFRA&&%N3?$P:4+V,<_GKW%_^3PY3S$'G^3C#<%!'C[=;1ZW!
MZ"C 6ZBCL(3NQ\<8AJ/#&5<XJQZL[;1Q?-R&'G/M^,=HT+;3?RZ&K!#4G0CJ
MW<E,JCGG8J+P?R@:+Q!/BB$@+84BU@)\#Z*CD',/X]TOD=(2[;J\<7@_E:/Q
M,'@77;(@V$\E4*-.2A]"0$Y[CSAW&.5J;H@S06/P%/OLARQ(F!3L+QGVG\H;
M*=A?"NQ_FDJ>:*V2/"BD >LY>$NBG-4?,<.-U=(K2L(R8O]U;H#<(N@U=L(]
MPEVOYF6?G[KR(34+7EK0R2+[8PGI_SE*L91@E850]/<9KTPFF)]-$BA$1A"G
MR2-M1$1.<G#.L *:)O.6B>];M>%!:'CFE>5"@(4 R_F"ETZ 4_XI3#\^D)C+
M#)*<J2XI9*T.R%B6/.56T[P)OL R5(4!"P.^)08L!R&6C0&GO'0;L126<Z1"
MM @F*>!"2RB2DBJ#5:!$/31@>0D8\&I9@_.D21?Y<):EJ$%.MC*H*X+:.KUG
M=LA_Z+1?ESPW"XLZO53&5YU/:C6G>KNXTVIUTAVV0V53JE.WY8Q@]:^M;Z.T
M9+TZ<UBK_RR)#J_!^PZ\Q^?<[*TZJ]:[28/ADH_0W)+[<'X.HBW>/-S:H])H
M2F(^D1 8XB1AY&BNU)>W5PWSGN>TO+-:YR(9ZG/D02V6L&A+V-W#6A#)A4#<
M18,XM@8Y0032H'TUETF87$)CCNR],(5,+7?*F/RX0J"8PWW-X>S#GE+ !3H0
M%'(*?DZH1$#5 GEOA4XF*.7"7 UP80Z]V#\>]7C[=)2U\OOQ:%J!.2I<)-3L
M@$%4A%9'8!L',+N,,WG:?K<#D_-I3O+8;]6IZ/,7KYOYKI3&/K*GV6+J>+2[
MYO%>7%[>T?.W.M<%S/4_GK_D[^-W+$9Y3<:\D\;A_IY+"CN6&%*DWC".#IE(
M-,**6$6)#T;C'\U6.6OI.*=F3EHYSBIOJU&.V5Y,PYQ[LVU;1Z-\GK-_'^4_
MS7EO>_6V8@[ILI6W_8/JV)[6:6AG4W^.<N.-O@^F'6*GE1/E+F-BX.W<T%$6
MR0S/X[H'?<S-KOMMDC.XE=/4Q/X@<_[?X86/8\>V:^A-\L_"Y3_(!MBY7' V
M\T*G']>J4?IZT+#>]X;CZA>9(29="X-U^<&7GOKCJA%7A>])K&M6]"]R""]K
MCN9,8^Y**N7XW9YG!7:C8@=;'_^H.RI30R?87G4:;0]Z)"<HA1<F&KBW-3@
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M5C69Y88B&9:+%E[UFDB1#(])"U.2 <1C !\B(:EU1%Q$@HRU' 5)J W64B*
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M< P%YT#_I6+($(&1!I67CL",*P>T36[@A8\"KC $//5GU.[''[@?UZN#E65
M5!6X5\267.^7I(O[);\; 'IS].?37VNN99(RDF133$)2#\L,LSQ*)KS0)DGL
M/"V\ ;<BD+4_<W77EX]S_!(K[XE2"5F?3QQ*)>&382AQ2I37F!D7US:7Z<U<
MAMZMBCOA)6Q_W$Q-[X<9M0?QJ4#%; 900 J9K$ "9AMQQ0BR I"#:^HBMLP(
M!U24L0V\<!:]U?,@+H1J]S["]@1V1N[6\2<&?$L!O"4>4;MR$&VKFT/QHX>/
M^[W\U1003D+M)I%VS^F4VN-AX'S5%T\CM0$Q++(Y[APR.!=QC<+C1+@!\K2\
MK#QWTJU5X42W+P-RZWX];I31G6#CVM,Y]_+9+>ETSJTA8H8K32)0IP)0]V._
M<_UIL'S4I(:0VT'(#(WB5#">"/ F$)&<B9@A'01%@@H@4I9SQH%&X0TZ>RKH
M+@%MXQ,W<'O\OI+65UZ]LA[8AQS8JR>>9P7\MB>@R?)/0'_WO/%/WY1=D"\6
M10 G^S5_]'N#P56O6FI]BP%=Q'[OR5O)"QS=)'O[S4,9D^9!)^0U=X@+)9$A
M8.KF9+S21Y4"E7>5B 73"]42\5,E0N=X.(8M$M@P!/.GD7/8HVB58S&Y /;@
M725BP:PGM43\5(E(4@IA+$:,)(P ZQ/2R1K$4XQ<N(1#WI3=[<V9@3_^8IQX
MHMHB.XO]6![^CB&GG"A/<6>06&_T^OD#+K?,?KKX+1@W5$M7EBZZN_WQ$!B#
M,=QZ6'=D0#S:@)PV"D GBJ0,IUK8%5B!Z@E?UH0+(ZFA&N#$$XJX$1%9I3W"
M,%M).$^$5FN;W5O R77H,<Z",\8/O-'8NK*G/ILC(F>]BHTS.[@CJ"QW"WD!
MW\=NKUM&$Y0;R'OI0]7<6OYFY8\U]]\>:I@5%[ !CAMA$?-8(,V<1RI@J:7T
MSEM\K?R!0/2C[QUUBVPB?FJR0.KRY]CHQ[;-:]>P!Q>7LW)52&?2C^179*EJ
M=4>VE/$IH[ RRC@M"QJ=]@:M?,VKXB6MK_$R3<A_7PV"J<Q(?'F+=8->>S2\
M^999)^JC&IS-'GQG&_^.MCT\]B"\ZXV=KM\H%+3Q.TAQ@V#T/XW_VU!J9OBF
M_CR>G!,_M4<1N7ZT7Y!-P]A_9=MG]GRP]J^K)C=8US,C/#LXY1AL_A_7_]?F
M=2^>F;Q2G6ABV LK9%"6 Y99,(P9QIS$P$WP8NVGIC[[SCR4;F> JEZ9[NC5
MJ!MB/U^UMOFV<]KNG<=8I>3Y>]3WQS9G=FC#ZQJ__/__'R@5?OWVP]]_%Q_)
MZU]OF69'/K)OXV/N4Y'Y+#=VO1%!Y%O9%Q^K'@X:'7O>.!UW<)P?K8#4AAW>
MO$ATJ_"=J^5$L7=8,ZN(UAP6 Q.T)/F\D=+4<7P'YTBG=_PJIU]L%DG<BNVM
MO?2F:%TQ)\!'\EX!B/X$X!%]>0C/][;](0PZ$P0,5XE] H;A*'))*D0C%3#,
MGH EL+:IQ1S"_W<F"CFW5+MW5N9RN5/RO-C*9**\I]4?#+/-TK;P][!OBU/'
M 40+[HW6'W\WW]F]Q.8:POH^C@7Y[WX/[*I.R5IWN@"J/M:9[Z9%YQW.MJY2
MCFD.E)02R1"WW"&KB4!@_E+)@]1. H(/6M\0S/SP>"Z562^EF,V#*AWB1N-M
MGNM3F[?O6H!RPYR3K-WJM"J6<)D';P(Y("#_=9>*Q4N%F'O[59IE-[8ZO5%W
M"&(V7C&>=SSC N)V!N\\]#)P[Z)'S/B(N/8Y,A'$S1H:HPY!2.'7-NGU 8F-
M7\!HZ40[&/5S=KOS2[":H%3^IH0GZ_]WU(+K?LV26>;.&Q[W>Z.C+)WG_5Z[
M#4(11KYDJ8U/L"(.AC!'P_C=Q[8*D[@Q&A1)%1K%;BM(PSAI7TY%FG_I]$)L
M;V0N-TG=-_A![K[2ZY.=/:7;)]_7ZIZ.AH,RJ2GH4?'4TNR#D4C0A][9X%6C
MWQI\0:D?\_5 _W+Z4F TL; "[>EIO_>MZ%?[_'$7<[8T'^8D#?,6C'ZG-"S>
M0Z=_AS[O5%U^#SULMKI9)U\R(8 ^@)H18P4SP !@<CR@>C)("V\1"!:3!FM/
MA<B;T/.1+/\]E<SVV8I)"=TO6TSVMM\>\J@T)UP@1<#@Y((P9# (C#(!C+GH
MO#82T'CC&N+XNG !Y,B3QM=>-L_;.57ISP6<Y84>7R=)XTB;?R;=K2&G(I+-
MDYU# RCC.=#'($D^:6 =<L(9)!F121H7@N8@2_/9!QX?<7Z*G-28D^7DZ% 8
M866,@#DA4<23#\A2&5#@S# EM&8:EB8Q7X'EO]<;H?6U%8!%-<Y;L1T&4UFT
M']T]\:"BLUWU,PO.RY:8W?VWA\)RL$AC0-3 O' #R**E"D!K+$W"P;)%+)"9
MZP0FLVG;;=@J#>=DR6JW4OQ1#O9E^"3NN]/Q/>%XEE&;"[DQMOVA$H:+*# *
M(4A8?228E"XQ!/ BDQ(8<RPSX15S#HS"-+O++L5W/=B7[MWKO.CY*<7T6$D8
M\2'QP 0'H]=I*I33D<KH#-'DD"B]=AM?\O7OGG$M:YK_MX!K>2X18^%:)GRC
MBGM_V%CI*[K3#6-'RV^Q&U-K6'CD]^%]O[7!/O_IXG\T%O_.P<G[3I-F\7\G
M/I^\Q: :[.#DW=GG_:.+SY\.SIHG6V>[VV_QWH=9\?_<VOWCX.(SB/_N=KO3
MW'_'\KMVMW^#9^VV/Y]LG3>WMS!\+_YS<?1M]^PP;R]+1QPR,,0YYC@A)[5!
MG$;NF2<J>EFNA"#1,6QEV" 6\^"%$@Q[4 YBL,>@-UBFG"W,PF(38>$YS5ME
M_='TCD@U[N56R(U!S#?O%_WPQ==)_'?E^X&V3C[%QN 4@+?7!PJ0X.=0#&&_
MY49%;S@FOWSYM7%:; D-C^T0?LZ%808CE]U"PU91K0;^F-IKN72D0S?.B_6I
M-1P4M[1"R_9;<;#1>#N_1P.+1/9C=5K#RH\Z:4FL"M!D=]'8M6H+IV1^=>^L
M])2U[5GAXX(EPQ]/W5&Z[>]&HI8? +M=#N^;J='-TE6)7+^9&ST^NC#^O=S^
M625V]-BJOX-WCPY3$HFSX)#4V('"BX)."\1]$,X'ZB*'A>\:-IU%\<J6_J5$
M%1(SD3V0Q\EF_R08H%5<WXVEO)RUAL>57%_.T& L8U?TI!3-4H;OXO5?>@WE
M&V3N36\ ;QSW\W;._)]_VNZQ1:_)]MX=4J*X$;#J,!FR+Y]H9()0B 7FDL*P
MYN02]GS>>31.7KU^)PE8>A'76@(6D0#>/#NT"7@E#@)YF K$!8B!8]H#%N5"
MUT22)( Y\'DO\Z4$Y!7P+E*P]'J2M10L(@6B^>[04QN9BA9):3'BW'CD1 C(
M4 #M)(0+F*QM4GVC%.35Y+Z[9/TXR&9QZVMLG\^7NOJN*?9(7)+0DDN"_/7&
MM>!@%%"N+MA*+>@KL,O8[\^&V.7ULJC]Y6-_:&&(OL0KJW(9V5/L"^9+IT)[
MIG;?R^B>X@6-TUZ_2LQ4;&BV^HWL=V@,;-OV2RKJ>MU1L6R?]GO9 ]48VF]H
MTKJC?N]L>+S1V,^%RXHOH4L%,PVM0:D\14JGPIL!'#-75\R4M5OV)\>!%*W/
M7HX<*=(K@D>J,HKK>4<SMDOWS*CJ6BP'(3>MV/2\"U LZS#_=M7]:2LT \36
M8!"'@QH8K@<&SYI;AT(J81CU2"N7@<&93! ,2H(G0AAFWF9@D#<#PUU7A_LE
MO:XG?5F3OGMVJ(7%BI&$(K#T7.=7("M90"20D%-4&T[4=^K\3F;^.S'L8_@G
MWX7_%7#B:;+Z3CSQ:$Z\3FM8)"#=ZA9L"PSZV/6M.-AN#7R[EX-Z5L6-M[?]
MME*=WMGG3Y^_-+>_L,_;6V=P#ZC.%M_[HPGJ\ON7@Y.=\X.3 P*J<++W9D9U
M3GYK?^Z\.]O;#W#_;]"^=ZRY?<0/+D!=/KUO-4_^;.V>?.1-VN3_N7@G\MX8
M\Y0Y12Q*4H%%%3'H3G0*11JM-]8XX_FL'X];$$$CN<QY!X+PQB>N>: \.,U@
MK9OUXTU-1*%'5Z:B<0]_WH\;<+7!025,# "S#XY'3C7P> *@K#4&15+7QXL_
MD/^O>,YUA;&O5Y;W\6C4ML,>T*4W]C3?UG@?BS"SR_$<[]W!+YD4E?%E/PH.
M_QGNS;U1OW%<G$ H73/KC;/CEC\N"-UEL>T>\#-;N82RA^<2<.'R7G'%6?:,
M3GLP2S[?R]QR6,2AP;_+9_=FWCE^_'KQ5GC&"3P[$]#BQNRU+ >U7PY\Z54Z
MMKFP<J?7/:HHY# [!P=Y,2CFHG*%YEBXKNWZ8J.O4X9I--H15HIB:<EO&!53
MZ<NI+!CHV-&;'6 YD+5H1TEY=XOWPY0#">CYUH34[G0!NHKW%*HU&,#WL7]Y
M2&!W:^?-^)# .A@ T*/0.\U#VA^U87"*D5EOM%*C!?2XD*3+Z,9R -<;0#LF
M?:C:V[HHF]"?EL!L+[0F#2K=S*W\@'\W]P:EW52.&5S=&N:Y<F!TY8C%'$18
MW'X\.952^K/M434 5UXTM%^J0,E>6<ZZ"$(LJ7_5P,D(O/]M,@#3?2Y,DZ_9
M]BCJ(9=3/I[[C<9$V0KY&?0Z$W'*]Q765.RF'-<]>>'5%F:/_+1(].,P][J<
MM2X,Z!D81,=%I?=O/@[*<,G"/3DH"5Z6[NH!Q824(A.S[7(ID!N-553NK7;[
M,F[UMCJ8A^%T"- &=FFOWVW9]<;OT,A6@ ]-.QB 0HQ $"N@VXUGC8->_\MZ
M9=160IU?"1->3G0I.&/!G5.YJQ-6>@&F4&-0F9*9#F8[L3KO4<Q3MYO-Y^R*
M/H7[6_#T/J@V+#+KW[NVZG<EW(/A8/[JL;7=;EF7HW<*[9E8JX .H%FMW/0\
M^U4')_TMU'@\$N[\-D,)C[X<2=\;M;-SW?=C-LV'4X,W,V2A*@M^B;(;C8SH
M5Q\^-<\E(L)_,'L_Q9#^ .L&#%PVH0:#(OBAUWTBCK7'YX-OP:SRAXEC,"4,
M0=[R@#@S&%D#I) *,*VYC-%(MK;)YCWL5VTI$/!BE/.2X&#00=-3JA;Q<4S\
M; 9NME[X@;(GJ<#!; ,/TOE$'"_Q<UZ' 7=+#%]%9/Q0@GA!%RY)1;$1VRU1
M_WIT*A:<?L7I"LT<MCI%:O/3,G"GBC8JMUX!2,;!:H.I57?B*)LPF6(Q<]EG
MURI/T0XR#2EPN]>N#AT SPJQ#U!3[J>!9A8>M%'_*NOJC ;#8LF'Z2IVY$HT
MG>IF<:C@O'AEMS<L<;O<!1ZC6FK';RU7!O/F[3O@$8/L.TRCW)&B?1N-W\:H
M[$?]?FY*M3#.<;7R$$,6%5LX3J8@?JKAZU-T(#<+1F/\WL*?6(Y*Y2,>TXUV
MKZ"L-GS-8EU"M+>#XZEAST?<KT8C/P+LZ5G8*P\([:6Q.1##;AR6?J3?>_TW
M.;Z@#<M"F<WO8]=/??%A:I!N!Y3FY0$EW]W>.K22:4R81-$+F<->/-)))"0!
MYL">3E@+#D!YS7F'AAL[G(8W>)M WJ.WHT&<)E0EC>E/F7BE-K>ZQZ ^)3Y8
M-PF*G^-<T[HUI1^%J)=:<PDDP%MM890 4\\9' ?PC0VM'%ORU;;:8QTYS8[^
MB?##%P5 7.)'0:@N#;NI,WE9;]9+[<F(]Q5$:6S-MHI#_24"'L?VQ"Z!A2$K
M?A7'DMD]H:]O.M;^8>2/;_N2^\8'.,L",]YYAR.G^0/#PD@K*&8>$W%;EO(&
M&IC_>WO91M#+#\>PU.7 RYW+IM;4Y7J-W#EOGFP=>F(M=@0C0JA'G!0'_8)"
M.!*I*'>!:PD:J7[$7>ZZ R #=]IZ;ID4G!/KE#+$ WHKZ9@TZ;8[ +4<+$,.
M_*'3,!<Q&>2C<8@GS@"9HT$"V*LRS!$E*<@!_\[N\.); :O!/+^?EF=NB3BV
MP";'>;ZOL9USSP>C_FE[=,U!SY_!=#Z,F[CE?0;QG#2J>+W/&:.JWRJ_:=:E
MLNV_V79F<#6_N4&++G:WOQPF&V/.'XRX8#[OI"JD!16(ASQ7H$-<JLQOYG?5
MQOQF3+(S*;[B\1I>>O;"Q+I[ 7)7.>YOZ8%X@8*'X?=#CS76FC'$(RMREW%D
M352():XMBRXZP?()T9L%KP@[GEB:8TZ<A<A/=J*F0TYR:OC*T3Z6./BU<,9?
M1Z3/CF,7&'26YNQ)SI=F]W>\=$/<++WC?:E\5R?&X=AT+:G]I>T_Z^*MDUC=
M+8F57OTD5D]X4_+-WC\[VXB8QM\@V['3\K?/1'6KP(.'.UUQ1?]ZL%#T^J4/
MK7 1E[ZN*B='J'8IBJP;<,FEQZH%%J@?CE>RR6"<5H.1KRYV]L HCU][[:^%
MO^GJNP%Z,GZL%R_N@#F]/MV,3ND7'>6SO-666^4I'([AS<5V*WZM,*>(@\]F
M+A!2^%PXIUROW^^=Y<8##EE?(.#$=K^,=GL#ZQ&T<PL6WWCI4BP>EMJ]L\IZ
MSZ-1[)A50U*D@@2PS8ZSP2BEEF]5F)J]@$6&DADOW]4Q&P]5^;;B2;%;MFPP
M/FHR'JK!Z#2'$1:=O'S]^DW(N0X+M\NX6OE(&ST':#6^J>Q<B<M%0D'H_"BG
M'4M5VA3X.PYB+-J21OFWGT7L[ZB3?P%Y:C?^SG(5<R*LE0P R#M74YN]K6X8
M#88P@:W!]$Y\-T>"]$ 2KMV,!Q%*,627TGKI\R]GM=T#VM0XRMO'W6H)S:%T
M[5:Q!S'EG+[VH1Y&P%T)![A\4M[F:\6SRF\$Z\1I=H\-RUCRG!(5I-<.IN71
M5OZY4?=+MW=6>A1&W:S<_:Q)=EC&T +.Q(W&WR#Y[6)?W%:[_#&4[?W:ZDUU
M^CNM;W5]>P1$9@#+<@N4,>? RD$%Y96GXQ<4VZW 0C*>%-H\B=HM0 XX^ND(
ME,4#J<[.]V*CLTAI5BE.R=LG>I7R/BBT<32 &S+URETK2%:["JJM]D?GV,QJ
M"&,.D"Z$L,#HXH!1NU"B\?15_O]>'_0I,SV@^OW2)^MR,J:,U.7(%WLR;C0L
M]A(NO9SK.=0@C\]T%+)OVU8>4!B9T"NV9TXG^Q@5(>U7%VTT/N00A,NYO](Z
M0*DO>0T#682V!=L!-I-W@\<MJAY2(-MIMHGRWMODLKG]CR+PHMQ"GD1S%"M-
M)?WERV$%&F:_;B'1IWG+H,#E\9HY*)W'=M#+:'[> %XY*.+#V[V\LE6"6^9O
M#9,8O#(2>\*H+^F[];X_*L[.3S;&B^Y<;4O^IK(T<Y1X[%3I!0?%4N+R!F3F
M[OV>*\O_%FV8-+%L.OQ0[*OG46Z-+8;+7I6;Y/XX'Z+/;;5YI1VU"R5(HWZY
MT9;C?'JGI4^Y6N>J)I9;]KW1T%?S.2-G68YRBN3N$!HTZE;Q !N-K6[>;8I9
MZ$*<#FP'R82)SQM0'5BO+B6D6-!R+K!J:,IVEV-Y^:QR*S;OIE4'Z";;/U,+
M]M@D6*^Z6AXDG5I_Q[M?F28,JHC.GZ7G-ZZ5UVO^_\!(C_R7\\;[W_^>+.^/
M!SR-O6[C0SP=EBR/KU?G2K:Z,(F=QJ1Q3=L%70V--QFE_B[.6Q36CBNVSX?%
MC/JQ.( 1W/T"KX)%;]0%V7W3ZOL1$#OX)W G>Y2C,,H]HLGS?V^5L6I9(;9"
M]L/ 6ES*UQM0 0"6]:LW5-\6"E?:8,6]OQ<C SWJ?VT5U+-@LI?10*F(W&MU
M\T82K!,A ]S5*,!+S,H".7G?U$4;5\?,3&46GVI?T5=XZ];I:<P'17* 3*BB
M]XH5-7N8^F%\2C3:/I#H_LQ8P4VY)46)A/RAFI9^)MRI?./5&P;'A99-MK=A
M0;%C?<I7Y]DM"/^HI*C56@K+PNR=-B?BR*MH>:K5EDRD;,#&N"$YG&]02D"&
M4. BV751L. "J*OMLLFH?!CE<*5X.3K%,EYVLKIV=N *4E+,QQC<JBMRD;WU
M&R>I)/+3W+V*\_H.NZY,D7PB?;RUWP3^ZG-LPG@0-AJ-)P(L?X\ NGN-]RW?
M^TFXLC4ZRC$9A(W/K<WY3/(\3[6S I5QX&3SWW^_GT1.IE:[DD;@+SF6JU%R
MV(+O3(?#CDE-=J:47K.) (^A9^J58_"X#&.=@9]Q8[8^O/TP;LP, EQV,%\T
MU=*\E=LOVE/B4*;:_8 RU3V?[DC5K-S?";E]4^XMY^4ZI[XL%E%0JTX1PC8=
M*CS%LZ><AZ>7QE<)@MULZ&=I+D^[ES9&QX:"0U0@5+&")V)E@GV98A%O#/W]
M:\*4)C.YHCP?Y!X LE, 2S%/EYVXI'N70<PS,<F#:F4#4<A@59H*A1NC#_RP
M\/06=@30Q>%TG-59GNQN$<R\TYT(2ND+*AM4K?#%_;'?[U7,NE?%= ]FVI07
MU2OW3%HV?E]E0:S@N22^^N>2Y,9WLW,MHP9K/,H,X'TL#L9VCU;Q'-*[\:X/
M7)-KF'[^<G#Q[FQO>POO?<K7'>'/^Z'=W-_]TOS4/#_H0!M:L[L^GUM%#=/.
M^Y/=[2W>S$< H4U[V^_;N_3CMV:NBWKQ9^OS=I/^YV+G6W/[RZ$640AJ$[(Y
M:2S'7"*C(D4A2HV)8P3/GT,2E)I 54HA$DX#=M(D3ES*R?ZT#V;V'%(U^O<Z
M<O3C=UUMFQ'<JA15/IK$J<_'J(@E6#I!$K/1K%+*H8IX 8<O6.C--7K*\7OP
MW#SC(CNEFF2R.)ZY^1QTW5%GDDU_11*=_Q05.GE[R(/G%,N(@C"Y#+!GR EJ
M$%-)I2!\4L*M;29@[_,[I_W)4#<&8RW)C@'@9(59EEXUR*^EC3^FYZ\;],HW
M_?BZP<;?%)4<@&IY^#*O:+SZ82_3Q?+8P'6O+ ])%*_-ED!ALQWWSHH5<R*D
MY0I8+, 3/UQ^1V']E%Z7_/;LF2T6R+B:[L?L$AJ/Y7IC/(8E<9P:O\O!@0'+
MUE.W-.,O_=.H<M8"0:B2ATUY;BO[:N(?*XHG3$C$-22G]%45\S1^]=A;6/BI
MIKEO%?%YQ8-T@[>H<E$/&FVP&E#V95V2EW*#O-CE*:4.'E!L7%]> H3K$ZR5
M632Z*QEIE0<M9\OHQ!R>"\,^J(I/7&XL3I^)J.(*[C3_14*VV9-'8TY;=KV\
M^<W[C?S'I< ,9L)[QS=='DHJG9I7CR7-O*L0C'[,)GSI!2EK%YT7_L8KK2A\
M@U-OS$'$E^<+[];GO"]_V=ZRJ3G]1U%'8;PK.3<J,SWOP'UY!S+C#;2GJN=0
MEHF9Q#=G^"A;66K'Y6YHJYK.ZCRJ/V[%E(O@^5$AI+V\_YFW4WMC%TRE ^OC
MV9^:^8EWK.>S8V2R85NJW:4$W5* KNAI;F@=-K)(V(A9_;"1)T,L*^RN,*&4
M[ZO?97F-.2=1X5.I?JIT.,<%%O%2@P*Q9GXMMHA"K_"<ECP"'E'$6I6'&O+)
MV4HG8,'PL=QOA?_/-]@;5&Q\QQ4UZU^GJW/VPD.:C/X8L*X=]]*L\;AS&1+R
MVWGUXXLV(R_\H;?!2NIS,2EE$#>*(V.,RG50([->1V+YK%FX(OJR7_C'<_[4
MO**6Q/AR%>N5IP-+W;@4[^Q9 @A"8]D=7U'&W%Z)!ZC\1U7RJ_&C8[@#G:K8
M^G@5R+L!*._VV]-!?#7^\#IO:;?M^:M6M^AD<=/KJYZ>C(9?LR,95O5J62A6
MB/+G2Z#<P"58#OOP7QB_N?IYH_CI7\,P_YLP&U3?_#/>(#?^]KW'$K(AB;G7
M8[__FV!U8R6EMWKLOPIA* 4"9"[+;E'19[(ZA^R!?X4;I)#9\?,FEQ(Q=RT]
M_9:O?CW%4C(/COU9(2WE<SFPH'_DE"Q$_R!7$7M[)3]A/B\]T=EEC,CEI95.
M9XV':QN%5=<8]^P)C%9>1*\,S0+=?!G#1>KANLMPX>L4;\:@8N5:^2BZ>(OG
M/+=7OBS\_V6G.SZ5./CU+JCOK/]RU.^-N@%5#?0^QI2^IVCMF.9XV3*[;'Y$
MA(LN[T]SW5>WP:<?=?4V<OABGW%G.4K%_\W*4:/XFVY0L8HR-78ZSDK373J)
M&RNK,O^U4+]>SWKG?GZ'[G"F,Q+,M;5<,NRXH]Y0P9.V1&M!!#;\SF4:WE=1
MZT_EE/W]/"T'G_X<?-[OD=WMK8O=3P?B\TG[9._31[S[Q_LO\"Z\M_];^_,?
M3=[LO,U%]/#!^)[__'GL.J&]=_(1-[>;!.[K['UJBL_[[_#G/]ZW<K[?YA__
M0!N.S@_VWYWO;;]O_>?BX[#Y 7_[:__M</?DB.V>'!RF1*6QBB/*943<QH@L
M=02I%%WP7')C4E&66>F;$O<N(O1CQ+J#\-\)<6=>.8O:->X\>=QA7@2BM-:,
M!^YYU (S;11\BDX+2^Y<'*3&G0?!G?.KN".XMY$GCQ@."7$5!-)!8>25#P+;
MP'G$@#MD'>:KQIT:=U8.=PR-WG*7H^4PEPYK)9*S@8*\DL2<N',YFAIW'@)W
M=F?X3L0LV1 =LD02Q#FWR-E($8O*J8@M3LSGW/CKE*@5PITE>1F>@G78CS?Z
M&NC=.GPM<CX]I+&<*)F4!IQAW% %1A8QB8I('?-<J=JR6@&D.9BSK%0*5G!%
MD0G4(#") 7.\Q<@4T0?2L!#LVB9;UW2^1N,=@>8[ROY0!.>V[K"7J;*1 C>
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MG;:5P,=9$Q],>8U3"BA:8A"WQ".M24(*.V9\U,0*X(_$K'.ZK+._/Q,?"\_
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M>D=LG;&5$PL\6,:02-E6QDP@YZE!3%)E#4P\UFEM4ZN%;>4E*EB-J36FKL!
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MC\U$0^OK^-G5(U"^_A6I0F?'7Q827,QX\>16-X"M] J9HN6/=Q2PU^GT\JM
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M!!-TR9)+6!_TAZ\^^.,81NVXE][T<FZL00QEO$:1R*<#6K.?=6\?WO=;NP@
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MV#-%Y#H)B%9TRQ  _RN8VE[1%["^L)CU!NRRXB+-Y#;R1T^46*#W?SYT*0N
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M]3W'HM1C8>@ZL9F$KFM%(?5]1>/P&\%WL34>AQFE"7Q?4$H=QPL]:OG,LN.
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M$![YD6E3G@2Z)M+F8GBAL4P:PXO"\%&[KADS8Q 5B<U";*/"0)6P7(^X2<B
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M^J?42S36%XCUMM/!<9CO6I3X >>$ FV3R#7AK/?=Q!6VS;@M0"6Q'AVRM"S
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MW*I_U9K)"J4P%31)7%]0BH[TT*.6SRP[#KA)HR125 ._$7P7BU)1QTTX]6G
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MUOQMN0.[ROBSGPD<C[,M+R*Z5YW\5L!&Q"NK1X"%DBN'GP_FP8![I;U;XUK
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M*[="95R=]J-5FU10./K=?D=Y!S'S(^]V0=4?Z"CHA&F::=.Z.H/\9-C14-S
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M0PO=8)A#?^N#SWWEGAK,B#)@IS*JMMK.N)GSH431FS"]#Q_1@,*E"P(9<,=
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MME14YD*&(VK([W"EZMH\!]VE]D'L&%]JGQI@.%691_BS@Z^-NU:&6958!4?
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M5H@;QS-?,=C (1_L_RO<_AM$31M'-N$FR3Y4T\QSH!G'?M7-+PDV<(,='-R
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M/'IBJYQK, 95I\GXWV4M^JH V!G3.I3'$K!GED?.)X75\ S+_\_VKVVL<^W
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MS^_*$*_F1>X2K]"GG_X?4$L#!!0    ( ,>"35;H6ITN^#0  ,P? @ 4
M;6]H+3(P,C(Q,C,Q7V-A;"YX;6SE?5ES&TF2YGO_"FWMZWI7W$?;=*^I5$=K
MK:HDDU33LT^P.#Q(3(& )@'JF%^_'@!X@R2.2#"I[38K42"4^47X%Q[N'A[N
M__:_OYQ-7GS";CZ>3?_^'?\K^^X%3M,LCZ<G?__NCP\_@_ON?__C+W_YM_\!
M\!\_O/OUQ8^S='Z&T\6+5QV&!>87G\>+TQ?_RCC_\T7I9F<O_C7K_AQ_"@#_
M6/ZC5[./7[OQR>GBA6!"WOYM][=@(AI$#\YA!B5T@AB8@8RA)*N2,IS_KY._
M,6U<L9Z#8QQ!\1(@,NE!>R>X\5$D^M?UH9/Q],^_U?_$,,<7-+CI?/G7OW]W
MNEA\_-OWWW_^_/FO7V(W^>NL._E>,":_O_CV=^NO?[GS_<]R^6WNO?]^^=O+
MK\['F[Y(C^7?_\=OO[Y/IW@68#R=+\(TU1?,QW^;+S_\=9;"8CGGC^)Z<>\W
MZM_@XFM0/P(N0/*_?IGG[_[QEQ<O5M/1S2;X#LN+^N<?[U[?>.79C+X23C%,
M%J<I=/C7-#O[OG[Q^U>SZ9Q^F:N4WR_HOU7L\UEY3?0XJV-9/GOQ]2/^_;OY
M^.SCY/*STP[+W[\[FYT2)"&X6 'ZGX\\\/LKP"E,TOED.3^_TM_7CZVH>L".
M7Q8XS;B:L L$DUFZ\:5)%=>LN_B7DQ!QLOQT=#Z'DQ ^CE:/_G4VG_],RX
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MM3=UJ0@.G? ,4DFUZ249<CYS#=)AX4FAR\T/#QX%M0UK_#?,FL,EU8MU="U
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MA'I]03$EHN:1^]2Z*M#.7:7=MT66_070HPI:]U:ZN-R_L<?2R&=G"[>"6$J
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MG#E@/@N!7@9O^UAECP(;4F[_TS&KO0R??I=^>;;,8UKF_?XR^X3==%E<O68
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M'Q44G&-Q$'D.I.^RA%A(AJDX(9"7XGWK/,U6V(>T/_;#RCNI4$\A]78W-@Y
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M\3%R95HG_1Z"=TA[^8!XV42\1R7D&]KANJLK/?.1TR)&+*4VG@J$U-6 F<K
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MRZRC7F>G44X2,7=U'E:5SH@'YHBJ9."D:,EO+QR<2>2\\T"V;Q$ZF=;>R T
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MQ$&7X(*FO[:GS68D0THP;LJ.!A._Y7'V^O/ZGQCF^(^__#]02P,$%     @
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M;!C( "R59+Q%EYUH70GE+HJC(4$C00^0*K/^CD+=/&G2MVXKO!I!')W62H&
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MN=E)8\$QJR(PC=DS  -,& ^@7:;OMC:;'@7U;5M,;74VP+',/0 KO.5=X X
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M_4+;(LE6Y8ZEHH,LLCAM!B/073B'GGW52Y$=LJ\VT<*0F>LWH,E+:(:;(K(
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M8# :YJ5,+$N [(0LQK4^9'@$TM&:]2U5,4!BT-O)="'FZP./->5:+DG=!>I
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M>MJG#YKH=Z;TG>J[8</.\Y$>F]YR6F^FM1!4O4:00%E'\%&YS+2SM>V<D\R
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M/ %KH_,I,#2%; O+D7DG/9.84LS9&6=;Y^YT@+6'7E!M.7*G75UC50Q@YGV
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M^N<T#$!W +H2-_;)(Z(H5H+5ACL(45HMK(Y1R:3BR?I';O=JUV<2*^;3\QI
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M#8^Q6&-#\ZWS0&M[-:_ 29-FP]NQ=SBJ_T)7^\*H),U1!JQ]07C-0LO@8LC
M@T">;1;2MVZT=ZBU_7@[3H$T&]Z.G:-/71;ZR]]?<R37\5_3"_J8.BES?2-
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M@!-D4 :IM.91!X?;=#K;[FDO4LV=A/E0W::-HS3"DA6CM4 (W)!G4%M_<:N
M*TM. SD&V'SFV@M6[Q[">ZA"NZ\*?QMCH!/FBEO+@<N?IQ?TV?-J(2^^WRQ5
ML%1;KCB(FM>XH_757U.T<G1%NZ!C:CU_:EML9QBBZZ*6#D['&L[[]P7:.B65
M3< T.4'*2 O.6!*$E"XE1OQN?DG_.)K#4Z2/!A^GR3[B[Q'570U FG_ [S6J
M4'WE&&>7.3V$/.(H4ZDYS%:G"I 7<#P56"8Z.#)91/,>MP/@'94Z>VGU_H'3
M224=V+,!D?!91R,SZ%1<W4T1?$R&OECNM)%,XE;EXGMM)V?#A3T%W.,DF4X^
MU8&Q/^>PJ.TTKE"IH*V7)D *NK:5%1Y0" LLY2C(F;'2M,X#V8SD7$^0_<7>
M@0SK-[+78OB^!H];J5 X!L7F7#O'$?4C3^ \FN*TSJ;YE/%G()TI/5HJHL.U
MYM(77A/$&K+DG:H)PK5!?*E=P\GP+D%!2HYYGH)"USJ"^SB:,V5'(_%WN(=<
M S6*TAM-IR$8)\G#YK2-!<\0C,C%*Y]";M[2:.WQ9ZKZ707<H\W5XRNL8V$P
ML@#95C.V> ;>!22+B;8GF6*0N76OB5.ZIC@($QJ)O\/UY-OIER_3R1+?,J7Q
M_>5BOL!)C<N-'#)G!-DV0L502XD0,&4ZQV3,WGF.S+8.A#X!YQ@W6&VT]J#9
M:QN1=_ I/\RNPB:WZ$9$\I "TR"BQSJTPH,33H'6(KA22N2ZM1VY <;9:']?
M$7?P)-ZDM)0E7GS <7HW>8M?QPN\6./IJ#!%?G2JD#SQTO-Z?Q\%1)%IM<P7
MV]R9>![5V7"BL0(Z.!%KZ3U+@[8.XIWES[51P[=\VQ[TC[QX7_["OT<ZH8W&
M./"Q!GTTUT!,9L"#$I;.2H/-6_X/A'@^Y.FHF@Y>Q\=:-SK)Z1><3>C$F]])
M'"OC.*ZIK:X@9[X>@B0-QC,YS-H ERH;E)YYT_H:\WE49\.7Q@HXB+,RLLX9
M&UT&C)+\Y5@GG?E8P',9K<V!_FD=67V(XFPHL*> .[@ASWEA(Z&SMR4;8/0+
M*$N_(QIR8($C!A>R8!U#&QLQG:FOVE05#;,Q:AGX;?.WIPK"K^;>:I>9,:56
M1"@RJD.&4,-ST3M#KXL(WFWEO3[3,&  I-X=N0]3*-]3#Z?5BIO.R,EB]2+4
MAF*<\Q@+-R!"'2[GR7IRKD1@N0YBB(4%V[8'[]WG'[KA8E<];^S-NX>\N_5A
MOL5TU:IG&U1=VG#?1W+,1MS[:.H9U>\AYL.1P 04.HI([I,UH*2.@-P8L%K&
MI- S4;:*N)^8\K=JR-U?]T.DVUCG'[!&YJH+C9/OU[.5,>K@,4#)SA,F5@#K
MD%+MO.!HDK-AJ[N,9Y2]X='':KF\GT:F[<3Y:.^<4VQ0=GN+M_:_':UKV9-H
M3J>5V?9"N]_?C!7R<0V:7'*=)Q-2B"QQAYPS0[_;M[_9D\ .U?2,!VU+0@,Q
M)%O?.TM./GET2*\=2D4.>VKAPQRTZ=G:K39M#^]GRT>E92#D0Y[]^9G8-1*2
M296$)GLD"%#.A-I7Q8'TF2G'#&T:K?.BMX!URBW/AC#EB8!D$XUTZ'BV!G&)
M9_[F<O%Y.AO_3TZC8 *+ADD0M"'4YID:?!265)S1)N.,;WXW^ 2<5T"2O330
M94CM/6CK$?58O.39*"A6<%"Y)MXHZ<!YI;75I7#6>H[&4WA>#3UVU4&'^/;=
MD/OC6QPZIBPOD#@6VN*05FZR!LR<Y50OPD7K1*CMD)TK9SKHI4\KI#64#_8^
MQ;@L1&E@@;PBY84#S^ET9,ISS,PP9ULGWS^-Z'6P92\]= AK;T+W;CZ_)&1>
M.Q$$XZ"-=K4W'.U^F1S>HE@P,A/>(@[ D!6:U\2.'>3?I9720V3KAV.)WB<>
M,QA5;#T<%82:WJ,**\F3:>UT:U_G&4BOB2.[:J)A#'QHH(5K(4VH(N!:U::C
MNK:N,."8-M$9D[C?:ESV.0<V=Z%)3SV<=&!3.V69K/.13.6]4!9<2 *TS"(4
M$8MT6W4"/=/ YB ];Q/8'"+OP\6TMD'UV@*;@S2U77!K%S$?,+J=A4[9>(@H
M:YJQ]N"29W5R&L.@C+!LJSJP$U/^+H'-#KH?(MT#!#:54DZ80%:.K+.X:@,#
M+YD%6W@,+ELE^%:6YPL.; [2R#.!S2'B//7 YNT9."U7\Y-)B(<,9CZ-X*@!
MS '"N1>TY%9%9GCB5@0BF_-$%1-BDB&$**/=(6CY-)A#!2JE,BD:3_LDJ^W*
MBS#@>9' E#),>\.+>G'3F5:U$S</N&UHQFU611G@R=1IPIF16Y$UL*A=L9F%
MJ%LWSG\$RBD[ZD,8\;"]Y_Z2[Q"$_)B_Y<EE7FMMQX6J59D@#*<=/Q,RCUF"
ML:+(PLD%W2XC=%"ARET,AT]";Z*<!S4I>TBV0T3QW61^.:NY(&\^Y4G\_CM.
M\--RM;_F/"):6^_)2(BLMBGF*4# 6&JN/09OC D=WO_'\1R> ?MIZ\&[WDC4
M76BPR+,\K_W/?QY_&]/N=]5/]NJ@K07;EJ#PVMU28VT"I!TX&3-H(84MT8KL
M6V\!SZ-Z\91H*O8N\W96RQV%:+2UW('WM5(NF$2_8PFR-SJ6& QCO4Z %Z[D
MG438HSW2-:>NIJW<KLZAIC-+1& LD!FC-0-7(TC%6*U$QF2;=W-]%,QY'/-M
M9-WA??Y'GA"RB]KN,7TAT594B_&W?(5S9%+14:L VF$F8Q9#';:C(&8A4I#9
M1-4ZR/\,I,,3HI'RIOTDW\$">&J621!9.ITM.&88;5S,0Y#H@8!%1.NE5.V;
M]9_0Y)D^A&@E\1Y]4FHW\G=?ON)X5K?$MY]Q]HD.L'JSA](:$%'1CACK*('L
M)>B<K<]<*]9G_.X#).="@09R[I$'-KT8Q^^K4NB?:-<JXT4MD'Y[@>,O\W>K
MIG[I?R\O&-\NT]:\8>BU 1.%J?60MG9\C. )>/!)!)>:C\<;!O%<^-)3,QU2
MQ=Y.YTM\US(8!3*A-?.:SKC:D24RL]K@I"^LSL6BW:U]BO)=#.="A;UDVR'Y
MZV:5MXUX1H*A5K6I&X9E/BO7Y+LF@H3:!A89:]^8=P.,,_,H=I1OES%BJ]N+
M:PN6R<BCMA*4%/1%)4]PG(3$L\VA",]TAW%RZQ#.0]7[R+7#+K[LM?7'=#*]
MR\!K=$5[C<%9\*7&0!2MU+%@@ Q5Q1CM0U*W'@?W-*+S($%#J??8[2NZFZ-'
MVL"SY![J<ND<<Y'.,3J$T,:LI#'%E.;W1^L SDCC.\FT88IN'3=V>\+\E,MT
MEF\FRRW[)*UZ([V;K 9;UKOJLCZ-<)1YSB+3FBVKW5%$X8#.,A#><:^X0"'O
MG0(;1[KM!>)E$^*P.N@P1NP&[!6;KUR5D67T3R)/1%N>:--R-?VHCH]6BBN?
MO5.R?0AI(Y2739"6<GZH?K?/WG'#R$K=7TD*;Z<3.KTNZ0"[S=E947I%XM_S
MXO,TK8TY_>5O$@Q!&4]P]GV985$'"="GD+0OEN?@RCH:H>,AH$.P]7I,*5;[
ML9 +5933]#U%VV7:8J,Y'.*73;H3UNY##OLV6]CU,M<WUYOVLE8RFY2T4,)R
MVDD=]^B56T[X1K+4D^>M&S4^C^IE<ZR3]#>$2_9.D;KS*HRBMT'4D9V"&PTJ
MR Q>* XY&3IM@W6QM*ZHO@/@/-2^NTPW:'BO)/(A53/"ZNPR*U#;@('RR4"H
M_I@R&(/VS$?=(B/T15>I[9(CV5,/)UVE%K7BR+F&5#1)+)(3Z$H,D)ES)5DE
MY7:-/,ZT2FV0GK>I4ALB[\,5*&V#ZK55J0W2U':52KN(^7 D8"HZYSF]/U+7
MP6G!0N!.@,=8-%G"W*:M;,P34_XN56H==#]$N@>H4D/A;1:^GHI.@LK. NHZ
M:]-QX;0V)=ISKU(;I)%GJM2&B/,E5:EM&'MRK'*U)Z"<3-W:MN*Z5\"F:QVC
ME,'*Q)4.$5'8&%2P2MFH"]^S@.T)5(>J9*-%H- R@2SD52DM$OB8/134@2PI
MY6-I5 %]N$JVNQZDC*BU7/8S2-7K</3R<YW!%+1(GD?AL75<ZDA>>5_M/^VG
M#Y%RAUJUFT6^+X]-A;JYG/ 87)T8 CY'10Z#UN =N:&\&.&#YES&UK'J ?#.
ME2Z]--0A"_HQ?/^<S.A@JNW7_O?THK90^@>)M[+__>3/'"]G*S-U-I[3MWZF
M/TX^?<BS\32M[L+K?66PQ2A6&)"=2EYKB!%<,!DPN:R<]]REUJEOW19SC/%0
MG2BT*09_=/V_ &+7)3'.DHF2@7&(H(2HX]Z]HMT_TS^UJ41J?>G=81D_R-Q+
MYQT*$[:9^_BAUE&0_A:+V3A<+NJ=X5_3E8,X(KQ,J)#!FD!OH=.*!*LLI)2M
MUE8DQKLDJ^T.^?71LX<N.V2_;D!^$YPL3)H<@P%GI0!E'0>'(8"PRCC)-:<M
MOWF>^Z-PSI="K730,&MV<,\]Q3D=_AJBR@64*@9";?Q<8K'*UEBGV^H0/>?H
MX2[.1T\]G'3T, B>2F$(Z&I[:&4-^'J9FF4,*8;BLGC-P_L&Z7F;Z.$0>1\N
M<+0-JM<6/1RDJ>TB2+N(^7 D<!BED,*#5IDL),)$/J?DD)AS46MO1-BJ'_N)
M*7^7Z&$'W0^1[@&BAX[6(<DY V3+C<U+P.01;!$8/<.(OH6R3SEZ.$@CST0/
MAXCS144/<?[YUXOI?X[6XO(!@-.)%#XIFGOQP9AU8K2%,&^-2AF=C\XR7113
MB3N7]XT/WL=RJ*B@L$C,-A$,K0]4X0$02R%;NW O+&<*&YF/AXL*KKFC-W*]
M\3^3E)J.A@11*@>**U;'J9#;:#!SZQ-IMG53BZ?PG'(0: @WG@@"[:>##B'$
M/_*B8OHPF]8>;.FG[_\DB;R;W)1<OXF+\;>5+7&-.*N26)0(TH4ZZ"L)<%QA
MG<GC,2C44FZ5]#LLM#P0Y5$O?O;4\L.0<T\5=8BX;(]X9&R(NMZG<YUY[?<2
MP5MR>X6R(D>=<VY>2;(]NL.3J+>N=Z;6($4=CE*K\JK-@A':>J.E!9:5(L12
MDT&K/'TQ*7 ;H^J1 C,0Y?GO4ZU4U&-F)'Y?78]-W\3_OAS/\OH\Z%4QWKO)
MG>IB$8.3LB!HHS2];-$"VBH?&7A@*F-H7NPT&.3)[%K--'^_%517M778O$@P
M,>>TK.B[;G8[_YAC'G_+:50,.>XR,)!9UO0(YL!GG\G=+CI&EA+WK5L%/0GH
M_/G33!V'V)-^Q]F_\S+\>YNA,(I"6D^;,F T 926 E"9NGQK2G::Q]R\[]PV
MP,Z?.\W5TV6:[2W!_\2+_&:2?L=%!??]?=D(6$1/)S^1ON0:,8YDYSGO2#A<
M9J&2\2ZU]ND&@SQ_;G556X]YN/=?!EH!N0Z+[Q\N<+*X:M;R]<LR8T4K:S X
M,BP+O1$8$4*B$[@PY[1E+EK6.OMH>W3GSZP^BNHQ2/<^TI\NY^-)GL_S_!^S
MFG+O6,H^"0X:LZC-,20=SV@(*9,LA$PO0>M.>\]A>GWTV4<IC3MVO?V,DT]Y
M_F[RYLOTDC#^?)D)YB31KW4??5/*^&),'N]\))/*/C $%J,GP\[1\6R\!VNB
MY9*K1,[ ,^&?00\\6UKT$WN'AES7W/UU.EL_7Y>Y>1L$,W*":8&<N&MK(%5C
M!/0BD?G/K/+":L9;#_X9"/%L>74(E37L^35<.B-;;#"FMNI9=FUPA==L/D=2
MX4ZCPM2^8>CVZ,Z>5YT4U:$%UR-(KR*5&P6CO4G*DMV60RJ@BLSD<K((V94@
M4-B"V+K(:CC*\[_M;J6B'K<"M]OJQ_SU<A8_XWR9-_KERW3RYV(:_ST*S"O-
M0H2"A$L%9FI3L0R&AZ"TMHYVU'Z'WR.H3F9?:J;;Q\^[%HII>(&]M/1N8?S7
M>/'Y<[Y(?TW_S(O%1?[ER]>+Z?=<B_S>AXOQIU43Q%$Q6BBT=9R/+Q5L@%"T
M(S\2M8G,(^=Q&T-[Z(//EBC]U=#O(IM(O>J4^6F99SB9DZ!6W3)_&V,@)V'Q
M?8.X1D&H$'V-+T>M0:7(:Q_7!$&45)((4F(G,WPWP&?+O<.KL_.%^+OY_+*.
M(GU?_LR3\73VVW3RZ:\\^_)S#HM14"YKFR(D$6N:EZ!WQ@L#7'G-#;KJOG:\
M!W\*V_DSK(>2.MQZTQE]=6!?HUNB*B9Z%#%6.Y(H;@VADE&"+X4G\B"D2>VG
MA&Y"<O9$::" #C?7ZZBNZ?I;O24E2VZ6TW@Q,B&45.>8B#KC6"T+/[&>RHA1
MD]\:??,^&,^">E5DV5\M#2^O-VU[=X'97(03=$K*4&L_T7H(6D;PS-%9*H4V
MN?7LR4?!G#U/VJBA[P7VNG?X7SBK%13S4;1%^>5L;.:)OMXH\%9A/1R]E+QD
M9@[DLU]#.G^N-%1)XR$42S'@.!&TE7-X=?<UG7S+LUI#^'Y9V3"*+,1L5*R5
M7718,L< T18H/@=:>TYXO[OJ9A]]N\>=+2-ZB;S#G?+Z!K?"MAB'B[PTG:)B
MI6BRFC"Z1/83K^Y9K/>BA@5C'2NY>7;&XW#.EBVM5=%CN,.ZO70?F\HYY.0,
M&%'#_(EK\+R.9M9%6J2MK?C6Q1I/P#E[FK121<L)$9LHO'8<+F.TFRZ HLW*
M%I=!U=1:);D!]"$ '8:)?J/H;UJ7&@Z$>/9TZJFR#13;^P)Y>_&06$2]4S20
MLE>U#VL Y[(')RQMF]J$K%NS:WMT9T^L3HK:P*G].Y<1SOI?S7?\AA?U%?B8
M203CN,BI?N/-)-W]B[6?7+4"?#>)LTSV_L]Y]2O]^>(R+6=<QV52U$=<Y%]*
MR215*WS.F0P]&76N?=HR!%Y(JD$+IVF?=KA58XH!O#SL"L\HH'_"U.@QGWZ?
MU8Z,*=PA&:FZSN%5I0CPGIR:[+()CA; 7/,F?_L _D'3'137X8Y\/_ :B[4V
MDKD;ZO2CY#30RZ)K,;(1W%OE[B?PGA+KMI?6T+YN$C$K5(K,,U>K&Y&V$N4#
M9.^-=EE[SK8*6IYS'\5=^G?TU,-)]U%<3IRIQF 2-M)"C*07S2FPO(X?"X8E
MO]65\IGV41RDYVWZ* Z1]^%:Z&V#ZK7U41RDJ>UZZ>TBYL.10/#DC>$66*@3
M3J(B@R$Q!@&S".076NZWRL,Z,>7OTD>Q@^Z'2/< ?12-XR)4[YRQ2 86\@+(
M@JZURUPSC8*9K3H1O. ^BH,T\DP?Q2'B/-$^BG],%V3=3I_\^0-T4QP"XQ@]
M%7<6T[W.BL+01D)FA$U&*13%1\&L\V1G\&3%D,EK0Q#M&S"ZJ.\1O0"+[W_1
MH^?DX:XD?F5Z!XO9,3*74L1J+BE?0Q4:R)5+12DEN&W=,^<Y3/L'R;[ER:K2
M<>U1]8*3)2=DBAY8SK7S@Q& H5AP*9LH,S)?6M_X/0KF\+<>3;GP,!S60N@]
MQK#=^ Z/K'_^T_<[WUEZ$2DY3)(35)8L@29+(CBL&=(,C=+:R](Z&W GH+U]
M^8-PI[^*3MJA-U)Y;ABYJ++VHZE%^@Z5A>*%-)IQ3G(](X?^@%K?QKT?(OW#
M>7;;H'IM[OT@36WGXNTBYL.1('/&0H@&8JKQ6"\RN3NB5CQS(73"8MUK&;+>
M0?=#I'L ]SZ('*6R#@27R[343"MD&FKRN\Z8C-]N:.$+=N\':>09]WZ(.%N[
M]P^LOZ5L<DY?_O]?JDLYKXEBOTPNO]P4Y\T76WCH RS,^L#YK>+KHX>YW@V6
M<.,][V>_OYG/\^*V1T%;F_O>A[<8 KGZR#^FDW@Y6\Y);(MX\S,.[DMNULK&
M28J/">31/?61M^[JK^N7@//\O_Z__P=02P,$%     @ QX)-5M:1NZ_?2
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MK'O05&GQ4J)^E(@ALE[4P@<\@SF12)S&7_#L/-2+''XW6V!W^9@.>JU@V8V
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M/*=RI/Y0*\)*\J=\"0T(<R'#:4"X,\E@Y5!WB'HO<;[=)/ZTX_:;CBG/F:W
MEUW0O;$^BW*82T$X&$] 708=B)55\TOFPYO]N54#OGLW/BW<8C1L&9>*.F=S
MIT,^R^G%3WV!*:LV&E#^.VW&!5IN&3=R>R8@Y4Z?[XIOM,M]%6,?A^^HQW(9
M94P_5)(!!-:-[T5CJ.3OV1E4JGJ47X&$S+[AL-9Y9'Z*Z-/5B D7I0\,SOK%
M"H]2^4Z^,(AIAP*?<AA1)IA0'0&7*DE)$+E0)'6WW_,"Y$U02MR%,D<GYFR[
ML:XG95<]-GWQ39O''!(,[$Z%96_67\1@E_\>&7";Z_(#_VQ6KZAC6 BZ&<U*
MG7(72?"07/&<NO/PX)2ACDY:$JHT==\M:GY:OB;P?KIJJ@A_=MOQSM+XL&.;
MQXJ6+7SE6K.6 P\BN"Z2%6Z>_?0NJ4X3E@B3/8W)UU&DME;G%N=ZYX-B776#
MB_3B9?RV/J^US[A(G$1(CN3+](K?:N@R9'-!5VZHEFQ C(FZ(2$+ O*=@Q8%
M[VEY2A8&OAOM&:-ZMSR\E,Q;D*W!ZU5MG+<\2KZT].Q9HIO0$]O)ZX/V-]?$
MO3.Z-,_7,_Y*D-]CF:/#3^]+,B3#)>9.QP,GSMJ8.O:O0'.PG4RMXRQDO0S:
MU',5R@TFNWCMC;5Z%&5V1 S%[[^!!1,V0G\J/]'K%]@1^:PL_$;.=VI@[4](
M1>,EB<>E'PG"N:X_.Q2[>GN(*_>SHN0;8-=U3E J:Q6.)A+X;HX<UXU9'4%B
MVP@&/)/?Z6AE" $Y$6OP.R'3T&U!/)+RY <-Z,O&)*WMBE>;6%NK4]R0JMZZ
M%P=_GN>)*JU&!AE3SY[.BMI%I?PM_G6^4-Z$2-OK?7639*OYD#Z@/T%LL4,K
M-$@Z0!ZQ/-- %#X?@6Q4S;E[R,YSI11>CA9;K7S=^W=H]O\VM#>L=*J_'-R:
M>P2\[=5ZR!BS6?4VY$/OW+T\4@"RW:Z!!NPU+M& JW'8P*;Q1]Z_24;P-C)J
M(--F'C3)*BC(O9 R Z4:8*[]#CJ=A7U%'J+/#9!?-1U+F[] /!RF 2\5_RBY
M>HO=LY$77X_WKF,I4^I!$5DWW7]7[T''HRQ?+U2%BW -_NG&A89=1EYU?RUA
MHGINY]8&\OLA%[3%E#W5[*/DML&AP3@Z:W=<VCK;^=FQ*.7N-H#AUV#!2W!O
M_AH=S<.@W*H53Q-<#YGWFA_R<NV%=C+$_2XY&%W2VUT!&1<4@FNM%CC][1!;
M0YBEVL<QXAU2L+T"&L 1<MP-R88]$8!L.=1,&O)]WKZY<+?E>JAICQATLW3S
M]GHK-HH2"7M$\II0;T"*7FB-A54H^*;I#A1#@6L! P;2>I=FU=^:?0P>=3NP
M/&Q=,,)^+ZN),'*O"105R4PRK/7,B;@%N7I,"I\Q1(W"2H(+AN"'V6!(2Y#T
M=$A2P82>/R.T5B#BV;?USJ<YSXY'+;OOH*FL*@00OCS1UGC7<F%_1'//6"AP
MC5W]\+H49?3!<0G3#R<VX-G\(F5+O9-I"[WDT[!Q&F S]/C/=NTUND+->883
M3SHN1/D;:FN5<]730_KI+7B$,5]K?G?,UX6GO.>$'\:@S-_JS;JO>TW6S"?G
MD<RH0\F2#/A,=:*H=E^?;[LYUF!+HO&747I3 &O-Y[%K_JIH>O+F!Y7R$#P$
MTR8(9$5.I\5Y3OAQZOU0X^;^7S\'NNN1?.4UJ)&P^-=TN)T<A94@'T..WNBI
ME%_&>(CO3(]8F@_6G*3ZD3S@+Y"E$=^U+I%N(LYA'TV\;%8SJY'LDBX0@]9?
MPLQT,DMMWZ:R?2&L+K7"!8JP8M;VW_K(Y[ZH+KK,G!T=./XXO:TK-DDO,Y 9
MX8/?:K#"\6H%S\VPK<P02(4S#0_X'$]PQ EY$T4ZB$?+=90#4KU$$?:$SW5:
M$3:J"H^VU[QW ]^_T :8 &WFYT@R'[R)L#93L?0J)^E:6]Z5P.?EN^U5\?Q4
MCE4D&]LXM!3+C/=,H8]2K11QP5JG-]=5+7Y\4F_&X;2(;(UDSKYTZE16%$<C
MUI2^]9(0XA7@!Y+Z:NKBDZ,C9.F9B>32T)W 2^Q/Z6G1MVV'XF![V$CWM1C;
MQQIMC3"Q,?O8D7U;B5W>N$N657[:P;&,L$^=%/2_,HO;#Q!#TFK(=4OA]"X,
M,%D@G5E\^WNQ:D)TZ@WQEB,-J+0 &^#T&A&O5Q=DA(Q$<N^:]2Q.K3S;#T>^
M]KW-SX*Q-WEN9E^ITTG!(1?[=*21HSG00PO.$"&K3=0&B0;(A!*DJ'7T"F4@
MWQU?':KG2,1065/^]L]Y'9)P]/XO\JM1!_#_I)/U 5P5V:"'6^P..4$#?FG2
M !.UBMTB!-W!F25I0.)YD+[\3[8H%R?ZV'T(1W%>N-F/L.U', AL4XH&Y(E]
M)5_!3&Z!LA#R!U13+RF2!JRTKH;E!,O#>Y>:O8ZM26I1LLGN&<N"O&Y!+4N1
M%:>JREXS_W9*MY3+_M'XD8LB?\B(:86.%Z]J;H%G!)*:97UO!^19QG.=3Y)_
MJK=R.0N1)NW%@1*/[&]_52#%(2"5+S6"[:"$(CTZL$QK9J!\J[JI4M/&5:^I
M7^TV:?H?<+%ZY&W'_2%?V8"E)UY(NO7#0QK=YT$EZFF$QF"2:GO2IFJ/Y)0W
M\3>CS/PIZ/801[+Y_B'JO02]PG@G\(,B,VG?%.PAT%->\LNN.TS_]YN74E]$
M.([-AIWO,88GP?&FL$DTE5LL6BD"QNW'K:6B<A!TH\2?;KDW/A\9F%[MOD)7
MMVWR]7:&F Y?OG;_9?Q$F&@)Z$IZY.J&KDR)*Y)M[N\INOHS^[A _,G'(<91
ME&Y,"VRBGI%N[*.C5T18FC4\]2AE59B)SJ/$*_=.D9P03G0H$2)I@07-Y^P#
M19OQ-.#1BI.)V,;M(Y%=F]%8TYQ'=96XT[C9PAD1W-PI\$,F6:/D^Y3CW)C.
M."(J0#WQM-RQ/?W*>'J1FAHJM3 E-*<4Z;<5CCT%AKJZXYHFF#>*DA:GFDR_
MGY',M+Z1-_UPK]C*:*BX_*[AH%G)IR*,AXS!;*I*1)SN_<ZF7]R0.7@%#0"0
M3@6<$*+2Z[GT$J_%NV"B4?*"Y:.;6O[^IX7/0Z>C]PUA:Y&8%B2/B_JT .%H
M7M;JDS0/(^/JY)^K?!UQUK^R,;.=>G-77.FE07WOFQ&<")8;O-WZK.;R<*%4
MJDO?HNY%L4<H*N-)>FE?[V[:!N-$:!-$IW]J/^WXG=IZ6S5IHZB[LNI9 D]8
M7R_?V?B$<UPC(HPLJG@4F5=I06BR'"I 5L:B5:S;53^IVI3>-'WUB27#:CN-
ML;;0?=<V3.TBDI4LAA]]I?IG]$$<#;@S&G.#>5BUSG#!['N45$R;V,V-WV?J
MVXTS%F1E:J).9URA\S##?]*8;HL("IW+ZC@-E2OS8#KD>XGJK#6:9]E0\,.W
M@G;@R_K4HJ^: E$KSK&S*911<;XX[R'_(W6=95K7YJ;46X*T?R85C+<@\WX5
M=QS_\!2223R^?6R1)_XNO[.),F7=$Z4IH2=@FWB8>\]@M_\"Q1.S'R+[$XV?
M2A6BL!VB*#0@#@5Z]K!3PX/UJ#2@#:Z.< '=91O1D4*'//&?RQF<RSX<UBI\
MRB&%L:']5)NLQJXI- Q%?;1$]: C'2X6:#4.)[&5&9H_"UD/0J!*<7,U%Y0.
M!?:@]% BX;4,K\Q[L:=NO34[?.%I4(=J=8<PV=&AC7J "<__FGP[W*U#=4<E
MK_5#K<2OQ+THRMF0W #3-E&6N$+CZ= "V]6W,5XDK1>ESAE.I,[@2($Z^+M#
M2*2J$OOJVU4-X]U#OUW9,]HU20\V-K6OS(Y.P\N0;5Z@7;4X,>A]')1G9?6S
MMW#CKQL!O/D;O1PLP.P^$"#\J]3:FJ2OV4;06QZ'" ST?#VK&K!]Y_FSD$_H
ME/E I0TZZYWP8J$!H^QH"IO&P3UL/J46MJA YX?#.1\:D*D'EQ\=<$)OOCV@
M/B:71=& 11_X;QJ0DT%'N"&=FW^Y9G=K/(UJE$>/[&NUZ$,9PSW,9!/UZC2$
M!A0+P0[Y_19Q9>KD%%-6^B"!L-V;26OPJM?D\%HH#;!71.Z>7FLLH@%2<O Y
MY)=#+@C5X+$5.$H=0V!T^:VJ0Q#_.M]>F?EW"7]4_]G3\X;*;*IW(%E\FRZ+
M P8NT(!<J5TWK!L]B$4'O _P(EXC8$<F=3*)=L?JR%WO]U$DHB0V"?,2.8N1
ME*/V@DITC2$%&XFW1SD'(5MZ3%S'#CT_0&;E=VX?YGHZ(1LDR[TA3;V1J<73
MGGY&[A[CX@=F98ZC5+L0G"T>!LH)U5N"7H0O"/<\N\ @2 RC/2SYNS7F+8,&
M>G^[].&>DFQN,+U"8OHPT(-:[_EJ+W#?"V'D=\[A>SNW75O#IO)K0CO&C?)-
MASEO@P4/;984></H;H8A1B0L@9[S3%DD%N9LV6]OTX>X#M&1,\>P,FYH%IU3
M ?ZM09H.)+T:NU#)==;$G/CSU+7,ASK=[D1Y8@:EL!Q%3SZEU>!^DVT8-G,^
M3?IU4XZX_JD/R@^E2MX8G=]U8@L:G;\>7ZNL]51*[R1O8<RY.W$9*-O5^Z-:
M5@3>P48=YJ@_2Q95I=^?W^4S8CEYR=/I5N?+X1E^_GYB+YD7.:L9@&I-;6L)
MMCQ)3#T3##-2^DGJX-L?0-:??(*SJ2N@9^2P-A>2)U;0[2LZ4%7,1BSNG,<'
M%@P!5B6YM^]<#WWU#'J$R@VZ-SQCL".I#>MVK\)&?U7U7,#A9<_>".+@&MZ&
MDP5(!CM83E#V]H3I>,6.1TT,1'GZ1AN&7$+1><<W1*[$8\NI8@2U^((6M(II
M3<3&L[UN3V''O%RD7GQG8FO"C35I3T;Y+^WW@[B#Y0\PF&7G6=-(5#26%62T
M4ZK;XSS2^OOG4_^*:D&FQ6W6XSL3H>UD=C EJVNN-W):;L"9H\S:;?19L5C^
MPP]#2S,GL;%TE>[#6YQ)=BYOVY_LV_KMGM_]_>H4#=CE]TR"4]GT\"$+<Z@-
MA4*W+ZQWH2V.I'LC=[_#5;\I\FF/Z;-#705KD41/\#V.)40S0+:5M\3.6-T\
M9JIT3W#K_5(;+GGK\K[>+I^N'A-AZIIX7WO9M9.O#:3N=W;>N,+DQW3GG4CX
M$V@Y2Z04'E./B[2MC>.V 4,.+:;BK.VPPX?)]5#;K;7Y7E#.N37:BQ'!:LIL
M]_-HQ?SXB(IH58_$1Y-2PZ4^E6.#Z9GHOKX+(;#192LRSU93HGT :5ZRKB*\
M[O,'+P<[+<'D6[.^B_.,,S&DT:6BD$ED@Q:5^1>"EY)>R%7P>&3Z!($_SZHN
M3K>IL3#S0>2^<,S1X[NNXG2Z4J,!7C,'] H:NK?"0DVZ!@\?)F630FA 1P9"
MGP9@]&&[7T7)BAGF8Q0ZDH<Y_?TBP(Z*W:(;[ZOA81;6ZC_K#;.VZH'CS;<.
M5*"1R'TN&C 86T2'H__ 7.5'?OUG)(7C=B>2J*Q-=&QSQ.]0YV&'WM497Z"&
MH_.OUU'>$C-D?L:FP>;)^13XT%VQX9O^3*(4#*8)/>9 \(-,FM;[N^4*!M]8
M-<O99K3[Z7W8=QK]??@@B4X;?)0(6-GD+1"#WS&1&8ZV=S]4*'3D)B37O-'#
M[\=?7DA9J8%^+A^7LG%\Z,<5<ZZSZ?C+L3ZI@V+,(!24]=KH\Z0!95A^Q+4A
MFV+EXWU^-3_TNL\=F3!LP[F,)7Y\1=U$=%'9!$@\T%=!GWJ;X8QC:/"JU^<>
M*OJ(=TYWV]?0@:.R<>UM7E>SL!),8<>DQ?$N2CYKIA.&$YJ]= K\7=N%%4%8
MY+2N)2CG>H2*/[=:WT#"D)RU-@7@ C$*+U-6/&/TQ2UQ;>*6L?^E[H1COR-4
MSS[_E/]#-C$FP4 &EV'(^H@%5>N:A[B$-ZF9C[4U53+N7\^M^[AXQ(*_LI_:
MWPILZ@N WOB\YB#U%O1$@0G!M+GGT:!!/V;OBVJ1[1\"*C'\T?MK@YLE[,+
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MEL2"]NTFN](NUWR[(K(<LKI05)UQU9H29)7@!L7KT0#)-K6SM7YS79%(G+=
ML_%HG_RS_8P@J!/9DU*'Y44(#7C::.FZSV_X7>%>/F1NM->\*,YZZM:M$Q^=
MO:?BHJ;D"6L+*:V]O"%]<%Y5B!"88#::<C%J>D#\0.VMXK-KPMK\#TD)UND&
MF$HM!?I:^P_GIJH19)NC-5UNL+?DKF!4U/,A4I\U=\HI\JLT(!3WS:K1--3?
M<B(I+H9ZDL#!I.%VN*/0''^NH=O[A53,R_;[-:_W_]XZGJ VX/"F4WJVP[LS
MD3-\Y1UG+SQ_9/=)_G(-ZG%5')>E:U],X>795U)*#1?AN$.4+C_?CQTO,K_#
MW ;.$1[I(;;^R(ZI?5.4.L8#AKGC#W$9R GYV5C,!@2/,<=K;WY10[D_O\!;
M-U5[5<^<OT &D.9ZMJ!=!I>UH>]L*)E=/,:SUG_^3*+XL0=ARI"A J3<T0]M
MU!9TE7,C+A17]N?U'(3_[FJ\NUJ*T"W#RDI..0>#J5$.B-8YS%T<'8%*$()E
M5N>M TI)[AY'9DQ>>8JLJO^L#7X27/")!KR^@J!S5F9O"_Q3%0T0_3J*_KM.
M# 9EZ^D:!'$)_\!^NP[TS0=6$A073D@ Y3WL,8:+.BS:&UE(OI2Q6GU'].RY
MKK.'F9%"RF7A9OD]XZP_W1FI;#9^IW#K_@O"@V+.W[_%;FNRM]L=Y!<IC5\C
MGAND 4X2[LVC0? HQ8JU8$_ADRZ*&Y9JD<WV$1Q%+S]MM,Z8N-=2<K",MB']
M-(#C,]Z)B/'.FNCQYQS\-7F]%+;9H7E9FBO81>@V_@C.'3G[8913?1TY=UW9
MBWL*GE7L4T:1LVRK.FNZ<,\:-HNB B3)P044KU@ALG![@^A,F?I +\\+5N'C
MF%D%]/H,OE/IJ+7;X)IE_U2/;Y45SUDO4B/7 (-4C%^&!]TZ4170=13[FE#K
M-:'QQW_0W>8)-6:5>H,"H ^);5H5M>&!'] U:ZD0C&;IGXMG_2MYGZ_ED('@
M_&JOCF_#U)&2ZZ2-GG 4<4&TCZN'_HH=)\LOPL+I['(3RH:0!</GD,*N.FJC
MLD/E1F-;'/YF5QW0KK_/ 7+'VG^:VO>QHEW[=?EY[PR7%VC[&-4,^HE98QXK
MG0Q05,B[3.@2.U(8 V'BUI>:Q@G!/+W&YO>)[H30X5U]IVKP>4%W:VN(_5C[
MTY N*;]99T=H;?8/2\S$ZE+("02L#WLF0-T"7_7FL=20[UT3/LYFR.B0,GK.
M[[CRMT7N8RN7!TM 3KP2U<BK:8LD[$L#*&?B<)D?_NU.8+1)AYZ2P\Q S8;I
M4WU[:U[B[HDS*[;OA B%(_@#DY-O+U[-<$[($)P"K49I #]"S(? -[>)FXN^
MZW#WJ/&]X4*T>56D@?1Y7)=,O7X3_]G,LNUDEH\.H54^!#'B1_!3,,DT9% 4
MFYV[61MV>*@-O?92^[X5SU5@H^[-4UC="<SD3$0Z2QGHC-]O2N<;/"CO+SQ1
M<J.5_<"%_\>^ SOTJ?MO6#@2;T0G:_(9\,.<E_ $B+$>/M6O:+FS;M77\KM'
M[F5)J!G;1G"A!N67?T]P]N5S7VU'4*[S"I+TS#QTPBZ:?2U0P?.$9\*-58MW
M)&[]@G(S _(J^19>8J9QZXVD##Z6N."3M<IG(_0 ==Z\W8JQ/\4=\DA@-X_,
M)[_PE*Q(R3B)WZ.T)66!C:J#<.\#RW7>D>[@+J$8Y*@MR9D81C>>-VA'? &6
MY(-_=IH/XU[K9'*P>KLZ>HBQ! P^HG0'O;LC<7$RW:>-DP9PQ> ]T8$>@=GD
MJP3%3X&>\]9Y 1G/#/C#8G(MGEP1H0%L[-4ZQ*P"5_PONQ5BR=U?[%WY\Q:I
MLS>D>+\#*AM,&QT=K0$]-O]C[%LPG2R@WNCE0(Z^0Q\J8QTPN4C/P$^U@7/+
M;PZ$C,^R_$AJH%[;QJ06[(K74$:@H[</"J(D=F+TOI+?FNL*K$ 5_V?/5/Z)
M6YU[>WK_X1#IAW+OOCZ"!J@%D>EUG50J#5"BG&+F-[^7N?U E]^,)2^D>V;[
MKA8=2^\NTH!^9:NB?USSG:)\P"U6!YA2:SIH0-9#C.T_#J7N"7@=B-RB >P4
MT[XGR&TC!UPKCMCT][*M;G!G]E\O=9O\0\3Y?_84/S;%RP7!VO>>H@^$']#C
M 91R!IIML0CEQKFC7B'9$%;^<Q@!\.?DC5$%"U'W2T7%POF^7'GR(BQR]7CW
MT35"(I4MEE>/9./V./]K;ZZ-RMMSUNM2LD.S#"#;7[8S7%JK:L)%3DN )7.:
M<+Z V[=$L>&^V])"T?SQA>$2\7B).V]%K)V%YROWC TG;PQZ[K%W:*496=\+
MS)FP<Y-+=GS!>A'8%<&@8;.?B!Z.)'&$1NS8>1>,4^>A]EY3Z('J\[:H;!LM
MI4*I?%_W2R_E.<+8)#F/:#F;4FJP3&[5X45)Z&8QH[2:+[>./8CK7"Z/ZQ:X
M Y'_(LVV7TT-PCF3;)2P6@CURFC)A].G!AUO?N1(RZ^G^E'8^FY;:MUNA5;Z
M-Z"! ,P=_&@DPNMH8K%K0J3GAN+9XM#8J CADPJ%Y^I_&XCO%:) KYD7T-U;
M9Y%XWC4:$&OU>Y3,K]:[#JM4;[:NVII2_?BC58>25+. GZ+S[#*%'JCOHT.Q
M,)!QUAAIAW><6@NJC/7R\PNJKEA_O%U]]!%;&9-X>JCWQF4;J E9%J3C*B1.
MST*2F2"N<YS:M8T=>Q!FW7R/7D(KI>C^1%2M?'3\^-"YKZ 3>Y3:C3U"^21F
M1P->B9E6#V:/,$'=XYYW*/*_1_2$^R?<H>Z5O?S)DAM4Q/0^1(WP.1J_U!B4
M]P:ABZCV?//YLJ=B\0<;<CET/?]L6P9PQ. X@_T6'=#BL$?!O:Q[JU2F4:N[
MWTI_D*2W@]/=GQFHR<_FY!?%G&MR9(E/YT30\P2S"]@\(=0TPT56&Z27.B8$
MSK9)S$(,N7%$4-(V?GE[%G4XZ[[4"YYR;H6 5ZB:]P)TMCU2O:*+M/*'TID7
M3^1$DIPXNC9M7.0F["DA7X-:B]PS5M0G/JW'"B2]@_AH18OI6UZXU7V5/C\
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M3YI=WKE#?E@3NS#^:$V]V#CE:K[W\C+YDJO/G 0+YQJ3=O0A/BUW8EHFRW9
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MBN V,^2I^D[2<2S4^^FXIO0-%+O,-5EM+96;[FJM(? -ZE7/'IN<Y!'4ZB:
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MMC*[:,$/F, *ZP"%6,@19Z>>'=6X%^3?Y0.-WK^<\)KJ6$=_'P)'/:KRZ.9
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M'&O25$]S'T^SI1FLQP=4!C(T.S )<J>8][Y4UOCK3# .#1,\=^[7UO2CXOF
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MAV)*_JNF44*&]Q53<C3=Y4UHZ=SEVE]Z=A'5I.>F583%>/E2G@Z8O?O=1V3
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M0DH+J=B3RKYS*8B$D'4J/$>I5D!CAGY<X-JFH;HI09SHTEQ@#/IFZTS<&S$
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M+ 9\?<+(1/S6E"^$=] 4)&8@\)9$+GT]"]EL??WFT:3]0+\(9>LL>K(>)RQ
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MR;4C7CA?BAF46GY,Z%L=5/Z5:&1B%EW,(%PDKPFN>"ODS_"3B!L''+N^C!N
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MEO9(?\SCA8'SGMF7&ZK'J4JX+Z9>7J#)QCVKJYC7U02EB (&!T9.19BK,,4
MS2ZT/I"W\@3+B;C37*9^AIT!?#QXN?U .GFG%:+W&C?D$YNVYC87:W#_[MA*
M2#ZXJ96 J\-!6U4[4*=U!'O)"VZM568?+\&"G9I&765_\XM*SCDD!J2?JDP^
M\N-Z+F1@G!(QYT.Y4N0X!P;_+"+;.Q>T?'=;O4 U&C_Z*>AU#/*[HC^/1)=]
ML6F73#NHK2FP^<!(;P^,<=^*=K4]ER'W2G*.H89C:D'T*V>IPN4WRU/"& V.
M3(PIQ1IXM@BJ15X 058?\CCL<^UV\6IL_) E_%@W<05<U8\-6_7*,/2";^%
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M,**(<5$H/C'\QG+R^F"72C?UK+?#MM+"T1=!F=%$#+>*9S+<CBF*HBBG'WY
M7197OO:YXW$1:_5^.8%KS6SOD+V:$?0EZUE( Q/073(\GF+%6,7>J^<)H16*
M0>"A^FVEAXGFS-,#]0TU ^M?ZT:=ST5N^@=8I/9V"B3H9J)\&$F/(78WNR1F
M);5=.>)D>1)[/$H9ZG&Z-^Q6.7/]P);=QEG1]QFK[=J:>*;10%CNE'@,OX(
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MH,5=933F-\_+OW4_\Z]LM,WZ+U!+ P04    " #'@DU6?WLW)0$" 0!.>@$
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MRT0JJIHT.[36)[3/.F99I^\_.*38^IP # 5J,;"?0LW@4G%FUYNA%4A90@Q
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M.\3K>]F9)_OE5R,%>G-*6ZN8 Q7L^C)_^*6AT0+%W!8C[WC96G6D*-A(FLY
M@DO<5H]U+ASTJ2S+[NG$,906G&IQ_&5I3(R]RD&[F[;X;N- <L"U'[(-EBE'
M4T-[8ZBO)]"I@6/_SHQNW81MJ>:$NL949ZXY/G;]7$)K0CPL0)(SWG&%Z=E4
M;1B\/+ITH3^WKTA1)"V-<K"4K8P)/ZJ3^:;D<I$*SCEC/N*:=)#AWH&1,Q<K
MPWC5NK4T?8B^5>+.9*2TV082QSP;;1:M>AQM,'GP]6Z7*^TW:BC?L^FON(.X
M/X.*:FKJ/M6J@[DA98N:C>2J%'J9<!#%!M1Q7$;AH[T4SO2W^0RG<Q[?*G5G
MOK[R/ GJ>0_(=I"GQH2HB<I#>(U_4$6D[L_^TO+L\P*LI$FQ;?HC/BF[^1)#
M::C1S.%MY2WPI>%&?G*(YD&)H7)1>D]Z6N*,\0QW-7^:-U7J"DZ<RI*Q:%G*
MY'.$O-J8%8*RL&AZ5G_V(=S4^"Q#WPH48S<C*^!NH"LU7^J[B $(]>4JW!TN
MRXJ,%=V+T@:B2O;N<XNY/09 TU<C5I$5M3IV_O/'%JM)G=Q=*>*^X'%>N:E6
M;-MO,^Z9&Y(G95*'5\N!G0JR]TI$J6]QV,AS$K\[2:J'_'.\<4%^QQ6J!2WD
MEU"Q!RGYKII?KK('SC\[/_(7IE@U(W,2F9,WB139?""DQO16Z/V9AR8U0SSH
MJ,*DW)8?U.Z]S)UE93#CR=IW\4;P@"6.2JX0" @"^U-02'H*#PX(''3I/%VN
M;;F,9XJ\*5T4MMS07:_^O)-"+B<L8/YMX0^'.L'V@JY$A9C8G.X]3<_]I[57
M?MA"WZ[[X<O8]]I2<CBP#\TZ768_":.4DJW-7XUF^\29UNPO%$>.UB\M,W@6
M51D.NL[#KL99$B _'-U%&YP%S1VZK,"%W([-XY&P;NOC"F#D[K@FO"=82IK+
MB2W!>+PW?WNL7#2(X2=OOOZ#GZ4\+^T<[3BQZU>88FGE(VIVB;MF#.X)K-R4
MCJG)T;F4TLDUT'ZQS>-S0[_AZS0;;,]-GO#H4NS@?%O]\TN8SY(A*:H(),GL
M_R(N:&>\-+T.'F.H&9D[(6)+VK64M/S]<K2PX=P#JW<M:@LL=:B3)B3UB9S]
M?GQUTH1\Z\!!:Z1_<(9-D9%LYGWNTI A@<?D<2$KXYGH9]WD=_2^*6.%JU!_
M.:FPSND0V,[F2'LVJ9HMVF$T \5](@4K?_Q8RG.^QCN'>&MZ-P'6_)+H!=F7
M%T1,P^<!7N5O+*UPBYHUN5KTM)O5)G3C;1;0]#YAA5O3P<FXHY9X.$55-]"<
M7[ZPG8KF&V0SC>V)9#%R$[S5=:U.2OPB'RF<\N6G7X]LZ>//-@A9EX"CE.)\
ML /,_+=3@O?__(H6\*: Z;\H*FN(9!"12C"%]N:BF0:K=BSU+3^_ZI5QX'&>
M8%  P46-+IBN4/8[[\)+I!D\+RLZ2\XWX/6=4@SP_=SU$KM,?K_C*L,R_;$B
M9R5OL?[D0P4&L-IJ/2*NP0"M!&ARZ!\KGJ!/AW>T]#! Y='".<@0NA!VA0WD
M_UB1?/'=[Y^KH6__*?.5_&JC]3-('/U\,N=T"=H1_X=RG/D)HPT^%P8XD<O
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M'_QZ6T3OZW"ODVVG[PK$CC%-2#2!;?C^)X84("G8LS4^\T>1E;]7Q*@,*0"
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M (K7^C^^=ZGH$V6G5)QA/M4RG,V97!K1<((V:1RQ -].+*!STHC*6\B-3D;
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MI\W7;2V660L;NGG3\9%U3*.J2S%,E(];3';Y1Q*N!#(E[WV)7/M"Z=,<:<-
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M9HZ%60U8YFY=EP.@M\R\D+,,XM)/9<^YH>1MJ>,2V^/P74PAR[OF$ L0B;R
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M Z3'(/;)I[-OJH*WCAH\EK2<T^O?\<@LA.29S(6'([C'UAT:7U>TEK1ZF47
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M<U$#7*1LMVYT,\-]BS;=9LJ"UT=?T&O5)!,_2KI+1$'9PVPJZJ5M5["40J@
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M#<Q6Q/L?)4W/MA/*?',6]#LT10]$K0TRG^<28%Q[MC((>;=X&?#;5]ARTK$
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ME_.XCTA HV.]I7O>_J1LA=W6CM!]\]6D\X6;E:9P"]'WE]L.//='NWX!,%9
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M:NAF?ODHP$_AS9-8%""B;(=%W6KZW63&3-!MRIU_!,\:E;AEB3UMO\30OW5
M 8XT6J7%+8"5X7_>_!MJ0X'Z'U7O_KG_WV$?[U& /U3FWG#>!D ETOVN->Q4
M?\>-8/RCAGK;[Q2G\7H5!5@I\?P==?)9XA]512B _)W/YC*V28T"$.I-_HY;
MZ?BG2N"ET0U:N9\@"H#\MO [\(41]P]5$G=VU1:ETT4?"M"CB?@=.?/2[P]U
MJG\0M+[H=^C-7[+_)?O_/;(75] "HW=+&H))!0?$BNXD^6K\/Y0DM;Q\F#"
MV?X'=9-#.O6/V-$[Q@8?4O\/&:LKYZ"M#2AHC#>-=FC\?,CMH'8W$#-29_]G
M9_&!3X4]"A#N,F:D_?\.?H3B7$,'\'U.Q NBWR-B97A4;*?Z5IOG&QJ4"M0O
M1]<HX![P(SIZ><84IJ,]M+H/<&.?7;\Y;$OEH*_]4F:[%N@^BJ56I"ES_8B@
M*?_FPZ]+GO$#EQ)L$=7OE2U90XV3E+EUBE'>O:H-40$!?>4L"/=N0^;&Z1:'
MI7E.@]C=R[,D/U&!2E>_N8RJBF_?-R+;PS)IVANF#FI&I/2,C5WHB9ITK8Y'
M4VAY8C/?%X)L/?$C//T,:E" E]6WS?!;8/6XH>*WZU=0W@$7&Q!IPH%:96W#
M^/,$!FR"A'AR)J6WC6-");Z$1P75*P9>79?O&_!';&Q$FW;"H!OQY(,:V\?K
M ;9</;SE>S<>-_/25>V(]?.,F_W&0M!E?DR&EV.E@37Z-(P?XSQ81G9,LN-
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MCSBXZI)B8)"'/?!YM1+67-%\A (\%V1 WFJ),2YV5[BL=N6]FC[>WI37F\S
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M<*9\#K9E3Y&O)CKG,,M\?G\O*5;3..K9OO4-P3W=/J4J"+MT71H(/0^P)OW
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MI-7.P<A+%"!S69I $_C^C[A9=/C;9-N?@G(/7PXW^V].5+5!BOW&YB3.5U&
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MTHZVY.4#=".">LFBO01L &]F@BU[X/[Y6T(*SGDIUY;+@D=HU9$$=R,V>AU
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M$88OB^B8!7@/>3UP"S"\QY- R9M-6ARA,KA4<T^R!/,A0^,3;'XJ1ZFNY2O
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MM+-G(OM(D;-5\-%[V$HI[+@_^19#UN4 _OE1R.7I_?\?O*L2Y.=&_;@]M<M
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MEF-<;[6HE0K17&9R+YQMBA</CXG'%G-=0++<^U&7;(YEA-67R742^P>VG[
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M^]3V;VHI-KRE<_4]K2;2@C^4QVAGW-"TZ%M,F^L74F!?J7J-%#028EY:8$^
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M+.[VT.RNM!:YJW*Z5FX#><CSGWGVP,4@[&9B4LM_MZV4J2Y>9J@Y_7YM^2T
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MNP#_*VT7V^CI(NVD@13JMB&-G$IV_<3J7!=X2U8E%.V8)=FL9A)<L2V2).G
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MO?W+ ;7.E&KY.DDVJ8"K6S9-DX4%_6OW2N<#ZW=;WDFA:M:<=-Y@P!^T4 5
M4G\L@E=-?^+869%]0NZPMS6&ZTK2@&FI^L)[OKHC)]$IAI[J7BE87:?= CBF
MR>^+:)S#,2M*1GQQC827%)SA88*VA9;74\P:X?=P#SCC%AI08>\/7US2"M.=
MRU-<J ]\,% 8;KAP?R9S=9!:>>]34Q9;D,7=)Z-%=/=()=$7$$SP5L@6[."L
M?S$Q5#3J.=@X:[@J?^Z.S?"2U0I9C[C0\7))#:VFWW,R$.QB[K001H2#]-!$
M#'X4B<5[=V"J1<JF83_)WOZN/MF@N4F(ZY=PC[1ZM;BN9DV4LRCCZTXF^-5/
M.^M,\T7>-^D?AZL"J5M -6^&!799\;\[GS=1\#;K=6G?IYN5(^0O_V;F(,<T
MUU#XDCES$:_'.7GHKDZG-7.,[&?0"W%23)A;-DG>QNSOEZM#D5N(YP>%)49*
M;%O<P_P$Q>WN5(A&N[2TI#3>)GP0\YO<^[)59*#OWC2I7U=L_6[*2K7$(_8:
M_,?\31XCQM ;TYD^CK'%CV@)B#BP,B@RLVUS,-8/H 97_(ICZ1: Y=X"KRN"
M%R%' 35[AY\"2WRT^"<V@A\%?%L:]R<G PU!^+;HS?I7N19$OJ%?F*ST$R\N
M#RHDK \0&]!3!6[BJSO3D4;2<T<A,-I]_"*CG3ZL;(YO.+&(+PX\QC4$ATJ2
M[Y/]7IO2!6S]:F)%JEBF'&7D:7^<&<87QUF1.*T:4/P,Y;QO$>VS3U?>Z,#_
MC,9@OMU4CKJAU2C87-_%B1VOGW+?W7>+/2KN9M?[H27ITD=%ZXZM&  A+>V"
M.>14V3'?!=W=QZA_G['H$RF2'H%IG1Q08FU0I.#63!P6C2-)O2A8"Y_8OKRW
M\30#1C#T[4HW_8O,S(Y0/DM_" LN$@PZ^F1Q8_@]M\*T['D#+=6)K)3_W6_S
M=[\4Y1KTW/.+NXQ+' SAF5(B [3_&U1/>&/L^-.7*IC+OGC*Z9&T[8OI+7WK
M9H]TDO/*L<VR1?>>-QLA[DJ><WK:,SRBL92?YBJK#JO8>B!\Y@:LCG1Q%6B$
MV)@A,IH-)LZ8"+ZXUN*Y5,-=*1%UWI.RFL6%B33=9W=&"R8>'$4RD:H\<' P
MF>4/$"Q#QBK/G)@\X!6_8><[$]?[I,4>YT-)1- ?RU/\3KD?*S5<\F7,L7\P
M'C)HFIF^.O)#'\TY1'5OXXE,(S\C$(Q'VO<E147475-LT,"9/7UTY7MKE(+K
M/FFJB(6$LL3Y&V=G(D;!DWS".WT7@=5IB*9G=9\Z6UL??G'ZEG* .# EM4G=
M7&,5?A$GAB,Q24?RK#W0GWV^H+HX;,?J. LC!;:^^\DN/9VI4"CMR/UH>)DQ
M1ST@'_-IDO\U?U\F1T3_CU:YO!+2-ISZ!M5/+1-R3R1&.!D^I%SV^3&4E/65
M[ACRY?D$.@,1.[ YMG0!'";NY.10M?43CA#)N5D^4;.00NT.#_;QM8CV\^P-
MGD.'ED2&[W.\_'TT9U$!M.\-'/RV<A=54NUDTD_]C 9$8JGT'@K5'P#+%2G$
MI*#!9<3R4(F!X@<"*5IIR)XN/YMAI3H+R0:MF 6MVZ!@3"9782A9!/:\1.&3
MTJCFY^ 0@!X#@!S[R-V=A<Z=S,[R5/+Q-/A6#8P?1FTW14Q99)DKL>>_[E7D
M6-5/=Q$1>*&^[[4_%"-JE$=F_\2>PB]@T;2 A]C$!!GCK^I(@GWT.;T")WKN
M303[" ]C:#/5\7F[:('Q[MV*9=M6S]9L2[*.E"D:JZ%'DK01<O4F2(<'LZ*V
M7AK7E(];9YGNO6S+G&+0'\VN7F!EQ4H.ZT&QV5Y7S5+D+3"@UW01?KSV[0RA
MY.#8-!T+"3-\:$02@=N=P;F%A84:NPH]4A4[1.:JB5(:Z:'RI5SVD2M^K[5=
MLM99S+D*O>J#X-<;%1$3BXMV6TU-$7>=C=6D!U\9ZN*2"9/,KH-2OX*T=Z2L
M(FK-3PT;TCI.BM[R8WS68',*2TY[H= #?,%Z UDPFZ\_1&HXF3V9MIGEN9):
MP'HR7;FZN#77/KG2OV>=%*)("4YH(>\2>U,XI,M V3+GY3F3D,-^%-R_"&5O
M;R8L7>L@ZK(OPQK3Q17?IL/WIEBE_;)W[.N9I4FK%::9)>>4K5OZ<22W+8F@
M1()>2:W"UN]QAV/ZQ5:&3=G]Q Z6]B:U-"-T9] K8#TYSP_XE8CCT)JS'=7.
M33Y8)CN7?+/8$..3$8N$9HJ&*@^BQ]?J1PS)"QXX"(T]SS.>JY<VRB.Q)]&W
M9V"=?\GO$H1X!U/Q(%/H&38%:%697 4S3_QO 2+;UNHLPKQR.PK*QB?D DO&
M1FS)@\_(3<J[7X6H4OT@L+1?!4TUF"BJ^_)4ZO8.&D5;S2R.T'"GI[EJ$+Y;
M^649EGK^!=T4K:79#89'V9Y[,:DYM]E0U]R<-+PE2.<XE2')_TDY69Q4:RQ4
M#;-U,71B=.%Q7<R,5F/$_"+Y$IV ,@FQ'P8=Z.D7D!+9DS_Z1_]SE7Q3CAH9
M6P-)A)U6O6=K?=Z0D./!6_>SB39ELS N>9O5HR.Z9RF^3<LX+HE(]WW[0K<\
MR8&,25F=R8X8Q?ROCIEO^K> E;$*VREB^+FE1D3J6-(&1NC=H08;@P"SKM A
MK7FO-B/A#PY2W@7!%ABM4N/8#>>ATNG,8Q\('U03*A,9 B>MW.%PE[B&0(U^
MA_>0>$?-N<%8E\KN>>UV^VA6,MNWPHVP2JS/ MBR&#[/_EM6_'\32DBS7R-"
M<2&BV'2:@T*&5!>[#\LJ;IC%-BTVZ2*_<+M_N+MKA(RWV3U?1W.5U8T!H"_@
M7=%>B=2VF4.Q>6KQGNQMQ#F"*/ZL(<S7;4 7] .='MQIU#S@D6Z&U8"SQR/B
MY'PZ:Y<I]J[4[E2<8F]<I'=WDU2*'(3[ 1,LIB4)CCE9Y *_AMN$>06*]X<9
M(VB_7I>O*35-Y6O<I5&RW3 ?9Z506C2(.E=VQ5H573)>7%I5W#3I(4-L2[/?
M[Y-7U)FZ3]V*QN-GI$+S^F%KR_/G5+CH!P#X(UI]A;3B+9 4T'5R[G4+%'ZO
MH@&XWL?\7Z#M%GTWP@M\G=+V4N)17N<B$0DPU;WCV%CM[Z9&:#WX3CVK?41=
M;A.X^TPO ']9\BT&&N2K,F3J1MI-LO.2C#AA*D]ZF/DM4*Q&W_OP%^;@?EM<
M%*;K QNZ>;D\!)'Q=*7+B19%8X>5OVAC86#QSXQY[RG#<3KI=Q;G3QY7EM7G
M;+H+^1Z ]H[U<B"L_7XSD%Y>L,GLTC.'2<(E!PV>)!7J\)51-9J]YQC"H<+I
M]",U2OGX^T0W"D>WP,+FPDUB2KW#_Y7CSCTA:A9!><.$V.^L@-%[N=1GJ<UO
M+2X;85>39'Q>(DG&QB ;?NS6O(X&&3GVXP*'3=W<^6F(E5#E=<UP=+HZ/Z,A
M1OQSZ\ 7C5'8U>F0^1S8&&5U=EU1$MN&5DUT^>(A%\RD9G73%[P;.TU2EM0I
M-M6E54<'#%[;V-Z+DE[//"S-)Y3O-<7,ZKMHF1,U>>ZE,3OS8GH]F;<])!U!
MJJQ\NKSW6,-5EDQ/S\/!Q9<HS0?]Z5#V7AH8_YI 0PFPA@2)1*K;PI14IW<V
MGY.]X+K3"="'V\U[1]X"3.?!NT>[MX#*B*'(?WNJT3;>JD40]5R 6/40'%F.
MN_.L[E6<UW"AM6(41U[JO5-K@BMK8?K"+5[X4=KY+? *(Y](]7W[T@U%;H</
MRI7$" ;.-PQYS@_K;X$OT84W=^2CSQ@1^_!&"<HZX]TO'DA0)G"<R3W>!65&
M-MX"/MT7(F:'.^NW +/*:=,@YV4G#?QS\.':<'!2/I$:JMU+HPWB76@-?M/T
MC<(UU\TBLK,C@!VZA;I3Y^4U%WC:MD8,16YC88N!AV@_CH);*EY=#3#"TZZ>
MFW7 %U$4>&7!G/'S$ZRB*5,G%!_V&9"_X!#K0LJC1AW5.=+#&)L;N_C2,ZDK
M^2M-P$_3(_B??0+:>.&*C9&2XQ;06X^G6+MILU]"W (!,57P#]LP]%P&>+M?
M?$(8923F.\# /%.WU;8?/"9QF9]:)Q\/^#W.*]/?.259L]-+/YM/V1YK;DRS
MC(>K2EBQT1&KS#[/W+I"66#97[B.:#"[EC#64[N/0::-4KTX2/"@W^;"D).*
M,H*PBR-I:EF-/C?9S5XF=NR%/G-\L_37EV<'DCTF1?@ D<W[]JZ^->(3?N(
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MNTJ!,5A!-K;]Z)%$S^N&0XS?<]L+CROAS74@A5]5+"4T:38+NI 5R:W(DCL
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M*O\*VW?PQD.&2%<2XM9HBS0V!7T[M<4L>W_6P5;FI5-R2'']N:JQPN":MV"
M=M*6(PV/DN6(SR.J^D47OO-L9@W&I)_%-1!%?_VU]H:^,^E^2^6L&31WE93
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M;" ]04^QPU'/-Q7 -R%^N-FF""W'-U1(U#6.:Z[1(MJOVVULU]."$\P\8?]
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M^+O7?56TK\79<"2(9Z)7Z'5F8)8-Z1_$[,!5T0'56.K*NR+GJL?"@!3-_CN
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M_,ZN;O[;KNG^KEM_ 9O2P[_M6N%ON\TBH.(0^[MU:?[]FC#EPX?_?EU_MR;
MV'_MX(L\[QM::KR^@\$K =I,%&6&;^X 39:8#Y\U8<[4 FS'_@:3OW>:[< ?
M'WS*FYOPRM;X/>9S $#_7 3@_!LW/ASPLPDE&6&^ B0BFK<C9H45EK34?A\4
M*R[A_0BXD">N  (2&2S"\_(AQUVIO66-]E#?<2/%HSX\P9JBIX?$W1$TI3^8
M.0(4Y<4?>&(:^875J JKHD^7Q':I17XT35I/6C1E*(SP<WW7F?-<(@S,&C@5
M#,R!M(ZLN/=&>,&G.3E=U G4V6WKXHVRY^ST'BK79/.Y?\*+%SDY-<NB*W=>
MF<<='M1M;IK,#IB53QYH3=70>>Y3W/%9GF+E[;+S(,9,>(G7ZCQVET+=E'7\
MS<E5&J]WLJ.MN[8\ T>]&)_\&^_FV-\,KF2=&:1J,[<X(*H#F#7!W(Q*$4@W
M_VU_6*Z!=P'@E%'B.UL^!HV_'8'"Z^1.J6"39UBAM>L368V N,8%$7*#9ZA'
M.*O2=-5Y.VZITPF@HNTJ2C /HT%6;.] "X4E$!^#$D<\'*X86ME;1/55#L!>
MV(XYJO4/X0&V++I$5IU4.&16*^1*!XS8WO_"W/>DUR!&[JI]*591E$8'C-='
M1X]B&9_=?E:EPAQ'F7T,MORJ3B'"0ZU8S*SA%/_U2]P.1_A?)?61?4RPDR6(
MX)NVC=[,3'SAA@(HR#TN1LM#2L;_%8#LR](AE2%D<84P9[5%7:>BMF*L].##
MV$E,+1LBDT%813PLHXN]A?>26Q]SRJ'9>;E%6*9QNOQ4'W:RJQ+&99DI9R8^
M^;$TG#>9H8C^A6A'KYT$J&^!"GGZR]$.$1:NX&\4FW3TDS&T0I,YZ&GH:$+4
MR)>9T9D4=%/GM.R9K:J"7E4PV'!&R6-<3_V4Q*@__M=[.DSR50GI_A$V@596
M 0Z8W8/MWLPCM G%OOGF+5OYQAH"JD$X5L=5Y7LL5ND/D-@W,)9]CE_*]T@4
M2VO*^%4_0O5'YIQAO]D;)&:W@LW/6UKVJ7\H0OH I42[NDJHJ[^N;4.XI/G5
M+):IS=I<K,\>!';T#RL4,";+H'PC5@SH)!@W=!,9E7[ID5?--H0=U\D9Z*@\
M[^@"*+1X;"32!2T11="QIRX@)*24)Z[%')S8.U.8<6(K3ZTD"^)!F<B^"+5:
MG,A6EL6=5+^SG*TCX+8G5^VXDF!>57K!]V(5RSR.25?S"08 D4D]:C,8+"#&
M]7%3-YR#]HTF06YD))4[5\W#=_;BY[V\(VJVY[Y"R-/H5A<03-9RI\:6E2$N
M.VCM#J ;K_SL([^;KIF:/ Z3I"N*J0-A$H*<E?:K[+R,3F--*<B;X#8P5TI^
M[L.GQ!RM[CF$3C;'F&I6R49[F6H7[\(]7>*W/AOP9JSKJE;)OK3$?E49[,T1
M]/OS8#J R/4? ^OPG6GJ65&8?8(W?^]8?P/3YXH.2IH3 8R Q2?>['6>0XMG
MDP3@'XU]?NS8ED&SV0$XPW]$.M<VUW=[#">N#7+L=(7/=<^U&&T;KBS<A8YD
MN-H&VGAHPLLPM&,5UUR&/**#8#:+^(>2;':,8UPG^WP'8Q]JZC2R$AX49W^9
MX%207,L\C?@Q?-G7-4(.TDM=@'JMT%,9&1JHVQ;,Y;9]"+<^8HP,8L-G\B 2
MOVY>"Y2FJ[H#D(BS)X/L$0D'+^V/I/ZP'BV1K@X<6_RI8_Q#0?C^2,+N-RK?
MWUOAYBO/L=_&=Z$+/@]?&]5;O33XX+'0<;7;GELY!SIO)8V(!%W&$_RR>/N2
M-<9A716VL&"4R]#;9 Q>F9-7NE#J@YNU3_WA!Z'0WKS&%MX*8$V8TLWF[PJ+
MX\J9P3]!\Q/B&C@M8_^@$J*AJ,,2#5A+0(27%&TG>0XG.Q78.7+UY/U\FLK*
MC*,]2:.!3>4MC\QMI+GL::VD[?DJG*/.-]O#W&K9P8[E5%S$EU!O;F:FP.1O
M-^G+-YJ'G%]HYE'>/F.9WLX->!N/+1NL%_;M=<7J.D="K/2:7L*6K\#$+86W
M!&HXGTLCM-G4#V1N3?55/C;Q=R -NW\NZH^:F!;:<\ "R961U]M4L$O5%B&N
MCG]9HF_$C.KL(AUX]$)Q1>25E_=\[PO,2;V^5FHP9&OEYG82_F8H;:_J@L-1
M&_)U"#Y(8G8S]&>$8H3,C9YT"R[Y$MJ5=/E5:^?L[ Y@FSK%U_OB"%O_B[^O
MY872\".1CB$/GM!K8^O5.T#$6>;3URW1R3_0#IKA7O"&!L6\21[BBMBWI3)F
M%$^<%B7.K-T5QESF\<[BZNO&.5=JPDUQ+XX>]5T.4)U&B-'E0K6W<.P I^S_
MZ*:'Z)45:A5;>^X\1;,@O '.2#)-Z8&/Z@",83OEG%*;1H=0@=4/,(,^+ZMQ
MYBBLG!?K%'QK[I2:'4LG#.& /M/0S&<)LE53^Z>L#=63;%Y>L@X@@2HCQ;Q
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M[:N)9M<\B+#<<1Y\?+\,]MRR_L6OXO$AX3FK#]$8 ,)TY[9GO2"PF,JHV;3
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M2=-O6VPPX?\"NIG_:[W-W9__#U!+ P04    " #'@DU60OKPQ'=I 0 RN@X
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M9 2:T$PE(IHFTC$*<YRYF"SE8T2LDP@G*F$8IB+0BYH,,4A#%D*"PI2$!,D
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MHAU4E66AR#!")**+E;PQN]!V/JFC!F[G_CL]QGNX:TWKL%3':I2.T-OYD6/
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M_$^[YWF1)3CB7"^E D2(?IT%@DPA"6,>4A8@CDB6N7D!/=+FZ 0894%EM+T
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M61U2'L(@C&.D*%&$6<7CC*+=W)AJ3U\W:O([9W9,]F(S,3+Q[=M5Y_ETEEV
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M0Y8\K[2B.9>?B^52%:6Y<4%5P%/,$ABDJ82(T@R2-$J@0"25@5Y[1CB;I(_
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MOJ6?3^JJS+78>R/7?'^N]13(!6-29I'*8"Q,@5_",20X2" 52G(AD(Q0,+S
MF+TB\SORT<]:,KP"F<,46'I)H\,ZMH_TJ(:9R4"NC7AHO:%:W7&*F;G#-4*U
M,P<E7JP<FCM0??72!HPVC/K^(I?BNNB>IR^FU$DM]K$2IDI[OM).MQ'[4:Y?
MT[)\T-[:Y9W))UJP0&8A)3$,1*R),$D99)*&$),P->5E.$L<*RWZ4&M^M'C9
M-(FN@](K_1IKMQ;D*U"L)'@P[W%1@J5VA]V8T\L,VO'HU+,R^NX86X.=%1?
MV ?7!=S1Z],9HTI[X^!RN2R^UU%$RA2"J+NU@_=%5>TSL[E(,ZV^M3XWTP L
MY?;/=5; &&M9GU/DB<F]J#0IK_L$\2G+>QU[&.<?66Q_U. T/1RWP;:?U-;A
MOBJJW 0GO/VQEJO*%,MXGU?K1<1%AE.6PHRC&**("(A326$<"*0BD0B6.*V7
M/>HVMS5VWP;7SKX+L+70U"/;K3<[(\'7G9G V.FX0O<Y^W:?C1>:TY&_'F-,
MY]N57M(VW5$];B>,@+^G3X-/S2;]0HP Z=,/Q1@BAGTO_DSSE?%N/JVV:5E_
MD>+&K$UX<;,R[M&[U5M:FK3N:I%E(LEH)*!D$=:+@81"&G(" T43)4..:)8N
M5O+&N$9VWP0G^58,01J&V-=B/*+8:0F6A:MW[X:]'1_[QW,:QC5Z@Y^,YC^;
MNIQ[Y24;]<$>TOK*S@)_1#H(.$]4Z29[4C(<!,M3NALVB'L$[&O386Z9BZ8N
MBB;0+E8SP3A#4H4PBPF%"(<*DB@.(8MXB*.$(R6X;0#L,2%S<TD?Z0EJ10?$
MOQZ%M)^.? $U,NL,PL@I^O44"&<$OQX=>K+8UU/&[8>^GKQV8!+XAE7R;QOM
M*;W]5M<Y,H7D%X@01 -$-& \@TAFVD\)B'[](RD4B4AB,@I=DK\/29G;"[]3
M$M1:.F9]'P32SNDX&YZ17_.GR("OC8H^\[W[(/"5YWU0QK3YW7UF/LOK[KW8
M2['5KN'L@3]5"YHE(4,B@3R*.40Q"B%.N80,,49X$+ L06>42^V3/3=NV#78
M8%T)1+ZG[EF5+7OGH)] 1D9V9%HY7$URU\WZT-]'A/JL,J"^('_10IY#H3^W
M *<->&XE-'M'?,DBF#:FGBAC:36$>Q[4F_;)N^K*U)ECN$6*),&QP#!.H]0<
M7\>0:<]0_U,2Q'"2AK&P384Z*&%N3-\I"1HM@5:S/I"TSX@Z#&0_D7N!9^PC
M85=DG'*C>JT?E!YU>,3),J1Z#=I/DNJ_T-W-Z_*COZP+_ON5GOU;6DF3)4U7
MHOY=6VBL7:(DE")*]3(/8R4ARC@R97L0Q)&0080S$0:!K9?G)GINK_ZV6D!E
M5 7WK?YU/^(Z4*'Y?7'OZ(@X3LAIEV\\F$>FD"W"M9:@4[TNR]"$@M2_;]4_
MO<P\%VI[EV\\R"?R^'Q#[^3S#4.OQ^5S'' RCV^8H?L.W\ 1W#\3[^HRDTV=
MN*;"9!=XTWR(%IG$(8T#!A'!^O\R%NCE?ZA@S$*98)F*@#';#\,I87/[%'1E
M:N^ZF+2F>#/XR<0@UF5N+>LE6R%]FO%]XC<RQ^^I>K$M][N-[6O4]8B=/87[
MQ' BTCX+2R>&M@6GAY-/#C$9"]L:L\^[UO<,+5S UKN QLMO-%^:QA&_%N47
MNI37=1\:JFDUHH'VQ DV.3,A@PR'*4Q4(BC"G*LX<CEUL9 Y-]Y]%G:\U1JJ
MHH25UAM\K35WC.RSP=_NL,8SJF,OVOL!_6(#Z(!:!]80>:MW<%KBQ#4/K"%X
M7O? _M9A9/3;:E-MZ/)3^6ZERN:$R9PHU\FHC(4$*QG!&.%,DU!$(*8\ACR(
M4"80TIZ?U8:?A:RYD4^KJDDUV2E;1S5<F-^]*M:W@_)^^^"VXQQ/(([,-1[P
M<Z8:"V0\44R?I$FIQ<+DIY1B<\LY3=072202R@6%46:.BG%&(6:QA!&GH<2)
MB%!,7>HN-<,Z$<1DY96:-NA#6IT[]3.?T8M]V6_QP);DGM_/=M 7:"Y^[*U[
M\M=A+UA7YD-__DT(J#2U#\T/N]YT;5FD!3&1Y813&$0D@:C>TH\(APF25.J?
M&,.9RSMH+7F>K^D]S1TKH-E#;?<>CP+@R*_Z-I>B3M_\;650W&_*V?ZX,Z&K
MF7;1_>FJ#W=GJG#&T!.;V,N=E'"<X7C*2>X##-_O>)-7?%E4FW+7/"%0,I58
MQ5!JXR'2;H/)AA<0R3!*58:S+'!*B3PL9FX+BWH1OE/3IH6""ZCV^Q;G037%
M5H4;2H-V)HZ#X'$SXH"0R?<?CAMZ:,NAY^IA%- EI%S)LFZ%MGU>">()2[#I
M-"L41+%>-N P2"%E 0YE%L6()&XE,8Z)<GFZIRES\5&N0=X4'-VVWG3L#'04
M5Q6(#,5)!E6 D5Z$!0B2A L81W%"91REF5V6CD]4)XG;:/4T!R)-V\K!#'L4
M6SN.]8'8R"P[#"QGHCV%A">J/2IF4K(]9>Q3NCUY_<"ZC5UR8+/P-)[=KO'/
M!TD-MXM/J\]F;[DT!3-6XF.Q*KM_OJ)57M7;RWO]>M* LU AF(1,>VE1F$$2
M8PXSK%@:1EG$0J?=8/\JSHV,OO!;*39+:7(%E,G"_59GX=XUMC7-$O6?*KG*
M]0)K5:REXU;2"+-L1VXO.W<CT^)>PO2'O:FZ %MSZN7OOD'MN1D8I9G0>&#[
MJI#I7\%IBVN.!O"SNISC21I8X\AT'#;]&$IY:RIA?)--B?7?M%"Z--GD?RF6
MIF/\+N]\[SRRS"O]IS<;HUL3&O%*JJ(T!=H7*&$D#C/]?<AB[=FG:0PQ9DK_
M'\%"(A$JNVR!T36=VU=C9Y!>'72!*."G95W/H5DO.%8R&FV.$TPR181V"7A(
M( H4AD2&#&)B0E1BQ43LV&UT%K,\S?+O[VB>[9R"6<S=R+[!I]?O+H!%(,T%
MV)O>UFRP5YCE K#:NOW=<^-4:&L]%K0:>T)\E;<:3<]IBUV-#?>STE>C"QQX
M3BE+/="=J?Q9KVFWZ4511&E",%2<1A!Q$T6.4@3#@-$P"66@%'5Q"8[(F=L'
M_>K+;X[KNF, 6IXUG@_+R"RZIV&S[^0SR<02!E^'@T>D3'L4V&_JLX._$Y</
M+!_3[G9\4L=JM[[/5[(N5[- 82"E2C@,J&$"(0BDV-1$C548<\51Q$.GHC+V
MLN?&#ON;1%UAY6VJR4Y_\-58T-15<MS(=ID8.X89">Z16><0TA^&(NU>U<8=
M,U^U;APD3UL!QQV29W5Q!@SAGA_W%^U.K6]-YMWK8E5OSYL&!(L@S:(TC@44
ML0P@2C--8$G$(9<)R0@+110DMEEQAT7,C:PZW8 6=F>?N74$OWZR\8/*R)S2
M*%AGSEZ +3K7/M"QSV8['Z6)<M@&H.64N=8/1$^^VI$;)\M2ZU=\/S?MQ)4#
M73?C!;ZBE11F-:F7DO5S<%F6>O*:PX]7#[MKVKBQR^^T%&T&\ML?LN1Y):MW
MJV8I^5>9W]RNI6CSY[J_7Y4Y-PVA BPR2C1;UCVUL2DXP3%$(1-Q*#'6SJ&3
M]S>I^G/CY$XY 7[*5T 4RR4MJUU$B65R\@L]"I;^YFPG>&R7U1@%:ZO ONE@
MWW; 'L#^A:W]H ;@HBOC< &V()BJSPT,%Z #8IM2W%T%:BP\^K\O,H>^7.AI
ME9_6"W^1B7GFR+^,%N,VC#9=:7[-OTF]4F!A*N,8$A10B!3/(),)APIS$268
M8$JLZF<,56!NWRS]@F7C-(C>0F[W91D3R)&_#8,:0AL;IN\(_12]B3M!;\7/
ML@/T4W"&=GY^-L[@CL_Y6B[U0.*=7A"N;DQWE#9<A?]MDY=2A M.%-7..X4\
M#36?"11!$J8,)A$/.8M5FB"KG0\7H7/CL$XQ<%?OGE>W^3WXGNOE+07WI;;E
M+E_1\F$O\,^Y0_3I>; C.=_HCDQLC;KPO=$7[!0&C<:@4]EK'VEK?/PUE3XM
M<NH.T]8@'&@W;7_O,%JJF_M5MU=E\2T74KQZ^*TRPMJ.3JN;2[[.O]4;OHM(
M8)1P',"(X1 BEJ20*4XA%E2&243"3$B7Y%=[T4X4-4'VJ\DPX5IU\-.FJL.,
M?M;4U%AA%HVJLP#0K0EN).4P*W94-0[6(Q.6@=EH#:[VP/WIMP[RK?+@\C3,
MSN3ECI@G"G,0/"F1N0/RE,X&C.!^IO3AX?5MH9>B?\TK;5B5K]H8CT@$).$L
M@W&02>U:A4(O&@F'02 #O894B-EMCO;(F)LG]>$!-'J"K:+VIR?'<#Q]N.0!
MG9&)Y0 P PKA'D/(_H#) U(3G3"Y/$I.1TLG(.@Y6SIVYV2'2R=4WS]=.G7I
MP,) G)MVS";.L%CFW 0?=KF4691&G"8!3'&&(<H0@306>B')E:EWB((T<RH"
M<%S4W$AOIRGH5!V<JMH#L)W;Y0>VD=EP(&+N)8E.@N&K3-%Q0=.6+CII\+-R
M1J?O&'@2;<I:?Y9=O7WM@MV4].YRL[XM2A/0W#1V#Q<L5ED:I]I!0I1 I!=V
MD(F00TG"(,),!8%*G8Z0[>3.C41>%W=WQ:IM1D"WVCH>^5IB;GE6ZQ_)L0]9
M:_1V*H-6YPNPTQHT:GL\#G6#R=<YIJ74:0\@W:!X=G+H>/O ([]\)3^IUZ44
M>=?0485"I#$C)J\QA2B.,62$"RB%YA\2TRQ,A%OVVW,A+J_)-&EK)MP(O"^H
M:2S-ZS,(QX.\YT!:'M6=!<[8AW$F9+A0H%%OA&R&X];[.DQ[+F#:X[*C!CX[
M$#M^Y1F%2U]1_KL4N[CA]MED* R3+ TA#D4$421-U0MDEBI,!(C'(DK(8B77
MELN3XY*L'F;2/,R=O!%];:,H9+6FH-JJ.J#2Z1%<TQ@1Q2,% \Q3L_!#D 8<
M:2X5:9(F2E#IY,"=B^R4*[^QL;5<\_E!;.Q%7PU6H^:C) WO#&N!A\_RM$<D
M35^SMM_D@X5L3]SBOAE^J92^U&10OS8UD/CZJI1W^>;NR[J.<_B?>M>P]>P^
MY]7ONZSICW)]11_JG@U9PI2,*8(\" *(.!+:'PNHYFLE>(8CR9%5S3-?"LV-
M=XR>@&X5O0#Z,P+N&UWM=Y.]3-7IS?FI)V!L&MN: XP]YB3P K0F@4<V[5:?
M]7Q=[LV7.6>\>I'YLC\JF'K>)CI7F&S^G XE?(+=<X+A1<QDQQT^0=D_&_$Z
M[AF[H[?%4M]1O?W;1J^]M_O\,J(R(SR "8_TQR_)L$FFEC#-8FI*?@8,.T48
M'Q<UM\_:OJ;_ZY]Q%&;_"F2ML6,QU1YT';8^S\9LBMW.5LE_ 8V:X'*]+G.V
M6=<$MRXT2Y4F@V2,TY73(/G<ZSPL:/KMS5Z##^YH]M\QL#!+*4T1_[:L^^5*
MU!5DFD"]UYO2S/F"8!0D)&60IAF%""D.292EVI4F$4NDV=ET2LZSD#DW1FE5
M!K+1N>EV4!BU 6\T'M3XQ09].Z+QC.G(C-/!V:I;HUDKW$;T7H!69X^U7^P!
M\E4'QD+BM#5A["%X5A_&X=9A1-34J3(EJ7[5BIM,YGRUR5<W;99#L:J:6E3-
M==?TAZS>_M ,J&744?5U08>/&@B3 UTLM:2;=RM-#;):U[E6(:;U.8PTGI F
M,($P3$+%" [24"7,)?QW1%V=B&^">.'&A*XT75N;?DU_=$SHQG=C3K(=3\YD
MZD;FUW;6FL*"P# !V)D*=K9V\]I>7YM[ 1Z;!SK[_''Q!)/@B</'U'12[I\
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MG]R,!F'BE]I2?Z?3FZ.ZCCJ_>7ZGV4YPCBHP/,,Y_H6Q!:#O\W6WOUAA%J'
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M===9;,0%E?IW_=+7)DE2>[M]W!J"_1_RRS")X';=S) \D4V@3<Z*X9"F<9!
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M[4R')[@FMAM#I'HYP>]W3>; )$$Y"UA\E<V<&6G>.I?+*A\4IEA<,C:"KU]
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M<5V^Y%K/MR<5;1+*/I:T,&S-[[67KE^AXG[O:S<^Q HE$8U$G$+$XUB;?)%
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M6$E% I5%0AL0:BHAPPR:)%F8<1JFA)&0Q6ZFQ%6"I9F7MG-SKP'8J0!V.MR
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M&0)MAFO3>W$  NA16.1C8E__L,S'9:;*B24^-DXU&///WIGJC1F%F:WN8WZ
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M8;P$8V^&V?9^N])>EW?BH1*L:"15/Z]$(W+)K^[7U:;K$'NTCLTR9Z',TTC
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MOEZB) ZR*.(P3'4;IDAR2% >JI\HBFF($$XR*T^SS>QSHZ9W@F[ 7LX%V.D
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M/'=CE1VZ\D:/,381I?ZA_ZOO='Z2E?87?!7UIBIT77S]!R7#TU\,/KE,PRS
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M^6T#D;-++H,I)[[:,@?A\$++XMEQQ/.A*(G2XV,;^:_>8$5_F@S+6BPEQD'
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M/JYW[=-9*WUSH5RW\MNG(8]?,S/BFFP=?!^Z=[#O%0$[31:#KO9O!\O2J;,
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M<64>E8W#T7<',GOIC=Y2W+ZE0QT\6EJ]B*_0AVS$ZAMZ;F>VHO\VO<M:_<$
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M,X@CQB$)PXP'61P'D54"S*G)YL;9+UUX@^]:7-#(:TF_)W$VXU17Z'DFRO'
M69.="2*.&.SD5)/2DHG2S[G&Z!D[ N&B6+XO-\7F\=L]6:WZ&991P'" PP B
MCA!$5 20(IE#&H4YPAG%041-../(^'.CB59$T,BX"Y(QHX9C")YF P>X>"8
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MK]($?U]N6D_#7T6]Q EG<9!FD&.D@Q82##$7#'(>IH)$(L!!;KHU')MDAOO
M3D[0"PJ^:U$MJ.8HI.=YQ050_DG$'B,KZC@'P@4\<73HR4CAG')#!CC[67L'
MWW7)*D%J\4ZT_W]==A7NN\I#.Y.V:?+4M'9Z7,:4Y'&F"(#'J8 H$#G,$V4T
M1EDLTRP,):+&N2)C!)@;3?2=T_A6@+M]VS32-<(R]WF,6HWS;C#?&'MFF%Y\
M\$NOP*^ZCTG?8Z,OS;9W+70=[%I%/*-O[BORO0H3>7E>6HWBW&ILSJZ&E5OF
M$BA/.%1&#3N9*^02I8=.C(O&&=F:3]2U$/L2NNWT-:N*)J5[UR2>A2D*9!S"
M(-'U@5@@8)[*4*U4B'@4QCA!5O6!#.>=VWZRKP6]TA+7_VG9J,\0;;-X  \8
M>MXO6HEUL8I=26TM] (,Q%8&:B>XRZ9^=E"Y:O%G..NT#?_LH#AH_V?Y^(@&
MWU+JWN&/?Q-DM?FA<WL4+W;YJ(CP**,T@(+&$B*.,DB0CMF,12(P"C,:FC?K
M/C[/W&BG%Q6TLC:I?KK2%K/HSWP"U?-VJB.L/-/+49A&)$6?PLNB-[4;W*;J
M,VW]-;-K$7T>C%/MGD\\/5WKYO,J/&G#;/#QL54=ZXWN<M==5]5+GG(2B22!
MF$2:&26%F&()U;F?T(!E.$3Y<J/K39H9:,\GL*+$W33^OJM-Z4RPWAD274E>
MRT#. QC3*)99 UZJBR5SDD.L_YFD>1XQ&>*4Y<M2W&E'SZU-.<P1:.(6S8/9
M_-IG_PENFBZQSJ$U,VHO^=YY]Z<JT=H$^W.(C"AI^;+:SJI7/AM^XD*5+RMW
M6)/RR.?LC4A=/E=]E%^7[\1#)5C1)R!U<<3DR7DKEB%B* VA0"B'*)$<YC25
M,$@SEN<)40=?HS;TUC//S=#LA==^(SX0O_G6DX$"A@=?^Z4X;XMZ ]@S?>RP
MO2[!4/*F",U0=I,3\(4HFUNPWM">R*9UBKJ5N3L*N1,&L-UXDYG$H]0<&LGC
M!AAG-NLX_>M2#=5\]3X6I=!]6NNE(#@*\E! GF4Q1 %/(!$RABP6A(<\5R:A
M4735F7GF1O=-WLU>3O!=2]IT%C:]13\'K)G1YP NS^0]"BEK*_ ,#HZ,P6.S
M3&H3GE'UN6EX[N/CZ.#-ME8CU?7;]3TMRAWOZ&)/5^R?VZ(N1KCE[0:=T7>\
M%QP,)&\,O[;ZU4!X+S[Z<;@Y>B<L)Y_T51D'S/,W:.0HX_?9?7;<U4]2K'3T
MVX=U]8VLFK#LHMRNM[5NL=16(=9)FU_6K1#:#7'[@Y1A]$E]\D=]Q92IN%UI
M+XC^F#JN98+I$J@DC1!$413K,&@$ Y:*2/",\]2J[)]7:>>VYRL[F("]3FU3
MVUZ7)O=#*P0V2B,01J#5:0%^J_3G]@@TS]GZA/Q^+<QMC5DL]A06RS"G>J<J
M5(L,M;*+X??@V=+NOA*+E[\/ \6;S[LU@KPOD$-3RI^LDQMDWF%_R:SS/^G8
MND%K]L=U76\%?[?5;>N_B*I8\[9[RLNM$I9!R*44$D,<I^H<&:8AS#.40D:E
MS!!-B)1683(C9)C;?M/V+*%-SY(G311_*4I0-XK\:EM9R'YAS/8&SW![9OQ6
M3-#*O^C:_"Q>;AHS[(G8UKY0[YP4Q69[HOW9B/I$H_%T5K'(7H*):QB-ANBP
MJM'XH4;6WWP2!K0+3UPBB9(P2@-(413HXID(THQBF/ HRV6.<LEC&QH\,L_<
MJ.[YG703(S@LY&!9!/,(NF9<Y@ SSWQU$ 6X$])A0<G3*+BJ"WEDEFG+.YY6
M]:!*XYF/C^AAHBCFGK#'-K5:;35-BF8B$DHBSB')\E1Q099!JHPD&"M^" *)
M@S0U;U_RT@QS8X%>2/#0RF?1B.-% ,_?B%X,B^<7?8=(5T[BBQM@+)J37 K0
M5'U)+(&R:TQR"H13/4E>?&ZZ=B2GQ'[2B>3D!T>> <6=7O:OXD%?199W+Y66
M%D)2GF4,\B!1Q@Y#"20Q"R!F282Q4(? U++GG,&L-E_>B4H"M$+;]A4U -CP
M[.86--]GM59:L!/7?VUM"X!<';X,9ISVL&4.P<'ARN+1<5S3E@P03\VQ[L!>
MO]N*)6,B05$FE/U$(V5)808)9PD4F<Q#*05G66 3XGMN0BO#:H*0WV];VDP#
M(-B67.&O<WL%[XY9#YW@=OQS%G0S\G$)I6?FZ40].',M="HH%<KF*+@[TC$%
MQA'CG)UN4KHQ5?XYUQ@_9W]&>WKJ:VY_ZS:E:Q?E0'!,PB"+8: (!Z(L482#
M<@PC'/!(ADDJ"#,]L)V?;FZGMZ\WOP/2R&E^/#$ ]?PASBU44[MN6GG;NT(A
M1D6P&J!H?N)SB^9$QS\'J%J=",U!.G$\-!ADLK.BN4+#@Z/%4_:$J[WMZU(3
M]XU\^T-?NNRR^MN#ZE7)WXA2R&+3GUF;0E'[XT^.<BX"CA4+"UW\7PB(8\E@
M&LHL"X, H3@V.U\ZD6=^)\^]2KH<W>:' *Q13"<QW'?%+]B^D"GMM+/WSUV^
MEN>W@4G7Q_,N,5B8&PE:;8;U83HOEX[$[U7J75Y=B3M@<A+VL$[F&\VDZS71
M/C31NEGM5<YP/K&573['9#N=,SB&&Z&[01UZ0/IF"\_>4()%*B3&$ ="]^PB
M%%*.*4R2@(HDRP(<6O7LLIA[;D>6_D3?^D'N=VTH''A"CH!_@5/D<DA?S3_R
MH:@U^S5-8G;M8WSPW04 ^O2C')GY]5TJIR$Q\JZ<&6(<GUV7/T5;5;QI$--U
MJ![VC=F=;#.D$Y 1AS+.,422!A#C-(49ER@3:9ADB5$-5_NIY\9F \EU72BZ
M;VFOWK:]^-8NAA&+8D9S?J#VS'(.4;:F-7O '+&:Q<23DIH](,\Y;<0(XRBM
M]T)_6%=?Q8/Z-OY0+'HC_TYT0.FF7DI. YKE(20HB2!"-(4Y2A29<2Q%%*<X
MCL(1]5/.3&OT8DU?3N4MJ7^ IH^*3JMY(-5&UW%7)'K?9]>M)?BST\&.Q<ZM
M@QEUN8!UHA"B3M(&R;VL&L"_GP/0FJ ,87'$2N=FFY2*#%5_SC^FCXTCG7UW
MEOIV?<5YD_Q!5OJF\KI\2QZ*#5DU18N6F&"6R)C K,F_$-I72@($LX@@C!*$
MN#0JY&(]\]RLJ%L7)&..NQG=>$'3,_$,9&YJ)>^D;B[*M8NY$WS1ULURQT+6
M:#GB(_-Y)V4F:SB><Y3] *.]6,5&G2Q_ZI(F&_5=*M21LKU5&E8TZ8I<:6_"
M[9_K)<%4\1-6YI*.'40A8Y#0*(,BRJ)<I@G'.;6+(APEQ_QN=SYL=4[2D^)3
M?46ZA>Z(B:S=7"-6Q]CAY1=Q_ZXO)3]L% ![#=IKZ$53]8[I@*NA,HO6'Z84
M<>KW&H^C.P_8"!FF]H6-A^D%K]@%@]G?BP^]<+KNWS)B5,1I1B!)I") F660
M<)Y#E-,PY;D(:1";1#>^-+B5=399\5+YQ&_?<9KY+><!@N<OER_!95JWNY;N
M BC,[V\O@62BZU@;:*SN5(_I?N**]."1R6X\CPD[O, \^IG7J&+35R6XJ3ZN
MRSM1/2]7DNBRS +G, R4V8<RS& >*?YC*!99FL2<(J-:]I-(.[?S[?DJ-KM:
M)6K)U4^5F$4-FW-?"C-#<S9+[7E3<%?#YLFWH55[OC5L#!=H%C5LSLGZ;U3#
MQA!VMS5L3"<=V=YI7WO@JN1-@8@?ZY5ZOF[OA_85L"G.>,@%I#)$NK<QA206
M 0RS/" QSSC*F9W[P73J^7D</EY?O;G^>'U[_?X;N/K\#GR[O7G[7W^[^?CN
M_==O__?_E4=A]O^"]__?[]>W_[#L_F2Z&&:;@ ^ /?/Y0.3A?;.7CD^6Z+AJ
M^60Z[;0]GRS!.&CZ9/O\.+9Z7V^*>\5\-_(#*:K_)JNMV/VPS[?LFO!@'!(A
M@APRGNM26X)!G)$ !E&2H2A,8X1"&_/99O*Y6<-:4-!(:L=(5H";L9(O&#TS
M4R^VOBS;HPD^J9.D$K<M^7RNAY0U1XW!RA%/64T]*5>- >4Y7XT:8^1M3S]N
MYRLM^8 LNZ\/ORF_:@-1U^12'_B\5I9@]\\WI"[:SO#+*(F3(,49)"D2$$5Q
M#G,=/T,C$04LD#)+C KE.)=LOFS79\@UQL30N.C5 ^L2[!1L/C54$30Z=B&\
MEF&$[M;=\&[I-5;3M\]WL) G5NG<^MC?+[G&TM6=DS.YIKV'<@WGP=V4\PE&
M%#<3ZDM?;LB=VE3VP0--Q^;F"F#U5?P4Y5:\)U4I^#)-.0Z9D!#' D.$$(.Y
M;L<7A#E'NI%<'DCSI$V[R>=WHM[+K^TKLH^A*?8J@*K5 8A&"8OB8'8K<_Z6
MS!_:GOET /.-'(8J#60'G?#@O5^8+8JS>8-[JJIM]M_N_W!4TFT4=*=JO=D-
M.%T1N%&*/JD.-VZ$D67CM@\/JV[<ZU*NJ_OF*_AA77VI='G8S>-;M6F1U>;Q
MNE2;E[ZS_+U4P_]9%=J ?JOV+?6L#K+8Y5UV/^QBV+I C&4<IPG*LA3B+*#:
M#1+!/ @$3"2G5 8RHSBSK#XWF?#SVZ@ZX<&CDMZRD-UT2VYV8)CG,GK> ?OU
M:V+2WNYK/O09ZSO1^Q:N#LOK38ZWJRI]TPD^;;&_R1?DH&;@]!+8'VR:T]&-
M_*)>P]Y4^KAKW\>#.$AQF$.:Y02BA(60BE1M-I*P!*5J,%URT*P6V*F)YN9B
M:AU#RH@>2CNB/>)9@,^?1ES!YIEY)T/,_&#A"KF)CA$7(&AU:#"!Y<01X>3C
MDQT(3)08FO]&GQ]G[/^?[MZU-VY<6Q/^/K^"P+R8Z0;,/9)(2>39P #.K7<P
MZ4Z0N'?/07\H\&KK=+G*NU1.)_O7OZ0N5;*K2D6J*%D]YY)V'$E<ZZ'T<'%Q
M77Y3Q>W=5LEK8Z*:[<4OC_94X:.NVVY\?-R66V.!6*]4>[R?Q'G$&),P4G$&
M<98@2$B:V]3_#,4*)XDA52^3W5>$^1G>K0: U2HTG8' >B^\8\OQP=."&2<Z
M,FL=1K9101KGD":(PURD0C#!2$:\>@"/.2G3- =>K:L<PO5F;.C==C1C CKR
MZKA[O1O902V\]1<U79LZ\E^!-\7RT5X]1F#,4!0#[3:\AY]TSS 4G.>6_^#G
M#%N";)"A?8S92WRV Y=-R ;B>4QY9"B-2V;;FFMCN2<,1BB1*(GR!".O1JDG
MQID;<[5B@DTE)(#@OI(3+ O7K))SR+HQ5@"\QG:8["4$M8@CQ+F<@2$0LYP:
M95(".:/J<YXX=_G MFPVB[GQ#)0+G<6,QBF'/,JEL6N8AD1I!&42<T:3*%:I
M]&K&UGWZW#[]I@6;%;'-J"NOP$IY?O9/$73[V ?C,O(G7LG5^CL#YC@<U3=4
M0[4GSYZVC=HQM0Z:IQV]R-_Y]@_%EMN[U\8J^+BY9:LFR=;L4N^+Q_L;]JTY
ME%K$R.X0$P4CEB<02ZP@C:F &491Q!5-8^345]9CS+E]V8V 8,N^M8>I[AXE
M5YS/N^-&0&_D[[^6&%B105?F*]!":L1NPP+"0^KNKQL!VHE<=V$@]O+B>8+5
MX]!S?=)DOCU/U;IN/M];A];U%.M[91YW_;B]6]NRH=??"F-H12(FG"10*VT[
M7:81)%FB(4IC+<R.*\^I5_&IX\/,C9=K*:L7?"<G^-U*ZEV8\RBJ;L;7Y5B-
MS,)#8!I06;,/A6!5-(\.,G'%S#Y%#ZMC]EX],,9'W"GYN%0?]3_44MZLVPK"
M^U30.KP[E]1\^%I 0FEL2]*ED*4<FSV8PFF":4*DD^GF.>[<:.(@E=M*#[=K
M>/^TDK8G:;C.@AN+C(#MR+1R$M:?76'U#W3Q RE4E(KCJ-.&F/A!<1 ?XGG[
M0**R3N=7K%32]G<P.];*)KJV!2%OJ^"45]_WES2%/*__9!OY\<%>6/Y3E=:3
MO9)M_:^;M?U5UXM]>[NIJNJ^7VTWQ:HL1!6MOTBH4$+*R%A B80XSJU!I!5,
M<I[+.&5)GGF=J+V8)G,CTR>'13N9P4[H(;F@+_>:.'+S7V'R1V;[2D%8:0BZ
M*( .#(!_!]WK&BA A<45:-"X C4>=1I^6]AONZY^?04N?,'\UY27GMQ0J]2+
MZ3'MNO?2TW6PDKZX0/Z^W[=:FZ&*KVJW/?EL'O]9V3DHED6EP2_KE30F@KG,
MV &-O[GV<>PB1IO$AD62R(A&,3>+;48A)E1"3G,%,X:PDD@11IS*B847;6ZK
MYQ/)P5WMNRNLT&H#M%+@!UOE)8G^_H_W[ZJ?XK__Z.X7#3RMYSW2+S=9(Z]V
M.\5 QWEB=0-/E;L"3V?T;5L=N''+[E2\ HV2+S:;[L[PEYO5B7SF+S"[7@[V
M<2:@QP\?>,#)W/7C -7UZH\TPL"2:NO5K>VN8#TO/^]Z[7U6#TT+#!MD7!BY
M'FS.A\W=>&<^F45,$9<)HS"G(C%;X22!9H6.(%.,<1%1FFC/-+U!<OCPP#2!
MO^8SR#S+J V: +=-YNB@CKQD6OFA5:#JZ76U:U/85&FWT@8LL78)6*'JK0V2
M8=KB:Y? =%")[:*'7=S&\/62E66A"R5??>_$KK6OV1M#R\]:A48)DBA.8XB1
M8+8A6 *YI@@RG3"5&PI,,?4CODO$F1__M3Y@&PHN.L&8^S:N]E^*O<Z#NQWZ
MSYWKT>LT\S'Z >U.#;#7PWK3NC&RNV,5J\NHS5]#P!J^;Z*_*"_527$P:#V]
M%8<_\](SYD^;M35N.UG$3=$X2:*<$0IY)%*(LXA 3@S;D@@K%A/!<^(5W'MV
MQ+DY<[K\V8@,.C)?>JI\"G??\^0 :(Y]MG AD!><(Y\!)_@)\JGQ7NCL^(SZ
MIT^-S]WH1SI2%8OK1UF86?M@)\]ZJ+#&1.2Q-=>T@IAI#CE*-!1,:,X$5UIK
M%WHY\NRY$4DC'FCE<V.,8Z#U<\.%4(S, LXH.'_N/?H>^;!+)?YVN_[ZO\Q=
M]3=M?MA_RL>>-<E'VZ-$^WGV73*@W. N9'67A9*@+*.4FP5>Q0G$/&:V5R"#
M3,E8")I+IIV6^N./G]OGV WW5^=R5US@.W^0<ADH(W^8W4#RL[D\+GAX%.B[
M")>)CA.N5X#99CYE%>RP5%^;S1L#Y=9NU0RIJ,VJ^D=CS&SOE$T* P\-JD5]
M!"'6RV5U_!NJ/M])Y/IJ\!W>-%V=O9,"/ZFE=_HJ?Y/C[6IKMD[OBJ7:O#83
M=;O>?%_@+*5*Y3G,>6YV-5KD9E>3<XBEXI(J(G7B5-O_Q//GQG6UB*"2$;1"
MNML?QQ \;X-<B,O89[]>D'@9(SV*#S)(CCUO,J.D1YFN8=)WV;A5;VSA';%(
M,ZT3&F602Y:9SQ@ED)$T@9+2))4QPEF<CE/RIAI_?F[?2BSP0[%J"MTX!I@,
M0Q\KG-)($4ASG$.L8@E))A.([.%CFL010:-4MO'&?N*R-E6?0%[-A#4&&B/@
MP3!.-2E338^;+VDTT$=F<L_2-Y7XTU>[>8+:Q*5NZK%G6>?F"2Q#B]P\?<C
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M9FX+32LH9,U^?VF$] R!NV1NW!P\4R$^]A+4J %J/6"E"-AK FI5CGAA:G7
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M/LP^/ F_0)BS"&50I@9YC+,<4LY2B%",<AI')-5.V:JCP#_! O#"\/N9W2%
MG<B<;I%\VX_:8'OX'!2![=R3P[V(_7I.^5-VZ=G[@J3@JLW](I-1FB@2P90;
M+L>I2B"7+((BSQ!EN<XQ]Z*5PR'F1B37MQM5]]ZQF;<7)=A: -V(X3)8QC8'
MGR;27H&;/F NS:+MZ#Y.$JT=X"5S:#L*GDFA[5XYE8>P_O4G>Z7=T*ZV_ZG8
M)E[$.):2DPPR@IBQ[C2!)$8:"BD50AH)I+A? Z!0HOE\*--T#6JD ]^->&-[
M 4],UUA>P,NG8+Y>P.:?K'+F+\T<_F??'$[@!.P'_,6<@"?$FKD3L!_,RYV
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M$>5UX#] AKDMM_N/M$ZFN-\58@I84?+$=+CM\T8&>>3ET*6RY*X>VIC5"2Z
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M=8KX<!]R;INZM_</R_5W96Q*\\0[FUKXL+'E'U@)&'C8B6U-T])J4O^S^][
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MQ@\K.!AY+K$$IR#Q"" X^8A+<PC/6I[E*=.S6C$76DJ)4I)"1=(88IDI2+7
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M*K\J):/(.3<J^K61$I3;M?@#K&OAP0_%"I25P#\.R- <87H=SVM??M)&9L0
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M/QV[KKDB?=Y?%AB_L>VTG;0U@'MY&Y_-V1JU@V!T=X(%AG,BM]?EL'KYN3Q
MZO%LN3QE,E^6ATI=[Y7/;:>XN#LG'\Q/__N_M;\Q?]AJC/_[O_W_4$L#!!0
M   ( ,>"358^EZRYN>P  "7E"@ 4    ;6]H+3(P,C(Q,C,Q7W!R92YX;6S<
MO5F36TF.+OA^?T5.S>N@TO>EK;NO*:54E>8J4S))U=D]+S1?X!'L8I!JDJ',
MJ%\_<#)6!AG!Q4^<H[*V5BFET'$LG\,!.!SXU__]Q\7DAV\X7XQGTW_[$_\S
M^],/.$VS/)Z>_=N?_O;E+;@__>]__U__ZU__+X#__.G3^Q_>S-+E!4Z7/[R>
M8UAB_N'W\?+\A]\R+O[^0YG/+G[X;3;_^_A; /CWU3]Z/?MZ-1^?G2]_$$S(
MS;^=_TLP$0VB!^<P@Q(Z00S,0,90DE5)&<[_G[-_8=JX8CT'QSB"XB5 9-*#
M]DYPXZ-(]*_K1R?CZ=__I?X2PP)_(.:FB]5__MN?SI?+K__RXX^___[[G_^(
M\\F?9_.S'P5C\L>;G_[3]8__\>CG?Y>KG^;>^Q]7?WO[HXOQMA^DS_(?__.7
M]Y_3.5X$&$\7RS!-=8'%^%\6JS]\/TMAN9+YLW3]L/,GZG_!S8]!_2/@ B3_
M\Q^+_*=__U\__+ 6QWPVP4]8?JC_^[=/[QXL>3&C'PGG&";+\Q3F^.<TN_BQ
M_N"/KV<$BX_AK)*]^LSRZBO^VY\6XXNOD]L_.Y]C^;<_7<S.:74AN%BO_7_?
M_=L?[\CX.L<%(6?%]GOZ@^M/U,5.(PG_6.(TXYKEF]4FL_3@AR95X+/YS;^<
MA(B3U9^.,HY'JR^_BHOE/*3E2&CGE(PDTE(T**\]@5))"%IR'95(T?*'$JCD
M+XC^E7X6F/Y\-OOV(WWXQRJ6^IN5?%:R>;3<6D;'T7VS';_0SXY"L;Q$3MM(
M"DZ;Q&;PBBDHCO:*L]%(@R>1?7^UAU3?U^VK>?IA-L\X)WMRLUR8IT=Z?HCE
MZY_X\2MI?+J$=#Z>Y)M_70U+"UTM9PTDMU8+D?NG'XCK@O,YYO=KK>QD;L79
MDJPLKGZRA<9?3:>78?()O\[FRQ%3:'F@O:]B,:"43.!XXH")-B4*%]"Z)IJ_
MO^I>"!##1\#1DAP($C[B?#S+/T_S&SJ01R:5D@C!1+LE:<@2Z6A-")B+EE'&
M(I)L H4'R^Z%!3E\+!PORY[!\/IR7B7U=KQ(8?)?&.8W/'#&=4C$@[$B@=+*
M@<\I F="):O1^7P:'G:MO!<DU' AT42B S$17^9ANAA7V5^;.>M<4#D'R#84
M4,D+<-$PT"0M*YF4WO@VKL+&RGNA0@\7%4TDVC,J?IXNQ\NKM^,)_GIY$7$^
MHM@K<)8-$)ED[&SA$).--0A#J5FQ:,)):-A<<2\4F.&BX"0)#D+[G_!L7(4P
M7?X:+G!$ADLYDQF@,^3V("8(A<)M:3W!.0;#3XQXMJVZ%PKLT%%P@B0'@81W
MTS2;DPE;"?XSR1]?SRZGR_G5ZUDF=KSPY ,QBH<2R::0/^QE)'^8*>Z28*'@
M:0?%'D3LA1,W=)RTD_,@8/,E_/$ND_C&9;S.9%U;PL(+BU89D)PDM8JG'18/
M!K/D(089> M+LF/YO:#BAPZ5%K(=!$A>Y4PJ6%S_S_OQ%/DHAN"2D2006P(Y
M2L) U+'ZT,9Q;K1-X;1<Q<ZE]TM9L:&CXU2A#A098B2XQ1)D 9&T(K$4<J$+
M.5&86)+D8&EA62?($/LA8\#9S#9"'1(R7M-O/\R_S'Z?CC+AUXFL 0O+H )1
M3[Z5( \K,B^#XSJE=KBX6W@_5 PXP]E"H$/"Q,IK^C#_.)]]&T\3CB)Z1.X-
M&*-(+CIF\%$[BKE3%9A*V3<\2C96WP\= \YY-A/MD"#R<;98ALG_-_ZZ\JJS
M#9%B+H1D P>5%4)(G$-QP0>7.2_ZM.3G[K7W@\> \Y^-Q-IW7KSR,,>PHMNZ
MHIAR"5!R#\H%14%6#D1WL=K$HFS6)\'A_FK[ 6# J<ZC1=>SRFMIQ>3C^6QZ
MDYP3TE)X31P;DRPH+!$B8PDHR$Y*2QTYMR>I?7/%_50_X/SF22+L6?V?,5W.
M";I<Q"_CY82.,F\CDQB 82J5]@ N!P_9*.&0Y!%+.4G]FRONI_X!)S9/$F'/
MZO\R#[5X[?/519Q-1CQQ6;BR$(E7,EO6@1.$V\S)A%GT05ISDNX?++>?X@><
MJ3Q>> /9]#__D<[#] Q7J?A@F<UT+D&2@8&2.D/4] LSFDZQXC#Y-AO__JK[
M86# *<B313F(<. WG$S^SY2"W<\8%G2.Y7>+Q24=9#%B0"\,! R),"V)$8J"
MP45KDF?1,=,B(MBQ_'XE4X//0+80[B!0\A^SR24I8+ZZRITOZB6^L#%DHCB3
MEYN8JPGV!()"7U&T,BR>9C&V+KL?*@:??3Q%F(- PW7%S[J@HQZ#I(3+Q4AF
M;8H5#KAU$A0+$3SCQ$<2UF7%DS@Q?'AJ]?VP,?@<9 /1#@(B[Z;T-1+'^!N^
M"<MPS=8H!:5<J0 OFO@H,4.0":$D+S7]@@I/<S.?6GT_B P^$=E M(. R,KZ
MO0Y+/)O-KT8AB8Q9:D#/'5"T9,F'EA)$YA0XB^B2;7&B/%AT/T ,/O5XO" '
M@8//%V$R^>ER,9[B@@Y#YHVR-66J&5($;4D43A.,,W-&VVQRB@UP\&#1_7 P
MX SDJ8(<! Y^OL#Y&1UY?YG/?E^>OYY=? W3JQ&FC(;^#XB5^J MUA=PPH-0
M&$P2*()N<:>Y=?']<#'@]&0KP?:,CW>IS%]=YC']Q*OE$A=K';R=A+.1]2JS
M("(83>&4DHH<(ZSW]YR%K(-0'$\+4W>OO1\Z!IR];"3601B/S^<4:M]"VRA,
M3F60,A+-EJ7Z:E: 3RHXH8KDJD69]OTU]P/#@#.:)XIQ$"#X>!DGX_1V,@O+
MD?(J26DH8HIQ55XL(,:4@3FEE!4VY=RBY.'>DOM!8, )S=.$. @$$'0O:M'P
M+/W]\SF);?'A<EG?E-=D_2A2H*Q]UB!])CQK*2#0.0?9BBR*T%Z&TVZUGZ=A
MO^=_@\]K-A/S0)Y]+>YJSC'_=/6I4H+3A%_PC^5/],-_'Q5,PF@D6Y@BH^C:
M:"!3J"%8EJT1&BGR/@D[>Y.R'X0&G 3M1NC#,#_$UCQ,WDTS_O%_\&JD-!E.
M;D@FEGPI9;0#IW@&+I-2+H2"H4528V/9_1 R_%3H"<+L&0VO"-^Y8GSE3#O%
M2!*,'">G$L'8&HC,2I(*=]K*X)0[+49YL-Q^VA]PEO-XX0WD-+E["?V6_F0Q
M\C$9YN@8C,9S8B$0"S($B/1G444L(8DF9\?&POLA8<#IS18"'10FUET3UDRX
M&'1@H@ =9.1;9V/ \R)!HPE<D<!$."W1N7/I_7 QX'1G&Z$V0\:__OA(D._I
M#T[M*[5*S;R;EMG\8O7-AW3OU5[JT2>:=IEZFL 3FTT1+Z/-!6Z!DYQ H[4"
MHQ49 !D\J=DC<(V!(E:7C3#/B.:I[Y]T]*\3:NMB("(QY1@(?K: 4D* XTP!
M\^36*I9E,:<%#?<6ZZ?-5#,M/7  CA1AWT[?FNSWUPWK1JR@0I&0CB6'M=%%
M[=@7'4A=E&-!)G-B.>W&@OVTF>H2 4>)<A@H>#N>7[S+(R=CL,YKT-8%4#IY
MBF"K"XN:4*Q=D.ZTDI@'R_737*I+!!PAQJ$?ZZ]GTP7]9:Y9C]5CLE4N9%9J
M-N3BN!Z23WZP<6/)_8D_T0&X7,!9"%]'ZT_?+G:++.>XMR6Y6N#B0;%8(' 7
M(1;&;:#_]N6I;&X)B[@"P/4ZZ_V%D^7BYD_N-MHSI!QK+FX^^PF_X?02%[>L
M18)[?3 "TLE4VZE)BGEY@I"+=%$F;LM3K2&.86V3AG[<B98ZO[$F3:1\M%&A
M<"?.3CQ6;CCX.,>+\>7%XN<PGV+^%2F "F@BUL=F0<B::F<05*#HAT?M?:T(
M4ZHQ4!X1T2]23M/JK*6 >W0\ZA'\UY6Y?DU2^S _"]/Q/U8ZN&;I2_CC6E(4
M(CN3LHS 8FW8J'TFEC3Y4H+.8L4H4MYL?KLU=MISN7Z<TJ;HZ$JX@\3+N^GB
M<H[SMX@W+-D<F3/UVK\Z;RI&":L'CJ74SJ\Z.\_#T7AYM%P_+NP+X>4TX0X2
M+[^$^=]Q^742$GX:+_[^>C:?C_-L_O]>YK.+51W[FD]C<]*R"-"!Q\IGH##>
MT[[PDG9*-$EG>S2(]J.AGS:K+X2L#M30(]QNA$8G\+OI-UPL*P]KGW!$81]B
M-!8*SPX45Z46O#O@/J WDBN^B:2379XM9/33G;43I^=4(0\ )ZL7$<3!JVE^
M,_XVSA1VKAGY\!5K&\'IV<@5Z[00 ;!D7OM^)8B2D9A4,<;*8+A\JN7_<='B
M<U3UT]VU$Q0U5L$ 0'4CGE&*T253+Y&8J3?0RM 9S3F)1=HB407#GNJV=DHT
MWD_CUTX <I0XCX?!;!DF36#P>K98+@C5/__Q%:>+>\)(*DL7,$!M\0/*(@.?
MI("D8^2>)?J_IZHZCH'%+EKZ#;*Z2-8TD?H@DC:5DP_E+[-9KOQ\QOFW<<+%
MY]DDCX31$:,L@%K7T0E2@\]TU*IHM2%K&(5[ZGKP6 1MIZ;?-$X;?6\!40/1
M#^ L^@M.Z12=$!>O\L5XNFJC7=]_7HMKQ .S1J $$Y"8R-Q!-*9>NFC&I5>8
M8NM<^#,D]6N2.H%32R7T:IIJ&'F7NKJ1$1W,R&V6$E+1 11F<OIS=)!5XJ5X
MGKS8>&FW-49__.5^<SI-L=! =(-,X]QEIF[0+*21I%L'P6!ME$QFTMM(OEX4
MPG,,V8CC,S:/ENLW.=,<(ET(>0#'T!NDE=-XK1<R@Q>U1\6:MY&)*>@0/#"L
M34R\5^"\-U L;0YIA36AM3O\!#G]YF<Z.7Y:"7\ .'JU6.#RW<77,)[7B.'U
M>9B?82WK169%CF ='9O*< 4A% ,N1,](^?3+4Q6QQT!H.R7]YF4Z04\#D0\
M.!^6YSBO\KD3SUU^B4E"N_<9)!.9_"_:!%X5#DDQG7+A1?/6\'F*GGYS-YV
MJ)GX!P"E30&-Z"@F'PX=,%<G)Q=A:S\N!E9E5J+-L?#6&>)-&OJ9W]-Y#'ZT
MF >0_KO%]SK+]7ZV(*/IN"PF2RBUTZ>JS=^]9X3T*),0A07QY%O0HPS-8S+Z
MF>#3K7TY4=A#P$LUD6ORMTF'Q5R$9JD:25.;KI#K3R<PR*"*9B8S+9^J"3_Z
MC-I)4;^Q>1>IXX8:&, Q=7.O=A,Q1NDBBE1H4SE.#ILI$(75$#21[W0RNOFM
MPP8)_2:*6VIWQQ7F,:(> %)6DOEU-IT]-*(WW.0H+7?%@@U)@!*9^++&@"B(
M/#(18O/@ZFF*^LT0=XBCAHHX'%9^#:LIGM42_395.#M9\=K8I'E]UU$SWK:V
ML*W5CDD7J;-%BT\.1SZJ%N<D.'5VD'4(IS;B/Q5)7YIY2'>^W5L2X^O9E!B[
M)-ZNG;_9=/$3EMD<US_W)?R!BY__(#&2"L?3,+]Z1[["@H22Z%\2A9.56-:6
M>Q0=LT&X&GYJ7X?1*Y*S\$""\$XK+MV33<N/?Q/2"3O])L6[\,V&HOL!! JW
M+%[OYI]PBF5,;##N55(!R,NH74Y2A&!(O*QPQ1(7*FR66S>"\"-2^LVA=P>_
MTV0^B**25<WF;8@<O&2F$/)YJM,$F)?@Q&KDE,E)^R38D]/]CBZ)/2@3T5FZ
MO N@'"_? 5B6^GJ)#./B(\Y7S=EN)6*9R,($!\@D>2&^-L<HH<XF2;:P%&-N
M'@+LHJ7?Y'@7D&DB]4$8ETU.?@J+<1HQ;;B6J(![1V%+?=[D;<R0*5[QEIQ8
MB:V-S%9"^DT_M-'R,] Y7. #2#]L,O%F/+FDN&$DM>!>A !6ROK"J08IB!*$
M\ZY()UUL_I9Y!RG])AQ>!#G'"'T V/D-QV?G1/<K,F/A['J4XH?RJ+7H72&Z
M"4'6MP.ZMBU72F8(WB*('(5(3.?\Y,"R8T!U*(W]WN5U<<)UJJ5!G'S[<K@V
MT%SZP&H-<1"2H@;G/$1>VY-8BCN5)1[=4[-LN@3A $[*;M%R)#0/5]R0<7EM
M[;=T8 Z!"9L,)$^67W$,$(- <"YYM"C0V?PRR-Q%8K]G\1"PV41Y#='YPMV.
MZHR!.9[C=#'^ALU;'VW[^HOT07J6K49-D6[7_%!N;QVVK'T+8.-9EID.>NE3
MO<M$)"<S!\#D3>$&LVK>+.E $MNFQ+3UQ0GBT@7B4A4R]C[33LJ6W&IT@;92
MZXN PU-BG9V]7:+CZ539(7(?Q-%Z7=+X2#:5&V+M0_D2_OA8*ZU)<\OE?!PO
MER%.\,OLXTH3=ZUL73!6!_*D ZMW<=E#D$R#Y ZM95:W?R3<B/1^C^*7A&H?
MNAY =+V+[;]-YW2RC?^!^:^S274]_A+&TRJ+#]/KT=9C7+R:CQ?T5V_H/Z=G
MZT[+ZRLZDM6H*.$=*Q(8JI5;5%,70D#F0AFCM RV=?NQSI@90%G32T-SS^WQ
MLCCY)]PP501)*+),QD'0=9*23!1]ZBR 1XQ"QUB">VJ,X1"VRKZ;I-N:K7^R
M37(H-@:\/?94P\@&Y2.%T\ %6E#!D+<H:P%<G>\BI4 56U>-G4CR &K+!@K[
M+G0^@"OT+9S><#DB3KA-6,!$+4!QIR 4$\'F:$2*Z$UH[>D_04Z_T'Q)[[V5
M3IK!ZP4R9C^%29@F_'R.N%R<F!][^*W.LF%/D-P^]_66")JF<9A\G"W&#_K.
M*^]MX=P#9RA!L93!!]3 M"Y&"\^$>FKFTHD)KYUT-7DY?5=7[#.ADQ'D"[)<
M&W+5U@%)@^,F:;0L<-ZZ*.,A!8/)<[5!PM97T\>)>Q#9K37]KR_G#QR!8%%*
M;R5$*Q%49 JBK#,95.(V9!%L:%UBNI60?L%SBFZWPN04,0\"+:_#XKP>X/0_
M/__/Y?A;F-1+C5?+UV$^OZ*(Y3_"I+8L3A2V2TF'MJ@3>=!P"$9G0#IZ#3J'
M1K=&SUZ$#0%-)T%@T]]IKHT!Q([K/L4U-+B+BJ^%-B*CK((@)XYDE>O= 6T^
M)SPP%C6J[&34K>/")\CI-]71'DZM)#\ $'W"A+0?B)4:>]XP8="PI!R9;4WX
M5R0J<+DXD$GQE)@TQ;2N"=M*2+\167O@G"[M01QN'^?X-8QOGN:185VE-!Z(
M:Y0\9]JB(Q_ DIA6C;F$49"RU6A09ZX[&*?R'%G]/@-K#ZC6FAB 17I(O$LA
MH]0<3+*T-Q0J<"8P"D"LMK0O1%2MRZ\.!TQG#[?: ^9XZ0X@E?AQ7E_O+J\^
M3L)TU3>)?+FOJYK<:5X'K?@>PP(_U2JQ#^5OM",JNZ\*H?-52I<7EY.:5GFJ
M^QL*+I@2"+840;:X]N_R-M9+A*"-M23VUL4]W7,U!/^K27 X,  ,XC!^1ZJ<
MGHW)IU@+>EU$-+E<79S-9OGW\60RRB49R5( AW582>W1''S.4*Q.'CDKA;=.
MM.]#UQ#\NR; ;*Z$04#K$Y)HQHEVS-U4D]63\1O/@O&<BT^0?;T%\QDA^LB!
M<2M%P*PPM;Z(?X:D(?AW30#54O2#P-*;ZX5OWXW?;I21EQ3MH/<@:XMO5>B7
M8(0$:06B,BB%;'V_L)N:(3A\31#42. #B CNQ33W=H!37H<@/!W4<M4GG*)F
M0U)*CND2E6,40W=1^K!)2+\O]AL"YG0Q#P K:_I'F4)>G6HV9178F.CHT'4.
M= HB9R^-,*TGFZU7[O<Q?O-[F(,$.8 (\?TXQ/%D72 VS9^7L_3W\]F$A+ZH
MH<+RZBZ&SMR)$B-@)N>>_/T GL<"7CHGN,D1FSO$^](VF"+R;NZ!.U'1(%R<
M>YQMIFR*J"T&F(;, H+2Q)#/)#4L.C&=1!&N=4/DW=3T>[O7C?YW@^P450P*
M5E=O9_/7DS"^J'*[_DW^[\MU;'#3Q\XE9C"3:Q<5UA@S6B Y(J"0J)C.C)?6
M52R'T#<8Z)V$BAU@:ZZ@WB<;_8)YG,C^KZ?TW/+YYA*_S%Z=X31=C81.7)I2
M>ZD$6:M1(T2N##D:4I#G&)/S^TPZ>GZE?H_%QM#I0+A#<+Y3FEU.EXN/X:K>
M<=;4:DKS2Z+CD?1&(MH2'>T#EYDA[S*3=8_T.R>T8\4:X5QS#WU_\OI-3'9D
MI[I2SR!.R=H LTKHM_'R_#79W-D%SF_WU U72B09,\_ )*?]9&HK@$@>;%+6
ME50X)M^\WFH/NOK-6G:$MN8*&8"!V[)1G"TR6<;)2Q5NW1XJUBC9>^.,C"4+
MWOK"\$ASU5G2LF.WZDAA#R$;,9N>?<'YQ1N,R_NY^Q@YF4^$+,RJ((/,JA(*
MA(_9"VM2:A\,;J5D,"Y5AX'@Z2H8Q/%V_W;[UHK>8\@P[XR*9$B](H:4YQ!<
MSN +DS77S[-L76[U#$F#<:&Z U=+I0P"9:LK@'NBN\>+)2N>ZC!6KFM[KZ)X
M+8G0H,F">ZFDE*F3EZ9;J1F,P]0=MAJI8EA.TXBV &<E!"!Z&2BI%#@F \0B
M;9#!^9Q;]_F[M_Q@W*0727P>).P!>$M/2"0*ZX4H'(S26"62P#N=R*ND,YQ9
M=#JW[K9]XOU,9Q>^+X*B1JH8@/%Y/;NXF$U7_*P>^=SO#FC(5IJ:>TU:D(2\
M%A"D$K65*TLYU%$7K5'U!#E]/_]LH_''#\V;B'\0WM''FY7O^!G)K$P(EH,,
MY-@IYB.XA IL-%Q;IAE%I>V?.6R2T?>5<2?8.57<@\#,JYQ75^=A\C&,\[OI
MZ_!U3 ?FO7TQ$A@I .4<2@FV3MPA=XX\.? :M116*-:\_.UYJOKNA=$)HAHK
M8Q@ NRMKWZ>QS(@XB!0W,(@RUOE.B7:0%!Z\D9F+E+3CK6MV#R2QW^"N*^AU
MJ*9!X/ 3+L-XBOEFC,*#YQ9EG,;+D12.NZ0<&%&KAFQ*X'(=!90Y4\D88T5K
M0_<\5?W&A!VAK;$R!N#'/Q;4B-R 9",GL6 *M01>TF:1&1Q)+EG.Z>]:7^8]
MIJ+?8+ C^)PH[ 'D$IZ+DD>)#G3)R;3R(!DH+3AXY1Q@$((BY\"5:CU*YSF:
M^BT=?NGLU.EJ&0#,[GF.CX</"$8&%4E0.J\>UTIR)24O('22B F+ZJ#88#<]
M?7OT'9<5-U-%L\/NI7O:K=M#GN.R5I4]Y.:T!G<//_PRW>Z>8.8E6]\Y4YRN
MP[^DT?6E5"K@/-= IYVU)1CI1>MCXB5:W]W;+"3H#_/5FGF58KD9?S;B4O H
MB.&2ZPM#)NK#GZ2AB)),2$99T6%V=!=9?6=)&V/F"2O61#&#" T?F>97E\OS
MV;PV>!Y9[0/Q(2![0]Y$$:E.9O04\=H<R'/5T76(LDUR^LZCOARZ3E+$ .+!
M)X_[HAR=ZQ3L1)^(@Y $A"PM9(S2H<-B?>N)-=^YY]445<>J8A#&ZN&MPTXC
MK'@T)7E# ; C(QP=(R/L)22=N&4Y>VM:VZW]*.L[>]HQV#I0SP!A]\@Z9\M]
M%('3OLD:E D"(E+0[9!DIDO!F%K'DD]3U'?:]$5A=I(Z!@NO=XO%)?$B#&9I
MN"1WTE=>LH60- ,M;8C%LH2Y=59^-S5]IU-[@-41:A@LI!Z4=R3FM#<,4%:&
M7*K]+:4 )367O#!;FC^,>(:D?A.LO8#K6(5\O\-0M^353TN%/?/Q%QF%^AQ3
M[5-B3UP H"7G2K@$+->., %K<SR;0'$=8T:O1>IP_NF^=9DG</^EOHX<><3$
M*3ZI/9P=*#K5P?L2(%F?#2]:RM"ZX/TA!8-)=37"PN-;QJ/E/8 $Q"WU:XG4
M>H[9M.[65W^,%R-7BD@R<W"IWKZZX-;MV="CX2ES8WSKMK5/$C00+!VAZ5V@
M.5GL \#0!@]O9A=A/!T)5SP+QH%S]6U:2@I\L1QL4IHAMXZIUMFKK80,!#.G
M*WK66NH#@,Z]I-LO>!%Q/HHAH[8Q@0Y(KJ,J IPP')@T*D1?;P<Z3'JNB>@7
M,@T4NSNU>824!P"3'16OU\SPH'C)/$*,J&NU10:?N:\#QWGDJ'7!YCTXGB*H
MW^N7]O!I)_TA0.GY"M9KQARS-J'24!0R4(98I#U20":;;2#6D+4.$/8FKM^[
MF X@UHE6!@"WS1+6:RYL8BD7'H"S4,B!I-]Y7XO1F,^!I:!<;M]R>ALE_=ZS
MM =2 WD/ #6W7N-[XN4=_78Q2MHHR[R%Y(RH5T$D%&<LF&Q-*9HK+EMW^GQ,
MQ4 *"QK&7\<)>  0(:,XKPT;WN#Z?]]-'^<W/LTFD[>S^>]AGD<N6V&=4J!7
M [TT*W5[10C%2F5,,$RT'YUP$(D#"=2.1,2C20K=J6< Z'N<EH_2,^9LAAQ+
M6O?XH]#" P\Q<J&5(0O>VCX==3/2&8(Z5?FF_3I)_D<#Z"O.Q[.:TI\ONWH.
M$RW#$%4$6<B6JQ@,!%X4))Z$R *=;3XIZ\@W#)V=<R\*I-,T,!@DK2?57#\_
M',G G>9!0$9E0'&+X,QJ^'N(B7BQS+3NS_* @'[#LY?$S_%R'\3M_THPG_#K
MY3R=DZ3RF\LY&=./:W"N;.R(D6=I-5,@8R##ZD4 5TQ]U\$,)LSD:;8?&_\<
M5?V&;2]NH-IIZ'#4^37JIGA6LQ-?VCX%W<'8NDL$3Q%U]%B;0U+0RKV"Z(6&
MR))%X3W+MG53CF>)ZK=@;BC .UP_P\'=72_WQ9?9CM3N*@<W4KXH7U^:I1@U
MN90E@[.>_((D"A>>,Q-;N_1[$]=OA=U+XK ;?0T@AMRG@<3'.M*2=+I<SL?Q
M<C6K_,ML_:B.(AYI!%:+7SOSK@8"NQ#(XRBYD/]:*.AI?3"?2'*_E7LO"=J7
MU.T H+P2Y+H"]K%_LOKUIWJ$5(&0--836K/S7BORD"4F1UZ++Q!B7M7V.U\8
M!>RB]8B3(\C<"[+NGP&R7>MPN#!=>3,[.+2Y1%E64]>Y "5R;>!C,EBT/OAH
MB=O6Y1B'4[D72/T_,4A;:7 (&'V4V61(/HWT#!!K,3G6V@+Z;U V2LNXL"(T
M#X..RRRS?PJ(G:2 $Q."/T]S5XGE$HTLU9LHCK: "K7ABPX<K$0LS"3N>2=Y
MG,,3R_R?XXKB-!4T!=(+/]YX'1;G;R>SWQ<-WVS<??-%GFKL8*']"XW;A6Z+
M\;-6R6LKP*1DJI%A!#H?@#RJ6)Q7%-BV+N=[BIX&-Q/UFQ_GLV]CDMQ/5W];
MU&G6'PBGI+?IV:NT''];]Y*ZE8"P.M<^/YRMMAUJB#HKR!3]9.NRL;GU7?WA
M5 [DNOY4!&VYT.A278.X]7AX:4,$6\>*!Y)3O3GV KS4'!@GYQ!E+!A:I_D.
MORSK#$A=Z_O)^[)#1#\(Y#Q(1G["-)NF\00?,/5E=J@\+3D22J@ V=?75\FM
M\N@9 LM6I\2M;IX)Z8*/?HL&7AC'O0-A$-OA#=+::;Q2,OU^@BMM3_.KBYK;
M_,<Z ">G5Z+.$HIWM,EK3\" 7M*1I#4=1$YGTSI^W8>N?LUN__B9=:S*00#T
M<<#WYIJ4M9R_A#]P,8KH>*E/ZED4Y"_)VD39"3($"CW%_#Q8WGJ2WUZ$]6M1
M!P?1]LH\]5:Z7<;O<=[2<V5B\0EL81R4JLF"$"TD&;@HSEFNFQ>\'Y]=[JR8
M:W H;*"NW@?"_R6,IU5R'Z9UH.8G_!JNJH3)'\^8,NT=ARR27)!#E'5"G246
M0E#&X$8HM'4*_([/]UNT-1@@M5+ ((S7J\6")'CQ-8SGE8'7M#G.JA$.F2PM
MN0?&,PN*'&T(*1JPF7O)M2K&M*YBWDY)O_5:@\%<0W4-X(YL55VQ140WF;#;
MY-B(E8#H*+J3F,EA-<I J!EWV@L!@TQ"F-:>W=[$]5O"-3AH=J/4 :#UL=MZ
MR^5U^=J=_ J+1F@-B653Y2?6]>.U?)R(9R79UF9S?^KZK=X:'%X[4NM PV:2
M.(Z_U1JUQ<AF)\@SL< <$CM5="%*#2Y*U%&&PF/W*+U'T-">O;7!P;-P.U8E
M@_ ;'[/S<4Y>\#C?A/0__U%C*WPU73=$6#DNBU'B&*TNEA@S&50I]6E\]%"L
M2]P7R0-K?3=Z'*5#>T'W0IALKL2!@O6OJU*"UZ2,=]/%Y;P./+D_LEOG.IA;
M(D17WX&EVJ.3U='NR-%K98)2W2<4GZ9Q:$_T7@B@#177>Q;G,7>_8*Z#=F@7
M7HPO+VX8NWISB5]FK\YPFJY&WHGL(C,@?.U\I3V#6"O+N?%83,ZF;$9$6U,\
MQZP]M$=[32'W(@H99#3S*J79Y;3.>KJJSDB],TII?DF4W=M8WAOTMF:RO.1U
M-GBD+<8R.$6N27".>]:Z#>MQE [M@=\+V<7F2AQH'/-Z-EV)[[<QG0(44%+H
M.+_=EB-B0,FD+>B$#A1Y*1 C8Y!C4D)HZX)J/0[D0!*']N[OA>#93FT#Q>7U
M;KMWD7F]$T>.\X \*N+&U9&M=#1XQFCG*:-=$,ATZ+YQT4[RAO:D[^7,90-U
M#> XW[]L:B1#<M;7L9Z^=M@Q3(-WU@&J4&1!;ARV/L+WIZ[?<.;EBRB[4-H
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M1*$7!ZELQ8X-X$+4=1!8Q"(YP;?UJ\Z#"&QWEWJS[+VXD\QP,DR DJAK[X$
MP09+.S6ES(H7*%NW:7N"G'Y]^>Y0L_L2]#2-#.#<O&/EB7+3#6/MB2ON789B
MZAT8V@R!H0#DAB%+)AC6>K+/$63V&S3T <9N-#C\=-4OF,<I3%Y/POAB08?5
M3SC%,EXN/H:K%=O'GKC[?;?ID7L$*\TJEVY:FMZ LEC&N>,!3,IDR9)RX)U&
MB(R%E*R5V;0N'WY$1#OS=NN!OIW-_S;]&L9Y+>3:@&#]F_S?E^N[JY__^%JG
MD8YX(&->6 %N:O^!:L]]"A%D2*C1%Y5"=P\F#J>W[_JC4_"SVZAUK+>>,VYU
MJ.UL6N]+/Y37YV2R\=WT@0UXM=T&W"M(\>169.WK4X]:RUH<Q&B)X\RDYSPY
M;?>YSSZ9D+Y+AUJ@[^4U,H@2H<_GL_DR7ZX[@MY*\J8>:K%F^PU^P\EL?>VU
MT3B(>\4P^?I(G9'S0LYN<'5ZI681'3DOY:[I;BLS>1+%?1<"-364+Z>[(40K
M3W/[L/"4]N\C[F>WQ\F&('BVI80B(*ZF],ILR?GF$6PHW),<-"^M;_HZ8Z;O
MHJ,7Q/<+:7SH*<=:W75TF'/O'S>-9781U2A@J9_?$DH+YI+EQD$0F&H+6 8N
MY@A8K# N%R9TZY9%VREI%[I<Y\S'2"[)^]GT[ O.+VZ%>R^'SE(46B; A(6V
M&>?@@BFUV,XX:2S*W/I2[5 :^PU1&B!F=YS2@9*&X1S><EBY(0N\G%]>/.S3
M5Q*2E\L<)(UD27VJQ0T4?IE$=C^[R)5M[@ ^2U6_\4BG4&NBB.&G]6XGI)Q0
MBO;X&XT?%3Y)8K/4W/4J6Q 5DK*:&P3FLB(KDCD$RRP8;IT,G ERXILGZ7:2
MT["O\+TP_';!ZP3/=?B]85DS(U^27#<0RM26>#Y#J&-T3%3)*F.3:/Z>\@1R
M^T[6M4'4$RV'.]7?P$[&GTO!M!Q_PUM./X4E/OD,LOB N8[,5)9< .5L >=J
MUQ:MN4[6EV)\9V@]G-Z^LWM=P[5C#0X,KV^N22 VMU4E;C :M4@B20$ZN4C<
M,H0@,PD\9*2 V6*)7;IW!Y#:=V*O:Y1VI[=A '35Q/3JWH%1\SSCZ:/NMS8[
M(;RG(,J1#!5YMN!0$GLL9A4T3YXU;PZP)VU]Y]XZ@F 7FAE^!/)Y23R=SR:D
MM,7ZY>3Q(U!V?:KMW).]"&[597:UP"V^I)0Q%(L@;*X#Y&H)YZI4--<$A[ J
MFM9E> \I./FE_.V>^5!N>I)BKHXL.:W76WA>+P174?=/5W<_\S%<K1Z;_1[F
M^5ZJ1T<6I'<D!C04C6L-SC@+VCKZ"U5K^5N7#S1FH><.M,?CZ]&K^!Y5.XRC
M]=:'^'6V>J.->=W5MSJ]C^]&G(P^^MH=/,>:FY0*O MUPA6+,=A42O/.@8=1
MV&\\TA"9'2IF8,#;ON]6)]:'KZO^ 3MX]IX<%XL,2@AUP&2].0Q8P'C$*)Q2
M2717;GHLU?V&(IT ]$44./2;UL]X=EJ;NXT/M'7_GB"ND=-WO<1Z0$EM='C[
M4LB:R+(-D&U.H(I@X+4OX#2*@.3WF_83C';0TM!F;:SP;EIF\XN5ALA)6/_E
MO> 'O4,7%>C &"CN%3BF.60ILW"AN(BQ.T-U"*G].G9-,/2$G>I,:<./6"DL
MSS7%?C.N*DSN<3\KG_!L7&4]/;Y:Y- 5FAJXD]@[T0(NYLO1D^M_*!]7\*^G
M8YA>?9A.KK8]];!H=701>.*U$4E6$)W7D(3ERF4ME-HK3"9R[AD(^J\[X]"&
MTF.M:%W]_CW0-1T_A4FMW/I\CKAY\Q.EBRZMKJV-!B5,A(CDH\C@BRLB*;/?
M2)9G1'(04?U8R!XP=F-'NU5;K['(#M;6N<S/I%7<4AGKK0W1>P^94;BE<I80
MHT&0G$EFDN<B[G5!=S@HGZ2KG\!W>+ALI[R!A<E5@G,\)R9O;R-KK\8-!@-)
M47ECP0J1ZE0D5R>;6W#22&YDX4QT=R>W%XG]!, ] O4E5-EC"?Z.?5B'][Z=
MS'[?M1.5#E*BLK03ZYMH+AU$JR44J666UJ,W>[6,/=R,/D-9/Q=UPS.D+14X
M_/CHP_PL3,?_6'VO/J^M<QEFY>.]5=[@,HPGQT1&^W^[:4QT)$N-\D'W5R=,
M+8C,?#,GZSX-J]?I:[3?(NVNS8S5QH?:9!@S7[69\> 4X3EDZ[-/3BG=^CAK
M0O@I3S]7BOKP0%&KK3?2H3K/.8"C P!4X )\R@*RD1AMY"YOII&VONC<]?U^
M<S\OCY?[CSN;R+SG0_A3O:=\]<=X,8K(C/7)@V?.@THVT.^$ (R*<[36EKQ7
M[>\S9^OM@OT@IYW>9J<*<0B:_P4O(LY'60:>A#<04HY$MD[@4=$!;:S)WCNK
MU%[I]GUTOUZROXS(D<K:5/<1DNM9X;^,I^.+RXL;PCG9-6<SR%IJH((DPH-2
M("B>34E$[?1>]23/J/S!HCTK_1B5S5K(KV_%AS_N$>YL]#&Q2"&A(-03H?5:
M!"'P8K0N-DELL=<?+-I?GJF)XH^6WQ >N=_X.S?39V^N=5<F4 0ZU53(@):[
M6GIDP4<900H=L_)*,=/\DO$I@OH!2G.GH+WPAX"D->UO9A=A/!TE&81W!4'K
M8$@L0=*&(#8BDS;PJ*5@IIL;^C4!/5\ZMU/L)F2.EG+/S8?^NLHFU*D&BVM+
MR8+F.<L,M<DTJ%PK'!.W4(+WF$50J6P4UF\-/1]]>!#U!L<H:-9*6H-0-<78
M?[V\"-//./\V3GC#ARZ82QV^ZT5]B<XP02R9@8@A!66E2\CVUOKV-?JMUVP)
M@ 8R',#)<&,$[T^QKW90^U2$T"0;GA&4*P:\\@FL1<-DUC[GUA/>=I#2S_U1
M9WY%"X$/%#?UMW/$Z]WEF!7,D[-MN21'744),:."&*/3244>=&O_]%FB^CU^
MFJA^#S@=KX>>#Z=?KEZ?S\B6_C9>I-F4&+LY7[7+M*T86%T"*,YJ0US#0'+)
M$W(G3"A[G$L[/C\\4)R@P%E;:?9]SWSCJ_\%9V?S\/6\=E]<^^E*Z<A,+>>(
MM&>"$! 3V6$3F$_6&"7U7C',<]?)NPCHY]:XDQ1X&R'WC92U9W>?A>OMPRU/
MF8(WT+GV85<\DH-7I22Y"B[GP-5>3YB>0\HN OK+G#92[*RUE/N$RO+K?/3K
MSZ.4ZZX0'@+GY*4;Y2 XZ4"HI&14P;/-2.<!*!:8_GPV^_9C_=P:%/5W]P"Q
M7J9'U;=1U.QXJ?6MY'>O1L)ZDY3V(#*K!5520LA.@B]!:CI+@PA/=0?82\GO
M7O67(.] R0=*K6\E__)YE%,0V<H()N=2QU-E\#$PX-G+DA,9./94F+&7DG_Y
MW%\18P=*/E!J/0<%6_R=]^0QOZ.C;3$BAS5PDRA6"M:!8DI57[: \,P7;J)U
MFRUI]BV1N5UC+]7KP7MZ344Y@ 3$KY<UF/E0UJ^[JEAN\OBCY*R(P27(0NLZ
MKA[!A5JX:&/A4GL*M5MG'G93,ZA:F2.U/>M$]'W;E>O ^_7L(HZG*_'<,+8.
ME!<_3\:KR3EO9_,OY[C.^KXFL7^<5UM\41,WJB2F!6A3(W-?-#CG-&@T@AD,
M(FF[C_4YF9)!W;V>!K(>5-,S$&]86X5KB]_&R_._S+[A?%IWU.>OM322Z/GK
M;<'O+8O"FJRD+%!6MT[,,ECU?!7!I(("I<%]!GX<N?R@TO*G0^XEE#"(J[]Z
M;WG3-;^VIAYYD8)E/H.T FM0A\0!K\;;.H'1N!#V<:&V?WU0:;+34=) A(,!
MP<^U[G]1*ZQ7/3L^XGP\RR.=8RG,!)"Q&% Z93K JW]IG,O>9OI5'X2&K<L,
MRJ=N"8O3A3H UWK+\5LK],<9U],WOLS#=+&FC(^"0>.S(3]/*DFQ" G.*9F@
MN)A9X"B%;-W<[!#Z]D*:^2Z0UKEZ!M]R9WPV'9=Q"M/EJY1FEZO&DQ_IQVOK
MR?I\K?Y_[7CT+4QJ-!*F^1,NEO-Q6JZ?MQW_I*O9TFW;_'0BD$8/PAY3=->&
MRF02+HNU(:T"5:* 2)(&$2.YY3S[(%N_\MI-S:G6LLJQSB!\*.I72PI'YE>T
MWG^$R26.F,ADYB-"UJ$V7>42?%(!.$7%(45O0FEM)O<BK-_+[T88V;20[54R
M@%/YX<Y]S-[(&ZS/<*L76G.ZS$L*>64$Q;/.M3^':-X,^3F:^JWVZPA=314Q
M &!M.2@>L?CP#^XS*RCX5:5VGHR^3D]C 6))=::-X)RG*HO6MOPD@OOMQ]BA
MP7L9%1Z/U]DR3'KV$5_EO"JP>M!HH2.G\,FU7LX+W)_E[MT^[65,DC,P0E5K
M*#2%P8Q!-B865-P(T_J ZL[MN^N@\7$^^XKSY56-_Y>TT>K6NANQ2EQ['I02
M4$=.URL1 T$X!TC^14HQF")38Z[WI6VPSM\A2-G==J>A8H;PX'M5N25=\*4F
M&)FP@4Z).E.:^PQ,9Q6SDTGSO= T[*?^W>IRZ_/_0P0[!#1<%_,JSKQ ;H#[
M6LFG R>OP07(/F<OE--"['77_7T]_S](63N>_Q\BN;Y?@3]XOEY"9.@L!_(3
M+3&?2ATPKT&SJ#*9RHB^1>GS )__'Z2RG<__#Y%?WXI_\'Q=^21<KC/:<WV^
M[@CZ062Y4IOP)=5)U2T4/[SG_T<K_FCY#2 N_]OT<G$9)A_FY+G/\7\N25[U
M\F!M '4)TD0/#%D&91V'8+('K%.7DF51Y-:N]!/D]/RHLTLGH;4RAHNKZZK2
MXB(=GHDVF(JKY%6=V64R[3>AO&+1HFP]/?5)@OIU0)NI?3\X':&#GNL)7G_X
MCW=ON+^VL/4U #?> =E211:6?@F"^$@J"NVCM(@;C<BV5@\\^.@@ 7",HF8M
MI-:S0T(6-E^FY8?Y]:OWU4;@.63C:S>>5;X[>#I7O120"M>AY/SX>>91?LFV
MM?O-YG8>GIXL[F' I8XGO6F3<+-SK$/I& =I/:]#GAE$\O%H(U'P%J-*V*2'
MV4X"^@MH3M?I8X"<*. !."7W2WCQ8GSKL\>D2]%: [=UP%ZBL"UZVCG%L)1M
M<<PDV=@=V4%*[X@Y5<FS]A(? '#>AO%\=9__T]7M;_\ZQCD1=7[U'K_A^L6K
M%8K^K5=@DX]T4C,&KLZ8#[5-MK*,E>:7X_M1UN^<X!>)G3I0T9" ]PN&VI-]
M]0#F,7_7.S4'97@0&KS"0,Q%DA\R0UM+:QLL%L_W:M%[#/[V(;!?+[L+A.P"
M87-U#0F+[Z9?+Y>+E<3D3;L/GVV,)9.4$MES)<FU,*B "5,"8[5-=F?(>TS.
M0'#6'@2[X':B1@8 KITGPT]77^@3JYW)C'"E\ 0ZV@0J*@Z^F  VJ,P4#PE-
MZTON/<CJYYG!BYZMK94S9+Q5AJZWIM88C91D_X,@QQ?YJDF!!BU*B<Z(*K>7
MPML=6?T:M^90V!=J1^IE %![3\< GL\F^=W%U_GLV_H\N(F#0HP^:@$NUUG)
MI3:&%!;!,$.[,U@15>LNN4^0,U!H':OZ63=ZZ+L)U<Z&2\Y20&XCJT.O<_TE
M@%-! D?.F7 Q9]UB0L=I[<J:/X-ZL3QI&\'WC9Z=G5Y*9 93]& R*Z!X))?4
M2PM>1&D*%][DO9)@_TPMS Y2[%XMS Z1<M^-CW[]KY'1(IM4GY)6WI4T'KPV
M"NK+0F=,3/AD1F&_%F;_-<069@<I:G:\U/J=55L)_O*?HV1DC,D6*"Q*4+KR
MJ211S6.VUC(IRU.-F/=2\Y?_'&(3LZ/5?*#4^E?S;Z]&+"F.@CGPLD0R9YF8
M33%!S.3P>.83>_(.=2\U_[9?K[H7;F-VM)H/E-H@QOON]'_>WSX-=RYIYI!!
M"G6:]NH=4%:JCA5@Q%%A/+3.USU/U5[ L=^E_]B1:GJNRWDW_8:+Y3J."LO+
M^9@86S>C<(C*!8P054F@0BGU=PZ*E )U5&0G-X9(;:W1V;G 0"/5([4X:RW2
MX>#B%1FV<(8;O%@9'?<H0=2N$:H.V0I8+'#%?9+1)+?7#)#GUNFW9/1E4'*Z
M@ >0(GLWI6\11Y\PX?C;RLH2H29Y$\%B)!^:(BVRLCY *DD[@S9;WKHFXS$5
M_59^=02@1D(? &RV-ZFIC_VPSC2_UZ[F_3C$\83VQRB@$585!AKK?9NA*,U[
M+.!R5+8V'^:JJXDA!Y#9;\%&Q\#K6FT#0.;'<%7E]78V?XZSZ\'3T[-7:3G^
M-EZ.L19]BZBC))O-3:W5K85Z+DE@F+,0 BGB<*V]\U,([O<*M&.TOIPJ!X!;
M8F&\Q/?C;YCI> C35?_35XL%+O^VP'(Y>3\N.(HF8_$,P4JI:T\;"HVY<6"X
MCC'JPKWSK8L]]J"KW^N'CE'87#$]AP@?OJYV#^V5:5[O&US=S[V[^!K&\Y7<
M9HO%J+#BBK8%C+2,MH\AD1FG 2WFI(W,;*_6Z_NMUF_^H<-PH0-A#\!6?;F_
M"^Y8>7T>YF=D>;E7!'G%P*G5!"J5P)D4@!5EF2))2M/ZC=G3%.T%+_>=P:L#
M90P 6N^F:5XWR!M<_^^[Z77Y^N)^L*2E5D[6AB&<8NS$"H3L$9A5*6,0Q9>G
MQOL<%Z$^3]=>,//?*<R:*^9PL/DUV*9X%I:8OS0Y#5^50HJIQ->G$N0^7G/U
M>;ER+?^Q4M]U._!/X\7?7^7_OESG?\@[72>EG6!)B@Q&>4.B#!%"JDGIG"O3
M2)9]GX/R9$+V2\RR[PQ^+Z^CGMVSXYF]MP^3\#)K@2 *UI9OCHR^S09,0%>$
MR]HKURDF#S2*_'N\,'AQ37VWR/P5;W=B#$4K723(A+4K:Z[-"*T#Z0,&S,YD
MVRTR[VC9#YG?XR7%BVNJ9V1^Q'FJNCO##^5^1\2T?@(2)I_PV__/WI<UN74C
MZ?ZBC(M]>91ENZ\B;$DAJ>_$/#&P)"1.ET@-BR6WYM??!&NO8E7QD#@\H#SM
M#ELKF<N'1&8B%UQ<X&]AM< \XU;(B Z!^*A/-'6 :XX2@BTZ"LNTQ; #!H=]
MZVYH.[47C9&EWTE1!U)0E3_@?'%^L:HA_+7G.TN:ZU2X!,L#6>]DR-\-KD!T
MRAK/E;:^?5_,4]3LAK!3?;IHI(4N0MPK!L@-J$N(:K+:)^W+9I55)J&0V740
MM+-0BJ]=C_1[MQ=1LXCV$1F[(>A4GQ,.E7L'T+F#_BLFPN66M'\NZN%X?1;F
M7^L<@:L?W%SKYW2;2^]3"&"\T)51\C-S<L!9X"QRIKQN_7*P-[&[P?!4WQ..
MH\,N]E!5[_/=ZG-87+F<5X[ K<,P,Q&EKS-1B =?Z[4CL<1#W5EN74B<L;3+
MDKL=OVXW8)WB.\,8\C[I?4&W(?;Y2!/@MWS#\>:^O\3>^-/>L6C&?<Y@A;#D
M=)&_%:).H%2A7^62L-JZ2NP8T]ZOON/\[7*-YW\LP^+\YN6.OO=6[)<%R3RP
M4 *6FDVD0YID F]% <<8SU9Y'F1K(>Q):K>SX(?@Z.E9\..IK0.O;U?F?OEQ
MA]'KEO B2[3*.(@R4;@M(E)<%(E77I@@QT%2A#3..=V+WEX&TH\(J.5$VNT
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M9NN.K#9SHF>8G8Z&*1"&;*\*OD"L4X*%D2D:IPMKWJOZD(;NT@N'H:B)J#N
MRA:XOR;$STD=FY]\6H7%^25E?":#4*)8#MP6\AVS">"R<36>QA"=8+;YRM8A
M]'67A&@#L=%4U '\+CW1LVV>Z%4&AWC*+GKFG $6:D50B.0TD-T%D4T2CGQ2
M\7"=1:/([WFZIATB-!K<FJND YC]8[G,?\W/SMY?-?;=3F"Z'1QX/HN^%!&R
M@9SKQ JDT-@C"F">9$<<6>=:-S/O1-A.0-,G![3V2NG/G7^_6GXGH2T7X>S-
MHBQ77S>_^H9.V#R<W3*\&9OR[0S7>,OZ];*/LS#_6C=X_8(++//U^?OP8Q-
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MQ.25P6<ZR"AK;D@;LOJRCC$510)=']9Z,OO!-1]3_#0YG>"L/0B>@MN!&ND
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MROK&$7N5UO/O&Z7,G#99A80@Y:9PDCL@(400Q!234:-*>0?/MAE!IY_T.0S
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MCOI($!Q&$#%RIP6R]/!1\><LWQY%[3N6< _100=0:OI:&VRT+!/O+%4!E%C
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M)EJ7/*"NAM,P<L^M<" PI9BSU=:T#F=V(*O3E-^>2-@5:'NJI0.D?;J;4*+
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M?1$T8;-3W4 6 E.)F>4XROO53_3D/P0@!S[Y#]'6:8'Q*C\=A(B8Z"PK8RF
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M:R92H,/$B^;)>!/'?4WIN,MWD(YW[?(=(O"IN_$>;E%E5I1HR/M'R44M=J:
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MTG9"FSL5M(VIEQ[AMDT_S62VN:0L@)M4N2@&4"%9WQBSC5J:Z-HOD'F(DIW
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M/7)M+JOJ Q=**DMGR:M81S;4I7E*0.(D*Q="%KEU9N >$3W<B <I=ME2RAW
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M' /2S:B2R\U?AN^3,7'D/SDV[CX8'*BH#K#V(:\WJWG<Y'23B12*K4.-R;%
M"<H(5@>Q!PJ-BTY!B6ALZX#P04(FC@Q[P]OARNH <>_S:IM:(_=V*[SU%1NJ
M"$T>+%T3/-?J%P5!. .1?!KGE61,M[9PCY RL:/8&^I:**P#W-TRUN^^WIA4
MPZQPL8JD!%_K1X*&$ .K+;!.):]K$<F8=^M-8J8MO>@.>VV4U@'Z_C@/Z_R_
MYS5M\8U^N?:5768RYF A8L2+6I2010%AK,;LI"RE=9?#(Z1,C+PNPN,66NH3
M;%=/4D(J%E3=4,MKF5(1X"4WP$N0*+4O036?C/88,1,'$RU4_3Q\]I![?P"Z
MFNAFG.4N)I!:^3H;HB;,D@66O=:JD-!"Z^+<!PGI#CC[*/EIZ.PA\1Y@\YSI
M?LQR_WK=HEID%EQ$#Z8.?E/,!G!!,]!<I,R2\SZTKG$XG.II!R9T<G4>5_<]
MH+WZI!_RU_-5_$Q,O5\M/ZWPRV5#QW_RY2@G/A/%)BNT J&KIRJ+ 4=B!:.=
M+[+&Z+EU7?>.I'7^G-<8,?<*QMJKKS]4II_/5_/%I\L.N6WX/G,E8$PZ@6'*
MT3$O$C Q#]9FFYBBNX:W;DA[GJK.G_J.BL5#E=8!#"]EM/YEN?K!U[MRHVYJ
M5@=!))8CZ/HXH*J'$[RU(.BJ29P">)=:P_!YJCI_^QL7AHV5U@$,/]8^S//5
M]RWQK^+_GL^)AE??\@H_Y=?+]8:.V%:@,W*T-0HC016)=3Y*A""2IBBP&&N\
M3ZQYY\6NM'7^)#@N)$=18 ? W/+S=KT^?\C8/RSSVF.6T)+UUY+\#R7JZ'_O
M*1J4W/$@,B_-%^+M0>;$P5 '%_F(:NT!N?M*^/?S^J9Q&:6N?SC:,Q.,1>T*
MB,#I3DDN _)H0<JZ43>X$)LWOC9G8MH!=5.C?E)(G/*9V/[RC[S>7)L*"CBU
M0,,T.?DFTR\J2/"2>%<E>;32:%M:]VNTI'_:,7BG>A(.!4('A^ Z5YM7W^:7
MM0+W1/'[<O&-N,P7#*^W&SEO?KWZ=+\O-_\W;SY<]]G/N(PA1\/!)DX.GN8!
MT&N$[%+DI6:4^6C%;ZV9V>EXN!=Z//J R$L^*Q>V8QO ;_^J?A^?*<$B03P"
MXSZ3SC"#DUY C$)1Q&Z=9*VOE.-RN-.I\O\]5<<&T\2-2#>GM=QDEE@J>4["
MV,Y1]L9YXY,%3KYE+=F5$+RB/WH7R=5$A^+.0^2#34D[?=AN*1?VPI ZCBXZ
ML.-;887GY1GNRO/-GU_GJ^TW7QRR&=J(03M76P/K*T!6X NY?:4$QU2QT4<Q
MAM??@OC=0/UB$XF38* 7\.\C]XM"SO7?Z!OKL,0+[O^V6J[7LQA2<<XDB.@B
M*&<]N(04\S!I>:#_Q>8;"49@8[<#\6*SF1/CHH>C\>0[\(]BYO6;/_,JSDD.
M,_21W(F4P >M04E)-Y\@-H747CA3(G/-D3^8RMV _5+SHR-KM0?<[GN773)^
M'67<?MF=11Y\TD:#",;3\0T<T"4&3B.6@,'(TKK%8B16=CL!+S4=VP,^)HXI
M?\'YZC=<_2MOZN*HV^419 _JT ;\E&?,2>0Z^3IQCP(9$Y&8T0H*%R%DS(6;
MYV9C[OYINX'RI25=1])&#V;XP=K$B]OF;8V88^8S9B/=+72K:&0(*G!#5TN6
MD%F1PIK ;1RYC.]!NG;#XHM-A;;6W,36;F]Q_H9_SK^<?[FHHB7^KQXI9]8'
M5PO*(69B64DM(.@8@*6<%0IFU-UNRP<-8W/"=L/M2TM<3J_C'LSMO@*HM\_V
MWGE%0<&7"Q?GPWS]KU]6.;]=$('DZ]1GS=_FBRJHF13!8\P!I&$&E+4.2"D.
MHC8\QF*-#<U-]I%XV^WXO-3$9I<(^DN<K L3-"M)<Y0!ZXI67LL_,[@8,O @
MD&>;A?1''^/4B+?=3M9+36YVB:"7=K+>_/DUU[$R_UB>T8\YFV^^W[0Y*'FQ
M62(D4;<AIXS@C;(@K94:A4]"CY*:.@IWN_4=O;2$;.<H^HN<KTO+DX4AN6@/
M7-5B/\<*><NH2(O6%%&<2K*;GN?!W.UVOEYT;K@_%+W4\_7S_-L\Y<5%*4DQ
MQOBZI%6ZNGO:(.E-A0#!"&]M*2Z6D[BV;C*UVVGZ;V+Y&)CIY1#MDXYY2B ?
M\^H+GUFML1C24]&FKCA&!K[N.3;*%),Y"J/4&*=G%&YV.S8O-FW=!TJ:G9>C
M[;K[L5MF61X68LO%=[M_VLA;\/9D>YR5>$ZY&#TGS*.M,VG(H_%,*J"S8(V)
MV@ELW?3:ZTJ\9",WQ1J(TB%%4"P!^L#)UTO1!PJH>&C>)_DB5^(-P=1X*_&&
MJ+,#7^/VC'<O%=TZ10"%'=O=%DCWD?$0??12,J%5:;WD9?@RAQ-8>3<(!$\N
M<QBBD0[@M+_@GA@U:Y-7DJ<$D2/%P,4K0.X]9%9?<%6V+AZ]>OC$ESD,@M4Q
MECD,T?'$Q1,_YK7C(MT<HWUC>KLPP7O)74V5DP=MD4.@2!.P,$4^OPWD3N]0
M#K'#1W4^[6UT+"S'4\S4^[9N3LE^?U5Z1*(B[FZ6)5]R9IFUO.AM3;($%1))
MS2D*+>FLRZQU23;M +EAG]KY?+=CHF]$=9W"Q?[\8X>VJA2!'IR1=;:[L(",
MT15D=) 6 W'??/?WP52_E"V6AWBD1]9]!VA_=;;]GIP>9KV^EBW6>1;(2Q)5
MGNB5!D6G%E"Q"%RC,MQPSTKK\I3=*.O<*6B,E[L!5'OE[0W);WD5ED<%Y>]Y
M\ZY\Q#]GDHO@32J0BZTS'5V"8$Q=I<&C"RP'A:VG0PRCL'/?H0>0[J7,AF ]
MVIO\DZ[[J[B9?Z-O:ODL/^@#1WZ9WY_Y<1[G?; YA^#)(8VIUAQ(\%H(P,A*
MM$71_YIO3NKT<5[&8%C$VIN,AH(!'0"Q)L92SE;'Q(UN[K.^R,?Y(9@:[W%^
MB#I[<$-OO=EEM,BX5F!%HH@Q!:PK21QDX4I0FF5]=\OV?Q_G#P;!DX_S0S32
M 9Q&>2YAR?LDL$!!;4%)E:I34I?!29.],H;\E/\^S@]ZG!\$JV,\S@_1<0<X
M?WBA:DT LV09&,V("2TS!*3(S['H8^8F9-W:?.Z__?:T'NP'X6.G[;=#E-4!
MXAY;ILJBS$;5T4]6>U"1;AF?; $*#44,'&7RV!ASAVR_/:V'^D-0UT)A'>"N
MP2.&0%9XO5V2KIE@7AUSI2RPJ)DL66>,_WV5[]$5/;+N3QGM%['HVP7=-.=;
MK;S;?,ZKCY]Q<7> S8?EV=DORU7]CV88;:(KJ "QXD#5H0Y!&23E.%-,"(S9
M;MJZ]^*P<T^D,7Y;'9_QP?37.&H7LZ)FT5E>G$_@=*QK?JP#E+5!HR@3T*LD
M6&L7Z6C,G>@!.P+"CW\8]X#;WN?PZ\4 P0VN-IV?QMM#.6=>9Z>B"\ ]2Q1V
M!=)A(H.:37 239*)G<Z5=YNWS@.@O\)9/ !L+_I*_,=6?]=RR47&XBR#9%3=
M>>=#+5'T$',IN3B31#F=&_$V;R>ZA_,E'<(#P#;\$/J+0[C(GVJI0^?'\'IE
MP;5PC*4H/"4-*08+RCI.&DP*7,S",EY$YMV,<!C.WHEN('U)A_$PR+WP\WC7
M=0]1D6!$ 1UJDY\FH^6]$F!=0L%CY#RU;D[K*U+L;]+O2SJ+A\#MP$CQS>)D
MSN(_\_S3Y\WULN:M2_\S&9/KH0(W%:U9]E)X\B:B)^?"J53W?2JPD4FADTNV
MGXK_<41PHE'GR3RQC@;'+BJ^>Q#@S 6O?,@(F>0'*M<(0=H(VKKLT7#,J9O=
M/0WY?O%OM^,=G0[-P" 4_^7>?9\7G]'>^Y@XJ! 2J"A#'?,HP#/2? J:D6MT
M,D9@(/,G>H?_I2S!F'A^X:[ [0?!YT57="*7,$0(L?9'YV0 4Y:0T%BI<R:I
MGDX8/I#Y%_]^_0),P9AX?M%IJ,O'R'-"]?-2D]Q@*B& 59'\*9TY8"X:-',E
MA=H_&TXGM!_"^8M_-7\!)F T)+]P5V! /)5TBER[""P(4S>W:G!::<*!5I)+
MI:/YR[X*G/([_0LX_2.AN.D;_]$:ZZ]Y79:M]"XBI6VG^86CU+*I?N</&[FA
M?C^FQVFFCXI+5B'&==2@/">()0HWK;7&Z51,L+RQH>RUF;Y$SJ/3'H2KZSJ]
MK_U<A8&F?Y34)L;8?%WPBVRF'X*I\9KIAZBS@\#I=H^M30X#Y@!:$MVJ1 \A
M> -%H4JBN*ACZZG++[*9?A (GFRF'Z*1#N T2DNCC#RE4B<*Q5C[P6KU3R1_
MI$[?UUX)+/C?2;?#FND'P>H8S?1#=-P!SA_IS_;,<^,%)&T=J-HBB[4VH BN
M' \:O6CMU?Q5FND'X6.W9OH!RNH <8_U9ILL5%*!Q.%TH*M&(03R@B Z9[DV
M 9UJ;1S_.LWTAZ"NA<(ZP%V#:BDGA8C!!##%6I*BK+.#M03I@^(A,H6LM5G\
M;S-]"U?TR+J?>++XR'GX']FW'R]MVGIN?3; 8ITZS.H 2ZL51!XU_4&)?'>'
MPX/3R8]/>><>1F-<+D\&)*=\80S,87]<;O#LAY2\,3DDNJ =7:2@;*3?)0IP
M2LI2*!FR8*UW9TW#:>=NUCA'[X3 =7JK_V[L81ACJ/ 3/W[DC,>NC(V3XT 5
ME8^6''TO--EMH<"GF"'GS(,BF"?G^\YQ['O8+H_4N_/->H.+-%]\NID?Y:*(
M4CQ"EBA!:<;!BXA@"Z:4*1X2HGG"8Q1.NLI^#$%;,ZO:3M&G[+C<E\)ELYR)
M4F8N+>@8*-3GQ+N+F=/%)TP6/!<?6EN YDR<J*??$)GC'98]8-)/%T:]6]^N
MU^<Y_7R^(F8N'*>+IZZ;FYW>_)E7<4ZRF D;HD?N0&(=;<($>5&Y+M^)GF.H
M&\A\\SS.8"I/U+T>$>_C*OK0=OV/'=M_Z7042)=PB9SN9!0,G%$:"F.!D6PR
M$]W$I ?9__Z*^T_)_@^!R:GWU-\7PIUZQ"LK\GXUC]NRRG*IL\BKRIP +5/-
MUWE+.J.0W/L2M-&6[M#6FYN.S^6TMT^?(<48 'E9X<93$IHA5[QDXZ$N.P1E
MC*T[9@HYFT*G%.I6MXZ#D*=8>S&AR2@(G^9 #H);/\',WDG6.[[O8\VVMV64
M9(@AUJH36<=922T@6+3 *= S0F@TQY]EV)3#%Q-$=7$RIP/?7^B:3"*PJ*(A
M[T9F<L(+ PPU->4S:5"8E&(W0WY'N"9/(8+KXC!. +<7$O-=9%A?+5)=XUJK
M,3\NZU_=D-BK3Y]6VU>=MXO-:KY8S^-%^E4$4IGW&9BN*V6%CH#(/6AA1$A<
MVB2[F;-R*+/3GM:.(L#CP*67&RX\+ZBPMZ#N6*(/N1:WTM^_7BZV>C['LX]Y
M]87/HF1*AUH33?8'E H*@O(*F"^Q!+29<S'&0>N"^VEG&+0^>5V(=!"@>B^<
M>?/EZ]GR>\X_Y44N\TTM%5_O7R?SU$]K6A:S,]F-JF#>+PD]V\_<0NWB4]?7
MP'8Q^QS)+S.%<*""*> QT"_DES'CB]&Z=8OATQ0=:KY_II^VJ$>M7D+AO"JJ
MROA2[*O?<$,G__)H7'V=/$&B9!:39CYS!49E4X?I<D F$W!F;?8Q:MY\:-3^
MU$[[VM8057?-Y9$4V,64E$=X?4W2_9#C\M-B_I^<9E:PJ#USD PGMK@UX'1F
M9+^U1JZ=B;)UJF4GPJ9]5CH^! ]02R]HVW[P33>D\O5JO<Z;-9T>H75D"1SC
MY!S$9" 8\A!J"$R> 2O.C0"S)RB:-O8:%U^M%-&[ET8L?IEOML^FY*O6$T6V
M.R_B/!_@K.WP0YOZ;$.9:.2ZW?C85W<_=KZ.9\OU^2I? S))S5/($@+J6A1/
M@$$1!6A#@4H)D0G9VGL91.#A%6ZX.:=O^?XJQN7Y]J/>UY\[CWE]T5O'#/$O
M7 (LB5WVUH60(>C$96&A&-5\W-]S1$WKIHV'H/ME:2VU,^$ST'JU(;$MUF0,
M4BUH>T.\;$A>VSD-TI<<<BETY9M$/&@.#NN]GVPN3L1BY$X/,O0A-]!%?_J!
MK*<^?^(,>UL5+QO+NT/,7+:MFZ!EDBE"4G2:%"NB/H ZB%Q%+W2*R>_48;$'
M:J8<==).L\] 90\Q3PR6]UO!5?</%]\O!Q%X9UW99LARDN3UU7VOM4<\$1.,
M&6;";GO<GD') Q_=%SSVT>:RG6A[R$ \86A_O>[;-,A]82R#S)E.4,B6;FM=
MER(RD^D$:=5^Y<DNA$U<;#+*)36>9GJ V]<<YWA6@\_U>AOK+A=IIK1$G0H%
MH:&^:4@*0AU#"\RA289QY71S9_HA0OKU>?94^%U('2S]#B#TZDL5SKOR8[33
M[WES\9KQRW)UT\I3&/+W1;SQ%W^<A_4\S7%%IG^66;2JB 0I:TMG,Z0ZEL=#
M$E)P*Q3+MC7H&I'>K]5K ],I--S%H^EK7'^N_Z\)X6]X=AE*__%YN=K4G.K;
M[1CG;80]"SYQQDT$&YT"I<B=I=M$UHEF7O'(M"RM.ZEWIV[BLK/1 3J2GCHP
MKD_)[OIKK_'K?$/7"+%\OOIZ=K[^"<_JK+-94*B*PPPB"/)]I97DZ3@'Z*R0
MVJ,PJ7DAY2$$3[RZ8OS[_FC:[,)\[L?NATRGF,B=Z>PPT<U 0A:JYM@0O)2V
M5JWD(E$XWKYE\R"*)]Z]T"E\]])G0_R.-;LG?]K>*+_C:D4_]%L^8$[/8S^J
M[4R>G0ANE+ZZ_+ /^2O=P;4^]"K/4 R%,LHST+X^QP0IP NKP7J='%<Q>]<\
MM'R$ED/-VT7+<'6+ZP^N[PM7(I[9R%%$BMETJ'M'?$' B.1T:(&%^"0G8Z?W
MO %</D[-Q%%T"R3<M42-1-][ OV*J:L1I,OR[FNNAW?QZ?)+;Q?;P;;U P^W
M/X,^9A3;M#^C8]LMDR4A2!APD450QFGPP7#P6-!S:UA)S9V1D>S6C8&V=S[A
MAI!_^G[YQ8N'4Y0N.)D=<)9J#70,=?"RAQSH*\Q[EUGSMH_A9'9JZ89@YXEM
M**,HJY,8]Z(6_GQ-?NIZ?64-+I*%(A;MG8?$,KF.O%APBD)W#(PQ8:+(JOF(
MNJ<(ZF8ORCAP>,#E;Z.;'H!V0?MEDA$+28+9!-ED.I6!.P@\&/ ^%I92X1F;
M#S&Y2<#TR8U&BKT+F;VE//'0\=]RFD><I\O$<=+>,T%!<N ^DPR8K&D8!E&4
ME&Q$99A^QK&Z_U.[N*'V4<VRB9RZT/ J7U)NK58."=O9"@$JQ3H?@WC03NMB
M,5LIX\X:OOJI$R>#&FIX+SE-K6%<_2MOOIYAO")>)L^2Q$+7':^#%E(AYXL5
MT%8H+F*RTJ5=E'SW!T^<4VFCYX.D-;&JMU/#WZ^6GU;XY9)ZEVU,=39X5$J2
MIQ,\A.SI%LN2Q:**0#0[Z/K^3YXX,=%$V0?*JQ__[2&7]\<#M_6\(*M"80J)
MIQ1),IY#2&3#,HK@>?,--SO0U<T.F^.$#:TUU0'Z/N1O>7%>RQA4UM93)"^X
M),%P3F</O08AO.4Z6YYLZ[>0J\_NPGULJ-5[V^'V$/$!4VLWQWO"K;V#BS@_
MFV]_\K+\;;5<K^G^_31?;)8W2VC>+NB_;9!,VO,#1WG6;<'\V ^\@NP:U]R"
M9,J"BG2C8L+M&DZ3A')"ZN;S-CIZX/68=#%DZ#7=^Z"03JQ/,8$5DI%?P*QN
M/]?GQ3SP#L%.BP?>(<KJIC6&V-C>$-L')D7?%8NV4##46@ M ,G_A!BTD[7J
M/^@6#0\/?_KI/>$.4OB#'3-[2[\[_%R%0<Y;A9*\BV($*%TB.%L8!&U9$2XQ
MK]LV5MW^_![Z9O;7Z9,0V4/ ';CG=Q/&5SM>@[)&.Y8ARKHWUI&5]H8ST#8R
M$51169;&%]LCI/0$F7UTO&PO\ YP\QOYG:LYGEW[J&2'JX2N5E,GK4/M/?,.
M(RBA K@2/%G>()4PQMG0NH3V:8JF>4@8#44-Q=\!F)[.J@G%),7&%-4&ET'9
ME"%($:%H9<A/-*;X,684');*[NI-:A\_J+UN>@#:K2=ASQR+.CJZ\26)I2@%
M3O((F(T6F66K3?-VT%-)90]2[).I["%2GCH-=CM%ZXM7-4*%)!4GRDD0(7D!
MK%B7LDM"FSL^T(FEL@>IYO%4]A Y=:'AZQ1M298SA@%49E@%(,$IHVJ)68@9
M51'![JSA'E/9AVEX+SE-K>%[R5GR=ISFA,>0"OE9@J([S[,"25YUG>!JN9>[
M*+GG5/;>>CY(6OVELG.65M1*415]'5M1*[ TV2.M;)U6[Q*YP2>?RMY7V0?*
MJQ__[>E46M))>,TY)(/5=;&U;M@)X)J'(+"@V&WBU!2I[/',Q;'#AM::Z@!]
MV_P;G9\RW\R41NWJP$FL=3[D+&>2C>; <RR891*L^>"\&Q_?A1/94+?+-H+N
MHGWW1S8^&ZFSSE#;X^DF-1("IU]XC!&#*9(NG2D+'L9V0<?#QUXB[@(<=1[R
M^G(OP6)-'#B-RCMG0,=:]\%=(L^Z]AF7%)1V"I-I;4?NTM"%'SL>6 X2>3^[
MG:_S!A?%'K^2A9S)XJTWL0"O@T>5#((B,AX@<Z.35W1C-R^I>H",+ESC\?!S
MJ. [<%Q^7RZ6M[FX/ QTNZH87>10-!T(Y9F!($R"7!><:^:9\JW3?(\2,_$<
MB+%QU$8)AQJD)GCZ<1)^(3E>S$@^)[8NC\IRL?XID_3RQ?=]Q#_S^LV?FQ62
M#N<+7'W?"I/D$>NV@.79-GNU(+CG]6;&LO0A(8+-=2&%HGL]R%( K1/:,C3!
MM-ZN,B([.V':G"RF>P'"_C9VN<&S8XST7Z1ZU-,O] V+.KSPABJ6Y4/^-*\U
M<74(Z^4W7DXO^N-SSIN#QOXW^>#&JP':"^/ ,M?+//WC9+TKMX;DOEN<?7]H
M&KR02L9"?H JB3Q+'\#5*1V%7$Y!!XM9M5/$]WQQU8&4'E):]N,EZ3X=USG%
MR\&Q%+IG9DR!@(7\I%1GQO)4('IG5/$B>-="( -(FK2:Z)CXNEFL-I;*NBER
MO#,IG7,>8^$&1*@-6CYJ<*Y$8+GZ5;&P8,>:'C]=H>RHBMYE\\ 0J7>(G.LA
MZBAT%+'N0C-UN7@$Y,: U3(F"NR8*#OMA'E)FP<&:7;7S0.[B[G#S0,)8QV4
M%:!DYXD'1GYI;2G5S@N.)CD;=GJV>S&;!P9H\YG- T-$.[T9>=3(OL:+5;0_
M BTGA%6V>"@BV_KNJ,#9*,$9+KA%(YC>:7+*8._P":*F*XL]TE4UDGXZ>-2[
M9N5=N6;O_7(]WRKO>EH@9Y$<PPA:> [*1$8R),9"9)%":DZL^ETPMT_M[!-T
M]>2%-X/$8X6SK?3310+K8G[]CR7?,C#!9 !;R"E029&Q-HD!G5//"B:E<^L2
MVML4=%)#VTS'=W<(["_NCN#R^GQ5I7G-1E:)V40<F!C(9\ <P;&0(,KL$V/9
MJ=1Z[^*#A$P+GD-T^R!,#A%S%VBIRPCJTL4[.PDVKW&U^CY??/H'GIWGF7>!
M1U0(06A&;"5!W@!YB8(GIB(*X0VV3IGO0E@/:#H( @^LAVBKC2Y =E'R>C'\
M.)ZOMF',I=AF!35&:1,D1^ZETBC!4S@")*W(C61>LM;7V1/D3%O%TQY0K23?
M@?/](9_5,)CBU\WWCRM<K.L\_^7BY_-<$V$?ES>_?L5BXHF8JZU^V=0)5$%2
MD)PT<.US4<$%SUO[XGN0.6TU4'O0C:VI#L#X?I6_XORJP(E,]K;0^Y8H9UX6
MS4TQX)6G\Y41P5N9:D1M B*JP%M?FCN0-6WI4'NPM=9$!^"Z3;Q)3K.B&&B6
M YV,J !EL1#(>EN=7%2Y^;:YP8 9K4:H/6#VEVZSDH=#[$XM:-I\?W^&)(Y%
MJE[BUQH-T^\OPN'\:\9U_C#_])DBY+_3B:CLOBJ$SE<QGG\YWYK>GS,Q$"^&
M7-%_^>I++5;YS_:/,Z'I8U.B(V*\!^6$AN#K'U.4&IGRPK2N<!R?JQ[\NB9A
M9V< Z,!:OB5%+C[-R<6]$//O>?-V$<_.$\5+?ULNT[_G9V>S[#$4CAZLEPC*
M^@R^R C"6I.%2D*RUHT!N]#5@^?7!);-E= %L*Z7,;Y=O"IE.Q4PKV\N"B5F
MEW'[MW2(_L]ROMC\@[[]G/0X,S8YR1E"NERE80"C"*!-\A[11<Y,<\0=0' /
M?F$C*!Y+;1U@].?+C[VN]KP^?K/,E;+<$_T6Z_Y0^@53J#NF4O622(;-.Q4>
MIZ8')[()NAH)?.(V[E?I6_44UK=B\?GV.-P(GV8\&E2N2+"U*%C)$, )<KB#
M5%KSJ(/#719+[/9IT]9M-X#(2(+MX@7WDFXL63'B'D+@AN*NNE^!6P5<60K)
M*.S"YKNC!X##=@R. P390=CYZQP#W:.72/YCLXS_^KP\(Z&O:_RQ^?YCOBQ+
MM4/80:Q#9A6WOD;2BB2%KF@7=&R^?&Y7VB9NT!T[;3V*BKJP/3<XN_L.I*U3
M4MD$3%. JHRTX(PET4GI4F)TFIHGCQZG9MIDY#CZ?QQDAZBB"UA=KH9>O\?O
M-3]67T%B7)T3)?>8G'&4J=2!;%:GRA(OX&HUW+94R9%C)YIO8!M 7C? .P@3
M=R_*D=33!?8>X$'XK*.1&70JKMI^!!^3H5\L=]I()K'U(N8]D33:'3D2D@X4
M=@_NUW+QZ6->??DYATUMW;SD0@5MO30!4M!UVYGP@$)88"E'0<&FE:9U3=?#
ME'0#FQ%OOL-5T&C]R_XPNID?N!+:]QO,<"L5"L>@V)SK:!<Z9)$G<!Y-<5IG
M8UMG&I\A:=KW\:, JZ52)D?8]HWCAMAN\)&\4X&1C!0OI2[?I+"F! 4I.>9Y
M"@I=ZVJ(QZF9]K'[*+AJI(K>W*59E-YHNN_!.&F(>#*VP3,$(W+QRJ>0FZ__
MN?'QT[YC'SO&&R3L#ORD)R125P-B9 &RK2%"\0R\"TC^))E1F6*0N?74G0.?
MHD9[ZCX*BAJIHH,4V^OEER_+Q9:?;?GUN_/->H.+FMF>.63."/+\A(JASG)%
MP)3IKI8Q>^<Y,MNZK. )<J9NS&FC\7NSY-J(?W+?Z/W5I_[@94;'*:3 -(CH
ML>ZK]N"$4Z"U"*Z4$KEN[7$_0,;4+^.CX.90<7=@>5ZEM,T/X-E[G*>WB]?X
M=4Y7Y8T3,2M,*:E29<'3"?"\9J&B@"@R28?Y8IN';,]3-?%TRW'PU%@9/<#K
M1SG@-EBH,P%6^7->K.??\H\Q8[_GS;OR$?^<Z80V&N/ QYKVU%P#G1H&/"AA
MR1LPV'S^\D 2)QZ+.1+P1E13!RC\4&>++7)Z@ZL%W>GK6T6J91[GM7S?%>3,
MUVN>I,=X!A>U 2Y5-B@]\Z;UT_CS5$T\.G,<K#561@?PNB^HF77.V.@R8)2.
MO,:<**B-!3R7T=H<Z)_6-0KWJ9AX2N4X\#E0V!V\(#P7&\^$SMZ6;(#1OT!9
M^AU!G@,+'#&XD 4;,4WW($W3UD8=^TWJ<+4TLTI]3B[]X:C>^,\F&V?Z)#4]
MS3C=76Q]##[5W/A2S2D3=2.1DA)04RQ;7(RHO2#$[]1?\&(&GW(MI EH@*)X
M5:<BZ%IY;< Q;:(S)G&_TQ3K_PX^'8RO?0>?#E'9]'/G'A[42#*Q3-9=G:;8
MNO?7@@M)@)99A")BD6ZG$0,O>O#I($7O,OATB-0[1,[E#$>>A4[9>(@HZX.1
M]N 2.=Q!"H9!&6'93KG,ES3X=)!F=QM\.D3,'0X^54HY88(B>NLFT%K=Z"6S
MY#CS&%RV2O"=BIQ?R.#30=I\9O#I$-%.;T8&3%'D0=N2JL$-R=;IL):B> J[
M4,:$4E%$GL89BW_R@T\/N*I&TD\'KV@WLAQTC-ZMMJRE;5+M?5[]\9DT,!.2
M296$AI2# .5,J%/)'$B?F7+,:%9:]V+L0%9//G@S0#R>(F^BG2YJOFXPM>5@
M_>I\\WFYFO\GIUDP@47#)(@89-W&J\%'80D@&6TRSOCF+[A/D#.=79L$8@=I
MHR];=L'*S8J26+SDV5"8:P4'E6O!FY(.G%=:6UT*9W)L9 VMZ&F>29\86OOJ
MHPNS=;OLY'%SC(XI2^YFXEC('"/)RF1R-3)G.=7DB&A=CK@;9=.DT(^+N!%T
MU"'V[MEIQ;@L=(2 !1TI<!(./"<_@"G/,3/#G&W=+O0T1=.DT*?$VD$ZZ19C
M;]?K<^+%:R>"8!RTT:[.DR5;G;F#HE@P,A.'11P!7Q?43)-?GQY;>^BB6US=
M= 1*]#[QF,&H^BR8A8)0"^Q4825Y"F"<;AU=/D/2-&GWZ1&VKU8:PJR;Q/L/
MN2_+CP6LQTRV/TW!Q GV >+I(ZDNK"U.<@DNA-IL:>EW7")H77S!0&A.C9)Y
M)Y)4%U9GEUFYV(ZM?#(4?V4ZX 9CT)[YV&2!UE\EJ3X$7_LFU8>H;-*K_\DT
M8-2*(^<:4J$+2T7NP948(#/G2K)*RMT>8EYT6GV0JG=)JP^1^O3YL,<RA$Q%
MYSS/D*2N_<V!G%_N1-UN4;1RFMNT4XWF2TJK#]+L;FGU(6+N,*V.PMLLO*18
MVTGR71VYQ+K.[W!<.*U-B?:OE%8?I,UGTNI#1#N]&1D02TEE4C2>#A"K6TJ*
M,.!YJ7PJP[0WO*C_[A-M?56-I)\.4E$7W5O7#/T8,,IM5D49X,F4NMZ"4;2>
M-;"H7;&9A:A;KRUZA)2>O.UFBK\W,/QP+73QAO8A?\N+\WQC4"T7JO;!@S <
MR0X3+QZS!&-%D85K6VSK<;UW:9AV)D$3U=[KD3M RET8'0I):]_#JT]Y$;__
MA@O\M)7.+SG/Z!!9[SV#R.J*!IX"!'( :L\.!F^,"2-8GL?IF18]AVGZGI5I
M)/8N3,W;!0$RK^O6F9_GW^9DJ2\GXE\^\]7A'):(YW5*ML8Z&D\[<#)FT$(*
M2QZ@R+ZU\7F>JFE'730&5%,5= &K*P'-0C3:6N[ ^]IE',AGI..1('NC(\6M
MAK&Q;JYIIU<TA<A>XIQ\4,XU?B]W^OV0A4---[.(P!B%ITIK!J[F-XNQ6HF,
MR3:?+O\H,=-:DC$<FS9R[\*._"TOB)>S.C0Z?9DOMGFIS?Q;ON1L9E+14:L
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MW'U]&Y _REO=L6F]_1!/-+]F;O6@6<%C&X<\<7/3Y-A)FN[VWU!+ P04
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MF-";ED7$4C@I4 YL=T37.@:BS-M\0VFF4T"*H:H6!-"JD '4.XQ% L4J!L#
MB$@1B2@"#9+#!"!6ID!.SPH5P0'KSWB<46*ART040?66,]BLV5"%7^R]JONM
M8[,+4;C+C869, #S(,>-J_XCE=GM!NS"9'PI+;"SB1[M\-BH:)D(U<+Y <RA
M"*+^YQ+%$'+;>>B!H[&'SRO@<N!!,+\@H9',50#E%=VYQIP;M$Z5L? [GL1!
MEPE T9\9$"^HWM\R)0)<0*K=D\X-A^Y0T/$#3R9)MK3KP%DUX6999C!)"4<B
M)/8B$L^990%GBQL!?^@(<D_>^V87?1-X?D7?>?@5?2>=M,,"<MXJDS"OU^.^
M2BJ,W!>4G <MP3(2'-H"JW)3<C'Z#;1.X1AJA?@,;XT4E!(<#R682'KV 2#
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M +;0_[5W<7KYC_XKM?FT-V17Y\SOM-H>.[UAIY_[L(NS;5#=R?ZLM&L_:NK
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M_9<D=ZO*;9Y1#"?T U/<KQ14\,V@AAG$(LM8K(]36' U!35E(%DNI *1P+E
M(P*GC*1J&A/)ZC#,8AMVM-KVUH'ON^V>F.4D6YH[K[T+Z.E$R!EXKO4[)$(:
MESD"%!08QDJASV(VFS"YO>7MN^V&5]<GJ__(Z96!4/G$5>OP&Y[D^13.;?AC
M/I%,%7?+.O2FG"4P>&#Q7/%[!J,DX3&3&KOVML)6!WRF>()_\KDLY@0)5@+6
MRJ6DH 1D:@9( 82*7+>%=9M'FCH95BN-B9R0C!76Z"%E2^C&AC^=#'64$PQE
M[Z#]DKS8?Y(70<M^Z[38\78APIC*38!DGJ9+3)19GG)6K*?)7W,NF>Y\A0[V
M"8D[!'-!@K>W0W>_L(3[)+%YHYO!0SPEV2VKJ/):C:!D?6:R! EKM8%D]&<A
MS2])XQGF_(R8BL+B4@0U*3XU\5>,$BZ1TERR0I-7UV*2IH!F3"-!:HL<V2SJ
MQBK!&LQB_1P=4C/[:&*TUCPMN1=88&;-XDGJVR\Y3ZM90)%)RBKY1$C*I(6L
MI20O6%C]:5->Y"E9ACPS+!BC]FHS)D(I,0OUE'*O2RXFZ6H-LUPI7@TPK9;=
M=)MZAE$XN"A:+;P:;VPSWCB*/I<%#7O?]S:*77NS[-_<MNQ@K_G#O1JP_HO<
M.H8(62FL\JO1,JF,AK@%!6[J8:U1JW1R0BD.K:$+GM&JUG@%U16Z[]GX^8.V
M6A_<4I8\RX<R%=ZJ1,VLW-=#OCF(X81-Y)S()0Y(IOLTOI3)#^7O_7*QO14T
MVX6Y?JNS/J+C.QN_.BC,Q)XC?)P9*%2X7R<_7[3D>R#_V3!IR/^/A+]NS;]?
MVC8,>W6XQ$[(=>,W;;&/0TFLA'Q.J6-ZU5HOW/CFO-8GG[Q\YZ+\^A!*EA(-
MX]GK^-<D-;W0_6I")IBI<[799-,[SL9W^]6U_-)@OGD<_0-02P,$%     @
MQX)-5M&<MLRX!   GA0  !$   !M;V@T<3(R7V5X,S(R+FAT;>U86V_;-A1^
MWZ\X=; V :R[?)/= *[M(,:2N(M5M'T::)&.N<JB1M%QO%^_0\IJ<YF3;%C3
M=*@?!$OGPN]\_$@=L?=B.!G$']^.8*&6*;Q]]^9D/(":Y3CO@X'C#.,A',>G
M)Q#:K@>Q)%G!%1<921UG=%:#VD*I/'*<]7IMKP-;R LG/G=TJM!)A2B8316M
M'?;T$[PR0@]_ZKVP+!B*9+5DF8)$,J(8A57!LPMX3UGQ"2QKZS40^4;RBX4"
MW_4#>"_D)WY)2KOB*F6'59Z>4][W'#-(;R;HYK!'^25P^KK&9P&94])IM<,P
M"!D-VHTD:+09:[)9RVLVO=\\!.F@>QE3J$W*7M>6/+,63(\?A;[=:N2JN^94
M+2+/=7^N&=?#WEQD"L>3&%_^+=/<2:;8E;)(RB^RR)14*T,K<R)2(:,]U_RZ
MVF+-R9*GF^A57W*2OJH72+Y5,,GGI;G@?S)$@J#,[;H$VL+HE&>L N[Y&NKH
MP_'XS3B&P+=]N GT>KU$7F#)2N21U\:\UR GR#&33XIY,#J/QT?C03\>H2[/
MI^_Z9S'$DYWHORU:KPWO[*D]L&$Z&L3CR1EX0<.M/U.T_2GTAY.W\6CX'5!;
M$=IQFS Y@OAX!-/^^9O^V6AJ33Z<C#Y"?Q!KB^^Z_F/$W:FTS3.*Y41^:!;W
M5RHJ_-NBQADD(LM8HK=36'.U +5@(%DNI (QAU.!002.&4G5(B&2U6&<)3;L
M:[>7>VW?=[L#L<Q)MC%W7O< ,-.1D$OP7.M7F MI4N8(4%!@6"N%(4O8<L;D
MRSVOZ78#KZYW5O]&TG,#H<J)H];AE,A/<&+#+XPOZS!8<#:'(T27)<@#3.9S
MGC"I0>LT6U!UP&>*S_%/OI+%BB"S2L"U=5+67B(QBP5( 82*7+\/KL?<\-0J
MV(XT)7)&,E98DZN4;:"?&.*T"NIH)UA#H]U]C"":MP01=NRGUL.^=P QUE2R
M#_-5FFY0(<L\Y:RXKH\_5EPR_<HK=+&W2-PG* ()7F.?'GQFB24KB6]M3#.Z
M2A8DNV 555XG"$O6ET8>2%BG"R2CWPMI?DD:SU#L2V*6$JXJ1="3XE-3?\4H
MX1(IS24K-'EU;29I"AC&-!*DMLB1S:)NHN:?Y8T)J6EZ-#'::Y66W M<66;,
MXI;T[7^TD2HR2UGE,!.2,FDA;2G)"Q95?[J4%WE*-A'/# TFJ+N=C9E02BPC
MW9]<ZC67D'0[B!FO-&];ET[';KDMW;TH;%D4K0;>-C:V:6P<1>_:PL!N^MY.
MLVOOMMV7MF.'C=9_GM6 ]1^5UC%$R,IA*["@8[2,@3@%!<[JZUI0JWQR0BFV
MJY$+GO&JQO@*KEMT#\7X^96.NMZRI6Q^1P^E%)YJC9HN>:C;>[,3PQ&;R161
M&VR-S'LG^+Q.'B;E&Q08/JJ^<NM]WI4\<JI>[H6M;F&N-U[Y-XI[0)#;#<Q\
M0^2(&[L8"A7@'Y/Y_"IYKA/V\,>!J?/?ZO3_,X$_*GDZM>WZ]-&=82P9*5:2
MR;LR=$R[=G\_^/NJT%]+M9TG2O>=-CU@N]7;5(=9N2A/\R+)4FQD+]F=XZTO
MFX3I,-TO(62&.\5*[0[9=6:P\ZQL>RU/[LP9XN%?4$L! A0#%     @ QX)-
M5C^M'#H2&00 E;DK !               ( !     &UO:"TR,#(R,3(S,2YH
M=&U02P$"% ,4    " #'@DU6G;V.<0$9  "5, $ $               @ %
M&00 ;6]H+3(P,C(Q,C,Q+GAS9%!+ 0(4 Q0    ( ,>"35;H6ITN^#0  ,P?
M @ 4              "  6\R! !M;V@M,C R,C$R,S%?8V%L+GAM;%!+ 0(4
M Q0    ( ,>"35:@R!WZL8@  &D:!@ 4              "  9EG! !M;V@M
M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( ,>"35;6D;NOWT@  ,51   3
M              "  7SP! !M;V@M,C R,C$R,S%?9S$N:G!G4$L! A0#%
M  @ QX)-5NQ6K/2SD   ^)4  !,              ( !C#D% &UO:"TR,#(R
M,3(S,5]G,BYJ<&=02P$"% ,4    " #'@DU6?WLW)0$" 0!.>@$ $P
M        @ %PR@4 ;6]H+3(P,C(Q,C,Q7V<S+FIP9U!+ 0(4 Q0    ( ,>"
M35;<?DEQEGL  ,>M   3              "  :+,!@!M;V@M,C R,C$R,S%?
M9S0N:G!G4$L! A0#%     @ QX)-5D+Z\,1W:0$ ,KH. !0
M ( !:4@' &UO:"TR,#(R,3(S,5]L86(N>&UL4$L! A0#%     @ QX)-5CZ7
MK+FY[   )>4* !0              ( !$K(( &UO:"TR,#(R,3(S,5]P<F4N
M>&UL4$L! A0#%     @ QX)-5AB_?L'2!0   5P  !$              ( !
M_9X) &UO:#1Q,C)?97@R,3$N:'1M4$L! A0#%     @ QX)-5O"0[>EH P
M20D  !$              ( !_J0) &UO:#1Q,C)?97@R,S$N:'1M4$L! A0#
M%     @ QX)-5BL+V[)H"   :"4  !$              ( !E:@) &UO:#1Q
M,C)?97@S,3$N:'1M4$L! A0#%     @ QX)-5K'RO&9#"   LR0  !$
M         ( !++$) &UO:#1Q,C)?97@S,3(N:'1M4$L! A0#%     @ QX)-
M5L85A>RL!   3A$  !$              ( !GKD) &UO:#1Q,C)?97@S,C$N
M:'1M4$L! A0#%     @ QX)-5M&<MLRX!   GA0  !$              ( !
K>;X) &UO:#1Q,C)?97@S,C(N:'1M4$L%!@     0 !   @0  &##"0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
